,nct_id,primaryOutcomes,startDate,status,study_type,phases,otherOutcomes,secondaryOutcomes
0,NCT01976351,The relationship between the mucosal morphology by imaging enhanced endoscopy and the presence of high-grade intraepithelial neoplasia from non-dysplastic specialized intestinal metaplasia.,2009-09,TERMINATED,OBSERVATIONAL,['NA'],,
1,NCT00759109,Number of Participants With the Development of Hepatocellular Carcinoma (HCC),2002-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI) at Baseline,Change in the Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI)
2,NCT04806243,os（overall survival）,2021-05-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DoR
3,NCT00877136,Evaluate patient experience with Therasphere.,2009-02,COMPLETED,OBSERVATIONAL,['NA'],,Tumor response to treatment with TheraSphere®
4,NCT01217450,"Tumor response, as evaluated by the RECIST",2012-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Toxicities graded using the NCI Common Toxicity Criteria
5,NCT05626309,1-year disease-free survival rate,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Percentage of Participants With Adverse Events
6,NCT04209491,Proportion of the following missions of the coordinator Nurse,2019-09-09,UNKNOWN,OBSERVATIONAL,['NA'],,Number of early unscheduled readmissions during the first month following interventional radiology treatment for patients included in the study.
7,NCT04745390,Treated lesion progression,2021-08-01,RECRUITING,INTERVENTIONAL,['NA'],,"Comparison of Quality of Life (QOL) Using a Standardly-Used Validated Instrument. Specifically, measures of physical, social/family, and functional well being. Overall symptoms, function, global health status will also be compared."
8,NCT04249739,ORR (objective response rate) per RECIST 1.1,2020-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Genomic analysis
9,NCT03789162,Blood-based biomarkers associated with genetic and epigenetic alterations,2018-12-20,RECRUITING,OBSERVATIONAL,['NA'],,
10,NCT01749865,Time to recurrence,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Adverse Events,Disease Free Survival
11,NCT05523271,Adenoma detection rate,2023-01-16,RECRUITING,INTERVENTIONAL,['NA'],,Non-neoplastic detection rate
12,NCT03476434,polyp miss rate,2015-02,COMPLETED,INTERVENTIONAL,['NA'],,adenoma miss rate
13,NCT02527824,overall response rate,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,toxicity profiles - the number of participants and grade of intensity of treatment related adverse events
14,NCT05134532,Progression-free survival (PFS) by RECIST v 1.1,2021-12-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety profiles by NCI-CTCAE version 5
15,NCT00689702,Complete pathological remission rate,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Rate of sphincter sparing surgical procedure Toxicity/safety
16,NCT01979549,Adverse events,2013-12,UNKNOWN,OBSERVATIONAL,['NA'],,
17,NCT00811447,Time to progression,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Laboratory toxicities/symptomatology
18,NCT04213794,Incidence of adverse events of cytoreductive surgery (CRS) with heated intra-peritoneal chemotherapy (HIPEC) in this patient population,2019-11-08,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Progression free survival (PFS)
19,NCT01830907,Infectious complication,2012-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Length of hospital stay
20,NCT02017509,Correlation of the number of infiltrating leukocytes within a biopsy sample with pathologic response,2014-01-24,COMPLETED,OBSERVATIONAL,['NA'],,
21,NCT00982449,To evaluate the potential for enzymatic targeting as evidenced by the ability to image 124I-FIAU tracer uptake in tumor at baseline and following chemotherapy or biologic therapy with agents that may induce viral TK activation.,2010-12,COMPLETED,INTERVENTIONAL,['NA'],,To describe changes in viral DNA in plasma as a function of chemotherapy and the association with imaging by FIAU-PET
22,NCT00427804,Fractional Absorption of Calcium,2007-01,COMPLETED,INTERVENTIONAL,['NA'],,
23,NCT03110068,Presence of microvascular invasion,2017-04-10,UNKNOWN,OBSERVATIONAL,['NA'],,
24,NCT03714555,CA19-9 Plasma Level,2019-10-17,TERMINATED,INTERVENTIONAL,['PHASE2'],Disulfiram/Copper Gluconate Serum Levels - Area Under the Curve (AUC),Incidence of Toxicities
25,NCT03904927,Progression-free survival,2019-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Local control
26,NCT00002896,,1993-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
27,NCT03714958,Part1: Dose Maximum Tolerated,2018-12-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS)
28,NCT04731428,Use of analgesic (See Table 1)(postoperative 3rd day),2018-03-15,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative serum cortisol levels (3rd. assessment)
29,NCT04964297,Hydrogen (H2) gas,2021-08-09,RECRUITING,INTERVENTIONAL,['NA'],,Response time of the Perf-AlertTM device.
30,NCT05945823,ORR by investigator assessment,2023-07-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,6-month PFS rate
31,NCT02270554,Incidence of pancreatic fistula grade B/C,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of pancreatic fistula stratified based on thickness of pancreas parenchyma
32,NCT03204201,Number of urethras identified under white light and fluorescence,2017-07-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of adverse events related to trial intervention
33,NCT00066430,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
34,NCT03199989,3-year disease free survival,2017-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Major adverse events
35,NCT02643173,Recurrence of HCC,2015-09,COMPLETED,OBSERVATIONAL,['NA'],,
36,NCT00359333,Tumor response,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to tumor progression Overall survival Quality of life
37,NCT03170115,Tumor downstaging after induction chemotherapy followed by chemoradiotherapy with or without aspirin,2017-11-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
38,NCT05519930,Evaluation of endoscopic ultrasound for early detection of pancreatic cancer in the high-risk group as defined by inclusion criteria to determine their level of risk and perform surveillance accordingly,2016-10-18,SUSPENDED,OBSERVATIONAL,['NA'],,
39,NCT04083365,Pathological complete response (pCR) rate after durvalumab treatment,2020-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease-free survival (DSF)
40,NCT06285097,Objective response rate (ORR) in Part 2 Expansion,2024-02-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,AUC of PF-07820435 and its active metabolite under fasted and fed conditions (Part 2 subset) subset of participants in Part 2
41,NCT00553683,Overall tolerability,2007-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Overall survival at 6, 12, and 24 months"
42,NCT01479465,Progression Free Survival (PFS),2011-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (ORR)
43,NCT04846842,Objective response rate (ORR),2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
44,NCT02934464,Progression-Free Survival (PFS),2016-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life EuroQol EQ-5D
45,NCT01394939,Determine Radiographic Response Rate of Patients Enrolled in the Phase 2a Portion of the Study,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
46,NCT03785743,5-year overall survival,2019-03-01,RECRUITING,INTERVENTIONAL,['NA'],,intraoperative indicators
47,NCT04609410,Total intra-operative blood loss,2020-10-30,RECRUITING,INTERVENTIONAL,['NA'],90-day quality of life,Surgery and hepatic resection time
48,NCT04721223,Objective response rate (ORR),2021-04-26,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants with Treatment-related Adverse Events(TRAE)
49,NCT04666688,Part 2: PFS or ORR [Preliminary Efficacy],2020-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 1: Pharmacodynamics (PD) of LYT- 200
50,NCT05438797,incidence of adverse events( AE )and Serious adverse events(SAE),2021-04-02,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Progression-free survival (PFS)
51,NCT05640726,progression free survival,2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,objective response rate
52,NCT05445973,Local tumor progression rate,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Technical success rate of radiofrequency ablation using contrast-enhanced US-CT/MRI fusion image
53,NCT05273931,Changes in adherence to the lifestyle recommendations between baseline and the 4 week follow-up,2022-03-16,COMPLETED,INTERVENTIONAL,['NA'],,
54,NCT03115398,Number of Missed Scheduled Radiotherapy Treatments,2017-02-16,COMPLETED,INTERVENTIONAL,['NA'],,Survival Status
55,NCT04685525,PRO-CTCAE questionnaire scores,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
56,NCT04991948,The objective response rate (ORR) at the tumor assessment on Day 94 [Visit 15]),2021-11-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,
57,NCT01445327,"Number of Participants With Specific Tumor Markers in Stool, Urine, or Serum Detected Prior to Treatment and After Treatment",2007-02-20,TERMINATED,OBSERVATIONAL,['NA'],Here is the Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Toxicity Criteria (CTC) v3.0.,Number of Participants With Chronic Gastrointestinal Injury After Radiotherapy
58,NCT03515850,classifications vascular branches of IMA,2018-01-05,UNKNOWN,OBSERVATIONAL,['NA'],,
59,NCT00464893,rate of all specific postoperative complications newly observed during a period of 30 days after surgery in those study patients who received at least the first 3 doses of catumaxomab,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"disease-free survival at 3, 6, 9, 12 18 and 24 months after EOT, defined as the time from study enrolment to the point of diagnosis of recurrent disease or death, whichever occurred first"
60,NCT06255912,Treatment Emergent Adverse Events,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,overall response rate
61,NCT04542837,ORR,2020-09-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,OS
62,NCT03575806,Recurrence-free Survival (RFS) Time,2017-01-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) Rate at 24 Months
63,NCT05566834,To determine any increase of treatment emergent adverse events when Minnelide capsules are given in combination with paclitaxel.,2020-11-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Plasma levels of Minnelide when given with paclitaxel
64,NCT02188901,False referral rate of HCC,2014-10-15,COMPLETED,INTERVENTIONAL,['NA'],,
65,NCT00000764,,na,COMPLETED,INTERVENTIONAL,['PHASE1'],,
66,NCT03961867,disease-free survival,2020-09-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment related Adverse Events
67,NCT00932308,The degree of inflammation in the rectosigmoid epithelium as judged by the density and composition of the cellular infiltration.,2006-09,COMPLETED,INTERVENTIONAL,['NA'],,Changes in bulk fecal and epithelial associated microbiota that may determine changes in colorectal epithelial cell biologic pathways.
68,NCT05095714,Incremental cost / QALY ratio,2021-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Compliance
69,NCT05386056,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in all participants,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change from baseline in the EORTC Quality Of Life Questionnaire Oesophageal Module (QLQ-OES18) Score
70,NCT03621852,tissue yield,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
71,NCT05534087,3-year disease-free survival rate,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,EORTC QLQ-C30 scale
72,NCT00001428,,1995-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
73,NCT00072748,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
74,NCT00467922,"Determine the relative effects of a standard, colloid or crystalloid based strategy for hand-assisted laparoscopic colectomy surgery on decreasing length of stay",2007-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,1. Determine the effects of the three fluid management strategies on post-operative fluid requirements in colorectal surgery. on the incidence and severity of post-operative complications. on return of gastrointestinal function.
75,NCT03620643,Percentage of Basket Cohort Participants With Objective Response Assessed Using RECIST v1.1,2019-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Assessment of overall survival in each cohort
76,NCT02311361,Number of Adverse Events in Each Cohort With Grade 1 Through 5 Related to Study Drug,2015-03-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)
77,NCT00531180,Correlation between 4-dimensional computed tomography (4D CT) derived ventilation and single photon emission tomography (SPECT) aerosol Tc-99m determined ventilation,2007-08-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,
78,NCT03312374,Disease Free Survival,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,
79,NCT06056336,2-year disease-free survival in non-pCR patients,2023-09-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival
80,NCT03493880,Pathological response,2015-09-01,RECRUITING,OBSERVATIONAL,['NA'],,yp TNM Stage
81,NCT04384601,Total Percentage of Patients With Pathological Complete Tumor Regression (TRG1a) and Sub-total Tumor Regression (TRG1b) in the Primary Tumour,2021-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease free survival (DFS)
82,NCT05443230,Long-term results,2022-06-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
83,NCT04455932,HCC detection with US surveillance versus aNC-MRI surveillance,2022-01,RECRUITING,INTERVENTIONAL,['NA'],,
84,NCT05374252,cCR rate,2022-05-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence rate of Grade ≥3 PD-1monoclonal antibody-related adverse events
85,NCT00313872,Second progress-free survival,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Toxicity, overall survival"
86,NCT05473156,Dose-Expansion: Overall response rate(ORR) (assessed by the Investigator according to RECIST version 1.1),2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
87,NCT05244174,Level of Fecal elastase-1,2022-01-25,RECRUITING,INTERVENTIONAL,['NA'],,Prevalence of PEI
88,NCT05342636,Objective Response Rate (ORR),2022-07-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants Who Discontinue Study Treatment Due to An AE During the Efficacy Phase
89,NCT02577393,Superiority of EGCG in reducing Grade II esophagitis as assessed by RTOG scores in patients with lung cancer receiving radiation,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Improved quality of life with usage of EGCG for treatment of radiation-esophagitis in patient with lung cancer.
90,NCT03992664,Through a randomized feasibility clinical trial to investigate the effectiveness of an educational intervention in conjunction with routine management of rash in patients receiving EGFRI therapy.,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Assessing the quality of life in relation to the rash through the QLQI questionnaire.
91,NCT05617755,Maximal tolerated dose of AB-1015,2022-11-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Co-expression of ALPG and MSLN targets on tumor cells
92,NCT00747292,Length of hospital stay,2007-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Pain, time till flatus, time till bowels open, incidence of nausea and vomiting, quality of life"
93,NCT04099901,Reduction of the incidence of fever during neutropenia,2019-11-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Tumor response evaluation
94,NCT01016639,,2003-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
95,NCT04770896,Overall Survival (OS),2021-04-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,Serum Concentration of Atezolizumab
96,NCT02550769,Evaluate the effectiveness of the T-TME versus L-LAR with the LARS score in patients with rectal cancer.,2015-04,COMPLETED,INTERVENTIONAL,['NA'],,
97,NCT00478634,Dose Limiting Toxicities,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective Response Rate
98,NCT02607072,3-year disease free survival,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
99,NCT00003125,,1998-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
100,NCT05045573,Pathological tumor response,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Rate of Healthy liver hypertrophia
101,NCT04821284,Progression-free survival,2021-12-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor stiffness
102,NCT01397305,Feasibility of Pemetrexed Prior to Surgery,2011-04-14,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Pharmacokinetic parameters of [6R] 5,10-mTHF, 5-formyl-THF, 5-methyl-THF and THF calculated from plasma"
103,NCT00377936,Overall survival,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of clinically significant abnormal laboratory values
104,NCT00593723,The study will evaluate the feasibility of using helical tomotherapy to deliver IMRT in patients with unresectable esophagus cancer.,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Evaluate overall survival rates
105,NCT05692895,Diagnosis and prognosis of colorectal carcinoma,2023-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
106,NCT03256994,Description of the clinical context in which SIR-Spheres are applied,2017-08-01,COMPLETED,OBSERVATIONAL,['NA'],,Diagnosis- and treatment-related considerations
107,NCT00473980,Immune reactivity,1998-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,
108,NCT06259292,Prospective Longitudinal Clinical Outcomes Assessment using HHT Clinical Outcomes Scale,2023-11-13,RECRUITING,OBSERVATIONAL,['NA'],,Treatment Outcomes Assessment with HHT Treatment Outcomes Scale
109,NCT05541146,Rate of complete peritoneal response after 04 cycles of intraperitoneal (IP) chemotherapy (CMT) associated with systemic CMT with XP.,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
110,NCT02327819,time until a new liver tumor is found,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],,
111,NCT03568630,"Result of MMTT which may indicate type 3c diabetes, which may be a risk factor for pancreas cancer.",2018-07-26,RECRUITING,OBSERVATIONAL,['NA'],,
112,NCT05131698,Objective response rate,2021-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
113,NCT01859728,Overall Response Rate,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Biomarker evaluation,Safety
114,NCT02112656,Overall Survival (OS),2014-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression-free survival (PFS)
115,NCT03843853,Progression-free Survival(PFS),2019-05-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
116,NCT02050503,Pain Intensity Difference,2012-12,COMPLETED,OBSERVATIONAL,['NA'],safety of intranasal transmucosal fentanyl,number of episodes of breakthrough pain requiring additional (rescue) analgesic treatment after administration of the study medication
117,NCT00989469,disease control,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival
118,NCT01627080,Evaluation of Cardiac Biomarker Elevation with Radiation Therapy,2014-04,WITHDRAWN,OBSERVATIONAL,['NA'],,Incidence of Adverse Cardiac Outcomes
119,NCT00403624,Tumour response,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease free and Overall survival ; Adverse events
120,NCT04830618,Metachronous recurrence,2012-09-11,COMPLETED,OBSERVATIONAL,['NA'],,
121,NCT03937453,Early Stage Pancreatic Cancer or Precursor Lesions,2018-01-19,RECRUITING,OBSERVATIONAL,['NA'],,Relative Risk of Pancreatic Cancer Among Individuals with Detiorating diabetes
122,NCT01211379,Change in Colorectal Cancer Screening Rate,2009-10,COMPLETED,INTERVENTIONAL,['NA'],,
123,NCT00492999,Resectability rate,2007-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Survival
124,NCT00991614,Patency of the stent,2009-12,COMPLETED,OBSERVATIONAL,['NA'],,"Procedural success, implant duration, symptom resolution"
125,NCT02003339,Modifications of functional MRI parameters,2013-11,COMPLETED,INTERVENTIONAL,['NA'],,Change of VEGF (vascular endothelial growth factor) release
126,NCT02401815,Part 2e: To identify the recommended phase 2 dose (RP2D) of PLX9486 in combination with sunitinib for further evaluation,2015-03-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 2: To determine the progression-free survival of PLX9486 treatment in combination with PLX3397 or sunitinib.
127,NCT01692873,Biomarkers,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,Histology
128,NCT01100814,,2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,
129,NCT00497224,Objective Response Rate,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tolerability of Erlotinib Dose Escalation
130,NCT03381651,Progression free survival,2018-02-22,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
131,NCT00659113,Response rate,2008-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Initial squamous cell carcinoma antigen and C-reactive protein correlation with response and survival
132,NCT05705219,Diagnostic yield of the 3D-MPUS data acquisition,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Relationship between baseline and one-month 3D-MPUS measurements and treatment response after three-months
133,NCT00922896,"To assess the response rate associated with gemcitabine, erlotinib and cisplatin in patients with advanced pancreatic cancer",2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
134,NCT03790111,Project Overall Survival Rate at Month 6,2019-03-13,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in Serum Albumin
135,NCT04304001,Rate of Colorectal Cancer Screening,2021-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Colorectal Cancer Screening Self-Efficacy Scale
136,NCT03577665,2-year local control ratio of the treated liver area,2018-05-21,RECRUITING,INTERVENTIONAL,['NA'],,5-year disease-free survival rate of treated patients
137,NCT04048421,Postoperative complications,2019-12-20,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
138,NCT03026881,"DLT and safety: Adverse Events (AEs), physical examination, vital signs including blood pressure (BP), pulse, electrocardiogram (ECG) and laboratory findings including clinical chemistry, hematology, urinalysis.",2017-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Plasma Clearance (CL/F)
139,NCT00869739,"Relationship functioning in survivors and partners as assessed by the Dyadic Adjustment Scale (129) and the Miller Social Intimacy Scale (130) at baseline, 2 months, and 5 months",2008-08,COMPLETED,INTERVENTIONAL,['NA'],,"Coping skills in survivors and partners as assessed by the Coping Strategies, Social Problem Solving Scale-Revised, and La Trobe Communication Questionnaires at baseline, 2 months, and 5 months"
140,NCT03821909,The difference of the exosomes acquisited from portal venous blood between patients with pancreatic cancer and benign pancreatic diseases,2018-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,The difference of the exosomes between portal venous and peripheral blood
141,NCT04024917,Cardiac Coherence Program Adherence Rate,2021-09-21,RECRUITING,INTERVENTIONAL,['NA'],,Duration of cardiac coherence sessions in minutes
142,NCT05169437,Overall Response Rate (ORR) - Independent Central Review (ICR),2022-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
143,NCT03347292,Dose Limiting Toxicities(DLTs),2018-06-18,COMPLETED,INTERVENTIONAL,['PHASE1'],,Duration of stable disease
144,NCT05643417,ORR,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,OS
145,NCT01937715,Progression-Free Survival (PFS),2014-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change From Baseline in Functional Assessment of Cancer Therapy-Colorectal (FACT-C) (Phase 2)
146,NCT05320497,"Intubation rates of bile duct ends, cystic duct openings, and left and right hepatic duct bifurcations",2022-04-14,UNKNOWN,INTERVENTIONAL,['NA'],,Biopsy accuracy
147,NCT04418401,Recurrence-free rate in one year,2020-06-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Adverse effects
148,NCT04387071,Objective response rate (CR + PR),2021-04-29,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Immune cell populations,Overall survival
149,NCT06102759,Progression Free Survival,2023-11-10,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
150,NCT00073736,Safety and tolerability,2003-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine effect of MB07133 on tumor size
151,NCT03695250,Objective Response Rate (ORR),2018-10-16,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
152,NCT00039403,Recommended phase II doses,2002-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Frequency, extent, and duration of any tumor responses"
153,NCT01732393,lower grade of mucositis,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,duration of mucositis
154,NCT04646928,5-year Cumulative hepatocellular carcinoma incidence,2017-03-17,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of cirrhosis regression
155,NCT01836991,the overall survival time,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
156,NCT04269083,"R0, number of patients achieving R0 resection.",2020-05-24,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,safety profile
157,NCT01671449,Progression-free survival,2012-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Adverse Events
158,NCT00687778,Uptake of C11-Acetate and F18-FDG in tumor will be measured in SUV PET units,2008-05,UNKNOWN,OBSERVATIONAL,['NA'],,
159,NCT05056116,Objective response rate(ORR),2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival (OS)
160,NCT03746353,perioperative complications,2018-09-05,TERMINATED,INTERVENTIONAL,['NA'],,Measure quality of life
161,NCT04014101,Objective response rate(ORR),2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
162,NCT03291561,Gastrointestinal function score,2017-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,Physical fitness index
163,NCT01110668,To evaluate time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine progression-free survival and the response rate of nilotinib in patients with advanced GIST previously treated with imatinib ≥600 mg.
164,NCT02331641,"Number of postoperative complications after MH or MMH, graded based on the Dindo's classification (Dindo et al. Ann Surg 2004;240:205-13)",2005-01,COMPLETED,OBSERVATIONAL,['NA'],,Long-term outcome (overall and disease-free survival)
165,NCT05253053,Dose limiting toxicity (DLT),2022-04-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",changes of main circulating metabolites of TT-00420 in plasma,Volume of Distribution
166,NCT00003780,,1998-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
167,NCT02750657,The feasibility of prospectively identifying subgroups of patients with advanced PDAC who have distinct genomic characteristics for better treatment selection while undergoing 1st-line chemotherapy using next generation sequencing.,2015-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Correlation with tumor molecular characteristics and toxicities to treatment using next generation sequencing.
168,NCT06182865,Measurement of liver reserve obtained from the Ga-68 Dolacga PET performed in HCC patients after proton therapy.,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
169,NCT00016965,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
170,NCT04864054,To determine the Recommended Phase II Dose (RP2D) of ECT204,2022-03-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,"To characterize the pharmacokinetic (PK) profile of ECT204, including the expansion and persistence of ECT204, in our study subject population"
171,NCT00081315,- Acute radiochemotherapy-induced esophagitis will be assessed from the time of randomization through up to 3 months after completion of radiochemotherapy treatment.,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,- Acute radiochemotherapy-induced pneumonitis will be assessed until 6 months after the last dose of XRT.
172,NCT05657743,Safety - Adverse events,2023-08-16,RECRUITING,INTERVENTIONAL,['NA'],Urine radioactivity measurements,Efficacy-Alpha DaRT seeds
173,NCT02762721,Estimate the frequency of FGFR2 fusions in archived iCCA or mixed HCC-CCA tumor tissue samples,2016-06-06,COMPLETED,OBSERVATIONAL,['NA'],,Formulate genetic screening recommendations for newly diagnosed patients with iCCA or mixed HCC-CCA
174,NCT02752360,Anastomotic Stenosis Rate,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,The time of reconstruction in the surgery of Intestinal Anastomosis
175,NCT02050737,Disease free survival or progression free survival,2013-10,TERMINATED,OBSERVATIONAL,['NA'],,To investigate the correlation between biomarkers identified in plasma samples with the expression of the same biomarkers at tissue level.
176,NCT01212887,Dose of MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes that gives the highest frequency in the circulation as measured by the primary assays (recommended phase II dose),2007-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Long-term follow up for insertional mutagenesis
177,NCT02680990,Feasibility of Large-Scale Trial: Adherence & Contamination,2015-12,COMPLETED,INTERVENTIONAL,['NA'],,Assessing the interaction between frailty and the Band Together program
178,NCT03904537,Disease-free survival (DFS）,2019-02-19,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"The quality of life by EQ-5D-5L (EuroQol Group, Chinese versions )"
179,NCT02869269,Circulating helper T cell activity,2015-10,COMPLETED,OBSERVATIONAL,['NA'],CD4 and Treg cell activity and change of percentage of CD39 and CD73,Cytotoxic T cell and natural killer cell activity
180,NCT02041481,DLT defined as an adverse event or abnormal laboratory value assessed as at least possibly related to the combination of MEK inhibitor MEK162 and FOLFOX graded according to NCI CTCAE v4.03,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Survival
181,NCT02139488,To quantify motion of the esophageal tumor over the course of chemoradiation,2014-04-18,COMPLETED,OBSERVATIONAL,['NA'],,
182,NCT04767503,Metabolomics,2021-02-20,UNKNOWN,INTERVENTIONAL,['NA'],,I-FEED scoring
183,NCT05631613,Deposition of of lipiodol-idarubicin emulsion,2022-12-28,RECRUITING,OBSERVATIONAL,['NA'],,Visibility of lipiodol-idarubicin emulsion under X-ray: image quality
184,NCT01285102,Overall Survival,2010-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
185,NCT04491955,Objective Response Rate (ORR) for Quadruple Therapy,2020-09-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Number of Participants Hospitalized Due to Serious Adverse Events Attributed to Progressive Disease (PD)
186,NCT03777943,Immunohistochemistry (IHC) analysis,2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],,Laser capture microdisssection (LCM) followed by gene expression analysis
187,NCT03867409,Interpersonal Distance,2018-11-05,COMPLETED,INTERVENTIONAL,['NA'],,
188,NCT01633411,Esophageal Stricture,2011-12,COMPLETED,OBSERVATIONAL,['NA'],,Presence of Residual Barrett's Esophagus
189,NCT00733889,• Complete clinical response rate and objective clinical response rate after the administration of 3 cycles of chemotherapy plus cetuximab and after induction chemotherapy followed by concomitant chemoradiotherapy plus cetuximab,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,• To determine EGFR expression in the tumour and attempt to correlate it with efficacy
190,NCT00270543,high-dose 5-FU/leucovorin chemotherapy for patients with inoperable advanced gastric cancer.,na,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival.
191,NCT05566899,Acceptability and feasibility of EGD-SC measured by Linear Scale,2023-02-08,RECRUITING,INTERVENTIONAL,['NA'],Acceptability and feasibility of EGD-SC measured by Linear Scale,Number of participants with AE's will be measured by the Cancer Therapy Evaluation Program Common Toxicity Criteria (CTC) Version 5.0
192,NCT00055848,,2001-12,COMPLETED,OBSERVATIONAL,['NA'],,
193,NCT06085365,the incidence of chemotherapy related adverse reactions,2023-07-24,RECRUITING,INTERVENTIONAL,['PHASE3'],,changes in immune microenvironment
194,NCT05693649,CRC screening completion at 3 years,2023-06-07,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Choice of test
195,NCT02207465,Number of Adverse Events,2014-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,
196,NCT01126840,Compare Predictors of Health-Related Quality of Life (QOL) among Colorectal Cancer (CRC) Survivors who have Lynch Syndrome (LS) with patients who have Sporadic CRC,2010-06-20,COMPLETED,OBSERVATIONAL,['NA'],,
197,NCT01674374,Proportion of patients with severe mucositis (WHO score 3 or 4),2013-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Quality of Life as assessed by EORTC QLQ Head and Neck Cancer-Specific Module function and symptom sub-scores between groups (with 1 being not at all and 4 being very much)
198,NCT02305758,Progression-Free Survival (PFS): Time to Event,2014-12-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (ORR)
199,NCT04834505,To construct a diagnosis model for distinguishing FAIP from PC and further validate its efficacy,2021-05-11,RECRUITING,OBSERVATIONAL,['NA'],,Compare the efficacy of EUS based on the model with that of CT/MRI/PET-CT in differentiating between FAIP and PC
200,NCT00956930,Time to Progression (TTP) in Patients Treated With TACE and Y90,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
201,NCT00666991,Determine maximum tolerated dose and to assess qualitative and quantitative toxicities,2008-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Determine pharmacokinetics of intraperitoneal administration
202,NCT03672422,Length of time from progression from Acute Recurrent Pancreatitis to Chronic Pancreatitis,2017-06-30,COMPLETED,OBSERVATIONAL,['NA'],,Number of subjects with abnormal oral glucose tolerance test (OGTT)
203,NCT03518502,Overall survival,2012-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Median survival time (MST)
204,NCT00001431,,1995-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
205,NCT00063401,"To determine the progression-free survival obtained with cetuximab (C225)/paclitaxel/carboplatin in subjects with newly diagnosed advanced stage ovarian, primary peritoneal, or fallopian tube cancer.",2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To access EGFR expression by immunohistochemical assay.
206,NCT02326727,Plasma concentration of cytokines,2015-04,UNKNOWN,INTERVENTIONAL,['NA'],,
207,NCT05930860,Recurrence rate,2021-12-12,RECRUITING,OBSERVATIONAL,['NA'],,
208,NCT02551250,sensitivity for detecting HCC,2015-09,UNKNOWN,OBSERVATIONAL,['NA'],,false referral rate for HCC
209,NCT01102088,Maximum Tolerated Dose (MTD) of Simultaneous Integrated Boost (SIB),2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pathologic Response
210,NCT05489289,Recurrence free survival (RFS) by BICR,2022-09-24,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Types and proportions of adverse events (AEs)
211,NCT05045976,Change of Functional Assessment of Cancer Therapy- Colorectal,2021-09-19,RECRUITING,INTERVENTIONAL,['NA'],,M.D. Anderson Symptom Inventory
212,NCT02185768,Rate of patients in objective response (complete or partial response),2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment tolerance
213,NCT04150705,Technical Feasibility of PET/MRI as Measured by the Completion of the Study With Acceptable Image Quality in ≥70% of Scans,2020-06-01,TERMINATED,INTERVENTIONAL,['NA'],,Percentage of Scans With Changes in Perceived Disease Status as Measured by PET/MRI Tumor Regression Grade Relative to the Conventional MRI Only Tumor Regression Grade
214,NCT00865709,Progression-Free Survival (PFS),2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
215,NCT02004262,"2nd-line Cohort: OS (All Data, FAS)",2014-02-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events in Each Treatment Arm Treatment Regimen
216,NCT01404156,treatment response,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,EORTC QOL
217,NCT03059147,Rate of dose limiting toxicities,2017-03-27,TERMINATED,INTERVENTIONAL,['PHASE1'],,Progression-free survival
218,NCT05246839,Impact of Brief Videos,2022-04-28,RECRUITING,OBSERVATIONAL,['NA'],,
219,NCT04487704,Assess Safety as defined by the NCI CTCAE v5.0,2020-04-07,RECRUITING,INTERVENTIONAL,['NA'],,overall survival
220,NCT03073226,Sensitivity,2016-02-06,COMPLETED,INTERVENTIONAL,['NA'],,Endoscopists confidence
221,NCT00782457,"Lymph nodes isolated, circumferential margin involved, rate of complications and length of stay",2002-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
222,NCT00489671,Risk of pancreatic cancer as determined by urine cadmium levels,2003-06,COMPLETED,OBSERVATIONAL,['NA'],,"Predictive value of urinary cadmium alone, CA 19-9 alone, and both tests together on development of pancreatic cancer"
223,NCT04077372,Difference in proportions of patients with documented goals of care,2019-09-16,TERMINATED,INTERVENTIONAL,['NA'],,Overall comparison of QOL survey
224,NCT04563416,the diagnosis efficiency of the computer-assist diagnosis tool,2020-07-10,UNKNOWN,OBSERVATIONAL,['NA'],,
225,NCT03010085,"Checklist of functional recovery (Questionnaire, liver function test of aspartate aminotransferase and alanine aminotransferase)",2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
226,NCT00414843,Establish Repository of Human Bile,2006-12,TERMINATED,OBSERVATIONAL,['NA'],,
227,NCT05381792,Serial gut microbiome changes after endoscopic resection of colorectal advanced neoplasia.,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],,"The differences in the bacterial gene markers (Fn, m3, Bc and Ch) between advanced adenoma and CRC"
228,NCT00878215,The Number of Participants Who Have Complete Ablation According to Early Post-ablative Imaging Studies as Well as no Recurrence of the Tumor Within 6 Months (Phase 4 Portion of the Study),2002-10-24,TERMINATED,INTERVENTIONAL,['PHASE2'],,
229,NCT00871169,Overall Response Rate (ORR),2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
230,NCT05381636,Progression free survival (PFS),2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
231,NCT05994001,Incidence of Treatment-Emergent Adverse Events(Phase I),2023-08-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,OS
232,NCT04940286,Incidence of adverse events,2021-09-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in circulating tumor deoxyribonucleic acid (ctDNA) levels,
233,NCT03355443,Adenoma miss rate in the proximal colon (AMR),2017-12,UNKNOWN,INTERVENTIONAL,['NA'],,Adenoma Detection Rate in the proximal colon (ADR)
234,NCT00392899,Disease-free survival,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Types and severities of adverse events
235,NCT00003810,,1999-08-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
236,NCT05312216,Objective response rate (ORR),2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AEs)
237,NCT01790035,Safety (phase I safety lead-in),2014-08-19,TERMINATED,INTERVENTIONAL,['PHASE1'],,Serum citrulline
238,NCT01754896,FIT Kit uptake,2012-04,COMPLETED,INTERVENTIONAL,['NA'],,Rejection rates
239,NCT04592393,Detection of pancreas cancer,2020-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Identification of super-high risk group of developing pancreas cancer,Detection of pancreas cancer
240,NCT01901042,Changes in quality of life,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
241,NCT03283540,Average intra-balloon pressure,2017-09-25,RECRUITING,OBSERVATIONAL,['NA'],,Low Anterior Resection Syndrome score (LARS)
242,NCT04221893,Overall response rate (ORR),2020-08-07,RECRUITING,INTERVENTIONAL,['NA'],,Time to new systemic therapy
243,NCT04501913,Staff ability to act on identified threshold healthcare parameters,2019-12-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Changes in PGHD/PROs
244,NCT06041425,Pain intensity at 24hours after the end of TACE.,2023-08-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,Nausea and vomiting scale
245,NCT04130854,Pathological Complete Response Rate,2020-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory Immunological Response,Disease free survival
246,NCT00109031,Number of Participants With Severe Oral Mucositis (WHO Grade 3 and 4),2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With WHO Grade 4 Oral Mucositis
247,NCT01929902,Placement of Aquamantys Device,2013-07,COMPLETED,OBSERVATIONAL,['NA'],,Device Complications
248,NCT00005843,,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
249,NCT05451160,30-day complete ablation rate,2022-03-16,RECRUITING,INTERVENTIONAL,['NA'],,Equipment failure rate
250,NCT04852250,Secondary intervention rate,2021-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"Type, incidence, relatedness, and severity of adverse events with severity ≥ Grad 3 (severity according to NCI CTCAE version 5.0)"
251,NCT05889949,Progression-Free Survival (PFS),2019-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Adverse events
252,NCT03878472,Immunotherapy-related biomarkers,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
253,NCT00057382,,2003-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
254,NCT06259149,VTE events within 28 days after surgery,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Any bleeding event within 28 days after surgery
255,NCT05540483,AEs,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],,Overal Survival
256,NCT01499576,Percent Agreement Between Acetic Acid Chromoendoscopy and Endoscopic Biopsy,2011-11,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants With Adverse Events
257,NCT00795301,,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
258,NCT01892527,Study of Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-Resistant MET High Subjects with Locally Advanced or Metastatic Colorectal Cancer with Wild-Type KRAS,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-Resistant MET High Subjects
259,NCT01349309,Functional Oral Intake Scale (FOIS),2007-06,COMPLETED,INTERVENTIONAL,['NA'],,
260,NCT04898504,Overall survival at 2 years,2021-08-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life using EQ-5D-5L
261,NCT02813967,Overall survival,2016-06,COMPLETED,INTERVENTIONAL,['PHASE3'],the oesophagus-specific quality-of-life,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
262,NCT05087459,Comparison of total amount of postoperative drainage fluid between treatment group and control group,2021-06-30,UNKNOWN,OBSERVATIONAL,['NA'],,The change of platelet count from baseline at different time points
263,NCT00003332,,1997-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
264,NCT06268379,RFS,2010-02-15,COMPLETED,OBSERVATIONAL,['NA'],,
265,NCT05675904,disease-free survival,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
266,NCT01435525,Number of Adverse Drug Reactions,2011-09,COMPLETED,OBSERVATIONAL,['NA'],,Rate of H.Pylori eradication
267,NCT02147145,Determine the natural history of small (< 30 mm) SELs discovered evaluated by EUS.,2008-08,COMPLETED,OBSERVATIONAL,['NA'],,"Compare SEL size estimation based on EUS, EGD and computer tomography (CT)."
268,NCT01558583,Participant-reported most important attribute from survey,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,Unlabeled screening test options
269,NCT01271504,Phase 2: Number of Participants With Markedly Abnormal Change From Baseline in Electrocardiograms (ECGs) Parameters,2011-07-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Percentage of Participants With Overall Response
270,NCT06283576,Cancer detection,2024-03-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Overall survival
271,NCT05495685,The sensitivity and specificity of multi-cancer early detection by the combined model in cancer arm and benign disease arm,2022-03-24,RECRUITING,OBSERVATIONAL,['NA'],,Sensitivity and specificity of the blood miRNA-based model in detecting pancreatic cancer.
272,NCT02066701,to determine if assay of aberrantly methylated gene markers can discriminate Barrett's Esophagus tissue (and presence of dysplasia) from esophageal squamous and gastric cardia tissue.,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,Assess the accuracy of candidate markers in stool for detection of Barrett's Esophagus
273,NCT05688761,Gastric adenocarcinoma,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Esophageal cancer
274,NCT05519410,1-year DFS%,2022-08-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,2-year DFS%
275,NCT04821765,Locoregional control rate,2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Radiomics analysis
276,NCT01904942,Proteomic investigations,2008-10,COMPLETED,OBSERVATIONAL,['NA'],,Infrared spectroscopic investigations
277,NCT04476082,Prevalence of Malnutrition According to the Global Leadership Initiative on Malnutrition criteria (GLIM criteria),2020-06-25,COMPLETED,OBSERVATIONAL,['NA'],,Intestinal Microbiome
278,NCT04127864,Cytokines in R848 stimulated blood,2019-10-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Cytokines in unstimulated blood
279,NCT00003596,,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
280,NCT00279292,injection for pain in pancreatic cancer patients at 1 month and 3 months.,2004-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,To estimate the effect of treatment on quality of life at 1 month and 3 month
281,NCT02378948,Functional recovery,2015-10,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life
282,NCT04611711,Overall response rate (ORR),2020-11-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
283,NCT04432870,Interest in colon cancer screening,2020-06-09,COMPLETED,OBSERVATIONAL,['NA'],,Risk perception on COVID-19
284,NCT01506336,overall progression free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
285,NCT05134961,3-year survival,1999-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Duodenal cancer recurrence
286,NCT00914615,"Determine one year local progression free rate, defined as lack of progression within the irradiated volume, using RECIST criteria.",2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Cytokine response to radiation and association with complications
287,NCT05023928,Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0,2021-09-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Disease-free Survival
288,NCT04961918,PFS,2021-07-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS
289,NCT04797624,Comparison of the clinical staging and pathologic TNM staging of the patients,2021-01-15,COMPLETED,OBSERVATIONAL,['NA'],,Comparison of the demographic data
290,NCT01034189,"To determine the clinical response rate in patients with loco-regional esophageal squamous cell carcinoma treated with cetuximab combined with twice weekly paclitaxel/cisplatin concurrent chemoradiotherapy (C-TP-CCRT, 40 Gy).",2008-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Safety and toxicity of cetuximab combined with twice weekly TP-CCRT, followed by surgery."
291,NCT01476631,"Exercise will decrease serum markers (insulin, C-peptide, IL-6 and PGE-2) in a dose response manner.",2008-11,TERMINATED,INTERVENTIONAL,['NA'],,Participants in the 60 minute intervention will have significantly higher physical activity levels (measured by pedometer and accelerometer) than those in the 30 minute intervention at three months.
292,NCT03492164,Number of Adverse Events,2018-03-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
293,NCT04207944,Percent of patients with IPMN progression as measured by a composite of several indicators,2020-07-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Percent of patients with Inflammatory Marker Progression,Percent of patients with cyst progression as measured by radiographic images
294,NCT02584998,The Number of Participants Who Completed the Mailed FIT Test Screening Within 6 Months,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],,The Number of Participants Who Received Any Colorectal Cancer Screening Test in the 6-month Period After Enrollment Into the Study.
295,NCT06278064,Plasma proteins in patients with esophagus cancer,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
296,NCT00041665,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
297,NCT00526617,Pharmacokinetic Profile,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
298,NCT04501887,Progression-free survival,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Positive rate
299,NCT04007640,fibroinflammatory lesions at histology in obese patients,2019-06-18,RECRUITING,INTERVENTIONAL,['NA'],,Biomarkers of pathways activation measured by immunohistochemistry on resected pancreatic parenchyma
300,NCT02785263,The fraction of enrolled patients choosing the lower radiation dose,2016-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Response evaluation assessed by diffusion weighted imaging
301,NCT03977220,Recommended dose for Phase II study,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
302,NCT02418052,Incidence of post-operative cervical esophagogastric anastomotic leakage,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],,
303,NCT00091312,Disease-free survival at 5 years,2004-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Correlation of clinical, histological, and biological prognostic factors with outcome"
304,NCT03670134,Determine association between thickness of neosquamous epithelium measured with volumetric laser endomicroscopy and recurrence of Barrett's esophagus following endoscopic therapy,2018-08-06,WITHDRAWN,INTERVENTIONAL,['NA'],,Develop a volumetric laser endomicrosopy feature scoring index to stratify the risk of disease recurrence in patients with Barrett's esophagus following treatment
305,NCT02452021,Rate of CTCAE acute grade 3 or higher adverse effects possibly attributed to neoadjuvant CRT,2015-07,COMPLETED,OBSERVATIONAL,['NA'],,Assessment of early cardiac toxicity after CRT using cardiac MRI
306,NCT02744729,Semiquantitative Assessment of Esophagus Lesions in 99mTc-3PRGD2 SPECT/CT Scan,2015-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Contrast-enhanced CT
307,NCT03620877,Evaluation of coordinated transmission,2018-09-24,UNKNOWN,INTERVENTIONAL,['NA'],,Adherence to personalized intervention
308,NCT00002897,,1992-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
309,NCT03186326,Progression-free survival (PFS) according to the investigator,2018-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
310,NCT03999658,Objective Response Rate,2023-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of STI-3031
311,NCT03208283,The mean independently performed flexible sigmoidoscopy completion rate in each study group,2014-10-28,COMPLETED,INTERVENTIONAL,['NA'],,Patients' satisfaction
312,NCT05844865,Development of individual patient-derived peritoneal carcinomatosis (pdPC) vascularized micro-tumor (VMT),2023-05-04,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival (OS)
313,NCT06281886,Progression free survival rate,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Distant metastasis-free survival
314,NCT05339581,PVTT RR/NR,2022-05-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Duration of response (DOR)
315,NCT05713994,Number of Patients Amendable to Curative Surgical Interventions,2020-05-19,RECRUITING,OBSERVATIONAL,['NA'],,Quality of Life (QoL) after treatment
316,NCT05247346,Incidence of intervention-emergent adverse events and serious adverse events,2022-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Scattering parameters
317,NCT01775267,Liver free of tumors [ Time Frame: At 3 months ] [ Designated as safety issue: No ],2012-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Postoperative liver and renal function
318,NCT03884179,Accuracy of EUS-FNA vs Radiology,2007-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,Accuracy of EUS FNA vs CEA
319,NCT05048524,The percentage of subjects with R0 resection after surgery,2021-09-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Biomarkers of treatment response by single cell RNA sequencing and whole exome sequencing
320,NCT03854890,The positive number of lymph nodes retrieved,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Detection rate of indocyanine green-positive para-aortic lymph node
321,NCT04714814,recurrence or metastasis provened by imageologic diagnosis (PFS),2021-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,
322,NCT02971956,Overall Response Rate (ORR),2017-01-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients Experiencing Grade 3-4 Treatment-Related Toxicity
323,NCT04778345,Maximum standardized uptake value [SUVmax (for PET/CT only)] for peritoneal carcinomatosis,2021-03,UNKNOWN,INTERVENTIONAL,['NA'],,1-year progression patterns
324,NCT02741401,Change from baseline in anxiety and depression as assessed by Hospital Anxiety and Depression Scale (HADS) questionnaire,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],,Patients' opinion and need about hand-foot massage's utility as assessed by questionnaire
325,NCT05770882,Progression-free survival (PFS),2023-04-25,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to progression (TTP)
326,NCT01384708,to determine whether or not tissue is neoplastic or non-neoplastic,2010-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
327,NCT04538404,New surgical score using preoperative parameters to predict 30-day mortality after colon cancer surgery in the elderly population,2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
328,NCT01482299,4-month progression-free survival,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biomarker assessment
329,NCT01075048,Progression-Free Survival (PFS) Using Computed Best Response Following Treatment With Tivantinib (ARQ 197) in Combination With Irinotecan and Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Received Front-Line Systemic Therapy,2010-01-26,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Treatment-Emergent Infection and Infestation Adverse Events Following Treatment With Tivantinib (ARQ 197) in Combination With Irinotecan and Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Received Front-Line Systemic Therapy
330,NCT03619759,Length of stay,2018-03-22,COMPLETED,OBSERVATIONAL,['NA'],,Time to first successful oral intake
331,NCT00586235,"Primary Endpoints: Global Fiducial Registration Error (FRE) of real-time US and fused CT images, Target Registration Error (TRE) and distance between lesional epicenters of real-time US and fused CT images.",2007-02,COMPLETED,OBSERVATIONAL,['NA'],,Secondary Endpoint: Number of coregistration attempts to realize separation of lesional epicenters of real-time US and fused CT images of ≤2 cm and the number of attempts to realize a separation of ≤0.3 cm.
332,NCT05275985,Overall Survival (OS),2022-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,
333,NCT01512407,1-year recurrence rate,2011-11,COMPLETED,INTERVENTIONAL,['NA'],,Health-related quality of life assessment
334,NCT01395030,Number of Participants Comprising Two Distinct PET/CT Imaging Phenotypes (High FCH Uptake vs. Low FCH Uptake) Between the Different Tumor Sub-classes,2011-08-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,
335,NCT05592886,The incidence of metachronous recurrent colorectal adenoma at year 1 (local or at other sites),2022-12-15,RECRUITING,INTERVENTIONAL,['NA'],,Changes in the levels of bacterial gene markers
336,NCT00624182,Safety (toxicities as assessed by NCI CTCAE version 3),2008-02,SUSPENDED,INTERVENTIONAL,['PHASE1'],,Survival rate
337,NCT03958435,Percentage of Participants with treatment-related Adverse Events as Assessed by CTCAE v4.0 for adjuvant therapy for stage II and stage III colon cancer,2018-11-09,UNKNOWN,OBSERVATIONAL,['NA'],,
338,NCT01464151,low- or high grade dysplasia or colorectal cancer during follow-up,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,
339,NCT04136236,The diagnosis efficiency of Artificial Intelligence,2019-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,Contrast the diagnosis efficiency of Artificial Intelligence with endoscopists
340,NCT02391038,Phase 2- Overall Response Rate,2014-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Phase 2- Number of Participants With ATA in Serum
341,NCT04597710,Proportion of patients for whom clinically-actionable data is provided by whole genome sequencing at the time of surgery.,2021-02-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Proportion of patients for whom actionable biomarkers of drug sensitivity are identified with WGS.
342,NCT01355302,Time to Maximum Concentration (Tmax) of Golvatinib,2011-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Progression (TTP)
343,NCT03930368,the change of glycated albumin,2019-04-15,UNKNOWN,INTERVENTIONAL,['NA'],,the change of uric acid
344,NCT04260191,Number of Participants Who Experienced a Treatment-emergent AE (TEAE),2020-06-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Survival
345,NCT02289053,Prevalence of advanced adenomas among 40-49 year old individuals with and without a family history of colorectal cancer,2006-04-01,COMPLETED,OBSERVATIONAL,['NA'],Risk factors associated with the presence of advanced adenomas,Absolute prevalence of advanced adenomas in 40-49 year old individuals with a family history of colorectal polyps
346,NCT06147492,urinary retention,2016-01-30,COMPLETED,INTERVENTIONAL,['NA'],,
347,NCT00075738,Objective response rate,2003-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
348,NCT01531777,ORR (Objective Response Rate),2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,QoL (Quality of Life)
349,NCT03439085,Objective response rate (ORR),2018-11-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
350,NCT02968069,Accuracy of the diagnostic model in histological prediction of gastric cancerous lesions,2016-12,UNKNOWN,INTERVENTIONAL,['NA'],,
351,NCT02301338,acute healthcare utilization (AHCU) rates,2014-11,TERMINATED,OBSERVATIONAL,['NA'],,
352,NCT01256034,Postoperative Infectious Complication,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Plasma IL-6, CRP, Th1/Th2 Balance"
353,NCT05012397,"Overall Response Rate (ORR) of treatment with milademetan, as defined as the percentage of patients who have achieved confirmed complete response (CR) or Partial Response (PR) according to RECIST v1.1 criteria",2021-11-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
354,NCT05585580,Objective response rate （ORR),2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE
355,NCT04709445,anastomotic leak,2020-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Length of hospital stay
356,NCT02266849,Output weight,2014-10,TERMINATED,INTERVENTIONAL,['PHASE3'],Patient evaluation,Gastrointestinal transit time
357,NCT02479217,Number of Participants with Adverse Events,2006-07,COMPLETED,OBSERVATIONAL,['NA'],,Disease free survival (DFS)
358,NCT02267343,Overall survival,2014-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety will be analyzed through the incidence of laboratory abnormalities
359,NCT05587556,The survial rate of the patients,2022-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
360,NCT02464618,Compliance with scheduled upper endoscopy and colonoscopy,2014-06-26,COMPLETED,INTERVENTIONAL,['NA'],Social contact's activity,Bowel preparation quality
361,NCT02535117,Overall survival,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0
362,NCT04322539,Overall Survival (OS),2020-08-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Health Care Resource Utilization: Number of Participants With Any Concomitant Medications Prescribed
363,NCT05210049,Sensitivity and Specificity of Esocheck/Esoguard in a Veteran population,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Cost of two screening strategies
364,NCT00242086,,2004-10,COMPLETED,INTERVENTIONAL,['NA'],,
365,NCT04913480,Progression-free survival at 1 year,2020-10-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Changes in PD-L1 and PD-1 positive circulating tumor cells before and after stereotactic body radiation therapy and durvalumab
366,NCT06090994,3-year disease-free survival rate (DFS),2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Changes in carcinoembryonic antigen (CEA) compared to baseline period (difference),"The incidence and severity of adverse reactions (ADR), severe adverse reactions (SADR), suspicious and unexpected severe adverse reactions (SUSAR)"
367,NCT06018077,Dİetary Total Antioxidant Capacity (DTAC),2022-10-15,RECRUITING,OBSERVATIONAL,['NA'],,
368,NCT00004256,,1997-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
369,NCT04701060,objective response rate,2021-01-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],To investigate the clinical efficacy of PD-L1 expression in predicting the combination of Camrelizumab and apatinib,Feasibility as measured by rate of enrollment
370,NCT03008499,Relief degree of tumors,2016-12-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
371,NCT02657044,Recurrence rate at follow-up colonoscopy after 6 months,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],,R0-resection rate
372,NCT04612712,Phase II part - Objective response rate(ORR),2021-01-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-Free Survival (PFS)
373,NCT04931420,Progression Free Survival,2025-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The Effect of Interventions on Circulating Tumor DNA (ctDNA)
374,NCT05359406,Early Tumor Shrinkage,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Acute toxicity associated with immunotherapy
375,NCT05465590,Volume of distribution (VZ),2022-12,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,
376,NCT00719199,• The primary objective of this study is to determine the recommended phase 2 dose of IMO 2055 when combined with FOLFIRI and cetuximab in patients with histologically proven advanced or metastatic colorectal cancer (CRC).,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,• To investigate potential markers of IMO 2055 immune activation and effect on cellular immunity.
377,NCT01914744,Incidence rate of HBV reactivation,2013-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of drug resistance of viral variants,Incidence rate and median time of HBV DNA level normalization
378,NCT03791398,Progression Free Survival,2019-11-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
379,NCT01413295,Progression Free Survival,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
380,NCT03730948,Adverse events experienced by subjects (i.e. safety of DC vaccine in subjects with surgically resected hypermutated CRC),2019-03-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Percentage of CD8+ cells in primary tumor tissue
381,NCT02439086,Accuracy of Texture analysis PET-CT,2015-09,UNKNOWN,INTERVENTIONAL,['NA'],,Accuracy of Texture analysis MRI
382,NCT00718211,,2006-05,COMPLETED,OBSERVATIONAL,['NA'],,
383,NCT02797197,"number of handgrip strength test measures per patient, number of handgrip test measures compared to the number of day hospitalisations, number of patients who had all of the measures, between 50 and 100% of measures, less than 50% of measures",2016-05-18,COMPLETED,INTERVENTIONAL,['NA'],,to study the association between the evolution of hand grip strength test and the evolution of nutritional indices (anthropometric and biologic)
384,NCT03744962,Frequency of microsatellite instability,2018-11-10,UNKNOWN,OBSERVATIONAL,['NA'],,
385,NCT00901173,Esophageal squamous cell carcinoma,2014-02-10,COMPLETED,OBSERVATIONAL,['NA'],,
386,NCT00746161,The %body weight ratio,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,"preoperative complication, PNI and QOL score"
387,NCT05385692,Phase Ib: Recommended Phase II Dose (RP2D),2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free Survival (PFS)
388,NCT04233840,"Phase II portion - Recurrence-free survival (defined as the time from randomization to HCC recurrence or death from any cause, whichever occured first)",2019-02-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,HBsAg level
389,NCT05434520,30-day Readmission,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Histological Specimen
390,NCT06189560,Video fluoroscopic swallowing study,2022-06-21,TERMINATED,INTERVENTIONAL,['NA'],,Rosenbek penetration-aspiration scale
391,NCT05641922,Safety,2023-07,WITHDRAWN,INTERVENTIONAL,['NA'],Assessment Module (2),Assessment Module (1)
392,NCT00529984,determine the safety of immunization with CEA(6D) VRP,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,evaluate CEA-specific immune response to immunizations
393,NCT02987907,proportions of participants with severe adverse events according to CTCAE v4.03,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,time to progression (TTP)
394,NCT00197405,,1999-08,UNKNOWN,OBSERVATIONAL,['NA'],,
395,NCT00696345,,2005-01,COMPLETED,OBSERVATIONAL,['NA'],,
396,NCT04764240,OS,2003-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
397,NCT03881501,PFS,2019-03-05,UNKNOWN,OBSERVATIONAL,['NA'],,Safety as measured by number and grade of adverse events
398,NCT02571036,Expansion Phase: Assess Antitumor Activity of DCC-2618 in all diseases,2015-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Escalation Phase: Assess Antitumor Activity of DCC-2618 in patients with advanced malignancies
399,NCT05988372,R0 Surgical Resection Rate,2023-10-23,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life (QOL)
400,NCT02269332,Adenomatous Polyps,2014-08,COMPLETED,OBSERVATIONAL,['NA'],,
401,NCT01465464,Overall Survival(OS),2010-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,Time to Transcatheter Arterial Chemoembolization (TACE) Failure
402,NCT03130166,Postoperative recovery,2018-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Whole blood gene expression profiling
403,NCT03233711,Disease free survival,2018-07-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of toxicities
404,NCT02959359,The primary objective of the study is annual recurrence-free survival after curative resection of HCV-HCC for up to 5 years.,2016-11,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Overall survival
405,NCT03172416,Tolerability of PIPAC with oxaliplatin in combination with IV nivolumab by monitoring dose limiting toxicities,2017-04-12,RECRUITING,INTERVENTIONAL,['PHASE1'],,Area under the curve (AUC) of oxaliplatin and in combination with IV nivolumab administered via PIPAC using blood drawn from patient.
406,NCT01386346,Evaluation of dose limiting toxicity (DLT),2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
407,NCT05114213,Mean cumulative pain index,2021-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Death from any cause
408,NCT00842244,Number of Participants With Cycle 1 Dose-limiting Toxicities (DLTs),2009-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Cisplatin and Capecitabine,Progression-Free Survival (PFS)
409,NCT05400681,Relative frequency of ctDNA in peritoneal lavage and peripheral blood,2020-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Prognostic value of ctDNA in peritoneal lavage and peripheral blood
410,NCT04780789,Interobserver variability of the methods used for assessing tumor response to the treatment,2015-02-01,COMPLETED,OBSERVATIONAL,['NA'],,"Response to the treatment, as assessed by volumetric analysis"
411,NCT00667641,Maximum tolerated dose of paclitaxel in combination with bortezomib,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
412,NCT03407495,The Sensitivity and specificity of IOP-enhanced MRI,2018-11-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,The size of lesions detected in liver
413,NCT05162248,Disease-Free Survival,2021-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
414,NCT00851968,overall survival,2008-12,COMPLETED,INTERVENTIONAL,['NA'],,"serum alanine aminotransferase (ALT), bilirubin, prothrombin time, serum albumin and pre-albumin on postoperative 1, 3, 7 day, resection rate, procedure-related complications and hospital mortality,expression of HIF and P-, E-, and L-selectin"
415,NCT03236051,Numeric rating scales (NRS) score with 24 hours after the surgery,2017-02-10,UNKNOWN,INTERVENTIONAL,['NA'],,Prealbumin
416,NCT06162468,The proportion of patients in whom EUS-PCA was completed as planned.,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The IPMN complete response rate in the injected lesion(s) on imaging 3 months post-EUS-PCA.
417,NCT03613142,Rate of reflux esophagitis after operation,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,postoperative quality of life
418,NCT03113214,Maximum Tolerated Dose,2017-02-02,COMPLETED,INTERVENTIONAL,['NA'],,Time to Local Failure
419,NCT01932918,lung injury score,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
420,NCT01545544,"presentation of NHL and HCV infection, and treatments of NHL and HCV infection",2006-11,UNKNOWN,OBSERVATIONAL,['NA'],,haematological response
421,NCT02438839,Proportion of patients with locoregional tumor control with chemoradiation alone two years after end of treatment,2015-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"Response and tumor control on MRI scans compared to clinical observations, including rectoscopic examination"
422,NCT02480114,"Change in Pain Associated With Radiation-induced Mucositis, (Pain Subscale of the Vanderbilt Head and Neck Symptom Survey (VHNSS))",2015-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Frequency and Severity of General Systemic Symptoms (Surveys Such as the Neurotoxicity Scale, Profile of Mood States, and Quality of Life Form)"
423,NCT05667298,Safety (proportion of patients developing Grade 3 or above adverse events),2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free survival
424,NCT02423811,Progression-free survival,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
425,NCT06006286,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-08-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
426,NCT02836925,SVR12,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity - Incidence of Adverse Events
427,NCT04576208,Number of Participants with Treatment Emergent Adverse Events (TEAEs) of ≥Grade 3 Diarrhea Occurring During the First 4 Cycles of TAK-788 Dosing,2020-11-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Health-Related Quality of Life (HRQoL) as Assessed by Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) Score
428,NCT06015035,Primary Endpoints: pCR,2021-04-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
429,NCT05622825,Image Assessment,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life assessment.
430,NCT00153881,To determine the maximum tolerated dose of oral capecitabine in combination with fixed doses of weekly docetaxel and concurrent radiation for the treatment of patients with clinical stage II-III cancer of the esophagus and gastroesophageal junction.,2000-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To investigate the feasibility of assaying thymidine phosphorylase, cyclin B, MPM-2, and perturbations in cell cycle as potential markers of efficacy."
431,NCT00829595,"Response, defined by postvaccination antibody titers",2005-05,COMPLETED,INTERVENTIONAL,['NA'],,
432,NCT06261125,Progression-free survival (PFS),2024-03-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation between serum cytokines and overall survival and immune-related adverse events,Treatment-related adverse events
433,NCT03385018,3 year relapse-free survival,2018-04-05,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life(EORTC QLC STO22)
434,NCT05659381,Progression-free survival,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Residual Disease
435,NCT05495217,Operative time,2021-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Tumor size
436,NCT04126733,Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Assessed by Investigator,2019-10-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5
437,NCT03057288,Success rate evaluation of the placement of two fiducial markers,2017-02-03,COMPLETED,INTERVENTIONAL,['NA'],,The presence of the markers at the end of the radiotherapy
438,NCT02907385,Incidence of overall anastomotic leak,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Incidence of post operative anastomotic leaks
439,NCT05443087,Trough concentration (Ctrough),2022-08-29,RECRUITING,INTERVENTIONAL,['NA'],,Safety: drug toxicity
440,NCT00819208,Disease-free survival,2009-06-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Predictors of physical activity adherence as assessed by Social Cognitive Determinants of Exercise questionnaire
441,NCT03753659,Objective response rate (ORR) according to RECIST 1.1,2019-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Identification of molecular biomarkers in tumor tissue and blood samples by immunohistochemical and molecular analyses in a central lab
442,NCT05436275,Nasal Congestion Score (NCS),2022-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Anti-drug antibodies (ADA)
443,NCT06105515,Severe complication,2023-12,RECRUITING,INTERVENTIONAL,['NA'],,Health-related quality of life
444,NCT05431244,Objective Response Rate (ORR),2022-07-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Best Overall Response Rate (BOR)
445,NCT04365751,Overall survival,2019-12-26,RECRUITING,INTERVENTIONAL,['NA'],,Local rate of progression
446,NCT03233555,Use of preventive services,2013-09-03,COMPLETED,INTERVENTIONAL,['NA'],,
447,NCT03742453,Diagnostic performance of CEUS for diagnosing HCC,2018-10-16,UNKNOWN,INTERVENTIONAL,['NA'],,Diagnostic performance of gadoxetic-acid liver MRI for diagnosing HCC using KLCSG-NCC guidelinev2018
448,NCT00332280,Improvement in clinical benefit response,2006-05,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Safety and tolerability
449,NCT01324284,Quality of bowel preparation in Same day Low volume PEG with placebo versus same day low volume PEG with Lubiprostone,2011-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
450,NCT01189877,Measure pO2 in rectal cancers,2010-08,COMPLETED,INTERVENTIONAL,['NA'],,Correlate immunohistochemical analysis of endogenous markers of hypoxia
451,NCT03879395,Overall survival,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Complications according to Clavien-Dindo within 90 days.
452,NCT03589443,Validate the binding of the peptides using the SFE,2018-05-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Use of the SFE to detect QRH and KSP via contrast
453,NCT05282433,Progression-free survival,2022-04-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,
454,NCT02376452,progression free survival,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,quality of life questionnaire
455,NCT02873598,The Maximum Tolerated Dose (MTD) of Stereotactic Body Radiotherapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients Who Have Not Developed Distant Progression After Induction Chemotherapies.,2016-11-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Quality of Life (QOL)
456,NCT05251038,Objective Response Rate (ORR),2022-09-13,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
457,NCT02495311,The corrleation coefficient between the size of myoma and Overactive Bladder Symptoms Scores,2014-11-15,RECRUITING,OBSERVATIONAL,['NA'],,Comparisons of the constipation/diarrhea rates between the adenomyosis group and the control group
458,NCT00103142,Recurrence-free Survival at 2 Years,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Positive Immune Response as Measured by (Enzyme-linked Immunosorbent Spot) ELISpot Assay
459,NCT00639522,Dose limiting toxicity,2008-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics
460,NCT04634357,The recommended phase 2 dose (RP2D) regimen of ET140203 T cell therapy primarily based on DLT,2022-07-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the pharmacokinetics of ET140203 T cells after infusion.
461,NCT05431621,Establish and evaluate the non-invasive early detection model for hepatocellular carcinoma,2020-11-15,RECRUITING,OBSERVATIONAL,['NA'],,
462,NCT04303403,Maximum Tolerated Dose,2018-07-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival
463,NCT00003018,Overall Survival,1997-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Resectability of patents who respond to this regimen
464,NCT04133155,Progression-free survival,2019-09-16,COMPLETED,OBSERVATIONAL,['NA'],,Toxicity profile
465,NCT00827684,Objective response rates,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Translational Research
466,NCT04587310,endoscopy performed on patients,2008-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
467,NCT01429038,"Incidence of infections (bacterial, viral, fungal, parasitic) and cancers",2012-02-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Anti-MSC donor HLA antibodies.
468,NCT02421536,"Change from baseline in ""out of clinic"" pain at 2 months",2016-01-14,COMPLETED,INTERVENTIONAL,['NA'],,Change from baseline mucositis pain at 2 months
469,NCT04317248,"Progression-Free-Survival (PFS), month",2020-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events
470,NCT01577758,AUC0-21 Days: Area Under the Curve Day 0 to Day 21 for MMAE,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Antitherapeutic Antibodies (ATA)
471,NCT02375958,Incidence rate of dose limiting toxicities,2015-04-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic paramater Tmax
472,NCT00026273,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
473,NCT03937830,"To evaluate the 6-month PFS in patients with BTC and HCC BCLC stage C treated with bevacizumab, durvalumab and tremelimumab",2021-03-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,"To determine the safety and feasibility of bevacizumab, durvalumab, tremelimumab in patients with advanced BTC"
474,NCT00737646,Changes in colorectal cancer screening rates (4 modalities),2009-07,COMPLETED,INTERVENTIONAL,['NA'],,"Changes in measures of attitudes, beliefs, opinions, and social influence surrounding CRC screening among patients, clinicians, and clinical staff."
475,NCT01831245,Pathological Anatomic diagnosis (PAD) on a tumor biopsy,2011-01,COMPLETED,OBSERVATIONAL,['NA'],Leakage of anastomosis,C - reactive protein
476,NCT00605150,Progression,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants With Unacceptable Side Effects After Treatment
477,NCT06318793,Concentration of C-reactive protein (CRP),2012-09,COMPLETED,OBSERVATIONAL,['NA'],,
478,NCT05573282,Progress Free Survival,2022-10-16,RECRUITING,OBSERVATIONAL,['NA'],,Tumor Response
479,NCT04151355,incidence of mucositis,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,serum levels of tumor necrosis factor α (TNF-α)
480,NCT05810792,Incidence and severity of Treatment-Emergent Adverse Events as assessed by NCI-CTCAE,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Carbohydrate antigen 19-9
481,NCT05971069,The safety and efficacy of the decision algorithm for the aberrant left hepatic artery preservation/ligation with real time near-infrared fluorescence imaging,2021-12-17,COMPLETED,INTERVENTIONAL,['NA'],,Number of participants with liver-related postoperative complications as assessed by serum aspartate transaminase(AST) and alanine transferase(ALT)
482,NCT05213312,Pathological Complete Response (pCR) rate,2022-06-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of Treatment-Emergent Adverse Events
483,NCT06298916,Primary Part 2 - Correlation of 64Cu-LNTH-1363S biodistribution with Immunohistochemistry FAP expression,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Exploratory Part 1 and Part 2,Secondary Part 2 Validate optimal radioactivity in patients with sarcoma or GIT cancer
484,NCT04377048,response rate,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
485,NCT05578287,Feasibility,2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
486,NCT04704661,Differential pharmacodynamic (PD) profile of tumor tissue (DNA damage & repair) (Dose expansion phase),2021-08-09,RECRUITING,INTERVENTIONAL,['PHASE1'],"Association of TP53, ATM, and RAS mutations with ORR",PD markers
487,NCT05612347,"Incidence of advanced neoplasia in each study group, annual FIT and colonoscopy, assessed by comparing the detection of advanced neoplasia between the two study groups.",2023-06-14,RECRUITING,INTERVENTIONAL,['NA'],,"Major and minor harms within 30 days of colonoscopy, as measured through chart review and telephone interview."
488,NCT04581876,progression free survival,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
489,NCT01575574,hepatocellular carcinoma diagnosed,2012-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,magnetic resonance imaging sensitivity
490,NCT04481828,Tumor stage (American Joint Committee on Cancer 8th Edition),2014-01,COMPLETED,OBSERVATIONAL,['NA'],,
491,NCT06191185,Colonoscopy completion,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Scheduled by GI for colonoscopy
492,NCT00815113,"Characterization of the high-rik individual for gastric cancer - ""Gastric Cancer Phenotype""",2009-10,COMPLETED,OBSERVATIONAL,['NA'],,Establish a screen plan for high-risk population for gastric cancer
493,NCT03187028,Feasibility - Participant satisfaction,2017-08-03,COMPLETED,INTERVENTIONAL,['NA'],,Wearable activity monitor (weekly minutes of physical activity)
494,NCT00151671,Factor V at day 3 after surgery,2003-04,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Infections
495,NCT01341210,The influencing factors of behavior intentions towards participating in clinical trials,2011-02,UNKNOWN,OBSERVATIONAL,['NA'],,The subjective norm and behavior intentions towards clinical trials in cancer patients
496,NCT01227772,Optimal dosing schedule,2010-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Induction of specific cytotoxic T-lymphocyte (CTL) response
497,NCT04951804,Change in Likert pain scores,2021-10-07,RECRUITING,INTERVENTIONAL,['NA'],,Difference in Global Rating Scale of Change at T3 vs all other follow-up time points
498,NCT04612569,Impact of a multimodal package of prehabilitation and rehabilitation in patients with low anterior resection syndrome,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Assessment of the improvement of pelvic floor contractility
499,NCT05851534,Time to functional recovery,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Evaluation of quality of life for cancer patients
500,NCT03476421,Rates of local recurrence,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
501,NCT05117723,Risk stratification for patients with IPMN into those that require more intensive screening and possibly intervention versus those that are unlikely to progress to malignancy.,2021-08-26,RECRUITING,OBSERVATIONAL,['NA'],,
502,NCT02557724,post operative liver injury,2015-09,COMPLETED,OBSERVATIONAL,['NA'],,(AST) Aspartate Aminotransferase
503,NCT00408772,Conversion rate of nonresectable disease to resectable disease,2007-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Duration of response
504,NCT00729677,Number of Participants by History of Nausea Who Reported Nausea During the First Week of Chemotherapy,2005-06,COMPLETED,OBSERVATIONAL,['NA'],,
505,NCT01380262,number of patients with a severe skin toxicity,2010-06,UNKNOWN,OBSERVATIONAL,['NA'],,quality of life assessed with DLQI
506,NCT03433703,Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs),2018-04-26,TERMINATED,INTERVENTIONAL,['PHASE2'],,Time to Progression (TTP)
507,NCT04135690,Progression free survival rate at 6 months,2019-10-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
508,NCT04111380,Objective Response Rate [ORR],2019-09-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
509,NCT04569799,No Viable Disease on CT/MRI Imaging.,2020-10-14,COMPLETED,INTERVENTIONAL,['PHASE4'],,Lesions Missed or Miscategorized on CT/MRI Imaging.
510,NCT00826501,Compare median time to pseudocyst recurrence between patients undergoing EUS or Surgical Cysto-gastrostomy,2009-01,COMPLETED,INTERVENTIONAL,['NA'],Compare pain medication usage,Median time to pseudocyst recurrence at 24 month follow-up.
511,NCT00316745,PFS of 1st line treatment,2006-04,SUSPENDED,INTERVENTIONAL,['PHASE3'],,safety
512,NCT03377361,Objective response rate (ORR) by investigator (Part 1B and Part 2),2018-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests
513,NCT05327517,Overall Survival,2022-04-10,RECRUITING,INTERVENTIONAL,['NA'],,Laryngo-esophageal dysfunction free survival
514,NCT02600949,Incidence of adverse events (AEs),2016-05-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Levels of intracellular cytokine staining of T cells
515,NCT01756183,radical resection rate,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival time
516,NCT02547480,Area Under the Curve (AUC),2015-11,COMPLETED,INTERVENTIONAL,['NA'],,Technical success - total dose delivered
517,NCT05015296,1-year recurrence-free survival after surgery,2021-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
518,NCT00444041,The primary objective of this study is the Resectability (R0) rate after neoadjuvant Bevacizumab in potentially resectable mCRC.,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
519,NCT05227378,Objective Response Rate (ORR),2022-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Lymphocyte
520,NCT04263948,Rates and grades toxicity and early tumor responses,2021-06-01,RECRUITING,INTERVENTIONAL,['NA'],,
521,NCT02658019,Number of Participants With Treatment-Related Adverse Events,2016-05-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response (DoR)
522,NCT02319018,"Maximum tolerated dose and the recommended phase II doses of mFOLFOX given in combination with alisertib, defined as the dose level at which the probability of dose limiting toxicities is 30%",2015-08-27,COMPLETED,INTERVENTIONAL,['PHASE1'],Tumor expression by immunohistochemistry,"Anti-tumor activity associated with this treatment, evaluated using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors version 1.1"
523,NCT03063918,Quality of life assessed by City of Hope-Quality of Life-Colorectal Cancer,2017-04-28,COMPLETED,INTERVENTIONAL,['NA'],Scores from the Decisional Conflict Scale,
524,NCT02423785,Changes in retinal surface before and after therapy as measured by optical coherence tomography,2014-05,TERMINATED,OBSERVATIONAL,['NA'],,
525,NCT05330429,Randomized Cohort: Progression-free Survival (PFS) as Determined by Investigator Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,2022-07-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety Run-in and Randomized Cohorts: Antidrug Antibodies (ADA) to Magrolimab
526,NCT02605044,Overall survival,2014-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival (PFS)
527,NCT04505696,Pre-post Questionnaire,2020-08-05,COMPLETED,INTERVENTIONAL,['NA'],,
528,NCT05588388,6- month Progression Free Survival (PFS) rate,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Tissue and blood based biomarkers,Incidence of adverse events
529,NCT04425564,Peak and trough levels of capecitabine and relation to dosing,2016-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
530,NCT03771508,Prospective collection of PillCam SB3 videos,2018-12-13,RECRUITING,OBSERVATIONAL,['NA'],,
531,NCT02333188,"DLT rate in course 1 for each of the three genotype groups, graded according to NCI CTCAE v 4.0",2014-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Cumulative doses of the drugs will be calculated as the sum of all doses received on protocol therapy for each patient
532,NCT02949258,2-year survival rate,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,in-hospital mortality rate
533,NCT01362582,Questionnaire EORTC - Quality of Life,2010-03,TERMINATED,INTERVENTIONAL,['PHASE3'],,Assessment of nutritional status
534,NCT00416351,Response Rate for Participants With Non-Hodgkin's Lymphoma,2006-06-27,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Participants Evaluated for Toxicity
535,NCT03983174,fecal incontinence,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
536,NCT05985109,Overall response rate,2023-10-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,treatment-related adverse event
537,NCT02235246,pain score,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,
538,NCT03795311,Number of Participants with Acute toxicities as a Measure of treatment specific Safety and Tolerability,2018-11-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
539,NCT05903703,Evaluation the clinical disease progression (PD) at 6 weeks intervals,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
540,NCT04741308,Change from baseline immune function at follow-up.,2021-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Change from baseline chemotherapy response at follow-up.
541,NCT06252142,International Prostate Symptom Score (IPSS),2024-02-19,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Treatment-related toxicities
542,NCT00669370,To determine the quality of life (EORTC QLQ-C30 and QLQ-STO22),2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"To evaluate time to progression (TTP), overall response rate (ORR) and overall survival (OS)."
543,NCT06301386,objective response rate (ORR),2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,advert events
544,NCT03803254,Overall Survival (OS),2019-01-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
545,NCT04380337,Clinical complete response (cCR),2020-05-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
546,NCT01411176,The proportion of patients had no or mild peristalsis during the therapeutic procedures,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events and adverse drug reactions
547,NCT00250822,"Response Rate ( CR + PR rate); namely, to determine response rate to the Gemcitabine and Oxaliplatin combination administered to patients with hepatocellular cancer. Furthermore, patients who achieve a response leading to tumor respectability.",2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
548,NCT03253536,Quality of life,2017-07-10,RECRUITING,OBSERVATIONAL,['NA'],,correlation Qol with late toxicity
549,NCT01769248,Diagnostic Yield of EUS-FNB and EUS-FNA,2012-09,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Patients in Whom a Diagnosis is Achieved After Crossover (%)
550,NCT04540146,cytokine levels,2020-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
551,NCT04761172,Primary tumor detection,2020-06-17,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Tumor to background ratio
552,NCT05730595,Overall survival,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Function score
553,NCT01617382,To improve the prognosis/survival of patients with malignancies localized on the peritoneal surface.,2012-05,RECRUITING,OBSERVATIONAL,['NA'],,
554,NCT06266832,Organ retention rate,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,QoL
555,NCT03595540,Quantification of FMD-emergent adverse events,2017-11-22,COMPLETED,INTERVENTIONAL,['NA'],,
556,NCT02788214,Bacterial DNA sequence,2016-07-27,TERMINATED,OBSERVATIONAL,['NA'],,
557,NCT00896467,Adjustment strategies and emotional regulation as assessed by the WCC and ERQ questionnaires,2007-09,TERMINATED,OBSERVATIONAL,['NA'],,
558,NCT01288625,Incidence and duration of oral mucositis,na,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,
559,NCT03682289,Objective response rate (ORR) for endometrial cohort,2019-01-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall percent change in tumor size
560,NCT03755440,Response rate,2018-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
561,NCT00031863,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
562,NCT03843749,Objective Response Rate(ORR),2019-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,
563,NCT04599179,Quality of life (QoL) after endoscopic or surgical treatment,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
564,NCT00262210,We expect to enter 25 patients per year and finish accrual of patients within 4 years.,1995-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
565,NCT02789826,The number of lymph nodes in the postoperative spicement.,2016-06,COMPLETED,INTERVENTIONAL,['NA'],,Duration of Surgery
566,NCT02470533,Time to progression,2015-04-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of life
567,NCT00074009,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
568,NCT04440930,Incidence of oral mucositis grade 2 or higher as measured by the Revised Oral Assessment Guide.,2020-09-02,COMPLETED,INTERVENTIONAL,['NA'],,Date of onset of oral mucositis grade 2 or higher as measured by Revised Oral Assessment Guide.
569,NCT02560974,Disease-free survival rate,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events
570,NCT04052152,Adverse reaction rate,2019-06-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
571,NCT04650451,Maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE),2020-12-07,SUSPENDED,INTERVENTIONAL,['PHASE1'],,Antitumor activity of BPX-603
572,NCT01860144,Objective response rate,2012-06,UNKNOWN,OBSERVATIONAL,['NA'],,resection rate
573,NCT04391933,Is MRI usefull in colon cancer patients,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],,
574,NCT05545124,1-year recurrence-free survival,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events
575,NCT04823793,Sensitivity and specificity of methylation biomarker and FIT for adenoma and colorectal cancer screening,2021-03-31,UNKNOWN,OBSERVATIONAL,['NA'],,
576,NCT01443481,Pharmacokinetic (PK) parameter of AUCinf following a single dose of TKI258,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics and Hepatic Function Abnormalities
577,NCT05661357,ORR,2023-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,
578,NCT01524848,Disease control rate,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall response rate
579,NCT04303429,Disease Free Survival (DFS),2020-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Cost Utility Analysis,Overall Survival (OS)
580,NCT01830647,Safety: Incidence of adverse events,2013-04,COMPLETED,OBSERVATIONAL,['NA'],,Efficacy: Time to disease progression
581,NCT05233553,Incidence of SSC-COVID in hospitalized COVID-patients of the first wave,2020-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
582,NCT02046278,Assessment of the overall Subject safety by incidence of pre specified procedure related Adverse Events.,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Performance Rate of anastomotic leak (both radiological and clinical leaks)
583,NCT05883176,Objective response rate (ORR) by RECIST 1.1 and mRECIST,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-related adverse events,Median overall survival time (mOS)
584,NCT05587738,Prevalence of type-specific HPV types,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
585,NCT03174444,Colorectal Cancer Screening,2017-08-15,COMPLETED,INTERVENTIONAL,['NA'],,
586,NCT00636883,"Response rate (partial and complete response, stable disease, and progressive disease)",2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
587,NCT01239095,Number of patients with adverse events or complications,2011-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,
588,NCT00379782,subject satisfaction with navigation,2006-10,COMPLETED,INTERVENTIONAL,['NA'],,
589,NCT04606914,Radiographic tumor assessment per RECIST v1.1 criteria,2021-05-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety profile of treatment with carboplatin-mirvetuximab soravtansine according to CTCAE v4.03
590,NCT02188342,VO2 peak,2015-01,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life
591,NCT00275951,Confirmed objective response rates,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Progression-free survival (PFS), overall survival (OS), treatment-related toxicity"
592,NCT04045236,Distant recurrence,2021-10-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Quality of life Scale (QOLS)
593,NCT04532515,Proportion of surgeries with full sealant coverage - successful application,2021-02-01,COMPLETED,INTERVENTIONAL,['NA'],,Hospital length of stay
594,NCT05821582,Primary Objective- Intestinal side effects of chemotherapy,2023-03-27,WITHDRAWN,OBSERVATIONAL,['NA'],,
595,NCT05747482,disease free interval,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,postoperatory mortality
596,NCT00078897,Median Selenium Blood Levels at One Year.,2005-01-20,TERMINATED,INTERVENTIONAL,['PHASE3'],,
597,NCT02473003,Change in Fatigue,2015-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Treatment completion rate
598,NCT00525915,Pathologic Complete Response Rate,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
599,NCT04804696,Pathologic complete response rate,2021-02-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
600,NCT01245816,Efficacy of Eflornithine plus Sulindac compared to Eflornithine alone and Sulindac alone determined by change in the number of polyps 2 mm or greater in a defined focal area of the rectum or pouch at baseline and after completion of the study treatment.,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Presence of high grade dysplasia or villous adenoma in any polyp resected.
601,NCT00582400,Number of Patients With Response to Treatment (RECIST Criteria),2004-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
602,NCT03306693,Change in patient emotional skills from baseline to 15 days after intervention,2017-10-26,TERMINATED,INTERVENTIONAL,['NA'],,Patient satisfaction
603,NCT00915863,the incidence of pancreatic fistula,2009-06,UNKNOWN,INTERVENTIONAL,['NA'],,"the incidence of other postoperative complications, mortality, delayed gastric emptying, intra-abdominal hemorrhage, and intra-abdominal abscess"
604,NCT00938080,"Safety (Adverse Events, laboratory assessments and the presence of sAGX0085 bacteria in blood)",2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Pharmacokinetics of serum samples, buccal smears and saliva samples"
605,NCT00478946,maximum tolerated dose,2006-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,safety and efficacy
606,NCT04896684,Biological collection associated with clinical data,2021-04-29,RECRUITING,OBSERVATIONAL,['NA'],,Optimize treatment success rates for IBD
607,NCT03869034,Progression Free Survival (PFS) assessed by RECIST 1.1,2019-03-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Biomarkers of treatment response by single-cell RNA sequencing,Recurrence-free survival (RFS)
608,NCT01068327,Maximally tolerated dose (MTD) of stereotactic radiotherapy and concurrent nelfinavir mesylate,2007-11-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacogenomic status of CYP2C19*2 (G681A) (correlative)
609,NCT01437007,"To evaluate feasibility of administering TKM-080301 via HAI, and establish MTD and DLT.",2011-08-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate the potential conversion rate from unresectable to resectable disease.
610,NCT03829462,Overall survival,2019-03-28,RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to Deterioration
611,NCT03690921,Acute Toxicity,2018-11-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Complete Response at 24 Weeks
612,NCT02534233,Number of patients with treatment-related adverse events (pain and dysphagia),2015-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Histological evaluation of treatment zone for intestinal metaplasia (BE patients)
613,NCT04961138,1-year disease free survival,2021-08,UNKNOWN,INTERVENTIONAL,['NA'],,objective response rate
614,NCT02436902,Overall survivals,2019-02-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Recurrence rates
615,NCT02989922,6-month Overall Survival Rate,2016-11-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
616,NCT03428958,"Number of patients with treatment-emergent clinically significant changes in laboratory parameters, ECG changes, or changes in physical examinations",2018-10-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tolerability of NUC-3373 in each combination cohort measured by dose intensity in Cycle 1
617,NCT05426135,"Treatment response of anti-cancer therapy at first evaluation in patients with lung/stomach/colorectal cancer (CR, PR, PD, SD).",2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
618,NCT05959395,"Safety of the VectRx treatment evaluated by incidence of Adverse events (AEs) such as first and second-degree burns, edema and abdominal pain, will be assessed [safety and tolerability].",2023-08-15,RECRUITING,INTERVENTIONAL,['NA'],,
619,NCT03297996,Prevalence and relative abundance of selected fecal microbial taxa,2011-11-23,COMPLETED,OBSERVATIONAL,['NA'],,
620,NCT00247260,"This is a multicentre, open label study to evaluate the safety and efficacy of three escalating radioactivity levels (MBq) of 32P BioSiliconTM in patients with unresectable hepatocellular carcinoma",2005-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To evaluate the association between tumour marker serum alpha-fetoprotein (AFP) and target tumour response with the three radioactivity levels (MBq)
621,NCT05391477,Comparison of the AIOD and HOD negative predictive value (NPV) for adenoma in rectosigmoid polyps ≤ 5 mm with respect to histology,2023-02-27,RECRUITING,INTERVENTIONAL,['NA'],,Proportion of patients accepting to have their polyps diagnosed by the AI system or human optical diagnosis (designed questionnaire)
622,NCT04687163,Overall survival,2020-12-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Events
623,NCT02728921,Change in plasma volume,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4'],"Change in heart rate, change in central venous oxygen saturation, change in haemoglobin concentration in blood, change in blood pressure, change in central venous pressure, change in plasma lactate and diuresis.",Incidence of postoperative complications
624,NCT00904839,Progression-free Survival Rate at 9 Months (PFS-9),2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Exploratory Biomarker and Pharmacogenetic Analysis for VEGF
625,NCT06001268,Participant Rating on Ease of Use the Mobile Application - Usability,2023-08-14,RECRUITING,INTERVENTIONAL,['NA'],,Malnutrition -Nutritional Status
626,NCT04915807,Progression-free survival,2021-06,UNKNOWN,OBSERVATIONAL,['NA'],,Adverse events of special interest
627,NCT06325891,Microbiome analysis using gastric mucosal brushing,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Microbiome analysis using gastric mucosal biopsy
628,NCT00780494,Progression-Free Survival (PFS),2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Vascular Endothelial Growth Factor Tumor Response Biomarker
629,NCT02753127,Overall Survival (OS),2016-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Patients With Adverse Events in the General Population
630,NCT01730586,Response Rate in CIMP-High Colorectal Cancer and Small Bowel Adenocarcinoma (SBA),2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival (PFS)
631,NCT05338866,3-year progression free survival rate,2022-01-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Patients' quality of life scale
632,NCT05443321,Total clinician-reported medical errors,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],,Time between transferred patient arrival and entry of admission orders
633,NCT03788447,total dose of remifentanil,2019-06-04,COMPLETED,INTERVENTIONAL,['NA'],,
634,NCT00543777,Overall Image Quality of Magnetic Resonance Elastography (MRE),2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Hepatic Steatosis
635,NCT01641458,Predefined fluoropyrimidine-related (index) toxicity,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Progression-free survival
636,NCT03154983,progress-free survival time,2017-05-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,disease control rate
637,NCT00296062,Phase II: Determine the toxicity of bevacizumab in combination with this regimen in patients with metastatic colorectal cancer.,2006-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Phase I: Maximum tolerated dose in patients ≥ 65 years of age measured by CTC version 3.0 at end of Safety in the Elderly component of study
638,NCT03095703,Number of participants with treatment-related adverse events,2017-10-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Immunohistochemistry of mTOR targets
639,NCT05458986,Intent to complete a colonoscopy,2023-05-15,RECRUITING,INTERVENTIONAL,['NA'],,Incidence of completed colonoscopies
640,NCT02670746,Adverse Event (AE),2015-10-01,TERMINATED,OBSERVATIONAL,['NA'],,Evaluate the resources utilized for treatment of pancreatic adenocarcinoma with the combination nab-paclitaxel/gemcitabine in routine clinical practice
641,NCT05651594,Overall response rate (ORR),2023-03-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,ORR
642,NCT06317896,2-year recurrence-free survival rate,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Correlation between metastasis，primary tumor and CTCs in blood through NGS and CTC-DNA
643,NCT05141721,Phase 3: Progression-free survival per Immune-based Response Evaluation Criteria in Solid Tumors (iRECIST) as assessed by blinded independent review committee (IRC),2022-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Phase 2 and 3: The feasibility of manufacturing a patient-specific vaccine defined by the proportion of patients for whom vaccine was successfully manufactured from those randomized to the vaccine arm.
644,NCT03993626,Immune Disease Control Rate (iDCR),2018-05-22,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
645,NCT05735912,Rate of adverse events,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Pancreatic insufficiency
646,NCT03167775,DCR and/or 6-months survival rate,2016-11-28,UNKNOWN,INTERVENTIONAL,['NA'],,the rate of incidence of adverse events
647,NCT00577538,,2006-04,COMPLETED,OBSERVATIONAL,['NA'],,
648,NCT01904890,Receipt of CRC Screening,2012-03,COMPLETED,INTERVENTIONAL,['NA'],,CRC screening Intention
649,NCT00079365,,2001-05,UNKNOWN,INTERVENTIONAL,['NA'],,
650,NCT04269369,The frequency of severe ﬂuoropyrimidine-related toxicity,2020-02-18,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
651,NCT03750175,Feasibility of ctDNA analysis for RAS mutation analysis,2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Lead time
652,NCT04466631,Utilization of specific competences by participants,2020-06-15,UNKNOWN,OBSERVATIONAL,['NA'],,Number of participants maintaining their social activities
653,NCT00003714,Patient Response,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
654,NCT04013347,number of patient with surgical complications,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,number of patient with anastomotic dehiscence
655,NCT05061082,Genetic and epigenetic changes of the tumor,2021-10-26,UNKNOWN,OBSERVATIONAL,['NA'],,
656,NCT05194878,Disease-free survival,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,CT assessment of response to neoadjuvant treatment
657,NCT03176485,Modulatory effect of systemic Raf inhibition in the MEK/Erk and PI3 /AKT/mTOR pathways in patients undergoing targeted therapy for metastatic disease,2014-10-17,COMPLETED,INTERVENTIONAL,['NA'],,Modulatory effect of Ras inhibition in Epidermal Growth Factor Receptor (EGFR) and Activating Protein-1 (AP1) signaling pathways (IHC and RPPA).
658,NCT04578444,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
659,NCT01995591,number of sentinel lymph nodes identified in pieces of colectomy from patients with colon cancer with Indocyanine Green,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
660,NCT03069508,Cmax Pharmacokinetic (PK) assessment of clemizole hydrochloride (200 mg vs. 300 mg vs. 400 mg vs. 500 mg by mouth),2017-02-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival associated with clemizole hydrochloride
661,NCT02125396,Overall survivals,2019-05-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Recurrence rates
662,NCT01765582,Progression-Free Survival During First-Line Therapy (PFS1),2013-01-23,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Adverse Events
663,NCT04722120,Quantitative image quality analysis,2016-06-01,COMPLETED,INTERVENTIONAL,['NA'],,
664,NCT00549276,,2006-05,COMPLETED,OBSERVATIONAL,['NA'],,
665,NCT03253939,3-years overall survival,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],,
666,NCT02900248,Time to Treatment Progression,2017-10-02,TERMINATED,OBSERVATIONAL,['NA'],,To determine rate of enrollment into existing and future therapeutic clinical trials.
667,NCT00973869,Concentration of curcumin in colorectal tissue after treatment,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Presence of curcumin and its metabolites in peripheral blood and urine
668,NCT03551470,Operative time,2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,
669,NCT01882660,"Wnt target gene expression (APCDD1, AXIN2, DKK1, LGR5 and ASCL2)",2013-07,TERMINATED,INTERVENTIONAL,['NA'],,Tumor differentiation
670,NCT04404673,Urinary and sexual outcomes after rectal resection,2020-02-21,UNKNOWN,OBSERVATIONAL,['NA'],,
671,NCT04592913,Event-free survival (EFS),2020-11-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,To compare Arm A relative to Arm B on pathological complete response (pCR) rate
672,NCT01056913,Anastomotic Leakage,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Clinical Relevant Stenosis
673,NCT00131911,Confirmed Response Rate,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
674,NCT00041197,Recurrence-free survival (RFS),2002-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Relationship between genetic and phenotypic characteristics of GIST and clinical outcomes
675,NCT04808466,overall survival,2021-09-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,The positive rate of cancer cells of participants by exfoliative cytology examination
676,NCT04298489,ex vivo Maximal Inhibition Index (MI),2017-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Progression free survival (PFS) after chemotherapy
677,NCT00470782,,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,
678,NCT05951231,Lactate level in microdialysate from hilar plate after normothermic machine perfusion - 4 hours,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Donor associated variables - Donor risk index,Pyruvate level in microdialysate from hilar plate after of Dual-end-ischemic Hypothermic Oxygenated Perfusion machine perfusion in extended criteria donors livers - 2 hours
679,NCT03233360,Time to treatment recurrence,2017-04-17,COMPLETED,OBSERVATIONAL,['NA'],,
680,NCT01762514,Effect on improving mucositis,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence and severity of Hypocalcemia
681,NCT02503150,"Progression Free Survival, PFS",2015-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Events
682,NCT03652467,Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer,2018-09-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Number of Participants With Drug-Related Treatment-Emergent Adverse Events
683,NCT03192644,recurrence-free survival (RFS),2017-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival (OS)
684,NCT04652492,TTP assessed by independent review committee(IRC),2020-10-27,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
685,NCT01269970,early metabolic response to predict pathological response and outcome,2004-01,COMPLETED,OBSERVATIONAL,['NA'],,"to study correlations between early metabolic response, late metabolic response, histopathological response and outcome."
686,NCT01726309,Correlation between the type and degree of reported skin and/or eye reaction and the SNP profile of the EGFR domain III region.,2011-05,TERMINATED,OBSERVATIONAL,['NA'],,Correlation between the SNP profile(s) and disease response
687,NCT01896869,Overall Survival (OS),2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor Marker Kinetics as Assessed by Median Carbohydrate Antigen 19-9 (CA19-9) Levels
688,NCT01854255,Clinical Benefit Rate,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],median time ot progression,Observed Survival
689,NCT03731754,Complication rate of perineal wound,2018-11-20,UNKNOWN,INTERVENTIONAL,['NA'],,The operation time
690,NCT03431311,"Incidence, nature, and severity of adverse events graded according to NCI CTCAE v4.0",2018-03-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
691,NCT03474822,Number of participants with treatment-related adverse events as assessed by NCI CTCAE 4.0,2018-08-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Immunological index
692,NCT03322969,disease free survival,2017-08-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
693,NCT05661643,Objective respone rate in SDH deficiency wild type GIST,2023-06-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,
694,NCT02524119,Progression Free Survival,2016-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (ORR) Based on mRECIST and RECIST 1.1
695,NCT00813163,Survival Rate,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,pharmacogenetics
696,NCT03639792,Postoperative Morbidity and mortality,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
697,NCT03756051,Psychosocial Harms,2018-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Physical Harms
698,NCT04131426,Recruitment and Retention,2020-04-24,COMPLETED,INTERVENTIONAL,['PHASE1'],,Porportion of subjects with improved cachexia-related symptoms 3 months
699,NCT02408406,Functional Assessment of Cancer Therapy-General (FACT-G) scores,2015-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Individual patient changes in Functional Assessment of Cancer Therapy-General (FACT-G) total scores,Change in health resource utilization
700,NCT04533490,DFS（disease-free survival）,2021-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Exploratory analysis of biomarkers for predicting efficacy,OS（overall survival rate）
701,NCT01696630,Variation of intraoperative Mean Arterial Pressure (MAP),2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Delay to intestinal transit recovery
702,NCT02786524,Change in Patient-Reported Symptom Burden as Determined by the National Comprehensive Cancer Network Distress Screening Tool,2016-02-15,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival Rate
703,NCT03822130,Successful conversion rate of operation,2019-02-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,PFS
704,NCT05221957,Complications,2022-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Mortality
705,NCT05800106,Relative bioavailability (F),2018-12-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Proportion of subjects with abnormal 12-lead electrocardiogram (ECG)
706,NCT05905887,Disease control rate,2023-09-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,
707,NCT00355355,Overall survival,2006-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
708,NCT00337545,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
709,NCT03009461,Overall survival,2017-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
710,NCT01768104,En bloc resection,2011-12,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life
711,NCT01211210,3-year disease free survival,2010-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,quality of life
712,NCT02108782,Progression-free survival,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Plasma levels of circulating angiogenic factors and soluble receptors,Incidence of adverse events graded according to National Cancer Institute (NCI) CTCAE version 4.0
713,NCT05965466,Number of gallstone patients,2023-07-21,RECRUITING,INTERVENTIONAL,['NA'],,Number of patients with bile duct stones
714,NCT02502630,Overall Survival (OS),2010-06,COMPLETED,INTERVENTIONAL,['NA'],,Treatment related adverse events
715,NCT06084299,Maximum tolerated dose [Safety and Tolerability],2020-05-27,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
716,NCT02814461,The maximal tolerated dose (MTD),2015-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
717,NCT03200249,Complete histological response rate,2016-12-22,COMPLETED,INTERVENTIONAL,['NA'],,Tolerance
718,NCT00860860,Toxicity defined by NCI Common Terminology Criteria for Adverse Events version 3.0,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,"pharmacokinetics and biodistribution of TF2 and Lu-177-labeled IMP-288, sensitivity of pretargeted imaging with In-111-labeled IMP-288, and tumor response using RECIST criteria"
719,NCT06015659,6-month Progression-Free Survival (PFS) Rate,2023-11-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Grade 3-5 Treatment-related Toxicity Rate
720,NCT01224652,progression-free survival,na,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival
721,NCT01678027,Gastric cancer incidence,2004-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,All-cause mortality
722,NCT04858334,Improvement in relapse-free survival (RFS),2021-06-22,RECRUITING,INTERVENTIONAL,['PHASE2'],RFS and OS differences with those who had resectable disease at diagnosis,OS in those who received any platinum-based perioperative chemotherapy versus no platinum-based perioperative chemotherapy
723,NCT05578677,"Size of biopsy specimen, as assessed by a blinded study investigator",2021-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"The percentage biopsies with the presence of dysplasia, as assessed by a blinded upper GI pathologist"
724,NCT04634526,Rate of R1 cases assessed by surgeon,2018-04-18,RECRUITING,OBSERVATIONAL,['NA'],,Disease free survival
725,NCT02355353,Tumor regression grade (TRG),2015-02,UNKNOWN,INTERVENTIONAL,['NA'],,"Histopathological measurements of tumor tissue cellularity /density, Necrosis, Proliferation (ki-67)"
726,NCT06280105,objective response rate (ORR) per RECIST1.1,2024-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Occurence of AE and SAE
727,NCT01374451,Progression-free Survival (PFS) Per Local Radiological Review,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Summary of Pasireotide Concentrations Following Intramuscular Injection of Pasireotide LAR 60mg
728,NCT00842491,Progression free survival,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,The alteration of relative regional blood volume of the tumor
729,NCT04247958,Number of SureForm™ Stapler fires and reload colors,2020-01-30,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of peri-operative and short term outcomes
730,NCT04192565,Complication rate (%),2020-09-09,COMPLETED,INTERVENTIONAL,['NA'],,
731,NCT05775900,Pharmacokinetic (PK) characteristics 2,2023-02-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Treatment-emergent genetic mutations,Quality of Life (QOL)
732,NCT02643498,maximum tolerated dose (MTD) of SBRT,2015-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
733,NCT00333788,Occurrence of at Least One Study-emergent Adverse Event During the Study (Maximum 164 Weeks),2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Occurrence of at Least 1 Concurrent Medical Procedure During the Overall Period
734,NCT02907099,Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors 1.1,2016-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
735,NCT01044732,Detection Rates for Adenomas and for Total Polyps,2009-03,COMPLETED,INTERVENTIONAL,['NA'],,Times for Withdrawal Phase and for Complete Procedure
736,NCT00217711,"Efficacy of Oxaliplatin, Irinotecan, and Capecitabine",2005-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
737,NCT05449873,Local tumor progression rate,2021-10-18,RECRUITING,INTERVENTIONAL,['NA'],,Complication rate
738,NCT05163665,Cost of each closure,2022-08-23,COMPLETED,INTERVENTIONAL,['NA'],,Successful Tissue approximation
739,NCT02311439,Number of Participants with Adverse Events as a Measure of Safety and Tolerability of FOLFIRINOX plus Concurrent Radiotherapy with Capecitabine,2014-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Number of Cases will have radical surgery,Tumor response
740,NCT01608646,Objective tumor response,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse event incidence
741,NCT05231382,Two-years progression-free survival rate,2022-03-28,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Evaluate the patient's cancer-related QoL using the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ), the EORTC QLQ-C30."
742,NCT02169908,Thermal thresholds,2014-05,COMPLETED,INTERVENTIONAL,['NA'],Characterization of pain neuropathy,Tactile sensitivity
743,NCT02537158,recurrence-free survival,2015-08,UNKNOWN,INTERVENTIONAL,['NA'],,overall survival
744,NCT03715517,Cumulative 72-hour opioid consumption (OC_0-72h),2018-10-04,RECRUITING,INTERVENTIONAL,['NA'],Cumulative incidence (proportion) of postoperative vasopressor and/or inotrope dependency (%),Comprehensive Complication Index (CCI) score Comprehensive Complication Index (CCI) score Comprehensive Complication Index (CCI) score
745,NCT00920803,To characterize the pharmacokinetic profile of SRT501 in blood and normal and malignant metastatic tissues when administered once daily for 14 days.,2008-08-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,To examine the pharmacodynamics of SRT501 activity in both normal and malignant tissue samples and blood.
746,NCT06020885,Tolerated fraction dose,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,The rate of grade 3 or 4 toxicities according to CTCAE5.0
747,NCT06267378,"The sensitivity & specificity of blood based biomarkers for the prediction of baseline clinical frailty levels & post-operative measures of frailty, mortality and adverse events",2023-08-30,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival at 3 months and 5 years (the latter via cancer registry returns)
748,NCT04871204,Weight change in percent (%),2021-06-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients completing treatment
749,NCT04599920,Changes in the intake of nutrients and nutritional status of participants as a measure of diet modification.,2020-09-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Changes in the concentrations of N-nitroso compounds in feces.
750,NCT04942626,Identification of the maximum tolerated dose for capecitabine administered concomitantly with standard radiotherapy in combination with Anakinra at a fixed dose of 100 mg s.c,2021-08-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Quality of life based on treatment arm and surgical procedures/organ preservation
751,NCT04813432,time-point of highest enhancement difference between a pancreatic lesion and background pancreatic parenchyma,2018-09-10,UNKNOWN,OBSERVATIONAL,['NA'],,
752,NCT02869802,Number of days between biopsy and return of comprehensive genomic results.,2016-10-06,RECRUITING,OBSERVATIONAL,['NA'],Targetable mutations,Overall Survival
753,NCT02110953,"Maximum tolerated dose of irinotecan-eluting beads, determined by dose limiting toxicities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",2016-01-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,Time to progression
754,NCT03983993,Clinical benefit rate (CBR),2019-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
755,NCT01850368,Tumor stabilization rate,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment related toxicity
756,NCT00307866,"To assess the proportion of correct final, therapy deciding diagnosis based on unenhanced plus SH U 555 A enhanced MR imaging compared to contrast-enhanced dual-phase spiral CT.",2001-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,To assess safety and tolerability of SH U 555 A administration.
757,NCT01274962,Compliance to chemotherapy - patients receiving at least 85% of planned full-dose of chemotherapy prescribed at each cycle for the 12 cycles,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival rate
758,NCT05176964,pathological complete response(pCR),2021-12-31,RECRUITING,OBSERVATIONAL,['NA'],,predictive biomarkers andquality of life(QoL)
759,NCT04260139,Lymph Node Yield in Colon Cancer Resection Specimens,2019-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
760,NCT02569242,Overall Survival,2015-12-14,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of Response
761,NCT01431599,downstaging effect of tumor,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,bladder and small bowel toxicity after chemoradiation
762,NCT04777604,Overall survival rate,2021-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
763,NCT00632515,Psychosocial + External factors influencing CRC patients' communication with FDRs about CRC risk & screening information,2008-01-29,COMPLETED,OBSERVATIONAL,['NA'],,
764,NCT01585727,Urogenital function,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Fecal incontinence
765,NCT06253650,ctDNA clearance (negative ctDNA status) at 1 year,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Translational analyses,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
766,NCT02173080,Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q) total score,2014-06,RECRUITING,OBSERVATIONAL,['NA'],,Total kidney volume
767,NCT03977233,Best disease control rate by Pancreatic ductal adenocarcinoma (PDAC) subtype,2019-06-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,proportion of patients whose tumor/stroma subtype changes after treatment with FOLFIRINOX
768,NCT01652079,Progression Free Survival,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Analysis of biopsies
769,NCT02979795,Tumor regression rate,2016-11,UNKNOWN,OBSERVATIONAL,['NA'],,Distant metastasis
770,NCT05351983,Feasibility of the process,2022-09-22,RECRUITING,INTERVENTIONAL,['NA'],,Chemosensitivity testing
771,NCT00729482,Progression-free Survival Rate at 4-month (16 Weeks),2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
772,NCT02244632,Frequency and severity of dose limiting toxicity (DLT) or other Adverse Events (AE),2014-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
773,NCT04931394,Disease free time,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Concordance between radiosensitivity test results and patients' treatment response (descriptive statistics).
774,NCT02402036,Serum microRNA Quantification,2015-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,
775,NCT06157814,Number of participants retained for entirety of the study,2023-06-16,RECRUITING,INTERVENTIONAL,['NA'],,Symptom Measures
776,NCT03730441,"correlation between ADR of screening and all colonoscopies (screening, surveillance, diagnostic)",2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
777,NCT03165591,Effect of V3-P on tumor burden,2017-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Effect of V3-P on sugar and bilirubin levels
778,NCT03812562,Recurrence rate,2019-02-07,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Overall increase in future liver remnant (FLR)
779,NCT05029869,The specificity of MRD detection using ctDNA as the biomarker,2021-10-04,RECRUITING,OBSERVATIONAL,['NA'],,Mutation profile of gastric cancer
780,NCT04125849,Postoperative respiratory complications,2020-04,UNKNOWN,INTERVENTIONAL,['NA'],,30-day mortality after surgery
781,NCT01442974,"Effect of nab-paclitaxel on pancreatic cancer stroma, new vessel formation and tumor cell metabolism.",2011-01,COMPLETED,INTERVENTIONAL,['NA'],,Activity of nab-paclitaxel in combination with gemcitabine against PDA in relation with changes in tumor stroma and tumor metabolic activity.
782,NCT03542136,"To evaluate the efficacy of evaluating the vibrotactile sense using a multi frequency tactilometry, in patients hand and foot. This is by assessing the changes in the measurements of a multi frequency tactilometry device in between each two time points.",2018-06-04,COMPLETED,INTERVENTIONAL,['NA'],,To evaluate if Oxaliplatin induced polyneuropathy can be earlier detected by using a multi frequency tactilometry compared with Common Terminology Criteria for Adverse Events scale (CTCAE).
783,NCT01489410,Number of Patients with Post-Embolization Syndrome,2012-10,WITHDRAWN,INTERVENTIONAL,['NA'],,Overall Survival
784,NCT00551057,,2007-10,UNKNOWN,OBSERVATIONAL,['NA'],,
785,NCT00425425,Response rate (histological remission) (Phase II),2006-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Metabolic response rate
786,NCT01817205,dose limiting toxicity,2013-03,TERMINATED,INTERVENTIONAL,['NA'],,treatment response by alphafetoprotein
787,NCT03186014,Recurrent dysphagia,2017-06,UNKNOWN,INTERVENTIONAL,['NA'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
788,NCT01374750,To evaluate recurrence-free survival,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the safety with sirolimus
789,NCT01289288,Receipt of CRC screening,2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
790,NCT02335151,Peak of CTC in the postoperative phase after curative tumor removal,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of surviving patients
791,NCT01320683,Progression-free Survival,2011-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
792,NCT02917798,baseline to post-results change in distress levels,2016-07-12,RECRUITING,OBSERVATIONAL,['NA'],,
793,NCT02272738,Number of patients with Adverse Events,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival time
794,NCT06052332,Grade ≥3 toxicities during treatment,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
795,NCT04447352,Comparison of progression-/disease-free survival (PFS/DFS) between arms,2020-12-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,Rate of post-operative morbidity/mortality at day 30 after surgery acc. to Clavien-Dindo classification
796,NCT01083875,Evaluation of mucositis using the Oral Mucositis Assessment Score,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Frequency of treatment-emergent, drug-related Serious Adverse Events"
797,NCT01470586,Comparison of Oxidative stress markers in patients with colorectal cancer and controls,2009-05,COMPLETED,INTERVENTIONAL,['NA'],,Validation of oxidative stress markers in patients with colorectal cancer undergo surgical resection
798,NCT02229136,Incidence of Grade ≥ 2 stomatitis,2014-09-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to Disease Progression of next anti-cancer therapy,Reduction in pain score on questionnaires
799,NCT00557557,Primary endpoint is to determine the maximum tolerated dose and dose limiting toxicity of 5-FU delivered with 40mg/m² of Oxaliplatin via IHP.,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Secondary endpoints will be to determine the response rate and survival after IHP with 5-FU and Oxaliplatin.
800,NCT01742806,Time to drain removal,2012-10,UNKNOWN,INTERVENTIONAL,['NA'],Time to discharge after surgery and postoperative complication,total amount of exudate drainage
801,NCT06006338,R0 resection rate,2023-09-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,Blood loss
802,NCT01488552,Complete Response Rate,2011-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Observing toxicity outcomes
803,NCT05418543,CH-EUS FNA has higher diagnostic accuracy for bile tuct tumors,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
804,NCT00005590,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,
805,NCT01018381,Patient survival,2006-06,COMPLETED,INTERVENTIONAL,['NA'],,Disease recurrence
806,NCT01172860,treatment safety,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
807,NCT02969681,Progression Free Survival,2017-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Assessment of treatment-related adverse events
808,NCT00037089,,na,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
809,NCT01532804,Disease-free survival,2011-07-28,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of life by using the quality of life questionnaire score
810,NCT02713529,Objective Response Rate (ORR) Per Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST),2016-04-14,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,AMG 820 Pharmacokinetic Parameter by Dose Group: Accumulation Ratio (AR)
811,NCT01434550,Number of Participants With Overall Survival (OS),2012-03,WITHDRAWN,INTERVENTIONAL,['NA'],,Number of Participants With Adverse Events (AEs)
812,NCT01283217,3-year disease free survival(DFS),2010-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
813,NCT00003424,,1997-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
814,NCT00955591,Comparison of anal cytology screening outcome derived from specimens collected by a flocked nylon swab vs a Dacron swab,2009-03-12,COMPLETED,INTERVENTIONAL,['NA'],,
815,NCT03803241,Liver volume,2019-05-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Liver volume
816,NCT00005094,"Percentage of patients with adenomas, aspirin use at baseline, and covariates",2000-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events coded using the MedRA dictionary
817,NCT01379521,Time to Progression (TTP) Based on the Modified RECIST Criteria,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With a Decrease in the Sum of the of Longest Diameters (SLD) of Target Lesions From Baseline to 30 Months
818,NCT03775395,Overall survival,2018-12-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Progression Free Survival (PFS)
819,NCT01516216,Median Progression-free Survival (PFS),2012-04-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Hazard Ratio Between Baseline Plasma 25(OH)D Levels and OS
820,NCT00634751,Overall Response Rate,2008-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
821,NCT00712751,"To investigate the feasibility, tolerability, acceptability (including adherence) and efficacy of CSI-SH, a psycho-educational intervention, on the primary outcome of sexual functioning among RC survivors.",2008-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"To explore baseline variables that may influence the effectiveness of CSI-SH (i.e., moderators such as socio-demographic and medical variables)."
822,NCT02288507,Safety and tolerability of concurrent sorafenib and yttrium-90 transarterial radioembolization (TARE) for patients with advanced hepatocellular cancer as measures by Adverse events,2014-11,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,"Efficacy of concurrent sorafenib and yttrium-90 transarterial radioembolization (TARE) for patients with advanced hepatocellular cancer as measured by response rate, time to progression (TTP), progression free survival (PFS), overall survival (OS)"
823,NCT02239900,Maximum Tolerated Dose (MTD) of Ipilimumab and Stereotactic Body Radiation Therapy (SBRT),2014-08-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response Rate of Ipilimumab and Stereotactic Body Radiation Therapy (SBRT)
824,NCT05714644,CRC Screening Completion Rates,2023-05-31,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Diagnostic Colonoscopy Completion Rates
825,NCT02005965,To compare global quality of life at two years post surgery in patients according to plane of surgery with or without sphincter preservation.,2007-08-13,UNKNOWN,OBSERVATIONAL,['NA'],,Investigation of potential association between length of operation with number of complications and length of post-operative ITU/HDU stay.
826,NCT02961140,Incidence of postoperative complication,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,Length of stay
827,NCT03000816,Progression-free survival,2015-04,COMPLETED,INTERVENTIONAL,['NA'],,overall survival
828,NCT06092944,Heart rate (HR),2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Analgesia satisfaction
829,NCT04245865,The rate of progression free patients at six months,2020-06-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
830,NCT05060471,cCR rate,2021-09-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],,overall sruvival
831,NCT06124378,pCR,2023-11-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Gene mutation signatures of colon cancer
832,NCT04823403,Maximum Tolerated Dose (MTD),2020-11-13,RECRUITING,INTERVENTIONAL,['PHASE1'],,
833,NCT03802097,Incidence of surgical site infections within 30 days,2018-12-27,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of remote non-surgical site infections
834,NCT03045484,Total Dose of Oxycodone,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,Quality-of-Life Index
835,NCT02741856,Primary endpoint in adenocarcinoma when switching chemotherapy,2016-11-04,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Health economics
836,NCT03793335,Colorectal cancer prevention,2019-04-14,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
837,NCT05862051,Progression free survival (PFS),2021-12-14,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life measure
838,NCT02923622,Overall survival,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],,Number of participants with treatment-related adverse events as assessed by Chinese version of CTCAE v4.0
839,NCT00459108,Four Month Progression-free Survival (PFS),2007-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
840,NCT02795429,Phase II: Overall Response Rate (ORR) Per RECIST v1.1,2016-06-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase Ib and Phase II: PD-L1 Percent Positive Tumor
841,NCT05663203,Attentional Function Index,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Short Form Health Survey
842,NCT04005690,Proportion of all pharmacodynamic feasibility-evaluable participants within a study arm that have a measurable change in post-treatment tumor biology from baseline,2019-08-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of >= grade 3 toxicities for each assigned window treatment (as described in sub-protocol)
843,NCT00282672,5 Year Extension: % of All Patients Enrolled in the Extension Protocol and Available for Analysis Demonstrating CR-D at 5 Years,2006-02,COMPLETED,INTERVENTIONAL,['NA'],,5 Year Extension: All Cause Mortality of the Group From 2 to 5 Years.
844,NCT00302094,Program to fuse 3D ultrasound and PET/CT data,2006-06,COMPLETED,OBSERVATIONAL,['NA'],,
845,NCT00407654,Progression-free Survival (Bevacizumab-treated Group),2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Response (Bevacizumab-treated Group)
846,NCT04714190,Overall survival (OS),2021-03-24,RECRUITING,INTERVENTIONAL,['PHASE3'],,Tumor progression time (TTP)
847,NCT02638909,"Clinical Benefit Rate (CBR) of ceritinib, as defined as the percentage of patients who have achieved complete response, partial response, and stable disease at 2 months per RECIST 1.1) to ceritinib by investigator assessment",2015-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Objective tumor response based on computed tomography scans (or magnetic resonance imaging if patients are allergic to iodinated contrast) per RECIST 1.1 criteria
848,NCT03368963,Overall response rate based on modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1,2018-01-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Response rate
849,NCT01689376,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
850,NCT00199654,Time to colorectal cancer relapse,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Comparison of the medical cost in the two detection strategies
851,NCT00142467,"Time to disease progression of gemcitabine, oxaliplatin and bevacizumab regimen in patients with hepatocellular carcinoma.",2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
852,NCT03630354,Perceived physical function incongruence,2019-01-18,COMPLETED,INTERVENTIONAL,['NA'],,Fear of recurrence
853,NCT00677443,To compare the combination of S-1 and oxaliplatin to the combination of capecitabine and oxaliplatin in terms of progression free survival in patients previously untreated by systemic therapy for advanced or metastatic colorectal carcinoma.,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,To evaluate and compare the quality of life of the patients and safety profiles of the two treatment groups.
854,NCT03707444,Change in Average pain as assessed by Brief Pain Inventory Question 3,2018-10-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Change in opioid use
855,NCT00656123,Number of Patients Experiencing a Grade 3 or Above Treatment-related Toxicity,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Percent Fold change in amount of interferon gamma-producing Ep-CAM-specific CD8 T cells after vaccination
856,NCT06202131,mOS,2023-11-01,RECRUITING,OBSERVATIONAL,['NA'],,
857,NCT05827471,Detection of protein for early rapid diagnosis of colon cancer.,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
858,NCT00753441,Serum bilirubin,2009-02-01,TERMINATED,INTERVENTIONAL,['NA'],,Procedure-related complications
859,NCT03956641,evolution of exercise tolerance,2019-09-17,UNKNOWN,INTERVENTIONAL,['NA'],,measurement of parameters reflecting the physical condition
860,NCT01970254,"Rate of a positive result (hepatitis B surface antigen [HBsAg], hepatitis B core antibody [anti-HBc], and hepatitis B surface antibody [anti-HBs]) before first chemotherapy",2013-06-24,COMPLETED,OBSERVATIONAL,['NA'],,
861,NCT02738697,Overall survival,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
862,NCT05696002,Quality of life (survey),2023-01-14,RECRUITING,OBSERVATIONAL,['NA'],,
863,NCT03891472,Improvement of the overall survival.,2017-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
864,NCT05185245,Overall Survival,2021-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Disease-Free Survival
865,NCT01379807,Objective response rate,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Exploratory Objectives
866,NCT05365256,Level of psychological well-being,2022-04-15,RECRUITING,INTERVENTIONAL,['NA'],,
867,NCT04042831,Progression-free survival (PFS) at first scan,2020-06-24,RECRUITING,INTERVENTIONAL,['PHASE2'],The number of patients that had biomarkers related to tumor evaluation and resistance,Incidence of adverse events
868,NCT00513539,Overall survival,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Quality of life as assessed by EORTC QLQ 30 and PAN 26 at baseline and 1, 3, and 6 months after completion of study treatment"
869,NCT05700188,Overall survival (OS),2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Progression-free survival (PFS)
870,NCT00004210,"Assessment of cancer risk perception, cancer screening practices, views regarding genetic services, and family communication about HNPCC / Lynch syndrome by family members",2000-02,COMPLETED,INTERVENTIONAL,['NA'],,
871,NCT02967848,Change in global and local liver function,2016-10-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Radiotherapy dose sparing of functional liver
872,NCT05208762,Number of participants with DLTs by dose level,2022-10-25,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of anti-drug antibodies (ADAs)
873,NCT01533311,,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,
874,NCT02565667,anastomotic leak rate,2015-09,UNKNOWN,INTERVENTIONAL,['NA'],,30-day mortality rate
875,NCT02190656,Number of participants with no LARS; minor LARS and major LARS,2014-05,COMPLETED,OBSERVATIONAL,['NA'],LARS score in participants who have had laparoscopic surgery and participants who have had open surgery,Correlation between LARS score and EORTC QLQ-C30 questionnaire score
876,NCT02951390,Adenoma detection rate,2016-07,COMPLETED,INTERVENTIONAL,['NA'],,Total procedure time
877,NCT04811703,Dose-limiting toxicities,2021-07-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Rates of adverse events and operative complications
878,NCT02459457,overall survival,2015-07-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,adverse event
879,NCT05182762,Clavien-Dindo Grade,2020-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Age comparison
880,NCT03086291,maximum tolerated dose,2018-01-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
881,NCT05783076,Overall survival will be determined,2023-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life will be determined
882,NCT00755534,Time To Progression,2008-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Correlation of the molecular characteristics of the tumor with the clinical outcome
883,NCT00003923,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
884,NCT02953782,Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1),2016-11-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
885,NCT00227734,Objective response (complete response [CR] and partial response [PR]) measured after completion of study treatment,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse drug reactions measured after completion of study treatment
886,NCT05826743,Study Success Case(Avoidance of ostomy),2023-12-04,RECRUITING,INTERVENTIONAL,['NA'],,
887,NCT06252649,PFS per Response Evaluation Criteria in Solid Tumors (RECIST v1.1),2024-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Maximum Plasma Concentration (Cmax) of Sotorasib
888,NCT04947371,Adverse events rate,2018-12-15,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival
889,NCT01273662,disease stabilization,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,time-to-tumor progression
890,NCT00844727,,2003-09,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
891,NCT03636308,Objective response rate,2018-07-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The incidence of treatment related emergent adverse events（Safety and Tolerance）
892,NCT06005974,To evaluate the preliminary anti-tumor activity of REC-4881 as measured by Objective Response Rate (ORR),2024-01-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,To assess the anti-tumor activity of REC-4881 as measured by to other efficacy endpoints
893,NCT05585073,surgery complicated,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
894,NCT05931445,HRQoL EORTC Quality of Life of Cancer Patients (QLQ-C30) global health status score,2021-01-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Communication between patients and healthcare providers (EORTC QLQ-COMU26 score)
895,NCT05334836,Prevalence of pancreatic steatosis determined by fat quantitation on MRI,2022-04-06,RECRUITING,INTERVENTIONAL,['NA'],,Risk factors for pancreatic steatosis in patients with presumed IPMN or MCN
896,NCT02695966,T lymphocyte changes,2015-05,COMPLETED,OBSERVATIONAL,['NA'],,T lymphocyte localisation
897,NCT00330915,Feasibility of Pemetrexed Prior to Surgery,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Receiving Sphincter Saving Surgery
898,NCT03980704,Infectious complications,2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Length of stay
899,NCT04977596,CT value of lesion portal phase,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
900,NCT01296984,3-year local recurrence,2011-02,COMPLETED,OBSERVATIONAL,['NA'],,Stoma function
901,NCT00506844,Pathologic stage Tumor regression grade,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease-free survival
902,NCT04706910,Minimum lesion detectability (SUV),2021-01-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,Gallbladder disease questionnaire
903,NCT02785146,Disease-free survival (DFS),2016-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],The effects of Huaier Granule on adverse events of adjuvant chemotherapy.,Metastasis-free survival (MFS)
904,NCT00003799,MTD of oxaliplatin when combined with radiation therapy and fluorouracil based on the incidence of DLT as assessed by CTC version 2.0,1999-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,
905,NCT02941562,Pathological Response,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,3-year Overall Survival
906,NCT02895464,Adverse events,2016-09,COMPLETED,INTERVENTIONAL,['NA'],,Discharge destination
907,NCT05824559,Progression Free Survival (PFS) rate at 16 weeks,2023-08-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,Safety and tolerability of ME-344 administered in combination with bevacizumab
908,NCT04089150,Locoregional control (Locoregional Response Rate LRR),2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],ePRO Acceptability,Overall Survival (OS)
909,NCT01957241,BIOMARKER PANEL SELECTION AND MODELING,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],,SURVIVAL AND RT-RELATED TOXICITY ANALYSIS AND MODELING
910,NCT05830292,Diagnostic accuracy of DRS probe to differentiate normal versus tumour tissue in vivo,2022-05-20,RECRUITING,INTERVENTIONAL,['NA'],,Feasibility of DRS probe to differentiate normal versus tumour tissue in vivo
911,NCT03001505,Overall survival,2017-05-04,WITHDRAWN,OBSERVATIONAL,['NA'],,Local recurrence
912,NCT02000739,Time to Disease Progression,2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,
913,NCT06257264,Part 2: Objective Response Rate,2024-02-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,Part 2: Plasma concentrations for BG-68501
914,NCT00383149,Percentage of Participants Surviving at 6 Months,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in FHSI-8 Total Score by Time-point
915,NCT06173466,Cumulative opioid consumption of 72 hours after surgery,2023-12-15,RECRUITING,INTERVENTIONAL,['NA'],,Sleep quality
916,NCT01718821,"Changes in pain, assessed by BPI-SF.",2012-09,COMPLETED,OBSERVATIONAL,['NA'],,"Changes in neuropathic pain. Neuropathic pain, assessed by DN4 questions."
917,NCT03822936,Progression free survival,2018-02-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,intra and perioperatory complications
918,NCT05731947,Phase 2: Progression Free Survival (PFS),2023-04-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: DOR as Assessed by the Investigator
919,NCT02424864,The estimation of tumor size of the primary esophageal tumor on 4Dvs 3D FDG PET,2014-08,COMPLETED,INTERVENTIONAL,['NA'],,"Measurement of SUV max, SUV mean, and SUV peak in 4D versus 3D images of esophageal cancer and lymph nodes and number of suspected involved lymph nodes"
920,NCT02671890,Maximum tolerated dose (MTD) (Cohort I),2016-02-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Changes in muscle messenger ribonucleic acid (mRNA) levels via real-time polymerase chain reaction,Changes in fist-grip strength as measured by hand dynamometer (Cohort II)
921,NCT01545141,Change in the Number of Tumor-infiltrating CD8+ Cells.,2012-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Treatment Related Adverse Events
922,NCT03206125,Esophageal squamous cell carcinoma,2017-08-01,TERMINATED,OBSERVATIONAL,['NA'],,
923,NCT03958500,Rate of anastomotic leakage,2019-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Timing of anastomosis leakage
924,NCT02045680,Improved tissue oxygen delivery,2014-03,UNKNOWN,OBSERVATIONAL,['NA'],,Time taken for patient to first mobilise following surgery
925,NCT03624725,Effects of quality of life,2018-04-01,COMPLETED,INTERVENTIONAL,['NA'],,
926,NCT06023121,Detection of levels of an exosome-based liquid biopsy signature,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
927,NCT01405638,Colorectal Cancer Screening,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,
928,NCT04459754,Disease-free Survival,2020-06-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,
929,NCT05043688,pCR,2021-09-14,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],PD-L1 expression,AE
930,NCT02066259,"Number of participants in each of the clinicaly defined groups (0,1 and 2).",2014-08,UNKNOWN,OBSERVATIONAL,['NA'],,
931,NCT05771480,Number of participants with Grade 3 or 4 possibly related adverse event (PRAE),2023-08-16,RECRUITING,INTERVENTIONAL,['PHASE3'],,EORTC QLQ-BIL21 Score
932,NCT01088581,2-year recurrence rate and adverse events,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,overall survival
933,NCT01881932,Proportion of Colorectal and Breast Cancer Patients in Each Arm Who Require Dose Reduction or Discontinuation Due to Chemotherapy-induced Peripheral Neuropathy.,2013-02,TERMINATED,INTERVENTIONAL,['NA'],,
934,NCT05286320,objective response rate,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Immune biomarkers,Progression-free survival and overall survival
935,NCT05017922,Number of bleeding episodes,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
936,NCT00997958,Identification of maximum tolerated dose of CellCept in patients with advanced pancreatic cancer,2004-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
937,NCT05913583,Graft rejection,2023-04-01,RECRUITING,OBSERVATIONAL,['NA'],pDC to mDC ratio,Early allograft dysfunction (EAD)
938,NCT03044613,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2017-07-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Recurrence-Free Survival
939,NCT06250166,Change from baseline in mean platelet-lymphocyte ratio at 12 weeks,2023-06-15,RECRUITING,INTERVENTIONAL,['NA'],,Change in mean daily energy and protein intake at 12 weeks
940,NCT03723720,correlation between ADR and PDR for all and screening colonoscopies,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
941,NCT01836432,Overall Survival,2013-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,Immune Response
942,NCT04957511,"Microbiome change through analysis of biological samples (fecal specimen, blood, vaginal swab, oral mucosal swab).",2021-06-29,RECRUITING,OBSERVATIONAL,['NA'],,
943,NCT02587884,Overall Survival,na,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Time to recurrence
944,NCT00808379,Side effects and other adverse effects in the two groups during radiotherapy and up to 2 years post radiotherapy.,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Comparison of pathological downstaging between the two groups who undergo surgery.
945,NCT01360892,Cumulative incidence of carcinogenesis of hepatocellular carcinoma,2010-09,UNKNOWN,OBSERVATIONAL,['NA'],,The cumulative incidence and severity of decompensated cirrhosis
946,NCT00681499,Quality of Life,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,
947,NCT05650918,Incidence of Dose Limiting Toxicities (DLTs) as assessed by CTCAE v5.0,2021-08-30,COMPLETED,INTERVENTIONAL,['PHASE1'],,Radiological response rate as defined by RECIST version 1.1 and iRECIST
948,NCT00003139,Acute salivary gland toxicity,1998-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Effects of continuing pilocarpine out to 6 months from the start of treatment
949,NCT02580253,Desease free Survival,2017-11-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
950,NCT00004193,"Determine the response rate, duration of response, and time to progression in patients with metastatic and/or locally recurrent adenocarcinoma of the colon or rectum treated with ISIS 2503, an antisense inhibitor of H-ras",1999-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Determine the safety profile of this regimen in these patients.
951,NCT01674959,feasibility of concurrent IMRT combined with capecitabine for the treatment of gastric cancer patients,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,efficacy of concurrent IMRT combined with capecitabine for the treatment of gastric cancer patients
952,NCT00100945,1-year overall survival rate,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
953,NCT06161818,Disease-free survival,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Future ctDNA analysis
954,NCT06034977,Overall survival,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
955,NCT02606994,Oral mucositis changes,2018-05-29,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of life changes
956,NCT04087889,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
957,NCT01523431,"Incidence of toxicity, especially neutropenia and diarrhea",2012-03-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Pharmacokinetics of irinotecan and its metabolites, SN-38 and SN-38G."
958,NCT01448655,Disease-free survival time (DFS).,2010-09,UNKNOWN,OBSERVATIONAL,['NA'],,"Number of patients with unexpected adverse events (UAE) contributed to conventional oncological therapy (radio-, chemo-, targeted therapy)."
959,NCT02842047,Repeated Measures ANCOVA Model (F-Statistic),2016-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Change in FAMCARE Scale
960,NCT04073615,(Phase 2) Progression Free Survival (PFS) per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator Assessment,2019-11-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,(Phase 1b and 2) Number of Participants with Adverse Events (AEs) that Worsen in Severity as Defined by the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
961,NCT03306901,3-year overall survival,2017-10-20,RECRUITING,INTERVENTIONAL,['NA'],,Treatment-related complications or adverse events
962,NCT00128622,Safety as measured by rate of adverse events during study drug treatment,2005-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Rate of immune response as measured by ELISPot at week 10
963,NCT03109041,Safety & Toxicity of Delivering Primary Radiation Therapy with CivaSheet using the CTCAE 4.0 scale,2017-09-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
964,NCT01706809,"The primary aim of the present study is to investigate different biomarkers like VEGF, EVGF and others ability to predict time to recidive and progressions free survival.",2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,
965,NCT01859182,"Proportion of patients who have a response (PR or CR), assessed by the RECIST v1.1",2013-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Changes in QOL evaluated using the Functional Assessment of Cancer Therapy - General (FACT-G)
966,NCT00005878,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
967,NCT06055010,Subproject dependent,2014-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
968,NCT05539417,The variation in treatment and awareness of lateral lymph nodes in patients with rectal cancer.,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Presence of presacral abscess
969,NCT04094454,incidence and grade of vaginal fibrosis,2019-10-01,RECRUITING,INTERVENTIONAL,['NA'],,assessment of quality of life
970,NCT01903018,Number of severe Radiation Induced Mucositis (WHO grade >=3),2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
971,NCT00423150,Tumor Responses (Complete and Partial Response),2007-01-26,TERMINATED,INTERVENTIONAL,['PHASE2'],,
972,NCT04781413,3-year relapse-free survival (RFS),2021-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Peritoneal metastasis rate
973,NCT01042782,maximum tolerated-dose (MTD) of RAD001 in combination with Mitomycin C,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,"safety and tolerability of the combination of RAD001 and Mitomycin C as assessed by frequency, severity, and duration of treatment-related adverse effects"
974,NCT01271582,Association between UGT1A1 polymorphism and grade 3/4 neutropenia after 1st cycle of FOLFIRI treatment,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Progression-free survival
975,NCT02866045,Proportion of patients receiving a definitive histologic diagnosis for gastrointestinal SELs by single incision needle-knife biopsy (SINK biopsy) vs. EUS-guided fine needle biopsy (EUS-FNB).,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Proportion of patients for whom a mitotic rate may be calculated for gastrointestinal stromal tumors (GISTs) using SINK biopsy vs. EUS-FNB
976,NCT02178358,Overall Survival (OS): Number of Events,2014-08-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in EORTC QLQ Hepatocellular Carcinoma (HCC-18) Questionnaire Score
977,NCT03013010,Disease free survival,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Proportion of patients with surgery-related complication
978,NCT01033578,Overall Survival,1999-10,UNKNOWN,INTERVENTIONAL,['NA'],,Time to Recurrence
979,NCT02216487,Safety,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
980,NCT02935764,progression free survival,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,quality of life questionnaire
981,NCT05987709,Assess colorectal cancer screening completion,2022-03-17,COMPLETED,INTERVENTIONAL,['NA'],,Assess the proportion who completed follow-up testing.
982,NCT06223022,Patients' reported Quality of life,2024-01-20,RECRUITING,INTERVENTIONAL,['NA'],Sick-leave,Patients' experiences of prostata cancer related to symptoms and side effects of treatment and diagnosis.
983,NCT03579732,Number of subjects with gastric cancer,2018-06-29,COMPLETED,OBSERVATIONAL,['NA'],,Number of fatal cases due to colorectal cancer
984,NCT03511170,time to failure of strategy（TFS）,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,time to failure of strategy（TFS）
985,NCT02164916,Progression-free Survival,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Response Rate in Patients Who Register to Arm 3 (Crossover) After Disease Progression on Arm 1,Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
986,NCT02812186,Peak Airway Pressures,2016-12-27,COMPLETED,INTERVENTIONAL,['PHASE4'],,Surgical Rating Scale
987,NCT02115373,Phase 2: Number of Participants Who Were Progression-free at 12 Weeks (PFS Status) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,2014-05-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 1b: Accumulation Ratio of AUC (Racc (AUC)
988,NCT03800953,overall radiographic response,2019-03-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,New metastasis-free survival
989,NCT03366012,Patient Tolerability determined by Score on Likert Scale,2018-08-01,SUSPENDED,INTERVENTIONAL,['NA'],,Number of Serious Adverse Events (SAEs)
990,NCT02092389,Percentage of Patients With Fecal Calprotectin (fC) Level ≤ 150 µg/g After 12 Months of Treatment With Adalimumab,2014-07,TERMINATED,OBSERVATIONAL,['NA'],,Correlation Between fC and Workability Determined by WPAI:UC Questionnaire
991,NCT00107536,Proportion of Patients Demonstrating Objective Response (PR+CR) as Defined by RECIST,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Expression Profile and Mutations of Genes Critical for EGFR and ERBB2 Signaling Pathways
992,NCT02702089,morbidity,2016-03,UNKNOWN,OBSERVATIONAL,['NA'],,Reintervention rate
993,NCT03604237,pathologic diagnosis,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,
994,NCT02804737,Effectiveness of Web-based instructions,2014-07,COMPLETED,OBSERVATIONAL,['NA'],,Benefit of web-based instructions
995,NCT04037241,Assess efficacy by overall survival,2021-11-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Assess the persistence of CAR-T cells in liver tumor biopsies over time.,Evaluation of Quality-of-Life using the 5-level EQ-5D version (EQ-5D-5L) questionnaire
996,NCT05056051,To assess the additive diagnostic yield as assessed by proportion of patients with recurrence be use of WATS-3D,2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],,To assess if the order by which tissue is sampled affects the diagnostic yield of WATS-3D by comparing the proportion of patients with recurrence between groups.
997,NCT05081687,cCR + PathCR,2020-02-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall toxicity
998,NCT03176264,Overall Response Rate (ORR) per investigator assessment using RECIST v1.1,2017-09-25,TERMINATED,INTERVENTIONAL,['PHASE1'],,Antidrug antibodies (ADA)
999,NCT00079833,Control is defined as gastric acid secretory rate below 10 mEq/h or below 5 meq/h for patients with prior gastric acid reducing Surgery,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,"The following safety variables will be assessed at Month 6 and Month 12: adverse events, clinical laboratory results (ie, chemistry, hematology, urinalysis), physical examinations, and EGDs."
1000,NCT01108705,Compare overall survival of subjects with advanced HCC who have progressed on/after or are intolerant to sorafenib and receive brivanib plus best supportive care (BSC) to those receiving placebo plus BSC,2010-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,"Assess serious and nonserious adverse events, laboratory evaluations, significant physical examination findings and ECG results"
1001,NCT00354224,Response Rate as Determined by RECIST.,2005-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival
1002,NCT03577067,renal resistive index (RRI),2015-02,COMPLETED,OBSERVATIONAL,['NA'],,
1003,NCT00997633,Detected volume measured by SPECT compared to the number of subsequent sequential postoperative intraperitoneal chemotherapy courses,1991-05,COMPLETED,OBSERVATIONAL,['NA'],,"The relationship between SPECT, feasibility of SPIC (intraperitoneal chemotherapy), and clinical variables"
1004,NCT00622999,Complication rate,2003-01,COMPLETED,OBSERVATIONAL,['NA'],,Mortality
1005,NCT04013152,Collection of clinical data following surgery with robotic assistance in colorectal pathologies,2018-06-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Quality of the mesorectum by using Quirke classification
1006,NCT03783936,Best Objective Response Rate (bORR),2019-01-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Grade 3-4 Treatment Related Adverse Events
1007,NCT05909995,"Incidence of TEAEs leading to dose interruption, dose reduction, or discontinuation of either of the study drugs",2023-08-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of Response
1008,NCT00006269,,1999-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,
1009,NCT00077987,Anti-tumor efficacy,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor control survival safety
1010,NCT04832763,Change in health-related quality of life (HRQoL),2019-09-27,TERMINATED,INTERVENTIONAL,['NA'],,Biomarker analysis - C-Reactive Protein
1011,NCT00086567,Create a multi-institutional repository from which investigations of serum proteomic signature profiles of epithelial ovarian cancer and relapse will be developed and validated,2005-12-12,COMPLETED,OBSERVATIONAL,['NA'],,
1012,NCT00341484,Genetic determinants,1998-06-01,COMPLETED,OBSERVATIONAL,['NA'],,
1013,NCT04264702,Determine the rate of recurrence of patients diagnosed with CRC while asymptomatic using SIGNATERA™,2020-04-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Examine the number of Stage I CRC patients that have recurrent disease detected post-surgery based on SIGNATERA™ test results
1014,NCT03346980,Inter-observer agreement of the Spigelman Score evaluated by expert endoscopists.,2017-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Inter- and intra-observer agreement of the Spigelman Score and the endoscopic sub-scores evaluated by novices.
1015,NCT05353127,Influence of different CPET data averaging intervals on the numerical values of CPET-,2022-04-12,COMPLETED,OBSERVATIONAL,['NA'],,High- or Low-risk for postoperative complications
1016,NCT00358566,Overall survival time,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival
1017,NCT05729867,Technical success rate,2020-04-27,RECRUITING,INTERVENTIONAL,['NA'],,Stent dysfunction rate
1018,NCT05275075,Proportion of African American pancreatic cancer patients with weight loss and cachexia.,2022-12-07,RECRUITING,OBSERVATIONAL,['NA'],,"Differences in cachexia-associated RNA signatures in African American pancreatic cancer patients, and other racial groups."
1019,NCT01558648,short -term quality of life (QOL),2012-03-14,COMPLETED,OBSERVATIONAL,['NA'],predict EUS T3/T4/stricture or earlier EUS disease,Complications
1020,NCT00016029,,2000-08,TERMINATED,INTERVENTIONAL,['NA'],,
1021,NCT03811379,Objective Response Rates (ORR),2018-11-21,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
1022,NCT04819516,Number of Participants With Abnormal Laboratory Values,2020-12-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,Numeric rating scale
1023,NCT00268333,Response rate,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
1024,NCT03493009,rate of adequate cleansing level,2018-05-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
1025,NCT04044859,To evaluate safety of ADP-A2M4CD8 as monotherapy or in combination with either nivolumab or pembrolizumab,2019-08-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
1026,NCT01526590,Lesion Margin,2012-07,WITHDRAWN,INTERVENTIONAL,['NA'],,Degree of venous washout
1027,NCT02938195,Percentage of patients completing adjuvant chemoradiotherapy and surgery,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Percentage of pathological complete response
1028,NCT01323166,Health Related Quality of life after rectal cancer surgery - possible differences due to choice of procedure,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,Impact of rectal cancer surgery and the level of intrusive thoughts
1029,NCT06100003,Specificity,2023-10-18,RECRUITING,OBSERVATIONAL,['NA'],,
1030,NCT01603004,Progression free survival,2012-05-14,COMPLETED,OBSERVATIONAL,['NA'],,best response
1031,NCT03167970,The overall diagnostic accuracy of capsule endoscopy in predicting the presence and extent of Barrett's esophagus in comparison to standard esophagogastroduodenoscopy,2017-05-03,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of Treatment related adverse events of capsule endoscopy in comparison to standard esophagogastroduodenoscopy
1032,NCT05893810,High-grade radiation-induced oral mucositis,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of Life according QLQ-H&N43
1033,NCT04705194,Correlation coefficient between preoperative FLR-GC and post-operative ICG R15,2019-07-08,UNKNOWN,OBSERVATIONAL,['NA'],,Correlation coefficient between growth in FLR volume and growth in FLR-GC after the first stage
1034,NCT00049712,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1035,NCT06048146,3 year disease free survival,2022-10-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
1036,NCT03910699,Anastomotic leakage rate,2019-04-10,UNKNOWN,INTERVENTIONAL,['NA'],,Serious adverse events rate
1037,NCT05468892,PFS,2019-10-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Safety and tolerability analysis: defined as the evaluation of incidence and severity of AEs, graded according to NCI- CTCAE, version 5.0 (v. 5.0)."
1038,NCT04194034,Disease Control Rate (Phase II part),2020-01-17,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1039,NCT04715321,Predictive performance of CT perfusion,2013-02-15,UNKNOWN,OBSERVATIONAL,['NA'],,Disease-free survival (DFS)
1040,NCT04594772,Measuring the proportion of patients undergoing surgical resection using historical data compared to 32 patients in current study.,2021-03-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Measuring the safety of neoadjuvant therapy will be determined using CTCAE v5, reported as proportions of patients experiencing toxicities, graded using CTCAE v. 5.0."
1041,NCT01007617,Mucositis scale - World Health Organization (WHO),2009-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Psychological impact
1042,NCT04147078,Disease-free Survival (DFS),2019-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of Treatment-Related Adverse Events [Safety and Tolerability]
1043,NCT04296019,PFS,2021-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
1044,NCT03825887,Total opioid consumptions,2018-02-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Assess serious adverse events
1045,NCT04707482,Difference of protein expression,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1046,NCT05699278,Rate of patients who remain in a gastric cancer clinical trial to trial completion,2024-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1047,NCT05697107,PFS,2021-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,OS
1048,NCT00004252,,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1049,NCT02394795,Overall Survival (OS) in All Participants,2015-05-29,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Treatment-emergent Adverse Events (TEAE)
1050,NCT00591461,The primary outcome will be the interobserver variability in the presence of columnar epithelium as well as the measured lengths.,2007-12,TERMINATED,OBSERVATIONAL,['NA'],,variables that predict endoscopic interobserver agreement and path-confirmation
1051,NCT04481659,The damage degree of anal function,2020-07-19,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Local recurrence
1052,NCT05494060,Disease Free Survival (DFS),2022-03-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Toxicity by CTCAE v5.0 criteria,Disease Free Survival (DFS) rate at 3 years
1053,NCT06144385,Rate and severity of clinically-significant abnormalities in laboratory testings,2022-03-24,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overal survival (OS)
1054,NCT02581709,Feasibility of intervention implementation,2016-05,TERMINATED,INTERVENTIONAL,['NA'],,Cognitive Reserve Scale
1055,NCT06333665,Disease-free survival,2024-02-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,perioperative 90-day mortality
1056,NCT06187103,Fraction of patients whose HyperSight CBCT images meet the criteria for CBCT-based treatment planning.,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Patient experience of HyperSight imaging
1057,NCT00830778,Reduction of clinical postoperative pancreatic fistula (POPF) rate,2009-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Reduction of the severity of postoperative complications
1058,NCT00928928,Oxidative stress markers in patients with colorectal cancer operated with open or laparoscopic approach,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
1059,NCT01008358,Tumor response by Response Evaluation Criteria In Solid Tumors (RECIST),2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in Hepatitis C Virus (HCV) viral load
1060,NCT04428437,Response rate (RR),2022-07-02,TERMINATED,OBSERVATIONAL,['NA'],,Adverse Events
1061,NCT05054959,complete remission rate,2021-06-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,local control
1062,NCT03410030,Phase II: Disease control rate (CR+PR+SD x18 weeks),2017-12-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Changes in circulating tumor stem cells,Changes in patient's self-reported pain levels
1063,NCT01136031,response rate (phase II part),2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,toxicities
1064,NCT01025882,Tumor samples for RNA and protein harvesting (when possible) from pretreatment biopsies and surgical specimens,2009-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1065,NCT02409472,Health Related Quality of Life,1998-04,COMPLETED,INTERVENTIONAL,['NA'],,Disease free survival (DFS)
1066,NCT05687474,Feasibility - reliability,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],,To improve the detection technique for disease related mutations that are not detected in classical screening by improving the classification of unspecified variants.
1067,NCT03403634,Change in Tumor-infiltrating Lymphocytes (TILs) in the Colorectal Cancer Lesions,2018-04-19,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,Objective Response Rate (ORR) Assessed by Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1
1068,NCT03168139,"Combination Therapy: Safety - adverse events, vital signs, ECG, hematology & safety laboratory",2017-04-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Combination Therapy: Efficacy - time to event analyses
1069,NCT03563170,"Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1",2018-05-25,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,ORR for Phase 2 Single Arm Component
1070,NCT01442155,Disease-Free Survival (Time to Event),2011-10,COMPLETED,OBSERVATIONAL,['NA'],,Safety: Percentage of Participants With Adverse Events
1071,NCT04965311,Rate of clinically relevant postoperative pancreatic fistula (POPF),2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of any POPF
1072,NCT06040541,Dose Limiting Toxicities,2023-09-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS)
1073,NCT01962649,Measurement of fluorescence intensity within focal hepatic lesions,2013-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
1074,NCT05908786,Major Pathologic Response (MPR) Rate,2023-12-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Post-Operative Mortality
1075,NCT01142388,Progression-free Survival,2010-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
1076,NCT04420026,"Evaluation of the primary success rate of percutaneous ablation treatment with IRE of hepatic tumors, as a function of the ultrasound visibility of the tumor, when using automatic CT cone-beam fusion and ultrasound",2020-07-06,COMPLETED,INTERVENTIONAL,['NA'],,Evaluate the global survival at 12 months
1077,NCT00051480,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1078,NCT06313047,CYP2B6,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1079,NCT01456156,overall survival,2008-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants with Adverse Events
1080,NCT00831493,Maximum Tolerated Dose (MTD) of Vorinostat + Chemoradiation,2009-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1081,NCT03158571,Overall survival,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1082,NCT03305913,Maximum Tolerated Dose (MTD),2017-07-31,COMPLETED,INTERVENTIONAL,['PHASE1'],,Incidence of Treatment-Emergent Adverse Events
1083,NCT03033186,Everolimus TDM to predict long-term toxicity,2017-05-16,UNKNOWN,OBSERVATIONAL,['NA'],,Everolimus TDM to predict dose reductions
1084,NCT03626350,Adverse Events,2018-06-12,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Submucosal endoscopy technique and device used
1085,NCT04791176,MST,2021-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of III-IV grade adverse events
1086,NCT03613168,Adverse events,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1087,NCT01226719,Overall Response Rate (ORR),2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
1088,NCT00386516,Stable disease (SD) rate and progression-free survival (PFS) times,2006-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,"Safety, tolerability and Quality of Life (QoL)"
1089,NCT01609361,Post operative morbidity at 30 days according to DINDO CLAVIEN classification,2012-11,COMPLETED,INTERVENTIONAL,['NA'],,Duration of laxation (gas and stool)
1090,NCT04239781,HCC patients' willingness and expectation for post-operative treatment.,2020-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1091,NCT02884154,diagnostic sufficiency,2016-08,COMPLETED,INTERVENTIONAL,['NA'],,complications
1092,NCT05493683,Objective response rate(ORR),2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of Response (DOR)
1093,NCT04573621,Number of participants with pelvic sepsis,2020-10,UNKNOWN,INTERVENTIONAL,['NA'],,Any complications associated with drain removal after surgery
1094,NCT06326346,16 week disease control rate,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event assessed by NCI-CTCAE Version 5.0
1095,NCT04406714,"Proportion of subjects, ages 50-75, who complete CRC screening within 6 months (Trial - Age Group 50-75)",2020-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Number of days from abnormal FIT result date to diagnostic colonoscopy (Trial - Age Group 50-75),Proportion of subjects who complete a follow-up diagnostic colonoscopy at 60 days (Sub-study - Age Group 45-49)
1096,NCT03734627,Area under the curve for paracetamol at 30 minutes after a 400kcal mixed meal stimulus,2016-07-01,COMPLETED,OBSERVATIONAL,['NA'],Duodenal enteroendocrine cell mRNA expression profile,EORTC health related quality of life
1097,NCT04278222,objective response rate,2020-02-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
1098,NCT04460937,Incidence of adverse events,2021-04-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Biomarkers
1099,NCT02718430,Safety and tolerability taking into account treatment-limiting toxicities (TLTs),2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biodistribution and shedding of VXM01
1100,NCT03516890,Overall survival of all patients,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence-free of staged partial hepatectomy patients
1101,NCT05897749,PFS,2023-06-16,RECRUITING,INTERVENTIONAL,['PHASE4'],,quality of life
1102,NCT01806675,Change From Baseline in Maximum Standard Uptake Values (SUVmax),2013-03-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free Survival (PFS)
1103,NCT05164848,Incidence of Treatment-related Adverse Events，afety and Tolerability,2021-12-25,UNKNOWN,INTERVENTIONAL,['PHASE1'],The correlation of biomarkers with efficacy,The incidence of neutralizing antibody (Nab)
1104,NCT00021398,tolerated dose of preoperative hyperfractionated radiation and concurrent chemotherapy,1996-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1105,NCT00345761,Safety (Common Terminology Criteria for Adverse Events [CTCAE] version 3.0),2006-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,concentrations of anti-bevacizumab antibody
1106,NCT00699569,,2008-07,UNKNOWN,INTERVENTIONAL,['NA'],,
1107,NCT01030042,Overall Survival,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression free survival
1108,NCT03215459,Survival at 6 months (followed up for 12mths),2021-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,Time-to-event endpoints
1109,NCT03662204,Biomarker Evaluation,2018-08-23,COMPLETED,OBSERVATIONAL,['NA'],,
1110,NCT00725712,Number of Participants Who Required Concomitant Medications,2007-03-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Duration of Overall Survival (OS)of GSK1363089
1111,NCT04246684,organ preservation,2020-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Translational / biomarker studies
1112,NCT01774019,"Number of Serious Pre-operative, Operative and Post-operative Adverse Events to 120 Days Post Randomization or to 30 Days Post Surgery, Whichever Comes Last",2013-02-20,COMPLETED,INTERVENTIONAL,['NA'],,All-cause Mortality
1113,NCT02056041,Safety of surgery for HCC,2004-01,COMPLETED,OBSERVATIONAL,['NA'],,Score systems HCC
1114,NCT01943253,Procedure time,2011-05,COMPLETED,INTERVENTIONAL,['NA'],,complication rate
1115,NCT00440934,Response rate,2007-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,To determine the influence of the treatment on the hepatic function of patients with a diagnosis of cirrhosis. To determine the impact of the treatment by means of electromagnetic waves on the overall survival of patients.
1116,NCT05213195,Maximal Tolerable Dose#MTD#,2021-12-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,Antitumor efficacy-Overall survival (OS)
1117,NCT00346281,Safety profile of the patients defined by the Adverse Events profile.,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Will assess ease of use, tumour response, duration of response, progression free survival and overall survival. Target tumour response summaries for the study will be performed."
1118,NCT00374985,maximum tolerable dose and safety,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1119,NCT00002551,Survival and Relapse-free survival,1994-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1120,NCT06291779,Urine,2022-11-30,RECRUITING,OBSERVATIONAL,['NA'],,
1121,NCT00365508,24-hour Point Prevalence Abstinence at the 6-month Follow up,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4'],,Rate of Compliance During the First 2 Weeks
1122,NCT04878692,Measurement of the percentage of Onco-Rash failure by counting the number of patients with a rash grade ≥ 2 (NCI-CTCAE scale).,2021-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,Percentage of patients for whom treatment for acne (anti-inflammatory or antibiotic) has been introduced
1123,NCT04683965,Objective response rate(ORR),2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
1124,NCT05183958,Progression-free survival (PFS),2021-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of Response (DoR),Adverse Events (AEs)
1125,NCT01500993,Overall survival,2002-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Local recurrence rate
1126,NCT04452266,Correlation between endometrial cancer and predictif factors,2020-08-14,COMPLETED,OBSERVATIONAL,['NA'],,Correlation between endometrial cancer and predictif factors in post menopausal woman
1127,NCT06017284,Rate of nausea/vomiting,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival (OS)
1128,NCT01234324,Frequency of pT3/T4 categories after surgery,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequencies of pN2/N3 categories after surgery
1129,NCT01767857,Overall Survival (OS),2013-03-31,TERMINATED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Disease Control
1130,NCT03723447,Cumulative 48-hour Post Surgical Opiate Use (Oral Morphine Equivalent),2018-10-23,COMPLETED,INTERVENTIONAL,['PHASE4'],,Postoperative Complications
1131,NCT01944930,Rate of Detectable Peritoneal Metastases,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1132,NCT00445549,Number of Participants With Clinical Efficacy,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,The Number of Participants With Adverse Events
1133,NCT02102789,Complete resection rates (R0 resection rates) (defined as no macroscopic or microscopic residual tumor) of both arms,2014-03,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Number of participants with surgical complications, AES and SAEs as a measure of safety"
1134,NCT04005521,Swallowing ability,2019-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Incremental Cost Effectiveness Ratio (ICER),Maximal Interincisal opening (MIO)
1135,NCT04591028,Number of lymph nodes removed for each lymphatic station of gastrectomy,2022-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,
1136,NCT00912743,Tumour Response,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
1137,NCT05502276,R0 resection rate,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
1138,NCT03601234,operation time,2018-04-16,UNKNOWN,INTERVENTIONAL,['NA'],,hospitalization expenses
1139,NCT06045715,disease-free survival,2022-08-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,distant metastasis-free survival
1140,NCT06307938,Inflammatory bowel disease,2025-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Treatment response
1141,NCT04888546,Overall response rate (ORR),2021-04-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The incidence and severity of SAE
1142,NCT01044420,adverse events,2009-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,response rate
1143,NCT05706974,Rate of bile duct cancer patients who remain in a clinical study to completion,2024-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1144,NCT05440357,Progression-free survival rate,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],To explore the association of cilinical outcomes with treatment pattern,Safety-TEAEs
1145,NCT00544700,Time to progression (TTP),2007-11-26,TERMINATED,INTERVENTIONAL,['PHASE3'],,Long-term bevacizumab treatment costs
1146,NCT04883450,Incidence of pancreatic ductal adenocarcinoma (PDAC) in the high predicted risk group,2021-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1147,NCT05202600,NNT of IA for the appendiceal neoplasm,2022-02-01,UNKNOWN,OBSERVATIONAL,['NA'],Definition of the elderly group for the complicated appendicitis or death,NNT of IA for the death due to appendicits in elderly
1148,NCT01063517,Progression Free Survival (PFS) in Patients With Tumours Defined as Homologous Recombination Deficient by Loss of Ataxia-Telangiectasia Mutation (ATM) Protein [ATM Negative Patients],2010-02-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Deterioration in QoL Anxiety Domain Score in the Overall Study Population
1149,NCT04524871,Objective Response Rate (ORR),2020-11-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percentage of Participants With Adverse Events During Stage 2
1150,NCT01234701,Inter-observer agreement among expert radiologists in diagnosing primary liver tumors by Magnetic Resonance Imaging (MRI).,2010-10,COMPLETED,OBSERVATIONAL,['NA'],,Investigate the diagnostic efficacy of radiologists' certainty of diagnosis (CoD) in accurately predicting primary liver tumors assessed by Magnetic Resonant Imaging (MRI)
1151,NCT03443492,progression free survival (PFS),2018-03-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1152,NCT00734513,Patient's psychological adjustment,2003-01,COMPLETED,INTERVENTIONAL,['NA'],,Gender and marital satisfaction as moderators of the effects of partner-assisted ED.
1153,NCT01693432,Objective response rate,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate
1154,NCT03972527,IThe primary effectiveness endpoint is the severity of oral mucositis at week 6 of radiation treatment according to the Oral Mucositis Index (OMI) score.,2022-08-05,RECRUITING,INTERVENTIONAL,['NA'],,Changes in overall quality of life over the 6-week treatment period
1155,NCT04145297,"Recommended phase 2 dose of ulixertinib in combination with a fixed dose of hydroxychloroquine in subjects with advanced, RAS, non-V600 BRAF, ERK or MEK mutated gastrointestinal malignancies",2020-03-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Efficacy of ulixertinib and hydroxychloroquine in the study population: Objective response rate (PR and CR)
1156,NCT04714957,"genetic and epigenetic data available for 20 ""multiplets"" biospecimens (peritoneal carcinomatosis + healthy tissue + primary tumor + tissue from other tumor metastasis - when applicable and available- )",2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
1157,NCT04963283,Disease Control Rate (DCR),2021-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Exploratory Biomarker analysis - Tumor tissue
1158,NCT02368886,Proportion of Patients in Each Arm Who Complete 2 Cycles of Protocol Treatment and Initiate Cycle 3,2015-03-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Pharmacokinetics (PK) Parameters of Regorafenib Using Liquid Chromatography Mass Spectrometry,Changes in QOL (According to the Linear Analogue Self-Assessment [LASA] Questionnaire)
1159,NCT03046862,Response rate,2017-02-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerability as measured by number and grade of toxicity events
1160,NCT03855800,High grade dysplasia (HGD) or cancer diagnosis in Immediate Surgery group,2018-05-11,RECRUITING,INTERVENTIONAL,['NA'],,High grade dysplasia (HGD) or cancer diagnosis in clinical follow up group
1161,NCT02860546,Immune-Related Overall Response Rate (irORR),2016-08-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
1162,NCT05820906,Overall response rate ( ORR) per RECIST 1.1,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate (DCR) per RECIST 1.1
1163,NCT01402180,Local control,2010-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse Events
1164,NCT03225937,Objective Response Rate according to RECIST 1.1 criteria,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
1165,NCT01035229,Overall Survival (OS),2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Pharmacokinetics Assessments - Cmax
1166,NCT03178383,Integration of health-relation practices assessed via church survey,2016-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Implementation: Extent to which intervention is implemented as intended as assessed by a fidelity checklist completed by staff
1167,NCT02905968,anastomotic leak rate,2016-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time Frame: Reoperation rate after anastomotic leak
1168,NCT03665506,Overall survival,2018-06-25,COMPLETED,OBSERVATIONAL,['NA'],Assessment of health economic parameters,Patient-reported outcomes (PROs) on quality of life (QoL)
1169,NCT00041249,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1170,NCT02763748,Tumor recurrence rate,2016-06,UNKNOWN,INTERVENTIONAL,['NA'],,"the all number of postoperative complications（ frequency,reflux esophagitis and bile reflux gastritis）"
1171,NCT04738214,Pathologic response rate,2021-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Disease free survival
1172,NCT00529113,Phase II - To determine if treatment with RTA 402 in combination with gemcitabine can increase the progression-free survival versus gemcitabine plus placebo in patients with unresectable metastatic pancreatic cancer.,2007-09-30,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Phase II - To determine the changes in quality of life (Functional Assessment of Chronic Illness Therapy (Fatigue), [FACIT-F])."
1173,NCT05807646,The changes of the level of circulating tumor cells in the peripheral blood,2025-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative recovery course
1174,NCT05285358,Incidence of adverse events,2022-09-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Functional status
1175,NCT05184400,Overall survival (OS),2015-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Incidence of adverse events
1176,NCT01147991,"Demonstration by ELIspot assays of the frequency of T-lymphocytes recognizing major histocompatibility complex (MHC) class I and II-restricted epitopes within EBNA1 and LMP2 in peripheral blood at sequential time-points before, during, and up to 9 mo ...",2005-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Measurement of EBV-genome levels in plasma
1177,NCT04333927,Overall Survival,2020-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
1178,NCT03631537,nutritional status,2018-08-20,UNKNOWN,INTERVENTIONAL,['NA'],,adverse events
1179,NCT00604409,"To determine the safety, toxicity, and recommended phase II dose (RPTD) of capecitabine when administered concurrently with SIR-Spheres in patients with advanced cancer.",2006-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Efficacy
1180,NCT02143869,body composition,2013-12,COMPLETED,OBSERVATIONAL,['NA'],comparison of the body composition obtained by BIA and anthropometric measurements.,perioperative complications
1181,NCT03586973,24-Week Progression-Free Survival Rate (PFSR),2018-08-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
1182,NCT03531320,"Part 2: Incidence of Dose Modifications, Including Dose Reduction, Interruption, or Discontinuation of Study Drug",2018-08-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 2: PK- AUC
1183,NCT00467142,Percentage of Participants in Objective Response (Partial or Complete Responses),2007-01-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Duration of Response
1184,NCT02132858,Tumor response measured using the tumor regression grading system,2014-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],PET-computed tomography parameters,Tumor heterogeneity in patients with partial response to radiation
1185,NCT02943603,number of adverse events related to toxicity,2017-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,PD-L1 expression in tumor cells
1186,NCT03714490,R0(microscopically margin-negative) resection rate,2018-10-23,RECRUITING,INTERVENTIONAL,['PHASE2'],"circulating tumor DNA, and other potential biomarkers such as T-cell receptor",QoL by QLO-CR29
1187,NCT03199274,Tumor perfusion measured by contrast-enhanced ultrasound between ultrasound-triggered microbubble destruction pulses,2017-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
1188,NCT02626728,morbidity,2015-09,COMPLETED,OBSERVATIONAL,['NA'],,short-term oncological result
1189,NCT03628248,Colonic perfusion in the marginal artery after inferior mesenteric artery ligation between groups,2020-03-10,COMPLETED,INTERVENTIONAL,['NA'],,Presence of post-surgery complications
1190,NCT00190541,Relapse-free survival,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of sexual and urinary dysfunction
1191,NCT01793805,To characterize common genetic/molecular profiles associated with colorectal cancer (CRC),2013-02,COMPLETED,OBSERVATIONAL,['NA'],,To conduct further analysis of tumor samples for the discovery of new potential targets and mechanisms of drug resistance
1192,NCT02575313,Measurement of Tolerability,2009-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Treatment Break Measurement
1193,NCT05223816,PFS,2024-01-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,anti-HSV-1 antibody
1194,NCT01457846,Median Progression Free Survival,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Patients Without Progressive Disease at 8 Weeks
1195,NCT00846482,Number of Patients With Excision Repair Cross-complementing Group-1 (ERCC1) Protein Change When Treated With Oxaliplatin,2008-02,COMPLETED,INTERVENTIONAL,['NA'],,Determine Extent of ERCC Polymorphism and Its Relationship to Change in Its Level
1196,NCT01048463,Serum level of proalbumin,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Records of food intake
1197,NCT01773785,Progression free survival,2013-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety of SPI-1620 when administered in combination with docetaxel
1198,NCT04834986,Feasibility as measured by rate of enrollment,2021-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],To investigate the clinical efficacy of PD-L1 expression in predicting the combination of Tislelizumab and Lenvatinib.,adverse reactions
1199,NCT01270893,Percent of Apoptotic Tumor Cells Pre- and 7 Days Post Nilotinib Treatment,2011-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
1200,NCT00482365,Etiologic factors associated with hepatocellular carcinoma in different ethnic groups across the US,2002-04,COMPLETED,OBSERVATIONAL,['NA'],,Serum repository for registry patients
1201,NCT03039062,Relationship of serum miR-122 level and DILI or hepatic failure,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],,Normal physiological range of miR-122 in healthy population
1202,NCT01459965,Documented change in Quality Of Life,1993-07,COMPLETED,INTERVENTIONAL,['NA'],,Documented change in symptoms and concerns specific for patients with MBDO
1203,NCT03768375,Progression Free Survival,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1204,NCT00099294,Overall Survival,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Performance Status
1205,NCT04889820,3-year overall survival,2021-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,circulating tumor DNA
1206,NCT03672305,The efficacy of c-Met/PD-L1 CAR-T cells in the treatment of HCC,2018-10-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,The amplification and persistence of c-Met/PD-L1 CAR-T cell in the subjects varied with time
1207,NCT00289445,activity,1999-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1208,NCT04525326,Conversion liver resection rate,2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,overall survival
1209,NCT00976508,Number of Participants With Dose Limiting Toxicities (DLT),2009-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Objective Response
1210,NCT00536523,Alterations in serotonin levels associated with increased constipation,2007-04,TERMINATED,OBSERVATIONAL,['NA'],,
1211,NCT05988918,Progression Free Survival,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Median Progression- Free Survival (PFS) within each cancer subtype
1212,NCT01713244,Recurrence-free Survival,2012-10,UNKNOWN,INTERVENTIONAL,['NA'],Number of participants with adverse events,Overall Survival
1213,NCT03766945,Fatigue,2017-07-27,UNKNOWN,OBSERVATIONAL,['NA'],,Quality of Life
1214,NCT04316975,Correlation of Mean Mutational Load (ML) and Treatment Resistance,2020-04-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Correlation of Mutational Load and Stricture Formation
1215,NCT03037437,Time to tumor progression evaluated via tumor imaging,2017-02-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,
1216,NCT02272504,Biomarker assays exceeding threshold,2014-08,UNKNOWN,OBSERVATIONAL,['NA'],,Surveillance until HCC development and detection
1217,NCT04321577,Gallbladder cancer risk score,2020-03-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Disease-free survival
1218,NCT02149784,Overall survival,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of Participants with Adverse Events both in surgery group and chemotherapy group
1219,NCT04023448,anterior resection syndrome incidence,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,Long-term postoperative complication incidence
1220,NCT03791905,clinical complete response,2019-01-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Chemoradiotherapy-related toxicity
1221,NCT02614703,Total Number of Subjects With Neoplasia When Using Acetic Acid Chromoendoscopy Versus Standardized Random Biopsies.,2017-03-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
1222,NCT00788281,operation mortality,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,fee
1223,NCT05461664,Duration Of Response,2022-07-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,serious adverse events
1224,NCT00994526,"Urinary biomarker (DHN-MA:dihydroxynonene mercapturic acid), will be measured before and after every interventional period",2009-10,COMPLETED,INTERVENTIONAL,['NA'],,Fecal biomarkers
1225,NCT04674267,Association of geriatric consultation with number of unplanned ED visits/hospitalizations among older adult participants,2022-01-18,RECRUITING,INTERVENTIONAL,['NA'],,
1226,NCT05323890,Pathologic complete response rate,2022-04-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-related Adverse Events
1227,NCT02248038,5 years overall survival rate,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
1228,NCT00220181,,2003-04,COMPLETED,OBSERVATIONAL,['NA'],,
1229,NCT00515866,To establish the maximum tolerated dose (MTD) or a tolerable and effective dose of KU 0059436 in combination with gemcitabine,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,To identify the dose-limiting toxicity of the combination therapy
1230,NCT02496273,ELISPOT assays,2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,overall survival (OS)
1231,NCT05520801,Objective response rates (ORR),2020-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Quality of Life (QoL) after treatment
1232,NCT04354064,Freedom from progression,2019-05-29,RECRUITING,OBSERVATIONAL,['NA'],,Distant-metastasis-free survival
1233,NCT01204177,Disease Control Rate (DCR),2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biomarkers
1234,NCT00666107,"Determine if vaccinations will activate the subject's immune systems sufficiently that the HIV-1 viral load either increases from the baseline value, or becomes detectable and stays detectable after being undetectable at the baseline visit",2008-06,UNKNOWN,INTERVENTIONAL,['NA'],,
1235,NCT00049335,Feasibility of enrolling patients aged 70 years or older to a Phase II trial including pharmacokinetic sampling,2003-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Explore, at a preliminary level, the feasibility of studying genetic polymorphisms and gene expression levels of enzymes involved in drug metabolism and resistance to capecitabine"
1236,NCT02251782,Comparison of Adherence to Screening for Each Group,2014-10,COMPLETED,OBSERVATIONAL,['NA'],,Diagnostic yield of colonoscopy:
1237,NCT03902678,Percentage of patients with portal vein thrombosis who underwent EUS guided FNA and had complications as a result of the invasive maneuver,2017-05-11,UNKNOWN,INTERVENTIONAL,['NA'],,
1238,NCT04561336,overall survival,2018-08-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1239,NCT04145193,ctDNA clearance,2020-10-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of subjects with detectable anti-drug antibody (ADA) to novel agents in combination with mFOLFOX6
1240,NCT01166490,Incidence of adverse events and laboratory abnormalities,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Incidence of antitherapeutic antibodies in blood
1241,NCT05766605,The one-year DFS rate,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse events
1242,NCT02487225,Change in Interleukin-8 (IL-8) Levels From Admission Baseline at One Week.,2015-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1243,NCT02015923,Assess the impact of overall survival in patients with unresectable metastatic colorectal cancer treated with chemotherapy alone vs surgery followed by chemotherapy.,2013-12,TERMINATED,INTERVENTIONAL,['PHASE4'],,Study of possible survival factors
1244,NCT03607656,3-year Disease Free Survival rate,2018-06-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,EORTC QLQ-C30 scale
1245,NCT06104267,Adherence rates,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],,self-rating depression scale（SDS）
1246,NCT02271646,pain score at recovery room both at rest and movement (cough),2014-08,COMPLETED,INTERVENTIONAL,['NA'],,"Distribution of local anesthetic drugs after performing ultrasound guided TPVB at T5-6, T7-8 and T9-10."
1247,NCT03957733,3-year disease free survival (DFS) rate.,2017-11-23,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Surgical complications.
1248,NCT02111941,"Incidence of dose-limiting toxicities (DLT), graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",2014-04-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Induction of antibodies specific for FRalpha,Time to disease recurrence (TDR)
1249,NCT01867892,"the response rate, disease control rate, overall survival, and patients' quality of life.",2013-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1250,NCT00637637,Progression-free survival at 6 months,2007-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Duration of use of anticonvulsive drugs
1251,NCT03570684,ratio of patients with 2 or more reloads,2018-01-05,UNKNOWN,INTERVENTIONAL,['NA'],,complication rate
1252,NCT04510285,Rate of ctDNA Clearance at 6 Months,2020-08-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1253,NCT05103501,Disease-free Survival (DFS),2021-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival Rate
1254,NCT03569137,difference in microbiome biomarkers between patients developing colitis after exposure to targeted therapy and those not developing colitis,2018-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,"Creation of a predictive score of the occurrence of diarrhea in patients treated with Ibrutinib for malignant hemopathy B, including the biomarkers of the intestinal microbiome and the clinical characteristics of the patient"
1255,NCT04511559,Analysis ctDNA methylation status and its Correlation to early diagnosis and prognostic evaluation of gastric cancer.,2020-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1256,NCT01178944,Overall Response Rate,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],MicroRNA Expression - miR-215-5p,Time to Progression (TTP)
1257,NCT03816774,Adequate bowel preparation rate,2019-06-15,COMPLETED,INTERVENTIONAL,['NA'],Patients characteristics questionnaire,Tolerability to the bowel cleansing regimen:questionnaire
1258,NCT04956107,Development of ´fear of cancer recurrence' after PE or CRS+HIPEC for colorectal cancer,2021-01-25,RECRUITING,OBSERVATIONAL,['NA'],,Risk factors associated with developing psychological distress
1259,NCT00522405,Survival rate- calculated from the start of TACE,2007-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"a) Tumor response on dual phase CECT b) Patient tolerance c) Childs' status of cirrhosis- will be ascertained at one and two years of follow up depending upon the Childs' scoreScore <6- Childs'A, 7-9 Childs'B and >10 Childs'C"
1260,NCT03037034,Complete resection rate,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Tumor status after endoscopic resection
1261,NCT03735589,Persistence of nCTLs after their adoptive transfer,2023-12-15,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival assessed by irRECIST,T cell populations and higher anti-tumor responses
1262,NCT04044430,Incidence of treatment-related grade 3 or higher adverse events (AEs),2020-08-31,TERMINATED,INTERVENTIONAL,['PHASE1'],,Disease control rate (DCR)
1263,NCT02569723,Feasibility of 14C Oxaliplatin Microdose as a Clinical Assay to Predict Oxaliplatin Exposure,2015-10-16,COMPLETED,INTERVENTIONAL,['NA'],,Response Rate Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
1264,NCT01917552,recurrence-free survival,2013-08-19,RECRUITING,INTERVENTIONAL,['PHASE3'],,Safety profiles
1265,NCT06084013,Perfusion status,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Best practice usage of ICG for pancreatic surgery
1266,NCT02127359,Describe Impact of Information Derived from Exome Sequencing,2012-09,COMPLETED,OBSERVATIONAL,['NA'],,
1267,NCT00002523,,1993-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1268,NCT02213692,Blood loss,2014-05,TERMINATED,OBSERVATIONAL,['NA'],,Postoperative complications
1269,NCT04802876,Overall Response rate (ORR) (Cohort 3),2021-04-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Incidence, seriousness, treatment-related and intensity of Treatment Emergent Adverse Events"
1270,NCT01116635,Histopathological correlation with surgically resected tumor,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,maximum tolerated dose
1271,NCT01845805,Progression-free Survival,2014-01-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
1272,NCT04745130,Overall Survival (OS),2021-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
1273,NCT03796702,Postoperative morbidity,2011-11-01,TERMINATED,INTERVENTIONAL,['NA'],,Quality of life of patients after ileostomy closure
1274,NCT02273206,"Changes From Baseline in Number of Participants With Colorectal, Breast, and/or Cervical Cancer Screening",2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Self-efficacy and Behavior Towards Cancer Screening/Mental Health Utilization
1275,NCT02327065,Diagnostic Yield on malignancy,2014-12,UNKNOWN,INTERVENTIONAL,['NA'],,Blood contamination and cellularity in specimens obtained by EUS-FNA and EUS-FNB with Slow-pull or suction
1276,NCT06306755,Detection rate of upper gastrointestinal (esophageal/gastric) malignant lesions,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Quality of life Scale Score
1277,NCT00332696,Number of Participants With Treatment Success From Day 10 to Day 13,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Participant's Quality of Life Using the Edmonton Scale
1278,NCT03418558,Objective Response Rate according to RECIST 1.1 criteria,2015-07-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
1279,NCT04701853,Parastomal hernia verified by computer tomography,2021-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Back pain
1280,NCT04275557,Radiogenomic Analyses,2020-02-18,RECRUITING,OBSERVATIONAL,['NA'],,Progression Free Survival
1281,NCT03079596,Afebrile status without major complications,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,Time to first bowel motion
1282,NCT06031584,Phase II: Objective response rate (ORR),2024-01-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase Ib/II: Anti-drug antibody (ADA)
1283,NCT05973227,"image quality (sharpness, brightness, etc) and surgeon's feedback regarding the ergonomics and safety of Trident System v1.0 during surgery.",2023-07-06,RECRUITING,INTERVENTIONAL,['NA'],,- level of oxygenation (StO2) of the exteriorized colon before resection with the Trident System v1.0 - the level of oxygenation (StO2) provided by the system at the site chosen by the surgeon based on the clinical evaluation.
1284,NCT00003025,,1997-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1285,NCT03572582,Objective Response Rate (ORR),2018-06-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment Emergent Adverse Events as assessed by NCI CTCAE V4.03 (Safety and Tolerability)
1286,NCT06177288,converted resection rate,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Adverse events
1287,NCT01167725,Overall survival (OS),2010-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Comparison of OS and PFS according to patients' peritoneal surface tumor genotype for the NAD(P)H
1288,NCT03803436,Overall Survival,2019-01-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Complications rate
1289,NCT03812874,Safety as measured by number of participants with a dose limiting toxicity (DLT),2020-10-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate change in AFP levels.
1290,NCT02319200,rate of HCC occurrence and liver related-death or transplantation.,2015-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,"occurrence of liver-related complications (Ascites , gastrointestinal bleeding, encephalopathy)"
1291,NCT02022553,tumor reduction,2006-02,UNKNOWN,INTERVENTIONAL,['NA'],,
1292,NCT05842317,Overall response rate (ORR),2022-09-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Conversion surgery rate
1293,NCT01345773,The incidence of symptomatic or asymptomatic VTE,2010-05,COMPLETED,OBSERVATIONAL,['NA'],,Risk factors for the development of VTE
1294,NCT03264404,Progression-Free Survival (PFS),2017-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
1295,NCT05997524,Loco-regional and Distant Tumor Control After Completion of Treatment,2021-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
1296,NCT00004257,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1297,NCT06215677,the rate of R0 resection,2024-02-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Safety and tolerability of Camrelizumab administered
1298,NCT02495532,Lymph nodes harvested,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],,Adjuvant therapy
1299,NCT04424043,"Progression-free survival, PFS",2020-07-08,RECRUITING,INTERVENTIONAL,['NA'],,"Overall survival, OS"
1300,NCT01915472,Safety,2013-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Assess PK
1301,NCT02098291,Pharmacodynamic,1999-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants with Serious and Non-Serious Adverse Events
1302,NCT06277453,3-year overall survival,2023-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1303,NCT01653171,Visibility at upper endoscopy,2012-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,
1304,NCT04837885,Standardized uptake value (SUVmax) on liver metastases,2021-09-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,177Lu-DOTA-peptide dosimetry
1305,NCT06271980,Recurrence Free Survival,2023-04-15,COMPLETED,OBSERVATIONAL,['NA'],,Overall Survival
1306,NCT00401570,"The proportion of patients, in each dose cohort, with a confirmed tumor response",2005-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the immunogenicity of M200
1307,NCT03333486,Relapse Rate,2017-12-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Myeloid Chimerism Expressed as a Percentage of Donor Cells,Transplant Related Mortality
1308,NCT05835960,Establish the feasibility of immune analysis and NGS in informing patient treatment decisions.,2019-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
1309,NCT01300143,Time of tumor progression radiologically (CTScan) measured by mRECIST (Modified Response Evaluation Criteria In Solid Tumor).,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
1310,NCT00193141,"To compare the efficacy of full dose radiation therapy versus preoperative radiation therapy plus surgical resection, when used in combination with neo-adjuvant chemotherapy, in the treatment of localized esophageal cancer",1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the toxicity of additional chemotherapy and radiation therapy following completion of neo-adjuvant treatment.
1311,NCT03117920,Disease Control rate (DCR),2017-04-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Biomarkers predictive of response to Minnelide,Pharmacodynamic effect of Minnelide on tumour using PET Scans
1312,NCT00462852,Incidence of venous thromboembolism reduction,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Effect of drug combination on serological markers of thromboangiogenesis
1313,NCT00757965,Exploration of mutations at other loci that may predispose to endometrial cancer,2008-02,UNKNOWN,OBSERVATIONAL,['NA'],,
1314,NCT00080873,Area under the curve (AUC) of the modified Walsh mucositis scale,2004-04,COMPLETED,INTERVENTIONAL,['NA'],,Two sample t test and the Wilcoxon sum test.
1315,NCT00731445,Phase II : Assess the objective tumor response rate in patients according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Determine the PFS
1316,NCT00020930,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1317,NCT00465842,Number of participants with presence of serum protein markers,2006-06-20,TERMINATED,OBSERVATIONAL,['NA'],,Number of participants with presence of serum protein markers with resectable and unrsectable HCC.
1318,NCT05734430,Prevalence and spectrum of pathogenic and likely pathogenic germline variants in appendix cancer patients and their biological parents,2022-11-11,RECRUITING,OBSERVATIONAL,['NA'],,"Association of germline genetic variants with clinical, pathologic and molecular features of appendix tumors"
1319,NCT00311610,Objective response rate,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1320,NCT01567631,Number of participants with operation complication,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],,Number of participants with abnormal liver function or discomfort symptoms induced by the operation
1321,NCT00431756,early predictors of esophageal cancer,2002-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1322,NCT00189345,Selection of better dose level based on the confirmed tumor response.,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Effects of removab(TM)
1323,NCT00455559,To determine the efficacy and safety of perifosine plus imatinib mesylate in patients with advanced GIST who develop progressive disease or recurrence while receiving imatinib mesylate.,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To determine whether inhibition of Akt phosphorylation correlates with survival, time to disease progression, or response rate in patients with advanced GIST treated with imatinib mesylate plus perifosine."
1324,NCT00951496,Median Progression-free Survival,2009-08-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Patient Reported Nausea
1325,NCT03958669,To prospectively evaluate molecular fingerprint analysis of HCC tumor tissue to predict therapy responses,2019-11-01,TERMINATED,OBSERVATIONAL,['NA'],,Changes of ultrasound elastography under treatment with Sorafenib
1326,NCT01646593,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
1327,NCT01675908,Complications related to stent dysfunction,2012-08-22,COMPLETED,INTERVENTIONAL,['NA'],,Procedural complications
1328,NCT01504256,Rate of macroscopic complete remissions of peritoneal carcinomatosis,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Detection of disseminated tumor cells via PCR
1329,NCT01751516,"Negative post-chemoradiation PET/MRI scan, as correlated with surgical pathology",2012-10,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
1330,NCT04390399,Progression Free Survival (PFS),2020-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL)
1331,NCT05360732,To assess the toxicity profile of a regimen of alternating FOLFOX and FOLFIRI patients assessed as per NCI's CTCAE v5.0 criteria.,2022-04-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,To assess the Delayed Toxicity Rate
1332,NCT04803019,Time to progression,2019-12-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
1333,NCT04670588,Mean serum ctDNA concentration,2021-03-31,WITHDRAWN,OBSERVATIONAL,['NA'],,Response based on standard clinical assessments
1334,NCT00938470,Percentage of Participants With Pathologic Complete Response (PCR),2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Overall Clinical Tumor Response (CR or PR)
1335,NCT02595957,Health impacts of SF receipt,2014-09-16,RECRUITING,OBSERVATIONAL,['NA'],,
1336,NCT05927844,severity of TEAE and SAE,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
1337,NCT05709886,Effectiveness analysis,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Alpha-fetoprotein levels
1338,NCT01888978,Timing of biopsy and treatment,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival
1339,NCT04345783,OS,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1340,NCT01759706,Adherence to the pathway,2010-10,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative outcome
1341,NCT01502410,Objective Response by RECIST Criteria v 1.1,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Presence of BRAF Mutation or RET/PTC Rearrangement
1342,NCT01037049,"The primary endpoint will be the difference in the proportion of patients in each arm, downstaged according to T stage [on MRI].",2009-10-16,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Radiotherapy related toxicity rates.
1343,NCT02710838,the lesion of early gastric cancer by infrared endoscopy,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],,the invasive depth of early gastric cancer by infrared endoscopy
1344,NCT00208260,Response,2004-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Secondary resection
1345,NCT06254300,Aerobic capacity,2022-03-23,RECRUITING,INTERVENTIONAL,['NA'],,Length of hospital stay
1346,NCT05645679,Efficacy of the Hybrid Argon Plasma Coagulation Technique,2021-04-02,RECRUITING,OBSERVATIONAL,['NA'],,
1347,NCT01032746,"Receipt of colorectal cancer screening exam (fecal occult blood test, flexible sigmoidoscopy, or colonoscopy) within 4 months following delivery of an electronic message within the personal health record",2005-03,UNKNOWN,INTERVENTIONAL,['NA'],,Distribution of risk-status among participants who complete the web-based risk-assessment tool
1348,NCT04693377,Pain response,2021-03-16,RECRUITING,INTERVENTIONAL,['NA'],,Technical success for cryoablation
1349,NCT01546519,The Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUC[0-24hours]) Following Multiple Doses of Vismodegib,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Apparent Non-renal Clearance (CLNR/F) of Vismodegib
1350,NCT02794805,13CO2/12CO2 ratio,2015-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1351,NCT00784290,Step 2(Phase II) Response rate(RR),2003-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Step 2(Phase II) Safety
1352,NCT04057274,Cell viability (%),2019-09-23,UNKNOWN,INTERVENTIONAL,['NA'],,Concentration of Insulin-like growth factor 1 (ng/ml)
1353,NCT05493878,Expression levels of ITGA2b and SELP on Tumor Educated PLatelets for diagnosis of pancreatic and biliary cancer,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Correlation between expression levels of ITGA2b and SELP on TEPs and the commonly used tumour marker CEA and CA 19-9 in the diagnosis of pancreatic and biliary cancer.
1354,NCT02762474,Progress free survival,2014-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,CTCAE 4.0 toxicity
1355,NCT04961125,germline variant detection rate in the polyposis population,2021-08-02,RECRUITING,OBSERVATIONAL,['NA'],,
1356,NCT02267707,Pharmacokinetics - CL,2015-05-27,TERMINATED,INTERVENTIONAL,['PHASE1'],,Gemcitabine PK profile
1357,NCT01821248,Curative resection rate,2013-07-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Response rate and toxicity
1358,NCT04268888,Time to TACE Progression (TTTP) - phase II primary outcome,2019-05-08,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,QOL: EORTC QLQ-C30
1359,NCT05203120,Number of participants with Radiation-induced liver disease (RILD),2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Reduction in mean liver dose
1360,NCT02873520,Quality of life,2016-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1361,NCT05321134,Assess safety & quality event rate for SP platform transabdominal and transanal colorectal operations,2022-04-28,RECRUITING,INTERVENTIONAL,['NA'],,
1362,NCT04541381,Grade 3 or Higher Toxicity (Co-Primary Endpoint),2022-02-07,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival
1363,NCT01861912,Time to Progression,2013-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Recurrence Rate,Safety
1364,NCT04460456,"Duration of response, defined as the time from date of first response (CR or PR)",2020-07-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression free survival
1365,NCT04049357,CCE detection rate of polyps compared to OC,2020-04-01,RECRUITING,INTERVENTIONAL,['NA'],,
1366,NCT05302011,pathological response,2020-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1367,NCT00003049,,1997-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1368,NCT02876224,Percentage of Participants with Adverse Events,2016-09-30,COMPLETED,INTERVENTIONAL,['PHASE1'],,Percentage of Participants with Anti-therapeutic Antibodies (ATAs) Response to Atezolizumab
1369,NCT04563338,Progression-free survival,2021-06-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival rate
1370,NCT03828227,"Health-related quality of life (HRQoL) at 6 months in the ""candidate group"".",2019-06-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Performance status geriatric (PSG) score.
1371,NCT05444478,Over-all survival (OS) rate at 36 months,2022-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Complication rate
1372,NCT01237990,The number of accepted liver registrations associated with laparoscopically acquired surface data compared with the number of accepted liver registrations associated with open liver acquired surface data.,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,Comparison of registration errors from the full and half sufflation pressures to determine an impact of insufflation pressure on registration accuracy.
1373,NCT01191385,"Evaluation of patient demographics, disease characteristics, methods of patient evaluation, diagnosis and follow-up of patients with HCC, regionally and globally (collection of data on demographics, medical history, diagnostic measurements, follow-up)",2010-11,WITHDRAWN,OBSERVATIONAL,['NA'],,To evaluate the comorbidities in patients with HCC and their influence on treatment options and outcome (collection of data on concomitant diseases)
1374,NCT05733598,Overall Response Rate per modified RECIST 1.1,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
1375,NCT04743102,pathological complete remission,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival
1376,NCT05300945,OS,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse Events
1377,NCT01526486,Nodal yield,2009-06,COMPLETED,INTERVENTIONAL,['NA'],,Oncologic outcomes--survival
1378,NCT04843943,Events Free Survival (EFS) Assessed by RECIST1.1,2021-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
1379,NCT00767468,Correlation between hepatic retention and clearance of technetium Tc 99m mebrofenin (MEB) and technetium Tc 99m sestamibi (MIBI) and clearance (and other pharmacokinetic parameters) of sorafenib tosylate,2008-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Median overall survival
1380,NCT02645981,Overall Survival,2016-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Percentage of adverse events
1381,NCT04954339,Distinct immunophenotypes and dynamic changes of tumor-infiltrating immune cells in Hepatocelluar carcinoma treated with treated with atezolizumab-bevacizumab assessed by flow cytometry (and/or CyTOF),2021-10-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Dynamic changes in T-cell receptor (TCR) repertoire of peripheral mononuclear cells
1382,NCT01417611,polyp/adenoma detection rate (per-polyp/adenoma analysis and per-patient analysis),2010-09,COMPLETED,INTERVENTIONAL,['NA'],,characterization of polyp
1383,NCT02102893,"To establish the database for GEP-NET by register the clinical presentation, diagnosis, stages, treatment and clinical outcome of GEP-NET patients.",2014-02-13,COMPLETED,OBSERVATIONAL,['NA'],,
1384,NCT01346280,,2011-04-16,COMPLETED,OBSERVATIONAL,['NA'],,
1385,NCT00673504,Time to Progression,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
1386,NCT01589419,Determine the maximum tolerated dose (MTD) and/or establish the recommended phase two dose (RPTD),2012-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Assess the pharmacokinetic profile by area under the curve vs. dose of veliparib
1387,NCT02873442,Progress-free survival,2016-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
1388,NCT00870961,Rate of accrual,2009-02,TERMINATED,INTERVENTIONAL,['NA'],,"Correlation of vitamin D levels with vitamin D modifiers (e.g., levels of skin pigmentation, dietary vitamin D intake, and sun exposure)"
1389,NCT02386618,Efficacy of endoscopic treatment od local residual neoplasia (absence of neoplastic tissue in post-EMR scar proven by endoscopic and histologic examination),2013-10,COMPLETED,INTERVENTIONAL,['NA'],,
1390,NCT02454686,Accuracy of Fibroscan in predicting complication after hepatectomy,2012-02,COMPLETED,OBSERVATIONAL,['NA'],,
1391,NCT00572143,Quality of life; EORTC-QLQ-C30 and EQ 5D,2007-06,COMPLETED,INTERVENTIONAL,['NA'],,Cost-effectiveness Serious clinical events
1392,NCT02759588,Overall Response Rate (ORR) by RECIST 1.1 (Phase 2),2016-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical Benefit Rate
1393,NCT02551471,Clinical resection rates in both countries,2015-05-01,COMPLETED,OBSERVATIONAL,['NA'],,Analyses of semi-structured interviews
1394,NCT00861783,maximum tolerated dose,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,tumor measurement
1395,NCT03515538,Duration of Severe Oral Mucositis (SOM),2018-07-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patient-reported pain
1396,NCT05587725,Prevalence of type-specific HPV types,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
1397,NCT02175654,Progression free survival rate at 6 months,2014-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Biomarkers associated with cell and tumour growth and/or the mechanism of action of regorafenib and their correlation with patients' clinical progression for efficacy and safety parameters.,Changes in ECOG performance status over time from baseline
1398,NCT04571489,Progression free survival (PFS),2020-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Patient-reported outcome (PRO)
1399,NCT04220242,Validation of predictive accuracy biophysics-visualisation model,2019-12-30,UNKNOWN,OBSERVATIONAL,['NA'],,Realtime delineation display of tumour area including margins
1400,NCT03612531,Incidence of adverse events,2018-08-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Improvement in tongue innervation on Electromyography (EMG) findings
1401,NCT04032392,Overall survival (OS),2019-07-23,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Patients-based Quality of Life Evaluation
1402,NCT05166239,6-month progression-free survival rate,2022-01-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients with treatment-related adverse events
1403,NCT01976494,"Efficacy: Analgesic effect, Accuracy of bolus 2 mL administration",2013-10,COMPLETED,INTERVENTIONAL,['NA'],,Safety: Frequency of complications occurring after bolus
1404,NCT00068003,"Bank of autologous blood, stem cells, and/or tumor tissue from patients currently with cancer",2003-09-08,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Long-term storage of data and biospecimens
1405,NCT01589471,Efficacy of intra-rectal Botox-A injection on anorectal function as documented with standardized Wexner score,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety of intra-rectal Botox-A injections as documented with adverse events monitoring
1406,NCT01236443,Toxicity of HPPH at different doses,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Determine optimal PDT parameters using HPPH in HGD, CIS and Barrett's esophagus"
1407,NCT01458353,Peritoneal contamination after finishing the ileocolonic anastomosis,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
1408,NCT01118897,To assess the feasibility of concurrent chemo-radiation with dose escalated IMRT in locally advanced inoperable gallbladder and pancreatic cancers,2008-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
1409,NCT01446874,Adherence to the Pre-operative Toothbrushing Regimen,2011-09-22,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of Fever
1410,NCT05763277,progression free survival,2022-07-22,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
1411,NCT01283204,progression free survival(PFS),2010-03-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1412,NCT02145416,Changes on DW MRI during CRT in anal cancer.,2015-01-27,COMPLETED,OBSERVATIONAL,['NA'],To use PET SUV data in a radiotherapy in silico modelling exercise to determine if dose sparing of active pelvic bone marrow (PBM) is possible without compromising target coverage by radiation.,Correlation of the change in functional images over CRT with outcome of CRT
1413,NCT03662035,Progression Free Survival,2018-09-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease Control Rate
1414,NCT06287749,3-year Disease-free survival (DFS),2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Time to molecular recurrence
1415,NCT05453292,Disease-free survival,2024-01-15,RECRUITING,INTERVENTIONAL,['NA'],,Re-treatment rate
1416,NCT03838913,Determination of involved signal pathways,2019-02-15,UNKNOWN,OBSERVATIONAL,['NA'],,
1417,NCT02545725,Questionnaire on Quality of Life,2015-04,COMPLETED,OBSERVATIONAL,['NA'],,
1418,NCT04029857,Patient well-being improvement,2019-03-14,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
1419,NCT05032014,(objective remission rate)ORR,2021-11-19,UNKNOWN,INTERVENTIONAL,['NA'],,OS
1420,NCT01191411,"Colorectal Cancer Screening Participation, Defined as Completion of a Guaiac or Immunochemical Stool Occult Blood Test, Colonoscopy, Sigmoidoscopy, or Barium Enem.",2010-10,COMPLETED,INTERVENTIONAL,['NA'],,
1421,NCT02316340,Efficacy Based on Progression Free Survival of Vorinostat and Hydroxychloroquine Compared to Regorafenib,2015-02-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival (mOS)
1422,NCT05776875,Grade 3 or higher Treatment Related Adverse Events,2023-06-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to untaceable progression
1423,NCT01483027,Hepatic Progression-Free Survival (HPFS),2012-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
1424,NCT05985954,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2024-01-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,
1425,NCT00575562,The primary objective of this study is to assess the safety and tolerability of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer.,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,"The secondary objectives are to determine the degree of immunogenicity, gain information on the pharmacokinetic profile, assess the anti-tumor effects of KRN330 and determine the maximum tolerated dose (MTD)."
1426,NCT05167448,Phase 2: The anti-tumor activity of ES104,2022-02-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: The immunogenicity of ES104
1427,NCT02661945,Accuracy (accurate if the distance (between margin dots and tumor margin measured by histopathology) was less than 1 mm),2015-07,COMPLETED,INTERVENTIONAL,['NA'],,
1428,NCT01477177,"Reduction in Barrett's Histology Grade, Using the Modified Vienna Classification",2011-08,TERMINATED,INTERVENTIONAL,['NA'],,"Reduction in Barrett's Histology Grade, Using the Modified Vienna Classification"
1429,NCT03291899,Response rate,2017-01-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,overall survival
1430,NCT00551759,Proportion of Patients With Pathologic Complete Response,2008-10-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1431,NCT05597384,Autogenous blood marker localization was not inferior to intraoperative colonoscopy localization,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse events related to endoscopic tattooing
1432,NCT00817934,"TOTAL COLON CLEANSING, TO BE ABLE TO PERFORM COLONOSCOPY",2009-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1433,NCT06084780,Overall Rate of Survival,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Rate of Mortality
1434,NCT05480891,community education,2023-04-05,RECRUITING,OBSERVATIONAL,['NA'],,
1435,NCT04108481,Determine the maximum tolerated dose (MTD) of Yttrium-90 radioembolization combined with immunotherapy durvalumab to treat liver-predominant metastatic colorectal cancer (mCRC),2020-10-05,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Abscopal effects,Determine duration of response
1436,NCT04834661,overall postoperative complication rate,2021-10-20,COMPLETED,OBSERVATIONAL,['NA'],,
1437,NCT00860665,Correlation of adenoma detection rate with case volume of endoscopists,2006-10,COMPLETED,OBSERVATIONAL,['NA'],,Patient acceptance in relation to procedural factors (e.g. sedation)
1438,NCT02309632,Detection rate of PC and precancerous lesion,2015-11,WITHDRAWN,INTERVENTIONAL,['NA'],,
1439,NCT00699816,Recurrence Free Survival(RFS) Rate,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Cancer-specific Survival Rate
1440,NCT00003118,Overall survival,1997-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1441,NCT00038701,Patient Survival Rate,1999-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1442,NCT00003029,,1997-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1443,NCT05040815,Disease free survival (DFS),2023-05-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Relationship between radiotherapy treatment planning variables and acute toxicity.,Exercise Behavior and Physical Fitness
1444,NCT05653934,Anxiety assessment,2023-05,RECRUITING,INTERVENTIONAL,['NA'],,Morbidity
1445,NCT02112357,The percentage of patients in whom a currently actionable molecular alteration was detected by genetic sequencing.,2014-02,UNKNOWN,OBSERVATIONAL,['NA'],Duration of response for patients who received a targeted treatment as a result of genetic sequencing.,The number needed to enroll into the trial to identify one patient with a targetable genetic alteration and the number needed to enroll into the trial to treat one patient with a targeted agent.
1446,NCT00667082,To determine the Maximum tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the combination NPI-0052 and Vorinostat,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate the anti-tumor activity of NPI-0052 and vorinostat
1447,NCT04615806,Sensitivity and specificity of lymph node dissection,2020-09-22,UNKNOWN,INTERVENTIONAL,['NA'],,The mapping of sentinel lymph nodes in esophageal cancer
1448,NCT03271073,Progression-free survival (PFS),2016-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life(QoL)
1449,NCT03697564,Progression Free Survival (PFS),2019-10-31,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
1450,NCT01418222,"Progression-free survival: time from randomization to tumor progression or death, tumor assessments according to RECIST criteria",2011-09-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety: Incidence of adverse events
1451,NCT02381249,Progressive ratio task breakpoint for a sweet-fat reward,2015-03,COMPLETED,INTERVENTIONAL,['NA'],Sigstad score,Subjective symptom score
1452,NCT03092128,Progression free survival,2014-06,UNKNOWN,OBSERVATIONAL,['NA'],,Number of patients with objective response and adverse events
1453,NCT01531595,Efficacy,2012-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Response
1454,NCT04905147,Postoperative time to the first passage of flatus.,2021-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Length of postoperative hospital stay
1455,NCT02379039,Loco regional control,2015-05,COMPLETED,OBSERVATIONAL,['NA'],,Site specific toxicity
1456,NCT06005493,Objective Response Rate (ORR),2023-07-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Preliminary antitumor activity with target expression pre- and post-delivery of AZD5863
1457,NCT01197612,Olfaction,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Sinonasal Health
1458,NCT01250158,To demonstrate the feasibility of the liver PILP intervention.,2010-09,UNKNOWN,INTERVENTIONAL,['NA'],,
1459,NCT02229071,Adverse events,2014-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Time to symptomatic progression(TTSP),Time to progression(TTP)
1460,NCT00075452,Overall survival,2003-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Progression-free survival
1461,NCT00049608,,2002-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1462,NCT02065765,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
1463,NCT05748145,Impact of metronidazole on F.n. loads in CRC tissues.,2023-09-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Potential effects of metronidazole on the intestinal metabolic profile
1464,NCT00533533,To define the dose-limiting toxicity and maximum tolerated dose in phase I study To evaluate the overall response rate in phase II study,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,1) To evaluate the safety and tolerability of the treatment combination. 2) To estimate overall survival. 3) To estimate the time to progression and the duration of overall response.
1465,NCT05833594,Disease Control Rate,2023-07-01,RECRUITING,OBSERVATIONAL,['NA'],,"1-, 2-, 3-year Progression-free survival rate (PFS)."
1466,NCT00273585,Colorectal cancer screening self-efficacy,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Colorectal cancer screening decisional conflict
1467,NCT05204173,1-year survival rate,2021-05-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,3-year progressive free survival (PFS)
1468,NCT04370925,Peritoneal recurrence free survival,2020-06-04,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of participants with adverse events
1469,NCT06003218,Area under curve of Numerical Rating Scale of pain during and within 24 hours after surgery.,2023-10-16,RECRUITING,INTERVENTIONAL,['NA'],Incidence of postoperative complications during hospital stay.,Numeric Rating Scale of subjective sleep quality on the first and second nights after surgery.
1470,NCT02734823,Changes in markers of ovarian reserve in premenopausal women undergoing tyrosine kinase inhibitor therapy for cancer,2016-03-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Ovarian response to controlled ovarian hyperstimulation in patients who elect to undergo IVF for fertility preservation
1471,NCT02013830,Percentage of Participants With Objective Response (OR),2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival - Percentage of Participants Event Free at 12 Months
1472,NCT03573791,Comparing gene expression differences between poor response group and complete response group by using RNA sequencing.,2018-05-21,RECRUITING,OBSERVATIONAL,['NA'],,Progression Free Survival(PFS)
1473,NCT01737827,Time to progression using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1,2013-03-25,TERMINATED,INTERVENTIONAL,['PHASE2'],,Plasma pharmacokinetic parameter: Racc
1474,NCT00920751,Primary outcome - success of cecal intubation without sedation,2009-03,UNKNOWN,INTERVENTIONAL,['NA'],,"Diagnostic yield, patients' current experience, willingness to repeat future colonoscopy, turn around time, and staff rating of satisfaction, and medication-related complications."
1475,NCT04080843,Objective response rate(ORR),2019-11-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety: NCI CTC AE Version 4.0.3
1476,NCT00782366,"Assess accessibility and feasibility, including positive and negative aspects of integrating predictive genomics at the clinic focusing on patients' and physicians' attitudes",2008-03,COMPLETED,OBSERVATIONAL,['NA'],,Assess effects of predictive genomics on self-reported health behavior and on physician-patient interaction
1477,NCT01303159,Change From Baseline in Bile Duct Stricture Diameter,2010-03,TERMINATED,INTERVENTIONAL,['NA'],,Number of Participants With Adverse Events
1478,NCT02292641,To change R0 resection rates for locally recurrent rectal cancers with the use of the proposed staging system.,2014-09-25,RECRUITING,INTERVENTIONAL,['NA'],,To map original radiotherapy volumes (including integrated boosts) against types of recurrence
1479,NCT01758341,Number of RFA-procedures with technical failures,2012-12,COMPLETED,INTERVENTIONAL,['PHASE4'],Mortality,Number of patients with interventional complications
1480,NCT03316222,Dose-Limiting Toxicity,2018-04-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1481,NCT05923450,Disease-free Survival,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1482,NCT03756636,Rate of adverse events (according to the lexiconA ASGE).,2018-06-01,COMPLETED,INTERVENTIONAL,['NA'],,
1483,NCT02574013,Length of hospital stay,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative complications
1484,NCT04200131,"Obtaining histological diagnosis by using ""The Moray"" micro forceps.",2020-01-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Quality of the sample
1485,NCT02365480,Number of Participants With Organ Toxicity Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v.) 4.0,2016-06-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,Severity of Histologic Inflammation
1486,NCT03673501,Progression Free Survival (PFS) in the All Patient (AP) Intent to Treat (ITT) Population,2019-02-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS) in the All Patient (AP) Intent to Treat (ITT) Population
1487,NCT06323291,Feasibility of Utilizing the Digital Health Coaching Program,2024-03-08,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
1488,NCT00220116,Objective response rates,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number undergoing liver resections/curative resection (Ro) rate
1489,NCT02420678,"Reliability of FACT-Hep, EORTC QLQ-HCC18 and NFHSI-18",2015-04,UNKNOWN,OBSERVATIONAL,['NA'],,Death rates
1490,NCT00584402,Percent of Tumors With Increased Echogenicity (Brightness) Following Contrast-enhanced Sonography,2007-04,COMPLETED,INTERVENTIONAL,['NA'],,"Number of Participants With an Increase in Echogenicity (Brightness) of Small Intrahepatic Tumors Following Contrast-enhanced Sonography Based on Tumor Type, Size, Location and Depth"
1491,NCT04088955,Compare the duration of actual vs. intended treatment for cancer patients on capecitabine who are prescribed capecitabine with sensor.,2019-09-06,UNKNOWN,OBSERVATIONAL,['NA'],,
1492,NCT03853278,Functional Assessment of Cancer Therapy- Colorectal,2018-01-15,COMPLETED,INTERVENTIONAL,['NA'],,The Functional Assessment of Chronic Illness Therapy-Fatigue
1493,NCT03095781,Recommended phase II dose of the combination of XL888 and pembrolizumab as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,2017-07-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Immune profile effects of pembrolizumab and Hsp90 inhibitor XL888 assessed in serum and tumor biopsies,Response duration as assessed by RECIST 1.1
1494,NCT05765357,Area under drug concentration - time curve (AUC0-t),2017-07-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,Apparent volume of distribution (Vd/F)
1495,NCT04781192,Progressin Free Survival (PFS),2022-03-22,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
1496,NCT05024539,Regorafenib in combination with other drugs,2021-06-20,UNKNOWN,OBSERVATIONAL,['NA'],,Survival differences among the patients with different clinical phenotypes and genotypes
1497,NCT04141449,Incidence of curative-intent treatment,2020-11-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Patients treated for cancer
1498,NCT06114251,Postoperative recurrence of liver cancer,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1499,NCT01694238,Stoma hernia frequency at 12 months,2013-06,COMPLETED,INTERVENTIONAL,['NA'],,30 day mortality
1500,NCT04814043,conversion rate to resection,2021-04-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1501,NCT02233205,Number of Participants with Serious and Non-Serious Adverse Events,2014-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Disease Progression
1502,NCT04751396,Decisional conflict scale,2022-04-20,RECRUITING,OBSERVATIONAL,['NA'],,Patient's perception of usefulness of the tool
1503,NCT00634894,Median Progression-free survival (PFS): Time to progression or death from complete response (CR),2008-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
1504,NCT03314935,Phase 2: Objective Response Rate (ORR),2017-11-21,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tlast of INCB001158 in Participants Treated With INCB001158 in Combination With Chemotherapy Following the First Dose on Cycle 1 Day 1 and on Cycle 2 Day 1 Following Repeated Dose Administration
1505,NCT01684098,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1506,NCT04220827,Incidence of adverse events,2019-12-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
1507,NCT02353052,Number of participants with tumor metastasis,2013-07,UNKNOWN,OBSERVATIONAL,['NA'],,
1508,NCT01094626,Difference in lesion conspicuity between S-MRI and N-MRI,2010-04,WITHDRAWN,INTERVENTIONAL,['NA'],,Concordance of tumor measurements between S-MRI images and tumor specimens post-resection vs. concordance of tumor measurements between N-MRI and tumor specimens post-resection
1509,NCT02885142,Number of complete excision for TEM compare to number of complete excision for ESD in rectal carcinomas staged usT1N0 and rectal adenomas.,2016-11,TERMINATED,INTERVENTIONAL,['NA'],,
1510,NCT06082648,Quality of life Scale (EORTC QLQ-CR38),2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Proctoanal manometry
1511,NCT01403883,Evolution of Psychological anxiety score (STAI/Beck),2011-10,UNKNOWN,INTERVENTIONAL,['NA'],,Specific stoma related morbidity
1512,NCT04811833,Comparison of anastomosis leakage rate at different timepoints in postoperative course,2022-07,WITHDRAWN,OBSERVATIONAL,['NA'],,Assessment of suture material handling parameters
1513,NCT04879979,Symbol Digit Modalities Test (SDMT),2021-01-12,RECRUITING,INTERVENTIONAL,['NA'],,PROMIS Short Form: Pain 3a.
1514,NCT04498689,Progression Free Survival,2019-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
1515,NCT00369460,"Collection of information on weight, body mass index, age, ECOG performance status, gait speed, concomitant medications, CA19-9, and total lymphocyte count",2006-01,COMPLETED,OBSERVATIONAL,['NA'],,
1516,NCT01068132,Progression free survival,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1517,NCT02992886,2-year disease-free survival probability (%),2016-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Exploratory endpoints,QOL
1518,NCT03468712,Postoperative overall morbidity rate,2018-03-31,UNKNOWN,INTERVENTIONAL,['NA'],,Completion rate of laparoscopic surgery
1519,NCT02838186,number of additional identified polyps with right colon scope retroflexion,2013-05,COMPLETED,INTERVENTIONAL,['NA'],,Rate of retroflexion-related adverse events.
1520,NCT05450835,Early operative morbidity,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],,The number of attempts to insert anvil fork into oesophagus
1521,NCT03237507,PFS: Progression Free Survival,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,Safety
1522,NCT00853931,Response rate,2009-10,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival
1523,NCT00967655,2-year survival rate,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1524,NCT06190639,Disease-free survival (DFS),2023-10-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
1525,NCT05113134,Patient and Observer Scar Assessment Scale (POSAS),2015-03-02,COMPLETED,INTERVENTIONAL,['NA'],,Female Sexual Function Index (FSFI) questionnaire
1526,NCT02345460,Number of Patients Undergoing Surgical Resection After Receiving at Least 4 of the 6 Courses of Preoperative Chemotherapy,2015-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants Experiencing Perioperative (30-day) Mortality
1527,NCT00300521,overall recurrence-free survival rate at three year,2000-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,hazard rate of vascular invasion on survival rate and recurrence-free survival rate
1528,NCT04660929,Assess the safety and tolerability of CT-0508 in combination with pembrolizumab by estimating the frequency and severity of adverse events in subjects with HER2 overexpressing solid tumors (CT-0508 and pembrolizumab substudy only),2021-02-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Estimate progression-free survival (PFS).
1529,NCT02283372,Maximum tolerated dose (MTD),2015-01-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Frequency of RT adaptation based on MR guidance
1530,NCT03937895,Phase 2a - Objective Response Rate (ORR),2019-12-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2a - Toxicity (according to CTCAE 5.0)
1531,NCT06331273,Tumor recurrence rate,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1532,NCT06108596,cCR,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease-free survival (DFS) and overall survival (OS)
1533,NCT03485209,Confirmed ORR per blinded independent central review (BICR) (Part E),2018-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of anti-therapeutic antibodies (ATAs)
1534,NCT00437424,The primary objective of this study is to determine the effect of BMS-582664 on subjects with varying levels of hepatic impairment and guide prescribers with regards to dosing in specialized populations,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,To assess efficacy of BMS-582664 in subjects with advanced solid tumor malignancies and subjects with HCC by CT or MRI
1535,NCT03599778,Disease-free survival (DFS),2018-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1536,NCT04593134,Quality of Life (EORTC QLQ-STO22),2020-11-10,RECRUITING,INTERVENTIONAL,['NA'],,Circadian rhythms(using Actigraph)
1537,NCT06216561,Drug concentration in tumor,2023-11-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Adverse Events (AEs)
1538,NCT02114164,Intraoperative Pneumoperitoneal Pressure (mmHg),2016-08,COMPLETED,INTERVENTIONAL,['NA'],,Smoke Evacuation Quality
1539,NCT03469596,presence of nodal status,2017-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
1540,NCT04715633,Clinical complete response or pathological complete response,2020-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
1541,NCT04522336,Clinical complete response (cCR),2020-09-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Tumor T cell infiltrate,PFS at 24 months
1542,NCT02267213,Disease Control Rate (DCR),2014-04-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,"PK parameters, including AUC, Cmax and Tmax of S,S-TLC388, S,R-TLC388, metabolites TLC-U1, TLC-U2, and topotecan"
1543,NCT02036008,Reader diagnostic accuracy using Gdfos vs. EcGd compared to gold standard,2013-08,UNKNOWN,INTERVENTIONAL,['NA'],,Reader diagnostic accuracy of EcGd-enhanced imaging vs. Gdfos-enhanced imaging compared to gold standard (subgroup analysis for small lesions less than or equal to 1cm)
1544,NCT04512937,Rate of patients with R0 resection,2020-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Progression-free survivial (PFS)
1545,NCT05092113,Overall incidence of chemotherapy-induced diarrhea ≥ grade 1,2021-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],Changes of fecal flora and enteritis-associated inflammatory factors,Overall incidence of grade 3/4 gastrointestinal adverse events
1546,NCT00652054,Overall tumor response rate (ORR - the proportion of patients with objective evidence of PR or CR),2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,To investigate the relationship of S-1 plasma levels (components and metabolites) with safety and efficacy parameters
1547,NCT01284231,Evaluate the safety profile in adult subjects with advanced gastrointestinal (GI) adenocarcinomas who have no available standard or curative treatments.,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunogenicity of MED-565
1548,NCT04405206,OPR(organ preservation rate),2020-05-25,UNKNOWN,OBSERVATIONAL,['NA'],,SFS(stoma-free survival)
1549,NCT00003001,,1997-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1550,NCT00425360,Survival at 1 year,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Survival and response as assessed by delayed-type hypersensitivity
1551,NCT03763266,Bowel preparation,2018-12-06,COMPLETED,INTERVENTIONAL,['NA'],,Withdrawal time
1552,NCT05111444,Objective Response Rate (ORR),2021-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
1553,NCT00014651,,2001-03,TERMINATED,INTERVENTIONAL,['PHASE3'],,
1554,NCT01694966,To Assess the Detection Efficacy of Chromoendoscopy Performed With 200mg Methylene Blue MMX® 25 mg Tablets Versus Placebo Tablets (White Light Endoscopy) in Terms of the Proportion of Subjects With at Least One Histologically Proven Adenoma or Carcinoma.,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1555,NCT04084496,Disease free survival,2019-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
1556,NCT01127555,Response rate,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,To estimate overall survival
1557,NCT03609151,Progression free survival,2018-06-30,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
1558,NCT06260111,Level of Pain,2024-04-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Triceps skinfold
1559,NCT01040559,Dose-limiting toxicity assessed according NCI CTC AE v3.0,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics parameters of idarubicin and idarubicinol
1560,NCT03223662,BH3 Profiling of Pre-neoadjuvant Tumor Biopsy and Outcome of Pathological Complete Response After Neoadjuvant Chemoradiotherapy in Patients With Esophageal Adenocarcinoma or Squamous Cell Carcinoma,2017-10-31,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) in Esophageal Adenocarcinoma (EAC) and Esophageal Squamous Cell Carcinoma (ESCC) Patients Undergoing Neoadjuvant Chemoradiotherapy (nCRT) and Esophagectomy
1561,NCT04182724,ORR(phase II),2019-11-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PFS(phase I/II)
1562,NCT06322147,R0 resection rate,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,Early Tumor Shrinkage
1563,NCT04697394,Continuous retention of patients completing electronic data.,2022-03-15,RECRUITING,OBSERVATIONAL,['NA'],,Symptom cluster identification
1564,NCT06241703,urinary dysfunction,2024-02-19,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,International Prostate Symptom Score
1565,NCT02210559,Number of Participants Who Had Surgical Complications Post-Resection,2014-07-31,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Progression-Free Survival
1566,NCT04481100,Objective response rate (ORR),2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
1567,NCT04215861,Raman spectra,2019-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,objective response rate
1568,NCT04440332,Postoperative pulmonary infection rate and its relationship between peripheral blood of lymphocyte and immunocyte.,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1569,NCT00384176,Progression Free Survival,2006-08-30,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time to Worsening of Health Related Quality of Life (QOL) Based on the FACT Colorectal Symptom Index (FCSI)
1570,NCT02219854,3-year disease free survival rate,2014-07,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative recovery situation
1571,NCT03652428,Maximum Tolerated Dose of Gemcitabine and nab-Paclitaxel in LAPC patients receiving proton therapy,2019-04-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life through and after treatment
1572,NCT01160926,To determine the MTD (maximum tolerated dose) of AZD6244 or AZD2171 when combined with pre-operative capecitabine and radiotherapy in patients with locally advanced rectal cancer.,2010-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,To explore biological and radiological markers of response or toxicity
1573,NCT00259532,,2005-02,UNKNOWN,INTERVENTIONAL,['NA'],,
1574,NCT02891083,Disease free survival,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,side effect of adjuvant therapy
1575,NCT01214720,Duration of Overall Survival - Time to Event,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Bevacizumab Concentration in the Presence of Gemcitabine and Erlotinib
1576,NCT04863144,plasma concentrations of 3'-p-hydroxypaclitaxel,2020-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of adverse effects
1577,NCT06251115,Number of subjects with adverse events (AEs) and laboratory abnormalities defined as dose limiting toxicities (DLT),2024-01-26,RECRUITING,INTERVENTIONAL,['NA'],Efficacy: antiviral activity of QY-1-T,Efficacy: antitumor activity of QY-1-T in subjects with HBV-related HCC
1578,NCT04104334,Clinical examination and laboratory tests show no evidence of complications or untreated medical problems,2019-05-08,TERMINATED,INTERVENTIONAL,['NA'],,Rate of hospital readmission and mortality postoperative
1579,NCT00309179,"Objective tumor response (CR or PR) and disease control (CR, PR or SD) rates will be evaluated in this study based on RECIST criteria and modified WHO criteria.",2007-09-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Pharmacokinetics: Blood samples will be taken on Days 1, 2, and 15 during Cycle 1 and Day 1. Pharmacodynamics: Blood will be taken prior to dosing on Day 1, Days 1, 2, and 15 during Cycle 1 and Day 1."
1580,NCT00841191,Percentage of Participants With Clinical Benefit Response (CBR),2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percent Change From Baseline in Hepcidin Level
1581,NCT01227746,,2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,
1582,NCT00003147,,1998-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1583,NCT03017690,The total time for product preparation and administration,2017-04-12,COMPLETED,OBSERVATIONAL,['NA'],,Patient satisfaction
1584,NCT02230176,To determine the 12 months PFS,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Best response
1585,NCT02578459,Visual Analog Scale Pain Scores,2016-04,WITHDRAWN,INTERVENTIONAL,['NA'],,Adverse Events
1586,NCT06234007,pathology complete response(pCR),2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AEs)
1587,NCT02667925,Quantification by visual analysis the intensity of fixation of the solvent characterized in the intraperitoneal cavity,2016-03,WITHDRAWN,INTERVENTIONAL,['NA'],,Correlate site of relapse to localisation of labeled intraperitoneal solvent by nanocis in peritoneal cavity
1588,NCT00907543,Quality of life as assessed by FACT-E,2009-04,COMPLETED,INTERVENTIONAL,['NA'],,Safety and morbidity
1589,NCT01452295,Gather data,2010-06,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
1590,NCT00580359,To evaluate each response rate of S-1 and capecitabine in the elderly and/or poor performance status patients with recurrent or metastatic gastric cancer,2007-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"the duration of response, time to progression, progression-free survival,overall survival,the safety profiles,the quality of life,the CYP2A6 genetic polymorphism and its association with clinical outcomes in patients treated with S-1"
1591,NCT00442507,Time to Progression (TTP),2007-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Incidence and Severity of Toxicities
1592,NCT00094978,,2004-10-25,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1593,NCT01726452,Overall survival,2013-01-24,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1594,NCT01200316,Efficacy of Rocking Chair Motion on Surgical-Induced Stress,2012-02-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1595,NCT05880992,Adherence rate,2023-07-24,RECRUITING,INTERVENTIONAL,['NA'],,Major complications
1596,NCT04580667,To determine the cut-off values from the RadTox test results during early radiation treatment from all evaluable subjects to differentiate high toxicity score from average or low toxicity score.,2020-10-01,RECRUITING,OBSERVATIONAL,['NA'],,To determine the cut-off values from the RadTox test performed during early radiation treatment with patients categorized according to demographics and treatment options to differentiate high toxicity score from average or low toxicity score.
1597,NCT01543607,Safety: Number of Bile Leak After RFA Procedure,2012-02,TERMINATED,INTERVENTIONAL,['NA'],,Effectiveness: Change From Baseline in Bile Duct Diameter.
1598,NCT01995942,The primary endpoint will be time to relapse pertaining to the primary objective of relapse rate at 1 year and 3 years.,2013-06-07,UNKNOWN,OBSERVATIONAL,['NA'],,"Measurement of the change in mrEMVI from pre to post pre-operative therapy, will be based on a new proposed EMVI-TRG classification (EMVI TRG 1-5)."
1599,NCT02490735,progression-free survival(PFS),2015-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Stage at diagnosis,overall survival(OS)
1600,NCT04278287,Local control rate,2019-10-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,ctDNA analysis
1601,NCT05508737,Objective response rate (ORR),2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with Adverse Events that are related to treatment
1602,NCT00202800,To evaluate the response rate,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,To describe the toxicity profile
1603,NCT01198535,MTD of RO4929097,2010-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1604,NCT04476537,Number of participants assigned therapy with OncoTreat,2018-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
1605,NCT02302794,3-year disease free survival rate,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
1606,NCT05783622,Incidence of Clinically Significant Laboratory Abnormalities,2023-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Correlation of EGFR expression level with anti-tumor activity and safety
1607,NCT04385147,procedure related complications,2020-05-18,COMPLETED,OBSERVATIONAL,['NA'],,Effect of COVID-19 precautions on staff number
1608,NCT00710697,ECG interval change,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Safety/Efficacy
1609,NCT04098471,5-years disease free survival rate,2019-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,postoperative quality of life as assessed by EORTC QLQ-C30 questionnaire
1610,NCT04528745,Thrombocytopenia,2020-05-04,COMPLETED,OBSERVATIONAL,['NA'],Other adverse event(s) added by patient,Hospitalization
1611,NCT01526239,Communication with primary care physicians about CRC screening,2008-11,COMPLETED,INTERVENTIONAL,['NA'],,
1612,NCT06316908,Pain Score using the Visual Analog Scale,2020-02-25,COMPLETED,INTERVENTIONAL,['PHASE4'],,Incidence of Vomiting
1613,NCT05473325,Signal to Noise,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1614,NCT00555672,Number of Participants With First-cycle Dose Limiting Toxicities (DLTs),2008-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS)
1615,NCT05604378,EBV positive gastric cancer is associated with increased Ki-67 and decreased EGFR.,2022-08-03,COMPLETED,OBSERVATIONAL,['NA'],,
1616,NCT03735407,Number of Incidence of Device and Procedure Related Serious Adverse Events (SAE),2019-02-01,COMPLETED,INTERVENTIONAL,['NA'],,To Evaluate Subject's Satisfaction
1617,NCT03000374,Pathologic complete response (pCR),2017-05-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1618,NCT00897039,Correlation of a statistically significant discriminator of sensitivity with complete response rate,2006-03,UNKNOWN,OBSERVATIONAL,['NA'],,
1619,NCT01506687,Completion of verified CRC screening event (FOBT;colonoscopy) event in experimental vs. control groups within 48 weeks,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Screening preferences; predictors of CRC screening and screening preference.
1620,NCT02248519,Post-operative hospital stay,2014-12,UNKNOWN,INTERVENTIONAL,['NA'],Time to return to daily activity,Oncologic outcomes (R0-resection rate and lymph node yield)
1621,NCT03076502,Pathological diagnosis,2017-04,UNKNOWN,OBSERVATIONAL,['NA'],,Tumor status（worse/ maintain/ better）
1622,NCT06261138,Progression Free Survival (PFS) per mRECIST,2019-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Adverse events (AEs)
1623,NCT03405909,Diagnostic value of standardised CEUS-based algorithms for the non-invasive diagnosis of HCC in high-risk patients,2018-04-21,COMPLETED,OBSERVATIONAL,['NA'],,Influence of histological grading on contrast enhancement behaviour
1624,NCT01080521,Cognitive function as measured by the HeadMinder Customized Research Tool (CRT),2010-04,COMPLETED,OBSERVATIONAL,['NA'],,Patient-reported cognitive function as measured by Patient Assessment Own Functioning scale and web CRT
1625,NCT00601406,"Correlation of association between common genetic variations, reported by single nucleotide polymorphisms (SNP) in relevant candidate genes, with individual patient variability in normal tissue radiation response and toxicity",2006-03,UNKNOWN,INTERVENTIONAL,['NA'],,"PRS analyses against tumor control probability (TCP), using survival as a surrogate for TCP where necessary, and normal tissue complications vs tumor control probability"
1626,NCT01811277,Objective response rate for SOX sequential S-1,2010-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
1627,NCT05191940,Locoregional tumor control,2022-05-16,RECRUITING,INTERVENTIONAL,['NA'],,"Incidence of CTCAE v5.0 Grade 2 - Grade 5 acute, subacute and late toxicities"
1628,NCT03677960,Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of aHSIL,2018-12-17,TERMINATED,INTERVENTIONAL,['PHASE1'],Histopathology of areas with biopsy-proven disease following multiple doses of ABI-1968 Topical Cream.,Systemic exposure to ABI-1968 Topical Cream following topical application to the anal canal.
1629,NCT02944539,Relative copy number of mitochondrial DNA,2016-03,COMPLETED,OBSERVATIONAL,['NA'],,
1630,NCT00785122,Safety assessment,2008-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Non-Cellular immunomonitoring
1631,NCT05967143,Change scores from baseline to follow-up timepoints of the European Organization for Research and Treatment of Cancer Quality of Life Hepatocellular Carcinoma module (EORTC QLQ-HCC18),2023-06-19,RECRUITING,OBSERVATIONAL,['NA'],,Healthcare Resource Utilization summarized at follow-up timepoints
1632,NCT02282111,Diagnostic Accuracy,2014-07,TERMINATED,INTERVENTIONAL,['NA'],,Percent Sample Contribution to Immunohistochemistry Diagnosis
1633,NCT02795156,Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations,2016-09-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations
1634,NCT02890979,Detection of gene mutations using next generation sequencing (NGS),2016-08-03,COMPLETED,INTERVENTIONAL,['NA'],,Sensitivity and specificity of the NGS probes to detect underlying esophageal dysplasia or cancer
1635,NCT00843375,Biospecimen Retention: Samples with DNA,2019-08-07,RECRUITING,OBSERVATIONAL,['NA'],,
1636,NCT03758209,Change in preoperative functional status - FVC by the end of rehabilitation,2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],,"Delay in beginning of adjuvant oncotherapy (chemotherapy, radiotherapy)."
1637,NCT03253302,Positive rate of circumferential resection margin (CRM) of the specimens,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,the rate of postoperative complications
1638,NCT05985239,Calculation postoperative of the Comprehensive Complication Index (CCI) for each patient,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],Adjuvant chemotherapy in patients after low anterior resection for rectal cancer.,Total hospitalization costs
1639,NCT00005809,,2000-07,COMPLETED,INTERVENTIONAL,['NA'],,
1640,NCT03470350,Phase II: Response rate (RR) of galunisertib in combination with capecitabine in patients with chemotherapy resistant activated TGF-β signature-like CRC.,2018-08-24,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Baseline molecular status of potential predictive markers of tumor response
1641,NCT02539342,"Measure the Development of Oral Mucositis (Grade >/= 2) in Children, Adolescents and Young Adults.",2016-10,TERMINATED,INTERVENTIONAL,['PHASE3'],Tolerability of Four Times Daily Caphosol Therapy,
1642,NCT05241210,Adenoma Detection Rate,2021-12-13,RECRUITING,INTERVENTIONAL,['NA'],,
1643,NCT00174616,MRI staging and TME surgery,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Measure safety - NCI-CTC version 2
1644,NCT02719782,Safety of the TCR-T treatment,2015-07-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],"1-year PFS (progression free survival) which is measured by the number of patients with stable disease after 1 year, using mRECIST",Systemic release of inflammatory cytokines after administration of transduced T cells compared to baseline
1645,NCT00469339,"Examine whether a family-centered feedback approach, as compared to an individual-focused approach, encourages communications regarding family risk and the development of strategies to adopt health promoting behaviors within the household.",2007-04-27,COMPLETED,OBSERVATIONAL,['NA'],,
1646,NCT02199236,maximum tolerated dose (MTD),2014-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,tumor response
1647,NCT04442581,Number of Participants With Objective Response (Complete or Partial Response),2021-04-20,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
1648,NCT00033657,Pathologic Complete Response Rate,2002-08-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Recurrence-free Survival Time
1649,NCT00164879,The stoma rate in the two groups of patients,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Hospital stay
1650,NCT00055419,"The objective of this study will be to monitor the safety of administering cetuximab,via an access program, to subjects with metastatic colorectal carcinoma who have exhausted all standard therapies or treatment options.",2003-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1651,NCT04475640,Impact of germline genetic testing on both therapeutic management and targeted cancer prevention,2019-12-13,RECRUITING,INTERVENTIONAL,['NA'],,
1652,NCT03706742,Hepatitis C Screening,2018-09-10,COMPLETED,INTERVENTIONAL,['NA'],,Cost: Cost per-HCV diagnosis
1653,NCT00639509,Best Overall Response Rate (ORR),2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival
1654,NCT01303029,Progression free survival,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of rash in patients treated with erlotinib and progression free survival and overall survival and treatment relationship
1655,NCT00923299,Objective response rate as assessed by RECIST criteria (Phase II),2008-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
1656,NCT05915351,Overall Response Rate (ORR),2023-06-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
1657,NCT05867901,Drug retreatment response rate,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,MRD versus imaging examination
1658,NCT02115022,Staging capability of each study procedure,2014-07,COMPLETED,OBSERVATIONAL,['NA'],,"Patient survival time, and tumor recurrence-free survival"
1659,NCT04409340,Detection of focal HCC lesions,2020-10-05,RECRUITING,OBSERVATIONAL,['NA'],,
1660,NCT03508180,Evaluation of nausea and vomiting,2018-06-14,COMPLETED,INTERVENTIONAL,['NA'],,Body image
1661,NCT02033213,Changes in Lactate Levels During Esophageal Carcinoma Surgery Using Restrictive or Liberal Fluid Management.,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,Total Volume of Administered Intraoperative Fluid
1662,NCT00677079,Objective response rate,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Cancer antigen 125 response (participants with elevated CA125)
1663,NCT01904955,data concerning evolving relapse,2010-09,COMPLETED,OBSERVATIONAL,['NA'],,
1664,NCT02395016,overall survival（OS）,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,To determine the safety of the treatment with Nimotuzumab and Gemcitabine (NCI Common Terminology Criteria for Adverse Events v4.03)
1665,NCT01871571,Rate of CPR in the pathology specimen,2013-08-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence and nature of AEs of special interest for bevacizumab (grades) according to NCI CTCAE v4.0
1666,NCT02313688,3-year disease free survival,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],,The positive rate of proximal resection margin
1667,NCT04298320,Incidence of Treatment-Emergent Adverse Events,2020-03-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PFS
1668,NCT01896310,The diagnostic accuracy of the new classification system,2013-06,COMPLETED,OBSERVATIONAL,['NA'],,
1669,NCT00789893,To examine the effect of dilator use in minimizing vaginal stenosis so that patients are able to use the pre-radiation baseline dilator size 6 months after starting dilator use.,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,To explore patient-reported self-efficacy as it relates to the use of the vaginal dilator.
1670,NCT02047188,NBI prediction for lesion histology and invasion,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,immunohistochemical outcome of microvessel count and MMP-7
1671,NCT00953511,histopathologic response to chemoradiation,2009-08,COMPLETED,INTERVENTIONAL,['NA'],,prognosis
1672,NCT03448302,Blood flow of tumor,2018-03-10,UNKNOWN,OBSERVATIONAL,['NA'],,Permeability surface of the tumor
1673,NCT06161207,3-year disease free survival rate,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Postoperative quality of life (measured by EQ-5D)
1674,NCT04128332,The feasibility of delivering pre-operative SABR followed by immediate surgery as determined by rate of post-operative complications at 30 days.,2020-10-26,UNKNOWN,INTERVENTIONAL,['NA'],,Acute and late toxicity of pre-operative SABR: Number of adverse events
1675,NCT05600608,"To determine the diagnostic accuracy of the augmented exhaled breath test, in the prediction of oesophago-gastric cancer (OGC).",2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,To identify the mechanistic pathways and origins of the production of breath Volatile compounds by investigating the tumour lipidome.
1676,NCT04819971,Percentage of Participants With Pathological Complete Response (pCR),2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of All Participants That Discontinued Study Treatment Due to AE
1677,NCT01002443,Histological grading improvement rate,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1678,NCT01583361,disease free survival,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,safety
1679,NCT03942900,Peripheral CD4 anti-telomerase immunity and MDSC (Myeloid-Derived Suppressor Cells) analysis,2020-04-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
1680,NCT03985046,Local Control Rate,2019-10-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
1681,NCT01606098,Overall survival,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall survival in patients in whom treatment according to protocol was initiated
1682,NCT05839197,Objective remission rate (ORR),2023-05-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events and toxicities of Apatinib in combination with Camrelizumab
1683,NCT04529668,histopathology,2015-10-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
1684,NCT00328770,Percentage of Participants Surviving With no Evidence of Recurrent Tumor at One and Four Years After Liver Transplant,1996-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Sirolimus Toxicity/Intolerance
1685,NCT00615056,Progression Free Survival (PFS),2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Change From Baseline in MDASI-D Symptom Interference Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal"
1686,NCT01835041,Maximum Tolerated Dose,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Participants with a Clinical Response,
1687,NCT04809025,Diagnostic accuracy,2021-05-24,UNKNOWN,OBSERVATIONAL,['NA'],,Procedure duration
1688,NCT01256047,postoperative infectious complication,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,"plasma IL-6, CRP, Th1/Th2 balance"
1689,NCT03630640,Local recurrence-free survival during a 1-year follow-up after Nivolumab neoadjuvant/adjuvant therapy and EP procedure,2018-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Frequency of discontinuations treatment due to AEs
1690,NCT04850027,Disease free survival,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative complications
1691,NCT01613053,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
1692,NCT02423278,Relapse-free Survival,2010-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Length of Hospital stay
1693,NCT04224779,Area under the Receiver Operating Characteristic (ROC) curve of total cfDNA (defined as circulating cell-free DNA in plasma) percent change between the baseline sample (T1) and the sample at the end of the neo-adjuvant treatment (T3),2021-02-18,RECRUITING,INTERVENTIONAL,['NA'],,Tumoral response assessed by Magnetic resonance Imaging (MRI)
1694,NCT05666271,Adjacent organ thermal injury rate,2022-08-29,RECRUITING,OBSERVATIONAL,['NA'],,
1695,NCT01109615,Response rate,2010-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
1696,NCT05296369,Progression-free survival(PFS),2022-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
1697,NCT00727441,"Change in the Number and Function of Peripheral Mesothelin-specific CD8+ T Cells and CD4+, FoxP3+, and GITR+ Tregs",2008-07-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Free Survival
1698,NCT01975064,Over all survival,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4'],,Over all survival
1699,NCT01816659,Comparison of Ki-67 in Tumor Samples,2013-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1700,NCT05550025,Objective response rate (ORR) by RECIST 1.1 and mRECIST,2021-12-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,The median overall survival time (mOS)
1701,NCT05965999,"Agreement between positive EsoGuard test results and upper endoscopy diagnosis (i.e., subjects with BE/EAC newly diagnosed by upper endoscopy)",2023-04-11,RECRUITING,OBSERVATIONAL,['NA'],,"Agreement between negative EsoGuard test results and upper endoscopy diagnosis (i.e., subjects determined not to have BE/EAC on upper endoscopy)"
1702,NCT00503685,"Percentage of Participants With Complete Response (CR) or Partial Response [PR, Objective Response Rate (ORR)]",2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Expression of IGF Binding Proteins (IGFBP2, IGFBP3)"
1703,NCT01804998,3 year disease free survival rate,2013-03-27,COMPLETED,INTERVENTIONAL,['NA'],,5 year disease specific death rate
1704,NCT00056030,Surgical resectability rate as assessed by surgical resection of liver metastases,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life as assessed by UNISCALE and Symptom Distress Scale every 6 weeks
1705,NCT03122509,Overall Response Rate,2017-04-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1706,NCT05912075,Dose-limiting toxicities (DLTs),2023-12-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Distant metastasis-free survival
1707,NCT03718897,Overall survival rate,2018-09-14,UNKNOWN,OBSERVATIONAL,['NA'],,
1708,NCT06115499,Overall Survival (OS) (Phase III),2023-12-06,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of adverse events
1709,NCT04913077,Rate of GIST tumors,2020-03-10,SUSPENDED,INTERVENTIONAL,['NA'],,data for cost-benefit calculation
1710,NCT04227353,Data completion rates,2021-01-30,COMPLETED,INTERVENTIONAL,['NA'],,Change in Quality of life
1711,NCT00934882,"Effect of BAY73-4506 on the pharmacokinetics of mFOLFOX6 and FOLFIRI (Cmax, AUC, through concentration of BAY73-4506 and Cmax, AUC of Platinum, Irinotecan and its metabolite SN-38, 5-Flourouracil)",2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor response
1712,NCT00251862,Patient Adherence (Test Completion),2005-01,COMPLETED,INTERVENTIONAL,['NA'],,Screening Intentions
1713,NCT04888806,12-month progression-free survival (PFS),2021-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival(OS)
1714,NCT04536077,Amount of intratumoral conventional dendritic cells (cDCs),2021-08-13,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1715,NCT01569672,"Amount of time from abnormal evaluation of the breast, cervix, and colon or rectum to needed tests and treatment",2006-11,COMPLETED,INTERVENTIONAL,['NA'],,Number of barriers and effect of barriers on receiving needed tests and treatment
1716,NCT04612530,Safety of the combination treatment IRE + immunotherapy based on adverse events,2020-09-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Pain based on the Visual Analog Score (VAS)
1717,NCT04751370,Pathological complete response,2022-02-08,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
1718,NCT00816634,Response rates of both regimens,2008-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,a) progression-free survival b) quality of life c) toxicity d) overall survival e) predictive markers
1719,NCT00897923,"Cellular uptake of PBMCs and PMNLs as measured by reader/visual interpretation, semiquantitative grading system, and tumor-to-background uptake ratios",2003-09,COMPLETED,OBSERVATIONAL,['NA'],,
1720,NCT04809935,Pain score,2020-09-21,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Cost-effectiveness of two types approach
1721,NCT04617821,overall survival,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,postoperative complications
1722,NCT03804372,Percentage of patients presenting hepatitis B virus reactivation,2020-07-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients experiencing adverse events.
1723,NCT00045526,Major response rate (complete and partial response),2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1724,NCT05997056,Efficacy of nab-sirolimus,2023-11-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
1725,NCT01318239,MR perfusion parameter,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,diffusion parameter
1726,NCT05990959,Disease free survival,2022-04-22,RECRUITING,OBSERVATIONAL,['NA'],,
1727,NCT04677504,Progression Free Survival (PFS),2021-02-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of ADAs to Atezolizumab
1728,NCT06324097,negative predictive value,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,intra-observer agreement
1729,NCT04791735,The primary objective of the study will be to demonstrate the superiority of the laparoscopic approach over the open approach in reducing postoperative morbidity in HCC patients.,2021-05-21,RECRUITING,INTERVENTIONAL,['NA'],,Overall and disease free survivals.
1730,NCT00021138,,2001-04,COMPLETED,INTERVENTIONAL,['NA'],,
1731,NCT05233358,Progression Free Survival,2022-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The incidence of adverse events and serious adverse events
1732,NCT00191646,Progression Free Survival (PFS),2002-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival
1733,NCT02887235,Quality of life measurement,2016-03,COMPLETED,INTERVENTIONAL,['NA'],,Food security assessment plus HDMTM from baseline to 12 weeks
1734,NCT01556399,Significant differences in molecular abnormalities.,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,
1735,NCT05301699,postoperative complications during hospitalization,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
1736,NCT03657641,Overall survival (OS),2019-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1737,NCT00209742,3-years disease-free survival rate (DFS),2005-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Dose intensity (compliance), 5-year disease-free survival rate, 3- and 5-year survival rate, incidence of other adverse drug reactions, QOL"
1738,NCT01107639,Progression-free survival (PFS),2010-05-27,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to progression (TTP)
1739,NCT04967495,Overall survival (OS),2021-07-09,RECRUITING,INTERVENTIONAL,['NA'],,Duration of portal patency
1740,NCT06160323,The mean change in VAS pain score at 3 months,2023-11-10,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
1741,NCT05349045,PFS,2022-05-05,RECRUITING,OBSERVATIONAL,['NA'],,OS
1742,NCT00016978,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1743,NCT01872377,Toxicity defined as grade 3 or 4 gastro-intestinal or other non-haematological toxicity,2013-07,TERMINATED,INTERVENTIONAL,['NA'],,CyberKnife radiation dose measured in Gy delivered to the tumour and surrounding organs vs. the frequency of grade 3-4 toxicity defined by CTCAE v4.0
1744,NCT03232814,Adherence rates,2017-10-05,WITHDRAWN,INTERVENTIONAL,['NA'],,Participants' Overall Experiences: Qualitative Interviews
1745,NCT01938027,Total Mesorectal Excision(TME) quality,2013-09,COMPLETED,INTERVENTIONAL,['NA'],"Oncologic outcome(2-year local recurrence free survival, 5-year survival)","30-day postoperative complications, No. of harvested LN"
1746,NCT04253249,Treatment pancreatic cyst without surgery,2018-05-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
1747,NCT06073483,The rate of postoperative complications,2023-10-15,RECRUITING,INTERVENTIONAL,['NA'],,Intraoperative instrument operation error rate
1748,NCT00814619,Pathological complete or near-complete response (Dworak grade 3 and 4),2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events
1749,NCT03021668,Rate of Surgical Site Infection,2017-01,COMPLETED,INTERVENTIONAL,['NA'],,30-d Readmission
1750,NCT03099486,Progression Free Survival (PFS) at 2 Months,2017-10-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Toxicities Due to Regorafenib and 5-FU/LV Combination Therapy
1751,NCT01350206,overall survival,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Time to progression
1752,NCT04663035,1-year recurrence-free survival (RFS) rate,2020-12-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Evaluate the patient's cancer-related QoL using the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ), the EORTC QLQ-C30 and the EORTC QLQ-HCC18."
1753,NCT02009631,To evaluate the effect of Veliparib on corrected QT interval calculated by Fridericia's formula (QTcF),2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor Assessment
1754,NCT01534546,3 year Disease Free Survival,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Event
1755,NCT02396745,Safety: Long-term (Study Related Adverse Events),2016-01-25,TERMINATED,INTERVENTIONAL,['NA'],,Additional Interventions (Number of Subsequent Follow up Treatment Interventions)
1756,NCT04181645,ORR：Objective Response Rate by IRC,2019-06-29,UNKNOWN,INTERVENTIONAL,['NA'],,OS: overall survival
1757,NCT04550260,Progression free survival (PFS) per RECIST 1.1 as assessed by BICR,2020-10-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse events (AEs),Progression free survival (PFS) per RECIST 1.1 as assessed by BICR
1758,NCT06242418,change in value of ctDNA concentration,2024-03-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,quality of life as assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).
1759,NCT03880721,Specificity,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1760,NCT05659290,Progression-free Survival (PFS),2023-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
1761,NCT02626312,Maximum dose constraint,2016-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Tumor biomarker expression in serum,Overall survival
1762,NCT00188565,- To determine the efficacy of celecoxib in combination with preop RT and continuous infusional 5-FU. Pathologic complete response rate (pCR) will be used as the endpoint.,2004-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Quality of life (FACT, EORTC)"
1763,NCT02363218,Overall survival rate,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression-free survival
1764,NCT01940237,Change in Hamilton Depression Scale (HAMD-17),2012-04,TERMINATED,INTERVENTIONAL,['NA'],,
1765,NCT01675934,Percentage of cases in which right-sided retroflexion is successful with the adult and pediatric colonoscopes.,2012-02,WITHDRAWN,INTERVENTIONAL,['NA'],,Reasons for failure of retroflexion.
1766,NCT00354887,Number of Participants With Overall Response,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1767,NCT00891930,Part 2: Objective Response Rate (ORR),2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Subjects With Worst Post-baseline Grade 3 or Higher Laboratory Toxicities
1768,NCT00682786,Rate of Tumor Downstaging Compared With Historical Controls.,2002-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine Patient Fears and Expectations of Pharmacogenetics.
1769,NCT01740648,Identify the maximally tolerated dose of Trametinib to be used in combination with 5FU and radiation in patients with rectal cancers.,2012-11-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Frequency of patients undergoing sphincter preserving surgery
1770,NCT03407417,Completion of initial FIT screening,2018-11-08,RECRUITING,INTERVENTIONAL,['NA'],,Completion of repeat Annual FIT screening
1771,NCT00216437,Dose-limiting toxicity.,2004-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1772,NCT05687318,PMR,2022-09-20,COMPLETED,INTERVENTIONAL,['NA'],,AMR
1773,NCT00020501,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1774,NCT00098579,MTD of alvocidib when given every three weeks in conjunction with doxorubicin hydrochloride,2004-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Therapeutic activity of alvocidib in combination with doxorubicin hydrochloride in patients with advanced solid tumors
1775,NCT03627559,Pyruvate concentration postoperatively,2013-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
1776,NCT05698992,General Quality of life,2023-02-27,RECRUITING,OBSERVATIONAL,['NA'],Discharge destination,Rehabilitation process
1777,NCT02780284,Percentage of participants retained at the end of study,2015-03,COMPLETED,INTERVENTIONAL,['NA'],,"Percentage of participants with collected, processed, and analyzed stool samples"
1778,NCT06256185,Sub-analysis (ML Model vs. Logistic Model vs. NCCN Guideline),2010-01-15,COMPLETED,INTERVENTIONAL,['NA'],,
1779,NCT02204306,disease control rate,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],drug toxicities,median overall survival
1780,NCT02745483,Cumulative 3-year LTP rate,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Technical success rate,3-year Recurrence free survival rate
1781,NCT00346099,Percentage of patients with clinical complete response rate in tumor in the pelvis at 4 to 6 weeks after completion of radiation therapy,2006-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,The toxicity of panitumumab in combination with chemotherapy and in combination with chemoradiotherapy
1782,NCT05795374,Postoperative morbidity.,2022-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence
1783,NCT06156748,Overall survival,2019-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
1784,NCT01549756,,2012-03,UNKNOWN,OBSERVATIONAL,['NA'],,
1785,NCT06199973,Progressive free survive assessed by Independent Review Committee,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Effectiveness: overall survive assessed by the researchers
1786,NCT05466565,recurrence-free survival time,2021-12-01,RECRUITING,OBSERVATIONAL,['NA'],,Dynamic changes of cccDNA
1787,NCT03821948,Blood-based biomarkers associated with genetic and epigenetic alterations.,2019-01-03,COMPLETED,OBSERVATIONAL,['NA'],,
1788,NCT01847794,HER2 positive CTC,2013-06,UNKNOWN,INTERVENTIONAL,['NA'],,clinical significance of HER 2 positive CTC
1789,NCT05131958,Perception measure,2021-12,UNKNOWN,OBSERVATIONAL,['NA'],,
1790,NCT01785537,Change from baseline in the number of traditional cigarette smoked,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],,Traditional and electronic smoking (overall smoking) cessation
1791,NCT03750669,Disease-free survival,2018-10-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Serious adverse events incidence
1792,NCT02426762,freedom from surgical site infection,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Pain Scores on the Visual Analog Scale
1793,NCT05620732,AE/SAE,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,ORR
1794,NCT02042859,"Improvement in size(patency of bile duct) measured by cholangiography or cholangioscopy, immediately post ablation",2013-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
1795,NCT00980603,response rate,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,time to progression
1796,NCT02459041,Strain histogram and contrast enhancement during EUS in pancreatic masses and lymph nodes,2015-01,COMPLETED,OBSERVATIONAL,['NA'],,
1797,NCT00176787,"e. The relationship of intratumoral levels of thymidylate synthase, dipyrimidine dehydrogenase and thymidine phosphorylase determined immunohistochemically to response",2000-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1798,NCT03878524,Feasibility of implementing an individualized treatment strategy (number of participants to receive first dose),2020-04-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Time to decline (TTD)
1799,NCT06090825,Descriptions and scores of real status of hospice care in different hospitals,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
1800,NCT04592029,Progression free survival (PFS) assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune-related RECIST (irRECIST).,2020-09-27,UNKNOWN,INTERVENTIONAL,['PHASE1'],,DOR assessed by investigators according to mRECIST.
1801,NCT05582018,Safety,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Precision,Assessment Module (1)
1802,NCT05453630,Number of participants who complete colonoscopy within 1 year of the colonoscopy referral,2022-06-16,RECRUITING,INTERVENTIONAL,['NA'],,Number of participants who have colonoscopies with cecal intubation
1803,NCT01073046,Influence of Naso-Gastric/Jejunal Tube on Postoperative complications,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,Influence of Naso-Gastric/Jejunal Tube on Postoperative Patient's Comfort
1804,NCT03261947,Disease Control Rate (DCR) in Tumor-Specific Cohorts,2017-10-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Percentage of Participants With Clinically Significant Changes in Vital Sign Measurements, Reported as Adverse Events in Tumor-Specific Cohorts"
1805,NCT03382600,Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR),2018-03-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Discontinuing From Study Treatment Due to AE(s)
1806,NCT06018857,Overall Survival,2017-05-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1807,NCT01876901,Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among 2SCA,2010-08-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among CAA
1808,NCT02216149,Frequency of coronary artery dysfunction,2015-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Survival status
1809,NCT05634720,Feasibility of HA Chemotherapy for PDAC,2024-01-02,RECRUITING,INTERVENTIONAL,['PHASE4'],,Overall Survival
1810,NCT00667628,Time to Appearance of New Lesions (TTNL),2008-04-24,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
1811,NCT03286738,percentage of use FOLFIRI regimen and target agents,2015-11,UNKNOWN,OBSERVATIONAL,['NA'],,
1812,NCT05445401,DMSM score,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative complication rate of grade IIIa or above.
1813,NCT05563766,Rate of pathological complete response with itraconazole,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Determine the utility of ctDNA and exosome characterization as a prognostic marker
1814,NCT05215379,The rate of cCR,2022-10-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,quality of life
1815,NCT02461043,3 year relapse free survival,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],5 year overall survival,3 year overall survival
1816,NCT00002933,Effectiveness of irinotecan in treating patients who have metastatic or recurrent colorectal cancer.,1996-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1817,NCT06184152,Early HCC Detection,2023-11-28,RECRUITING,OBSERVATIONAL,['NA'],,Early HCC Detection
1818,NCT03150706,"Serum CEA, TSH, T3, free T4, EKG,CT (or MRI) scans of evaluable/measurable lesions by RECIST 1.1.",2017-05-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1819,NCT04974047,pCR Rate,2021-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number Of Participants Experiencing Treatment-Emergent Adverse Events
1820,NCT00056992,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1821,NCT03832985,Initiation of risk reduction behavior,2020-11-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Health Education Impact Questionnaire (heiQ)
1822,NCT03489707,Compliance as assessed by the number of participants who provide specimens for annual anal HPV DNA screening,2020-01-09,COMPLETED,INTERVENTIONAL,['NA'],Host/viral methylation and its association with high-grade squamous intraepithelial lesions.,Number of participants who attend high resolution anoscopy
1823,NCT01470404,germline polymorphisms in xenobiotic metabolism genes in toxicity profile,2008-07-10,COMPLETED,OBSERVATIONAL,['NA'],,
1824,NCT04138381,Clinical benefit rate (CBR) for the use of selinexor in monotherapy,2019-08-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical benefit rate (CBR)
1825,NCT05303818,Deep venous thrombosis and embolic pulmonary disease,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,Safety of rivaroxaban
1826,NCT02817126,Locoregional recurrence rate,2016-07-10,UNKNOWN,INTERVENTIONAL,['NA'],,Self reported sexual function for female patients
1827,NCT02228785,Antibody Levels,1994-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Intra-gastric pH
1828,NCT05604573,detection sensitivity of genetic mutation by mmADPS,2022-02-09,RECRUITING,OBSERVATIONAL,['NA'],,correlation of genetic mutation and prognosis
1829,NCT01104129,Positive mutation rate in tumors/IPMN lesions vs. control,2009-07-09,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of patients with genetic abnormalities correctly detected in stool samples
1830,NCT00005926,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1831,NCT01104077,Percentage of IPMN patients with relatives with pancreatic cancer or IPMN,2008-11-17,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of IPMN patients exhibiting higher malignant potential or recurrence following surgical resection
1832,NCT05533541,Primary End point,2023-10-01,RECRUITING,OBSERVATIONAL,['NA'],,Secondary End point 4
1833,NCT04806464,Part2:ORR,2021-03-16,UNKNOWN,INTERVENTIONAL,['PHASE1'],,"Part 2:PD-L1, PD-1"
1834,NCT04720521,Detection rate of gastric neoplastic lesion,2019-05-10,UNKNOWN,INTERVENTIONAL,['NA'],,Sensitivity of detecting gastric neoplastic lesion
1835,NCT02268435,Maximal tolerated dose and recommended dose,2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,"Imatinib and dovitinib plasma concentrations vs time profile, and basic pharmacokinetics parameters"
1836,NCT01196390,Disease-free Survival (DFS),2011-02-14,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Any Cardiac Adverse Events Regardless of Attribution
1837,NCT00637364,"Safety of the FEP-BY02 HIFU system determined by the frequency and severity of adverse events (AEs) categorized and graded for severity according to the Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE)",2008-03,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1838,NCT02316834,Change in ribonucleic acid (RNA) protein expression,2015-06-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Change in RNA protein expression
1839,NCT02576964,Objective response rate,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
1840,NCT04627142,Objective Response (OR) according to RECIST version 1.1,2020-11-23,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of patients experiencing grade ≥3 treatment-related AEs during the entire treatment period
1841,NCT03073694,Comprehensive Complication Index (CCI) score.,2017-07-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,
1842,NCT02597465,"Progression Free Survival (PFS) of subjects treated with SPARC1507 versus IC, per Response Evaluation Criteria in Solid Tumors version 1.1",2018-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
1843,NCT01606241,"Proportion of patients who experience severe toxicities (grades 3-5 of the National Cancer Institute's Cancer Therapy Evaluation Program [CTEP] Common Terminology Criteria for Adverse Events, version 4.0)",2012-07-24,COMPLETED,INTERVENTIONAL,['PHASE1'],Percent change in antigen-specific cytokine profiles,Percentage change in plasma concentration of cytokines and chemokines
1844,NCT03744247,Overall Survival (OS),2019-04-21,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Time to Progression (TTP)
1845,NCT00199173,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1846,NCT05983367,Overall Response Rate,2023-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate
1847,NCT04953585,overall survival time,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1848,NCT02358395,Pharmacokinetic profile of BBI608 when administered in combination with Sorafenib.,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
1849,NCT01310699,Number of Participants With Nonpolypoid (Flat and Depressed) Colorectal Neoplasm,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Nonpolypoid (Flat) Missed Lesions
1850,NCT01250015,Comparison of the two groups' overall wish to be screened,2007-09,COMPLETED,OBSERVATIONAL,['NA'],,Impact of different summary points on subject's desire to be screened
1851,NCT03245346,Overall survival (OS),2017-12-19,UNKNOWN,INTERVENTIONAL,['NA'],,Plasma levels of ropivacaine and sufentanil
1852,NCT03828318,Global quality of life (QoL),2019-09-01,RECRUITING,INTERVENTIONAL,['NA'],,
1853,NCT04724070,Construction of a personalized drug screening platform for individuals using novel cancer models established from patient-derived cancer cells and tissues.,2019-10-16,RECRUITING,OBSERVATIONAL,['NA'],,Describe the prevalence of actionable genomic aberrations in patients with advanced cancers in Hong Kong
1854,NCT05328960,Yearly incidence of rectal cancer,2022-02-15,RECRUITING,OBSERVATIONAL,['NA'],,Treatment changes
1855,NCT05040347,Concentration of NETs markers and anti-β2 glycoprotein I,2020-08-18,COMPLETED,OBSERVATIONAL,['NA'],,
1856,NCT02689284,Duration of Response,2016-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Terminal Half-life
1857,NCT04390243,Objective Response Rate (ORR) at 24 Weeks,2020-11-16,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Grade 3+ Adverse Events
1858,NCT01416168,Feasibility of the Intervention,2008-12,COMPLETED,INTERVENTIONAL,['NA'],,Effect Size Estimates for Within-group Changes Between Baseline and 1-month
1859,NCT03812796,Main Phase IIB (efficacy) phase: Objective response rate using RECIST 1.1 criteria,2019-01-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Duration of objective response according to RECIST 1.1
1860,NCT02931890,Event-Free survival,2017-12-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity
1861,NCT00003137,response rate,1997-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,survival
1862,NCT03026452,Tumor size assessed by MRI,2013-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Alpha Fetoprotein (AFP) level assessed by ELISA
1863,NCT04362449,Nausea according to the Common Terminology Criteria for Adverse Events (CTCAE) V4.03,2019-01-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Health economics in the context of duration of hospital attendance
1864,NCT04289792,Kaplan-Meier Estimate of Progression-Free Survival (PFS),2020-05-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Participants With Treatment Emergent Adverse Events (TEAEs)
1865,NCT02781337,Disease-free survival,2012-05,RECRUITING,OBSERVATIONAL,['NA'],,Molecular characteristics of colorectal adenocarcinoma.
1866,NCT01143285,Toxicities frequently associated with chemotherapy,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival
1867,NCT06202066,PFS (Part 2),2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events (Part 2)
1868,NCT02584400,"Quantification of tumor hypoxia with [18F] HX4 PET imaging, evaluated by the measurement of a tumor-to-background (T/B) ratio on the [18F]HX4 PET/CT",2016-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Spatial correlation of [18F] HX4-PET with imaging three months after treatment using a correlation coefficient
1869,NCT05190575,ORR,2022-01-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety & tolerability
1870,NCT05293496,Number of participants with AEs leading to study treatment discontinuation,2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of PSA response for mCRPC
1871,NCT01729221,Incidence of hepatocellular carcinoma post stem cell therapy in hepatitis C virus infected patients,2010-01,UNKNOWN,OBSERVATIONAL,['NA'],asses liver functions in both groups,Compare the incidence of hepatocellular carcinoma in patients who had received stem cell therapy to those who had received the standared line of care
1872,NCT04623749,"Yield, as defined by the percentage of patients in whom a histologically interpretable specimen will be retrieved by Trans abdominal US-FNAC. diagnostic accuracy",2021-12,UNKNOWN,INTERVENTIONAL,['NA'],,"Yield, as defined by the percentage of patients in whom a histologically interpretable specimen will be retrieved by EUS-FNAC. diagnostic accuracy"
1873,NCT00447122,Overall Survival for Patients With Metastatic Pancreatic Cancer.,2007-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1874,NCT01966133,Disease-free survival,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],Health-related quality of life assessment,Complications of transarterial chemoembolisation
1875,NCT05610163,Clincal Complete Response (cCR) Rates,2022-12-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events (AEs)
1876,NCT03869294,Overall survival,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,adverse events
1877,NCT02654288,The dynamic change patterns of sera IgG4 and IL-10 of pancreatic cancer after gemcitabine-based chemotherapy will be recorded.,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,The correlation of the changes of IgG4 and IL-10 with the overall survival after chemotherapy will be analyzed.
1878,NCT01184482,Maximum tolerated dose,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Genetic variations and activation status for EGFR and ErbB2 pathways
1879,NCT00155103,,2004-08,UNKNOWN,OBSERVATIONAL,['NA'],,
1880,NCT05221775,adverse effect,2021-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,OS
1881,NCT03768414,Overall survival (OS),2019-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Changes in carbohydrate antigen 19-9 (CA 19-9) levels
1882,NCT05650216,pCR,2022-12-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
1883,NCT04124991,TTP,2020-06-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with treatment-related adverse events
1884,NCT01216345,best overall response (according to RECIST 1.0),2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety of the treatment combination
1885,NCT02989870,Occurrence of Treatment Related Adverse Events,2017-03-27,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
1886,NCT06325826,Hepatocellular Carcinoma,2022-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1887,NCT06239870,pCR,2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,TRG
1888,NCT03889795,Maximum Tolerated Dose and/or Recommended Dose within the tested C3 dose range,2019-06-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Assess molecular changes induced by C3 administration in the blood for biomarker sensitivity/resistance assessment
1889,NCT04042805,Objective Response Rate (ORR),2019-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Tumor mutation burden in association with ORR and survival.
1890,NCT03752086,pancreatic fistula,2019-01,UNKNOWN,INTERVENTIONAL,['NA'],,major complications (Clavien-Dindo ≥III)
1891,NCT03185988,Response Rate(RR) for each cohort in intent to treat (ITT) population,2017-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
1892,NCT02885753,progression-free survival,2016-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,
1893,NCT00372944,Median time to death (TTD),2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess the safety and tolerability of AZD6244 in the treatment of advanced or metastatic pancreatic cancer by review of adverse events (AEs) and laboratory parameters.
1894,NCT01735955,Number of Participants With Adverse Events and Serious Adverse Events,2013-03-29,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Participants With Clinical Benefit From Nilotinib
1895,NCT00937248,Comparing the use of a prone pillow and simple ankle fixation device vs. the use of a CVID for immobilization rectal patients during the course of preoperative radiation therapy using KV CBCT for IGRT.,2009-04,COMPLETED,INTERVENTIONAL,['NA'],,quantify interfractional set-up displacements using either of the two devices;determine a standard planning target volume margin; evaluate the role of soft-tissue image matching for IGRT using CBCT.
1896,NCT00303914,"Prevalence, severity, and interference due to physical and psychological symptoms experienced by cancer patients as assessed by MD Anderson Symptom Inventory at baseline and days 28-35 following initial assessment",2006-03-14,COMPLETED,OBSERVATIONAL,['NA'],,Focus and scope of interventions chosen to improve symptom control
1897,NCT00020787,To determine whether a concomitant G17DT-chemotherapy regimen affects tumor response in subjects with gastric or gastroesophageal cancer.,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Time to disease progression, best overall response, and survival will be evaluated in the intent-to-treat population and the evaluable population."
1898,NCT03778879,Percentage of patients who are ineligible for surgical resection due to toxicity from SBRT + CCX872-B or SBRT alone,2019-08-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Mean time to death
1899,NCT03518489,Change from Baseline Numeric Rating Scale for Pain(NRS scale) at 7 weeks,2018-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,The Adverse events Related to lappaconitine
1900,NCT03381053,Number of participants with tumor metastasis,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1901,NCT06128551,Dose Limiting Toxicities,2023-11-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS)
1902,NCT05712356,Incidence of adverse events,2023-08-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,
1903,NCT00154804,Clinical and pathological response rates,2001-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
1904,NCT01071655,progression-free survival,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of KRAS status as a molecular marker
1905,NCT02309177,Grade 3 or 4 TEAE,2015-01-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Duration of Response
1906,NCT02659852,Median patency duration,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,complication rate
1907,NCT00004195,Primary Goal to demonstrate that eniluracil at current clinical doses,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Specific Aims,Evaluate DPD recovery and uracil levels
1908,NCT04106856,Grade 3 or higher gastrointestinal toxicity rate,2019-08-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Patient reported quality of life assessment- review of symptoms and how they interfere in life,Number patients that require a medical intervention or hospitalization due to hypotension
1909,NCT05379595,Cohorts D and E: Number of Participants with Vital Signs Abnormalities,2022-07-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Cohorts D and E: Progression Free Survival (PFS)
1910,NCT00220246,,2004-03,UNKNOWN,OBSERVATIONAL,['NA'],,
1911,NCT04395469,Tumor Hypoxia,2021-05-18,RECRUITING,INTERVENTIONAL,['NA'],,
1912,NCT05619172,Objective response rate (ORR) according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1),2022-12-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Time course of ADAs against nanrilkefusp alfa
1913,NCT03894917,Characterize the Change in disease and treatment patterns of advanced hepatocellular carcinoma (HCC) in older patients in the US.,2019-09-13,RECRUITING,OBSERVATIONAL,['NA'],,
1914,NCT05661292,Asian Pacific Colorectal Screening (APCS) score validation in Mexican population.,2019-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Optimal Fecal Immunochemical Test (FIT) valued for Advanced Colorectal Neoplasia (ACN) detection.
1915,NCT01736410,Overall Response Rate (ORR),2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Treatment Failure (TTF)
1916,NCT05599932,Pharmacokinetics (PK): AUCinf,2022-12-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1917,NCT04776148,Overall Survival (OS),2021-03-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score
1918,NCT02094625,Target Serum Level NAC,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Glutathione serum level
1919,NCT04933669,Progression free survival（PFS）,2021-09-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
1920,NCT03285906,progression-free survival,2017-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,median Overall Survival
1921,NCT05925413,Objective response rate (ORR),2023-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (safety)
1922,NCT05743049,"To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use.",2023-02-27,RECRUITING,OBSERVATIONAL,['NA'],,To integrate the data and specimens to permit the most informative clinical-biologic research platform.
1923,NCT00622440,Final Response of Anal High-grade Squamous Intraepithelial Lesions (HSIL),2008-05-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response With >75% Adherence
1924,NCT00068692,3-year Overall Survival Rate,2003-10-15,COMPLETED,INTERVENTIONAL,['PHASE3'],,Failure Pattern
1925,NCT05361954,Incidence of immune-related adverse events (IrAEs),2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Assess immunoglobulin levels
1926,NCT01048216,To evaluate feasibility of conformal radiation therapy in patients with metastatic colorectal liver cancer and determine its safety,2006-11,UNKNOWN,INTERVENTIONAL,['NA'],,Set up verification with cone-beam CT (OBI on Boar Imager)
1927,NCT02404363,Response to treatment based on RECIST 1.1 criterion,2016-01-11,TERMINATED,INTERVENTIONAL,['PHASE3'],,Bleedings
1928,NCT00154102,Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety - Number of Patients Experiencing Any Adverse Event
1929,NCT00533975,,2007-09,UNKNOWN,OBSERVATIONAL,['NA'],,
1930,NCT02376985,Incidence of oral mucositis (Over Grade 1) after everolimus treatment,2015-03-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,Health-related quality of life (HRQOL)
1931,NCT05902988,Dose Expansion: Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1,2023-10-18,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Dose Escalation & Dose Expansion: Increase in Micronuclei in Circulating Tumor Cells
1932,NCT04469426,Assessing 'Change' via European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire - C30 questionnaire after 6 months,2020-08-15,RECRUITING,INTERVENTIONAL,['NA'],,Bowel function Low Anterior Resection Syndrome score
1933,NCT00006472,,2000-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1934,NCT01845467,Evaluating the additive benefit of Secretin MRCP in differentiating focal AIP and Pancreatic malignancy,2013-02,WITHDRAWN,OBSERVATIONAL,['NA'],,Efficacy of Secretin MRCP in monitoring therapeutic improvement in AIP patients on steroid trial
1935,NCT03783442,Overall Survival (OS),2018-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants Experiencing Adverse Events (AEs)
1936,NCT05718492,Progress Free Survival (PFS),2022-10-18,RECRUITING,INTERVENTIONAL,['NA'],,Adverse Events (AEs)
1937,NCT00629265,Change in Penetration-Aspiration Scale (PAS) Score,2008-03,COMPLETED,INTERVENTIONAL,['NA'],,Performance Status Scale for Head and Neck Cancer Patients (PSS); The Head and Neck Cancer Inventory (HNCI)
1938,NCT01372202,Pathological Complete Response,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Esophageal Tumor CHFR Methylation and Detection in Plasma
1939,NCT04880772,Inflammatory cytokines,2021-07-15,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life measure (Mental Adjustment to Cancer Scale)
1940,NCT06053996,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival (OS)
1941,NCT03888859,Frequency of ARTEMIS T cell treatment-related adverse events,2017-12-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,"Time to baseline for serum IL-2, IL-4, IL-6, IL-10, TNF-α and INFγ"
1942,NCT03050333,Proportion of complete resections without recurrence,2013-04-25,UNKNOWN,OBSERVATIONAL,['NA'],,
1943,NCT03888092,Number of patients with adverse events (AEs) as a measure of safety and tolerability,2017-08-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
1944,NCT00069940,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1945,NCT03517852,"Tumor blood flow (velocity, mm/sec)",2018-08-15,COMPLETED,INTERVENTIONAL,['NA'],,Post-operative correlation of the microscopic observation of the tumor microvasculature tumor-specific and overall survival.
1946,NCT06271291,Follow subjects longitudinally and collect biospecimens and follow-up data and record medical outcomes,2024-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1947,NCT00427310,Survival,1984-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1948,NCT00349817,skill in discussing these issues with patients,2005-10,UNKNOWN,INTERVENTIONAL,['NA'],,
1949,NCT00640692,,2007-12,WITHDRAWN,OBSERVATIONAL,['NA'],,
1950,NCT03364114,Rate of device- and procedure-related serious adverse events (SAEs),2018-02-09,RECRUITING,INTERVENTIONAL,['NA'],,Post Procedure Pain
1951,NCT03178812,Prediction of malignant potential of pancreatic cyst by measuring TNF levels,2017-06,UNKNOWN,INTERVENTIONAL,['NA'],,
1952,NCT03661671,Detection rate of gastric neoplastic lesion,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Sensitivity of detecting gastric neoplastic lesion
1953,NCT05111795,Lung shunt prediction,2022-01-17,COMPLETED,OBSERVATIONAL,['NA'],,Number of patients downstaged to liver resection or liver transplantation
1954,NCT03464968,6 months overall survival rate,2015-07-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-Related Adverse Events as Assessed by NCI CTC version 4.0
1955,NCT00081237,Maximum tolerated dose and recommended dose for future trials as measured by CTC v3.0,2004-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to progression as measured by Kaplan Meier and RECIST every 6 weeks during treatment and then every 8 weeks
1956,NCT02400398,Weight,2015-04-27,COMPLETED,OBSERVATIONAL,['NA'],,Changes in microbiome analysis
1957,NCT05665348,Overall survival (Phase III),2023-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Objective response rate (OR) under treatment (Phase III)
1958,NCT00825955,To compare overall survival of subjects with advanced HCC who have progressed on/after or are intolerant to Sorafenib and receive Brivanib plus best supportive care (BSC) to those receiving placebo plus BSC,2009-02-17,COMPLETED,INTERVENTIONAL,['PHASE3'],,"To assess safety profile of brivanib. Safety will be assessed by the number of adverse events (AEs), serious adverse events (SAEs), periodic data monitoring committee (DMC) review"
1959,NCT01388790,Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments
1960,NCT00448760,Pathologic Complete Response,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
1961,NCT02073500,Overall survival (OS),2009-09,RECRUITING,OBSERVATIONAL,['NA'],,Disease-free survival (DFS)
1962,NCT03002051,Clinical success for obstructive jaundice,2016-10,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
1963,NCT01704690,Response rate,2012-08,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Number of Participants with Adverse Events and the degree of each adverse event
1964,NCT00313599,Maximum tolerated dose (MTD) of lapatinib in course 1,2006-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics during the first 2 weeks of treatment
1965,NCT02639026,Number of Adverse Events,2016-01-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1966,NCT04256226,Overall survival,2020-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence-free survival
1967,NCT01316263,"Percentage of Participants With Tumor Response of Stable Disease (SD), Partial Response (PR) or Complete Response (CR) (Clinical Benefit Rate) at 12 Weeks",2011-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Human Anti-Olaratumab (IMC-3G3) Antibody Results
1968,NCT05334849,Levels of circulating exosomal lncRNA-GC1,2018-11-01,COMPLETED,OBSERVATIONAL,['NA'],,Survival outcomes of circulating exosomal lncRNA-GC1
1969,NCT02597712,Change in Ki67 Biomarker Expression,2013-05-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Abundance of Biomarkers of ECL Cell Hyperplasia
1970,NCT04759638,Overall Survival (OS),2017-03-21,COMPLETED,OBSERVATIONAL,['NA'],,Pathological Complete Response (CR)
1971,NCT01373125,To characterize reflux symptomatology before and after radiofrequency ablation in subjects with dysplastic Barrett's Esophagus (BE).,2011-06,COMPLETED,OBSERVATIONAL,['NA'],,Correlate the physiologic and morphologic changes in the neosquamous epithelium (NSE) after ablation with the frequency and type of refluxate seen on pH-Impedance.
1972,NCT04224636,24-months survival rate,2020-06-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
1973,NCT01998230,Postoperative complication,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Length of postoperative stay
1974,NCT05816837,Displacement distance,2022-04-20,RECRUITING,OBSERVATIONAL,['NA'],,
1975,NCT01716949,Number of hyperthermia applications by patient,2012-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Rate of acute and late toxicity
1976,NCT02564666,Drug compliance for patients with HCC who is taking Sorafenib compliance,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],The satisfaction with Information about Medicines Scale (SIMS) score,Duration of dosing period
1977,NCT02715882,"Safety and tolerability evaluation as measured by adverse events and assessed as changes in vital signs and clinical laboratory measurements, physical examination findings and ECG readings",2015-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Blood leukocytes by FACS
1978,NCT00768157,Overall survivals,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Recurrence rate
1979,NCT04906434,vital signs changes from baseline,2020-02-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,PFS
1980,NCT05099237,Cohort 3 - Primary outcome measure: feasibility of monitoring for the daily weights:,2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],,"Cohorts 1,2 and 3 Device acceptability"
1981,NCT02704156,The Median Survival Time Will be Determined.,2016-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Quality of Life Will be Analyzed.
1982,NCT00910572,Time to progression (TTP),2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time-to-symptomatic progression (TTSP)
1983,NCT00083785,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1984,NCT03727633,Percentage of participants presenting a disease control at 4 months,2018-07-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life questionnaire (QLQ) QLQ-C30
1985,NCT05241249,R0 resection rate,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Ki-67 expression in tumor cells
1986,NCT02677038,Objective response rate (defined as complete response or partial response) assessed using Response Evaluation Criteria in Solid Tumors 1.1,2016-11-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of unacceptable toxicity
1987,NCT02494687,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
1988,NCT01298570,Progression Free Survival (PFS),2011-04-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Patients With Severe Adverse Events
1989,NCT04083651,Overall Survival,2020-01-06,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
1990,NCT02564614,Change From Baseline to Week 6 in HIF1A mRNA Level in Tumor Tissue,2016-05-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Plasma Decay Half-Life (t1/2)
1991,NCT05659251,Pathological Complete Response (PCR),2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,The changes in the peripheral blood immunoprofile and tumor tissue sample among non-PCR (NPCR) and PCR patients
1992,NCT03216135,Microbial community profiling,2017-07-20,UNKNOWN,OBSERVATIONAL,['NA'],,Generate a tissue microarray
1993,NCT04490733,Neuropsychological battery test,2020-08-17,RECRUITING,INTERVENTIONAL,['NA'],Self-report Questionnaire,Self-report Questionnaire
1994,NCT02184195,Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified RECIST Version (v) 1.1 (RECIST v1.1),2014-12-16,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Adverse Events (AEs)
1995,NCT02226666,Survey,2013-08,COMPLETED,OBSERVATIONAL,['NA'],,Respiratory Rate
1996,NCT00512304,feasibility of treatment,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1997,NCT01923155,Adenoma detection rate,2012-03,COMPLETED,INTERVENTIONAL,['NA'],,Cecal intubation TIME
1998,NCT03163992,Overall Response Rate,2017-12-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival (PFS) and Overall Survival (OS)
1999,NCT04733963,Progression Free Survival,2021-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory Endpoint,QoL
2000,NCT02871804,the incidence of pancreatic fsitula grade B/C,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,the incidence of conversion from laparoscopic surgery to open surgery
2001,NCT03096717,incidence of dysplasia in relation to therapy performed,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
2002,NCT05475613,For patients with liver transplantation: The 2-year event-free survival rate,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,For all patients with HCC downstaging: Rate of successful tumor downstaging
2003,NCT03781154,Physical Activity,2019-10-17,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of Life Assessment
2004,NCT03306966,Number of patients with adverse events related to the index-procedure.,2018-05-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Number of patients with colectomy related re-interventions.
2005,NCT04151524,Overall Survival,2019-10-23,UNKNOWN,OBSERVATIONAL,['NA'],,
2006,NCT04716257,Ovarian specific overall survival,2021-01-14,UNKNOWN,OBSERVATIONAL,['NA'],,Quality of life questionnaire
2007,NCT05458115,Adverse effect,2022-09-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2008,NCT01173250,,na,COMPLETED,INTERVENTIONAL,['NA'],,
2009,NCT01268384,R0 resection rate,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
2010,NCT04000802,MODE-MDT scores,2019-05-23,COMPLETED,OBSERVATIONAL,['NA'],,Decision factors
2011,NCT02828124,Incidence of Laboratory Test Toxicity Grade Shifting From Baseline,2016-08-23,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Positive Anti-drug Antibody (ADA)
2012,NCT02531620,Number of participants recruiting,2015-09,UNKNOWN,INTERVENTIONAL,['NA'],,Bowel Function Assessment
2013,NCT05008809,Progression-free survival (PFS) time,2021-12-06,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life (QoL)
2014,NCT00576680,Response Rate,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To Determine the Safety and Tolerability of This Drug Combination.
2015,NCT05144854,Overall survival (OS),2021-11-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse event
2016,NCT01857141,Heart rate variability analysis,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,Epidural injection
2017,NCT04065984,Mean muscle attenuation pre and postoperatively,2019-04-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Sequential CT changes in body composition
2018,NCT03693378,Validation of IMMray™ PanCan-d test,2016-01-19,COMPLETED,OBSERVATIONAL,['NA'],,Evaluation of the IMMray™ PanCan-d test performance
2019,NCT05745909,Ileus,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life in patients with ostomy
2020,NCT02888743,Overall response rate,2017-08-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Patient reported symptomatic adverse events(AEs),Prognostic effect of T-cell infiltration
2021,NCT03208777,presence of telomeric abnormalities,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,
2022,NCT02011594,PFS (Progression free survival),2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Disease control rate (DCR)
2023,NCT02062632,Change in Mouth Pain as Measured by Average Area Under the Curve Per Assessment,2014-04-14,TERMINATED,INTERVENTIONAL,['PHASE2'],Quality of Life Using European Organization for Research and Treatment of Cancer Quality of Life-Lung Cancer 13 and Functional Assessment of Cancer Therapy-Lung,Patient Preference for Continued Therapy at Initial Dose and Crossover
2024,NCT06304987,AE rate,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,immune-related adverse event rate
2025,NCT05191498,Feasibility of intratumoral implantation of QuiremSpheres® by SPECT imaging,2021-12-13,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Tumor response by RECIST 1.1
2026,NCT06232434,increased survival,2024-02-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,blood chemistry
2027,NCT00855634,Overall survival,2009-08,TERMINATED,INTERVENTIONAL,['NA'],,Quality of life Perioperative morbidity and mortality 1-year survival and 2-year survival
2028,NCT02392377,Biological Pathway Perturbation Upon Exposure to Chemotherapy,2015-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Occurrence of Grade 3 or 4 Toxicity Per the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.0
2029,NCT02555501,Lesion size,2014-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2030,NCT05559229,To evaluate the efficacy of measuring value of AFP for patients with gallbladder cancer.,2021-01-15,COMPLETED,OBSERVATIONAL,['NA'],,
2031,NCT02422147,This study will evaluate the clinical outcomes (effectiveness) of all patients with pancreatic cyst lesions undergoing EUS-guided ethanol ablation. This will include complete resolution of the pancreatic cyst lesion at the end of the treatment period.,2016-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
2032,NCT05777707,Disease-free survival (DFS),2020-10-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
2033,NCT05514769,Gastroesophagus reflux disease apprised by questionnaire,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Long-term outcome
2034,NCT04299048,Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities,2020-11-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Serum Total Ctrough of PF-06946860
2035,NCT02723578,Progression-free survival,2015-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
2036,NCT01691391,The predictive value of 18F-FDG-PET for the absence of response compared to the lack of clinical benefit at convential CT at 2 months,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,Grade of skin toxicity
2037,NCT04649671,Improvement of insulin resistance,2021-03-02,TERMINATED,INTERVENTIONAL,['NA'],,Adverse events
2038,NCT01726296,Percentage of eligible CRC and NSCLC survivors with medical record documentation of compliance with NCCN guidelines,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Change in percentage of eligible survivors with documentation of compliance with NCCN survivorship guidelines after conducting the targeted educational initiative at participating sites
2039,NCT01889303,Disease free survival,2013-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,feasibility (including adverse events )
2040,NCT02969473,Overall survival (OS),2010-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Acute treatment-related toxicities
2041,NCT04932187,Rate of adverse events as assessed by CTCAE v5.0,2021-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of response
2042,NCT02662465,Oral mucositis WHO classification,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,Visual analog scale
2043,NCT00658593,Overall survival,2008-10-10,TERMINATED,INTERVENTIONAL,['PHASE3'],,Toxicity
2044,NCT05222854,proportion of patients with genomic alterations,2017-10-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,The proportion of patients with actionable genomic alterations in all patients
2045,NCT05927298,Precision-Matched Treatment Utilization Rate,2023-03-06,RECRUITING,OBSERVATIONAL,['NA'],Genetic and Environmental Factors in Pancreatic Cancer,Correlation of Immune Phenotypes and Molecular Profiles
2046,NCT00400569,Number of Participants With Overall Response (OR),2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Serious Adverse Events (SAEs)
2047,NCT01896856,Progression Free Survival (PFS),2013-10-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Objective Response Rate
2048,NCT01952210,General nutritional status,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Treatment tolerance
2049,NCT04136769,Feasibility of visceral debranching,2020-02-07,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
2050,NCT00923052,To study and characterize both quantitatively and qualitatively SOCSC from various primary and metastatic solid organ cancers from time of surgery or other cancer directed therapy to time of recurrence or progression using an exhaustive list of ...,2009-02-09,TERMINATED,OBSERVATIONAL,['NA'],,"To determine whether SOCSC are present in the blood and/or bone marrow, and study their quantitative and/or qualitative changes over the course of the disease, from time of initial presentation to time of recurrence and/or metastasis.To sp..."
2051,NCT03213054,Incidence rate of adverse event,2017-07-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Tumor response
2052,NCT00508001,Tumour Stabilisation Rate,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2053,NCT01106261,Feasibility of recruitment,2010-12-02,COMPLETED,INTERVENTIONAL,['NA'],,Survival
2054,NCT02833246,objective pill count,2016-06-28,COMPLETED,INTERVENTIONAL,['NA'],,
2055,NCT04979611,Standard uptake value (SUV),2020-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2056,NCT05702684,Patient experience,2023-07-31,RECRUITING,OBSERVATIONAL,['NA'],,
2057,NCT01602406,Incidence rate of Dose Limiting Toxicities,2012-09-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Frequency of stable disease according to RECIST
2058,NCT02926040,Change from baseline in HRQol measured by health questionnaire,2016-10,TERMINATED,OBSERVATIONAL,['NA'],,
2059,NCT01945177,Detection rate of intestinal metaplasia,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,Aggregate detection rate of focal gastric lesions
2060,NCT05582278,Cancer embolism withdraws,2021-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2061,NCT03203837,"Percentage change in angiogenic, inflammatory and immune biomarkers",2017-07-05,TERMINATED,OBSERVATIONAL,['NA'],,Treatment Response- Overall Survival
2062,NCT00580021,The overall objective of the protocol is to examine the hypothesis that hereditary cancers are distinct in clinical characteristics and outcome from those that arise in the absence of a known predisposition.,2006-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
2063,NCT03233776,"Establish the maximum tolerated dose of anakinra (MTD, 100, 200 or 300 mg).",2017-08-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Short term overall survival
2064,NCT03513705,1-year overall survival,2018-05-22,COMPLETED,INTERVENTIONAL,['NA'],Quality of life with Area Under the Curve (AUC) up to 1 year after diagnosis,Use of smartphone application
2065,NCT00405561,Progression free survival;at 18 weeks after registration,2006-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Safety and Tolerability
2066,NCT00198081,"Concentration of PGEM in Serum at Baseline, Surgery, 1 wk, 4wks, and 6 Months",2005-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Clinical Changes in IPMN Progression.
2067,NCT04307901,Complete mucosal visualization combining incomplete investigations,2020-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Patient preference
2068,NCT03486379,response rate (confirmed complete and partial response).,2016-03,COMPLETED,OBSERVATIONAL,['NA'],,Toxicity
2069,NCT05009069,Percentage of Participants With Pathological Complete Response (pCR),2022-03-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Adverse Events
2070,NCT03696472,5-years overall survival rate,2018-12,UNKNOWN,INTERVENTIONAL,['NA'],,Recovery time after surgery
2071,NCT01346410,Local Control Rate,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,Late Toxicity Rate
2072,NCT00546065,recurrence-free survival,2006-08,TERMINATED,INTERVENTIONAL,['NA'],,
2073,NCT01439633,Number of Subjects in Which the Targeted Locations Identified Through OFDI Imaging Correlates With the Biopsies.,2010-10,COMPLETED,INTERVENTIONAL,['NA'],,
2074,NCT02465983,Safety of IV administration of CART-meso-19 with cyclophosphamide as lymphodepleting chemotherapy in patients with pancreatic cancer using the NCI CTCAE v4.03 criteria,2015-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,
2075,NCT05017207,Risk factors relate to pancreatic fistula,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Short-term result in treatment of post-operative pancreatic fistula
2076,NCT03356535,Hepatocellular Carcinoma,2015-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
2077,NCT03969576,Objective response rate,2020-09-15,UNKNOWN,INTERVENTIONAL,['NA'],,Duration of response
2078,NCT03178409,Survival analysis,2004-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
2079,NCT00263029,Response rate (both clinical and pathological) of the primary rectal cancer observed after the chemoradiotherapy. Histologically confirmed complete resection rate (R0 rate).,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events collection
2080,NCT05819099,Accuracy,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2081,NCT04204382,Clinical grade of radioactive oral mucositis,2019-12-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Recovery time of oral mucositis
2082,NCT03077334,Clinical PET type assessed by surgeons from preoperatively preformed PET imaging,2014-10-07,COMPLETED,OBSERVATIONAL,['NA'],,Number of patients with recurrence of cancer or mortality from cancer following operation
2083,NCT02991196,Dose Escalation Part: Number of Participants with Immune-related Response (per Criteria Modified from RECIST Version 1.1 [irRECIST]),2016-12-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Participants with Primary Pharmacodynamic (PDy) Effects of the Combination Regimen on Myeloid-Derived Suppressor Cells (MDSCs) and their Subsets in Peripheral Blood
2084,NCT01493713,Correlation of overall objective responses evaluated by conventional imaging techniques with the morphologic response evaluated by MDCT and the histopathologic response after the resection of hepatic metastases.,2011-11-16,COMPLETED,INTERVENTIONAL,['PHASE4'],,Examine the influence of a potential predictive and prognostic tumour biomarker -mutations in K-RAS- after start of therapy on progression free survival
2085,NCT03048266,Relationship of Serum Global Metabolic Profiles with Subsequent Development of Aggressive PNET,2015-11-05,RECRUITING,OBSERVATIONAL,['NA'],,Prospectively Identify Potential miRNA Biomarkers of Serum with miRNA Sequencing in MEN1 Patients Who Have Developed Aggressive PNETs (Cases) and MEN1 Patients Who Have Developed Non-Aggressive PNETs (Controls)
2086,NCT03448835,Incidence of adverse events following treatment (safety),2018-03-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,pathological tumor regression grade
2087,NCT04654403,DOR,2022-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,ORR
2088,NCT00255827,"To assess the side effects, dose-limiting toxicity and maximum tolerated dose.",2005-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To assess the rate of recurrence after treatment.
2089,NCT04126655,TS inhibition in plasma,2020-02-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2090,NCT01826396,R0 resection rate,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse reactions,disease free survival
2091,NCT03511222,Recommended phase II dose (RP2D) of vorolanib plus nivolumab,2018-09-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Safety and toxicity of vorolanib plus nivolumab as measured by the number and type of adverse events experienced by participant
2092,NCT03594929,"serum AST (unit/L) following liver resection, measured at 24 hours",2016-08-15,UNKNOWN,INTERVENTIONAL,['NA'],,Mortality
2093,NCT01422993,Number of Screened Patients Who Participate and Complete the Study,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants With Measured Improvement
2094,NCT00824161,Percentage of Progression Free Survival,2009-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2095,NCT04109924,Median progression free survival (PFS),2019-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Aggregate rates of adverse events
2096,NCT03099382,Overall Survival (OS),2017-05-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2097,NCT00593008,To determine the dosing regimen appropriate for Phase 2 studies of the combination,2007-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,To document objective response rate and progression-free survival in patients treated with this combination
2098,NCT00629486,cytokine polymorphisms increase risk for hepatocellular carcinoma,2007-01,COMPLETED,INTERVENTIONAL,['NA'],,
2099,NCT04571710,Objective response rate,2020-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Cmax
2100,NCT04270500,"Sleep quality by an Actigraphy: ""change"" is being assessed",2020-09-15,UNKNOWN,INTERVENTIONAL,['NA'],"Weight: ""change"" is being assessed","Hospital Anxiety and Depression Scale (HADS): ""change"" is being assessed"
2101,NCT03413904,Conversion to open,2018-03-27,UNKNOWN,INTERVENTIONAL,['NA'],,Long-term postoperative complications
2102,NCT02634645,Overall improvement of patient outcomes in patients treated with endoscopic eradication therapy (EET).,2015-01,RECRUITING,OBSERVATIONAL,['NA'],,Median time to recurrence of neoplasia
2103,NCT03510871,the percentage of subjects with tumor shrinkage after study drug treatment,2019-02-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
2104,NCT06098898,Maximal Tolerable Dose,2023-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['EARLY_PHASE1'],,Overall response rate (ORR)
2105,NCT04718909,Progression free survival (PFS) assessed by investigators according to Response Evalutaion Criteria in Solid Tumors (RECIST) v1.1 and immune-related RECIST (irRECIST),2021-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,DCR assessed by investigators according to mRECIST.
2106,NCT05358704,Positron emission tomography (PET),2022-05-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST v1.1),Magnetic resonance imaging (MRI)
2107,NCT03861702,Disease Control Rate (DCR),2020-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life Assessment
2108,NCT03198338,opioid consumption up to 24 hours,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,sedation score
2109,NCT05213221,Objective reponse rate (ORR),2022-03-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety of treatment
2110,NCT03418428,Intestinal microbiome composition,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Serum DAO
2111,NCT01228734,Progression Free Survival (PFS) Time,2010-09-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Subjects With Curative Surgery of Liver Metastases
2112,NCT02428101,"Correlation of single nucleotide polymorphisms of ABCG2 gene (G34A - rs2231137 and A/A -rs3114018 genotypes) with peripheral neuropathy grades, using the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE)",2014-11,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
2113,NCT03941873,Phase 2: Objective response rate (ORR),2019-02-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2114,NCT02824484,Change in post-traumatic growth from baseline to post-intervention assessment and at 6 months follow-up. Post-Traumatic Growth Inventory (PTGI) will be used to assess this outcome,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],"Expectancy about change in personal growth as a result of the intervention (Treatment Expectancy, TE)",Change in anxiety and depression from baseline to post-intervention assessment and at 6 months follow-up. Hospital Anxiety and Depression Scale (HADS) will be used to assess this outcome
2115,NCT01775254,Change in Quality of Life,2013-01,COMPLETED,OBSERVATIONAL,['NA'],Psychometric analysis of a modified version of the Neurotoxicity Sub-scale.,Change in Demands of Illness
2116,NCT01291407,"To define dose limited toxicities(DLT) of S-1, peroral BID, in treatment days concurrently with radiation therapy (RT) in locally advanced or recurrent gastric cancer.",2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To define maximum tolerated dose(MTD) of S-1, peroral BID, in treatment days concurrently with radiation therapy"
2117,NCT00869843,Efficacy of the technique on surface liver tumors using saline lined RF Surface ablation.,2002-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Determine a safe (non-popping upper limit) of power per area that will permit a 1 cm depth of tissue destruction without inflow occlusion and a 2 cm depth with inflow occlusion.
2118,NCT00503737,"Increase the knowledge of providers as it pertains to current guidelines and strategies about CRCS; assist offices design a CRCS policy, assist offices adopt a CRC reminder system and increase the screening rates of CRC.",2007-09,COMPLETED,INTERVENTIONAL,['NA'],,"synthesize information about the strengths and weaknesses of the toolbox from the primary care physician's (PCP) point of view to aid in future development of an interactive, web-based version of the Toolbox."
2119,NCT04949646,"Change in the quality of life of the patient at 3 months postoperatively, based on the SF-36 questionnaire",2021-09-19,RECRUITING,INTERVENTIONAL,['NA'],,"Difference in the low anterior syndrome symptoms of the patient, based on the LARS questionnaire"
2120,NCT00366457,Time to Tumor Progression,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2121,NCT06009029,Overall survival (OS),2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
2122,NCT00077259,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2123,NCT04340986,Overall survival,2020-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Progression time under chemotherapy
2124,NCT05661110,"Relationship between the status, numerical changes of ctDNA during HIPEC combined with PD1/PDL1 inhibitor conversion therapy and postoperative R0 resection rate.",2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Genetic and transcriptional profiling results.,Genomic changes of ctDNA and see if they are predictive of relapse-Free Survival.
2125,NCT05937295,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of the peptide vaccine in combination with anti-PD-L1 immune checkpoint inhibition,2023-09-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2126,NCT03071198,Disease Free Survival (DFS),2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Predictor efficacy of neoadjuvant chemotherapy for DFS
2127,NCT06203600,Overall survival (OS) (Phase III),2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of adverse events
2128,NCT04689594,Proportion of subjects without stenosis,2021-02-04,TERMINATED,INTERVENTIONAL,['PHASE3'],,
2129,NCT01934829,Prophylactic topical application of ointment to reduce the hand-foot skin reactions in patients with hepatocellular carcinoma treated with sorafenib,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,The percentage of patients discontinuing treatment
2130,NCT00006221,,2000-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2131,NCT04196465,Major pathologic response rate,2019-09-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Discovery of predictive and/or prognostic biomarkers,Patterns of cancer progression/relapse
2132,NCT03128281,Incidence of Shoulder Pain After Laparoscopic/Robotic Surgery,2018-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
2133,NCT03641118,Skeletal muscle radiation attenuation at L3,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],,oxygen uptake at lactate threshold
2134,NCT01851941,"clinical response rate as assessed using RECIST criteria, with computed tomography (CT) scans at baseline and after 4cycles of chemotherapy",2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Pharmacologic Genetic Marker,overall survival
2135,NCT01086683,psychosocial well-being (as assessed by the EORTC-QLQ C30 Quality of life core questionnaire by the European Organization of Research and Treatment in Cancer (EORTC-QLQ C30) and the Profile of Mood States Short form (POMS-SF),2004-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,self-efficacy as measured with the General Self-Efficacy Scale (GSE)
2136,NCT00624260,Percentage of patients with a non removable recurrence,2008-06,COMPLETED,INTERVENTIONAL,['NA'],,Cost of the strategy
2137,NCT04920955,Specificity for relapse detection,2021-02-10,COMPLETED,OBSERVATIONAL,['NA'],,Sensitivity for CRC detection
2138,NCT04066491,Double-blind Part: Overall Survival,2019-09-20,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Double-blind Part: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (SAEs), Treatment Related TEAEs and Adverse Events of Special Interest (AESIs) According to NCI-CTCAE Version 5.0"
2139,NCT04202523,DFS,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,OS
2140,NCT06221423,Overall Survival (OS),2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
2141,NCT04275986,Adverse events (AE),2020-01-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of Life (QOL): questionnaires
2142,NCT00002475,Survival (patients without evaluable disease),1991-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2143,NCT02153450,Dose-limiting toxicity (DLT) rate scored according to the National Cancer Institute Common Toxicity Criteria version 4,2015-05-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Overall survival
2144,NCT03694522,Progression-Free Survival (PFS),2018-09-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-emergent Adverse Events (TEAEs)
2145,NCT05786482,Hospital Anxiety and Depression Scale (HADS),2023-02-12,RECRUITING,INTERVENTIONAL,['NA'],Sleep (Exploratory),Satisfaction and Adherence
2146,NCT02871115,Rates of study enrollment,2017-01,COMPLETED,INTERVENTIONAL,['NA'],,Rates Of Appropriate Influenza Vaccinations
2147,NCT05412589,ORR,2022-06-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,TRAE
2148,NCT03794440,Progression-free survival (PFS),2019-02-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,EORTC QLQ-HCC18
2149,NCT02363374,"Number of patients with pathological complete response (pCR), i.e. ypT0N0.",2015-03-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
2150,NCT00052507,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2151,NCT01486745,,2008-09-15,COMPLETED,OBSERVATIONAL,['NA'],,
2152,NCT02024217,R0 resection rate,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],over-all survival,safety and tolerability of the treatment regimen
2153,NCT05234177,Recurrence-Free Survival,2022-06-21,RECRUITING,OBSERVATIONAL,['NA'],Lead Time,Positive Predictive Value
2154,NCT00336609,,2005-11,UNKNOWN,OBSERVATIONAL,['NA'],,
2155,NCT03332433,Incidence of hypoxia,2017-11-10,COMPLETED,INTERVENTIONAL,['NA'],,Other adverse events
2156,NCT03820921,Feasibility of MMR status analysis on EUS-FNB pancreatic specimens,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,Progression-free survival
2157,NCT04193696,Objective response rate,2020-01-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Abscopal effects rate
2158,NCT04831827,Primary Endpoint (intention-to-treat),2021-09-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Secondary Outcome (per protocol analysis)
2159,NCT02159898,Mellow and Pinkas Dysphagia Score at Baseline and 2 Weeks Following the Treatment,2015-01,COMPLETED,INTERVENTIONAL,['NA'],,GERD-HRQL
2160,NCT01322178,Resection rate (R0),2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
2161,NCT00068380,"Baseline Gene Expression Levels of the Target Genes (PDGF-R and PDGF), Genes Associated With Induction of Apoptosis (Bcl-2, Bax), and Cell Cycle Regulatory Genes (p53, p21, p27",2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2162,NCT06158919,PFS,2023-11-20,RECRUITING,INTERVENTIONAL,['NA'],,OS
2163,NCT03348150,overall survival,2017-10-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,costs and health benefits
2164,NCT02344810,Progression-free survival (Phase II),2015-03-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Evaluation of MET amplification and MET expression as determined by DAKO IHC (Phase II)
2165,NCT02981524,Objective Response Rate (ORR),2017-05-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response (DOR)
2166,NCT00002716,Time to progression,1996-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2167,NCT00614653,"Highest Tolerated Dose of Capecitabine, Erlotinib Hydrochloride, and Bevacizumab + Radiation",2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response Rate of Addition of Bevacizumab and Erlotinib to Capecitabine-Based Chemoradiation
2168,NCT00215956,Side Effect Profile of Topotecan,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response Rate
2169,NCT00508443,Patient Response (Pain Relief),2002-10-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2170,NCT02964455,Maximum tolerated dose,2016-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Dynamic plasma concentration of docetaxel and nedaplatin
2171,NCT05451849,Phase 2 - Disease Control Rate (DCR),2022-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2172,NCT02498353,pathological complete remission rate,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],,toxicity of radiotherapy based on the CTCAE v3.0 (common terminology criteria for adverse events，CTCAE v3.0)
2173,NCT01909856,Complete Response(CR) within 24-120 hours after chemotherapy,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse events
2174,NCT04121273,Number of patient with dose limiting toxicity,2019-10-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Number of Peripheral CAR-T cell
2175,NCT02328664,Sensitivity of biopsies for residual cancer,2015-08,TERMINATED,INTERVENTIONAL,['NA'],,The proportion of patients with residual cancer in the resected specimen if malignancy was unsuspected during the endoscopic polypectomy
2176,NCT01955837,Overall Survival（OS）,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression-free Survival (PFS) (Mutant Type KRAS)
2177,NCT00025168,,2001-11-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2178,NCT00971841,Number of Adverse Events (AEs) Per Participant,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Complete Response to Tumor
2179,NCT02774447,Number of patients who were able to return home after day-case closure of loop-ileostomy,2015-08,COMPLETED,OBSERVATIONAL,['NA'],,
2180,NCT04262609,faecal incontinence after prostate radiation therapy,2019-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Quality of life after prostate radiation therapy
2181,NCT04693754,"Rate of patient report of symptoms related to procedure (Acute pancreatitis, abdominal pain, infection/abscess, venous thrombosis, & fever)",2020-07-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
2182,NCT02356471,Number of Patients Who Self-report Wearing the Consumer-based Activity Monitor at Least 16 Days of the 21 Day Period,2015-03,COMPLETED,INTERVENTIONAL,['NA'],,Change in Fatigue Assessment- Fatigue Visual Analog Scale (FVAS).
2183,NCT00819780,Progression-free Survival (PFS),2009-04-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events (AEs)
2184,NCT03375281,1 year local tumor progression,2017-11-20,COMPLETED,INTERVENTIONAL,['NA'],,
2185,NCT00508404,Objective Response Rate,2007-05-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Resection Rate
2186,NCT02060669,Progression free survival,2010-06-20,TERMINATED,INTERVENTIONAL,['PHASE3'],,
2187,NCT00538850,Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30),2007-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Global Evaluation of the Study Medication at 30 and 60 Minutes After Dosing
2188,NCT03061435,Prevalence of abnormal anal cytology and hrHPV DNA in women with VIN 2/3 or vulvar cancer,2021-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,"Assess t he correlation between abnormal anal cytology, hrHPV DNA, and AIN"
2189,NCT01160419,Collection of the R0-Resection rate,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
2190,NCT03156777,Number of circulating tumor cell (CTC),2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
2191,NCT00699881,time to progression,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicity
2192,NCT02852525,Sensitivity and Specificity of probe based endomicroscopy as compared to histopathology in diagnosing Barrett's metaplasia,2014-02,COMPLETED,INTERVENTIONAL,['NA'],,Tissue and blood Biomarker evaluation in targeted biopsies obtained at endomicroscopy in patients diagnosed to have Barrett's metaplasia and dysplasia
2193,NCT01318447,Local recurrence-free survival,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Local recurrence-free survival
2194,NCT05394246,Tumor lesions,2022-05-20,RECRUITING,INTERVENTIONAL,['NA'],,
2195,NCT01003808,"To evaluate the maximum tolerated dose, dose-limiting toxicities, type/frequency/degree of adverse events and NY-ESO-1 antigen-specific immune response of IMF-001 alone in patients with esophageal cancer.",2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate clinical activity (tumor response and time to progression).
2196,NCT03413436,overall survival,2018-01-31,COMPLETED,INTERVENTIONAL,['PHASE4'],,toxicities of adjuvant chemotherapy
2197,NCT01416688,Psychometric properties of the FACT-EGFRI 18,2011-11-15,COMPLETED,OBSERVATIONAL,['NA'],,"Feasibility as measured by accrual, time to specified accrual, time to complete forms"
2198,NCT05092373,"To assess the safety and tolerability of TTF, including the maximum tolerated dose (MTD).",2022-04-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,"To assess the objective response rate, progression-free survival and overall survival"
2199,NCT01178801,the relationship between the clinical data and the decision of treatment strategies,2010-03,UNKNOWN,OBSERVATIONAL,['NA'],,
2200,NCT01790633,Accessibility of Testing Results,2013-02,COMPLETED,INTERVENTIONAL,['NA'],Proportion of Rapid Test Failures,Access to Care
2201,NCT03147768,PRIMARY EFFICACY AS A SEALANT: Intra-operative blood loss,2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE1'],SECONDARY EFFICACY: Total hospital stay (Duration and cost Metric ),SECONDARY SAFETY: Surgical space abscess
2202,NCT01434147,occurence of toxicity,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,post-surgery morbidity
2203,NCT04780256,recurrence rate,2021-03-15,UNKNOWN,OBSERVATIONAL,['NA'],,costs
2204,NCT03444051,pancreatic mass anatomopathological characterization,2017-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
2205,NCT02563054,Time to disease progression,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events
2206,NCT01869088,Overall survival time,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Tumor response
2207,NCT01374425,PFS According to RECIST Version 1.1 in Participants With High Vascular Endothelial Growth Factor (VEGF)-A Levels Versus Participants With Low VEGF-A Levels,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Complete Liver Metastasis Resection in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels
2208,NCT00422877,Response Rate,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Survival
2209,NCT05215574,Incidence of Adverse Events,2022-03-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of Patients with Objective Responses
2210,NCT03415919,confirmation of diagnosis by pathologist,2018-07-13,UNKNOWN,OBSERVATIONAL,['NA'],,
2211,NCT04129177,Surgical site infection rate,2018-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
2212,NCT02317731,Bowel preparation quality,2014-12,TERMINATED,INTERVENTIONAL,['NA'],,Tolerability will be measured by subjective survey including a 5-point scale and a visual analog scale filled by the subjects the day of the colonoscopy
2213,NCT05379985,Number of Participants with Dose-Limiting Toxicity (DLT),2022-05-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS)
2214,NCT02106884,QOL Global Health Status Deterioration-free Median Survival,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Laboratory Safety Assessment
2215,NCT00040599,,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2216,NCT01516489,FOBT completion and return,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,FOBT completion rate among previously non-adherent patients and FOBT kit return time by arm
2217,NCT06034964,OS,2020-11-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Safety and Tolerability
2218,NCT00749450,3-year disease-free survival,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Quality of life as assessed by EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and GOG Ntx4"
2219,NCT06308328,The AUC of the predictive model,2024-04-01,RECRUITING,OBSERVATIONAL,['NA'],,The important predictors of severe oropharyngeal mucositis in the predictive model
2220,NCT03279289,Progression-free survival,2017-10-25,COMPLETED,INTERVENTIONAL,['PHASE2'],Biomarkers in serum and tumour tissue associated with cell and tumour growth and/or involved in the mechanism of action of FOLFIRI+aflibercept and their correlation with efficacy parameters,VES-13 score (Vulnerable Elders Survey) as the utility measure for health deterioration
2221,NCT00004931,DFS rate,2000-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Survival rate
2222,NCT04319757,Phase Ib/II starting dose for ACE1702,2020-05-19,RECRUITING,INTERVENTIONAL,['PHASE1'],"Shift in serum tumor marker values (CA-125, CA 19-9, and CEA levels, in applicable tumor types)",Evaluate immune function after administering ACE1702
2223,NCT04941300,Colonoscopy after abnormal FIT (primary),2021-06-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3'],Repeat screening (exploratory outcome),Follow-up process
2224,NCT03928652,Tumor regression grade,2019-04-24,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
2225,NCT06201065,Overall Survival (OS),2023-12-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse Events
2226,NCT03190941,Frequency and severity of treatment-related adverse events,2017-09-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2227,NCT02139475,Boston bowel preparation scale (BBPS),2013-12,TERMINATED,OBSERVATIONAL,['NA'],,
2228,NCT02242786,oral morphine equivalent doseresponse criteria,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of Life
2229,NCT05448677,Progression-Free Survival (PFS),2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective response rate (ORR)
2230,NCT02213497,Number of Adverse Events,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
2231,NCT04175912,Objective response rate,2020-03-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Specimen banking,Overall survival
2232,NCT01739465,stent patency,2012-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,overall survival rate
2233,NCT00832689,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2234,NCT04602026,Health-related quality of life (composite measure),2020-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
2235,NCT05154474,Rate of patients with sarcopenia diagnosed with metastatic cancer.,2022-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Rate of patients with sarcopenia at diagnosis across the inclusive population
2236,NCT02962063,pathologic complete response rate,2016-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival (OS)
2237,NCT05704192,Overall Survival(OS),2023-05-04,RECRUITING,OBSERVATIONAL,['NA'],,Progression free survival(PFS) per mRECIST
2238,NCT01418729,Overall survival,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,time to symptomatic progression (TTSP).
2239,NCT02840331,Peritoneal metastases in terms of location,2017-07-31,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Histological evidence of apoptosis
2240,NCT00510692,Absolute Change in the Number of Polyps Measured in a Focal Area of the Rectum.,2006-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Number of Subjects With Adverse Events.
2241,NCT02640586,Predictive value of preoperative MRI(7-9 weeks after the completion of preoperative chemo-radiotherapy) for assessing pCR,2016-01-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Predictive value of preoperative MRI(7-9 weeks after the completion of preoperative chemo-radiotherapy) for assessing pathological response according to Tumour Regression Grade (TRG)
2242,NCT06100692,oral mucositis scale,2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2243,NCT03724591,Anastomosis leakage rate,2019-01,UNKNOWN,INTERVENTIONAL,['NA'],,postoperative quality of life as assessed by EORTC QLQ-C30 questionnaire
2244,NCT03329183,Objective Response Rate(ORR),2019-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
2245,NCT02412579,Using next-generation sequencing methods to detect isomiRs across different HCC cohorts at all stages undergoing liver transplantation.,2015-03,COMPLETED,OBSERVATIONAL,['NA'],,
2246,NCT02971345,Overall Survival,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Time To Progression
2247,NCT01560533,Body representations,2011-11,COMPLETED,INTERVENTIONAL,['NA'],,
2248,NCT02033070,Endoscopic clearance rate for Barrett's Esophagus,2013-11,UNKNOWN,OBSERVATIONAL,['NA'],Histological clearance rate for dysplasia,Histological clearance rate for intestinal metaplasia
2249,NCT02406118,TME quality & circumferential resection margin (CRM),2015-03-01,UNKNOWN,INTERVENTIONAL,['NA'],5-year overall survival,Number of harvested Lymph Nodes
2250,NCT04522908,Treatment discontinuation rate due to treatment-related adverse events,2020-10-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Correlation of biomarkers potentially associated with clinical efficacy (OS, PFS and ORR)"
2251,NCT00284258,Progression free survival,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Over all survival, Response rate, Adverse event, Medical economy"
2252,NCT02524925,"Analyzing Neuropeptide Y, Cortisol and Adrenocorticotropic hormones levels in blood samples",2012-04,COMPLETED,INTERVENTIONAL,['NA'],,Evaluating postoperative pain between the two protocols with scale
2253,NCT02580422,"The number of patients who have changes in echocardiography, pulmonary function or one or more part of their functional evaluation tests",2015-10-01,TERMINATED,OBSERVATIONAL,['NA'],,Change in levels of cytokines
2254,NCT03107650,Evaluation of the circumferential margin status in the rectal specimen according international consensus (positive margin if tumor ≤ 1mm from circumferential margin),2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Survival
2255,NCT04729855,HOTTIP gene expression,2022-04-15,UNKNOWN,OBSERVATIONAL,['NA'],,EIF4EBP
2256,NCT04755452,Surgical rating scale,2020-12-23,COMPLETED,INTERVENTIONAL,['NA'],,"Other Kidney injury markers, include; TFF,VEGF, Osteoactivin, Clusterin, and Calbindin"
2257,NCT05039060,The change of gut microbiota diversity,2021-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,The change of gut microbiota metabolite
2258,NCT00538291,Response Rate,2005-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
2259,NCT02018757,time to progression,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Proportion of Participants with Adverse Events
2260,NCT00025246,Determination whether patients with completely resected high-risk primary GIST who undergo adjuvant treatment with imatinib mesylate have prolonged survival compared to historical controls,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Toxicities, graded according to the National Cancer Institute Common Toxicity Criteria"
2261,NCT00470184,Complete Response,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life Improved Rate
2262,NCT04717947,Quality of the specimen,2020-02-25,UNKNOWN,OBSERVATIONAL,['NA'],,
2263,NCT02538341,GMFR (Geometric Mean Fold Rise ) in Varicella Zoster Virus (VZV) Enzyme-linked Immune Absorbent Spot (ELISpot) Interferon Gamma (IFNg) Levels From Baseline at 6 Weeks,2016-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluate Rheumatoid Arthritis Disease Activity Using the Clinical Disease Activity Index (CDAI)
2264,NCT00336856,Response Rate (RR),2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2265,NCT05607186,Correlation between mrTRG and pTRG,2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Prognostic value of mrTRG on survival outcomes of rectal cancer patients
2266,NCT06003673,recurrence-free survival (RFS),2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Overall Survival (OS)
2267,NCT03637686,Patients with high risk of recurrence can be identified with ctDNA profiling performed immediately after treatment for CRC.,2018-06-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Can ctDNA detect recurrence earlier than standard-of-care?
2268,NCT01289821,Objective Response (OR),2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Stable Disease (DOSD)
2269,NCT00004087,maximum tolerated dose,1997-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2270,NCT06335654,high confidence diagnosis rate,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2271,NCT02698462,Diagnostic yield,2016-04,COMPLETED,INTERVENTIONAL,['NA'],Comparison of diagnostic yield in detecting advanced neoplasia of FIT with the national CRC screening yield,Positive predictive value
2272,NCT01046487,For safety: NCI-CTCAE scale version 3.0,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,For anti tumoral efficiency : RECIST criteria
2273,NCT03852238,exposure to Viral hepatitis B,2010-08-18,COMPLETED,OBSERVATIONAL,['NA'],fats,exposure to viral hepatitis C
2274,NCT01333709,Ro resection rate,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of metastases
2275,NCT00741481,compare fdg-pet variations after 1 course of chemotherapy to chemotherapy outcome measured by time to disease progression,2006-06,COMPLETED,OBSERVATIONAL,['NA'],,compare fdg-pet variations after 1 course of chemotherapy to chemotherapy outcome measured by tumour response rate following RECIST criteria.
2276,NCT03013153,5-years overall survival rate,2016-12,UNKNOWN,INTERVENTIONAL,['NA'],,Sexual function scoring
2277,NCT05984576,Local control,2023-06-21,RECRUITING,OBSERVATIONAL,['NA'],,
2278,NCT05646355,Number of Participants who Completed Colonoscopy at 6 Months,2023-03-15,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants with Positive FIT Test who Complete Colonoscopy at 6 Months
2279,NCT06282809,Evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
2280,NCT03978078,Number of biological risk factors for metastatic digestive cancer,2016-09-12,RECRUITING,INTERVENTIONAL,['NA'],,
2281,NCT05873972,response rate,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,overall survival
2282,NCT04694521,intestinal function,2016-09,COMPLETED,INTERVENTIONAL,['NA'],,the overall postoperative morbidities
2283,NCT02802124,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2015-06,TERMINATED,INTERVENTIONAL,['NA'],,Number of participants with tumor response as assessed by RECIST 1.1
2284,NCT02728219,overall survival,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,
2285,NCT04924075,Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR),2021-08-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to Surgery (TTS)
2286,NCT03640208,Difference in paired pre-/post-test score,2019-02-27,RECRUITING,INTERVENTIONAL,['NA'],,Barriers faced to scheduling colorectal cancer screening
2287,NCT01031628,Evaluation of Lesions for Progression or Response Via RECIST Criteria,2010-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,
2288,NCT00003076,,1995-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2289,NCT00515931,Target tumor response rate,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse effects of radiation therapy
2290,NCT05040464,Variation of the endoscopic response between AZA and MTX groups,2021-08-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,
2291,NCT00350142,Rate of Local Control,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival Time
2292,NCT04898426,Bowel preparation quality,2021-08-13,UNKNOWN,INTERVENTIONAL,['NA'],,Polyp detection rate
2293,NCT04360577,Total AUC of FACT-Gastric TOI,2020-05-27,RECRUITING,INTERVENTIONAL,['NA'],Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Average trajectory of Modified Edmonton Symptom Assessment Scale
2294,NCT04401787,oncological outcome,2016-12-11,COMPLETED,INTERVENTIONAL,['NA'],,early locoregional recurrence
2295,NCT03174405,Progression Free Survival Rate (PFS) @ 12 months,2017-07-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Translational research
2296,NCT03659292,Overall survival (OS),2018-09,UNKNOWN,INTERVENTIONAL,['NA'],,Blood levels of ropivacaine and sufentanil
2297,NCT04585919,Conditional Odds Ratio of Patients Screened for Social Needs During Intervention Compared to Patients Screened During Usual Care,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of Reminders Per FIT Return
2298,NCT04535492,"Rate of successful completion of colorectal cancer screening noted via electronic health record having colonoscopy, fecal occult blood, or non invasive screening option result for the patient.",2022-01-04,WITHDRAWN,INTERVENTIONAL,['NA'],,Average score of clinician experience and satisfaction as assessed via Likert scale survey.
2299,NCT05092880,progression-free survival,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Cost-effectiveness: Productivity Cost Questionnaire (PCQ)
2300,NCT05059665,Evaluate the performance (sensitivity/specificity) of the HelioLiver Test for all stage HCCs,2020-04-20,COMPLETED,OBSERVATIONAL,['NA'],,
2301,NCT00083720,Number of Participants With Serious Adverse Events,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2302,NCT04053231,Overall Survival,2019-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Number of redo-surgery
2303,NCT04711434,The percentage of patients from randomization to the first appearance of one of the following: adenomatous polyps or second primary tumors,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall Survival
2304,NCT01939223,Disease Free Survival (DFS) as Assessed by the Investigator,2013-12-02,TERMINATED,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
2305,NCT05174845,Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens),2021-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Sub-analyzes of the primary and secondary outcomes
2306,NCT00179751,"Phase II-To explore the anti-tumor activity of the combination of lenalidomide on days 1 - 21 and gemcitabine days 1, 8, and 15 every 28 days in subjects with advanced pancreatic carcinoma.",2005-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II-To evaluate the safety profile of the combination of lenalidomide and gemcitabine as combination therapy in subjects with advanced pancreatic carcinoma.
2307,NCT02804802,Colorectal cancer diagnosed by colonoscopy after a positive fecal occult blood test (Hemoccult II),2013-02,UNKNOWN,OBSERVATIONAL,['NA'],,
2308,NCT05662813,Objective response rate,2022-11-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
2309,NCT00411450,Time to Response,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Who Developed Antibodies to Panitumumab
2310,NCT06190652,PFS,2018-10-13,COMPLETED,OBSERVATIONAL,['NA'],,RP
2311,NCT03977272,Overall survival,2019-03-27,COMPLETED,INTERVENTIONAL,['PHASE2'],,EORTC QLQ - PAN26 score
2312,NCT03813953,Overall survival in months,2019-02-20,UNKNOWN,INTERVENTIONAL,['NA'],,Disease free survival
2313,NCT01248299,Overall survival,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Cost analysis
2314,NCT00843830,"The Percentage of Participants That Patients Complete Radiation Therapy, All Three Vaccinations, and Evaluation for Tumor Response Four Weeks After the Third Vaccination.",2006-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Patients That Respond to Treatment
2315,NCT05176834,Proportion of patients performing at least 50% of expected daily treatments during radiotherapy period.,2022-01-31,UNKNOWN,INTERVENTIONAL,['NA'],,The proportion of the patients that will experience severe oral mucositis
2316,NCT02916511,Local control rate,2016-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
2317,NCT03275974,Change in tumor size,2021-04-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
2318,NCT00540943,The safety and tolerability of the maximum tolerated dose defined as a dose regimen where no more than 1 of 6 subjects experiences a dose limiting toxicity.,2007-07-13,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to progression
2319,NCT05713903,Mesocolic Resection Plane,2023-02-06,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival
2320,NCT01189227,Recurrence-free Survival (RFS),2010-08,TERMINATED,INTERVENTIONAL,['PHASE3'],,Frequencies of Adverse Events as Assessed by the NCI CTCAE v4.0
2321,NCT04288661,POD of intra-abdominal complication detection,2020-02-28,RECRUITING,INTERVENTIONAL,['NA'],,Readmissions
2322,NCT06289803,diagnostic efficacy,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Rate of R0 resection
2323,NCT01590147,"Feasibility of implementing a YST among patients undergoing chemotherapy (participating rate, adherence, and retention)",2011-06,COMPLETED,INTERVENTIONAL,['NA'],,"Mediating variables (self efficacy, response expectancies, inflammatory biomarkers) intervention effect on fatigue, treatment-related symptoms, and QOL"
2324,NCT01930383,Numbers of circulating tumor cells,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],,Clinical characteristics
2325,NCT02535988,The proportion of patients with an abscopal response assessed at 7-8 weeks after the initiation of treatment.,2015-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,"The proportion of patients alive with abscopal responses from the date of enrollment until date of death from any cause, assessed up to 2 years from the opening of the study."
2326,NCT00513461,Change in Serum AFP Levels,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in Quality of Life - Mental Score
2327,NCT01804179,Rate of Test Kit Completion,2011-02-11,COMPLETED,INTERVENTIONAL,['NA'],,Time to Kit Return
2328,NCT00069121,Disease-Free Survival (DFS) [Time to Event],2003-04-18,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With at Least One Adverse Event by Most Severe Intensity
2329,NCT00168987,improvement of quality of life at two months,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,"improvement of nutritional state (body weight, muscle mass, body cell mass, phase angle, serum albumin)"
2330,NCT06328738,Incidence of electrocardiogram abnormalities,2024-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Brain metastases response (Phase 1b only)
2331,NCT02009423,Recurrence Free Survival (RFS),2015-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
2332,NCT03500874,3 Year Relapse Free Survival Rate,2018-05-28,TERMINATED,INTERVENTIONAL,['PHASE3'],Serum ctDNA methylation levels,Liver-specific RFS
2333,NCT03459339,Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy,2017-04-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
2334,NCT01839773,Progression Free Survival (PFS),2013-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety
2335,NCT01097265,Percentage of successful sentinel lymph node mapping procedures using multivariate analysis (stage 2),2010-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Stratified analysis of DFS and OS according to total harvested lymph nodes per resected specimen and chemotherapy regimen (capecitabine and oxaliplatin versus capecitabine alone) (stage 2)
2336,NCT04168931,Frequency of HER2 expression,2020-01-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
2337,NCT02948985,Correlation of RAS status on CTCs with clinical outcomes,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],,Correlation of mutant gene in ctDNA with cetuximab resistance.
2338,NCT03197155,Hepatocellular recurrence event,2016-06-01,COMPLETED,OBSERVATIONAL,['NA'],,
2339,NCT04430179,Change in Lund-Mackay sinus computed tomography (LMK-CT) score,2020-12-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in biomarkers concentrations in nasal secretion measured by enzyme-linked immunosorbent assay (ELISA)
2340,NCT04517448,Change in the response scores to the standardized questionnaire Quality of life questionnaire in cancer patient,2020-10-16,UNKNOWN,OBSERVATIONAL,['NA'],,Change in the Activity of daily living score
2341,NCT06016829,EORTC-QLQ-CR29,2021-07-25,COMPLETED,OBSERVATIONAL,['NA'],,
2342,NCT02515344,Patient participation rate to colorectal cancer screening,2015-08,COMPLETED,INTERVENTIONAL,['NA'],,Number of cancers screened in (versus diagnosed outside) the screening procedure.
2343,NCT01434069,Maximum Tolerated Dose (MTD),2011-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Tumor Response
2344,NCT04131062,MyCode enrollment decision,2019-11-01,COMPLETED,INTERVENTIONAL,['NA'],,
2345,NCT05771584,Immunologic efficacy of AST-301 immunization,2023-07-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in central memory T-cell populations between Arm 1 and Arm 2
2346,NCT05116917,Objective response rate (ORR),2021-11-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-related adverse events as assessed by CTCAE v5.0
2347,NCT01652833,Proportion of oncologists who administer Vectibix simultaneously with oxaliplatin-containing chemotherapy in mCRC patients with mutant KRAS tumors or patients with tumor KRAS status unknown,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
2348,NCT03750461,Number of Participants With Wound Occurrences in Current Study Compared to Historical Controls,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Quality of Life After Mesh Implantation
2349,NCT01086618,Overall survival for ≥ 2 years (phase III),2010-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Economic evaluation (phase III)
2350,NCT05262855,"Performance [sensitivity, specificity, accuracy] of [68Ga]FAPI-46 PET imaging to detect FAP-expressing cells, using histopathology as truth standard.",2022-05-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,[68Ga]FAPI-46 accumulation observed by (PET)/ (CT) pre and post in patients undergoing Neoadjuvant treatment.
2351,NCT04140435,The increment in diagnostic yield,2019-10-22,RECRUITING,OBSERVATIONAL,['NA'],,The inter-observer agreement
2352,NCT05220722,Phase 2: To Assess Overall Response Rate (ORR),2022-03-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: To Assess Overall Survival (OS)
2353,NCT03259828,Interfraction sigmoid colon organ motion,2017-12-06,COMPLETED,INTERVENTIONAL,['NA'],,Setup errors
2354,NCT05861505,Overall survival (OS) per patient,2023-04-24,RECRUITING,INTERVENTIONAL,['PHASE3'],,Cost-effectiveness ratio (ICER)
2355,NCT00598546,"Instrument: EORTC QLQ-C30, QLQ-STO22, and MSK-10. The intent of this study is to assess QOL in long-term survivors of all surgical procedures performed for the treatment of gastric cancer.",2004-09,COMPLETED,OBSERVATIONAL,['NA'],,
2356,NCT00002783,,1996-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2357,NCT03045770,Adverse Event（AE）,2017-02-10,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of Life (QoL)
2358,NCT00795977,To establish the maximally tolerated dose (MTD) and dose limiting toxicities (DLT) of intratumoral autologous dendritic cell vaccination in combination with OK-432,2003-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate the immune response of patients treated with this regimen based on the presence and characterization of tumor-infiltrating white blood cells
2359,NCT00132704,apoptotic response,2004-08,COMPLETED,OBSERVATIONAL,['NA'],,
2360,NCT02850783,Identification rate of SLNM with preoperative PET/CT imaging and intraoperative NIR fluorescence imaging in patients with colon carcinoma.,2015-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
2361,NCT01774786,Overall Survival,2013-06-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Cmin of Trastuzumab
2362,NCT04649372,Incidence of Treatment-Emergent Adverse Events (CTCAE),2021-01-13,COMPLETED,INTERVENTIONAL,['NA'],,Evaluation of Pain pre and post-treatment
2363,NCT03362177,Incidence of a Thrombocytopenia-induced chemotherapy dose modification during the second or third on study chemotherapy cycles.,2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,AEs/SAEs overall safety of romiplostim
2364,NCT06202716,Progression-free Survival (PFS),2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety
2365,NCT01416038,Number of reported adverse events,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Levels of cell mediated immunity targeting the survivin epitopes
2366,NCT02013089,Overall survival,2013-12,UNKNOWN,INTERVENTIONAL,['NA'],Disease control rate,Response rate
2367,NCT01048892,Recommended phase II dose of Seneca Valley virus-001 (NTX-010),2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Development of antibodies to NTX-010
2368,NCT00155272,The primary endpoint is the feasibility and tolerability of thalidomide plus radiotherapy.,2005-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The secondary end point is correlation of parameters of tumor perfusion assessed by DCEMRI and serum cytokine levels with objective tumor response.
2369,NCT04965259,Changes in the profile of metabolome in urine and plasma as high-risk patients develop HCC.,2021-04-15,RECRUITING,OBSERVATIONAL,['NA'],,
2370,NCT01008917,Maximum tolerated dose,2009-11-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Incidence of progression-free survival, overall survival, and disease control rate"
2371,NCT02507765,"Feasibility of SBRT in combination with TACE, measured by the number of patients able to tolerate all study procedures",2015-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Change in plateau signal intensity calculated from the DCE curve,Progression-free survival
2372,NCT00873600,"Chemotherapy tolerability as measured by dose reduction, treatment delay, and incidence of grade 3-5 toxicities",2007-10,WITHDRAWN,OBSERVATIONAL,['NA'],,3-year disease-free survival
2373,NCT00054249,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2374,NCT03461354,AUC for the Oral Mucositis Daily Questionnaire mouth and throat soreness question #2,2018-04-09,RECRUITING,INTERVENTIONAL,['NA'],Drug-related adverse events,Oral mucositis grade
2375,NCT00343408,,2005-11-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2376,NCT03110510,Overall Overall Response Rate,2019-09-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival
2377,NCT03239184,Relief degree of tumors,2017-09-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall survival（OS）
2378,NCT05400408,identification of Volatile Organic Compounds that can be related to Colorectal malignancy.,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Test Sensitivity and specificity for pancreatic cancer.
2379,NCT05065515,Degree of tumor regression,2021-10-01,RECRUITING,OBSERVATIONAL,['NA'],Species richness,The relative abundance of species
2380,NCT06295094,Peritoneal disease-free survival,2024-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients not receiving adjuvant chemotherapy
2381,NCT01379872,"Synthesise the data obtained for objectives 1-3 together with information from previous studies and expert opinion to estimate the safety, clinical efficacy and cost-effectiveness of new technologies compared to conventional standards",2011-06,COMPLETED,OBSERVATIONAL,['NA'],,
2382,NCT01774643,"Engraftment rate compared to clinical data (response to treatment, disease-free survival, overall survival)",2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
2383,NCT04907643,Patient-Reported Outcomes Measurement Information System Gastrointestinal Belly Pain over 30 days from the baseline,2021-10-05,RECRUITING,INTERVENTIONAL,['NA'],Dosage of VR (minutes per week),Opioid prescriptions of Morphine Milligram Equivalents (MME)
2384,NCT00427570,,1977-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2385,NCT01112046,Short-term morbidity,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Local recurrence
2386,NCT00550836,Overall Survival,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency and Severity of Observed Adverse Effects
2387,NCT00138060,tumor response rate,2005-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,pharmacokinetics
2388,NCT01661972,Median Progression Free Survival (PFS),2012-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Survival
2389,NCT01298999,Number of Participants That Experienced Change in Any Biomarker Expression,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants That Experienced Adverse Events
2390,NCT05848154,Objective response rate (ORR) of neoadjuvant therapy in patients with non-metastatic pancreatic cancer,2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The mechanisms of drug resistance to neoadjuvant chemotherapy
2391,NCT00220129,2 year overall survival,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to improvement of dysphagia
2392,NCT01376453,Maximum Tolerated Dose (MTD),2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Serious Adverse Events (SAEs)
2393,NCT05066139,Impact of EPODIG-G program on treatment.,2021-09-17,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
2394,NCT06019702,Dose-limiting Toxicity (DLT),2023-09-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Cytokines Level [immunogenicity]
2395,NCT03740165,PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants,2018-12-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Pathological Complete Response (pCR) Rate
2396,NCT03306394,Abnormalities in vital signs,2016-10-18,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life using the questionnaire EORTC QLQ-C30
2397,NCT05410535,The survival rate of gastric cancer,2021-09-15,RECRUITING,INTERVENTIONAL,['PHASE4'],,
2398,NCT04316182,Rate of AEs leading to treatment discontinuation,2020-07-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of patients who develop new extra-hepatic spread
2399,NCT05248750,Overall survival,2021-07-22,RECRUITING,OBSERVATIONAL,['NA'],,
2400,NCT01980407,Response rate,2013-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate
2401,NCT00767936,identify mutations in the hepatitis B virus genome that predisposes these high risk individuals to the development of liver cancer,2008-03,TERMINATED,OBSERVATIONAL,['NA'],,
2402,NCT03011255,Local control,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
2403,NCT05446558,Overall survival,2022-02-28,RECRUITING,INTERVENTIONAL,['NA'],,Cost of tests during hospitalization
2404,NCT00362739,Establish a set of normal ranges for various parameters in healthy individual specimens and compare to specimens from individuals with lung disease to determine parameters resulting in disease susceptibility and severity.,2005-09,COMPLETED,OBSERVATIONAL,['NA'],,
2405,NCT04525807,Objective response rate,2020-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
2406,NCT06060769,HCC incidence rate,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
2407,NCT05380414,"Number of patients with at least one actionable alteration defined as an alteration shown to predict for sensitivity to a drug FDA/EMA approved for use in another cancer type, or a relevant alteration for inclusion in a clinical trial.",2022-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Duration of response (DoR)
2408,NCT01197118,overall survival,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
2409,NCT03929094,Progression Free Survival,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
2410,NCT04410601,Evaluation of Dysphagia- Esophago-gastro-duodenoscopy (EGD),2020-05-14,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluation of Standard Dysphagia Rehabilitation
2411,NCT00815087,The Change From Baseline and Cut Point VFSS in Velocity of Displacement of Hyoid Bone at 1 to 3 Months,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Questionnaire of Life Quality
2412,NCT05493995,Disease Control Rate (DCR),2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival (PFS)
2413,NCT03960021,Immune response triggered by RFA: Quantification of interaction of PD-1 and PD-L1 in lung metastases using immune Förster Resonance Energy Transfer (iFRET).,2019-03-04,COMPLETED,INTERVENTIONAL,['NA'],,Change from baseline metastatic disease at 12 months
2414,NCT01483040,The primary endpoint is reaching the cecum of the colon with PeerScope B S,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,
2415,NCT06189482,Body Mass Index,2022-06-01,TERMINATED,INTERVENTIONAL,['NA'],,Penetration-Aspiration Scale
2416,NCT02150733,Composite of plasma pharmacokinetic parameters of Tivantinib,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Composite of plasma pharmacokinetic parameters of Tivantinib metabolites
2417,NCT02368236,"Participation in risk-appropriate colorectal cancer testing (i.e., participation in any CRIS-recommended test based on patients' risk factors).",2008-12,COMPLETED,INTERVENTIONAL,['NA'],,Testing difference in receipt of any type of colorectal cancer testing.
2418,NCT05751850,Overall survival (OS),2023-06-13,RECRUITING,INTERVENTIONAL,['PHASE3'],,Progression free survival (PFS)
2419,NCT00828594,Time to disease progression assessed when 60 events have been observed,2008-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Pharmokinetics of RAD001 at pre-dose and 1 hour and 2 hours post-dose
2420,NCT01715363,Clinical tolerance of immediate preoperative chemotherapy,2012-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,
2421,NCT05074589,Overall Survival(OS),2018-01-25,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life（QoL）
2422,NCT01923948,Postoperative Opioid Consumption,2013-05,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative Pain Scores on the Visual Analog Scale
2423,NCT01771146,Progression Free Survival (PFS) as defined by the length of time that a patient survives without any signs or symptoms of that cancer or any other type of cancer,2012-10,UNKNOWN,INTERVENTIONAL,['NA'],,• R0 resection as defined as microscopically negative margins
2424,NCT02908451,Adverse events (AEs) graded according to CTCAE v4.03.,2017-04-24,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Response Rate Evaluated by Response Evaluation Criteria in Solid Tumor (RECIST)
2425,NCT03641313,Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 response criteria,2020-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Presence of other deoxyribonucleic acid (DNA) damage response defects (DDRD),Overall survival (OS)
2426,NCT01085617,Event-free survival,2010-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Mucositis score in patients treated with palifermin
2427,NCT03393416,Incidence of Treatment-Emergent Adverse Events（Safety）,2018-04-19,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
2428,NCT00005050,,1999-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2429,NCT02503111,Anal dysplasia treatment on a per-patient basis,2015-11,TERMINATED,INTERVENTIONAL,['NA'],,Acceptability of treatment
2430,NCT02845479,Feasibility of study protocol,2018-12-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Natural kill cell activation,Feasibility of recruitment
2431,NCT05723718,Tumor Regression Grade,2022-12-20,RECRUITING,OBSERVATIONAL,['NA'],,Quality of Life score
2432,NCT00491855,Maximum Tolerated Dose (MTD),2007-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2433,NCT02024438,The incidence of neurotoxicity including acute neurotoxicity and accumulating neurotoxicity,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,quality of life
2434,NCT01468688,Frequency and characteristics of dose limiting toxicities (DLTs) at each dose level during the first cycle of therapy,2012-04-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Clinical benefit rate (CBR) defined as the rate of confirmed complete response (CR) or partial response (PR), or stable disease (SD) which lasts for at least 16 weeks."
2435,NCT01830270,curative resection rate,2011-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,global survival
2436,NCT04067960,"Changes in symptoms, quality of life (QOL), and perceptions about pharmacogenomics (PGx) testing",2019-06-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Provider opinions surrounding the clinical utility/relevancy of PGx testing in cancer patients
2437,NCT03286244,Percentage of patients who suffer at least one adverse event,2018-03-15,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression-free survival
2438,NCT01524094,Overall survival,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Side effects of treatment
2439,NCT03592641,Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1),2019-07-25,TERMINATED,INTERVENTIONAL,['PHASE2'],,Months of Progression-Free Survival (PFS)
2440,NCT00001603,,1996-12,COMPLETED,OBSERVATIONAL,['NA'],,
2441,NCT02450656,Progression Free Survival (Phase II),2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pharmacogenetics profiling to assess predictors of response and resistance- inducing mutations,"Efficacy (Phase II) (Overall response rate (ORR), duration of response (DOR) , time to response (TTR) and overall survival (OS) per RECIST v1.1)"
2442,NCT06116136,Objective Response Rate (ORR),2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Objective Response Rate (ORR)
2443,NCT01352728,Two-year survival rate,2011-05-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tissue and Serum Biomarkers
2444,NCT03722121,"distance ""home of patients - treatment center""",2017-03-23,UNKNOWN,OBSERVATIONAL,['NA'],,
2445,NCT05361538,Comparison of progression-free survival between MSA and traditional MWA in HCC,2022-06-22,RECRUITING,INTERVENTIONAL,['NA'],,Comparison of the complications rate of MSA and traditional MWA in HCC
2446,NCT05128032,Radiotracer distribution,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Technical success of radiotracer delivery as measured by ability to deliver radiotracer
2447,NCT01961778,Percentage of Barrett's esophagus ablated during the initial treatment session.,2013-11,COMPLETED,INTERVENTIONAL,['NA'],,Patient discomfort
2448,NCT00192088,The primary objective of this study is to determine the response rate of Pemetrexed plus oxaliplatin as first-line therapy in patients with advanced gastric carcinoma.,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Determinants of efficacy and toxicity of the treatment with pemetrexed and oxaliplatin in the patient population by means of pharmacogenomic and pharmacogenetics investigations: Quantitative analysis of TS, DHFR, GARFT, RFC, MRP5, DPD, TP, FPGS and ERCC1"
2449,NCT02877368,sarcopenia,2014-05,COMPLETED,OBSERVATIONAL,['NA'],,Imatinib-induced toxicities
2450,NCT05422547,Tumour recurrence,2022-04-01,RECRUITING,OBSERVATIONAL,['NA'],,Possible economic impact
2451,NCT02348229,Compartition of postoperative hospital stay,2013-09,COMPLETED,INTERVENTIONAL,['NA'],,Change from baseline in C-Reactive Protein( CRP) and visceral proteins level
2452,NCT01274624,Pharmacokinetic parameters for irinotecan and 5-FU when combined with REOLYSIN®,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,"In vitro studies in human-derived colorectal cancer cells including the isogenic cell lines, to study the mechanism and scientific basis of synergy between irinotecan and reovirus"
2453,NCT05681234,Evaluation of tissue distribution of 18F-RD2,2022-08-24,COMPLETED,INTERVENTIONAL,['NA'],,
2454,NCT03981510,Children with NF1 and gastrointestinal symptoms has a longer transit time through the colon and fewer fast bowel movements than healthy children.,2019-06-13,UNKNOWN,INTERVENTIONAL,['NA'],,
2455,NCT02911974,The total area of procured tissue between the FNA and FNB needles,2016-08,COMPLETED,INTERVENTIONAL,['NA'],,Diagnostic adequacy between the FNA and FNB needles
2456,NCT05530343,Diagnostic yield of intestinal metaplasia (Screening population only),2022-10-03,RECRUITING,INTERVENTIONAL,['NA'],,Diagnostic yield of dysplasia (Screening population only)
2457,NCT01266564,Progression-free survival in a real life setting assessed by computer tomography,2010-09-03,COMPLETED,OBSERVATIONAL,['NA'],,Safety: incidence of adverse events
2458,NCT06196788,Overall survival，OS,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,disease control rate (DCR)
2459,NCT01610895,Quality of Bowel Cleanliness,2011-12,UNKNOWN,INTERVENTIONAL,['NA'],,Patient satisfaction with preparation
2460,NCT00121745,To determine the dose limiting toxicity and maximum tolerated dose of Rexin-G administered as intravenous infusions; To evaluate pharmacokinetics of Rexin-G,2005-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,To assess anti-tumor activity of intravenously administered Rexin-G and obtain preliminary data on biochemical markers of tumor response
2461,NCT05379790,Maximum-tolerated dose,2022-05-25,RECRUITING,INTERVENTIONAL,['PHASE1'],,Area Under the Curve (AUC) ratio intraperitoneal/systemic irinotecan
2462,NCT01381913,,2005-10,COMPLETED,OBSERVATIONAL,['NA'],,
2463,NCT03871790,Identification of tumor specific mutations on the genomic level,2019-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Identification of neo-antigens epitopes at protein level
2464,NCT00364078,,2006-06,COMPLETED,OBSERVATIONAL,['NA'],,
2465,NCT00027495,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2466,NCT05679674,Median Progression Free Survival (PFS),2023-09-21,RECRUITING,INTERVENTIONAL,['NA'],,Chemotherapy-Free Interval
2467,NCT04343950,Intervention 3: Participation in breast cancer screening program,2020-09-15,UNKNOWN,INTERVENTIONAL,['NA'],,Incremental cost ratio
2468,NCT02994888,Track and validate specific known mechanisms of resistance/response to anti-EGFR therapies through,2012-11,COMPLETED,OBSERVATIONAL,['NA'],,Identify novel biomarkers of resistance to anti-EGFR therapies through whole exome sequencing
2469,NCT00262847,Progression-free Survival,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Impact on Quality of Life Measured by the Functional Assessment of Cancer Therapy-Ovary Trial Outcome Index (FACT-O TOI)
2470,NCT05724992,Presence - absence of predisposing mutations,2022-12-20,RECRUITING,INTERVENTIONAL,['NA'],,Correlation of genetic mutations with familial oncological history
2471,NCT00424827,"Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy.",2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity Associated With This Regimen.
2472,NCT03950908,Identification of signet ring cell carcinoma (SRCC) foci.,2017-10-12,COMPLETED,INTERVENTIONAL,['NA'],,Dose of sedation.
2473,NCT01433016,PDR Peak,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
2474,NCT04550897,Adverse Events related to BM7PE,2020-08-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Radiological response to BM7PE
2475,NCT01171924,Number of Participants With Adverse Events,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2476,NCT03349398,the incidence of Roux stasis syndrome,2017-11-10,UNKNOWN,INTERVENTIONAL,['NA'],,the quility of life according to the RGB standards
2477,NCT06281145,Primary endpoint - Working memory,2024-03-15,RECRUITING,INTERVENTIONAL,['NA'],,Secondary endpoint - Serious Adverse Events (SAE)
2478,NCT06010212,ORR（Objective response rate）,2023-08-25,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PFS（Progression-free survival）
2479,NCT06087263,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2024-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
2480,NCT03083951,Total number of lymph nodes and lymph node ratio.,2017-09-01,COMPLETED,INTERVENTIONAL,['NA'],Defecatory dysfunction assessed by FSFI and erectile dysfunction questionnaires,Survival
2481,NCT04347772,Length of hospital stay,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Nutritional status - Dietary Intake
2482,NCT05817370,Change in HSIL treatment,2023-05-02,RECRUITING,INTERVENTIONAL,['NA'],,Change in Maintenance of HSIL screening and treatment
2483,NCT03582306,Feasibility - adherence,2018-07-23,COMPLETED,INTERVENTIONAL,['NA'],,Acceptability
2484,NCT03002064,Progression free survival,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life--Score of the questionnaire
2485,NCT03338647,"Progression (total of local, intra- and extrahepatic)",2017-10-26,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Cost-benefit
2486,NCT06323421,Acceptability,2024-04-22,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Systemic inflammation,
2487,NCT05818982,Progression-free survival,2023-02-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
2488,NCT05948826,Recommended Phase 2 Dose (RP2D),2023-09-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Accumulation ratio (Rac) of TORL-3-600
2489,NCT00971399,complete response of RINV (no vomiting and no rescue medication),2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2490,NCT04117958,Number of subjects with changes in electrocardiogram (ECG),2020-01-20,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Overall survival (OS), 2-year OS"
2491,NCT03904667,Operative outcomes,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Disease-free survival,Postoperative survival
2492,NCT03998566,Safety Endpoint,2019-04-24,COMPLETED,INTERVENTIONAL,['NA'],"Changes From Baseline Final RT Appointment, 3 Months, 6 Months, 12 Months, and 18 Months in QLQ-PAN26","Changes From Baseline at the Final RT Appointment, 3 Month, 6 Month, 12 Month and 18 Month in EORTC QoL (QLQ-C30)"
2493,NCT02082886,Overall survival rate,2014-02,COMPLETED,OBSERVATIONAL,['NA'],,Rates of complications
2494,NCT03427684,Maximum tolerated dose AND Dose limited toxicity,2016-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,2-year disease-free survival
2495,NCT01950572,sample aquisition,2013-09-09,RECRUITING,OBSERVATIONAL,['NA'],,
2496,NCT05398380,Five years overall survival,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],Percentage of patients with circulating tumor DNA (ctDNA),Changes in quality of life assessed by EORTC QLQ-C30 questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30)
2497,NCT00888797,Rate of recurrent and metastatic cancer,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Early postoperative morbidity and mortality
2498,NCT03690323,Overall survival,2015-04-07,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of Life questionnaire
2499,NCT02102022,Objective response rate (ORR),2014-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,AFP (alpha feto-protein) changes
2500,NCT01324141,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE),2011-03-18,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Human Immunodeficiency Virus (HIV) in Biopsy Tissue From Rectal Mucosa
2501,NCT03671252,3-year disease free survival rate,2018-11-16,RECRUITING,INTERVENTIONAL,['PHASE3'],,Long term quality of life
2502,NCT06266871,pCR rate,2024-03-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,2-year OS rate
2503,NCT04258072,Progression-Free Survival (PFS),2021-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2504,NCT01669044,Cardiac output,2012-05,UNKNOWN,OBSERVATIONAL,['NA'],Systemic Venous Resistance Index,Stroke Volume
2505,NCT02598687,Dose Limiting Toxicity (DLT ),2015-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,metabolic response
2506,NCT00125034,Best Overall Response Rate - Independent Review Committee (IRC),2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety - Number of Patients Experiencing Any Adverse Event
2507,NCT01347333,Local Tumor Recurrence Rate,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,Late Complication Rates
2508,NCT01310478,Dose limiting toxicity and maximum tolerance dose of continous intravenous Endostar in combination with mFOLFOX6,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Parameters of human pharmacokinetics of continous intravenous Endostar in combination with mFOLFOX6
2509,NCT02135822,Overall response rate,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety and tolerability
2510,NCT01770275,Overall survival,2008-04,COMPLETED,OBSERVATIONAL,['NA'],,Survival distinction
2511,NCT06284746,Objective Response Rate（ORR）,2023-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidence of adverse events during treatment
2512,NCT04744831,Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review Following IV Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2-overexpressing Metastatic Colorectal Cancer,2021-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of Participants Positive for Treatment-emergent Anti-drug Antibodies (ADAs) and Neutralizing Antibodies (NAb) in Participants Who Were Administered T-DXd
2513,NCT04294784,objective response rate(ORR),2020-04-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,patient-reported outcomes (PROs)
2514,NCT02864849,Major adverse events,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module 29 (EORTC QLQ-CR29)
2515,NCT03931304,Evaluation of 3-years disease free survival,2018-02-01,COMPLETED,OBSERVATIONAL,['NA'],,
2516,NCT00967616,"Percentage of Participants With Progression-Free Survival at 16 Weeks After Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (5-FU) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer",2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Treatment-Emergent Adverse Events Occurring in ≥10% of Participants Following Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer"
2517,NCT06178198,Duration of response according to localized mRECIST,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Post-treatment dosimetry based on Y90 PET-CT,Changes in regional liver function
2518,NCT05385900,"Pathological complete response, pCR",2022-06-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,"major pathologic response, MPR"
2519,NCT03723915,Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1,2018-11-14,TERMINATED,INTERVENTIONAL,['PHASE2'],,Immune Response Determined by Analysis of pre-and Post- Treatment Biopsies and Blood-based Immune Markers
2520,NCT01123876,Determine the MTD and establish the recommended phase 2 dose of Veliparib in combination with two different FOLFIRI regimens that include a reduced regimen (150 mg/m2 irinotecan) and the standard regimen (180 mg/m2) in subjects with advanced solid tumors,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To assess the safety and tolerability, pharmacokinetic profile of the combination at each of the FOLFIRI regimens."
2521,NCT01749722,Number of adverse events,2012-11,COMPLETED,INTERVENTIONAL,['NA'],,
2522,NCT03597204,"Number of subjects diagnosed colonic adenoma, advanced adenoma or cancer",2015-10-07,COMPLETED,INTERVENTIONAL,['NA'],,
2523,NCT03026140,Disease free survival,2017-03-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Relapse free survival
2524,NCT01651832,proportion of eligible patients undergoing adjuvant chemo therapy,2012-07,COMPLETED,INTERVENTIONAL,['NA'],,Quality of inpatient care
2525,NCT04487717,Prognostic group's 5-yr Overall Survival(OS) rate,2020-07-29,RECRUITING,OBSERVATIONAL,['NA'],,Subgroup analysis
2526,NCT05391321,"Preference ranking of 4 validated sexual QOL questionnaires in French, FSFI, PISQ-IR, PISQ-12, BISF assessed on the collection of questionnaire returns by patients",2023-05-12,RECRUITING,INTERVENTIONAL,['NA'],,
2527,NCT02371135,"association of the gut microbiome and dietary factors (To validate said associations, individual questions from the Brief Diet and Lifestyle Questionnaire will be primarily used in the overall analyses)",2015-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
2528,NCT03207724,"Maximum Tolerated Dose (MTD) of onivyde, 5-fluorouracil/folinic acid in combination with Xilonix",2017-10-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,Mean change in global score of patient-reported response to therapy (FAACT questionnaire- Functional Assessment of Anorexia/Cachexia Therapy)
2529,NCT04425876,R0 resection rate,2020-12-17,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Minimum concentration (Cmin)
2530,NCT00921661,Dose-limiting toxicity (DLT) combination with FOLFIRI,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunogenicity
2531,NCT04170257,"Negative predictive value (NPV) of WLE, NBI and ISE in the diagnosis of mild, moderate, severe dysplasia and above lesions in esophagus",2019-10-18,UNKNOWN,INTERVENTIONAL,['NA'],,Discrimination of visualized abnormal features
2532,NCT04822103,Feasibility of immunochemotherapy defined as at least 80% of the patients completed all planned courses,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Major pathological response
2533,NCT05157451,Feasibility of enrollment (enrollment rate),2023-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Time to next treatment
2534,NCT00280007,"to assess collateral tumor vessel growth on MRT / CT after 3, 6, and 12 months",2006-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,cost
2535,NCT03283956,Safety of the DC bead TACE,2017-09-13,UNKNOWN,OBSERVATIONAL,['NA'],,Tumor response
2536,NCT03607370,Complete pathologic response assessed by pathologist Dworak scale,2017-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Urinary catheter removal timing
2537,NCT04443322,Recurrence-Free Survival (RFS),2020-09-19,RECRUITING,INTERVENTIONAL,['NA'],,Percentage of Participants who Experience an Adverse Event (AE)
2538,NCT00949312,Disease-free survival (time to local or distant recurrence after resection),2009-05,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival (time to death from colorectal cancer)
2539,NCT05643859,Change in microbiome colonic mucosa: microbiome diversity,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,
2540,NCT04134897,2-year local recurrence rate,2019-10-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3'],,Preoperative tumor-associated complications rate
2541,NCT02041507,Adenoma Detection Rate.,2014-02,COMPLETED,INTERVENTIONAL,['NA'],Patients willingness to repeat the examination.,Need for sedation/analgesia and its dosage
2542,NCT03517488,Determine the safety and tolerability profile of XmAb20717,2018-07-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2543,NCT03744624,Operative time,2017-04-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Mortality
2544,NCT05411783,Anastomotic leak,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Post-operative complications
2545,NCT00193128,"Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in Their Surgical Specimen Following Surgery",2004-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
2546,NCT04394585,Eating restriction score (XEatR) at 3 months postoperatively,2020-04-20,RECRUITING,INTERVENTIONAL,['NA'],,seum hemoglobin
2547,NCT02613260,Completion of FIT- one year,2016-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Cost
2548,NCT00769405,Overall survival,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Morbidity from surgical complications (abdominal, extra-abdominal, aplasia)"
2549,NCT06029010,"Descriptive analysis of biomarkers of patients with mCRC who had a long-term response to regorafenib monotherapy, as indicated by a treatment duration of ≥5 months",2023-08-31,COMPLETED,OBSERVATIONAL,['NA'],,"Descriptive analysis of biomarkers of patients with mCRC who had a long-term response to regorafenib monotherapy, as indicated by a treatment duration of ≥4 months"
2550,NCT01897454,Percentage of Participants Achieving R0 Resection (R0 Resection Rate),2012-01-27,TERMINATED,INTERVENTIONAL,['PHASE2'],,Vascular Reconstruction
2551,NCT01210235,Completion of colorectal cancer screening by eligible patients within 3 months of their flu shot,2009-10,COMPLETED,INTERVENTIONAL,['NA'],,
2552,NCT02576509,Overall Survival (OS),2015-12-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Efficacy Based on PD-L1 Expression - ORR
2553,NCT04017455,clinical complete and near-complete response rate,2019-10-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,local recurrence rate at 1 year follow-up
2554,NCT03493763,Time of hepatocellular carcinoma recurrence,2018-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,Adverse effect of 5hmC blood test
2555,NCT00648635,Quality of Life (QOL) Survey Responses,2008-03-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
2556,NCT01944137,Change from baseline (i.e. first chemotherapy administration visit) in patient-reported symptoms as measured by the Memorial Symptom Assessment Scale-Short Form.,2013-09,COMPLETED,INTERVENTIONAL,['NA'],,"Frequency of urgent outpatient Cancer Center visits, emergency department visits, and hospital admissions during six months post-baseline"
2557,NCT00030862,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2558,NCT02461966,Serum Aflatoxin Level in Liver Cancer Patients,2014-06,COMPLETED,INTERVENTIONAL,['NA'],,
2559,NCT02392143,Colorectal Cancer Screening,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,
2560,NCT04031625,Patient survival,2012-11-26,UNKNOWN,OBSERVATIONAL,['NA'],,Collection of patient and treatment characteristics
2561,NCT00931229,enroll 150 patients,2009-06,UNKNOWN,INTERVENTIONAL,['NA'],,
2562,NCT00897429,Cancer-specific mortality (B6),2007-07,COMPLETED,OBSERVATIONAL,['NA'],,Evaluation of up to 768 new genes for their relationship with colon cancer recurrence (B4
2563,NCT05511116,Inter-observer reproducibility,2022-07-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Tumor response on morphological imaging vs. tumor response grade on pathology
2564,NCT00534131,Oncological safety assessment - where appropriate,2004-04-01,COMPLETED,INTERVENTIONAL,['NA'],,
2565,NCT03416699,The grade score of the specimens integrity,2017-11-15,UNKNOWN,OBSERVATIONAL,['NA'],,the grade of anastomotic leakage
2566,NCT02028845,The cannulation success rate,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,"The duration of the cannulation, immediate and late complications."
2567,NCT02402699,Identify and describe observed adverse events (AEs) based on liver function abnormalities and changes in hepatitis viral load,2015-12-15,COMPLETED,OBSERVATIONAL,['NA'],,
2568,NCT03439462,"Progression-free Survival at 6 Months (Phase 2) for All Patients, at the RP2D, as Well as Based on PTEN Status (Positive and Negative)",2018-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Overall Response Rate (Phase 2) for All Patients, at the RP2D, as Well as Based on PTEN Status (Positive and Negative)"
2569,NCT02035072,Proportion of resectable patients,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression free survival (PFS/local PFS)
2570,NCT00155727,,2000-01,UNKNOWN,OBSERVATIONAL,['NA'],,
2571,NCT02301481,R0 resection rate,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Comparison of dosimetric differences between radiation techniques,Overall survival
2572,NCT05604560,Pathologic Response Rate as assessed by number of patients with a grade 0-2 pathologic response,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Free Survival (DFS)
2573,NCT03158779,Overall survival,2017-05-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression free-survival of treated patients
2574,NCT05897138,Objective response rate (ORR),2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival(OS)
2575,NCT01351194,overall survival,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],,disease-free survival
2576,NCT05178524,Species composition and differential analysis of gut microbiota,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],,
2577,NCT04296058,Disease free survival (DFS),2007-01-08,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
2578,NCT02400996,Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,
2579,NCT04713332,Matrix metalloproteinases(MMPs),2019-07-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
2580,NCT02442583,Change in number of minutes per day of bouts of sedentary behaviors.,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,"Covariation between baseline use of an ActiGraph, and self-reporting of sedentary behaviors"
2581,NCT05431530,Frequency of major LARS after surgery,2022-06-22,RECRUITING,OBSERVATIONAL,['NA'],,EOTC QLQ-C30
2582,NCT00721916,Progression free survival (PFS),2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
2583,NCT00474097,"to assess if follow-up telephone calls after surgery affects patient satisfaction, surgical outcomes and quality of life in the early post-operative phase after colorectal surgery",2006-02,COMPLETED,OBSERVATIONAL,['NA'],,"to track readmissions, complications and emergency room visits via telephone calls to ensure communication between the patients and the surgical office is optimal."
2584,NCT00096967,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2585,NCT01064622,Progression-free Survival,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Activity (Overall Response Rate) in Crossover Patients
2586,NCT04462354,Postoperative pancreatic fistula rate (PPF),2020-06-04,UNKNOWN,INTERVENTIONAL,['NA'],,Other complications.
2587,NCT05744219,Recovery after iv Iron,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Performance status
2588,NCT01005225,Solid tumor biological insights,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,
2589,NCT05497947,SOAL- VF,2021-07-03,COMPLETED,OBSERVATIONAL,['NA'],,
2590,NCT06157216,3-year Disease-Free Survival (DFS) rate,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],Association between prognosis with multi-omic sequences,3-year Overall Survival (OS) Rate
2591,NCT01236989,the prognostic impact of anatomical resection by means of intraoperative ultrasound (IOUS) guided vessel compression versus nonanatomical resection in terms of disease free and overall survival,2011-01,UNKNOWN,INTERVENTIONAL,['NA'],,the impact of anatomical resection versus non-anatomical resection in terms of postoperative mortality and morbility
2592,NCT06184698,Objective Response Rate,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
2593,NCT01401699,Number of Subjects in Which the Entire Distal Esophagus Can be Visualized Using the Balloon Based Optical Coherence Tomography Screening,2006-09,COMPLETED,INTERVENTIONAL,['NA'],,
2594,NCT02538562,Incidence of HER2 positivity among gastric and gastroesophageal junction tumor samples,2011-10-11,COMPLETED,OBSERVATIONAL,['NA'],,Correlation between HER2 status and gender
2595,NCT04780529,Number of participants with CAR-T treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: 24 months ],2021-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Efficacy will be assessed according to RECIST1.1 or EORTC or PERCIST criteria
2596,NCT04140318,ORR,2019-11-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS
2597,NCT05447923,Colorectal cancer disparities seen in people of color and minority populations,2022-05-22,RECRUITING,INTERVENTIONAL,['NA'],,
2598,NCT02448693,Number of residual neoplastic tissue detected with both techniques (NBI versus WLE),2015-05,COMPLETED,INTERVENTIONAL,['NA'],,Number of missed lesions on basal colonoscopy
2599,NCT01231399,Overall Survival,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2600,NCT04548531,Shared Decision Making (SDM) Process Scale Score,2020-09-10,COMPLETED,INTERVENTIONAL,['NA'],,Colon Cancer Screening Rate
2601,NCT02280811,Duration of Response,2014-10-14,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Expression of Programmed Cell Death 1 (PD-1) by Circulating E6 T-Cell Receptor (TCR) T-Cells
2602,NCT00200200,To determine whether the addition of concurrent intravenous bevacizumab to HAI plus systemic chemotherapy increases the time to progression in patients with completely resected hepatic metastases from colorectal cancer,2004-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,"To compare plasma levels of VEGF-A, VEGF-C, VEGF-D, and CD133+ VEGFR2+ circulating endothelial progenitors"
2603,NCT00145314,"To compare efficacy, as measured by time to disease progression, of treatment with cetuximab in combination with the FLOX regimen compared to FLOX alone, in first- line treatment of patients with metastatic cororectal cancer",2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,"To measure response rates, response duration, secondary surgical curative resection frequency, safety profile, overall survival and quality of life in the treatment groups."
2604,NCT01675505,,2012-05,UNKNOWN,OBSERVATIONAL,['NA'],,
2605,NCT02157246,Group B Percentage change in FMISO-PET SUVmax and uptake volume,2013-10,COMPLETED,INTERVENTIONAL,['NA'],Radiotherapy planning feasibility study,Comparison of changes in T1/T2* MRI
2606,NCT01459757,Mutational status data retrospectively accessed correlated with A6181036 clinical outcomes data in GIST subjects treated with sunitinib,2011-10,COMPLETED,OBSERVATIONAL,['NA'],,
2607,NCT06104215,Dose-limiting toxicity（DLT）,2023-10-22,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,PFS
2608,NCT05642962,Change in body mass index/BMI from baseline to 4 months,2022-11-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2609,NCT00341705,,2001-04-27,COMPLETED,OBSERVATIONAL,['NA'],,
2610,NCT00262951,Number of Patients in Whom Tumor Was Resectable,2005-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2611,NCT06168786,Progression-free survival (PFS),2023-06-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,AEs
2612,NCT02337465,Percent of Patients Whose Plan Quality Was Not Not Affected in the Presence of the Ultrasound Probe,2015-09-22,COMPLETED,INTERVENTIONAL,['NA'],,
2613,NCT00056459,Progression free survival,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Tolerability and safety profile
2614,NCT05452382,Overall survival,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Positive resection margins
2615,NCT05807984,local control,2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,progression free survival
2616,NCT05364788,Characterise the genes of appendiceal cancer.,2024-02-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Descriptive analysis in proportions
2617,NCT02538913,Anal incontinence,2015-09,TERMINATED,INTERVENTIONAL,['NA'],,In-hospital time
2618,NCT06087289,"Evaluate the safety and tolerability of KAND567 in combination with carboplatin therapy in recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as measured by lab safety tests",2023-04-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the plasma exposure of KAND567
2619,NCT01085331,Part 2 or Phase 2 Randomised Part: Progression Free Survival (PFS),2010-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Part 2 or Phase 2 Randomized Part: Number of Subjects With TEAEs, Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death"
2620,NCT05451719,Progression-free Survival (PFS),2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidence of adverse events
2621,NCT03544736,Incidence of Treatment-Emergent Adverse Events,2018-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Health Related Quality of Life (EORTC QLQ-OG25)
2622,NCT06068127,GCSI score,2023-10-12,RECRUITING,OBSERVATIONAL,['NA'],,Pyloric distensibility
2623,NCT00987935,Time to Progression (TTP) in Phase II,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"fe0-12,ss (Fraction Excreted in Urine Between 0 and 12 Hours at Steady State) for Nintedanib"
2624,NCT01726010,diagnostic yield,2012-09,UNKNOWN,INTERVENTIONAL,['NA'],,
2625,NCT04465214,"Outcomes from: PRO-CTCAE, Neuro-QOL, Numeric Rating Scale for Pain, 6-Minute Walking Test, Stroop Test, and Normalized Reaction Time Tests",2020-11-23,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Evaluation of iPhone based tests of cognitive functioning and reaction time for reliability and validity
2626,NCT00411229,Clinical laboratory tests,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2627,NCT01462903,• the safety and tolerability of autologous tumor infiltrating lymphocytes (TIL) in combination with Interleukin-2(IL-2) in patients with nasopharyngeal carcinoma (NPC).,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],,• immune efficacy and anti-tumor effects of autologous tumor infiltrating lymphocytes (TIL) in combination with Interleukin-2(IL-2) in patients with nasopharyngeal carcinoma (NPC).
2628,NCT02109146,DFS(Disease free survival),2014-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
2629,NCT00017537,Determine the optimum biologic dose of MVF-HER-2 (628-647)-CRL 1005 vaccine that will induce snit-HER-2 antibody in patients with metastatic or recurrent cancer,2000-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Document any clinical responses to this drug in these patients.
2630,NCT03273686,postoperative complication,2017-09-15,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Length of postoperative stay
2631,NCT03254836,Actigraphy,2017-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,"Follow-up cancer treatment (Adjuvant chemotherapy, timing and duration)"
2632,NCT02811666,muscle strength using a hand gauge,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,
2633,NCT02871336,Optimization of the surgical care of the patients,2014-11,RECRUITING,OBSERVATIONAL,['NA'],,
2634,NCT04221347,Detection of spectroscopic markers differences among specified groups,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Measure of sensitivity and specificity of identified biomarkers for surveillance of HCC
2635,NCT02009774,Accuracy optical biopsy,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,Adenoma detection rate
2636,NCT05165264,Overall Survival (OS),2022-02-16,RECRUITING,OBSERVATIONAL,['NA'],,OS measured by Programmed Death-Ligand 1 (PD-L1) combined positive score (CPS)
2637,NCT06282484,corelation between the gastric xanthoma and gastric mucosa diseases,2022-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
2638,NCT03416582,Percentage of patients using Intervention materials,2018-11-29,COMPLETED,INTERVENTIONAL,['NA'],,Influence of Nurse-Delivered Telephone Intervention on Symptom Self-Management
2639,NCT00876148,,na,COMPLETED,OBSERVATIONAL,['NA'],,
2640,NCT04994236,Objective response of intrahepatic lesions,2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The rate of adverse events
2641,NCT04502082,The recommended phase 2 dose (RP2D) regimen of ET140203 T-cell therapy primarily based on DLT,2021-04-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the pharmacokinetics of ET140203 T cells after infusion.
2642,NCT01311232,Hepatitis B virus reactivation,2010-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
2643,NCT04081168,One-year local tumor progression-free survival,2020-12-15,RECRUITING,INTERVENTIONAL,['NA'],,Mortality
2644,NCT01552434,"MTD of temsirolimus, defined as the dose level below the dose at which 2 of 6 patients experience DLT",2012-03-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],The properties of the tissue microvasculature.,Levels of surrogate anti-angiogenesis markers
2645,NCT01567488,Percentage of patients with progression-free survival (PFS),2011-06-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of patients with Adverse Events
2646,NCT05317819,Overall Survival (OS),2022-03-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,Progression free survival
2647,NCT06070740,Objective Response Rate,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
2648,NCT01095432,Study samples of rectal mucosa (the moist lining of the rectum) using PWS.,2010-03,COMPLETED,OBSERVATIONAL,['NA'],,
2649,NCT06144762,the integration of in vivo and ex vivo MRI with histology and molecular caracteristic in order to increase the pancreatic cancer detection and therapeutic response monitoring,2023-12-19,RECRUITING,INTERVENTIONAL,['NA'],,Correlate MRI results with hematological molecular biology results.
2650,NCT01251536,PFS Probability Rate at 9 Months in the Dose Escalation Arm,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Deaths Till 30 Days From Last Cetuximab Administration
2651,NCT02642978,Surgical Complication,2015-09-01,UNKNOWN,INTERVENTIONAL,['NA'],liver function,locoregional recurrence rate
2652,NCT00455247,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2653,NCT02702414,Objective Response Rate (ORR),2016-05-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
2654,NCT01978249,Comparison of the overall survival between patients who underwent primary tumor resection and patients who received chemotherapy without primary tumor resection,2013-09,TERMINATED,INTERVENTIONAL,['NA'],To compare the quality of life between the two groups using the Korean version of EORTC QLQ (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire)-C30.,Analysis of primary tumor related complications in the chemotherapy group and postoperative complications in the primary tumor resection followed by the chemotherapy group.
2655,NCT05673512,Progression-Free-Survival（PFS）,2023-05-12,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
2656,NCT01394497,Graft survival,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Primary graft dysfunction
2657,NCT04148092,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
2658,NCT05021263,Quality of Recovery 40 Questionnaire,2022-05-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,
2659,NCT05643833,Overall survival,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
2660,NCT01413451,Background ratio of maximum counts,2011-07-12,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Antibody uptake vs. IHC mesothelin expression
2661,NCT01505842,Prevalence of dysplastic lesions,2011-02,UNKNOWN,INTERVENTIONAL,['NA'],,Number and rate of targeted and non-targeted biopsies detecting dysplasia and non-dysplasia
2662,NCT05462236,Objective response rate based on Response Evaluation Criteria in Solid tumors (RECIST) Version 1.1,2023-04-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,PK evaluation
2663,NCT00844233,Tumour resectability at surgery,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Safety assessed by SAE and AE monitoring (NCI CTCAE v3.0)
2664,NCT00965861,To perform testing on the tissue samples to learn more about specific types of cancer and/or other diseases,2010-05,TERMINATED,OBSERVATIONAL,['NA'],,
2665,NCT02760199,"The quantitative uptake op 89Zr-AMG211 in tumor tissue, organs and blood circulation expressed in SUV (Standardized Uptake Value)",2016-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Evaluate 89Zr-AMG211 as a complementary tool for improved patient selection for targeted therapy with AMG 211.,"Number of patients with adverse events after 89Zr-AMG211 injection as a measure of safety and tolerability. Incidence, nature and severity of adverse events (according to CTCAE version 4.03) will be measured."
2666,NCT04001569,Progression-free survival rate,2019-05-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse event
2667,NCT05096715,Dose Limiting Toxicity Rate,2022-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Out of field response rate
2668,NCT03317483,Treatment response,2015-11-12,COMPLETED,OBSERVATIONAL,['NA'],,Adverse events (AEs)
2669,NCT02648841,Disease-free survival,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Event
2670,NCT03180437,OS,2017-06-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,CA 19-9
2671,NCT03904732,Number of deaths due to any other cause,2019-04-15,COMPLETED,OBSERVATIONAL,['NA'],,
2672,NCT05216133,36-Item Short Form Survey Instrument (SF-36),2023-03-22,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
2673,NCT05659576,Reduce opioid use,2022-12-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2674,NCT05730686,To describe the natural history and clinical outcomes of patients with Fibrolamellar carcinoma of the liver,2023-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2675,NCT03277209,Causality of adverse events (AEs) and serious adverse events (SAEs) and grading according to NCI CTCAE v.4.03.,2017-07-25,TERMINATED,INTERVENTIONAL,['PHASE1'],Correlation between changes in T cell distribution and diurnal cortisol variation.,Assessment of metabolic changes in tumour using non-invasive imaging (18FDG-PET)
2676,NCT05551052,Specificity for CRC of the Next-Gen CRC Screening Test,2022-09-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Specificity for no colorectal neoplastic findings of the Next-Gen CRC Screening Test
2677,NCT00113763,Progression-free Survival Time,2004-01-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of Stable Disease
2678,NCT01216644,median overall survival,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,R0-Resection rate
2679,NCT00597610,To measure the response of primary rectal cancer to neoadjuvant chemotherapy and/or radiation therapy using 3-D TRUS,2003-11,COMPLETED,INTERVENTIONAL,['NA'],,To correlate these findings with post-operative pathologic examination
2680,NCT05053555,To prospectively evaluate the clinical effectiveness of the use of high dose rate brachytherapy (HDRBT) for the treatment of both primary liver malignancies.,2022-04-24,RECRUITING,INTERVENTIONAL,['NA'],,
2681,NCT06277531,Patient is diagnosed with malignant disease from biliary system,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2682,NCT02579460,Change in esophageal mucosal inflammation using histopathological assessment from baseline to 14 days,2015-11,COMPLETED,INTERVENTIONAL,['NA'],,change in HIF expression from baseline to 14 days
2683,NCT02534337,Progression-Free-Survival,2015-09,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time-to-Progression
2684,NCT05620498,Objective response rate (ORR),2022-09-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,AE
2685,NCT05619614,Mean gaze time per area of influence,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,
2686,NCT00642746,Response Rates of Radiographically Measurable Disease,2008-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Time to Second Progression (From Start of First-Line Regimen)
2687,NCT03086369,Phase 2: Overall Survival (OS),2017-06-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Health Status on the EuroQol 5-Dimension 5 Level (EQ-5D-5L)
2688,NCT00600522,"The primary outcome measure was the rate of failure of conservative resection, i.e. the rate of patients who received TSs or MHs despite they fitted in the eligibility criteria.",2004-01,COMPLETED,OBSERVATIONAL,['NA'],,"The secondary outcome measure was the safety of the procedure. For that, we studied morbidity, mortality, amount of blood loss, rate of blood transfusions, and postoperative trend of liver function tests."
2689,NCT02568787,Change from baseline in immunological markers,2016-05,COMPLETED,INTERVENTIONAL,['NA'],,Change from Baseline in Quality of Life
2690,NCT05331040,Model,2020-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
2691,NCT00004891,Determine if fludeoxyglucose F 18 positron emission tomography (FDG-PET) is superior to CT scan,1999-09,COMPLETED,INTERVENTIONAL,['NA'],,Determine the accuracy of FDG-PET
2692,NCT03455608,Duration of feeding tube dependence,2018-09-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Hospitalization/Emergency Department (ED) Presentation
2693,NCT05441254,Progression Free Survival(PFS),2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],"Adverse event (AE) rate, serious adverse event (SAE) rate, etc",Peritoneal Cancer Index (PCI) assessed on preoperative CT (CT-PCI)
2694,NCT04324294,"The results obtained by EUS versus contrast EUS to diagnose pancreas cystic lesions, mass lesion, and origin of pancreatitis.",2020-02-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,Quantitative Parameters of Pancreas Lesions
2695,NCT05220800,Changes in T-cell function - mRNA expression analysis,2022-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,5 year cancer free survival
2696,NCT02851381,FG-3019 treatment regimen to increase OS (overall survival),2016-08,WITHDRAWN,INTERVENTIONAL,['NA'],,
2697,NCT00652366,OS Assessed From Point of Randomization,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,PFS Assessed From the Start of 4-Week Run-In
2698,NCT00305643,Incidence of Hand/Foot Syndrome (HFS) > Grade 1 at 16 Weeks Based on the CTC 3.0 Criteria.,2006-02,TERMINATED,INTERVENTIONAL,['PHASE3'],,Incidence of Hand/Foot Syndrome (HFS) > Grade 1 at 16 Weeks Based on WHO Criteria.
2699,NCT06136026,The detection rate of Colorectal Adenomatous Polyp.,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The canceration rate of Colorectal Adenomatous Polyp.
2700,NCT02586987,"Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Ophthalmic examination (slit lamp fundoscopy)",2015-12-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,MEDI4736 and/or tremelimumab anti-drug antibody (ADA) level in Plasma
2701,NCT00934791,Liver Volume at 2 Years After Kidney Transplantation,2009-02,TERMINATED,INTERVENTIONAL,['NA'],,
2702,NCT00313560,Recurrence Free Survival,2006-03-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Death as Assessed by Median Overall Survival (Months)
2703,NCT02644863,Overall survival,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Phenotypic analysis of T cells
2704,NCT04313868,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2014-06-13,RECRUITING,INTERVENTIONAL,['PHASE1'],,"Clinical research testing for antibodies to retrovector gp70 env, replication-competent retrovirus in peripheral blood lymphocytes (PBLs); vector integration into genomic DNA of PBLs, and circulating hGM-CSF protein"
2705,NCT02670265,Weight loss,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Length of hospital stay
2706,NCT01157052,The primary objective of this study is to determine potential pharmacokinetic interactions between oxaliplatin and calcium and magnesium.,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
2707,NCT02650986,Number of Participants With Feasibility Concerns in Manufacturing of NY-ESO-1/ dnTGFbetaRII Engineered Cells,2017-07-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor Response (Complete and Partial Response)
2708,NCT03396354,Number of retrieved LN,2018-01-02,UNKNOWN,INTERVENTIONAL,['NA'],,
2709,NCT00017043,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2710,NCT02036112,The perioperative morbidity,2013-08,UNKNOWN,INTERVENTIONAL,['NA'],Three years local recurrence postoperatively,Three years survival postoperatively
2711,NCT04006769,Adverse Events (AE) And Serious Adverse Events(SAE),2020-10-30,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Quality of Life(QOL)
2712,NCT00197444,Response rate,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival rate
2713,NCT03164486,Assessment of safe administration of 18F-αvβ6-BP,2016-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Level of αvβ6-BP expression in tumors
2714,NCT01163305,Tumor metabolic response via FDG-PET at 4 weeks after chemotherapy,2010-06-30,COMPLETED,OBSERVATIONAL,['NA'],,RECIST-based tumor response at 10 weeks after chemotherapy
2715,NCT00408681,Functional Recovery,2006-06,COMPLETED,INTERVENTIONAL,['NA'],Agents Added to Treat GVHD More Than 3 Days After Enrollment,Causes of Death
2716,NCT03940417,"Docking time,min",2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,cost
2717,NCT04835246,Sensitivity of Spectra IMDx system,2019-10-07,UNKNOWN,INTERVENTIONAL,['NA'],,Accuracy of Spectra IMDx system
2718,NCT03976999,Proportion of patients who gave their consent to participate in the study,2017-07-05,RECRUITING,INTERVENTIONAL,['NA'],,
2719,NCT00331682,Objective Response Rate as Measured by RECIST Criteria,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2720,NCT03117348,Morbidity of infection,2017-04-15,COMPLETED,INTERVENTIONAL,['NA'],,Mortality
2721,NCT01426646,Relapse-free survival,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
2722,NCT00553696,Number of Participants With First Cycle Dose-limiting Toxicities (DLTs),2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to Progression (TTP)
2723,NCT06331260,Tumor recurrence rate,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2724,NCT01503372,progression-free survival rate at 6 months,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,evaluation of the predictive and prognostic relevance of biomarkers
2725,NCT00941967,Progression-free survival,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2726,NCT03611504,Rebleeding rate,2018-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Mortality
2727,NCT06022770,Nutritional risk screening（NRS） 2002 scale,2023-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,quality of life of patients with esophageal and gastric cancer before and after chemotherapy
2728,NCT03415763,Disease free survival,2018-11-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,The quality of life postoperatively
2729,NCT03541629,Data accuracy,2018-07-26,COMPLETED,OBSERVATIONAL,['NA'],,
2730,NCT03961776,Predictive value of Apparent Diffusion Coefficient measured using MRgRT system,2020-06-08,RECRUITING,OBSERVATIONAL,['NA'],,
2731,NCT00515411,6 Month Progression Free Survival (PFS),2006-10-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2732,NCT04773769,Blood Counts,2018-11-07,UNKNOWN,INTERVENTIONAL,['NA'],,
2733,NCT05524155,Overall response rate ( ORR),2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
2734,NCT00320294,Safety,2005-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
2735,NCT00012922,,na,COMPLETED,INTERVENTIONAL,['NA'],,
2736,NCT00366509,"procure and analyze gastrointestinal, oropharyngeal, lung and/or blood specimens from healthy research volunteers and subjects with lung disease",2006-09-18,COMPLETED,OBSERVATIONAL,['NA'],,
2737,NCT00524706,"Evaluate the response rate of S-1, Leucovorin, and Oxaliplatin with recommended dose in phase II",2007-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II - Safety - Time to treatment failure (TTF) - Progression free survival (PFS) - Overall survival (OS)
2738,NCT05586516,Incidence of treatment-emergent adverse events [Safety and Tolerability],2022-10-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival [OS]
2739,NCT00030524,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2740,NCT01155440,Restoration of bowel function,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pain intensity
2741,NCT00747448,"Primary objectives of the study are to enable analysis of patient outcomes 2 years after final treatment and report on the effectiveness of the device in eradicating, decreasing or downgrading of the lesions.",2009-05,COMPLETED,OBSERVATIONAL,['NA'],,
2742,NCT02748161,Objective tumor response,2015-08,TERMINATED,INTERVENTIONAL,['NA'],,Number of repeat DEB-TACE procedures per lesion
2743,NCT01082419,The elasticity parameter will be for each patient the median of ten ARFI values (m/s) in the right liver.,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,Median (m/s) of ARFI values between before and after effective treatment for liver reversible disease
2744,NCT03208621,Change in treatment strategy,2017-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Mortality
2745,NCT00637390,safety & maximally tolerated dose,2008-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Alemtuzumab effect on patients' response rates to chemotherapy given after the discontinuation of chemotherapy.
2746,NCT01396148,Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hours Post Dose AUC(0-8) for Sunitinib and Its Metabolite,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Estimated Sunitinib Plasma Concentration at Which 50% of the Maximum Effect (EC50) for Each Selected Safety Endpoint (e.g., Absolute Neutrophil Count) Was Observed"
2747,NCT05528367,the rate of resectable patients with negative incisal margin R0 resection rate,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2748,NCT02037646,Time to diagnosis of advanced colorectal neoplasms,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Patient anxiety levels
2749,NCT02647099,Time To Recurrence (TTR),2016-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Frequency and severity of adverse events (AE)
2750,NCT02813278,Length of hospital stay,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2751,NCT01880658,Disease-free Survival rate(DFS),2013-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Over all survival,genetic patterns, quality of life, toxic effects, convenience"
2752,NCT06024356,pathologic complete response,2023-09-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],The expression of PD-1,overall survival (OS)
2753,NCT05435313,objective response rate (ORR),2022-07-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events as assessed by NCI CTCAE v5.0
2754,NCT05644379,Adverse Events (AEs),2022-11-25,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2755,NCT01394159,Compare the Median Number of Passes Required to Establish a Diagnosis,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,Technical Failure
2756,NCT03321396,Number of Patients With Postpolypectomy Electrocoagulation Syndrome,2017-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of Patients With Late Tissue Injury
2757,NCT02395224,survival,2014-09,UNKNOWN,OBSERVATIONAL,['NA'],,Health related quality of life
2758,NCT05109468,Change in Sexual quality of life score,2021-06-06,RECRUITING,OBSERVATIONAL,['NA'],,
2759,NCT03581435,The expression of protein A in the circulating exosomes from patients,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
2760,NCT03901651,Adenoma detection rate with standard colonoscope and retroview colonoscope.,2019-01-02,COMPLETED,INTERVENTIONAL,['NA'],,Size of lesions (adenomas and polyps) detected with the standard colonoscope and Retroview colonoscope.
2761,NCT03146377,Objective response rate,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
2762,NCT05590117,variation in grades of mucositis,2022-10-11,ENROLLING_BY_INVITATION,INTERVENTIONAL,['EARLY_PHASE1'],,Change in the biological marker Citrulline
2763,NCT00002951,Locoregional control rate,1996-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2764,NCT02562716,Overall Survival (OS),2016-01-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease-free Survival From the Time of R0 or R1 Resection.
2765,NCT03898921,3-year overall survival rate,2019-03-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],Radiation-induced liver injury,Safety profile: incidence of complications
2766,NCT04321850,Pain intensity: Visual analog scale,2019-06-10,TERMINATED,INTERVENTIONAL,['NA'],,Neutropenia
2767,NCT06046794,Percentage of alive GemCore+ patients treated with Gemcitabine,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Overall survival of GemCore- patients,Progression-free survival
2768,NCT01585805,Response rate of single-agent veliparib (Part II),2012-05-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Differentially expressed genes found,Overall survival (Parts I and II)
2769,NCT00561990,Time to tumor progression (TTP) and overall survival (OS) in chemotherapy-naive patients. To assess the efficacy of Nimotuzumab as add on therapy to Gemcitabine in comparison with Gemcitabine and placebo,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,To evaluate the objective tumor response (overall response rate [ORR]) and duration of response (DR) To evaluate the safety profile of Nimotuzumab in combination with Gemcitabine To evaluate quality of life (QoL) according to EORTC
2770,NCT05298722,Prediciton of surgical resectability,2022-12-12,RECRUITING,INTERVENTIONAL,['NA'],,Measurement of quality of life in patients with pancreatic cancer
2771,NCT01468389,Progression free survival,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,adverse events
2772,NCT01544790,Postoperative complications modified Clavien-Dindo classification (MCDC) grade 2 and higher,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Costs (euro)
2773,NCT00827047,Overall survival and disease free survival,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,"Bleeding and blood transfusion ,hepatic function of patients after surgery, the incidence rate of complications"
2774,NCT04284943,The success rate of biochemical improvement of diabetes as measured by HbA1c < 6.5%,2020-12-01,RECRUITING,INTERVENTIONAL,['NA'],,The success rate of biochemical improvement of diabetes as measured by HbA1c < 6.5%
2775,NCT01788995,Treatment discontinuations/modifications,2012-10-15,COMPLETED,OBSERVATIONAL,['NA'],,Progression-free survival
2776,NCT03827967,Primary Immunologic Endpoint-Per Dosing Cohort Immunoscore of the tumor microenvironment,2019-07-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Secondary Endpoint-CD4+ and regulatory T cells expression comparison within the Tumor Microenvironment
2777,NCT00954876,Primary objective is to assess PFS in patients with WT KRAS CRC treated with the combination regimen of capecitabine and cetuximab,2009-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To perform exploratory analyses of serum and tumor biomarkers (EGFR mutations and genotyping) on toxicity and efficacy.
2778,NCT01919541,Protein Synthesis,2016-12,WITHDRAWN,INTERVENTIONAL,['NA'],,
2779,NCT04090645,Evaluate SAE's associated with TheraSphere® treatment,2014-05-22,COMPLETED,INTERVENTIONAL,['NA'],,
2780,NCT05928819,Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists and correlation with final histology reading.,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
2781,NCT02102984,Relief of malignant biliary obstruction,2014-04,COMPLETED,INTERVENTIONAL,['NA'],gallbladder in situ,cost/effecacy
2782,NCT03017326,Response in HCC is defined as complete (CR) or partial (PR) response according to RECIST version 1.1 criteria,2017-08-24,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adherence to surgical guidelines
2783,NCT05568667,Assessment of the programme feasability,2022-10-17,COMPLETED,INTERVENTIONAL,['NA'],,Assessment of the evolution on CRC risk factors knowledge
2784,NCT01048281,NER activity by routine pathologic analysis,2002-08,RECRUITING,OBSERVATIONAL,['NA'],,
2785,NCT01885884,perceived effectiveness,2013-07,COMPLETED,INTERVENTIONAL,['NA'],caregiver depressive symptoms,patient quality of life
2786,NCT04155242,Diagnostic accuracy of methylation panel for diffuse IM at the GOJ,2020-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Safety of Cytosponge
2787,NCT05840341,Overall survival (OS),2023-05-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease Free Survival
2788,NCT02052050,Abdominal isometric endurance,2012-09,COMPLETED,INTERVENTIONAL,['NA'],Muscle structure,Lower back muscle strength
2789,NCT00433927,Objective response rate,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Safety and toxicity (according to NCI-CTCAE)
2790,NCT05843955,Non-alcoholic fatty liver disease (NAFLD) grade,2015-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
2791,NCT04145726,The portion of frail patients undergoing esophageal resection and 6 -month all-cause of mortality,2019-09-25,UNKNOWN,OBSERVATIONAL,['NA'],postoperatively complications in frail vs. non-frail,One-year all-cause mortality in frail vs. non-frail patients One-year all-cause mortality in frail vs. non-frail patients One-year all-cause mortality in frail vs. non-frail patients
2792,NCT05917431,PFS,2023-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,Recurrence pattern
2793,NCT00003994,Toxicity rates assessed using National Cancer Institute (NCI) Common Toxicity Criteria (CTC),1999-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2794,NCT05993234,Real-World Time to Next Treatment (rwTTNT1) in Participants With HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma,2023-12-05,RECRUITING,OBSERVATIONAL,['NA'],,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Stomach (EORTC QLQ-STO22) Score in Participants With HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
2795,NCT02229045,PFS(Progression-free survival ),2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],ORR (Overall tumor response),OS (Overall survival )
2796,NCT04135781,3 years Diseases-free Survival rate(3 years-DFS),2020-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Safety as measured by number and grade of adverse events
2797,NCT00005634,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2798,NCT05034692,The incidence of early complications,2022-03-21,RECRUITING,INTERVENTIONAL,['NA'],,pain score
2799,NCT05747716,Progression free survival,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicities
2800,NCT05532319,Progression-free survival,2022-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,objective response rate
2801,NCT00713427,Number of Participants With Absence of Recurrent Biliary Obstruction,2007-07,COMPLETED,INTERVENTIONAL,['NA'],,Change in Bilirubin
2802,NCT05523245,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of models in prediction tumor response,2022-06-24,RECRUITING,OBSERVATIONAL,['NA'],,The negative predictive value of models in prediction tumor response
2803,NCT05701488,Number of Participants with Adverse Events,2023-04-21,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of Participants with Surgical Complications
2804,NCT01292681,Correlation early changes in imaging and treatment outcome,2009-08,UNKNOWN,INTERVENTIONAL,['NA'],,Correlation pretreatment imaging values and treatment outcome
2805,NCT04727996,Disease control rate,2020-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival
2806,NCT01714622,the changes of metabolic syndrome,2012-10,WITHDRAWN,OBSERVATIONAL,['NA'],,the changes of insulin resistance after gastrectomy
2807,NCT04348916,Recommended Phase 2 Dose (RP2D) of ONCR-177,2020-05-20,TERMINATED,INTERVENTIONAL,['PHASE1'],,Changes in the level of HSV-1 antibodies compared to baseline
2808,NCT02323464,Prevalence of sleep apnea,2015-01-07,COMPLETED,OBSERVATIONAL,['NA'],,Sex differences
2809,NCT02080702,Frequency of anastomosis leakage rate,2014-08,TERMINATED,OBSERVATIONAL,['NA'],,Handling of the device
2810,NCT05371223,Disease Control Rate (DCR),2022-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Identification of pancreatic cancer disease evolution trough pathway analysis a in primary tumor and peritoneal sites during treatments,The Overall Survival (OS)
2811,NCT00782886,"The overall purpose of this NIH-funded study is to evaluate the effectiveness of image-guided liver surgery by measuring variables before, during and following surgery.",2008-04,COMPLETED,OBSERVATIONAL,['NA'],,
2812,NCT03609892,Helicobacter pylori eradication,2018-08-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,adverse events
2813,NCT01360853,Survival,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Full Pharmacokinetics
2814,NCT03595722,Complications,2019-07-11,UNKNOWN,INTERVENTIONAL,['NA'],,Radiological changes
2815,NCT00040092,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2816,NCT05946226,Incidence and severity of dose-limiting toxicity (DLTs) within 28 days after IMC002 infusion,2023-09-07,RECRUITING,INTERVENTIONAL,['PHASE1'],long-term safety,CAR-positive cell counts in peripheral blood
2817,NCT00030732,Gemcitabine + Capecitabine vs. Gemcitabine alone,2001-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2818,NCT06050317,AE,2023-08-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response
2819,NCT06186089,Composition and diversity of gut microbiota,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Inflammatory factor
2820,NCT06248580,The frequency of HDV in certain regions of Southern Anatolia,2024-01-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The rate of HIV and HCV co-infection in HDV positive patients
2821,NCT03777540,Post-operative mortality In-hospital mortality was defined that occurred during hospitalization up to 90 days excluded post-operative mortality. Postoperative mortality,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
2822,NCT02847767,Changes in tumour vasculature as assessed by changes PL derived model parameters,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],,Association (correlation) between aggregate QOL scores and PK derived model parameters
2823,NCT04884581,Negative Predictive Value (NPV),2021-05-12,COMPLETED,INTERVENTIONAL,['NA'],Performance metrics of the endoscopist with the aid of GI Genius CADx,
2824,NCT05771181,objective response rate (ORR),2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,advert events
2825,NCT03943043,maximum tolerated dose,2017-07-21,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Number of responder (in term of CR, PR, SD) to GEMOX plus nab-paclitaxel as assessed by RECIST 1.1"
2826,NCT00786643,Best Response (BR),2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Progression
2827,NCT03669237,Postoperative bowel function of 1 year after surgery,2018-10-12,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative bowel function of the long stable result
2828,NCT04201717,surgical site infection，SSI,2020-06-12,RECRUITING,INTERVENTIONAL,['NA'],,hospital stay
2829,NCT02784028,Maximum tolerated dose (MTD),2014-12,COMPLETED,INTERVENTIONAL,['NA'],,
2830,NCT03299036,Tumor response in patients with hepatoma who received Taiwan ACE beads (TACE) microspheres embolization evaluated with mRECIST criteria,2017-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Serum Level of AFP
2831,NCT02591667,Percentage of viable cells within the resected peritoneal deposits after completion of neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab.,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
2832,NCT06024837,Comparison of peritoneal and hepatic lesion mapping between spectral scanning and conventional scanning,2023-06-07,RECRUITING,OBSERVATIONAL,['NA'],,Comparison of evaluation of response to chemotherapy (if indicated) in RECIST 1.1 and Radiomics
2833,NCT00587600,The primary assessment for our first specific aim will be to determine the effect of photodynamic therapy on biomarkers after photodynamic therapy.,2002-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The primary assessment for our second specific aim will be to assess if specific biomarkers can be correlated with the confirmed histological elimination of their Barrett's esophagus.
2834,NCT02030769,Detection rate of high grade dysplasia and carcinoma in iodine void lesion,2014-01,COMPLETED,INTERVENTIONAL,['NA'],observation time for esophagus,overall detection rate of iodine void lesion
2835,NCT01396681,recurrence/metastasis free survival,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and tolerability
2836,NCT00727376,Clinical benefit of the Polyflex Esophageal Stent as a means to maintain oral nutrition during chemotherapy and/or radiation,2008-03,COMPLETED,OBSERVATIONAL,['NA'],,
2837,NCT06136949,Frequency of overexpression of STARD3 in both early and advanced CRC patients,2023-05-22,RECRUITING,OBSERVATIONAL,['NA'],,Concordance between the presence of selected molecular alterations on primary tumour tissues and organoids
2838,NCT04504565,the sensitivity of SPECT/CT with 99mTc-3PRGD2 in the diagnosis of lymph node metastasis,2020-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,The Incidence of Adverse Events
2839,NCT01366183,"Percent of women, who are 70 years or older, able to complete at least 4 cycles of treatment regardless of dose reduction and delays",2011-08-15,UNKNOWN,OBSERVATIONAL,['NA'],"Pharmacokinetic parameters including paclitaxel AUC, carboplatin AUC, paclitaxel total body clearance, and time that plasma paclitaxel concentration remains above threshold 0.05 uM/L",Percent of patients reporting adverse events as assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events
2840,NCT00952016,"Objective response rate, to include complete response and partial response, as defined radiologically using RECIST (Response, Evaluation Criteria in Solid Tumours) on imaging CT scans performed during treatment.",2009-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Disease stabilisation rate; progression free survival; 1 year survival and median overall survival; Quality of Life assessment; toxicity assessment.
2841,NCT01765231,the incidence of hepatitis B virus reactivation and hepatitis B virus reactivation related hepatitis,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,"the incidence of hepatitis B virus maintained response, the incidence of hepatitis B virus sustained response, the incidence of hepatitis B virus relapse and hepatitis B virus relapse related hepatitis"
2842,NCT05513716,Proportion of genetic mutations,2024-02-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Association with molecular subtypes and categorical variables
2843,NCT02863783,Relative Ease of Detection of the Tumor with Fiducial,2016-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"Pancreatitis, abdominal pain, infection, bleeding following placement."
2844,NCT05724563,Objective Response rate of combination zimberelimab and domvanalimab.,2023-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with Adverse Events (AEs) (serious / non-serious) as defined by CTCAE v5.0
2845,NCT04735900,Optimize cutoff value,2020-09-14,UNKNOWN,INTERVENTIONAL,['NA'],Exploratory objective 3,Determine progression free and 9-month survival
2846,NCT04850040,Major Pathological Response(MPR) 10%,2021-05-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Intraoperative and postoperative complications
2847,NCT06310590,Localized Objective response rates (ORR),2023-08-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,"Radioactivity of Yttrium-90 for 9 participants, assessed by liquid scintillation counter"
2848,NCT01249443,"Incidence of adverse events during paclitaxel and carboplatin treatment according to dose-limiting toxicities (DLTs), graded using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)",2013-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Effects of therapy on HIV viral load and CD4 cell count
2849,NCT04008030,"PFS by BICR (arm B vs C, 1L, centrally confirmed)",2019-08-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,"ORR by BICR (crossover cohort, centrally confirmed)"
2850,NCT03775473,progastrin rate,2019-02-07,TERMINATED,INTERVENTIONAL,['NA'],,
2851,NCT00006379,Evaluation of Donor Engraftment,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Event free and overall survival
2852,NCT02086461,Symptoms suggestive of delayed gastric emptying,2014-05,UNKNOWN,INTERVENTIONAL,['NA'],,Delayed gastric emptying
2853,NCT03417921,Emergent Adverse Events,2021-04-26,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2854,NCT03782831,Progression Free Survival (PFS),2018-12-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
2855,NCT05675462,Serious adverse event (SAE).,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Detection of systemic and local immune activation in tumors and peripheral blood mononuclear cell will be assessed by single cell RNA seq and/or bulk RNA seq.
2856,NCT05510908,Number of cancers in people with HIV (PWH) who present for care at domestic AMC sites,2023-07-25,RECRUITING,OBSERVATIONAL,['NA'],3. State of planned cancer therapy for cancer patients with HIV initiating therapy or currently under treatment,Proportion of participants eligible for AMC trials who are successfully enrolled
2857,NCT03427411,Percentage of Participants That Achieved an Objective Confirmed Complete or Partial Overall Tumor Response,2018-02-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),Duration of Response (Complete Response or Partial Response)
2858,NCT00390364,Response Rate: The Total Number of Participants With Progression of Disease,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
2859,NCT04404491,PFS,2020-06-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,OS Qol
2860,NCT05596760,EHR documentation of Goals of Care discussions,2023-09-11,RECRUITING,INTERVENTIONAL,['NA'],,Anxiety and depression (HADS)
2861,NCT00145665,correlation FLT-uptake in colorectal liver metastases and the histologically determined proliferation,2005-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,correlation FLT and recurrence rate
2862,NCT00008099,Disease Recurrence,1998-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
2863,NCT03096899,Overall Survival,2016-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
2864,NCT02934984,Rates of recurrence in pancreatic cancer patients,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],,Rates of death in pancreatic cancer patients
2865,NCT02578264,Determining sensitivity of assay in known cancer patients,2015-06,COMPLETED,OBSERVATIONAL,['NA'],,
2866,NCT01387295,Response Rate,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,PFS
2867,NCT05420870,Anorectal manometry,2022-05-23,RECRUITING,INTERVENTIONAL,['NA'],,
2868,NCT06005883,Recurrence of tumor,2021-04-10,COMPLETED,OBSERVATIONAL,['NA'],,
2869,NCT03974074,Serum albumin level,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Rate of postoperative complications
2870,NCT03221608,Incidence of endoperitoneal recurrence at 36 months,2017-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,HIPEC toxicity rate
2871,NCT04888299,Feasibility of Raman spectroscopy to identify mucosal healing in IBD and IBD-related dysplasia against the gold standard of histopathology,2021-04-14,UNKNOWN,INTERVENTIONAL,['NA'],,Diagnostic performance of Raman spectroscopy for assessment of mmucosal healing in IBD and IBD-related dysplasia against the gold standard of histopathology
2872,NCT03254394,Area Under the Curve (AUC) of Intensity of Oxaliplatin-induced Cold Pain/Unpleasantness vs Time,2017-09-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The Cumulative Dose of Oxaliplatin
2873,NCT00690300,tumor response,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,toxicity / safety
2874,NCT04407416,Breath analysis sensitivity,2020-05-02,UNKNOWN,INTERVENTIONAL,['NA'],,
2875,NCT01932125,Safety: Incidence of adverse events,2018-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,Clinical benefit rate (complete response + partial response + stable disease)
2876,NCT02096354,Overall Survival,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life (QOL) by QOL questionnaire
2877,NCT00448136,PFS - Percentage of Participants Estimated to be Progression Free at 12 and 24 Months,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,EORTC QLQ-C30 Functional and Symptom Scale Scores
2878,NCT01623258,Define the rate of upstaging of colon carcinoma lymph node metastasis with define the rate of upstaging of colon carcinoma lymph node metastasis with sentinel lymph node (SLN) mapping,2002-12,COMPLETED,OBSERVATIONAL,['NA'],,
2879,NCT02132325,Change in level of distress as measured by distress scores on the Distress Thermometer,2014-04,COMPLETED,INTERVENTIONAL,['NA'],,
2880,NCT04661046,Progression Free Survival,2020-11-30,UNKNOWN,INTERVENTIONAL,['NA'],,
2881,NCT04620538,"Determine the diagnostic accuracy of breath test for detection of fibrosis, cirrhosis or hepatocellular carcinoma.",2021-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
2882,NCT03658772,Define the recommended phase 2 dose (RP2D) of grapiprant combined with pembrolizumab,2018-09-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Observed accumulation ratio
2883,NCT02132403,Maximum Tolerated Dose (MTD),2014-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Disease Response based on RECIST Criteria
2884,NCT05843877,"Duration between surgery and time ""fit for adjuvant treatment"" (postoperative day X)",2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Comparison of long-term oncological course (24 months) in both arms: occurence of metastases
2885,NCT00079872,The primary objective is to compare the antitumor activity of pemetrexed plus a comparator with that of leucovorin modulated 5 FU plus a comparator as measured by tumor response rate for patients with locally advanced or metastatic colorectal cancer,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,to characterize the quantitative and qualitative toxicities of both treatment arms in this patient population
2886,NCT03812705,Response rate,2018-12-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response
2887,NCT01621048,"toxicity: EORTC QLQ H&N35 questionnaire, the university of Michigan Xerostomia questionnaire (XQ) and the MD Anderson Dysphagia Inventory.",2012-06,WITHDRAWN,OBSERVATIONAL,['NA'],,
2888,NCT01196247,Determine the percent of patients who are alive at one year,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2889,NCT01418391,amount of post-operative morphine consumption,2011-06,UNKNOWN,INTERVENTIONAL,['NA'],,evaluation of post-operative pain status using visual analog scale (VAS) and superimposed face pain severity scale
2890,NCT03273920,3-year relapse-free survival,2017-09-25,UNKNOWN,INTERVENTIONAL,['NA'],,Immune response
2891,NCT00683631,,2004-01,COMPLETED,OBSERVATIONAL,['NA'],,
2892,NCT05913661,Objective Response Rate,2023-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
2893,NCT06078930,Overall Survival (OS),2021-04-06,RECRUITING,OBSERVATIONAL,['NA'],,Disease Free Survival (DFS)
2894,NCT05184946,3 years disease free survival rate,2021-10-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival time
2895,NCT03190616,Progression-free Survival(PFS),2017-07-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
2896,NCT01283893,Evaluation of operative procedure according to predetermined criteria,2010-12,UNKNOWN,OBSERVATIONAL,['NA'],,
2897,NCT03986294,Progression free survival of NaI-IRI with S1,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],ctDNA,Quality of life QoL (QLQ-C30)
2898,NCT01606124,"Percent Change in Rectal ACF, Pre- and Post Intervention at 6 Months",2012-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Tolerability as Estimated Using the Percent Dose of Treatment Received at 6 Months
2899,NCT00851084,Progression Free Survival (PFS) Rate at 12 Months,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Immunogenicity of Intravenous (IV) Aflibercept
2900,NCT00192842,time to tumor progression,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicity
2901,NCT00976612,nilotinib pharmacokinetics,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,
2902,NCT00956072,Progression-free survival,2009-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,Quality of life as measured by EORTC QLQ-C30
2903,NCT00925015,Number of Participants With an Adverse Event (AE),2009-06-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,"AUC0-24 of Irinotecan Following Administration of Cetuximab / Irinotecan Alone, or in Combination With 10 mg/kg Dalotuzumab"
2904,NCT03412799,Recommended dose of SBP-101,2018-06-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Peak plasma concentration (Cmax) for all three drugs
2905,NCT04492033,P2: Objective response rate (ORR) of CTX-009 (ABL001) in combination with paclitaxel in patients with BTC,2020-06-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,P2: Overall survival (OS)
2906,NCT02349594,Change of TNF-α production in pg/ml,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,(anti-) Oxidant status and oxidative damage
2907,NCT04447443,Therapeutic effect on the chemotherapy-related grade 2 to 4 diarrhea,2020-06-30,WITHDRAWN,INTERVENTIONAL,['NA'],,Gut microbiota changes in response to intervention
2908,NCT03430778,difference between SpHb value and SaHb value (SpHb - SaHb),2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
2909,NCT03140332,Scannographic evaluation of tumor response with mRECIST criteria,2017-02-27,COMPLETED,INTERVENTIONAL,['NA'],,
2910,NCT00684229,cancer recurrence,2007-12,WITHDRAWN,INTERVENTIONAL,['NA'],,length of post operative hospitalization
2911,NCT02457390,Detection of synchronous liver metastases with CE-LUS,2015-01,COMPLETED,INTERVENTIONAL,['NA'],,CE-LUS feasibility
2912,NCT03891953,Tolerability of DKY709 single agent treatment or DKY709 in combination with PDR001.,2019-05-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Time to Progression (TTP)
2913,NCT00318370,Serologic Response (Change in Cancer Antigen [CA-125] Level),2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants Who Had a Prolongation of Remission
2914,NCT05807542,Pathological complete response,2022-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (ORR)
2915,NCT01571284,Number of Participants With Cycle Delay and/or Dose Modification,2012-05-30,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in HRQL EQ-5D-3L VAS Score
2916,NCT00003797,,1999-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
2917,NCT04292990,Pain Intensity Measure,2020-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Quality-of-Life composite Index
2918,NCT03429530,the role of circulating miRNAs in diagnosis of HCV related hepatocellular carcinoma.,2018-02-15,UNKNOWN,OBSERVATIONAL,['NA'],,
2919,NCT01281761,response rate,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2920,NCT04490668,Comparison of the rate of anastomotic leakage,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
2921,NCT03949231,Overall survival,2019-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse event rate
2922,NCT04310176,progression-free survival (PFS),2019-05-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,metastases resection rate (R0/R1/R2)
2923,NCT05541783,Scores on the physical function and pain symptom scales of EORTC QLQ-C30 questionnaire,2022-09-15,RECRUITING,INTERVENTIONAL,['NA'],,Scores on ST22 questionnaire
2924,NCT02123381,changes of serum vascular endothelial growth factor（VEGF）level before and after radiotherapy,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,grade 3-5 adverse events
2925,NCT01333124,Complete resection rate,2011-09-28,TERMINATED,INTERVENTIONAL,['PHASE2'],,The feasibility and compliance
2926,NCT02456051,Pancreatic cancer diagnosis,2015-04,TERMINATED,OBSERVATIONAL,['NA'],,Mortality
2927,NCT02764944,En bloc resection,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,successful closure of resection site
2928,NCT00002801,,1996-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2929,NCT04167293,24-week progression-free survival (PFS) rate,2019-11-16,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse Events
2930,NCT03391687,Incidence of Pancreatic Fistula,2017-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,The mortality of Grade B and C Pancreatic Fistula
2931,NCT04790227,Secondary outcome after chemo-radiotherapy,2022-01,UNKNOWN,OBSERVATIONAL,['NA'],,
2932,NCT03515941,Number of Participants Who Complete the Recommended Therapy From Each Arm,2018-06-22,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Median Time to Recurrence
2933,NCT02937389,"The classification of gastric conduit ischemia by endoscopic findings predicts the major complications of gastric conduit (strictures, leakage, necrosis)",2015-05,COMPLETED,OBSERVATIONAL,['NA'],,Biological examination of gastric conduit as assessed by the Mitochondrial DNA copy number
2934,NCT01446458,Maximum tolerated total dose of stereotactic body radiation to patients with resectable or borderline resectable pancreas cancer following FOLFIRINOX chemotherapy,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Clinical and pathologic objective response rate as measured by MRI (clinical response) and histopathology and rate of complete resection (R0) (pathologic response)
2935,NCT02676349,To assess the efficacy of two neoadjuvant therapies in patients with borderline resectable pancreatic carcinoma evaluated on histological R0 resection margin rate,2016-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Evaluate the progression-free survival
2936,NCT01487785,Incidence rate and category of dose limiting toxicities (DLTs),2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Serum tumor marker Ca 19-9
2937,NCT02448979,Long term survival,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Postoperative complications
2938,NCT05524974,Objective response rate,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"The prediction performance of Exosome contents (including proteins, nucleic acids)"
2939,NCT03469726,Diagnostic accuracy of CE-DW-MRI,2017-12-22,UNKNOWN,INTERVENTIONAL,['NA'],Progression free survival,Assess local resectability
2940,NCT03597126,Change in Female Sexual Function Index [FSFI],2018-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,
2941,NCT05616390,Overall survival (OS),2022-11-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL)
2942,NCT03203304,Number of participants with adverse events,2017-08-25,TERMINATED,INTERVENTIONAL,['PHASE1'],,Rate of local control of the SBRT treated lesion
2943,NCT02110498,To develop and prospectively validate a panel of molecular markers to differentiate benign pancreatic cysts from those with malignant potential using surgical pathology as the gold standard,2014-03,RECRUITING,OBSERVATIONAL,['NA'],To determine the proportion of patients with malignancy in operable pancreatic cysts,"To determine the sensitivity, specificity, and overall accuracy of imaging (CT, MRI and EUS) in patients with pancreatic cysts"
2944,NCT05853692,Oral Mucositis,2022-10-10,RECRUITING,INTERVENTIONAL,['NA'],,Severity of Oral Mucositis
2945,NCT01807156,Number of Patients With Advanced Hepatocellular Cancer (HCC) Receiving Tivozanib Who Are Free From Progression,2013-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria
2946,NCT04118114,Treatment related adverse events rate,2019-09-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2947,NCT03326375,Local tumor control (efficacy fo SBRT),2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Radiation induced liver disease (RILD)
2948,NCT05354388,1-year Progression free survival rate,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Duration of continuous medication before surgery
2949,NCT00415454,Toxicity,2006-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Gene expression in pancreas
2950,NCT03745326,Frequency and severity of treatment-related adverse events,2019-05-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2951,NCT01276405,Disease-free survival,2010-03,TERMINATED,OBSERVATIONAL,['NA'],,Safety (Incidence of adverse events)
2952,NCT04764006,Objective response rate (ORR),2021-10-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Assess the anti-tumor activity:DCR
2953,NCT06037954,Attrition rates,2023-09-07,RECRUITING,INTERVENTIONAL,['NA'],,Treatment satisfaction
2954,NCT03445936,Incisional hernia,2018-02-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Cost analysis
2955,NCT03271255,Progression-free Survival (PFS) Time,2018-05-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Percentage of Participants Achieving a Stable Disease (SD) or a confirmed CR or PR (Disease Control Rate)
2956,NCT03325361,Anastomotic leakage,2017-10,UNKNOWN,INTERVENTIONAL,['NA'],,
2957,NCT01821729,Number of Participants With R0 Resection,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To Measure Utilization of Health Services
2958,NCT00579891,establish a serum and tissue bank,1989-03-28,COMPLETED,OBSERVATIONAL,['NA'],,
2959,NCT03722511,Effect of amino acids in tightening the intestinal barrier and protecting from antigenic translocation by evaluating plasma circulating cytokine levels in peripheral blood sample.,2018-12-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of increased bacterial translocation and systemic inflammation.
2960,NCT06185374,National Annie Colonoscopy Survey Score,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Percentage of Participants who Had Adequate Bowel Preparation at Colonoscopy Appointment
2961,NCT01456585,Number of participants with adverse events,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
2962,NCT05319639,The maximum dose tolerated,2023-02-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
2963,NCT04712292,Rate of radical surgery,2020-09-08,UNKNOWN,OBSERVATIONAL,['NA'],,Mortality
2964,NCT02436044,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
2965,NCT00833508,Change of Anaerobic threshold of 1.5ml/min/kg or more,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,Operative outcome
2966,NCT00003833,overall survival,1999-02,COMPLETED,OBSERVATIONAL,['NA'],,
2967,NCT03838406,Objective response rate,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival
2968,NCT01853644,Overall Response Rate (ORR),2013-06-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) in Platinum-resistant Ovarian Cancer to Treatment With Single Agent Tivozanib
2969,NCT02375581,all cause mortality,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,incidence rates of radiation-related pneumonitis and esophagitis
2970,NCT01037790,Response Rates,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2971,NCT00137683,colorectal cancer screening,2001-09,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,knowledge
2972,NCT01342354,Identify the appropriate dose for treatment of unresected carcinoma of the ampulla or pancreas,2009-04-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in patient reported outcomes using FACT-Hepatobiliary (FACT-Hep) quality of life questionnaire.
2973,NCT02917759,Number of successful xenografts established,2014-02,RECRUITING,OBSERVATIONAL,['NA'],,
2974,NCT04597151,Categorical responses to program evaluation survey,2020-10-12,COMPLETED,INTERVENTIONAL,['NA'],Change in Lifestyle Score on the National Institute of Health (NIH)/ National Cancer Institute (NCI) Automated Self- Administered 24-hour Dietary Assessment Tool (ASA24),Frequency of responses to the baseline socio-demographics survey
2975,NCT00597129,safety MTD,2004-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,efficacy
2976,NCT04642690,Serum and Tissue Biomarkers,2020-09-24,TERMINATED,OBSERVATIONAL,['NA'],,Biomarkers and disease progression
2977,NCT03962179,Technique - % of patients with successful implantation of VACStent,2019-09-22,UNKNOWN,INTERVENTIONAL,['NA'],,Sealing of leak - % of patients with successful implantation of VACStent
2978,NCT06051851,Progression-free survival（PFS）,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
2979,NCT06085677,"Serologic concentrations of ghrelin, gastrin, pepsinogens and vitamin B12",2023-11-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2980,NCT01852890,"Number of grade 3, 4, & 5 adverse events during radiation",2014-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,"Number of grade 3, 4, & 5 adverse events post-treatment"
2981,NCT03775798,Incidence of hepatocellular carcinoma after direct-acting antivirals for HCV,2016-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Adverse events after direct-acting antivirals for HCV
2982,NCT03462524,Global health-related quality of life (HR-QL) score as assessed by Eastern Co-operative Oncology Group QLQ-C30 questionnaire,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
2983,NCT02159248,Evaluate safety and toxicity,2014-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Assess the anti-tumor response.
2984,NCT03564405,Objective Response Rate,2016-12-05,COMPLETED,INTERVENTIONAL,['NA'],,
2985,NCT03948958,TIVAD function,2019-06-28,COMPLETED,INTERVENTIONAL,['NA'],Patient-reported outcome measure,Catheter tip and port chamber culture
2986,NCT04074135,Characterization of the natural and clinical histories of VHL pancreatic neuroendocrine tumors and cystic lesions,2020-06-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,distribution of time from initial presentation with pancreatic tumors to the time that surgery is recommended
2987,NCT03356236,Progression-free survival (PFS),2018-04-17,RECRUITING,OBSERVATIONAL,['NA'],,severity of Adverse events (AE)
2988,NCT01641276,Identification of different group of specific frequencies of modulation in hepatitis B carriers with and without hepatocellular carcinoma associated with biofeedback response,2012-04,COMPLETED,INTERVENTIONAL,['NA'],,Characterization of differences biofeedback response in hepatitis B carriers with and without hepatocellular carcinoma
2989,NCT00336700,2-year Recurrence Free Survival (RFS),2006-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,KRAS Mutational Status
2990,NCT00641615,Safety (toxicities as assessed by NCI CTCAE version 3),2007-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Specific CTL induction in vitro, Objective rate as assessed by RECST criteria"
2991,NCT02195232,Percent Change in D-dimer Value,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Cumulative Incidence of VTE at 56 Days
2992,NCT00165594,Response rate based on Response Evaluation Criteria in Solid Tumors (RECIST),2005-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse drug reaction.
2993,NCT01155609,Decrease in mucositis severity and time to complete response,2010-09,COMPLETED,INTERVENTIONAL,['NA'],,Improvement in quality of life
2994,NCT00004895,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2995,NCT01904630,Data on association between sequence variants in exons and CRC risk,2012-12,COMPLETED,OBSERVATIONAL,['NA'],,
2996,NCT03699111,Stratification Tools,2018-09-19,COMPLETED,OBSERVATIONAL,['NA'],,
2997,NCT00027274,Risk of Cancer with Specific Mutations,2001-11-28,RECRUITING,OBSERVATIONAL,['NA'],,
2998,NCT04868773,Recommended Phase 2 Dose [RP2D],2021-07-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of Participants with Objective Response Rate
2999,NCT04906954,"Step 2 : Number of patients with improvement of 10 points between baseline and week 8, assessed using the EORTC QLQ-C30 physical functioning scale",2021-06-29,UNKNOWN,INTERVENTIONAL,['NA'],,Overall Survival (OS)
3000,NCT05962450,Progression-Free Survival (PFS),2023-10-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to Quality of Life (QoL) Deterioration
3001,NCT00035100,Tumor response rate,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,pharmacogenetic analyses with blood and tumor samples from these patients
3002,NCT03510923,Costs,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Other aberrant findings requiring additional therapy
3003,NCT05376423,Recurrence-free survival rate,2022-06-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3004,NCT04003792,conversion rate to complete resection in patients with initially inoperable liver-only metastases due to colorectal cancer after treatment with HAI of oxaliplatin with FOLFIRI and bevacuzimab systemic treatment.,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
3005,NCT03899428,Time to decline to ≥ 2 log10 IU/mL of serum HBsAg,2019-05-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Adverse events assessed in terms of seriousness, severity, and relationship to the study material according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0"
3006,NCT06190782,Progression-free survival difference of PD-1 inhibitor+radiotherapy and PD-1 inhibitor alone,2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,local control rate
3007,NCT01030757,Tumor Response Rate (Complete Response + Partial Response).,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Toxicity, Progression Free Survival, Clinical Benefit Rate (Complete Response + Partial Response + Stable Disease), Median Duration of Clinical Benefit, and Median Overall Survival of Subjects."
3008,NCT01111591,Short term outcome,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Long term outcome
3009,NCT00881816,maximum tolerated dose,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,dose limiting toxicity
3010,NCT01167712,Progression-Free Survival,2010-09-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Changes in the Tumor Perfusion Parameters as Quantified by Vascularity or Blood Volume; Perfusion or Blood Flow; Mean Transit Time; and Microvascular Permeability or Permeability Surface Area Product,Quality of Life Score as Measured by Functional Assessment of Cancer Therapy-Ovary-Total Outcome Index (Fact-O TOI)
3011,NCT01131078,Time to Progression (TTP),2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Overall Complete Response
3012,NCT04926324,Determination of the clinical complete response rate,2022-07-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determination of the organ preservation rate
3013,NCT01283802,the technical feasibility,2004-06,COMPLETED,OBSERVATIONAL,['NA'],,Efficacy
3014,NCT02335970,Degree of physical disability estimated by the Disability Rating Index (DRI),2005-09-05,COMPLETED,INTERVENTIONAL,['NA'],,PEF (Peak Expiratory Flow)
3015,NCT01465308,Change from baseline in oral mucositis grades,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in baseline weight in one month
3016,NCT04011033,Disease Control Rate (DCR),2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Alpha-fetoprotein (AFP)
3017,NCT02955069,Overall Response Rate (ORR) by RECIST 1.1 and as Per Blinded Independent Central Review (BIRC).,2017-02-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,PDR001 ADA Incidence On-treatment
3018,NCT01015833,Overall Survival,2010-02-15,COMPLETED,INTERVENTIONAL,['PHASE3'],,Best Overall Response Rate
3019,NCT04293835,the height of sigmoid take-off,2019-06-01,COMPLETED,OBSERVATIONAL,['NA'],,"The distances of the sacral promontory, third sacral segment, and superior, inferior margin of cancers, and anterior peritoneal reflection from the anal verge."
3020,NCT01779583,"• Correlation of plasma level and kinetics of gastric cancer derived exosomes (at baseline and monthly during therapy until tumor progression or death) and time-to-event end-points: Overall survival, Progression-free survival and Overall response rate.",2013-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3021,NCT05750290,Best objective response rate,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3022,NCT03305146,Comparison between gene mutations found into the pancreatic cystic tumor fluid to gene mutations found into tissue specimen,2017-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Evaluate the feasibility of the molecular biology analysis of the pancreatic cystic tumor fluid to distinguish the pancreatic cysts.
3023,NCT02148406,Changes in fatigue (recalled),2014-08,COMPLETED,INTERVENTIONAL,['NA'],Changes in circadian disruption (daily and recalled) as assessed by actigraphy and the Godin's Leisure Score Index,Regulation of psychological stress (daily and recalled) as assessed by Positive and Negative Affect Schedule-Expanded Form and Cancer Behavior Inventory
3024,NCT03300921,Number of Adverse Events,2017-09-28,TERMINATED,INTERVENTIONAL,['PHASE1'],,
3025,NCT00444795,"Percentage of Participants With Adverse Events (AEs)/Adverse Drug Reactions (ADRs), Serious AEs (SAEs)/Serious ADRs (SADRs), Unexpected AEs/ADRs, and Unexpected SAEs/SADRs",2007-05,COMPLETED,OBSERVATIONAL,['NA'],,"Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) According to Response Evaluation Criteria in Solid Tumors (RECIST)"
3026,NCT03302637,Presence or absence of bacterial taxa will be compared in oral and pancreatic samples.,1992-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
3027,NCT03179540,Rate of macroscopically positive resection margin,2018-03-16,RECRUITING,INTERVENTIONAL,['NA'],,Bowel Function
3028,NCT02730702,Whether rectal LEBS readings can predict the presence of advanced adenomas in the colon.,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],,
3029,NCT04452396,study arm 2 - using Continuous Glucose Monitoring of interstitial fluid as a proxy marker of blood glucose to optimise hypoglycaemia treatment in patients with an established diagnosis of spontaneous or reactive hypoglycaemia,2019-12-01,TERMINATED,INTERVENTIONAL,['NA'],,assessing concordance between CGMS and lab/finger prick glucose testing
3030,NCT03397654,Incidence of treatment-emergent adverse events (safety and tolerability),2018-01-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Improvement of progression-free survival rate (PFSR; efficacy)
3031,NCT05070104,Recommended Phase 2 Dose,2023-03-30,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Overall Survival
3032,NCT03015168,overall survival,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,grade 3 or higher treatment related small bowel toxicity
3033,NCT02318784,Overall Response Rate (ORR),2015-07-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability
3034,NCT01043523,Vital Signs: Mean Change From Baseline in Diastolic Blood Pressure,2009-12,COMPLETED,OBSERVATIONAL,['NA'],Change in Information About Lesion Characterization Obtained From the Combined Precontrast and Postcontrast Images as Compared With the Precontrast Images,"Sensitivity, Specificity and Accuracy of Blinded Read of Precontrast and Combined Precontrast/Postcontrast Images Based on Final Diagnosis."
3035,NCT01387555,Survival,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time-to-symptomatic-progression
3036,NCT00801294,PFS,2006-07-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Effectiveness of dose reduction guidelines in managing adverse events
3037,NCT02809534,12-week Progression-free survival rate(PFR 12w),2016-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
3038,NCT06194981,Overall Survival,2024-01-11,RECRUITING,OBSERVATIONAL,['NA'],,Adverse Events
3039,NCT02485119,"tmax (time to reach maximum drug concentration in plasma) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me",2015-08-14,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunogenicity evaluation based on anti-BAY94-9343 antibody count
3040,NCT05201430,3-year disease free survival,2021-08-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,adverse event
3041,NCT00663819,Proportion of Subjects Who Experience a Clinical and/or Radiologic Anastomotic Leak,2008-04,TERMINATED,INTERVENTIONAL,['NA'],,"Determine the Efficacy and Further Substantiate Safety of CBSG Used in Conjunction With Circular Staplers When Performing High-risk Colorectal, Coloanal, and Ileoanal Anastomoses."
3042,NCT01699399,Proportions of patients requiring sedation,2012-08,COMPLETED,INTERVENTIONAL,['NA'],post-procedure discomforts and 30 days complication rate,patient pain during insertion
3043,NCT02151448,"Adverse Events Possibly, Probably or Definitely Related to Study Treatment",2014-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor Necrosis Factor (TFNα) Cytokine Levels
3044,NCT03329495,number of lymph nodes retrieved,2018-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,operative time
3045,NCT06102785,Progression Free Survival,2023-11-10,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
3046,NCT00427349,Four-month Progression-free Survival Rate,2008-11-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
3047,NCT02842203,ctDNA assessment and relation to clinical outcome,2016-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,ctDNA versus CEA
3048,NCT06076265,Positive detection rate of CEA,2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],,
3049,NCT00074867,"At the completion of Stage 1 of the study, it did not meet the objective response criteria to proceed to Stage 2 of the trial.",2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Given the outcome of the primary objective, analysis of secondary objectives were not formalized."
3050,NCT04184960,Operative links on gastric intestinal metaplasia (OLGIM),2019-12-05,RECRUITING,OBSERVATIONAL,['NA'],,
3051,NCT03060642,Oral and esophageal 16S rRNA gene sequencing,2018-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Gastric aspirate mass spectrometry
3052,NCT04109105,Effectiveness and security analysis in the prevention of anastomosis leakage through the protection of ileocolic anastomosis with NHS-PEG coated collagen patch.,2019-01-15,UNKNOWN,OBSERVATIONAL,['NA'],,Number of hospital readmissions.
3053,NCT01439594,Feasibility of OFDI Imaging as Determined by Number of Successful Imaging Sessions,2008-10,COMPLETED,INTERVENTIONAL,['NA'],,
3054,NCT02668380,Adverse Events,2015-09,UNKNOWN,OBSERVATIONAL,['NA'],,Objective response rate
3055,NCT01058655,Progression-Free Survival (PFS) [Phase II],2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS) [Phase II]
3056,NCT04970316,Development of stoma-related issues after PE or CRS+HIPEC for colorectal cancer,2021-01-25,RECRUITING,OBSERVATIONAL,['NA'],,Risk factors associated with developing organ specific late adverse effects
3057,NCT00822718,,2005-01,COMPLETED,OBSERVATIONAL,['NA'],,
3058,NCT04209933,helicobacter pylori eradication,2020-05-25,COMPLETED,INTERVENTIONAL,['PHASE4'],adverse events,symptoms effective rates
3059,NCT00578071,Number of Participants With Dose-limiting Toxicities (DLTs),2007-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pathological Complete Response Rates Associated With This Regimen.
3060,NCT00081848,,2004-04-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3061,NCT03699332,Fluorescent signal at time of surgery,2018-12-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Optimal dose of the dual-labeled antibody preparation
3062,NCT02673710,Sarcopenia quantified via CT-scan defined as a skeletal muscle index at the 3rd lumbar vertebra below 41 for women and below 43 or 53 for men with a Body Mass Index below or above 25 respectively,2016-03-14,COMPLETED,OBSERVATIONAL,['NA'],,First Progression Free Survival (PFS1) is defined as the time between initial diagnosis and first progressive disease
3063,NCT05128708,detection of post operative wound infection in both groups,2020-08-07,COMPLETED,INTERVENTIONAL,['NA'],,
3064,NCT05704530,To observe the ctDNA MRD dynamics during adjuvant immunotherapy .,2023-03-29,RECRUITING,INTERVENTIONAL,['NA'],,
3065,NCT04777942,"Progression-free survival, PFS",2021-02-20,RECRUITING,INTERVENTIONAL,['NA'],,"Overall survival, OS"
3066,NCT05304936,Determine the maximum tolerated dose (MTD),2022-10-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of Response
3067,NCT05445570,Specificity of the InterVenn test,2022-05-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
3068,NCT05669339,Maximally tolerated dose,2024-04,RECRUITING,INTERVENTIONAL,['PHASE1'],,Change in the biomarker TGF-B
3069,NCT00974389,Disease-control rate,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
3070,NCT05506943,Best Overall Response,2023-01-09,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Exposure Response by Pharmacokinetic (PK) Sampling
3071,NCT05407519,RFS rate,2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,AEs
3072,NCT00504361,"Genomic DNA will be extracted, and genome wide SNP analysis and promoter sequences for genes will be obtained.",2006-05,COMPLETED,OBSERVATIONAL,['NA'],,
3073,NCT05967429,Assess the quality of life,2023-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3074,NCT00185081,"Pharmacokinetics, biodistribution and dosimetry of In-IMP-205",2005-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3075,NCT00066651,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3076,NCT01853059,Functional quality of life after chemoradiotherapy for anal cancer,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],,Patient-reported treatment-related toxicity after chemoradiotherapy for anal cancer
3077,NCT03755739,Complete response (CR) rate before or at Month 6,2018-11-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Cause of death (COD) when appropriate
3078,NCT01156142,Total Pain Reduction (Mouth and Throat),2010-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Patient Preference for Continuing Therapy With Oral Doxepin Hydrochloride
3079,NCT04154748,Complete ablation rate 6 weeks after APC treatment.,2002-06-04,COMPLETED,INTERVENTIONAL,['NA'],,Complete ablation rate at the end of follow-up
3080,NCT03909724,Progression Free Survival,2019-10-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Liquid biopsies
3081,NCT00812864,"Mean value and dispersion of the main plasmatics pharmacokinetics parameters of capécitabine, 5'DFUR, 5-FU and FBAL.",2009-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Objective response comparing lesions' targets according to RECIST criteria, at course n°3 and n°6."
3082,NCT03406299,6-month progression-free survival rate,2018-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Biomarker study
3083,NCT04729322,Objective response rate,2021-02-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
3084,NCT00454519,overall survival time,2007-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,perioperative morbidity and mortality
3085,NCT05038397,Recurrence free survival (RFS) after resection,2018-01-30,COMPLETED,INTERVENTIONAL,['NA'],,Rate of post operative hepatic decompensation
3086,NCT01205711,Progression-free survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
3087,NCT03702309,Collection and annotation of biospecimens,2017-08-03,RECRUITING,OBSERVATIONAL,['NA'],,Correlative Studies Questionnaire
3088,NCT03041532,Proximal retroflexion improve adenoma detection rate in colorectal cancer screening,2017-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Pre-procedure factors
3089,NCT00763646,To determine the impact of chemotherapy on the ability of your surgeon to completely remove the cancer as well as the impact on your survival.,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
3090,NCT02548910,Trial Feasibility,2016-04,COMPLETED,INTERVENTIONAL,['NA'],,Change in Physiologic Parameters (Cardiac Index)
3091,NCT05254327,Efficacy of BMX-001 as measured by Grade 3 and above associated with hematologic Toxicities,2022-08-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3092,NCT02547064,Time to Intubation,2015-10,COMPLETED,INTERVENTIONAL,['NA'],,Airway Injury
3093,NCT03679338,Rate of success of the use of a treatment based on radiofrequency for all the target stenosis.,2018-03-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
3094,NCT00115765,Objective Tumor Response Through Week 12 (Irinotecan),2005-06-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to Treatment Failure (Irinotecan)
3095,NCT02528110,overall survival,2015-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,complication rate
3096,NCT01563991,Morbidity,2007-02,COMPLETED,INTERVENTIONAL,['NA'],,
3097,NCT01915693,patient-reported dysphagia,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,cost
3098,NCT05601388,evaluate the immunohistochemical (IHC) expression of IMP3 in CRC and to correlate its expression with some known clinicopathological parameters.,2022-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
3099,NCT04771715,Overall Survival,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of treatment-related adverse events (TRAE)
3100,NCT03362684,Prognostic and predictive value of miR-31-3p expression on Disease Free Survival (DFS),2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Distribution of miR-31-5p expression,Prognostic and predictive value of miR-31-3p expression on SAR
3101,NCT02340949,Number of Patients Achieving Pathologic Complete Response (pCR).,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Free Survival (DFS) Rate at 3 Years
3102,NCT02754180,Disease free survival,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
3103,NCT00588575,,2004-10,COMPLETED,OBSERVATIONAL,['NA'],,
3104,NCT02361320,Correlation Between Local Control and Changes in Mass Transport by Computed Tomography (CT),2015-03-09,RECRUITING,INTERVENTIONAL,['NA'],,
3105,NCT02825550,Tumor Response (Efficacy),2016-04,COMPLETED,INTERVENTIONAL,['NA'],,Serum Level of AFP
3106,NCT03685708,Number of Participants With HEPLISAV-B Seroprotective Titer (Anti-HBs 10mIU/mL),2018-12-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants That Did Not Complete Study Due to Intolerance of the HEPLISAV-B Vaccine Among CLL Patients.
3107,NCT01583686,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),2012-05-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3108,NCT02575378,Progression-free survival,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
3109,NCT03222895,Distribution of lymph node metastases,2019-03-01,RECRUITING,OBSERVATIONAL,['NA'],,3- and 5-year overall and disease free survival
3110,NCT01143545,Tabulation of toxicity type and grade,2010-12-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,"To determine if metronomic oral CP and celecoxib reduce the number, percentage and function of CD4+ CD25+ Fox P3+ regulatory T cells (T reg) in peripheral blood of thoracic oncology patients."
3111,NCT05185505,Proportion of Patients Receiving Liver Transplant Experiencing Acute Rejection,2023-01-30,RECRUITING,INTERVENTIONAL,['PHASE4'],,Immune Cell Biomarkers
3112,NCT01969591,solid diet time,2011-01,COMPLETED,INTERVENTIONAL,['NA'],,"Complications:anastomotic leakage,intestinal obstruction,wound infection"
3113,NCT00256269,To assess the overall response rate,2005-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Evaluation of Time to Death
3114,NCT03950141,progression-free survival,2017-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety and tolerability as measured by number and grade of toxicity events,overall survival
3115,NCT05944809,The highest grade of thrombocytopenia (CTCAE 4.0) during the radiotherapy and 1 month after the radiotherapy.,2023-07-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"The highest grade of leukopenia, neutropenia,anemia (CTCAE 4.0) during the radiotherapy and 1 month after the radiotherapy."
3116,NCT04831814,Rate of accurate diagnosis of sessile serrated polyps/adenoma by the Endoscopists in the two groups.,2019-04-04,COMPLETED,INTERVENTIONAL,['NA'],,Diagnostic Characteristics
3117,NCT01151852,Progression-free Survival,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety and Tolerability of Imatinib
3118,NCT05961982,Efficacy of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA),2023-04-24,RECRUITING,INTERVENTIONAL,['NA'],,Safety of EUS-guided RFA of pancreatic cystic neoplasms at one year
3119,NCT04190498,The study will compare OSA prevalence in a group of patient curatively resected for NASH-related HCC with a group of HCV-related HCC.,2020-01-21,WITHDRAWN,OBSERVATIONAL,['NA'],,The study will compare non-recurrence-free survival rate between groups.
3120,NCT00234429,Determine the progression free survival,2003-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Determine objective tumor response
3121,NCT02164149,CT scan after colon cancer surgery. The length of the tumour feeding artery will be measured on the images.,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],,
3122,NCT04451512,Complete resection rate,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,related costs of treatment
3123,NCT05343013,To determine the 6-month ctDNA clearance rate in colorectal cancer patients with minimal residual disease following 6 months of TAS-102 therapy.,2022-06-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3124,NCT06287723,3-year disease free survival,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Time to molecular recurrence
3125,NCT01930318,Insulin resistance in perioperative period of gastrointestinal laparoscopic surgery,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Self-rating anxiety scale and self-rating questionnaire for depression before surgery
3126,NCT01845753,Rate of Lynch Syndrome in a population of primary colorectal cancer,2012-10,COMPLETED,OBSERVATIONAL,['NA'],,
3127,NCT05435014,Phase II part: target lesion response at 6 weeks after TAE/TACE treatment.,2022-09-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II part: Safety variables evaluation - ECG test
3128,NCT02085460,Incidence of Grade ≥3 Oral Mucositis Determined by Clinical Examination and Assessed by Central Review According to the Common Terminology Criteria of Adverse Events (CTCAE) Version 3.0.,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Subjects Who Did Not Developed Grade ≥3 Mucositis
3129,NCT03985072,Incidence of treatment-emergent adverse events (TEAEs) through stages 1 and 2 of the study,2019-04-26,COMPLETED,INTERVENTIONAL,['PHASE1'],Evaluate the exploratory response of tumor markers,Incidence of Andes-1537 anti-drug antibodies (ADAs) in the plasma
3130,NCT03645187,number of patients with improved radiology,2018-08-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,
3131,NCT04989855,ORR,2021-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
3132,NCT02314117,Progression-free Survival (PFS),2015-01-20,COMPLETED,INTERVENTIONAL,['PHASE3'],,PK: Minimum Concentration (Cmin) of Ramucirumab
3133,NCT01375569,Time to Tumor Progression (TTP) for TRC105 in Hepatocellular Carcinoma (HCC).,2011-06-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Count of Participants With Adverse Events
3134,NCT05342350,GALAD performance for liver cancer early detection,2022-04-15,RECRUITING,OBSERVATIONAL,['NA'],,Establishment of a bio-repository of longitudinally collected from patients with cirrhosis to be used for future studies
3135,NCT05474794,Sensitivity and Specificity of DFI-EUS in the diagnosis of SELS,2022-07-20,RECRUITING,INTERVENTIONAL,['NA'],,
3136,NCT02121366,Safety of EUS-guided ethanol ablation,2014-03,UNKNOWN,INTERVENTIONAL,['NA'],,Technical feasibility
3137,NCT05983419,Safety for full resection in BE,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,
3138,NCT05420415,5-year DFS,2018-09-01,COMPLETED,OBSERVATIONAL,['NA'],,5-year OS
3139,NCT01010360,,2009-08,COMPLETED,OBSERVATIONAL,['NA'],,
3140,NCT04258644,R0 resection rate,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,3-year OS
3141,NCT02447679,tumor recurrence,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3142,NCT05257694,Recurrence-free survival (RFS),2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Recurrence
3143,NCT05970627,Rate of pathological complete responses (pCR),2023-07-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidences and types of adverse events (AE) and severe adverse events (SAE)
3144,NCT03269903,Through-the-scope stent placement (feasibility): incidence of device related adverse device events at moment of stent placement,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,"Retrosternal pain related to esophageal stent, measured with the Visual Analog Scale (functional outcome)"
3145,NCT00502671,"Percentage of Participants With an Adverse Event (AE), Serious AE, or Death Due to an AE",2007-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,Percentage of Participants With Early Withdrawal or Discontinuation Due to an AE
3146,NCT03121729,occurrence rate of severe complications,2017-06-21,UNKNOWN,INTERVENTIONAL,['NA'],,Procalcitonin
3147,NCT01900002,Median Progression Free Survival (PFS),2013-09-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0"
3148,NCT04659382,Progression-free survival at 9 months,2020-10-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3149,NCT04573088,Postoperative pain as measured by VAS score,2020-06-22,UNKNOWN,INTERVENTIONAL,['NA'],,Anxiety and depression measured by State-Trait Anxiety (STAI) questionnaire
3150,NCT02856815,Recurrence Free Survival (RFS),2018-05-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Hematological examination
3151,NCT06246344,surgical difficulty,2023-12-01,RECRUITING,OBSERVATIONAL,['NA'],,QLQ-CR29
3152,NCT03475004,Objective Response,2018-09-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
3153,NCT00457743,Number of Subjects With Clinical Benefit Response (CBR) Based on the Extramural Review Committee Assessment in Recommended Dose Group,2005-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival Time
3154,NCT01034358,Twelve Month Antibody Response to the Human Papillomavirus (HPV) Vaccine (Geometric Mean Titers [GMT]),2010-02,COMPLETED,INTERVENTIONAL,['PHASE4'],,
3155,NCT00287859,Maximum tolerated dose,2004-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,
3156,NCT04229537,Rate of adverse events,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
3157,NCT01491217,Overall response rate(ORR) evaluation,2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3158,NCT04235660,Feasibility of Recruitment (Recruitment Rate),2020-07-22,TERMINATED,INTERVENTIONAL,['NA'],,Objective Response Rate
3159,NCT01549275,Correlation Between the Growth Speeds of the Cultured Cells and the AJCC TNM Stage (7th Eds) at Entering of the Study.,2010-04,COMPLETED,OBSERVATIONAL,['NA'],,Correlation Between the Growth Speeds of Cultured Cells and Worsening of AJCC TNM Stages or HCC Related Death 6 Months After Plating of Cells
3160,NCT02748798,Signal to Noise Ratio,2020-11-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Correlation with PFTs
3161,NCT01325649,Locoregional recurrence rate,2009-02,COMPLETED,OBSERVATIONAL,['NA'],,Rate of involvement of circumferential resection margin (pCRM positive of resected specimens
3162,NCT04158349,"Assess the maximum tolerated dose of intraperitoneal (IP) oxaliplatin with systemic IV 5-fluorouracil, leucovorin, and irinotecan (mFOLFIRI) every 2 weeks in patients with unresectable peritoneal carcinomatosis of colorectal or appendiceal origin",2021-03-22,TERMINATED,INTERVENTIONAL,['PHASE1'],,The efficacy of IP oxaliplatin plus systemic mFOLFIRI in patients with peritoneal carcinomatosis of colorectal or appendiceal origin will be measured.
3163,NCT01552200,NaviAid™ G-Eye procedure adenoma detection rate compared to the standard colonoscopy procedure adenoma detection rate,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,
3164,NCT04444167,Objective response rate (ORR),2020-07-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of subjects who develop detectable anti-drug antibodies (ADAs)
3165,NCT06068452,Cardiopulmonary Exercise Testing (CPET)/ Portsmouth - Physiological and Operative Severity Score for the enumeration of Mortality and morbidity (P-POSSUM) predicted mortality versus actual 30 day mortality,2021-03-24,COMPLETED,OBSERVATIONAL,['NA'],,Cardiopulmonary Exercise Testing (CPET) / Portsmouth - Physiological and Operative Severity Score for the enumeration of Mortality and morbidity (P-POSSUM) predicted morbidity versus actual post-operative morbidity
3166,NCT01461525,Quality of life outcome,2011-10,UNKNOWN,INTERVENTIONAL,['NA'],,Anal function
3167,NCT00991003,The primary endpoint was the number of cancerous lesions and polyps detected on CCE compared to conventional colonoscopy,2007-11,COMPLETED,INTERVENTIONAL,['NA'],,"Secondary endpoints were completeness of the exam completeness, patient acceptance and adherence to preparation regimen"
3168,NCT00215514,"To assess patient tolerance and toxicity of postoperative adjuvant regimen using epirubicin, cisplatin, and infusional 5-FU before and after a course of radiotherapy among patients with curatively resected gastric or gastroesophageal adenocarcinoma.",2000-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
3169,NCT03956940,Detection rate of total circulating free deoxyribonucleic acid (cfDNA) concentration at the baseline.,2019-10-04,TERMINATED,INTERVENTIONAL,['NA'],,Overall Survival
3170,NCT03430700,Progression-Free Survival (PFS) measured from start of study treatment to the date of objective progression (investigator assessed using RECIST 1.1) or date of death from any cause (in the absence of progression).,2019-05-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease response
3171,NCT01043484,Rate complete pathologic responses,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of sphincter preservation
3172,NCT02270450,Number of Days Alive and Outside of the Hospital,2015-03-09,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
3173,NCT00309530,Overall survival,1990-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3174,NCT04838496,The main study parameter is the proportion of patients with a pathological complete response (pCR) and those patients who started a wait and see strategy and have sustained clinical complete response (cCR) at 1 year.,2021-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Costs
3175,NCT04771637,ASA status,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],heart rate,internal environment
3176,NCT02599324,Phase 1b/2 RP2D: Overall Response Rate (ORR) as Assessed by Investigator in Cohorts 3 to 6,2015-12-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 1b: Apparent Total Clearance at Steady-State (CLss/F) for Ibrutinib in Cohorts 1 to 4
3177,NCT04850430,Mortality rate,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
3178,NCT06258525,To evaluate the efficacy of SAMe in preventing oxaliplatin associated liver injury as determined by lack of injury on histopathologic analysis in patients with liver only stage IV colorectal cancer.,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,To evaluate safety and tolerability of SAMe in combination with SOC oxaliplatin based systemic therapy.
3179,NCT05307198,pCR rate,2022-05-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Concentration of DAMP
3180,NCT01478594,Investigator-assessed Progression-Free Survival (PFS),2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival Events by Tumor Placental Growth Factor (PIGF) RNA Level
3181,NCT05148494,Quality of bowel preparation,2022-03-16,RECRUITING,INTERVENTIONAL,['PHASE4'],,Post-operative complications
3182,NCT01571024,Maximum Tolerated Dose (MTD),2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biomarkers of Clinical Benefit
3183,NCT03602885,Number of Participants With Accurate Understanding of Chemotherapy Benefits at 8-12 Weeks,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Discussions About End-of-life Care Preferences With Healthcare Proxy and Care Team
3184,NCT04218253,Incidence of complications at 30 days after surgery,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative hospital stay
3185,NCT05963490,ORR,2023-04-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
3186,NCT04440605,Diagnostic Accuracy of cIII,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,Diagnostic Accuracy of cTN
3187,NCT05900583,pathological complete response (pCR),2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Overall survival (OS)
3188,NCT03685799,Influence of histological concordance on the risk of recurrence,2016-05,COMPLETED,OBSERVATIONAL,['NA'],,Identification of histological factors of recurrence.
3189,NCT03097276,proportion of patients with total hospitalization of less than 15 days during the first postoperative month,2017-04-17,COMPLETED,INTERVENTIONAL,['NA'],,
3190,NCT04071184,Maximum tolerated dose (MTD) or Recommended phase 2 dose (RP2D),2019-05-26,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Objective response rate (ORR)
3191,NCT00005021,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3192,NCT04812808,Change in IL-6/GP-130/STAT3 pathway expression (%),2022-02-01,RECRUITING,INTERVENTIONAL,['NA'],,Number of patients with adverse events
3193,NCT02150317,the overall survival rate of each group,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],,
3194,NCT02509143,Number of patients who experience moderate or severe level nausea or vomiting,2015-07,COMPLETED,INTERVENTIONAL,['NA'],,Serious adverse events
3195,NCT04257526,Improvement in lifestyle score assessed via lifestyle questionnaires,2022-03-23,RECRUITING,INTERVENTIONAL,['NA'],,
3196,NCT04066153,Unmet physical functioning needs,2019-08-20,COMPLETED,OBSERVATIONAL,['NA'],,Physical activity level
3197,NCT00024258,Response Rate After Every 3 Courses During Treatment and Then Every 2-3 Months for 1 Year After Completion of Treatment,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3198,NCT03349827,radical resection rate,2018-01-05,TERMINATED,INTERVENTIONAL,['NA'],,complication rate
3199,NCT02308319,Recurrence free survival,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Reactivation of hepatitis B
3200,NCT05610826,Progression-free Survival,2023-03-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Difference in imaging characteristics
3201,NCT01774162,Sampling Adequacy,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
3202,NCT01351220,Change from Baseline in receipt of CRC screening at 6 months and 24 months,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,Change from Baseline in frequency of patient provider communication at 6 months and 24 months
3203,NCT00212589,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3204,NCT04808687,Objective response rate,2021-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
3205,NCT02721576,Objective response rate,2016-07-05,TERMINATED,INTERVENTIONAL,['PHASE4'],,Progression free survival
3206,NCT05531331,The change in the adaptation of the experimental group according to the Ostomy Adjustment Inventory-23 scores at the end of the second month,2021-11-01,COMPLETED,INTERVENTIONAL,['NA'],,The change in the ability of individuals with stoma to care for their stoma at the end of the 2nd month
3207,NCT02589860,Melphalan exposure,2015-10-30,WITHDRAWN,OBSERVATIONAL,['NA'],,
3208,NCT00635323,Overall response rate,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Laboratory tests
3209,NCT01887041,Outcome of Quality of Life.,2010-01,TERMINATED,INTERVENTIONAL,['PHASE4'],,"The incidence of surgical complications and complications, with regard to the endo-scopic stent insertion, are further aspects that shall be examined in this study."
3210,NCT03743883,Incidence rates of oesophageal cancer and stomach cancer with use of low-dose ASA by sex-specific compared to non-use,2018-10-30,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of oesophageal cancer and stomach cancer among new users of low-dose ASA for primary or secondary cardiovascular prevention
3211,NCT05602935,Pathologic complete response (pCR) rate,2020-09-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival(OS)
3212,NCT02882503,To evaluate pancreatic tumor ablation effect,2016-06,WITHDRAWN,INTERVENTIONAL,['NA'],,Biochemical profile
3213,NCT01279330,Completion of Fecal Occult Blod Test,2010-09,UNKNOWN,INTERVENTIONAL,['NA'],,Proportion of uninterpretable test.
3214,NCT05726097,Adequate cleanliness rate,2023-02-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Assessment of patient tolerance of the bowel preparations
3215,NCT04341909,any procedure related adverse outcome,2020-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
3216,NCT04637048,Evaluate the overall survival rate of all patients with hepatobiliary tumor,2017-02-16,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Evaluate the Progression Free Survival rate of patients with hepatobiliary tumor
3217,NCT04786600,Overall survival,2021-11-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Best overall response
3218,NCT05872841,disease control rate (DCR),2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival(OS)
3219,NCT00005979,,1998-07-22,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3220,NCT05629065,Proportion of patients with an SIC at 60 days for arm 1 (patient +clinician nudge) vs arm 2 (no nudge).,2022-11-28,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Patient preferences
3221,NCT02780700,Progression Free Survival (PFS),2016-07-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Patients With Grade 3 or Worse Adverse Events
3222,NCT01801930,Dose Limiting Toxicity (DLT),2013-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor Response Rate in Cycle 1
3223,NCT04892342,Objective Response Rate (ORR) by Independent Central Review (ICR),2021-09-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,ADA
3224,NCT00003522,,1997-08-13,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3225,NCT06213519,Overall survival,2024-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
3226,NCT01861873,volumetric uptake values of 18-FDGal will be measured and the 18-FDGal PET/CT one month after stereotactic body radioation therapy will be compared to the baseline status in sub-volumes receiving more than 15 Gy,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,evaluate toxicity to SBRT by toxicity scoring system that includes biochemical measures as well as symptomatic scores.
3227,NCT04955119,Positive predictive value,2021-07-30,UNKNOWN,INTERVENTIONAL,['NA'],,The sensitivity and specificity of CEUS LR-5
3228,NCT00244348,overall survival of patients resected for cure versus (vs.) resected for palliation vs. not resected.,2005-10,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,cost
3229,NCT05766748,Recommended Phase 2 Dose,2023-06-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Body Weight
3230,NCT01985763,Percent Change in Tumor Size,2013-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
3231,NCT01342653,disease free survival,2011-01,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Quality of life after phase I and Phase II
3232,NCT05223036,Percentage change in duodenal polyp burden,2022-09-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Future candidate biomarkers measured by genomic and transcriptomic platforms in residual tissue biopsies of adenomas and normal mucosa
3233,NCT03668418,Correspondence with chemo-sensitivity data collected in zebrafish model,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,Time to tumour progression
3234,NCT02898415,Cancer specific survival,2015-06,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence Free Survival
3235,NCT00183833,To determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of Gleevec in combination with a fixed dose of Xeloda po bid daily in patients with colon cancer.,2002-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Toxicity.
3236,NCT02465502,Percentage of participants without disease progression or death at the end of 8 weeks,2015-07-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Percentage of participants with grade 1 or higher adverse events, using NCI Common Terminology Criteria for Adverse Events (CTC-AE) Version 4.03"
3237,NCT03024684,3-year cumulative incidence of recurrent HCC between the intervention group and control counterpart,2017-01-03,RECRUITING,INTERVENTIONAL,['PHASE4'],,occurrence of clinical complications related to hepatic decompensation
3238,NCT04776655,Progression free survival (PFS) in patients with RASmut at liquid biopsy and RASwt on tissue.,2021-04-30,RECRUITING,INTERVENTIONAL,['PHASE3'],,Compliance
3239,NCT05879328,Recurrence-free survival (RFS),2022-12-23,RECRUITING,OBSERVATIONAL,['NA'],,Comparison with historical series
3240,NCT01691625,the quality of life,2012-09,COMPLETED,INTERVENTIONAL,['NA'],Immunological assessment,progression-free survival
3241,NCT04672980,Dose limiting toxicities (DLTs) of RTX-321:,2021-04-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Anti-tumor activity of RTX-321
3242,NCT06178939,incidence of postoperative delirium,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,total score of QOR-40
3243,NCT01636674,time to recurrence,2009-07,UNKNOWN,INTERVENTIONAL,['NA'],,
3244,NCT05579444,Identification of microbial determinants of gastrointestinal diseases.,2022-11-11,TERMINATED,OBSERVATIONAL,['NA'],,Quantify change in microbial species over time post colonoscopy
3245,NCT05740995,Major pathological regression (MPR) rate,2020-12-01,RECRUITING,OBSERVATIONAL,['NA'],,"The correlation between detection of genomic, immune, microbial and metabolite features and the rate of therapeutic responses."
3246,NCT02323360,Local control (efficacy of SBRT in selected HCC patients with an incomplete response after TACE/TAE),2014-11,TERMINATED,INTERVENTIONAL,['NA'],,toxicity (incidence of acute and late complications)
3247,NCT06267417,To measure grade of oral mucositis in patients receiving laser arm placebo arm.,2023-04-10,RECRUITING,INTERVENTIONAL,['NA'],,
3248,NCT01749332,ctDNA differences,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,collect preliminary data
3249,NCT02128958,Number of Subjects With Overall Survival,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Pharmacokinetics (PK) Parameters of CF102 - AUC_0-12, Steady State (ng*h/mL)"
3250,NCT00000611,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3251,NCT01639326,Overall objective response rate (RR) by RECIST criteria v1.1,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall response duration
3252,NCT04386772,Hypertrophy degree of standardized FLR,2020-05-27,UNKNOWN,INTERVENTIONAL,['NA'],,Immunohistochemical stainings of liver parenchyma
3253,NCT04980443,Sensitivity of CELTiC,2021-08-03,COMPLETED,INTERVENTIONAL,['NA'],Association between CELTiC test score and FIT concentration,C-statistic of CELTiC
3254,NCT00724503,Progression-Free Survival (PFS) at Any Site,2006-08,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Participants With Overall Response
3255,NCT02615665,Overall survival,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
3256,NCT01865071,Mortality,2011-09,UNKNOWN,INTERVENTIONAL,['NA'],,
3257,NCT05815303,pCR,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
3258,NCT03447691,score of QoR40 (Quality of Recovery 40),2017-08-27,UNKNOWN,INTERVENTIONAL,['NA'],,score of QoR40 (Quality of Recovery 40)
3259,NCT00991094,Dose-response relationships for normal tissue toxicity after proton therapy,2005-05-27,RECRUITING,OBSERVATIONAL,['NA'],,Symptom burden
3260,NCT01359397,Progression free survival,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
3261,NCT01078311,To demonstrate the correlation of trough sorafenib level with overall survival in advanced hepatocellular carcinoma,2010-02,UNKNOWN,OBSERVATIONAL,['NA'],,To correlate trough sorafenib level with side effects (rash and hypertension)
3262,NCT05881746,relapse-free survival,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,postoperative mortality
3263,NCT02527577,consumption of morphine over the first 48 hours postoperative.,2010-04,TERMINATED,INTERVENTIONAL,['NA'],,pharmacokinetic of ropivacaine (plasma concentrations)
3264,NCT04929015,Correlation of ctDNA clearance with activity of chemotherapy,2021-04-29,RECRUITING,INTERVENTIONAL,['NA'],,Associations between CA125 levels and ctDNA levels
3265,NCT02119026,Efficacy Duration of Disease Control by Tumor Assessment (CT/MRI/Clinical Examination),2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumour Assessments (Based on RECIST Criteria) in 2nd-line
3266,NCT05939401,ctDNA,2023-12-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
3267,NCT03512756,Overall Survival,2018-03-27,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Progression Free Survival
3268,NCT04308837,Pathological Response,2018-12-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Peritoneal Disease-free Survival
3269,NCT05620771,Progression Free Survival (PFS),2022-11-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
3270,NCT01688557,Diagnostic accuracy of innovative colonoscopy,2012-09,COMPLETED,INTERVENTIONAL,['NA'],Area under the ROC curve (AUC),Pain intensity (VAS scale)
3271,NCT03954548,Adenoma miss rate [AMR],2020-02-17,COMPLETED,INTERVENTIONAL,['NA'],,Polyp Miss Rate [PMR]
3272,NCT02983578,Physical Examinations,2017-03-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Radiomic measurements,Overall survival
3273,NCT03613194,Identification and characterization of the tumoral intermediaries on the hepatic metastasis and/or peritoneal),2018-06-25,UNKNOWN,INTERVENTIONAL,['NA'],,
3274,NCT02273362,Response (at Least a 50% Reduction in Liver Phospho-EGFR Staining),2014-11-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Erlotinib Hydrochloride Plasma Level,Adverse Event Profile
3275,NCT01180166,progression-free survival,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival time
3276,NCT00846131,To Evaluate sorafenib as an adjunct to Y-90 for control of HCC as a bridge/downstage to transplant,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,To identify predictive and prognostic markers of how the liver cancer will respond to treatment.
3277,NCT04522011,The incidence of postoperative complications,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3278,NCT04847297,rate of serious complications,2021-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Mortality
3279,NCT05833815,Progression free survival,2022-11-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Chemotherapy Toxicity
3280,NCT04724226,Objective response rate (ORR) by RECIST 1.1 and mRECIST,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-related adverse events,Median overall survival time (mOS)
3281,NCT04515615,The incidences and types of adverse events,2020-09-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment completion rate
3282,NCT05517811,Post-operative thrombotic and hemorrhagic complications,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,pre-operative distant metastasis
3283,NCT03435107,Objective response rates (RECIST 1.1),2018-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
3284,NCT05797805,Evaluate efficacy of tegavivint as a single agent,2023-09-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Evaluate efficacy of combination of tegavivint plus pembrolizumab,
3285,NCT03068052,Colonoscopy participation,2017-05-08,COMPLETED,INTERVENTIONAL,['NA'],,Risk assessment completion
3286,NCT04891900,Objective Response Rate (ORR),2021-05,UNKNOWN,INTERVENTIONAL,['NA'],,Duration of Overall Survival (OS)
3287,NCT01432314,Time to tumor progression,2011-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Best tumor response by modified RECIST (mRECIST) and RECIST criteria
3288,NCT00084604,"Time to progression, evaluated using RECIST",2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Incidence of toxicity, evaluated using CTCAE version 3.0"
3289,NCT05846594,Median Time to Diagnosis,2023-09-14,RECRUITING,INTERVENTIONAL,['PHASE4'],,Incidence and Severity of Liquid Biopsy Sample Collection-Related Adverse Events
3290,NCT02850172,severity of symptom (QLQ-OES18 questionnaire),2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,length of mechanical ventilation
3291,NCT01126346,"Assess feasibility of instituting an orientation program, brief follow up care and phone calls in this patient population",2010-05,COMPLETED,INTERVENTIONAL,['NA'],,"Improve overall post-operative QOL ratings at 3 months, relative to discharge"
3292,NCT04182386,Future liver remnant hypertrophy,2012-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,Effect of sarcopenia on hypertrophy
3293,NCT00565708,Disease-free survival,2008-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival
3294,NCT04536922,Treatment,2021-01-27,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
3295,NCT03716531,2 Year Overall Survival,2019-03-19,RECRUITING,INTERVENTIONAL,['NA'],,Adverse events associated with IORT
3296,NCT06335147,pathologic complete response（pCR）,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of Treatment-Emergent Adverse Events
3297,NCT05620628,PFS (progression free survival),2023-01-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,ORR (objective response rate)
3298,NCT04404777,3 year survival,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,MDT effect on treatment of local recurrence
3299,NCT06013774,Device Feasibility,2021-05-25,COMPLETED,INTERVENTIONAL,['NA'],,Radioactivity distribution in 3D
3300,NCT00023634,toxicity,2001-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,
3301,NCT04677244,Procedure impact,2021-11-11,RECRUITING,INTERVENTIONAL,['NA'],,
3302,NCT04334421,Comprehensive Complication index,2020-04-03,COMPLETED,OBSERVATIONAL,['NA'],,Perineal hernia
3303,NCT02887612,Positive Predictive Value,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],,prognostic molecular markers
3304,NCT05994638,Side effects after radiotherapy,2023-08-21,RECRUITING,INTERVENTIONAL,['NA'],,Impact of dysphagia on quality of life
3305,NCT01694342,,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],,
3306,NCT00526578,Identification of susceptibility genes in high risk familial pancreatic cancer (FPC) pedigrees using cutting-edge genetic analysis methods,2002-06-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
3307,NCT04738240,Clinical anastomotic leak,2019-03-11,COMPLETED,INTERVENTIONAL,['NA'],,
3308,NCT00503776,Number of Patients With Each Degree of Swallowing Dysfunction,2006-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Changes in the Frequency and Types of Dietary Intakes
3309,NCT04290364,Use of healthcare services,2019-09-21,COMPLETED,OBSERVATIONAL,['NA'],,Carer satisfaction with palliative care
3310,NCT04802954,Stratification of the risk of hepatocarcinogenesis in high-risk patients by a deep learning-based cross-analysis.,2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Characterization of the interface of the nodules with the adjacent hepatic parenchyma by a deep learning-based cross-analysis
3311,NCT04682158,Progression Free Survival,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
3312,NCT05327738,Proportion of progression-free participants,2022-12-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Descriptive summary of tumor and tumor immune cell populations,Incidence of grade >= 3 adverse events
3313,NCT02486497,Recurrence free survival,2015-06,COMPLETED,INTERVENTIONAL,['NA'],,Toxicity
3314,NCT05531864,visual analogue scale,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Intraoperative heart rate changes
3315,NCT02157454,Self-efficacy for coping with cancer (measured by the German short form of the Cancer Behavior Inventory),2014-06,COMPLETED,INTERVENTIONAL,['NA'],,Patient competence (assessed by a self-rating measure of patient competence in oncology in validation process)
3316,NCT00579579,"To prospectively evaluate bowel, sexual and bladder function in patients who undergo resection for stage I-III rectal cancer.",2006-11-28,COMPLETED,OBSERVATIONAL,['NA'],,"To evaluate the expectations, informational needs and satisfaction with the surgical consent process in patients undergoing resection for stage I-III rectal cancer."
3317,NCT00326911,Progression-free Survival (PFS),2006-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Change From Baseline in Assessment of Pain Using BPI Short Form, Interference, at Cycle 2 Week 4"
3318,NCT02219893,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2014-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease free survival
3319,NCT06061146,PFS,2023-10-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,AE
3320,NCT06219096,Fluorescence imaging effect of the live,2023-12-10,RECRUITING,INTERVENTIONAL,['NA'],Disease-free survival,Postoperative hospital stay
3321,NCT03724071,Phase II part - Overall response rate,2018-10-16,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3322,NCT01980810,response rate,2013-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,number of adverse event
3323,NCT04512833,Local control time,2020-08-12,RECRUITING,OBSERVATIONAL,['NA'],,Adverse reaction
3324,NCT03061162,Side effects of pulsed low dose rate radiation therapy,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Time to progression
3325,NCT02760537,self-reported status of the series of HBV vaccinations by follow-up calls in seven months after mailing the results verified by the medical records,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,
3326,NCT03869892,Progression-free Survival (PFS),2019-03-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to treatment failure (TTF)
3327,NCT06063928,Changes in genomic knowledge,2022-05-25,RECRUITING,OBSERVATIONAL,['NA'],,
3328,NCT05319431,Progression-free survival (PFS),2022-06-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events (AEs)
3329,NCT06141109,PFS,2022-01-18,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Area Under the Plasma Concentration Versus Time Curve (AUC) of MB07133
3330,NCT02859753,Time to disease progression according to American Society of Interventional Radiology criteria,2014-01-15,COMPLETED,INTERVENTIONAL,['NA'],,
3331,NCT01065818,"Optimal Timepoint During the Course of Neoadjuvant Therapy [CRT, CT (Chemotherapy) or RT Radiotherapy)] That FLT-PET Imaging Can Predict Response",2009-08,TERMINATED,INTERVENTIONAL,['NA'],,
3332,NCT05646537,stoma compliance scores of the participants,2023-01-01,COMPLETED,INTERVENTIONAL,['NA'],,comfort level of the participants
3333,NCT02515734,Best deepness of response,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of adverse events
3334,NCT00030498,Maximum tolerated dose (MTD) of OSI-774 determined by dose-limiting toxicities,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3335,NCT03401814,"Quantify tissue mechanical properties of the liver and liver tumor using MRE in patients receiving radiation therapy + immunotherapy at baseline, mid-treatment and time of followup imaging determined by standard of care to assess response to therapy",2018-08-02,COMPLETED,OBSERVATIONAL,['NA'],,
3336,NCT05990569,Patient satisfaction assessed using the Likert scale after receiving Bupivacaine pudendal nerve block with or without Methylene Blue.,2023-08-12,RECRUITING,INTERVENTIONAL,['NA'],,Complications
3337,NCT02575339,Phase II: Time to Progression (TTP),2016-07-18,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Radiographic Response Rate (RRR)
3338,NCT05544929,Dose intensity,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,Elimination half-life (T1/2) of KFA115 or pembrolizumab
3339,NCT04764409,Identification of all the kinds of complications according to the Common Terminology Criteria for Adverse Events (CTCAE v4.0) and their systematization.,2021-01-12,UNKNOWN,OBSERVATIONAL,['NA'],,
3340,NCT03896958,Assessment of benefit of return of research results by SpeciCare Outcome Monitor Board,2019-03-21,UNKNOWN,OBSERVATIONAL,['NA'],,
3341,NCT00309543,Overall survival,1993-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3342,NCT02517554,Completion of Surveys,2015-08,COMPLETED,OBSERVATIONAL,['NA'],,
3343,NCT03595904,Number of Participants Who Completed a Screening Colonoscopy,2017-11-20,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants Who Were No-show Appointments
3344,NCT05958433,duration of hospital stay,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,assess the effects of preoperative education using stoma appliance on quality of life in colorectal cancer patients with a stoma
3345,NCT05967533,Natural killer (NK) cell killing activity,2023-06-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunologic effects of FWG (Immune Correlates): serum cytokines analysis
3346,NCT04132505,Maximum tolerated dose (MTD),2019-10-22,RECRUITING,INTERVENTIONAL,['PHASE1'],Effect of this binimetinib/hydroxychloroquine treatment on changes in muscle and fat mass,Overall survival
3347,NCT04779151,Overall Response Rate (ORR),2021-04-07,SUSPENDED,INTERVENTIONAL,['PHASE2'],,
3348,NCT04241276,To assess the efficacy of ATRA when given in combination with gemcitabine and nab-paclitaxel based on progression free survival (PFS).,2020-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,To assess quality of life (QOL) of patients receiving ATRA in combination with Gemcitabine and Nab-Paclitaxel: EQ-5D-5L
3349,NCT04247256,Objective Response Rate,2020-05-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Biomarkers ABCG2, ABCB1, SRPK1"
3350,NCT00610636,Both groups of patients were analyzed with intention-to-treat principle. The primary end-point was time-to-progression. The secondary points were overall survival and surgical morbidity.,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Surgical morbidity, Chemotherapeutic complications"
3351,NCT03535259,MST,2018-05-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of III-IV grade adverse events
3352,NCT02198898,incidence of adhesive intestinal obstruction,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
3353,NCT01843049,Dose limiting toxicity(DLT),2013-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Local recurrent rate within the >50% SUVmax region of the primary tumor,Late toxicity
3354,NCT01438476,Postoperative Pain Experience,2012-01-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3355,NCT02792842,The discontinuation rate of oxaliplatin due to OIPN,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3356,NCT02744651,Number of correct histopathological diagnoses from submucosal tumors in the upper GI tract.,2017-02-17,TERMINATED,INTERVENTIONAL,['NA'],,
3357,NCT00576940,The ratio of postoperative complications (infectious and surgical),2004-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,assessment of visceral protein turnover
3358,NCT04514484,Incidence of dose limiting toxicities (DLTs),2021-11-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Change in infiltrating immune cell markers,Human immunodeficiency virus (HIV) viral loads
3359,NCT04164602,incidence of pancreatic ductal adenocarcinoma in patients with new-onset diabetes,2019-10-09,RECRUITING,OBSERVATIONAL,['NA'],,Cost-benefit analysis
3360,NCT03400657,overall survival,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,Differences in overall survival after performing MDT at center
3361,NCT00081900,To establish the MTD and dose limiting toxicities of DENSPM intravenous infusion in patients with unresectable HCC.,2004-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate the pharmacokinetics of DENSPM in plasma and HCC tissue in patients unresectable HCC.
3362,NCT03506321,Compare chromoendoscopy predictions and HD-WL/NBI predictions of submucosal invasive cancer (SMIC) and residual or recurrent adenoma (RRA) to compare correlation with histological findings,2018-02-07,COMPLETED,INTERVENTIONAL,['NA'],,Compare the difference between live endoscopic assessment and use of carefully selected endoscopic images to predict SMIC
3363,NCT05955833,"89Zr-trastuzumab uptake (standard uptake values (SUVmean, %ID/kg) in normal organs/tissues and bloodpool in historical controls with HER2+ breast cancer (n = 20) who underwent 89Zr-trastuzumab PET imaging.",2023-06-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,HER2 expression measured by IHC on tumor biopsies
3364,NCT03255811,Evaluation of apatinib mesylate tablets as first-line maintenance treatment for advanced gastric or gastroesophageal junction progression free survival site adenocarcinoma,2017-03-25,UNKNOWN,INTERVENTIONAL,['NA'],,
3365,NCT02665741,Adenoma Detection Rate,2016-01,COMPLETED,INTERVENTIONAL,['NA'],,Withdrawal Time
3366,NCT04893876,Global Quality of Life (QoL),2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Frailty
3367,NCT01126645,Primovist®-enhanced MRI is non-inferior or superior compared with contrast-enhanced multislice CT,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety of SIR Spheres
3368,NCT06001372,The rate of study completion by enrolled participants. Study completion is defined as participating in at least 2 of the 3 Ketamine-Assisted Psychotherapy (KAP) sessions.,2023-10-13,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,The proportion of screened patients that meet criteria on the Existential Distress Scale (EDS: Single domain ≥ 3 or total score ≥ 6).
3369,NCT00976898,Median Overall Survival,2009-08,COMPLETED,INTERVENTIONAL,['NA'],,Patterns of Failure
3370,NCT04267549,R0-surgery conversion rate,2019-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],pathological response,surgery-related complications
3371,NCT05515796,ORR (objective response rate) per RECIST 1.1,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],EORTC QLQ-CR29,R0 resection rate
3372,NCT05914077,Proportion of patients with IPMN with GNAS and KRAS mutations in intracystic fluid obtained by EUS-FNA versus pancreatic juice obtained by ADPJ-secr after both techniques.,2023-09-13,RECRUITING,INTERVENTIONAL,['PHASE3'],,Proportion of patients with Serious Adverse Events
3373,NCT05278728,The rate of grade 3/4 toxicity,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The disease control rate
3374,NCT03041129,Hepatic fat fraction,2017-04-14,COMPLETED,OBSERVATIONAL,['NA'],,Hepatic phosphate concentrations
3375,NCT03084133,Participation rate in screening colonoscopy for first-degree relatives of patients with RCC or advanced adenoma.,2017-04-10,COMPLETED,INTERVENTIONAL,['NA'],,"Quality criteria for screening colonoscopy using the following parameters: visualization rate of the bottom of the colon, the withdrawal time of the colonoscope (Withdrawal time), quality of the colic preparation using the Boston scale."
3376,NCT02674815,Compliance,2016-02,COMPLETED,INTERVENTIONAL,['NA'],,Clavien-Dindo Classification Sore
3377,NCT02912949,Duration of response per RECIST v1.1 as per local Investigator's assessment.,2015-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Evaluation of overall survival (OS)
3378,NCT00096070,1-year survival rate,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to treatment failure
3379,NCT04889404,Incidence of adverse events related to the safety specifications,2021-05-22,RECRUITING,OBSERVATIONAL,['NA'],,
3380,NCT05518903,Relationship between 68Ga-FAPI-46 PET metrics and staging examinations in PDA,2022-11-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3381,NCT00112918,Disease-free Survival in Stage III Cancer Patients - Number of Events,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival in Stage III Cancer Patients - Number of Events: Final Analysis
3382,NCT03916809,Feeding-tube-free food intake (days),2017-07-12,RECRUITING,INTERVENTIONAL,['NA'],M.D. Anderson Dysphagia Inventory (MDADI) (number),Upper esophageal sphincter (UES) opening width (mm)
3383,NCT02143401,Incidence of adverse events,2014-11-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Change in cleaved and total CK18 levels in serum,Time to treatment failure
3384,NCT05173246,Objective response rate (ORR),2020-11-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Severe toxicity
3385,NCT01041612,Obstruction of 1st C-SEMS or presence of jaundice at death without stent exchange,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Death of patients
3386,NCT04800549,Nurse Observation Chart of Child Mucositis Evaluation,2016-02,COMPLETED,INTERVENTIONAL,['NA'],,
3387,NCT05512793,Adenoma miss rate (AMR),2023-05-24,COMPLETED,INTERVENTIONAL,['NA'],,Withdrawal time. (First/second colonoscopy)
3388,NCT00280332,The prevalence of advanced colonic adenoma in the re-screening population,2006-03,COMPLETED,OBSERVATIONAL,['NA'],,The time to adenoma adenoma development according to different baseline characteristics of patients and colonoscopy findings
3389,NCT00936832,Response rate at 3 months as assessed by RECIST criteria,2009-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Translational research including pharmacodynamic studies of plasma and rectal tumor biopsies and histological and molecular studies
3390,NCT05745558,Percentage of patients willing to participate in prehabilitation program,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Work status
3391,NCT00443040,Time to Return of Upper and Lower GI Function,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Laboratory Values
3392,NCT00569309,Number of Participants Experiencing Immune Reconstitution,2007-12-12,COMPLETED,INTERVENTIONAL,['NA'],,Collection of Baseline Immune Reconstitution and Quality of Life Pilot Data for Comparison in Future Post-transplant Immunotherapy Trials
3393,NCT00122291,response,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
3394,NCT04509492,The number of patients with occult hepatic metastasis missed by CT or MRI during staging of pancreatic and GI malignancy.,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
3395,NCT04301557,Pathological Complete Response(pCR),2020-07-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,3 year disease free survival
3396,NCT05443217,Long-term outcomes after treatment,2022-06-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Objective response rate
3397,NCT06067620,Time to first passage of faeces,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of incisional hernia
3398,NCT03908333,Disease Control Rate,2019-05-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Changes in patient's self-reported pain levels: Brief Pain Inventory (BPI)
3399,NCT05173909,"Serum LEVELS of IL-2, IL-4, IL-6, IL-10, TNF-ɑ, IFN-γ",2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
3400,NCT01373021,total amount of administered fentanyl,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,
3401,NCT00006081,Number of Patients with Response after 2 Cycles of Treatment,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3402,NCT01878422,Progression Free Survival (PFS) of first and second line treatment strategy,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of partecipants with adverse events as a measure of safety and tolerability
3403,NCT02366819,R0 (analysis will be performed evaluating the R0 rate),2014-12-11,RECRUITING,INTERVENTIONAL,['PHASE4'],Change in SUVmax for the primary esophageal tumor,Progression free survival
3404,NCT00756548,Efficacy - Preparation Quality Using a 4 Point Scale,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Serum Chemistry Results (Osmolality)
3405,NCT01350167,Efficacy of screening measure to detect very early/early stage HCC (Barcelona Clinic Liver Cancer Staging System),2001-11,UNKNOWN,INTERVENTIONAL,['NA'],,Cost - Effectiveness of screening measure
3406,NCT00341276,Linkage of genetic markers,1995-07-06,COMPLETED,OBSERVATIONAL,['NA'],,Gene environment interactions (case control)
3407,NCT00056355,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3408,NCT00030108,Nerve growth factor levels before and after drug administration,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Tubulin polymerization in PBMCs prior to the start of the infusion, just before the end of the infusion, 5 hours after the end of the infusion and before the start of the infusion on day 2 of the ixabepilone on course 1"
3409,NCT04854434,Arm B and C: Progression-free Survival (PFS) as Assessed by the Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,2021-06-29,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Arm A, B and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs"
3410,NCT01772407,Cost during the 2 postoperative years,2009-09,COMPLETED,OBSERVATIONAL,['NA'],,"Mortality, morbidity and quality of life during the 2 postoperative years"
3411,NCT04010071,Progression-free Survival (PFS),2020-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor mutation burden,Rate of 6-months and 1-year overall survival
3412,NCT00778102,Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Complications Related to Second Resective Surgery
3413,NCT05519319,Overall survival (OS),2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Progression-free survival(PFS)
3414,NCT02243358,Frequency of R0 Resection,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3415,NCT06238193,MSI status,2003-01-01,COMPLETED,OBSERVATIONAL,['NA'],PD-L1 level,Copy-number variations (CNVs)
3416,NCT02597075,Change in Patient-reported symptoms as measured by ESAS-r,2016-03-17,TERMINATED,INTERVENTIONAL,['NA'],,Initiation or increase of anti-hypertensive drugs
3417,NCT01676714,Overall Response Rate,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients Who Experienced Treatment Related Toxicities
3418,NCT00023946,Overall survival,2001-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3419,NCT04751773,Serious adverse events,2021-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],LPS-induced TNF-a production of whole blood,Surgical stress: Noradrenaline
3420,NCT00414570,correlate 18F-FLT uptake with hENT1 expression with biopsy samples where available,2007-11,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,to demonstrate the safety of 18F-FLT manufactured at the Edmonton PET Centre
3421,NCT03993743,Incidence and type of adverse events induced by CD147-CART hepatic artery infusions,2019-05-27,UNKNOWN,INTERVENTIONAL,['PHASE1'],,CD147-CART detection in extrahepatic sites
3422,NCT02965976,Delayed Gastric Emptying Assessed Radiographically by Nuclear Medicine Emptying Study,2016-12-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life Score as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 OES18
3423,NCT02207959,Gastric neoplasia presence,2015-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Specificity for the detection of neoplasia
3424,NCT00569699,Progression free survival,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Safety, Response rate, Time to progression, Time to treatment failure, Overall survival, Treatment situation"
3425,NCT04070313,Relapse-free survival (RFS),2019-07-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,safety profile
3426,NCT04690972,Surgery for a hepato-bilio-pancreatic issue,2020-12-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3427,NCT02890511,Number of participants with dose limiting toxicity(DLT) to determine maximum tolerated dose(MTD),2010-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PK parameters for DHP107 derived from determining their plasma concentrations using validated assays.
3428,NCT02511522,Proportion of patients achieving improvement of liver cancer pain/discomfort,2015-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Proportion of patients reporting clinically significant improvement in QoL from baseline to day 30 and day 90
3429,NCT00769730,HBV viral load,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,
3430,NCT03993873,Define the Recommended Phase 2 Dose,2019-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
3431,NCT00673322,Determine the safety of using modified T cells by documenting the type and severity of any side effects and establishing the Maximum Tolerated Dose (MTD).,2008-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,Pharmacodynamics
3432,NCT00120172,"To evaluate the efficacy (measured by time to progression) of oxaliplatin, capecitabine, and bevacizumab as first-line therapy in elderly patients with metastatic colorectal cancer.",2005-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Vulnerable Elders Survey (VES-13) and Geriatric Depression Scale (GDS) scores
3433,NCT03423056,Peak oxygen comsumption,2017-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,Peak oxygen comsumption - 3 weeks
3434,NCT03598166,Percentage of Participants Who Undergo Screening Within 6 Months of Outreach,2018-10-11,COMPLETED,INTERVENTIONAL,['NA'],,Self-reported Most Common Reasons for Refusing Blood Test on Questionnaire in Intervention Group
3435,NCT02980029,Malonyl carnitine and tripalmitin levels will be measured in the preand post-treatment blood samples using mass spectrometry blood samples using mass spectrometry.,2017-10-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,"Toxicities will be graded as per NCI-CTCAE v4.03, based on recorded adverse events, physical examinations, and clinical laboratory assessments."
3436,NCT01908322,"Characteristics of patients with intermediate stage HCC (BCLC-B) treated with Nexavar will be determined by evaluating demographic data, medical history, previous treatment of HCC, specific concomitant conditions (amongst others).",2013-08,COMPLETED,OBSERVATIONAL,['NA'],,Safety variables will be summarized using descriptive statistics based on adverse events collection.
3437,NCT03082079,progression-free survival,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,patient satisfaction scores
3438,NCT05687747,Sensitivity of FAPI-PET/MRI to detect intrahepatic HCC using contrasted multiphasic MRI liver as standard comparison,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Sensitivity estimation of 68Gallium-FAPI-46 PET/MRI in per-lesion analysis for all lesions with available surgical resection samples for histopathology assessment
3439,NCT02125929,Pancreatic fistula rate,2014-04,COMPLETED,INTERVENTIONAL,['NA'],Hospital stay time,Mortality rate
3440,NCT01222689,Survival at 24 Weeks,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Plasma Biomarkers Potentially Predictive of Dual MEK/EGFR Inhibition,Number of Patients With Dose Modifications and Reason for Dose Modification.
3441,NCT02510118,Quality of life,2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Progression-free Survival (PFS)
3442,NCT02022033,Feasibility of Adjuvant FOLFOX-A,2014-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease-free Survival
3443,NCT04454099,Develop a predictive model of CRC or advanced colorectal neoplasm which includes qFIT.,2020-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Explore the effect of aspirin or other anticoagulants to the diagnose accuracy of qFIT
3444,NCT06115837,Cancer specific survival,2023-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
3445,NCT01879904,curative resection rate (3 month),2010-02,COMPLETED,INTERVENTIONAL,['NA'],,Curative resection rate (1 year)
3446,NCT06032767,RTOG/EROTC Acute Radiation Reaction Scoring Standard,2023-08-14,RECRUITING,OBSERVATIONAL,['NA'],,
3447,NCT05448846,Change in functional capacity,2022-04-08,RECRUITING,INTERVENTIONAL,['NA'],Colorectal Surgery Procedure,Rate of mortality
3448,NCT00025415,Toxicity evaluation graded according to the NCI common toxicity criteria and relationship to the study drug,2001-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Child-Pugh Classification
3449,NCT04136600,Objective Response Rate,2019-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Effect
3450,NCT00799474,Willingness to Receive the Human Papillomavirus (HPV) Vaccine,2008-12,COMPLETED,OBSERVATIONAL,['NA'],,Knowledge of HPV
3451,NCT05170256,Progression free survival (PFS) .,2022-02-04,RECRUITING,INTERVENTIONAL,['PHASE2'],Frequency of PD-L1 status by CPS score,Overall survival
3452,NCT00390195,Disease control rate in Phase II,2006-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor marker
3453,NCT02627729,Short Form 36 Quality of life Questionnaire,2009-06,COMPLETED,INTERVENTIONAL,['NA'],,Functional outcome measured with Overactive Bladder validated 8 scale
3454,NCT02352688,Length of postoperative hospital stay,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,30-day mortality
3455,NCT00559741,Improvement of hematologic and gastrointestinal tolerance to therapy,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to progression
3456,NCT01393340,Effect of Omalizumab on nasal polyp size and evolution of nasal polyps,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Evaluation of adverse events, directly or by general physical examination, blood sampling , review of concomitant medication or symptom scores."
3457,NCT00690677,To evaluate the effect of LBH589 on overall survival (OS) in patients with colorectal cancer,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to tumor progression and response rates
3458,NCT05414461,Durable clinical benefit,2019-03-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3459,NCT06035471,cfDNA methylation markers,2023-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3460,NCT01176604,Overall survival,2010-08-04,COMPLETED,INTERVENTIONAL,['NA'],,
3461,NCT02837874,Dumping syndrome,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],,Gastritis
3462,NCT00001452,"Genotype and clinical phenotype correlation in patients with PPNAD, Carney Complex, Peutz-Jeghers Syndrome and related conditions.",1995-12-14,COMPLETED,OBSERVATIONAL,['NA'],,
3463,NCT04867590,"The rate of full eradication of Barrett esophagus (metaplasia), which is defined by the absence of residual Barrett esophagus in the check-up endocopy after 3 months",2022-03-25,RECRUITING,INTERVENTIONAL,['NA'],,Build a model to predict incomplete response for eradication of Barrett's eosophagus on the basis of each independent predictor coefficient in the multivariate regression logistic model
3464,NCT04004234,Progression-free survival (PFS) at 6 months,2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with laboratory test abnormalities
3465,NCT00355212,Sustained complete response at one year after the treatment.,2001-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,costs.
3466,NCT00419159,The Number of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biomarkers Predictive of Clinical Benefit (Median PFS and OS by PTEN ) on Everolimus (RAD001) 10mg/Day
3467,NCT04464967,Phase 2a - To assess objective response rate (ORR) of SNK01 in combination with cetuximab in subjects with advanced EGFR cancers.,2021-03,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2a - Impact of SNK01 in combination with cetuximab on quality of life in subjects with advanced EGFR cancers evaluated using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Lung Cancer 13 (QLQ-LC13).
3468,NCT04327050,success rate,2020-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,complications
3469,NCT03399071,Pathological complete response rate of combination FLOT-A,2017-07-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Median overall survival by Kaplan Meir method
3470,NCT02118077,Number of Participants with Serious and Non-Serious Adverse Events,2001-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Objective tumor response
3471,NCT06054685,PFS,2023-04-17,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
3472,NCT05127759,ORR,2022-03-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
3473,NCT00004235,objective tumor response rate,2000-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,treatment response
3474,NCT03507998,Number of participants with adverse events and/or abnormal laboratory values that are related to treatment,2017-06-17,UNKNOWN,INTERVENTIONAL,['PHASE1'],,CGX1321 half life
3475,NCT03766633,Accuracy of the LiverVision® software volumetric measurements,2018-04-29,UNKNOWN,OBSERVATIONAL,['NA'],,Comparison
3476,NCT01862718,Safety of Ablation plus radiation,2013-11-19,TERMINATED,INTERVENTIONAL,['PHASE1'],,
3477,NCT05873621,Number of harvested extra-mesorectal lymph nodes,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Time of surgery
3478,NCT02205307,Anastomotic Leak Rate,2015-01,TERMINATED,INTERVENTIONAL,['NA'],,Incidence of Post-Operative Abscess Requiring Surgical Management
3479,NCT02619266,Appetite Visual Analog Scale,2015-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",The Questionnaire of Acupuncture-related Events(QAE),Nutritional status
3480,NCT03465202,Area under the curve (AUC) of capecitabine and metabolites,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Time of maximum plasma concentration (Tmax) of capecitabine and metabolites
3481,NCT03611712,Fatigue by the Brief Fatigue Inventory-Taiwanese Form,2019-02-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,"The change of of biomarkers (inhibitory immune factors, dendritic cells makers, tumor-associated macrophages, immune-regulatory markers and oncogenic-mediated immune markers) will be combined to report the immune profile."
3482,NCT04767906,time on treatment (TT),2021-12-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,occurence of clinical symptoms of liver dysfunction (safety endpoint)
3483,NCT02032914,The prevalence of colonic neoplasm,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,Prevalence of intestinal tuberculosis
3484,NCT04476329,Overall Survival,2021-01-21,TERMINATED,INTERVENTIONAL,['PHASE2'],,FACIT FACT-Hep Quality of Life Measurements
3485,NCT04615143,Disease-free survival,2020-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Major pathological response rate
3486,NCT03938324,Change in Patient activation as measured by the Patient Activation Measure (PAM-13),2019-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Change in Emotional Health as measured by the Brief Symptom Inventory (BSI 18)
3487,NCT06184594,Colorectal Cancer (CRC) Screening completion,2024-01-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,The Colorectal Cancer Screening Beliefs Instrument Score
3488,NCT02817178,Progression-free survival,2013-03,COMPLETED,INTERVENTIONAL,['NA'],,
3489,NCT06225921,Feasibility of combination adebrelimab and dalpiciclib as assessed by number of participants who experience adverse events,2023-12-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
3490,NCT01346839,Differences in Time to Documented Follow-up of a Red Flag Suggestive of Cancer,2011-02,COMPLETED,INTERVENTIONAL,['NA'],,Trigger Positive Predictive Value
3491,NCT06114082,Objective response rate (ORR),2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-related serious adverse event
3492,NCT05092750,To assess the feasibility how the Sentinel Lymph Node (SLN) mapping by using novel magnetic tracers (FerroTrace) and using the indocyanine green (ICG) for colorectal cancer.,2021-09-15,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3493,NCT01324856,abdominal complications,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
3494,NCT05493358,5 year disease-free survival by Kaplan Mayer,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,The percentage of pattern of recurrence/metastasis
3495,NCT05101148,Proportion of patients who take each gastrointestinal medication,2021-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Time to last measurable concentration (tlast) of selumetinib and N-desmethyl selumetinib
3496,NCT06123455,Overall survival (OS),2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in CD8+ T cell infiltration in tumor tissue,Safety profile
3497,NCT05534841,Complete response MRI criterion,2022-04-01,COMPLETED,OBSERVATIONAL,['NA'],,MRI accuracy
3498,NCT00004005,Disease-free survival,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3499,NCT01038544,The primary outcome measure will be the accuracy of the combination of EUS and EBUS to correctly diagnose the presence or absence of mediastinal lymph node metastases compared to EUS alone.,2009-12,COMPLETED,INTERVENTIONAL,['NA'],,Change in treatment plan based on EBUS
3500,NCT01134601,Maximum Tolerable Dose of Selumetinib (AZD6244) Hyd-Sulfate in Combination With Radiation Therapy (RT) and Capecitabine in Participants With Locally Advanced Adenocarcinoma of the Rectum.,2010-05-24,TERMINATED,INTERVENTIONAL,['PHASE1'],Dose-Limiting Toxicity (DLT),"Changes in Phosphorylated ERK (pERK) in Peripheral Blood Mononuclear Cells and Tumor, and Transforming Growth Factor Alpha (TGFa) Levels"
3501,NCT01032291,Percentage of Participants With a Response to Treatment During the Proof of Concept Period,2009-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Participants With Treatment-Emergent Adverse Events (TEAE)
3502,NCT02089737,Number of Participants With Adverse Drug Reactions,2010-06,COMPLETED,OBSERVATIONAL,['NA'],,Overall Survival
3503,NCT02550847,The tumor recurrence rate after operation at 6 months,2014-08,UNKNOWN,OBSERVATIONAL,['NA'],,The overall survival after operation at 6 months
3504,NCT00291473,adverse events,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,immune responses including HER2 and NY-ESO-1 specific IgG and T cells
3505,NCT05653960,Adverse event rate of EMR or ESD for colorectal neoplasms,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3506,NCT06118060,Heart rate variability,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Abdominal pain
3507,NCT03484195,The ratio of tumor downstaging to stage 0 and stage I,2018-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life (QLQ C30)
3508,NCT02372162,Availability of comprehensive imaging and molecular fingerprint data of individual tumors,2015-07,COMPLETED,OBSERVATIONAL,['NA'],,Biomarker analysis
3509,NCT04600466,To identify environmental and clinicopathological factors in Hispanics associated with specific molecular changes,2021-01-22,RECRUITING,OBSERVATIONAL,['NA'],,
3510,NCT03614546,Overall Survival(OS),2018-10-10,UNKNOWN,INTERVENTIONAL,['NA'],,Minimal volume of liver free from radiation
3511,NCT02182804,Accuracy,2013-02,COMPLETED,INTERVENTIONAL,['NA'],,
3512,NCT03889093,Change in concentrations of PBMC,2018-08-09,RECRUITING,INTERVENTIONAL,['NA'],,Change in concentrations of PBMC
3513,NCT00681330,Safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate immunological responses
3514,NCT02583815,Number of Participants Who Use PAM Device,2015-08,COMPLETED,OBSERVATIONAL,['NA'],,Brief Fatigue Inventory (BFI)
3515,NCT06217094,Maximum tolerated dose,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
3516,NCT04750772,finial clinical staging（TNM）,2019-10-16,RECRUITING,INTERVENTIONAL,['NA'],,SUVmax
3517,NCT02784652,Pain relief rate,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
3518,NCT04503694,"Evaluation of the efficacy of the combination of nivolumab and regorafenib when administered before and after standard, pre-operative short-course radiation therapy.",2021-03-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Evaluation of the efficacy of the combination of nivolumab and regorafenib when administered before and after standard, pre-operative short-course radiation therapy."
3519,NCT04727723,Progression Free Survival (PFS),2021-03-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Information about the patient's diagnosis-related group (DRG)
3520,NCT01929460,Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Median Cyst Fluid Amylase
3521,NCT00703365,To evaluate the efficacy (progression free survival (PFS)) of sorafenib in patients with advanced/unresectable HCC.,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate overall, survival, overall response rate (RECIST), time to progression (TTP), disease control rate (DCR) and side-effect profile of sorafenib in combination with gemcitabine in patients suffering from HCC."
3522,NCT01807325,Gene classifier that will classify lesions as benign or malignant with 95% certainty,2012-12,COMPLETED,OBSERVATIONAL,['NA'],,
3523,NCT03694431,Caregiver preparedness for caregiving using the Preparedness for Caregiving Scale,2019-01-07,TERMINATED,INTERVENTIONAL,['NA'],,HBPC clinician perception of facilitators and barriers to implementation of HBPC services
3524,NCT04986566,Intervention Acceptability as reported by participants,2021-10-19,RECRUITING,INTERVENTIONAL,['NA'],,"Healthcare resource use (e.g., hospital readmission)"
3525,NCT00342186,Collection of 3400 samples,2002-09-27,COMPLETED,OBSERVATIONAL,['NA'],,
3526,NCT00895388,Quality of LIfe (EQ 5D),2009-05,WITHDRAWN,INTERVENTIONAL,['NA'],,ICIQ Urinary function Short form
3527,NCT00107679,Time to high-grade anal dysplasia or anal cancer,2005-02,COMPLETED,OBSERVATIONAL,['NA'],,time from low-grade anal dysplasia to normal
3528,NCT01528878,Tolerability of Stereotactic Body Radiotherapy (SBRT) Based on Number of Cumulative Acute Toxicities Occurring Within 90 Days of Treatment and Related to SBRT.,2009-04,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival of Patients With Liver Cancer or Metastases to the Liver
3529,NCT02038114,Impact of Patient Pamphlets on knowledge,2013-09,COMPLETED,INTERVENTIONAL,['NA'],Impact of patient education pamphlets on patient satisfaction with care,Impact of patient education pamphlets on health-related quality of life (HRQoL)
3530,NCT00003411,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3531,NCT04214119,Difference in methylation of gene markers to discriminate gastric cancer from non-pathological esophageal squamous and gastric cardia tissue.,2016-01-12,RECRUITING,OBSERVATIONAL,['NA'],,Specificity of candidate biomarker HPP1
3532,NCT04155671,Overall Survival(OS),2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Objective Overall Response Rate (ORR)
3533,NCT03870607,Response rate (clinical and radiological),2019-03-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Variation of systemic immune parameters
3534,NCT01754636,Inclusion in at least one Clinical trial (amendment n°3 -02/2014),2012-11,COMPLETED,OBSERVATIONAL,['NA'],,Invitation to participate in in at least one Clinical trial (amendment n°3 -02/2014)
3535,NCT05471596,Prospective Power/Time Analysis of In Vivo Laparoscopic Microwave Ablation Thermodynamics in Hepato-Pancreato-Biliary Sold Tumors Utilizing a Single Generator at a Single Surgical Center,2022-02-14,COMPLETED,OBSERVATIONAL,['NA'],,90 day complication rate
3536,NCT00867321,Time to Progression (TTP) (Phase II),2009-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor Response at 6 Months
3537,NCT05359939,Hepatocellular carcinoma - sensitivity and specificity of two PET tracers,2023-01-16,RECRUITING,INTERVENTIONAL,['NA'],,Hepatocellular carcinoma - sensitivity and specificity of MRI and CT
3538,NCT04410887,Pathological response rate,2020-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease free survival (DFS)
3539,NCT00382811,The primary efficacy end-point is progression-free survival (PFS). PFS is the time from randomization until disease progression or death,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,The secondary efficacy end-point is overall survival (OS)
3540,NCT03402477,Rate of regrowth,2018-01-10,RECRUITING,OBSERVATIONAL,['NA'],,Diagnostic accuracy of MRI to detect regrowth during follow-up after complete response
3541,NCT06111274,Objective Response Rate (ORR),2023-10-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,The Minimum Concentration of ABSK021
3542,NCT02526095,DIsease free survival,2014-06,RECRUITING,OBSERVATIONAL,['NA'],,Death
3543,NCT01761266,Overall Survival (OS),2013-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Percent Change From Baseline in Serum Biomarker,Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib
3544,NCT03050814,"Progression Free Survival Between the Standard of Care (SOC) Arm A, and Standard of Care (SOC) Arm B + lead-in",2017-04-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Number of Participants That Are Hospitalized Because of Adverse Events Attributed to Disease Progression
3545,NCT03378128,Percentage of patients experiencing grade 3 or 4 post-operative complications,2018-01-12,COMPLETED,INTERVENTIONAL,['NA'],,Score of Suidan preoperative predictive index parameters
3546,NCT05270642,local tumor progression,2021-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,
3547,NCT01175291,Progression Free Survival,2010-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events
3548,NCT02342600,Disease Control Rate (DCR),2017-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number and type of adverse events
3549,NCT01077817,"Number of Cases of Esophageal Cancer Per 100,000 Woman-Years (Intent-to-Treat Analysis)",2010-02-26,COMPLETED,OBSERVATIONAL,['NA'],,
3550,NCT04660812,Number of Participants With Treatment-emergent Adverse Events,2021-05-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Anti-Drug Antibodies to the Biologic Component(s) of Combination Therapy
3551,NCT00028834,Objective response rate (complete or partial responses),2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
3552,NCT00089635,Duration of Response,2004-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
3553,NCT01215578,Predictive molecular markers of response to sunitinib,2008-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Residual concentration
3554,NCT03077594,Mucosal Impedance as measured by an endoscopic probe,2016-09-26,COMPLETED,OBSERVATIONAL,['NA'],,Volumetric Laser Endomicroscopy
3555,NCT01916148,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
3556,NCT02500199,Part 2 Overall Response Rate (ORR),2015-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression Free Survival (PFS)
3557,NCT02994693,Longitudinal assessment of the Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy,2016-12,RECRUITING,OBSERVATIONAL,['NA'],,
3558,NCT01664494,Number of Participants With Routine Clinical Use of Capecitabine as Per the Line of Treatment,2010-04,COMPLETED,OBSERVATIONAL,['NA'],,Median Dose of Capecitabine
3559,NCT05438420,Tumor response using RECIST version 1.1 throughout study,2023-01-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in the area under curve (AUC) of Q702 and its primary metabolites
3560,NCT04394598,the morbidity of hematological adverse events and diarrhea as assessed by CTCAE v4.0,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of the concurrent chemotherapy cycles that patients can receive during radiotherapy
3561,NCT05980481,Safety(adverse event),2023-08-04,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Duration of relief (DOR)
3562,NCT01927497,30-day Uncomplicated Perineal Wound Healing,2013-03-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3563,NCT06220617,Sensitivity and specificity of the screening test with comparison to colonoscopy,2024-01-11,RECRUITING,OBSERVATIONAL,['NA'],,
3564,NCT00006037,,1999-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3565,NCT01975688,"Area under the concentration-time curve extrapolated to infinity (AUC(0-∞)) of THC, 11-hydroxy-THC, CBD, 7-hydroxy-CBD and 6-hydroxy-CBD after a single dose of Sativex",2014-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,The incidence of adverse events as a measure of subject safety
3566,NCT00577889,Six Month Survival Rate,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Confirmed Response Rate
3567,NCT05720338,Composite endpoint comparison,2023-04-13,RECRUITING,INTERVENTIONAL,['PHASE3'],,Cost analysis for overall healthcare costs
3568,NCT04385641,Non hematologic toxicity,2019-10-08,UNKNOWN,INTERVENTIONAL,['NA'],,Tumor assessment
3569,NCT02460835,Median Time to Local Progression,2016-01-26,COMPLETED,INTERVENTIONAL,['NA'],Incidence of Radiation Induced Liver Disease (RILD),Overall Survival
3570,NCT00506571,Maximal overall response rate,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Progression-free survival, Overall survival, Toxicity assessment, & Pharmacokinetic characteristics and association with genetic polymorphism"
3571,NCT03804593,"Rate of SEPT9 gene promoter methylation positivity in patients with cirrhosis, based on the HCCBloodTest.",2018-12-17,COMPLETED,OBSERVATIONAL,['NA'],,
3572,NCT00853203,To collect information about factors affecting colon and rectal cancer patients' quality of life (QOL) in order to develop a QOL program.,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],,"To look at acceptability of an Expressive Disclosure Group Program for colon and rectal cancer patients, and examine its effect on quality of life."
3573,NCT00331422,Number of Patients Who Underwent Optimal Cytoreduction After Chemotherapy,2005-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of Life Score of Patients Receiving Neoadjuvant Chemotherapy
3574,NCT05178030,The negative predictive value of the ddPCR assay with regard to KIT exon 11 circulating tumour mutation,2021-05-11,RECRUITING,OBSERVATIONAL,['NA'],,Determination of time between first detection of secondary mutations and progression
3575,NCT04853017,Evaluate the safety of ELI-002,2021-10-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Determine the biomarker reduction and clearance rate
3576,NCT01731821,the postoperative pancreatic fistula(POPF) rate,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,morbidity and mortality
3577,NCT00319683,,na,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3578,NCT02959151,Number of patients with adverse event,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Detection of transferred T cells in the circulation using quantitative -PCR
3579,NCT01946646,maximum-tolerated dose,2013-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
3580,NCT04130763,The number of adverse events,2019-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,The number of adverse events
3581,NCT06253598,Objective response rate using RECIST v1.1,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AE
3582,NCT01764789,Quality of life(QoL),2010-10,COMPLETED,INTERVENTIONAL,['NA'],,Inflammation
3583,NCT01621919,,2010-12,UNKNOWN,OBSERVATIONAL,['NA'],,
3584,NCT01798173,Dosage of the vitamin B12 and the folates,2008-06-20,COMPLETED,INTERVENTIONAL,['NA'],,
3585,NCT04518449,incidence of diarrhea,2022-12-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
3586,NCT00005944,,1999-07-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3587,NCT01035385,progression free survival (PFS),2009-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"response rate, incidence of postoperative complications,pathological response rate,R0 resection rate, 5-year overall survival,duration of disease control"
3588,NCT02929186,FIT Completion Rate,2017-01,COMPLETED,INTERVENTIONAL,['NA'],,Mail/Electronic Message Engagement
3589,NCT05998122,Complete response rate (CR),2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Wexner score
3590,NCT05796245,Incidence rate of Serious infections,2023-12-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Incidence rate of malignancy
3591,NCT04601272,Shared Decision Making Process Measure,2020-09-29,COMPLETED,OBSERVATIONAL,['NA'],,Knowledge
3592,NCT01494077,Accuracy of diluted CEA level,2011-04,COMPLETED,OBSERVATIONAL,['NA'],,
3593,NCT06277921,the type of complications and the incidence of it,2024-03-18,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3594,NCT04166318,Change in FIQoL in the de-intensified CRT arm,2020-01-02,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,Incidence of and predictors for cardiovascular toxicity in patients receiving fluorouracil or capecitabine
3595,NCT05449483,R0 Surgical Resection Rate .,2022-05-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
3596,NCT03342417,Clinical Response,2018-02-14,TERMINATED,INTERVENTIONAL,['PHASE2'],Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - QLQ-OV28,Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - Recurrence rate
3597,NCT04641923,Incidence of peri-hepatic adhesions at the time of repeat liver surgery,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,30-day mortality and morbidity
3598,NCT05716620,HCC detection rate of US vs AMRI in cirrhotic patients,2022-02-08,RECRUITING,OBSERVATIONAL,['NA'],,Survival of patients
3599,NCT02648386,Safety and Tolerability assessed by Adverse Events,2016-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Maximum Flow Rate (Qmax)
3600,NCT02958566,Hospital stay cost,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Patient satisfaction
3601,NCT04044651,Overall survival (OS),2019-10-30,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",AFP level change,OS stratified according to degree of PVTT (Vp0-3 vs Vp4)
3602,NCT05791136,Progression-free survival (PFS),2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to death or distant metastasis (TTDM)
3603,NCT04812743,Increase in knowledge and intentions related to biospecimen donation and clinical trial participation.,2020-01-10,TERMINATED,INTERVENTIONAL,['NA'],,
3604,NCT01806740,Correlation Coefficient Between DCE-MRI Perfusion Parameters and the Response of Target Lesions to Sorafenib,2013-05-09,TERMINATED,INTERVENTIONAL,['PHASE4'],,Correlation Coefficient Between DCE-MRI Perfusion Parameters at Baseline and Time to Progression
3605,NCT05916443,Identification of EO-CRC specific signatures and pathways,2023-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3606,NCT01204749,Progression-Free Survival,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall health status using EuroQOL(EQ-5D)
3607,NCT02618447,Ability of the 4D PC MRA to measure flow direction of flow as compared to reference standards of the Doppler Flow Analysis,2014-08-05,TERMINATED,INTERVENTIONAL,['NA'],,
3608,NCT02736448,Progression free survival,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,toxicity
3609,NCT00821990,Survival,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3610,NCT04960072,Overall Survival (OS),2021-06-30,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Change in Quality of Life
3611,NCT00209638,objective tumor response,2000-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Response duration, time to progression, overall survival, and safety will also be assessed."
3612,NCT00003354,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3613,NCT02514278,Rate of organ preservation and absence of stoma,2016-01-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease-free survival
3614,NCT01785212,transection speed,2013-03,COMPLETED,INTERVENTIONAL,['NA'],Costs and health economics,Perioperative T-cell subsets
3615,NCT05508503,Accuracy,2022-10-21,COMPLETED,OBSERVATIONAL,['NA'],,Combined specificity
3616,NCT05028231,Pathologic Complete Response,2021-06-05,RECRUITING,OBSERVATIONAL,['NA'],Intestinal flora,Objective Response Rate
3617,NCT02530983,Completion of the Mayo Clinic Upper Digestive Disease Survey by patients at varying time points following surgery,2015-08,RECRUITING,OBSERVATIONAL,['NA'],,"Establishment of ""normal"" or expected scores from the Mayo Clinic Upper Digestive Disease Survey"
3618,NCT04212286,"The sensitivity, specificity and accuracy of CEUS and EOB-MRI",2019-10-23,COMPLETED,INTERVENTIONAL,['NA'],,"The sensitivity, specificity and accuracy of combined CEUS and EOB-MRI"
3619,NCT02324374,"Unblinded Analysis of Endocytoscopic Images of Colorectal Lesions (Technical quality of the images will be compared to histology and rated on a scale of 1-5 (1-worst, 3- acceptable, 5-being equal to histology)",2011-06,COMPLETED,INTERVENTIONAL,['NA'],,
3620,NCT00686543,Participants With a Mean POS Plasma Concentration ≥/<350 ng/mL on Day 8 and ≥/<700 ng/mL on Day 15,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,
3621,NCT00688766,Compare the progression free survival (PFS) in both study arms,2008-08,TERMINATED,INTERVENTIONAL,['PHASE3'],,Evaluate the safety and tolerability of IPI-504 in this patient population
3622,NCT02985944,Adenoma detection rate,2016-06,COMPLETED,OBSERVATIONAL,['NA'],,Factors affecting the withdrawal time
3623,NCT03621319,Rate of stricture-free eradication of dysplastic BE,2019-07-24,TERMINATED,INTERVENTIONAL,['NA'],,Cost-effectiveness of HAPC vs. RFA in the treatment of dysplastic BE
3624,NCT04340193,Number of treated participants with laboratory abnormalities,2020-09-15,TERMINATED,INTERVENTIONAL,['PHASE3'],,
3625,NCT04593446,The rate of surgical site infection,2020-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The patient's tolerability for bowel preparation
3626,NCT01497457,Determination of the distance between a rectal tumor and the pouch of Douglas,2011-12,COMPLETED,INTERVENTIONAL,['NA'],,
3627,NCT01286428,Phase II: The number of surgical oblation procedures that present data showing equivalent location of the ablation probe when compared to the US and Pathfinder Guidance System 3D image data.,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
3628,NCT04083053,High Resolution Anoscopy (HRA) discomfort scale,2019-09-17,COMPLETED,INTERVENTIONAL,['NA'],,
3629,NCT02377232,Colon Cancer Screening Intent,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,Colon Cancer Screening Completed
3630,NCT00258180,"Number of Participants Experiencing Intervention-related Adverse Events, as Defined by CTCAE at 1 Month",2005-08-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3631,NCT02328365,Postoperative mortality at one year,2014-03,COMPLETED,INTERVENTIONAL,['NA'],Findings and interventions at medical visits,Medical complications
3632,NCT05635630,Relapse-free survival (RFS) time,2022-06-24,RECRUITING,INTERVENTIONAL,['NA'],,The rate of achieving NED status when relapses happen.
3633,NCT03847636,Complete eradication rate of DAs,2019-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Median number of CryoBalloon treatments to complete eradication.
3634,NCT05846971,The impact of methylation assay on physician confidence in clinical care decision-making.,2021-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
3635,NCT02579330,Grade of macroscopic contamination according to adjusted Boston Bowel Preparation Score (0-3).,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative pain (VAS-score)
3636,NCT05051046,Rate of complete colonoscopies,2022-01-31,RECRUITING,INTERVENTIONAL,['NA'],,Medico economic criteria
3637,NCT01210911,Survival after 6 months,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicity profile
3638,NCT03829410,Phase 2: Number of Participants with an Objective Response Rate (ORR),2019-05-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Onvansertib
3639,NCT02076906,Toxicity,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Immune Markers
3640,NCT01627119,To measure the expression level of CTGF in patient blood and tissue,2009-07,UNKNOWN,OBSERVATIONAL,['NA'],,To determine the survival probability of gastric cancer patients after surgery
3641,NCT05800080,The pathological complete response;,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,"major pathologic response, MPR"
3642,NCT06276764,"The number of pancreatic ductal adenocarcinomas or their precursor lesions, dysplasia, identified only with LINFU® will be compared to standard screening methods",2024-04-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Yearly survival rate of patients with early pancreatic ductal adenocarcinomas or their noninvasive precursor lesions identified only with LINFU®,Determine the number of patients with early pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified only with LINFU® that require medical or surgical intervention.
3643,NCT05676190,objective response rate (ORR),2023-01-09,RECRUITING,INTERVENTIONAL,['NA'],,
3644,NCT06314646,Rate of anastomotic leak,2024-05-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Cancer recurrence
3645,NCT00002930,,1996-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
3646,NCT03065855,Post-operative urinary retention requiring re-catheterisation,2017-02,UNKNOWN,INTERVENTIONAL,['NA'],,Urethrorrhagia
3647,NCT02849015,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2016-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
3648,NCT03040453,Immunological response,2017-01-01,WITHDRAWN,INTERVENTIONAL,['NA'],,"Number of participants with complete radiological response at follow up 3, 6, 9 and 12 months."
3649,NCT02578888,"FAMCARE Survey will be administered, a 20 item scale measuring the degree to which family members are satisfied with the healthcare providers' behaviors. Comparison of family member scores between 2 arms, as well as at face value will be evaluated.",2015-04,COMPLETED,INTERVENTIONAL,['NA'],,
3650,NCT04801459,Late postoperative recovery results,2021-04-02,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative complications,
3651,NCT02970526,Intensity of neuropathy induced by oxaliplatin evaluated by the QLQ-CIPN20 Questionnaire (EORTC).,2016-07,COMPLETED,OBSERVATIONAL,['NA'],,pain assessed by visual analog scale (VAS).
3652,NCT00096031,Overall Survival at 6 Months,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Progression
3653,NCT03957564,The relationship between tumor response and mutation of ctDNA pre- and post-neoadjuvant chemotherapy and after operation.,2019-05-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Types of tumor-associated DNA in tumor tissues after operation.
3654,NCT05246982,PFS,2022-03-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DOR
3655,NCT04146298,Objective response rate,2021-10-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
3656,NCT00253812,The primary outcome measure will be the mean number of adenomas detected on the blinded video review for each endoscopy,2005-11,UNKNOWN,INTERVENTIONAL,['NA'],,Primary endoscopist adenoma count for each modality.
3657,NCT02399995,changes in the quality of life (QoL),2015-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
3658,NCT00544349,Efficacy: objective tumor response rate (RECIST criteria),2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor progression rate
3659,NCT06311032,Number of Decisions to Continue Surveillance Imaging,2023-03-29,COMPLETED,OBSERVATIONAL,['NA'],,
3660,NCT03344289,polyp detection rates,2018-01-21,COMPLETED,INTERVENTIONAL,['NA'],,"sensitivity, specificity, and accuracy of optical diagnosis on a per polyp basis"
3661,NCT03094351,Overall Survival Rate,2017-07-29,RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease Free Survival Rate
3662,NCT01999478,Early cancer changes in the colon,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,
3663,NCT05674097,Six pattens of blood flow and AMCA based on the preoperative observation,2020-06-08,COMPLETED,OBSERVATIONAL,['NA'],,
3664,NCT01480128,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
3665,NCT04221854,"The Detection Rate of Colorectal Polyps, Advanced Adenomatous Polyps and Cancer by Two Screening Methods",2020-01-06,UNKNOWN,INTERVENTIONAL,['NA'],,
3666,NCT01231022,Protective effection of peripheral hematopoietic stem cell infusion for DILI,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,Change of cytokines
3667,NCT00109941,Survival,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Opioid growth factor markers
3668,NCT00336960,Pathologic complete response rate,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
3669,NCT01991678,Pharmacokinetics (PK) of NKTR-102 and its metabolites,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety and tolerability of NKTR-102
3670,NCT04025437,Overall survival,2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Recurrence-free survival
3671,NCT03637569,Overall survival,2018-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
3672,NCT00172861,,2005-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3673,NCT05604716,scores of digestive physiological and social psychological functions,2001-01-01,RECRUITING,OBSERVATIONAL,['NA'],,progressive-free survival
3674,NCT03930043,Metagenomic Linkage Groups (MLGs),2017-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3675,NCT01479803,Diagnostic accuracy of fine needle aspiration Echo Tip® HD ProCore™ versus EchoTip® in the etiological cyto histological in pancreatic solid tumors explored under endoscopy ultrasonography.,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,ease of puncture between the 2 types of equipment.
3676,NCT05199285,Confirmed objective response rate (ORR),2023-01-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
3677,NCT04522544,Objective response rate (ORR) [according to RECIST 1.1] at 6 months.,2020-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Translational research,Quality of Life (QoL)
3678,NCT06208748,To estimate the median progression free survival (mPFS),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,To describe patient-reported quality of life outcome measures.
3679,NCT02580929,mortality,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],,
3680,NCT02484833,Incidence of grade 3-4 AEs,2015-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life assessed by EORT QLQ-C30 and DLQI questionnaires
3681,NCT00176761,To assess the antitumor response of this immunotherapy regimen.,2000-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,To evaluate the toxicity of this treatment regimen.
3682,NCT01858649,the major pathological response rate,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Post operative complication
3683,NCT00988897,"Primary endpoint for the first thirteen patients according to the Simons Design: Clinical DCR (Disease Control Rate) at the end of stage I, based on Response Evaluation Criteria on Solid Tumors (RECIST) criteria.",2009-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall response rate of stage I and II
3684,NCT04144907,13C Phenylalanine Oxidation,2021-04-26,RECRUITING,INTERVENTIONAL,['NA'],,
3685,NCT03414125,One-time Screening Completion,2018-09-07,COMPLETED,INTERVENTIONAL,['NA'],,Choice of FIT versus Colonoscopy
3686,NCT03634683,Safety based on Incidence of Treatment-Emergent Adverse Events (AEs) and Serious AEs,2018-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life of patients
3687,NCT02767986,causal attributions of breast cancer,2016-05-10,COMPLETED,OBSERVATIONAL,['NA'],,
3688,NCT03736720,Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,2019-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Grade 3+ Treatment Related Adverse Events (TRAE)
3689,NCT01177631,Recurrence,2009-02,COMPLETED,INTERVENTIONAL,['NA'],,
3690,NCT00956475,Most common areas of concern,2008-10,COMPLETED,OBSERVATIONAL,['NA'],,
3691,NCT02695628,Post-treatment Maximum Standardized Uptake Value (SUVmax) in Tumor and Normal Tissue,2016-09-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse Events Related to 18F-fluoromisonidazole (18F-FMISO)
3692,NCT00539617,Progression Free Survival (PFS),2007-10-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Time to Progression (TTP)
3693,NCT00016198,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3694,NCT02305186,Safety: Incidence of Dose-Limiting Toxicities (DLTs),2015-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Response Rate (RR)
3695,NCT05095831,Clinical condition at one-year follow-up,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3696,NCT04741152,No hidden insulinomas,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,
3697,NCT04791293,MELD-Na score difference between the groups,2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
3698,NCT04889768,R0 resection,2021-07-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Adverse Events
3699,NCT01146769,Maximum Squeeze Pressure,2010-04,UNKNOWN,INTERVENTIONAL,['NA'],,Functional Outcomes
3700,NCT00514930,To estimate the local and remote intra-hepatic and extra-hepatic recurrence rates and their impact on survival.,2007-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Complications and unexpected adverse events (early and late) related to RFA aspirator treatment to be assessed. Data points to be collected as per proforma for trial.
3701,NCT02273752,Incidence of Stomatitis,2014-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Response Rate Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria
3702,NCT01741038,Overall Survival,2017-12,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Longitudinal changes in tumor burden,Health-Related Quality of Life (HRQoL)
3703,NCT03780946,Pancreatic fistula,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,Discharge of the magnets
3704,NCT00243841,6 Month Local In-field Control,2004-05,COMPLETED,INTERVENTIONAL,['NA'],,Phase II: Number of Patients With Treatment Related Grade 3 or 4 Adverse Events
3705,NCT01117428,Number of Participants With Adverse Events (AEs),2010-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Terminal Half-Life (T½)
3706,NCT02428270,"Percentage of patients who experience complete response, partial response, or stable disease",2016-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Interval between the first date of CR or PR and the earliest date of disease progression or death due to any cause.
3707,NCT06196294,Number of Patients with Dose Limiting Toxicity,2024-01-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Median γδT cell persistence
3708,NCT04735133,surgical wound complications (SWC),2018-11-18,COMPLETED,INTERVENTIONAL,['NA'],,length of stay in the hospital
3709,NCT02829788,Peritoneal carcinomatosis staging,2015-11,UNKNOWN,OBSERVATIONAL,['NA'],,
3710,NCT05185531,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
3711,NCT02388256,Recovery of physical function,2015-03,COMPLETED,INTERVENTIONAL,['NA'],Adherence to enhanced recovery program after surgery,Adverse events related to acupuncture
3712,NCT02575014,Number of participants with hyperbaric oxygen treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03,2013-10,UNKNOWN,INTERVENTIONAL,['NA'],,Change in Carcinoembryonic antigen
3713,NCT00761345,To Determine the Dose Limiting Toxicities,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,To Measure Progression Free Survival and Overall Survival
3714,NCT05652361,Incidence of discrepancies between the surgeon's preparation and the prediction of the CoBot system,2021-05-19,RECRUITING,INTERVENTIONAL,['NA'],,Assessment of oncological outcomes: Frequency of Loco-Regional Tumor Free Survival (LRFS)
3715,NCT04285008,rate of adequate cleansing level after using the Pure-Vu System as compare to sandard of care colonoscopy procedure,2020-03-03,WITHDRAWN,INTERVENTIONAL,['NA'],,
3716,NCT00704600,phase I: Incidence of any grade 3 or higher non-hematological or grade 4 or higher hematological toxicity (CTCAE v3.0) and of grade 4 or higher postoperative toxicity within 30 days post-surgery phase II:rate of pathological complete remission,2008-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3717,NCT05316103,Accuracy of pCLE-targeted optical biopsy,2021-11-04,RECRUITING,INTERVENTIONAL,['NA'],,Complications of biopsy
3718,NCT02333409,pain scores in numeric rating scale (NRS),2015-03,TERMINATED,INTERVENTIONAL,['NA'],,Quality of Life scores
3719,NCT05953662,DFS rate,2023-09-15,RECRUITING,INTERVENTIONAL,['NA'],,3 years OS Rate
3720,NCT01441492,60-day ≥ Grade II Complication Rate,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,Composite Quality of Life Scores
3721,NCT05662488,Response of total lesion activation to anti-PD1-based combination therapy shown in [68Ga]FAPI and [18F] FDG PET Scans,2020-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival after treatment
3722,NCT04140526,Rate of treatment related adverse events (TRAE) according to CTCAE v5.0,2020-09-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
3723,NCT04613570,Carcinoma,2021-01-02,RECRUITING,INTERVENTIONAL,['NA'],,Advanced gastric cancer
3724,NCT00086762,Quality of life as measured by Functional Assessment of Cancer Therapy,2004-06,COMPLETED,INTERVENTIONAL,['NA'],,"Immune suppression as measured by cytotoxicity, stimulated release of IL-12, -4, -10, intracellular cytokines and lymphocyte phenotype"
3725,NCT01589146,"symptomatic objectively confirmed VTE, asymptomatic ultrasonography-confirmed DVT or VTE-related death",2010-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
3726,NCT03261791,recurrence-free survival,2017-07-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety: the potential side effects
3727,NCT01450696,Overall Survival - FAS,2011-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,Trastuzumab Serum Concentration on Day 1 of Cycle 1 - FAS
3728,NCT01415063,overall survival,2011-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],,disease-free survival
3729,NCT03675243,Fecal incontinence quality of life scale,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Sphinctrometry
3730,NCT02279719,Assessment of Disease Control Rate in the Intent to Treat Population- Phase II,2014-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Assessment of the Pharmacodynamic Studies as Well as the Concentration of Study Drug (Either Napabucasin or Amcasertib) in Tumors
3731,NCT06036563,specificity,2023-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3732,NCT06268015,Proportion of subjects with a best overall response of complete response or partial response according to iRECIST,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Months of progression-free survival
3733,NCT01092689,"Quantify and characterize HCA-DNA adducts in resected human pancreatic tissue after a dietary relevant dose of PhIP, the most mass abundant HCA in charred meat.",2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Quantify [14C]PhIP and [14C]PhIP metabolites in urine and plasma.
3734,NCT03745794,Number of Participants Discharged Opioid-Free,2019-02-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Patients and Family Free of Opioid Use
3735,NCT03716063,Metastasis recurrence rate in 1 year,2018-10-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Metastasis recurrence rate in 3 years
3736,NCT03440515,treatment success rate,2014-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3737,NCT05609656,The incidence rate of adverse events according to CTCAE v. 4.0,2023-01-26,RECRUITING,INTERVENTIONAL,['PHASE2'],immune infiltration by PD-1 and PD-L1 staining,Overall survival
3738,NCT05615129,Overall survival,2021-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Pathologic complete response rate (pCR)
3739,NCT04854213,To assess the efficacy of SBRT in inducing a regressive genetic trajectory of KRAS gene (evaluated by NGS technique) after SBRT treatment.,2021-10-06,RECRUITING,INTERVENTIONAL,['NA'],,Metabolic response (exploratory studies)
3740,NCT04981119,Percentage of screened participants experiencing loss of heterozygosity (LOH) of HLA-A*02 identified by next generation sequencing,2021-10-29,RECRUITING,OBSERVATIONAL,['NA'],,Percentage of enrolled participants who experience an adverse event (AE) related to apheresis
3741,NCT05945797,Shortening of CBD cannulation time,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,
3742,NCT00878163,Maximum tolerated dose of erlotinib hydrochloride defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients,2009-03-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Time to treatment failure
3743,NCT05602792,"In part III, Evaluate the safety of multiple dose IT T3011 in the following indications,including sarcoma, Malignant head and neck tumor, breast cancer, esophagus cancer, lung cancer and non-melanoma skin cancer.",2020-04-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","In part II and part III,Exploring the proliferation and activity of immune cells in blood after IT T3011","In part III,Overall Survival (OS)"
3744,NCT00051545,"Time to relapse, relapse being defined as the first recurrence of HCC (intra- or extrahepatic).",1999-11,TERMINATED,INTERVENTIONAL,['PHASE3'],,Dose of Seocalcitol
3745,NCT05026268,Post-operative complications rate,2021-09,UNKNOWN,INTERVENTIONAL,['NA'],,The time to discharge from hospital
3746,NCT03093129,recurrence free survival 2 years after surgery,2018-01-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Predictive value of tumour biomarkers in terms of predicting response to artesunate therapy
3747,NCT02561273,Overall Response Rate,2015-09-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free Survival
3748,NCT02038621,Progression Free Survival (PFS),2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,health-related quality of life (HRQOL
3749,NCT00623883,"number, size, and location of ACF identified",1999-01,COMPLETED,INTERVENTIONAL,['NA'],,"complications of stain-enhanced, magnification colonoscopy"
3750,NCT03828799,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2019-05-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determination of circulating free DNA concentration
3751,NCT02831556,Experimental ultrasound diagnosis agreement with final reference standard diagnosis,2016-07,RECRUITING,OBSERVATIONAL,['NA'],,Experimental ultrasound image quality.
3752,NCT05518110,Patients free of disease progression,2023-05-31,RECRUITING,INTERVENTIONAL,['PHASE2'],Comparison of new methods of multi-omics data integration vs existing models using AUROC,Safety and tolerability
3753,NCT02423720,"Adherence to the intervention, as assessed by frequency and duration of practicing the exercises (recorded in a log and responses to text messages)",2015-04-28,COMPLETED,INTERVENTIONAL,['NA'],"Sleep quality, as assessed by NCCN Distress Thermometer and NIH PROMIS instruments at the beginning, midpoint and end of the study","Adherence to the intervention, as assessed by frequency and duration of practicing the exercises (recorded in a log and responses to text messages)"
3754,NCT01210027,"Measure of Liver Function Before, During and After Radiation",2007-03,RECRUITING,OBSERVATIONAL,['NA'],,Association Between Liver Perfusion and Changes in Tumor and Clinical Outcomes
3755,NCT03597672,The number of new cases of gastric carcinoma,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Time of finding nee cases
3756,NCT04802486,Number of patients that adhered to the exercise conditions of the study,2016-06-29,COMPLETED,INTERVENTIONAL,['NA'],,Porportion of subjects with improved cachexia-related symptoms 3 months
3757,NCT06103435,Survival,1996-01,COMPLETED,OBSERVATIONAL,['NA'],,Rate of readmissions
3758,NCT04988971,Overall incidence of chemotherapy-induced diarrhea ≥ grade 1,2021-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],Changes of fecal flora and enteritis-associated inflammatory factors,Overall incidence of grade 3/4 gastrointestinal adverse events
3759,NCT00305760,Safety of Combining the Pancreatic Tumor Vaccine in Sequence With Cyclophosphamide and Erbitux. Safety is Defined as the Number of Treatment-related Grade 3 or 4 Adverse Events Observed in Greater Than 5% of the Patient Population,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3760,NCT02785068,To correlate disease response according to RECIST with levels of irinotecan and SN-38 in tumor tissue,2016-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Presence of anti-drug antibodies will be assessed
3761,NCT03140670,Progression-Free Survival (PFS) at 6 Months (PFS6),2017-09-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity at Least Possibly Related to Rucaparib
3762,NCT03399331,severity of OM,2017-07-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,pain
3763,NCT01339754,Progression-free survival (PFS) rate at 6 months,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Impact of pharmacogenomic and pharmacokinetic profile on anti-tumor activity
3764,NCT04668781,Fluid volume intraoperatively and postoperatively,2020-12-21,RECRUITING,INTERVENTIONAL,['NA'],,Mortality
3765,NCT04550494,Percent of patients who demonstrate simultaneous Rad51 activation,2021-04-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor genomic alterations potentially associated with sensitivity or acquired resistance to talazoparib,Overall response rate
3766,NCT04027348,Proportion of Patients With Obstruction Clearance,2019-06-26,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3767,NCT00730158,Proportion of Participants With Grade 2-4 Toxicities,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Circulating Tumor DNA - Percentage of Patients With DNA Mutations
3768,NCT03310892,Colonoscopy completion rate,2017-10-09,COMPLETED,INTERVENTIONAL,['NA'],,Colonoscopy scheduling rate
3769,NCT04837508,Objective Response Rate (ORR) by Independent Review Committee (IRC),2021-06-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of anti-drug antibody (ADA)
3770,NCT01759056,Safety and tolerability of AVX-470 over 28 days of treatment,2013-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Evaluate the effects of AVX 470 on biomarkers of ulcerative colitis activity over 28 days of treatment compared to Baseline,Measure the induction of or change in a human anti-bovine immunoglobulin antibody (HABA) response to AVX 470
3771,NCT03215355,Improved image quality after injection as determined by contrast-to-background calculation and expert observation.,2017-08,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,"Toxicity with ""off label"" dosing"
3772,NCT01229943,Progression Free Survival,2010-10-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
3773,NCT01795274,Acute toxicity of carbon ion radiotherapy observed within 3 months of study treatment,na,WITHDRAWN,INTERVENTIONAL,['NA'],,overall survival
3774,NCT01957852,Reoperation rate for intra-abdominal bleeding after CRS and HIPEC,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,Length of hospital stay
3775,NCT05600933,"To collect biologic samples from participants undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors and hematologic malignancies",2023-05-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,"To collect detailed history, demographic, treatment data, and perioperative findings."
3776,NCT00507351,Pain and symptom data across multiple institutions,2006-07,COMPLETED,OBSERVATIONAL,['NA'],,
3777,NCT05543304,Objective response rate,2018-12-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Progression free survival
3778,NCT05609253,Itraconazole drug and blood levels,2022-09-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,Effects of itraconazole on angiogenesis
3779,NCT03435666,AUC0-t,2018-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],,AUC_%Extrap_obs
3780,NCT02892643,Vitamin B12 cumulative supplement quantity,2016-10-27,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival
3781,NCT00192712,time to treatment failure,2002-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"response rate, survival, toxicity"
3782,NCT01181609,Percentage of Participants Achieving Overall Disease Control (ODC),2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,OS - Time to Event
3783,NCT04883970,Standardized uptake value（SUV）,2021-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
3784,NCT05890339,The Proportion of Patients With Reflux Esophagitis Within 12 Months Postoperatively,2023-06-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Proportion of participants need to rehospitalized after surgery
3785,NCT05122091,Pathological remission rate (PRR),2021-11-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
3786,NCT04193904,To assess the safety of MRx0518 in combination with hypofractionated preoperative radiation through the collection of adverse events,2019-12-20,TERMINATED,INTERVENTIONAL,['PHASE1'],Genomic changes,Margin status
3787,NCT03070574,Reduction in the occurrence of any colorectal neoplasia in LS patients,2017-11-24,TERMINATED,INTERVENTIONAL,['PHASE2'],,Significant findings & illnesses - adverse events
3788,NCT03210129,Change in physical activity behavior,2017-07-06,COMPLETED,INTERVENTIONAL,['NA'],,Cost-effectiveness of the intervention
3789,NCT03126058,occurrence rate of severe complications,2017-06-21,UNKNOWN,INTERVENTIONAL,['NA'],,Procalcitonin
3790,NCT01152437,Percentage of Participants With Disease Control (DC),2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Pre-dose Concentration of Afatinib in Plasma at Steady State on Day 8 (Cpre,ss,8)"
3791,NCT03689712,Cumulative Incidence of Severe Oral Mucositis,2018-10-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3792,NCT02179463,Pathological Response,2014-06,UNKNOWN,OBSERVATIONAL,['NA'],,downstage proportion
3793,NCT02166190,Clinical Success- composite,2014-06,TERMINATED,INTERVENTIONAL,['NA'],Safety Profile and Quality of Life,Mutational Profile of DNA post interventional procedure
3794,NCT03741517,Protocol adherence,2019-01-30,RECRUITING,OBSERVATIONAL,['NA'],Safety of core needle biopsy: NCI Common Terminology Criteria,
3795,NCT01675128,Number of Participants With a Change in elF4e Protein Levels in Matched Pre and Post Tumor Biopsies,2012-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With a Decrease in elF4E mRNA Expression in Peripheral Blood
3796,NCT00003546,overall survival,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3797,NCT04483284,Progression Free Survival,2020-06-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The incidence of AEs and SAEs by NCI-CTCAE v5.0
3798,NCT01552291,Morbidity,2012-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,Perioperative immunocompetence
3799,NCT05041335,Aggregate specimen length (ASL),2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Adequacy of diagnosis
3800,NCT00589563,Severity of Chronic GVHD,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Disease Relapse/Progression at 2 Years Post HSCT
3801,NCT01320319,Nutritional supplementation with 960mg EPA three times a day positively affects muscle function and mass,2011-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The secondary aim is to look at the aerobic performance.
3802,NCT02326779,Overall survival,2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Adverse events
3803,NCT02567396,Tolerability of talazoparib in patients with varying degrees of hepatic and renal dysfunction,2016-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],The pharmacodynamic effects of talazoparib,Response rate
3804,NCT02233712,Diptheria Toxoid Antibody Levels,1999-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse Events
3805,NCT04863768,association between gene mutational status and disease-free survival,2006-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Descriptives
3806,NCT00048126,Tumor measurements (RECIST criteria),2001-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Time to progression, time to response, duration of response, time to treatment failure, survival.\n"
3807,NCT04948125,Objective response rate(ORR),2021-04-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Duration of response(DOR)
3808,NCT00003769,,1999-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3809,NCT04237441,survival following pancreatic surgery,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
3810,NCT00063986,Peri-operative Mortality at 30 Days,2004-06-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of Conversion to Open Operation After Neoadjuvant Therapy
3811,NCT04069949,Incidence of Treatment-Emergent Adverse Event,2019-12-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of response
3812,NCT02938481,Distribution of metastatic LNs,2013-05-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Prognostic outcomes according to the central radicality
3813,NCT02882659,Safety of DKC as assessed by laboratory examinations,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Efficacy of DKC as assessed by change in quality of life
3814,NCT06024252,Overall survival,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Treatment pattern
3815,NCT01354795,"Compare the degree of cytologic quality in specimen obtained by EUS-FNA with or without suction, pushing the stylet or injecting air.",2010-09,COMPLETED,INTERVENTIONAL,['NA'],,"Compare the diagnostic yield in specimen obtained by EUS-FNA with or without suction, pushing the stylet or injecting air."
3816,NCT02238821,Scoring the expression of COX-2 in colorectal cancer tissue sections by Immunohistochemical analysis,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,
3817,NCT01790230,Assessment of subject's safety by incidence of related Adverse Events,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Assessment of the device's application technique
3818,NCT05042336,MPR,2021-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,ORR
3819,NCT05001347,Objective Response Rate (ORR) in each Tumor Type,2021-11-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Assessment of PK parameter: tmax
3820,NCT05151068,The change of sleep,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
3821,NCT03700541,Change in number of circulating tumor cells prior to surgery to 2 - 4 weeks after surgery,2019-01-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,Pain assessment
3822,NCT00772083,self-reported seeking of medical care for diagnosis of anemia found at time of blood donation,2008-11,COMPLETED,INTERVENTIONAL,['NA'],,
3823,NCT01796782,overall survival (OS),2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of adverse events of QYHJ Formula
3824,NCT03267173,Number of patients with tumor response,2017-06-15,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Number of patients with adverse event
3825,NCT05911217,Disease free survival (DFS),2023-07-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,The immunogenicity in subjects receiving CT041 infusion in this study
3826,NCT00735917,Six Month Survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival
3827,NCT06208371,Five-year survival rate,2024-01-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment-related Adverse Events
3828,NCT06172634,treatment related adeverse event,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall response rate
3829,NCT00810771,Colorectal Cancer (CRC) Screening Rate.,2009-02,COMPLETED,INTERVENTIONAL,['NA'],,If Colorectal Cancer Screening Screening (CRCS) Discussed With Provider.
3830,NCT01421680,Postoperative complication rate,2011-08,COMPLETED,INTERVENTIONAL,['NA'],,Patient compliance of oral nutritional supplements
3831,NCT00260585,,1999-06,RECRUITING,OBSERVATIONAL,['NA'],,
3832,NCT01492127,Variation of plasma proteasome,2011-12,UNKNOWN,INTERVENTIONAL,['NA'],,Variation of plasma proteasome
3833,NCT05631574,"To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC.",2023-01-12,RECRUITING,INTERVENTIONAL,['PHASE1'],,"To evaluate the efficacy of BMF-219 monotherapy in subjects with unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC."
3834,NCT01356628,Time to Disease Progression,2011-05-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Response Rate (RR)
3835,NCT03629691,PFS (progression-free survival),2015-02-01,COMPLETED,OBSERVATIONAL,['NA'],,LRC (duration of locoregional control )
3836,NCT00072787,,2003-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3837,NCT04552236,Predicting early HCC recurrence after treatment by Ultrasound elastography,2021-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3838,NCT04928625,Recommended Phase II Dose (RP2D),2021-08-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Objective response rate (ORR)
3839,NCT02607540,"overall survival, OS",2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"disease control rate,DCR"
3840,NCT05740956,Efficacy of HS-10502: Objective response rate (ORR)（Stage 2）,2023-06-09,RECRUITING,INTERVENTIONAL,['PHASE1'],,[Stage 1 and Stage 2] Efficacy of HS-10502: Time to PSA progression (for prostate cancer only)
3841,NCT01648894,Percentage of pathological complete response after pathological examination of surgical specimen defined by the absence of persistent tumor cell invasion and lymph node (ypT0N0) in group 7 weeks versus 11 weeks in the group,2012-10-25,COMPLETED,INTERVENTIONAL,['PHASE3'],,Functional results (LARS score)
3842,NCT05803382,Recommended phase 2 dose (RP2D),2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Molecular subpopulations particularly sensitized to BETi and capecitabine
3843,NCT03380858,fistula incidence,2017-11-02,UNKNOWN,OBSERVATIONAL,['NA'],,infection
3844,NCT03886571,"Measuring cell-free and exosomal-miRNA biomarkers using small RNA-Seq in matched tissue and plasma from patients with PDAC, PNs, pancreatitis and normal pancreas for early detection.",2018-09-15,RECRUITING,OBSERVATIONAL,['NA'],,
3845,NCT01902823,Satisfaction with Care,2011-11,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The Inventory of Recent Life Experiences for Cancer Patients
3846,NCT05543863,platelet function testing at 5 days,2022-08-20,RECRUITING,OBSERVATIONAL,['NA'],,postoperative complications
3847,NCT00949182,Safety and tolerability as assessed by NCI CTCAE v3.0,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"AFP and VEGF serum levels as assessed at baseline, prior to each HACE treatment, and then every 3 months thereafter"
3848,NCT00075647,Overall survival (OS),2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Expression and phosphorylation status of p70s6k
3849,NCT04374877,[Part D] Objective response rate (ORR),2020-04-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,[Part D] Summary of adverse events (AEs) based on treatment emergent AEs (TEAEs)
3850,NCT00606385,Recurrence rate,2007-12,UNKNOWN,INTERVENTIONAL,['NA'],,Survival
3851,NCT01407107,The Number of Participants Experiencing Dose Limiting Toxicities (DLT),2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With a Pathological Complete Response (pCR)
3852,NCT05451862,confirmed Objective Response Rate (ORR) by localized mRECIST,2023-08-21,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life using EQ-5D-5L questionnaire
3853,NCT05310565,Patient Retention,2024-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Patient-reported outcomes
3854,NCT03610100,"Number of participants that have survived throughout treatment and also into follow-up, as measured by the primary cause of death and date of death CRFs.",2015-12,SUSPENDED,INTERVENTIONAL,"['PHASE2', 'PHASE3']","Discovery of possible biomarkers which may predict any additional benefit of Acelarin over gemcitabine. These will be assessed from plasma, cell pellet and serum samples collected from participants throughout the trial.","Number of patients with treatment-related adverse events as assessed by CTCAE v4.03. Toxicity is assessed by CTCAE v4.03 alongside Quality of Life Questionnaires, QLQ-C30 and QLQ-PAN26."
3855,NCT02624895,"average relative dose intensity of every drug""",2015-12-30,COMPLETED,OBSERVATIONAL,['NA'],,Questionnaire score
3856,NCT00588367,"A reproducible technique to measure CT perfusion parameters may provide a method for non-invasively monitoring tumor response during treatment, or differentiating between autoimmune and chronic pancreatitis.",2006-04,COMPLETED,OBSERVATIONAL,['NA'],,
3857,NCT02854839,Time To progression,2016-11-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Safety of MG4101 as evaluated by Incidence of adverse events (AEs), serious adverse events (SAEs)"
3858,NCT01004003,Time to Progression (TTP) in Phase II,2009-10-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
3859,NCT01287637,Postsurgical morbidity.,2011-02,COMPLETED,INTERVENTIONAL,['NA'],,Socio-economic effect of early reversal of temporary ileostomy
3860,NCT00644254,Overall cancer-specific survival,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,Disease-free survival (DFS)& Correlation of ECLNI with other pathological variables
3861,NCT02628951,objective response rate,2016-05-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,response rate according to molecular subtypes
3862,NCT04316078,Feasibility of PEP (percent of patients using videos/complete questionnaires),2020-03-15,COMPLETED,INTERVENTIONAL,['NA'],,Secondary clinical outcomes 4 (treatment intensity and continuity)
3863,NCT03285867,The change of LSM(kpa) measured by FibroScan(a kind of external harmless ultrasonoscope),2018-06-25,UNKNOWN,OBSERVATIONAL,['NA'],,
3864,NCT03796884,Pharmacodynamics effect on cGMP levels,2019-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],PCNA expression,Guanylin levels
3865,NCT01103128,BRCA1 vs. BRCA2 mutations,2009-03,TERMINATED,OBSERVATIONAL,['NA'],,Interaction of other cancer genes with BRCA1 and BRCA2
3866,NCT06208397,Radiological assessment of CRLM,2023-12-24,RECRUITING,OBSERVATIONAL,['NA'],,
3867,NCT06121700,Overall survival (OS),2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Surgical mortality
3868,NCT04500990,Objective Response Rate,2020-09,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
3869,NCT06048367,Safety and Tolerability Assessment of CNSI-Fe(II),2022-10-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,PK Parameters Assessment: t1/2 (h) Profile Assessment of CNSI-Fe(II)
3870,NCT04103372,Demonstrate a change in rectal preservation rates,2019-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Assess patient willingness to be randomised
3871,NCT05097911,Evaluable Non-Target Disease Response,2021-08-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Evaluation of Best Overall Response
3872,NCT01019382,Objective response rate (complete and partial response) on CT according to RECIST criteria,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pharmacokinetic analysis of blood samples
3873,NCT04687410,Total tissue area,2020-06-15,UNKNOWN,INTERVENTIONAL,['NA'],,Suitability for molecular analyses
3874,NCT05371197,Pathological complete response (pCR) rates,2022-05-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Drug feasibility
3875,NCT04694391,genomic characteristics of relapsed esophageal cancer,2012-09-14,UNKNOWN,OBSERVATIONAL,['NA'],,
3876,NCT00548626,Evaluate if the early change of needle during EUS-FNA for suspected pancreatic cancer can reduce the number of passes needed to obtain a preliminary cytological diagnosis of neoplasia.,2007-10,COMPLETED,INTERVENTIONAL,['NA'],,Influence of different factors in obtaining a positive cytological result
3877,NCT01276795,Protein balance,2010-01,COMPLETED,INTERVENTIONAL,['NA'],,
3878,NCT06126406,Obtained the recommended dose and infusion regimen of CAR-T cells for the treatment of patients with CEA-positive advanced malignancies[Safety and Tolerability],2023-11-06,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival(OS)of CEA CAR-T treatment in patients with CEA-positive advanced malignancies[Effectiveness],Pharmacodynamics of CEA CAR-T cells[Cell dynamics]
3879,NCT02742935,The severity of adverse events (AEs) determined as per NCI CTCAE V4.03.,2016-04-27,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3880,NCT03545711,ORR,2018-05-26,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PFS
3881,NCT03137706,Young's modulus (stiffness) on fresh tissue,2016-11-14,TERMINATED,OBSERVATIONAL,['NA'],,
3882,NCT03599947,Sensitivity and specificity of the model in the diagnosis of colorectal cancer,2018-07-16,UNKNOWN,OBSERVATIONAL,['NA'],,
3883,NCT04687969,Diagnostic value of multimodal imaging in primary prostate cancer patients,2022-10-23,RECRUITING,OBSERVATIONAL,['NA'],,Scan-rescan repeatability
3884,NCT03473574,Objective response rate (ORR),2018-05-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life
3885,NCT05010863,Getting serum,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
3886,NCT01243619,Feasibility: Determined by the Number of Participants Who Had All Three Sets of Completed Serial PET Scans That Were Imported for Analysis,2010-08,COMPLETED,INTERVENTIONAL,['NA'],"Analyze Correlation Between FDG and FLT PET Scans, and the Correlation Between Both Types of PET Scan and the Response to Treatment.",
3887,NCT00582335,Evidence of mutations in selected candidate genes,1998-02-10,COMPLETED,OBSERVATIONAL,['NA'],,
3888,NCT06120127,Progression free survival,2023-09-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Grade 3-4 adverse effect rate
3889,NCT00034034,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3890,NCT03971747,Incidence of treatment related adverse events as assessed by CTCAE v4.0[Safety of C-TCR055],2019-08-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],DCR,OS
3891,NCT01555489,Safety of Ascorbic Acid in Combination With Gemcitabine and Erlotinib for Stage IV Pancreatic Cancer,2011-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Evaluate Quality of Life Using Functional Assessment of Cancer Therapy-General (FACT-G) Quality Assessment Instrument
3892,NCT05989724,MTD (Maximum tolerable dose) / RP2D (Recommended dose for phase II),2023-09-19,RECRUITING,INTERVENTIONAL,['PHASE1'],SON-DP concentration in tumor biopsy tissue,CL
3893,NCT06221878,Short-term outcome,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,Long-term Oncologic outcome
3894,NCT04659148,Oncological outcome,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3895,NCT05245968,Progression-free survival (PFS),2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Metabolite ratio
3896,NCT01096745,Time to progression,2010-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Response rate Overall survival Safety profile
3897,NCT05888675,Overall survival,2016-07-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Immune function
3898,NCT02913066,Complete Remission Rate (CR),2016-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression-Free-Survival (PFS)
3899,NCT02117479,Overall Survival (OS),2014-03,TERMINATED,INTERVENTIONAL,['PHASE3'],,Participants With Treatment-Emergent Adverse Events (TEAEs)
3900,NCT02604615,"overall survival, OS",2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"disease control rate,DCR"
3901,NCT03308773,Time to development of type 2 diabetes,2009-01-05,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
3902,NCT00602745,Overall Survival,2008-02,TERMINATED,INTERVENTIONAL,['PHASE3'],,Clinical Benefit assessed by Time to Symptoms Worsening (TTSW)
3903,NCT04835142,ORR,2021-02-24,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival (OS)
3904,NCT03796429,overall survival (OS) of GS regimen plus PD-1 antibody (Toripalimab),2018-12-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of adverse Events of GS regimen plus PD-1 antibody (Toripalimab)
3905,NCT04087421,"Bowel function, change in symptom 1 score assessed using the Measure Yourself Medical Outcome Profile (MYMOP2) Score.",2019-09-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,Health economics assessed using the ICEpop CAPability measure for Adults (ICECAP-A).
3906,NCT01624285,"Recurrence-free survival, evaluated using the new international criteria proposed by the Modified Response Evaluation Criteria in Solid Tumors (mRECIST) Committee",2012-07-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to first HCV viral recurrence
3907,NCT05253313,One-year survival after randomization,2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
3908,NCT00047710,"Safety of combination Radiation, Bevacizumab, and Capecitabine.",2002-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate quality of life in patients receiving this therapy.
3909,NCT05997459,PFS,2023-08-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
3910,NCT03387904,Disease Control Rate (DCR),2019-01-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],,NGS(Next Generation Sequencing) detecting
3911,NCT04985357,Best overall response (BOR),2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3912,NCT02233374,Predictive value of PET/CT and MRI 2 weeks into chemo-irradiation for developing a pathologic complete response at surgery.,2014-09,COMPLETED,INTERVENTIONAL,['NA'],,Impact of pCR rates on long term disease control
3913,NCT03274011,Progression Free Survival,2017-07-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Response Rate
3914,NCT05394740,ORR in Phase II part,2022-06-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Biomarkers in the PhIb and PhII cohort,Incidence of adverse events
3915,NCT00077142,Maximum Tolerated Dose (MTD) of TAC-101,2001-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3916,NCT01927341,Overall Response Rate (ORR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Based on Local Radiology Assessment: Phase 2,2013-11-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
3917,NCT02722395,Planning target volume (PTV),2016-08,COMPLETED,OBSERVATIONAL,['NA'],,
3918,NCT05998447,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the Investigator.,2023-09-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
3919,NCT02178436,Overall Survival (Phase II),2014-10-31,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Change in Gene Expression (Including Forkhead Box Protein O, I-kappaB, Cyclin-dependent Kinase Inhibitor 1B, Par4 and Phosphorylated Signal Transducer and Activator of Transcription 3) (Phase II)",Progression Free Survival (Phase II)
3920,NCT03606928,Objective response rate,2018-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Safety: adverse events as assessed by CTCAE v4.0
3921,NCT00891878,Comparison of Progression-free Survival,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
3922,NCT02780648,Acute toxicity rates of grade 3 gastrointestinal and hematologic toxicities (as raw percentage),2016-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Patient self-report of quality of life
3923,NCT00789958,Stratum-specific (R0 and R1) 2-year Overall Survival,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,2-year Overall Local Relapse Rate
3924,NCT04362839,Recommended dose level of the combination,2020-05-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Immune response,Objective response rate (ORR)
3925,NCT05862792,Postoperative Dysphagia with Dysphagia Survey,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative Pain Medication Usage
3926,NCT06123117,cumulative opioid consumption during the stay at the recovery,2024-01-16,RECRUITING,INTERVENTIONAL,['NA'],pain-control failure & possible causes,cumulative opioid consumption (emergency and inpatient surgery)
3927,NCT00084643,"MTD of the combination of GTI-2040, oxaliplatin and capecitabine based on the incidence of dose-limiting toxicity (DLT) as assessed by CTCAE version 3.0",2004-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change in biochemical and molecular correlates
3928,NCT04443036,PFS,2020-06-11,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse events
3929,NCT04842916,Peripheral blood mononuclear cells (PBMCs) and host immunity parameters in responders and non-responders,2020-09-22,UNKNOWN,OBSERVATIONAL,['NA'],,Psychological status of patients in relation to therapy response
3930,NCT01591733,Rate of R0 Resection,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Utilization of Health Services (Emergency Room, Hospital and Intensive Care Unit)"
3931,NCT00617708,Progression-Free Survival,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity
3932,NCT05697198,The percent adoption of the OmniSeq next generation sequencing (NGS) testing platform in an advanced cancer patient population compared to baseline over a 2 year period,2021-04-19,RECRUITING,OBSERVATIONAL,['NA'],,
3933,NCT03416322,Adenoma detection rate,2018-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Boston Intestinal Preparation Scale
3934,NCT03223779,The Duration of Local Control,2017-10-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serial ctDNA
3935,NCT00516347,"Gene-environment interactions, such as smoking, alcohol, and Helicobacter pylori status, on familial susceptibility to heartburn and Barrett's esophagus",2002-06,UNKNOWN,OBSERVATIONAL,['NA'],,Comparison of the mortality from esophageal adenocarcinoma in family members with heartburn and Barrett's esophagus with deaths from other causes
3936,NCT06335576,C-index,2024-03-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Sensitivity and specificity of model
3937,NCT01783951,Progression free survival（PFS）,2013-02-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
3938,NCT05472948,Progression-free survival (PFS),2023-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety variables (Incidence of Adverse Events [Safety and Tolerability])
3939,NCT01525771,Maximum tolerated dose,2011-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,efficacy
3940,NCT03114631,Number of Participants Who Survived at 1 Year,2017-01-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants Who Survived at 3 Years or more
3941,NCT04601961,HIF-1 gene expression,2020-03-04,RECRUITING,INTERVENTIONAL,['NA'],,Number of Circulating tumour cells
3942,NCT00080951,tumor response rate,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,quality of life
3943,NCT02549456,Major postoperative complications,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,Functional outcome
3944,NCT03950609,Objective response rate,2019-07-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
3945,NCT00909103,Value of endoscopic ultrasound elastography for the differential diagnoses of pancreatic masses.,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,
3946,NCT01005199,Progression-free survival,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlation between vitamin B12 and overall survival
3947,NCT05176223,Time to progression,2022-01-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3948,NCT00052689,Proportion of patients alive at 6 months (Arm II),2002-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to treatment failure
3949,NCT00814242,tumor recurrence rate in one or two years; Disease-free survival;Overall survival.,2008-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Overall survival rate in one, two，three or five years; Disease-free survival in one, two，three or five years; hepatic function of patients after surgery, the incidence rate of complications and the decline level of serum AFP concentration."
3950,NCT05320029,Number of Participants With Anastomosis Success,2018-08-30,COMPLETED,INTERVENTIONAL,['NA'],,
3951,NCT02586285,Time to tumor recurrence,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Overall survival
3952,NCT00715325,To determine the success rate in reaching within working distance of the Cecum with no complications.,2008-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To assess the ability to perform routine therapeutic interventions such as biopsies, polypectomies, APC etc. as compared to therapeutic interventions with standard colonoscopes found in the literature."
3953,NCT00551421,"Objective Tumor Response Rate Defined as the Proportion of Patients With a Best Overall Response of CR or PR, Per RECIST Criteria (Phase II)",2007-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
3954,NCT00308516,"Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment",2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death"
3955,NCT03142282,Progression free survival,2019-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
3956,NCT00089960,Objective response rate as defined using modified RECIST criteria.,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Pharmacokinetic Endpoints: 1. The AMG 706 PK parameters (Cmax, t1/2, AUC0-24, C24); 2. To explore the PK/PD relationships"
3957,NCT00118261,Number of patients that develop study drug related toxicity,2005-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of patients that can increase the erlotinib dose to 200mg
3958,NCT00030511,,2001-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3959,NCT01481805,Biomarkers predictive,2010-01-14,COMPLETED,OBSERVATIONAL,['NA'],,The RTK activation status.
3960,NCT02415023,safety and tolerance,2014-11-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetic profiles of Fruquintinib combined with Paclitaxel
3961,NCT04971525,Cumulative Occurrence of Malignancies in CD Participants With PAF,2023-04-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Number of Participants With Comorbidities
3962,NCT01038154,all cause mortality,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,free time of disease recurrence
3963,NCT03170869,Local Recurrence Rate (LRR),2017-04-12,TERMINATED,INTERVENTIONAL,['NA'],,Survival Time
3964,NCT05755594,Rate of long-term Survival,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of postoperative complications
3965,NCT05107219,Cyclic guanosine monophosphate (cGMP) levels,2022-10-25,RECRUITING,INTERVENTIONAL,['PHASE1'],Cellular response,Vasodilator-stimulated phosphoprotein (VASP) phosphorylation in normal appearing duodenal mucosa
3966,NCT03073785,Local control,2016-09-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Pharmacokinetics parameters of zoledronic acid,Tumor and organ motion
3967,NCT04749108,3-year Disease free survival (DFS) for Phase III,2021-11-26,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Evaluation of sexual function in women by Female Sexual Function Index (FSFI) questionnaire score
3968,NCT06285019,objective response rate (ORR),2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse event (AE)
3969,NCT06283303,Treatment Emergent Adverse Event（TEAE）,2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free survival (PFS)
3970,NCT01836913,"Preventable locoregional recurrence by the use of PET/CT-based treatment planning, instead of CT-based",2009-05,COMPLETED,OBSERVATIONAL,['NA'],,Cost-effectivity analyses
3971,NCT01774851,Progression Free Survival (PFS),2013-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3972,NCT05575986,Days required for platelet recovery to ≥75×10^9/ L,2022-10,RECRUITING,INTERVENTIONAL,['PHASE4'],,Safety of treatment
3973,NCT02428907,patient perception of colonoscopy,2012-10,COMPLETED,OBSERVATIONAL,['NA'],,Staff perception of teamwork
3974,NCT03491878,R0 rescetion rate,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,
3975,NCT04093141,2-year survival proportion from 1) diagnosis and 2) IRE,2019-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Nutritional status assessment (PG-SGA-SF)
3976,NCT01643499,DLT rate in course 1 for each of the two most common genotype groups (*1*1 and *1*28),2012-03-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Cumulative dose intensity of irinotecan hydrochloride
3977,NCT00988936,To explore the usefulness of [F-18]RGD-K5 PET/CT to predict efficacy or early response to Avastin® (the anti-angiogenesis drug) plus chemotherapy treatment before the full course of treatment is completed.,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To gain experience with [F-18]RGD-K5 PET/CT in order to improve the study design and conduct of future studies.
3978,NCT00578396,Expression and cellular localization of beta-catenin in intestinal mucosa: localization of β-catenin. Expression of Wnt pathway target genes in intestinal mucosa: Wnt target gene expression,2007-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Monitor resveratrol content of grapes throughout the course of the study. Grapes will be obtained from the same source as participants monthly throughout the study and the content of resveratrol will be measured.
3979,NCT04341012,Utility of breath profiles for disease diagnosis or prognosis,2019-09-10,COMPLETED,OBSERVATIONAL,['NA'],,
3980,NCT04317352,Mortality,2019-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
3981,NCT02417753,Changes in Immune Parameters in the Malignant Ascites of Patients With Advanced Cancer Following Therapy With AZD9150,2015-04-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (PFS) in Patients With Malignant Ascites Treated With AZD9150
3982,NCT02880306,the risk of developing hepatocellular carcinoma,2014-07,COMPLETED,OBSERVATIONAL,['NA'],,
3983,NCT04329494,Incidence of adverse events,2020-08-21,RECRUITING,INTERVENTIONAL,['PHASE1'],,Cytoreductive surgery rate (Arm 3)
3984,NCT06009705,Assessment of the incidence of treatment-related adverse events Incidence of Treatment-Emergent Adverse Events.,2022-10-01,RECRUITING,OBSERVATIONAL,['NA'],,Assessment of progression-free survival (PFS) in elderly esophageal cancer patients treated with toripalimab in combination with S-1 and radiotherapy.
3985,NCT05443841,number of patients who had positive pleural lavage cytology,2022-07-18,RECRUITING,OBSERVATIONAL,['NA'],,Time period from date of surgery to the date of death
3986,NCT02461979,number of HCC patients with abnormal (APAL) VDR polymorphism,2015-02,UNKNOWN,INTERVENTIONAL,['NA'],,
3987,NCT02148549,Number of participants with toxicity of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,The optimal treatment schedule of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
3988,NCT05593458,Major Pathological Response rate,2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,pathological Complete Response rate
3989,NCT04443543,clinical complete response rate,2020-06-22,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival
3990,NCT05916261,Disease control rate (DCR),2023-04-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,overall survival (OS)
3991,NCT04029909,Dose limiting toxicity(DLT),2019-07-11,UNKNOWN,INTERVENTIONAL,['PHASE1'],T1/2,Maximal tolerable dose(MTD)
3992,NCT01133990,Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Electrocardiograms (ECGs) Parameter,2010-03-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Overall Survival (OS)
3993,NCT05144698,Safety of RAPA-201 Cell Therapy,2021-08-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",T Cell Immune Reconstitution,Quality of Life (QOL)
3994,NCT03088163,Response rate,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
3995,NCT04816045,Tumor stage,2021-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,VAR2
3996,NCT05621824,Number of Participants with no clear pancreas lesions,2022-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Number of Participants with other pancreas diseases
3997,NCT04744649,Major pathologic response (MPR),2021-03-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event incidence rate
3998,NCT00713128,frequency of delayed emesis (vomiting/retching),2008-04,COMPLETED,OBSERVATIONAL,['NA'],,"Freq. of mild-severe nausea D 2-6 Freq. use of antiemetics D 2-6, Pts.with complete response(no emesis/use of rescue antiemtics)D 1, Pts. with total control (no:emesis,nausea, use of rescue antiemetics)D 2-6, Overall satisfaction"
3999,NCT05746195,Feasibility of Intervention Measure (FIM),2023-11-03,RECRUITING,INTERVENTIONAL,['NA'],,Change in mean total daily fiber intake (g/d) reported on the Food Frequency Questionnaire (FFQ)
4000,NCT05174117,3 month objective response rate,2022-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,3 month Quality of Life score
4001,NCT04007744,Response rate of sonidegib in combination with pembrolizumab (Part B),2020-02-13,RECRUITING,INTERVENTIONAL,['PHASE1'],Level of serum soluble PDL-1,Progression-free survival (PFS)
4002,NCT02834013,Overall response rate (ORR),2017-01-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival (PFS)
4003,NCT04843215,Disease Free Survival(DFS),2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],Postoperative morbidity,Overall Survival(OS)
4004,NCT00111761,Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 1),2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Initial Objective Tumor Response (Part 1)
4005,NCT00556803,Overall survivals,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Recurrence rates
4006,NCT00834236,Number of Participants With Accurate Diagnosis for Gastric Cancer,2008-03,COMPLETED,INTERVENTIONAL,['NA'],,
4007,NCT06078982,Objective response rate (ORR),2023-06-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,Drug-related safety indicators
4008,NCT05823987,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,2023-05-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
4009,NCT03988998,the 2-years recurrence rate,2022-01-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,the 2-years overall survival.
4010,NCT01642446,Overall survival,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life(Qol)
4011,NCT04920019,Amount of postoperative opioid consumption,2020-10-22,COMPLETED,INTERVENTIONAL,['NA'],,Mortality
4012,NCT03633539,Postoperative complications,2020-08,WITHDRAWN,INTERVENTIONAL,['NA'],,5-year overall survival rate
4013,NCT02704988,Increased lymph node sample,2015-03,COMPLETED,INTERVENTIONAL,['NA'],,Indication for adjuvant treatment
4014,NCT00001191,,1983-02-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4015,NCT03082378,survival,2017-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,complication
4016,NCT04908813,Objective Response Rate (ORR) per RECIST 1.1 assessed by IRRC,2021-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AE)
4017,NCT06079242,Liver-specific overall response rate (ORR) according to RECIST 1.1,2023-10-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Duration of liver-specific DOR assessed by the investigator
4018,NCT01912222,Number of Participants Reporting Clinically Significant Change From Baseline in Vital Signs,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4019,NCT05628610,objective response rate,2022-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,progression free survival
4020,NCT02529579,6-month SR,2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Serum tumor biomarker,QOL
4021,NCT03469375,Progression free survival,2014-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Histopathologic staging
4022,NCT05854368,"Characterization and validation of a signature combining plasmatic proteins related to inflammation and carcinogenesis process, associated with the presence of gastric mucosal dysplasia lesions compared with an H. pylori negative control group.",2023-07-03,RECRUITING,INTERVENTIONAL,['NA'],,"Characterization of the plasma levels of the proteins biomarker composing these signatures specific for the different stages of gastric cancer cascade, between the different studied pathology groups"
4023,NCT02399228,"Patients Achieving Less Than or Equal to ""2"" RTOG Score At Visit 9",2015-10-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety Will be Assessed Based on the Frequency and Severity of Adverse Events.,NRPS (Numerical Rating Pain Scale)
4024,NCT02426450,Safety and Tolerability,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
4025,NCT05350007,Tanatophobia,2022-05-25,RECRUITING,OBSERVATIONAL,['NA'],,lack of social support
4026,NCT04247165,"Incidence of treatment-related AEs, SAEs, AEs leading to discontinuation, death, and laboratory abnormalities",2020-06-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Rate of downstaging to surgical resection
4027,NCT01471132,Overall Survival,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
4028,NCT00539877,"The objectives of this study are to assess the feasibility, to determine the maximum tolerated dose, and to assess the toxicities of intraperitoneally administered CPT-11 in gastric cancer patients with peritoneal seeding.",2004-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4029,NCT02784639,Area under ROC curve,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,
4030,NCT00047346,"Pharmacokinetic (PK) and pharmacodynamic profile, as measured by Cmax, Tmax, AUC0-24, AUC0-infinity, Cl/F, T1/2, accumulation ratio, and Cssmin",2002-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Objective response rates (partial, complete, stable disease), as measured by CT scans using RECIST criteria"
4031,NCT04495621,Best overall response rate (ORR) according to RECIST v.1.1,2020-07-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of treatment emergent adverse events (TEAEs)
4032,NCT05677113,The primary outcome will be the 2-year Progression-Free Survival (PFS) rate,2023-08-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Five-year overall survival
4033,NCT02112214,The incidence of gastric cancer between the intervention and placebo groups,2014-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Modification of atrophy score
4034,NCT03013712,Toxicity profile of the EpCAM targeted CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0,2017-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Anti-tumor efficacy of CAR-T therapy by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1
4035,NCT02672657,Changes in burden of patients' caregivers as assessed by the Zarit burden inventory questionnaire,2016-02,UNKNOWN,OBSERVATIONAL,['NA'],,"Prognostic value of baseline HRQoL measurements on patient's functional decline, defined as any decrease in the ADL scale"
4036,NCT02450032,Change in Subject's World Health Organization Performance Status,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse Events
4037,NCT04076761,Median progression-free survival (PFS),2019-12-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of life: European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30
4038,NCT03728348,"Specificity of the Multi-target Stool DNA Test in Average Risk Population, Ages 45-49",2018-11-06,COMPLETED,OBSERVATIONAL,['NA'],,
4039,NCT03521765,WHOQOL-BREF(the World Health Organization Quality of Life-BREF),2017-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Barthel Index (BI)
4040,NCT00735241,Toxicity and safety,2008-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
4041,NCT00452751,overall survival,2006-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,cost-effectiveness
4042,NCT02449967,Number of participants with Adverse events,2015-05,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
4043,NCT01542294,chemotherapy complete rate,2011-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival(OS)
4044,NCT00902291,Survival rate at 6 months,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control (Stable Disease or better per RECIST criteria)
4045,NCT05888623,Adenoma Detection Rate,2022-10-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Bowel preparation quality,Adenocarcinoma detection rate
4046,NCT03748134,OS in PD-L1 positive population,2018-12-24,COMPLETED,INTERVENTIONAL,['PHASE3'],,PFS - PD-L1 positive
4047,NCT04009876,cCR (clinical complete response) rate in LARC ( locally advanced rectal cancer ) patients treated with chemo - chemoradiation.,2019-05-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall toxicity
4048,NCT03258450,The acceptability of the intervention will be assessed through the Client Satisfaction Questionnaire.,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Psychological distress will be accessed through The Hospital Anxiety and Depression Scale (HADS)
4049,NCT04338763,Determination of the maximum tolerated dose (MTD) and the recommended dose for phase II of RP72 monotherapy and RP72 in combination with Gemcitabine,2021-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,
4050,NCT06203587,Establishment and optimization of imaging method for [68Ga]Ga-NOTA-WWH347 or [18F]F-H3RESCA-WWH347 PET/CT.,2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],,
4051,NCT03918499,Progression-free Survival,2019-04-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Response
4052,NCT03136406,Objective response rate by irRC,2017-08-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Incidence of treatment-emergent AEs, SAEs, graded using the NCI CTCAE Version 4.03."
4053,NCT01658917,"To collect biologic samples from patients undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors.",2012-07-24,COMPLETED,OBSERVATIONAL,['NA'],,"To collect detailed history, demographic, treatment data, and perioperative findings."
4054,NCT04589247,Proportion of participants with change in their physician-assessed burden score,2020-11-16,RECRUITING,OBSERVATIONAL,['NA'],Management changes as assessed by a Clinician Feedback Form,
4055,NCT02182778,Overall survival rate,2014-07-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants with Adverse Events as a Measure of Safety
4056,NCT00872014,Progression free survival (PFS) rate at 4 months,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Baseline values of and changes from baseline in pharmacodynamic, immunologic, biochemical, transcriptional, pharmacogenetic and angiogenic markers"
4057,NCT03098758,specific markers in peritoneal cells,2017-05-08,UNKNOWN,OBSERVATIONAL,['NA'],,
4058,NCT01325961,Medico-economic study : medical cost differential between 3 ways of Radiotherapy by IMRT (helical tomotherapy and dynamic arc therapy : RapidArc and VMAT).,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,clinical response and safety of the treatment by radiotherapy
4059,NCT02651987,Median Progression Free Survival (PFS),2015-12-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Mean Change From Baseline in PanNet Specific Tumour Biomarkers: Glucagon
4060,NCT05796700,Progession-free survival,2008-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
4061,NCT02466724,Patients with Excelent Colonoscopy preparation,2015-03,COMPLETED,INTERVENTIONAL,['NA'],,Use of web-based educational platform
4062,NCT04189809,Rate of therapeutic proposals correctly predicted by the BCLC international classification,2019-11-30,UNKNOWN,OBSERVATIONAL,['NA'],,Rates and causes of discrepancies
4063,NCT00964080,To determine the dose of MBP-426 for use in the Phase II portion of this study of MBP-426 administered every 21 days in combination with leucovorin (folinic acid or FA) and fluorouracil (5-FU),2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To characterize the safety profile of the combination therapy
4064,NCT06047379,Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 in combination with select SOC regimens in patients with select solid tumors with uncontrolled metastases to the brain.,2023-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4065,NCT03151213,visual analogue pain scale (VAS Pain) post operatively,2017-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
4066,NCT04109573,Manometric indices,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Patient reported outcomes
4067,NCT02078700,percentage of cancer patients that accept and attend the early palliative care programme,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,percentage of cancer patients that receive the proposal of early palliative by the oncologists-pneumologists
4068,NCT01552226,Post-operative pain control day 5,2010-01,UNKNOWN,INTERVENTIONAL,['NA'],,Patient use of supplemental narcotic analgesia day 5
4069,NCT04165018,Diagnostic yield between FNB samples placed in formalin for pathology evaluation from two different types of needle,2021-04-09,COMPLETED,OBSERVATIONAL,['NA'],,"Rate of adverse events of utilizing the FNB technique, including pancreatitis, bleeding, or perforation"
4070,NCT00984048,Changes in biomarkers in patients that have acquired clinical resistance.,2009-08,COMPLETED,OBSERVATIONAL,['NA'],,Number of participants with adverse events relating to the liver biopsy procedure
4071,NCT00436774,Quality of life (QOL) as measured by pediatric cancer quality-of-life inventory or Short Form 36 questionnaires,2006-06,UNKNOWN,OBSERVATIONAL,['NA'],,
4072,NCT06276153,overall survival,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,progression-free survival
4073,NCT04564313,Objective Response Rate (ORR),2020-09-21,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Graft Rejection (GR)
4074,NCT03139487,Rate of clinical relevant bleeding,2017-08-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to recurrent or aggravated venous thromboembolism
4075,NCT00052910,Overall Survival,2002-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease Free Survival
4076,NCT02575859,Positive predictive value of preoperative/intraoperative assessment of primary tumor-related risk factors for the development of metachronous peritoneal metastases in patients undergoing curative surgery for colorectal cancer.,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-free survival,Peritoneal progression-free survival
4077,NCT04038736,Evaluation of the performance of the C-scan System in detecting polyps≥10 mm compared to FIT results,2019-12-26,COMPLETED,INTERVENTIONAL,['NA'],,
4078,NCT01579812,Recurrence-Free Survival,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
4079,NCT02728427,Catherization time,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],,Catheter obstruction
4080,NCT04958044,Safety,2021-05-25,COMPLETED,INTERVENTIONAL,['PHASE1'],,90 days survival
4081,NCT03228667,Objective Response Rate,2018-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
4082,NCT06076811,The prognostic value of ctDNA status,2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Molecular characterization
4083,NCT02902575,Morbidity,2016-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
4084,NCT04721301,Number of participants and severity of treatment-related adverse Events as assessed by CTCAE v4.0,2017-01-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tissue Response
4085,NCT01794676,Modified genetic factors that exist and may influence the phenotypic presentation of disease in unrelated MEN 1 families.,2013-03,COMPLETED,OBSERVATIONAL,['NA'],,
4086,NCT02215044,Occurence of dose limiting toxicity according to CTCAE,2007-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,Tumor marker (CA19-9) response to treatment with BI 2536 and gemcitabine
4087,NCT05428553,Adverse events,2022-06-01,UNKNOWN,INTERVENTIONAL,['NA'],Number of clips,Recurrence after 6 months
4088,NCT01835223,"PFS, Assessed Using Standard RECIST Criteria",2013-07-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Drug Exposure, as Assessed by Steady State PK",Overall Survival Rate
4089,NCT03907527,Maximal tolerated dose of PRGN-3005,2019-04-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of PRGN-3005 T Cells
4090,NCT01943864,Number of Participants With Indicated Non-progressive Disease as Assessed by Independent Radiologist Per Response Evaluation Criteria In Solid Tumor Version 1.1 (RECIST 1.1) at Week 12,2013-09-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Independent Radiologist Assessed Duration of Response
4091,NCT01411826,Feasibility,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,Colon cancer screening attitudes
4092,NCT01658436,Stage 1 - Progression Free Survival (PFS) Rate Analysis at 16 Weeks as Per Local Radiology Review,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Stage 1 - Disease Control Rate
4093,NCT05014360,Percentage Change from Baseline in Colorectal Polyp Burden for Polyps >=2 mm at Week 24,2021-11-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Levels of JAK/STAT Pathway Signaling Effector Proteins including pSTAT-3 Relative to Baseline Levels in Colorectal Polyps
4094,NCT05841706,Rate of Protocol adherence,2023-08-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Number of blood products received
4095,NCT02430701,Number of participants with Adverse events,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival (OS)
4096,NCT06041945,Non-inferiority in Adenoma Detection Rate,2023-09-21,RECRUITING,INTERVENTIONAL,['NA'],,Change in the cost of polypectomy and histology in screening programs
4097,NCT03137628,metabolomics,2017-03-20,UNKNOWN,OBSERVATIONAL,['NA'],,
4098,NCT02856568,"MTD of ricolinostat or a dose up to 240 mg/day whichever is lower, of ACY-1215",2017-05-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Laboratory correlates measured from tissue by immunofluorescence,Time to treatment failure
4099,NCT00586989,1. The number of patients and the number of lesions with HGD or early ACA detected with WLE and ETMI 2. The number of patients with HGD and early ACA detected with targeted biopsies only with ETMI and WLE,2007-12,COMPLETED,OBSERVATIONAL,['NA'],,1. The positive predictive value (PPV) of HRE and AFI 2. The reduction of false-positive findings after NBI (both the initial in vivo NBI assessment as well as later assessment based on still images)
4100,NCT05240950,Efficacy (recurrence-free survival),2022-08-25,RECRUITING,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (PK) indicator (AUC)
4101,NCT05812430,Objective Response Rate(ORR),2023-04-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate(DCR)
4102,NCT01193452,response rate,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
4103,NCT03601351,Disease free survival.,2018-05-04,COMPLETED,OBSERVATIONAL,['NA'],,Perioperative complications.
4104,NCT03798769,Rates of completion,2019-01-31,COMPLETED,INTERVENTIONAL,['NA'],Progression free survival,Cumulative dose of FOLFIRINOX received
4105,NCT01026753,Fecal Occult Blood Test (FOBT) completion rate,2010-08,COMPLETED,INTERVENTIONAL,['NA'],,"The most common patient questions and comments about colorectal cancer, screening, and the fecal occult blood test during the intervention(s). A patient and primary care provider survey."
4106,NCT02047474,Progression free survival rate,2014-03-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective response rate
4107,NCT02599103,The changs of metabolomics profile between before and after oil consumption,2013-09,COMPLETED,INTERVENTIONAL,['NA'],,
4108,NCT02503384,Annual caseload for pediatric liver transplantation,2015-07,UNKNOWN,OBSERVATIONAL,['NA'],,
4109,NCT02785523,"Assessing the quality of life(QOL) in 5 grades and recording: appetite, mental state, sleep, fatigue, pain, attitude towards treatment, daily life ability, treatment of severity of side effects.",2016-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Vanillylmandelic acid (VMA) in urine.
4110,NCT06023147,Objective response rate (ORR),2023-09-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Disease control rate (DCR)
4111,NCT02669914,Overall Response Rate of Intracranial Disease,2016-09-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
4112,NCT05585554,Overall Survival (OS),2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Treatment-related toxicity
4113,NCT00165568,To compare the percent change in tumor radioactivity uptake and retention after radiolabeled fluorouracil administration in subjects who receive bevacizumab versus those who do not receive bevacizumab.,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,to evaluate the relationship between initial change in tumor radioactivity uptake and retention.
4114,NCT03311776,Predictive biomarkers,2008-07-03,RECRUITING,OBSERVATIONAL,['NA'],,
4115,NCT01955122,Adenoma and Polyp Miss Rate,2013-07,COMPLETED,INTERVENTIONAL,['NA'],,Patient Satisfaction
4116,NCT05420480,Overall survival(OS),2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Disease free survival (DFS)
4117,NCT01722903,Quantity of CTCs isolated during liver and/or lung metastasectomy,2012-08,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
4118,NCT04409990,SWE accuracy,2020-03-02,COMPLETED,INTERVENTIONAL,['NA'],,SWE and ADC measurement
4119,NCT05048017,Progression Free Survival (PFS),2021-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Drug Reaction (ADR),Mortality at 12 months
4120,NCT01766986,Overall Survival,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,
4121,NCT03850912,'Emergency Department - Treat and Release' (EDTR) Rate at 30-days,2019-07-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Sustainability of ePRO symptom management within a health system
4122,NCT04780477,Change in Ki-67+ Level,2021-06-29,RECRUITING,INTERVENTIONAL,['NA'],,Change in CD68+ Lamina Propia Macrophages Count
4123,NCT01167049,Tumor response will be evaluated using RECIST criteria. Survival data will be analyzed by Kaplan Meier method. 95% CI will be provided,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4124,NCT02487992,Overall Survival(OS),2015-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,Disease-free survival
4125,NCT01248663,Delayed gastric emptying,2007-04,COMPLETED,INTERVENTIONAL,['NA'],,Measurement of plasma intestinal peptides
4126,NCT01248403,overall survival,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,disease control rate
4127,NCT05856864,Adverse Events（AEs）,2023-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,
4128,NCT03705013,The number of subjects with discordant results that can be attributed to intercurrent disease,2018-10-30,TERMINATED,OBSERVATIONAL,['NA'],,
4129,NCT01248273,To determine the maximum tolerated dose over three dose levels.,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,To record the progression free interval
4130,NCT05233098,Effective dose (Gy) for the whole body,2023-02-04,COMPLETED,OBSERVATIONAL,['NA'],,
4131,NCT00499850,"Safety and tolerability of ZD6474 in combination with 5-Fluorouracil, Leucovorin and Oxaliplatin",2005-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4132,NCT00040833,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4133,NCT01401309,Detecting,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
4134,NCT00375999,Overall Survival,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4135,NCT04195828,major pathological response,2020-06-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
4136,NCT01251640,Tumor Response (Adjudicated Blinded Read Assessment): Phase II,2011-01-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS): Phase II
4137,NCT05740111,Number of resectable cancers detected in patients diagnosed through the surveillance programme compared to the unscreened individuals as reported to the Cancer Registry of Norway.,2022-09-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,The psychological well-being of participants undergoing surveillance as assessed by the Psychological Well-being Questionnaire
4138,NCT05770739,postoperative length of stay,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,30-day readmission rate
4139,NCT00427089,"Efficacy was measured as the degree of cleansing using a 5 grades scale for each of the predefined colon areas resulting into a final grading of the overall quality of gut preparation (A or B: ""success"" versus C or D: ""failure"").",2004-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Laboratory tests (such as blood chemistry and hematology) were conducted to support the safety data as well as measurement of body weight, blood pressure and pulse rate, but also tolerance."
4140,NCT00102011,Level of participation in screening with FOBT-directed colonoscopy vs a single colonoscopy,2000-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,
4141,NCT03902379,Examine feasibility of an online CCI as defined by participant's evaluation of the online intervention,2016-07-27,WITHDRAWN,INTERVENTIONAL,['NA'],,Examine acceptability of an online CCI
4142,NCT06123156,the patient's response,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse and suspected adverse events
4143,NCT01693848,Effect of resection of metastasis on urinary excretion of modified nucleosides,2012-09,COMPLETED,OBSERVATIONAL,['NA'],,Identification of modified nucleosides as biomarkers for colorectal cancer
4144,NCT05392413,Imaging examination,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,
4145,NCT06018246,Patient-generated subjective nutrition assessment,2021-07-20,COMPLETED,INTERVENTIONAL,['NA'],Adverse reaction,Walking time
4146,NCT00716976,Incidence of Hearing Loss,2008-06-23,COMPLETED,INTERVENTIONAL,['PHASE3'],,Hearing Loss Among Patients Carrying/Not-carrying Two Key Gene Mutations (TPMT and COMT)
4147,NCT03110484,Overall response rate,2021-07-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,
4148,NCT05821452,MPR rate,2023-05-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,PFS
4149,NCT02362048,Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer.,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4150,NCT02873741,Presence of Anal hr-HPV,2016-07,COMPLETED,OBSERVATIONAL,['NA'],,
4151,NCT00332163,Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in Overall Dermatologic Quality of Life Index (DLQI) Score
4152,NCT00865527,Proportion of enrolled patients who attend for their assigned screening test,2010-03,TERMINATED,INTERVENTIONAL,['NA'],,Proportion of patients found to have invasive colorectal carcinoma
4153,NCT02698137,procedure-related adverse events,2016-03,COMPLETED,OBSERVATIONAL,['NA'],,technical failure of the procedure
4154,NCT04271813,Objecitve response rate,2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate
4155,NCT04840264,60-day Obstruction Clearance Rate,2022-01-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life assessed by EORTC QLQ-OG25
4156,NCT05255588,"Sensitivity and specificity of the EarlyTect® CRC test for detecting CRC compared to the colonoscopy, both in terms of detecting CRC.",2022-02-10,RECRUITING,OBSERVATIONAL,['NA'],,Clinical sensitivity of the EarlyTect® CRC for detecting Tis
4157,NCT04695262,EUS-E accuracy in terms of qualitative and quantitative elastography,2021-01-27,RECRUITING,OBSERVATIONAL,['NA'],,
4158,NCT00827580,the frequency of HFS; evaluation of eniluracil dose response; and assessment of any toxicity related to the topical product.,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,
4159,NCT05129215,Area under the curve (AUC),2020-03-06,COMPLETED,OBSERVATIONAL,['NA'],Net reclassification index (NRI),Negative prediction value (NPV)
4160,NCT05387876,Microbiome alterations,2022-02-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
4161,NCT01741636,"Satisfaction with the timing, content, and delivery of the intervention",2013-01,COMPLETED,INTERVENTIONAL,['NA'],,
4162,NCT01804621,Colorectal cancer screening,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,
4163,NCT01580202,The cumulative probability of HBV reactivation,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of hepatic decompensation and liver-related mortality
4164,NCT01519609,Degree of bowel cleansing,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,
4165,NCT02773524,Overall Survival,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],Evaluation of regorafenib Maximum Plasma Concentration [Cmax] between Asia and Rest of World cohorts.,Rates of Adverse Events
4166,NCT01916239,Gene expression profiling in colon tissues,2012-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,microRNA expression profiling in colon tissues
4167,NCT02445209,Overall Survival,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety as assessed by adverse events according to CTCAE v4.0
4168,NCT01446666,Detection Rate of Patients With HCC,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,Positive Predictive Value for HCC
4169,NCT03524820,response to treatment,2017-10-17,TERMINATED,INTERVENTIONAL,['PHASE2'],,
4170,NCT05348187,therascreen® KRAS RGQ PCR Kit,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,
4171,NCT03588533,Adverse event,2018-06-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survivals (OS)
4172,NCT01282658,,2010-11,UNKNOWN,OBSERVATIONAL,['NA'],,
4173,NCT01406249,Progression-free survival rate,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
4174,NCT05692284,Patient Identification Form,2022-02-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,SELF CARE ABILITY SCALE
4175,NCT05698459,MTD (Maximum Tolerance dose),2023-05-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity
4176,NCT01129570,The maximum tolerated dose of siliphos in patients with advanced hepatocellular carcinoma,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor response as measured by RECIST criteria and AFP concentrations
4177,NCT01340508,Pathological complete response rates,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Sphincter Preservation rates
4178,NCT01182116,Improved function and capacity of the neorectum.,2009-03,COMPLETED,INTERVENTIONAL,['NA'],,
4179,NCT05723965,accuracy of artificial intelligence with experienced physician,2010-10-01,COMPLETED,OBSERVATIONAL,['NA'],,real life survival outcome of diagnosis by artificial intelligence.
4180,NCT00096733,Survival of the potential liver transplant recipient,2004-10,COMPLETED,OBSERVATIONAL,['NA'],Recipient complications,Recipient survival from time of transplant (either living or deceased donor)
4181,NCT00022334,Dose limiting toxicity and maximum tolerable dose.,2001-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,clinical response in patients with measurable disease.
4182,NCT04499833,hepatocellular carcinoma recurrence,2021-03-25,RECRUITING,INTERVENTIONAL,['NA'],,hepatocellular carcinoma recurrence through liquid biopsy
4183,NCT00513357,Change in Appetite as Measured by ESAS,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
4184,NCT02474537,Vz/F of INC280,2015-06-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Unbound fraction and Vz/F based on unbound concentration in plasma
4185,NCT04046887,Frequency of Dose Limiting Toxicities (DLTs),2019-09-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,European Organization for Research and Treatment of Cancer quality of life questionnaire
4186,NCT00719303,Progression-free survival,2012-06-18,UNKNOWN,INTERVENTIONAL,['PHASE3'],Vitality measured using RAND-36 and GSRS-IBS,Change in self-reported quality of life measured using RAND-36
4187,NCT03911167,Postoperative complication rate，%,2017-09-01,COMPLETED,OBSERVATIONAL,['NA'],,"hospitalization expenses,yuan"
4188,NCT05759325,Progression-free survival,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
4189,NCT01971775,Amount of drain at postoperative period,2011-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,4. Postoperative hospital stay Complications
4190,NCT00034333,,2002-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
4191,NCT04245644,Overall survival,2019-03-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
4192,NCT01832948,Objective Response Rate (ORR),2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
4193,NCT01039506,Progression free survival,2009-10-15,COMPLETED,OBSERVATIONAL,['NA'],,Safety events
4194,NCT04931381,6-month disease control rate,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Concordance between radiosensitivity test results and patients' treatment response (descriptive statistics).
4195,NCT02139215,The pharmacoeconomic impact of panitumumab for the treatment of metastatic colorectal cancer in a real-life setting,2014-04,COMPLETED,OBSERVATIONAL,['NA'],,
4196,NCT04789200,Marking and distension of the bowel lumen at CT of the abdomen,2020-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Delineation of bowel wall enhancement related to concurrent intravenous contrast at CT of the abdomen and pelvis
4197,NCT03104569,Number of participants with Acute cholangitis,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Number of participants with Post-ERCP pancreatitis
4198,NCT06130826,Recommended phase 2 dose,2024-06-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics of M5A-IL2 (M5A-ICK blood clearance )
4199,NCT02370849,Objective response rate as measured by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1),2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment safety and toxicity as measured by Common Toxicity Criteria for Adverse Effects(CTCAE 3.0)
4200,NCT00804817,Health Related Quality of Life (HRQoL),2007-12,COMPLETED,INTERVENTIONAL,['NA'],,Symptom experience (Common Terminology Criteria for adverse events - CTCAE v. 3.0)
4201,NCT02928224,"(Phase 3) Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm",2016-10-13,COMPLETED,INTERVENTIONAL,['PHASE3'],(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Final Analysis,Phase 3: Number of Participants With Shifts in Left Ventricular Ejection Fraction (LVEF) From Baseline to Maximum Grade On-treatment
4202,NCT00210249,Number of Participant Deaths,2002-09,COMPLETED,OBSERVATIONAL,['NA'],,
4203,NCT03812770,Progression Free Survival (PFS),2018-08-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
4204,NCT04730544,Progression-free survival (PFS) at week 24 for two combination schemes.,2021-04-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to Health-related quality of life (HRQoL) score definitive deterioration (TUDD)
4205,NCT00529412,incidence of small bowel obstruction,2003-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,intraoperative and postoperative morbidity and mortality.
4206,NCT01994681,Obtaining a set or sets of VOC bio-markers that will provide the best discrimination between Pancreatic Cancer sick population and healthy population.,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],,
4207,NCT00215644,Percentage of Participants With Objective Response Assessed by Independent Review Committee,2005-08-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Matuzumab Serum Concentration
4208,NCT05730192,Positive percent agreement (PPA),2023-05-10,RECRUITING,INTERVENTIONAL,['NA'],,
4209,NCT01569620,"Change from baseline of colonoscopy at 3 months, 6 months, and 12 months.",2012-04,COMPLETED,INTERVENTIONAL,['NA'],,
4210,NCT03830606,objective response rate（ORR）,2016-03-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety profile: assessed by CTCAE v4.0
4211,NCT03264716,Hepatic Progression free survival,2017-08-31,COMPLETED,INTERVENTIONAL,['NA'],,An overall tumor response classification
4212,NCT02869477,Survival of patients,2002-01,RECRUITING,OBSERVATIONAL,['NA'],,Collection of patients characteristics
4213,NCT03410641,"Incidence of the group of cancers related to smoking, diet or body mass index",1972-01-15,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of prostate cancer
4214,NCT03039595,Correlation Between Tumour: Stroma Ratio With Local Recurrence of Cancer,2017-03-29,COMPLETED,OBSERVATIONAL,['NA'],,Correlation Between Tumour:Stroma Ratio and Overall Survival After TEM Surgery to Remove Rectal Cancer
4215,NCT05131815,Feasibility of BurnAlong,2022-01-10,COMPLETED,INTERVENTIONAL,['NA'],,Measure of Experiential Aspects of Participation (MeEAP)
4216,NCT04699539,1-year Local Control Rate (1y-LCR),2021-03-31,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival(OS)
4217,NCT04062656,Rate of pathological complete responses,2019-09-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Patient-reported outcome (PRO)
4218,NCT04686942,sensitive of detection tumor,2020-12-17,UNKNOWN,OBSERVATIONAL,['NA'],,
4219,NCT03152487,Subject assessment of abdominal pain,2017-04-24,COMPLETED,INTERVENTIONAL,['NA'],,Pain per the VAS tool.
4220,NCT03398122,PFS,2017-11-14,UNKNOWN,INTERVENTIONAL,['NA'],,QOL
4221,NCT00838578,Number of Participants With Serious and Other (Non-Serious) Adverse Events According to the CTCAE v.3.0,2009-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4222,NCT01795027,overall survival,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of Participants with Adverse Events
4223,NCT01801904,number of patients alive and without disease progression,2012-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],gene expression on tumor tissue,worst grade toxicity per patient
4224,NCT01077986,phase II part: response rate,2009-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacodynamics: biomarkers in blood and tumor tissue
4225,NCT05429203,Number of participants with procedure-related adverse events,2022-10-25,RECRUITING,INTERVENTIONAL,['NA'],,Ability to perform interventions
4226,NCT01443260,"Determine safety of administering GL-ONC1 intraperitoneally by the evaluation of the number of patients experiencing Adverse Events (type, frequency, and severity)",2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Detection of Anti-tumor Activity
4227,NCT04187937,R0 resection rate,2020-06-17,TERMINATED,INTERVENTIONAL,['NA'],,Time for resection
4228,NCT06148402,Objective Response Rate,2024-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,ctDNA and efficacy
4229,NCT02529007,Number of polyps detected per patient,2014-09,COMPLETED,INTERVENTIONAL,['NA'],,Patient comfort score
4230,NCT03915171,Sensitivity and specificity of blood MSI detected by NGS,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Correlation between MMR gene and other gene mutations
4231,NCT03806218,Minimum diameter of ablation zone per unit time,2015-05-16,COMPLETED,INTERVENTIONAL,['NA'],Ablation time,Local tumor progression (LTP)
4232,NCT03202992,Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of aHSIL,2017-08-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Histopathology of areas with biopsy-proven disease following single and multiple doses of ABI-1968 Topical Cream.
4233,NCT00257426,Median survival,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,number of subjects with toxicities
4234,NCT02898649,Safety (frequency of procedure-related complication and death),2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,Change in CA 19-9
4235,NCT02806661,Recurrence rate,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],,Inflammatory factors
4236,NCT00352404,Histological proof of neoplastic tissue (Intraepithelial neoplasia or cancer),2003-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Prediction of extent and severity of inflamed mucosa
4237,NCT00564265,Number of Patients Who Survived,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,
4238,NCT01912131,assess the acceptability of this piloted P-COCC intervention,2013-07,COMPLETED,INTERVENTIONAL,['NA'],,qualitative analyses
4239,NCT00790218,Maximum Plasma Concentration of CF102 (Cmax),2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Relationship Between Biomarkers of Peripheral Blood Mononuclear Cell (PBMC) Adenosine A3 Receptor (A3AR) Expression and Clinical Effects of CF102
4240,NCT05963724,Adenoma Detection Rate,2022-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Withdrawal Time
4241,NCT04607668,Myelopreservation,2020-10-16,TERMINATED,INTERVENTIONAL,['PHASE3'],,Anti-tumor Efficacy
4242,NCT02897778,Change from Baseline in T-Cell Morphology,2016-08-24,COMPLETED,INTERVENTIONAL,['PHASE1'],"Variability and Changes in Protein Lysine Acetylation in Peripheral Blood Cells after a Single Dose of Entinostat, when given at a Supratherapeutic Dose and Examine the Underlying Biological Variation",λz (Terminal Elimination Rate Constant) of Entinostat when given as a Single Supratherapeutic Dose
4243,NCT04172714,Tumor to Normal Liver Activity Ratio (TNR),2019-12-16,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants With Tumor Response Using Imaging Modified Response Criteria in Solid Tumors (m-RECIST) Post Y90 Embolization
4244,NCT00765869,Involvement in screening decision,2008-07,UNKNOWN,INTERVENTIONAL,['NA'],,Influence of doctor on screening decision
4245,NCT01013805,Tolerability Rate of patients treated with integrated pre-operative radiotherapy with FOLFOX chemotherapy regimen,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Dose Intensity of the treatment drug
4246,NCT04450758,Number of patients with 90 day mortality,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],,colorectal surgeon performing resectional surgery
4247,NCT04271657,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of the radiopathomics artificial intelligence model,2020-01-10,COMPLETED,OBSERVATIONAL,['NA'],,The sensitivity of the radiopathomics artificial intelligence model
4248,NCT00743964,Failure-free survival,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,progression-free survival
4249,NCT02324114,Hsp90α Concentration(ng/ml) of plasma,2012-09,UNKNOWN,INTERVENTIONAL,['NA'],,
4250,NCT01919151,Survival,2008-06,UNKNOWN,OBSERVATIONAL,['NA'],,
4251,NCT01350726,,2008-01,UNKNOWN,OBSERVATIONAL,['NA'],,
4252,NCT03941184,Incidence Rate of SCAD,1995-01-01,COMPLETED,OBSERVATIONAL,['NA'],Odds of validated rheumatoid arthritis in SCAD cases compared to controls,SCAD recurrence
4253,NCT03085992,Disease-free survival rate at 2 years,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pathological complete response rate
4254,NCT02446379,The location of PET imaging agent as measured by the LightPathTM Imaging System,na,WITHDRAWN,OBSERVATIONAL,['NA'],,Number of participants with adverse events
4255,NCT01551589,radiation pneumonitis and radiation esophagitis,2012-03,COMPLETED,INTERVENTIONAL,['NA'],,Local control rate/ Inside irrational field recurrence rate
4256,NCT00004066,,1999-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4257,NCT03313596,"Progression-free survival, PFS",2013-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Median overall survival time
4258,NCT03187184,PGx Test Interpretation,2017-05-20,COMPLETED,INTERVENTIONAL,['NA'],,Chemotherapy Toxicity
4259,NCT03283761,Objective Response Rate,2017-09-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and Toxicity Profile of the Combination of Nab-paclitaxel and FOLFOX
4260,NCT05329766,Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2022-06-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of participants with anti-drug antibodies to zimberelimab
4261,NCT02108444,the incidence of hepatitis B virus delayed reactivation,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,overall survival rate
4262,NCT05039944,Optimal combination dose (only IIa),2021-11-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,ADA
4263,NCT01520259,gallbladder cancer/pre-cancer,2012-01-10,COMPLETED,OBSERVATIONAL,['NA'],,
4264,NCT05980689,Complete response (CR) rate,2023-10-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Long-term anal function
4265,NCT06218420,To evaluate the efficacy of stereotactic body radiotherapy (SBRT) as bridging therapy for patients with hepatocellular carcinoma (HCC) enlisted for liver transplantation (LT).,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,To assess the occurrence of adverse events related to SBRT during waiting time period and after LT
4266,NCT01695772,Percentage of Participants Achieving Complete Resection (R0 Resection),2012-10-16,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Percent Probability Of Being Alive and Disease Free at Months 3, 6, 9, and 12"
4267,NCT00068575,Median Overall Survival (OS),2002-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4268,NCT03047603,PIVKA-II,2016-05-01,COMPLETED,OBSERVATIONAL,['NA'],,"ALT, AST，γ-GT， AFU"
4269,NCT02205008,relapsed free survival,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],surgery and intraperitoneal chemotherapy-related morbidity and mortality,overall survival
4270,NCT05501379,Comparison of physical activity assessments within 1 week after initiation of cancer therapy,2022-09-21,RECRUITING,OBSERVATIONAL,['NA'],,Relation of cancer therapy modality to changes in physical activity between assessements within 1 week and 12 weeks after initiation of cancer therapy
4271,NCT03883802,ctDNA as surrogate marker for disease free period,2019-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Thymidine Kinase activity,ctDNA in Wnt-5a high patients
4272,NCT00979329,,2008-05,COMPLETED,OBSERVATIONAL,['NA'],,
4273,NCT04969835,Percentage of patients with Adverse Events (AEs) at RP2D AVA6000 dose level in tumour-specific expansion arms.,2021-07-16,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
4274,NCT00068744,"Event-free survival as measured by Logrank at 12 and 26 weeks, then every 6 months thereafter (Phase III)",2003-07,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Quality of life as measured by EORTC Quality of Life Questionnaire-C30 and ASCT at 12 and 26 weeks, then every 6 months for 2 years after entry"
4275,NCT01426490,Antioxidant and DNA methylation,2011-08,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
4276,NCT01761461,The primary endpoint of the study is disease-free survival (DFS).,2013-02-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
4277,NCT00879333,Overall Survival (OS),2009-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Everolimus Steady State Concentraions at Predose (Cmin) and Cmax by Region Asia vs. Rest of the World (ROW) at Week 5
4278,NCT01104181,HC2 can accurately test for oncogenic HPV in anal specimens,2010-03,COMPLETED,INTERVENTIONAL,['NA'],,Sensitivity and specificity of cytology with HC2
4279,NCT04111978,Progression-free survival (PFS) for each study group,2020-11-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Health related quality of life (QoL) assessed by Functional Assessment of Cancer Therapy - Ovarian (FACT-O) questionnaire for each study group
4280,NCT01504997,The Incidence of Post-operative Intra-abdominal Infectious Complications,2011-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
4281,NCT00937482,MTD defined as the dose at which no patients develop treatment-related grade 5 toxicity and less than 30% of patients develop acute dose limiting toxicities (DLT) assessed using NCI CTCAE version 4.0,2009-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Vascular MRI studies
4282,NCT03851939,ORR,2019-02-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DCR
4283,NCT04091295,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
4284,NCT05408169,Number of screening tests returned to the central laboratory and successfully processed providing an adequate result.,2022-06-20,COMPLETED,INTERVENTIONAL,['NA'],,Acceptability of interventions (qualitative)
4285,NCT00063960,overall survival,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,time to hepatic recurrence or progression
4286,NCT04605913,Determine safety of (m)-GCN+TTF,2022-04-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
4287,NCT06296706,OS,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Plasma concentration of docetaxel (free and total)
4288,NCT06094868,Progression-free survival (PFS),2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Security
4289,NCT00511446,Progression-free survival rate,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median overall survival
4290,NCT01033240,Time to Progression (TTP) Following CS1008 in Combination With Sorafenib Compared to Sorafenib Alone in Participants With Advanced Liver Cancer,2010-07-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment-Emergent Adverse Events Following CS1008 in Combination With Sorafenib Compared to Sorafenib Alone in Participants With Advanced Liver Cancer
4291,NCT01057953,genetic variation assessment,2010-01,COMPLETED,INTERVENTIONAL,['NA'],,
4292,NCT06261047,Progression free survival,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Duration of control
4293,NCT04099134,Quality of life in pancreatic cancer patients,2018-10-10,RECRUITING,OBSERVATIONAL,['NA'],,Evaluation of predictive and prognostic markers
4294,NCT04305145,Proportion of patients with Steroid-Free Colitis,2020-08-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Response Rate
4295,NCT02889276,"Change in Global Health Status/QoL (subscale of EORTC QLQ-C30, Version 3) scores in cancer survivors",2017-02-20,TERMINATED,INTERVENTIONAL,['NA'],,Change in Self-efficacy to regulate exercise scale score
4296,NCT05706025,Testing difference in Biomarkers between Control and BE/EAC patients,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Testing difference in Multiple Biomarkers between Control and BE/EAC patients
4297,NCT03867084,Overall Survival (OS),2019-05-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,"Change from Baseline in European Quality of Life (EuroQoL)-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Health Utility Score"
4298,NCT00483782,Progression-free survival,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Health economics
4299,NCT05191667,Number of participants with Dose Limiting Toxicities (DLTs),2022-01-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
4300,NCT04408599,Define a maximum tolerated dose (MTD) or pharmacologically active dose (PAD),2020-06-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Half-life (t1/2) of NC410
4301,NCT05012527,Completeness rate of the procedures,2021-06-11,COMPLETED,OBSERVATIONAL,['NA'],,
4302,NCT00122876,Safety,2005-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival
4303,NCT02483884,Sensitivity and specificity of [68Ga]RM2 PET to identify lesions in comparison to whole-mount histopathology (number of histologically verified cancer lesions identified),2015-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of patients with adverse events,Evaluation of SUV threshold
4304,NCT00387387,"Plasma AUC(0-24) of pazopanib on Day 1, 14 and 21 Plasma AUC(0-46) of 5-FU and AUC(0-8) of platinum on Day 1 Plasma AUC(0-24) of capecitabine, 5-FU, and platinum on Day 1",2006-10-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Pharmacokinetic endpoints (AUC, C24, Cmax, tmax, and half-life)collected predose and 1, 2, 3, 4, 5, 6, 8, and 24 hours on Day 1. Assessment of disease by imaging"
4305,NCT03407001,Accuracy of contrast enhanced ultrasound (CEUS) with contrast agent sulfur hexafluoride lipid-type A microspheres and B-mode non-contrast enhanced ultrasound,2018-01-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Assessment of CEUS and contrast enhanced magnetic resonance imaging (CE-MRI) Liver Imaging Reporting and Data Systems (Li-Rads)
4306,NCT01640860,Response rate,2007-12,COMPLETED,OBSERVATIONAL,['NA'],,"progression free survival, overall survival and adverse events"
4307,NCT03549494,Quality of Life,2018-10-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,Results of laboratory tests
4308,NCT02647476,Postoperative complication rate,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall survival
4309,NCT04164017,Accuracy,2019-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,
4310,NCT03770689,Number of Participants Who Experienced Dose Limiting Toxicity (DLT) Confirmed by Safety Monitoring Committee (SMC),2019-03-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Apparent Terminal Half-life (t1/2) of Peposertib
4311,NCT00025025,,2001-10,COMPLETED,OBSERVATIONAL,['NA'],,
4312,NCT01738633,"items DY (dyspnoea), AP (appetite loss) and QL2 of the QLQ C30",2013-01,TERMINATED,INTERVENTIONAL,['NA'],,item EA (eating) of OES18
4313,NCT00001805,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4314,NCT01167738,Progression-free survival at 6 months,2010-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity
4315,NCT02745197,Muscle fatty acid content,2017-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Plasma C-reactive protein
4316,NCT04194879,Sensitivity & specificity of colorectal cancer detection,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
4317,NCT00321958,HGD or inoperable intramucosal or submucosal carcinoma and severe squamous dysplasia: measure of reduction in size of HGD or carcinoma,2006-04,TERMINATED,OBSERVATIONAL,['NA'],,Number of treatment sessions needed to ablate dysplasia
4318,NCT02656524,Number of participants with treatment emergent adverse events as a measure of safety and tolerability,2016-07-01,COMPLETED,OBSERVATIONAL,['NA'],Time frame between the baseline computed tomography and the first drug delivery,Resource utilization per patient
4319,NCT01758965,Delayed bleeding rate after ESD,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
4320,NCT02367001,Evaluate the effect on the participation (of the population) in cancer screening of an intervention involving the general practitioner (integration of signature) in the invitation letters,2014-02,COMPLETED,INTERVENTIONAL,['NA'],,"Cost-effectiveness of different strategies for each cancer screening (breast, colorectal and cervical) as measured by cost effectiveness ratio (total costs in Euros divided by total screened people)"
4321,NCT03536208,Determine change in AXL pathway,2019-05-15,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Antitumor effect
4322,NCT02252250,Adequacy of the total mesorectal excision(TME) based on standard guidelines on pathologic evaluation of TME specimens.,2014-10,COMPLETED,INTERVENTIONAL,['NA'],Quality of life outcomes evaluation,Oncologic outcomes in subjects receiving transanal hybrid-laparoscopic total mesentery excision.
4323,NCT03741088,Acute Technical Performance of the VORTX Rx® Medical Device for the Ablation of Primary and Metastatic Liver Tumors,2018-03-21,COMPLETED,INTERVENTIONAL,['NA'],,Analgesic Requirements After the Ablation Procedure
4324,NCT05124743,Results of HLA typing in combination with tumor genetic testing of subjects to identify a TCR match for treatment on the TCR001-201 study.,2021-09-24,SUSPENDED,OBSERVATIONAL,['NA'],,
4325,NCT03975465,Timing of Aspiration (category),2018-09-10,RECRUITING,INTERVENTIONAL,['NA'],M.D. Anderson Dysphagia Inventory (MDADI) (number),
4326,NCT05068752,Disease Control Rate of Vemurafenib in Combination with Sorafenib,2021-10-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Clinical Activity of Vemurafenib in Combination with Sorafenib,Measure phospho ERK and phospho AKT in plasma
4327,NCT01775280,Primary endpoint ist the percentage of patients that can be downstaged to resectability,2012-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Immunological response to radioembolization
4328,NCT05063019,"Predicting intraoperative PCI scores for patients with peritoneal carcinomatosis, using MR Enterography and CT",2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],,
4329,NCT01167374,Maximum Tolerated Dose (MTD),2011-08,TERMINATED,INTERVENTIONAL,['NA'],,Progression-free Survival
4330,NCT03160924,Post-operative hospital stay,2016-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Direct hospital costs
4331,NCT00387348,Change in Hamilton Depression Rating Scale (HAM-D) Scores,2006-03,TERMINATED,INTERVENTIONAL,['PHASE3'],,Side Effect Burden
4332,NCT03515369,3-year disease free survival,2018-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],safety and tolerability,EORTC QLQ-C30
4333,NCT02618356,Median disease progression free survival (mPFS) of Raltitrexed combined with S-1,2015-12-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4334,NCT01859858,Pharmacokinetics of SN-38,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4335,NCT03991104,Response rate,2019-05-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Health-related Quality of life (HR-QoL, Phase II)",Progression-free survival time
4336,NCT01190462,Percentage of patients free from progression and alive after 12.5 weeks following the first dose of treatment,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Correlation between overall response rate, progression-free survival, overall survival, and safety with skin toxicity and efficacy"
4337,NCT00299299,,2006-06,UNKNOWN,OBSERVATIONAL,['NA'],,
4338,NCT00792363,Response Rate,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression free survival
4339,NCT06041477,OS,2023-09,RECRUITING,INTERVENTIONAL,['PHASE3'],,Safety profiles of all participants
4340,NCT05319730,Objective Response Rate (ORR),2023-05-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants Who Discontinue Study Treatment Due to An AE During the Efficacy Phase
4341,NCT02706301,Change in Pain Severity assessed using the Brief Pain Inventory (BPI),2016-07,COMPLETED,INTERVENTIONAL,['NA'],Patient Satisfaction assessed using the Client Satisfaction Questionnaire 10-item version,Change in Self-Efficacy for Pain Control assessed using the subscale of the Chronic Pain Self-Efficacy Scale
4342,NCT00010062,,2000-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4343,NCT00450788,cancer incidence,2007-03-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Mortality
4344,NCT03820544,Intraoperative Estimated Blood Loss,2017-09-01,TERMINATED,INTERVENTIONAL,['NA'],,
4345,NCT03596411,Sleeve gastrectomy,2018-05-17,UNKNOWN,OBSERVATIONAL,['NA'],,Obesity related comorbidity
4346,NCT03144661,Safety and tolerability of INCB062079 as measured by assessment of adverse events (AEs),2017-05-25,TERMINATED,INTERVENTIONAL,['PHASE1'],,Analysis of biomarkers
4347,NCT04629326,Standardized uptake value（SUV）,2021-07-20,RECRUITING,INTERVENTIONAL,['NA'],,
4348,NCT03160209,Risk factors for ESCC - Tobacco and alcohol consumption,2017-07-26,COMPLETED,OBSERVATIONAL,['NA'],,The germline genetic and epigenetic alterations associated with susceptibility to ESCC.
4349,NCT04834011,"Preoperative radiologic assessment of patients with diagnosis of right-sided colon cancer. The investigators evaluated: fascia of Fredet; vascular structures (ileocolic vessels; right colic artery, middle colic artery, trunk of Henle); lymph nodes.",2013-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,perioperative outcomes: rate of conversion
4350,NCT02433639,progression-free survival at 4-months (PFS4mo),2015-04,COMPLETED,INTERVENTIONAL,['PHASE2'],"protein/genomic biomarkers of efficacy from serum, plasma or tumor",safety and tolerability as measured by number and grade of toxicity events
4351,NCT04498520,Incidence of treatment-related adverse events (AE),2021-03-31,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Median progression-free survival (PFS)
4352,NCT02151032,Gist and Verbatim Knowledge for a Colorectal Cancer Screening Program,2012-11,COMPLETED,OBSERVATIONAL,['NA'],,
4353,NCT03686709,Therapy Monitoring Using Whole-Body Post-therapy PET/CT Imaging,2018-06-19,RECRUITING,INTERVENTIONAL,['NA'],,
4354,NCT01995084,Optimal time frame between administration of 18F-HX4 and PET scan,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,
4355,NCT06006260,Self-report Questionnaire,2023-11-20,RECRUITING,OBSERVATIONAL,['NA'],,
4356,NCT01863355,Pain score(VAS) within 48hrs after surgery,2013-05,UNKNOWN,INTERVENTIONAL,['NA'],,
4357,NCT00700102,Overall Survival: Time From Randomization to Death From Any Cause,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Response Rate: Participants With Response Status Based on RECIST Criteria
4358,NCT04970914,Progression-free survival (PFS),2021-11-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of TB cells count and interleukin-6/8/10,Overall Survival (OS)
4359,NCT06092242,Progression Free Survival,2023-10-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life score
4360,NCT05742438,MMP,2023-04-12,COMPLETED,INTERVENTIONAL,['NA'],,Mortality
4361,NCT05141617,24-week re-bleeding,2021-11-03,UNKNOWN,INTERVENTIONAL,['NA'],,24-week adverse events
4362,NCT01317069,duration of survival after operation,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,disease free survival
4363,NCT02005913,tumor recurrence,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],,
4364,NCT04306458,Total number of dissected lymph nodes,2021-01-18,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life after esophagectomy
4365,NCT03082911,Participation,2017-03-13,COMPLETED,INTERVENTIONAL,['NA'],,Help to decide about participation
4366,NCT04658589,Number of harvested lymph nodes in D2 lymph node dissection,2021-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Conversion to open surgery
4367,NCT03959696,Shared Decision Making Process (SDMP) Scale Score,2019-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Clinician attitude toward shared decision making,Clinician satisfaction with the visit
4368,NCT00833131,The rate of patients with R0 resection,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,The rate of complete pathological response
4369,NCT00280761,Correlation of NF-kappa B pathway activation with therapeutic outcomes,2003-12,COMPLETED,OBSERVATIONAL,['NA'],,Correlation of p53 pathway-mediated events with clinical outcomes
4370,NCT04702230,DWI/IVIM values,2017-09-11,TERMINATED,OBSERVATIONAL,['NA'],,early responders
4371,NCT01895530,Difference in gene expression of citokynes,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative complications
4372,NCT04789980,Overall Survival (OS),2021-01-29,RECRUITING,OBSERVATIONAL,['NA'],Adverse drug reactions(ADR) caused delay/discontinuation of planned chemotherapy,Eastern Cooperative Oncology Group Performance Status (ECOG PS) scores
4373,NCT05999812,"Objective Response Rate of of ATRA, bevacizumab and atezolizumab combination",2023-12-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Frequency of adverse events
4374,NCT05029102,Progression Free Survival,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
4375,NCT01505530,Overall Survival (OS),2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Anti-LY2495655 Antibodies
4376,NCT04926532,Objective response rate (ORR),2019-08-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
4377,NCT02291133,Number of Participants With Toxicity Related to Electrochemotherapy,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical Response Evaluation According to RECIST v1.1
4378,NCT04358328,Mortality,2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Mortality
4379,NCT03303352,"Cytological diagnostic accuracy of EUS FNA, for ""fast"" and ""slow"" passages",2017-07-24,COMPLETED,INTERVENTIONAL,['NA'],Subgroup analysis for trans-gastric and trans-duodenal route,"The linear relationship between needle acceleration and outcomes 1,2,3 and 4"
4380,NCT02079389,"A change in the stage of Tumor, lymph Node and metastases (TNM-stage)",2013-05,COMPLETED,INTERVENTIONAL,['NA'],Does the use of contrast enhanced ultrasound examination during surgery for colon and rectum cancer provides more findings of liver metastases?,A change in the postoperative treatment strategy
4381,NCT05477576,Phase 3: PFS as determined by BICR,2022-03-24,RECRUITING,INTERVENTIONAL,['PHASE3'],Phase 3: QTc,Phase 3: DoR
4382,NCT00087334,Response rate,2004-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival in (phase II)
4383,NCT06327269,Recurrence-free survival with adjuvant therapy,2021-04-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
4384,NCT01092091,Tumor response,2010-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Plasma arginine levels
4385,NCT04390724,Patient Group 2: HCC Resection,2020-07-17,RECRUITING,OBSERVATIONAL,['NA'],,
4386,NCT01326845,Difference in the Frequency of Overall Newly Occurring GI Adverse Events (AEs) in the Two Treatment Arms,2011-12,TERMINATED,INTERVENTIONAL,['PHASE4'],,Difference in Reducing Serum Ferritin After Each Month of Study Drug Administration Between the Two Groups
4387,NCT03609710,Anastomotic leak rate,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Reoperation rate after anastomotic leak
4388,NCT00061958,"Objective response (OR) defined as a complete or partial remission, evaluated using RECIST criteria",2003-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity graded according to the Common Toxicity Criteria version 2
4389,NCT05565066,Diagnostic yields of EUS-FNA with EUS-FNB for solid masses,2014-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Quality of histologic specimen
4390,NCT02603757,Increase in serum Vitamin D3 level during chemotherapy in the active supplementation group compared to the control group.,2016-03,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival (OS)
4391,NCT00024063,,na,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
4392,NCT06074432,Mortality,2023-07-25,COMPLETED,OBSERVATIONAL,['NA'],,
4393,NCT01712958,"identifying specific, relevant miRNAs that may serve as biomarkers to stratify CRC patients according to their clinical characteristics",2012-11,UNKNOWN,OBSERVATIONAL,['NA'],,
4394,NCT04552405,Evaluate changes in calprotectin levels,2017-09-12,COMPLETED,INTERVENTIONAL,['NA'],,Evaluate changes in stool inflammatory markers
4395,NCT04642664,Objective Response Rate (ORR),2018-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Clinical benefit rate (CBR),Incidence of Treatment-Emergent Adverse Event
4396,NCT06214533,Postoperative opioid use,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Post-operative hospital time
4397,NCT00746590,Overall Best Tumor Response Rate (Proportion of Subjects With Complete or Partial Response) as Defined by Modified RECIST,2008-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Changes in Laboratory Measurements
4398,NCT04440865,Adenoma Detection Rate (ADR),2021-02-01,COMPLETED,INTERVENTIONAL,['NA'],,Morbidity: bleeding rate (%)
4399,NCT01604798,Serum peptide mass fingerprinting (PMF),2007-01,COMPLETED,OBSERVATIONAL,['NA'],,Expressed peptide peaks
4400,NCT04386057,Dose Limiting Toxicity-Lead In,2020-05-27,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
4401,NCT01697449,Percentage of Participants With At Least One Adverse Event (AE),2009-03,COMPLETED,OBSERVATIONAL,['NA'],,Progression Free Survival (PFS)
4402,NCT04123379,Significant Tumor Necrosis (STN),2020-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
4403,NCT01110941,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Tumor response according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, and follow up till disease progression or withdrawal from study due to intolerable adverse events (AE)"
4404,NCT00270166,Proportion of patients without transfusion after first month.,1995-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Proportion of responders, change of hemoglobin (not by transfusion), cumulative transfusion rate, proportion of patients transfused during the double-blind phase, excluding the first month; mean change score of baseline quality of life parameters; safety"
4405,NCT04380103,objective response rate (ORR),2020-04-26,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,the surgical resection rate of patients with liver-only metastases
4406,NCT03704077,Overall response rate (ORR),2019-10-31,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
4407,NCT01126463,Maximal tolerated dose,2010-05-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Bio-availability
4408,NCT05068739,Success rate of cannulation,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Procedure time
4409,NCT03446157,Disease Control Rate,2018-03-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity of Treatment
4410,NCT01349881,"Event rate, defined as rate of high-risk adenoma or second primary colorectal cancer (CRC)",2013-08-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Cancer type (colorectal vs rectal)
4411,NCT06119425,Opted to be screened by either SOC or study diagnostic test,2023-10-12,RECRUITING,INTERVENTIONAL,['NA'],,Opted to be screened by the study diagnostic test instead of SOC
4412,NCT04429542,Incidence of Dose Limiting Toxicities (DLTs),2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity of BCA101 and pembrolizumab
4413,NCT04466891,Confirmed objective response rate (ORR) by independent central review (ICR),2020-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of anti-drug antibodies (ADAs)
4414,NCT05603572,To determine the Recommended Phase 2 Dose (RP2D) for oral + IT administration,2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To assess area under the curve (AUC) of KAT (oral and oral + IT)
4415,NCT03806075,Mutation of gene associated with Peutz-Jeghers syndrome,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA'],The association of STK11 with intestinal microbiota of patients with PJS,Intestinal microbiota of patients with PJS
4416,NCT02331914,Secondary GIST mutations in circulating tumor DNA of patients with progressive disease on TKI treatment,2014-12-08,RECRUITING,OBSERVATIONAL,['NA'],,Secondary mutations in circulating tumor DNA related to pharmacokinetics of TKI
4417,NCT06059885,Tumor recurrence rate (DRR),2021-12-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,
4418,NCT05402592,Shorter Length Of Hospitalization,2022-07-13,COMPLETED,INTERVENTIONAL,['NA'],,Higher quality of life on the 30th day after surgery in patients given a carbohydrate-rich beverage before surgery
4419,NCT04287218,Change of total score on Fear of Cancer Recurrence Inventory (FCRI) from baseline to 2nd follow-up,2023-05-10,RECRUITING,INTERVENTIONAL,['NA'],Perceived risk of recurrence measured by the visual analogue scale from 1-100,Comparison of changes in health care usage between intervention arm and aTAU
4420,NCT04253106,Number of subjects in whom somatic mutations or methylation profiles are detected.,2020-11-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Replicability of observations over successive endoscopies. Correlation between blood and gastric fluid.
4421,NCT04939103,the accuracy of predicting pCR after nCRT,2021-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
4422,NCT03351647,Measurement of serum ustekinumab trough concentrations (expressed in microg/mL) at week 8.,2018-02-14,COMPLETED,OBSERVATIONAL,['NA'],,Clinical evaluation at week 24
4423,NCT00064051,Objective response rate (partial and complete response) as assessed by RECIST criteria,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and feasibility
4424,NCT06221748,Overall Survival (OS)(Phase III),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of echocardiograms abnormalities
4425,NCT02696759,Number of Subjects Who Complete Fecal Collection,2016-07,TERMINATED,INTERVENTIONAL,['NA'],,
4426,NCT02536183,Feasibility of treatment,2016-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Determine the Changes in Pharmacodynamic Immune Markers in Participants
4427,NCT05047510,HCC lesions,2021-09-10,RECRUITING,INTERVENTIONAL,['NA'],,
4428,NCT05542680,Reflux symptoms,2022-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Skin pressure injury
4429,NCT01983371,Prospectively evaluate the diagnostic accuracy of ferumoxytol-enhanced MRI in the setting of colorectal cancer with histopathologic analysis as the gold standard.,2013-12,WITHDRAWN,INTERVENTIONAL,['NA'],,
4430,NCT04656782,Standardized imaging protocol consensus among panelists,2021-01-26,UNKNOWN,OBSERVATIONAL,['NA'],,Description of heterogeneity of mCRC imaging protocols
4431,NCT03555149,Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2018-09-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percentage of Participants With at Least One Adverse Event (AE)
4432,NCT04858009,Progression-free survival,2024-01-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Morbidity
4433,NCT05279612,Investigate patients ORR,2021-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,R0 resection
4434,NCT01744639,Nutritional Status,2012-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Minimal hepatic encephalopathy
4435,NCT01465802,Median Time of Occurrence of Cmax (Tmax) for Dacomitinib and Its Metabolite PF-05199265 on Cycle 1 Days 10 to 15 for Cohort III,2011-12-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Mean Plasma Ctrough for PF-05199265 by Visit for Cohorts I, II and III"
4436,NCT05247164,Proportion of patients with procedure-related Adverse Events,2022-05-17,RECRUITING,INTERVENTIONAL,['NA'],,Baseline portal CTC concentration in patients with progressive versus non-progressive diseases
4437,NCT06255041,"Sensitivity of detection of any cancer (breast, lung, prostate or colorectal cancer) by the breath test.",2021-02-10,RECRUITING,OBSERVATIONAL,['NA'],The duration for which a breath sample collected on an alternative mask substrate remains effective for detection by a detection dog,Intra-observer variability among the detection dogs
4438,NCT01345175,To compare the efficacy of rifaximin and placebo in the treatment of bowel dysfunction as measured by MSKCC Bowel Function Instrument (BFI score) in patients following Anterior Resection (AR) or Sphincter Preserving Surgery (SPS) for rectal cancer.,2011-04-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,efficacy of metronidazole
4439,NCT00961571,Progression-free Survival,2009-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
4440,NCT03700593,Rate of postoperative complications and mortality of the SP robot,2018-10-15,UNKNOWN,OBSERVATIONAL,['NA'],,Assessment of patients' postoperative body image satisfaction
4441,NCT05034783,Metabolic parameters,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],GLP-1R expression and SUV,Diagnostic value
4442,NCT02682485,Anastomotic Healing Score (ordinal scale ranging from 0 to a maximum of 18),2017-03-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Anastomotic Healing Score (ordinal scale ranging from 0 to a maximum of 18)
4443,NCT01899976,Maintenance of a total serum bilirubin level ≤ 3.0 mg/dL or a reduction of >30% if baseline value was greater than 3.0 mg/dL,2013-08,COMPLETED,INTERVENTIONAL,['NA'],,total number of adverse events
4444,NCT00144378,median survival,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,"quality of life, response rates, time to tumor progression, toxicity"
4445,NCT04258150,Objective response rate (ORR),2020-04-16,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Incidence of treatment-related AEs, SAEs, AEs leading to discontinuation, death, and laboratory abnormalities"
4446,NCT05667350,The sensitivity and specificity of the combined model in detection of biliary tract cancers.,2022-02-28,RECRUITING,OBSERVATIONAL,['NA'],,The sensitivity and specificity of the combined model in detection of different stages of biliary tract cancers.
4447,NCT03524300,3-year disease free survival rate,2018-06-01,RECRUITING,INTERVENTIONAL,['NA'],,operation time
4448,NCT02631499,Early recurrence rates,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Overall Survival
4449,NCT01705340,MTD of Akt inhibitor MK-2206 and lapatinib ditosylate in combination with trastuzumab determined by dose limiting toxicities as measured by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4,2012-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Overall response rate (ORR), evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1"
4450,NCT04826003,Percentage of Participants with Adverse Events,2021-07-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change on 4-1BB tumor expression levels
4451,NCT01494506,Overall Survival,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Pharmacokinetic Measurements of Total Irinotecan
4452,NCT00536874,Overall Survival at 18 Months,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Specific Tumor Marker Response (Ca 19-9) to Neoadjuvant Therapy
4453,NCT00822562,Overall survival rate,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,"non-tumor life span, intra-liver recurrence rate, metastasis rate"
4454,NCT04652180,Respiratory postoperative complications.,2020-11-06,RECRUITING,INTERVENTIONAL,['NA'],,Postoperative quality of life.
4455,NCT00303771,Progression Free Survival (survie sans progression),2003-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival (survie globale)
4456,NCT02557490,Progression-free survival (PFS),2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,overall survival (OS)
4457,NCT04589234,Progression Free Survival,2020-10-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Radiologic response
4458,NCT05673148,Overall Survival (OS),2023-01-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to local recurrence (TLR)
4459,NCT05185869,Adverse Events (AEs),2022-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
4460,NCT01518829,Differantiate between post- embolization syndrom and sepsis following locoregional treatment for hepatocellular carcinoma,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,
4461,NCT01330823,TNF-alpha,2006-06,SUSPENDED,INTERVENTIONAL,['PHASE3'],,hospital stay
4462,NCT01389583,disaese control rate,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,response rate
4463,NCT05939063,Lymph node positive rate,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival (OS)
4464,NCT05737615,SUV mean measurement,2023-02-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,
4465,NCT02909062,EAM Max Step-count On-Chemotherapy - EAM Max Step-count Pre-Chemotherapy,2016-05,COMPLETED,OBSERVATIONAL,['NA'],,
4466,NCT03718650,Radiosensitivity Index and Degree of Pimonidazole Staining,2021-04-01,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Correlative Biomarkers
4467,NCT06205173,The effectiveness of Cold and Hot Compress Nursing Interventions on the Quality of Life,2020-08-19,COMPLETED,INTERVENTIONAL,['NA'],,The Effectiveness of Cold and Hot Compress Nursing Interventions on the Neurological Changes in the Hands and Feet.
4468,NCT04481256,Feasibility difined as the percentage of patients completing at least two cycles of bintrafusp alfa,2020-11-11,RECRUITING,INTERVENTIONAL,['NA'],Biomarker,adverse events
4469,NCT05768282,The proportion of patients with esophageal stenosis after RFA,2016-01-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,The adverse events rate
4470,NCT03219918,Adenoma detection rate,2017-06-19,TERMINATED,INTERVENTIONAL,['NA'],,Malignancy detection
4471,NCT03333967,Progress free survival,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],adverse events,Disease-free survival
4472,NCT05898828,Phase II Component: To assess the frequency of immunologic responses to purified cancer-testis (CT) antigens in EsC participants receiving adjuvant vaccinations with H1299 cell lysate/Montanide(R) ISA-51 VG in combination with entinostat and niv...,2024-04-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II Component: To determine progression free survival (PFS) in EsC participants receiving the investigational adjuvant vaccine regimen
4473,NCT04752358,Efficacy: Overall Response Rate (ORR),2021-09-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs
4474,NCT05627427,Progression-free Survival (PFS) (RECIST1.1),2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,TEAE rates
4475,NCT02494973,3-year RFS rate,2015-05-26,SUSPENDED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
4476,NCT06212817,Dietary fiber intake,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Length of hospital stay
4477,NCT03399253,Overall survival,2017-12-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,progression free survival
4478,NCT00845689,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4479,NCT02682589,disease-free survival,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,postoperative quality of life as assessed by EORTC QLQ-C30 questionnaire
4480,NCT00617981,Progression Free Survival Will be Measured From the Date of Randomization to the First Date on Which One of the Following Occurs. o Local Recurrence o Any New Distant Intrahepatic HCC Tumor o Any New Extrahepatic HCC Tumor o Death From Any Cause,2008-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety
4481,NCT02296658,Distant metastasis free survival,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Comparison of dosimetric differences between radiation techniques,Chemoradiotherapy-induced toxicities assessed by CTCAE 4.0
4482,NCT01700283,"Developing Objective Fatigue Indicators: Exploring the Relationships Among Fatigue, Muscle Power and Metabolomics Through Fatigue Management and Individualized Exercise Education Program in Colorectal Cancer Survivors",2012-10,UNKNOWN,INTERVENTIONAL,['NA'],,
4483,NCT05572801,Disease free survival,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Health related quality of life
4484,NCT00857805,Overall survival,2009-01-07,COMPLETED,INTERVENTIONAL,['NA'],,Downstaging
4485,NCT01717014,Distal Margins,2013-05,TERMINATED,INTERVENTIONAL,['NA'],,Usability: Manueverability
4486,NCT02359058,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies (TE-ADA)
4487,NCT04637893,Colorectal Cancer prevention,2020-12-16,COMPLETED,OBSERVATIONAL,['NA'],,
4488,NCT04048317,Evaluate the effectiveness of drug-eluting bead trans-arterial chemo-embolization in patients of hepatocellular carcinoma,2019-09-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
4489,NCT00445965,response rate,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,cumulative toxicities
4490,NCT02255669,duration of stent patency,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],,stent related complication
4491,NCT00851305,To compare the rate of EGCs/GCs using CLE versus conventional gastroscopy.,2008-08,COMPLETED,INTERVENTIONAL,['NA'],,To evaluate the efficacy of in vivo CLE on different pathological characteristics of EGCs.
4492,NCT01875380,Progression-free survival rate at 6 months,2013-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Biomarkers associated with cell and tumour growth and/or the mechanism of action of regorafenib and their correlation with patients' clinical progression for efficacy and safety parameters.,Changes in ECOG performance status over time from baseline
4493,NCT00313755,with at least one adenoma after white light NBI in the right colon.,2006-04,COMPLETED,INTERVENTIONAL,['NA'],,Number of hyperplastic polyps detected by white light vs NBI.
4494,NCT02089633,Time To Progression (TTP),2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],To evaluate the association between the biomarkers of ornithine transcarbamoylase (OTC) and argininosuccinate synthetase (ASS) in liver tissue and clinical response treated with PACOX regimen,Safety events
4495,NCT05478083,Liver growth,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Symptoms of depression
4496,NCT03562234,Change in liver function,2018-10-22,UNKNOWN,OBSERVATIONAL,['NA'],,Post-operative 30 day complications using the International Study Group for Liver Surgery (ISGLS) complications score
4497,NCT06196775,Progression-Free-Survival,2024-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
4498,NCT02965794,Length of stay,2014-10,COMPLETED,OBSERVATIONAL,['NA'],,Time to return to normal diet
4499,NCT00002955,,1995-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4500,NCT04797884,Quality of Life Survey,2023-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Frequency of Adverse Events - PRO-CTCAE
4501,NCT03397745,Change in Bispectral index score,2018-01-15,COMPLETED,INTERVENTIONAL,['NA'],,The changes of BIS
4502,NCT02389751,"MTD and recommended phase II dose of ganetespib, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",2015-04-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,pCR for patients who undergo surgical resection after neoadjuvant therapy
4503,NCT00145769,Local recurrence,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life
4504,NCT01834469,Feasibility study of the (intravenously injected) ICG imaging of tumoral implants in patients with peritoneal carcinomatosis from ovarian carcinoma,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4505,NCT03316872,Overall response rate,2018-02-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival rate
4506,NCT02278458,The number of patients who suffer adverse events,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression-free survival
4507,NCT02595021,Postoperative complications,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Hospitalization days
4508,NCT05159479,Relationship of baseline cardiovascular risk with FIC,2021-10-13,RECRUITING,OBSERVATIONAL,['NA'],,Cardiovascular symptom assessment
4509,NCT04776421,comprehensive complication index,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall Survival
4510,NCT05332821,Overall Survival(OS),2022-12-28,RECRUITING,OBSERVATIONAL,['NA'],,Adverse event(AE) per Common Terminology Criteria for Adverse Events(CTCAE) 5.0
4511,NCT01538498,Devleopment for the peritoneal carcinomatosis index (PCI),2008-04,COMPLETED,OBSERVATIONAL,['NA'],,
4512,NCT05246943,Compare the D-dimer results of DVT positive subjects to DVT negative subjects to identify a specific result range seen in the DVT positive subjects.,2022-05-25,WITHDRAWN,OBSERVATIONAL,['NA'],,
4513,NCT00813072,objective tumor response,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"progression-free survival, duration of tumor response, time to progression, time to treatment failure, disease control rate, 1-year survival rate,and overall survival; pharmacokinetics and pharmacogenetics of PEP02 and irinotecan"
4514,NCT04140500,"Part B: Progression-free Survival (PFS), Defined as the Time from the First Study Treatment to the First Occurrence of Progression per Investigator Assessment or Death from any Cause, Whichever Occurs First",2019-11-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part B: Percentage of Participants with Adverse Events
4515,NCT04017650,Incidence of treatment-related grade 3 adverse events,2019-06-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of response
4516,NCT04389177,Major pathologic response,2020-07-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
4517,NCT03604614,PFS,2017-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Median survival
4518,NCT04714086,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
4519,NCT06031129,Visceral Pain,2023-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Visceral Pain
4520,NCT05444491,To investigate the prediction and monitoring effect of plasma ctDNA methylation on postoperative recurrence of primary colorectal cancer patients after radical surgery,2022-06-20,RECRUITING,OBSERVATIONAL,['NA'],,
4521,NCT06115655,Specificity,2023-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
4522,NCT05803928,"Recurrence-free Survival, RFS",2023-04-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Biomarkers in tumors and peripheral blood
4523,NCT05044312,Correlating the sleep disturbance and its types among patients with gastrointestinal cancers.,2024-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
4524,NCT04791254,Differences in patterns of plasma gut hormone and cytokine levels as measured by ELISA between study participants.,2021-07-15,RECRUITING,OBSERVATIONAL,['NA'],,"Correlation between nutritional status, body composition and physical fitness"
4525,NCT04324567,"Peak value of surgically induced C-reactive protein (CRP), expected to occur 1-3 days after surgery",2019-10-09,COMPLETED,OBSERVATIONAL,['NA'],Monitoring intermediate metabolites in the remnant muscular tissue of the pelvis floor in up to 10 patients with microdialysis catheters after neoadjuvant CRT and subsequent APR for LARC.,Dehiscence of the perineal wound at 3 months follow-up
4526,NCT03609359,"Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST",2018-10-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Tests of various biomarkers,Disease control rate (DCR)
4527,NCT00851955,All cause mortality,2007-05,COMPLETED,OBSERVATIONAL,['NA'],,"For pancreatic patients from whom tissue samples will be available, we will examine the association between presence/absence of each marker in the tissue versus the marker level in blood and in pancreatic juice."
4528,NCT00980889,confirmed stent failure,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,Survival
4529,NCT04745403,Analysis of modifications of tumour microenvironment caused by mRNA HBV/TCR T-cell treatment,2022-05-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Evaluation of anti-tumor efficacy of mRNA HBV/TCR T-cell treatment
4530,NCT04422730,comparaison of quality of life score between 4 groups,2020-06-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
4531,NCT03245736,Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE),2017-08-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Increased Prostate Specific Antigen (PSA)
4532,NCT00981110,The rate of patients with a Surgical site infection,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
4533,NCT05136092,The abundance of fructose in tumor extracts,2022-02-16,RECRUITING,INTERVENTIONAL,['NA'],,The abundance of Xylose and [13C]-Xylose in the in the tumor
4534,NCT02399137,Progression Free Survival,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of adverse events reported with the combination of MM-141 with nab-paclitaxel and gemcitabine versus the comparator arm
4535,NCT05772923,Rate of successful organ preservation,2021-04-16,RECRUITING,INTERVENTIONAL,['NA'],,Number of patients with complications after completion or salvage TME-surgery
4536,NCT00254137,Objective response rate (CR+PR),2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Grade 3/4- toxicities.
4537,NCT04131946,Characterize individual -level facilitators and barriers to engaging in CRC screening and related diagnostic tests and treatment when applicable,2019-11-12,COMPLETED,INTERVENTIONAL,['NA'],,
4538,NCT01341366,Duration of hospital stay,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Lymphocyte subsets
4539,NCT01885351,CRCS adherence provided by the electronic medical record,2013-03-01,COMPLETED,INTERVENTIONAL,['NA'],Development of MyCRCS+ intervention content,Feasibility of MyCRCS+ in target setting - patient survey
4540,NCT01387880,Clinical benefit (SD+PR+CR),2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4541,NCT00305838,Number of patients required to detect a significant difference in CA 125 doubling time before and after starting tamoxifen,2004-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4542,NCT02841657,Postoperative complications,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,Oncological radicality
4543,NCT03238885,Pathological complete response(pCR),2013-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
4544,NCT00669734,"MTD of falimarev, defined as the dose level that 0/6 or 1/6 patients experience dose-limiting toxicity (DLT) and that at least 2/3 or 2/6 patients treated with the next higher dose have had DLT",2010-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Cytokine production
4545,NCT02645864,Maximum tolerance dose,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
4546,NCT05041153,Overall response rate,2022-02-14,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
4547,NCT06054984,Characterize the Peak of Peripheral Blood Concentration and Area under the Peripheral Blood concentration versus time curve of TCRT cells and observe their proliferation and persistence in body,2021-09-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],To explore the correlation between the proliferation and persistence of TCRT cells in body and the efficacy,"Evaluate tumor size (mm) , tumor biomarker CA19-9 (U/ml), ORR/DCR/PFS and OS of patients with advanced pancreatic cancer"
4548,NCT03209349,Full colon exam,2017-06-14,COMPLETED,INTERVENTIONAL,['NA'],,Adenoma detection rates
4549,NCT04631692,Colorectal cancer screening uptake,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
4550,NCT01180452,Frequency of dysplasia and adenocarcinoma,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Success of endoscopic detection
4551,NCT02861885,patients with sessile serrated lesions,2016-02-24,UNKNOWN,OBSERVATIONAL,['NA'],,Detection techniques diagnosis performance
4552,NCT01642186,Efficacy Endpoints for Part 1 of the Study is Progression-free Survival at 6 Months (PFS6),2012-07-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Tissue Biomarkers Collected
4553,NCT00005036,Overall survival,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life
4554,NCT00127036,"Number of Participants Per Treatment Arm, Per Tumor Tissue Response Classifier",2003-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Serious Adverse Events (SAEs)
4555,NCT04215471,Objective Response,2020-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Correlation between genetic profile and tumor response
4556,NCT05739981,Minimal Residual Disease,2023-02-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,OS
4557,NCT00310362,Appointment Nonadherence-colonoscopy,2007-07,COMPLETED,INTERVENTIONAL,['NA'],,Preparation Non-adherence-flexible Sigmoidoscopy
4558,NCT00087256,To determine whether celecoxib 400 mg bid for 3 years will decrease the incidence of adenomatous polyps of the colon and rectum in participants with Stage I adenocarcinoma of the colon.,2004-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,To monitor the toxicity and safety of celecoxib in this population.
4559,NCT00943280,The primary outcome variable for this aim will be the number of subjects in each group that need to be contacted until 20 in each group agree to participate in this study.,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,"To access variables for prediction of non-participation: age, gender, education level, employment, marital status, esophageal symptoms"
4560,NCT06012318,Prevalence and severity of adverse symptoms,2023-09-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Trajectory of adverse symptoms
4561,NCT00248053,polyp number and size,2005-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,side effects and medication compliance
4562,NCT02024009,Progression free survival,2016-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
4563,NCT03718351,En-block resesction rate,2018-09-24,UNKNOWN,INTERVENTIONAL,['NA'],,Morbidity defined by the Clavien-Dindo classification
4564,NCT05200325,CPV-measured cost savings,2021-06-06,COMPLETED,INTERVENTIONAL,['NA'],,CPV-measured use case analysis
4565,NCT05572528,The recurrence rate after LDLT in high risk patients,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
4566,NCT00116454,"to determine if the Lipiocis treatment decreases the % of tumoral recurrence after 24 months, judged on the rise of alpha-fetoprotein and the reappearance of one or more tumours on the hepatic CT scan",2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Deterioration of the hepatocellular function
4567,NCT03509428,Post-operative length of hospital stay,2018-03-26,UNKNOWN,INTERVENTIONAL,['NA'],,Nutrition -4
4568,NCT03006302,6 Month Survival,2018-01-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants experiencing drug-related adverse events (AEs) requiring treatment discontinuation
4569,NCT05570487,The number of lymph nodes,2022-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
4570,NCT03177382,disease free survival,2017-06-15,UNKNOWN,INTERVENTIONAL,['PHASE3'],,assessment of nutritional status
4571,NCT02599909,"To collect blood/urine/tumor samples, stool, and rectal swabs from HCC patients undergoing resection of primary liver tumors at the Mount Sinai Medical Center and to perform an analysis of the interaction of tumors, immune responses and the gut ...",2015-11-06,WITHDRAWN,OBSERVATIONAL,['NA'],,Correlation between microbiome and patients' clinical outcome
4572,NCT04657042,DVF errors in healthy volunteers and cancer patients,2020-11-05,RECRUITING,OBSERVATIONAL,['NA'],,
4573,NCT04852211,2-year recurrence-free survival,2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],,5 - year Overall survival
4574,NCT03278015,median overall survival time (mOS),2017-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate(DCR)
4575,NCT05371873,MRD monitor,2021-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
4576,NCT01218841,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4577,NCT00126633,Micrometastases for predicting time to progression and overall survival,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4578,NCT04640480,"Number of clinically significant Chest radiograph findings(chest x-ray, CXR)",2024-06-21,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Time to progression(TTP)
4579,NCT03468335,Time to Treatment Failure of second-line treatment (TTF2),2018-03-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Growth modulation index (GMI)
4580,NCT05858385,Incidence of severe RTOM,2022-09-22,RECRUITING,OBSERVATIONAL,['NA'],Changes from the pain in xerostomia combined with RTOM patients,Risk factors of severe RTOM
4581,NCT02231385,Additional serrated lesions diagnosed after acetic acid spraying,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],,Complication rate
4582,NCT02578368,Overall survival (OS),2016-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Toxicity - Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
4583,NCT05405530,The incidence of hypoxia,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],,The incidence of other adverse events
4584,NCT01632722,2 years recurrence-free survival (2Y-RFS),2012-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4585,NCT03785496,To evaluate efficacy of PDR001 by Objective Response rate by RECIST(Response Evaluation Criteria In Solid Tumors),2020-02-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To evaluate antitumor efficacy of PDR001
4586,NCT00003530,,1977-03-21,TERMINATED,INTERVENTIONAL,['PHASE2'],,
4587,NCT03503071,Brief pain inventory (BPI),2018-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Brief pain inventory (BPI)
4588,NCT00208936,,1996-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
4589,NCT01607788,Post-transplant survival,2009-11,UNKNOWN,OBSERVATIONAL,['NA'],,
4590,NCT02452424,Treatment-emergent Adverse Events (TEAEs) in Participants Regardless of Causality While Taking PLX3397 in Combination With Pembrolizumab,2015-07-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Summary of the Percentage of Participants With Objective Response Rate Assessed by RECIST v1.1 During Pembrolizumab and PLX3397
4591,NCT00558233,Receipt of colorectal cancer screening,2007-11,COMPLETED,INTERVENTIONAL,['NA'],,Number of polyps and cancers found by screening tests performed
4592,NCT04117087,Fold change in interferon-producing mutant-KRAS-specific cytotoxic (CD8) and helper (CD4) T cells at 16 weeks,2020-05-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
4593,NCT06212128,operative time required for primary resection of rectal tumour,2016-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,duration of hospitalisation
4594,NCT01411579,Apparent Diffusion Coefficient (ADC) value changes of the lesion during chemotherapy.,2011-02,COMPLETED,OBSERVATIONAL,['NA'],,
4595,NCT04973046,The tissue oxygen saturation score of gastric tube during esophagectomy,2020-11-01,COMPLETED,OBSERVATIONAL,['NA'],,The rate of anastomotic leakage
4596,NCT05544474,Degree of consensus,2023-11-28,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
4597,NCT02606396,Change in dysphagia severity according to validated symptom score,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],,"Incidence of procedure related adverse events, classified according to the American Society of Gastrointestinal Endoscopy lexicon"
4598,NCT00653107,Dysphagia measured with the dysphagia grading scale at week +2 after start of treatment. Pain at rest measured with ESAS at week +2 after start of treatment.,2008-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Health related quality of life
4599,NCT04893408,long time survival in patients operated for pancreatic cancer,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
4600,NCT03682276,Incidence of treatment-emergent adverse events [Safety and Tolerability],2019-03-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pathologic response rate
4601,NCT02758951,Phase III (n=358): histological response of colorectal PM to neoadjuvant systemic therapy,2017-06-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
4602,NCT03391232,Number of Participants With Treatment Related Adverse Events,2018-05-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants Having Induced Recruitment of TILs,Number of Predicted Antigen Specific T Cell Responses Per Patient
4603,NCT05932836,Accuracy of Organoid drug sensitivity test in predicting the response to mFOLFOX6 infusion in HCC patients with successful Organoid culture,2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],,The predictive effect of Organoid drug sensitivity test on the survival of patients with HCC.
4604,NCT05752357,Percentage of disease recurrence,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival
4605,NCT03061591,Size of polyps,2017-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Curcumin and curcuminoid levels in urine.
4606,NCT00020774,,1998-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
4607,NCT04605042,diagnostic specificity of WS technique and SNP technique by EUS-FNB,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Cell density of WS technique and SNP technique by EUS-FNB
4608,NCT00436267,Hepatic and systemic toxicity,2006-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Survival
4609,NCT03350126,Disease Control Rate (DCR),2017-12-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Toxicity according to NCI-CTCAE version 4.0 (National Cancer Institute Common Terminology Criteria for Adverse Events),"
4610,NCT01525550,Progression-Free Survival (PFS): Investigator Assessment,2012-06-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Participants With Eastern Co-operative Oncology Group Performance Status (ECOG-PS)
4611,NCT06099821,Progression free survival,2023-10-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,treatment-related adverse event
4612,NCT02106806,oxidative stress markers,2011-05,COMPLETED,INTERVENTIONAL,['NA'],CTCAE,FACIT-F
4613,NCT00583479,Compare the clinical effectiveness of EUS-guided CB performed with a single injection versus two injections of medication into the celiac ganglion region,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,complications related to CB
4614,NCT00582647,"To obtain & store tissues, blood, peritoneal, pleural, cyst & other gastrointestinal fluid from patients with benign or malignant tumors in order to carry out future laboratory studies on the causes, prevention, diagnosis & treatment of certain cancers.",2000-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
4615,NCT04207918,Local control rate,2019-11-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,ctDNA in predicting tumor response rate and prognosis
4616,NCT05212025,Overall Response Rate (ORR),2022-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Incidence of Grade 3 or Higher Treatment-Related Toxicity
4617,NCT03223376,Progression free survival (PFS),2017-10-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,The European Organization for Reasearch and Treatment of Cancer（EORTC ） Quality of Life Questionnaire-Core 30 V3.0 (QLQ-C30 v3.0)
4618,NCT05451043,Investigating and establishing the efficacy of propranolol in boosting the effects of immunotherapy in biliary tract tumors,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
4619,NCT02961296,The rate of exceeding the resistance criteria in Helicobacter pylori(H. pylori) antibiotic susceptibility test(Agar dilution method),2016-10,UNKNOWN,OBSERVATIONAL,['NA'],,The success rate of H. pylori strain separation
4620,NCT05462717,Dose Limiting Toxicities,2022-09-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS)
4621,NCT03115008,Number of polypectomies for gastroenterology trainees to achieve competency,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],,
4622,NCT01460745,Percentage of patients who undergo liver resection following downsizing chemotherapy with or without Erbitux,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,"Percentage of liver resection outcomes R0, R1 and R2"
4623,NCT03278925,"Change in gamma-hydroxy-1,N(2)-propanodeoxyguanosine (gamma-OHPdG) expression in cirrhotic liver",2018-08-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Incidence of hepatocellular carcinoma,Polyphenon E pharmacokinetic data in blood and urine in patients with cirrhosis
4624,NCT03488667,Number of Adverse Events related to toxicity.,2018-06-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Programmed cell death ligand 1 (PD-L1) expression in tumor cells
4625,NCT01717729,recurrence rate,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Complete Ablation
4626,NCT00978549,Overall survival,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Health economic evaluation as assessed by EQ-5D
4627,NCT00253383,Correlate preferences for care and care received as measured by After Death Bereaved Family Member Interview with a family member of the deceased,2003-01,COMPLETED,INTERVENTIONAL,['NA'],,"Caregiver burden as measured by Montgomery-Borgatta Caregiver Burden Scale at baseline, one month, and every three months thereafter (given to caregivers of patients)"
4628,NCT02995850,II: Safety,2017-02-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,RR (response rate)
4629,NCT03316599,The Maximum Tolerated Dose of ficlatuzumab when administered in combination with gemcitabine and nab-paclitaxel,2018-01-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,The progression free survival in this population of patients.
4630,NCT00968175,The efficacy of EUS-CPN and analgesic therapy in pain relief of patients with unresectable pancreatic cancer when compared with analgesic therapy,2009-06,COMPLETED,INTERVENTIONAL,['NA'],,To evaluate the efficacy of EUS-CPN and analgesic therapy in improvement of quality of life (QOL)
4631,NCT01575340,change in inflammatory markers,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,assessing the risk of inflammatory and nutritional complications
4632,NCT01688336,Median Overall Survival (OS) of FOLFIRINOX in Patients With Unresectable Locally Advanced (ULA) Pancreatic Cancer,2012-01,TERMINATED,INTERVENTIONAL,['PHASE2'],"Correlation of Tumor Markers (Ca19-9, CEA) With Outcomes (RR, DCR, PFS, and OS).",Rate of Resectability (RR)
4633,NCT04194268,survival,2019-12-03,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life EORTC QLQ Pan26
4634,NCT04022746,Change in percent non-viable/necrotic tumor,2019-06-11,RECRUITING,INTERVENTIONAL,['NA'],,Change in tumor size and enhancement
4635,NCT03811652,Percentage of patients with changes in laboratory parameters from baseline,2018-12-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
4636,NCT04670718,Visualisation of gastrointestinal tract,2020-12-10,COMPLETED,INTERVENTIONAL,['NA'],,Ability to asses depth of invasion of resected GI early tumor
4637,NCT00825669,overall survival,2008-12,COMPLETED,INTERVENTIONAL,['NA'],,the changes of the PVTT
4638,NCT03168594,Overall response rate (ORR),2017-04-29,TERMINATED,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events （Safety and Tolerability）
4639,NCT00730353,Progression Free Survival Rate at 24 Weeks,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity Profile
4640,NCT04444921,Progression-free survival,2020-11-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events
4641,NCT05278351,Progression free survival time (PFS),2022-07-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
4642,NCT02526836,Lymph nodes harvest,2014-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Survival outcome
4643,NCT02869581,Survival of patients with pancreatic neoplasms,2000-01,RECRUITING,OBSERVATIONAL,['NA'],,Collection of patients characteristics
4644,NCT02491372,Change in psychological flexibility assessed using the Acceptance and Action Questionnaire II,2015-09,WITHDRAWN,INTERVENTIONAL,['NA'],,Change in Quality of life using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Oesophageal and Gastric Cancer
4645,NCT03064308,Feasibility of a home based exercise programme following surgery in the older patient.,2017-06-26,COMPLETED,INTERVENTIONAL,['NA'],Intervention Compliance Questionnaire,Hand Strength Test
4646,NCT04444232,Alters' intent to become screened for CRC in the next six months,2014-09-09,COMPLETED,INTERVENTIONAL,['NA'],,
4647,NCT01079767,3-month disease-control rate according to RECIST criteria,2010-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,3-month objective response rate according to RECIST criteria
4648,NCT03522649,Overall Survival (OS),2018-04-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Disease Control Rate in biomarker positive patients
4649,NCT04072198,ORR,2019-09-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life with QLQ-C30 questionnaire
4650,NCT00583271,,2002-06,COMPLETED,OBSERVATIONAL,['NA'],,
4651,NCT03035279,Number of participants with dose-limiting toxicities (DLT),2017-03-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Maximum observed serum concentration (Cmax) of SC-006
4652,NCT05433402,Disease-free survival,2022-07-20,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Biological Markers,Time occurrence of new primary colon cancer and new polyps
4653,NCT01669356,postoperative body composition change compared to preoperation measurement,2012-07,COMPLETED,INTERVENTIONAL,['NA'],complicatons incidence after surgery,
4654,NCT00885066,Clinical or laboratory toxicities as assessed by CTC,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4655,NCT01882933,Overall survival,2013-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Score QLQ-STO 22
4656,NCT04213222,estimated ORR,2020-10,UNKNOWN,OBSERVATIONAL,['NA'],,estimated OS
4657,NCT02871999,"Pain degree change after surgery, Graded according to Numerical Rating Scale(NRS)",2016-08,COMPLETED,INTERVENTIONAL,['NA'],,Testosterone(Male) in blood
4658,NCT03469284,Change in Pain Scores Assessed Within the Numeric Rating Scale (NRS) Component of the Modified Harris Mucositis-related Pain Assessment Tool,2019-02-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pain Duration
4659,NCT02632864,two-year overall survival,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Hepatobiliary phase signal change after proton beam therapy
4660,NCT05982834,objective response rate,2023-05-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4661,NCT04713891,Clinically significant abnormality in physical examinations,2021-03-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression free survival (PFS)
4662,NCT02585687,Global survival,2012-07,TERMINATED,INTERVENTIONAL,['NA'],,
4663,NCT00378066,time to progression,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"overall survival, safety, response"
4664,NCT04526314,Overall survival,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
4665,NCT01843829,Efficacy,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Efficacy
4666,NCT04081779,Response rate among primary care providers (PCPs) to the PCP survey,2020-02-19,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Local oncology clinics' attitudes towards survivorship care implementation
4667,NCT05914389,TRG0/1,2023-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Minimal Residual Disease (MRD)
4668,NCT00477841,"Relief of dysphagia measured by dysphagia scores, survival time from the interventional procedure to the last follow-up.",2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Successful rate of stent placement, Stent-related complications and morbidity, Overall rate of mortality"
4669,NCT05024097,Number of treated patients who achieve complete pathologic response,2022-03-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
4670,NCT03030508,Disease-free survival,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,Three year disease free survival rate
4671,NCT04310839,30-day readmission rate,2020-11-03,COMPLETED,OBSERVATIONAL,['NA'],,Ileus
4672,NCT02323906,Dose-Limiting Toxicity (DLT),2015-01-16,TERMINATED,INTERVENTIONAL,['PHASE1'],,Time to progression (TTP)
4673,NCT03407040,Availability of stored specimens and/or data,2018-01-30,TERMINATED,OBSERVATIONAL,['NA'],,
4674,NCT01047111,Disease free survival,2010-05,COMPLETED,INTERVENTIONAL,['NA'],,Locoreginal recurrence and recurrence pattern
4675,NCT06088459,All adverse events (AE),2023-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity
4676,NCT03874871,R0 resection rate,2019-03-20,RECRUITING,OBSERVATIONAL,['NA'],,overall survival
4677,NCT04083378,Impact of software use on the minimal margins of ablated lesions properly covered by ablation on a three-dimensional analysis,2020-01-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Liver function
4678,NCT05876338,Change from Baseline in Quality of Life Level on the EORTC QLQ-CR29 Quality of Life,2023-07-11,RECRUITING,INTERVENTIONAL,['NA'],,
4679,NCT03425058,"The concordance and accuracy of response evaluation results determined by ctDNA, CTCs compared with imaging and serum tumor biomarkers(CEA, CA19-9,CA72-4 et al)",2017-11-22,COMPLETED,OBSERVATIONAL,['NA'],,The concordance of mutations in tumor tissue and ctDNA
4680,NCT06168357,Correlation between tumor enhancement in arterial phase expressed as Hounsfield unit number and ADC value.,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
4681,NCT01862003,Best overall response,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Occurrence and Severity of Adverse Events
4682,NCT00023868,,2001-11-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,
4683,NCT02288195,Local-regional failure-free survival,2014-08-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Rate of receiving pre-operative or post-operative chemoradiation
4684,NCT01053182,morbidity of postoperative pulmonary complications,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"diaphragm movement, pulmonary function, stomach emptying"
4685,NCT00630045,disease free survival rate,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,response rate and safety of XELOX as a neoadjuvant regimen
4686,NCT02633098,Recurrence free survival at 2 years,2017-04-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Wnt/β-catenin proliferation pathway protein expression (e.g. c-myc and cyclinD1 proteins)
4687,NCT05333809,Objective response rate (ORR),2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
4688,NCT01003015,Adverse Event Collection,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Full Pharmacokinetics profile of BAY73-4506 and metabolites (for Korea only)
4689,NCT02407392,"Feasibility as assessed by the ratio of patients approached to recruited, percentage of patients who complete both endoscopies",2015-07,UNKNOWN,INTERVENTIONAL,['NA'],,Number of adverse events
4690,NCT01263353,Evaluate safety and tolerability profile of pasireotide LAR in combination with everolimus in patients with advanced metastatic NET,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To assess the biochemical response (chromograninA, CgA) to pasireotide LAR in combination with everolimus"
4691,NCT05577143,Area under the ROC curve (AUC) of the TFPI-1 biomarker,2022-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Extension of c-index to the 3-group case proposed by Van Calster B et al.
4692,NCT04930991,Safety and Tolerability,2021-09-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Correlation
4693,NCT01281943,Progression free survival (PFS),2011-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Polymoprhism assessment
4694,NCT00894725,short-term morbidity rate,2000-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,long-term outcome
4695,NCT05687552,comparison of pet -ct finding with ct finding,2023-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
4696,NCT04518852,overall survival (OS),2020-09-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],conversion rate of hepatectomy,duration of response
4697,NCT05394714,Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D),2022-03-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,Changes in Biomarkers (CEA and CA19-9)
4698,NCT06061744,recurrence,2023-04-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
4699,NCT00093379,2 Year Failure Free Survival,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Progression-Free Survival at 2-Year
4700,NCT05110378,Oxford NOTECHS II,2015-10,COMPLETED,OBSERVATIONAL,['NA'],,
4701,NCT03766607,"Progression free survival, PFS",2019-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse event
4702,NCT02727153,Mortality,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Readmission rate
4703,NCT00899626,Development of new screening strategies based on substances found in tissue and biofluid samples,2002-06,RECRUITING,OBSERVATIONAL,['NA'],,
4704,NCT00489515,Ability of surgically defined sentinel lymph nodes to predict whether other lymph nodes are involved with the tumor,1999-02,COMPLETED,OBSERVATIONAL,['NA'],,
4705,NCT01617278,Mean number of adenomas per colonoscopy,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,To estimate the recruitment rate
4706,NCT05639153,"Part 2: Number, severity and duration of treatment-emergent adverse events (TEAEs) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0",2022-05-13,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity by measurement of Incidence of anti-drug antibodies (ADA)
4707,NCT00842686,Pathological complete remission rate (pCR),2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
4708,NCT00884767,"Correlation of genetic profiles and peptide, protein, and neurotrophic factors with neurological toxicity",2007-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4709,NCT05070156,Evaluate incidence of treatment-emergent adverse events [Safety and Tolerability] after B010-A injection.,2021-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Disease control Time (DDC)
4710,NCT00121914,time to tumour progression,2000-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,causes of death
4711,NCT03462992,AUC of the MonoMark test,2012-12-11,UNKNOWN,OBSERVATIONAL,['NA'],,
4712,NCT04278144,"Objective response rate (ORR) of confirmed complete or partial responses (CR, PR)",2020-02-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of potential-immune related toxicities
4713,NCT00539253,Nodule Enhancement,2007-09,COMPLETED,INTERVENTIONAL,['NA'],,
4714,NCT05751265,Objective Response Rate (ORR),2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival
4715,NCT05609396,Uptake,2022-05-03,COMPLETED,INTERVENTIONAL,['NA'],,"Uptake by deprivation, sex and age"
4716,NCT02349412,Change in Quality of Life (QOL) From Baseline to Week 12 Per the Functional Assessment of Cancer Therapy-General (FACT-G),2015-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Concordance Between Patient and Family Caregiver Report of Prognosis/Curability
4717,NCT04811898,The recommended phase II dose of LNA-i-miR-221 (RP2D),2019-01-14,COMPLETED,INTERVENTIONAL,['PHASE1'],,To assess the efficacy of LNA-i-miR-221
4718,NCT00786058,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
4719,NCT02328716,disease-free survival period,2012-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Study of Ex vivo correlation.
4720,NCT01681446,disease free survival,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of Participants with Adverse Events
4721,NCT00224692,Pain score,2003-02,TERMINATED,INTERVENTIONAL,['PHASE3'],,
4722,NCT02425683,Number of Patients Completing Full 6 Cycles,2015-03-26,TERMINATED,INTERVENTIONAL,['PHASE2'],,Disease-free survival (DFS)
4723,NCT04121286,Find Recommended Phase 2 Dose (RP2D) of JAB-3312,2020-06-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of response ( DOR )
4724,NCT05785975,To assess if positive subjects are complying with follow-up screening,2023-06-15,RECRUITING,INTERVENTIONAL,['NA'],,
4725,NCT00152217,Overall survival,2001-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Relapse-free survival, adverse events"
4726,NCT05994456,Pathological complete remission (pCR) rates,2023-03-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Related Adverse Events
4727,NCT00073138,Objective Response Rate in subjects with Recurrent Colorectal Cancer,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicities associated with treatment administration
4728,NCT02587793,survival,2014-10,COMPLETED,OBSERVATIONAL,['NA'],,cancer progression
4729,NCT02724202,Determine the safety using curcumin in patients with metastatic colon cancer; where toxicities will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.,2016-03,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Duration of Quality of Life
4730,NCT01262417,abdominal and peri-hepatic adhesion during the second operation,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,tumour evolution in patients
4731,NCT02931929,"Preliminary targeting properties of 68Ga-NeoBOMB1 in advanced, GRP positive GIST tumours as assessed by SUV",2016-11-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To extrapolate absorbed tumour doses for potential application of 177Lu NeoBOMB1 (in first 6 patients)
4732,NCT03085004,Incidence of serious and minor adverse events occurring within 30 days post ablation,2019-04-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,
4733,NCT00411762,Median Progression Free Survival,2006-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Overall Survival
4734,NCT02816879,Accuracy of cytology specimens for Dacron swab compared to flocked nylon (NF) swab in predicting histology outcome,2013-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"Cost effectiveness analysis evaluating differences in survival, the cost of out-patient procedures & in-patient hospitalizations for invasive anal cancer."
4735,NCT03130621,Pedigree analysis,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],,somatic mutation landscape of hereditary upper gastrointestinal cancer
4736,NCT00630240,"The blood levels of anticancer drugs (epirubicin, mitomycin C and cisplatin) will be determined within one hour and at the third day after TACE.",2008-02,COMPLETED,OBSERVATIONAL,['NA'],,
4737,NCT02717923,Progression-Free Survival of maintaining treatment（mPFS）,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4738,NCT04030637,Accuracy of COLOSAFE,2019-02-11,UNKNOWN,OBSERVATIONAL,['NA'],,
4739,NCT01251458,• To establish the maximum tolerated dose (MTD) and a suitable dose for Phase II evaluation of Torisel® given as a weekly dose in patients with advanced hepatocellular carcinoma (HCC),2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,• To determine overall survival (OS)
4740,NCT03278327,Suggest that there are significantly more than 60 % of patients with a relative decrease of at least 50 % between the total percentages of esophageal time crossed in pH4 (Ph metric dosage) before and after endoscopic treatment.,2017-06-27,UNKNOWN,INTERVENTIONAL,['NA'],,Use of Inhibitor of the pump with proton (PPI)
4741,NCT02968810,Change in serum AFP-L3%,2017-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Change in serum immune markers,Change in Model for End-Stage Liver Disease score
4742,NCT02607787,Feasibility,2015-04,UNKNOWN,INTERVENTIONAL,['NA'],,Capillary blood sample
4743,NCT02404753,3-year progression-free survival,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Postoperative quality of life
4744,NCT02859415,Number of Participants Whose Best Response is a Complete Response (CR) or Partial Response (PR),2019-08-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With a Dose-limiting Toxicity (DLT),"To Develop Methodologies for Assessing Effects of Mithramycin on Cancer Stem Cells, Hematopoietic Stem Cells, Mesenchymal Stem Cells, and Circulating Tumor Cells (CTC)"
4745,NCT00594113,CRC screening completion,2007-08,COMPLETED,INTERVENTIONAL,['NA'],,"PAPM stage and perceived barriers among participants preferring various screening methods (iFOBT, Colonoscopy)"
4746,NCT01128387,MTD of Panitumumab in Combination With Cisplatin/Fluorouracil and Radiation for Locally Advanced Esophageal Cancer Determined by Number of Participants Experiencing DLT,2010-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pathologic Response
4747,NCT00598247,RECIST Response,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Toxicity
4748,NCT05728606,Total incidence of postoperative complications,2023-01-20,RECRUITING,INTERVENTIONAL,['NA'],,Robotic surgical completion rate
4749,NCT01624025,disease control rate according to the RECIST v1.1,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4750,NCT02175914,CT and MRI imaging for desmoids,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
4751,NCT04885439,Patient and Caregiver Anxiety,2015-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Patient Symptom Burden
4752,NCT00492193,Time to upper and lower GI recovery and post-operative hospital length of stay.,2007-06,COMPLETED,OBSERVATIONAL,['NA'],,Postoperative ileus related mobidity.
4753,NCT05616039,Clinical outcomes- Microscopic positive resection margin rate,2022-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Complications
4754,NCT05904886,Overall Survival (OS),2023-09-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
4755,NCT01730937,Overall Survival,2013-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality Adjusted Life Years
4756,NCT01996969,Predictive biomarker in terms of disease control rate,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,Assessment of adequate response evaluation modality after regorafenib treatment
4757,NCT01669720,Number of Patients Who Progressed,2012-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Number of Participants Who Experienced a Toxicity Profile of Adjuvant Ziv-aflibercept, up to 2-years of Duration, for Patients Who Previously Received Systemic Perioperative Therapy (Regimen) and Surgical Resection/Ablation."
4758,NCT02576184,radiological incisional hernia rate,2015-12,COMPLETED,INTERVENTIONAL,['NA'],,Clinical incisional hernia rate
4759,NCT02484404,Ph I Determine the recommended phase II dose (RP2D) and the safety of doublet therapies of Durvalumab/olaparib (Durvalumab-O) and Durvalumab/cediranib (Durvalumab-C) in patients with advanced solid tumors,2015-06-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Ph I doublet tx: determine the pharmacokinetics of the doublets and correlate with safety.
4760,NCT01418742,"Time until unblinding of skin therapy allocation (basic skin treatment with or without doxycycline) due to insufficient efficacy (i.e. unbearable skin toxicity, measured by patient's allocating point 6 through 10 on a visual analogue scale)",2011-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Severity of panitumumab related adverse events
4761,NCT06196658,Objective Response Rate,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,5) Volume of ascites measured by ultrasonography and/or frequency and volume of ascites aspiration
4762,NCT03253107,Discovery of predicting bio-markers for gastric cancer chemotherapy response,2015-11-30,RECRUITING,OBSERVATIONAL,['NA'],,Combination prediction model for palliative chemotherapy response in gastric cancer
4763,NCT03898895,"Progression-free survival, PFS",2019-12-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Disease control rate, DCR"
4764,NCT05830019,local progression-free survival,2021-06-01,RECRUITING,INTERVENTIONAL,['NA'],,adverse events
4765,NCT04141566,Specific Quality of life of patients with PCPC and PLIC,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,90 day morbidity and mortality rate
4766,NCT01671891,circulating tumor cells level changes after radiotherapy,2012-02,UNKNOWN,OBSERVATIONAL,['NA'],,RECIST-based tumor response at 10 week after radiotherapy
4767,NCT03169842,Cyst fluid glucose level,2017-05-25,COMPLETED,INTERVENTIONAL,['NA'],,
4768,NCT01457287,Cognitive Function,2003-10,COMPLETED,OBSERVATIONAL,['NA'],,Potential mechanisms leading to fatigue and/or cognitive decline
4769,NCT02065037,Polyp Detection Rate,2014-06,TERMINATED,INTERVENTIONAL,['NA'],patient comfort by a validated nurse administered comfort score,advanced lesion per patient detection rate
4770,NCT05914987,Number of Subjects Receiving Targeted Therapy,2023-12-04,RECRUITING,OBSERVATIONAL,['NA'],,
4771,NCT04980157,Colorectal Cancer Screening Status,2021-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
4772,NCT03748485,disease free survival,2019-04-30,RECRUITING,INTERVENTIONAL,['NA'],,complication in 30 days post surgery
4773,NCT02808780,"Long-term Safety: Participants with Adverse Events of Interest (AEIs) and Serious Adverse Events (AEs) Including Malignancies, Pregnancies, and Non-serious Malignancies",2016-12-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Health Care Utilization: Evaluate the Reasons for Hospitalization in Participants in Each Cohort
4774,NCT02191969,To measure the change in fatigue after three months between the intervention and control arm,2014-06,COMPLETED,INTERVENTIONAL,['NA'],,To measure changes in Self-Efficacy at baseline between the intervention and control groups.
4775,NCT00988741,Evaluate time to progression among all patients treated with ARQ 197 compared to placebo,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Further evaluate pharmacokinetics of ARQ 197.
4776,NCT00651677,operative time,2011-04,WITHDRAWN,INTERVENTIONAL,['NA'],,urinary and sexual function
4777,NCT03544255,Number of organoids successfully generated from pancreatic cancer biopsies,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Response of the pancreatic cancer organoids to the selected anti-cancer drugs
4778,NCT02298907,Oxygen uptake at lactate threshold,2010-06,COMPLETED,OBSERVATIONAL,['NA'],,Number of patients with adverse post-operative outcome measures
4779,NCT03951337,Relationship between early tumor uptake of 64Cu-ATSM PET/CT images and prediction of histological response to neo-adjuvant chemo-radiotherapy treatment,2019-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,64Cu-ATSM toxicity
4780,NCT05419011,"Cumulative incidence rate of the composite endpoint of adenomas (tubular, tubulovillous and serrated), advanced adenomas and colon cancer",2023-03-22,RECRUITING,INTERVENTIONAL,['PHASE2'],Immune cell gene enrichment analysis,Incidence of extracolonic neoplasms
4781,NCT03221335,Severe adverse events,2016-05,RECRUITING,INTERVENTIONAL,['NA'],,Survival
4782,NCT03276156,Incidence of adverse events,2016-02-23,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Quality of life(QoL)
4783,NCT04336241,Recommended Phase 2 dose (RP2D) of RP2,2019-10-17,RECRUITING,INTERVENTIONAL,['PHASE1'],,Percentage of stable disease (SD)
4784,NCT02512263,Muscular strength measured by Microfet,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],,Depression measured by questionnaire
4785,NCT01897636,pancreatic tumor response rates,2013-12,UNKNOWN,INTERVENTIONAL,['NA'],,survival rates
4786,NCT01883336,Progress of pancreatic cyst,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
4787,NCT05752890,To distinguish the clonality of recurrent HCC as the original or a de novo one for post-radiotherapy patterns of failure,2023-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
4788,NCT00088933,Number of patients experiencing each of the toxicities by grade for each treatment arm,2004-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,Average quantity of circulating CEA cells determined by quantitative real time RT-PCR
4789,NCT01821482,progression-free survival(PFS),2013-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Laboratory findings,quality of life (QOL)
4790,NCT04160897,The 5-year cumulative incidence of hepatocellular carcinoma,2019-10-22,UNKNOWN,OBSERVATIONAL,['NA'],,The 5-year cumulative liver disease-related mortality
4791,NCT01618474,disease free survival,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,CTC negative conversion rate
4792,NCT00734890,Toxicity,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4793,NCT02549755,To Compare Changes in 11C-acetate Uptake at One and Three Months Following Radiotherapy With Pre-treatment Uptake of 11C-acetate,2015-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
4794,NCT00161213,Progression-free Survival,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
4795,NCT03319459,Incidence of dose-limiting toxicity (DLT),2018-01-18,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (PK) of FATE-NK100
4796,NCT03496441,Evaluate the feasibility of fecal samples' analysis,2018-01-30,COMPLETED,OBSERVATIONAL,['NA'],,Evaluation the presence of a correlation between fecal microbiota composition and the risk of anastomotic leak.
4797,NCT05440708,Phase 2: Overall Response Rate (ORR) to TTI-101,2023-03-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Cohort A and Cohort B: Pharmacodynamics of TTI-101 as Measured By Change from Baseline in Percentage of Phosphorylated Signal Transducer and Activator of Transcription 5 (pY-STAT5) Positive Cells in Tumor Biopsy Samples
4798,NCT03554434,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
4799,NCT06250075,The use of probiotics can modify the incidence of postoperative complications,2020-12-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Modulation of nutritional parameters using probiotics-phase angle
4800,NCT04779554,Drug Half-Life (T1/2) - Pharmacokinetics,2021-06-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,
4801,NCT01946854,Tumor Growth Rate,2013-07-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
4802,NCT04506983,Percentage of adverse events,2022-06-10,SUSPENDED,INTERVENTIONAL,['PHASE1'],,Proliferation ratio of CAR-T cells
4803,NCT05358249,PhaseII: Overall Response Rate by Blinded Independent Review Committee (BIRC) per RECIST 1.1,2022-10-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Dose intensity by treatment
4804,NCT04302363,Diagnostic efficacy of colorectal cancer model in Chinese people,2018-02-01,UNKNOWN,OBSERVATIONAL,['NA'],Effects of intestinal microflora and DNA methylation under different stool characteristics,Effect of diet on intestinal flora and DNA methylation in Chinese people
4805,NCT01234246,,2010-03,UNKNOWN,OBSERVATIONAL,['NA'],,
4806,NCT01962246,Disease-free survival(DFS),2012-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Death related to operation
4807,NCT00511576,To determine the overall tumor response of orally administered MGCD0103 in combination with IV docetaxel according to Response Evaluation Criteria in Solid Tumors (RECIST) methodology.,2007-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,
4808,NCT03500757,Standard System Usability Score on a Likert Scale,2018-04-29,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
4809,NCT03472833,25(OH) vitamin D,2018-04-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,Quality of Life questionnaire
4810,NCT00006009,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4811,NCT03429816,Aim 2: Correlation of molecular subtypes with histological response after neoadjuvant therapy in patients,2018-04-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Aim 2: Correlation of molecular subtypes with overall survival,Aim 2: Correlation of molecular subtypes with relapse-free survival
4812,NCT00988195,"Plasma arginase and arginine levels,as well as tumour response, i.e. an effect on growth in the milieu of arginine depletion.",2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Overall Survival, Time to Progression"
4813,NCT00164892,Recurrence free survival and the quality of life score within the two years of study period,2004-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival in long term
4814,NCT03963726,PFS,2019-06-03,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life score of tumor patients(0-60)
4815,NCT05533892,Objective response rate (ORR) at 6 months,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of response (DOR)
4816,NCT02592603,Number of serrated lesions >=5mm,2015-10,COMPLETED,INTERVENTIONAL,['NA'],,Proportion of minor adverse events
4817,NCT02106871,Skeletal Muscle Fatigue,2014-04,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
4818,NCT01460589,3-year disease free survival rate,2011-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,side effects of chemotherapy
4819,NCT01972373,Sensitivity of the marker bevacizumab-IRDye800CW,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Collection of safety regarding administration of Bevacizumab-IRDye800CW
4820,NCT02336724,Disease Control Rate,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
4821,NCT01227239,Phase II: pathological complete response rate,2010-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,safety
4822,NCT05818267,duration of disease control(DDC),2023-06-26,RECRUITING,INTERVENTIONAL,['NA'],,The incidence of adverse events
4823,NCT03757754,The number of dose-limiting toxicity,2015-06-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Area under the concentration-time curve from zero extrapolated to infinity (AUC0-∞)
4824,NCT05739110,Overall survival,2022-07-15,COMPLETED,OBSERVATIONAL,['NA'],,Disease-free survival
4825,NCT06189898,Progression free survival,2023-12-15,RECRUITING,OBSERVATIONAL,['NA'],,loco-regional recurrence free survival
4826,NCT00003431,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4827,NCT04172532,Progression-free survival rate (Phase II),2021-01-11,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Gene signature of cell-free DNA from peripheral blood,Gene signature of tumor
4828,NCT00795184,"Comparative Histopathology-confirmed Measures of Per Lesion Sensitivity and Per Lesion Specificity, by Using pCLE Associated With WLE, or WLE Alone, for the Detection of High Grade Dysplasia and Early Carcinoma in Barrett's Esophagus.",2008-11,COMPLETED,INTERVENTIONAL,['NA'],,
4829,NCT01938326,Maximum pain score using VAS at postoperative day#1,2017-09-01,COMPLETED,INTERVENTIONAL,['NA'],,EORTC-C30 and STO22
4830,NCT03115957,Morbidity of infection,2017-04-14,COMPLETED,INTERVENTIONAL,['NA'],,Laboratory examination
4831,NCT04058236,Changes in serum heparan sulfate concentrations,2019-08-15,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Changes in levels of Inflammatory markers Interleukin-1 and CRP
4832,NCT03043313,Confirmed Objective Response Rate (cORR) Per RECIST 1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B,2017-06-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-Emergent Laboratory Abnormalities (Chemistry)
4833,NCT01834014,To evaluate the values of angiogenesis-related growth factors in plasma with Progression-free survival (PFS),2013-05,COMPLETED,INTERVENTIONAL,['NA'],,Exploratory analysis of the relevance of tumor size and expression level of angiogenesis-related growth factors in plasma
4834,NCT04372992,Percentage of participants with good compliance to adjuvant therapy,2020-09-01,TERMINATED,INTERVENTIONAL,['NA'],,Costs analysis
4835,NCT02138929,"Maximum Tolerated Dose (MTD) of LDE225 in Combination with Everolimus in Participants with Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction (GEJ) or Stomach in the Second or Third Line Setting",2014-11-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Safety of LDE225 in Combination with Everolimus in a Cohort of Participants with Metastatic Nuclear Gli-1 Expressing Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach per CTCAE."
4836,NCT03404076,Progression free survival after a three year follow-up,2014-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
4837,NCT04246203,DFS,2021-12-12,RECRUITING,OBSERVATIONAL,['NA'],,
4838,NCT03042416,Immediate safety evaluation,2017-06-29,COMPLETED,INTERVENTIONAL,['PHASE3'],,Perceived clinical benefit
4839,NCT00094809,Grade 4 Neutropenia,2003-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Antibiotic Use Due to Febrile Neutropenia
4840,NCT02800330,"As primary endpoint, AUC of regorafenib alone and AUC of regorafenib with esomeprazole (concomitantly and 3 hours before regorafenib intake, respectively) will be related.",2016-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,The clearance of regorafenib alone and regorafenib with esomeprazole (concomitantly and 3 hours before regorafenib intake respectively) will be related
4841,NCT05817201,Overall survival,2022-07-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Progression-Free survival
4842,NCT00131599,,2002-08,UNKNOWN,OBSERVATIONAL,['NA'],,
4843,NCT05280379,Levels of pro-inflammatory cytokines en chemokines,2022-09-19,RECRUITING,OBSERVATIONAL,['NA'],Carcino-embryonal antigen,
4844,NCT01246986,Time to Progression (TTP),2011-03-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Worsening (TTW) of Symptoms (FACT-Hep)
4845,NCT00010270,,2001-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
4846,NCT00982059,The proportion of screened patients with any polyp or any high risk polyp will be calculated.,2008-05,COMPLETED,OBSERVATIONAL,['NA'],,Proportion calculation/identification of: demographic/treatment influences on polyp prevalence; subgroups w/polyp prevalence >20%; pts with polyps beyond 30cm flexible sigmoidoscope; pts with adenomatous polyp(s) on colonoscopy in/outside prior RT fields
4847,NCT01640665,Maximum Tolerated Dose / Safety,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response
4848,NCT02915965,overall survival rate,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of adverse event based on CTCAE 4.0
4849,NCT05638048,Incidence of Peripheral central venous catheter-associated thrombosis in patients with PICC tube,2022-07-10,COMPLETED,INTERVENTIONAL,['NA'],,Patients' satisfaction with health education after PICC catheterization
4850,NCT00525785,Complete Pathologic Response Rate,2004-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4851,NCT02399943,"Percentage of patients who experience complete response, partial response, or stable disease",2015-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Date of first confirmed response to the first date in which progression is observed
4852,NCT06089369,Recurrence-Free Survival (RFS) at 24 Months,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Hepatocellular Carcinoma Module (EORTC QLQ-HCC18) Scale Score
4853,NCT01129206,Overall Response,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlation of FDG PET Response With Response Rate
4854,NCT05987514,predicting HCC response to treatment,2021-10-07,RECRUITING,INTERVENTIONAL,['NA'],,predicting disease-free survival
4855,NCT02325648,pulmonary vascular permeability index,2014-12,COMPLETED,OBSERVATIONAL,['NA'],,
4856,NCT03412994,Progression-free survival (PFS),2018-02-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life(QoL)
4857,NCT01574027,Reduction in ACF biomarkers,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4858,NCT05686499,ratio of low-fidelity simulator trained endoscopists with improved colonoscopy performance on real patients to high-fidelity simulator trained endoscopists with improved performance on real patients,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
4859,NCT05303714,Secondary Resectability Rate (percent),2022-03-31,RECRUITING,INTERVENTIONAL,['PHASE3'],,Complication rate
4860,NCT05880472,Number of adverse event per patient per grade by CTCAE v5.0,2023-05,RECRUITING,INTERVENTIONAL,['NA'],Implantation experience by questionnaire to the operator,Operator hand and total body dose (mSv)
4861,NCT04358354,Overall Survival (OS),2020-10-22,RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment associated toxicities
4862,NCT00974948,"Absolute and relative changes in 7-point Likert-score for abdominal pain at 1 and 3 months post-randomization. Secondary endpoints were change in morphine equivalent consumption (MEQ), quality of life (DDQ-15), and overall survival.",2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,2. Quality of life 3. Survival
4863,NCT00994864,"Examine the predictive value of PET-assessed tumour FDG uptake response after one course of preoperative chemotherapy on the outcome of adjuvant therapy, measured by 3-year DFS.",2009-11,COMPLETED,INTERVENTIONAL,['NA'],,Create a frozen tumour bank for future studies
4864,NCT04595838,The incidence of severe oral mucositis symptomatic events observed during the second cycle of chemotherapy.,2020-08-31,COMPLETED,INTERVENTIONAL,['NA'],,Analgesic use to control mouth pain
4865,NCT04736121,Duration of Response (DoR),2021-05-28,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life metrics - EQ-5D-5L Questionnaire
4866,NCT00449163,Overall Survival up to 2 Years,2006-03-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Rate of Toxicity in Study Participants
4867,NCT02621658,Adenoma Detection Rate,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,Patient satisfaction
4868,NCT00882869,To evaluate the efficacy of AEG35156 in combination with sorafenib based on PFS(PII) using sorafenib alone for comparison,2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To determine the response rate of AEG35156 in combination with sorafenib in advanced HCC
4869,NCT01560949,Number of Participants With Resectability Rate,2012-06-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Correlative Studies Including DPC4 (SMAD4) Staining and Circulating Tumor Cells (CTC) Post-Surgery
4870,NCT03499626,Definition of MTD (maximum tolerable dose),2017-05-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression Free Survival
4871,NCT02074202,The pathological diagnosis of the liver tumor will be compared with the test result of the PET/CT scan findings.,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
4872,NCT02415699,Disease free survival,2015-08,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Side Effect
4873,NCT04695847,Part 2: Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigators,2021-01-13,COMPLETED,INTERVENTIONAL,['PHASE1'],,Part 2: Number of Participants with Corrected QT Interval (QTc)
4874,NCT06084234,Proportion of HCC detected at late stage,2023-12-26,RECRUITING,INTERVENTIONAL,['PHASE4'],,Number of participants who encountered screening related Psychological harm
4875,NCT04514497,Occurrence of grade 4 hematologic AEs (Dose Expansion Phase),2021-10-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Tumor deoxyribonucleic acid damage response (DDR) gene mutations present,Changes in tumor expression patterns of pS343-NBS1
4876,NCT06252974,Accurate diagnose the invasion depth of early esophageal squamous cell carcinoma by endoscopy NBI images through deep neural network analysis,2024-02-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
4877,NCT02499939,Functional Assessment of Cancer Therapy Gynecological Oncology Group Neurotoxicity-12 item scale,2016-02-10,COMPLETED,INTERVENTIONAL,['NA'],,Balance Assessment
4878,NCT00062283,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4879,NCT01442324,Effectiveness of IRE for the treatment of metastatic liver cancer or cholangiocarcinoma.,2011-02,UNKNOWN,INTERVENTIONAL,['NA'],,Time to in situ recurrence
4880,NCT05621707,Overall Survival Rate,2022-11-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment related complications
4881,NCT00593073,Baseline assessment while waiting to see primary care physician and 90-day follow-up telephone survey.,2005-07,COMPLETED,INTERVENTIONAL,['NA'],,Follow-up survey to assess participant discussion of colorectal cancer with their healthcare provider and compliance with CRC screening
4882,NCT05277675,1-year overall survival,2021-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,immune-related adverse events
4883,NCT03665714,Change of Serum Prealbumin level,2018-10-23,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of postoperative Infections
4884,NCT02999217,Changes in haemoglobin level,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Duration of hospital stay
4885,NCT06149546,Effectiveness of a multi-modal nutrition-led intervention in preventing loss of muscle strength (hand-grip strength) during chemotherapy,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Effectiveness of the intervention compared to the control on Overall Survival
4886,NCT00398333,"To assess the efficacy of a nutritional intervention with supplementation enriched in EPA to improve the tolerance to the antineoplastic treatment, using the variation in quality of life changes as the tolerability index.",2005-06,TERMINATED,INTERVENTIONAL,['PHASE4'],,To assess the effect of a nutritional supplement over the nutritional status of the patient with disseminated neoplastic illness.
4887,NCT05708924,Determine Maximum Tolerated Dose (MTD) of FT538,2023-04-28,SUSPENDED,INTERVENTIONAL,['PHASE1'],Tumor biopsies (if feasible) at the time of catheter placement and catheter removal for study related analysis,Adverse Events
4888,NCT02448966,Long term survival,2015-01,UNKNOWN,OBSERVATIONAL,['NA'],,Postoperative complications
4889,NCT02157974,Hepatic glucose release,2014-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Bile Acid Metabolomics: sphingosine-1-phospate,Hepatic de novo lipogenesis
4890,NCT05368051,pathologic complete response（pCR）,2021-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
4891,NCT05612477,Feasibility -Accrual,2023-01-21,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Safety- HCC recurrence
4892,NCT03925883,Rate of follow-up colonoscopy,2019-07-29,COMPLETED,INTERVENTIONAL,['NA'],,
4893,NCT01624090,Number of Participants With an Objective Response (Complete Response + Partial Response),2012-09-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Serious and Non-Serious Adverse Events
4894,NCT04692545,Length of hospital stay,2016-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Prolonged length of stay
4895,NCT05983406,DEP accuracy,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,
4896,NCT05334069,Provision of blinded reference set of cancer versus non-cancer blood samples,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Test performance at the time of initial cancer diagnosis by clinical stage
4897,NCT04206254,2-year recurrence-free survival rate,2019-12-19,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall survival
4898,NCT04667403,Satisfaction of patients with advanced or metastatic pancreatic cancer of the impact of telemedicine in the management of their pain.,2022-02-07,UNKNOWN,INTERVENTIONAL,['NA'],,Number of unscheduled hospitalizations recorded of each patient.
4899,NCT05327452,Change in Physical Activity Participation,2022-10-31,RECRUITING,INTERVENTIONAL,['NA'],,Biomarkers for Cardiovascular and Metabolic Health - c-reactive protein
4900,NCT05118724,Disease-free Survival (DFS),2021-12-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
4901,NCT05617430,Progression free survival (PFS) per RECIST v1.1,2022-11-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
4902,NCT00124163,,2005-07,UNKNOWN,OBSERVATIONAL,['NA'],,
4903,NCT04430985,Disease-free Survival at 3 years,2020-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],"Explorative analysis of biomarkers predictive of response to the combination of nivolumab, ipilimumab in combination with FOLFOX",Safety and tolerability of the treatment
4904,NCT02230553,overall response rate,2014-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
4905,NCT01347697,Performance in Timed-Stands Test,2011-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Local recurrence
4906,NCT05797870,The objective response rate,2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
4907,NCT01464918,Total time taken to complete the ESD procedure,2011-11,UNKNOWN,INTERVENTIONAL,['NA'],,Safety
4908,NCT02869503,Survival of patients with colorectal cancer,2001-01,RECRUITING,OBSERVATIONAL,['NA'],,Collection of patients characteristics
4909,NCT00077298,Time to tumor progression,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
4910,NCT02647671,Colonic-mucosal Associated Metabolomic Profile.,2016-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biomarkers of liver function
4911,NCT05030493,Progression-Free Survival (PFS),2021-08-31,RECRUITING,OBSERVATIONAL,['NA'],,"Evaluation of Correlation between Change in Gene Expression Region in Tumor Tissue at Baseline and Discontinuation of Protocol Treatment of Main Study, and Efficacy Endpoints (OS and PFS)"
4912,NCT00524121,Overall Survival,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response by EGFR Mutation Status
4913,NCT02916199,Incidence rate of post-endoscopic retrograde cholangiopancreatography,2016-10-04,COMPLETED,INTERVENTIONAL,['NA'],,Success rate of stone removal
4914,NCT02460822,Patient Satisfaction and Usability of the MyChemoCare Application,2014-10,COMPLETED,INTERVENTIONAL,['NA'],,Improved Quality of Life
4915,NCT05969899,Objective Response Rate（ORR）,2023-07-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate（DCR）
4916,NCT05175092,Overall Survival (OS),2023-11,WITHDRAWN,INTERVENTIONAL,['NA'],,Quality of Life Survey Score: EORTC QLQ-LMC21
4917,NCT06009484,Postoperative venous thromboembolic event,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
4918,NCT05453435,12-month HBV reactivation rate,2022-07-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of HBV-related chemotherapy disruption
4919,NCT06252545,The clinical trial education and communication needs,2024-02-02,RECRUITING,INTERVENTIONAL,['NA'],,
4920,NCT02119065,Absolute difference in post-therapy Yttrium-90 microsphere and pre-therapy Technetium-99m macroaggregated albumin hepatopulmonary shunt fraction values,2014-01-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,In vitro Technetium-99m macroaggregated albumin particle size and microsphere size for each patient
4921,NCT04461561,"The NoMAD Instrument, to describe respondents' experiences of using the intervention in the workplace.",2020-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,"The interview, using framework analysis, informed by normalization process theory toolkit"
4922,NCT04847063,To determine the correlation between ex vivo simulated HIPEC in the SMART system and in vivo HIPEC with respect to two measures of response to treatment: percent necrosis and Ki-67,2021-10-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,To measure Quality of Life by FACT-C and EQ-5D-5L
4923,NCT00049296,"Determine the maximum tolerated dose of docetaxel when administered with thalidomide in patients with advanced solid tumors, multiple myeloma, and non-Hodgkin's lymphoma.",2002-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4924,NCT02699606,Objective Response Rate (ORR),2016-07-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Plasma Concentration of Erdafitinib
4925,NCT02380443,To evaluate the anti-tumor effect of AlloStim combined with cryoablation at the new proposed dose and frequency schedule (Part 2),2016-09,COMPLETED,INTERVENTIONAL,['PHASE2'],"Immunological response 9whether immune response correlates with Overall Survival (OS), RECIST and histopathology)",To assess change from baseline in Health-Related Quality of Life (HRQoL)
4926,NCT05524844,Correlation between Enterobacteriaceae (from 16S) and NOTCH3 expression in BE tissue.,2021-02-09,RECRUITING,OBSERVATIONAL,['NA'],,
4927,NCT05512182,objective response rate (ORR),2022-09-15,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0
4928,NCT04687631,Conversion resection rate of liver metastases,2021-01-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,time interval from chemotherapy to hepatectomy
4929,NCT02239328,Patient Reported Outcomes Measurement Information System (PROMIS) Scores.,2014-08,COMPLETED,OBSERVATIONAL,['NA'],,
4930,NCT00940316,Tumor Response Rate Based on Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD),2010-01-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Effect on Downstream Targets of Epidermal Growth Factor Receptor (EGFR) in Skin Rash Associated With Pharmacologic EGFR Inhibition
4931,NCT03628079,Tumour response: CT/MRI assessed according to RECIST 1.1,2018-05-25,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Association between S-mebendazole and efficacy and safety,Change in tumour load and TTP according to irRECIST
4932,NCT01392027,Validation of glycoprotein panel as a pancreatic cancer biomarker,2011-04,COMPLETED,INTERVENTIONAL,['NA'],,
4933,NCT00242502,Progression-free Survival (PFS) Rate,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4934,NCT05469061,pCR,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease-free Survival，DFS
4935,NCT04217083,Test Sensitivity and specificity for colorectal cancer,2019-01-02,UNKNOWN,OBSERVATIONAL,['NA'],,Test Sensitivity and specificity for colorectal polyps
4936,NCT04787354,disease-free survival,2021-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Toxicity profiles
4937,NCT00159445,"To assess time to progression in patients with metastatic colorectal cancer treated with a combination of gemcitabine and capecitabine after progressing on two or more therapies for advanced disease, and having failed both CPT-11 and Oxaliplatin bas",2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,To test the hypothesis that increased gene expression levels predict chemoresistance to capecitabine.
4938,NCT01276379,Progression Free Survival,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumoral Response
4939,NCT04033107,Progression-free survival,2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v3.0
4940,NCT03990532,Overall survival (phase II),2019-04-30,RECRUITING,INTERVENTIONAL,['NA'],,1-year local progression-free survival
4941,NCT02066233,Median Tolerability Score on 10-point Visual Analog Scale (VAS),2014-03,COMPLETED,INTERVENTIONAL,['NA'],,"Preference for Either of the Two Procedures, EG II Scan Versus Standard Endoscopy"
4942,NCT01693861,Effect of chemotherapy on urinary excretion of modified nucleosides,2012-10,COMPLETED,OBSERVATIONAL,['NA'],Identification of modified nucleosides as biomarkers for colorectal cancer,
4943,NCT05587387,Overall survival (OS 2),2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Adverse event
4944,NCT03828266,Abdominal Infection rate after colorectal surgery.,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Outcome of Abdominal Infection Treatment
4945,NCT04512417,Progression-free Survival (PFS) per RECIST 1.1,2020-08-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Failure mode
4946,NCT03995017,Overall Response Rate (ORR),2020-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
4947,NCT04494945,Cascade screening rate among Lynch or HBOC positive carriers,2020-03-09,RECRUITING,INTERVENTIONAL,['NA'],,
4948,NCT02044224,Patient Satisfaction With Anaesthesia Technique,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Description of patient characteristics
4949,NCT02693847,Proportion of patients who developed a first liver decompensation of cirrhosis during follow-up,2006-02,COMPLETED,OBSERVATIONAL,['NA'],,All cause mortality
4950,NCT05412576,The incidence of moderate to severe pain (NRS score≥4）during movement (i.e.deep breathing) 24 hours after surgery,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Length of hospital stay
4951,NCT04201730,The time to first flatus,2019-12-25,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of postoperative complications
4952,NCT00193817,Overall survival,2005-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of Life
4953,NCT01077869,Feasibility of FDG-PET in the evaluation of radiation-induced mucositis.,2010-01,TERMINATED,OBSERVATIONAL,['NA'],,
4954,NCT02638766,Disease Control Rate,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life by EQ-ED-5L questionnaire
4955,NCT00416793,Overall Survival Rate at 6 Months,2006-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Response Rate
4956,NCT06286956,Assess that the use of the device meet the established functional requiremnt of allowing the removal of polyps,2021-04-19,RECRUITING,INTERVENTIONAL,['NA'],,Assessment of anorectal continence
4957,NCT00004234,,1999-08-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
4958,NCT04181970,Percentage of patients with advanced GIST with available molecular status of KIT/PDGFR before initiating systemic therapy for advanced disease,2019-06-30,RECRUITING,OBSERVATIONAL,['NA'],,Percentage of amputation
4959,NCT01060423,Progression free survival rate,2010-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
4960,NCT03516448,OS （Overall Survival）,2016-03-24,UNKNOWN,INTERVENTIONAL,['PHASE3'],,RFS(Recurrence Free Survival)
4961,NCT02205398,Incidence of Dose Limiting Toxicities (DLTs),2014-07-28,TERMINATED,INTERVENTIONAL,['PHASE1'],,Progression Free Survival
4962,NCT03196791,Number of Retrieved Lymph Nodes Per Participant,2017-10-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Intraoperative Blood Loss Amount
4963,NCT00633334,"The first goal of this proposal is to collect cells from the peripheral blood, tumor draining lymph nodes and tumor infiltrating lymphocytes in patients with early or late stage gastrointestinal cancers.",2003-09,COMPLETED,OBSERVATIONAL,['NA'],,"The second goal is to evaluate using novel proteomic, CellomicTM, and genomic techniques the serum and peripheral blood lymphocytes of these patients for protein, cellular changes and genetic markers that correlate with the presence of cancer."
4964,NCT02570893,The overall survival,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Scores of Quality of life
4965,NCT03227926,Overall response rate (ORR) to panitumumab according to RECIST v1.1.,2017-10-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity according to CTCAE version 4.03.
4966,NCT00034502,,na,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4967,NCT05174325,Pathologic complete remission (PCR),2020-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Radiographic response
4968,NCT05179824,Create robust data set of health information,2020-10-19,RECRUITING,OBSERVATIONAL,['NA'],Review medical information for standard of care decisions and health outcomes,Evaluate longitudinal paired tissue and cell free molecular testing
4969,NCT04804956,Identification of mesorectal microbial biomarkers as prognostic factor for rectal cancer,2021-04-01,RECRUITING,OBSERVATIONAL,['NA'],,Evaluation of mesorectal dysfunctionality and dysbiosis on tumor progression
4970,NCT02192983,Response rate,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,
4971,NCT05247905,Progression free survival (PFS),2022-03-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in Overall Quality of Life Question (Q30) from the EORTC QLQ-C30 questionnaire
4972,NCT05829291,Safety - Adverse events,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],,To evaluate the radiological response of liver metastases using the RECIST criteria .
4973,NCT02055313,Qualitative Data Collection: Patients' Experience of Exceptional Disease Course,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,
4974,NCT02868242,Percentage of Participants Who Permanently Discontinued Study Drug Due to an Adverse Event,2016-08-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Virologic Failure
4975,NCT02335411,Objective Response Rate For PD-L1 Positive Participants in Cohorts 1 and 3,2015-02-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate For PD-L1 Positive Participants
4976,NCT01867918,Overall survival from time of randomization,2013-05,TERMINATED,INTERVENTIONAL,['NA'],,
4977,NCT02192541,Maximum Tolerated Dose (MTD) of the Combination of Ganetespib and Ziv-aflibercept,2014-12-02,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of Participants Who Had a Dose Limiting Toxicity (DLT),Number of Cycles on Treatment
4978,NCT06163365,Primary hypothesis,2022-07-26,RECRUITING,OBSERVATIONAL,['NA'],,Secondary hypothesis
4979,NCT05604950,Selection of treatment modalities for elderly patients with oesophageal cancer,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
4980,NCT05190445,Overall response rate (ORR) as defined by RECIST v1.1,2021-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Compare levels of HER2 protein expression and/or gene amplification and HER2 gene amplification in ctDNA isolated before treatment initiation with clinical benefit derived from study treatment,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
4981,NCT03132792,"Number of subjects with dose-limiting toxicity (DLT) and adverse events (AEs) and determination of optimally tolerated dose range, including serious adverse events (SAE).",2017-05-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Interval between the date of first T cell infusion and date of disease progression or death due to any cause
4982,NCT02072486,Overall survival (OS),2013-11-18,COMPLETED,INTERVENTIONAL,['NA'],Proportion of cluster of differentiation (CD)8+ T cells expressing granzyme B,"Granzyme B level variations by presence of grade 3 or higher AE, characterized using National Cancer Institute Common Terminology Criteria for Adverse Events severity grade"
4983,NCT00719797,Progression free survival,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Surrogate markers predictive of bevacizumab activity
4984,NCT06147037,Maximum tolerated dose of [225Ac]-FPI-2068 and FPI-2053,2024-02-27,RECRUITING,INTERVENTIONAL,['PHASE1'],,"To assess the immunogenicity of [111In]-FPI-2107, [225Ac]-FPI-2068, and FPI-2053"
4985,NCT00303745,Stable disease rate,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression-free and overall survival
4986,NCT04829383,Frequency and severity of toxicities,2021-03-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Median overall survival (OS)
4987,NCT05892354,The incidence of severe oral mucositis,2023-06-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Number of participants with adverse events
4988,NCT02382263,"PHASE II: Evaluate the effectiveness of two selected schemes of gemcitabine and nab-paclitaxel, vs. gemcitabine alone. (Six months overall survival)",2013-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: change in FAP and Cav-1 tumor markers as an inidicatior of treatment efficacy
4989,NCT05648955,Change in cross-sectional skeletal muscle mass area on the third vertebral level (L3) [cm2],2023-03-31,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Change in physical function,Change in health-related quality of life as measured with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30 global health score)
4990,NCT04102098,"Recurrence-Free Survival (RFS), as Determined by IRF",2019-12-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
4991,NCT01349517,Health related quality of life,2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Morbidity Mortality Survival rate
4992,NCT01688908,Cost for saving 1 quality-adjusted life year (QALY),2012-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Change of life quality due to early diagnosis and treatment
4993,NCT03922152,"Assessment of symptoms [odynophagia, chest-back pain, dysphagia, regurgitation]",2009-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Assessment of the Overall Survival
4994,NCT04751955,Progression free survival,2022-01-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life by FACT-C v4.0
4995,NCT00682227,Safety (toxicities as assessed by NCI CTCAE version 3),2006-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Immunological and clinical response
4996,NCT05194072,Number of participants with dose limiting toxicities (DLTs),2022-01-12,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of antidrug antibodies (ADAs)
4997,NCT02613650,Incidence of dose limiting toxicities (DLTs) of combination MEK162 and mFOLFIRI,2016-08-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4998,NCT06167421,Severe complication rate,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative quality of life assessment
4999,NCT03391934,Progression Free Survival (PFS),2018-01-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,immunogenicity
5000,NCT05180864,Overall survival,2024-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Cost-effectiveness
5001,NCT01541709,progression-free survival (PFS),2012-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,percentage of successful dose escalation
5002,NCT06233708,Multivariate Cox regression analysis of HCC recurrence at 5-year follow-up,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Multivariate Cox regression analysis of overall survival at 5-year follow-up
5003,NCT03802747,Dose-Limiting Toxicity of Y-90+SBRT in Combination with Dual Immune Checkpoint Blockade,2019-08,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Time to Tumor Progression (TTP)
5004,NCT03482791,Physician-reported toxicity of PBT for esophageal cancer,2018-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival (OS)of PBT for patients with resectable versus unresectable esophageal
5005,NCT00094029,,2004-09,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
5006,NCT03449264,Proportion of patients who consent to participate in the study,2017-07-27,RECRUITING,INTERVENTIONAL,['NA'],Quality of life assessment at baseline for all participants in the study,
5007,NCT05030363,Change of FACIT-F score,2021-10-25,UNKNOWN,INTERVENTIONAL,['NA'],,"Exploratory biomarker studies - Urine malondialdehyde - ALDH2 polymorphism (ALDH2 *1/*2, rs671 A/G) - Change of inflammatory cytokines"
5008,NCT01369420,Safety,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Efficacy
5009,NCT03623984,Comparison of intraoperative findings to preoperative PET scan findings,2019-06-07,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Determine threshold levels of gallium dotatate uptake in order to determine tumor involvement
5010,NCT05423886,Detection rate of colorectal cancer and advanced adenomas,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Acceptability
5011,NCT01339650,Pharmacokinetic profile,2011-05-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety (number of subjects with adverse events and/or dose limiting toxicities)
5012,NCT05788224,mortality and morbidity correlated with the management of older (=>75 years old) patients admitted to emergency department with a complicated colorectal cancer,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
5013,NCT04679597,pathological complete response,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],number of participants with acute side effects,Neoadjuvant rectal cancer score
5014,NCT00965965,Comprehension of randomly assigned educational document,2009-08,COMPLETED,INTERVENTIONAL,['NA'],,Readiness to undergo colorectal cancer screening
5015,NCT05613478,Recurrence-free survival (RFS),2022-11,RECRUITING,INTERVENTIONAL,['PHASE3'],,Safety and toleraty
5016,NCT04282980,Progression-Free Survival(PFS) based on independent imaging review,2020-04-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate(DCR)
5017,NCT03389126,response rate,2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5018,NCT01789658,Mucositis grade - WHO Oral Toxicity Scale,2012-10,COMPLETED,INTERVENTIONAL,['NA'],S-Albumin,Emotional and Psychological status
5019,NCT01198145,Maximum Severity of Diarrhea Toxicity as Measured by the CTCAE v4.0 During and After Radiotherapy (RT),2011-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Patients in Each Arm That Experience Clinically Significant Deficits in Overall Quality of Life and Fatigue
5020,NCT02797405,Validation of the correlation between the clinical tumor response and the results of A/MS bioassays using tumor samples,2016-10,TERMINATED,INTERVENTIONAL,['NA'],,Validation of the correlation between the healthy tissue response (i.e. AE reported as per CTCAE v4) and the results of MS/A bioassays using skin biopsies
5021,NCT03454620,Dose Limited Toxicity (DLT),2018-04-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Immunogenicity of GC1118
5022,NCT03258541,Clinical performance,2017-01-15,TERMINATED,INTERVENTIONAL,['NA'],,Comparative dosimetric studies
5023,NCT06066931,The assessment of the frequency of early postoperative complications,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The assessment of the frequency of late postoperative complications and quality of life
5024,NCT05674123,Incidence of adverse events,2020-01-15,COMPLETED,INTERVENTIONAL,['NA'],,
5025,NCT00256334,Test the hypothesis that resveratrol modulates Wnt signaling in vivo in colon cancer and normal colonic mucosa,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5026,NCT02356276,5-year overall survival,2015-05-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],CEA mRNA expression of peritoneal lavage fluid,side effects
5027,NCT04172571,Objective response rate (ORR),2018-11-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of subjects who develop detectable anti-drug antibodies (ADAs)
5028,NCT04947020,Overall survival,2021-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Lymph node ratio,Disease-free survival
5029,NCT04162535,Evaluation of patients serum on cell culture,2018-11-26,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Survival Comparison
5030,NCT04869618,Diagnostic performance of SPECTRA IMDx for assessment of lower risk lesion (GIM/LGD/Gastritis/Normal) and higher risk lesions (HGD/EGC) against the gold standard of histopathology from gastric resection specimen,2021-05,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluation of performance of HD-WLE combined with NBI in detection of HGD/EGD prior to ER.
5031,NCT00101348,MTD of bevacizumab combined with cetuximab and erlotinib hydrochloride determined by DLT graded according to the CTCAE version 3 (Part II),2005-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free survival
5032,NCT02009449,Pharmacokinetic (PK) parameters,2013-11-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Anti-Pegilodecakin antibody formation
5033,NCT01438450,Survival,2007-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Change from baseline in Child status at 1 year
5034,NCT00376987,Reversal of cadmium-induced inhibition of mismatch repair,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5035,NCT04232384,Yield of malignant cells,2020-06-15,TERMINATED,INTERVENTIONAL,['NA'],,Cellularity of the smear of the smear
5036,NCT02087475,Progress Free Survival,2011-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Life Quality
5037,NCT00062257,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5038,NCT03259035,Measurement of organ preservation rate,2018-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Cost effectiveness using the EQ-5D-5L questionnaire
5039,NCT05385549,PFS,2022-09-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,
5040,NCT03033927,Progression Free Survival,2017-01-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5041,NCT01004159,12-week Progression Free Survival Rate Upon Escalation of Cetuximab Dose to 500mg/m2 in Combination With Irinotecan After Progression on Standard Dose Therapy in Patients With KRS Wild Type Colorectal Cancer,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Response Rate of Cetuximab 500mg/m2/Week in Combination With Irinotecan in the Enrolled Patient Population
5042,NCT01736904,Progression free survival which is calculated from the start of treatment to disease progression or death,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival which is calculated from the start to treatment to the death,Objective response rate which includes complete response(CR) and partial response(PR) participants
5043,NCT00974610,Detection of peptide and protein markers in serum,2008-08,COMPLETED,OBSERVATIONAL,['NA'],,Identification of the protein/peptide involved
5044,NCT03250637,Colorectal cancer,1993-12,COMPLETED,OBSERVATIONAL,['NA'],,
5045,NCT01465113,Arm 2 (high grade dysplasia): 15-Prostaglandin dehydrogenase expression,2010-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,effects on insulin resistance
5046,NCT05297955,Data analysis of relationship between CTC and pathological indicators of hepatocellular carcinoma,2013-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
5047,NCT03708042,Overall survival,2018-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Comparison of pathological diagnosis between specimens of endoscopic biopsy and surgically resected in esophageal cancer
5048,NCT02715141,life time health effects of stool-based surveillance strategies using the ASCCA (Adenoma and Serrated pathway to Colorectal CAncer) model,2015-10,COMPLETED,OBSERVATIONAL,['NA'],,presence of previously identified progression biomarker on resected tissue samples of polyps
5049,NCT01267305,TEG values,2011-01,COMPLETED,INTERVENTIONAL,['NA'],,inhospital mortality
5050,NCT02273141,Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens),2014-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Polyp Detection Rate (Overall Colon)
5051,NCT04549064,Diagnosis of Pancreatic Cancer,2020-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5052,NCT00522665,To evaluate the objective response (CR or PR) rates of patients treated with irinotecan and cetuximab with or without RAD001 in patients with metastatic colorectal cancer,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To evaluate the time to progression, duration of objective response (CR or PR) and overall survival of patients treated with irinotecan and cetuximab with or without RAD001"
5053,NCT03230318,Substudy 2: Progression Free Survival at 3 Months (PFS 3),2017-09-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Grade 3-5 Treatment-emergent Adverse Events (TEAEs)
5054,NCT04846309,"frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NIH CTCAE, version 5.0), seriousness, duration, and relationship to study treatment",2021-10-12,RECRUITING,INTERVENTIONAL,['PHASE1'],,Pathological complete response (pCR) rate
5055,NCT05985252,Calculation postoperative of the Comprehensive Complication Index (CCI) for each patient,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Adjuvant chemotherapy in patients after low anterior resection for rectal cancer.,Total hospitalization costs
5056,NCT00786006,Progression-free survival,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
5057,NCT06089382,Recurrence-Free Survival (RFS),2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Hepatocellular Carcinoma Module (EORTC QLQ-HCC18) Scale Score
5058,NCT05301842,Progression Free Survival (PFS) for Arm A vs Arm C,2022-03-28,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS) for Arm B vs Arm C
5059,NCT02512172,Number of Patients Experiencing a DLT (dose-limiting toxicity) as defined by NCI CTCAE v4.0,2016-02-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
5060,NCT01393197,Time to progression,2011-03,UNKNOWN,INTERVENTIONAL,['NA'],,remission rate
5061,NCT02336087,"Toxicity of the combination of gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, metformin hydrochloride, and a dietary supplement (National Cancer Institute Common Terminology for Adverse Events criteria version 4)",2016-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],"Quality of life, assessed using the FACT-G questionnaire",Time to treatment failure
5062,NCT01243372,Progression-free survival as measured by RECIST,2009-11,COMPLETED,OBSERVATIONAL,['NA'],,tumor response as measured by RECIST
5063,NCT04451603,"Use of prediction software or tools to estimate volume and health of the future liver remnant (FLR), monitor changes in liver volume and health post treatment",2018-10-19,COMPLETED,OBSERVATIONAL,['NA'],,
5064,NCT04294953,morphine consumption,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Postoperative patient satisfaction
5065,NCT00845039,Progression-Free Survival (PFS) Rate at 18 Weeks,2009-05,TERMINATED,INTERVENTIONAL,['PHASE2'],The Number of Participants Who Died During 30-Day Follow-Up,Serum Anti-IMC-A12 Antibody Assessment
5066,NCT00898378,Creation of an OMIC profile to predict the risk of colorectal cancer (CRC),2009-01,COMPLETED,OBSERVATIONAL,['NA'],,Identification of interactive molecular pathways that underlie the development and progression of CRC
5067,NCT01646697,Local recurrence at the site of resection,2011-11-07,COMPLETED,INTERVENTIONAL,['NA'],,
5068,NCT01943500,The number of circulating tumor cells (CTCs) per milliliter of whole blood. Reported unit of measure will be the number of CTCs/milliliter.,2013-09-30,COMPLETED,OBSERVATIONAL,['NA'],,
5069,NCT01391611,Non-progression Rate Based on RECIST 1.0 Criteria (CR+PR+SD),2011-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Response Per Choi Criteria
5070,NCT04548947,Incomplete resection rate (IRR),2021-01-12,COMPLETED,INTERVENTIONAL,['NA'],,Incomplete resection of colorectal polyps
5071,NCT02354898,Pharmacokinetic profile of BBI503,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
5072,NCT01466569,"Safety will be assessed by analysis of adverse event, clinical laboratory tests and physical examination",2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor response rate by Response Evaluation Criteria in Solid Tumors (RECIST)
5073,NCT03818997,Objective response rate,2019-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Duration of stable disease using RECIST 1.1 and iRECIST
5074,NCT01532427,Safety,2012-06,COMPLETED,OBSERVATIONAL,['NA'],,usability
5075,NCT04916054,to determine whether the time between each anti-tumor therapy has a prognostic impact on recurrence-free survival,2021-06-04,COMPLETED,OBSERVATIONAL,['NA'],,To evaluate the impact on overall survival
5076,NCT01054911,Number of Participants With Adverse Events,2009-10,TERMINATED,INTERVENTIONAL,['NA'],,Alteration in Diffusion and Vascularity Kinetics
5077,NCT04145141,"To establish a biospecimen repository for genomic, genetic and epigenetic analysis to study the biology of PLC development and progression",2021-07-28,RECRUITING,OBSERVATIONAL,['NA'],,To estimate 3 years progression-free survival following immunotherapy for PLC
5078,NCT01489566,RFS(Recurrence Free Survival),2011-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,QOL score
5079,NCT05264896,3 year disease free survival,2022-03-21,RECRUITING,INTERVENTIONAL,['PHASE3'],,Pathology - tumor regression grade
5080,NCT02683655,Progression free survival,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5081,NCT04715074,Impact of #iBeatCRC Mass Media Campaign on EOCRC early detection benefit.,2023-05-27,COMPLETED,INTERVENTIONAL,['NA'],,
5082,NCT03525067,Postoperative infectious complications at postoperative day 90,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Mortality post operative day 90
5083,NCT02119663,Overall Survival (OS),2014-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Participants With Treatment-Emergent Adverse Events (TEAEs)
5084,NCT05435053,Incidence of treatment related adverse events [Safety and Tolerability],2022-09-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of life using EORTC QLQ-C30
5085,NCT03746249,Progression Free Survival (PFS),2018-12-17,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
5086,NCT03246516,Time limit of first doctor consultation,2017-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Survival
5087,NCT00049101,,2002-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5088,NCT02395640,progression free survival,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,quality of life questionnaire
5089,NCT00674973,Progression-Free Survival,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events (AEs)
5090,NCT05432934,Total postoperative opioid consumption in the first 48 hours after surgery (hydromorphone equivalents.,2022-09-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Length of stay in hospital (days).
5091,NCT05811546,Difference in DNMT1 and EZH2 expression.,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
5092,NCT04473625,Stool-based test for colorectal cancer,2020-07-21,COMPLETED,OBSERVATIONAL,['NA'],,
5093,NCT02537340,Detection rate,2016-09,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
5094,NCT02351219,Radical resection rate,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Progression-free survival
5095,NCT02407977,Dosimetric accuracy of the device with reference to a commercially available dosimeter,2015-11-13,COMPLETED,OBSERVATIONAL,['NA'],,Feasibility of clinical application of the nanaoFOD for dosimetric monitoring of external beam radiotherapy.
5096,NCT00053222,Objective response,2003-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5097,NCT03760822,Quality of life at 4 months as assessed by the following dimension of the EORTC QLQ-ELD14 questionnaire: illness burden,2018-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival
5098,NCT02550119,"Proportion of patients with complete response, defined as no emesis and no use of rescue medication",2006-04-19,TERMINATED,INTERVENTIONAL,['NA'],,Proportion of patients who agreed to be randomized out of all patients who qualify for randomization
5099,NCT01360086,Non-toxicity rate,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life as assessed by QLC-C30 and STO-22 questionnaires
5100,NCT05221398,Recurrence-free survivial,2019-03-03,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
5101,NCT01217034,Overall Survival,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to Extrahepatic spread
5102,NCT02585908,Reduced size of the tumor.,2019-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety, as measured by the rate of adverse events and serious adverse events"
5103,NCT04731220,Number and percentage of cases and controls who complete each part of the study,2020-07-14,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
5104,NCT05955196,Establishment of patient derived organoids (minimum n=30) resembling the primary tissue sample,2023-01-09,RECRUITING,OBSERVATIONAL,['NA'],,"To assess the effect of immunotherapy on the antitumor activity of autologous T cells from peripheral blood samples using tumor viability measurements (cell titer glo, FACS)"
5105,NCT03286348,Local Control rate,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall Survival
5106,NCT06300489,MTD（maximum tolerable dose）,2024-03-03,RECRUITING,INTERVENTIONAL,['PHASE1'],,
5107,NCT03100708,Overall Survival (years),2016-04,UNKNOWN,OBSERVATIONAL,['NA'],,Quality of lfe questionnaire (EORTC QLQ-C15-PAL)
5108,NCT04037007,Cannulation success rate within 5 minutes,2019-07-03,RECRUITING,INTERVENTIONAL,['NA'],,Technical success
5109,NCT01419483,Frequency of Adverse Events (Safety),2011-07,TERMINATED,INTERVENTIONAL,['NA'],,Progression Free Survival (months)
5110,NCT02827682,Duration time in PACU,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],,length of hospital stay (LOS)
5111,NCT03698253,Progression-free survival,2013-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Rate of treatment-associated adverse events.
5112,NCT05038254,Rate of acute care visits,2021-05-12,RECRUITING,INTERVENTIONAL,['NA'],,Change in symptom management
5113,NCT05472753,Change in the alpha diversity index (Shannon),2022-11-16,UNKNOWN,INTERVENTIONAL,['NA'],,Change in stool calprotectin
5114,NCT02295774,Gamma H2AX Histone Levels in Colonic Biopsy During Standard White Light Colonoscopy and Colonoscopy for Which Methylene Blue MMX Was Taken Prior to Initiating the Colonoscopy,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,To Evaluate the Staining Quality Obtained With Oral Methylene Blue MMX® Tablets.
5115,NCT04833036,PFS,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,ORR
5116,NCT03166553,Objective response rate and/or 1-year survival rate,2016-11-28,UNKNOWN,INTERVENTIONAL,['NA'],,the rate of incidence of adverse events
5117,NCT00003157,Maximum tolerated dose,1998-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Survival
5118,NCT04166435,Overall Response Rate,2020-06-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
5119,NCT01882478,Response,2013-06,COMPLETED,OBSERVATIONAL,['NA'],,Predictors of response
5120,NCT02614157,3-year local recurrence,2016-05,TERMINATED,INTERVENTIONAL,['NA'],,postoperative complications
5121,NCT05746962,proportion of colonoscope loop formation,2023-03-06,RECRUITING,INTERVENTIONAL,['NA'],,evaluation of risk factors about loop formation
5122,NCT04984096,Progression-Free Survival (PFS),2021-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall Survival (OS)
5123,NCT04781270,conversion resection rate,2021-04-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Early tumor shrinkage
5124,NCT05934981,Number of patients with pain at 24 hours after the end of the intervention by VAS ≤ 3 without taking opioids (without step 2 and step 3 analgesics).,2023-08-30,RECRUITING,INTERVENTIONAL,['NA'],,Evaluation of predictive factors of opioid intake
5125,NCT04880148,Change from baseline in Xerostomia Grade (CTCAE) at weekly assessments,2021-11-03,RECRUITING,INTERVENTIONAL,['NA'],,Change from baseline in health-related QoL (EORTC QLQ-H&N43) questionnaire
5126,NCT04049461,Bone alkaline phosphatase,2019-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Overall survival,Incidence of distant metastasis and local recurrence
5127,NCT02216799,Achievement of target blood glucose (140 mg/dL to 200 mg/dL),2013-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,Developement of hypoglycemia ( blood glucose < 70 mg/dL)
5128,NCT02396498,DFS: Disease-Free Survival,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Safety as measured by Adverse Events and Serious Adverse events In the process of the total treatment according CTCAE4.0
5129,NCT03294343,Occult cancer or precancerous lesion in histological specimen,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,Incidence of primary uterine cancer
5130,NCT00378716,Compare the relative efficacy of UFT + LV with that of 5-FU + LV in prolonging disease-free survival and survival,1997-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Compare quality of life in patients with stage II and III carcinoma of the colon treated with either 5-FU + LV or UFT + LV regimen
5131,NCT01834235,Overall Survival,2013-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Immunologic Correlates
5132,NCT00007826,,2000-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5133,NCT03579758,Overall survival,2019-04-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Incidence of residual disease after or at the time of re-resection
5134,NCT02861209,Change in self-management skills,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],Change in perceptions on self-management in HCPs using the Clinician Support for Patient activation measure,Cost of care
5135,NCT00004879,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5136,NCT01902953,Efficacy of Lymphoseek for Detection of Sentinel Nodes,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Localization Rates
5137,NCT05919095,Radical resection rate,2023-06-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidence of treatment-related adverse event
5138,NCT01209325,Incidence of Penile/Scrotal Condyloma in HPV 18 Naive and Prior Exposed Participants,2011-06-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Geometric Mean Titers for HPV 18 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level"
5139,NCT00354705,Occurence of Recurrent Colon Cancer,2006-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5140,NCT01907607,Number of Participants With Non Progression at 4 Months,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Efficacy Assessment of PD-0332991 in Terms of Overall Survival Time
5141,NCT06209099,Organ-preservation rate,2023-12-05,RECRUITING,INTERVENTIONAL,['NA'],,Major adverse events
5142,NCT03337841,One-year recurrence-free survival rate,2017-11-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
5143,NCT04010006,operating time,2019-07-15,UNKNOWN,INTERVENTIONAL,['NA'],,3-year overall survival rate
5144,NCT03560817,Health utilities for SF-6Dv2 after the start of the chemotherapy,2017-01-04,COMPLETED,OBSERVATIONAL,['NA'],,Health related quality of life (HRQoL) scores from the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaires after chemotherapy
5145,NCT01619475,Pain control in living donors following partial hepatectomy,2011-02,COMPLETED,OBSERVATIONAL,['NA'],,
5146,NCT01695447,pancreatic fistula,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],,Hospital stay
5147,NCT00383760,Objective Response (Complete and Partial) Evaluated Using RECIST Criteria,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Stable Disease Rate
5148,NCT02287025,Proportion of Patients Who Discontinue Prior to Documented Progression of Disease (PD) or Death,2014-11-11,TERMINATED,INTERVENTIONAL,['PHASE4'],,Satisfaction of Investigator/Nurse With Enhanced Drug-specific Information Via SMART Questionnaire
5149,NCT02140723,Interaction between the status of the biomarker TP53 and response to treatment,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],,overall survival
5150,NCT00003591,To determine the one-year and median survival rates after PXRT,1998-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,To correlate p53 status with treatment response to PXRT
5151,NCT01191814,Complications related to stent dysfunction,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,Procedural complications
5152,NCT05289726,incidence of grade 3 hand-foot skin reaction,2022-04-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],,tumor control rate
5153,NCT03096054,Determination of the maximal dose,2017-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Determine the median progression
5154,NCT05170360,1. association between some risk factors and colorectal cancer,2021-12,UNKNOWN,OBSERVATIONAL,['NA'],,1. Estimation of KRAS and BRAF genes mutations associated with CRC. 3. Association between these risk factors and gene mutations on different types of CRC.
5155,NCT00677781,Postoperative morbidity,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,Mortality
5156,NCT00568750,Response as assessed by fusion PET/CT scan according to EORTC PET Study Group criteria,2008-01-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse drug reactions according to NCI CTCAE v3.0
5157,NCT05143151,Objective response rate (ORR),2021-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival rate (OS)
5158,NCT02588443,Number of Adverse Events,2015-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5159,NCT03891784,Objective response rate (ORR),2019-10-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
5160,NCT01882205,The difference in total number of neoplastic lesions detected by chromoendoscopy and virtual chromoendoscopy,2008-05,UNKNOWN,INTERVENTIONAL,['NA'],Number of biopsies per colonoscopy taken in the different groups.,The difference in the ratio number of neoplastic lesions/ total number of lesions between chromoendoscopy and virtual chromoendoscopy
5161,NCT01789983,"To measure the feasibility of implementing the WWE program among cancer patients, age ≥60, as they undergo cytotoxic chemotherapy treatment.",2012-10,COMPLETED,OBSERVATIONAL,['NA'],,To measure relationships between physical activity levels and p16 levels.
5162,NCT02649361,Progress free survival (PFS),2016-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
5163,NCT01863745,Number of participants with adverse events,2013-06-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5164,NCT05617352,The number of lymph nodes,2022-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
5165,NCT06303583,Complete pathological response rate,2022-06-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety will be analyzed through the incidence of adverse events, serious adverse events"
5166,NCT01819961,infective complications,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,plasma immunological markers
5167,NCT05741372,"Maximum measured concentration of the analyte in plasma) for each component of the transporter cocktail: digoxin, furosemide, metformin, and rosuvastatin (Cmax)",2023-04-25,RECRUITING,INTERVENTIONAL,['NA'],,
5168,NCT02574637,Percentage of Participants With Crohn's Disease Activity Index (CDAI) Remission at Week 8,2016-01-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Abdominal Pain Remission
5169,NCT00427973,Progression-free Survival,2009-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
5170,NCT02425605,Overall survival,2014-12-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicity defined as NCI-CTC(version 4.02)
5171,NCT05253651,Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR),2022-10-24,RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to meaningful change in EORTC QLQ30 score
5172,NCT06162143,Low Anterior Resection Syndrome (LARS) score,2023-11-15,RECRUITING,OBSERVATIONAL,['NA'],,Diarrhea
5173,NCT05632939,The recommended dose,2023-02-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
5174,NCT04973098,Adverse Event of Special Interest,2021-08-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
5175,NCT00089024,Number of Participants Experiencing Grade 3-4 Toxicity While Receiving the Study Treatment,2004-02-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5176,NCT04605796,ORR,2020-04-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],ADA,Overall survival (OS)
5177,NCT02720601,Progression-free survival (PFS),2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Toxicity
5178,NCT01175460,Maximum tolerated dose (MTD) of s-1 in combination with nedaplatin and thoracic radiotherapy,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective response rate
5179,NCT02446574,Maximum tolerated dose of weekly paclitaxel and cisplatin with concurrent radiation(Phase I endpoint),2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease-free survival of weekly paclitaxel and cisplatin with concurrent radiation(Phase II endpoint)
5180,NCT01447927,Percent Change in Median pS6K1 Immunostaining Among Participants With Barrett Esophagus,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Adverse Event Rates
5181,NCT02425137,Disease control rate (DCR),2015-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"safety profile (percentage of patients with at least one occurrence of preferred term will be included,according to the most severe NCI-CTCAE v4.03 grade)"
5182,NCT03910140,The response to treatment,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,Lifetime (months)
5183,NCT02592902,Occurrence of EER (percentage),2014-04,COMPLETED,INTERVENTIONAL,['NA'],,Presence of pepsin
5184,NCT01092975,Safety: the presence or absence of mucosal or systemic toxicity related the the topical application of phenylephrine.,2010-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Efficacy: the the mucositis severity area-under-the-curve (AUC) where the severity of oral mucositis on each treatment day will be scored, summed, and plotted graphically."
5185,NCT03840928,RAPID-3 (MD-HAQ with visual analogue scale for pain and patient global measure for overall health),2015-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
5186,NCT06229197,Incidence of reflux gastritis assessed according to RGB classification,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Long-term complications
5187,NCT04752670,Technical Success rate,2021-05-27,COMPLETED,OBSERVATIONAL,['NA'],,Adverse Events
5188,NCT05785234,Total consumption of fentanyl in 24 hours after surgery,2023-04,RECRUITING,INTERVENTIONAL,['NA'],,
5189,NCT03217253,Recommended phase 2 dose (RP2D) of tazemetostat in patients with varying degrees of hepatic dysfunction,2018-03-16,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Best response
5190,NCT04443049,Progressive disease requiring change of therapy in both groups,2020-07-10,UNKNOWN,INTERVENTIONAL,['NA'],,Decompensation of underlying cirrhosis in both groups
5191,NCT03989180,"Performance of the C-Scan system in terms of communication between the C-Scan Capsule and the System Track in different locations, positions and configurations.",2016-01-06,COMPLETED,OBSERVATIONAL,['NA'],,
5192,NCT03338543,pain score,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],complications,times of breakthrough pain (BTP)
5193,NCT00025142,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5194,NCT00868998,Response Rate,2005-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity
5195,NCT01178151,To determine the response rate of Everolimus in patients with advanced cancer and PJS.,2010-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To assess markers for activated mTOR pathway (including phospho-S6 and phospho-4E BP1) in all pre-treatment tissue specimens and collected specimens during treatment and correlate with response to treatment.
5196,NCT05183295,Tolerability of the NEAAR medical food,2022-04-27,WITHDRAWN,INTERVENTIONAL,['NA'],,Progression-free Survival
5197,NCT03223740,Progression Free Survival,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,R0 Resection Rate
5198,NCT02672488,Overall Survival,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
5199,NCT04134832,The survival will be evaluated by Kaplan Meier Method. The prognostic factors will be evaluated with univariate and multivariate analysis by Cox regression model.,2019-06-27,UNKNOWN,OBSERVATIONAL,['NA'],,
5200,NCT01056809,Overall survival,2010-01,TERMINATED,INTERVENTIONAL,['NA'],,Complications and side effects
5201,NCT04685395,Incidence of oral mucositis,2019-12-26,UNKNOWN,INTERVENTIONAL,['PHASE3'],,The pain score
5202,NCT00423696,Progression-free survival at 6 months,2006-03-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
5203,NCT01271166,Tumour response as assessed by CT scan and RESIST,2007-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
5204,NCT05335460,TRG0/1,2022-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],PCR rate,ORR
5205,NCT05984485,3-year Disease Free Survival,2022-07-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of participants with treatment-related adverse events
5206,NCT02581462,Phase III: Median Progression Free Survival,2016-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Phase III: Median OS
5207,NCT05047146,Clinicopathological factors of Hepatocellular Carcinoma,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
5208,NCT05164406,Transfusion,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
5209,NCT05129774,5-year OS,2022-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative complications
5210,NCT02270606,Dose limiting toxicity for continuous infusional 5-Fluorouracil given concurrently with short course pelvic radiation,2014-12-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Postoperative mortality rates
5211,NCT01401075,Quality of Life,2006-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,Safety and tolerability
5212,NCT00470353,Change in proliferative labeling index of normal rectal mucosa as measured by Ki67 IHC staining,2006-09,TERMINATED,INTERVENTIONAL,['NA'],,"Effects of cholecalciferol on biological markers of proliferation (i.e., cyclin D1, protein kinase C, vitamin D receptor, p21, and p27) as measured by IHC at baseline and after 6 months of study treatment"
5213,NCT06229080,Mean absorbed dose ratio between the protected perfused liver and unprotected perfused liver,2023-03-15,RECRUITING,INTERVENTIONAL,['NA'],,Serious adverse event
5214,NCT04808791,Safety/Tolerability,2021-08-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
5215,NCT02619942,Disease-free survival,2016-01-09,UNKNOWN,INTERVENTIONAL,['NA'],,Metastasis rate of central lymph node (3rd station)
5216,NCT05737953,Types and concentrations of cfDNA and proteins contained in the vesicular fluid,2022-07-13,RECRUITING,OBSERVATIONAL,['NA'],,Development of a progressive benign malignancy prediction model
5217,NCT01170104,Time to progression,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To evaluate the toxicity profiles
5218,NCT01324076,Progression-free survival,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
5219,NCT04064034,Quiescin Sulfhydryl Oxidase 1 (QSOX1) in the blood,2019-08-01,COMPLETED,INTERVENTIONAL,['NA'],,
5220,NCT02584985,R1 resection rate,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Disease-free survival at 3 years
5221,NCT01187901,Change in Duodenal Polyp Burden From Baseline to 6 Months,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in Number of Duodenal Polyps From Baseline to 6 Months in Attenuated FAP Participants
5222,NCT04493905,30-day postoperative morbidity assessed by Clavein-Dindo classification,2021-12-01,RECRUITING,OBSERVATIONAL,['NA'],,"Cancer recurrence or cancer-related death at 90 days, 1, 3- and 5-years"
5223,NCT02205047,Near Complete Pathological Response Rate,2015-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity
5224,NCT04498117,Investigator Assessed Progression Free Survival,2020-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Potential Biomarkers,Change in Quality of Life
5225,NCT01439698,Number of Participants with Adverse Events,2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,Number of overall stent occlusion-free days post intervention
5226,NCT02501603,compare progression free survival as measured by RECIST 1.1,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety as measured by CTCAE
5227,NCT01815853,Disease-free Survival,2013-06,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse effects
5228,NCT03563274,Safety,2018-06-21,TERMINATED,OBSERVATIONAL,['NA'],,"Percentage of patients downstaged to surgery, transplantation or any local ablative therapy (RFA/MWA…)"
5229,NCT00659867,The primary objective is to investigate whether chromoscopy-guided endomicroscopy has a higher sensitivity than standard endoscopy with respect to detection of IN and to compare the proportion of patients with at least one IN,2008-12,TERMINATED,INTERVENTIONAL,['NA'],,Efficacy of chromoscopy-guided endomicroscopy in the detection of lesions and in the reduction of the number of biopsies. Time needed for the examination will be measured and compared between the two groups.
5230,NCT01558921,Disease related Treatment Failure (DrTF),2011-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life LARS
5231,NCT00498407,• Objective response rate (RR),2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,• Characterize the quantitative and the qualitative toxicities of the CP-4055 treatment in this patient population
5232,NCT04572542,Objective response rate,2020-01-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease Control Rate（DCR）
5233,NCT03014284,Expression of B7-H1,2017-01-20,WITHDRAWN,OBSERVATIONAL,['NA'],,
5234,NCT04928807,pathological complete response (pCR) rate,2021-07-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,dverse events (AEs) were graded according to the NCI CTCAE version 5·0
5235,NCT01116271,"Objective Response Rate will be assessed by the RECIST guideline documented in the European Journal of Cancer, 2009.",2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS) for patients with K-ras or B-raf mutations treated with combination of irinotecan and Selumetinib (AZD6244)
5236,NCT00896753,"Development of cell lines from primary colon tumors metastatic to the liver, lungs, or peritoneum",2003-09,COMPLETED,OBSERVATIONAL,['NA'],,
5237,NCT04511455,Time-on-treatment,2020-12-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Translational research
5238,NCT04056260,sensitivity and specificity,2020-03-20,UNKNOWN,INTERVENTIONAL,['NA'],,
5239,NCT03038217,5y OS,2017-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Changes of ctDNA level when disease recurs
5240,NCT06197438,Objective response rate(ORR),2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate(DCR)
5241,NCT05154812,Tumor progression rate,2020-10-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,quality of life (QOL) questionnaire
5242,NCT05194293,Objective response rate (ORR) (unconfirmed),2023-06-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Immune biomarkers,Pathologic complete response
5243,NCT01514786,Number of Participants Reporting Preferred Screening Type as Reported by Chart Audits,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,
5244,NCT06107413,Progression Free Survival (PFS),2023-11-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of Participants Achieving Best Overall Response (BOR)
5245,NCT02400788,Phase 2 : Time To Progression (TTP),2013-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5246,NCT00828620,PET response on day 7,2009-01,TERMINATED,OBSERVATIONAL,['NA'],,To asses the correlations between biomarkers and PET changes after Cetuximab
5247,NCT03957096,Number of patients with dose-limiting toxicities (DLTs),2019-07-17,TERMINATED,INTERVENTIONAL,['PHASE1'],,Incidence of antidrug antibodies (ADA)
5248,NCT05957744,Length of stay,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
5249,NCT01320852,Overall Survival,2010-12,COMPLETED,INTERVENTIONAL,['NA'],,
5250,NCT03044587,Progression-free survival [PFS],2018-01-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor Evolution under systemic therapy,Retrospective central radiological review
5251,NCT04432597,Level increase in CD3+ tumor infiltrating T cells post-treatment compared to pre-treatment,2020-08-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall response rate (ORR)
5252,NCT01963182,severe toxicity (according to NCI-CTC cotation) and response with adapted dose of irinotecan,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"evaluation of treatment efficacy (progression-free survival, duration of response)"
5253,NCT06251297,number of sessions performed,2023-05-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,concordance of peripheral neuropathy evaluation
5254,NCT04635527,Number of participants experiencing clinical and laboratory adverse events (AEs),2020-12-24,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival (OS) in two arms
5255,NCT03781934,Incidence of clinically significant changes in ECGs,2018-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Plasma levels of α fetoprotein (AFP)
5256,NCT01906021,To measure accuracy of temperature monitoring using non-invasive thermomap (temperature imaging profile) method compared to the currently accepted invasive thermocouples method,2013-09-23,COMPLETED,INTERVENTIONAL,['NA'],,
5257,NCT05173298,collected blood samples,2021-08-02,RECRUITING,OBSERVATIONAL,['NA'],,Biomarkers on the efficacy of Atezolizumab+Bevacizumab for advanced HCC
5258,NCT00061815,"Compare overall survival in subjects with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-FU, and LV (FOLFOX4) and cetuximab with FOLFOX4 alone.",2003-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Conduct an economic assessment comparing healthcare resource utilization between the two treatment arms.
5259,NCT05555316,Down stage rate,2019-11-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,TACE frequency and ablation frequency
5260,NCT01411436,Incidence of adverse drug reactions and serious adverse events in subjects who received Nexavar,2009-05,COMPLETED,OBSERVATIONAL,['NA'],,"The status of therapy with Nexavar [duration of treatment, daily dose] in a various settings according to baseline data [such as demographic data, Child-Pugh status, ECOG-PS]"
5261,NCT03803930,The diagnostic yields,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,the tissue integrity
5262,NCT00386828,The primary endpoint is pathologic complete response (pCR) rate,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Post-Surgical Complication Rates:
5263,NCT00209612,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.,2004-04,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the MST(Median Survival Time) and PFS(Progression Free Survival) in Phase II setting.
5264,NCT05064670,Health-related quality of life,2022-01-11,RECRUITING,INTERVENTIONAL,['NA'],,Health-related quality of life
5265,NCT05846867,recommended phaseII dose,2023-05-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Correlation between biomarkers and efficacy
5266,NCT02635347,Percentage of Participants Completing Entire Intervention Protocol,2015-11,COMPLETED,INTERVENTIONAL,['NA'],,Number of Subjects Not Completing Intervention Protocol
5267,NCT05999019,ClassIntra grade,2016-08-01,COMPLETED,OBSERVATIONAL,['NA'],,3-year disease-free survival
5268,NCT05867303,Incidence of Adverse Events [Safety and tolerability],2023-06-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression Free Survival (PFS)
5269,NCT00119899,Economic evaluation (9 months),2002-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Economic evaluation
5270,NCT02830633,The postoperative voiding function assessed by IPSS questionnaire.,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,C-reactive protein
5271,NCT01265810,"Assess the severity of patient-reported oral adverse events as determined by the change in the Modified-VHNSS2.0 score 3 times a week, from onset of oral adverse events during the active oral rinse period with Caphosol versus NaCl 0.9%",2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Side Study: Explorative analysis of polymorphism in genes encoding for pharmacokinetic and pharmacodynamic variables related to the pharmacodynamics of the TKIs
5272,NCT06310993,Primary Outcome Measure,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Secondary Outcome 7
5273,NCT00025337,Overall survival,2001-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression free survival
5274,NCT00457327,Morbidity and mortality until day 30 postoperative,2006-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Ranking of factors influencing quality of life
5275,NCT02707796,"Evaluation of the correlation between partial oxygen pressure in arterial blood sample and oxygen reserve index calculated by pulse co-oximetry, and sensitivity and specificity of oxygen reserve index in patients undergoing hemicolectomy",2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,Sensitivity and specificity of oxygen reserve index
5276,NCT00017199,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5277,NCT03299660,Pathological Response rate,2018-04-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine rate of downstaging
5278,NCT04594811,Phase 2: Objective response rate (ORR),2021-01-21,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of participants with anti-drug antibodies (ADA) to NT-I7
5279,NCT00601692,Maximum tolerated dose of docetaxel when administered together with irinotecan hydrochloride and radiotherapy,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Clinical and pathological complete response rate
5280,NCT04215731,Disease-free survival,2020-03-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,local recurrence rate
5281,NCT01560377,PINPOINT System Utility in Left Colectomy Surgery,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety of the PINPOINT System
5282,NCT00950417,Safety and toxicity of this new treatment. Both acute and chronic toxicity will be evaluated.,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,To determine the complete response rate、partial rate、disease responserate、disease control rate in the patients subject to treatment
5283,NCT03895255,Anastomotic Leakage Rate,2016-10-02,UNKNOWN,INTERVENTIONAL,['NA'],,The postoperative hospital stay
5284,NCT00877071,The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Local Effects of the LC BeadTM in the Explanted Liver of Those Patients Who go on to Receive Liver Transplantation
5285,NCT02775695,Determine the Efficacy of Doxycycline in Inducing Metakaryotic Cell Death in Primary Pancreatic Tumors as Measured by Pathologic Response,2017-04-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5286,NCT03616574,Number of subjects with treatment-related adverse events as assessed by NCI-CTCAE v5.0,2019-04-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Analysis of urinary COX-2 metabolites by LC-MS/MS,Serum concentration of CA102N
5287,NCT05872334,Incisional hernia,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Wound dehiscence
5288,NCT05195281,Evaluation of molecular subtype modification,2021-07-14,RECRUITING,INTERVENTIONAL,['NA'],,
5289,NCT02870920,Overall Survival,2016-10-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
5290,NCT03775707,overall survival (OS),2018-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
5291,NCT02177552,The proportion of participants alive one year after randomisation,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Analysis of cmet by immunohistochemistry,Registration of further lines of therapy
5292,NCT04891874,Participants Without Recurrence (Disease-free).,2015-08-01,COMPLETED,INTERVENTIONAL,['NA'],Number of Participants Occured Adverse Events(AE),Overall Survival (OS) Rate.
5293,NCT04478110,CRC screening rates,2010-12,COMPLETED,INTERVENTIONAL,['NA'],,
5294,NCT01781520,Treatment toxicity,2013-06-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phenotypic analysis of peripheral blood immune cells
5295,NCT00681798,Define Recommended Dose (RD),2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Determine antitumour activity as determined by overall response rate (RR), progression free survival (PFS), disease control rate and duration of response"
5296,NCT04584008,Objective response rate (ORR) of patients receiving targeted agent,2020-09-23,RECRUITING,INTERVENTIONAL,['NA'],,Differences of OS between 2 groups
5297,NCT05493800,The incidence of Severe Oral Mucositis(SOM).,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Auto hematopoietic stem cell engraftment,Total cumulative dose of opioid analgesics
5298,NCT04159974,Evaluation of Safety and efficacy (measured by an increase of pathological complete response rate),2019-09-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Assessment of the subject's esophageal-cancer-related quality of life using the Functional Assessment of Cancer Therapy-Esophageal (FACT-E) questionnaire
5299,NCT05037461,Change in tumor size,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],,overall survival
5300,NCT02289547,Progression free survival,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Toxicity profile of each patients measured by NCI-CTCAE ver 4.0
5301,NCT00498134,"Changes in cell proliferation, apoptosis and oncogene expressions",2004-03,UNKNOWN,INTERVENTIONAL,['NA'],,The incidence of gastric cancer in a high risk area
5302,NCT04660695,Clinical Success,2019-08-15,COMPLETED,OBSERVATIONAL,['NA'],,Type of fluid employed
5303,NCT03357757,Proportion of subjects who complete 4 doses of Avelumab in combination with VPA,2018-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Hsp90 concentration in serum
5304,NCT00460681,disease-free survival,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,overall survival
5305,NCT03535207,overall survival rate,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,toxicities
5306,NCT00043004,Survival rate as measured by Kaplan Meier method at 30 months,2002-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Response to treatment (arm II) as measured by RECIST criteria from start of treatment until disease progression
5307,NCT05111353,Safety of neoantigen SLP vaccine as measured by number of subjects experiencing each type of adverse event,2022-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity of neoantigen peptide vaccine as measured by the phenotype of neoantigen-specific T cells (only Arm 1 and Arm 2)
5308,NCT01271322,Correlation between change in tumor metabolism (detected by PET) and histopathological response,2010-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,association between change in tumor metabolism between PET Baseline and PET1 and overall survival as well as disease-free survival
5309,NCT00327119,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5310,NCT00977717,neuropathy,2008-09,COMPLETED,OBSERVATIONAL,['NA'],,
5311,NCT06296056,potential efficacy,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
5312,NCT04513418,Rate of postoperative nutrition and immune-related complications,2020-11-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Long-term survival
5313,NCT00196885,"muscle cross-sectional area, peak forces",2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,muscle 31Phospho-magnetic-resonance spectroscopy
5314,NCT05082948,Composite of stent migration or total stent dislodgement,2021-07-20,RECRUITING,INTERVENTIONAL,['NA'],Dysphagia,Length of procedure
5315,NCT06302751,Unplanned hospital readmissions,2024-02-26,RECRUITING,INTERVENTIONAL,['NA'],,Healthcare costs
5316,NCT02338778,efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,immunology index
5317,NCT01262482,Progression free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
5318,NCT01736072,End of Conversion to Open Surgery,2011-12,COMPLETED,INTERVENTIONAL,['NA'],Sexual Disfunction Assessment,Oncological Efficacy
5319,NCT06277518,admitted to ICU after surgery,2023-09-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5320,NCT04940442,Number of patients with screening completion,2021-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,
5321,NCT06255262,Progress Free Survival 1 (PFS1),2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival(OS)
5322,NCT00540982,Number of Participants With Grade 3 and 4 Toxicities,1996-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5323,NCT06225622,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2024-03-11,RECRUITING,INTERVENTIONAL,['PHASE1'],Gene polymorphism,R0 resection
5324,NCT03747068,"to determine whether preoperative exposure to anti-TNF therapy affects histological measures of fibrosis in the rectum, as increased rectal fibrosis may be a potential factor in adverse anastomosis complications following IPAA surgery",2009-10-09,COMPLETED,OBSERVATIONAL,['NA'],,
5325,NCT05041608,Safety of procedure,2021-02-17,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Quality of Life after procedure
5326,NCT02998268,Disease free survival rate,2017-03-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Association of anti-PD1 therapy with increased intra-tumoral immune cell infiltration.,Reduction of local immune infiltration.
5327,NCT06294808,Agreement between TBI calculated from pre-operative imaging versus those obtained from post-surgical pathological assessment.,2017-07-17,COMPLETED,OBSERVATIONAL,['NA'],,
5328,NCT02154646,Number of Participants with LY2157299 Dose-Limiting Toxicities (DLT),2014-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Percentage of Participants with a Tumor Response
5329,NCT05919030,Progression-Free Survival (PFS),2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of participants experiencing Adverse Events (AEs)
5330,NCT04409002,Disease Control Rate With RECIST 1.1 Criteria,2020-07-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Treatment-Related Adverse Events Per CTCAE v5.0
5331,NCT00005877,,1999-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5332,NCT04728139,Evaluation of Glypican 3 role as a predictive and diagnostic marker of colorectal marker .,2022-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Addition of Glypican 3 to the routine markers of colorectal cancer . - Correlatin of this marker with the disease pathology and management procedures .
5333,NCT01833637,"Trend perceived symptom burden and quality of life in our female patients with advanced gynecologic, breast, thoracic, or gastrointestinal malignancies.",2012-10,COMPLETED,INTERVENTIONAL,['NA'],,Assess level of understanding about advance care planning in both the control and intervention group.
5334,NCT01455831,Disease Free Survival,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Other post-operative (day 0 - day 28) complications
5335,NCT02772575,response,2016-04,WITHDRAWN,OBSERVATIONAL,['NA'],,
5336,NCT04489368,"Perform a clinical audit of patient outcomes (OS, RFS, pCR rate) after new-adjuvant chemoradiation and esophagectomy",2020-01-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5337,NCT05646511,Organ-preservation adapted DFS,2022-11-21,RECRUITING,INTERVENTIONAL,['PHASE3'],Artificial Intelligence (AI) (deep learning) analysis,Proportion of radical resection in salvage surgery cases in the NOM subgroup
5338,NCT02321969,Recurrence/Number/Size of metachronous colorectal adenoma(s),2010-08,COMPLETED,INTERVENTIONAL,['NA'],,Adverse effect(s) of GTE supplementation
5339,NCT06123338,Pathological Complete Response Rate (pCR),2024-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
5340,NCT04268654,Anastomotic leakage,2017-06-13,COMPLETED,INTERVENTIONAL,['NA'],,Hospital Stay
5341,NCT06122493,1-year progression-free survival,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
5342,NCT03706326,Number of participants with adverse events and dose limiting toxicities as assessed by CTCAE v4.0,2018-09-28,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median CAR-T cell persistence
5343,NCT04379596,"Part 2, Part 3 and Part 4: Endpoint assessed by Investigator per RECIST v1.1: Confirmed Objective Response Rate (ORR)",2020-06-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Comparison of OS
5344,NCT02965248,peritoneal metastasis rate,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Toxicity by NCI CTCAE v.4.0
5345,NCT00559013,"Number of Participants With Major Colorectal Related Adverse Events: Leak, Stricture and Hemorrhage.",2007-03,COMPLETED,INTERVENTIONAL,['NA'],,
5346,NCT00557713,Pathologic Complete Response Rate,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Surgical Morbility
5347,NCT00085410,Objective Response Rate,2004-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Correlation of Treatment With Changes in Phenotypic Expression of Molecular Markers
5348,NCT00087503,To assess the antitumor activity of edotecarin by repeating radiographic assessments at 6-week intervals for all patients.,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Blood samples for PK evaluation will be collected during Cycles 1 and 2 and limited to the patients included in the first stage of the study.
5349,NCT04171986,Incidence of 3 and 4 degrees neutropenia within 6 weeks from the start of hyperfractionated radiotherapy,2019-11-10,UNKNOWN,INTERVENTIONAL,['NA'],,
5350,NCT00032344,"Phase I: Risk factors include: family history; dietary; fat, fiber, calcium; alcohol history; tobacco use; physical activity; obesity; NSAID use; and, biomarkers: BRDU, PCNA",1993-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Phase III: Medical outcomes including mortality. Colonoscopy outcomes in subgroup of polyp free patient at baseline to determine long term risk.
5351,NCT02319356,maximal oxygen uptake (VO2Max),2015-03,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
5352,NCT04125914,Percent weight loss,2017-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Physical activity
5353,NCT02796820,Disease-free survival (DFS),2016-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],The adverse events of Huaier Granule,Metastasis-free survival (MFS)
5354,NCT03254511,R staging (residual of tumor),2016-07-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,heparin induced thrombocytopenia
5355,NCT03785210,Best Overall Response (BOR),2019-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Overall Survival (OS) of Nivolumab Combined With Oral Vancomycin and Tadalafil in Participants With Refractory Hepatocellular Carcinoma (HCC) or Liver Dominant Metastatic Cancer From Colorectal Cancer or Pancreatic Ductal Adenocarcinoma (PDAC)
5356,NCT05276791,Primary endpoint is the proportion of patients with no evidence of residual or local recurrent neoplasia during 12 months follow-up after baseline.,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Additional histopathologic evaluation may be performed to evaluate potential differences between the two techniques.
5357,NCT04729283,LARS score,2021-04-12,UNKNOWN,OBSERVATIONAL,['NA'],,IIEF5
5358,NCT03419247,Number of participants with gene testing data available at 8 weeks from baseline tumor biopsy.,2020-01-01,WITHDRAWN,INTERVENTIONAL,['NA'],,"Potential predictive biomarkers of response to treatment such as BRCA, PALB2 and ATM mutations."
5359,NCT02736500,toxicity rate,2015-09-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival in association with the receptor and metabolic status at OctreoScan and FDG PET
5360,NCT03336775,The change of Videofluoroscopic Dysphagia Scale (VDS) from baseline to week 4.,2018-06-21,UNKNOWN,INTERVENTIONAL,['NA'],,The change of Quality of Life (QOL) scores from baseline to week 4 and week 16.
5361,NCT05798884,Score Changes on the FACT/GOG-Ntx questionnaire,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Short Form 12 item(version 2) Health Survey (SF-12V2)
5362,NCT00114946,"To compare the efficacy, as measured by progression-free survival (PFS), of FOLFOX/Avastin followed by FOLFIRI/Avastin versus FOLFOX/Avastin followed by 5-FU/LV/Avastin as first-line therapy for previously untreated metastatic colorectal cancer.",2005-05,TERMINATED,INTERVENTIONAL,['PHASE4'],,To evaluate the tolerability of sequential treatment in subjects and to evaluate the safety of an irinotecan/Avastin-based regimen versus a 5-FU/Avastin regimen for previously untreated metastatic colorectal cancer.
5363,NCT02672774,Real-time imaging of angiogenesis in gastric and colorectal tumors by using M-NBI and pCLE examinations,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],,Validation of endoscopic imaging findings from immunohistochemical analysis with MVD calculations
5364,NCT05622071,Objective Response Rate,2023-10-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life questionnaire - Hepatocellular Carcinoma (QLQ-HCC-18)
5365,NCT05395910,Safety Profile of PIPAC/ePIPAC with Paclitaxel by monitoring adverse events,2022-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,Area under the curve (AUC) of Paclitaxel administered via PIPAC/ePIPAC using blood drawn from patient.
5366,NCT04531228,progression-free survival,2020-10-11,UNKNOWN,INTERVENTIONAL,['NA'],,adverse effects
5367,NCT05509478,ORR,2022-08-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) Rate at 12 months
5368,NCT02192333,"Mean of the two z scores of the two highest scores for the symptoms that determined the participant's eligibility as ""high need"" assessed using patient-reported outcomes (PRO) survey",2015-08-03,COMPLETED,INTERVENTIONAL,['NA'],,Social support assessed using the patient-reported outcomes (PRO) survey
5369,NCT00837135,"To evaluate the feasibility of incorporating GI-4000 vaccine and activated T-cell infusion into a regimen of chemotherapy, radiation, and surgical resection to treat locally advanced pancreatic cancer.",2008-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
5370,NCT03468244,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Overall Survival of Personalized mRNA Tumor Vaccine
5371,NCT04249622,"Reduction rate of >= grade 2 abdominal toxicities including abdominal distension, abdominal pain, diarrhea, dyspepsia, stomach pain, and typhlitis",2020-09-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Difference in the fecal microbiome, hydrogen breath test, and permeability test","Other pertuzumab induced gastrointestinal toxicities (PIGT) such as abdominal pain, bloating and flatulence"
5372,NCT01570166,overall survival,2011-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,disease-free survival
5373,NCT03109938,Diagnostic Accuracies,2016-10,UNKNOWN,OBSERVATIONAL,['NA'],,
5374,NCT03020342,vh-chimera DNA,2016-05,UNKNOWN,OBSERVATIONAL,['NA'],current HCC marker (AFP ng/ml),recurrence-free survival time ----measurement in weeks
5375,NCT06001658,Average minimum Euclidean distance from CD8+ T cells to immunosuppressive tumor-associated macrophages (TAMs) at the per-cell level in patients with a major pathologic response versus pathologic non-responders.,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
5376,NCT04323722,Evaluate using imaging techniques and dosimetric analysis the performance of empty versus filled bladder radiotherapy treatment,2020-09-08,RECRUITING,INTERVENTIONAL,['NA'],,IMRT (Intensity-Modulated Radiotherapy) dosimetric study in patients with filled or empty bladder
5377,NCT02393703,successful isolation of exosomes,2015-03,RECRUITING,OBSERVATIONAL,['NA'],,evaluation of the liver microenvironment
5378,NCT04390945,Progression-free survival，PFS,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Objective Response Rate, ORR"
5379,NCT01311050,,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5380,NCT00628784,"Confirm the feasibility and safety of endoscopic cryotherapy in patients with Barrett's esophagus with LGD, HGD, intramucosal cancer and in patients with severe squamous dysplasia.",2007-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],,"Assess the incidence of side effects, complications, adverse events and number of treatment sessions needed to reach primary endpoints."
5381,NCT05398822,Local recurrence of rectal cancer,2019-07-18,COMPLETED,OBSERVATIONAL,['NA'],,
5382,NCT06326892,Surgical Site Infections (SSI),2023-07-31,RECRUITING,OBSERVATIONAL,['NA'],,Overall postoperative complications
5383,NCT01511146,"tumor response according to RECIST 1.1. Number of patients with CR, PR, SD and PR will be recorded.",2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Progression free survival, adverse events"
5384,NCT00242723,"permit evaluation of patients referred to the Thoracic Surgery Branch, NCI in order to identify individuals who will be suitable candidates for treatment/intervention protocols",2005-11-09,RECRUITING,OBSERVATIONAL,['NA'],,
5385,NCT00217568,Overall survival,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5386,NCT04739202,Objective response rate,2021-03-19,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Safety, treatment-related adverse events"
5387,NCT00969410,To evaluate safety and tolerability of AV-299 (formerly SCH 900105) administered IV in subjects with advanced solid tumors who have liver metastases,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,To investigate the effect of AV-299 (formerly SCH 900105) on gene expression patterns in peripheral blood mononuclear cells and liver biopsies in subjects with advanced solid tumors who have liver metastases
5388,NCT03939975,Response,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
5389,NCT02561494,Change of the administered fentanyl dose from postoperative 6 h to postoperative 5 day,2015-06,COMPLETED,INTERVENTIONAL,['NA'],,Change of the pain score from postoperative 6 h to postoperative 5 day
5390,NCT06087718,Clinical feasibility of the Maastro boosting technique.,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Collecting 3D ultrasound measurements of the gross tumor volume (GTV) and intestinal wall layers at every fraction of Maastro applicator brachytherapy.,Complications within the first 30 days after completion of salvage total mesorectal excision (TME) surgery up to 3 years after treatment.
5391,NCT03570502,Postoperative pancreatic fistula according the 2016 update of the International Study Group (ISGPS),2016-11,UNKNOWN,OBSERVATIONAL,['NA'],,Diabetes
5392,NCT00660699,Incidence of Severe Toxicities,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
5393,NCT01813253,Overall Survival,2013-05-13,TERMINATED,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events
5394,NCT04076631,Pathological stage of liver cirrhosis,2019-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,The effect of cirrhotic severity and extent of hepatectomy on the incidence of post-hepatectomy liver failure (PHLF)
5395,NCT03782428,"Level of circulating inflammatory cytokines (TNF-α, IFN-γ, IL-6, IL-10, IL-12, IL-17A, IL17C &IL-22) pre and post intervention.",2016-08-26,COMPLETED,INTERVENTIONAL,['NA'],,Number of patients with chemotherapy induced diarrhoea assessed by CTCAE v3.0
5396,NCT02862587,Progress-free survival,2016-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
5397,NCT02657850,Change in rate of dysphagia symptoms,2016-06-09,WITHDRAWN,OBSERVATIONAL,['NA'],,change in rate of secondary treatment side effect
5398,NCT01164202,Percentage of Patients With Occurrence of Severe Bleeding and/or Liver Failure,2010-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Disease-free Survival
5399,NCT01477866,All cause mortality,na,SUSPENDED,INTERVENTIONAL,['NA'],,
5400,NCT03204019,Objective Response Rate(ORR),2016-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression free survival(PFS)
5401,NCT04868877,To evaluate the ORR of MCLA-129 alone or in combination with Osimertinib in molecularly defined populations of advanced/metastatic solid tumors.,2021-04-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Proportion of patient with treatment discontinuations
5402,NCT04556253,The rate of pathologic complete response(pCR%),2020-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5403,NCT05068076,Comparison of treatment response two hours post procedure with Perfluorobutane with routine CECT/CEMRI done at 1 month post procedure using modified RECIST criteria for HCC.,2021-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Targeting of lesions (fulfilling CEUS LIRADS 4/5 criteria) in the Kupffer phase for ablation
5404,NCT01175317,Peak Value of I-FABP,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Average Intraoperative CO2 Gap
5405,NCT05673343,disease free-survival,2023-01-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,overall survival (OS
5406,NCT03567850,Healthcare Utilization of Patients,2018-10-19,COMPLETED,INTERVENTIONAL,['NA'],,
5407,NCT02648282,Distant Metastasis Free Survival (DMFS),2016-07-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Experiencing a Grade 3 or Above Treatment Related Toxicities
5408,NCT04673955,Overall Survival,2020-09-03,RECRUITING,OBSERVATIONAL,['NA'],,Duration of treatment interruptions
5409,NCT01461057,Number of Participants With Adverse Events (AEs),2011-12-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5410,NCT02057146,Accuracy of single operator endoscopy plus pCLE in the biliary and pancreatic ductal system diagnosing premalignant and malignant lesions.,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,
5411,NCT04695184,anastomotic leak,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Length of post-operative hospital stay
5412,NCT03079427,2-year disease-free survival,2017-05-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
5413,NCT06322563,SAE-Safety and Tolerability,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
5414,NCT02597348,5 years overall survival (OS),2016-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"Quality of life (QOL) of patients of Group LT followed by chemotherapy, using the NIDDK questionnaire of Liver Transplantation Database"
5415,NCT00391118,Part 2: Progression-Free Survival (PFS),2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"PK: AUC During the Dosing Interval at Steady State (AUCτ,ss) for Part 2 of Study"
5416,NCT01717066,time to recurrence,2012-04,COMPLETED,INTERVENTIONAL,['NA'],side effect,overall survival
5417,NCT04192734,Incidence of adverse events,2019-12-18,COMPLETED,OBSERVATIONAL,['NA'],,Adverse events of special interest
5418,NCT04514835,Progression-free survival（PFS）,2021-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Exploratory analysis of biomarkers for predicting efficacy,Objective Response Rate，ORR
5419,NCT03289533,Number of Participants With Abnormal Laboratory Parameter Values (Chemistry) as Graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) Version (v) 4.03,2017-09-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Positive Anti-Drug Antibodies (ADAs) and Positive Neutralizing Antibodies (nAbs)
5420,NCT04915833,Polyp detection rate of computer-aided following standard colonoscopy.,2021-04-26,UNKNOWN,INTERVENTIONAL,['NA'],,Adenoma miss rate of standard high-definition colonoscopy.
5421,NCT01985958,Number of Participants With Adverse Events,2013-07,COMPLETED,INTERVENTIONAL,['NA'],,
5422,NCT01131234,Incidence of adverse events as graded by the NCI CTCAE version 4.0,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Preliminary antitumor efficacy
5423,NCT01105650,Response Rate,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
5424,NCT03484000,Fatigue,2018-06-01,RECRUITING,INTERVENTIONAL,['NA'],,
5425,NCT00858858,Protection Against DNA Damage by UDCA,2009-03,COMPLETED,INTERVENTIONAL,['NA'],,
5426,NCT04392479,Overall response rate (ORR).,2020-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Exploratory biomarkers
5427,NCT00826982,To determine the if molecular biomarkers increase the sensitivity by at least 5% for detection of malignant lymph nodes in patients with pancreatic ductal adenocarcinoma as compared to EUS-FNA cytology of lymph nodes alone.,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,To determine the degree of RNA overexpression of pancreas cancer specific biomarkers in the pre-operative fine needle aspirate of lymph nodes and tumors of patients with pancreatic cancer using a set of pancreas cancer specific biomarkers
5428,NCT05768178,Durable Clinical Benefit (DCB),2023-03-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,EQ-5D Standardised Area Under Index Value Curve (EQ5DSAUC)
5429,NCT03767517,Patient symptom burden (Edmonton Symptom Assessment Scale [ESAS]),2020-08-24,COMPLETED,INTERVENTIONAL,['NA'],Exploratory Aim 1f. Caregiver bereavement (Caregiver Bereavement Items ([CBI]),Patient satisfaction with care (Feeling Heard and Understood)
5430,NCT05513261,Adenoma Detection Rate (ADR),2023-11-17,RECRUITING,INTERVENTIONAL,['NA'],,Characterization of the detected lesions.
5431,NCT00325078,Efficacy of Treatment With Study Drug,2006-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Gut Immune Cell Types and Their Cytokine Profile,
5432,NCT00020917,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5433,NCT03309917,Change in internal carotid artery blood flow when mean arterial pressure (MAP) is set to 80-85 and 60-65 mmHg,2017-12-27,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of the slope of linear regression of MAP and internal carotid artery blood flow for the evaluations when MAP is set to 80-85 and 70-75 mmHg and that of the evaluations when MAP is set to 70-75 and 60-65 mmHg
5434,NCT04631731,"Expression of TIM-3, LAG3, VISTA and other inhibitory checkpoint molecules on tumour-infiltrating T cells.",2020-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Association of pre-treatment BMI, neutrophil-to-lymphocyte ratio and other clinical parameters with irAEs."
5435,NCT06212635,Correlation between systemic inflammation and hemostasis measured by novel assays,2022-12-02,RECRUITING,OBSERVATIONAL,['NA'],,Number of participant going to transplant
5436,NCT01679054,Expected and Unexpected Provider Costs,2011-10,COMPLETED,OBSERVATIONAL,['NA'],,Expected and Unexpected Societal Costs
5437,NCT03823079,the duration after returning to normal,2019-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,the rate of pathological complete response.
5438,NCT02819869,relapse-free survival of hepatocellular carcinoma patients,2016-08-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
5439,NCT02912052,Disease free survival，DFS,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],number of lymph nodes retrieved,Overall survival
5440,NCT02558205,Correlation of CT perfusion metrics to radiation dose deposition of Y-90 as measured by PET/CT,2015-07,WITHDRAWN,OBSERVATIONAL,['NA'],,Correlation between CT perfusion metrics and post treatment response as measured by RECIST 1.0 criteria
5441,NCT01683864,Disease Free Survival,2012-09,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Kinetics of Mitomycin and Cisplatin,
5442,NCT03428074,Overall survivals in patients with esophageal cancer who received surgeries,2017-12-01,COMPLETED,OBSERVATIONAL,['NA'],Extents of lymph metastases,Death rates within 30 days after surgeries
5443,NCT05566249,Cost,2022-10-01,RECRUITING,OBSERVATIONAL,['NA'],,Oncologic outcomes
5444,NCT03543514,Crompehension Complexity Index (CCI),2022-02-02,RECRUITING,OBSERVATIONAL,['NA'],,Hospital Anxiety and Depression Scale (HADS)
5445,NCT06287814,3-year disease-free survival (DFS),2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Time to molecular recurrence
5446,NCT05512377,Objective response (OR),2022-11-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change from baseline in EORTC QLQ-BIL21 tiredness domain score
5447,NCT05765214,CRC-KPSS change and screening uptake,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,
5448,NCT01061515,Overall survival,2011-05-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
5449,NCT00290719,Pathological response (complete and partial) post-operatively,2005-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Compare the effects of gefitinib on biomarkers that effect EGF signaling and genomic composition of tumor samples before and after treatment
5450,NCT00012324,Overall survival,2000-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Response to treatment in patients with and without prior therapy
5451,NCT02616926,overall survival,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,disease free survival
5452,NCT02813096,early recurrence,2016-10,UNKNOWN,INTERVENTIONAL,['NA'],,overall survival
5453,NCT03616431,Determine prevalence of pancreatic enzyme insufficiency in patients with pancreatic neoplasms.,2018-07-03,COMPLETED,OBSERVATIONAL,['NA'],,"To identify, through semi structured interviews and thematic analysis, diet-related themes of interest in a subset of patients involved in this study"
5454,NCT05281211,Number of participants experiencing 90 day morbidity,2022-03-15,RECRUITING,INTERVENTIONAL,['NA'],,Number of participants being disease free (Disease free survival)
5455,NCT05047991,Progression-Free Survival (PFS),2021-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,UGT1A1
5456,NCT03511963,PFSR9m,2018-04-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Ctrough,SAE
5457,NCT00962312,6-month survival rate,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumour biomarker analysis
5458,NCT01438645,Sedation Score,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,Ancillary maneuvers to facilitate procedure
5459,NCT04975932,Progression free survival(PFS),2021-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Adverse event(AE)
5460,NCT05942560,Change in anxiety symptoms at 12 months,2023-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
5461,NCT04752930,Peritoneal Metastasis Free Survival (PMFS),2020-08-24,RECRUITING,INTERVENTIONAL,['NA'],,The Overall Survival (OS) at 3 years after radical resection of colorectal cancer
5462,NCT04923932,Objective response rate (ORR) evaluated by the Independent Review Committee (IRC) (RECIST 1.1 criteria),2021-07-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,incidence of various adverse events (AE)
5463,NCT01152710,complete pathological remission rate,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,long-term rectal and urogenital morbidity
5464,NCT05336058,Screening of genetic targets for kit development,2022-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5465,NCT00086996,Pathological Complete Response,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival
5466,NCT00261378,Objective response rate measured according to RECIST and EASL,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time To Progression
5467,NCT02950025,"Number of Grade 3 or Greater Toxicity Occurring in Patients Receiving Online, Adaptive, MRI-guided SBRT to the Abdomen and in Patients Receiving Non-adaptive SBRT",2017-01-19,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Local Failure
5468,NCT05520788,Progression-free survival (PFS),2020-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Quality of Life (QoL) after treatment
5469,NCT05465993,recurrence rate,2017-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Incremental cost-effectiveness ratios (ICERs)
5470,NCT05825664,Curative rate,2023-04-07,RECRUITING,INTERVENTIONAL,['NA'],,Procedure time
5471,NCT04021277,Number of patients with adverse device effects,2019-09-17,RECRUITING,INTERVENTIONAL,['PHASE1'],,Best overall response (Part 1b only)
5472,NCT02226289,Response rate,2020-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression free survival
5473,NCT05020132,Change in the Bristol stool chart between baseline and 12 months,2015-11-01,COMPLETED,OBSERVATIONAL,['NA'],,Multivariate analysis of risk factors for LARS
5474,NCT04976439,Description of survival,2021-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
5475,NCT04478175,Program faisability,2021-04-29,COMPLETED,INTERVENTIONAL,['NA'],,Patient's satisfaction measured by VAS
5476,NCT03007225,Number of Participants With Complete Response,2015-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,
5477,NCT02976909,R0 resection rate,2016-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse envents
5478,NCT02466009,Number of Subjects Who Experience Grade 3-5 Toxicity as a Measure of Safety and Tolerability.,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Subject's Quality of Life as Assessed by the Comprehensive Geriatric Assessment Form While Receiving Study Treatment.
5479,NCT03762837,Gallbladder cancer,2019-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
5480,NCT00217581,Time to Progression,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
5481,NCT03585673,Overall response rate,2018-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse event
5482,NCT03572400,Disease-free survival rate,2018-11-29,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate
5483,NCT05828875,Quality of Life Assessment survey,2023-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
5484,NCT06233253,Satisfaction with the intervention (Acceptability),2023-09-29,RECRUITING,INTERVENTIONAL,['NA'],,Intent for future CRC screening
5485,NCT00003216,,1998-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
5486,NCT04801511,PCR rate,2021-03-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,2-year disease-free survival rate
5487,NCT01290783,Progression Free Survival (PFS),2011-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Safety
5488,NCT00207831,Compare the rate of pathologic complete response of the primary tumor in patients with operable rectal cancer receiving preoperative chemoradiotherapy versus patients receiving radiotherapy alone,2004-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,Compare overall survival
5489,NCT00006115,,1999-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5490,NCT04955730,Surgical Site Infection - Organ/Space Incisional,2021-08-05,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time to Initiation of Planned Oncologic Therapy
5491,NCT00030797,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5492,NCT04477343,Maximum tolerable dose [Safety and Tolerability],2020-11-23,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival
5493,NCT00005586,All-cause mortality,1997-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease recurrence
5494,NCT01797770,anastomotic leak,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],,Readmission
5495,NCT05710809,Dynamic Gait Index (DGI),2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Recurrence of cancer,Body composition
5496,NCT00855218,Time to Progression (TTP) - Independent Radiological Review (Primary Analysis),2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor Response - Investigator Assessment
5497,NCT01129778,Percentage of Time Esophageal pH< 4,2009-11,TERMINATED,INTERVENTIONAL,['NA'],,Reflux Disease Questionnaire Score on Day 1 After Therapy Completion
5498,NCT06281405,Complete response (CR) rate,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of surgical complications
5499,NCT06218433,Sensitivity and specificity of positive utDNA for urothelial cancer within one year of follow-up,2023-04-10,RECRUITING,INTERVENTIONAL,['NA'],Cost of utDNA screening,Urothelial cancer grade
5500,NCT01555801,Diagnostic accuracy,2012-02,UNKNOWN,INTERVENTIONAL,['NA'],,
5501,NCT01339273,Morphine Consumption in the First 48hours After the Operation,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,Time to Hospital Discharge
5502,NCT00001240,,1989-01,COMPLETED,OBSERVATIONAL,['NA'],,
5503,NCT02979470,progression free survival,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],,
5504,NCT02122523,Number of fluorescent lymph nodes,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of Lymph nodes with metastasis
5505,NCT04728321,Objective response rate (ORR),2021-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events (AEs)
5506,NCT03386825,"BRAF mutation (yes, no, unknown)",2018-01-31,COMPLETED,OBSERVATIONAL,['NA'],,Duration of treatment (months)
5507,NCT02156557,Validation of binding of peptide,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5508,NCT03606590,Overall response rate,2019-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Severity and frequency of adverse events
5509,NCT05722288,Percentage of patients completing 4 weeks of time-restricted eating during RT,2023-01-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Oxidative DNA damage
5510,NCT06115629,All-cause mortality,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Fear of cancer recurrence as determined by the cancer worry scale score
5511,NCT00010166,,2000-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5512,NCT00861107,evaluation of any drug-related toxicity associated with AlloStim administration as well as the reversibility of such toxicity.,2009-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,evaluation of the immunological response to AlloStim administration
5513,NCT00129870,Time to treatment failure (TTF) for the conventional oxaliplatin (CO) schedule in comparison with the intermittent oxaliplatin (IO) schedule,2005-02,TERMINATED,INTERVENTIONAL,['PHASE4'],,Reasons for treatment discontinuation
5514,NCT05270889,Overall Response,2022-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
5515,NCT00884520,Safety will be the outcome demonstrated in this clinical trial through analyses of adverse events in subjects who receive study drug.,2009-04,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
5516,NCT05182255,Number of participants with clinically relevant device migration,2022-04-28,RECRUITING,OBSERVATIONAL,['NA'],,
5517,NCT02945878,gradings of oral mucositis,2016-10,UNKNOWN,OBSERVATIONAL,['NA'],,
5518,NCT00003439,,1998-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5519,NCT05051670,major complication,2021-12-16,COMPLETED,INTERVENTIONAL,['NA'],,Hospital stay
5520,NCT03719716,Health related quality of life: EuroQol EQ-5D-5L,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Trial feasibility assessment: conversion rate
5521,NCT05917990,Changes in constructive communication,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
5522,NCT01202409,Response Rate (RR),2010-11-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Progression-free Survival (PFS) for CAPOX and Panitumumab
5523,NCT02845258,Repeated drainage frequency,2006-01,RECRUITING,OBSERVATIONAL,['NA'],,Long time complication rate
5524,NCT00503867,Number of Participants With Adverse Events Grade 3 or Higher,2007-07-18,TERMINATED,INTERVENTIONAL,['NA'],,Overall Survival
5525,NCT05257863,Development of a preoperative score for morbidity/mortality in colorectal surgery,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
5526,NCT01233713,Overall post-operative complication rate defined according to the Clavien-Dindo Classification,2006-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,In-hospital costs
5527,NCT02723942,Radiological assessment,2015-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,CAR-T cell testing
5528,NCT00752063,Progression-free survival,2007-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Tumor response rate, overall survival and safety of the regimen in HCC patients"
5529,NCT05274204,,na,TEMPORARILY_NOT_AVAILABLE,EXPANDED_ACCESS,['NA'],,
5530,NCT04824053,"Change from baseline levels in pro-inflammatory circulating markers C-reactive protein (CRP), interleukin (IL)-6, macrophage inhibitory cytokine 1 (MIC-1) and tumour necrosis factor alpha (TNFα), as well as in fecal calprotectin.",2022-02-28,RECRUITING,INTERVENTIONAL,['NA'],,To assess the effect of treatment on colorectal adenoma recurrence
5531,NCT05871164,Carcinological efficacy of pancreatic radiofrequency,2023-06-12,RECRUITING,OBSERVATIONAL,['NA'],,
5532,NCT01930435,Mean Change in Quality of Life as Measured by the Subscale MDASI-HN Score.,2013-07,COMPLETED,INTERVENTIONAL,['NA'],,Rate of Hospitalization in Patients Who Use Personalized Sterile Humidification
5533,NCT02740985,The incidence of adverse events,2016-06-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression free survival
5534,NCT00940030,"Anastomotic leakage, wound infection (including deep abscess)",2007-10,COMPLETED,INTERVENTIONAL,['NA'],,patient's symptoms (through questionaire)
5535,NCT03963544,Overall survival (OS),1990-01,RECRUITING,OBSERVATIONAL,['NA'],,
5536,NCT03364907,change in tissue platinum exposure before and after flushing,2018-03-01,COMPLETED,OBSERVATIONAL,['NA'],,total and unbound platinum concentration in instillate
5537,NCT00227747,Rate of complete surgical resection,2005-11-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Acute and late toxicity
5538,NCT01209013,Incidence of esophageal stenosis,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Measure oligomer concentrations
5539,NCT00372450,Change in health-related quality of life from baseline to 30 days and 3 months after self-expanding plastic stent or self-expanding metal stent placement,2006-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Overall rate of mortality
5540,NCT01821612,Completion rate of all preoperative and operative therapy,2013-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Overall survival
5541,NCT00666926,Percentage of Participants With Tumor Metabolic Response (Reduction of ≥15%) in Positron Emission Tomography With F-18-fluorodeoxyglucose (FDG-PET),2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Caspase-3
5542,NCT04148378,Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing,2020-03-02,UNKNOWN,OBSERVATIONAL,['NA'],,Validation of Sequencing Methods
5543,NCT06313970,Objective response rate (ORR),2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
5544,NCT00087191,Toxicity as assessed by NCI Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE) version 3.0,2004-05,TERMINATED,INTERVENTIONAL,['NA'],,
5545,NCT00687596,Overall Survival (OS),2008-08-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Relationship Between Tumor Gene Expression of Messenger Ribonucleic Acid (mRNA) Ratio of Co-activators, Co-repressors and Efficacy Parameters"
5546,NCT04329299,Gastric cancer,2012-12-03,COMPLETED,OBSERVATIONAL,['NA'],,
5547,NCT05715255,Change in reported PRO-CTCAE Symptoms,2023-05-08,RECRUITING,INTERVENTIONAL,['NA'],,Change in unscheduled health care visits
5548,NCT01807117,Negative Predictive Values for PET-CT and PET-MRI,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,
5549,NCT03717402,Frequency of Symptom Survey Completion,2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Usability
5550,NCT03035006,Best objective response evaluation of portal vein tumor thrombosis,2017-04-14,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival of overall disease
5551,NCT00468416,Functioning anastomosis and no occurrence of adverse events related to device use,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5552,NCT04098237,Feasibility of completing pancreatic enzyme replacement therapy during the first 8 weeks of the study: daily compliance diary,2020-12-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Mean change in daily active minutes from baseline
5553,NCT02141945,Performance of Metabiomics Colon Polyp and Colorectal Cancer Assay,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,
5554,NCT02928120,Diagnostic potential of hypermethylated DNA as a biomarker for colorectal cancer,2015-02,UNKNOWN,OBSERVATIONAL,['NA'],,Hypermethylated DNA as a follow-up biomarker for disease recurrence
5555,NCT02403050,Intra- and inter-observer variability of tumor target volume (cubic centimetres) estimation,2015-03,UNKNOWN,OBSERVATIONAL,['NA'],,local recurrence of tumor
5556,NCT06055166,PFS rate,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AEs
5557,NCT05773248,Perioperative morbidity,2023-03-13,COMPLETED,OBSERVATIONAL,['NA'],,Readmission rate
5558,NCT05235932,3-year disease free survival rate,2022-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,inflammatory immune response
5559,NCT03658837,Quantitative Assessment using EORTC QLQ-OES-24,2019-01-03,COMPLETED,OBSERVATIONAL,['NA'],,Qualitative analysis
5560,NCT05237310,Additional Adenoma Detection,2022-02-02,UNKNOWN,INTERVENTIONAL,['NA'],,
5561,NCT02174549,Overall Response rate (ORR) by RECIST,2014-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progressive Free Survival,Duration of Response
5562,NCT04769414,Overall response rate (ORR),2021-02-20,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
5563,NCT03311789,The percentage of patients alive and without progression at 6 months,2017-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,List of adverse event frequency and grade
5564,NCT05902624,Effectiveness of Hepatitis B virus vaccine(HBV) in treatment of cutaneous warts .,2023-06-10,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
5565,NCT05673434,Safety assessed by Incidence of Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs),2023-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,CAR-T cell testing
5566,NCT03535727,Progression-free Survival (PFS) Using RECIST 1.1 Criteria,2018-06-21,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety of the Combination of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Patients With Untreated Metastatic PDA."
5567,NCT00251355,To assess the maximum tolerated dose of weekly gemcitabine when administered with continuous infusion 5-fluorouracil and external beam radiation.,1998-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,to obtain a preliminary assessment of the efficacy of this regimen in this patient population.
5568,NCT06027515,Completion Rate (Feasibility),2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],Patient-Reported Measures on Physical Function Score,Actigraphy Compliance Rate (Feasibility)
5569,NCT02076594,Progression Free Survival (PFS),2013-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,"Tolerability of the treatments evaluated in term of occurrence of: side effects graded according to the NCI-CTCAE scale (version 4.0); serious adverse reactions, expected and unexpected"
5570,NCT00852228,Incidence of complete macroscopic resections (R0+R1) of unresectable liver metastases following chemotherapy.,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The per-operative and post-operative complications associated to liver surgery
5571,NCT00955344,Colorectal Cancer Screening Rates,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,Content of practice improvement plan
5572,NCT05429866,Modification(s) in the immune blood markers of treated subjects on treatment at the occurence of any grade 3 or 4 irAE.,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
5573,NCT04828486,Progression-free survival (PFS),2021-05-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in quality of life (QOL)
5574,NCT01698710,Frequency of Pancreatitis,2012-11,TERMINATED,INTERVENTIONAL,['NA'],,Size of Cystic Lesion
5575,NCT00012363,6-month survival rate,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicities
5576,NCT00009880,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5577,NCT01391208,Safety of peptide application,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5578,NCT01258608,Time to Progression-Blinded Independent Central Review (BICR) Assessment,2011-02-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum Concentration of Mapatumumab
5579,NCT05575622,"CTC-PD-L1, exosomal PD-L1, and exosomal LAG-3",2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
5580,NCT05254171,Overall Survival (OS),2022-08-08,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Exploratory,Progression Free Survival (PFS)
5581,NCT05970666,Occurence of AE and SAE,2023-11-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival（OS）
5582,NCT03766659,Diagnostic yield,2019-06-19,RECRUITING,INTERVENTIONAL,['NA'],,morbidity rate
5583,NCT03331562,Progression- Free Survival at 6 Months From Initiation of Trial Treatment,2017-12-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Exploratory: Monitor and Compare the Gut Microbial Communities in Both Arms of the Trial,Cellular VDR Targets in the Immune Microenvironment With PD1 Blockade
5584,NCT06057831,Correlation between PET/MRI reported pCR and complete(pCR) or incomplete response(non-pCR) to total neoadjuvant therapy determined by final pathology will be defined.,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,A feasibility study done to evaluate the benefit of using PET/MRI with respect to improved identification of the target and hence target delineation
5585,NCT00813605,Progression Free Survival,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of antibody formation
5586,NCT00364013,Progression-free Survival,2006-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Adverse Events (AEs)
5587,NCT05233436,Objective response rate (ORR) in Dose Expansion (Part 2),2022-02-24,TERMINATED,INTERVENTIONAL,['PHASE1'],,Time to event endpoints (OS) in Dose Expansion (Part 2)
5588,NCT00797485,Time to failure of strategy,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Quality of life as assessed by EORTC QLQ-C30 questionnaire (v 3.0) at baseline, every 3 months during induction chemotherapy, and at discontinuation of treatment"
5589,NCT05500157,PLD-Q 4 weeks,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Cost-effectiveness iMCQ
5590,NCT02217020,The ratio of tumor downstaging to stage 0 and stage I,2014-08-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Reported Adverse events
5591,NCT04930016,specific need for QoL therapy of colorectal cancers survivors in specific QoL dimensions,2021-04-14,COMPLETED,OBSERVATIONAL,['NA'],,colorectal cancer survivors' recollections of their illness an therapy
5592,NCT00942461,Inflammatory reaction of the patients organism in laparoscopic vs open colorectal surgery for cancer,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,
5593,NCT01087658,"Occurence of peripheral sensory neuropathy (PSN) grade 2, 3 and 4 assessed by the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE)",2010-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival / PFS (for metastatic patients)
5594,NCT02150746,Percentage of patients with successful in vivo animal engraftment of isolated circulating tumor cells,2015-02,COMPLETED,OBSERVATIONAL,['NA'],,
5595,NCT05201612,Objective response rate (ORR),2022-07-07,RECRUITING,INTERVENTIONAL,['PHASE2'],Biomarker molecular substudy,Duration of response (DOR)
5596,NCT01639443,Percentage of GI Clinic Capacity Filled,2013-07-08,COMPLETED,INTERVENTIONAL,['NA'],,Cost Comparisons
5597,NCT00870558,Tumor recurrence at 2 years,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
5598,NCT02355249,The incidence of respiratory complications,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],blood biomarker analysis,Health-related quality of life scores（HRQoL）
5599,NCT02956772,Progression free survival,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life using EuroQol five dimensions five levels questionnaire,Incidence of adverse events
5600,NCT05850884,evaluate the intestinal parasitic infections in patients with intestinal cancer in comparison to non-cancer individuals,2023-11-30,RECRUITING,OBSERVATIONAL,['NA'],,
5601,NCT00997802,sensitivity in the detection of colorectal polyps and cancers in CTC,2009-10,COMPLETED,INTERVENTIONAL,['NA'],,specificity and predictive values in the detection of colorectal polyps and cancers in CTC.
5602,NCT01875549,Stent patency,2013-05,WITHDRAWN,INTERVENTIONAL,['NA'],complication,survival period
5603,NCT05238922,Number of Participants Discontinue study due to TEAE,2022-07-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of Response (DOR)
5604,NCT05999227,18F-FDG PET analysis,2023-06-20,RECRUITING,INTERVENTIONAL,['NA'],,
5605,NCT05859581,Coincidence rate with pathological result,2023-04-02,RECRUITING,INTERVENTIONAL,['NA'],,
5606,NCT03210064,ORR,2017-05-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,QoL
5607,NCT06143579,Overall response rate (ORR),2023-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
5608,NCT00109850,Overall Survival at 2 Years,2005-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
5609,NCT02701088,Tolerance profile: Proportion of patients with no significant toxicities responsible for irradiation breaks,2015-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The acute and late toxicities assessed according the SOMA/LENT scale
5610,NCT03088423,tumor response assessments,2011-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
5611,NCT05424432,Pathologic complete response,2022-04-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Health related quality of Life related to esophageal carcinoma
5612,NCT02191761,Determine the MTD,2014-06-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,Total Clearance of SM04755 after oral administration
5613,NCT05929820,Rate of completion of a CRC screening test,2023-09-15,RECRUITING,INTERVENTIONAL,['NA'],,Qualitative feedback on details of CRC screening test
5614,NCT04744792,Disability of patients and spouses,2006-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
5615,NCT01627808,Stroke volume variation,2011-09,COMPLETED,OBSERVATIONAL,['NA'],,Stroke volume variation
5616,NCT06232538,UCAD can be used as a diagnostic technology for gallbladder cancer with the sensitivity more than 90%,2024-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5617,NCT06253520,Safety,2024-04-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,Safety
5618,NCT03017807,Number of patients with dose limiting toxicity.,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of anti-EGFR antibody after single dose and under the stable blood concentration.
5619,NCT04119830,Objective response rate,2022-02-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Objective response rate
5620,NCT04237883,Aggregate Focus Quality Measure order rates at the first visit,2019-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of Open Tests
5621,NCT04147481,Incidence of postoperative chronic pain,2019-10-21,UNKNOWN,INTERVENTIONAL,['NA'],The numeric rating scale of postoperative pain,Gastrointestinal decompression
5622,NCT03427814,Progression Free Survival (PFS) by Investigator Assessment,2018-07-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
5623,NCT00003260,,1998-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
5624,NCT00620295,Maximum tolerated dose of bortezomib and gemcitabine,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Characterization of gemcitabine and metabolite pharmacokinetics (as part of co-enrollment in Population Pharmacokinetics and Pharmacogenetics of Gemcitabine in Adult Patients with Solid Tumors"")"
5625,NCT05692596,Database creation,2022-10-06,RECRUITING,OBSERVATIONAL,['NA'],,
5626,NCT02475499,Incident pancreatic cancer,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,
5627,NCT03783871,Primary Technical Efficacy,2019-02-17,COMPLETED,INTERVENTIONAL,['NA'],EORTC QLQ-HCC18 Questionnaire,Local tumor progression (LTP)
5628,NCT01543620,,2012-02,UNKNOWN,OBSERVATIONAL,['NA'],,
5629,NCT04235114,The observation of differences in 89Zr-DFO-nimotuzumab uptake between the tumors and normal tissues using PET/CT.,2020-02-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Lesion detection rate of FDG PET/CT compared with 89Zr-DFO-nimotuzumab in patients with EGFR-positive (by IHC) lung and colorectal cancers using PET/CT.
5630,NCT04859582,Overall Survival (OS),2018-11-08,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Percentage of Participants Discontinuing Study Drug Due to AEs
5631,NCT05584592,Changes in patient's comprehensive quality of life composite,2020-07-01,RECRUITING,INTERVENTIONAL,['NA'],,"Skeletal muscle mass index (Skeletal muscle mass index, SMI) changes"
5632,NCT00532740,,2004-12,COMPLETED,OBSERVATIONAL,['NA'],,
5633,NCT00921869,Determination of the MTD of E7050 given orally twice daily. MTD is the highest dose at which no more than 1 out of 6 patients experiences dose-limiting toxicity (DLT),2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Best overall tumor response, duration of response and stable disease, assessed by Response Evaluation Criteria in Solid Tumors."
5634,NCT02650661,Change in percentage of patients meeting the posttraumatic growth inventory (PTGI) goal,2015-11-23,COMPLETED,INTERVENTIONAL,['NA'],,Cost effectiveness analysis
5635,NCT00728585,Incidence of WHO grade 3 or 4 oral mucositis,2008-03-13,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Incidence of febrile neutropenia and invasive bacterial infections
5636,NCT06247956,ORR based on RECIST v1.1 assessment.,2024-03-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,DCR based on RECIST v1.1 assessment
5637,NCT00112099,Overall survival,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,perioperative blood loss
5638,NCT00104065,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5639,NCT00851136,Incidence and nature of dose-limiting toxicities,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Incidence of anti-PRO95780 antibodies
5640,NCT05262491,Phase Ib: Recommended Phase II Dose (RP2D),2022-02-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free Survival (PFS)
5641,NCT05012007,Percentage of returned FIT Kits,2021-08-01,COMPLETED,INTERVENTIONAL,['NA'],Interim analysis,Percentage of returned FIT Kits
5642,NCT00391183,Improvement in the physical functioning scale (containing five items) of EORTC QLQ-30 one month after after biliary stenting.,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Performance status change
5643,NCT01364376,overall survival,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants with grade 3/4 adverse Events
5644,NCT05916001,Surgical site infection (SSI),2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Adipocytes cross sectional area (CSA) in the subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT)
5645,NCT02000999,"• Sensitivity accuracy of cytology, FISH and mutation profiling using histologic diagnosis in conjunction with clinical and/or imaging follow-up as the gold standard.",2013-11,COMPLETED,OBSERVATIONAL,['NA'],,• Technical success and ease of procedure
5646,NCT01126450,"Safety / Tolerability (type, frequency, severity, and relationship of adverse events to study drug)",2009-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Lab correlatives (FCGRIIa and FCGRIIIa polymorphisms, K-Ras and B-Raf mutations)"
5647,NCT02191878,Maximum tolerated dose (MTD),2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Assessment of Pharmacodynamic Effect,Clinical Benefit Rate at maximum tolerated dose (MTD) in Expansion Cohort
5648,NCT05304234,Feasibility of screening protocol,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
5649,NCT02052921,Disease-free survival (DFS),2011-11,TERMINATED,INTERVENTIONAL,['NA'],Overall survival (OS),Operative complication rate
5650,NCT03275987,screening mammography or colonoscopy,2014-04-23,COMPLETED,INTERVENTIONAL,['NA'],,
5651,NCT05549960,Feasibility of pre-planned laser setting in lesion ablation,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],,Rate of resectability
5652,NCT01613950,Incidence rate of Dose Limiting Toxicities.,2012-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Severity of adverse events (AEs)
5653,NCT02508532,"Part 2: Objective Response Rate (ORR) Determined by Central Radiology Assessment Per mRECIST, Version 1.1",2015-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"KIT, PDGFRA, and Other Cancer-relevant Mutations Present in Tumor Tissue at Baseline and EOT"
5654,NCT04454762,Blood pressure [Safety and Tolerability],2020-07-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Health-related quality of life (HRQOL)
5655,NCT04991090,the responsive rate of dose escalation of LLN,2021-08-13,RECRUITING,INTERVENTIONAL,['NA'],,prognosis outcome-3-year Lateral Local Recurrence
5656,NCT01640782,"Progression Free Survival will be defined as the time from date of randomisation to date of first appearance of local, regional or distant relapse, or death from any cause; patients alive without relapse will be censored at date last known to be alive.",2005-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events
5657,NCT00075868,"Prevention of the incidence of moderate, severe, or life-threatening diarrhea",2003-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Prevention of the incidence of severe or life-threatening (i.e., grade 3-5) diarrhea"
5658,NCT01677468,Survival rate of the subjects,2012-08,UNKNOWN,INTERVENTIONAL,['NA'],,Complication rate of TACE
5659,NCT00151476,Time From Start of Study Follow-up to Time of First Excisional Polypectomy of a Rectal Polyp Post IPAA,2004-11,TERMINATED,OBSERVATIONAL,['NA'],,Rectal or Pouch Adenoma Burden Based on Polyp Counts
5660,NCT04984018,OS,2021-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],PD-L1 CPS,DCR
5661,NCT03724851,Maximum Tolerated Dose,2018-11-28,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacodynamics of TEW-7197
5662,NCT05628545,Overall Survival,2021-11-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PFS（Progression-Free Survival )
5663,NCT03342937,Months of Progression-free Survival (PFS),2018-01-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Months of Overall Survival
5664,NCT04663763,pCR rate,2020-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life Scale
5665,NCT01689792,Polyp detection rate,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4'],,Acceptability and tolerability of medication using patient questionnaires
5666,NCT00855985,pancreatic fistula rate,2004-07,UNKNOWN,INTERVENTIONAL,['NA'],,major complication
5667,NCT00718562,Disease Control Rate (DCR) in all patients with either sunitinib-resistant GIST or in patients with GIST who are intolerant of sunitinib,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,PK profile
5668,NCT03467308,Measure TRIM59 in the study groups.,2018-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Targeting new prognostic and therapeutic markers for colorectal cancer.
5669,NCT05384444,Disease-free Survival,2022-06-08,RECRUITING,INTERVENTIONAL,['NA'],,insulin
5670,NCT03760614,Dose limiting toxicity (DLT),2021-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Overall response rate (ORR)
5671,NCT01165346,non-progression part,2009-08-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Medical costs
5672,NCT03707080,Time to HCC recurrence - Prospective Cohort,2018-03-09,COMPLETED,OBSERVATIONAL,['NA'],,Number of events of early HCC recurrence - Prospective Cohort relative to Historical Cohort
5673,NCT02439385,Progression-free survival,2015-08-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Fatigue (FACIT-Fatigue scale (version 4, Korean version)"
5674,NCT00096278,Disease-free Survival,2004-09-15,COMPLETED,INTERVENTIONAL,['PHASE3'],Proteinuria After Completion of Bevacizumab,Survival
5675,NCT05627297,Good/Poor overall survival,2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],,
5676,NCT04319354,Ryan tumor regression grade system (number of patients with complete/partial/no response),2019-11-18,COMPLETED,INTERVENTIONAL,['NA'],,Number of participants with 1 and 2-year disease free recurrence
5677,NCT02464215,Postoperative complication rate,2014-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,3-year disease free survival rate
5678,NCT03822572,Primary Endpoint - disease free survival (DFS),2019-02-14,RECRUITING,INTERVENTIONAL,['NA'],,Exploratory Endpoint - molecular and biochemical markers (will be defined during the course of the study)
5679,NCT04999332,Curative resection rate,2021-12-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-emergent adverse event rate
5680,NCT00084929,Number of Participants With Advanced Adenomas (>=5mm) Detected by CT Colonoscopy (Per Patient),2005-02,COMPLETED,INTERVENTIONAL,['NA'],,Interobserver Sensitivity Variability
5681,NCT04214418,Phase 1: Estimated maximum tolerated dose (MTD),2020-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 1: Incidence of Treatment-Emergent Adverse Events with drug combination (Safety and Tolerability)
5682,NCT02515513,Identify gene networks within the skeletal muscle between the groups,2016-03,WITHDRAWN,INTERVENTIONAL,['NA'],,Survival data
5683,NCT05920980,Pain scores of movement-evoked pain at postoperative 24 hours,2023-06-05,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,plasma lidocaine concentration
5684,NCT05161624,"Receiver operating characteristic curve, ROC",2021-12-15,UNKNOWN,OBSERVATIONAL,['NA'],,"Area under curve, AUC"
5685,NCT03066557,PFS,2017-03-15,UNKNOWN,INTERVENTIONAL,['NA'],,QoL
5686,NCT04513951,Progression-free Survival,2020-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
5687,NCT03375060,Composite histologic score of neosquamous epithelium following endoscopic eradication therapy (EET),2017-08-02,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence rate of intestinal metaplasia (Barrett's esophagus)
5688,NCT01585662,recurrence rate of pancreatic pseudocyst,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,The complication rate
5689,NCT00480584,Maximum Tolerated Dose (MTD),2007-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Recommended Phase II Dose (RPTD)
5690,NCT00517920,Objective Response Rate,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5691,NCT05626569,1-year progression-free survival,2022-12-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-related adverse events
5692,NCT00003835,Survival,1999-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
5693,NCT01738217,"Third step: assess the rate of patients in whom, among the 7 liver segments, the surgeon will be able to selectively target a predefined area.",2013-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Third step: assess the ability of the medical device to detect tumor lesions which were previously known.
5694,NCT00902733,"Quality of life, psychological distress, symptom relief, geriatric assessment outcome, and resource use at 3 months",2008-07,COMPLETED,INTERVENTIONAL,['NA'],,Long-term impact at 6 months
5695,NCT01263002,Proportion of patients with HBV DNA levels < 60 IU/mL,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,
5696,NCT00209690,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.,2003-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the MST(Median Survival Time) and PFS(Progression Free Survival) in Phase II setting.
5697,NCT00004103,,1998-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5698,NCT00166881,Overall survival (OS),2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Objective response rates (CR, PR)"
5699,NCT04269941,number of patients operated for gastric GIST,2000-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
5700,NCT01444014,Visual assessment of the distribution of gastric carcinoids.,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Plasma or serum concentrations of biomarkers such as gastrin and chromogranin A (CgA)
5701,NCT02737228,Overall Response Rate (ORR),2016-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical laboratory tests
5702,NCT05099211,Acceptability of the program in terms of the number of sessions attended,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
5703,NCT00216034,Time of recurrence (calculation of 3-year disease-free survival and overall survival rates),2005-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Relations of survival rate with compliance, postoperative complication, QOL, adverse events, recurrence status, and expression of immune or tumor markers"
5704,NCT02598414,Anastomotic leak rate,2015-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Mortality
5705,NCT04097444,Progression-free survival (PFS),2019-10-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Functional Assessment of Cancer Therapy (FACT) / Gynaecologic Oncology Group (GOG) Neurotoxicity 4
5706,NCT02230410,Eradication of Barrett's Esophagus,2014-08,COMPLETED,INTERVENTIONAL,['NA'],,
5707,NCT01893801,Complete Response Rate,2013-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-Free Survival
5708,NCT05636618,Area under the concentration-time curve (AUC) [Time Frame: 42 days following last dose of [212Pb]VMT-α-NET; up to 3 years,2023-09-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Biodistribution of [212Pb]VMT-α-NET using a microdose of the therapeutic surrogate, [203Pb]VMT-α-NET"
5709,NCT05562297,2-year overall survival after the application of sintilimab and gemcitabine plus nab-paclitaxel,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Correlation among ctDNA, serum tumor markers, and CT evaluations before and after neoadjuvant therapy, before and after curative resection, during and after adjuvant therapy, and during and after the maintenance treatment of immunotherapy."
5710,NCT01309256,Acute-inflammatory response after undergoing robotic and laparoscopic gastrectomy,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,
5711,NCT04869956,Surgical site infection,2021-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Recurrences of CRC after surgery
5712,NCT05801965,Cancer-specific Quality of Life,2023-04-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,User engagement
5713,NCT03521037,Area under the plasma rucaparib concentration-time curve from time zero up to the last time point with quantifiable concentration (AUC0-last),2018-02-27,COMPLETED,INTERVENTIONAL,['PHASE1'],Cumulative amount of rucaparib metabolite(s) excreted in urine during urine collection period post rucaparib dose,Incidence of dose modifications [Safety and Tolerability]
5714,NCT00699374,Overall Survival (OS),2008-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,European Quality of Life (EQ-5D)- Health State Profile Utility Score
5715,NCT00245362,Overall survival,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5716,NCT03150615,Incident rate of delayed gastric emptying,2016-09,COMPLETED,INTERVENTIONAL,['NA'],,Maximum Plasma Concentration fasting plasma GLP-1 level
5717,NCT04732494,Objective Response Rate (ORR) Assessed By The Investigator's Review Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1,2021-03-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events And Serious Adverse Events
5718,NCT00165633,Relapse-free survival period.,2004-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
5719,NCT05297903,Objective Response Rate (ORR),2022-04-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (ORR) in patients who did not received prior immunotherapy
5720,NCT01402687,Develop and validate a clinically applicable SNP-based screening platform for mucositis risk,2010-10,COMPLETED,OBSERVATIONAL,['NA'],,
5721,NCT03886753,Change in symptoms,2019-05-15,TERMINATED,OBSERVATIONAL,['NA'],,Assess therapeutic range
5722,NCT02606305,"Dose Expansion (Regimens A and D) and Triplet (Regimen E): Objective Response Rate (ORR); Percentage of Participants With Confirmed Response, as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1",2016-03-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Immunogenicity: Number of Participants With Anti-Drug Antibody (ADA) Response to Mirvetuximab Soravtansine
5723,NCT00281788,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5724,NCT06165328,Diagnostic yield in diagnosis colorectal tumor,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Procedure-related adverse events
5725,NCT04535401,"Maximum tolerated dose (MTD) of elimusertib (BAY 1895344) in combination with irinotecan, fluorouracil, and leucovorin (FOLFIRI)",2021-08-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Status of deoxyribonucleic acid damage repair (DDR) genes,ATM status
5726,NCT04566133,Median Progression Free Survival (PFS),2022-02-15,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Overall Survival
5727,NCT03852290,Assessment of C677T and A1298C MTHFR polymorphisms and response rate,2019-01-16,UNKNOWN,OBSERVATIONAL,['NA'],,Assessment of C677T and A1298 MTHFR polymorphisms and toxicity
5728,NCT05930496,Acceptability,2024-04-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Effects of an 8 week supervised exercise intervention on fecal concentrations of other short chain fatty acids
5729,NCT01891552,time to progression,2013-05,COMPLETED,OBSERVATIONAL,['NA'],quality of life,number of adverse events
5730,NCT04651504,Number of colonoscopy completions after positive fecal immunochemical test,2020-12-02,RECRUITING,INTERVENTIONAL,['NA'],,Proportion of patients who complete a complete diagnostic evaluation within 60 days of positive fecal immunochemical test
5731,NCT02542670,Number of cancer patients with abnormal genetic mutations .,2015-07,UNKNOWN,OBSERVATIONAL,['NA'],,
5732,NCT00427102,Determine pharmacokinetic parameters of oral MRX-1024.,2007-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Possibly show a trend in activity of MRX-1024 in preventing or reducing oral mucositis.
5733,NCT06190301,The cumulative occurrence rate of complications of grade ≥2 within 2 years after treatment commencement,2024-01-11,RECRUITING,INTERVENTIONAL,['NA'],,overall survival
5734,NCT01050426,"One year overall survival, measured from the date of registration.",2009-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Evaluation of the role of FDG-PET in predicting overall survival, progression free survival and objective response rate in locally advanced pancreatic cancer."
5735,NCT04632199,Incidence of Treatment-emergent adverse events,2021-03-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Optimal injected radioactivity range
5736,NCT00230451,To determine the rate of complete histologic response induced by this neoadjuvant chemotherapy and radiation therapy regimen.,1997-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess the qualitative and quantitative toxicities of this regimen.
5737,NCT00518557,"Safety and tolerability, Mortality",2007-04,UNKNOWN,INTERVENTIONAL,['NA'],,"Tumor volumetry, Changes of Tumor markers such as AFP, Curriculum survival"
5738,NCT00071994,Progression-free survival rate in patients treated with ZD 1839,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,EGFR expression
5739,NCT04571294,Overall Survival (OS),2020-05-26,RECRUITING,INTERVENTIONAL,['NA'],,post-operative outcomes
5740,NCT05842187,PFS (Progressive free survival),2023-03-03,RECRUITING,INTERVENTIONAL,['NA'],,DCR (Disease control rate)
5741,NCT06078657,1 year overall survival rate,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],biomarker,adverse events
5742,NCT02799251,Presence of post operative infection,2016-06,COMPLETED,OBSERVATIONAL,['NA'],,Anesthetic and surgical parameters
5743,NCT05196334,Comparison between organoid's and patient's response,2021-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5744,NCT04015804,Conversion rate for robotic surgery,2015-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Operating time
5745,NCT00766142,Median Progression-free Survival (PFS) Time,2007-05-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) Time
5746,NCT00637988,Measure PGE production in Barrett's metastatic tissue & determine the reduction from baseline of PGE production would be equivalent on Day 10 in esomeprazole 40mg bid + aspirin treatment compared to esomeprazole 40 mg bid + rofecoxib 25 mg qd treatment,2002-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,"To determine in which of the four treatment groups the reduction in the baseline in PGE2 production, COX-2 enzyme activity and PCNA expression in Barrett's metaplastic tissue is the greatest."
5747,NCT01926236,Overall survival,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality adjusted life years (QALYs)
5748,NCT03009253,translational resection rate,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],,Local control rate
5749,NCT02532803,Measurement of the accuracy of a novel MRI assessment tool to accurately stage Early Rectal Cancers and Polyps,2015-08-13,UNKNOWN,INTERVENTIONAL,['NA'],,Measurement of the Sensitivity and specificity of MRI for lymph node metastasis
5750,NCT03463876,Objective Response Rate (ORR),2018-02-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival(PFS)
5751,NCT00784446,Dose limiting toxicity.,2008-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Assessment of overall response rate and progression free survival.
5752,NCT00207051,determination of maximum tolerated dose (MTD),2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Efficacy based on duration of response and time to progression based on assessment
5753,NCT00759226,Primary endpoint rate of freedom of progression (PR+CR+SD).,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Secondary endpoint median survival, progression free survival and toxicity."
5754,NCT01724775,Prognosis assessment of postoperative patients,2012-11,UNKNOWN,OBSERVATIONAL,['NA'],,Safety assessment of the patients in perioperation period
5755,NCT00381706,Response Rate (Complete and Partial) in Patients With Measurable Esophageal or GE Junction Adenocarcinoma,2006-09-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Treatment Failure in Patients With Adenocarcinoma
5756,NCT04082364,Objective response rate (ORR) for non-microsatellite instability-high (non-MSI-H) patients (Cohort A),2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Number of patients who have ADA to tebotelimab
5757,NCT04852367,To quantify the enhancement in intratumoural doxorubicin concentration when delivered with ThermoDox® and mild hyperthermia generated non-invasively by focused ultrasound (FUS) compared to free drug alone,2021-06-16,WITHDRAWN,INTERVENTIONAL,['PHASE1'],To assess effects of ThermoDox® and FUS treatment compared to free drug alone on pancreatic tumour biomarkers,Change in patient symptom scores in patients with pancreatic cancer treated with of ThermoDox® and FUS compared to those treated with doxorubicin
5758,NCT02254941,Overall survival,2014-08,UNKNOWN,OBSERVATIONAL,['NA'],,Study other variables to identify whether there is group of patients who may benefit from monoclonal antibodies for the treatment of first-line chemotherapy
5759,NCT04534309,Weight change at 6 months in Coach-Directed Program,2020-09-22,COMPLETED,INTERVENTIONAL,['NA'],Weight change at 12 months by program,Weight change at 6 months in Self-Directed and App-Directed Weight Loss Programs
5760,NCT03342677,Comparison of Gd-EOB-DTPA enhanced liver MRI and CT scan images in characterizing cirrhotic nodules and HCC in liver transplant candidates,2017-11-07,UNKNOWN,INTERVENTIONAL,['NA'],,Investigation of Gd-EOB-DTPA enhanced MRI efficacy in diagnosis and staging of HCC in cirrhotic patients and its potential impact on liver transplantation eligibility in patients who are liver transplant candidates
5761,NCT02877589,hepatitis B virus (HBV) serological status,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,hepatitis C virus (HCV) serological status
5762,NCT05204433,effectiveness of methylation markers from stool samples,2019-01-05,UNKNOWN,OBSERVATIONAL,['NA'],,assess the capacities of RF model in screening potential clinical biomarkers.
5763,NCT05511051,Overall Survival,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Safety and tolerance evaluated by incidence, severity and outcomes of AEs"
5764,NCT04715308,To assess the impact of urinary diversion/reconstruction subtypes on quality-of-life,2020-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,To measure the rate of reintervention for complications associated with urinary diversion/reconstruction
5765,NCT05536362,Measurement of Post-operative Pain,2021-02-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5766,NCT02818907,"disease-free survival according to the consensus DATECAN (Bonnetain F et al, European Journal of Cancer 2014)",2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,
5767,NCT01221324,postoperative inflammatory complications,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,Anastomotic leakage
5768,NCT01787864,Presence of dysplasia before and after ablation,2013-02,COMPLETED,OBSERVATIONAL,['NA'],,
5769,NCT02359565,Change in the percentage of CD8+ T cells that are PD-1+ due to treatment with pembrolizumab (Stratum C),2015-05-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,Changes in quantitative imaging parameters
5770,NCT04095364,Progression-free survival (PFS),2019-09-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adherence to letrozole maintenance therapy
5771,NCT00164944,To find the prevalence of adenomas and advanced neoplasms of the first degree relatives,2004-04,COMPLETED,OBSERVATIONAL,['NA'],,
5772,NCT05409417,Drug Safety,2022-10-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,DCR
5773,NCT00012389,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,
5774,NCT01939665,Safety (number of adverse events),2013-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor response
5775,NCT03716596,overall survival,2018-10-22,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Related tumor markers
5776,NCT01275664,Number of Participants With Complete Control Defined as no Vomiting and no Use of Rescue Medications (for Nausea or Emesis),2011-06,TERMINATED,INTERVENTIONAL,['NA'],,Percentages of Patients With NIDL Based on FLIE
5777,NCT03447431,To develop biological tools to simplify screening in future clinical assays,2018-04-05,UNKNOWN,OBSERVATIONAL,['NA'],,
5778,NCT02591030,overall survival,2015-12-15,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,quality of life (EORTC QLQ-C30 )
5779,NCT00991952,Overall Response Rate,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5780,NCT01471249,improvement of dysphagia post stenting,2011-06,TERMINATED,OBSERVATIONAL,['NA'],,Quality of life post stenting
5781,NCT06309485,Efficacy of WGI-0301 in combination with Sorafenib based on ORR per RECIST 1.1.,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Anti-tumor activity if WGI-0301 in combination with Sorafenib based on OS.
5782,NCT05600309,Overall Survival (OS),2022-06-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,TTD in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score
5783,NCT03721653,Progression Free Survival (PFS),2018-11-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,2nd-PFS
5784,NCT05128123,"The primary objective will be to assess the rates of curative treatment (either resection, ablation or liver transplantation) according to the social determinants of health",2022-01-21,RECRUITING,OBSERVATIONAL,['NA'],,Assessment of the relationship between social health determinants and the quality of life of patients at 6 and 18 months after inclusion in the CHIEF cohort study
5785,NCT03751176,Progression-free survival at 6 months,2018-11-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Biomarkers analysis by liquid biopsies.
5786,NCT00503321,progression-free survival,2006-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Anticancer effect, time to treatment failure (TTF), QOL (FACT-BRM), compliance, adverse drug reactions and immunological factors"
5787,NCT00083122,Proportion of Confirmed Tumor Responses Defined to be Either a Complete Response (CR) or Partial Response (PR),2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Progression
5788,NCT01310972,"OS, PFS, DFS",2007-09,COMPLETED,OBSERVATIONAL,['NA'],,
5789,NCT03972956,Confirmation of diagnosis by pathologist,2020-12-23,RECRUITING,OBSERVATIONAL,['NA'],,
5790,NCT04027088,Surgical fistulas,2019-08-10,UNKNOWN,INTERVENTIONAL,['NA'],,Weight loss
5791,NCT01790139,Colonic bubble-related image quality,2013-02,COMPLETED,INTERVENTIONAL,['NA'],,diagnostic performance
5792,NCT04820712,Overall survival,2020-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Cancer-specific survival
5793,NCT00853684,Time to progression,2009-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
5794,NCT03837301,complete resection rate (%) of tumor,2018-09-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5795,NCT06216743,Sensitivity and specificity of different MRI sequences to diagnose T4 colon carcinoma.,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Establishing an MRI Protocol that is optimized for the clinical staging of colon tumors
5796,NCT02495896,Progression-free survival,2015-09-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,
5797,NCT00290615,Response Rate (Percentage of Participants With Partial or Complete Response),2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Effect on Wound Angiogenesis,Overall Survival
5798,NCT02981498,progression-free survival rate,2015-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,AE event
5799,NCT02560623,DNA Yield,2015-10-15,COMPLETED,INTERVENTIONAL,['NA'],,Specificity of Barrett's Dysplasia Detection
5800,NCT04269499,Feasibility of MR imaged administration of holmium microspheres,2019-11-11,COMPLETED,INTERVENTIONAL,['NA'],,Tumor response after 3 months based on CT imaging (according to RECIST 1.1 criteria)
5801,NCT03631641,Incidence rate of non-colonic cancers,2018-08-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
5802,NCT02776683,Percentage of Patients With Treatment-Emergent Adverse Events (TEAEs) in the Specified Categories Selected for Primary Endpoint Assessment,2016-06-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression-Free Survival (PFS) Time as Assessed by Central Imaging Review
5803,NCT04942665,Quantitative Assessment - Bile Duct-to-liver Fluorescence Intensity Ratio,2021-09-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Qualitative Assessment of Overall Intraoperative Visualization of the Extrahepatic Biliary Tree (Common Hepatic Duct, Cystic Duct, Common Bile Duct, Aberrant Ducts)"
5804,NCT02077777,Molecular analysis of gene expression levels of μ-protocadherin and other related proteins,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Evaluation of protein expression level of μ-protocadherin, Ki-67, Caspase-3 and Histone H2AXγ, evaluation of DNA oxidative damage and intra-mucosal concentration of 5-Acetylsalicylic acid"
5805,NCT06314737,Overall Survival,2010-10-02,COMPLETED,OBSERVATIONAL,['NA'],,
5806,NCT04417699,Achieve a reduction by at least 5.8 in Neoadjuvant Response (NAR) score compared to historic controls with NAR of 14.59,2022-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
5807,NCT01505205,,2011-04,COMPLETED,OBSERVATIONAL,['NA'],,
5808,NCT03528863,Acceptability as assessed by adherence to practice instructions,2018-05-07,COMPLETED,INTERVENTIONAL,['NA'],,"Efficacy as assessed by a ""Are You at Peace?"" one-item spiritual probe"
5809,NCT00002689,Survival,1995-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patterns of failure
5810,NCT00660894,Disease-free survival,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Identification of predictive markers
5811,NCT01874938,Progression Free Survival (PFS) Rate,2013-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,PFS
5812,NCT06223061,"Compliance to pre-, intra-, and post-operative audit standards",2023-07-31,RECRUITING,OBSERVATIONAL,['NA'],,Rates of unsuspected gallbladder cancer.
5813,NCT01133340,To define the usefulness of Endoscopic clip placement and 3T-MRI imaging for accurate target volume definition in rectal cancer patients undergoing pre-operative chemoradiation.,2010-06,COMPLETED,INTERVENTIONAL,['NA'],,To assess the differences in pelvic lymph node (CTV) volume definition between Ct and MRI images.
5814,NCT00047762,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5815,NCT02715089,Progression-free survival (PFS),2015-12,UNKNOWN,OBSERVATIONAL,['NA'],,Adverse Drug Reaction (ADR)/Adverse Event (AE)
5816,NCT00349076,"Disease free survival at 3 years defined as the interval from randomization to locoregional or metastatic recurrence or the appearance or a secondary colorectal cancer or death, whichever occurs first.",2006-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Resection rate, rate of sphincter preservation, tumor regression, cumulative incidence of local and distant recurrences, overall survival, toxicity, quality of life"
5817,NCT05523960,the rate of major complications,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
5818,NCT02632188,Progress-free survival,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
5819,NCT03434834,Percentage of Imaged Sites Correctly Categorized as Barrett's Mucosa,2018-09-25,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Imaged Sites With Adequate Tissue Contact to Acquire a High Quality Image
5820,NCT04258137,Assessment of cancer outcome in terms of overall survival (2 distincts population),2020-09-04,RECRUITING,INTERVENTIONAL,['NA'],,Proportion of patients treated with a targeted therapy (in 2 distincts populations)
5821,NCT03564912,DFS,2018-08-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
5822,NCT00620607,response rate,2007-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,effect of huC242-DM4 on tumor uptake of FDG
5823,NCT06331988,Relapse free survival,2022-07-21,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
5824,NCT03479645,Colorectal screening rate,2018-03-23,COMPLETED,INTERVENTIONAL,['NA'],,FIT kit return rate by insurance status
5825,NCT02942329,Overall survival rate,2016-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety as measured by the rate of AEs, deaths and laboratory abnormalities (e.g. Grade 3 or higher per CTCAE v4 )"
5826,NCT01978444,3-year disease free survival,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative intraperitoneal free cancer cell (IFCC),3-year overall survival
5827,NCT00587145,To evaluate the clinical responses to preoperative S-1 plus docetaxel,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"the clinical downstaging,the pathologic responses, toxicity profile,the disease-free survival,overall survival,the effect of CYP2A6 genetic polymorphisms on the pharmacokinetics and the difference in pharmacokinetics between before and after gastrectomy"
5828,NCT03649321,Overall Response Rate (ORR),2019-01-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With an Adverse Event of Grade 3 or Higher
5829,NCT05522894,Objective response rate (ORR),2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],The level of ctDNA in blood,Incidence and severity of adverse events(AEs)
5830,NCT00858871,To compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic treatment,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,To compare health-related quality of life
5831,NCT06134765,The incidence of reduced absolute neutrophil count(ANC) of grade ≥3 in the first cycle of chemotherapy,2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
5832,NCT03064828,Sensitivity and specificity of low-dose CTC for the polyp detection,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],,Sensitivity and specificity of CTC for the detection of poly malignancy
5833,NCT03008343,Relief degree of tumors,2016-12-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
5834,NCT05137899,Hepatectomy,2022-10-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity to Atezolizumab/Bevacizumab
5835,NCT02570399,Feasibility in terms of toxicity related to radiation therapy,2015-02-26,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life questionnaire of treated patients
5836,NCT02019199,Tumor Motion,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,
5837,NCT02329106,Evaluate the safety of IRE for unresectable liver cancer close to diaphragmatic dome using Common terminology Criteria for Adverse Events (CTCAE).,2014-12-01,COMPLETED,INTERVENTIONAL,['NA'],,Evaluate the efficacy of IRE for unresectable liver cancer close to diaphragmatic as measured by cell death of CRLM after IRE is demonstrated macroscopically by using vitality-staining with triphenyl-tetrazoliumchloride (TTC)
5838,NCT03302858,Percent of patients who have histologically cleared high-grade squamous intraepithelial lesions (HSIL) at the SCJ at 12 months as measured by HRA,2017-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Percent of patients who have histologically cleared low-grade squamous intraepithelial lesions (LSIL) at the SCJ at 12 months as measured by HRA
5839,NCT03448731,Efficacy in the prevention of skin toxicity,2018-05-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events
5840,NCT05239507,"To describe the OS rate in patients with unresectable HCC including estimates of survival rates at 6, 12, and 18 months and at 2 years",2022-02-01,COMPLETED,OBSERVATIONAL,['NA'],"To investigate the correlation between survival outcomes and clinical characteristics, liver function, and underlying disease in unresectable HCC",To describe the demographic and clinical characteristics of patients with unresectable HCC
5841,NCT03137004,six-month overall survival,2017-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Event（AE）
5842,NCT01465451,disease-free survival,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,safety profiles
5843,NCT02498613,Objective response rate,2016-08-31,TERMINATED,INTERVENTIONAL,['PHASE2'],Changes in levels of angiogenesis/ inflammatory markers (angiome panel) (all cohorts),Progression-free survival
5844,NCT00033735,Survival of Irofulven vs. 5-FU,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Objective Tumor Response of Irofulven vs. 5-FU and Clinical Benefit of Irofulven vs. 5-FU
5845,NCT00784667,To determine the response rate (RECIST criteria). Responses will be evaluated for the whole patient group and separately for k-ras wild-type and k-ras mutant tumours,2008-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
5846,NCT02793479,Elimination Rate of Barrett's Esophagus in the study population,2017-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5847,NCT00874224,Time to functional Recovery,2010-01,COMPLETED,INTERVENTIONAL,['NA'],,Reasons for delay of discharge after functional recovery
5848,NCT03386500,"Count of Adverse events, serious adverse events and dose limiting toxicities",2017-11-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Single-dose and repeated-dose pharmacokinetic profiles of BMX-001,Effect of study treatment on locoreginal progression free survival survival (PFS).
5849,NCT04800497,Association between circulating tumor cells and disease-free-survival,2019-02-07,RECRUITING,OBSERVATIONAL,['NA'],,Association between circulating tumor cells and overall survival
5850,NCT00321594,Tumor Response in Patients With Inoperable HCC Using Belinostat (Phase II),2006-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5851,NCT05022927,Safety of ERY974 (Dose limiting toxicities) [Mono dose escalation part],2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Biomarkers of ERY974 [Mono dose escalation part]
5852,NCT03731819,Table time of Abbreviated PB MRI,2018-11-05,COMPLETED,INTERVENTIONAL,['NA'],,Requirement for re-examination
5853,NCT01977053,"emotional state (anxiety, depression, confusion, angry, fatigue, force and interpersonal relation)",2013-09,COMPLETED,INTERVENTIONAL,['NA'],intervention cost,relationship between psychosocial criteria and anxiety
5854,NCT02513849,"A change in Ki67 expression following tamoxifen therapy, by comparing the pre- and post- tamoxifen biopsies",2015-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,A change in ER-β expression
5855,NCT04947696,Changes in DNA-methylation patterns from the pre to postoperative setting,2021-07-30,UNKNOWN,OBSERVATIONAL,['NA'],,Relapse of pancreatic cancer
5856,NCT00711191,Number of Participants With Dose Limiting Toxicities (DLTs),2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Recommended Phase 2 Dose (RP2D) of CP-870893 in Participants With Advanced Pancreas Cancer,Carbohydrate Antigen 19-9 (CA 19-9)
5857,NCT05566743,PFS,2022-09-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
5858,NCT02974556,Incidence of endoperitoneal recurrence at 36 months,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,EORTC QLQ-C30 Summary Score
5859,NCT05197933,3-year disease-free survival rate (DFS),2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Postoperative recovery course（Highest Body Temperature）
5860,NCT02210182,pharmacokinetics,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biomarker
5861,NCT05364489,Progression Free Survival (PFS),2022-06-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Drug-Related Safety Indicators
5862,NCT00091026,Objective Response Rate (Complete or Partial Response) Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST),2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
5863,NCT00004884,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5864,NCT01539018,time to progression (TTP):recist criteria,2012-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of Life Using EQ-5D questionnaire.
5865,NCT02309619,Mortality and complications.,2008-01,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life.
5866,NCT00386984,Overall survival time,1999-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Prognostic relevance of the Somatostatin receptors
5867,NCT00044967,overall survival,2002-05,COMPLETED,OBSERVATIONAL,['NA'],,
5868,NCT05320692,PFS assessed by BIRC,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE3'],,The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0
5869,NCT00539643,Response to Treatment by RECIST Criteria,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
5870,NCT02546973,HRQL in patient's with anal cancer 3 years after diagnosis,2015-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"HRQL (measured by questionnaires) differences between patient groups such as age, gender and educational level"
5871,NCT01075633,Advanced colorectal neoplasm detection rate [Time Frame: 2 years] [Designated as safety issue: No],2006-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Complications rate
5872,NCT05034185,To evaluate the diagnostic performance of the CADx support tool compared to optical prediction of polyp histology by the Clinician in real-time colonoscopy in a clinical setting,2021-03-03,COMPLETED,OBSERVATIONAL,['NA'],,To determine the diagnostic performance of CADx versus optical prediction of polyp histology by endoscopist in the subgroup analysis
5873,NCT05002127,Phase 3,2022-01-15,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
5874,NCT01057355,Decrease in volume of the pancreatic cyst by cross-sectional imaging studies (CT or MR) performed before and after treatment,2010-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
5875,NCT02482259,Time taken to complete assessments,2013-12-01,COMPLETED,OBSERVATIONAL,['NA'],Biomarker assessment of frailty and associated factors,Muscle mass and timed get up and go as predictors of outcome
5876,NCT02034110,Overall Response Rate (ORR) in the Multiple Myeloma (MM) Cohort,2014-03-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events (AEs)
5877,NCT02873845,Objective burden score in the dimensions of the COBQoL questionnaire with good psychometric properties,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],,
5878,NCT00345696,Progression Free Survival,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Resection rate of hepatic or pulmonary metastases
5879,NCT00004904,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5880,NCT00720993,- To select a threshold for Mahalanobis distance to determine the best operating characteristics (sensitivity and specificity) in subjects with cancer and subjects without cancer. - To explore other empirical metrics based on previous exploratory data,2008-08,UNKNOWN,OBSERVATIONAL,['NA'],,"- To obtain data to estimate sensitivity, specificity, and the ROC curve for a test based on M-distance. - To determine the variability of sensitivity and specificity estimates"
5881,NCT02151019,Reduction in incidence of grade 2 or higher GI toxicity,2014-10-17,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Differences in the toxicity profile between the two types of neoadjuvant concomitant chemotherapy, graded by the NCI-CTCAE Version 4"
5882,NCT01775449,Cold pain thresholds,2013-02-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,QLQ-C30 (Quality of Life questionnaire C30)scores
5883,NCT01415479,Intention to undergo CRC screening in the next six months,2011-08,COMPLETED,INTERVENTIONAL,['NA'],,Completion of CRC screening
5884,NCT04720131,Objective response rate,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
5885,NCT05871099,5-years Recurrence-free survival,2022-11-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,Toxic and side effects of the program
5886,NCT04687384,Changes in levels of systemic inflammatory response expressed by CRP and IL-6 in serum between the two groups,2021-08-01,UNKNOWN,INTERVENTIONAL,['NA'],Time to local cancer recurrence or metastatic spread,Time to first bowel movement
5887,NCT05231850,Primary End point: Disease Free survival [ Time Frame: 3 years ],2022-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
5888,NCT02891538,Change in methylation from baseline when compared to the control arm,2017-01-31,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
5889,NCT01544413,Completement of performance of laparoscopic sentinel lymph node biopsy,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,"Detection rate of laparoscopic sentinel lymph node, learning curve"
5890,NCT04599790,Progression free survival (PFS) assessed by investigators according to Modified RECIST (mRECIST),2020-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,DOR assessed by investigators according to mRECIST.
5891,NCT03807518,Change in Physical Fitness,2019-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Change in concentration of blood markers of Inflammation- White Cell Differential
5892,NCT01279291,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2011-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,"To describe any anti-tumor activity observed when KHK2866 is administered i.v. as monotherapy, or in combination with chemotherapy."
5893,NCT03034850,Blood loss,2015-04,COMPLETED,OBSERVATIONAL,['NA'],,Maximum Lysis (ML) HEPTEM Rotational thromboelastometry (ROTEM)
5894,NCT03219593,Progression-free survival (PFS),2017-09-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Tumor biomarkers,Adverse Events(AEs)
5895,NCT01501240,"Diagnostic sensitivity of gadoxetic acid-enhanced MR imaging to detect HCC in the cirrhotic liver, using thin-section whole-explant as the standard of reference",2012-01,WITHDRAWN,OBSERVATIONAL,['NA'],,To characterize borderline hepatocelluar nodules
5896,NCT02394535,Maximum tolerated dose defined as the highest dose level in which 6 patients have been treated with at most 1 instance of dose limiting toxicity (DLT) according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,2015-11-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Changes in MD Anderson Symptom Inventory Gastrointestinal Cancer Module (MDASI)
5897,NCT01657773,Statistical analysis,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,Laboratory Assay and Measurement
5898,NCT00677586,Severe complication rate after resection of primary and metastatic lesions,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative hospital stay
5899,NCT04720716,Objective response rate (ORR),2021-02-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,The incidence and severity of Treatment-Emergent Adverse Events
5900,NCT02780921,percentage of patients reaching the complete oncological treatment fixed in a multidisciplinary tumour board,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,quality of life
5901,NCT05887505,Ratio of liver failure,2023-06-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Complications after surgery
5902,NCT04803318,Assessing Incidence of Treatment-Emergent Adverse Events during the treatment and various responses to the treatment.,2021-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Assessing overall survival
5903,NCT02893930,Overall Response Rate,2017-04-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
5904,NCT03839550,Recurrence-free survival(RFS),2019-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5905,NCT03960775,CRP level in blood,2019-04-30,COMPLETED,INTERVENTIONAL,['NA'],,HOD (hospital days)
5906,NCT05242991,Hyposalivation,2021-03-01,RECRUITING,INTERVENTIONAL,['NA'],,
5907,NCT06056726,Peri-operative complications,2021-02-18,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
5908,NCT01321450,Total operation time,2009-03,COMPLETED,OBSERVATIONAL,['NA'],,postoperative intervention
5909,NCT02133612,3 year overall survival,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants with Adverse Events,3 year disease-free survival
5910,NCT04887805,Progression free survival,2021-07-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
5911,NCT05714878,Duke Activity Status Index before surgery,2023-03-22,RECRUITING,INTERVENTIONAL,['NA'],,30-day readmission rate
5912,NCT05021250,ORR,2021-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Frequency of AE
5913,NCT05853094,Microbiome functional gene capacity in postoperative stoma pouch and distal intestine by metagenomic sequencing,2023-06-23,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival
5914,NCT03778593,Response rate of treated participants,2019-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],EORTC -QoL-C30,Incidence of Treatment-Emergent Adverse Events of participants
5915,NCT03970694,5-year overall survival rate,2019-05-11,TERMINATED,INTERVENTIONAL,['PHASE3'],,3-year progression-free survival rate
5916,NCT00554125,Disease-free survival,2007-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,overall survival
5917,NCT04177875,Objective Response Rate (ORR),2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The incidence of adverse events and the incidence of severe adverse events（ grade 3-4)
5918,NCT02842749,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2016-03-14,COMPLETED,INTERVENTIONAL,['PHASE4'],,Progression free survival
5919,NCT01421940,Change from baseline in International Index of Erectile Function (5-item Version) at 12 and 24 week,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of patients with adverse events during 24 weeks of the study
5920,NCT06119867,Comparision of the incidence of stage III colon cancer between European and Japanese pathological investigation methods.,2023-11-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Comparison of the extramural invasion (venous, lymphatic, perineural) between the European and Japanese pathological approaches"
5921,NCT04752267,Different pattern in radiomics mpMRI and FMAU PET kinetic analysis parameters,2021-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
5922,NCT05745857,Evaluate if the combination of tracers improves lesion detection by the number of invisible lesions detected,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Eventually further specify and objectify the improvement of qFME by standardisation
5923,NCT03187314,Objective response rate (ORR),2017-06-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Health-related quality of life (HRQoL)
5924,NCT05781568,Biomarker dosage,2023-02-24,RECRUITING,OBSERVATIONAL,['NA'],,
5925,NCT03432806,successful isolation of exosomes,2017-11-28,RECRUITING,OBSERVATIONAL,['NA'],,
5926,NCT00235898,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5927,NCT03529760,HBV-DNA positive,2018-05-08,UNKNOWN,OBSERVATIONAL,['NA'],,
5928,NCT00869258,Conversion Rate of Inoperable to Operable,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5929,NCT05693519,Overall survival,2022-12-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Standardized incidence of second primary malignancies
5930,NCT01261962,Gene expression,2011-02,UNKNOWN,INTERVENTIONAL,['NA'],,Humoral immunity and neutrophil function
5931,NCT02703714,Overall Response Rate (ORR),2016-05-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival (OS) Stratified by Sub-type of Biliary Cancer
5932,NCT05525286,Parts C and D: The assessment of the efficacy of SOT102 in monotherapy and in combination with first-line SoC treatment,2022-03-31,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Parts C and D (monotherapy and combination with SoC): Relationship between the intensity of CLDN18.2 expression and clinical outcome,Parts C and D (monotherapy and combination with SoC): Number of participants with antibodies against SOT102
5933,NCT01488487,Time to Progression (TTP),2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (ORR)
5934,NCT03897543,Incidence of adverse events (AEs),2019-08-30,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Alpha Fetoprotein Serum concentrations
5935,NCT06000553,"the aim is to search for immune and metabolic abnormalities in patients with at-risk TIPMP in the blood or by echo-endoscopic sampling, then compare and combine them with the criteria used in clinical practice.",2023-10-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
5936,NCT05083780,Number of participants with treatment-related adverse events assessed by CTCAE v5.0,2021-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Objective Response Rate
5937,NCT02523053,Time to tumor recurrence,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
5938,NCT06230328,Epidemiological profile and pathological staging,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Description of clinical condition
5939,NCT06225011,Immune cell composition and microenvironment,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
5940,NCT00899132,Characterization of TAB3 and its signaling networks that are involved in tumorigenesis,2007-02,TERMINATED,OBSERVATIONAL,['NA'],,
5941,NCT05954429,objective response rate (ORR),2023-07-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events
5942,NCT06179602,Safety as assessed by complications according to CTCAE v6.0.,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
5943,NCT05672316,Overall response rate (ORR) (Phase II),2023-05-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of toxicity (Phase II)
5944,NCT00300547,Feasibility of MR colonography to diagnose possible synchronous carcinomas and polyps,2007-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,Altered operative strategy due to findings on MR colonography
5945,NCT00189683,,na,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
5946,NCT04406857,Incidence of Dose-limiting Toxicities (Part IB),2021-03-17,TERMINATED,INTERVENTIONAL,['PHASE1'],"Interactions of Capecitabine, IPdR and Their Metabolites",Neoadjuvant Rectal Score at the Maximum-tolerated Dose
5947,NCT06032338,Performance of colonoscopy in FIT positive patients,2023-09-14,RECRUITING,INTERVENTIONAL,['NA'],,Cost-effectiveness analysis
5948,NCT04415853,Overall survival,2021-01-21,RECRUITING,INTERVENTIONAL,['PHASE3'],,Apparent Volume of Distribution (Vd/F) of Lerotinib
5949,NCT03938623,number of patients screened positive using the patient-centered approach after training of face to face training or e-learning,2018-01-24,UNKNOWN,OBSERVATIONAL,['NA'],,
5950,NCT01774266,Early detection of gastric cancer,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],Detection of H.pylori and gastric atrophy,Monitoring progression of disease
5951,NCT01904968,"Mutational status evaluation of BRAF, KRAS and PI3KCA :",2011-12,WITHDRAWN,OBSERVATIONAL,['NA'],,
5952,NCT02444897,VAS score,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Bowel motility
5953,NCT04204850,Disease control rate,2020-08-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Side Effects Reported
5954,NCT02578732,Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer.,2016-07-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival for Patients With Locally Advanced Pancreatic Cancer Treated With FOLFOX-A
5955,NCT01281683,,2011-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5956,NCT00595985,time to progression,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,toxicity
5957,NCT05245877,"Venous thromboembolism, number of patients",2022-08-17,RECRUITING,INTERVENTIONAL,['PHASE4'],,Post-operative hemoglobin below 70 g/l
5958,NCT02325323,Incidence of gastric cancer or high grade dysplasia of the gastric mucosa,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],,Percentage of development of gastric cancer or high grade dysplasia
5959,NCT00209625,objective tumor response,2000-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Response duration, time to progression, median survival time, and safety"
5960,NCT04435977,PFS,2020-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety and tolerability
5961,NCT01014039,Colorectal cancer mortality,1983-03,COMPLETED,INTERVENTIONAL,['NA'],,colorectal cancer incidence
5962,NCT01789502,Adverse events related to the stent insertion,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,Surgical outcomes
5963,NCT04713241,Feasibility as measured by acceptance rate of participation in study,2022-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Nasogastric tube (NG TB) output
5964,NCT04677673,Overall Survival,2021-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Disease-free survival (DFS)
5965,NCT05535569,(Phase II) PFS,2017-07-17,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PFS
5966,NCT00106054,To determine the rate of R0 resection or pathologically confirmed CR in patients with hepatic only metastases,2006-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,"oTo determine the resectable rate, defined as the number of subjects with R0 resection, pathologically staged CR, or undergoing non-surgical ablative procedures with curative intent divided by the total number of evaluable subjects following treatment"
5967,NCT03808272,Clinical success rate,2019-04-17,COMPLETED,INTERVENTIONAL,['NA'],,
5968,NCT00969033,Determine the difference in progression-free survival (PFS) for CS-1008 administered in combination with irinotecan and irinotecan alone.,2009-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,To determine the Incidence of anti- CS-1008 antibody formation.
5969,NCT04985136,Stage II：Overall survival （OS）,2021-09-26,TERMINATED,INTERVENTIONAL,['PHASE3'],,Proportion of neutralizing antibody (Nab)
5970,NCT00844675,Frequency of bleeding after EMR is performed,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Measurement of a change in the size of ulcer
5971,NCT03250078,Early Stage Pancreatic Cancer or Precursor Lesions,2016-11,RECRUITING,OBSERVATIONAL,['NA'],,Serum Bio-bank
5972,NCT05791747,social representations,2023-03-21,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Intention to turn to hypnosis
5973,NCT01832246,diagnostic accuracy between endoscopic ultrasonographic staging and conventional endoscopic staging,2014-12,UNKNOWN,OBSERVATIONAL,['NA'],,
5974,NCT01395017,Overall Survival,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
5975,NCT04411589,detection rate of GIN and EGC,2020-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,diagnostic accuracy in a per-biopsy analysis
5976,NCT05828446,To compare the diagnostic performance of US+/- CEUS and AMRI for HCC detection in an at-risk population,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,To perform a cost-effectiveness analysis comparing US to different alternative screening strategies for HCC in Switzerland.
5977,NCT03574493,"Efficacy of surgical method (success determined by composite of Oncologic, morbidity and functional outcomes)",2018-10-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5978,NCT00810953,"Any severe events, tumor marker CA19-9, and tumor size (CT scan)",2009-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,TDP
5979,NCT03280407,Disease free survival,2017-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life (QoL)
5980,NCT00644020,DFS(disease free survival),2007-12,UNKNOWN,OBSERVATIONAL,['NA'],,1.OS （Overall Survival） 2.QOL (quality of life)
5981,NCT00669812,Survival at 1 year,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity
5982,NCT03140189,rate of major postoperative complications,2017-06-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,disease-free survival
5983,NCT01125865,Stent patency,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Technical success
5984,NCT04625894,Dose-limiting toxicities (DLT),2020-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Quality of life assessment
5985,NCT03524508,Progression Free Survival by independent central reviewer,2018-09-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rates determined by the independent central reviewer
5986,NCT05346757,Sensitivity for advanced colorectal neoplasm,2022-03-23,RECRUITING,INTERVENTIONAL,['NA'],,Cost-effectiveness for advanced colorectal neoplasm detection
5987,NCT05530785,Objective Response rate,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],,number of participants with treatment-related adverse events
5988,NCT00648102,"To establish safety and tolerability profile of CDX1307 alone and with adjuvant in patients with breast, colorectal, pancreatic, bladder and ovarian cancer",2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Investigate clinical activity
5989,NCT05173610,Treatment efficacy (Disease free survival),2021-09-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events (acute and late toxicity) as assessed by CTCAE v4.0
5990,NCT00603863,"safety will be evaluated based upon physical examinations, hematology and chemistry laboratory testing as well as toxicity",2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Efficacy and Clinical benefit measures such as quality of life, pain assessments, etc."
5991,NCT00002997,,1998-02-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5992,NCT04607291,Model Development for Prediction of Intent and Colorectal Cancer (CRC) Screening Behaviors,2019-09-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Prediction of Which CRC Screening Test is Most Acceptable
5993,NCT03272984,Postoperative length of stay,2015-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Time to semi-liquid diet
5994,NCT02602327,Maximum tolerated dose (MTD),2017-01-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biomarker response
5995,NCT05933122,Number and proportion of women with sexual dysfunction defined as a total FSFI,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,"Differences (Month 6 - Month -1 and Month 12 - Month 6) in the score of the ""satisfaction"" dimension of the FSFI scale (Q14-Q16) between the groups with and without treatment by a sexologist (cohort here vs. elsewhere)"
5996,NCT01132755,Number of Study Participants With Adequate Percutaneous Lavage Specimen Collection,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety of Peritoneal Lavage in Place of Laparoscopic Lavage.
5997,NCT05391867,Overall survivability,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
5998,NCT05181826,Independent performance measure of sensitivity and specificity of a multi-analyte blood test,2019-05-21,RECRUITING,OBSERVATIONAL,['NA'],,Ascertain Sample Stability
5999,NCT06017141,Neutrophil extracellular traps (NET) formation,2023-05-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,Changes in gene expression
6000,NCT01266720,Toxicities as assessed by NCI-CACAE ver3,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Survival
6001,NCT03809247,16sRNA and metagenomics,2019-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
6002,NCT05349331,Progression-free survival,2022-05-05,RECRUITING,INTERVENTIONAL,['NA'],Correlation of serum tumor molecular marker with survival,pCR rate in surgery group
6003,NCT00296322,Relapse-free Survival,2001-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival
6004,NCT06040632,ctDNA analysis,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative morbidities
6005,NCT00607282,"Improvement of erectile function using IIEF-5 (International Index of Erectile Function-5), SEP Q2, Q3 (Sexual Encounter Profile Q2,Q3), and GEQ (Global efficacy Question)",2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Improvement of erectile function using IIEF-5, SEP Q2,Q3, and GEQ"
6006,NCT03006263,overall postoperative morbidity rates,2016-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,The variation of C-reactive protein
6007,NCT06085755,ORR (Objective response rate),2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival (PFS)
6008,NCT03038984,cancer,2016-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"Disease course, Copenhagen IBD Disease course Type"
6009,NCT01444521,Overall response rate,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to event efficacy
6010,NCT03665571,NK cell activity,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],,Survival of participants
6011,NCT05250648,Peritoneal Recurrence Free Survival,2022-03-02,RECRUITING,INTERVENTIONAL,['PHASE4'],,Quality of Life with EORTC validated questionnaire Colorectal Cancer Module (QLQ-CR29).
6012,NCT02321579,Oxidative stress marker (MDA concentation),2014-12,UNKNOWN,INTERVENTIONAL,['NA'],,Glutathione related enzyme activities
6013,NCT03833661,Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC),2019-03-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Durable Response Rate (DRR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by an Independent Review Committee (IRC) According to According to Microsatellite Instability (MSI) Status
6014,NCT04595929,Comparison of Overall survival (OS) in both arms,2020-02-10,RECRUITING,INTERVENTIONAL,['NA'],,Rate of post-operative morbidity/mortality at day 30 after surgery acc. to Clavien-Dindo classification
6015,NCT00002506,,1992-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6016,NCT04342676,"LNR and K ras were evaluated with correlated with different clinicopathological parameters (Gender, CEA, tumor size, tumor grade and response to treatment).",2017-03-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,LNR and K ras were evaluated and ASSOCIATION with PFS and OS.
6017,NCT05757492,Assessment of the number of participants with treatment-emergent adverse events (TEAEs) receiving CHS-006 administered in combination with toripalimab,2023-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS) using RECIST v1.1 assessed by the investigator
6018,NCT02043184,Medication Adherence using pill count and self report,2013-03,COMPLETED,INTERVENTIONAL,['NA'],,Healthcare Utilization is the use of Emergency room and Hospital admissions
6019,NCT04701645,Number of implanted microdevices successfully retrieved,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Correlate extent of tumor response with genetic features of the tumor tissue,
6020,NCT01286987,Part 1: Recommended Part 2 Dose of Talazoparib,2011-01-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Part 1: Apparent Volume of Distribution (Vz/F) of Talazoparib,
6021,NCT04800991,Score of each domain of the 'feasibility assessment of the investigational device (website)' questionnaire for investigators,2021-03-17,COMPLETED,INTERVENTIONAL,['NA'],Frequency of Adverse Events,The investigational device(application) usage compliance by underlying disease
6022,NCT04745091,Complete pathologic response,2021-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6023,NCT02641925,HOMA-IR change,2015-08,UNKNOWN,INTERVENTIONAL,['NA'],,HOMA-IR change according to anastomosis type
6024,NCT05396560,Fecal Immunochemical Test Sensitivity and Specificity,2022-04-15,RECRUITING,OBSERVATIONAL,['NA'],,
6025,NCT05645094,cCR and pCR rates,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Acute toxicity associated with Envafolimab
6026,NCT00629421,development of hepatocellular carcinoma,2001-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6027,NCT06328283,glutamine synthetase,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6028,NCT01742169,Completion of fecal occult blood test (FOBT),2013-01,COMPLETED,INTERVENTIONAL,['NA'],,
6029,NCT00730483,Safety - Number of CTCAE v3.0 Events 1 Month Post DEB-TACE,2009-02,TERMINATED,INTERVENTIONAL,['NA'],,Symptomatic Response by Assessing Symptom Severity in Patients
6030,NCT03579004,Disease free survival,2017-07-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Pathological complete response rate following chemoradiotherapy
6031,NCT03475966,Change in functional walking capacity as measured by the six-minute walk test (6MWT),2017-02-22,UNKNOWN,INTERVENTIONAL,['NA'],Lower extremity strength - assessment of change over time,Heart rate - assessment of change over time
6032,NCT02047513,Time to Disease free survival (DFS),2015-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor recurrence
6033,NCT02983045,Part 2 and Part 4: Objective Response Rate (ORR) Per RECIST 1.1 at Recommended Phase 2 Dose (RP2D),2016-12-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6034,NCT04605419,Registration of treatment related pain through a Visual Analogue Score (VAS),2020-10-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,The rate of patient's that have gained from the treatment
6035,NCT03281447,Self evaluated Self Efficacy for Cancer,2016-02-26,COMPLETED,INTERVENTIONAL,['NA'],,Health-related Quality of Life
6036,NCT02954302,"Delayed gastric emptying,rate",2016-09,UNKNOWN,INTERVENTIONAL,['NA'],"nonsurgical complications,rate","wound infection,rate"
6037,NCT02070419,Difference in tumor grade,2014-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Survival rate
6038,NCT02363049,overall survival,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Rate of secondary curative resection (R0)
6039,NCT03733197,Scale development,2024-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Pilot intervention
6040,NCT03688555,Change From Baseline to Week 12 in Nasal Polyp Score as Measured by Nasal Endoscopy (Assessed Centrally),2018-10-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patient Global Impression of Change in Disease Severity
6041,NCT00126867,,2005-05,TERMINATED,OBSERVATIONAL,['NA'],,
6042,NCT01703910,gene expression profiles,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6043,NCT01104116,Positive and Negative Predictive Value of PET Imaging for Identifying Malignant IPMN,2009-09,TERMINATED,INTERVENTIONAL,['NA'],,Change in Lesion Characteristics to Assess Benefit of PET Scans
6044,NCT04927260,Survival,2021-03-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Quality of life in real-life according to FACT-G questionnaire
6045,NCT00188331,,2003-11,COMPLETED,OBSERVATIONAL,['NA'],,
6046,NCT01386697,,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,
6047,NCT02050178,Safety and tolerability of OMP-54F28 in combination with nab-paclitaxel and gemcitabine in patients with previously untreated Stage IV pancreatic cancer,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (PK) of OMP-54F28 when administered in combination with nabpaclitaxel and gemcitabine to patients with previously untreated Stage IV pancreatic cancer
6048,NCT04205071,Measure the improvement in balance for patients with chronic CIPN,2020-11-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Nerve conduction test (NCT) result analysis,Improvement in patient-reported chemotherapy-induced peripheral neuropathy symptoms
6049,NCT00791544,Dose-limiting toxicities (DLT) based on grade = or > 3 hematological or non-hematological toxicity and on fasting hyperglycemia,2008-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Anti tumoral activity
6050,NCT00349024,"Symptoms, other than pain, considered important to the pediatric population",2005-07,UNKNOWN,INTERVENTIONAL,['NA'],,
6051,NCT00400179,Median Survival,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to Treatment Failure (TTF)
6052,NCT01066624,Incidence of Oral Mucositis,2009-08,COMPLETED,INTERVENTIONAL,['NA'],,
6053,NCT00911820,7-month Progression-Free Survival,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival
6054,NCT04705818,Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort D,2021-07-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Blood kynurenin level
6055,NCT01786122,Changes in Health Related Quality of Life (EORTC QLQ-C30),2013-04,UNKNOWN,INTERVENTIONAL,['NA'],,progression-free survival
6056,NCT00474812,Median Overall Survival,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Gait Speed
6057,NCT00536614,Overall survival,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"response to treatment, and toxicity"
6058,NCT01725321,Detection rate of proximal serrated polyp,2012-10,COMPLETED,OBSERVATIONAL,['NA'],Adenoma detection rate,Missed rate for proximal serrated polyps
6059,NCT02189226,Complete resection rate,2013-11,COMPLETED,INTERVENTIONAL,['NA'],,adverse event
6060,NCT04591379,Safety - Adverse reactions are classified according to CTCAE version 4.0,2021-02-26,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of recovery,Efficacy - local immunological changes
6061,NCT03546569,ctDNA/cfDNA levels in relation to colorectal stent placement,2018-05-01,COMPLETED,OBSERVATIONAL,['NA'],,Metastatic ability of the cancer cells
6062,NCT06331403,Acceptability of Intervention,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6063,NCT04494919,The technical success rate,2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],,The adverse events rate
6064,NCT03448874,Incidence of overall subject pre-specified* procedure related Adverse Events,2018-04,WITHDRAWN,INTERVENTIONAL,['NA'],,"Incidence of ""deployment failure"""
6065,NCT00230191,The primary objective of the study is to assess the effect of RK-0202 versus placebo on the incidence and severity of oral mucositis.,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,The secondary objectives of the study are to assess the safety and tolerability of RK-0202 in these subjects and to explore whether the ProGelz™ vehicle alone is active in these subjects.
6066,NCT02563002,Overall Survival (OS),2015-11-30,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Discontinued Study Treatment Due to an AE
6067,NCT02784353,The incidence and severity of general complication,2016-10-04,COMPLETED,INTERVENTIONAL,['NA'],,"Grasping power(dynamometer, kg)(Changes in the parameters of rehabilitation)"
6068,NCT02500147,Difference in percentage liver fat between Metformin arm and Placebo arm in adolescents and young adults with PCOS and with elevated percentage liver fat (>/=4.8%),2011-09-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,"The association of percentage liver fat with M30, a hepatic apoptosis marker"
6069,NCT02227667,Best Response Rate,2014-12-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Evaluated for Toxicities to Determine Safety
6070,NCT03711890,Measure accuracy of using OCT to diagnose pancreatic cancer and compare with histology.,2019-03-26,RECRUITING,INTERVENTIONAL,['NA'],,
6071,NCT05975645,Overall response rate (ORR),2023-08-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of Serious adverse events (SAEs)
6072,NCT01130805,Response rate,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicities
6073,NCT04937322,Adverse Events,2016-01-25,COMPLETED,OBSERVATIONAL,['NA'],,stent occlusion-free duration
6074,NCT00448838,Progression-free survival,2006-05,COMPLETED,INTERVENTIONAL,['NA'],,Time to progression
6075,NCT02145559,Pharmacodynamic Biomarker p70S6K,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Fasting Serum Glucose and Triglycerides
6076,NCT06245798,overall survival rate,2023-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6077,NCT03233724,Maximum Tolerated Dose (MTD) of Tetrahydrouridine,2018-04-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With a Dose Limiting Hematologic Toxicity (DLT),"Changes in Gene, Endogenous Retroviral (ERV), Micro Ribonucleic Acid (RNA) Expressions, Deoxyribonucleic Acid (DNA) Methylation Signatures and Tumor Microenvironment"
6078,NCT03443921,Overall mortality at one year after randomization;,2018-03,UNKNOWN,INTERVENTIONAL,['NA'],,Performance status at 3 years after randomization
6079,NCT00003087,,1997-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6080,NCT00160836,Sensitivity and specificity for the diagnosis of malignancy with both devices,2004-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,unusual findings at histopathological examination of surgical specimens.
6081,NCT00586053,To optimize diagnostic performance of CTC in the unprepared colon for colorectal polyp detection using electronic stool subtraction and computer-aided diagnostic techniques.,2000-08,COMPLETED,OBSERVATIONAL,['NA'],,The cost-effectiveness ratio of CTC in the unprepared colon will compare favorably with other colorectal screening tests
6082,NCT04297423,Adenoma detection rate,2020-03-11,COMPLETED,INTERVENTIONAL,['PHASE4'],,Tolerability and satisfaction with preparation
6083,NCT05593328,Overall Response Rate,2023-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety: Exposure Response Evaluation of Onvansertib
6084,NCT04338191,3-year Disease-free survival,2020-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of Life assessed by SF-36
6085,NCT04344158,Overall survival (OS),2020-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Duration of Response (DOR)
6086,NCT04046250,Mucositis,2019-05-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence Adverse Events That Are Related to Treatment
6087,NCT03449914,Evaluate the prognostic value of baseline G8 screening tool for survival.,2017-10-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
6088,NCT04520295,Change from baseline in molecular biomarkers at time on best overall response,2020-05-19,RECRUITING,OBSERVATIONAL,['NA'],,Change from baseline in molecular biomarkers at time on disease progression
6089,NCT05787587,Part 2 (Dose Expansion): To evaluate preliminary anti-tumor activity of IDE161 monotherapy in participants by measuring Duration of Response using RECIST criteria v1.1,2023-04-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Area Under the Plasma Concentration Versus Time Curve (AUC) of IDE161
6090,NCT01630798,validate binding of the fluorescent-labeled peptide to esophageal neopla,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6091,NCT04401124,assorted surgical parameters,2020-05-25,UNKNOWN,OBSERVATIONAL,['NA'],,hospitals' protection measures and extent of implementation
6092,NCT00683787,Overall Response Rate,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity
6093,NCT05442138,Tumor Regression Grading,2022-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6094,NCT05001763,"Time to defaecation, measured in hours, from the time the surgery ends till the first observed",2021-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events related to drug usage
6095,NCT05500391,2-year compliance to the customized surveillance plan,2024-02-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Evaluation of the causes of recruitment failures,Support care needs identified
6096,NCT02488161,Mortality,2010-06,COMPLETED,OBSERVATIONAL,['NA'],,Number of participants with Cancer recurrence
6097,NCT06280248,Complete resolution or a decrease in the sizes of pancreatic fluid collections (PFCs),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6098,NCT02167087,Number of procedures with successful identification of sentinel nodes,2015-03,COMPLETED,INTERVENTIONAL,['NA'],,"Localization of the identified sentinel nodes, and whether or not they are included within the normal resection lines"
6099,NCT04633122,PFS assessed by independent central review,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To compare the safety profile of DCC-2618 (ripretinib, ZL-2307) to the safety profile of sunitinib by using AE/SAE/AESI collection during study."
6100,NCT05408221,ORR,2022-11-11,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,OS
6101,NCT04762914,Complication rate,2018-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Anaerobic threshold
6102,NCT00813540,Safety (Monitoring for Adverse Events),2009-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Feasibility (Adherence to the exercise training program)
6103,NCT02988934,Incremental yield for dysplasia due to WATS sampling above that noted from routine forceps biopsies in various clinical settings.,2016-04,TERMINATED,OBSERVATIONAL,['NA'],,Outcomes of patients undergoing WATS sampling.
6104,NCT04837118,Aerobic fitness,2021-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Feasibility of Automated Self Assisted 24-hour recall (ASA24) (24-hour dietary recall)
6105,NCT02505750,"Rate of rectum preservation either with local excision or watch and wait strategy after neoadjuvant treatment without non salvageable locally progressive disease at 3 years post treatment, or permanent stoma.",2015-06-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of Life,Tumour regression score on the operative specimen
6106,NCT03697044,Time to Hepatic Progression (TtHP),2019-01,UNKNOWN,OBSERVATIONAL,['NA'],,Quality of Life post DEBIRI delivery
6107,NCT01270438,Progression-free survival of patients treated with FOLFOX6 plus bevacizumab with or without gamma-secretase inhibitor RO4929097,2010-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Pharmacokinetics and pharmacodynamics of gamma-secretase inhibitor RO4929097
6108,NCT01905150,12-month survival rate,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse Events,Overall Survival
6109,NCT04009811,Voice Handicap Index (VHI) overall score,2020-07-17,COMPLETED,INTERVENTIONAL,['NA'],,Head and Neck quality of life EORTC QLQ-H&N35 questionnaire score
6110,NCT00669292,Safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),2006-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,survival(Phase II)
6111,NCT05076279,number of retrieved lymph nodes,2021-11-15,RECRUITING,INTERVENTIONAL,['NA'],,3 year relapse-free survival
6112,NCT04267575,Number of Participants With Complications Due To Cold Plasma Application,2019-07-30,UNKNOWN,INTERVENTIONAL,['NA'],,
6113,NCT06159478,Overall response rate (centrally assessed),2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event rate
6114,NCT00045747,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6115,NCT03043508,Time to Pancreatic Neuroendocrine Tumors (PNET),2015-04-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival in Participants Who Have Confirmed MEN1 with or without PNET
6116,NCT04040374,Per patient diagnosis of gastric cancer,2019-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Agreement on image and IOU based diagnosis of gastric cancer between AI and expert endoscopists
6117,NCT00051532,"Overall survival, defined as the time from start of treatment to death",1999-09,TERMINATED,INTERVENTIONAL,['NA'],,Dose of seocalcitol (seocalcitol treated patients)
6118,NCT01022541,Overall response rates,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Other parameters of efficacy (response and survival) in patients with unresectable liver-only metastases treated with this neoadjuvant combination
6119,NCT02733809,Overall and disease-free survival genes.,2014-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Potential genetic targets for resistance.
6120,NCT05381753,"Dose adjustment of avapritinib in cohort 1, 2, and 3",2022-08-29,RECRUITING,OBSERVATIONAL,['NA'],,
6121,NCT03867370,Pathological response rate,2019-04-26,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of adverse events
6122,NCT01911832,quality of life,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,short-term complication of the surgery
6123,NCT02404935,Progression Free Survival at 6 months,2013-11-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6124,NCT01591421,Recommended phase II dose of BKM120 (Phase I Component),2012-09-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Translational Research
6125,NCT02919644,immunological efficacy,2016-12-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,evaluation of the predictive role of immune cells in tumor microenvironment
6126,NCT00215995,Number of Participants With Desired Response,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Overall Survival
6127,NCT06334458,Validation of igenetic biomarker testing in liquid biopsy followed by radiological exam as early cancer diagnostic tool,2023-02-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
6128,NCT01246960,Progression-Free Survival (PFS),2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Adverse Events (AEs),Number of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies
6129,NCT05962502,Objective response rate (ORR),2023-08-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Drug-related adverse reactions
6130,NCT01903395,utilization of preventive colonoscopy,2012-03,COMPLETED,INTERVENTIONAL,['NA'],,time delay between signed informed consent and utilization of colonoscopy
6131,NCT00007813,,1997-05-31,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6132,NCT00626158,To establish the maximum tolerated dose of fixed-dose rate gemcitabine plus capecitabine given by biweekly administration in patients with advanced pancreatic and biliary tract malignancies.,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Frequency, type, and grade of adverse events using this combination in this patient population"
6133,NCT01551641,Treatment efficacy,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
6134,NCT00049699,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6135,NCT02122185,Progression free survival (PFS) evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 and Gynecological Cancer Intergroup (GCIG) criteria,2015-02-25,SUSPENDED,INTERVENTIONAL,['PHASE2'],,"Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0"
6136,NCT02324335,Incidence of Severe OM During Radiation Therapy in Subjects Receiving a Cumulative IMRT Dose of at Least 55 Gy,2014-08-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Onset of Severe Oral Mucositis (WHO Grade ≥3)
6137,NCT01508520,diagnosis accuracy of ME-NBI,2009-12,COMPLETED,OBSERVATIONAL,['NA'],,
6138,NCT04701476,Overall Response Rate (ORR) for the NSCLC cohort,2021-05-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,TTP
6139,NCT00063947,Maximum-tolerated dose (MTD) of erlotinib hydrochloride based on the incidence of dose-limiting toxicity (DLT) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0,2003-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
6140,NCT04665362,Treatment related adverse events,2021-01-25,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression free survival
6141,NCT05428358,Change in treatment strategy,2022-08-30,RECRUITING,INTERVENTIONAL,['NA'],,Healthcare costs
6142,NCT05293158,HBsAg change from baseline to week 6,2024-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Change of Cellular response (IFN gamma)
6143,NCT01411072,Overall Survival,2011-09,UNKNOWN,INTERVENTIONAL,['NA'],,
6144,NCT03785665,Measure the variability of the motility (Whole gut transit time from ingestion to excretion {hours}) of the MD1 (Motility dummy 1) capsules in the Gastrointestinal tract of human subjects with and w/out polyps in previous Colonoscopy.,2019-06-15,COMPLETED,INTERVENTIONAL,['NA'],,
6145,NCT00558155,"During the postoperative period, all patients were observed for both surgical and non-surgical complications",2001-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,"The secondary objective of the study was to evaluate the effect of nutritional intervention on overall morbidity and mortality rates, and hospital stay."
6146,NCT01507103,Change From Baseline in IFN-gamma Secretion of Mononuclear Cells in Response to Carcinoembryonic Antigen (CEA) by ELISpot at Post-baseline,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in Immunological Response in Peripheral Blood at Week 18 (Follow-up / end-of Trial)
6147,NCT01179724,bleeding incidence after ESD,2009-07,UNKNOWN,INTERVENTIONAL,['NA'],,the size of healing ulcer after ESD
6148,NCT02125448,"Distinct and combined sensitivity, specificity, predictive values, and accuracy of MRI and PET-CT for identifying histopathological complete response.",2013-10,COMPLETED,OBSERVATIONAL,['NA'],,Experienced patient burden (UMC Utrecht only).
6149,NCT04668872,Correlation of tissue necrosis and radiation-induced cell injury levels with delivered dose at 14-21 days,2020-12-07,RECRUITING,OBSERVATIONAL,['NA'],,
6150,NCT05750030,"Safety of atezolizumab/bevacizumab in combination with FMT, measured by incidence and severity of treatment-related adverse events, determined according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.5.0.",2023-05-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Differences in serum and stool metabolomic and lipidomic signatures in patients before and after FMT.,Quality of life (QoL) as assessed by the patient-reported outcome EQ-5D-5L (European Quality of Life 5 Dimensions 3 Level Version) questionnaire.
6151,NCT00836992,"Overall quality of life (QOL) scores at baseline, weeks 1, 3, 5, and end of treatment as assessed by LASA",2009-01,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of patients for which physician reports indicate that availability
6152,NCT03487016,Progression-free survival,2019-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Kinetics of circulating tumor DNA during first-line chemotherapy,Quality of life as assessed by EORTC-QLQ-C30
6153,NCT02181140,Diagnostic Accuracy,2011-08,COMPLETED,INTERVENTIONAL,['NA'],,Complication Rates
6154,NCT01145456,"Recommended phase II dose of RO4929097 in combination with gemcitabine hydrochloride, defined as the dose level in which no more than 1 of 6 patients or 0/3 experience DLT, graded according to NCI CTCAE version 4.0",2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective response according to RECIST criteria 1.1
6155,NCT05450393,Prospective collection of PillCamTM SB3 capsule endoscopy and DAE procedures data,2024-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6156,NCT02038738,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2014-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"We want to determine if the 68Ga-DOTATATE PET Scan changes care plans compared to conventional imaging/diagnostic techniques (Octreoscan, MRI, CT)"
6157,NCT01641939,Overall Survival (OS) - Phase 2 (Dose Selection Portion of the Study),2012-09-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Systemic Clearance (CL) - Stage 1
6158,NCT00777192,Association between inflammatory cytokines and development of treatment-related symptom burden in colorectal cancer patients,2008-08,TERMINATED,OBSERVATIONAL,['NA'],,Neurocognitive and neuropsychiatric symptoms in colorectal cancer patients
6159,NCT04127396,Time to progression,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,adverse events(AEs)
6160,NCT00326495,Overall Rate of Response,2006-05-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Count of Participants With Adverse Events
6161,NCT05464030,Part 2A: Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigators,2022-08-04,RECRUITING,INTERVENTIONAL,['PHASE1'],,Part 2A: Number of Participants with Symptomatic Adverse Events (AEs)
6162,NCT02674373,Progression free survival (PFS),2015-09,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival (OS)
6163,NCT02833298,HCC screening rates,2016-11,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of liver transplant
6164,NCT00049348,Percentage of margin-free resections produced by each program,2003-10-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Effect of therapy and recurrence on CA19-9 values
6165,NCT03900910,The reinfection rate,2018-04-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
6166,NCT01011010,Safety and toxicity as assessed by NCI CTCAE v3.0 criteria,2009-07-22,COMPLETED,INTERVENTIONAL,['PHASE1'],,Correlative studies
6167,NCT02575898,Feasibility of a creative writing intervention in an advanced cancer population,2016-01-14,COMPLETED,INTERVENTIONAL,['NA'],,
6168,NCT01813942,The number of patients correctly identified by recurrence predictive model,2013-03,UNKNOWN,OBSERVATIONAL,['NA'],,
6169,NCT05736705,Speed of Endoscopic Submucosal Dissection,2024-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Rate of esophageal stricturing post-procedure
6170,NCT01243047,To evaluate two different schedules of erlotinib in combination with a modified XELOX regimen in terms of response rate,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine the effect of intermittent versus continuous erlotinib administration on pharmacodynamic endpoints using tumor biopsies
6171,NCT01234272,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4'],,
6172,NCT00986661,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of hepatic administration of PV-10,2009-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Exploratory Correlative Endpoints,Overall survival
6173,NCT01164722,Complete Response Through 1 Year,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of Metachronous Lesions
6174,NCT05652348,Next generation sequencing of organoid cultures,2022-12-08,RECRUITING,OBSERVATIONAL,['NA'],,
6175,NCT02966483,Overall survival,2016-04,RECRUITING,INTERVENTIONAL,['NA'],,The patient's Quality of life: EORTC QLQ-30 questionnaire
6176,NCT04203160,Phase 2: Overall Response Rate (ORR),2020-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Toxicities
6177,NCT00549952,incidence and severity of oral mucositis,2007-10,UNKNOWN,OBSERVATIONAL,['NA'],,
6178,NCT04136002,Specificity of advanced neoplasia detection,2019-10-08,RECRUITING,OBSERVATIONAL,['NA'],,Sensitivity and specificity of advanced adenoma detection
6179,NCT06116019,Number of Successfully Completed Adaptive Radiotherapy Sessions in Patients with Various Tumor Entities,2023-10-11,RECRUITING,OBSERVATIONAL,['NA'],,Local Control
6180,NCT03589339,[Dose Expansion Part]: Safety Evaluation at RP2D,2019-01-16,RECRUITING,INTERVENTIONAL,['PHASE1'],,Evaluation of the body kinetic profile of intratumorally injected NBTXR3
6181,NCT03032874,To determine colonoscopy polyp and cancer detection rate,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,To detect colorectal cancer early using symptoms based assessment
6182,NCT01098422,PFS,2010-01,TERMINATED,INTERVENTIONAL,['NA'],,60 Day All-cause Mortality Rate
6183,NCT02312817,Repeat Screening (Every 6 Months),2014-12,COMPLETED,INTERVENTIONAL,['NA'],,Suspicious Lesion
6184,NCT02067754,Circulating tumor cell,2013-09-11,COMPLETED,OBSERVATIONAL,['NA'],"Circulating Free DNA Analysis in Gastrointestinal Cancer, Genitourinary Cancer",mutation profiling of circulating free DNA
6185,NCT03062358,Overall Survival (OS),2017-04-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Discontinued Study Treatment Due to an AE
6186,NCT04522752,Correlation between size and pathological type of benign epithelial gastric polyp and polyp development.,2020-09-30,UNKNOWN,OBSERVATIONAL,['NA'],,Correlation between helicobacter pylori infection and pathological type of benign epithelial gastric polyp.
6187,NCT01554059,Pathological complete response rate,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety data of this regimen
6188,NCT02118064,Number of Patients with Serious and Non-Serious Adverse Events,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6189,NCT00768001,,2008-06,TERMINATED,OBSERVATIONAL,['NA'],,
6190,NCT05200221,Incidence of adverse events and serious adverse events.,2022-01-19,UNKNOWN,OBSERVATIONAL,['NA'],,overall survival(OS)
6191,NCT01899118,Pathology complete remission rate,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
6192,NCT04124406,Enrollment of Subjects,2019-10-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,National Rates Comparison
6193,NCT03287843,Pathological Complete Response Rate,2006-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
6194,NCT03933449,Overall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus,2016-12-29,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE)
6195,NCT01098760,For subjects randomized into HFSR study subgroup: overall HFSR incidence in the first 3 weeks of Sorafenib treatment,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4'],,For HFSR study subgroup: a mean HFSR grade determined at the end of the first 3 weeks of sorafenib treatment.
6196,NCT06091748,Specificity of 68Ga-DOTATOC PET-CT Imaging for Detection of Somatostatin Receptor Positive GEP-NET,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence and severity of AE and SAE
6197,NCT02443883,Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab,2015-07-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of Progression Free Survival (PFS) at the First 6-Week Tumor Assessment
6198,NCT03464305,5 year overall survival,2018-02-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to Treatment Failure
6199,NCT04495387,change of taste chemotherapy-related alterations,2021-07,UNKNOWN,OBSERVATIONAL,['NA'],,Emotions elicited by foods
6200,NCT05336266,Feasibility determined by the number of patients that take the prescribed dose of ketorolac (4 times daily) for 5 consecutive days.,2022-07-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Mean change in calories consumed from baseline through the End-of-Treatment visit
6201,NCT03457896,Progression free survival (PFS) with neratinib plus cetuximab therapy,2018-05-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Frequency of adverse events assessed using CTCAE 4.0
6202,NCT06035133,"tumor regression grading, TRG",2023-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6203,NCT03941938,Anastomotic leak,2019-05-02,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative complications
6204,NCT02842294,"time to health related quality of life score deterioration (targeted dimensions of EORTC QLQC30 : global health, fatigue, emotional functioning)",2013-05,UNKNOWN,OBSERVATIONAL,['NA'],,treatment preference
6205,NCT03888313,The patient's experience of participating in a pretreatment group consultation,2019-04-26,COMPLETED,OBSERVATIONAL,['NA'],,
6206,NCT00535041,safety,2007-09,COMPLETED,INTERVENTIONAL,['NA'],,
6207,NCT00512681,Maximal overall response rate,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Progression-free survival,Overall survival,Toxicity assessment,&genetic polymorphism and association with chemical outcomes"
6208,NCT04844112,Rate of complete ablation of the tumor after 1 month clinical follow up,2015-08-01,COMPLETED,INTERVENTIONAL,['NA'],,Safety of the approach route before and after the fusion process
6209,NCT03314961,Lymph node metastases in rectal cancer,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,
6210,NCT05222971,6-month progression-free survival rate,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival
6211,NCT03263429,Recommended phase 2 dose of CB-839 in combination with panitumumab and irinotecan hydrochloride (Phase I),2017-08-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
6212,NCT05337137,Overall Response Rate (ORR) by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2022-05-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with adverse events (AEs)
6213,NCT01100801,Response Rate (RR),2010-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6214,NCT00143533,Dose limiting toxicities,2003-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6215,NCT04068610,Percentage of Participants With Objective Response (OR) Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) in Part 2,2019-09-13,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Positive ADA to Bevacizumab in Part 1 (S1)
6216,NCT02581501,Identification of Maximum Tolerated Dose and Dose Intensity in Patients with Pancreatic Cancer,2016-02,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Assess Safety and Toxicity based upon NCI Common toxicity criteria version 4.1.,Progression Free Survival
6217,NCT05376943,The occurrence of HCC after direct acting antiviral HCV treatment.,2022-05-10,UNKNOWN,OBSERVATIONAL,['NA'],,The difference in liver function tests among the population of patients treated with DAAs and those who were not receiving the therapy.
6218,NCT04030260,The progression-free survival (PFS) rates at 6 months,2019-07-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety variables will be summarized using descriptive statistics based on adverse events collection
6219,NCT01461148,immune response against FSP peptides,2011-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,safety
6220,NCT06143644,2-year recurrence free survival rate of the cohort evaluated by ctDNA,2022-01-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Time point of ctDNA MRD test for recurrence monitoring
6221,NCT02478892,"identifying pancreatic neoplastic lesions lesions in patients with BRCA1/2 mutations and other less common, but related mutations (ATM, PALB2) as well as mutations identified in the future.",2015-05,RECRUITING,OBSERVATIONAL,['NA'],,
6222,NCT02387307,Recommended dose (RD) of rSIFN-co,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1'],"Evaluation of levels (counts) of 2'5'-oligoadenylate synthetase, before and after administration of rSIFN-co",FDG-PET response (lesion volume) before and after administration of rSIFN-co
6223,NCT05000294,Objective response rate (ORR),2021-12-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease control rate (DCR)
6224,NCT06008925,Phase IIa:ORR,2022-11-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase Ib :Pharmacokinetic parameters: Blood concentrations of VG161 at different time points after single and multiple doses
6225,NCT03855904,To evaluate the efficacy of TC-325 in preventing 30-day rebleeding following the index malignant hemorrhage: Rebleeding rate,2019-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"1. To evaluate the efficacy of TC-325 in immediate hemostasis and rebleeding at 24 hours, 72 hours, 90 days and 180 days following presentation at initial bleeding episode as well as 6-month survival rate"
6226,NCT00063141,Overall Survival,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Health Economics
6227,NCT00172627,,2005-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6228,NCT04660123,helicobacter pylori eradication,2020-12-20,COMPLETED,INTERVENTIONAL,['PHASE4'],adverse events,symptoms improvement rates
6229,NCT03608046,Tumor response rate,2018-10-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
6230,NCT04456283,5 years Survival,2019-05-20,UNKNOWN,OBSERVATIONAL,['NA'],,
6231,NCT04786704,Detection of advanced colorectal neoplasia,2021-03-22,COMPLETED,OBSERVATIONAL,['NA'],,Efficacy of sDNA in the detection of advanced colorectal neoplasia in low-risk asymptomatic subgroup.
6232,NCT02649868,To determine the imaging characteristic of radiopaque beads including qualitatively comparing virtual and actual bead perfusion in evaluating tumor vascularity in the treatment of hepatic tumors using bead embolization.,2016-01-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],,
6233,NCT01899261,Severe Treatment-related Toxicity,2010-10-07,COMPLETED,INTERVENTIONAL,['NA'],,Time to Local Progression (TTLP) of Treated Lesions
6234,NCT05546879,Percentage Proportion of patients experiencing adverse events,2023-03-15,RECRUITING,INTERVENTIONAL,['PHASE1'],PK-PD evaluation,Best overall objective response rate (ORR)
6235,NCT04107623,perfusion assessment,2020-06-16,COMPLETED,INTERVENTIONAL,['NA'],,Anastomotic leakage
6236,NCT02973750,Association of Age With Changes,2016-10-20,COMPLETED,OBSERVATIONAL,['NA'],Overall Survival (OS),Impact of Inflammation on Toxicity and Relative Dose-Intensity (RDI)
6237,NCT04917263,pathological complete response on the operative specimen,2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
6238,NCT02754661,Number of Participants With an Actionable Lesion on CCE vs. CTC Confirmed by Optical Colonoscopy,2016-09,COMPLETED,INTERVENTIONAL,['NA'],,Predictive Value of a Negative (NPV) of CCE Versus CTC in the Detection of Polyps ≥6 mm
6239,NCT03057171,"Expression of THRIL, PACER",2015-05,UNKNOWN,OBSERVATIONAL,['NA'],,
6240,NCT01278381,Major Complication rate,2002-01,COMPLETED,OBSERVATIONAL,['NA'],,
6241,NCT04520932,Treatment response,2021-03-30,RECRUITING,INTERVENTIONAL,['NA'],,
6242,NCT05406024,Acceptability rate,2022-09,UNKNOWN,OBSERVATIONAL,['NA'],,European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaires (EORTC-QLQ-C30)
6243,NCT00070434,"Response (confirmed and unconfirmed response, complete response, partial response)",2004-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
6244,NCT00219557,Overall Survival (OS),2005-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in 26-item Pancreatic Cancer-specific Quality of Life Questionnaire (QLQ-PAN26) Score at Day 1 of Every Cycle and End of Study
6245,NCT00005862,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6246,NCT01946711,Change of Inflammation of the Nasal Mucosa and Paranasal Sinus,2013-08-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Nasal Obstruction,Safety Assessment
6247,NCT05396781,Procedure time,2022-01-13,COMPLETED,INTERVENTIONAL,['PHASE2'],Performance Characteristics,Clinical impact
6248,NCT04107766,Target lesion recurrence (local recurrence) rate,2020-01-15,RECRUITING,OBSERVATIONAL,['NA'],,Numeric Pain Rating Scale
6249,NCT05769725,DFS,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6250,NCT00201331,To compare the DFS and OS of HDFL vs. weekly bolus 5-FU plus high dose LV as adjuvant chemotherapy for N2 colon cancer,2002-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"3. To assess the disease-free survival of patients with high or low TS level of N2 colon cancer, when adjuvant chemotherapy of 5-FU was administered by bolus or continuous infusion ."
6251,NCT00003044,,1996-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6252,NCT05296005,Incidence of adverse events,2022-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Standard uptake value SUVmax Tumor-to-liver metrics,18F-FDG dPET/CT to evaluate and characterize residual primary tumor following neoadjuvant chemotherapy and initial chemoradiation therapy for subsequent adaptive boost radiation delivery.
6253,NCT05907824,Disease-free survival (DFS),2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Life quality satisfaction evaluated according to a scale.
6254,NCT04559451,Postoperative liver function failure,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Postoperative morbidities and mortalities
6255,NCT04259398,five year survival,2020-02-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,3 year survival
6256,NCT01850667,Treatment related toxicity-free survival,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Local control rate
6257,NCT03189030,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability),2017-05-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,
6258,NCT00112632,"Overall tumor response (complete response, partial response, stable disease, and progression of disease)",2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
6259,NCT01366144,"MTD of veliparib in combination with carboplatin and paclitaxel, determined according to incidence of DLT as graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 4.0",2011-06-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Change in gamma-H2AX levels,Time to progression
6260,NCT05084833,Proportion of patients who report completing a colonoscopy or Cologuard test (Cologuard test plus colonoscopy if Cologuard is positive) within 12 months of randomization,2022-02-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Cost and Cost-Effectiveness Analysis
6261,NCT05690048,Adverse event documentation of FMT in advanced HCC,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change of Hepatic function
6262,NCT01805622,Effectiveness (RE-AIM Framework),2012-08,UNKNOWN,INTERVENTIONAL,['NA'],Cost-effectiveness analysis,Implementation (RE-AIM Framework)
6263,NCT04929652,Objective response rate (ORR),2021-06-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Assess the anti-tumor activity:DCR
6264,NCT01144195,Objective Response Rate,2009-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
6265,NCT00041652,,2000-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6266,NCT03314649,prognostic molecular markers,2017-12-21,COMPLETED,OBSERVATIONAL,['NA'],,DFS
6267,NCT05961111,Systemic Immune Response,2023-06-24,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Quality of Life Assessment
6268,NCT03654534,"body weight loss ratio at 1, 3, 6 months",2019-04-16,UNKNOWN,INTERVENTIONAL,['PHASE3'],,severe side effects on digestive tract
6269,NCT04196075,Symptomatic relief and quality of life after AP,2018-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,AP side effects
6270,NCT01010334,Number of courses delivered (relative dose intensity for adjuvant studies),2009-03,TERMINATED,INTERVENTIONAL,['NA'],,"Measure quality of life using a FACT G tool, before and at best response and at the end of the treatment"
6271,NCT00300027,Echocardiogram every 2 cycles (q 2 cycles),2006-04,TERMINATED,INTERVENTIONAL,['PHASE1'],,Fluorodeoxyglucose positron emission tomography (FDG-PET) (3 scans prior to C3)
6272,NCT04357873,"Objective Response Rate (ORR), investigator assessment",2020-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
6273,NCT02435433,Overall Survival (OS),2015-07-20,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to Deterioration in Eastern Cooperative Oncology Group Performance Status (ECOG PS)
6274,NCT05700110,To develop a Radiomics model based on pre-operative CT porto-venous phase imaging that accurately predicts Resection Margin status in pancreatic head malignancy,2022-05-05,RECRUITING,OBSERVATIONAL,['NA'],,
6275,NCT05738980,RFS,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],,OS
6276,NCT03112668,Feasibility defined as survey follow ups,2017-12-06,COMPLETED,INTERVENTIONAL,['NA'],,
6277,NCT00006016,Survival,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6278,NCT02318888,Surgery for small bowel obstruction,2009-12,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative complications
6279,NCT05913895,"Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0,Change From Baseline in Pain Scores on the Brief Pain Inventory-Taiwan Scale at 2 Weeks",2023-12-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
6280,NCT00003427,,1998-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6281,NCT05360745,Change in quality of life,2022-06-29,WITHDRAWN,INTERVENTIONAL,['NA'],,Adverse events due to chemotherapy
6282,NCT04593615,3-year disease free survival rate,2020-11-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Inflammatory and immune response
6283,NCT00426153,Percent Change in Liver Volume,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Change in Subject Reported Outcomes Using Mean Health Related Quality of Life (HRQoL) Scores
6284,NCT05918224,The incidence of Severe Oral mucositis (WHO grade ≥3),2022-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Oral activities scores
6285,NCT01768741,Total survival time and disease free survival time,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],Hospital costs,Regulatory T cells and associated cytokines in liver cancer、para-carcinoma and healthy liver tissue
6286,NCT02937506,Patient Satisfaction,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4'],,
6287,NCT01612546,CRLX101 (CPT) Uptake in Tumor and Nearby Normal Tissue,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
6288,NCT05558436,Diagnostic sensitivity,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,"Diagnostic specificity, accuracy, positive predictive value and negative predictive value"
6289,NCT00471328,Progression-free Survival (PFS) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Clinical Benefit (Complete Response [CR]/Partial Response [PR] or Stable Disease [SD]) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set
6290,NCT03807999,3-months deterioration-free rate,2015-02-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
6291,NCT04455282,Difference in CTC detection rate between peripheral and tumor draining veins.,2021-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Dynamic Biobank
6292,NCT03680508,Objective Response Rate,2019-12-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.0
6293,NCT04188535,Ability to measure disease control (for imaging registry expansion cohort),2020-01-15,RECRUITING,INTERVENTIONAL,['NA'],,Dosimetric change
6294,NCT04892810,To compare induced immunomodulation by RFA and MWA in HCC patients,2021-05-31,UNKNOWN,OBSERVATIONAL,['NA'],,To evaluate early induced immunomodulation after MWA in HCC patients
6295,NCT05438459,Progression Free Survival (PFS) rate at 6 months (Phase II),2022-06-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Biomarker of GAIA-102(Phase II)
6296,NCT00006062,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6297,NCT06245785,overall survival,2023-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6298,NCT02314871,Change from baseline number of circulating cancer cells at 3 weeks after surgery,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Pain intensity assessment
6299,NCT03040986,Proportion of Participants With an Objective Response (Partial Response + Complete Response),2017-07-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Overall Percent Change in Variant Allele Fraction (VAF, %) of KRAS in Participants With Detectable KRAS Mutant Circulating Tumor Deoxyribonucleic Acid (ctDNA) at Baseline and After Treatment"
6300,NCT05810402,Percentage of patients with CTCs-PD-L1+ by CellSearch® technique,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Progression Free Survival
6301,NCT04796025,Objective response rate (ORR) by RECIST 1.1 and mRECIST,2021-09-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-related adverse events,Median overall survival time (mOS)
6302,NCT03505320,Objective Response Rate (ORR) of zolbetuximab as a single agent by central review (Cohort 1),2018-06-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Minimal Residual Disease (Cohort 5)
6303,NCT06028724,Real world prevalence of clinically useful mutations in solid tumors,2023-05-26,RECRUITING,OBSERVATIONAL,['NA'],,To evaluate the association between somatic genetic alterations and the clinical characteristic of the enrolled patients
6304,NCT01651013,Percentage of patients with K-Ras mutation,2010-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],predictive factors for response to treatment,
6305,NCT01097304,Reversal of Oxidative DNA Damage as Assessed by Changes in 8-hydroxy-2' -Deoxyguanosine (8OHdG) Immunostaining,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Changes in Cell Proliferation in BE Epithelium From Baseline to Post-intervention as Assessed by Proliferation-related Ki-67 Antigen (Ki67) Immunostaining, Percentage of Positively Stained Nuclei, in BE Tissue Sections"
6306,NCT00103298,Response and duration of response,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlation of health-related quality of life with length of survival
6307,NCT03303495,Overall survival,2011-11-14,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Incidence of Adverse Events (Adverse Reactions)
6308,NCT01482520,Genotypes,2008-08,COMPLETED,OBSERVATIONAL,['NA'],,
6309,NCT02568748,Number of patients with ablated hcc,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
6310,NCT02843191,Pathologic complete response,2016-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,Peripheral neuropathy
6311,NCT03356002,Sensitivity and specificity of C-Scan Capsule System in detecting per segment polypoid lesions 10 mm and up as compared with Colonoscopy,2018-01-28,COMPLETED,INTERVENTIONAL,['NA'],,Quantify the variance of the Interpretation of the data from the C-Scan System between the reviewers
6312,NCT05674526,Maximum Tolerated Dose,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Response Rate
6313,NCT05009953,Objective Response Rate (ORR),2021-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,UGT1A1
6314,NCT02453490,Objective response rate,2015-10-11,TERMINATED,INTERVENTIONAL,['PHASE3'],The early tumor shrinkage （ETS）and depth of response(DPR),R0 resection rate of liver
6315,NCT02672865,Post Operative Complications,2016-02-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6316,NCT00633607,"Establish a Hereditary Colorectal Tumor Registry to facilitate development and implementation of epidemiological, clinical and cancer control research.",2012-04,COMPLETED,OBSERVATIONAL,['NA'],,
6317,NCT03360461,To investigate the ability of EMI-137 to produce visible fluorescence in regional lymph nodes draining the colon cancer.,2018-02-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Study of in vivo imaging compared against ex vivo fluorescent detection
6318,NCT02811497,Overall response rate (ORR),2016-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of treatment-emergent adverse events (AEs)
6319,NCT01345526,"PFS rate, toxicity, compliance",2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6320,NCT02774512,ZAK expression level by immunohistochemistry on frozen material (surgical specimen) by Western blot and on paraffinembedded tissues section using an immunohistochemistry approach,2016-05,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Half-life of nilotinib
6321,NCT03482102,Best Overall Response rate,2018-05-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to Disease Progression
6322,NCT05703750,Overall Survival(OS),2023-05-04,RECRUITING,OBSERVATIONAL,['NA'],,Progression free survival(PFS) per mRECIST
6323,NCT04513119,The incidence of local tumor progression (LTP),2017-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Tumor-free survival
6324,NCT00599833,Progression-free survival rate at 6 months,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Clinical benefit response
6325,NCT04066660,Disease Control Rate,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL)
6326,NCT00559351,"mean, median, 1-year, 3-year, 5-year overall survival",2001-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,curative resection rate
6327,NCT02399306,Body Weight Change from baseline to the end of treatment,2014-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival
6328,NCT02789800,Evaluation of Intervention Effectiveness - Change in Self-Management outcomes,2016-04-22,COMPLETED,INTERVENTIONAL,['NA'],,Evaluation of Intervention Effectiveness - Change in Patient-Centredness
6329,NCT00706576,Number of participants with opioid growth factor toxicity,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change in plasma opioid growth factor levels
6330,NCT03635489,Progression-Free Survival (PFS),2018-08-15,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Adverse Events (AEs)
6331,NCT02757859,Overall Survival,2016-04-27,RECRUITING,INTERVENTIONAL,['NA'],Presence of cells in cytologic washing,Site of first recurrence
6332,NCT00803647,Reported Adverse Events.,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Recurrence-free Survival (RFS). Time From Study Entry Until First Recurrence.
6333,NCT04217954,Overall response rate,2020-07-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival
6334,NCT00059982,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6335,NCT03213314,Correlation between the pre-operative liver health assessment score and the post-operative liver function composite integer-based risk score.,2017-09-07,COMPLETED,INTERVENTIONAL,['NA'],,• To evaluate LiverMultiScan image interpretations correlated with post-operative length of stay.
6336,NCT01312857,to determine if panitumumab with Hepatic Arterial Infusion (HAI) in combination with systemic chemotherapy can increase the recurrence free survival (RFS) for colorectal cancer patients with resected liver metastases,2011-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,to analyze tumor tissue for predictive biomarkers
6337,NCT00072332,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6338,NCT00051467,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
6339,NCT00488332,Optical assessment of oral mucositis in patients undergoing radiation or chemoradiation for head and neck cancer treatment,2006-03,TERMINATED,OBSERVATIONAL,['NA'],,
6340,NCT02983500,Rate of patients with loss of > 5 % body weight,2016-08-28,COMPLETED,OBSERVATIONAL,['NA'],,Cachexia assessment
6341,NCT02231203,Change in ex vivo production of pro-inflammatory cytokine IL-6 in LPS stimulated whole blood,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4'],Cognitive function,Change in in vivo systemic inflammatory response parameters
6342,NCT02435186,progress-free survival,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"safety as measured by adverse events, vital signs, clinical lab tests, ECG and physical examination"
6343,NCT01659632,,2010-04,UNKNOWN,OBSERVATIONAL,['NA'],,
6344,NCT05715632,pCR rate,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse reactions and perioperative complications (Security)
6345,NCT00075504,Response Rate According to RECIST Criteria,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
6346,NCT03914443,Rate of participants with dose limiting toxicities (DLTs),2019-05-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
6347,NCT00137592,colorectal cancer screening,2005-10,COMPLETED,INTERVENTIONAL,['NA'],,colorectal cancer screening knowledge
6348,NCT03214939,Сytotoxicity,2016-09-27,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Relapse-free period
6349,NCT04517019,Evaluation of the impact of an Activity tracker based Fitness programme on the Qualitiy of Life after oncological Therapy,2020-08-01,RECRUITING,INTERVENTIONAL,['NA'],,
6350,NCT01080248,Response Rate by RECIST Criteria.,2010-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
6351,NCT03654131,Freedom from local lesion progression (analyzed on patient-level),2018-07-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life as descriptive statistics: EORTC QLQ-C30
6352,NCT05593393,"The termination of the follow-up of IPMN patients, including death termination and recommended surgery termination.",2022-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The new development of worrisome features or high-risk stigmata
6353,NCT06017583,Complete response rate,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease free survival
6354,NCT02051283,Predictive value of MRI determined contrast-enhanced and diffusion-weighted sequence pattern towards outcome (tumour recurrence < 1 year versus > 1 year),2014-02,UNKNOWN,OBSERVATIONAL,['NA'],,"Correlation of predictive MRI parameters with histology obtained from biopsy during radio-frequency ablation (tumor grade, microvascular invasion, Keratin 19 status)"
6355,NCT04909866,PFS,2021-01-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,OS
6356,NCT05497531,Comparison of the amount of ctDNA in draining vein plasma sample to peripheral vein sample through ratio of mean allele frequency,2022-09-07,RECRUITING,INTERVENTIONAL,['NA'],,Number of unique alterations found in ctDNA compared to number of alterations derived next generation sequencing (NGS)
6357,NCT06109961,Phase 1 recruitment rate,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2 numbers of closure all external openings of fistula tracts
6358,NCT02071862,Safety and tolerability of CB-839: Incidence of adverse events,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Clinical activity: Change in tumor volume from baseline
6359,NCT02523170,Diagnostic accuracy,2014-07,COMPLETED,INTERVENTIONAL,['NA'],,Assess margins
6360,NCT01338948,rate of conversion (to laparotomy or laparoscopy assisted),2009-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6361,NCT05322486,Overall survival,2020-10-29,UNKNOWN,OBSERVATIONAL,['NA'],,Progression free survival (PFS)
6362,NCT01070355,Histological Ki67 cancer cell proliferation index,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Urinary markers of prostaglandin metabolism
6363,NCT05894837,Objective Response Rate,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overal survival
6364,NCT00826384,Overall survival,2008-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6365,NCT03735511,Overall Survival,2018-11-20,UNKNOWN,OBSERVATIONAL,['NA'],,Progression-Free Survival
6366,NCT02289183,3-year disease free survival rate,2015-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,3-year recurrence pattern
6367,NCT02521129,Number of participants with complications,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6368,NCT00393068,Pathologic Complete Response (pCR) Rate,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival
6369,NCT04083573,Consistency between the result from medical monitor and that from medical augmented reality glass,2019-09,UNKNOWN,OBSERVATIONAL,['NA'],,
6370,NCT00995358,Overall survival after the 1st vaccination,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to progression after the 1st vaccination
6371,NCT01951521,Complete response rate,2014-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,(disease-free) survival
6372,NCT00058201,Overall survival,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Survival rate at 2 and 5 years
6373,NCT05367284,Treatment acceptability questionnaire,2022-01-15,UNKNOWN,OBSERVATIONAL,['NA'],,
6374,NCT01471353,Sorafenib Activity,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlative Tissue Analysis
6375,NCT02922049,Detection of persistent or recurrent intestinal metaplasia/dysplasia and esophageal and gastric lesions by confocal laser endomicroscopy and classic histopathology,2016-04,COMPLETED,INTERVENTIONAL,['NA'],,Sensitivity and specificity of the procedure
6376,NCT05033392,Pathological complete response rate,2021-09-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
6377,NCT03614013,Survival,2018-07-04,UNKNOWN,OBSERVATIONAL,['NA'],,
6378,NCT03078361,Rate of Feedback from Community Advisory Board,2014-04-28,COMPLETED,INTERVENTIONAL,['NA'],,Rate of Receipt of Assessments from Participants
6379,NCT01139138,Dose limiting toxicities,2010-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
6380,NCT01198704,Predictive factors of HCC recurrence,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,Correlation of HCC differentiation between liver biopsy and explant liver
6381,NCT00421824,Response rate,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
6382,NCT01459614,Percentage of Participants Without Disease Progression (Progression-Free Survival) at 6 Months,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
6383,NCT04357483,Incidence of POPF,2018-02-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Postoperative complication
6384,NCT02358161,Dose limiting Toxicity (DLT) and MTD of LDE225 co-administered with gemcitabine and nab-paclitaxel,2015-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival
6385,NCT06091423,Progression free survival (PFS),2023-10-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event (AEs)
6386,NCT04329000,Number of tablets consumed,2010-02-02,COMPLETED,INTERVENTIONAL,['NA'],,
6387,NCT05004831,PFS,2022-03-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerance
6388,NCT05681949,The reproducibility of the therapy recommendations made by ADBoard (yes/no),2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Time between primary presentation and start of diagnostics/therapy as recommended
6389,NCT00892424,Determine the MTD of sorafenib and RT in patients with liver metastases using an iso-toxicity radiation dose allocation scheme. Determine the acute toxicity (< 3 months) of sorafenib when combined with RT in patients with liver metastases.,2008-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Document any observed late toxicities of treatment. Determine 1) the in-field local control based on CT response at 3 months;2)the time to progression and overall survival of this cohort, 3)changes in quality of life in these patients"
6390,NCT02300922,To determine the maximum tolerated dose for 90Y-IMP288.,2015-01-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6391,NCT01344330,Cruciferous vegetable intake correlated with SFN and I3C urinary metabolites,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,Cruciferous vegetable intake correlated with HDAC activity (in PBMCs)
6392,NCT01077999,Percentage of pathologic complete responses,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profile
6393,NCT04610086,Satisfaction,2020-11-19,UNKNOWN,OBSERVATIONAL,['NA'],,Participation in cancer decision making
6394,NCT04491942,Recommended phase 2 dose (RP2D) of BAY 1895344,2021-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free survival (PFS)
6395,NCT03359850,Apparent Total Body Clearance (CL/F) of Niraparib and M1 During PK Phase,2018-02-20,COMPLETED,INTERVENTIONAL,['PHASE1'],Clearance of Unbound Niraparib and M1 (CLfu/F) During PK Phase,Change From Baseline in Temperature During Extension Phase
6396,NCT04952688,retinal vascular density retinal vascular density,2020-12-14,RECRUITING,INTERVENTIONAL,['NA'],,
6397,NCT03367247,Feasibility of the BOLSTER Intervention,2018-04-24,COMPLETED,INTERVENTIONAL,['NA'],,Acceptability of the BOLSTER Intervention
6398,NCT02751892,Change in minutes spent in moderate and vigorous intensity physical activity measure with the International Physical Activity Questionnaire long version,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,Change in minutes spent in moderate and vigorous intensity physical activity with accelerometry
6399,NCT01224392,reduction in metabolic tumor activity,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,cost evaluation
6400,NCT04660058,corelation between the bile acid profile and gastric microbiota in different groups,2020-12-20,COMPLETED,OBSERVATIONAL,['NA'],,
6401,NCT05608967,Usability,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Complications
6402,NCT03642067,Cohort C: Objective response rate (ORR),2019-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants experiencing study drug-related toxicities
6403,NCT01621295,Frequency/duration/content of routine cancer consultations surrounding key topics in the clinical dialogue.,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,
6404,NCT02407561,Gene expression profiling will be undertaken to determine if RNA is a superior biomarker to protein,2015-02,TERMINATED,OBSERVATIONAL,['NA'],,
6405,NCT00504257,Six Month Progression Free Survival (PFS),2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
6406,NCT04103567,"The ratio between the proportions of poor response to neoadjuvant treatment in populations so-called ""exposed"" (patients colonized by bacteria producing toxins (cyclomodulin) and unexposed (patients not colonized by bacteria producing toxins)",2020-01-14,RECRUITING,INTERVENTIONAL,['NA'],,Types of other bacteria forming the overall bacterial composition before neoadjuvant treatment
6407,NCT05317325,The number of treatment-related adverse events,2022-04-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Disease-free Survival
6408,NCT00001568,,1997-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6409,NCT04229004,Overall Survival,2020-01-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Duration of Clinical Benefit
6410,NCT06294548,Phase II,2024-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease Control Rate (DCR)
6411,NCT01012011,Adverse events collection,2009-09,COMPLETED,OBSERVATIONAL,['NA'],,Performance status
6412,NCT06109467,Objective Response Rate (ORR),2024-01-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
6413,NCT03323996,Semi-Structured interviews,2017-07-26,UNKNOWN,OBSERVATIONAL,['NA'],,
6414,NCT01351103,Maximum Tolerated Dose or Recommended Dose for Expansion of LGK974 as a single agent or in combination with PDR001 in patients treated,2011-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Absorportion and plasma concentrations of PDR001
6415,NCT03436563,Clearance of circulating tumor DNA (cohort D),2018-03-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease-Free Survival (DFS) - cohort D only
6416,NCT02958683,Change in volume of each thoracoabdominal compartment during breathing,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,Synchrony of chest wall movement
6417,NCT00586404,"To determine the prevalence and incidence of low grade dysplasia, high grade dysplasia and adenocarcinoma in a large cohort of patients with Barrett's esophagus",2007-11,TERMINATED,OBSERVATIONAL,['NA'],,"To determine the magnitude of the contribution of selected factors (e.g. age, gender, ethnicity, obesity, tobacco use, alcohol use, ASA/NSAID/PPI use, duration of GERD symptoms, length of BE, HH) to the risk of HGD and CA"
6418,NCT00780169,"Toxicity spectrum of Sorafenib (MTD, DLT) and the recommended dose (RD) for phase II studies of Sorafenib when combined with FOLFIRI in first line patients with metastatic colorectal cancer (mCRC)",2008-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to Progression and Overall Survival
6419,NCT01935778,disease-free survival,2013-10-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,safety profile
6420,NCT02522520,Maximum oxygen uptake - ( VO2 peak),2015-06,COMPLETED,INTERVENTIONAL,['NA'],,Pedometer Step Count
6421,NCT02987296,"NK cell killing as measured on peripheral blood mononuclear cells (PBMC) between the control (placebo) and experimental cohorts, using a standard NK cell killing assay.",2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Compliance with perioperative arginine supplementation
6422,NCT01666184,,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],,
6423,NCT02614339,Disease free survival,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,recurrence rate of polyps after polypectomy
6424,NCT03132922,Measurement of RCL in genetically modified T cells.,2017-05-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],MAGE-A4c1032T cell trafficking in tumor lesion(s).,Number and % of subjects having any Long Term Follow Up Adverse Events (AEs)
6425,NCT05484687,the concentration of tumor micrometastasis markers were determined by ELISA,2020-03-24,COMPLETED,INTERVENTIONAL,['NA'],,the concentration of immune indexes were determined by ELISA
6426,NCT02433938,bowel function recovery (Time to first bowel movement or flatus),2015-07,COMPLETED,INTERVENTIONAL,['NA'],,Use of NG Tubes (Nasogastric tube (re)insertions)
6427,NCT05605197,Incidence of Adverse events after U87 CAR-T cells infusion [Safety and Tolerability],2022-10-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Pharmacodynamics of U87 CAR-T cells
6428,NCT05030246,Overall Survival (OS),2021-07-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
6429,NCT04666558,Lower Extremity Functional Scale (LEFS),2020-11-30,COMPLETED,INTERVENTIONAL,['NA'],Program acceptability (Unified Theory of Acceptance and Use of Technology - UTAUT),General health-related quality of life (5-Level EQ-5D [EQ-5D-5L])
6430,NCT03144765,Quality of Mesorectal Excision,2018-01-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,3-year oncologic outcomes
6431,NCT03800602,Overall response rate (ORR),2019-01-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Biological response: carcinoembryonic antigen (CEA)
6432,NCT05138094,Time to functional recovery,2021-08-06,RECRUITING,INTERVENTIONAL,['NA'],,Three and five-year overall survival
6433,NCT00702884,Progression-free Survival Rate,2008-06-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quantitative Assessment of Proliferating Tumor Cells and Apoptosis
6434,NCT04229524,The incidence of anastomotic fistula,2020-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,
6435,NCT02422680,Patient Satisfaction,2015-03-23,WITHDRAWN,OBSERVATIONAL,['NA'],,Patient Pain (own Perception)
6436,NCT06326437,the Kessler psychological distress scale-10,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Locke-Wallace Marital Adjustment Scale
6437,NCT02012231,Phase 1 dose escalation: Identification of Recommended Phase 2 Dose Safety of PLX8394,2014-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,Identification of Recommended Phase 2 dose (RP2D)
6438,NCT05732181,Pain severity,2017-05-09,COMPLETED,INTERVENTIONAL,['NA'],,
6439,NCT03581890,Postoperative 1-year mortality rate (study 2),2007-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,Postoperative 90-day mortality (study 2)
6440,NCT02010567,Pathological Complete Response (pCR) Rate,2013-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS) Based on Pathological Complete Response (pCR).
6441,NCT04227808,1-year RFS rate,2019-12-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Health-related quality of life
6442,NCT04337879,Progression-free survival (PFS),2020-07-20,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of response (DOR)
6443,NCT06233994,Progression Free Survival (PFS),2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6444,NCT05257135,Number of biological risk factors for colorectal cancer,2021-12-23,RECRUITING,INTERVENTIONAL,['NA'],,
6445,NCT00686569,Early detection of postoperative complications,2007-04,COMPLETED,OBSERVATIONAL,['NA'],,
6446,NCT00390416,1-year Survival,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patients With Measurable Disease the Confirmed Response Rate
6447,NCT01679756,Overall surgical morbidity,2013-03,UNKNOWN,INTERVENTIONAL,['NA'],,Readmission
6448,NCT01938313,Recovering Rate,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
6449,NCT06115174,Difference in overall survival 'OS' between the two groups.,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,
6450,NCT05901519,Mitigation of liver inflammation as reflected by sTNFR1 levels,2024-02-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Assess tumor response
6451,NCT05168163,Progression-free survival (PFS),2022-05-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events (AEs)
6452,NCT06206707,Clinical remission of immune-mediated diarrhea,2024-01-23,RECRUITING,INTERVENTIONAL,['NA'],,Endoscopic remission
6453,NCT03065868,Compare regression rate of gastric polyps between H. pylori eradication and non-eradication groups. Regression of gastric polyp: one of below 1) Disappearance of gastric polyp 2) Reduction of polyp size over 50%,2015-12-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
6454,NCT04139135,EFS,2019-12-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,5-year OS rate
6455,NCT05278078,"Expression analysis of slimming myokines, cachectic factors, cytokines genes by Real-Time PCR",2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6456,NCT00228189,Toxicity,2003-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6457,NCT04559087,Postoperative complications,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,survival
6458,NCT00582699,"The levels of specific cytokines (IL-1, Il-6, TNF-alpha, as well as IL-10, Il-15 and IFN-gamma), the diagnosis of Depression, depressive symptom severity, and the pattern of depressive symptoms.",2005-11,COMPLETED,OBSERVATIONAL,['NA'],,
6459,NCT05655780,Molecular profile of the tumor,2023-01-09,RECRUITING,OBSERVATIONAL,['NA'],,
6460,NCT00028405,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6461,NCT02704130,Intrahepatic Disease-free Survival,2016-03,TERMINATED,INTERVENTIONAL,['NA'],,Postoperative Morbidity
6462,NCT01531712,Resectability rate after neoadjuvant treatment with chemotherapy plus chemoradiotherapy.,2011-02-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Adverse events
6463,NCT05497726,Safety of SLN(s) or lymph node metastases with intravenous bevacizumab-800CW,2023-01-27,COMPLETED,INTERVENTIONAL,['NA'],,Number of SLN identified
6464,NCT02110082,"The primary safety endpoint is the incidence, potential significance, and clinical importance of adverse events",2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Trough observed concentration (Cmin) of BMS-663513 in combination with Cetuximab
6465,NCT02012023,mortality,2014-01,COMPLETED,INTERVENTIONAL,['NA'],hospital costs,operation data
6466,NCT00553332,Objective Response Rate (CR and PR),2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Protein Levels of RAS/RAF/MEK/ERK Signaling Pathway Activation
6467,NCT02609451,Quality Of Life (GQLI - Questionnaire),2007-11,TERMINATED,INTERVENTIONAL,['NA'],,Quality Of Life (GQLI - Questionnaire)
6468,NCT02691052,Global Health Status/Quality of Life Score at 3 months,2014-12,COMPLETED,OBSERVATIONAL,['NA'],,Correlations of tumor response and survival with genetic alterations
6469,NCT06106750,Clinical success,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse events
6470,NCT02198092,Septin9 Plasma Levels,2014-07,COMPLETED,OBSERVATIONAL,['NA'],Circulating Colonic Epithelial Cells at Blood Draws,Septin9 Levels Versus Circulating Colonic Epithelial Cell Numbers
6471,NCT03448549,3 year disease free survival,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,The accuracy of assessment of preoperative CT images on the stage
6472,NCT02422433,Feasibility of the marking OFDI capsule for diagnosing BE by comparing OFDI images and biopsy diagnosis,2014-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Sensitivity of the marking OFDI Capsule to correctly detect and mark the region of interest in BE
6473,NCT01094561,S-MRCP and S-EUS Concordance,2006-07,COMPLETED,INTERVENTIONAL,['NA'],,The Positive Predictive Value of S-MRCP
6474,NCT03526952,Change in mutual identity from four different time points,2018-05-04,UNKNOWN,INTERVENTIONAL,['NA'],Therapeutic Alliance,Patients' change in adjustment to bladder cancer from four different time points
6475,NCT04599660,To evaluate the onset of other neoplasms in very-low and low risk GIST patients,2020-11-25,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival (OS).
6476,NCT05006326,Sensitivity and specificity of 68Ga-PSMA PET/MR for diagnosis and staging in hepatocellular carcinoma.,2021-08-16,UNKNOWN,INTERVENTIONAL,['NA'],,Correlation of 68Ga-PSMA uptake in HCC patients with PSMA expression levels in tissues.
6477,NCT03188432,Quality of life (QOL) assessed using Functional Assessment of Cancer Therapy-Ovarian questionnaire,2017-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Response rates evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
6478,NCT03143140,completed tumor necrosis,2014-05-22,UNKNOWN,INTERVENTIONAL,['NA'],,tumor recurrence
6479,NCT02171286,Number of days between receipt of archival tumour tissue and generation of the OncoPanel Report,2014-10,COMPLETED,OBSERVATIONAL,['NA'],Concordance between Oncopanel results and ctDNA sequencing,Percent of cases in which a Oncopanel report is generated on a tumour specimen that has been received
6480,NCT02347904,The percentage of patients completing the preplanned number of 6 cycles of SOX.,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1'],AUC of S-1,Overall survival
6481,NCT02423226,Progression free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment related adverse events
6482,NCT04042298,Brachial artery flow mediated dilation (FMD),2019-06-25,UNKNOWN,OBSERVATIONAL,['NA'],,Arterial blood pressure
6483,NCT05121571,Progression free survival,2016-04-21,COMPLETED,INTERVENTIONAL,['NA'],,tumor response
6484,NCT05375643,Genomic testing uptake,2023-04-03,RECRUITING,INTERVENTIONAL,['NA'],,Acceptability of questionnaire modality
6485,NCT03936179,overall survival rate,2018-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,acute and late toxicities
6486,NCT00647153,Tumor targeting properties of iodine I 123 anti-CEA recombinant diabody T84.66,2006-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety of iodine I 123 anti-CEA recombinant diabody T84.66
6487,NCT00473941,Depressive symptoms,2005-09,COMPLETED,INTERVENTIONAL,['NA'],,
6488,NCT00149578,chemotherapy and concurrent chemoradiotherapy in locally advanced pancreatic cancer. .,2004-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"The secondary end points are to evaluate the distant metastasis rate and time to tumor progression, overall survival time and quality of life after induction"
6489,NCT01309126,Overall Survival (OS),2011-04,TERMINATED,INTERVENTIONAL,['PHASE3'],,Change in Quality of Life
6490,NCT01880918,The rate of anastomotic leakage.,2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,Rate of other device related complications and measures during hospitalization and post procedure.
6491,NCT02832882,12 month local tumor progression (LTP) rate,2016-10-21,COMPLETED,INTERVENTIONAL,['NA'],Technical efficacy 2,Technical success rate
6492,NCT02164136,Sexual function,2014-06,UNKNOWN,INTERVENTIONAL,['NA'],,5-year recurrence pattern
6493,NCT05721846,Adverse events,2023-05-03,RECRUITING,INTERVENTIONAL,['PHASE1'],,Disease control rate
6494,NCT03889626,Progression Free Survival (PFS),2019-03-22,UNKNOWN,INTERVENTIONAL,['PHASE3'],Adverse Events,Overall Survival (OS)
6495,NCT00686114,overall survival,2008-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Health-related quality of life
6496,NCT00692211,Colorectal Cancer Screening,2008-06,COMPLETED,INTERVENTIONAL,['NA'],,
6497,NCT03564834,Postoperative complication rate,2018-08-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Postoperative pain
6498,NCT04668976,Percent frequency liver toxicity,2020-11-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival
6499,NCT00061308,response rate,2002-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,response duration time to response time to progression survival safety
6500,NCT05180565,To measure the incidence of serious adverse events related to using the device,2019-12-18,COMPLETED,INTERVENTIONAL,['NA'],,To measure the patient tolerability of the device using a patient questionnaire
6501,NCT03951324,Frequency and type of criteria visually identified on malignant VLE clips,2019-05-10,UNKNOWN,OBSERVATIONAL,['NA'],,Number of procedures needed to view and conduct to use VLE for diagnostic confirmation
6502,NCT00966277,Number of Participants With Venous Thromboembolic Events (VTE),2010-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,
6503,NCT00268463,Progression-free Interval (PFI),2006-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,"Quality of Life as Measured by the Functional Assessment of Cancer Therapy Trial Outcome Index at Baseline, at 4-6 Weeks Following Surgery (Before Initiation of Chemotherapy), and Periodically During Study"
6504,NCT00788957,Part 2: Percentage of Participants With an Objective Response,2008-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 2: Minimum Observed Drug Concentration During the Dosing Interval (Cmin) for Ganitumab
6505,NCT04956640,To assess the antitumor activity of LY3537982 monotherapy in participants with advanced pancreatic cancer with KRAS G12C mutation,2021-07-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To characterize the PK properties of LY3537982: Maximum drug concentration (Cmax)
6506,NCT04948034,Objective Response Rate,2021-08-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Acute Toxicity
6507,NCT03959150,One year disease-free survival,2020-01-05,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Exploratory biomarkers
6508,NCT03299946,Number of patients who complete pre-op treatment and proceed to surgery.,2018-05-14,COMPLETED,INTERVENTIONAL,['PHASE1'],,Disease free survival (DFS)
6509,NCT06189547,overall survival (OS),2023-02-02,COMPLETED,OBSERVATIONAL,['NA'],,cancer-specific survival (CSS)
6510,NCT05667259,Overall Survival,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6511,NCT01249638,TFS,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"ORR, OS, Quality of Life, PFS-1"
6512,NCT04080154,Progress free survival (PFS),2019-09-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
6513,NCT01704703,Objective response rate (TRO),2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events
6514,NCT00568308,Disease-free Survival,2007-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,Compliance
6515,NCT04212026,The objective response rate (ORR) after the 5th dose of nivolumab of the reference liver metastasis that was not biopsied.,2020-06-28,TERMINATED,INTERVENTIONAL,['PHASE2'],,Adverse events
6516,NCT02337673,Change of regional ventilation partition (ROI analysis in 8 pulmonary ROIs) from preoperative to postoperative state.,2014-05,COMPLETED,OBSERVATIONAL,['NA'],,Ventilator-obligatory-free days
6517,NCT03766776,PFS,2018-12-31,UNKNOWN,INTERVENTIONAL,['NA'],,
6518,NCT05153304,Treatment-related Adverse Events,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of response
6519,NCT01335074,Maximum Tolerated Dose,2011-04,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall response rate
6520,NCT05742568,Changes in the diversity and structure of fecal microbiota,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Eradication rate of Helicobacter pylori
6521,NCT01471470,R0 resection rate,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Angiogenetic biomarkers
6522,NCT00002883,,1996-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
6523,NCT05044676,Measurement of the phenotype of expression of CD226 3 weeks after the start of treatment,2023-09-08,RECRUITING,OBSERVATIONAL,['NA'],,Correlation between pathology features (tumoral and non-tumoral liver) and the frequency and phenotype of expression of CD226
6524,NCT05580445,Recommended phase 2 dose (RP2D) of CT-707 in combination with toripalimab and gemcitabine,2022-08-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Predictive biomarkers for response to the combination of CT-707, toripalimab and gemcitabine",Disease control rate (DCR) according to RECIST v1.1
6525,NCT01203163,Proportion of patients experiencing Adverse Reactions of Special Interest,na,WITHDRAWN,OBSERVATIONAL,['NA'],,Overall safety in patients with renal insufficiency (disease)
6526,NCT02704299,Progression-Free-Survival(PFS),2016-03,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Incidences of adverse events or serious adverse events
6527,NCT04112940,Amount of Residue in the Pharynx,2016-12-19,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants Reporting Dislike of Thickened Liquid Stimuli
6528,NCT02688712,Evaluation of pathologic response,2016-03-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Immunologic monitoring parameters
6529,NCT00209703,Incidence and severity of adverse event,2005-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Determine the clinical response rate, disease-free survival(DFS), overall survival(OS)"
6530,NCT01747642,Number of patients who have prolonged survival,2012-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Reduction in serum alpha-fetoprotein level and decrease in tumor size
6531,NCT04609813,Diagnostic performance of the sponge cytology-based machine learning model for the main target lesions,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Diagnostic performance of abnormal cell count
6532,NCT01964534,Progression-free survival (PFS),2013-12-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Adverse Events
6533,NCT02385578,The rates of EGC detection,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],,
6534,NCT00769652,Change in Patient Generated Subjective Global Assessment (PG-SGA) Score at Time of Initial Presentation and Throughout Study,2006-10,TERMINATED,INTERVENTIONAL,['NA'],,
6535,NCT00084461,Objective response rate,2004-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Incidence of toxicity
6536,NCT00594984,Safety and tolerability of interventions will be collected,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Efficacy on tumor progression and progression free survival will be collected on all enrolled subjects
6537,NCT01982994,Percentage of patients with diagnosed gastrointestinal cancer who showed daily compliance using activity monitors and tablet computers to measure physical activity.,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of patients with a diagnosis of gastrointestinal cancer that benefit from an intervention of physical activity daily planning and education.
6538,NCT00700570,Percentage of Participants With Conversion From Unresectable to Resectable Liver Metastases,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants by Best Overall Tumor Response According to RECIST Version 1.1
6539,NCT05663515,Hazard ratio of primary diagnosis of pancreatic cancer among exenatide exposed population,2024-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6540,NCT00004909,,1999-11,COMPLETED,OBSERVATIONAL,['NA'],,
6541,NCT00687843,Relapse-free survival,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Overall survival, quality of life, drug compliance, adverse events, serial changes of tumor markers"
6542,NCT01191632,Purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximal number of tumor infiltrating T-cells. The total T-cell activity serves as primary surrogate parameters for anti- tumor activity,2010-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To determine the number of patients with adverse events as a measure of safety and tolerability according to CTCAE, Version 4.0 criteria"
6543,NCT00730860,disease free survival,2009-12,UNKNOWN,INTERVENTIONAL,['NA'],,overall survival
6544,NCT01313078,"Evaluation of Safety in Patients With Ovarian, Fallopian Tube, and/or Primary Peritoneal Cancer.",2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6545,NCT00040183,,2001-11-29,COMPLETED,INTERVENTIONAL,['PHASE3'],,
6546,NCT06310473,Pathologic complete remission rate (pCR),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
6547,NCT04675138,Concordance Rate,2020-08-20,UNKNOWN,OBSERVATIONAL,['NA'],,Reason for Discordance
6548,NCT01251237,Overall Acceptance on VAS (100mm) rating,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Efficacy on five-grade scale for pre-defined colon areas
6549,NCT04230187,Progression-free survival (PFS),2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Toxicity assessed using the NCI common toxicity criteria, version 5.0."
6550,NCT05438771,Oral Care Control Chart,2021-06-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],patient education,Number of participants with abnormal laboratory test results
6551,NCT04152265,Completion of the assigned screening strategy,2019-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,Determination of anthropometric data
6552,NCT02517268,Percentage of Patients Discharged by Post-operative Day 5,2015-06-24,COMPLETED,INTERVENTIONAL,['NA'],,"Incidence of Post-operative Complications (DGE, Anastomotic Leaks, Intra-abdominal Abscesses, Wound Infection, UTI, Respiratory Compromise, Renal Failure, Etc.)"
6553,NCT05205330,Disease Control rate (DCR),2021-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Safety and Tolerability of CR6086 combined with AGEN2034
6554,NCT04798898,Overall survival,2022-11-14,RECRUITING,INTERVENTIONAL,['NA'],Complications,Recurrence rate
6555,NCT03500471,Overall postoperative morbidity and mortality,2018-04-16,COMPLETED,OBSERVATIONAL,['NA'],3-year Overall survival rate,cost
6556,NCT05352204,overall survival,2020-04-30,COMPLETED,OBSERVATIONAL,['NA'],,disease-free survival
6557,NCT00227617,Best Objective Response,2005-06-08,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Biochemical Marker Response
6558,NCT00004102,,1999-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6559,NCT04952753,Expansion: Progression-free survival (PFS) by investigator assessment per RECIST 1.1,2021-11-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,ADA incidence on treatment
6560,NCT02200315,Postoperative surgical site infection,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Hospital stay
6561,NCT03646591,Completion rate of preoperative FLOT regimen,2017-11-15,COMPLETED,OBSERVATIONAL,['NA'],,Postoperative mortality
6562,NCT00554372,Proportion of Subjects Achieving Disease Control (Non-progressive Disease) at 8 Weeks After Initiation of Treatment,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival
6563,NCT03463616,Percentage of patients who needed additional radiology examination/s before treatment planning after routine MRI of abdominal organs compared with routine CT of abdominal organs.,2018-03-15,COMPLETED,OBSERVATIONAL,['NA'],,Disease free survival after 3 years
6564,NCT06061432,Rate of complications during endoscopic gastrointestinal anastomoses using transmural self-expandable prostheses to restore the gastrointestinal continuity in patients after Hartmann procedure (Endo-HARP),2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Rate of clinical success of endoscopic gastrointestinal anastomoses using transmural self-expandable prostheses to restore the gastrointestinal continuity in patients after Hartmann procedure (Endo-HARP)
6565,NCT04697303,Overall survival,2020-10-26,COMPLETED,OBSERVATIONAL,['NA'],,FSFI-6
6566,NCT00562640,Best Response,2007-10-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6567,NCT02857608,Concordance (the proportion of the number of subjects with lymph nodes identified by Lymphoseek and standard of care methods compared to the number of subjects with lymph nodes identified by standard of care methods),2016-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
6568,NCT00155558,To determine the maximum tolerated dose and dose limiting toxicity,2001-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,response
6569,NCT02531607,Sensitivity and specificity of biomarkers in the diagnosis of cancer,2014-11-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Medical Record Review
6570,NCT05638438,the objective response rate (ORR),2022-12-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Adverse events
6571,NCT00080236,Peak absolute change in aspartate transaminase (AST) values measured from baseline to up to 3 days post-transplantation,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6572,NCT05448222,progression free survival,2022-07-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Hospital cost
6573,NCT05088811,Diagnostic value of long non coding RNA UCA-1 and WRAP53 in Hepatolcellular carcinoma,2021-08-21,UNKNOWN,OBSERVATIONAL,['NA'],,
6574,NCT04107077,The PD-L1 expression can be upregulated after administration of HIPEC with greater frequency,2019-11-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Perioperative mortality at 30 days
6575,NCT04434989,Disease-free survival,2020-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse events
6576,NCT01385748,Cumulative Radiation Dose at Which Severe Oral Mucositis (World Health Organization [WHO] Score ≥ 3) Was First Observed,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Treatment Compliance According to the Patient Diary,Overall Survival
6577,NCT06196671,Overall survival，OS,2024-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,disease control rate (DCR)
6578,NCT01528059,Glycemic control,2012-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Nutritional status assessment
6579,NCT02502760,Post operative complications,2015-08,COMPLETED,INTERVENTIONAL,['NA'],Cost Effectiveness of treatment,Health Related Quality of Life
6580,NCT06332716,Progression-free survival（PFS）,2022-08-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival（OS）
6581,NCT01844375,Meters Walked During 2-Minute Walk Test,2013-05,COMPLETED,INTERVENTIONAL,['NA'],,Nitrogen Balance
6582,NCT04024345,Multidimensional Scale of Perceived Social Support,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,
6583,NCT00357474,overall survival rate,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease free survival rate and recurrence rate
6584,NCT02005419,Recurrence-free survival at one year after curative resection,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of grade 3 and 4 toxicities according to NCI CTCAE version 4.0
6585,NCT05715905,Rate of patients who remain in a colon cancer clinical trial to trial completion,2024-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6586,NCT06130644,MSI status,2003-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Tumor Mutation Burden (TMB)
6587,NCT02809287,Blood loss,2015-01,COMPLETED,OBSERVATIONAL,['NA'],,
6588,NCT03428126,Immune-related Best Overall Response Rate.,2018-03-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate
6589,NCT04493060,Disease control rate at 12 weeks (DCR12),2020-12-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in the cytokine profile pre- and post-treatment,Incidence of adverse events (AEs)
6590,NCT06065371,Primary Endpoint,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Exploratory Endpoint,Overall Survival (OS)
6591,NCT01723969,Tumour markers assessment,2013-09,COMPLETED,OBSERVATIONAL,['NA'],,
6592,NCT02556281,Number of patient with a first relapse,2012-10-15,UNKNOWN,INTERVENTIONAL,['NA'],,Number of free tumoral DNA in blood of patient with colorectal cancer
6593,NCT04489238,Establish a prospective database of patients with Young Onset Colorectal Cancer,2020-07-22,RECRUITING,OBSERVATIONAL,['NA'],,
6594,NCT00311272,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6595,NCT00107250,Dose limiting toxicity,2005-01-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumour Response
6596,NCT06091137,Appendectomy is associated with risk of subsequent CRC incidence,2022-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
6597,NCT04755907,Response of 3D tumor models/organoids to the same chemotherapy drugs as the corresponding patients.,2021-03-01,RECRUITING,OBSERVATIONAL,['NA'],Response of the colorectal cancer patients to adjuvant chemotherapy.,Response of the colorectal cancer patients to neoadjuvant chemotherapy.
6598,NCT04111692,Change in Polycystic Liver Disease Quality of Life,2017-11-06,RECRUITING,OBSERVATIONAL,['NA'],,
6599,NCT04857528,Rate of Participants With Detectable Circulating HPV DNA in Blood/Tumor Samples,2020-10-06,RECRUITING,OBSERVATIONAL,['NA'],,Accuracy of HPV DNA Levels in Predicting Cancer Recurrence at 24 Months
6600,NCT00710632,"Clinical condition, defined as diagnosis and stage of disease, treatment, and performance status at baseline",2007-09,UNKNOWN,INTERVENTIONAL,['NA'],,
6601,NCT01183780,Overall Survival (OS),2010-12-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Observed Maximum Concentration (Cmax) and Observed Minimum Concentration (Cmin) of Ramucirumab
6602,NCT01203969,rate of 30 day morbidity and mortality,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Duration of postoperative hospital stay
6603,NCT05216653,The primary objective of the study is to evaluate the pathologic complete response (pCR) rate following short-course radiation then Envafolimab Plus CAPEOX,2022-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life of the patients in a neoadjuvant setting of short-course radiation then Envafolimab Plus CAPEOX as assessed by FACT-C questionnaire
6604,NCT05991544,Oral Mucositis Grading Index:,2023-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
6605,NCT01034865,,2001-05,COMPLETED,OBSERVATIONAL,['NA'],,
6606,NCT04448652,Postoperative opioid-consumption,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,mortality
6607,NCT04609137,"Number of patients (n, %) developing a clinically-relevant pancreatic fistula (CR-POPF)",2020-10-13,COMPLETED,INTERVENTIONAL,['NA'],,"Number of patients (n, %) requiring an unplanned hospital readmission after discharge"
6608,NCT00486954,Overall Survival (OS) in the Randomized Part of the Study,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Mutations That May Correlate With Response and Toxicity to Lapatinib
6609,NCT04484636,"Distribution of mutations in patients with HCC, intra- and extrahepatic CCA, GBCA, PDAC and gastric cancer",2020-10-28,RECRUITING,INTERVENTIONAL,['NA'],,Number of patients receiving therapies in accordance to their genomic profiles
6610,NCT04090450,MR radiomics extracted features.,2019-09-23,UNKNOWN,OBSERVATIONAL,['NA'],,
6611,NCT04672005,Time to treatment failure (TTF),2021-01-06,RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation between variation of ctDNA and progression free survival,Correlation between variation in variant allele fraction (% cfDNA) or amplifications and tumor objective response during chemotherapy
6612,NCT05537129,3 year-DFS,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,morbidity and mortality rates
6613,NCT01734967,"Describe confocal imaging criteria for pancreatic masses, lymph nodes or liver metastases",2012-11,COMPLETED,INTERVENTIONAL,['NA'],,Feasibility
6614,NCT06138028,PFS,2023-09-20,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,toxicities
6615,NCT04603339,Feasibility - acceptability of the intervention (2),2021-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Bio-sample Collection
6616,NCT02195180,Progression free survival (PFS),2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life status
6617,NCT03848962,Collection of Biospecimens for Novel Research Uses,2016-06-30,RECRUITING,OBSERVATIONAL,['NA'],,
6618,NCT03416803,2-year overall survival,2018-02,UNKNOWN,INTERVENTIONAL,['NA'],,
6619,NCT03132025,Progression-free Survival of Patients with Apatinib and Capecitabine Combination That is prolonged,2017-04-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6620,NCT00066274,,2002-07-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6621,NCT03673072,Primary efficacy endpoint is overall survival (OS),2019-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of patients with any serious perioperative morbidity or mortality
6622,NCT04749862,Participant Recruitment,2021-03-22,RECRUITING,OBSERVATIONAL,['NA'],Information systems,Intervention implementation process measures: frequency of reported problems
6623,NCT04822506,time to first flatus (TFF),2021-07-31,RECRUITING,INTERVENTIONAL,['NA'],,Adverse Event Assessment
6624,NCT00445861,"Determine the safety of neoadjuvant radiotherapy in combination with cetuximab, docetaxel, and cisplatin",2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the duration of response and patterns of failure
6625,NCT01008475,Randomized Part: Progression Free Survival (PFS),2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Treatment Failure (TTF)
6626,NCT03926039,Decisional Conflict Scale,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],Decision Regret Scale,Liver Cancer Treatment Options Related Knowledge Scale
6627,NCT02322593,Overall Survival,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease Control Rate
6628,NCT03685591,"Number of Participants With Tumor Reponse per PCWG2 and RECIST v1.1 (Parts 2A, 2B)",2018-10-04,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Median Intra-Tumor T cells (Parts 2A, 2B)"
6629,NCT04371042,Registry creation,2019-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
6630,NCT04002778,Procedure duration,2015-08,COMPLETED,INTERVENTIONAL,['NA'],,Diagnostic yield
6631,NCT02908165,EASL criteria for tumor response,2016-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
6632,NCT01596790,Predictive value of the CTC on the Progression Free Survival,2012-04,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of the results with the CellSearch system vs EPISPOT
6633,NCT00047229,Rate of objective response (complete and partial),2002-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and tolerability
6634,NCT02013154,Number of subjects with treatment emergent adverse events related to study treatment (DKN-01 as monotherapy or in combination with paclitaxel or pembrolizumab),2014-05-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression Free Survival (PFS)
6635,NCT02101918,Objective Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,2014-06-18,COMPLETED,INTERVENTIONAL,['PHASE2'],Tumor Perfusion Parameters at Time of Progression,Baseline Permeability Surface (PS)
6636,NCT04254107,Number of participants with a dose-limiting toxicity (DLT) at each dose level,2020-05-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of participants with antidrug antibodies (ADA)
6637,NCT01708824,Whether the PA and dietary intake targets are met at the end of intervention;,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Possible side effects arising from the intervention
6638,NCT05648006,Progression-free survival,2023-10-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity by CTCAE v5.0
6639,NCT03589131,Operative time of robotic-assisted rectal cancer surgery.,2015-04-29,COMPLETED,INTERVENTIONAL,['NA'],,Accurate safety margin
6640,NCT00654342,Accuracy & sensitivity of sentinel lymph node mapping,2007-10,UNKNOWN,INTERVENTIONAL,['NA'],,
6641,NCT01130363,Number of patients with fundic gland polyps and PPI use that have a higher gastric pH,2006-10,TERMINATED,OBSERVATIONAL,['NA'],,
6642,NCT02199002,acid pocket position,2014-07,COMPLETED,INTERVENTIONAL,['NA'],acid pocket contents,number of reflux episodes
6643,NCT00286130,the percentage of patients surviving without disease progression in each arm at 9 months,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
6644,NCT02268006,Pathological complete remission rate (pCR),2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
6645,NCT01628640,Tumor necrosis,2012-08-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
6646,NCT04938986,Number of cases where the recommendations for patient care according to the Immunoscore® are considered beneficial compared to the standard care decision,2022-04-04,RECRUITING,INTERVENTIONAL,['NA'],,"Actual survival (patient alive without recurrence, alive with recurrence, dead)"
6647,NCT00022698,Tumor Response Rate Based on Tumor Measurement as Per Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST 1.0),2001-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Number of Participants With Any Adverse Events, Serious Adverse Events and Deaths"
6648,NCT01339169,Visual assessment of the distribution of gastric carcinoids.,2011-01-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Plasma or serum concentrations of biomarkers such as gastrin or chromogranin A (CgA).
6649,NCT02809846,Change in Daily Opioid Use Assessed as Recorded by the Subject in Their Analgesia Diary.,2016-07,TERMINATED,INTERVENTIONAL,['NA'],,
6650,NCT04146441,Volume change of primary tumor,2020-02-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of reported toxicity
6651,NCT04430738,Incidence of dose alterations (Cohort 1D),2020-09-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Objective response rate (ORR) (Cohorts 1C, 1E, 1F, and 1G)"
6652,NCT00051987,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6653,NCT03005756,"Total radiation exposure (DLP, mGy*cm)",2017-01-25,UNKNOWN,INTERVENTIONAL,['NA'],,Procedure time
6654,NCT04471194,Difference in Percentage of Participants Who Completed Any Cervical PLUS Colorectal Cancer Screening Tests,2021-02-18,COMPLETED,INTERVENTIONAL,['NA'],,Difference in Percentage of Participants Who Completed At-home Cervical PLUS Colorectal Cancer Screening Tests
6655,NCT00101998,"Change in weekly SCBM frequency. A SCBM is a spontaneous and complete bowel movement, which means a bowel movement that occurs with no laxative use in the prior 24 hours and leaves the subject with the feeling of complete evacuation of the rectum.",2003-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Additional measures of Bowel movement (BM) frequency and symptoms, safety profile of the treatment regimens and any changes in pain intensity or opioid use."
6656,NCT01031784,Toxicity of Ho-166 poly lactic microspheres using CTC vs 3 criteria,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,tumor response according to RECIST criteria
6657,NCT05943951,"the analysis of lymphadenectomy in the course of right hemciolectomy, in relation to the radicality of surgical resection that is performed",2022-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Vascular anatomical variability
6658,NCT04490694,Objective remission rate（ORR）,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
6659,NCT01460641,Tumor stage change from Computed Tomography (CT) perfusion measurement,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,Tumor perfusion as measured by perfusion CT.
6660,NCT06069297,Cancer cachexia related factors,2023-07-14,RECRUITING,INTERVENTIONAL,['NA'],,Disease-specific health-related quality of life
6661,NCT03831698,Retention rate of participants,2019-02-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of participants with treatment-related adverse events in each arm.
6662,NCT01541683,measurement of Palatability of the PEG-electrolyte solution,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,Side effects
6663,NCT03298451,Overall Survival (OS) - Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 400 mg,2017-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Summary of Tremelimumab Concentration Over Time
6664,NCT04683497,Number of new liver metastases identified using CE-IOUS,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Number of new liver metastases using CE-IOUS in the subgroup of patients with missing metastases.
6665,NCT05375604,To characterize the safety and tolerability of CDK-004.,2022-06-28,TERMINATED,INTERVENTIONAL,['PHASE1'],,
6666,NCT05299411,Serum Hb level,2023-04-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life associated anemia,Serum hepcidin level
6667,NCT06172478,Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy,2024-02-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Pharmacokinetic Parameter Area Under the Concentration Curve for HER3-DXd
6668,NCT01598077,Dose-limiting toxicities (DLTs),2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Serum concentration of LJM716,"
6669,NCT04144738,Specificity with the mt-sDNA 2.0 test,2019-11-15,COMPLETED,OBSERVATIONAL,['NA'],,Specificity for no colorectal neoplastic findings
6670,NCT06124729,cCR,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Disease-free survival (DFS) and overall survival (OS)
6671,NCT04295473,3-year survival rate,2020-03-02,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life in PGSAS-45 scale
6672,NCT05708872,Effect of methods of self-regulation of mental state on postoperative pain perception changes,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Effect of methods of self-regulation of mental state on anxiety changes
6673,NCT02525965,Overall survival rates of each group,2015-08,UNKNOWN,INTERVENTIONAL,['NA'],,Occurrence rate of recurrence of each group
6674,NCT01504711,Percentage of Participants With Control of Vomiting and Rescue Medication Control,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
6675,NCT04436679,Relationship between known prognostic histological markers of pancreatic adenocarcinoma and patient survival.,2021-02-02,RECRUITING,OBSERVATIONAL,['NA'],,Relationship between newly described histological markers for pancreatic adenocarcinoma and patient survival.
6676,NCT03001726,overall survival,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],adverse events,progression-free survival
6677,NCT01360801,Accuracy of Agreement Between Imaging and Histology,2011-02,TERMINATED,OBSERVATIONAL,['NA'],,Presence of Residual Disease
6678,NCT04943419,Level of MDSC in patients with postoperative complications,2016-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Level of MDSC in patients with left and right sided tumours
6679,NCT04851132,Progression-free survival (PFS),2021-03-11,UNKNOWN,INTERVENTIONAL,['NA'],Quality of Life (QOL): questionnaire EORTC QLQ-OES18,Quality of Life (QOL): questionnaire EORTC QLQ-C30 (version 3)
6680,NCT00716157,Assess incidence and patterns of nausea and vomiting in patients undergoing concurrent chemotherapy and radiation,2004-10,COMPLETED,OBSERVATIONAL,['NA'],,Study the incidence of mucositis and esophagitis
6681,NCT04482257,λz,2020-07-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
6682,NCT00848783,Number of Patients With One-year Recurrence-free Survival,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival Rate; Toxicity; Evaluation of Sites of Relapse of Failing Patients
6683,NCT00356889,Number of Confirmed Tumor Responses.,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
6684,NCT02421354,"Objective Response Rate, Defined as Complete Remission + Partial Remission + Clinical Improvement",2015-05-14,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6685,NCT03699319,MTD of CPI-613 when given in combination with mFOLFIRINOX,2018-12-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Surgical resection rates
6686,NCT02841800,survival benefit,2016-06,COMPLETED,INTERVENTIONAL,['NA'],,repeated biliary interventions
6687,NCT00003225,To assess the toxicity profile of Irinotecan and Ethyol when administered together on this schedule.,1997-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To determine the clinical benefit of intravenous Irinotecan and Ethyol in patients with colorectal cancer, as measured by performance status, analgesic consumption, quality of life and survival."
6688,NCT06200363,Adverse event,2023-09-21,RECRUITING,INTERVENTIONAL,['PHASE1'],,Quality of life questionnaire (QLQ-C30)
6689,NCT01090505,overall survival,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,response rate
6690,NCT02943837,"Diagnostic accuracy (proportion of correctly classified subjects (ture positive + true negative) among all subjects ) , compared to the gold standard diagnosis",2016-10-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
6691,NCT00960427,Correlation of disease-free survival with post-treatment value and change in expression of colorectal cancer stem cell markers after neoadjuvant chemoradiotherapy,2009-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
6692,NCT05212012,Disease control rate 12 weeks after randomization (ITT-population),2022-02-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse events
6693,NCT03298945,Population level adenoma detection rate (ADR),2018-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],renal failure,Adequate bowel prep quality
6694,NCT02290977,Adverse event assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 after scheduled TACE-RT for HCC with PVTT,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Radiologic response assessed by modified Response Evaluation Criteria for Solid Tumors (mRECIST) after scheduled TACE-RT for HCC with PVTT
6695,NCT03116984,3-year overall survival(OS),2017-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
6696,NCT00774839,Self-reported expenses associated with colon cancer treatment and living with this illness.,2008-10,COMPLETED,OBSERVATIONAL,['NA'],,"Identify the medical, social and economic risk factors that are most closely associated with perceived adverse impact on financial and social well-being and unmet resource and service needs."
6697,NCT04672603,Incidence of urinary dysfunction,2021-04-08,RECRUITING,INTERVENTIONAL,['NA'],,Positive Circumferential Resection Margin Rate
6698,NCT04842812,Safety of TILs/CAR-TILs treatment in advanced solid cancers,2021-01-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Primary clinical efficacy of the TILs/CAR-TILs treatment in advanced solid cancers
6699,NCT03023722,Response Rate as Measured Per RECIST 1.1 Criteria,2017-05-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Drug Toxicity
6700,NCT05836246,Quantitative ultrasound information,2020-09-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
6701,NCT04005170,clinical complete response rate,2019-06-25,COMPLETED,INTERVENTIONAL,['PHASE2'],The impact of IDO1 expression on clinical response,Incidence of treatment-related adverse events as assessed by CTCAE v4.0
6702,NCT00285701,,2006-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6703,NCT02806076,12 month local tumor progression (LTP) rate,2016-07-01,UNKNOWN,INTERVENTIONAL,['NA'],Technical efficacy 2,Technical success rate
6704,NCT01313026,changes in LARS score,2011-01,TERMINATED,INTERVENTIONAL,['NA'],,Patient Satisfaction
6705,NCT04500392,The incidence of hypoxia,2021-05-06,RECRUITING,INTERVENTIONAL,['NA'],,Other adverse events include other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force and HFNC supportive oxygen therapy-related adverse events.
6706,NCT03294252,Recommanded dose for the extension phase,2017-05-24,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-Free Survival
6707,NCT00026364,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6708,NCT04993131,Overall survival,2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Survival in relation to biological markers
6709,NCT04947995,The sensitivity and specificity of blood-based multi-omics assay for early detection of gastric cancer with comparison to EGD and/or histological diagnosis.,2021-06-15,UNKNOWN,OBSERVATIONAL,['NA'],,
6710,NCT00902902,,2008-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6711,NCT05833672,ORR (objective response rate),2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
6712,NCT01584830,Overall Survival (OS),2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety variables will be summarized using descriptive statistics based on adverse events collection
6713,NCT02781155,Adherence to moxa regimen assessed by Daily Moxa Diary,2016-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidents of additional interventions administered as prophylaxis or therapy to maintain or improve blood counts
6714,NCT06278493,Maximum tolerated dose (MTD),2018-08-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6715,NCT02547142,Quality Of Life,2016-01-18,TERMINATED,INTERVENTIONAL,['NA'],,Total duration of time from date of metastatic diagnosis to date of death
6716,NCT03029611,Rate of Pathologic Complete Response (CR),2017-04-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Predictive Signature of CR Induction When Vaccinated With an IGFBP-2 Vaccine in Combination With Neoadjuvant Chemotherapy Assessed by Whole Exome Sequencing on Vaccinated Patients' Tumors,Tumor Burden
6717,NCT05250791,Clinicians' reasons for not recruiting patients.,2023-02-02,RECRUITING,INTERVENTIONAL,['NA'],Pro-inflammatory cytokine levels,Total hospital stays including readmission
6718,NCT04488159,Disease-free survival (DFS),2024-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Cost analysis
6719,NCT00493428,"Document and Compare the effects of the GABAb receptor agonist Baclofen on the time to develop tumor metastasis in patients with non-metastatic HCC at diagnosis who subsequently undergo surgical resection, ablation or chemoembolization.",2007-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Document and compare the effects of the GABAb receptor agonist Baclofen on changes in serum tumor markers ( alpha-fetoprotein andd CA19-9 levels) in patients with no-metastatic HCC at diagnosis.
6720,NCT00057980,Overall survival,2002-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Cyclooxygenase-2 expression in tumor tissue and nonmalignant liver tissue in correlation to response
6721,NCT00815308,Number of Participants With Overall Response Rate (RR),2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With K-ras Gene Mutation
6722,NCT04525989,Incidence of acute grade 2-5 gastrointestinal toxicity,2021-04-20,RECRUITING,INTERVENTIONAL,['NA'],Exploratory: Difference in concentrations of CEA (carcinoembryonic antigen) between treatment arms,Cost effectiveness analysis measured by QALY
6723,NCT02726243,Composition of fecal microbiota by 16S sequencing,2014-11,COMPLETED,OBSERVATIONAL,['NA'],,Profile of fecal bile acids
6724,NCT01929122,Stool Microbiome Composition and Metabolome,2010-08,COMPLETED,INTERVENTIONAL,['NA'],,"Navy Bean or Rice Bran metabolites in stool, urine and blood."
6725,NCT00507585,"To study the highest tolerable dose of oxaliplatin used in combination with 5-fluorouracil, leucovorin, and Avastin® (bevacizumab) for patients with advanced cancer that has spread to the liver.",2006-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6726,NCT00492752,Overall Survival,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time of Maximum Concentration (Tmax) After 21 Days of Sorafenib Treatment
6727,NCT02129218,"Individual patient compliance, defined by following assigned target glycemic load index >= 75% of the time between weeks 4 and 12",2015-02-16,COMPLETED,INTERVENTIONAL,['NA'],Change in serum levels of proteins affected by carbohydrate metabolism,Hours of nutritionist time per week
6728,NCT03817567,Objective response rate (ORR),2018-07-17,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
6729,NCT02299843,mortality during perioperation,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],,
6730,NCT02984501,Incidence of Treatment-Emergent Adverse Events,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Local-regional Tumor Control
6731,NCT00908752,"To compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy",2009-07-20,COMPLETED,INTERVENTIONAL,['PHASE3'],,To evaluate the safety of brivanib in combination with TACE
6732,NCT03164382,Overall survival,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to Intrahepatic tumor Progression
6733,NCT01257035,Response to chemoradiotherapy measured by TRG,2010-11,TERMINATED,OBSERVATIONAL,['NA'],,Survival
6734,NCT01768195,the incidence of hepatitis B virus reactivation and hepatitis B virus reactivation related hepatitis,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,the incidence of hepatitis B virus relapse and relapse related hepatitis
6735,NCT05199584,Objective Response Rate (ORR),2022-05-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in steady-state exposure to study medication
6736,NCT00766155,Disease-free survival,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Toxicity according to CTCAE v.3.0 weekly during treatment, at 4-8 weeks after surgery, at therapy completion, and every 6 months for 5 years after therapy completion"
6737,NCT05958550,Whether hypothermia occurs,2024-03-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6738,NCT06040099,Progression Free Survival (PFS),2024-02-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of Response (DoR)
6739,NCT04966195,overall survival,2015-12-01,COMPLETED,INTERVENTIONAL,['NA'],,objective response rate
6740,NCT01598597,Percentage of subjects who complete the survey and who provide evaluable genetic information (DNA),2012-03,COMPLETED,OBSERVATIONAL,['NA'],,"Demographic distribution (age, sex) of subjects participating in this study"
6741,NCT00646100,survival rates,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,quality of life
6742,NCT05196867,Change in FIB-4 score,2022-02-11,RECRUITING,INTERVENTIONAL,['NA'],,
6743,NCT01525082,Radiographic Response (RR),2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,O6-methylguanine DNA Methyltransferase (MGMT) by Promoter Methylation
6744,NCT05551247,ORR,2022-09-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,SAE
6745,NCT02564263,Overall Survival (OS) in All Participants,2015-12-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE)
6746,NCT05400031,Oral mucositis grading,2022-06-01,COMPLETED,INTERVENTIONAL,['NA'],,
6747,NCT03365986,The incidence of hereditary colorectal cancer,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,cost-effect for hereditary colorectal cancer screening
6748,NCT00288925,"Safety, Pharmacokinetics",2005-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Tumour shrinkage, Tumour objective response rate"
6749,NCT02724436,Postoperative complication,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
6750,NCT04328948,Major progression-free survival,2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Long term toxicity
6751,NCT02982486,Response to therapy as evaluated by RECIST 1.1,2017-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
6752,NCT01043016,Maximum tolerated dose,2009-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Treatment efficacy as measured by computed tomography (CT) or magnetic resonance imaging (MRI) and endoscopy exam 3 weeks after the start of study treatment according to the Response Evaluation Criteria In Solid Tumors (RECIST) standard
6753,NCT03141034,Progression-free survival (PFS),2017-11-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity and tolerability of regimen as measured by the count of the worst grade of adverse event experienced by each participant
6754,NCT00004911,,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6755,NCT05663450,Rate of R1-resection during oncologic surgery,1996-05-01,COMPLETED,OBSERVATIONAL,['NA'],,Post-surgical survival
6756,NCT02013050,Duration of Severe Oral Mucositis (SOM),2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Percent of Patients With RECIST 1.1 Classification of ""Complete Response"""
6757,NCT06205485,Quality of Life defined using the LARS score,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Validate the magnetic resonance tumour regression grade (MR-TRG) in patients with T1 and T2 rectal cancer
6758,NCT03738111,Maximum Tolerated Dose,2018-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Molecular Marker,Overall Survival
6759,NCT05749900,"Phase II: Objective response rate, ORR",2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of Life (QoL)
6760,NCT03732235,time to progression,2018-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Number of adverse events
6761,NCT00495625,Number of Participants With Progressive Disease (PD) at Interim Analysis,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Serious Adverse Events (SAEs)
6762,NCT05397444,Hospital readmissions,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,prolonged length of stay
6763,NCT01032590,Impact of an Internet-based intervention on weight loss,2009-07,WITHDRAWN,INTERVENTIONAL,['NA'],,Potential moderators of weight loss
6764,NCT02841865,Response to treatment,2015-07-24,COMPLETED,OBSERVATIONAL,['NA'],,Impact of Choi criteria and Progression of Disease
6765,NCT01888965,Biomarker Discovery,2013-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety
6766,NCT04090554,Distribution of acceptability scores,2019-09-24,COMPLETED,INTERVENTIONAL,['NA'],,Prevalence of other benign esophageal pathologies
6767,NCT01676194,Survival,2012-08,TERMINATED,INTERVENTIONAL,['PHASE3'],,Efficacy of TACE
6768,NCT01618643,"Timing of disappearance of aceto-whitening for Barrett's metaplasia, HGD and cancer",2010-11,UNKNOWN,OBSERVATIONAL,['NA'],,To differentiate mucosal neoplasia from invasive cancer
6769,NCT05152472,Progression-Free Survival (PFS),2022-01-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Tolerability profile
6770,NCT00023933,Maximum tolerated dose of 131I-HuCC49^CH2 based on dose-limiting toxicities,2001-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immune response
6771,NCT00316420,MTD and DLT for the combination therapy of gemcitabine and capecitabine,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor Response
6772,NCT00139633,local control at 4 years,2000-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6773,NCT01776346,Progression to esophageal adenocarcinoma,2011-01,UNKNOWN,OBSERVATIONAL,['NA'],,"Evaluate the natural history of BE with and without treatment based on clinical, functional and economic outcomes of the cases"
6774,NCT01498289,Overall Survival (OS),2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
6775,NCT03093688,Objective Response Rate (ORR),2017-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-Free Survival (PFS),Tumor Marker
6776,NCT04117945,Overall survival (OS),2020-03-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
6777,NCT04490551,Yield of Advanced Neoplasia,2019-12-05,COMPLETED,INTERVENTIONAL,['NA'],,Yield of Proximally Located Advanced Neoplasia
6778,NCT02466113,Disease free survival,2016-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
6779,NCT03082495,Change in Cardiorespiratory fitness,2017-06-26,COMPLETED,INTERVENTIONAL,['NA'],Number of positive lymph nodes,Safety: Adverse event rate
6780,NCT01639352,Disease Control Rate (DCR),2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity Profile of Protocol Therapy
6781,NCT02394834,Overall survival (OS),2015-05-29,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"Evaluation of the Relationship between a Change in Each Biomarker in Tumor Tissue at Baseline and the Discontinuation of the Protocol Treatment of the Main Study, and Efficacy Endpoints"
6782,NCT04810585,Progression free survival,2020-04-20,RECRUITING,INTERVENTIONAL,['PHASE4'],,Prognostic or Predictive Biomarker for Aflibercept (plasma biomarker)
6783,NCT05334719,Incidence of treatment-related adverse events (TRAE) that have led to treatment discontinuation,2022-02-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Incidence of Adverse Events (AEs)
6784,NCT00910676,To reduce by 30 % the frequency of folliculitis by a local corticotherapy beginning at the same time that the treatment by EGF-R inhibitors began,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess the patient quality of life with the DLQI questionnaire
6785,NCT01684904,To assess overall survival of patients treated with proton-chemotherapy (PCT) followed by surgery in patients with resectable primary esophageal or esophagogastric cancer,2013-02-20,RECRUITING,INTERVENTIONAL,['NA'],,Number of participants with adverse events as a measure of safety and tolerability
6786,NCT06278454,Adverse events (AE) and severe adverse events (SAE),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Distribution of NRT6008 injection in human body and radioactivity of biological samples,Resection rate (R0 and R1)
6787,NCT03393182,Postoperative 30-day morbidity rate,2018-03-01,COMPLETED,INTERVENTIONAL,['NA'],,QOL measurement : EORTC QLQ-C30/STO22
6788,NCT05243966,Proportion of participants with treatment emergent adverse events during the study,2022-01-10,RECRUITING,OBSERVATIONAL,['NA'],,Percentage of split thickness skin graft take at 1 week post Matrix™ application
6789,NCT04197310,Objective Response Rate (ORR),2019-12-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants with Treatment Related Adverse Events
6790,NCT05653453,Overall survival (OS),2022-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Progression Free Survival rate at 6 months
6791,NCT00052364,Time to progression,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival
6792,NCT00469443,Time To Progression,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Symptoms improvement
6793,NCT01641887,Participant Satisfaction,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],,Patient decisions
6794,NCT04355156,Overall survival,2012-09-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Monitoring dose reductions and the reasons behind them
6795,NCT06242613,Compare robotic gastrectomy with the conventional laparoscopic approach in terms of oncologic safety.,2023-05-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Compare robotic gastrectomy with the conventional laparoscopic approach in terms of cost-utility outcomes.
6796,NCT06070623,Role of elastography and color Doppler to follow up after TACE.,2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6797,NCT02759601,Determine Maximum Tolerated Dose,2013-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase I & II: To determine the impact of HDACi on anti-tumour immune responses.,Phase I & II: To determine pharmacokinetic parameters for tefinostat and CHR-2847 when administered orally at different dose levels and dose schedules.
6798,NCT00386399,6-month overall survival,2006-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To explore pharmacogenetic factors that may influence the toxicity and efficacy of MMC in this patient population.
6799,NCT01772706,To evaluate the efficacy of preventive and curative low energy laser induced mucositis in patients receiving concomitant chemotherapy and radiotherapy for squamous cell carcinoma of the head and neck with stage III-IV,2008-10-30,UNKNOWN,INTERVENTIONAL,['NA'],To document the Overall survival calculated from the date of randomization to death from any cause or up to 5 years.,To assess the quality of life using the QLQ-HN35 questionnaire.
6800,NCT02468726,Success of bowel cleansing,2011-11,COMPLETED,INTERVENTIONAL,['NA'],,Stool weight
6801,NCT06110598,Relapse-free survival (RFS),2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
6802,NCT00095992,Response,2005-03-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Molecular correlates on archival tumor specimens and peripheral blood mononuclear cells (PBMCs)
6803,NCT01102556,Creation of a registry and blood/tissue bank,2004-07,RECRUITING,OBSERVATIONAL,['NA'],,"Improvement in the diagnosis, prevention, detection, and treatment of pancreatic cancer."
6804,NCT03721952,Hospital Anxiety and Depression Scale (HADS) - family,2019-04-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Key Implementation Outcomes,QUAL-E (Fam)
6805,NCT00335491,Patient perception and pattern of change,2006-03,COMPLETED,INTERVENTIONAL,['NA'],,Structural and function changes
6806,NCT01799044,Safety,2012-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Feasibility,Efficacy
6807,NCT04637698,The objective response rate of patients with pancreatic cancer receiving OH2 injection.,2021-02-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate the impact of OH2 in patients with pancreatic cancer on the quality of life
6808,NCT03511703,overall survival,2018-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6809,NCT02685631,Response to treatment with Y90 microspheres either as mono therapy or as part of multidisciplinary management of their specific disease,2015-07,COMPLETED,OBSERVATIONAL,['NA'],,Time to Progression
6810,NCT05476796,Progression free-survival,2023-06-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life questionnaire - Core 30 (QLQ-C30)
6811,NCT06036745,Disease-free survival,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
6812,NCT05540925,Overall survival (OS),2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Local recurrence
6813,NCT05441475,To evaluate the objective response rate of ABSK-011 combined with atezolizumab in subjects with advanced FGF19 overexpression or unresectable HCC,2021-12-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6814,NCT02173990,Progression-Free Rate will be assessed according to RECIST 1.1 with central radiological review.,2014-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety and tolerance
6815,NCT05901376,The different of MiR-223 level between gastric cancer and control group,2023-04-25,RECRUITING,OBSERVATIONAL,['NA'],,
6816,NCT04966143,Overall Response rate（ORR）,2021-08-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
6817,NCT02023541,Overall survival,2014-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Toxicity
6818,NCT05529940,2-year survival rate,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Response rate in neoadjuvant setting
6819,NCT02929797,Disease-free survival,2016-08,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Quality of life
6820,NCT02439580,Nutritional Status,2013-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Cytotoxicity
6821,NCT05211323,Progression free survival (PFS),2022-12-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall response rate
6822,NCT03144804,Overall Response Rate,2017-10-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Disease Control Rate
6823,NCT00165464,"To assess the response rate of patients with esophageal or gastric carcinoma to weekly Taxotere, Cisplatin, and Irinotecan (CPT-11).",2001-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess the toxicity of this combination in esophageal or gastric carcinoma.
6824,NCT05635279,Death,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,Censored
6825,NCT04753359,Exfoliated intestinal epithelial cell transcriptomics,2022-02-01,RECRUITING,INTERVENTIONAL,['NA'],Bowel habits,Fasting insulin
6826,NCT06229340,Objective response rate,2023-10-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
6827,NCT02013986,Change from baseline in salivary cortisol at the first day after surgery,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Days of stay in intensive care unit (ICU) after surgery
6828,NCT05211388,Conformity with planned ablation zone,2022-07-11,RECRUITING,INTERVENTIONAL,['NA'],,
6829,NCT00444093,Treatment Efficacy,2007-03-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,Diarrhea Assessment
6830,NCT04180033,Diagnostic yield advanced colorectal neoplasia,2020-02-18,COMPLETED,INTERVENTIONAL,['NA'],,Burden of colonoscopy
6831,NCT03411707,"Sensitivity and Specificity of Multiple Screening Methods With Comparison to Colonoscopy, Both With Respect to Cancer.",2018-03-19,RECRUITING,OBSERVATIONAL,['NA'],,
6832,NCT03995459,Evolution from baseline of liver volume and liver function values,2019-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Evolution from baseline of liver volume and liver function values
6833,NCT00202111,Five-year survival,1998-01,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of Life outcomes
6834,NCT02649569,Number of patients who successfully use the activity monitor (i.e. wearing the activity monitor throughout the treatment course),2015-06,COMPLETED,OBSERVATIONAL,['NA'],,
6835,NCT00004897,,1999-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6836,NCT00571740,Progression-free survival (PFS) rate at 6 months,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Quality of life
6837,NCT00960167,Maximally tolerated dose of RT,2009-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],,"Tumor control, patterns of failure and survival"
6838,NCT05406167,Health Related Quality of Life (HRQOL) scores,2022-04-12,RECRUITING,OBSERVATIONAL,['NA'],,Long-term toxicities related to Radiotherapy
6839,NCT03704727,Intestinal permeability,2018-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Gastrointestinal adverse events
6840,NCT05522738,RP2D,2022-08-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Safety and tolerance evaluated by incidence of SAE
6841,NCT02665312,Assessment of the incidence of cardiovascular events during the first three cycles of therapy with capecitabine or 5-FU,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6842,NCT04023136,"Estimation of the intraoperative portocaval post-hepatectomy gradient This pressure differential is performed before the parietal closure, after resection. We consider that the simulation is accurate if the difference with the measurement is ≤ 4 mmHg.",2019-07-15,UNKNOWN,INTERVENTIONAL,['NA'],,Prediction of changes in portal vein flow
6843,NCT01186705,Overall Objective Response Rate (ORR),2010-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6844,NCT02624154,The survival rate,2015-12,UNKNOWN,OBSERVATIONAL,['NA'],,
6845,NCT01384253,Safety and tolerability: To measure the number of participants who experience adverse events after intraperitoneal (IP) administration of ²¹²Pb-TCMC-Trastuzumab.,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics: To determine the plasma pharmacokinetics and assess the extent of exit of radioactivity from the peritoneal cavity by γ-camera imaging.
6846,NCT02129322,Time to Recurrence (TTR),2015-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Circulative tumor cell (CTC) level change,Overall survival (OS)
6847,NCT05737563,Overall survival (OS),2023-02-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease Control Rate (DCR)
6848,NCT05225428,Video Education Acceptability (Qualitative Interview Study),2022-08-04,RECRUITING,INTERVENTIONAL,['NA'],,
6849,NCT01721954,Overall Survival (OS),2013-05-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression-free Survival
6850,NCT03096951,Change in cardiorespiratory fitness,2017-04-04,COMPLETED,INTERVENTIONAL,['NA'],,Adherence
6851,NCT02523911,Overall bowel cleansing,2016-03,WITHDRAWN,INTERVENTIONAL,['NA'],Degree of haziness,Number of patients completing the bowel preparation
6852,NCT01702116,measurement of circumferential resection margin,2011-07,UNKNOWN,INTERVENTIONAL,['NA'],,estimated blood loss
6853,NCT05232357,"Expression levels of PGP9.5, GFAP, VIP, nNOS, TH, ChAT and SOM of different gastrointestinal lesions",2022-03-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
6854,NCT00297791,locoregional recurrence rate,2004-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,out-of-hospital postoperative costs
6855,NCT01272791,Overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
6856,NCT02969148,the 3-year disease-free survival rate,2016-11,RECRUITING,INTERVENTIONAL,['NA'],the time of hospital stay,the number of bowel obstruction
6857,NCT03474861,The adverse events associated with infusion of the anticancer medication or the immune cells will be assessed.,2018-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Tumor Response of the treatment in patients with advanced gastrointestinal cancer.
6858,NCT04838964,Objective Response Rate (ORR) by Independent Review Committee (IRC),2021-04-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of anti-drug antibody (ADA)
6859,NCT05202236,objective response rate (ORR),2021-10-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6860,NCT02047305,Complete Response,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,
6861,NCT03645980,Phase II: Time to progression (TTP2),2018-10-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Adverse Events
6862,NCT01995240,"Reproducibility of DCE, T2* and DWI MRI in pancreatic cancer.",2013-04,COMPLETED,INTERVENTIONAL,['NA'],,"To explore the relation between in vivo measurements of tumor vascularity, hypoxia and stroma using DCE-MRI, T2* MRI and DWI and treatment outcome."
6863,NCT03140007,Diagnostic accuracy of cholangioscopy or cholangiography,2017-06-15,UNKNOWN,INTERVENTIONAL,['NA'],,Correlation between impression of malignancy and cytopathology in the ERCP arm compared to the cholangioscopy arm
6864,NCT01065441,The primary endpoint is the evaluation of any drug-related toxicity associated with AlloStimTM administration as well as the reversibility of such toxicity.,2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The tertiary end-point is the evaluation of the immunological response to AlloStim-TM administration.
6865,NCT00342004,All cancer incidence,1997-05-01,COMPLETED,OBSERVATIONAL,['NA'],,All deaths
6866,NCT03028155,Assessment of 3-month overall morbidity and mortality,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Assessment of health related quality of life (HRQOL): SF-36
6867,NCT06081647,The incidence of hypoxia,2023-10-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],The incidence of other adverse events,The incidence of severe hypoxia
6868,NCT04046445,valuate anti-tumor effect of study treatment by measure of Progression-free survival (PFS),2019-07-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Assess shedding and viremia of VSV-GP128,Evaluate anti-tumor effect of study treatment by measure of Relapse Free Survival (RFS)
6869,NCT04058964,Progression free survival (PFS),2020-02-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Overall survival,Incidence of adverse events
6870,NCT00982592,Median Progression-free Survival (PFS),2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Toxicities (grades1 and 2)
6871,NCT01836120,Progression-free survival (PFS),2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
6872,NCT06030895,Safety Outcomes,2022-12-12,COMPLETED,INTERVENTIONAL,['NA'],,
6873,NCT00411112,Survival without recurrence after 3 years,2007-03,UNKNOWN,INTERVENTIONAL,['NA'],,
6874,NCT03482362,Doubling of progression free survival,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Overall response rate of vinorelbine in patients with KRAS mutant, BRAF wildtype, BRAF-like colon cancer vs. KRAS wildtype, BRAF mutant, BRAF-like colon cancer.","Gene alterations/expression profiles (i.e. baseline, relapse) in tumor tissue upon progression"
6875,NCT05158907,Improvement in detection rate of adverse effects of patient reported adverse effect (AE) scale versus the standard CTCAE grading by a physician.,2021-11-23,SUSPENDED,INTERVENTIONAL,['NA'],,Reduction in cost of cancer care using patient reported AE scale.
6876,NCT02443948,Correlation of change in cf-DNA levels with disease status in GIST patients harboring specific DNA mutations,2014-06,UNKNOWN,OBSERVATIONAL,['NA'],,Correlation of the level of cf-DNA related to disease status in GIST patients harboring specific DNA mutations
6877,NCT01238666,Phase II: The number of surgical oblation procedures that present data showing equivalent location of the ablation probe when compared to the US and Pathfinder Guidance System 3D image data.,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,
6878,NCT05368805,PK parameter for dabigatran and rosuvastatin: Cmax:,2022-03-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,PK parameters of fruquintinib and metabolite M11: Cmax:
6879,NCT06281925,Proportion of Participants with Peripheral Neuropathy at Visit 5,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6880,NCT05296681,Tumor Response by RECIST v1.1 Criteria,2022-05-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6881,NCT00323011,,2006-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6882,NCT01291420,Immunogenicity of intradermal DC vaccination,2010-05-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6883,NCT01031056,None: Biospecimen will be collected for future research.,2010-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
6884,NCT02881554,Sulfur colloid (SC) uptake on single photon emission computed tomography/computed tomography (SPECT/CT) imaging,2016-12-21,RECRUITING,INTERVENTIONAL,['NA'],,Changes in sulfur colloid uptake in single photon emission computed tomography/computed tomography imaging
6885,NCT01677559,Dose-limiting toxicities (DLTs),2013-05-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor activity of MLN8237 and nab-paclitaxel combination therapy
6886,NCT00518349,Patient Assessment of Pain Experienced During Colonoscopy,2003-08,COMPLETED,INTERVENTIONAL,['NA'],,
6887,NCT00112697,Progression-free survival rate at 6 months,2003-10-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
6888,NCT06100016,Specificity,2023-10-18,RECRUITING,OBSERVATIONAL,['NA'],,
6889,NCT03189719,PFS Per RECIST 1.1 As Assessed By Investigator in All Participants,2017-07-25,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in the EORTC QLQ-OES18 Subscale Scores in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10)
6890,NCT01941953,Disease Control Rate according to RECIST 1.1,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse Events
6891,NCT02351089,Change in incidence of loose/watery stools,2015-02,TERMINATED,INTERVENTIONAL,['NA'],,
6892,NCT03146234,Safety and tolerance,2017-03-17,COMPLETED,INTERVENTIONAL,['NA'],Anti-tumor responses to CAR-GPC3 T cell infusions,Engraftment
6893,NCT01441453,Cut-off value of liver stiffness measured in kilopascal (kPa) able to predict the occurrence of postoperative liver failure.,na,UNKNOWN,INTERVENTIONAL,['NA'],,
6894,NCT04097028,Number of Patients With a Pathologic Complete Response,2019-12-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Patients With Grade 3 or Higher Treatment Related Adverse Events
6895,NCT02129829,Incidence of HCC or decompensated cirrhosis,2011-10,COMPLETED,OBSERVATIONAL,['NA'],Accuracy of non-invasive fibrosis assessment,Treatment rate
6896,NCT05596370,correlation of genetic mutation burden and prognosis,2022-01-06,RECRUITING,OBSERVATIONAL,['NA'],,correlation of microbiome in stool and prognosis
6897,NCT03807947,Pain and discomfort during and after procedures,2019-01,UNKNOWN,INTERVENTIONAL,['NA'],,Access-related adverse events
6898,NCT02228200,Change in quality of life,2012-06,COMPLETED,INTERVENTIONAL,['NA'],Intervention nurses' experience,Health care utilization
6899,NCT04866290,Overall Survival,2016-09-22,COMPLETED,OBSERVATIONAL,['NA'],,Time to Progression
6900,NCT04659590,Stability of buffer transfer medium,2020-11-06,COMPLETED,OBSERVATIONAL,['NA'],,Comparison between tumour surface imprint and rectal mucous imprint
6901,NCT05647941,Detection of levels of circulating exosomal lncRNA-GC1,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
6902,NCT05179486,Significant factors that may contribute to the etiology of biliary tree cancer,2017-09-25,RECRUITING,OBSERVATIONAL,['NA'],,
6903,NCT05063565,Objective Response Rate (ORR),2023-11-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Whole liver and remnant liver volumes at baseline and follow-up imaging assessments measured using Simplicit90Y software.
6904,NCT06282120,Progression Free Survival,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,EORTC-QLQ (European Organization for Research and Treatment of Cancer - Quality of life Questionnaire) C30 (version 3.0)
6905,NCT04957407,pepsinogen value for precanceous lesion and Gastric cancer,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6906,NCT04272268,Rate of respiratory complications within 30 days after surgery,2019-10-01,RECRUITING,OBSERVATIONAL,['NA'],,Recruitment rate
6907,NCT03990675,Growth rate,2018-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,
6908,NCT04104672,Number of participants with clinically significant changes in vital signs and clinical laboratory parameters,2019-11-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],AB680 gene expression,Overall response rate
6909,NCT05156307,Colorectal cancer,2021-05-20,RECRUITING,OBSERVATIONAL,['NA'],,
6910,NCT04000906,Determine the maximal tolerated dose (MTD) of Nab paclitaxel (Abraxane®) administered IP by PIPAC in concomitance with cisplatin.,2020-11-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,The QoL
6911,NCT05301556,Serum Pre-Albumin,2022-06-24,COMPLETED,INTERVENTIONAL,['NA'],Adverse Events,Nutritional Risk Screening (NRS) 2002
6912,NCT06202417,DCR,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6913,NCT03254498,Adenoma miss rate,2016-04,COMPLETED,INTERVENTIONAL,['NA'],comparison of surveillance intervals,Comfort score
6914,NCT00497107,Disease-free survival,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Overall survival, compliance, adverse events, QOL, tumor markers"
6915,NCT06066138,Feasibility of reducing drug exposure while maintaining plasma drug concentration,2024-04-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,"Minimal frequency (median, range) of atezolizumab dosing to keep the trough concentration at or above 6 microgram/mL"
6916,NCT03924804,1. The change of bladder volume,2019-06-19,COMPLETED,INTERVENTIONAL,['NA'],,
6917,NCT02149914,gastroesophageal reflux disease questionnaire,2014-05,UNKNOWN,INTERVENTIONAL,['NA'],,Upper gastrointestinal endoscopy
6918,NCT05986890,Gastric emptying as per gastric emptying scintigraphy at 7 days post-operatively.,2023-08-17,RECRUITING,INTERVENTIONAL,['NA'],,Improvement of quality of life as measured GIQLI
6919,NCT02618811,Complications,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,Need for opioid analgesia postoperatively
6920,NCT01533090,Evaluation of the overall quality of bowel preparation,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,compliance
6921,NCT06008119,Progression-free Survival (PFS),2023-11-24,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease control rate (DCR)
6922,NCT04510129,PD-L1/PD-1 inhibitor response,2020-02-05,RECRUITING,OBSERVATIONAL,['NA'],,
6923,NCT01690715,Prognosis (disease graduation),2012-07,TERMINATED,OBSERVATIONAL,['NA'],,Relation established between survival and degree of underlying liver dysfunction
6924,NCT05799820,Objective Response Rate (ORR),2022-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
6925,NCT04158908,Potential Improvements to the Oncolo-GIST Manual According to Structured Qualitative Surveys,2020-01-17,COMPLETED,OBSERVATIONAL,['NA'],,
6926,NCT03862768,Progression-free Survival,2019-07,UNKNOWN,INTERVENTIONAL,['NA'],,Overall Survival
6927,NCT00423345,findings compared across investigation modes,2006-10,TERMINATED,OBSERVATIONAL,['NA'],,Delayed diagnosis of CRC
6928,NCT00461929,~ presence or absence of genetic abnormality as seen in CML patients on imatinib,2005-02,TERMINATED,INTERVENTIONAL,['PHASE4'],,
6929,NCT00165048,Symptom-free susrvival and the quality of life score within the two years of study period.,2004-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival in long-term.
6930,NCT01371942,,2010-05,UNKNOWN,OBSERVATIONAL,['NA'],,
6931,NCT05339321,Number of subjects with adverse events (AEs) and laboratory abnormalities defined as dose limiting toxicities (DLT),2021-04-14,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Efficacy: antiviral activity of SCG101
6932,NCT01579721,morbidity,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,oncology
6933,NCT00664482,Treatment-emergent changes in localized injection site reactions following each dose,2007-05,COMPLETED,INTERVENTIONAL,['NA'],,Feasibility
6934,NCT05200299,2-year Disease-free survival,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life assessed by SF-36
6935,NCT00357682,Conversion of Barrett's esophagus to adenocarcinoma of the esophagus or high-grade dysplasia,2005-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,All causes of mortality
6936,NCT00924690,Elaboration using the Elaboration Likelihood Scale,2009-06,COMPLETED,INTERVENTIONAL,['NA'],,Behavioral Intention to Engage in Colorectal Cancer Screening or Physical Activity
6937,NCT05186116,Disease free survival,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Donor quality of life
6938,NCT03473587,Change in colorectal cancer screening rate,2014-11-07,UNKNOWN,INTERVENTIONAL,['NA'],,
6939,NCT02873455,Change of APAIS ((Amsterdam preoperative anxiety and information scale) from baseline APAIS to watching video.,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative hospital stay
6940,NCT01676259,ORR at 6 months,2018-03-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6941,NCT03222076,"Safety and Tolerability of Presurgical Nivolumab With or Without Ipilimumab, Defined as the Number of Participants With of Adverse Events.",2017-09-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
6942,NCT01922492,Changes of insulin secretory function,2008-05,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse effects
6943,NCT05197322,Pathological complete response rate (pCR),2022-07-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Health-related Quality of Life (QoL) and functional outcome
6944,NCT05170802,CT scan finding new lymph nodes,2017-12-20,RECRUITING,OBSERVATIONAL,['NA'],,Data on adverse events and complications related to Irreversible Electroporations.
6945,NCT02483832,CRC screening follow-up rate,2015-02,COMPLETED,INTERVENTIONAL,['NA'],,Changes in attitudes towards CRC and CRC screening as measured by survey
6946,NCT03986502,Caregiver burden,2021-01-22,COMPLETED,INTERVENTIONAL,['NA'],,
6947,NCT00003326,,1997-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6948,NCT06319404,The immune function of tumor draining lymph nodes of colorectal cancer patients was previously identified based on radiomics,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6949,NCT01591109,,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,
6950,NCT05113264,Patient Engagement with the Penny chatbot,2021-08-02,RECRUITING,INTERVENTIONAL,['NA'],,Patient Satisfaction with the Penny chatbot interactions will be measured by the Promoter Score
6951,NCT04370574,Predictive value of each protein contained in Cytolyt® for the positive diagnosis of pancreatic ductal adenocarcinoma,2021-01-14,RECRUITING,OBSERVATIONAL,['NA'],,Identification of prognostically significant biomarkers
6952,NCT01308645,Evaluating Tumor Response Rate,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Determine duration of response rate by measuring time to progression
6953,NCT03770988,Objective Response Rate,2019-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety assessed by incidence of treatment-emergent adverse events
6954,NCT05550701,cancer specific survival,2021-05-05,COMPLETED,OBSERVATIONAL,['NA'],,
6955,NCT03879811,response rate of TMZ followed by nivolumab in participants with MMR-proficient Colorectal Cancer,2019-03-13,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
6956,NCT02614534,Locoregional Control (LC),2015-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life questionnaires QLQ-CR29
6957,NCT05148767,Toxicity effect,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,
6958,NCT01154335,To Determine the Maximum Tolerated Dose (MTD) of the Combination of OSI-906 and Everolimus for the Treatment of Patients With Refractory Metastatic Colorectal Cancer.,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response Rate
6959,NCT02215889,Percent of transplanted patients receiving second stage hepatectomy within 4 weeks of segment 2/3 transplantation.,2014-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
6960,NCT04826432,postoperative digestive leakage,2020-09-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6961,NCT05657210,5-year Overall survival (OS) of KRAS wildtype and each codon-specific KRAS mutation,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence-related factor
6962,NCT01537107,MTD (Cohort I) ) and toxicity profile of combination of vismodegib plus sirolimus every 28 days.,2012-03-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor effect of molecularly targeted agents non-invasively by F18-FDG PET or PET/CT (Cohort II)
6963,NCT03946033,Modification rate of adjuvant therapeutic strategy,2019-05,WITHDRAWN,INTERVENTIONAL,['NA'],,
6964,NCT00478309,Factors that moderate the impact of GERA feedback on CRC screening utilization,2007-03,COMPLETED,INTERVENTIONAL,['NA'],,
6965,NCT06114420,Cancer-specific survival,2023-01-30,RECRUITING,OBSERVATIONAL,['NA'],,Find a differentially expressed gene
6966,NCT06048926,PFS evaluated by IRC,2022-07-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Progression-free survival evaluated by Researchers
6967,NCT05891301,gastrointestinal dysfunction,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Patient Mobility in the hospital
6968,NCT06316882,number of gastric adenocarcinoma,2023-02-03,RECRUITING,INTERVENTIONAL,['NA'],,Socio-demographic characteristics of population in screening program
6969,NCT04418843,Complete resection of the lesion,2020-06-08,COMPLETED,INTERVENTIONAL,['NA'],,Sub-analysis by center participating in the study
6970,NCT02813824,Number of patients with at least one adenoma seen on chromo-endoscopy 48 months after complete withdrawal of polyps and initiation of treatment (aspirin or placebo),2017-11-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,Load serrated polyps after 24 and 48 months of treatment
6971,NCT02745847,The toxicities following SBRT will be determined.,2016-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,The quality of life will be analyzed.
6972,NCT03614650,percentage of adverse effects after EIE cell injection,2018-07-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The anti-cancer effects
6973,NCT04291755,Checkpoint inhibitor response,2019-06-28,UNKNOWN,OBSERVATIONAL,['NA'],,
6974,NCT05468177,Objective response rate (ORR),2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
6975,NCT06184867,Number of Participants with Genetic Testing Uptake,2023-10-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Acceptance and Usability of the Relational Agent
6976,NCT02330497,Safety of the pancreatic radiofrequency ablation under EUS guidance,2015-02,COMPLETED,INTERVENTIONAL,['NA'],,Safety of the pancreatic radiofrequency ablation under EUS guidance
6977,NCT04618809,"Percentage of treatment plan changes. (Count # of treatment changes 2-3 months after comprehensive geriatric assessment. Site coordinators will complete follow-up chart review of each patient to see what, if any, changes were made)",2020-09-22,RECRUITING,INTERVENTIONAL,['NA'],,Fitbit assessed functional status. Fitbit data: heart rate
6978,NCT04982653,Radiographic incidence rate of incisional hernia,2022-01-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events (AEs)
6979,NCT03288987,Progression Free Survival (PFS),2016-10-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Positive Anti-drug Antibody (ADA) Samples Among Patients (Immunogenicity)
6980,NCT00336648,Number of Patients with Resection,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6981,NCT05348668,Progression-free Survival,2022-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6982,NCT06311279,Anastomotic leak amount,2024-03-05,RECRUITING,INTERVENTIONAL,['NA'],,
6983,NCT04560894,Progression-free survival(PFS)evaluated by the Blinded Independent Central Review Committee (BICR) based on RECIST V1.1,2020-11-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Anti-drug antibody (ADA)
6984,NCT02716207,The maximum tolerated dose will be determined,2016-03,COMPLETED,INTERVENTIONAL,['NA'],,Pain intensity will be determined.
6985,NCT02289378,Progression-free survival,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Response rate
6986,NCT04169347,Efficacy/objective response rate,2019-12-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Evaluating for the velocity of tumor response to this regimen
6987,NCT01496521,occurrence of high grade dysplasia and invasive ESCC,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,occurrence of high grade dysplasia and invasive ESCC
6988,NCT06275958,Progression-Free Survival,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Cost-effectiveness
6989,NCT00002793,,1991-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
6990,NCT05244798,"Pathology complete response rate, pCR",2022-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,"Circulating tumor DNA, ctDNA"
6991,NCT00069095,PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of Complete Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
6992,NCT05195970,Correlation of colonic lesion gene expression with urolithin production,2022-01-24,RECRUITING,INTERVENTIONAL,['NA'],,Correlation of dietary behavior with urolithin production
6993,NCT05056896,Change of ISC marker gene expression,2022-06-03,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Change in Microbiome
6994,NCT03813641,Progression-free Survival (PFS) Time,2019-01-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Percentage of Participants Achieving a Stable Disease (SD) or a confirmed CR or PR (Disease Control Rate)
6995,NCT03681951,Percentage of Participants Achieving Complete Response or Partial Response Based on RECIST 1.1 Criteria-Part 4,2018-11-16,TERMINATED,INTERVENTIONAL,['PHASE2'],,Time Invariance Following Repeat Dose of Pembrolizumab-Part 3
6996,NCT01547260,Immunomodulatory effect (phase II).,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical efficacy
6997,NCT03531125,Comparison of whole transcriptome RNA sequencing of EUS derived pre-operative sample and whole transcriptome RNA sequencing of biopsies either taken from the pancreatic cancer during resection or repeat biopsy using EUS,2018-07-02,TERMINATED,OBSERVATIONAL,['NA'],,"Percentage and number of patients that undergo EUS and follow up EUS or surgery that have a) histopathological evidence of adenocarcinoma in their biopsy and surgical samples, and b) of suitable RNA quality for analysis"
6998,NCT00963612,To assess the ability of BOLD MRI to predict microvascular invasion in hepatocellular carcinoma via assessment of intratumoral oxygenation.,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,To identify a quantitative threshold tumor R2* value using BOLD MRI technique reasonably sensitive of predicting microvascular invasion in HCC pre-operatively.
6999,NCT02234986,Overall Response Rate,2015-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Frequency and severity of adverse events,Progression Free Survival (PFS6) rate
7000,NCT03300609,Progression free survival 1,2018-02-27,TERMINATED,INTERVENTIONAL,['PHASE3'],,Treatment Response
7001,NCT04244552,"Incidence of DLTs (dose escalation cohorts only), treatment emergent adverse events (TEAEs), and changes in safety parameters",2020-02-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,For the PLD Combination Therapy Cohort: ATRC-101 immunoreactivity in tumor biopsies at baseline and during treatment
7002,NCT01167816,Toxicity,2010-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,Determine the effect of azacitidine therapy on DNA methylation in peripheral blood cells
7003,NCT01998009,The proportion of participants with a positive colonoscopy finding indicating an advanced colorectal neoplasia who also have a positive fecal occult blood test result,2011-05,COMPLETED,INTERVENTIONAL,['NA'],,The proportion of participants with a negative colonoscopy finding who also have a negative fecal occult blood test result
7004,NCT04880044,Proportion of participants negative via EC/EG who subsequently are proven negative via EGD,2022-01-05,RECRUITING,INTERVENTIONAL,['NA'],,
7005,NCT03349762,Distant Metastasis-Free Survival rate,2018-11-02,RECRUITING,OBSERVATIONAL,['NA'],,Immunity function
7006,NCT05908643,"Safety of pTTL administration, as determined by assessment of incidence and severity of adverse events (AE). Immunological AEs and AEs known to be associated with T cell therapies will be classified as AEs of special interest (AESI).",2023-03-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Evaluation of the importance of neoantigen selection to clinical outcome.,Disease-specific survival
7007,NCT01229839,overall survival,2013-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to progression
7008,NCT03430843,Overall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set,2018-01-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Experiencing Adverse Events (AEs)
7009,NCT03207594,Number of patient who self-report smoking cessation,2016-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Compliance with smoking cessation
7010,NCT00986518,"Tumor size of hepatic and/or lung metastases, as measured with tomodensitometry (RECIST 1.1 criteria)",2012-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Laboratory test: hepatic function, immune function, haematology"
7011,NCT01315795,Reduction of total liver volume after 18 months of treatment by means of CT-scan,2011-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Assessment of quality of life after 18 months of treatment
7012,NCT04560751,Objective response rate（ORR）,2020-09-30,UNKNOWN,OBSERVATIONAL,['NA'],,Adverse events(AEs)
7013,NCT01861691,Early complication rate,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Health-related QOL score
7014,NCT02976896,Disease control rate,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life using esophageal special scale QLQ - OES18
7015,NCT02669992,Number of participants with postoperative stoma site hernia,2015-06,RECRUITING,INTERVENTIONAL,['NA'],,Postoperative Hospital stay
7016,NCT01433861,Rate of reflux esophagitis,2012-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,
7017,NCT04437212,Major Pathological Response Rate (MPR),2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Perioperative complication rate
7018,NCT05883683,Identification of effective drugs or drug combinations,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Correlation between organoid and PDX drug sensitivities
7019,NCT00234182,Occurrence of recurrent disease,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Death of the patient
7020,NCT03695952,Objective response rate,2018-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Adverse events
7021,NCT01262560,Change in Radiation Esophagitis-related Pain at 4 Weeks as Measured by the Numerical Rating Pain Scale for Pain on Swallowing (NRPS),2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patient Reported Difficulty in Swallowing Associated With Manuka Honey Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
7022,NCT01163812,Compliance of lymph node dissection,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,distance to resection margin and number of harvested lymph nodes
7023,NCT05068635,Number of patients who developped morbidity after subgastrectmy for gastric cancer,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7024,NCT01239056,Technical Success of Endoscopic Ultrasound-guided Single-access Pseudocyst Drainage With a Fully Covered Self-expanding Metal Stent ; Anchored With a Double Pigtail Plastic Stent Inserted Through the Metal Stent Lumen,2009-08,COMPLETED,OBSERVATIONAL,['NA'],,Adverse Events
7025,NCT05623150,Primary outcome measure CHALNA2,2022-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,7th outcome measure CHALNA2
7026,NCT02155088,Maximum Tolerated Dose (MTD),2014-10-30,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS)
7027,NCT00008281,,2000-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7028,NCT04371198,Number of Participants With Biopsies That Form Spherical Organoids,2020-09-18,COMPLETED,INTERVENTIONAL,['NA'],,
7029,NCT01072981,The primary objective is to assess overall survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,The secondary objective is to assess disease free survival and to conduct correlative scientific studies of subject samples to determine the mechanism of any observed anti-tumor effect.
7030,NCT04258111,ORR,2020-08-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events (AE)
7031,NCT03152370,Number of participants with any non-serious adverse event (AE),2017-05-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Mean peak-trough fluctuation (PTF) of E7046 and its metabolite ER-888188 in plasma
7032,NCT05742750,Objective Response Rate (ORR),2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
7033,NCT00923520,Determine the Maximum Tolerated Dose,2009-03-25,COMPLETED,INTERVENTIONAL,['PHASE1'],,Anti-tumor Effects
7034,NCT01666730,Median Overall Survival (OS),2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Grade 3 and 4 Toxicities According to NCI CTCAE Version 4.0
7035,NCT02689401,Assess the safety of intravenous ferumoxytol for the use in esophageal cancer patients,2016-05,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Determine the accuracy of MRI-ferumoxytol for the identification of positive metastatic nodes in patients with esophageal cancer
7036,NCT05007912,Anastomosis complication,2021-06-21,UNKNOWN,OBSERVATIONAL,['NA'],,
7037,NCT05756699,HCC detection rate,2023-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Positive predictive value
7038,NCT06014372,Rate of pCR,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],OS,DFS
7039,NCT02582034,"The primary endpoint is to compare the response rate of the treated lesion at the first radioembolization, evaluated using European Association for the Study of the Liver (EASL) criteria of yttrium-90 marked glass microspheres SIRT",2015-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Post-therapeutic dosimetry measured by Positron emission tomography-computed tomography PET / CT
7040,NCT05201404,Overall Survival (OS),2023-03-15,RECRUITING,INTERVENTIONAL,['PHASE3'],"Quality of Life (QOL), using the hepatocellular carcinoma- (HCC-) specific module of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Hepatocellular Carcinoma 18-question Module (EORTC QLQ-HCC18)",Pharmacokinetics (PK) of namodenoson in this population
7041,NCT02078804,Mortality from colorectal cancer in the Swedish population.,2014-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,To study the flora of fecal bacteria among participants and outcome of FIT and colonoscopy.
7042,NCT03683446,Postoperative Complications,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7043,NCT04156087,Progression-free survival (PFS),2020-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
7044,NCT04352023,Comparison of analgesic efficacy after major surgery in pancreatobiliary cancers: Intravenous patient-controlled analgesia versus patient-controlled epidural analgesia,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Investigation and comparison of pain and clinical progress during rest after surgery, side effects of drugs administered to IV-PCA and PCEA, and complications related to PCEA procedure"
7045,NCT00006015,Overall toxicity,2000-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7046,NCT02822352,To compare the rates of neoplasia detection using virtual chromoendoscopy compared to high definition white light (HDWL) endoscopy,2016-08,COMPLETED,INTERVENTIONAL,['NA'],,To compare the duration of time taken using each technique
7047,NCT04159363,Caregivers' quality of life,2020-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Caregivers' anxiety and depression
7048,NCT02347956,morbidity,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,mortality
7049,NCT04968145,30-day re-admission,2017-07-19,COMPLETED,INTERVENTIONAL,['NA'],,Patient reported outcomes
7050,NCT03890731,Severity (by Worst Grade) of Participants With Drug-related Adverse Events (AEs) and Serious AEs (SAEs),2019-04-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Dose Modifications
7051,NCT04680598,HBV Reactivation rate,2020-12-25,RECRUITING,OBSERVATIONAL,['NA'],,adverse event
7052,NCT02364024,Time to Recurrence (TTR),2005-11,COMPLETED,OBSERVATIONAL,['NA'],,Disease-Free Survival (DFS)
7053,NCT00559455,"Tumor Response Rate evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) by physical examination, chest X-ray, abdomen-pelvis CT (Computed tomography) scan",2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Time to Progression (TTP), 6 month survival, overall survival, AFP"
7054,NCT01664169,Number and percentage of responder,2012-08,COMPLETED,OBSERVATIONAL,['NA'],,
7055,NCT02718729,Incidence of anastomotic leakage,2015-06-01,COMPLETED,INTERVENTIONAL,['NA'],,30 days postoperative morbidity and mortality
7056,NCT02728167,Normalized blood loss (ml/cm2),2016-04,TERMINATED,INTERVENTIONAL,['NA'],,Number of patients with postoperative complications assessed using Dindo-Clavien classification
7057,NCT05679960,Accuracy of Urine PolypDx device in detecting colorectal cancer,2022-08-15,RECRUITING,INTERVENTIONAL,['NA'],,Negative Predictive Value Urine PolypDx device in detecting colorectal cancer (CRC)
7058,NCT01308190,Local recurrence,2010-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7059,NCT01045200,Patient satisfaction,2002-01,COMPLETED,OBSERVATIONAL,['NA'],,Resource utilisation
7060,NCT03330561,Incidence and severity of AEs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03,2017-09-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Biomarkers (CD137, soluable HER2, cell surface antigens for immunotyping) in tumor tissues and blood samples"
7061,NCT01791361,The prevalence of KRAS testing and impact of the KRAS test results on patterns of Vectibix use in patients with metastatic colorectal cancer (mCRC) treated with Vectibix,2012-09-19,COMPLETED,OBSERVATIONAL,['NA'],,"To characterize the results of KRAS testing in the three rounds of chart abstraction that will be carried out at 0, 12 and 24 months to indicate if there are any differences in results from each of the three rounds"
7062,NCT03937362,Accuracy of clinical response evaluations for detecting substantial residual locoregional disease,2019-08-08,UNKNOWN,OBSERVATIONAL,['NA'],,Accuracy of clinical response evaluations for detecting any residual locoregional disease
7063,NCT06205472,The 3-year Overall Survival,2024-01-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Local Control Rate
7064,NCT05238584,3y Disease Free Surveillance,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],Duration of the hospital stay,Postoperative immunological changes (Interleukin monitoring)
7065,NCT03952442,Quality of Life (QOL),2019-02-21,UNKNOWN,INTERVENTIONAL,['NA'],,Knowledge-Attitude-Practice
7066,NCT00150670,Overall survival,2002-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Overall response rate, lesion-directed response rate, time to treatment failure (TTF), hospitalization-free survival period within the periods of TTF, and safety profile"
7067,NCT05192044,Feasibility of enhanced recovery after pancreatico-dudenectomy,2021-12-25,UNKNOWN,INTERVENTIONAL,['NA'],,
7068,NCT01042041,"Dose adjustment, number and percentage of subjects with adverse events, laboratory changes, number and percentage of subjects with laboratory values that are outside the pre-determined ranges, cumulative toxicity, and TLT.",2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to Disease Progression
7069,NCT02785887,Relative dose intensity,2014-08-01,COMPLETED,INTERVENTIONAL,['NA'],Optional Translational Substudy: Blood metabolites,Early mortality
7070,NCT02017678,Radiographic response of ovarian peritoneal carcinomatosis to JX-594 treatment,2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Time to progressive disease
7071,NCT03298204,Overall survival,2017-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Distant metastasis free survival
7072,NCT03688906,"Diagnosis of colorectal cancer or advanced adenomas in patients undergoing routine screening colonoscopy, or post-colonoscopy",2018-01-12,COMPLETED,OBSERVATIONAL,['NA'],,
7073,NCT02821533,Tumor response,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,overall survival
7074,NCT03492671,Curative Intent Resection (R0) rate,2019-07-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival Rate
7075,NCT03732781,Explore efficacy (expansion cohort),2020-05-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7076,NCT01492049,Colorectal cancer screening (CRCS) Rate of Participants,2012-08-07,COMPLETED,INTERVENTIONAL,['NA'],,
7077,NCT04948398,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
7078,NCT00464919,To determine the progression- free survival of sorafenib plus tegafur/uracil (UFUR®) for the treatment of advanced or metastatic HCC.,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the changes of circulating biomarkers indicating the angiogenesis activity and their correlation with objective tumor response.
7079,NCT03847428,Recurrence-free survival (RFS) for Arm A vs Arm C,2019-04-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time from randomization to recurrence/progression on next therapy (RFS2/PFS2) for Arm A vs Arm C and Arm B vs Arm C
7080,NCT02252913,safety and tolerability,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,PK parameters
7081,NCT01086267,Toxicity will be evaluated according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 3,2010-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetics (PK) for BMS-908662 as determined by accumulation index [AI].
7082,NCT02088775,Local control,2014-02,COMPLETED,INTERVENTIONAL,['NA'],,Change in dose measured by PET-CT scan
7083,NCT05116696,All-cause mortality,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Hospital adverse event
7084,NCT06099314,Overall survival 2(OS2),2023-10,RECRUITING,OBSERVATIONAL,['NA'],,"Disease control rate 2 (DCR2, investigators based on RECIST1.1)"
7085,NCT01310062,,2010-08,UNKNOWN,OBSERVATIONAL,['NA'],,
7086,NCT01660971,"Maximum tolerated dose of gemcitabine hydrochloride and dasatinib given together with erlotinib hydrochloride, determined by incidence of dose-limiting toxicity graded according to NCI CTCAE v 4.0",2012-07-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,"Serious and other significant adverse events (AEs), graded according to NCI CTCAE v 4.0"
7087,NCT06197425,The time to recurrence (TTR),2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,
7088,NCT01693445,maximum tolerated dose,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,disease control rate
7089,NCT03413514,The cycle of neoadjuvant chemotherapy,2018-01-03,UNKNOWN,INTERVENTIONAL,['NA'],,The involvement of patients during the shared decision making
7090,NCT05632744,Safety of the CG-100 Intraluminal Bypass Device,2023-03-15,RECRUITING,INTERVENTIONAL,['NA'],,Safety of the CG-100 Intraluminal Bypass Device
7091,NCT06237582,Evaluate the incidence of IELN invasion by ovarian cancer,2022-06-16,COMPLETED,INTERVENTIONAL,['NA'],,"In cases of IELN positivity, review thoroughly preoperative scans and MRIs in order to detect radiological features, usually overlooked, that could help identify the positivity of these LNs prior to pathological analysis."
7092,NCT05592626,Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR),2023-01-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 1 and 2 (Dose Escalation and Expansion): Anti-drug Antibody (ADA) formation
7093,NCT05219539,Change of general surgical skills score,2021-11-11,COMPLETED,OBSERVATIONAL,['NA'],,Changes of clinical research possibilities score
7094,NCT04090060,Number of persons who practice the companion examination,2020-01-17,COMPLETED,INTERVENTIONAL,['NA'],,Concordance between self-examination and clinician examination stratified by waist circumference.
7095,NCT05370001,Carbon dioxide level from an arterial line (PaCO2) after 15 minutes of HFJV.,2022-06-13,COMPLETED,INTERVENTIONAL,['NA'],,Injury of the airway following endotracheal intubation.
7096,NCT05131919,"To assess the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancers by objective response rate (ORR)",2022-12-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,To assess the date of relapse
7097,NCT01343212,,2011-03,UNKNOWN,OBSERVATIONAL,['NA'],,
7098,NCT05773144,Chemotherapy Relative Dose Intensity,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,
7099,NCT06293898,To determine the maximum tolerated dose (MTD) if reached or maximum administered dose (MAD) and two or more recommended doses for dose expansion (RDEs) of BL-M07D1,2024-02-09,RECRUITING,INTERVENTIONAL,['PHASE1'],,
7100,NCT05778851,The impact of EsoCheck/EsoGuard on health care provider's decision for upper endoscopy referral,2023-04-12,RECRUITING,INTERVENTIONAL,['NA'],,The impact of EsoCheck/EsoGuard on health care provider's patient risk assessment for BE
7101,NCT00002625,,1995-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7102,NCT01938716,To Quantifiably Assess Intratumoral Gemcitabine Levels in Human Pancreatic Cancer Tissue After a Single Intraoperative Infusion in Patients.,2012-03,TERMINATED,INTERVENTIONAL,['NA'],,To Correlate Intratumoral Gemcitabine Levels and Its Tumoricidal Activity With Ki67 Index and Intratumoral Apoptosis.
7103,NCT05142709,OS from start of 1st line treatment in metastatic ESCC,2021-10-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,the role of radiotherapy for patients treated with 1st immunotherapy.
7104,NCT00659022,Difference in response of liver metastases between control group and experimental groups determined by FDG-PET,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Complications of surgery
7105,NCT04511039,Maximum tolerated dose/ recommended phase II dose,2021-06-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of subjects with DNA damage response
7106,NCT02893540,PFS1,2016-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,QOL
7107,NCT00471484,Objective tumor response rate as measured by RECIST criteria,2007-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Tissue VEGF expression
7108,NCT04999007,The morbidity of anastomotic leakage.,2021-09-02,RECRUITING,INTERVENTIONAL,['NA'],,
7109,NCT04473794,Clinical utility of Compcyst in pancreatic cysts as assessed by patient chart review,2022-07-20,RECRUITING,OBSERVATIONAL,['NA'],,
7110,NCT04851054,VEGF in serum on postop day 4,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
7111,NCT03336658,correlation of ITB based calculated N stage with real N stage in CRC - patients,2015-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,correlation of ITB based calculated DFS with real DFS in CRC - patients
7112,NCT04958720,Diagnostic and therapeutic approach,2020-04-27,RECRUITING,OBSERVATIONAL,['NA'],,Create and validate a predictive model
7113,NCT02596113,Genes' mutations rate in patients who are submitted screening colonoscopy and they presented with cancerous lesion,2015-07,COMPLETED,OBSERVATIONAL,['NA'],,
7114,NCT01516944,Disease-free survival(DFS),2012-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,R0-resection rate
7115,NCT01370928,Patients´ evaluation of pain and discomfort,2011-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Caecum intubation rate
7116,NCT04259762,Completion of a Pap Smear test to screen for cervical cancer,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Change in Self-Efficacy measured using the Health Behavior Survey
7117,NCT01450046,Number of Participants With Treatment Related Adverse Events,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacodynamic (PD) Markers of Vitamin E δ-Tocotrienol Activity in Peripheral Blood
7118,NCT05224882,The assessment of the prevalence of oral adverse events induced by chemotherapy in pediatric cancer patients .,2023-08-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Assessment of dental awareness among parents of pediatric cancer patients .
7119,NCT01051167,Response rate (RECIST-Criteria),2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Secondary objectives: Safety, Quality of life"
7120,NCT01921751,Overall Survival,2013-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Correlation Between SMAD4 Status Determined by Immunohistochemistry (IHC) and Genetic SMAD4 Status
7121,NCT01516710,Perioperative morbidity,2012-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of incisional hernia
7122,NCT00265876,Response (complete [CR] and partial response [PR] or stable disease [SD]) at 8 weeks,2006-04-26,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity
7123,NCT04555135,Average Number of Adenomas Per Extraction,2020-09-28,TERMINATED,INTERVENTIONAL,['NA'],,Procedure Time
7124,NCT00460837,Patient experience and compliance with reduced laxative tagging versus standard preparation,2007-11,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Comparison of per polyp specificity between the two preparation regimens
7125,NCT00005858,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7126,NCT01897610,To assess progression-free survival (PFS),2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events
7127,NCT02623621,Progression Free Survival,2015-11,COMPLETED,OBSERVATIONAL,['NA'],,
7128,NCT02786329,Incidence of recurrences:,2016-06,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Rate of local anaesthetics systemic toxicity incidence,Rate of postoperative complications after TIVA versus inhalation anaesthesia
7129,NCT02032953,Net protein balance,2013-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,
7130,NCT03917173,Disease free survival,2020-06-01,RECRUITING,INTERVENTIONAL,['NA'],,patients performing the adjuvant chemotherapy.
7131,NCT06031779,serum bile acid profile before treatment,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,concentration of serum tumor markers before treatment
7132,NCT00116389,6 month survival,na,TERMINATED,INTERVENTIONAL,['PHASE2'],,performance status
7133,NCT00002722,,1996-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7134,NCT04917276,Specificity,2021-06-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
7135,NCT05911152,3-year overall survival,2016-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative pain score
7136,NCT00943449,Progression Free Survival Rate (PFSR) of repeated oral doses of 4SC-201 and of the treatment combination of Sorafenib plus 4SC-201,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,To investigate biomarkers
7137,NCT06037980,median PFS,2023-11-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Perioperative morbidity and mortality
7138,NCT04616534,Overall survival (expansion cohort),2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],"Pharmacodynamic (biological endpoints, toxicity and efficacy) parameters",Increase in deoxyribonucleic acid (DNA) damage level (expansion cohort)
7139,NCT00290966,to detect a significant increase in time to progression in favor of docetaxel plus cisplatin and 5-FU compared to cisplatin plus 5-FU. Tumor assessments (assessed with WHO criteria) had to be performed every 8 weeks until progression,1998-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Patients were to be followed until death (overall survival). Clinical and laboratory were assessed with NCIC-CTG scale, before each cycle. Quality of life and clinical benefit were assessed every 2 weeks until progression and then every 3 months."
7140,NCT00162526,To evaluate the tolerability and the safety of a Tocopherol formulation in the prevention or suppression of the serverity of oral mucositis induced by myeloablative agonist.,2005-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To evaluate the toxicity and the safety of a Tocopherol formulation in the prevention or suppression of the serverity of oral mucositis induced by myeloablative agonist.
7141,NCT06321081,progression free survival,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overal survival
7142,NCT01245582,Overall Survival (OS),2011-07,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Response Rate (RR)
7143,NCT04548440,R0 resection rate of patients who underwent surgery following preoperative treatment,2020-08-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of patients with adverse events and severity according to NCI CTCAE v5.0
7144,NCT04028479,Progression-free survival (PFS) - 5th line of therapy,2021-05-05,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival (OS)
7145,NCT00084942,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7146,NCT00303888,Safety,2006-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,
7147,NCT06256315,30-day overall complication rate,2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],,The rehospitalization rate within 30 days after surgery
7148,NCT03610490,Objective response rate (ORR),2018-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Health-related quality of life,Incidence of adverse events
7149,NCT01524783,Probability of Participants Remaining Event-Free in Progression-Free Survival (PFS) Based on Central Radiology Assessment,2012-03-30,COMPLETED,INTERVENTIONAL,['PHASE3'],,Pharmacokinetics (PK): Predose Concentration (Cmin) of Everolimus at Day 29
7150,NCT01403103,Comparison of the expression of 15-PGDH mRNA and protein levels in normal colorectal mucosa,2012-04,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,"Number of patients with grade 3 related toxicities of a single 100,000 IU dose of 25-OH-vitamin D3"
7151,NCT00263354,To evaluate the progression-free survival in the ITT population,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,To investigate safety using NCI-CTC criteria version 2
7152,NCT00385515,Duration of Ulcerative Oral Mucositis,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Ulcerative Oral Mucositis
7153,NCT02754856,Incidence of adverse events,2016-07-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7154,NCT00003085,,1996-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7155,NCT05304741,Overall Survival,2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Diagnostic Indicators
7156,NCT01405183,Prevalence of hepatitis C in renal cell carcinoma patients,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
7157,NCT03681600,3-year disease free survival,2018-01-01,TERMINATED,OBSERVATIONAL,['NA'],,"Availability/performance of CT chest, abdomen and pelvis scan performed for pre-operative staging"
7158,NCT05397171,All Substudies: Incidence of AEs leading to discontinuation of AZD8853,2022-06-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Substudy 1 - Part B: Change in CD8 tumor infiltration in paired biopsies
7159,NCT04774679,Correlation of a macroscopically visible fragments in the 22g EUS-FNA needle specimens with final histologic diagnosis,2021-02-06,UNKNOWN,INTERVENTIONAL,['NA'],,Area Under the size of the macroscopically visible core size versus histologic core size
7160,NCT02314819,overall survival,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Safety and tolerance evaluated by incidence, severity and outcomes of AEs"
7161,NCT01015820,Mean Blood Vessel Radius (BVR),2010-06,COMPLETED,INTERVENTIONAL,['NA'],,
7162,NCT03724435,Survival,2019-12-06,TERMINATED,OBSERVATIONAL,['NA'],Impact on Quality of Life and Cost,
7163,NCT00854854,Determine response rate,2009-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Determine safety of combination,time to treatment failure, overall survival time"
7164,NCT02465593,anti-tumor activity,2015-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7165,NCT02201797,repeatability coefficient (RC),2014-10,COMPLETED,INTERVENTIONAL,['NA'],,
7166,NCT05201872,The positive rate of bacterial contamination of peritoneal washings,2022-01-15,UNKNOWN,OBSERVATIONAL,['NA'],,Postoperative complications
7167,NCT01812876,Number of participants with adverse events; incidence of Shenqifuzheng'ADRs and identify factors that contributed to the occurrence of the adverse reaction,2012-12,UNKNOWN,OBSERVATIONAL,['NA'],,
7168,NCT04795180,Length of hospital stay (number of days),2013-12-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Anorectal functional outcome assessed by Colorectal Functional Outcome Questionnaire (COREFO) questionnaire
7169,NCT01156831,Locoregional control,2007-11,COMPLETED,OBSERVATIONAL,['NA'],,Tumor regression grade
7170,NCT00422773,"To assess a maximal tolerable dose and the safety of a chemotherapy-combination of cetuximab, irinotecan, oxaliplatin and 5-FU/folinic acid as first-line treatment for metastatic colorectal cancer",2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To assess the treatment regarding the following: feasibility, toxicity, response rate, resection rate, progression free and overall survival"
7171,NCT01659346,First Variceal Bleeding,2016-02,WITHDRAWN,INTERVENTIONAL,['NA'],,Reappearance of Esophageal varices in presence of Portal Vein Thrombosis
7172,NCT03427268,Progression-free Survival Rate at Three Months,2018-01-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Response Rate (ORR)
7173,NCT02879721,"Change in expression of proteins associated with inflammation, proliferation and cancer development",2009-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Change in regulation of potential new biomarkers associated with esophageal cancer
7174,NCT04601610,ORR,2021-06-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,OS
7175,NCT00004127,Clinical response rate,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7176,NCT01498757,Biomarkers predictive,2012-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
7177,NCT05648084,Artificial intelligence's sensitivity and accuracy to predict the stage of the cancer,2022-12-15,RECRUITING,OBSERVATIONAL,['NA'],,"to evaluate the post-treatment mortality, morbidity rates and complication rates of the patients"
7178,NCT00350753,Time to progression,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biomarkers
7179,NCT02308345,Length of visit (minutes),2014-12,COMPLETED,INTERVENTIONAL,['NA'],,Participant-rated usefulness of video summary
7180,NCT02638051,Objective Response Rate (ORR),2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL)
7181,NCT00250835,Pathologic Complete Response (PCR),2005-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Pelvic Local Control Rate
7182,NCT06134011,The differences of the metabolism information,2023-09-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
7183,NCT01538550,colorectal cancer mortality,2012-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Pain reduction during Colonoscopy,Psychological effects of screening
7184,NCT00387530,Evidence of Epstein-Barr virus (EBV) lytic phase activation (expression of EBV antigens BZLF1 and LMP2) as assessed by biopsy on day 3 of course 1,2006-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Tumor response in patients with measurable disease as assessed by RECIST criteria
7185,NCT03771456,Anastomotic Leakage rate,2019-01-07,UNKNOWN,OBSERVATIONAL,['NA'],,Length of postoperative hospital stay
7186,NCT00031616,,2001-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7187,NCT02246725,"Quality of Life, such as pain, anxiety.",2014-10,UNKNOWN,OBSERVATIONAL,['NA'],Numbers of chemotherapy cycles,Survival
7188,NCT04784520,progression-free survival,2021-06-22,TERMINATED,INTERVENTIONAL,['PHASE2'],HA121-28 plasma concentration,duration of response
7189,NCT05625932,Incidence of any VTE,2023-03-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of bleeding events according to genetic risk
7190,NCT06086457,Overall survival (OS),2024-02-04,RECRUITING,INTERVENTIONAL,['PHASE3'],Biomarkers for the predicting of efficacy,QUALITY OF LIFE: Change From Baseline in the EORTC QLQ-OES18 Subscale Score in Participants
7191,NCT05529667,PFS,2019-05-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
7192,NCT01913223,Safety outcome,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Effectiveness of the procedure in terms of complete neoplasia resections
7193,NCT03042442,Rate of patients with loss of > 5% body weight,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,"Assessing the survival rate by phone-calls follow-up every 6 months, up to 2 years"
7194,NCT00128596,Safety and tolerability,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7195,NCT00604721,Number of Participants With Radiographic Objective Response (OR),2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival (OS)
7196,NCT02124317,Objective response rate,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety and tolerability
7197,NCT01180088,OVERALL BLOOD LOSS,2010-08,UNKNOWN,INTERVENTIONAL,['NA'],,BLOOD TRANSFUSION RATE
7198,NCT02338518,3 year progression free survival,2015-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Sensitivity analysis of primary outcome adjusted for stratification factors,Adverse events of preoperative chemotherapy
7199,NCT05763927,pCR following neoadjuvant chemotherapy,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,1 year OS(overall survival) rate
7200,NCT02069145,Safety and tolerability of OMP-54F28 in combination with sorafenib in patients with hepatocellular cancer,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (PK) of OMP-54F28 and sorafenib when administered in combination to patients with hepatocellular cancer
7201,NCT00680901,Overall Survival in All Randomized Participants,2008-06-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants With a Worst-case on Therapy Grade 3 or Grade 4 for the Indicated Hematology Parameters
7202,NCT01745874,Evaluate the diagnostic accuracy of whole-body MRI for the staging of rectal cancer before and after neoadjuvant treatment,2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,Tumoral regression after neoadjuvant treatment
7203,NCT01232829,Survival Rate,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Disease Progression
7204,NCT00103311,Objective Response (CR or PR) as Determined by the RECIST Criteria,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
7205,NCT04973631,histologic type,2003-05,COMPLETED,OBSERVATIONAL,['NA'],,
7206,NCT03853733,Genitourinary toxicity after the end of radiotherapy,2016-10-01,COMPLETED,OBSERVATIONAL,['NA'],,palliative colostomy after the end of palliative radiotherapy
7207,NCT02853474,Overall survival (as intent-to treat analysis),2016-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of patients treated with chemotherapy
7208,NCT00533884,Delirium and delirium symptoms by the NEECHAM Confusion Scale and Confusion Assessment Method (CAM),2007-10,COMPLETED,OBSERVATIONAL,['NA'],,"Falls, injuries, and other complications"
7209,NCT00322712,Time to Death,2006-09,TERMINATED,OBSERVATIONAL,['NA'],,
7210,NCT04224415,Objective Response Rate,2020-01-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events(AE) and severe adverse events(SAE)
7211,NCT04299880,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],2020-02-24,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7212,NCT05229783,Rate of both high grade dysplasia and esophageal adenocarcinoma lesions detected by electronic chromoendoscopy versus rate of such lesions detected by white light endoscopy plus systemic biopsies according to Seattle protocol.,2022-05-11,RECRUITING,INTERVENTIONAL,['NA'],,Cost effectiveness of the detection of both early esophageal adenocarcinoma and high grade dysplasia with electronic chromoendoscopy versus cost effectiveness of Seattle protocol.
7213,NCT06308510,Sensitivity mFast-SeqS,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Concordance detection rates peritoneal dissemination
7214,NCT00949949,"MTD of the combination of everolimus, gemcitabine hydrochloride, and cisplatin",2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Timed endpoints
7215,NCT06298123,Recurrence-Free Survival (RFS),2019-02-01,COMPLETED,OBSERVATIONAL,['NA'],"Imaging data (enhanced CT and MRI） and histopathology data, if available.",Overall Survival (OS)
7216,NCT01963949,Biopsy of Liver Masses,2013-10,WITHDRAWN,OBSERVATIONAL,['NA'],,
7217,NCT05016245,Safety assessed within 60 days post treatment using NCI-CTCAE v5.0,2021-09-13,RECRUITING,INTERVENTIONAL,['PHASE3'],,Procedure technical success
7218,NCT01949194,A biomarker (in blood or tissue) that may be predictive of level of response to regorafenib,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (RR)
7219,NCT00623805,Progression-free Survival,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With a R0 Resection
7220,NCT04404595,Phase 2: Objective Response Rate (ORR) per independent central read,2020-10-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 1b/2: Cytokine expression level in blood after CT041 infusion
7221,NCT01595321,Number of participants with adverse events as a measure of toxicity,2012-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Time to disease progression using immune correlates
7222,NCT04005365,ORR,2019-11-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7223,NCT05229874,Total Number of Retrieved Lymph Nodes,2022-01-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Postoperative lymph node anatomy duration
7224,NCT02604979,Evaluate the heart-rate corrected QT (QTc) interval (msec) during robotic-assisted laparoscopic gastrectomy,2015-09-23,COMPLETED,OBSERVATIONAL,['NA'],,
7225,NCT01697891,Change in Subjective Dysphagia Assessment Score: EAT-10 from baseline,2012-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in M. D. Anderson dysphagia inventory from baseline
7226,NCT03874026,Activity,2019-09-05,RECRUITING,INTERVENTIONAL,['PHASE2'],Type of cells infiltrating the tumor microenvironment.,Toxic effects
7227,NCT05055635,Local control,2021-07-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,To investigate 6-month surgical site morbidity
7228,NCT01569984,Tumor perfusion,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Blood flow
7229,NCT05822557,Health and feeding related quality of life,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse Events
7230,NCT00137852,"Response rate of combination of chemotherapy, radiation therapy and surgery in resectable esophageal carcinoma",2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine the side effects of chemotherapy and radiation therapy in patients with resectable esophageal carcinoma
7231,NCT01715441,Non-progression rate,2012-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Cmax and Tmax of sorafenib and irinotecan,Response rate
7232,NCT02624726,Overall Response Rate,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity profile (CTCAE v4.0)
7233,NCT05961423,The time to recurrence of cancer after curative resection,2020-06-19,RECRUITING,INTERVENTIONAL,['NA'],,Assessment of disability
7234,NCT05313854,Patient overall survival,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Progression-free Survival,Pathology diagnosis
7235,NCT00426829,Toxicity (during and within 1 month after completion of radiotherapy),2007-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,
7236,NCT05462873,Dose intensity,2023-04-04,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of anti-drug antibody (ADA)
7237,NCT04007770,Cognitive difficulties as measured by the Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog),2019-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
7238,NCT05068531,Time to tumor recurrence as assessed by detection or change in level of circulating tumor DNA after tumor resection with curative intent,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Disease-specific survival after complete tumor resection
7239,NCT00642577,Progression-free survival.,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"AEs, laboratory tests"
7240,NCT02365441,Objective tumour response (complete or partial response) as determined by RECIST v1.1,2015-06-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Macroscopically complete removal of all residual disease by surgery,Overall survival
7241,NCT00220649,"To determine the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine",2004-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To document any antitumor activity with biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine administered on this schedule"
7242,NCT05870748,Objective Response Rate (ORR),2023-07-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerabilty
7243,NCT01180153,objective response rate,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
7244,NCT02959385,Overall survival,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Determination of internal target volume (ITV) of thoracic esophageal cancer by evaluating movement of ultrasonic endoscopically placed titanium clips, with or without swallowing, during radiotherapy simulation"
7245,NCT02978612,Functional decline in instrumental activities of daily living (IADL) and/or activities of daily living (ADL),2016-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
7246,NCT05338307,Determine whether oral BHB supplementation is safe and tolerable,2022-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Investigate whether oral BHB supplementation leads to transcription and protein expression changes in the colonic mucosa
7247,NCT01632020,Mucosal Apoptotic Status of CRC Tumor and Adjacent Normal Tissue Following Metformin Therapy,2012-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7248,NCT04737187,Survival Probability at 18 Months,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAEs)
7249,NCT03594422,Safety and tolerance,2018-07-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Anti-tumor activities of HQP1351
7250,NCT00002525,5-year Overall Survival Rate in Patients With Dukes' B3/C Disease,1993-10-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,5-year Disease-free Survival Rate in Patients With Dukes' B2 Disease
7251,NCT00112658,Survival (Phase III),2004-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall response rate (Phase III)
7252,NCT02830594,Changes in Myeloid-derived Suppressor Cells (MDSC) in Non-irradiated Sites Assessed by Flow Cytometry,2016-10-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
7253,NCT05937438,1-year disease-free survival,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,3-year overall survival
7254,NCT01233505,Dose-limiting toxicities of veliparib in combination with oxaliplatin and capecitabine as assessed by NCI CTCAE version 4.0,2010-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Anti-tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST)
7255,NCT03200340,Duration of Severe Oral Mucositis (SOM) during the active treatment and short-term follow-up periods,2018-07-03,COMPLETED,INTERVENTIONAL,['PHASE2'],"Healthcare resource use including reliance on gastrostomy feeding, unplanned office visits, emergency room visits, and hospitalizations",Reduction in patient-reported mucositis-related mouth pain and analgesic use
7256,NCT02921139,freedom form local progression,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,Grade of toxicity
7257,NCT02603159,"overall survival, OS",2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,pathologic complete response rate
7258,NCT03222635,"Overall survival (descriptive statistics in SPSS, percentages, survival analysis)",2017-07-25,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life during follow-up endoscopies (questionnaires)
7259,NCT01169558,Safety: Number of Participants With Serious and Specific Adverse Events,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Efficacy: Progression-free Survival
7260,NCT05182112,determine the maximum tolerated dose of focal simultaneously integrated boost (SIB),2021-12-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
7261,NCT02100189,Specificity of Sponge Cytology Using FISH,2014-02,COMPLETED,INTERVENTIONAL,['NA'],,Tolerability of FISH Spongy Cytology
7262,NCT04782557,"Variant allelic fraction (expressed in %) of serum ctDNA from HVB, PVB and peripheral blood",2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse events of EUS-PVA and HVA
7263,NCT01894828,Improvement of nutritional status,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Reducing number of complications
7264,NCT03138044,Overall survival rate,2017-05-20,UNKNOWN,INTERVENTIONAL,['NA'],,Tumor response rate
7265,NCT03902600,Acute grade 3 or higher GI AEs,2018-05-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,overall survival
7266,NCT00014456,Define dose limiting adverse events associated with the combination,2000-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective antitumor response
7267,NCT04948762,Resection status,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,Return of bowel function
7268,NCT04506398,molecular-subtype heterogeneity between primary HCC and post-transplant HCC recurrence,2020-09-10,UNKNOWN,OBSERVATIONAL,['NA'],,Recurrence-Free Survival (RFS)
7269,NCT05101616,major pathologic response rate,2022-07-01,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,perioperative complications
7270,NCT05201105,Recurrence-free survival after abdominal-perineal amputation in case of failure of radiochemotherapy,2021-10-15,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival after abdominal-perineal amputation
7271,NCT05240404,Disease-free survival,2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Predictive Biomarkers
7272,NCT05518032,Objective response rate,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective response rate
7273,NCT01658943,Overall Survival,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Objective Response Rate,Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
7274,NCT04767984,Reduction in mutant p53 staining in biopsy samples obtained during colonoscopies done before and after intervention,2021-09-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Banking of colorectal specimens
7275,NCT05352802,The incidence and severity of postoperative complications,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Oncological outcomes
7276,NCT04741490,1-year disease-free survival rate (1-year DFS),2021-02,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival (OS)
7277,NCT02334332,"Patient/informal caregiver satisfaction with timing, content, and delivery of the intervention",2015-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Change in mean survey scores
7278,NCT00091117,MTD,2004-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7279,NCT04972149,complication,2021-05-18,UNKNOWN,OBSERVATIONAL,['NA'],,number of use for each surgical instruments
7280,NCT04351321,The incidence of postoperative morbidity,2020-07,UNKNOWN,INTERVENTIONAL,['NA'],,Overall incidence of postoperative morbidity
7281,NCT02872779,Difference from baseline in the number of free mutant DNA in blood,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluation of response based on the RECIST 1.1 guideline
7282,NCT03088150,Overall survival (OS),2017-07-13,RECRUITING,INTERVENTIONAL,['NA'],,Time to progression
7283,NCT04172194,overall survival,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,tolerance
7284,NCT05740852,Pneumonia,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7285,NCT02687230,Half-life (T1/2) of MVT-2163 alone and in combination with MVT-5873,2016-07-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Presence of anti-drug antibodies (ADA) using an MVT-5873 ADA assay
7286,NCT04172779,Modulation of gene expression signatures associated with hepatocellular carcinoma (HCC) risk,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in GSTp levels in the liver,Change in quality of life (QOL)
7287,NCT05424068,Measuring safety/practicality as assessed during one-on-one with the health coach (analyzed as qualitative data),2022-12-02,RECRUITING,INTERVENTIONAL,['NA'],Measure of performance status,Physiological measures of Performance
7288,NCT00474734,,2007-05,UNKNOWN,OBSERVATIONAL,['NA'],,
7289,NCT05344820,level of fatigue,2022-05-19,RECRUITING,INTERVENTIONAL,['NA'],,level of rumination
7290,NCT05411757,Adverse Events (AEs),2022-06-30,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Lymphocyte subtype,Best of response (BOR)
7291,NCT01694511,Incidence of detected dysplasia by each endoscopic technique.,2009-11,COMPLETED,INTERVENTIONAL,['NA'],The endoscopic prediction capability of present dysplasia compared to histopathology for HRME.,The number of biopsies taken and the duration of the different endoscopic techniques.
7292,NCT02036216,"To collect the DNA samples from the plasma, blood cells and solid tumor tissues in the patients with HCC.",2014-01,UNKNOWN,OBSERVATIONAL,['NA'],,"Early diagnosis, treatment monitoring and prognosis evaluation."
7293,NCT02677129,Short Physical Performance Battery,2014-08,COMPLETED,INTERVENTIONAL,['NA'],,Activities of daily living
7294,NCT05514301,Sensitivity of polydeep vs high experienced endoscopist blinded to polydeep,2023-01-30,COMPLETED,INTERVENTIONAL,['NA'],,To compare the diagnostic yield of the optical diagnosis
7295,NCT00459030,Comparison of traditional print versus simple electronic communication versus usual care in terms of increasing colorectal cancer (CRC) screening rates,2005-10,COMPLETED,INTERVENTIONAL,['NA'],,Mediating effect of potential cognitive-affective factors related to CRC screening
7296,NCT05368688,"The molecular features of Fusobacterium (Fn) correlated with colorectal cancer (onset, recurrence, metastasis and survival)",2022-06-30,TERMINATED,OBSERVATIONAL,['NA'],,
7297,NCT02089919,The number of participants with adverse events,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The dose of CSC vaccine,The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
7298,NCT00652132,Rate of Brock grade ≥ 1 hearing loss,2007-12-15,COMPLETED,INTERVENTIONAL,['PHASE3'],,Feasibility of central audiology review
7299,NCT05216120,Overall response rate of pemigatinib,2022-06-14,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE V4.0
7300,NCT03087071,Response rate,2017-12-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
7301,NCT03830801,The number of subjects from which we will be able to collect biopsy samples using IVLCM technique,2017-12-06,RECRUITING,INTERVENTIONAL,['NA'],,
7302,NCT01288612,Percentage of Subjects Who Agreed to Participated in the Esophageal Assessment,2011-02,COMPLETED,INTERVENTIONAL,['NA'],,Acceptability
7303,NCT04009954,The time ranging from operation day to the day of first defecation,2019-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,Concentration of fecal calprotectin
7304,NCT04978350,Reach of Genetic Testing Among Family Members,2021-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Integration of Workbook into Genetic Counselor Work Environment
7305,NCT05646030,Feasibility of CEA assessments at home using (automated) capillary sampling,2022-03-25,RECRUITING,INTERVENTIONAL,['NA'],,Clinical laboratory sample processing time:
7306,NCT02857218,Technical feasibility of ultrasmall superparamagnetic iron oxide (USPIO) - magnetic resonance imaging (MRI) of the chest,2018-04-27,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Sensitivity and specificity of PET/CT imaging
7307,NCT05690451,Accuracy per patient,2021-12-28,RECRUITING,OBSERVATIONAL,['NA'],,Sensitivity per patient
7308,NCT02280070,3-years Disease Free Survival rate,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Pattern of first recurrence
7309,NCT02393248,Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2,2015-02-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 3: Accumulation Ratio of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
7310,NCT05742620,3y-DFSR,2023-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,3y-OSR
7311,NCT00060567,"To determine the Maximum tolerated dose of E7070 in combination with irinotecan in patients with GI tract, pancreatic or lung tumors.",2003-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Safety, E7070 activity and Pharmacokinetics"
7312,NCT05186402,Overall survival,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7313,NCT02552121,Part 2: Number of Participants Reporting One or More Treatment-related Adverse Events,2015-11-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 2: Duration of Response
7314,NCT02529774,Liver Relapse-Free Survival Rate,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Disease free survival
7315,NCT00017056,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7316,NCT06155318,Diagnostic Accuracy,2019-09-05,RECRUITING,OBSERVATIONAL,['NA'],,
7317,NCT02278653,Functional outcome,2014-03,UNKNOWN,OBSERVATIONAL,['NA'],,Early detection of local failure (standard surgery still possible)
7318,NCT02995096,Overall survival,2016-01,COMPLETED,OBSERVATIONAL,['NA'],,Hepatocellular carcinoma specific survival
7319,NCT05859477,1-year progression-free survival (PFS),2022-06-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity Summary
7320,NCT05805956,progression-free survival,2022-02-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7321,NCT04994093,Optimization of pHLA:TCR binding affinity and toxicity,2021-10-06,UNKNOWN,OBSERVATIONAL,['NA'],,
7322,NCT05131243,ctDNA dynamic detection,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Tumor Marker examination
7323,NCT01372735,Local recurrence rate,2011-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
7324,NCT04047173,2-year local progression-free survival rate,2019-08-12,UNKNOWN,INTERVENTIONAL,['NA'],Radiation-induced liver injury,incidence of complications
7325,NCT05833126,Objective Response Rate,2023-12-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Graft Rejection
7326,NCT02539537,Progression-Free-Survival (PFS),2015-10-23,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life questionnaire - Core 30 (QLQ-C30)
7327,NCT03859128,BICR-RFS,2019-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of AEs
7328,NCT02478996,peak oxygen uptake (VO2peak),2015-08,UNKNOWN,INTERVENTIONAL,['NA'],feasibility of the online-based sports program,quality of life
7329,NCT05790590,lesion conspicuity on portal venous phase,2023-05-30,RECRUITING,INTERVENTIONAL,['NA'],,Contrast media (CM) dose
7330,NCT06030180,Clinical Utility,2023-02-23,RECRUITING,INTERVENTIONAL,['NA'],,Patient Compliance
7331,NCT00335829,Time to Tumor Progression (TTP) of Targeted Lesions,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and Treatment Toxicity - Cycles 2 and 3
7332,NCT03235167,metastasis free survival time,2017-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
7333,NCT01716546,Objective response rate,2011-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Maximum Tolerated Dose of the combination
7334,NCT02940067,Peak power - measured using cardiopulmonary exercise testing,2017-03-28,COMPLETED,INTERVENTIONAL,['NA'],,Well-being
7335,NCT02209441,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
7336,NCT00578838,To determine whether magnetic resonance techniques can detect changes in normal liver morphology and metabolism caused by chemotherapy in patients with colorectal cancer.,2006-08,COMPLETED,OBSERVATIONAL,['NA'],,
7337,NCT05067374,Adherence to the hepatitis C screening,2022-03-23,RECRUITING,OBSERVATIONAL,['NA'],,Care access and prospective care cascade : percentage of cured women
7338,NCT03585062,R0 resection rate,2017-11-20,TERMINATED,INTERVENTIONAL,['PHASE2'],,The quality of life
7339,NCT00760721,Obtaining HBV Screening Test,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Knowledge and Attitudes Regarding HBV Screening
7340,NCT00249301,The safety of MLN8054 will be based on the continuous monitoring and observation of patients and the collection and evaluation of adverse events and serious adverse events and the assessment of their potential relationship to the study medication.,2005-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
7341,NCT03182270,Diagnostic performance of the Cellvizio nCLE system in the characterization of pancreatic cysts,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],,Feasibility data on nCLE during EUS-FNA procedure (rate of successful nCLE procedure)
7342,NCT00726037,T-reg Suppression From a Fractionated Dose of Ontak in Patients With Metastatic Pancreatic Cancer,2008-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Optimal Time for Future Dendritic Cell Vaccine Administration
7343,NCT05426811,Progression-free Survival (PFS),2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence and severity of adverse events (AE) and serious adverse events (SAE)
7344,NCT02886104,Overall survival,2016-08,RECRUITING,INTERVENTIONAL,['NA'],,Complete ablation rate in CRLM
7345,NCT02883790,Quality of sleep assessed using the PSQI scale,2015-10,TERMINATED,INTERVENTIONAL,['NA'],Number and typology of adverse events,Quality of Life evaluated according to SF-12 scale
7346,NCT01181245,To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Maximal tumor response as determined by RECIST criteria
7347,NCT00513851,Determine the maximum tolerated dose (MTD) for both the once daily (QD) and twice daily (BID) dosing schedules and establish a recommended phase 2 dose of OSI-930,2006-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Safety, Pharmacokinetic profile, Pharmacodynamic relationships, Preliminary antitumor activity"
7348,NCT04966819,Short Form-Survivor Unmet Needs Survey (Unmet needs) at 12 months,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Short Form-Survivor Unmet Needs Survey (Unmet needs)
7349,NCT02860234,Organ preservation rate,2016-08,COMPLETED,OBSERVATIONAL,['NA'],,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module 29 (EORTC QLQ-CR29)
7350,NCT03186898,Overall Survival (OS),2017-06-22,RECRUITING,INTERVENTIONAL,['PHASE3'],,Exploratory - Overall Quality of Life (QOL)
7351,NCT00253370,The Proportion of Patients With Objective Response (Complete Response or Partial Response),2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
7352,NCT02148562,genetic variants of Hepatitis B,2014-04,UNKNOWN,OBSERVATIONAL,['NA'],,genetic variation in host-specific immune markers
7353,NCT05844371,The 1-year DFS rate,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
7354,NCT03156036,Pathologic complete response rate(Pathologic staging and tumor regression grade.),2017-11-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7355,NCT01332669,tumor response,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of treatment required to achieve objective response
7356,NCT06307327,Evaluation consistency,2024-03,RECRUITING,OBSERVATIONAL,['NA'],,
7357,NCT04189393,"Compositional changes of the oral and gut microbiome, assessed by alpha-diversity using 16S rRNA (ribosomal ribonucleic acid) sequencing, described in a surgical patient journey from moment of diagnosis until full recovery",2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,"Compositional changes of the oral and gut microbiome, assessed by beta-diversity using 16S rRNA sequencing, correlated to the development of infectious complications (30-day)"
7358,NCT02829918,Overall Response Rate (ORR) After 4 Cycles of Treatment,2016-10-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
7359,NCT00025441,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7360,NCT03734952,overall survival,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Side effects
7361,NCT04051450,Generation of candidate biomarkers PD-L1/PD1/GEP by laboratory assay qPCR for prognostication.,2020-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
7362,NCT00936572,"Primary Efficacy Parameters: morphological and microbiological evaluation of the colonic microflora, gastrointestinal function",2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Secondary Efficacy Parameters: immune and inflammatory response, bacterial translocation"
7363,NCT05178303,The test uses sound waves to measure the stiffness of liver tissue on patient cirrhosis (Arm 1),2015-11-30,COMPLETED,INTERVENTIONAL,['NA'],,The test uses sound waves to measure the stiffness of liver tissue on patient cirrhosis/Hcc (Arm 2)
7364,NCT02189421,Technical success of the direct peroral cholangioscopy,2014-04,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse events associated with direct POC
7365,NCT03847532,Patients with germIine mutations in MutYH,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA'],,
7366,NCT00004941,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7367,NCT04208958,Objective Response Rate (ORR),2020-01-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of VE800 Bacterial Strain Colonization in Stool
7368,NCT02928627,presence of miR-221 and mR-222 in the blood,2017-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,correlation of expression of miR-221 and miR-222 in tissue and blood samples
7369,NCT01462994,"Percentage of patients with histologically proven GIST, measurable lesion in imaging and activating CKIT and PDGFRA mutation, where detection of tumor specific DNA encoding for mutated CKIT or PDGFA is possible in the plasma at least at one timepoint",2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7370,NCT01364493,Objective response rate,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,adverse events
7371,NCT05800561,predictive accuracy of HVPG and ICG-r15 on PHLF,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
7372,NCT06029829,Compare Progression Free Survival (PFS) Regimen using RECIST 1.1.,2023-01-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,
7373,NCT05361668,Incidence of treatment-emergent adverse events (TEAEs),2022-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Pharmacokinetics (PK) of paltusotine
7374,NCT02494037,Survival,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Qualitative Experience of Care (QEC)
7375,NCT05608044,Objective Response Rate,2022-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants Positive for Balstilimab Anti-drug Antibodies Following Treatment with Balstilimab
7376,NCT03151564,Metastasis Detection Accuracy,2017-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
7377,NCT04152343,Rate of Local Occurrence,2019-12-07,COMPLETED,INTERVENTIONAL,['NA'],,
7378,NCT04941287,Progression free survival (PFS),2021-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor microenvironment modulation and immunologic response,Immunogenicity
7379,NCT00415168,Percentage of Participants With Objective Response (Objective Response Rate),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Who Died During the Study
7380,NCT02664974,Maintenance of body weight,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Improvement of tolerance to chemotherapy
7381,NCT02928081,5-year overall survival rate,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,5-year disease-free survival rate
7382,NCT02208804,Posttreatment tumor to non-tumor activity concentration ratio on SPECT/CT,2014-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Clinical and laboratory toxicity
7383,NCT04384575,Specificity,2020-02-22,COMPLETED,OBSERVATIONAL,['NA'],,
7384,NCT02726334,Maximum Tolerated Dose,2016-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,
7385,NCT00215982,response rate,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicity and tolerability
7386,NCT03244683,Postoperative complications,2017-08-28,TERMINATED,INTERVENTIONAL,['NA'],,Length of stay and readmission
7387,NCT05709899,postoperative analgesia,2023-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
7388,NCT02028949,tolerance: toxicity will be evaluated according to the NCI CTC AE version 4.03 scale to determine the limiting dose,2012-11-22,COMPLETED,INTERVENTIONAL,['PHASE1'],,Evaluate the rate of objective response
7389,NCT05471401,"Percentage of participants who undergo successful inflation of the gastric balloon with oral contrast agent, with verification by MR or CT imaging",2023-04-25,RECRUITING,INTERVENTIONAL,['NA'],,Translation movement of stomach between CBCT scans with and without balloon insufflation
7390,NCT05421702,Type of anastomosis,2022-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Preoperative colonoscopic examination result
7391,NCT05199168,Incidence of the recurrent laryngeal nerve injury,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Operation time (thoracic phase)
7392,NCT04721132,Incidence of adverse events (AEs),2021-02-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
7393,NCT05159440,Recommended Phase 2 Dose (RP2D),2022-01-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Accumulation ratio (Rac) of TORL-2-307-MAB
7394,NCT05561699,safety（AE or SAE）,2022-09-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Disease free survival（DFS）
7395,NCT04091165,Acceptability of Smart Phone Application,2019-09-23,COMPLETED,OBSERVATIONAL,['NA'],,Adherence to Recommended Nutritional Plan
7396,NCT05704985,"Incidence of Adverse Events (AE) of DK210 (EGFR) in combination with radiation, chemotherapy, or checkpoint blockers in Parts B, C, D",2023-04-03,RECRUITING,INTERVENTIONAL,['PHASE1'],,"Serum concentrations of proinflammatory cytokines such as IL-6, IL-10, TNFa, IL-1b, and interferon (IFN)-g will be assessed at various time points"
7397,NCT00123851,"To determine the response rate of OSI-774 when given in combination with oxaliplatin and capecitabine in patients with previously-treated locally advanced, locally recurrent, or metastatic colorectal adenocarcinoma",2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate the toxicities of the combination of OSI-774, oxaliplatin and capecitabine in this population of patients with colorectal cancer"
7398,NCT04392609,pTRG,2020-01-15,UNKNOWN,OBSERVATIONAL,['NA'],,
7399,NCT02486601,Complete pathological response rate,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Assessment of genetic polymorphism involved in tumor-response when appropriate
7400,NCT01870791,Survival,2012-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety profile
7401,NCT00051688,,2003-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7402,NCT01917617,Completion rate during the 12 weeks in the short hydration group,2013-05-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
7403,NCT02823860,Presence of biological and tumoral factors related to resistance to oncological treatments,2016-02-12,COMPLETED,INTERVENTIONAL,['NA'],,"behavioral characteristics of patients by HADS Scale, according to their therapeutic car modalities"
7404,NCT03914950,Participants With Increased Tracer Uptake Over the Pancreatic Lesion With and Without TOF,2014-02-07,COMPLETED,INTERVENTIONAL,['NA'],,Lesion Size
7405,NCT01828047,Postoperative ileus symptoms; microvascular flow index (MFI),2013-11,COMPLETED,OBSERVATIONAL,['NA'],,
7406,NCT06178445,ORR,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"The incidence, nature, causality, seriousness, and severity of adverse events using NCI CTCAE 5.0"
7407,NCT00508573,Number of Women Participating in Registry,2007-05,RECRUITING,OBSERVATIONAL,['NA'],,
7408,NCT06010862,Obtain the maximum tolerated dose of CEA CAR-T cells[Safety and Tolerability],2023-09-30,RECRUITING,INTERVENTIONAL,['PHASE1'],Duration of Response (DOR) of CEA CAR-T treatment in patients with CEA-positive advanced malignancies[Effectiveness],Pharmacodynamics of CEA CAR-T cells[Cell dynamics]
7409,NCT04037787,Length of stay,2019-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Healthcare costs
7410,NCT05980403,Lymphatic metastases,2023-07-18,RECRUITING,OBSERVATIONAL,['NA'],,
7411,NCT01629524,Association between immune related cytokine and number of lymph nodes retrieved.,2012-06,COMPLETED,OBSERVATIONAL,['NA'],,
7412,NCT00698204,Clinical Oral Mucosal Injury Score at Cumulative Radiation Dose of 5000 cGy,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of Pain Severity at 5000 cGy Radiation
7413,NCT00835679,Patients With a Biologic Response,2009-12,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Number of Patients With the Given Severity of Post-operative Complications Within the Specified Duration
7414,NCT01929499,DFS (Disease free survival),2013-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,QoL (quality of life)
7415,NCT05470452,AFROC-AUC,2021-07-28,RECRUITING,INTERVENTIONAL,['NA'],,Cancer Identification Diagnosis Compliance Rate
7416,NCT05678218,Lymph nodes identified compared to surgery,2022-09-05,RECRUITING,OBSERVATIONAL,['NA'],,Short term and long term complications of the EUS (+/- tissue acquisition) procedure for patients with pCCA and iCCA
7417,NCT05281276,Pharmacokinetics profiles-(DF),2022-09-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Objective response
7418,NCT00830557,Collection of information regarding food preparation and intake by survey,2000-10,RECRUITING,OBSERVATIONAL,['NA'],,
7419,NCT01214512,Colonoscopy and CD24 assay correlation,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
7420,NCT04799431,Number of participants experiencing study drug-related toxicities,2023-05-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
7421,NCT05576571,Evaluate efficacy (methylation profiling results),2020-10-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
7422,NCT00019084,,1996-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7423,NCT03731910,Treatment response mRECIST,2018-12-11,UNKNOWN,INTERVENTIONAL,['NA'],,Time to Progression
7424,NCT01307878,Progression-free survival,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Toxicity of chemotherapy
7425,NCT04644068,"The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.",2020-11-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Module 6: To evaluate the effect of AZD5305 on the PK of Camizestrant.
7426,NCT00566800,Histologic regression of Barrett esophagus with high-grade dysplasia by chemoprevention with erlotinib hydrochloride,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Toxicity
7427,NCT04473677,The accuracy of the new qFIT to diagnose colorectal advanced adenoma.,2020-08-17,COMPLETED,OBSERVATIONAL,['NA'],,Develop a predictive model of advanced colorectal neoplasms which includes the value of qFIT.
7428,NCT03328065,Type of determinants which are privileged by the patients to choose a treatment,2017-12-19,TERMINATED,OBSERVATIONAL,['NA'],,
7429,NCT02269683,R1 resection rate,na,WITHDRAWN,INTERVENTIONAL,['NA'],,
7430,NCT06123637,Remifentanil requirement,2024-01-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
7431,NCT00534664,,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7432,NCT05487443,Progression free survival (PFS),2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall survival (OS)
7433,NCT03069599,Immunological outcome,2017-02-15,TERMINATED,OBSERVATIONAL,['NA'],,Cancer specific survival
7434,NCT00883454,The primary outcome was to investigate the value of preoperative cholinesterases in predict postoperative adverse outcome after hepatic resection for hepatocellular carcinoma in cirrhosis.,na,COMPLETED,OBSERVATIONAL,['NA'],,
7435,NCT01289028,Percent of Patients Achieving Complete Response (CR),2008-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival (PFS) of the Patients Who Were Included Due to an Intolerability of a Prior Treatment.
7436,NCT05744362,Overall survival,2022-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
7437,NCT05833971,pathologic complete response (pCR),2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease-free survival(DFS)
7438,NCT01163396,Progression-free survival (PFS),2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of potential surrogate markers predictive of bevacizumab activity
7439,NCT05587972,Create data set,2022-10-06,RECRUITING,INTERVENTIONAL,['NA'],,
7440,NCT03010813,Perioperative complications,2016-12,COMPLETED,INTERVENTIONAL,['NA'],,Voice function after TORS
7441,NCT01458509,feasibility of electronic PRO assessment,2011-10-11,COMPLETED,OBSERVATIONAL,['NA'],,problems people experience
7442,NCT04114006,Diagnostic yield of the WATS approach versus standard gastric biopsy mapping,2019-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
7443,NCT02491593,Number of patients with high fecal blood output in relation to colorectal cancer,2014-04,COMPLETED,OBSERVATIONAL,['NA'],,Number of patients with low fecal blood output in relation to colorectal polyps
7444,NCT04270929,Safety of oxaliplatin PEDD-PRVI: maximum tolerable dose (MTD),2019-12-23,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Serologic response rates (CA 19-9)
7445,NCT00006112,,1996-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7446,NCT00132067,Toxicity as assessed by CTCAE v 3.0,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of survival
7447,NCT00116506,Evaluate 1 year progression-free survival,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Determination of the observed response rate, median duration of response and overall survival"
7448,NCT00960557,To determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,To determine progression-free survival (PFS).
7449,NCT05893667,Overall survival Disease-free survival,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Pathological response through Ryan Tumor Regression Grade
7450,NCT02829359,HBV reactivation on the recovery of liver function,2012-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
7451,NCT01910909,To evaluate the SBRT effect on adverse events,2013-08,COMPLETED,INTERVENTIONAL,['NA'],RT response prediction probability evaluation by diffusion-weighted (DW) MRI and positron emission tomography,To measure the progression free survival
7452,NCT04519151,PFS of patients treated with pembrolizumab in combination with lenvatinib.,2021-04-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Impact of the treatment protocol on health-related quality of life using the QOL questionnaire (EORTC) QLQ-OV28.
7453,NCT01137162,,2008-08,TERMINATED,OBSERVATIONAL,['NA'],,
7454,NCT00419627,,2007-02,UNKNOWN,OBSERVATIONAL,['NA'],,
7455,NCT00003220,,1998-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7456,NCT02025036,OS-2 year,2014-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,pathologic complete response rate
7457,NCT03475953,Phase II (cohort A'): Assessment of the antitumor activity of regorafenib,2018-05-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II (cohort B): assessment of the antitumor activity of regorafenib
7458,NCT01776307,Disease Control Rate,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Adverse Events and Serious Adverse Events
7459,NCT05400122,Persistence of donor NK cells,2022-09-09,SUSPENDED,INTERVENTIONAL,['PHASE1'],,Clinical Response
7460,NCT03516942,Change in level of self-reported financial burden,2018-06-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Change in level of self-reported financial burden
7461,NCT02640924,Local control rate (treatment in-field control rate),2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Patient report outcome - quality of life as assessed by the EQ-5D-3L
7462,NCT02113683,active tumor growth before and after cancer therapy,2014-05,TERMINATED,OBSERVATIONAL,['NA'],,
7463,NCT00205322,"Does the combination of oxaliplatin, 5-FU, leucovorin and capecitabine improve the activity of the FOLFOX regimens in metastatic colorectal cancer patients",2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Is the oral drug an advantage in this patient population
7464,NCT03717935,Change in Hepatic Fat Fraction,2018-10-08,COMPLETED,INTERVENTIONAL,['NA'],,Change Bile Acid Metabolomics: sphingosine-1-phospate
7465,NCT02116894,Recommended phase II dose (RPTD) for the combination of PF-03446962 plus regorafenib,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression free survival associated with PF 03446962 plus with regorafenib
7466,NCT01216813,Patients' opinion of how to manage any of the issues that arise,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,Theories and a hypothesis from data collected for use in a future interventional study
7467,NCT00109226,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7468,NCT01677884,Efficiency of treatment based on objective response rate,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Total area under the curve of contrast-enhanced liver ultrasound,Hepatic metastasis resection rate
7469,NCT03340974,Radiographic Stable Disease (SD) or Better Based on RECIST Criteria,2018-02-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7470,NCT04204577,Progression-Free-Survival(PFS),2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life score(QOL)
7471,NCT03732105,"Recurrence Free Survival,RFS",2019-03-06,RECRUITING,INTERVENTIONAL,['NA'],,health related quality of life
7472,NCT05576506,AUC (95% CI),2022-10-08,RECRUITING,OBSERVATIONAL,['NA'],,To record and evaluate any unknown risks and adverse events of hyperspectral imaging in specimen image acquisition
7473,NCT00353457,Pathologic complete response,2006-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Disease free survival
7474,NCT04995809,Reason for attrition,2021-06-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Microbiomic profiling by bacterial 16S rRNA metabarcoding sequencing,The number of participants required to take part in a larger multicentre trial which will identify potential therapeutic targets from metabolomic and microbiomic profiling
7475,NCT00320749,Maximum Tolerated Dose (MTD),2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Therapeutic Response
7476,NCT02641873,AUC0-24h (Area under the plasma concentration versus time curve),2015-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression Free Survival (PFS)
7477,NCT02630056,the grade of acute hematologic toxicity,2015-12,UNKNOWN,OBSERVATIONAL,['NA'],,
7478,NCT03975491,Interleukin-6,2019-08-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Tumor Fraction,Circulating Tumor Cells
7479,NCT05633641,ORR,2022-10-19,RECRUITING,OBSERVATIONAL,['NA'],,
7480,NCT00357422,overall survival rate,2005-10,COMPLETED,INTERVENTIONAL,['NA'],,disease free survival rate and recurrence rate
7481,NCT05704010,Small bowel adenoma,2018-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
7482,NCT03460769,"Protocol and Regulatory Compliance Monitoring of Regulatory Documents for Consortium Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)",2017-11-01,RECRUITING,OBSERVATIONAL,['NA'],,
7483,NCT04895709,Incidence of AEs leading to death,2021-05-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free survival rate (PFSR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator
7484,NCT03671265,"Adverse events (AE), Serious Adverse Event(SAE) Adverse events",2018-09-17,UNKNOWN,INTERVENTIONAL,['NA'],,OS
7485,NCT02033538,response rate,2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse events
7486,NCT00536809,Overall Response in Phase II,2007-09-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Change From Baseline to Study Completion in Aspartate Aminotransferase, Alanine Aminotranferease, and Alkaline Phosphatase"
7487,NCT03184493,Number of participants with tumor recurrence,2017-06-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7488,NCT06206876,CL/F,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
7489,NCT01727908,The percentage of increasement of endoscopic detection of (pre)malignant for gastric cancer by staining of the gastric mucosa.,2012-11,TERMINATED,INTERVENTIONAL,['NA'],,"To determine the psychosocial impact of the screening protocol in this population, measured as the amount of stress and anxiety by use of the Hospital Anxiety and Distress Scale and the amount of cancer-worry by use of the Cancer Worry Scale."
7490,NCT05535894,Concomitant Analgesic/Narcotic Use,2022-08-10,RECRUITING,OBSERVATIONAL,['NA'],,
7491,NCT00444678,Response Rate for the Combination Treatment,2004-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival
7492,NCT01202136,Prevalence and incidence of malignant pancreatic cysts,2012-10,COMPLETED,OBSERVATIONAL,['NA'],,Model for prediction of malignant pancreatic cysts
7493,NCT00522795,Complete Pathologic Response,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7494,NCT03620916,Severity of pain at rest,2018-08-17,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative complications
7495,NCT04911517,pathologic complete response（pCR）,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,3-year overall survival (OS)
7496,NCT00384800,To assess the overall response rate of tegafur/uracil (UFUR®) and thalidomide in the treatment of advanced or metastatic hepatocellular carcinoma.,2006-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To evaluate the changes of circulating factors indicating the angiogenesis activity and their correlation with objective tumor response.
7497,NCT04541875,To use the MAR-Scale to identify the top patient-reported reasons for non-adherence to specific medications indicated to treat these rare diseases.,2021-01,WITHDRAWN,OBSERVATIONAL,['NA'],,To perform psychometric analysis of the MAR-Scale questionnaire based on data collected from rare disease patients.
7498,NCT05257590,Objective Response Rate (ORR)_mRECIST,2022-05-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Pharmacodynamics analysis for the relationship of AUC and AE
7499,NCT05241574,Rate of patients with clinical complete response.,2021-08-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Acute and late toxicity assessed by Common Terminology Criteria for Adverse Events (CTCAE), version 5."
7500,NCT01155882,To determine range of morbidity and mortality,2010-09-20,COMPLETED,OBSERVATIONAL,['NA'],,Effect of occlusion of the splenic vein at the confluence.
7501,NCT03170310,Progress free survival,2017-02-21,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
7502,NCT05429697,Progression Free Survival,2022-06-09,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of Life
7503,NCT03611309,Patient quality of life,2018-09-25,COMPLETED,INTERVENTIONAL,['NA'],,Caregiver prognostic awareness assessment
7504,NCT00005591,,1999-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
7505,NCT03274349,"Muscle mass maintenance or increase, as assessed by Bioelectrical Impedance Analysis",2017-03-17,UNKNOWN,INTERVENTIONAL,['NA'],,Maintenance or increase in Body Mass Index (BMI) in kg/m^2-analysis (combination of weight in kilograms and height and in meters
7506,NCT05400915,(Phase II) Progression-free survival,2019-07-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Adverse Events That Are Related to Treatment
7507,NCT01814631,image quality,2013-03,WITHDRAWN,OBSERVATIONAL,['NA'],,
7508,NCT03130712,Safety of CAR-T cell infusion mediated by intratumoral injection as measured by number of participants with adverse Events,2017-04-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum cytokine levels
7509,NCT04595266,Objective response rate (ORR),2021-06-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of patients with liver surgery
7510,NCT03554395,Objective response rate,2018-04-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Symptom remission rate
7511,NCT03408665,SBRT efficiency in term of L-PFS for patient who are to be treated with SBRT in patients with primitive hepatic tumor of hepatic metastatis,2019-03-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Estimate the impact of the different SBRT techniques on SBRT efficacy according to OS.
7512,NCT03738280,Lesion borders (smooth or irregular),2016-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
7513,NCT06314022,Compliance with the laxative intake with the use of the mobile application,2024-05-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Evaluate colonoscopy quality indicators
7514,NCT05263219,Overall survival (OS),2022-02-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse Events (AEs)
7515,NCT00183807,To assess the time to progression of CPT-11 and cisplatin in combination with celebrex in patients with metastatic or unresectable carcinoma of the esophagus,2003-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,"To evaluate the effects of celebrex on a variety of histological and molecular biomarkers of angiogenesis, including in vitro activity assays on endothelial cell proliferation, migration and invasion."
7516,NCT05331911,The presence of disease progression,2022-04-26,RECRUITING,INTERVENTIONAL,['PHASE4'],blood loss and blood transfusion,Length of hospital stays
7517,NCT01661114,The Percentage of Untreated and Previously Treated Patients That Had a Partial Response to Treatment,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival of Previously Treated and Previously Untreated Patients
7518,NCT04709510,The incidence of thromboembolic events by radiological assessment,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Rate of predisposing factors of the patients
7519,NCT03940131,Overall response rate (ORR),2020-06-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
7520,NCT03435770,To measure side effects and adverse event of EUS-guided RFA,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,
7521,NCT02504229,Progression free survival,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7522,NCT00274885,Relationship between residual platinum levels in the blood and persistent neurotoxicity,2005-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Pharmacokinetics
7523,NCT00002759,,1996-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7524,NCT01209962,Diffusion MRI,2008-05,COMPLETED,OBSERVATIONAL,['NA'],,Apparent Diffusion Coefficient (ADC)
7525,NCT02162823,Survival,2007-05,COMPLETED,OBSERVATIONAL,['NA'],,Factors influencing survival
7526,NCT04653818,HCC recurrence,2020-10-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,changes in Child-Pugh scores over time
7527,NCT02610764,"Change of numbers of CTCs in patients with resectable EAC at diagnosis, after neoadjuvant treatment and after surgery.",2015-11,COMPLETED,INTERVENTIONAL,['NA'],Progression free survival,"Number of patients with detectable CTCs at diagnosis, after neoadjuvant treatment and after surgery."
7528,NCT05970900,Organ preservation,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Anorectal function
7529,NCT04918992,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of AI prediction system in prediction radiation proctitis,2021-06-22,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],The sensitivity of AI prediction system in prediction the radiation proctitis candidates,The specificity of AI prediction system in prediction radiation proctitis
7530,NCT04688242,Major LARS at 1 years after proctectomy,2021-02-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Other complications within 1 years after proctectomy
7531,NCT05278260,Number of participants who develop grade 3 oropharyngeal mucositis,2022-05-25,RECRUITING,INTERVENTIONAL,['NA'],,
7532,NCT00044512,Percentage of Participants for Each Type of Response,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
7533,NCT05592197,Overall Survival (OS),2018-10-01,WITHDRAWN,INTERVENTIONAL,['NA'],,ncidence of Adverse Events (AE)
7534,NCT02966054,Physical activity,2014-08,COMPLETED,INTERVENTIONAL,['NA'],,Colorectal cancer-specific quality-of-life (FACT-C)
7535,NCT01570075,overall survival,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,disease-free survival
7536,NCT04559139,Difference in overall survival,2021-02-24,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Difference in progression-free survival
7537,NCT01096914,Tumor response,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,time to local recurrence
7538,NCT04050085,Incidence of adverse events,2019-08-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
7539,NCT02512237,Maximum tolerated dose of ARX788,2016-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of subjects developed anti-ARX788 antibody
7540,NCT06171321,Accuracy of postoperative ctDNA in monitoring recurrence and metastasis,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,ctDNA clearance rate
7541,NCT01931644,Biospecimen & Clinical Data Collection,2013-07,RECRUITING,OBSERVATIONAL,['NA'],,
7542,NCT02431715,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
7543,NCT00002533,,1993-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
7544,NCT00178763,"Tumor response, disease-free survival",2003-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Allow inoperable pancreatic cancer to be converted to operable disease
7545,NCT00561522,The primary end point was to determine the effect on disease-free survival and overall survival by oral capecitabine.,2007-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The secondary end point was to analyze the relationship between preventive effectiveness of capecitabine with thymidine phosphorylase expression level of tumor tissue.
7546,NCT06011772,Immunogencity of vaccine,2023-12-04,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Progression free survival
7547,NCT03356158,Incidence of Adverse Events [AEs],2017-11-15,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Cancer antigen [CA19-9]
7548,NCT05867810,nutrition assessment,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Biochemical data
7549,NCT02843945,Safety of CivaSheet Radiation Treatement,2017-05-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Length of Hospital Stay
7550,NCT05864105,Objective Response Rate,2022-04-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,
7551,NCT02240212,Assessment of PR (vital signs) in Phase I Dose Escalation,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Assessment of composite pharmacokinetics of afuresertib and paclitaxel in expansion cohort
7552,NCT01336985,To determine the safety of hepatic chemoembolization with drug-eluting beads containing 100mg of irinotecan,2011-03-28,TERMINATED,INTERVENTIONAL,['PHASE1'],,To determine the serum pharmacokinetics and tumor tissue concentrations achieved following hepatic chemoembolization with irinotecan-eluting beads
7553,NCT01955629,Part 2: Number of Participants With Progression Free Survival (PFS) at 6 Months After the Start of Maintenance Therapy,2013-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 2: Aflibercept Biomarkers Evaluation
7554,NCT04792684,Samples Collected for Plasma Circulating Free-DNA (cfDNA) Marker Testing,2020-12-30,RECRUITING,OBSERVATIONAL,['NA'],,
7555,NCT02840890,episode of nausea and / or vomiting,2015-11-05,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life questionnaire(QLQ-C30)
7556,NCT00758186,The primary endpoint was postoperative complication rates.,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Secondary outcomes evaluated included type of surgery performed, bowel preservation, presence of a stoma, postoperative bowel function, length of hospital stay, and hospitalization costs."
7557,NCT02799420,The percentage of cancer cells in biopsy samples,2016-06-20,COMPLETED,INTERVENTIONAL,['NA'],,The expression ratio of tumor marker in biopsy samples
7558,NCT04466592,general quality of life,2019-12-13,COMPLETED,INTERVENTIONAL,['NA'],,Number of participants maintaining their social activities
7559,NCT03929666,Objective response rate (ORR) (Part 2),2019-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of lab abnormalities (Part 2)
7560,NCT05452668,Pain Assessment,2023-05-16,RECRUITING,INTERVENTIONAL,['NA'],,Oral Mucositis Severity:
7561,NCT00501605,"primary objective is to evaluate the safety and tolerability of ascending single&multiple oral doses of AZD2171 by assessment of AEs,BP,HR,RR,ECG,clinical chemistry,haematology,urinalysis incl 24hr collection for protein&creatinine and physical exam.",2003-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,"PK,assess the effects of AZD2171 on surrogate markets of activity and to make a preliminary assessment of anti-tumor activity by measurement of tumor response and time to progression"
7562,NCT01120288,Determine the modulation of HIF-1 alpha mRNA in tumor biopsies pre- and post- administration of EZN-2968.,2010-04-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Assess the safety of EZN-2968 in patients with liver-predominant solid tumors. Determine the modulation of HIF-1 alpha protein levels in tumor biopsies pre- and post-administration of EZN-2968.
7563,NCT04966611,OS,2021-07-15,RECRUITING,OBSERVATIONAL,['NA'],,PFS
7564,NCT01335555,What is the effect of chemotherapy on the fitness of patients prior to cancer surgery?,2007-08,COMPLETED,OBSERVATIONAL,['NA'],,Survival outcome at 1 year
7565,NCT05965921,Number of additional Barrett's neoplasia found on quadrantic biopsies,2023-07-26,RECRUITING,OBSERVATIONAL,['NA'],,Impact of AI (WISE VISION) in real-life
7566,NCT03585530,Overall survival(OS),2018-09-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life(QOL)
7567,NCT02082782,Efficacy,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7568,NCT05929885,The Grade 3-5 Toxicity Rate.,2023-08-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS).
7569,NCT00525655,Pilot Test FAP Website (Interviews),2007-08,COMPLETED,INTERVENTIONAL,['NA'],,Participant Assessment of FAP Website (Questionnaire)
7570,NCT00199277,Preoperative variations in hemoglobin.,na,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Length of hospital stay
7571,NCT04699188,Dose expansion: ORR per RECIST 1.1 of JDQ443 single agent in patients with non-small cell lung cancer (JDQ443 dose randomization group only),2021-02-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Dose expansion: Duration of intracranial response (DOIR) per mRANO-BM
7572,NCT04739072,Detection of recurrences post completion of curative therapies,2019-11-22,RECRUITING,OBSERVATIONAL,['NA'],"Nature and frequency of detection of incidental non-colorectal cancer related DNA, RNA and / or proteomic alterations",Overall survival (OS)
7573,NCT04192929,Adenomas per colonoscopy,2023-09,WITHDRAWN,INTERVENTIONAL,['NA'],,Inspection time
7574,NCT01823471,"The primary endpoint of the study was the difference in adenoma detection between HD-WLE and i-scan, expressed as the miss rate for polyps for each technique.",2010-11,COMPLETED,INTERVENTIONAL,['NA'],The difference in advanced adenomas between HD-WLE and i-scan and between the first and second inspection round.,The difference in overall adenoma detection between HD-WLE and i-scan
7575,NCT04810299,Nausea-vomiting,2021-04-16,COMPLETED,INTERVENTIONAL,['NA'],,
7576,NCT00835185,Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response ),2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Kirsten Rat Sarcoma (KRAS) Mutation Status
7577,NCT00258297,Effect on the signaling pathways by immunohistochemistry after 2-3 weeks of exposure to gefitinib,2004-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7578,NCT02454140,Maximum Tolerated Dose,2014-06-20,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
7579,NCT06218511,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability),2022-11-22,RECRUITING,INTERVENTIONAL,['PHASE1'],Assessment of the potential impact of the standard therapy on the natural immune response to peptides contained in IMA970A,OS
7580,NCT04730102,Existence of intraluminal malignant cells in fluid samples from rectal washout,2020-02-13,COMPLETED,OBSERVATIONAL,['NA'],,Fluid volume needed to perform rectal washout during transanal total mesorectal excision to eliminate intraluminal malignant cells
7581,NCT00100841,Progression Free Survival Rate,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7582,NCT05064410,"Change in Knowledge Related to Colorectal Cancer Risk, Prevention, and Screening",2017-05-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
7583,NCT05320328,Prospectively evaluate the safety and efficacy of combining intraductal Radio frequency ablation with biliary metal/ plastic stent placement for patients with malignant biliary obstruction.,2021-06-10,UNKNOWN,OBSERVATIONAL,['NA'],,Stent patency at 1 year
7584,NCT03680261,3-year Overall Survival,2018-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse effect (Safety and Tolerability)
7585,NCT00525200,Tumor response (clinical and pathological) to neoadjuvant treatment in relation to p53 genotype,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease free and overall survival and relation to p53 genotype
7586,NCT03559335,Postoperative inflammatory complications,2018-01-15,COMPLETED,OBSERVATIONAL,['NA'],,
7587,NCT03097224,Change in cardiorespiratory fitness,2017-04-04,UNKNOWN,INTERVENTIONAL,['NA'],,Adherence
7588,NCT03032224,Changes in Body composition after surgery for esophageal cancer with curative intent.,2015-03-23,COMPLETED,OBSERVATIONAL,['NA'],,Mortality
7589,NCT03593681,Sensitivity and Specificity of Cytological Samples for Fallopian Tube Involvement,2018-08-27,COMPLETED,OBSERVATIONAL,['NA'],,"Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy for Subject Level Analysis"
7590,NCT00188305,Colon screening behaviour,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Satisfaction
7591,NCT01726465,A decrease of 100 UI/L of AST and ALT compared with placebo.,2012-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Difference in blood transfusions.
7592,NCT00526110,Progression Free Survival,2004-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Overall Survival
7593,NCT01142713,Dose and irradiated volume of small bowel and urinary bladder,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7594,NCT00561548,Relative variation (%) in apoptotic cells calculated according to the formula: (% of induced apoptotic cells) - (% of spontaneous apoptotic cells),2007-05,TERMINATED,INTERVENTIONAL,['NA'],,Lymphocyte activation markers and macrophage activation markers
7595,NCT03594188,cell proliferation,2018-07-23,COMPLETED,INTERVENTIONAL,['NA'],,cell metastasis
7596,NCT06149741,Low anterior resection syndrome (LARS),2023-11-20,RECRUITING,INTERVENTIONAL,['NA'],,Bowel ischaemia
7597,NCT05909423,Pathological response,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Analysis of perturbations in the immune activity with a focus on effector and memory CD8+ T cells
7598,NCT05269381,Incidence of adverse events,2022-03-31,RECRUITING,INTERVENTIONAL,['PHASE1'],Pre-existing Immunity,Immunogenicity responders
7599,NCT01277120,Correlation of the time from the start of chemotherapy to the start of Avastin treatment with progression-free survival,2010-04,TERMINATED,OBSERVATIONAL,['NA'],,Safety: Incidence of adverse events
7600,NCT00661154,Determine whether[18F]-5-Fluorouracil PET/CT scanning can demonstrate a difference in [18F]-5-Fluorouracil tumor uptake before and after the administration of Avastin,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,Determine if [18F]-5-Fluorouracil PET/CT imaging demonstrates that there is a difference in maximal [18F]-5-Fluorouracil tumor uptake that is dependent on the time point of post-Avastin scanning
7601,NCT00332943,Sensitivity of VAS score vs. ReCon score,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,
7602,NCT04910386,Progression-free survival (PFS),2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate (DCR)
7603,NCT02316535,disease free survival,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,quality of life
7604,NCT01116687,Number of Participants With Objective Radiographic Response (ORR),2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Related Serious Adverse Events (SAEs)
7605,NCT00661167,Overall response rate,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease control rate
7606,NCT01034332,To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT,2007-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7607,NCT02932956,Number of Patients with Dose Limiting Toxicity,2018-12-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Median T cell persistence
7608,NCT02308722,Maximum tolerated dose (MTD),2015-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival and progression free survival at 12 and 24 months post D1 SBRT
7609,NCT00020605,,2000-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7610,NCT01727388,realization of a full digital rectal examination,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Evaluation of the position by the patient
7611,NCT00270647,Major cardiovascular events,1997-07,COMPLETED,INTERVENTIONAL,['NA'],,Colorectal cancer
7612,NCT04031872,Phase II: Response rate (RR) of galunisertib in combination with capecitabine in patients with chemotherapy resistant activated TGF-β signature-like CRC.,2020-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival (phase II only)
7613,NCT03046979,Objective Response Rate(ORR),2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events [Safety]
7614,NCT02651415,Number of Participants That Have Any Grade HFSR Toxicity,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Time to Progression Free Survival (PFS)
7615,NCT04926376,Overall Response Rate (ORR) by mRECIST,2021-11-02,COMPLETED,INTERVENTIONAL,['NA'],,
7616,NCT04124601,Incidence of treatment-emergent adverse events (safety and tolerability),2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Pathologic therapy response to neoadjuvant treatment
7617,NCT01925274,Progression Free Survival (PFS) as Assessed by Investigators,2013-11-15,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in Functional Assessment of Cancer Therapy-Colorectal (FACT-C)
7618,NCT01344902,Determine the carcinoma- and adenoma lesion true detection rate,2009-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7619,NCT00829465,OS of 1 years; TTP,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,
7620,NCT05782465,Gastric Cancer,2019-08-23,RECRUITING,OBSERVATIONAL,['NA'],,
7621,NCT01918527,Two-year disease free survival,2013-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Rate of patients fulfilling the criteria for adjuvant chemotherapy
7622,NCT02785835,Overall survival,2014-05,COMPLETED,OBSERVATIONAL,['NA'],,
7623,NCT04192539,serum taurine levels,2017-01-18,COMPLETED,INTERVENTIONAL,['NA'],,
7624,NCT05733611,Objective Response Rate (ORR),2023-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Complete Response Rate
7625,NCT03719573,30-second chair stand test (30s-CST),2019-02-21,COMPLETED,INTERVENTIONAL,['NA'],,doses of adjuvant chemotherapy
7626,NCT00461708,Overall Survival (OS) During the Study,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Disease Control According to RECIST
7627,NCT04527939,"Degree of parietal invasion (T),",2020-08-07,UNKNOWN,INTERVENTIONAL,['NA'],,
7628,NCT03648073,Number of Patients Demonstrating Somatostatin Receptor Positivity in Hepatocellular Carcinoma Using [68Ga]DOTATATE-PET,2019-01-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7629,NCT00942266,Disease Control Rate (Stable Disease or Objective Response),2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Fluorouracil Steady-state Pharmacokinetics
7630,NCT00005648,Overall survival of patients with advanced pancreatic cancer after treatment with gemcitabine with or without R115777.,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,The incidence of adverse events with respect to severity and relationship to the study medication as a measure of safety
7631,NCT00623077,Maximum tolerated dose of tomotherapy up to 12 Gy,2005-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Disease-Free Survival
7632,NCT01244022,Postoperative changes of serum cytokine levels,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,Early postoperative complications
7633,NCT00003172,,1997-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7634,NCT04749381,Postoperative complications,2020-09-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Length of hospital stay
7635,NCT00565487,To determine optimal dosage for Capecitabine and Tarceva combination in the setting of radiation.,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,To assess treatment efficacy and overall survival.
7636,NCT02016534,Objective Response Rate (RECIST v1.1) in subjects with MET Amplified measurable G/GEJ/E adenocarcinoma (Cohort 1),2014-02,TERMINATED,INTERVENTIONAL,['PHASE2'],"Response to AMG 337 and MET amplification, expression or presence of mutation in tumor specimens",Objective Response Rate (per RECIST v1.1) in subjects with other MET amplified solid tumors (subjects with measurable disease in cohort 2).
7637,NCT00517621,Validation of a french version of FACT-GOG/NTX of peripheral neurotoxicity questionnaire,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,- Incidence of the thrombo-embolic events according to whether the patients are treated or not by EPO
7638,NCT00319007,"Pouch mucosal apoptosis index at 0, 1 and 2 months",2006-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Faecal cytotoxicity at 0, 1 and 2 months"
7639,NCT02292173,Maximum Tolerated Dose (MTD),2015-02-18,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
7640,NCT00652587,overall survival rates,2002-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7641,NCT00935779,,2002-10,COMPLETED,OBSERVATIONAL,['NA'],,
7642,NCT01164215,Achievement of targeted AUC using pharmacokinetic (PK)-guided 5 fluorouracil as part of mFOLFOX6 therapy,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Toxicity differences between PK-guided therapy versus non-PK-guided therapy
7643,NCT02964468,Gastrointestinal toxicity,2016-09,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of Life during the treatment
7644,NCT06042842,(1) To evaluate the clinical utility of plasma circRNAs (hsa_circ_0004001)by Q-PCR as a non invasive diagnostic biomarker for HCC patients and to differentiate between malignant and nonmalignant hepatic disorders,2023-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
7645,NCT00005871,,1998-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7646,NCT01497392,"Overall safety profile characterized by type, frequency, severity (according to National Cancer Institute [NCI] CTCAE version 4.0), timing, seriousness and relationship to study treatment",2012-03-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacodynamic effects of dovitinib lactate and Gem-Cap combination on vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptors (FGFR) dynamics in serum and tumor specimens
7647,NCT03451773,Duration of Treatment-related Adverse Events (AEs),2018-05-17,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Overall Progression Free Survival
7648,NCT02735057,maximum tolerated dose (MTD),2016-04-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival
7649,NCT02777801,Incidence of hepatitis B virus associated hepatitis,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Interruption of chemotherapy due to hepatitis
7650,NCT01989000,"Predictive value of pretreatment DWI, DCE-MRI, T2*, and 18F-HX4-PET/CT on overall survival in patients with pancreatic cancer treated with surgery and adjuvant chemotherapy or with neoadjuvant radiochemotherapy, surgery and adjuvant chemotherapy.",2013-11,COMPLETED,INTERVENTIONAL,['NA'],Immunohistochemically determined parameters of the tumor microenvironment assessed in pretreatment tumor biopsies and post-surgery resection material correlate,Immunohistochemically determined parameters of the tumor microenvironment assessed in a pretreatment tumor biopsy to predict overall and recurrence-free survival
7651,NCT02291211,PFS: Progression Free Survival,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety as measured by recording the subjects' Adverse Events from randomization to termination
7652,NCT00961077,To evaluate response rate of attenuated SOX as first-line chemotherapy in elderly patients with relapsed or metastatic AGC,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"To evaluate progression free survival, overall survival, and toxicities of aSOX-regimen"
7653,NCT04524442,Mean change from baseline in serum potassium levels over 24 hours,2021-01-27,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Participants with Notable Changes in Electrolyte and Blood Gas parameters
7654,NCT00290524,Hospitalisation stay measured in days,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Post-surgery complications
7655,NCT01842971,number of complete surgical procedure,2013-06-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,quality of life
7656,NCT05233332,ORR（by ICR）,2022-02-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Adverse Events
7657,NCT00735566,"Relationship between antiangiogenic factor and tumor, node, metastasis",2006-04,COMPLETED,OBSERVATIONAL,['NA'],,"Overall survival, treatment failure"
7658,NCT01089595,Progression Free Survival,2009-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Best Overall Response Using Response Evaluation Criteria in Solid Tumors, Choi Criteria, and Positron Emission Tomography Imaging"
7659,NCT04736485,Pathologic response after pre-operative treatment,2021-06-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-Related Adverse Events
7660,NCT00045175,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7661,NCT04603586,1-year Disease Progression-Free-Survival (DPFS),2020-10-20,UNKNOWN,INTERVENTIONAL,['NA'],,Overall Survival
7662,NCT03935282,Proportion of patients reporting at least one non-ideal or missing CVH topic,2020-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Measure of tool acceptability with Tool Assessment
7663,NCT02192034,Navigation role in colorectal cancer screening,2013-03,COMPLETED,INTERVENTIONAL,['NA'],,
7664,NCT04380766,Changes in pancreatic cancer management during the COVID-19 pandemic,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7665,NCT03788499,Incidence of severe radioactive oral mucositis,2019-01-11,COMPLETED,INTERVENTIONAL,['NA'],,the time at which the radioactive oral mucosa occurred; Difficulty in opening your mouth.
7666,NCT02245217,RECIST 1.1 Therapeutic Responses to 1 Cycle,2014-12-12,COMPLETED,INTERVENTIONAL,['NA'],,
7667,NCT04759794,The usefulness of new staining method,2021-02-04,RECRUITING,INTERVENTIONAL,['NA'],,
7668,NCT05464706,Quality of life after liver surgery,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
7669,NCT02687009,Dose limiting toxicity,2017-11-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,Niclosamide blood levels
7670,NCT00003873,Overall survival,1999-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7671,NCT03647540,the number of the dissected lymph nodes,2018-08-30,UNKNOWN,INTERVENTIONAL,['NA'],,The mean postoperative hospital stay
7672,NCT05117047,Disease free Survival,2015-02-14,COMPLETED,OBSERVATIONAL,['NA'],,Textbook Outcome in liver surgery (TOLS)
7673,NCT03698643,Patient effective radiation dose per TACE,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Tumor response
7674,NCT01863303,incidence of CRC,2012-06,UNKNOWN,OBSERVATIONAL,['NA'],,
7675,NCT01305980,Evaluating Tumor Response Rate,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Determine duration of response rate by measuring time to progression
7676,NCT01834963,Two-year overall survival rate,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,toxicity
7677,NCT06084897,EFFICACY:1-year overall survival probability,2023-10-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Biomarkers for the predicting of efficacy,QUALITY OF LIFE: Change From Baseline in the EORTC QLQ-OES18 Subscale Scores in Participants
7678,NCT00024375,,2001-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7679,NCT02052557,PCA (Patient Controlled Analgesia) Usage,2013-02,COMPLETED,INTERVENTIONAL,['PHASE4'],NG (Nasogastric) Placement,Home Oral Narcotic Use
7680,NCT06162520,Area under the Receiver Operating Characteristic curve (AUROC) of the diagnostic models for the differential diagnosis of congenital and secondary biliary dilatation and the identification of intrahepatic involvement,2021-12-17,COMPLETED,OBSERVATIONAL,['NA'],,Accuracy of the diagnostic models for the differential diagnosis of congenital and secondary biliary dilatation and the identification of intrahepatic involvement
7681,NCT00783172,progression measured with CT scan,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,
7682,NCT02570529,Gastrointestinal ulcer incidence,2015-10,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Adverse event of gastrointestinal hemorrhage
7683,NCT05536713,Blood-based test compliant rates,2023-02-09,RECRUITING,OBSERVATIONAL,['NA'],,Patient satisfaction with the blood-based test
7684,NCT02712112,disease control rate,2016-03-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7685,NCT01288833,Rate of Accurate High Confidence Polyp Histology Predictions by the Endoscopist in the Two Groups.,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,Learning Curve
7686,NCT00487552,Success Rate Associated With the Creation of a Gastro-jejunal Anastomosis Using the Cook Magnetic Anastomosis Device With Trans-anastomotic Deployment of a Gastro-jejunal or Duodenal Stent,2008-01,TERMINATED,INTERVENTIONAL,['NA'],,
7687,NCT02882269,disease-free survival,2016-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,number of lymph nodes retrieved
7688,NCT02380131,progression-free survival(PFS),2013-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],The number of Participants with adverse events,Objective response rate (ORR)
7689,NCT00598117,To prospectively evaluate the quality of life of patients before and after esophageal cancer resection.,2003-08,COMPLETED,OBSERVATIONAL,['NA'],,To describe a cohort of long term survivors of esophageal cancer in order to identify significant features in patients more than 18 months post surgery.
7690,NCT04002128,Number of the patients with hoarseness,2008-01,COMPLETED,INTERVENTIONAL,['NA'],,One year survival and complications
7691,NCT00501176,Intra-operative measurement of the Culture from the bile.,2006-12,COMPLETED,INTERVENTIONAL,['NA'],,"Intraoperative measurements of inflammatory reaction in the liver, hepatoduodenal ligament and around the bile ducts with biopsies. Stent dysfunction and cholangitis after ERCP and pre-operative bile flow relief. Postoperative analysis."
7692,NCT03357978,Infections in A-T,2016-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,Cancer risk
7693,NCT00777894,Best objective response of target liver lesions (TLLs),2008-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum alpha-fetoprotein level (Phase II)
7694,NCT00440167,TTF2,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Toxicity
7695,NCT02866383,Clinical benefit rate (CBR),2016-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,QoL
7696,NCT02405585,Progression Free Survival,2015-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Resection Rate
7697,NCT02947165,"Incidence of DLTs, AEs, SAEs and dose reductions/interruptions for NIS793 in combination with PDR001",2017-04-25,COMPLETED,INTERVENTIONAL,['PHASE1'],,Characterization of tumor infiltrating lymphocytes by immunohistochemistry using markers such as CD8 and PD-L1
7698,NCT05953337,Incidence of serious adverse events (SAEs),2023-09-21,RECRUITING,INTERVENTIONAL,['NA'],,
7699,NCT05576909,Downstaging success rate,2023-03-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
7700,NCT03893695,Dose-limiting Toxicity(DLT),2019-05-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Exploratory Biomarker: circulating tumor deoxyribonucleic acid (ctDNA)
7701,NCT02484079,Complete resection rate,2015-05-18,COMPLETED,INTERVENTIONAL,['NA'],,Factors explaining the primary outcome
7702,NCT00149565,134 patients for each of the two treatment arms are needed.,1997-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7703,NCT03981497,Time to Local Progression,2018-02-28,RECRUITING,OBSERVATIONAL,['NA'],,Organ specific Progression Free Survival (PFS)
7704,NCT05498194,The neoantigen landscape of patients with gastric cancer,2022-08-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The ratio of predicted neoantigens being immunogenic.
7705,NCT02542215,Overall mean Area Under the Curve (AUC) of oral mucositis severity over time,2015-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Mean cumulative radiation dose at time of severe (WHO grade 3 or 4) oral mucositis onset
7706,NCT04268290,Postoperative hospital stays,2020-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Morbidity and mortality rates
7707,NCT02961374,Number of Participants With Grade 2/3 Adverse Event (AE),2017-10-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Differentially Expressed Genes of Duodenal Polyps and Uninvolved Tissue,Absolute and Percent Change in Desmoid Tumor Size
7708,NCT05396326,The incidence of treatment related adverse events (TRAE).,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Progressive free survival (PFS)
7709,NCT03331055,visal analogue scale (VAS) score,2017-10-27,COMPLETED,INTERVENTIONAL,['NA'],complications,times of breakthrough pain (BTP)
7710,NCT02872831,Diagnostic Accuracy of the 22G SharkCore™ and the 22G BNX EUS-FNA needle,2016-07,TERMINATED,INTERVENTIONAL,['NA'],,Specificity of the 22G SharkCore™ needle and the 22G BNX EUS-FNA Needle for the diagnosis malignancy in solid lesions of the pancreas and gastrointestinal tract.
7711,NCT01386931,Compare the percent of patients with inadequate samples (defined by an absence of cellular elements to account for a mass/lesion) between the two groups,2011-06,COMPLETED,OBSERVATIONAL,['NA'],,Compare the percent of patients requiring repeat procedures between the groups
7712,NCT05251233,Incidence of delayed gastric emptying as measured by Modified Accordion Grading System (MAGS),2022-04-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Marginal ulcer-free survival (MUFS)
7713,NCT01503983,Overall Survival,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,time to response
7714,NCT05871333,change in severity of intestinal mucositis,2023-07-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Laboratory evaluation of Interleukin-1β level
7715,NCT03561948,Positive peritoneal lavage,2018-01-09,COMPLETED,INTERVENTIONAL,['NA'],,
7716,NCT01276002,Recurrence of pancreatic pseudocyst,2011-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
7717,NCT05836064,Re-scheduled colonoscopy,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,GastroBot functionality
7718,NCT00006357,,2000-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7719,NCT00065117,,2003-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7720,NCT04410302,Establish and characterize at least 200 patient-derived cancer xenografts (PDXs),2019-11-12,RECRUITING,OBSERVATIONAL,['NA'],,
7721,NCT01116804,"To evaluate the efficacy of PET-imaging versus classic response assessment (MRI, CT-scam) in patients with inoperable liver cancer",2010-06-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7722,NCT03154190,Hospitalization Visits (Chart Review),2017-08-08,UNKNOWN,INTERVENTIONAL,['NA'],,Palliative Care Consult (Chart Review)
7723,NCT03246321,Major toxicity,2017-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Procedure-related characteristics: blood loss
7724,NCT02243007,Survival Rate at 18 Month,2014-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Local Control Rate
7725,NCT04987788,Colonoscopy completion,2021-08-19,COMPLETED,INTERVENTIONAL,['NA'],,
7726,NCT05476978,The model's ability to differentiate pancreatic cancer from other pancreatic solid lesion,2022-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"The model's ability to specify the pancreatic solid lesions such as pancreatic cancer, CP, AIP and NET"
7727,NCT01598194,Comparison of Diagnostic Adequacy Scores With SST vs. CST for Histologic Diagnosis Using a 22G Core Needle.,2012-01-30,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of Diagnostic Adequacy of Single Pass With 22G Core Needle and Standard 25G Needle for Cytologic Diagnosis
7728,NCT00673673,Progression Free Survival,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
7729,NCT03591705,progression-free survival,2018-07-06,RECRUITING,INTERVENTIONAL,['NA'],,Downstage hepatectomy rate
7730,NCT00931840,Response Rate,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
7731,NCT00059826,Overall survival at 18 months,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Distant disease control
7732,NCT06332079,Progression-free survival (PFS) Rate,2024-03-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL) assessed using the EuroQol EQ-5D questionnaire
7733,NCT01506167,Overall Survival,2012-07-06,COMPLETED,OBSERVATIONAL,['NA'],,Response to the Burden of Illness Question: Has your cancer resulted in a family member seeking support?
7734,NCT04136522,2 years recurrence free survival,2020-01-10,RECRUITING,INTERVENTIONAL,['NA'],,Recurrence pattern
7735,NCT04708951,Comparison between adenoma detection rate of G-EYE® colonoscopy and EndoCuff Vision®,2021-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
7736,NCT03885817,Patient reported peripheral sensory neuropathy,2019-03-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Diagnosed with type 2 diabetes.,Overall- and disease free survival
7737,NCT02676791,Local carcinoma recurrence,2016-02-16,COMPLETED,INTERVENTIONAL,['NA'],,
7738,NCT02082691,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
7739,NCT03916510,MRI tumour regression grade,2019-07-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Analyse the immune microenvironment as evidenced by immune cell infiltrates,Neoadjuvant Rectal (NAR) score
7740,NCT00487851,"Primary outcome consist of a composite score (i.e. number of hospitalizations, episodes of cholangitis, degree of jaundice, other complications requiring therapeutic interventions). Secondary outcome are QoL,hospital stay and health economic burden.",2007-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
7741,NCT03578224,Accuracy rate of traditional endoscopic ultrasonography (EUS) with suspicious node biopsy and lymphosonography for sentinel node identification,2018-09-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Number of nodes identified
7742,NCT01387373,Response rate,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
7743,NCT05162352,Progression free survival (PFS) assessed by investigators according to modified Response Evalutaion Criteria in Solid Tumors (mRECIST).,2021-12-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DCR assessed by investigators according to RECIST 1.1.
7744,NCT02807337,Oral mucositis will be assessed daily for all 75 pediatric patients at the oncology ward and at home by use of the Children International Mucositis Evaluation Scale (ChIMES scale) and WHO oral mucositis scale.,2016-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7745,NCT00275210,Every 3 years colonoscopy for polyp free patient,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Every 2 weeks clinical and laboratory tests (hematological, creatinine and liver tests) for safety evaluation during treatment then every 6 months neurological examination Date of death for OS"
7746,NCT00738478,Quality of life,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,"complication, hematological data,"
7747,NCT05281926,Area Under the Concentration-Time Curve(ACU 0-22 weeks),2021-10-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Area Under the Concentration-Time Curve(ACU 0-24 weeks)
7748,NCT02184910,the change of pepsinogen level before and after H. pylori eradication,2013-12,UNKNOWN,OBSERVATIONAL,['NA'],,
7749,NCT05276973,Incidence of adverse events,2022-09-08,RECRUITING,INTERVENTIONAL,['PHASE1'],Tumor response,Tumor response
7750,NCT00428220,Number of Participants With Treatment-emergent AEs (Treatment-Related),2007-07,COMPLETED,INTERVENTIONAL,['NA'],Summary of Duration of Clinical Benefit,
7751,NCT01384994,Progression Free Survival,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
7752,NCT01829178,Urine concentration of NGAL,2013-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Tissue activity of caspase 3
7753,NCT02167321,Disease free survival (DFS),2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Evaluation for rate of various events after surgery
7754,NCT04776837,Treatment Response at 1st Scan,2019-05-15,COMPLETED,OBSERVATIONAL,['NA'],,Skeletal Muscle Analyses
7755,NCT01609504,oncological result in term of local and/or systematic recurrence,1997-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,cancer-related mortality
7756,NCT06228209,The proportion of screened eligible patients,2024-01-26,RECRUITING,INTERVENTIONAL,['NA'],,Patient-Reported Goals of Care Discussion (GOCD)
7757,NCT02327494,the central venous oxygen saturation (ScvO2),2015-01,UNKNOWN,OBSERVATIONAL,['NA'],,postoperative outcome
7758,NCT05498766,3-year DFS rate,2023-10-12,RECRUITING,OBSERVATIONAL,['NA'],,"Incidence and severity of adverse reactions, serious adverse reactions, suspicious and unexpected serious adverse reactions"
7759,NCT04595058,Recurrent biliary obstruction (RBO),2020-11-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Survival
7760,NCT04047771,Occurrence of adverse events (AEs) and serious adverse events (SAEs),2019-09-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (AUC 0-inf)
7761,NCT01750918,Part 3: Progression Free Survival (PFS),2012-12-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 3: Number of Participants With Treatment Emergent Adverse Events
7762,NCT04359498,Surgical complications,2020-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
7763,NCT03468634,Device safety testing (no detectable damage in biopsy samples when reviewed by histopathology),2023-09-21,RECRUITING,INTERVENTIONAL,['NA'],,Diagnostic model developed (algorithm able to discriminate disease with >50% specificity and >50% sensitivity)
7764,NCT04939051,Mean change Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR) 5+ cells,2023-07-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety profile of treatment with OCA,
7765,NCT06233864,"Object Response Rate, ORR",2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AE)
7766,NCT02071069,The progression free-survival,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Grade 3 and 4 adverse Events as a Measure of Safety and Tolerability
7767,NCT03006432,progression-free survival,2016-12-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Toxicity events according to NCI-CTC v4.0
7768,NCT00016952,tumor response rate,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,quality of life
7769,NCT05547828,Objective Response Rate (ORR),2022-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Drug-Related Safety Indicators
7770,NCT06324409,First round screening participation,2024-03-22,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall screening participation
7771,NCT01284413,one year survival rate,2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity and response rate
7772,NCT00358683,"For ethical reasons, provide the opportunity for patients > 18 years suffering from Crohn's disease who both completed the therapeutic confirmatory study C87055 of certolizumab pegol and benefited from the treatment, to receive treatment with certolizum",2007-11,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events reported by the patients during the long-term treatment period of the study.
7773,NCT00802555,To evaluate the safety of ARQ 197 when administered in cirrhotic patients diagnosed with HCC,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To evaluate dynamic changes of hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and soluble c-Met in patients' peripheral blood that are associated with ARQ 197 treatment"
7774,NCT01651949,Percentage of Participants Who Had Study Vaccine Discontinued Due to an Adverse Event,2012-10-29,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Seroconversion to the HPV Types Contained in the 9vHPV Vaccine
7775,NCT00039611,,2002-05,COMPLETED,INTERVENTIONAL,['NA'],,
7776,NCT03284684,Change in integrity index of circulating DNA for KRAS gene,2018-01-22,COMPLETED,OBSERVATIONAL,['NA'],,Change in plasma concentration of BRAF DNA fragments with V600E mutation
7777,NCT01693835,Circadian rhythms in urinary excretion of modified nucleosides,2012-08,COMPLETED,OBSERVATIONAL,['NA'],,
7778,NCT04487067,Number of Participants With Grade 3-5 NCI CTCAE v.5 Bleeding/Haemorrhage,2020-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants Reporting Symptoms in Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Questionnaire
7779,NCT04205097,total dose of remifentanil,2019-12-23,COMPLETED,INTERVENTIONAL,['NA'],,
7780,NCT00004604,Safety,1997-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immune response
7781,NCT05121038,Drug Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2021-10-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pathological response rate (PCR) .
7782,NCT01830621,Overall Survival,2013-05-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change of Global Quality of Life at 8 Weeks From Baseline
7783,NCT00662246,all cause mortality,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7784,NCT02692911,Cancer/precancer,2017-01-11,COMPLETED,OBSERVATIONAL,['NA'],,
7785,NCT06010225,Total medical costs,2020-05-01,COMPLETED,OBSERVATIONAL,['NA'],,adherence to the ERAS protocols
7786,NCT05171517,Microflora analysis accomplished,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7787,NCT05986383,Postoperative liver failure rate (50-50 criteria),2023-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Clavien-Dindo grade of postoperative complications
7788,NCT01946282,FIT Completion Among Patients Offered Any Incentive vs. Outreach Alone Each Year,2013-11,COMPLETED,INTERVENTIONAL,['NA'],,"FIT Completion for Groups Offered $5 vs. Outreach Alone, $10 vs. Outreach Alone, and $5 vs. $10 Incentive"
7789,NCT00176774,Toxicity,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine the success rate of TM leading to target levels of copper depletion in patients treated concurrently with chemotherapy
7790,NCT04128657,Validation of the moroccan arabic version of the Wexner score,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7791,NCT00172640,,2005-01,UNKNOWN,OBSERVATIONAL,['NA'],,
7792,NCT06211933,Survival rate at 12 months after HIFU intervention,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical benefice rate regarding performance status
7793,NCT00222898,,2004-06,COMPLETED,OBSERVATIONAL,['NA'],,
7794,NCT04547881,Total time for lesion removal,2016-12-12,COMPLETED,OBSERVATIONAL,['NA'],,
7795,NCT04358341,Disease control rate (DCR),2020-06-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],,EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores
7796,NCT00510627,To evaluate Overall Survival in subjects receiving chemotherapy + RFA compared to chemotherapy alone.,2007-08,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,To determine if there are differences in the incidence or severity of adverse events in the RFA + chemotherapy arm compared to the chemotherapy only arm.
7797,NCT00588549,To assess if whole body 18F-FDG-PET enhances our ability to detect metastatic colorectal cancer restricted to liver and lung over conventional imaging such as CT and to determine the accuracy of PET in imaging extrahepatic tumors.,1998-07,COMPLETED,OBSERVATIONAL,['NA'],,To determine whether PET plays a role in altering clinical management of patients undergoing evaluation for liver resection for hepatic colorectal metastases.
7798,NCT05738421,To provide objective data on the bolus transit during swallowing in tracheostomized patients with tracheal tube and without tracheal tube,2021-12-06,RECRUITING,OBSERVATIONAL,['NA'],,To evaluate the features of swallowing
7799,NCT00693342,Progression-free survival,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Correlation of outcome with antigen-specific immune titers in a limited sampling of patients
7800,NCT01939275,"Number of HER2 Negative, Positive, or Equivocal Participants With Either Negative or Positive Tumor Readings",2014-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
7801,NCT04561453,Success Rate of Obtaining circulating tumor DNA (ctDNA) quantification and Ability to assess change in ctDNA levels across those time points,2020-07-08,RECRUITING,OBSERVATIONAL,['NA'],,Predictive Value of circulating tumor DNA (ctDNA) for Response to Medical Therapy
7802,NCT00002773,,1996-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7803,NCT01633203,Rate of downstaging,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,HER 2 expression
7804,NCT00584129,"To test whether pre-treatment swallowing exercises compared with ""usual care"" (where exercises are taught post-treatment) improves quality of life in patients undergoing chemoradiation therapy for advanced head and neck cancer.",2006-02,COMPLETED,INTERVENTIONAL,['NA'],,To test whether pre-treatment swallowing exercises compared with usual care improves secondary outcome measures related to dysphagia in this patient population.
7805,NCT02310477,Overall survival (OS),2014-02,COMPLETED,OBSERVATIONAL,['NA'],,Progression-free survival (PFS)
7806,NCT03008304,Relief degree of tumors,2016-12-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
7807,NCT02149771,Median survival time,2014-05,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Time to Disease Progression
7808,NCT04486378,Disease-free survival (DFS),2021-03-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Occurrence of dose reduction and discontinuation of IMP due to a TEAE.
7809,NCT01628211,overall survival,2012-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,list of therapies and clinical outcomes of patients who had radiologic evidence of disease within 6 months after initial surgery
7810,NCT04694183,R0 resection rate,2020-08-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Serious adverse events(≥grade 3）
7811,NCT04775056,Immunogenicity index-seroconversion rates of neutralizing antibody,2022-08,WITHDRAWN,OBSERVATIONAL,['NA'],,Immunogenicity index-seropositive rates of neutralizing antibody
7812,NCT03192462,Number of Patients Who Received 6 Infusions of multiTAA-specific T Cells,2018-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival Using the Kaplan-Meier Method
7813,NCT03180411,Development of Decision Tool to Guide Participants in Making Individualized Decisions Regarding Colorectal Cancer (CRC) Surveillance Through the Use of Cognitive Testing Interviews,2017-02-14,COMPLETED,OBSERVATIONAL,['NA'],,
7814,NCT00633295,To evaluate the efficacy of nilotinib in GIST patients resistant or intolerant to imatinib and or 2nd line TK inhibitor as measured by tumor up take of FDG PET quantitated by maximum,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess the safety and tolerability of nilotinib as measured by rate and severity of adverse events
7815,NCT00190554,Disease free survival,2000-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,Operative morbidity
7816,NCT05187312,Diagnostic yield,2022-01-14,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
7817,NCT01378013,Sepsis,2011-08,COMPLETED,OBSERVATIONAL,['NA'],,Mortality
7818,NCT02732483,Rebleeding rate,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Mortalities
7819,NCT00972465,Safety and toxicity of this new treatment. Both acute and chronic toxicity will be evaluated.,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"To determine the complete response rate, partial rate, disease response rate, disease control rate in the patients subject to treatment"
7820,NCT05768503,Progression-Free Survival (PFS),2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CR29 (EORTC QLQ-CR29)
7821,NCT03191487,"The rate of prescriptions for chemotherapy in the outpatient clinic prepared at the latest the day before a session (except for predefined, limited stability products) and administered in full, per patient, during a follow-up period of 6 months",2018-04,WITHDRAWN,INTERVENTIONAL,['NA'],,Overall costs
7822,NCT00220168,Time to disease progression (TTP),2003-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Toxicity (incidence of febrile neutropenia, in-patient admissions, severity of diarrhea, mucositis, aesthesia, transfusion requirements)."
7823,NCT06061263,recurrence-free survival,2022-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
7824,NCT00143403,Disease Free Survival (DFS),2001-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival Rates
7825,NCT01763489,feeling able to judge the applicability of the trial,2014-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
7826,NCT06233877,Response Rate,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
7827,NCT03949907,Combined endpoint - overall survival and weight maintenance,2020-04-14,RECRUITING,INTERVENTIONAL,['NA'],Serum levels of immunologic profiles,Abnormal values in safety laboratory variables
7828,NCT05673772,5-year disease-free survival,2020-10-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Distant metastasis
7829,NCT01751919,Area under the plasma concentration-time curve from zero time until the last measurable concentration (AUClast) of Imatinib mesylate,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Terminal Elimination Half-life (t1/2) of Imatinib mesylate
7830,NCT01919879,Non progression rate at 6 months,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tolerance of the treatment
7831,NCT04414306,Change in non-screening cancer prevention behaviors,2020-10-08,COMPLETED,INTERVENTIONAL,['NA'],,Uptake of tobacco quitting behaviors
7832,NCT03812783,Overall Survival (OS),2018-11-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
7833,NCT00960518,the progression free survival (PFS),2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,the rate of overall survival
7834,NCT05688033,Number of Participants Experiencing Adverse Events,2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Number of Participants in Who Experienced Tumor Down-staging
7835,NCT05341622,FIT Completion,2022-05-27,COMPLETED,INTERVENTIONAL,['NA'],,FIT Positive Follow-up Completion
7836,NCT00883792,Comparison of the screening group vs. the control group in an intention-to-treat model after 15 years of follow-up with regard to CRC mortality and CRC incidence,2009-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Mortality from all causes
7837,NCT04825834,"Accuracy of lung cancer detection measured by sensitivity, specificity, and the AUC of the ROC.",2021-03-22,RECRUITING,OBSERVATIONAL,['NA'],,"Accuracy of multi-cancer detection measured by sensitivity, specificity, and the AUC of the ROC and tissue of origin (TOO) accuracy"
7838,NCT02142322,response rate,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,resection rate
7839,NCT00003426,,1998-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7840,NCT03949777,Aer-O-Scope Validation of Cecal Intubation,2020-01-06,COMPLETED,INTERVENTIONAL,['NA'],,
7841,NCT05780736,Disease-free Survival (DFS),2023-08-04,RECRUITING,OBSERVATIONAL,['NA'],,Participant Treatment History
7842,NCT01029418,To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the combination of AZD6244 and sorafenib in patients with advanced hepatocellular cancer.,2009-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To investigate if the combination sorafenib and AZD6244 increases Time To Progression (TTP) over sorafenib alone in patients with advanced hepatocellular carcinoma patients.
7843,NCT03662412,overall survival,2018-06-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,Response rate
7844,NCT04456218,Image quality evaluation: the light brightness and the imaging sharpness in Likert scale,2020-07-01,COMPLETED,INTERVENTIONAL,['NA'],,In biliary stricture arm: Number of the lesions with or without presenting of the specific features for DDx of the benign or malignant stricture
7845,NCT05046756,"Change of body composition (weight, kg)",2021-05-11,RECRUITING,INTERVENTIONAL,['NA'],,The Wexner score
7846,NCT00114842,Sensitivity/specificity for water versus air for distension of colon in MR colonography,2006-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,Sensitivity/specificity of MR colonography versus colonoscopy
7847,NCT03927495,Objective response rate assessed by investigator based on RECIST 1.1,2019-05-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7848,NCT00019786,Overall survival,1999-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7849,NCT01140347,Overall Survival (OS),2010-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Treatment Emergent Positive Anti-Ramucirumab Response [Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)]
7850,NCT04330716,Rate of patients who have germline genetic tests,2020-12-01,COMPLETED,INTERVENTIONAL,['NA'],,Cascade testing in positives
7851,NCT00093496,Proportion of Patients Who Experience a Confirmed Response According to Modified RECIST Criteria.,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
7852,NCT01169220,Quality of colon cleansing,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,Patient satisfaction
7853,NCT01366833,To investigate the change in dysphagia score (0-4 Likert scale) measured at baseline and at 10 weeks,2011-06,TERMINATED,INTERVENTIONAL,['NA'],,
7854,NCT03274882,Progression free survival (PFS) rate,2017-03-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Abnormalities in 12-leads ECG parameters [safety and tolerability]
7855,NCT03432676,Best objective response rate,2019-07-31,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
7856,NCT02287168,elimination,2014-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,dissemination
7857,NCT05163873,Assessing the feasibility of the trial based on overall QoL reported in intervention group compared with standard care group,2021-12-09,RECRUITING,INTERVENTIONAL,['NA'],,
7858,NCT00464620,6 Month Progression-free Survival Rate of Gastrointestinal Stromal Tumors (GIST),2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Tumors With Mutations in Kinases
7859,NCT03321630,Progression-Free Survival (PFS),2017-10-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7860,NCT03748667,The presence or absence of deep invasion according to the gold standard (histology),2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Number of genome copies using SNP-arrays
7861,NCT02645084,"Percentage of all included patients who have received a recommendation for regular surveillance colonoscopies for himself/herself and/or relatives, provided by a clinical geneticist.",2015-02,COMPLETED,INTERVENTIONAL,['NA'],,Usability of the questionnaire for health care providers and patients by using a self-created online or paper questionnaire
7862,NCT01368419,Objective Response Rate (ORR),2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
7863,NCT01381211,Time to Progression (TTP).,2011-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicities and adverse events (recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 3.0)
7864,NCT05950503,Surgery conversion rates,2023-07-10,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
7865,NCT02269631,Change in Weight,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,Satiety
7866,NCT00195585,Relapse-free survival time,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Disease-free survival time, survival time, safety"
7867,NCT03333265,Cumulative the numbers and diameters of those colorectal adenomas during Berberine hydrochloride or placebo treatment in patients with familial adenomatous polyposis,2017-09-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
7868,NCT06157996,Progression-free Survival (PFS),2024-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response (DoR)
7869,NCT05316480,Overall response rate (ORR),2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
7870,NCT01130701,"To estimate the 3 year progression-free survival of patients with localized, resectable pancreatic cancer",2010-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To estimate resection rate
7871,NCT00057395,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7872,NCT01839630,Summarized patient characteristics,2013-05-30,COMPLETED,OBSERVATIONAL,['NA'],,Treatment pattern of Sorafenib
7873,NCT02436564,Number of tumour-derived organoids successfully cultured in vitro for a minimum of 3 months.,2015-07,UNKNOWN,OBSERVATIONAL,['NA'],,Proportion of tumour-derived organoids that are genetically identical to the source tumour.
7874,NCT05498506,the number of linear stapler cartridges,2022-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
7875,NCT02142803,Most Common Related Toxicities That Led to Dose Hold/Reductions,2014-05-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Mutation Analysis of Tissue From Biopsies of Patients With Ovarian and Endometrial Cancers,Number of Patients That Discontinue Study Drugs Due to Treatment Related Toxicity
7876,NCT00355238,The Number of Participants Experiencing Adverse Events (AEs),2006-12-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline to End of Treatment in FHSI-8 Total Score
7877,NCT04919577,Roux stasis syndrome,2014-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Gender
7878,NCT01384617,Incidence of pancreatic fistula defined by ISGPF classification,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of pancreatic fistula stratified based on thickness of pancreas parenchyma
7879,NCT06203613,To assess the sensitivity and specificity of using [18F]F-H3RESCA-3A12 and [68Ga]Ga-NOTA-3A12 for the diagnosis of metastatic gastric and pancreatic cancer,2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],,
7880,NCT00278863,Response Rate,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Adverse Events
7881,NCT00478374,To assess the safety and tolerability of the administration of sorafenib in patients with hepatocellular carcinoma treated with TACE by determining the MTD.,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,changes in the blood concentration of tumor marker AFP
7882,NCT03797625,Progression Free Survival,2017-05-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7883,NCT02812550,adenoma detection rate in the two different colonoscopies,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,colonoscopy withdrawal time
7884,NCT04516174,The prognosis of aged patients,2020-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,
7885,NCT05546411,Major pathological response rate (MPR),2023-01-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival (OS)
7886,NCT02885376,"Incidence of severe oral mucositis, defined as grade 3 or 4 on the World Health Organization (WHO) scale",2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Use of opioid analgesics for oral mucositis pain, as expressed in morphine equivalents."
7887,NCT05354856,Difference in gastric perfusion,2022-03-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,Short term outcome
7888,NCT06085976,Incidence on intraoperative bleeding.,2023-08-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of postoperative complications
7889,NCT03070613,Number of dysplastic and cancerous lesions identified under white light and under fluorescence,2017-04-23,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Resection margin of of lesions undergoing TEMS resection under white light and under fluorescence.
7890,NCT05617872,cfDNA concentration,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],,Weight
7891,NCT05507411,1-year DFS of CCR-Watch and Wait group,2022-08-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,EORTC QLQ-30
7892,NCT02703545,Proportion of patients and resected lesions with pancreatic cancer in situ (high grade dysplasia) or invasive malignancy,2014-02,COMPLETED,OBSERVATIONAL,['NA'],,Calculate survival time from point of diagnosis and treatment
7893,NCT02437851,To determine if the proportion of participants who develop treatment failure by 3 years is less than 25%.,2015-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Collection of clinical specimens (composite),"The rate of treatment related adverse events including non-healing ulcer, fissure, persistent pain and bleeding, stricture, incontinence, and colostomy 6 months after excision of SISCCA."
7894,NCT00757640,Reduced biliary complications,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,Improved quality of life
7895,NCT03523546,Utilization of acute and specialty care,2018-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Survival
7896,NCT01911000,Hyperthermia effect and averse event in RT for HCC with PVTT,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate RT response prediction probability by diffusion-weighted (DW) MRI
7897,NCT03385434,Evaluation of the adenoma detection rate during screening colonoscopy,2018-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,
7898,NCT00685763,"Cumulative Incidence of grade3+ Bowel Perforation, Grade 3+ Bleeding (Ocurring Withing 1 Years) and grade4+ Nonhematologic Acute Adverse Events (Limited to Within 90 Days of Treatment Start)",2008-03,COMPLETED,INTERVENTIONAL,['NA'],,Collect and Analyze Tumor Control Measures
7899,NCT05181332,Hepatic decompensation,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
7900,NCT01083537,Time to Resolution of Bowel Obstruction,2010-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Evaluation of Toxicity
7901,NCT02782949,Absolute Change in IL-1beta Cytokine Levels in the Gastric Mucosa,2017-04-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Proinflammatory Cytokine Genotype Status (IL-1beta, IL-8, and TNFalpha Single Nucleotide Polymorphisms)",Gastric Mucosal Deoxyribonucleic Acid (DNA) Damage
7902,NCT01824953,Newly developed gastric neoplasm,2010-01,COMPLETED,OBSERVATIONAL,['NA'],Helicobacter pylori,Degree of gastric atrophy
7903,NCT00002650,,1995-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7904,NCT02403024,Change in VO2peak,2015-08,COMPLETED,INTERVENTIONAL,['NA'],,Change in VO2peak (secondary comparisons)
7905,NCT03238404,Postoperative length of stay,2015-08-01,COMPLETED,INTERVENTIONAL,['NA'],,Prealbumin
7906,NCT03824366,Feasibility of Same-session MRI-only Simulation as Defined as More Than 70% of Patients Receiving at Least 70% of Their Scheduled Treatment Fractions on the First On-table Attempt for Each Respective Fraction.,2019-04-23,COMPLETED,INTERVENTIONAL,['NA'],,
7907,NCT00339560,Gallbladder Cancer,1997-05-16,COMPLETED,OBSERVATIONAL,['NA'],,
7908,NCT06040177,Objective response rate(ORR),2023-02-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
7909,NCT05497869,pectoralis minor length through Rigid standard plastic transparent right angle,2022-08-10,COMPLETED,INTERVENTIONAL,['NA'],,
7910,NCT06318234,Evaluation efficacy of tumor regression level,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,SUV
7911,NCT04101929,Progression Free Survival,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Response Rate
7912,NCT00276302,To recommend a dose for subsequent studies of IPI-504,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,To explore potential pharmacodynamic (PD) markers of biologic activity of IPI-504 in GIST and STS.
7913,NCT05412706,Progression-Free Survival 1,2023-09-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Translational objectives 3 for evaluated association between in vitro drug screening sensitivity on Patient-derived organoids and clinical outcome,Incidence of Treatment-Emergent Adverse Events
7914,NCT02587247,Evaluate the sensitivity of the immuno-PET PET / CT pretargeted with the bispecific anti-CEA x anti-HSG TF2 antibody and IMP-288 peptide labeled with Gallium-68,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate the clinical impact (new lecture of imaging, new examens)"
7915,NCT04340401,pathologic complete response rate(pCR rate),2020-05-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Major adverse events
7916,NCT04923620,Pathological response rate,2021-10-20,RECRUITING,OBSERVATIONAL,['NA'],,disease-free survival
7917,NCT04232891,relapse rate in MRD- patients,2019-11-18,UNKNOWN,OBSERVATIONAL,['NA'],,minimal residual disease detection rate
7918,NCT02436395,Superficial incisional surgical site infections,2015-05,UNKNOWN,INTERVENTIONAL,['NA'],,
7919,NCT01074996,Progression Free Survival(PFS),2010-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety and tolerance
7920,NCT03485027,PFS,2018-01-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,OS
7921,NCT03912857,Objective Response Rates (ORR),2018-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
7922,NCT01490203,Correlation of hepatic extraction fraction (HEF) of future remnant liver function (RLF) obtained from Gd-EOB-DTPA enhanced MRI with postoperative ICG R15 clearance test results,2011-12,COMPLETED,OBSERVATIONAL,['NA'],,Exploratory analysis of MRI parameters and ICG R15 derived from potential liver donors
7923,NCT04639284,Objective response,2020-12-23,UNKNOWN,OBSERVATIONAL,['NA'],,"Time to deterioration in patient-reported quality of life, physical functioning, and role functioning"
7924,NCT03941626,"Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0",2019-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical response
7925,NCT05794750,Pathologic complete response rate (pCR),2023-04-24,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],"Relationship between the expression of immune markers in tumor tissues and blood,the distribution of immune cells, and the efficacy and prognosis of patients",Incidence and severity of adverse events (AEs) and clinically meaningful abnormal laboratory test results
7926,NCT00383695,Pathological complete response rate at time of total mesorectal excision (TME),2005-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Quality of life, including long-term bowel function"
7927,NCT04707365,overall survival,2021-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
7928,NCT00070213,Compare health assessment in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap at baseline and 14 weeks,2003-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Compare health economics in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap
7929,NCT00875771,Progression free survival (PFS),2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of hepatic metastases resection
7930,NCT05618821,Total Number of Retrieved Lymph Nodes,2022-06-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Intraoperative situation
7931,NCT05634590,Progression-Free Survival (PFS),2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
7932,NCT05362344,Sensitivity of multi-target stool DNA test and quantitative fecal immunochemical (FIT) test,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],Ease of stool testing,Specificity of multi-target stool DNA test and quantitative fecal immunochemical (FIT) test
7933,NCT04212221,Objective response rate (ORR),2020-04-20,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
7934,NCT01972737,Antibody responses,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Time to recurrence and disease-free survival and immune responses,Persistent immunological responses
7935,NCT03792048,Incidence of anastomotic fistula,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Incidence of pancreaticojejunostomic stricture
7936,NCT00561470,Overall Survival (OS),2007-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay
7937,NCT03670199,Variation of the Medical Outcome Study Short Form 36 score,2019-01-29,RECRUITING,INTERVENTIONAL,['NA'],,Length hospitalization
7938,NCT04093687,Endoscopist adjusted painful colonoscopy rate change,2019-11,UNKNOWN,INTERVENTIONAL,['NA'],,Adjusted painful colonoscopy rate for screening centres (in which assessed endoscopists are working)
7939,NCT01707758,,2012-10,WITHDRAWN,OBSERVATIONAL,['NA'],,
7940,NCT05463328,"Rate of postoperative anastomosis leakage(pancreatic,billary and intestinal).",2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative 30 days mortality rate.
7941,NCT01472770,Rate of patients progression free at 3 months,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
7942,NCT02156700,Tumor stiffness,2013-09,COMPLETED,OBSERVATIONAL,['NA'],,tumor to parenchyma stiffness ratio
7943,NCT03754192,Pefusion parameters,2019-01-30,UNKNOWN,INTERVENTIONAL,['NA'],,Pathological examination
7944,NCT00266097,Maximum Tolerated Dose (MTD) of erlotinib hydrochloride and gemcitabine hydrochloride (Part 2),2004-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7945,NCT00006001,,2000-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7946,NCT00958386,Objective response rate,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of molecular predictive markers
7947,NCT03986541,Progression free survival,2019-09-23,UNKNOWN,OBSERVATIONAL,['NA'],,Disease control rate
7948,NCT02630108,Overall Survival,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of participants with adverse events and severe adverse events in TACE alone and TACE combined with ablation groups
7949,NCT01423604,Overall Survival,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Summary of Clinical Benefit
7950,NCT02310230,Average minute ventilation in patients cared for using the ExSpiron Respiratory Variation Monitor (RVM) compared to patients with routine monitoring in patients undergoing upper gastrointestinal endoscopy,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],,The ability of respiratory parameters with capnography to assess states of hypoventilation between the two groups
7951,NCT04852679,Clinical Benefit Rate (CBR) of tumour response assessed using RECIST (Version 1.1) and confirmed by Blinded independent central review (BICR),2021-05-24,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of Adverse Events (AEs)
7952,NCT03142516,Progression-free survival at one year,2017-10-31,COMPLETED,INTERVENTIONAL,['PHASE2'],RAS/BRAF mutations' detection proportion,Combined analysis of prognostic factors in metastatic disease
7953,NCT05055726,Number of responders,2021-12-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,Frequency of adverse events
7954,NCT02519140,Lift Efficacy,2014-08-01,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Dissection Adequacy
7955,NCT00003867,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7956,NCT05799443,Objective response rate(ORR),2023-04-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
7957,NCT05234450,Establishment of the number of tumor subgroups by integrating data from all multi-omics analyses,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
7958,NCT00304135,Overall survival,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Biliary complication rate
7959,NCT06218888,Objective Response Rate（ORR）,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
7960,NCT05742425,Disease-free survival (DFS),2023-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence rate of adverse events
7961,NCT00588263,determine the prevalence of recurring BRCA1 and BRCA2 mutations,2000-07,WITHDRAWN,OBSERVATIONAL,['NA'],,
7962,NCT06253949,rectal cancer-low anterior resection syndrome (LARS),2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],,1-year overall survival
7963,NCT01787500,Maximum tolerated dose of vemurafenib defined as the highest dose studied in which the incidence of dose limiting toxicity was less than 33% as graded by the National Cancer Institute Common Toxicity Criteria version 4.0,2013-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
7964,NCT00950820,Progression-free survival rate at 6 months for subjects with KRAS wild-type tumours,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,safety-endpoints
7965,NCT00148226,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7966,NCT00550589,Safety and Tolerability of Topical Cidofovir as Assessed by NCI CTCAE v3.0,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in Gene Expression in Perianal HSIL After Exposure to Cidofovir as Assessed by RNA Microarray Analysis
7967,NCT00288275,Progression Free Survival,2004-07,TERMINATED,OBSERVATIONAL,['NA'],,Tumor Response
7968,NCT01703026,,2009-08,COMPLETED,OBSERVATIONAL,['NA'],,
7969,NCT01290523,Number of Participants With Adverse Events,2010-05,TERMINATED,INTERVENTIONAL,['NA'],,Radiographic Response by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
7970,NCT04819958,3-year disease free survival rate,2021-03-31,UNKNOWN,OBSERVATIONAL,['NA'],,Duration of postoperative hospital stay
7971,NCT03816358,Maximum tolerated dose (MTD),2019-12-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Biomarker analysis
7972,NCT04842968,At least 12 lymph nodes harvested,2021-04-15,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
7973,NCT03597581,RGX-202-01 treatment-emergent adverse events,2018-06-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,RGX-202-01 area under the curve
7974,NCT02863107,Adherence score,2012-06-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
7975,NCT03460925,Clinical response to the treatment in terms of resectability,2018-05-02,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life
7976,NCT02764268,Number of Participants With Dose Interruptions,2016-11-02,COMPLETED,INTERVENTIONAL,['NA'],,Disease Control Rate(DCR)
7977,NCT03205501,"Safety: the number of participants with symptoms or changes in vital signs (blood pressure, heart frequency and temperature) and/or (serious) adverse events that are related to administration of EMI-137.",2017-02-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Visualization of the localization and distribution patterns of EMI-137 in the esophagus using ex vivo fluorescence microscopy.
7978,NCT06018714,2-year recurrence and metastasis rate,2023-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],completion rate of maintenance therapy,2-year disease-free survival rate
7979,NCT04487002,recurrence rate,2016-01,COMPLETED,INTERVENTIONAL,['NA'],,post-operative complications
7980,NCT03632746,The specificity of the Nomogram combining sentinel lymph node in predicting lymph node metastasis in early gastric cancer patients,2018-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,The sensitivity of the Nomogram alone in predicting lymph node metastasis in early gastric cancer patients
7981,NCT01303393,,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,Information needs - patients' and next of kins'
7982,NCT04365946,Analysis of microbiome in subtypes of intestinal metaplasia and gastric cancer,2020-04-18,UNKNOWN,OBSERVATIONAL,['NA'],,
7983,NCT01787006,Rate of Participants Who Were Alive at 2 Years,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in Quality of Life Between Baseline and End of Treatment (After 5 to 13 Weeks)
7984,NCT01824004,Disease free survival,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Health -related quality of life,Number of participants with adverse events as a measure of safety and tolerability
7985,NCT03150992,Change in incidence of pain,2017-07-19,UNKNOWN,INTERVENTIONAL,['NA'],,Nutritional intake
7986,NCT02973685,Overall survival,2016-10-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of of Patients developed Adverse Events
7987,NCT00677144,overall response rate,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Safety, time to progression, and overall survival"
7988,NCT06007846,Patients Progression Free Survival at 6 months,2023-07-31,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Change from baseline as assessed by the European Organization for Research and Treatment of Cancer (EORTC-HCC18) over treatment,
7989,NCT04367025,Major pathologic response (MPR),2020-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OSR
7990,NCT02024841,Maximum tolerated dose and recommended dose,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
7991,NCT01203787,Cumulative Dose of Sorafenib,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Subjects With Dose Reductions
7992,NCT05802485,Predict response to systemic therapies in patients with non-metastatic pancreatic adenocarcinoma,2023-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
7993,NCT01458717,2-year survival rate,2011-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,efficacy of imaging study after neoadjuvant chemoradiation
7994,NCT04465734,tumor assessment,2022-11-15,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
7995,NCT00628186,the length of hospital stay after pancreaticoduodenectomy,2005-04,COMPLETED,INTERVENTIONAL,['NA'],,early and late complications after pancreaticoduodenectomy
7996,NCT01336452,characteristic of Perfusion MR,2011-04,UNKNOWN,INTERVENTIONAL,['NA'],,
7997,NCT05593419,TIIC signature,2022-10-31,RECRUITING,OBSERVATIONAL,['NA'],,
7998,NCT06037655,Objective response rate (ORR),2023-09-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Major Pathological Response Rate (MPR),overall survival (OS)
7999,NCT01784861,Objective Response Rate (Complete Response + Partial Response) - Phase II,2013-05-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Toxicity - Phase II
8000,NCT05830097,Incidence and severity of Adverse Events (AEs),2023-03-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,MTD/RP2D of CBP-1019.
8001,NCT04648020,To demonstrate the efficacy of HCl MBT to prevent SOM in OPC patients receiving CRT.,2021-02-11,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
8002,NCT01402401,efficacy of AUY922 in combination with trastuzumab as assessed by RECIST,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
8003,NCT05468944,Complication rate,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival rate
8004,NCT05516628,"Recurrence-free-survival (RFS) in relation to the multi-omics (epigenomics, genomics, transcriptomics, proteomics and metabolomics) and spatial TME profiles of both tissue and peripheral blood.",2023-02-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS).
8005,NCT02845908,"Progression-Free Survival,PFS",2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival(OS)
8006,NCT05690958,Intended uptake of EAC screening,2023-02-13,RECRUITING,OBSERVATIONAL,['NA'],Acceptability of screening test accuracy,Views on the organization of EAC screening
8007,NCT04606888,S100 calcium-binding protein β,2020-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Numeric Rating Scale score
8008,NCT03156582,Number of participants whose tumoral characteristics on the liver explant were under the criteria of the AFP score,2016-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Progression free survival after LT for HCC
8009,NCT04943653,6-month progression free survival (6-month PFS),2021-06-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Ascites response
8010,NCT04027764,objective response rate,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
8011,NCT00059865,Survival after 6 months of treatment,2004-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity as assessed by CTC v3 every 4 weeks
8012,NCT05178095,ADR,2020-09-30,COMPLETED,INTERVENTIONAL,['NA'],,Procedural time
8013,NCT03364621,Utilization rates of characterized genomic and epigenetic features associated with chemotherapy resistance and tumor recurrence in clinical environments,2017-08-29,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Non-invasive detection of cfDNA methylation profiles by performing cfMeDIP-seq on blood samples
8014,NCT03869151,increased over all survival,2019-04-05,UNKNOWN,OBSERVATIONAL,['NA'],,
8015,NCT02399033,Hepatocellular carcinoma recurrence rate in the three years after hepatectomy,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,The incidence of adverse reaction.
8016,NCT04310111,Tumor size,2020-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
8017,NCT01598584,quality of life,2012-06,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,chemotherapy induced nausea and vomiting
8018,NCT00042900,,2002-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8019,NCT03398512,radical resection rate,2018-02-01,TERMINATED,INTERVENTIONAL,['NA'],,complication rate
8020,NCT02530593,QoL in colon cancer patients,2015-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Analyse health economy aspects of QoL and morbidity in the patient population
8021,NCT03925662,number of patients with tumour response,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,
8022,NCT03307941,Phase II: pCR rate,2017-07-20,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Number of the tumour-infiltrating lymphocytes (TILs)
8023,NCT01941992,"Proportion of subjects with Grade III or IV of mucositis assessed by the WHO mucositis scale, developing at any time during the whole study period.",2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life assessed by European Organization for Research and Treatment of Cancer quality of life core questionnaire (EORTC QLQ-C30) and specific head and neck module (QLQ-H&N35),Incidence of adverse events assessed by NCI-Common Terminology Criteria for Adverse Effects (CTCAE version 4.0)
8024,NCT02570711,Overall Response Rate (ORR),2015-10-13,TERMINATED,INTERVENTIONAL,['PHASE2'],,
8025,NCT01915589,Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review,2013-09-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events as a measure of safety and tolerability
8026,NCT04952272,Assessing safety and treatment efficacy on intratumor injection of CpG-ODN and in situ tumor antigen release for advanced tumors,2021-03-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,
8027,NCT00479817,Progression Free Survival,2007-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of the occurence of AMG 386 Antibody formation
8028,NCT05076591,Number of patients with Adverse Events（AEs）,2022-06-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,
8029,NCT02024412,The incidence of neurotoxicity including acute neurotoxicity and accumulating neurotoxicity,2013-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,quality of life
8030,NCT03698461,Serial changes in Cluster of Differentiation(CD) 8+ T cell densities,2019-05-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Microbiome profile
8031,NCT00419614,,na,UNKNOWN,OBSERVATIONAL,['NA'],,
8032,NCT01711450,Dose of intravenous sedation required during and after the procedure,2012-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Complication rate of paravertebral block
8033,NCT05344924,Progression free survival (PFS),2022-10-12,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse effects
8034,NCT05753163,1-year recurrence-free survival rate (1-year RFS),2022-08-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,health-related quality of life (HRQol)
8035,NCT06044142,Assess the impact of photo-bio-modulation low level (LL) laser treatment in managing mucositis,2023-03-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,
8036,NCT06160557,"Disease Free Survival, DFS",2023-11-29,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
8037,NCT05221320,"The incidence and frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NCI CTCAE, version 5.0), seriousness, duration, and relationship to study treatment.",2022-05-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival (PFS) as defined as the time from study drug initiation to the time of documented disease progression (as assessed by RECIST 1.1) or death from any cause.
8038,NCT01442649,Progression-free survival (PFS) at 4 months,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
8039,NCT02774187,Overall survival,2016-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of of Patients developed Adverse Events
8040,NCT04854668,Progression Free Survival (PFS) assessed by IRC,2020-07-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Duration of Response (DOR)
8041,NCT05980182,Colorectal Screening Status,2023-08-05,RECRUITING,INTERVENTIONAL,['NA'],,Determine the feasibility of the mHealth Application - Sharing Content
8042,NCT01157039,To evaluate potential pharmacokinetic interactions between oxaliplatin and glutamine at 30g and 40g in patients with metastatic colorectal cancer.,2011-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To compare the toxicity profile of glutamine and FOLFOX to historical data.
8043,NCT05040438,Objective Response Rate (ORR) of administering VAX-NK/HCC combined with HAIC,2019-10-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,The serum cytokine levels
8044,NCT05383976,Adenoma Detection Rate,2023-02-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
8045,NCT00136227,colorectal cancer screening initiation rate,2005-10,COMPLETED,INTERVENTIONAL,['NA'],,making decisions about colorectal cancer screening that are consistent with their values and preferences
8046,NCT00253526,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
8047,NCT03602417,Clinical success rate,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
8048,NCT03249727,"Test performance of NK Vue (ability of NK Vue to detect CRC in those subjects in risk categories P2, P3 or P4)",2017-07-05,TERMINATED,INTERVENTIONAL,['NA'],,Test performance of NK Vue in combination with FIT
8049,NCT03648879,Percentage of Participants With Detectable Confocal Endoscopic Microscopy (CEM) w/Greater Sensitivity for Detection of Signet Ring Cells (SRC)Foci in Cadherin-1 (CDH1) Germline Mutation Carriers Compared to Current Method of Standard White Light Endoscopy,2019-02-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Percentage of Participants Who Have Signet Ring Cells (SRC) Foci Not Identified by Confocal Endoscopic Microscopy (CEM)
8050,NCT03136354,Complication,2009-05,COMPLETED,INTERVENTIONAL,['NA'],,Disease free survival
8051,NCT04654494,disease free survival,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
8052,NCT03570996,Pain scores,2018-01-01,TERMINATED,INTERVENTIONAL,['NA'],,Hypotension
8053,NCT00238381,Composite evacuation score after total mesorectal excision,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Morbidity
8054,NCT01068483,Maximum Tolerated Dose (MTD) of BKM120,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Clinical tumor response in patients with tumors that show PI3K pathway activation
8055,NCT05002686,1 year Progression Free Survival (PFS),2021-08-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Potential biomarker to predict prognosis,Percentage of pathologic complete response(pCR)
8056,NCT01818973,The pathologic tumor regression grade (TRG),2013-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,5-y local relapse free survival
8057,NCT04621474,Inter-observer agreement,2019-04-08,UNKNOWN,OBSERVATIONAL,['NA'],,Preferred imaging modality
8058,NCT02241499,Improvement of dysphagia.,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Metabolic response,Endoscopic response of the primary tumor.
8059,NCT01627379,Overall Survival,2012-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,Quality of life
8060,NCT01243346,The primary end-point is overall response rate,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,PKPD analysis
8061,NCT06044311,Metabolic Response,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Ability to take vactosertib before and after standard of care chemoradiation
8062,NCT06210971,Pathologic Complete Response,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
8063,NCT03206827,Changes in the intake of nutrients and nutritional status of participants as a measure of diet modification,2016-11-29,COMPLETED,INTERVENTIONAL,['NA'],,Genotoxicity testing of human fecal water in 2D and 3D cell cultures
8064,NCT01224990,The aim of the study is to asses whole body diffusion weighted imaging (WB-DWI) in patients with proven gastro-intestinal tumors and to evaluate this non-invasive method for staging and therapy monitoring.,2010-11,UNKNOWN,INTERVENTIONAL,['NA'],,
8065,NCT05694559,genetic risk screening tool (GRST) questionnaire,2022-11-23,RECRUITING,INTERVENTIONAL,['NA'],,
8066,NCT04287868,Best Overall Response (BOR) in Checkpoint Naive and Immune Checkpoint Blockade (ICB) Resistant Disease in Participants With Advanced or Metastatic Human Papillomavirus (HPV) Associated Malignancies,2020-06-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Duration of Response (DOR)
8067,NCT04161092,Five-year overall survival,2020-12-01,RECRUITING,INTERVENTIONAL,['NA'],,Health economic evaluation
8068,NCT06333769,complete response (CR) rate,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,3y-DFS
8069,NCT04252456,"Overall survival (OS) according to VEGFR2 levels, evaluating the difference in terms of median OS among patients with high VEGFR2 activity and patients with low VEGFR2 activity",2018-04-23,UNKNOWN,INTERVENTIONAL,['NA'],,Angiogenetic factors levels concentration before and during treatment.
8070,NCT05702385,CPV-measured differences in cost of care between control and intervention arms,2023-09-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
8071,NCT01921283,procedure satisfaction score of propofol addition,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,
8072,NCT00327652,Dose-limiting toxicities (DLTs) for 7 days after dosing,2006-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8073,NCT04009265,Overall Survival,2019-08-23,RECRUITING,INTERVENTIONAL,['PHASE3'],,Scores of Quality of Life
8074,NCT05155475,Evaluation of the common bile duct size,2019-06-04,COMPLETED,OBSERVATIONAL,['NA'],,
8075,NCT04695470,PFS(progression free survival) rate at 6 months,2020-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
8076,NCT04705363,Credibility score,2021-06-29,RECRUITING,INTERVENTIONAL,['NA'],,
8077,NCT03133286,Obtain pre- and post-irradiation participant-collect blood samples,2017-04-06,UNKNOWN,OBSERVATIONAL,['NA'],,
8078,NCT00625586,Number of Patients Alive at 8 Months,2008-04-15,TERMINATED,INTERVENTIONAL,['PHASE2'],,Cmax
8079,NCT05608213,Overall survival (OS),2022-11-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse Events (AEs)
8080,NCT05894824,PFS rate at 24 weeks,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,adverse events categorized in accordance with CTCAE 5.0 Criteria.
8081,NCT01722162,Progression Free Survival (Arm B),2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence and Severity of Adverse Events as Measured by Number of Participants Who Experience Grade 3 and Higher Adverse Events
8082,NCT02222753,Disease-specific survival,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],Disease-free survival,Overall survival
8083,NCT03245190,16 weeks progression-free rate (16W-PFR),2018-04-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Screening characteristics of ctDNA measurement (multi-gene analysis).,12 months overall survival rate
8084,NCT03432624,Fourfold Table Analysis Indexes,2018-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,Statistical Analysis Indexes
8085,NCT03713229,Incidence of anal cancer,2010-09-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
8086,NCT00936689,survival of all randomized patients at month 24 (favorable event). Mortality by month 24 and withdrawal from the study will be considered to be unfavorable events.,2008-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,Radiological tumor response; TTSP; TTP; Overall duration of response; Quality of life; ECOG score; Impact on liver function; No.of treatments administered.
8087,NCT04348838,Variation of overall survival time (OS) after pharmaceutical treatment,2019-08-26,RECRUITING,OBSERVATIONAL,['NA'],,Variation of serious adverse event rate of HCC treatments in clinical practice
8088,NCT02857270,Number of Participants with LY3214996 Dose Limiting Toxicities (DLTs),2016-09-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS) (Dose Expansion Arms Only)
8089,NCT02743221,Progression Free Survival (PFS),2016-04-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8090,NCT00004190,overall response rate,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,objective tumor response
8091,NCT06172205,ORR,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,conversion rate
8092,NCT02317471,Number of participants with adverse events related to gp96 immunotherapy,2014-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
8093,NCT02421432,TME quality & circumferential resection margin (CRM),2017-12-01,UNKNOWN,INTERVENTIONAL,['NA'],5-year overall survival,Number of harvested Lymph Nodes
8094,NCT06041009,"The diagnostic value (sensitivity, specificity, accuracy, and positive and negative predictive values)",2023-12-20,RECRUITING,OBSERVATIONAL,['NA'],,"The diagnostic value (sensitivity, specificity, accuracy, and positive and negative predictive values)"
8095,NCT02008422,progression-free survival (PFS),2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,overall survival (OS)
8096,NCT06301672,Body Mass Index,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Feeding amount
8097,NCT04018872,Percentage of pathological complete response with itraconazole,2019-06-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Levels of itraconazole and metabolites in esophageal tissue
8098,NCT04980950,The impact of immunonutrition on gut microbiota in gastric and colorectal cancer patients.,2021-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,The impact of immunonutrition on intestines in gastric and colorectal cancer patients.
8099,NCT03646409,VTE- and bleeding incidence,2018-06-11,COMPLETED,OBSERVATIONAL,['NA'],,Arterial thromboembolism (ATE) incidence
8100,NCT00003360,,1998-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8101,NCT03037385,(Phase 2) Number of Participants with AEs and SAEs,2017-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,(Phase 2) Assess Intracranial Response Rate and Time to Intracranial Progression in Participants With NSCLC
8102,NCT00084721,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8103,NCT05957016,Pathologic complete response (pCR),2023-08-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival (OS)
8104,NCT06129604,EP2 and EP4 receptor subtypes tumor biomarker expression within the PGE2 signaling pathway.,2024-04-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidences of TPST-1495 drug therapy based potential adverse events
8105,NCT04832776,ORR,2021-04-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,PFS
8106,NCT00002692,,1994-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8107,NCT01269255,maximum tolerated dose,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8108,NCT00034827,Overall objective response and clinical benefit response,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Time to objective response, duration of response, time to progression and survival"
8109,NCT02458573,soft diet intake after surgery,2015-06-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,postoperative pain
8110,NCT01833286,overall survival,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],Morbidity,disease-free survival
8111,NCT03067792,response rate,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,progression free survival
8112,NCT02638857,Overall survival,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
8113,NCT04604158,Absolute change in patient-reported anxiety scores at Day 30 compared with baseline.,2020-12-02,UNKNOWN,INTERVENTIONAL,['NA'],,Participant's experience with Elly app at Day 180-360.
8114,NCT02613221,Progression Free Survival (PFS) Rate at 6 Months,2015-12-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs)
8115,NCT01545063,Number of catheter related infections,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,
8116,NCT02161029,Amount of submucous tissue in gastrointestinal submucosal tumors harvested with a new drill biopsy instrument used with flexible endoscopes.,2014-07-02,COMPLETED,INTERVENTIONAL,['NA'],,
8117,NCT05053386,"Objective Response Rate, ORR",2021-10,UNKNOWN,INTERVENTIONAL,['NA'],,"Overall survival, OS"
8118,NCT02556762,Overall survival,2015-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Biomarkers
8119,NCT04762953,Incidence of Treatment-Emergent Adverse Events [Safety],2021-02-18,RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation of Plasma and Ascite Exosomal Gene Signature (EXOSIG) to Treatment Response,Patient Reported Quality of Life Outcomes
8120,NCT04202978,R0 resection rate,2020-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,pathologic complete response
8121,NCT00560846,Length of stay,2007-11,TERMINATED,INTERVENTIONAL,['NA'],,Body composition
8122,NCT00788125,Maximum Administered Dose of Dasatinib (Phase I),2008-09-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
8123,NCT03252821,Change in fatigue,2017-08-15,COMPLETED,INTERVENTIONAL,['NA'],,Adherence
8124,NCT03997188,Degree of dysphagia,2015-12-21,COMPLETED,INTERVENTIONAL,['PHASE3'],,
8125,NCT04416854,Overall survival,2020-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,The proportion of surgical intervention in control group
8126,NCT00576654,Recommended phase II dose (RP2D) of study drugs,2007-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Excision repair cross-complementation group 1 (ERCC1) expression levels,Tumor response
8127,NCT02767752,Disease-free survival (DFS),2016-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Determination of plasma IL-6,Quality of Life
8128,NCT01697488,Safety: Incidence of adverse events,2012-02-02,COMPLETED,OBSERVATIONAL,['NA'],,Treatment duration
8129,NCT03731130,QoL (EORTC QLQCR29) absolute values and change over time,2018-10-05,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
8130,NCT05816902,lung metastasis,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
8131,NCT00514761,Progression event count,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety and tolerability
8132,NCT03968406,Maximum tolerated dose (MTD),2019-09-26,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall quality of life as assessed by the FACT questionnaire,Overall survival
8133,NCT01062919,Postoperative functional recovery,2009-07,TERMINATED,INTERVENTIONAL,['NA'],,length of hospital stay
8134,NCT00004867,Proportion of these patients with FDG-PET findings that contraindicate surgery,1999-11,COMPLETED,INTERVENTIONAL,['NA'],,The proportion of false positive lesions found by FDG-PET.
8135,NCT02369939,Improvement of complete remission,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
8136,NCT06324357,Dose optimization (Phase II): Objective response (OR),2024-05-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Dose optimization (Phase II): Patient-reported outcome (PRO) - EORTC IL19
8137,NCT03775850,Evidence of anti-tumor activity of EDP1503 based on ORR,2018-12-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
8138,NCT01933789,Occurrence of Discussion About Goals of Care at Target Visit,2013-09,COMPLETED,INTERVENTIONAL,['NA'],Group Differences - Stable Treatment Preference (Filter for Subgroup Analysis of Goal-concordant Care),Palliative Care Consultation and/or Referral - Patients Most Likely to Benefit
8139,NCT04999306,patient adherent to the program.,2023-05-17,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life questionnaire-Core 30 (QLQ-C30)
8140,NCT00471146,Overall Survival (OS),2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Population Pharmacokinetic (PK) Analysis for Axitinib (AG-013736)
8141,NCT02568046,"Number of Participants With Adverse Events (AEs) by Nature, Severity, and Occurrence Measured From Baseline to End of Trial Participation, as Assessed by the Common Terminology Criteria for AEs (Version 4.03) (CTCAE v4.03).",2016-03-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
8142,NCT05594927,Overall survival (OS),2022-12-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,Mean area under the concentration-time curve during the dosing interval (AUC0-t)
8143,NCT04270851,Change in decision making on technical resectability,2020-04,UNKNOWN,OBSERVATIONAL,['NA'],,Level of agreement between liver surgeons on technical resectability
8144,NCT02539225,Progression Free Survival (PFS),2015-10-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Anti-Ramucirumab Antibodies
8145,NCT03102229,Number of patients hospitalized during treatment or within 4 weeks after completing radiotherapy.,2016-07,COMPLETED,INTERVENTIONAL,['NA'],,Modified Glasgow Prognostic Score
8146,NCT05996458,Cancer or precancerous lesions detected,2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],,
8147,NCT03542422,Progress free survival（PFS）,2018-06-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
8148,NCT04054908,Acceptability of specimens for analysis,2018-04-13,COMPLETED,OBSERVATIONAL,['NA'],,Change in relative abundance of following gut bacteria that occur with oral fluoropyrimidine therapy
8149,NCT04069702,Number of Participants With VR Side Effects,2020-03-12,COMPLETED,INTERVENTIONAL,['NA'],,Change in Pain Self-efficacy as Measured Using Items Adapted From the Self-efficacy for Pain Management Subscale of the Chronic Pain Self-Efficacy Scale
8150,NCT06027242,Change of area of psoas muscle,2023-02-21,RECRUITING,INTERVENTIONAL,['NA'],,Change of serum pre-albumin value
8151,NCT03793725,R0 (resection rate),2019-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,RFS
8152,NCT03980288,Dose limited toxicity and Maximum Tolerated Dose,2019-07-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor efficacy-Disease control rate (DCR)
8153,NCT00612586,Progression Free Survival (PFS),2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,PFS From Start of First Line Therapy
8154,NCT03353311,Adherance to ERAS protocol,2014-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Number of items of the ERAS protol correlated wih adverse events as described by the Clavien Dindo Classification and with a longer hospital stay
8155,NCT01044511,"HRQoL, EORTC C-30, EOS-18",2010-01,UNKNOWN,INTERVENTIONAL,['NA'],,
8156,NCT00006994,Effectiveness of L-glutamine for mucositis,2001-11,TERMINATED,INTERVENTIONAL,['PHASE3'],,Compliance (dose taken) in patients treated with L-glutamine when given with radiation treatment
8157,NCT03253289,Change in mRNA levels,2017-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,A panel of CAR downstream target genes
8158,NCT02332499,Overall Survival (OS),2014-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
8159,NCT03237130,pathological local lymph node status,2017-02-15,COMPLETED,OBSERVATIONAL,['NA'],,
8160,NCT01483144,Number of Subjects With Any FAP-related Event.,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Improvement in Investigator Lower GI Assessment
8161,NCT02530398,the grade of adverse events,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
8162,NCT00010088,,1999-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
8163,NCT05420584,Imaging Tumor Regression Rate,2022-11-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Pathological Tumor Regression Rate
8164,NCT05908838,Overall survival,2017-01-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Immune function
8165,NCT05397548,Detection of levels of circulating exosomal lncRNA-GC1,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
8166,NCT00665197,Dysphagia relief,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Treatment Toxicity
8167,NCT02305459,Description of the clinical context in which SIR-Spheres are applied,2014-11,COMPLETED,OBSERVATIONAL,['NA'],,Hepatic PFS
8168,NCT02548780,Area under the Curve (AUC),2016-04,COMPLETED,INTERVENTIONAL,['NA'],,Progression Free Survival
8169,NCT01158287,Disease control rate after 4 months,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tolerability and toxicity
8170,NCT01608841,disease control rate,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,progression-free survival
8171,NCT03280511,The number of patients with peritoneal recurrence,2017-12-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,"1-, 3- and 5-year overall survival rate"
8172,NCT04984369,ORR,2021-08-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
8173,NCT03776435,Age and sex-standardized incidence rate ratio (IRR) for malignancies of hematologic system,2018-01-15,UNKNOWN,OBSERVATIONAL,['NA'],Subgroup analysis,Age and sex-standardized incidence rate ratio (IRR) for all cancers
8174,NCT04006041,Pathologic complete response rate,2019-06-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Perioperative mortality
8175,NCT05369234,Management of Oral Mucositis and Esophagitis,2022-01-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,
8176,NCT06333561,Overall survival,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],Objective response rate,Progression-Free-Survival
8177,NCT04150081,Validation of molecular signatures,2019-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,Sensitivity and specificity of follow-up tests
8178,NCT03403465,Progression free survival (PFS),2018-03-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Measure the potential sparing of radiation dose to critical normal tissue
8179,NCT06040021,OS,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
8180,NCT04327986,Best Overall Response (BOR) According to the Response Evaluation Criteria in Solid Tumors (RECIST) of Bintrafusp Alfa (M7824) & NHS-IL12 (M9241) in Combination With Stereotactic Body Radiation Therapy in Participants With Locally Advanced Pancreas Cancer,2021-06-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With a Dose-limiting Toxicity (DLT),Complete Pathological Response Rate(s) For Participants Who Underwent Surgical Resection After Bintrafusp Alfa (M7824) and NHS-IL12 (M9241) in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment
8181,NCT01182831,immediate pain relief,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
8182,NCT00595972,time to progression,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicity
8183,NCT06023758,pCR rate,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival (OS)
8184,NCT03353753,Progression-Free Survival (PFS),2018-02-27,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of Life & Disease-Related Symptoms - EuroQol Visual Analogue Scale
8185,NCT02852915,Disease free survival,2016-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse events (mortality and morbidity)
8186,NCT01212510,Prediction of tumor progression,2010-10,COMPLETED,INTERVENTIONAL,['NA'],,Prediction of tumor response
8187,NCT04262687,The rate of patients alive and without progression at 10 months after inclusion,2021-04-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,Histological response in case of secondary resection
8188,NCT05166577,Phase 2: Overall response rate (ORR),2021-10-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetic parameter - area under the plasma concentration-time curve [AUC]
8189,NCT04774757,3-year DFS,2021-03-10,RECRUITING,INTERVENTIONAL,['NA'],,1-year DFS
8190,NCT04538677,Attitude and satisfaction with video consultation,2017-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Satisfaction of surgeons: Questionnaire
8191,NCT04682665,Effect of human faecal samples from patients treated with EPA or placebo on anti-tumour immune response in gnotobiotic mice with colorectal cancer liver metastasis,2021-09-16,RECRUITING,OBSERVATIONAL,['NA'],,
8192,NCT01816607,Presence of metastatic disease 5 years after rectal cancer treatment,2013-10,COMPLETED,OBSERVATIONAL,['NA'],Detection of regional malignant lymph nodes at time of diagnosis,Histomorphological response to preoperative chemoradiotherapy
8193,NCT01191684,Safety and tolerance of modified vaccinia virus ankara vaccine expressing p53 assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4 toxicity scale,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunogenicity
8194,NCT02919787,Overall survival 18 month after randomization,2016-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Health economics
8195,NCT02576548,"Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs) and dose-limiting (DLTs).",2015-09-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,Area under the plasma concentration versus time curve (AUC)
8196,NCT01876927,the difference in percentage of patients receiving all the planned chemotherapeutic cycles between the two arms.,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biologcal profile of treatment response
8197,NCT06249672,Low anterior resection syndrome,2023-01-17,RECRUITING,OBSERVATIONAL,['NA'],,
8198,NCT03280277,Technical feasibility of ultrasmall superparamagnetic iron oxide (USPIO) - magnetic resonance imaging (MRI) of the chest,2018-04-27,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Accuracy of USPIO - MRI
8199,NCT00508690,Incidence and classification of surgical site infection (SSI),2007-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Incidence of colitis, other infectious diseases and other postoperative complications."
8200,NCT00976976,"This protocol will evaluate the possible benefit of adjuvant docetaxel, capecitabine, and cisplatin combination chemotherapy in patients with resected gastric cancer pathologic stage IIIB and IV in terms of relapse free survival.",2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Investigate the safety profiles, patient tolerance, and overall survival in this population"
8201,NCT03590275,Overall survival,2017-10-02,COMPLETED,OBSERVATIONAL,['NA'],,Toxicity rate
8202,NCT02194829,Progression-free Survival,2014-08-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease Control Rate
8203,NCT01897038,Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs),2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Anti-therapeutic Antibodies (ATAs) Against Onartuzumab
8204,NCT05171426,incidental cancer,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
8205,NCT00155415,Cleansing level of colon and detected lesion number during colonoscopy,2005-04,COMPLETED,INTERVENTIONAL,['NA'],,
8206,NCT04286711,Dose-Limiting Toxicity [DLT],2020-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival [OS]
8207,NCT00204373,"Long-term Medical(Non-surgical)Control of Gastric Acid Production Assessed From Time of Study Enrollment, up to 240 Months Post Enrollment.",2003-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,The Median Survival From the Time of Diagnosis.
8208,NCT01570010,Overall survival,2012-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Health related quality of life and fatigue
8209,NCT03874559,Exosomal Biomarkers Assessment,2018-02-13,UNKNOWN,OBSERVATIONAL,['NA'],,Exosomal Functionality Assessment
8210,NCT02725125,Disease control rates,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],,Duration of remission
8211,NCT06194877,Part 2: ORR as Assessed by Initial Investigator Review,2024-03-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Part 2: Number of Participants with Reductions in Dosing with BGB-3245
8212,NCT03079778,Intrahepatic progression,2019-07-31,WITHDRAWN,INTERVENTIONAL,['NA'],Extrahepatic failure,QoL-quality of life
8213,NCT02999893,Establish the safety profile of combined APR-246 plus cisplatin and 5FU as measured by the satisfactorily low rate of adverse events described according to NCI CTCAE v 4.03.,2017-04-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of patients who will benefit from APR-246 therapy as assessed by quantitation of ctDNA levels in patient serum and plasma samples.,Evidence of clinical efficacy of a combined APR-246 and cisplatin/5FU chemotherapy regimen as confirmed by CT/PET/MRI scan.
8214,NCT00869271,overall survival,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,progression free survival
8215,NCT05934331,PFS,2023-07-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
8216,NCT00288093,MTD as assessed by the number of patients with dose-limiting toxicity (DLT),2006-12-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Therapeutic response as assessed using the Response Evaluation Criteria in Solid Tumors (RECIST)
8217,NCT01833832,Intraperitoneal Progression Free Survival (PFS),2013-04-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)
8218,NCT00006981,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8219,NCT01978717,The changes of peripheral immune cells and cytokines,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,
8220,NCT04104230,Knowledge and Tissue Bank,2012-03-12,RECRUITING,OBSERVATIONAL,['NA'],,
8221,NCT01633333,Pain during colonoscopy,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Dose of medication
8222,NCT03297710,Maximum tolerated dose (MTD),2017-12-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Time until treatment related grade 3+ toxicity,
8223,NCT05129787,Local tumor progression,2021-12-16,RECRUITING,INTERVENTIONAL,['NA'],,Inflammatory response
8224,NCT00005864,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8225,NCT01129700,To evaluate the pathologic response,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Acute/ late toxicities
8226,NCT01781403,Recommended Dose (RD),2013-05-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Disease-free Survival,Pathological Complete Response
8227,NCT03415451,The success rates of fiberscope-guided NG tube insertion,2017-10-01,COMPLETED,INTERVENTIONAL,['NA'],,
8228,NCT05215899,Mindfulness-based yoga and meditation intervention may reduce fatigue level of colorectal cancer patients,2021-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,
8229,NCT04411706,Objective Response Rate (ORR),2020-06-21,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety as measured by the rate of AEs
8230,NCT02942901,Overall Survival,2015-01,COMPLETED,OBSERVATIONAL,['NA'],,Number and sites of metastases detected by PET-CT
8231,NCT01306630,"To determine the safety, tolerability, and maximum tolerated dose of tivozanib when administered in combination with capecitabine (Xeloda®) to subjects with advanced solid tumors",2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To evaluate the antineoplastic activity of tivozanib and capecitabine, when given together, to slow the growth of or shrink tumor as measured by CT/MRI imaging assessment and according to RECIST criteria."
8232,NCT05882370,Objective response rate (ORR) by RECIST 1.1 and mRECIST,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-related adverse events,Median overall survival time (mOS)
8233,NCT00899210,Kinetics of postoperative changes of serum matrix metalloproteinases (MMP) and their inhibitors (TIMP),2003-09,COMPLETED,OBSERVATIONAL,['NA'],,Correlation of postoperative serum HGF/SF with plasma levels in MMPs
8234,NCT04063683,Progress free survival (PFS),2019-10-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Duration of Response(DOR)
8235,NCT06143748,Progression-free survival,2024-03-02,RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation between genetic biomarkers and survival,Treatment-related adverse events
8236,NCT01327521,Freedom from local progression at 6 months and 12 months,2011-02,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Serum AFP levels
8237,NCT00952003,To determine efficacy in terms of response rate according to RECIST criteria,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine overall survival time following treatment with a chemoimmune therapy
8238,NCT03892681,Specificity,2019-04,UNKNOWN,INTERVENTIONAL,['NA'],,Inter-reader agreement between two radiologists
8239,NCT00745134,Number of Participants With Pathologic Complete Response (pCR) Rate,2008-08-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Tumor Downstaging
8240,NCT06283134,MTD,2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Serum neutralizing antibody level
8241,NCT05898789,Disability,2023-07-07,RECRUITING,INTERVENTIONAL,['NA'],,Physiological measures of performance
8242,NCT01719549,Progression-free survival,2012-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,FGFR2 copy number
8243,NCT00392470,Pathologic response rate and histological degree of tumor regression as measured by Mandard TRG score,2006-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
8244,NCT02057562,Adenoma detection rate,2014-02,UNKNOWN,OBSERVATIONAL,['NA'],,Frequency of colon diverticulosis
8245,NCT03416478,Disease Free Survival,2018-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
8246,NCT05408897,recurrence,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
8247,NCT02089269,Treatment reality in Germany,2013-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
8248,NCT05194371,Overall survival,2021-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Proportion of using chemotherapy or target therapy concurrently with radiotherapy
8249,NCT06208436,Recurrence-free survival,2023-10-07,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
8250,NCT02786602,"Clinical characteristics (age, sex, tumor location) compared between LRP1 high and low methylation groups.",2016-05,COMPLETED,OBSERVATIONAL,['NA'],,
8251,NCT04143048,Genetic mutations of patients with stromal tumor assessed by next-generation sequencing,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,Genetic mutations of patients with stromal tumor assessed by next-generation sequencing
8252,NCT03161925,Overall survival,2016-11-28,UNKNOWN,OBSERVATIONAL,['NA'],,
8253,NCT05834543,ORR,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of serious adverse events (SAEs)
8254,NCT01074333,Safety and toxicity of Erbitux treatment,2008-09,TERMINATED,OBSERVATIONAL,['NA'],,Clinical efficacy of Erbitux treatment
8255,NCT01568723,Response to therapy,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,
8256,NCT02250053,"1. The biological efficacy of aerobic exercise on soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular adhesion molecule-1 (sVCAM-1) prognostic biomarkers.",2015-12,COMPLETED,INTERVENTIONAL,['NA'],,Circulating tumor cells measured at baseline and six-months.
8257,NCT01816256,Incidence of asymptomatic portal vein thrombosis (PVT) and/or portal hypertension (PHTN) in patients with Philadelphia negative myeloproliferative neoplasms (MPNs),2013-05,COMPLETED,INTERVENTIONAL,['NA'],Identify any genetic markers or biomarkers associated with asymptomatic PVT and PHTN,Comparison of survival and number of patients with leukemic transformation in patients with or without asymptomatic PVT/PHTN
8258,NCT05498779,Recurrence after ablation,2022-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival related to HCV virus
8259,NCT04293458,Primary Efficacy,2020-02-28,COMPLETED,INTERVENTIONAL,['NA'],Safety of EsoCheck device administration,Secondary Efficacy
8260,NCT06313190,Progression-free survival (PFS) rate,2024-04-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation between ctDNA and overall survival,Treatment-related adverse events
8261,NCT02624115,FAZA PET uptake in locally advanced rectal cancers prior to and after chemoradiotherapy,2016-05-01,COMPLETED,OBSERVATIONAL,['NA'],,Correlation of FAZA-PET and blood oxygen level-dependent MRI to Pimonidazole staining in locally advanced rectal cancer
8262,NCT03495674,Retention,2018-04-04,COMPLETED,INTERVENTIONAL,['NA'],,
8263,NCT04198766,MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab,2019-12-10,RECRUITING,INTERVENTIONAL,['PHASE1'],Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab,Immunogenicity of INBRX-106
8264,NCT00088816,Overall survival,2003-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
8265,NCT05354817,Assess response rate after 4 cycles of FOLFIRINOX,2021-10-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
8266,NCT02584244,"Correlate LUM015 fluorescence in gastrointestinal cancers (pancreatic, esophageal, and colorectal) with pathology results",2016-08-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Number of safety events in humans with colorectal, pancreatic, and esophageal cancer."
8267,NCT03974594,Bioequivalence based on Peak Plasma Concentration (Cmax),2019-05-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Adverse Event
8268,NCT01486251,Echography measure,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,
8269,NCT04295109,effective bolus times,2020-03-02,UNKNOWN,INTERVENTIONAL,['NA'],,postoperative hospitalization days
8270,NCT01157598,the satisfaction of patients and endoscopist in midazolam and meperidine induced sedation with BIS monitoring during ESD,2009-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,the dose of midazolam and meperidine during ESD with BIS monitoring
8271,NCT00640081,Failure-free survival at 10 months,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity of each treatment regimen by NCI CTCAE v3.0
8272,NCT02293954,Tumor Uptake of 64Cu-DOTA-hT4.66-M5A at Day 2,2015-11-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,The Average Increase of Tumor-to-blood (T:B) Ratio From Day 1 to Day 2
8273,NCT00426127,Tumor Response Measured by CT Scans After Each Set of 3 Cycles of Chemotherapy,2006-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety and Effect of Chemo Regimen on D-Dimer Measured by Drawing D-Dimer Levels Every Cycle
8274,NCT01831726,Clinical Benefit Rate (CBR),2013-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8275,NCT05080907,Collection of Biospecimens for Novel Research Uses,2016-07-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Number of subjects enrolled
8276,NCT02520453,Disease-free survival,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
8277,NCT02007876,Muscle Mass,2013-06,WITHDRAWN,INTERVENTIONAL,['NA'],Effect of MAT of Hospital Length of Stay,Effects of Individual MAT Program Segment
8278,NCT04274868,Establish a national bank of rare biological material,2015-09-10,RECRUITING,OBSERVATIONAL,['NA'],,
8279,NCT00558051,The primary endpoint of this study is to evaluate the feasibility and safety of semi-continuous intralymphatic vaccination dendritic cells.,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,"The secondary objective of this study is to evaluate the immunity results from either single injections or semi-continuous infusion, intradermal or intranodal, administered immunization with the DC vaccine for colorectal cancer (CRC) patients."
8280,NCT02703571,Objective Response Rate (ORR),2016-06-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,overall survival
8281,NCT05536427,Tolerance(DLT/ MTD/ OBD),2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
8282,NCT04520737,Physical Fitness- 6MWT,2020-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Nutritional status- UMA
8283,NCT05576480,Pathological complete remission rate (pCR),2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number and severity of adverse events
8284,NCT04544046,Proportion of participants requiring a hospital admission or emergency department visit,2020-09-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Change in Instrumental Activities of Daily Living (IADLs)
8285,NCT00149266,overall survival,1995-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,quality of life
8286,NCT01264822,Transition rate to secondary therapy for eradication of Helicobacter pylori,2011-01-13,COMPLETED,OBSERVATIONAL,['NA'],,
8287,NCT01336062,Objective response rate,2011-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,biomarkers
8288,NCT06263088,Biomarker testing rate of Black participants diagnosed with GI cancer,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Change in Health literacy score among black participants diagnosed with GI cancer
8289,NCT04032119,Overall procedural time,2020-01-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Lymphovascular invasion
8290,NCT03396705,Gene expression,2017-09-12,TERMINATED,OBSERVATIONAL,['NA'],,
8291,NCT02098239,Patient Survival,1999-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Injection Tolerability
8292,NCT00948337,Screening behavior for second primary cancer,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Knowledge and attitudes of Secondary cancer screening and dietary supplement
8293,NCT05203627,Objective measures of patient nutrition - Skeletal mass Index,2020-01-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
8294,NCT04775862,Progression-free survival (PFS),2021-02-21,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Determine the prevalence of RAS G12C mutation via using cfDNA
8295,NCT03652077,Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390 (Part 1 only),2018-09-24,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunogenicity of INCAGN02390
8296,NCT02966223,Primary,2017-08-17,TERMINATED,INTERVENTIONAL,['NA'],,Secondary
8297,NCT04777162,objective response rate,2021-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
8298,NCT00037804,,na,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8299,NCT01443065,Progression-free survival at 4 months,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tolerance of the treatment
8300,NCT03959839,local recurrence rate,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,Short-term local recurrence rate
8301,NCT00972036,"To determine the safety, toxicity, and maximum tolerated dose of SIR-Spheres® in patients with unresectable metastatic colorectal cancer to the liver (CLM) who have received previous hepatic arterial infusion chemotherapy (HAC).",2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,To obtain preliminary evidence of any clinical efficacy of the SIRT therapy in these heavily pretreated patients with unresectable CLM who have received hepatic arterial infusion pump and have failed at least one line of prior chemotherapy.
8302,NCT02679495,gastric caner occurrence,2015-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,gastric tissue DNA methylation change of selected genes
8303,NCT05323929,scar area,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
8304,NCT01688817,Effect of primary care physician's (PCP) counseling on participation rate in primary colonoscopy screening program,2008-05,COMPLETED,INTERVENTIONAL,['NA'],,Effect of primary care physician's (PCP) counseling on a patient's decision to choose unsedated colonoscopy (not in sedation).
8305,NCT05993702,Progression-free Survival (PFS),2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Incidence and severity of adverse events (AE) and serious adverse events (SAE)
8306,NCT05369650,Immediate postoperative plasma lidocaine concentration,2019-07-27,RECRUITING,INTERVENTIONAL,['NA'],,Patient satisfaction scores
8307,NCT02136836,The proportion of HER2 overexpression in gastric cancer patients,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],The practice pattern of Herceptin use in stage IV gastric cancer,Gastric cancer specific survival according to HER2 expression in each stage
8308,NCT05332002,Adverse Event Rates,2022-07-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,
8309,NCT06249841,"The primary endpoint of this study is feasibility of percutaneous cryobiopsy in the bile duct, i.e., successful retrieval of at least one cryobiopsy specimen per patient.",2024-03-04,RECRUITING,INTERVENTIONAL,['NA'],,"Rate of safety-relevant aspects, like for example bleeding, post-bleeding, perforation, infection and abscess"
8310,NCT04596865,Patterns of disease recurrence,2020-10-12,COMPLETED,OBSERVATIONAL,['NA'],,"Determine if/how specific patterns of recurrence (local only, distant only, synchronous local and distant) following pancreaticoduodenectomy for pancreatic head malignancy correlate with the following factors:"
8311,NCT02444572,Incidence of asymptomatic Deep Venous Thrombosis (DVT),2015-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Incidence of both Enoxaparin formulations immunogenicity
8312,NCT00897832,Determination if a method of extracting and identifying biomarkers from tissues of the quantity obtained from typical biopsy can be applied in the setting of pancreatic cancer,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,
8313,NCT01317433,reduction of Grade > or = 2 acne-like skin rash by 30%,2010-12-29,TERMINATED,INTERVENTIONAL,['NA'],,Resectability rate
8314,NCT00580281,"This pilot study will collect longitudinal data on bone metabolism for patients treated with imatinib. Sixty patients will be followed over a two-year period on this protocol, with bone marker assessments ascertained every 3 months (+2 weeks).",2006-11,COMPLETED,INTERVENTIONAL,['NA'],,
8315,NCT02081755,"Disease free survival (DFS) defined as the time from randomization to the time of tumor recurrence or death, whichever occurs first.",2014-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,Hepatic arterial thrombosis
8316,NCT02311907,"Paclitaxel/Carboplatin (PC) Induced Peripheral Neuropathy as Assessed by EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer (EORTC), Quality of Life (QLQ), Chemotherapy Induced Peripheral Neuropathy 20 (CIPN20)).",2009-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Times to Onset of CTCAE Grade 3+ PN
8317,NCT05711823,Complete response rate,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,
8318,NCT05181605,Overall Survival,2022-04-15,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse events
8319,NCT00663741,Safety and pharmacokinetics,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Duration of response
8320,NCT02640781,Duration of stent patency between stent insertion and recurrence of obstructive symptoms,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,Number of patients with complications
8321,NCT00534053,Our primary outcome is FOBT card return rate,2007-06,COMPLETED,INTERVENTIONAL,['NA'],,Predictors of Non-compliance to fecal occult blood testing
8322,NCT00060411,The relationship between CYP3A4 activity and OSI-774 clearance,2003-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Pharmacokinetics of OSI-774 given with FOLFOX 4, and Bevacizumab"
8323,NCT02227940,"MTD and RP2D of ceritinib in combination with gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation, defined as the highest dose level at which < 2 of 6 patients experience treatment-related DLT (Arms 2 and 2E)",2015-01-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Levels of serum and tumor biomarkers,Response rate as assessed by the RECIST 1.1
8324,NCT01198743,local recidivism or metastasis reappearance,2005-11,COMPLETED,OBSERVATIONAL,['NA'],,specificity and global safety
8325,NCT00920023,To Determine the Specificity of High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles to Identify Small and Otherwise Undetectable Lymph Node Metastases.,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,
8326,NCT01945879,Incidence of NCI CTC Toxicity III°/IV° and severe bleedings,2003-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival
8327,NCT04050462,Objective Response Rate (ORR) of Cabiralizumab or BMS-986253 in combination with Nivolumab in comparison to Nivolumab monotherapy,2019-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
8328,NCT03046849,Pathogenic germline mutation,2017-03-08,COMPLETED,OBSERVATIONAL,['NA'],,Variant of uncertain significance of germline mutation
8329,NCT01956149,Disease Control Rate (DCR),2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlation of circulating tumor cells with the clinical response
8330,NCT00482586,"Development of a data repository for health-related quality of life outcome measures by administering the Medical Outcomes Study Short Form questionnaire at baseline, during routine follow-up after image-guided therapy, and then annually thereafter",2003-10,COMPLETED,OBSERVATIONAL,['NA'],,
8331,NCT06276140,Overall morbidity,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Values of different erythrocyte indices
8332,NCT03257280,Hospital stay,2017-10-20,UNKNOWN,INTERVENTIONAL,['NA'],,Impedancemetry
8333,NCT02815150,preoperative gastric residual volume of gastric fluid,2016-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Reoperation rate within 30 days post operation
8334,NCT06218810,1-year Progression Free Survival rate,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,irORR
8335,NCT00237185,Best Tumor Response (Core + Extension),2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Progression (Core + Extension)
8336,NCT06010888,Objective Response Rate（ORR）,2023-10-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival（OS）
8337,NCT03393234,3-year disease free survival,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,sexual function
8338,NCT03498885,Anastomotic leakage,2018-01-01,RECRUITING,INTERVENTIONAL,['NA'],,5-years disease free survival rate
8339,NCT00650988,Number of patients that experience toxicity with cryotherapy,2005-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Assess the degree of tumor ablation of inoperable early esophageal cancer
8340,NCT05250843,Recurrence-free Survival,2022-05-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse effects
8341,NCT02163759,"Percentage of Participants in Remission at Week 10 With Etrolizumab as Compared With Placebo, as Determined by the Mayo Clinic Score (MCS), GA28948 Population",2014-11-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Number and Percentage of Participants With Anti-Drug Antibodies (ADAs) to Etrolizumab at Baseline and Anytime Post-Baseline, GA28948 Population"
8342,NCT02502474,Number of patient with Staphylococcus aureus colonic carriage,2015-02-02,COMPLETED,INTERVENTIONAL,['NA'],,Number of patient with Staphylococcus aureus carriage in the groin
8343,NCT04340141,Overall survival (OS),2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Computed tomography (CT)-based radiomics as non-invasive predictors of overall survival
8344,NCT03816163,Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities and or adverse events,2019-03-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Health Related Quality of Life (HRQoL) measured by the Patient Global Impression of Severity (PGIS) Scale
8345,NCT01746771,Safety evaluation(phase I),2012-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Efficacy evaluation(Phase II)
8346,NCT03252938,Feasibility rate,2017-08-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immune response in whole blood and tumor tissue
8347,NCT01966289,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2014-04-14,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression Free Survival (PFS)
8348,NCT03768687,Progression free survival,2018-12-20,UNKNOWN,OBSERVATIONAL,['NA'],,
8349,NCT01477229,"To describe QoL, symptoms and functional impairments in an unselected population of rectal cancer patients",2012-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,QoL in an unselected population of rectal cancer patients
8350,NCT02892721,Difference in sensitivity between arms,2017-04-20,COMPLETED,INTERVENTIONAL,['NA'],,Characteristics of radiologists performing well versus those that do not.
8351,NCT00656838,"To determine the effectiveness and maintenance of a colon-rectal cancer screening patient reminder program.Identify patient, primary care team, and system factors important to implementation success.",2008-04,COMPLETED,INTERVENTIONAL,['NA'],,"Create, refine, and disseminate an implementation guide for colon-rectal cancer screening reminder programs by combining the findings from the primary aim."
8352,NCT03693170,Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments,2019-01-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,PGIC Scores Over Time
8353,NCT02500043,Overall Survival (OS),2016-02-24,COMPLETED,INTERVENTIONAL,['PHASE3'],EORTC Quality of Life Questionnaire - Gastric-specific Module (EORTC QLQ-STO22): Percentage of Participants With Overall Compliance,Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE)
8354,NCT05736731,Phase 2: The Overall Response Rate (ORR) for patients,2023-04-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Cytokine analysis
8355,NCT02632682,Probe-based confocal laser endomicroscopy (pCLE) will be compared to standard histologic analysis in the evaluation of Barrett's esophagus.,2016-02,COMPLETED,OBSERVATIONAL,['NA'],,
8356,NCT06138223,Quality of life (EORTC-QLQ-30) summary score,2023-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],(Serious) Adverse Events potentially related to the exercise intervention,Health-related quality of life: fatigue
8357,NCT03043183,complication,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,
8358,NCT00005639,Minimal Effective Dose (MED) of Azacitidine with Phenylbutyrate,2000-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Gene-re-expression of epigenetic modulation in Peripheral Blood Mononuclear Cells (PBMC) as measured by change in Epstein-Barr Virus (EBV) viral load (number of copies per 1 million cells) after treatment with Azacitidine
8359,NCT00321685,Pathologic Complete Response Rate,2006-07-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,5-year Recurrence-free Survival Rate
8360,NCT02316496,Objective response rate (ORR),2015-09-23,TERMINATED,INTERVENTIONAL,['PHASE2'],,PFS
8361,NCT05156866,Recommended Phase 2 Dose (RP2D),2022-02-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Accumulation ratio (Rac) of TORL-2-307-ADC
8362,NCT01509911,Disease Control Rate as defined by Percentage of patients experiencing a Complete Response or a Partial Response or a Stable Disease according to RECIST measured at 16 weeks after treatment initiation,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
8363,NCT02331927,Randomized part: PFS rate at 6 months after first cycle after randomization,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Prognostic value of CAF at baseline and/or during treatment
8364,NCT04699994,"Histological response rate (Grade 2 or 3 in Japanese Classification of Esophageal Cancer, 11th Edition)",2020-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence rate of all adverse event
8365,NCT00003939,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8366,NCT04605237,Survival,2014-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Number of histologically confirmed recurrences
8367,NCT05775159,Progression free survival (PFS),2023-04-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective response rate (ORR)
8368,NCT01252498,Salivary levels of PGE2 and PGI2 during and after radiotherapy,2010-12,COMPLETED,OBSERVATIONAL,['NA'],,Patient reports of oral pain during and after radiation therapy
8369,NCT04315883,Evaluate the efficacy and clinical utility of TARE-Y90 by examining clinical course,2021-02-11,RECRUITING,OBSERVATIONAL,['NA'],,
8370,NCT00838968,5-years survival rate,2008-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
8371,NCT01082757,Mutational status of KRAS: study of codons 12 and 13 in exon 1 of KRAS gene,2009-06,COMPLETED,OBSERVATIONAL,['NA'],,Subject and tumour characteristics and their association with KRAS mutational status
8372,NCT02139605,primary endpoint:Overall Survival,2013-07-05,RECRUITING,INTERVENTIONAL,['NA'],,Disease-free survival
8373,NCT00834158,the rate of tumor resection after intervention,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,rate of survival
8374,NCT00960284,1-year progression-free survival (Phase II),2003-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Pattern of relapse
8375,NCT04120935,Number of patients longitudinally monitored,2019-10-15,RECRUITING,OBSERVATIONAL,['NA'],Correlation of new prognostic and predictive biomarkers with clinical outcomes,Number of patients triaged in proof-of-concept (POC) clinical trials
8376,NCT02137343,Overall Survival,2014-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,"Incidence of subject adverse events, laboratory abnormalities and immunogenicity"
8377,NCT01034683,objective response rate(ORR) time to progression (TTP) toxicities,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,1-year survival rate KPS score
8378,NCT00003063,,1991-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8379,NCT01897584,arterial oxygenation (PaO2),2013-07,COMPLETED,INTERVENTIONAL,['NA'],,cerebral perfusion pressure
8380,NCT06271109,complete resection of the neoplasm,2021-12-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,recurrence rate
8381,NCT06026618,Change in Hemoglobin,2012-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,number of complications related to IVI administration
8382,NCT03659357,the size in centimeters,2018-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,intensity of the neoplasms measured in the CTE in Hu
8383,NCT05816980,Resection rate,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Comparative dose planning study
8384,NCT01186081,Disease-free survival,2004-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Treatment related toxicities
8385,NCT02980510,Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab.,2016-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
8386,NCT00960609,First outcome was the rate of CVs detectable with e-flow IOUS along clamping of the HV for which resection could be needed.,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,"Secondary outcome was safety (morbidity, mortality, blood loss, blood transfusions) of the procedure."
8387,NCT04810156,Time to response or downgrading of liver injury in days,2021-04-07,RECRUITING,INTERVENTIONAL,['PHASE2'],Description of changes in the fecal microbiome,Overall survival rates at 6 months
8388,NCT02005614,Rate of Local Control Over time (RECIST Criteria),2013-11,TERMINATED,INTERVENTIONAL,['NA'],,
8389,NCT00838318,"To look at the knowledge, beliefs, and attitudes toward screening for colorectal cancer among Hispanic colorectal cancer patients and their close relatives.",2004-02,COMPLETED,OBSERVATIONAL,['NA'],,To study how these families communicate with each other and health care providers about colorectal cancer risk and screening.
8390,NCT04984733,Tumour Response to nivolumab,2021-09-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,The percentage of patients who have achieved response
8391,NCT03781050,Total load of PJS-related intestinal polyps Total load of PJS-related intestinal polyps Total load of PJS-related intestinal polyps,2018-09-16,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Adverse events
8392,NCT01867697,Response rate (RR),2012-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency of secondary micro-radical surgical resection (R0 resection)
8393,NCT05494086,Early operative morbidity,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],,5 year overall survival rate
8394,NCT01911273,Overall Survival (OS),2013-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Observed Serum Concentration of Circulating Protein
8395,NCT00010023,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8396,NCT00257322,Participants Exhibiting Immune Response,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response Rates and Overall Survival.
8397,NCT05978193,PFS,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Grade III and higher treatment-related adverse events
8398,NCT01440959,Disease Control Rate (DCR; OR + Stable Disease),2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
8399,NCT04582981,progression free survival (PFS),2020-09-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],quality of life score (QOL),disease control rate (DCR)
8400,NCT03862378,Predictive value of the nomogram prediction model (APPEAL-GC score),2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Abdominal infection outcome.
8401,NCT00184834,,1999-06,COMPLETED,OBSERVATIONAL,['NA'],,
8402,NCT02827201,Rate of patients alive without progression 6 months after inclusion,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival:
8403,NCT05239169,Recurrence free survival at 12 months (RFS@12).,2022-05-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,QoL EQ-5D-5L
8404,NCT04276909,Assess the initial safety and efficacy of the LUM Imaging System for detection of primary pancreatic cancer and peritoneal invasion from primary pancreatic cancer during surgery,2026-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Correlate resected tissue with LUM Imaging System to identify imaging threshold
8405,NCT02960620,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
8406,NCT00885469,"Accuracy parameters (sensitivity, specificity, NPV, PPV) of PillCam ESO 2 in detecting suspected Barrett's Esophagus (BE) as compared to standard EGD, using unblinded EGD as the reference standard.",2007-12,COMPLETED,OBSERVATIONAL,['NA'],,Subjects' satisfaction will be assessed by a post procedure questionnaire
8407,NCT05645198,Ratio of (patient who suffers from) pancreatic fistula,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE4'],,
8408,NCT05440864,Number of greater than grade 3 adverse events (AEs) or immune related adverse events that leads to treatment cessation,2023-10-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Taxonomic profiling of gut microbiome,Rates of R0 resection
8409,NCT05018182,Pathological response,2021-08-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of patients with 30-day post-operative mortality
8410,NCT01643070,R0 resection rate after simultaneous surgery of the rectum and the liver,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
8411,NCT04343456,Disease free survival,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
8412,NCT03452774,Proportion of patients Eligible for CTE versus Actual CTE,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Time from Intervention to Actual CTE (months)
8413,NCT02113202,"Number of fluorescent adenomatous polyps during surveillance endoscopy using the near-infrared fluorescence endoscopy platform in patients with Familial Adenomatous Polyposis (FAP), after administration of the fluorescent tracer bevacizumab-IRDye800CW.",2014-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Measure the mean fluorescent intensity of adenomas and compare this between the three different dosing groups to determine the best tracer dose for the fluorescence endoscopy procedure.
8414,NCT01622569,Change in Total Polyp Grade,2013-11-19,COMPLETED,INTERVENTIONAL,['PHASE3'],,Nasal Polyp Surgery Eligilbilty
8415,NCT00740753,"Tumor response after treatment based on tumor marker and lab results, CT scan and patient's symptoms.",2004-08,COMPLETED,INTERVENTIONAL,['NA'],,
8416,NCT04166240,EPRP Outcome,2018-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
8417,NCT03925428,Maximum tolerated dose,2020-09-18,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Effect of GSK525762C and entinostat combination therapy on gene expression patterns,Duration of response
8418,NCT00296335,Relapse-free Survival Rate,2002-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Patients With Adverse Events
8419,NCT04104139,Proportion of dose limiting toxicity (DLT)s for TAS-102 at the maximum tolerated dose (MTD),2019-12-11,RECRUITING,INTERVENTIONAL,['PHASE1'],Rate of pathologic complete response after standard total mesorectal excision (TME),Incidence of grade 3 or higher treatment emergent adverse events (TEAEs) during FOLFOX or CAPOX treatment
8420,NCT00976768,Progression-free survival,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rate
8421,NCT03216174,Complete resection,2017-07-11,UNKNOWN,INTERVENTIONAL,['NA'],,
8422,NCT05012540,The overall survival,2013-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
8423,NCT03876561,Severity of Low Anterior Resection Syndrome Score (LARS score),2019-05-27,UNKNOWN,INTERVENTIONAL,['NA'],,Medico-economic impact of pelvic floor prehabilitation including the fecal incontinence related costs
8424,NCT02930291,3-year disease free survival rate,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],,Visual Analog Score for pain
8425,NCT02198976,Number of Serious and Non-Serious Adverse Events,2014-04,RECRUITING,OBSERVATIONAL,['NA'],,Number of Participants with Serious and Non-Serious Adverse Events
8426,NCT04825288,Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0,2021-05-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Cardiotoxicity measured by the number of required ECGs and cardiotoxicity related events summarized by treatment arm and compared over time,Change in (CD14+CD16+IL-1⍺+) triple positive tumor associated monocytes in peripheral blood
8427,NCT01171755,Response rate,2008-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,
8428,NCT01766765,The time to the first adjuvant chemotherapy,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Rehospitalization rate
8429,NCT04656392,Specificity of the eNose for detecting confirmed BE,2021-04-20,RECRUITING,INTERVENTIONAL,['NA'],,Safety of eNose based on reported Adverse Events.
8430,NCT00905710,"The primary endpoints of the study are the number of adenomas, advanced adenomas, carcinomas at baseline and the number of the number of adenomas, advanced adenomas, carcinomas and the number of patients requiring colectomy at 2-year follow-up.",2008-09,COMPLETED,INTERVENTIONAL,['NA'],,The secondary endpoints of the study are the number of complications from colonoscopy at baseline and at 2-year follow-up.
8431,NCT04719988,Clinical complete response (cCR) at 10 months,2022-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
8432,NCT00042939,Proportion of Patients With Objective Response Evaluated by RECIST (Solid Tumor Response Criteria),2003-12-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Proportion of Patients With Thromboembolic Events
8433,NCT02562963,"Objective Response Rate (ORR), confirmed by CT or MRI, or confirmed by biopsy",2015-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor Marker
8434,NCT03499808,Overall confirmed hematologic response rate,2018-06-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival
8435,NCT05101382,Number of retrospectively recruited CRC cases,2020-10-28,RECRUITING,OBSERVATIONAL,['NA'],Biomarkers correlation with OS,
8436,NCT00466856,Tumor response,2003-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Patient report of Health-related quality of life (HRQOL)
8437,NCT01449864,Acute Toxicity,2011-08,COMPLETED,INTERVENTIONAL,['NA'],,
8438,NCT04160416,Incidence of adverse events,2019-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
8439,NCT02095678,Mean Transit Time (MTT),2013-12-01,COMPLETED,INTERVENTIONAL,['NA'],,Minimal Breathhold Time
8440,NCT04751448,Microbiome-Based Prediction of Chemotherapy-induced Diarrhea in Colon Cancer,2021-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Dietary-Based Prediction of Chemotherapy-induced Diarrhea in Colon Cancer
8441,NCT04444622,Incidents of Adverse Events (AE),2021-07-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,
8442,NCT01821105,Detection of Position Accuracy With Handheld Probe on Anatomical Location.,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor Detection
8443,NCT01458925,safety - transit time (less than 300 hours),2011-11-20,TERMINATED,INTERVENTIONAL,['NA'],,"Colon Capsule correlation map (Empirical, qualitative)"
8444,NCT04180072,Best overall response rate,2020-03-12,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
8445,NCT05832372,Prevalence or occurrence of upper gastrointestinal diseases,2023-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
8446,NCT05368506,Incidence of adverse events,2023-07-30,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],Cellular and molecular characteristics,Overall survival
8447,NCT00224601,Number of pre-cancer lesions or early cancer detected.,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Anatomopathologic criteria (size of lesions, …)."
8448,NCT04406974,Patient experiences after local recurrence,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
8449,NCT02650271,overall survival,2021-02-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Perioperative reactivation of hepatitis B virus replication,Recurrence rate
8450,NCT05699746,Recurrence-free survival,2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Clearance of circulating tumor DNA (ctDNA)
8451,NCT01774344,Overall Survival (OS),2013-05-14,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall Survival (OS),Disease Control Rate (DCR)
8452,NCT01767597,Percentage of Patients Appropriately Seeking Care,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,
8453,NCT02766842,Diagnostic accuracy of needle as assessed by diagnostic yield of needle and final diagnosis method,2016-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Procedure time
8454,NCT03144843,Progression-free survival (PFS),2017-01-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety (incidence of adverse events) [
8455,NCT02656134,Genetic profile in FAP patients,2015-03,UNKNOWN,OBSERVATIONAL,['NA'],,
8456,NCT00441337,Percent of Participants With Prostate-Specific Antigen (PSA) Response After the First Dose by Day 85 In Participants With Hormone-Refractory Prostate Adenocarcinoma (HRPC),2006-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Mean Systolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in in 1mg, 3mg, and 10 mg Cohorts - Safety Population"
8457,NCT04273477,The prediction accuracy of the radiomics prediction model,2020-01-10,UNKNOWN,OBSERVATIONAL,['NA'],,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of the radiomics prediction model
8458,NCT03043950,Overall Survival (OS) of pre-defined risk groups low vs. high,2017-01-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Adverse Drug Reactions,Antineoplastic treatment in later lines
8459,NCT04726319,Changes in risk-appropriate screening based on family history,2021-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Attitudes towards the FHAMe intervention
8460,NCT01763450,To assess the objective response rate(ORR),2012-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],To assess the incidence of adverse events of level 3-4 （Bleeding、Gastrointestinal Perforation、Anastomotic Fistula、Hypertension、Wound Healing Delay）,To assess the R0 resection rate of liver metastases
8461,NCT03682744,Safety of Intraperitoneal CAR-T Cell Infusions as Measured by Number of Participants with Adverse Events,2018-09-13,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Serologic response rates
8462,NCT03840590,"Adenoma detection rate, ADR",2019-07-10,COMPLETED,INTERVENTIONAL,['NA'],,"Polyp detection rate, PDR"
8463,NCT05076305,Assessment of resectability,2021-10-15,UNKNOWN,OBSERVATIONAL,['NA'],,Assessment of staging
8464,NCT03921684,Incidence of Treatment-Emergent Adverse Events (Safety),2019-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8465,NCT05919758,Recurrence rate,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Health related Quality of Life at follow-up moment for this study
8466,NCT05990257,pain control,2018-07-01,RECRUITING,INTERVENTIONAL,['NA'],,
8467,NCT01427647,Plasma levels of several cytokines after colorectal cancer surgery,2007-06,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of adverse clinical outcomes between groups
8468,NCT02078245,MRI accuracy,2010-08,RECRUITING,OBSERVATIONAL,['NA'],,Outcome of surveillance program
8469,NCT02178644,pCR Rate,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8470,NCT01303172,Safety and Tolerability.,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival in Metastatic Patients Only
8471,NCT05547568,Major postoperative complications (Dindo-Clavien ≥ 3 grade),2012-09,COMPLETED,OBSERVATIONAL,['NA'],,
8472,NCT00210184,2-month Response Rate,2004-07-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival
8473,NCT00972881,Histologically confirmed R0 resection rate,2009-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Local failure-free survival
8474,NCT04241887,Effectiveness of PVB on pain intensity,2017-09-09,COMPLETED,INTERVENTIONAL,['NA'],,Surgeon's satisfaction
8475,NCT00182611,Overall survival,2004-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events
8476,NCT02618850,change from baseline in highest value SUVmax (maximum standardized uptake values in PET/CT scan),2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],"prognostic value of metabolic response (SUVmax, SUVmaxsum, TLGmax, TLGsum) by different cut off values (other than 50% reduction)","prognostic value of metabolic response (SUVmax, SUVmaxsum, TLGmax, TLGsum) and recist response"
8477,NCT05004350,Randomized Phase 2: Progression-free Survival (PFS) by Blinded (to treatment received) Independent Central Review (BICR),2021-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Randomized Phase 2: Microsatellite Instability (MSI) status in Formalin-fixed and Paraffin Embedded (FFPE) samples using established Polymerase Chain Reaction (PCR) assays in tumor sample versus germline control at screening,Randomized Phase 2: Population pharmacokinetic (PK) analysis using the ARRAY 818 302 study PK data
8478,NCT02979691,Overall survival,2016-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Clinical target contouring guided by MRI or CT simulation,Chemoradiotherapy toxicities
8479,NCT05183425,The consistency of drug sensitivity,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,The establishment of PDO
8480,NCT04005742,Serum high-sensitivity C-Reactive Protein concentrations (marker of systemic inflammation),2017-03-13,COMPLETED,OBSERVATIONAL,['NA'],Sedentary behaviour assessed using Lifestyle Questionnaire,HbA1c in whole blood
8481,NCT01521702,progression-free survival,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,complication
8482,NCT05620485,Long-term complications,2022-11-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,length of nutritional support in hospital
8483,NCT00352833,safety and efficacy data,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8484,NCT04179773,"Frequency of patients with ENT, upper digestive-tract or colorectal cancer with a diagnosis of cirrhosis",2019-01-24,RECRUITING,OBSERVATIONAL,['NA'],,Frequency of chemotherapy side effects according to CTCAE version 5.0 classification in cirrhotic patients who have received chemotherapy
8485,NCT05924880,The incidence of Possible related adverse events(PRAE) Grade 3 or 4,2023-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse Events(AEs) resulting in study intervention interruption and discontinuation
8486,NCT03843905,Overall survival (OS),2018-11-15,UNKNOWN,OBSERVATIONAL,['NA'],,Microbiota composition
8487,NCT02054598,Colorectal cancer screening completion,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Colorectal cancer screening related intent
8488,NCT05665322,Efficacy of conventional CT versus porto-scanner for thermoablation of colorectal cancer liver metastases between groups,2023-01-31,RECRUITING,INTERVENTIONAL,['NA'],,Reason for for failure of technique requiring switch to different guidance technique
8489,NCT02600481,Troponin T level is set as the marker of myocardial injuries after robot-assisted surgeries,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,Chest CT scan is used to determine pulmonary complications
8490,NCT01777698,Changes in body composition,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,
8491,NCT04665947,[177Lu]Lu DOTA-ABM-5G dose escalation therapy,2020-12-18,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Assessment of organ dosimetry of [177Lu]Lu DOTA-ABM-5G
8492,NCT05257408,Progression-free Survival as Assessed by BICR,2022-06-29,RECRUITING,INTERVENTIONAL,['PHASE3'],,Combined Response According to RECIST v1.1 and GCIG Criteria
8493,NCT00036790,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8494,NCT02891447,Patterns of tumor recurrence,2016-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
8495,NCT03093116,Overall Response Rate (ORR) Phase 2,2017-03-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Intracranial objective response rate (Phase 2)
8496,NCT03650517,Clavien Dindo Complication,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA'],Pain evaluation,C-Reactive Protein value (CRP) days 1 & 3 postoperative
8497,NCT04716062,Clavien Dindo score (post-operative complications),2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Lenght of specimen
8498,NCT01243398,Overall survival,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression-free survival
8499,NCT03177317,Complete response (CR),2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Complete protection (CP)
8500,NCT01657175,Quality of Life,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,Contacts with the health care system
8501,NCT01876069,The rates of diagnostic sufficiency,2013-07,COMPLETED,INTERVENTIONAL,['NA'],Procedure related complications,The presence of histologic core
8502,NCT06326736,Incidence of Treatment Emergent Adverse Events (TEAEs),2024-04,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Disease control rate (DCR)
8503,NCT05940740,Nightingale Symptom Evaluation Scale,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Self-Care Needs Evaluation Form
8504,NCT05495048,disease-free survival rate,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],,
8505,NCT04303286,Species differential analysis,2018-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
8506,NCT06178211,pCR rate,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Potential biomarkers such as ctDNA or PD-L1 expression
8507,NCT05643989,Bowel preparation (absence of feaces) according to Boston Bowel Preparation Scale,2019-11-01,RECRUITING,INTERVENTIONAL,['NA'],,Late complications rate during resectional surgery
8508,NCT06199115,Neuropathic Pain Synptom Inventory : pain,2023-05-31,RECRUITING,INTERVENTIONAL,['NA'],,Evaluation of sensitive and motor symptoms
8509,NCT03415126,"Part B: evaluate the overall response rate (number of Complete Responses + Partial Responses) in subjects receiving ASN007 for the treatment of metastatic melanoma, CRC, NSCLC, or pancreatic cancer.",2018-01-19,COMPLETED,INTERVENTIONAL,['PHASE1'],Evaluate the change from baseline in the amount of circulating tumor DNA,Calculate the terminal elimination rate (T 1/2).
8510,NCT00969657,Pathological complete response (ypT0N0),2009-08,COMPLETED,OBSERVATIONAL,['NA'],,"Several extra outcomes are registered for research: Local relapse at 2 years, metastases free survival, survival and relapse free survival"
8511,NCT06006390,Obtained the recommended dose and infusion regimen of CAR-T cells for the treatment of patients with CEA-positive advanced malignancies[Safety and Tolerability],2023-09-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival(OS)of CEA CAR-T treatment in patients with CEA-positive advanced malignancies[Effectiveness],Pharmacodynamics of CEA CAR-T cells[Cell dynamics]
8512,NCT05771025,Overall survival time,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Unplanned reoperation rate
8513,NCT05519202,Pathological complete response(pCR),2022-08-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,tumor regression grade(TRG)
8514,NCT06307548,Changes in carcinoembryonic antigen (CEA) and circulating tumor deoxyribonucleic acid (ctDNA) (Phase II),2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Correlation between disease free survival and changes in levels of ctDNA (Phase II)
8515,NCT02943265,Patient Perception of Care (Scale),2017-09-18,COMPLETED,INTERVENTIONAL,['NA'],,
8516,NCT02473094,Pathological Complete Response,2015-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of Life
8517,NCT06228599,Adverse Events,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
8518,NCT01399684,Progression-Free Survival Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 as Determined by the Investigator,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in ATAs Levels of MEGF0444A
8519,NCT02002195,progression-free survival,2013-11,UNKNOWN,OBSERVATIONAL,['NA'],,time to treatment failure
8520,NCT05253846,complete pathologic response (pCR),2022-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation of FFS and pCR with ctDNA status,Rectal Continence
8521,NCT00408070,Progression Free Survival Rate at 9 Months,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Determine Tolerability to 12 Months (q 3 Weeks) of Bevacizumab Maintenance Therapy
8522,NCT05061537,Objective response rate in the dose expansion (Part 2) arms,2021-10-20,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival (Part 2)
8523,NCT01637805,Objective response rate,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
8524,NCT04874259,1 year patient survival,2022-08-22,RECRUITING,INTERVENTIONAL,['NA'],,Recurrence
8525,NCT05103904,Overall response rate (ORR),2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response (DR)
8526,NCT04464668,Change in Colorectal Cancer Screening Rates - Repeat FIT,2020-06-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Differences in Screening Rates
8527,NCT02843217,"Colorectal Cancer Screening, beginning age 50",2010-09,COMPLETED,INTERVENTIONAL,['NA'],,
8528,NCT02560376,Standardized uptake value of 68Ga-NOTA-exendin-4 PET/CT in Diagnosis of Insulinoma and Nesidioblastosis,2014-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Adverse events collection
8529,NCT01205022,Maximum tolerated dose of yttrium-90 (90Y) M5A anti-CEA antibody when given in combination with FOLFIRI chemotherapy and bevacizumab,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Estimation of radiation doses to whole body, normal organs, and tumor through serial nuclear imaging"
8530,NCT06154538,pCR rate,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],serious adverse event,OS
8531,NCT04038619,Clinical response/remission of immune-related diarrhea/colitis,2021-02-01,RECRUITING,INTERVENTIONAL,['PHASE1'],"Frequencies of immune cells (CD4/8 T cells, regulatory T cells [Treg], macrophages, etc.) in tissue/blood/stool samples",Recurrent immune-related diarrhea/colitis within 3 months post-FMT after initially achieving clinical remission/response
8532,NCT00780117,Annual lumbar-sacral MRI is performed,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,Annual serum alpha-foeto protein level monitoring
8533,NCT03602079,Phase I: Maximum Tolerated Dose,2018-07-16,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase I Volume of distribution at steady state (Vss).
8534,NCT04250402,Number of gallstone patients,2020-02-14,RECRUITING,OBSERVATIONAL,['NA'],,"Number of physical regurgitation, nausea, vomiting, diarrhea, constipation"
8535,NCT06107920,the success of a full curative therapeutic,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life evaluated using EORTC QLQ-C30 and QLQ-CR29 dedicated to CRC
8536,NCT06141031,Phase 2: To assess pathologic response rate (R0 resection) for those who revert to resectable status,2024-01-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Assess quality of life associated with treatment protocol using EORTC QLQ-C30
8537,NCT02728193,Death,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
8538,NCT06080204,Disease-free survival time,2008-03,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival time
8539,NCT00045461,Quality of life,2000-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
8540,NCT04258969,Feasibility of Pedaling Concurrent to Chemotherapy Infusion,2020-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Symptom Severity
8541,NCT05339230,Incidence of diarrhoea CTCAEv5.0 ≥ grade 2.,2020-12-15,RECRUITING,INTERVENTIONAL,['NA'],Change in liver metastasis tumor blood flow.,Incidence of adverse events CTCAEv5.0 grade ≥ 3 considered probably related to investigational products/placebo.
8542,NCT02307539,Qualitative interview data,2014-11,COMPLETED,INTERVENTIONAL,['NA'],,"Patient/family out of pocket expenses, as measured by the Finances and Out of Pocket Costs Tool"
8543,NCT03164655,Curative-intent (R0-R1) resection (and/or ablation) rate (CRR) of CRLM,2018-07-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8544,NCT05879861,Status of frailty,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,
8545,NCT01538680,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
8546,NCT02017600,the R0 resection rate of participants,2013-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,1-year overall survival rate of participants
8547,NCT02674100,Adverse Events,2016-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival
8548,NCT00637559,"To compare the total percent time during the 24-hour monitoring period that gastric pH is above 4.0 at steady state in patients when taking: esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole 20 mg three times daily.",2002-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,Compare total percent time distal esophageal pH is above 4.0 at steady state for each treatment period.
8549,NCT04821843,Overall survival,2002-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Radiomics analysis,Distant metastasis free survival
8550,NCT04161560,relative adverse drug reaction,2019-11,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
8551,NCT03334708,Change in biomarkers to determine sensitivity and specificity of the assay to diagnose early stage pancreatic cancer,2017-10-30,RECRUITING,OBSERVATIONAL,['NA'],,
8552,NCT01659502,Clinical Benefit Measurement,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
8553,NCT01722175,Liver free of tumors,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Liver synthetic and transport function
8554,NCT05232721,Diagnostic performance of advanced neoplasms,2022-02-20,UNKNOWN,OBSERVATIONAL,['NA'],,Diagnostic performance of Colorectal Cancer
8555,NCT04917289,Overall Survival,2021-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse event
8556,NCT01895504,Cecal intubation rate,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,Pain
8557,NCT03721744,Overall survival (OS),2018-10-25,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of Life (QoL)
8558,NCT01473940,Number of Dose Limiting Toxicities (DLTs) Seen in Patients With Pancreas Adenocarcinoma Treated With Ipilimumab and Gemcitabine Combination in Order to Define the Maximum Tolerated Dose (MTD),2012-06-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Recovery of Tumor Immune Surveillance: T-cell Response to Defined Pancreatic Cancer Tumor Antigens
8559,NCT01845337,The primary endpoint of the study will be a difference in the duration of ST deviation pre-treatment and during treatment.,2014-02-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8560,NCT04391049,Dose Limiting Toxicity,2020-06-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival
8561,NCT00154778,To evaluate the response rate,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine time to progression and safety
8562,NCT06218914,Adverse events and Serious adverse events,2024-02-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,"Preliminary anti-tumor activity of NT-112 in subjects with unresectable, advanced, and/or metastatic solid tumors"
8563,NCT02027948,feasibility of a nutritional management algorithm,2013-12-23,COMPLETED,INTERVENTIONAL,['NA'],,treatment toxicity of chemoradiotherapy
8564,NCT04628182,post-operative anastomotic leakages,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
8565,NCT05582109,Objective response rate,2022-10-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
8566,NCT03417570,Number of Participants Who Had a Diagnostic Yield Obtained,2017-12-22,TERMINATED,INTERVENTIONAL,['NA'],,Safety as Measured by Number of Participants With Procedure-related Adverse Events
8567,NCT03048123,Disease control rate,2015-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse Events
8568,NCT02861690,Response rate,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events (Toxicity)
8569,NCT03678428,Overall Response Rate and bilateral 95% confidence interval,2021-12-31,TERMINATED,INTERVENTIONAL,['PHASE3'],,"Adverse events, servere adverse events and surgery-related adverse events rates"
8570,NCT04516083,Number of patients who have a somatic mutation at the same time as a germline mutation,2019-12-21,UNKNOWN,OBSERVATIONAL,['NA'],,
8571,NCT02372929,Evaluate the relationship between tightness of esophageal stricture encountered at endoscopy with cancer staging at EUS.,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,
8572,NCT02767375,Recurrence Free Survival,2015-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse Events That Are Related to Treatment
8573,NCT00779688,Comparative histopathology-confirmed measures of Cellvizio endomicroscopy and ERCP accuracy in the differential diagnosis of suspicious lesions.,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,
8574,NCT00486460,,2005-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8575,NCT02887599,Difference of the severity of the pancreatic cancer,2016-08-08,COMPLETED,INTERVENTIONAL,['NA'],,Correlation of the cytotoxic immune status
8576,NCT01052922,Adherence to FOBT test kit,2009-08,COMPLETED,INTERVENTIONAL,['NA'],,
8577,NCT05036486,To perform large-scale NGS analysis for specific populations,2021-10-25,RECRUITING,OBSERVATIONAL,['NA'],,"To correlate the clinical characteristics, treatment and outcome of Biliary tract cancer with the genetic profile in Taiwan."
8578,NCT03471403,Number of serious and non-serious adverse events,2017-10-10,RECRUITING,OBSERVATIONAL,['NA'],,Change in Spigelman stage
8579,NCT02589483,"Evidence of clinical anastomotic leak( elevated C reactive protein and white blood corpuscles, fever, nausea). Suspicion of a leak will be investigated with a Ct scan.",2016-02,UNKNOWN,INTERVENTIONAL,['NA'],,
8580,NCT01850654,Determine the Incidence of Hereditary Cancer Syndromes among Newly Diagnosed Colorectal Cancer Patients,2012-12-26,COMPLETED,INTERVENTIONAL,['NA'],,
8581,NCT02789371,the overall diagnostic accuracy of modified wet suction technique and 5ml dry suction technique to the solid occupying lesions,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,Blood contamination and cellularity in specimens obtained by modified wet suction technique and 5ml dry suction technique
8582,NCT03231722,Overall response rate,2017-09-13,COMPLETED,INTERVENTIONAL,['PHASE3'],,R0 Resection Rate
8583,NCT05691491,Dose limiting toxicity and the maximum tolerated dose,2023-09-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Rate of >= grade 3 adverse events (AE)
8584,NCT00004095,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8585,NCT00425841,Clinical response rate as assessed by RECIST criteria,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Histologic response rate
8586,NCT03171389,clinical benefit rate (CBR),2017-03-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Fatigue assessment
8587,NCT01923233,Safety,2014-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Anti-Tumor Response
8588,NCT05591534,Tolerance,2024-01-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Surgical morbidity for recurrence
8589,NCT00533078,efficacy of an omega-3 PUFA containing lipid emulsion in reducing the incidence of °3-4 colitis (CTC AE v3.0),2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8590,NCT00777478,Maximum Tolerated Dose,2008-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,determine the safety and toxicity profile using the CTCAE criteria.
8591,NCT00898287,To determine the maximum tolerated dose (MTD) of P276-00 administered along with Gemcitabine.,2009-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To characterize toxicities of P276-00 in combination with Gemcitabine.
8592,NCT03914352,Disease-free survival,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,
8593,NCT00497263,functioning anastomosis & no occurrence of adverse events related to device use,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8594,NCT02321202,hospital stay (time of hospital stay after surgery),2010-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,mortality
8595,NCT00639327,"In phase II part, progressive disease rate will be measured for the safety. In phase III part, overall survival will be measured for the benefit of doublet.",2008-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Adverse events, response rates, progression free survival, time to treatment failure, change over rates to 3rd line"
8596,NCT00287755,Overall survival rate,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Side effect
8597,NCT05734300,Change in patient-reported postoperative recovery - Quality of Recovery 15,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Rate of secondary standard resection
8598,NCT05706558,. Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery),2016-12-13,RECRUITING,OBSERVATIONAL,['NA'],,"Survival outcomes stratified by use of adjuvant therapy (i.e., adjuvant therapy or no adjuvant therapy)."
8599,NCT01405573,overall survival,2011-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,progression free survival
8600,NCT00004136,Efficacy of Radiofrequency Ablation in Patients with Primary or Metastatic Liver Cancer,1998-03-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8601,NCT02117557,Early morbidity rate,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Inflammatory and immune response
8602,NCT02192671,Hospital mortality,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Recurrence rate
8603,NCT03920202,Bowel function assessment using Low anterior resection syndrome questionnaire,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Risk factors: preoperative chemoradiotherapy
8604,NCT01341197,Important Lower and Upper GI tract Lesions,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,
8605,NCT04379830,Change in Mesorectal Fat Volume (efficacy),2022-08-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Intraoperative Adverse Events
8606,NCT01621243,Part B: Overall Survival,2012-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part B: Duration of progression-free survival
8607,NCT03974984,Changes in neutrophil to lymphocyte ratio from preoperatively to day 1 postoperatively,2020-06-04,WITHDRAWN,OBSERVATIONAL,['NA'],,Changes in quality of recovery-15 score from preoperatively to day 1 postoperatively.
8608,NCT00006094,Latent toxicities graded using the Common Toxicity Criteria (CTC) version 2.0,2000-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
8609,NCT00381862,Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy.,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Patients With no Emesis and no Rescue Therapy Within 5 Days of the First Course of Chemotherapy
8610,NCT03550482,Quality of life improvement,2017-11-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Nutritional level
8611,NCT01428141,Determination of the maximum tolerated dose (MTD),2011-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8612,NCT02678806,overall survival,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,
8613,NCT05265169,Local tumor progression free survival at 24 months,2023-01-13,RECRUITING,INTERVENTIONAL,['NA'],,Proportion of subjects with CTCAE grade 3 events or greater within 90 days after MWA
8614,NCT03083613,Objective Response Rate,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival
8615,NCT05074966,median PFS,2021-09-06,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall Survival OS
8616,NCT01291823,Tumor response rate,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The safety (The safety was evaluated according to the National Cancer Institute Common Toxicity Criteria version 3.0.)
8617,NCT05977764,to identify D-CEUS quantitative parameters useful for characterizing FLLs.,2020-03-13,RECRUITING,INTERVENTIONAL,['NA'],,
8618,NCT04230759,Disease-free survival (DFS),2020-01-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life questionnaires
8619,NCT04770207,Assessing safety and treatment efficacy on intra-tumor injection of DEB for advanced tumors,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
8620,NCT00002485,Determine why eligible patients are not enrolled on available Pediatric Oncology Group therapeutic clinical trials.,1992-02,COMPLETED,OBSERVATIONAL,['NA'],,
8621,NCT00892255,Measure of the tissue destruction with the MedWaves Microwave Ablation/ Coagulation Ablation System,2009-04,WITHDRAWN,OBSERVATIONAL,['NA'],,
8622,NCT04298021,Disease control rate of AZD6738 + Olaparib cohort,2020-06-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,quality of life measurement of AZD6738 + Olaparib cohort
8623,NCT04777708,Objective response rate (ORR),2021-10-13,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of adverse events
8624,NCT02254889,A 10-cm VAS was used to evaluate pain after ESD.,2011-04,COMPLETED,INTERVENTIONAL,['NA'],,
8625,NCT04573738,The distant metastasis rates of rectal cancer,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],,
8626,NCT06271629,Impairment in the quality of sleep and quality of life in patients with Low Anterior Resection Syndrome (LARS).,2022-02-26,COMPLETED,OBSERVATIONAL,['NA'],,European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-CR29)
8627,NCT05751733,Progression-Free survival (PFS),2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],,Disease Control Rate (DCR)
8628,NCT01681368,Objective Response (Complete Response (CR) or Partial Response (PR) Defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Criteria) or Disease Stabilization for Greater Than 6 Months,2012-08-15,TERMINATED,INTERVENTIONAL,['PHASE2'],,Total Clearance of Birinapant After Administration
8629,NCT01657695,Survival,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,Response to therapy
8630,NCT04164069,Incidence of adverse events,2020-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Dasatinib on pharmacokinetics (PK) of oxaliplatin,
8631,NCT00069953,Overall Survival (1-year Rate Reported),2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency of Patients With Persistent or Recurrent Disease Eligible for Surgical Salvage Resection
8632,NCT06016725,Physical function,2023-08-28,RECRUITING,INTERVENTIONAL,['NA'],,Anthropometry measuring waist circumference in centimeters
8633,NCT03129607,Pancreatic fistula,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Mortality
8634,NCT05412628,To analyze the similarity of microbiota distribution between the buccal field and the esophageal area in the same patient,2022-03-15,RECRUITING,INTERVENTIONAL,['NA'],,To analyze the distribution difference of microbiota among the patients with esophageal cancer/oropharyngeal cancer and non-cancer control
8635,NCT02343692,Presence of pancreatic cyst,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],,Preliminary health economics analysis from questionnaires and cost diaries (Self-completed EQ-5D-5L questionnaire and cost diary.)
8636,NCT04098081,response rate,2019-12-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival
8637,NCT00226811,Objective Response (Complete Response (CR) or Partial Response (PR)),2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
8638,NCT01566474,Oxidative stress,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,The presence of DNA anomalies (tetraploidy and aneuploidy.
8639,NCT01996306,Overall survival,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Correlation between UGT1A1 genotype and safety
8640,NCT04461275,Rate of the successful and safe application of the 23-hour accelerated ERAS 2.0 protocol for patients undergoing elective colorectal surgery.,2020-06-19,COMPLETED,INTERVENTIONAL,['NA'],• Groningen Frailty Index (GFI),• Patient satisfaction evaluation by means of a questionnaire to evaluate the patients subjective experience during the duration of this study.
8641,NCT04588051,Median Progression-free survival (PFS),2020-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of adverse events according to CTCAE v5.0
8642,NCT00828672,"Pathologic Response at Surgery. Overview of Complete Pathologic Responses, Good and Little Tumour Regression Rates at Surgery.",2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Death Rates and Overall Survival
8643,NCT05568095,Overall survival,2022-11-21,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
8644,NCT05303740,PFS,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,OS
8645,NCT00609622,Progression-free Survival (PFS),2008-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in Functional Assessment of Cancer Treatment - Gynecologic Oncology Group Oxaliplatin-Specific Neurotoxicity (FACT&GOG-Ntx) Score
8646,NCT02970136,Percentage of Participants Who Are Screened for All Conditions,2017-04-11,COMPLETED,INTERVENTIONAL,['NA'],,Median Number of Screenings Completed
8647,NCT00004099,,1999-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,
8648,NCT04454151,Evaluation of changes in size of adenomas measured by upper endoscopy,2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Evaluation of changes in size of desmoid tumors,Evaluation of changes in size of adenomas measured by lower endoscopy
8649,NCT05081024,Complete clinical response (cCR),2021-09-03,RECRUITING,OBSERVATIONAL,['NA'],Specificity,Overall survival
8650,NCT05268549,"The first recurrence of colorectal cancer with liver metastasis (CRLM) after radiofrequency/microwave ablation, assessed up to 18 months",2022-03-12,UNKNOWN,OBSERVATIONAL,['NA'],,"Patients with colorectal cancer with liver metastases (CRLM) developed new metastases after radiofrequency/microwave ablation,assessed up to 18 months"
8651,NCT02359968,Short-term benefit of 2 preoperative regimen: complete resection rate AND severe (grade ≥ 3) postoperative morbidity/mortality according to the Clavien-Dindo classification,2015-02-26,COMPLETED,INTERVENTIONAL,['PHASE2'],Prognostic factor and treatment effect controlling for possible confounding factors,Evaluation of the efficacy of both regimen in term of quality of life
8652,NCT01392352,Change in endothelial dependent function,2011-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change in endothelial independent function
8653,NCT01631539,Feasibility of chemoembolization with DC Bead loaded with Irinotecan,2012-09,WITHDRAWN,INTERVENTIONAL,['NA'],,progression-free survival
8654,NCT03195699,Pharmacokinetics - AUC(0-t),2017-11-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Assess the bioavailability between different formulations of TTI-101,Best Overall Response
8655,NCT04929392,Clinical complete response (CR),2022-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
8656,NCT06109779,Recurrence free survival (RFS) for Arm A vs. Arm B,2023-12-04,RECRUITING,INTERVENTIONAL,['PHASE3'],Progression Free Survival (PFS) following recurrence Arm A vs. Arm B.,Overall Survival (OS) for Arm A vs. Arm B
8657,NCT05343832,Plasma samples of patients with and without HCC to evaluate test performance(accuracy) of the kit. diagnostic(sensitivity and specificity) of the kit.,2021-11-29,UNKNOWN,OBSERVATIONAL,['NA'],,
8658,NCT06008522,Number of Adverse Device-related Events (ADEs) and Serious Adverse Device-related Events (SADEs) using immuno-OCT,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,validation of OCT system: immunohistochemistry
8659,NCT05975593,Changes in tumor microenvironment,2023-12-19,RECRUITING,OBSERVATIONAL,['NA'],,
8660,NCT00573404,Maximum tolerated dose of imatinib mesylate in combination with sunitinib malate,2007-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,Preliminary data on anti-tumor activity of these drugs as assessed by RECIST
8661,NCT04602013,PFS,2020-10-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,HRQoL
8662,NCT02721550,pathologic Complete Response,2016-08-01,TERMINATED,INTERVENTIONAL,['PHASE4'],,Disease-Free Survival
8663,NCT00394602,Longitudinal Quality of Life + Symptom Assessment Data,2004-04-07,TERMINATED,OBSERVATIONAL,['NA'],,
8664,NCT01970722,Incidence of treatment-related toxicities according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) guidelines,2014-05-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free survival (PFS)
8665,NCT00440817,Occurrence of lymphoma,2006-02,COMPLETED,OBSERVATIONAL,['NA'],,Evaluation of association of Epstein-Barr Virus (EBV) with the lymphoma
8666,NCT03936530,metastasis rate,2019-10-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,3-year DFS
8667,NCT04144751,Blood-based biomarkers associated with genetic and epigenetic alterations.,2019-11-15,COMPLETED,OBSERVATIONAL,['NA'],,
8668,NCT04348643,Adverse events that related to treatment,2020-02-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Levels of CRP in Serum
8669,NCT01587872,Cecal intubation rate,2011-10,TERMINATED,INTERVENTIONAL,['NA'],,Detection of additional colonic pathology
8670,NCT01364454,Patient's participation to colorectal cancer screening program,2010-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
8671,NCT04373928,OS,2017-11-10,RECRUITING,INTERVENTIONAL,['NA'],,DFS
8672,NCT01211132,The primary outcome is the prevalence of adenomas in the two groups.,2009-09,UNKNOWN,INTERVENTIONAL,['NA'],,"The secondary outcomes are the number of adenomas detected per subject, cecal intubation rate, insertion times, withdrawal times and complication rates in the two arms."
8673,NCT04408105,"To characterize the association between patient-level knowledge, attitudes, and barriers regarding BE screening.",2020-02-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
8674,NCT02512224,Mortality Calculated From Outcome Section From DPC Database at 90 Days,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,Mortality Calculated From Outcome Section From DPC Database at 30 Days
8675,NCT05520619,Progression-free survival,2022-09-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor mutational burden at baseline,Treatment-related adverse events
8676,NCT02259725,PFS,2016-08-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Biomarkers Such as Messenger Ribonucleic Acid (mRNA) Levels or Germline Variations of Genes Related to Angiogenesis,"Incidence of Adverse Events, Assessed According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0"
8677,NCT05161143,1 year RFS rate,2021-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AFP
8678,NCT01821196,Density of PGP9.5 in gastric adenocarcinoma related to TNM stage and survival of stomach cancer,2012-12,WITHDRAWN,INTERVENTIONAL,['NA'],,
8679,NCT02328677,Recurrence,2007-03,RECRUITING,OBSERVATIONAL,['NA'],,Treatment toxicities
8680,NCT02165800,Sexual function,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],,5-year overall survival rate
8681,NCT04313114,CRC Screening,2021-09-20,RECRUITING,INTERVENTIONAL,['NA'],,
8682,NCT00970138,Progression free survival,2009-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Toxicity
8683,NCT05867966,Change in emotional distress,2024-01-16,RECRUITING,INTERVENTIONAL,['NA'],,Change in perception about their fatigue
8684,NCT02376543,Total Time Comparison,2015-03-06,WITHDRAWN,INTERVENTIONAL,['NA'],,Complication Comparison
8685,NCT04683783,Percentage of patients who complete the entire cycle,2019-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Morbidity rate
8686,NCT06112704,Objective response rate (ORR) determined by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.,2024-02-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,Assess the incidence of anti-drug antibodies (ADAs)
8687,NCT02905578,Overall survival,2018-11-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event frequency and categorization
8688,NCT00039078,Adverse experiences,2000-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
8689,NCT02332551,Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],Progress free survival(PFS),Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria.
8690,NCT00982618,Postoperative functional recovery,2009-07,COMPLETED,INTERVENTIONAL,['NA'],,opioid side effects
8691,NCT03727126,Lymph node yield,2018-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,Conversion rate
8692,NCT05863052,Treatment related Adverse Events,2022-01-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Demographic differences,Difference in cancer related mortality
8693,NCT00035087,Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST),2002-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
8694,NCT04479111,1-year local recurrence,2020-01-01,COMPLETED,INTERVENTIONAL,['NA'],,3-year disease free survival
8695,NCT02711969,Dose-limiting toxicities (DLTs) of Apatinib mesylate in patients with unresectable locally advanced or metastatic gastric cancer,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Duration of Response(Stable disease, partial response or Complete response)"
8696,NCT04090164,Prevalence of HCV Seropositivity in Breast Cancer Patients.,2019-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Disease-related Events
8697,NCT05493930,diagnosis of lymph node metastasis,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
8698,NCT05014737,postoperative nausea and vomiting,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,
8699,NCT06079554,Metabolomics results of lesions and atrophic gastritis.,2023-10-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],endoscopic observation,microbiomics of lesions and atrophic gastritis.
8700,NCT02482909,The patient survival,2005-07,TERMINATED,INTERVENTIONAL,['NA'],,The disease-free survival
8701,NCT05732493,pCR,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Surgical complications
8702,NCT00101894,"Part 2 - The overall objective tumor response rate (complete and partial response) in subjects treated with AMG 706 (at the dose determined in Part 1b), with either the FOLFIRI or FOLFOX-4 chemotherapy regimen",2004-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Part 1a - The PK of 5-FU when administered as a part of the FOLFIRI or FOLFOX-4 regimen with panitumumab and AMG 706
8703,NCT01895790,Complications (Safety),2014-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival
8704,NCT05760391,OS from start of 1st line treatment in metastatic ESCC,2023-02-28,RECRUITING,INTERVENTIONAL,['NA'],,Disease control rate
8705,NCT05671822,Phase II: Objective Response Rate (ORR)[,2023-03-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Occurrence of adverse events (AEs), and serious adverse events (SAEs) （Phase II）"
8706,NCT04420013,Plasma CD154 level dosage,2020-09,UNKNOWN,OBSERVATIONAL,['NA'],,Clinical evolution parameters
8707,NCT02945267,TTP,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Adverse Events
8708,NCT04137289,"Phase Ib - Progression-free survival (PFS) is defined as the time from first treatment administration until tumor progression according to RECIST 1.1 or death from any cause, whichever occurs earlier.",2020-03-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Phase Ib - AUC0-t2: area under the concentration-time curve of BI 905711 in plasma
8709,NCT05629845,90-day death adjusted cumulative incidence of variceal rebleeding after secondary prevention by EUS-guided therapy or conventional endoscopic therapy,2022-11-22,RECRUITING,INTERVENTIONAL,['NA'],,procedure related adverse events within 30 days of secondary prevention
8710,NCT01175733,Phase II: safety and tolerability,2010-07-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time-to-progression (TTP) and overall survival
8711,NCT00494611,Safety of peri operative Cetuximab.,2007-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,
8712,NCT04273451,The prediction accuracy of the radiopathomics artificial intelligence model,2020-01-10,UNKNOWN,OBSERVATIONAL,['NA'],,The F1 score of the radiopathomics artificial intelligence model
8713,NCT03355495,Decrease in Cecal Intubation Time,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Increase in Adenoma Detection Rate
8714,NCT01171300,Pathologic complete response (ypT0N0) rate,2010-10,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of mesorectal excision.
8715,NCT01623206,"Presence or absence of grade 3 or 4 adverse events related to the study drug, in a maximum of 2 out of 6 patients assessed in each dose level.",2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of patients with partial or complete response in clinical endpoints
8716,NCT00233935,Toxicity defined according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (Version 3.0),2005-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Dose-related biologic effects and pharmacodynamic properties of Poly E
8717,NCT00807313,Metabolic complete remission rate,2008-12,COMPLETED,OBSERVATIONAL,['NA'],,Late toxicity
8718,NCT01186263,Percentage of liver volume for which the accumulation of SIR spheres was correctly predicted by the preceding Tc-99m MAA scintigraphy,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events as elicited upon indirect questioning.
8719,NCT02074046,The primary study purpose to determine the safety of immunization with cancer stem cells vaccine by the number of participants with adverse events,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The dose of CSC vaccine,The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
8720,NCT05839470,Overall Response Rate (ORR),2023-11-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival (PFS)
8721,NCT01665937,Phase 2 dose of STA 9090 given once weekly in patients with advanced hepatocellular carcinoma,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
8722,NCT04654247,Gastric precancerous detection rate,2019-04-20,COMPLETED,INTERVENTIONAL,['NA'],,Adcanced ADR
8723,NCT04296630,Screening intention,2020-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,Post comments
8724,NCT01831609,Biomarker analyses to predict treatment response in metastatic cancer,2011-08-31,RECRUITING,OBSERVATIONAL,['NA'],,
8725,NCT01035008,"Differentiate between non-mucinous, mucinous non-malignant & malignant pancreatic cysts in vivo",2009-12,COMPLETED,INTERVENTIONAL,['NA'],,
8726,NCT02992340,Phase 2B: Progression Free Survival (PFS),2016-12-13,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Pharmacokinetics of Gemcitabine, dFdU (gemcitabine metabolite) and Cisplatin (Phase 2B)"
8727,NCT00585637,"Levels of Plasma 25(OH)D at Baseline, 3 Months and 6 Months.",2007-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change in CRP From 0 to 3 Months.
8728,NCT02633436,optical density (ODs) of each slice by immunohistochemistry assay,2015-12,UNKNOWN,OBSERVATIONAL,['NA'],,SLC1A5 expression detected by WesternBlot
8729,NCT00081536,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
8730,NCT03143270,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2017-04-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
8731,NCT00979680,Sphincter preservation rate,2001-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival
8732,NCT01515046,Overall Survival,2012-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Ascorbate Levels
8733,NCT00006368,,1998-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8734,NCT05461235,Progression-free Survival (PFS),2022-07-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8735,NCT04296240,pathologic complete response rate,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity of neoadjuvant chemotherapy
8736,NCT00385970,3-Year recurrence-free survival rate,2006-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"5-Year survival rate, incidence of adverse events, treatment compliance, QOL, type of metastasis/recurrence, and 3-year and 5-year recurrence-free survival rates and survival rates based on each parameter including colon/rectum, stage, and IAP."
8737,NCT00118105,Correlation of clinical outcome with expression of biomarkers and telomere length,2006-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
8738,NCT00294827,Survival,2006-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to progression side-effects
8739,NCT01454180,Overall survival,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8740,NCT05143619,Teaching rates of the hepatocellular carcinoma diagnosis guidelines,2019-05-10,RECRUITING,OBSERVATIONAL,['NA'],,
8741,NCT00295035,,2006-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8742,NCT05313282,The progression-free survival (PFS) by RECIST 1.1,2022-06-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
8743,NCT00816491,"The primary endpoint of the study will be to compare the accuracy of two procedures (FICE with target biopsies only, versus conventional white light colonoscopy)",2008-10,COMPLETED,INTERVENTIONAL,['NA'],,To quantify the number of true positive and false positive lesions by comparing the number of targeted biopsies performed for suspicious lesions and the resulting histological findings.
8744,NCT01477190,postoperative pain,2010-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,opioid side effects
8745,NCT00025532,,2001-04,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
8746,NCT05356897,Progression-free survival rate,2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
8747,NCT02773459,Progression-free survival (PFS),2016-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
8748,NCT02894775,Number of participants included in a clinical trial,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
8749,NCT01515787,DFS,2012-06-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Neoadjuvant Rectal Score
8750,NCT00500968,Drain fluid content analyses,2006-11,COMPLETED,INTERVENTIONAL,['NA'],,"Co-variables measured in the form of: operation time, complications in relation to diagnosis, duration of hospitalization and cost. Patients receiving a pancreas stent are followed in order to evaluate the natural course of the pancreas stent"
8751,NCT01306058,Phase II: Time to Progression (TTP) for the Combination of TR105 With Sorafenib in Hepatocellular Cancer (HCC),2011-02-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percentage Signal Change in Response on Magnetic Resonance Imaging (MRI)
8752,NCT00955721,Phase II: Obtain an Estimate of the 9-month Progression-free Survival Rate in Patients With Advanced BTC Receiving the RPTD of the Combination Sorafenib and GEMOX.,2009-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Explore Biomarkers of Response to the Combination
8753,NCT03510858,Proportion of patients which have been tested for CRC,2018-03-14,UNKNOWN,INTERVENTIONAL,['NA'],,Intention to prescribe colonoscopy vs. FIT within the next 6 months
8754,NCT05177068,Surgical complete resection rate (R0),2022-05-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse event (AEs)
8755,NCT03791918,Overall survival,2019-01-01,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Progression free survival
8756,NCT05291728,the detection rate of early gastric cancer,2020-10-01,RECRUITING,OBSERVATIONAL,['NA'],,"the prevalence of dyspepsia, gastroesophageal reflux disease and precancerous lesions in the natural population of Shaanxi Province, as well as the prevalence of helicobacter pylori infection, radical treatment and recurrence rate."
8757,NCT05740189,Safety: Incidence of Dose-related SAEs,2023-02-19,RECRUITING,INTERVENTIONAL,['NA'],,BE regression
8758,NCT04733521,preliminary antitumor activity of SC-43,2021-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",phosphorylated signal transducer and activator of transcription 3(p-STAT3) status in peripheral blood mononuclear cells (PBMCs) of subjects,overall survival(OS) according to RECIST criteria version 1.1
8759,NCT00568438,,2000-10,COMPLETED,OBSERVATIONAL,['NA'],,
8760,NCT01997684,Rates of primary colorectal anastomosis,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],Clinical success,Recurrence of colorectal cancer
8761,NCT04517032,Catastrophic Expenditure at 6 months,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Colorectal cancer stage at the time of diagnosis
8762,NCT00363584,Survival at 2 years,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Health economics
8763,NCT05129046,DFS,2021-11-15,UNKNOWN,OBSERVATIONAL,['NA'],,Surgical Outcomes
8764,NCT05307835,Relapse Free Survival Rate,2021-12-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,EORTC QLQ-C30 (version 3)
8765,NCT00296608,,1993-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
8766,NCT05471674,Pathological tumour response rate,2020-07-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Exploratory analyses,Safety and tolerability of nivolumab
8767,NCT00254683,PET/CT specificity and sensitivity for tumor response,2005-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Correlation between PET/CT and complete clinical Response
8768,NCT01557101,Participation to colorectal cancer screening in first-degree relatives of patients with colorectal cancer,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,
8769,NCT00091078,"Toxicity defined as any of the following events: regimen-related death, transaminitis, infection, or leukopenia grade 3 or higher using NCI CTCAE version 3.0",2005-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
8770,NCT05463796,"Identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal.",2023-04-25,RECRUITING,OBSERVATIONAL,['NA'],,
8771,NCT05425472,Objective response rate,2022-07-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,ECOG Score for performance status
8772,NCT01747707,overall survival time (OS),2012-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety profile
8773,NCT02352935,Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria.,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],Over Survival (OS),Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.
8774,NCT05300269,Percentage of participants with Pathological complete response ( pCR ),2022-07-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease-free survival ( DFS )
8775,NCT03821545,Concentration of inflammatory markers,2019-01-28,COMPLETED,INTERVENTIONAL,['NA'],,Length of hospital stay
8776,NCT03236883,Survival,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Karnofsky Performance Status（KPS）
8777,NCT01035398,Analyses of dietary factors and Helicobacter pylori infection (previous vs current),2000-04,UNKNOWN,OBSERVATIONAL,['NA'],,
8778,NCT02243384,Survival rate,2014-09-01,COMPLETED,INTERVENTIONAL,['NA'],,postoperative complications
8779,NCT01121939,Objective Response Rate (ORR),2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate
8780,NCT05723562,Number of Participants with Sustained Complete Clinical Response for 12 Months (cCR12) as assessed by Independent Central Review (ICR),2023-04-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants with Anti-Drug Antibodies against Dostarlimab
8781,NCT05068180,Incidences of POD after general anesthesia in elderly patients undergoing non-cardiac major surgery,2021-10-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Duration of postoperative delirium
8782,NCT05971199,Progression-free survival(PFS),2021-11-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to progression(TTP)
8783,NCT06207981,Disease-related event free survival (DREFS) at 2 years,2024-02-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,
8784,NCT05029973,Overall response rate ( ORR),2021-05-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
8785,NCT00468455,Evaluate the quality of life in patients with abdominal wall hernias using a user-friendly survey that is designed specifically for this population of patients,2005-10,COMPLETED,OBSERVATIONAL,['NA'],,
8786,NCT04542291,Tolerability as Measured by Number of Participants With Related Adverse Events,2021-02-25,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change in Tumor Necrosis
8787,NCT01234051,Response rate,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
8788,NCT02365662,Recommended Phase 2 dose of ABBV-221,2015-01-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,Objective Response Rate (ORR)
8789,NCT04014465,progression free survival,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,Adverse Events
8790,NCT03193814,Progression-free Survival (PFS) Time,2019-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8791,NCT02297607,Quality of Life after surgery,2014-11,TERMINATED,INTERVENTIONAL,['NA'],Length of hospital stay,Jejunostomy tube-specific complications
8792,NCT03219723,Percentage of Participants Who Had One or More Adverse Drug Reactions,2015-09-01,COMPLETED,OBSERVATIONAL,['NA'],,H. Pylori Eradication Rate
8793,NCT04170556,Incidence of Treatment-Emergent Adverse Events,2020-03-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum and tissue marker characterization
8794,NCT03527784,Incidence of parastomal hernia,2018-05-03,TERMINATED,INTERVENTIONAL,['NA'],,Quality of Life measured by RAND 36
8795,NCT02407119,Incidence of metachronous gastric cancer,2003-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival
8796,NCT04890015,Anastomotic leakage rate between treatment arms,2017-07-10,UNKNOWN,INTERVENTIONAL,['NA'],,Definitive and / or temporary stoma rate after anastomotic leakage
8797,NCT04685759,Proportion of patients with a primary GI tumor who complete neoadjuvant treatment and are cleared for surgical resection,2022-04,WITHDRAWN,INTERVENTIONAL,['NA'],Mean total Patient Satisfaction score of In-Person Exercise Therapy,Change in quality of life assessment
8798,NCT03881332,Glomerular filtration rate,2019-12-26,COMPLETED,OBSERVATIONAL,['NA'],,
8799,NCT00806663,"reduction of tumor vessel permeability (TVP) and blood flow (BF) measured by DCE-MRI and DCE-USI, measured on liver metastases.",2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,drug treatment safety
8800,NCT00723996,The primary outcome will be determined through review of medical records or a telephone follow-up 6 months after enrollment,2003-09,COMPLETED,OBSERVATIONAL,['NA'],,
8801,NCT04883775,Biodistribution of MVT-2163,2021-05-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,
8802,NCT01141114,completion of colorectal cancer screening,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of detection of polyps and cancers in intervention vs. control groups
8803,NCT03884400,Distribution of Biospecimens From Biorepositories/Biobanks for Research Use,2021-01-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
8804,NCT00039273,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8805,NCT05494658,The proportion of postoperative blood glucose>8mmol/L,2022-08-26,RECRUITING,INTERVENTIONAL,['NA'],,Postoperative hospital stay
8806,NCT03520283,Retention Rate,2018-05-29,COMPLETED,INTERVENTIONAL,['NA'],,Qualitative Assessment of Changes in Outcomes With Semi-structured Interviews
8807,NCT04229849,Overall Survival (OS),2020-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Assessment of Health-related quality of life
8808,NCT06326879,Incidence rate ratio of colorectal cancer recurrence,2023-11-30,RECRUITING,OBSERVATIONAL,['NA'],,Correlation between socioeconomic characteristics and incidence rate of colorectal cancer recurrence
8809,NCT00868816,disease-free survival,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,overall survival liver metastasis-free survival
8810,NCT01283906,To evaluate the efficacy of MuGard on reducing the symptoms of oral mucositis using an Oral Mucositis Daily Questionnaire (OMDQ),2011-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,To evaluate the efficacy of MuGard on delaying the onset of oral mucositis symptoms and reducing the impact on health and resource outcomes.
8811,NCT06153368,Objective response rate (ORR),2023-12-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (safety)
8812,NCT01056796,"To evaluate for the occurrence of adverse events related to the use of the CAR™ 27 device, include anastomotic leak, bleeding, ring evacuation and strictures at 6 months.",2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Evaluation of the creation of a functioning CAR™ 27 anastomosis in radiated patients
8813,NCT04057365,Overall Response Rate,2019-10-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Median Overall Survival
8814,NCT05576896,Objective Response Rate (ORR),2022-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
8815,NCT05941481,pathological complete remission (pCR) rate,2023-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8816,NCT04168346,The need for blood transfusion,2019-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,Use of IV iron after operation
8817,NCT06205862,CRA recurrence rate,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Changes in intestinal mucosal microbiota Pre- and Post-FMT
8818,NCT04006600,Persistence of a stomy 2 years after rectal surgery when stoma was primarily intended to be temporary,2018-03-16,COMPLETED,OBSERVATIONAL,['NA'],,
8819,NCT02648880,Change in 400-meter Walk Time,2016-05-10,COMPLETED,INTERVENTIONAL,['NA'],,Determination of Hospital Readmission
8820,NCT00027638,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8821,NCT02747862,Chart Review of Outcomes of Participants with Attenuated Familial Adenomatous Polyposis (AFAP) and Deleterious Familial Adenomatous Polyposis (FAP) Undergoing Endoscopic Surveillance,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,
8822,NCT01744821,Other Surrogate Endpoint Biomarkers Markers of Cancer Prevention,2012-10,TERMINATED,INTERVENTIONAL,['NA'],,Review of the Differences in the Types and Incidence of Toxicities Associated With Vitamin D3 Replacement.
8823,NCT05753748,Neoplastic Progression,2023-01-24,RECRUITING,INTERVENTIONAL,['NA'],,Patient-Reported Gastroesophageal Reflux
8824,NCT02110329,Recurence rate according to molecular results,2010-05,COMPLETED,INTERVENTIONAL,['NA'],,Survival rate according to molecular results
8825,NCT02713386,Progression-free survival (PFS) (Phase II),2016-11-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in serum C-reactive protein (CRP),Overall survival (OS) (Phase II)
8826,NCT01777594,Time to progression,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
8827,NCT02226380,The 3-year overall survival rate in patients who will receive mFOLFOX6 regimen as neoadjuvant chemotherapy regimen,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],The R0 resection rate in the patients who will receive mFOLFOX6 regimen as neoadjuvant chemotherapy regimen,The 3-year disease-free survival rate in the patients who will receive mFOLFOX6 regimen neoadjuvant chemotherapy regimen
8828,NCT05807776,MPR rate,2023-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AE and SAE
8829,NCT03203005,Immunogenicity (T-cell response in peripheral blood),2017-09-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
8830,NCT03775980,Local Tumor Control,2019-09-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Treatment specific quality of life
8831,NCT00856115,Factors that influence appraisal and diagnostic delay,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,
8832,NCT04792515,pathologic complete response (PCR),2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Percentage of Progression-free survival (1-PFSR)
8833,NCT02269995,Safety and Tolerability as measured by Adverse Events,2014-03-06,COMPLETED,OBSERVATIONAL,['NA'],,Efficacy of DC bead as assessed by embolic performance
8834,NCT00109954,Toxicity as measured by NCI CTCAE version 3.0,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
8835,NCT02723604,Number of Participants With Severe World Health Organization [WHO] (Grade 3-4) Oral Mucositis in Patients Treated to a Cumulative Radiation Dose of at Least 5000 cGy,2016-03,COMPLETED,INTERVENTIONAL,['NA'],Time to Reach Planned Dose of Radiation Therapy,Time to Onset of Severe (CTCAE v. 4.0 Grade 3-4) Oral Mucositis Following the Initiation of Radiotherapy
8836,NCT04091620,Incidence rate of achieving a composite of pathologic endpoint indicating adequate surgical resection,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,Direct/indirect medical costs and out-of-hospital economic costs
8837,NCT01150045,Disease-free Survival,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall Survival
8838,NCT01484444,Analyzed of DNA mutations,2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,
8839,NCT02216110,Patient's death,2003-05,COMPLETED,OBSERVATIONAL,['NA'],,Development of metachronous cancers
8840,NCT00845611,Safety(Phase I:toxicities as assessed by NCI CTCAE version3),2008-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,evaluate immunological responses
8841,NCT01024504,Overall response rate,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
8842,NCT05438108,AEs,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
8843,NCT05660213,ORR,2024-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,Incidence and severity of adverse events of special interest (AESI)
8844,NCT00479752,"The primary endpoint of the trial is: • Objective response (CR/PR), as assessed by RECIST criteria",2008-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,• Progression Free Survival (PFS) • Overall survival • Safety/Adverse events Safety
8845,NCT04478929,gastroscopy image data set,2020-08,UNKNOWN,OBSERVATIONAL,['NA'],,
8846,NCT05787535,"Incidence of treatment related AEs, AEs of special interest and serious adverse events (SAEs).",2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of TCR T cells in-vivo persistence
8847,NCT01258868,Tabulation of patient toxicities and their grades,2010-12-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of patients of first 20 lung CA patients with cell line development greater than or equal to 5.
8848,NCT03129139,Anti-tumor activity,2017-10-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,
8849,NCT02409186,Over Survival,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8850,NCT02570516,Number of adenomas and / or adenocarcinoma detected during each procedure (NBI vs Indigo carmine),2015-11,COMPLETED,INTERVENTIONAL,['NA'],,Number of subject with adverse events as mesure of safety.
8851,NCT05146297,Change in Clinical Trial Accrual,2022-12-24,RECRUITING,INTERVENTIONAL,['NA'],,Physician Post -intervention survey
8852,NCT02293850,"Evaluation of safety parameters (adverse events, laboratory data, EKG, body weight, vital signs) on patient-base.",2014-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Dose-Limiting Toxicity (DLT) for patients using OBP-301.
8853,NCT03428529,Clinical downstaging,2011-01-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Pathological downstaging
8854,NCT01561014,Toxicity rate of combination chemotherapy followed by surgery and erlotinib hydrochloride,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Test the predictive value of FDG-PET-CT imaging in identifying patients who will have a complete response
8855,NCT04686747,"Rate of advanced Esophageal, Gastric, Pancreatic and Colorectal cancer in 2020 compared to 2019.",2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Rate of patient unable to performer adjuvant treatment in 2020 compared to 2019
8856,NCT04770623,Overall response rate (ORR),2021-03-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
8857,NCT03241680,Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III),2017-08-02,UNKNOWN,INTERVENTIONAL,['NA'],,
8858,NCT03801668,Progression-free Survival (PFS),2019-03-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Safety as measured by number and grade of adverse events
8859,NCT01233544,Local progression-free survival,2010-09,TERMINATED,INTERVENTIONAL,['PHASE3'],,Quality of life
8860,NCT00536770,Overall survival rate at 6 months,2007-09,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Duration of overall survival
8861,NCT03540953,dysphagia,2015-01-05,TERMINATED,INTERVENTIONAL,['NA'],,number of sessions of endoscopic dilations
8862,NCT04232748,Overall survival,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Chemotherapy interruption
8863,NCT05013125,Adenoma missed rate,2021-08-09,UNKNOWN,INTERVENTIONAL,['NA'],,Number of CAD assisted abnormality
8864,NCT05928897,ORR,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
8865,NCT01051596,Percent of Patients With Disease Control,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percent of Patients With an Objective Response
8866,NCT01348256,Progression Free survival,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
8867,NCT00006786,,2000-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8868,NCT06334926,overall survival,2017-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
8869,NCT06043921,Cohort of patients with resectable pancreatic cancer; Success rate of WES assays and selections of personalized genes using tumor tissue specimens obtained by EUS-FNA/FNB,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,Cohort of patients with resectable pancreatic cancer; to investigate the lead time of ctDNA detection of recurrence before detection of recurrence via imaging methods
8870,NCT02564835,Program Evaluation,2015-09,COMPLETED,INTERVENTIONAL,['NA'],Beliefs about Treatment,Pro-inflammatory Markers
8871,NCT01023984,Incidence of recurrence at 12 months,2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Number of days not spent in hospital from initial treatment until 2 years afterwards
8872,NCT03732508,Duration of Progression-Free Survival (PFS),2018-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events(AE)
8873,NCT01869725,Compare Specificity of 68Ga-DOTATOC PET/CT With Octreoscan,2013-04-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8874,NCT02595320,Twelve-week Progression Free Survival (cohort 1 only),2015-10-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Objective response rate (cohorts 1 and 2),Grade 3 or higher toxicity (cohorts 1 and 2)
8875,NCT02707159,Change in levels of circulating tumor cells (CTCs) during treatment,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in quality of life during treatment
8876,NCT02560298,Best ORR defined as the percentage of patients achieving confirmed partial (PR) or complete responses (CR) as per RECIST v1.1,2016-08-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in expression of tumor biomarkers,Sensitivity analysis of ORR
8877,NCT03783156,Number of participants with presence of adenomatous tissue al the base of polypectomy,2019-02-18,COMPLETED,INTERVENTIONAL,['NA'],,Number of participants with Postpolypectomy Complications
8878,NCT05379907,Impact of SIGNATERA™ on treatment decisions,2022-08-23,WITHDRAWN,OBSERVATIONAL,['NA'],,Patient satisfaction of SIGNATERA™ ctDNA on treatment recommendations
8879,NCT00748449,Percentage of patients who refuse to undergo an examination,2008-06,TERMINATED,INTERVENTIONAL,['NA'],,
8880,NCT04545957,Proportion of patients with QOL decline exceeding 2 x MID,2020-10-14,RECRUITING,INTERVENTIONAL,['NA'],,Performance of the synthetic CT in RT planning
8881,NCT03644511,"Identification of current treatment patterns by means of individual treatment lines in the systemic HCC therapy with regards to Nexavar and Stivarga, i.e. when both drugs are used in ≥ 2nd-line under current practice conditions",2019-01-24,TERMINATED,OBSERVATIONAL,['NA'],,Incidence of treatment-emergent adverse events (TEAE)
8882,NCT02688023,3-year disease-free survival,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with surgery complications
8883,NCT01815463,Correlation of Adnab-9 stool result with outcome of colonoscopy,2006-08,TERMINATED,OBSERVATIONAL,['NA'],,Define the origin of the Adnab-9 bound antigen
8884,NCT04095468,Percentages of pCR in the patients after total mesorectal excision performed because of tumour persistence.,2017-09-18,RECRUITING,OBSERVATIONAL,['NA'],,Anorectal function assessed by low anterior resection syndrome (LARS) score
8885,NCT02906397,Safety based upon standard laboratory and clinical adverse event monitoring,2017-03-30,COMPLETED,INTERVENTIONAL,['PHASE1'],,Promotion of anti-tumor immunity with addition of intervention to SBRT
8886,NCT02092298,Overall Survival (OS) From the First Laparoscopic HIPEC,2014-05-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8887,NCT05889806,Enrollment and collection totals for a diverse population of subjects/conditions involved in diseases and in healthy/control populations.,2023-05-10,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
8888,NCT05832892,Objective response rate (RECIST 1.1),2023-10-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Predictive biomarkers
8889,NCT04115254,Rate of Improvement in Tumor Control-Phase II,2019-10-22,SUSPENDED,INTERVENTIONAL,['NA'],,Overall Survival Rate-Phase II
8890,NCT05336643,Lymph node detection with technetium 99m colloid and SENSEI gamma probe,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Concordance of nodes seen on PET MRI/CT and SPECTCT
8891,NCT03605706,Overall Survival,2019-05-31,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS) rate at 9 months and 12 months
8892,NCT05589675,Participation rates to the screening program,2023-04-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Participation rates to the screening program
8893,NCT01548482,Safety profile of trebananib and temsirolimus as assessed by NCI CTCAE version 4.0,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,PD effects of both drugs when administered in combination
8894,NCT01084746,Increase patient completion of colorectal cancer screening (CRCS) among patients ages 50 to 64 years old.,2005-01,COMPLETED,INTERVENTIONAL,['NA'],,Secondary goals are to increase understanding of factors that predict completion of CRCS and to assess the cost-effectiveness of the intervention.
8895,NCT00328887,"Since this is a dose escalation, phase I design to evaluate toxicity, the analysis for this section will be purely descriptive. Adverse events will be considered on an individual basis.",2004-11,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
8896,NCT00716820,Objective Response Rate,2008-04,COMPLETED,OBSERVATIONAL,['NA'],Number of Participants With Treatment-Related Adverse Events Grade 3 or Higher in Common Toxicity Criteria for Adverse Events (CTCAE),Numbers of Participants With Treatment-Related Adverse Events Corresponded to Items for Priority Investigation
8897,NCT00849264,overall survival,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,disease-free survival
8898,NCT03754075,Risk of recurrence,2008-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,Number of mesocolic lymph nodes
8899,NCT02604784,Overall Response Rate (ORR) according to RECIST criteria (version 1.1) after 2 and 3 cycles of PIPAC.,2015-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The Peritoneal Carcinomatosis Index (PCI) before and after therapy
8900,NCT01778595,"Participation rate, data quality",2013-01-08,COMPLETED,OBSERVATIONAL,['NA'],,
8901,NCT01469611,Determine the maximum-feasible dose,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8902,NCT03918369,Rate of Re-interventions,2019-03-07,COMPLETED,INTERVENTIONAL,['NA'],,
8903,NCT02149108,Overall Survival (OS),2014-09-25,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease Control (Complete Response + Partial Response + Stable Disease) by Central Review Assessment
8904,NCT05835947,The incidence of anal HSIL and cancer in women with genital HSIL and/cancer in England,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],,The amount of time in years and months between the diagnosis of genital HSIL/SCC and anal HSIL/SCC
8905,NCT02850991,Overall Survival,2016-04,COMPLETED,INTERVENTIONAL,['NA'],"local control rate, recurrence pattern",Progression-free survival
8906,NCT04843306,Effectiveness of motion management for SBRT for pancreatic cancer with real-time coaching for the ABC procedure using an augmented reality platform,2021-06-24,RECRUITING,INTERVENTIONAL,['NA'],,Anxiety of patient with the ABC procedure with real-time coaching using an augmented reality platform during SBRT for pancreatic cancer as assessed by patient reported outcome measures (PROMs)
8907,NCT05172713,Retrospective study of the patient outcomes who had an incomplete colonoscopy after a positive immunological fecal test,2021-01-16,UNKNOWN,OBSERVATIONAL,['NA'],,
8908,NCT02347618,Incidence of grade 2 or greater toxicity,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,Time to death
8909,NCT00259402,"Efficacy endpoints include tumor response, progression free and overall survival.",2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Safety endpoints include summary of adverse events assessed by history, physical exams and laboratory evaluations."
8910,NCT02943031,Overall Survival (OS),2016-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Progression-Free Survival (PFS)
8911,NCT00990860,"Safety and tolerability (such as adverse events and laboratory changes (haematology, clinical chemistry))",2009-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,No. of TACE cycles
8912,NCT03705442,Incidence of grade III/IV diarrhoea between the two groups of patients,2018-02-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Difference in quality of life using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORTC QLQ-C30) between the two groups of patients
8913,NCT03526328,cell-specific expression patterns of putative intestinal stem cell biomarkers in BE patients; correlation of markers with serum/plasma protein expression and disease progression.,2013-03,COMPLETED,OBSERVATIONAL,['NA'],,
8914,NCT02716766,Time to progression (TTP),2016-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life (QoL),Frequency and severity of adverse events and laboratory abnormalities
8915,NCT01379482,Overall survival,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8916,NCT03243734,Change from baseline dysphagia scale at 14 days post cryotherapy procedure,2017-11-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Mean change in the amount of residual tumor from baseline to follow-up cryospray delivery session
8917,NCT05027737,Complications,2022-02-22,RECRUITING,INTERVENTIONAL,['NA'],,EORTC QLQ-CR29 score
8918,NCT00807300,Time to untreatable progression,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
8919,NCT02366286,Rate of HBV vaccination in subjects with negative HBV serology,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of HCC over the period of the study
8920,NCT03022110,Cyst recurrence rate,2017-02,UNKNOWN,INTERVENTIONAL,['NA'],,Complication rate
8921,NCT01572324,Response rates,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
8922,NCT04050787,3-year disease free survival rate,2019-07-21,UNKNOWN,INTERVENTIONAL,['NA'],,The number of positive lymph nodes
8923,NCT06060847,Comprehensive Complication Index,2024-03-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Control of obesity-induced comorbidities
8924,NCT05447221,The diagnostic performance of AI model to assess the severity of intestinal metaplasia,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,"Accuracy of digital pathological AI models to identify glands, mucosal epithelium, and intestinal metaplasia in non-neoplastic areas"
8925,NCT01268943,Dose Related Toxicity,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8926,NCT01967823,Percentage of Participants With a Response,2013-10-24,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and Non-serious Treatment Related Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),Percentage of T Cell Receptor (TCR) in Cluster of Differentiation 3 (CD3) + Cells
8927,NCT05147389,Neoplastic bile duct diagnosis confirmation after one year follow-up,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
8928,NCT03329950,Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0,2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic evaluation
8929,NCT05115786,Recurrence of colorectal cancer,2023-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
8930,NCT01855724,Objective Response Rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1),2013-06-28,TERMINATED,INTERVENTIONAL,['PHASE2'],,Evaluation of potential prognostic and/or predictive biomarkers in tissue and blood samples
8931,NCT05187338,Duration of remission (DOR),2021-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
8932,NCT02136069,"Percentage of Participants With Both Clinical Response at Week 10 and Clinical Remission at Week 54, as Determined by the Mayo Clinic Score (MCS)",2014-12-24,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Anti-Therapeutic Antibodies (ATAs) to Etrolizumab
8933,NCT02355262,Total number of months uninsured (total gap months),2014-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
8934,NCT03304210,Maximally Tolerated Dose (MTD) of Abraxane,2017-09-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,Decreased Platelets - Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
8935,NCT03248375,Number of Participants With Local Tumor Response According to mRECIST,2016-08-03,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants With Treatment-related Laboratory Adverse Events
8936,NCT06227871,Complication occurrence,2019-11-01,COMPLETED,OBSERVATIONAL,['NA'],,Associated intra-abdominal injuries
8937,NCT00035919,dose-limiting toxicity and maximum tolerated dose,2002-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,objective tumor response by CT scan or MRI
8938,NCT04723004,Overall survival (OS),2020-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,ADA
8939,NCT00026338,Overall survival,2001-10-29,COMPLETED,INTERVENTIONAL,['PHASE3'],,Pharmacokinetics
8940,NCT02468362,Disease Free survival,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,5 year survival
8941,NCT04597268,Ramsy sedation score (RSS),2020-11-01,COMPLETED,INTERVENTIONAL,['NA'],,
8942,NCT04177407,postoperative complications,2017-03-23,UNKNOWN,INTERVENTIONAL,['NA'],,Overall complication rate within 30 days after surgery.
8943,NCT02043821,DDC:Duration of Disease Control,na,UNKNOWN,INTERVENTIONAL,['NA'],Safety,DCR:Disease Control Rate
8944,NCT00470951,Disease free survival,2006-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],Immunologic response,Quality of life
8945,NCT04681274,Specific tumor phenotypes,2020-08-31,COMPLETED,OBSERVATIONAL,['NA'],,Small lesion detection and characterization
8946,NCT02375997,Overall survival,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse event
8947,NCT02564224,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
8948,NCT03038568,assess the stability (reproducibility) of radiomic measurements obtained from repeat abdominal CT scans,2017-01-27,RECRUITING,OBSERVATIONAL,['NA'],,
8949,NCT03267641,Time to recurrence,2016-05-16,COMPLETED,OBSERVATIONAL,['NA'],,Overall Survival
8950,NCT03344172,Proportion of Grade IIb or Higher Histolopathologic Responses,2017-12-13,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change in Coagulation Index (CI)
8951,NCT04888663,"Phase 2: Progression-free survival in patients with HER2-positive gastric cancer receiving trastuzumab, ramucirumab, and paclitaxel combination treatment",2018-02-13,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE v4.02
8952,NCT01748851,Progression free survival,2012-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,performance status (quality of life)
8953,NCT01930864,Non-Progression at week 12th of treatment,2015-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
8954,NCT02778308,Disease Free Survival,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,Gastrointestinal system Adverse events
8955,NCT02485561,Intentions to Get Screened for Colon Cancer,2015-06-01,COMPLETED,INTERVENTIONAL,['NA'],Perceived Benefits and Barriers of Colorectal Cancer Screening,Absolute Perceived Susceptibility to Colon Cancer
8956,NCT04787523,Immun cell infiltrate in pathology sections from the tumour,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
8957,NCT05441163,HRQoL deterioration free survival (QFS),2023-04-08,RECRUITING,INTERVENTIONAL,['NA'],,
8958,NCT03983057,Progression-free survival,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Carbohydrate antigen 19-9
8959,NCT02363647,Overall response rate (ORR),2015-01,TERMINATED,INTERVENTIONAL,['NA'],,Overall survival (OS)
8960,NCT02577588,Safety,2016-05-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,evaluation of p53 specific T cell Responses by analysing data from EliSpot assay
8961,NCT04508452,Reintroduction Rate,2020-05-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],,ORR2
8962,NCT00956436,To evaluate the safety and tolerability of BIIB022 given once every 3 weeks in combination with sorafenib in subjects with advanced HCC.,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,To assess the anti-tumor response in this study population
8963,NCT03802214,"Analysis of blood and tissue leukocytes (T cells, B cells and Dendritic cells)",2020-10-29,TERMINATED,OBSERVATIONAL,['NA'],,Analysis of the serum and tissue concentrations of vedolizumab
8964,NCT00280709,"Clinical follow-up every month, starting one month after stent insertion. Clinical and/or laboratory signs of stent dysfunction?",2006-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
8965,NCT06216834,psychosocial status,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
8966,NCT01368094,Surgical Site Infection at D30,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,
8967,NCT00112086,proportion of clinical complete remission,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival among all enrolled patients.
8968,NCT03267524,Geriatric assessment,2017-11-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
8969,NCT05951127,2-year OS,2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,3 years PFS
8970,NCT01004978,Progression-free Survival (PFS),2009-10-28,COMPLETED,INTERVENTIONAL,['PHASE3'],To Evaluate the Effects of Intra-hepatic vs. Extra-hepatic Progression on OS.,Progression-free Survival (PFS) Among Patients With Intra-hepatic Progression
8971,NCT05289895,Proteomic analysis of blood and urine,2022-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
8972,NCT02437071,response rate,2015-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity
8973,NCT04368182,Safety of C-TCR055,2020-04-13,UNKNOWN,INTERVENTIONAL,['PHASE1'],,DOR
8974,NCT05130073,Overall survival (OS),2019-07-31,COMPLETED,OBSERVATIONAL,['NA'],,
8975,NCT02327481,Operating time,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Recurrence patterns
8976,NCT04564898,activity,2022-01-25,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Clearance,survival
8977,NCT05658016,Mucositis,2022-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence Adverse Events That Are Related to Treatment
8978,NCT04935853,Rate of patients with advanced bile duct cancer (BDC) experiencing overall survival (OS) less than 6 months,2022-05-23,RECRUITING,OBSERVATIONAL,['NA'],,The complications and postoperative mortality rates in patients who underwent surgery
8979,NCT05185739,"Major pathological response rate, defined as the proportion of patients with less than 10% viable tumour at resection.",2022-08-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Determine the toxicity of pre-operative therapy according to Common Terminology Criteria for Adverse Events (CTCAE) V5.
8980,NCT02050659,tumorload in the greater omentum,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
8981,NCT02299648,molecular screening ( biopsy of their tumor and will be analyzed using cancer panel/nanostring CNV and immunohistochemistry),2014-07-25,COMPLETED,INTERVENTIONAL,['NA'],,OS/PFS
8982,NCT03019588,Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1),2017-02-16,TERMINATED,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Discontinue Study Treatment Due to an AE
8983,NCT03639935,Proportion of patients alive and without radiological or clinical progression at 4 months,2019-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS) time as measured from start of 1st line platinum therapy
8984,NCT03602677,Anastomosis leakage rate,2018-09-24,RECRUITING,INTERVENTIONAL,['NA'],,Hospital costs
8985,NCT04624282,Metabonomic difference in patients with chronic gastritis and gastric carcinoma,2020-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,Association of different metabolic substances and disease results in chronic gastritis and gastric carcinoma
8986,NCT05657249,Comparison of alternative surveillance program (alternating focused MRI + US in 6 month interval) and conventional surveillance (biannual US) for HCC detection,2023-01-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],comparison between incidental findings between biannual US and annual focused MRI,comparison between false referral rates of biannual US and annual focused MRI
8987,NCT01714726,Percentage of Participants With Crohn's Disease Activity Index (CDAI) Response at Week 8,2013-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With ADA Positive to MEDI2070 in Open-label Period
8988,NCT05878977,response prediction in first line immune checkpoint inhibitors treatment in metastatic melanoma assessed by human gastrointestinal microbiome (bacterial and viral) and exosomal mRNA expression of PD-L1 and IFNγ,2022-10-05,RECRUITING,INTERVENTIONAL,['NA'],,
8989,NCT06101836,Patient comfort during colonoscopy - Sedation,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],,
8990,NCT03793322,The accuracy of positive margins of resection detected by ICG fluorescence.,2017-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
8991,NCT02260440,Objective Response Rate (ORR),2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8992,NCT00222469,"To determine the overall survival (OS) rate at 1 year in this patient population, treated with the combination therapy of bevacizumab plus gemcitabine and oxaliplatin",2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine the tolerability and toxicity profile of this regimen in this patient population
8993,NCT03908255,Overall Survival,2021-06-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],International normalized ratio (INR),Quality of life using FACT-Hep
8994,NCT01279278,Completion of Fecal Occult Blod Test,2010-09,UNKNOWN,INTERVENTIONAL,['NA'],,"Compare the rate of completion of colonoscopy after a positive test (information received by ADECA in the follow-up), according to the specifications."
8995,NCT05243862,Administration safety,2022-06-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Measured Memory T Cell Immune Response
8996,NCT03245203,R0 resection rate,2017-08,UNKNOWN,INTERVENTIONAL,['NA'],,overall response rate (ORR)
8997,NCT04829032,Number of Hartmann's procedure vs colic resection with primary anastomosis performed in 3-months in urgent or emergency setting for left-sided acute colonic diseases.,2021-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,The number of patients treated with Hartmann's procedure with a permanent stoma after one year.
8998,NCT02927626,Survival rate,2016-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,quality of life(QOL)
8999,NCT01318200,Freedom from local progression,2011-02,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Freedom from local progression
9000,NCT05462470,overall survival,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Severe complication rate after resection of primary and metastatic lesions
9001,NCT05546970,Efficacy of the echo-guided TAP Block on analgesia,2022-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
9002,NCT04896879,Needs and experiences of healthcare professionals caring for patients with LARS through focus groups,2016-11-22,COMPLETED,OBSERVATIONAL,['NA'],,
9003,NCT01809756,severity of esophagitis (NCI Common Terminology Criteria for Adverse Events (CTCAE) 4.0 score),2014-02-25,TERMINATED,INTERVENTIONAL,['NA'],,weight loss (NCI CTCAE 4.0 score)
9004,NCT00351572,,2006-07,COMPLETED,OBSERVATIONAL,['NA'],,
9005,NCT00899093,YKL-40 measurements,2007-09,TERMINATED,OBSERVATIONAL,['NA'],Variability of YKL-40 measurements,
9006,NCT05565417,Phase 2a Cohort(s) Overall Response Rate (ORR) based on RECIST 1.1 or Lugano criteria (lymphomas only) to assess anti-tumor activity of IMT-009 in each cohort,2022-11-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2a Cohort(s)- Number of participants with adverse events following administration of IMT-009
9007,NCT06195904,Genetic variants of pancreatic cysts associated with malignancy assessed by next-generation sequencing,2024-01-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Genetic variants that differentiate mucinous from serous cysts assessed by next-generation sequencing
9008,NCT03189992,Complete patient recruitment,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
9009,NCT03444194,Tissue biopsy,2017-05-12,UNKNOWN,INTERVENTIONAL,['NA'],,RECIST
9010,NCT04655807,Change from Baseline in the Crohn's Disease Activity Index (CDAI) Score at Week 12,2021-03-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Change in PD Biomarker Levels of Fecal Lactoferrin from Baseline Compared with Placebo
9011,NCT05984342,disease-free survival rate,2023-08-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Rate of adverse events
9012,NCT02931981,Overall Survival,2016-10,UNKNOWN,OBSERVATIONAL,['NA'],,Relapse-free Survival
9013,NCT02347852,Amount of physical activity assessed by a pedometer (smartLAB) and an international physical activity questionnaire,2015-01-20,COMPLETED,OBSERVATIONAL,['NA'],,"Relation of the amount of physical activity to PFS (Progression Free Survival) data assessed in CORRELATE (NCT02042144, 'Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings')"
9014,NCT01934179,"Incidence of chemotherapy related grade 3 or higher adverse events, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0",2013-10,TERMINATED,OBSERVATIONAL,['NA'],"Association of each geriatric scale, and pro-inflammatory markers to the incidence of chemotherapy related adverse events and TL",Change in TL after chemotherapy
9015,NCT03814369,Adenoma detection rate,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],,caecal intubation time
9016,NCT01328223,Response rate,2010-09,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
9017,NCT02649153,Time to first peristalsis,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
9018,NCT00019474,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9019,NCT02421185,Number of participants with Objective Response,2015-05-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of Objective Response (DOR)
9020,NCT03144856,Progression-free survival (PFS),2017-02-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety (incidence of adverse events)
9021,NCT03491709,Pharmacokinetic Parameters: Area Under the Serum Concentration-time Curve From Time Zero to the Last Sampling Time (AUC0-t) After First Infusion,2018-07-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Immunogenicity indicators: neutralizing antibodies
9022,NCT06236594,Image quality rate,2023-09-18,RECRUITING,OBSERVATIONAL,['NA'],,Diagnosis accuracy according to image
9023,NCT05550974,complication,2022-09,RECRUITING,OBSERVATIONAL,['NA'],,number of use for each surgical instruments
9024,NCT01417000,Overall Survival (OS) in Subjects Receiving Test Treatments (FAS),2011-09-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To Assess Safety of the Cyclophosphamide, GVAX Pancreas Vaccine, and CRS-207 Treatment Regimen"
9025,NCT01237132,Overall survival of resected patients for HCC,na,COMPLETED,OBSERVATIONAL,['NA'],,Disease-free survival of resected patients for HCC
9026,NCT03003078,Safety / Tolerability of Device according to CTCAE V4.0,2017-03-27,COMPLETED,INTERVENTIONAL,['NA'],tumour response,Pain Scores
9027,NCT05995990,Raman spectroscopy is able to discriminate between healthy liver tissue and colorectal liver metastases.,2020-11-25,COMPLETED,INTERVENTIONAL,['NA'],,Tissue sections can be analysed by Raman spectroscopy more time effectively than normal clinical practice.
9028,NCT04563975,disease control rate,2020-07-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival rate
9029,NCT04257448,Recommended dose for expansion (RDE),2020-05-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival (PFS)
9030,NCT06223763,Overall Survival at 5 years,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Homologous Recombination Deficiency (HRD) deficiency influence
9031,NCT05365412,"Survival (overall/disease-specific) according to sex, molecular profiles and sex hormone receptors",2019-01-01,RECRUITING,OBSERVATIONAL,['NA'],,"Disease-free survival according to sex, molecular profiles and sex hormone receptors"
9032,NCT00262808,Proportion of patients with a change in tumor-associated macrophage VEGF expression,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease-free and overall survival
9033,NCT05601609,Overall survival outcome in young colorectal cancer (yCRC) and elderly colorectal cancer (eCRC),2020-11-11,COMPLETED,OBSERVATIONAL,['NA'],,Cancer-specific survival outcome in young colorectal cancer (yCRC) and elderly colorectal cancer (eCRC)
9034,NCT00985777,Maximum Tolerated Dose (MTD),2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Adverse Events (AEs)
9035,NCT04716166,FEV1/FVC ratio,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],,
9036,NCT00065234,,2003-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
9037,NCT00081354,Case Control,2004-04-06,COMPLETED,OBSERVATIONAL,['NA'],,
9038,NCT00222664,,1983-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
9039,NCT00606788,weaning duration,2005-11,SUSPENDED,INTERVENTIONAL,['NA'],,reintubation rate
9040,NCT06061874,Correlation of the Ga68-FAPI PET/CT derived PCI (peritoneal cancer index) score with the intraoperative PCI based on histopathology of resected specimen (the reference standard),2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Assessment of the impact of neoadjuvant chemotherapy on the FAPI expression of target lesions at baseline.
9041,NCT02066363,Changes in body composition,2014-03-01,TERMINATED,INTERVENTIONAL,['NA'],Survival in study,Time to to exacerbate Quality of Life
9042,NCT01111292,The Effect of Myo-inositol (Inositol) on P-β-catenin Staining in Areas of Low Grade Dysplasia in Subjects With Known Colitis-induced Low Grade Dysplasia.,2010-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9043,NCT04248569,Fold change in interferon-producing DNAJB1-PRKACA-specific cluster of differentiation 4 (CD4) T cells at 10 weeks,2020-04-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
9044,NCT00292279,Systemic inflammatory response syndrome (SIRS),2002-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Post operative nutritional cost & total treatment cost
9045,NCT02090101,Response rate after 2 months in patients with colorectal cancer with liver metastases treated with anakinra and LV5FU2/bevacizumab,2014-10-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate and safety profile according to NCI-CTCAE v4
9046,NCT06133439,Implementation outcomes,2023-01-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Maintenance,
9047,NCT02807844,Phase Ib: Number of Participants With Dose Limiting Toxicities (DLTs) During the First 2 Cycles of Study Treatment,2016-06-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase Ib and Phase II: All Collected Deaths
9048,NCT05394129,Diagnostic accuracy,2019-04-09,RECRUITING,OBSERVATIONAL,['NA'],,Cytomorphologic feature
9049,NCT05345678,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
9050,NCT05682898,Incidence of surgical complications,2023-01-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9051,NCT06333392,Proximal sessile serrated lesion detection rate,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Single use accessories for the procedure
9052,NCT02718235,The HCC immune score (HCCIS) is a survival prognosticator of patients after liver resection for HCC,2016-06,UNKNOWN,OBSERVATIONAL,['NA'],,The HCC immune score (HCCIS) to prognosticate disease free survival of patients after liver resection for HCC
9053,NCT04568200,pathological response,2020-06-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
9054,NCT02442362,Tumor respone,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Side-effect
9055,NCT02015169,complete resection rate (R0 resection rate) (defined as no macroscopic or microscopic residual tumor).,2012-07-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Exploratory biomarker analysis
9056,NCT01736813,"safety as occurence of adverse events ≥ Grade 3 according to CTCAE, Version 4.0 criteria, that are definitely, probably, or possible related to the administration of the investigational agent",2012-11,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
9057,NCT00904813,Time to Local Recurrence.,1998-11,COMPLETED,INTERVENTIONAL,['NA'],,Tumour Regression Based on the Dworak Grading Scoring System
9058,NCT04071431,Rate change,2019-05-29,UNKNOWN,INTERVENTIONAL,['NA'],,
9059,NCT04563897,Diagnostic performance of contrast-enhanced ultrasound in different liver background and liver turmors by sonazoid,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9060,NCT05190042,The rates of complete closure of mucosal/submucosal defects,2022-01-18,COMPLETED,INTERVENTIONAL,['NA'],,Post polypectomy syndrome
9061,NCT02073435,Complications,2010-10,COMPLETED,OBSERVATIONAL,['NA'],,
9062,NCT04871321,collected blood samples,2021-04-14,RECRUITING,OBSERVATIONAL,['NA'],,Biomarkers on the efficacy of Gemcitabine/Cisplatin/Nab-paclitaxel for advanced biliary tract cancer
9063,NCT01489865,Dose limiting toxicities,2011-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Objective Response
9064,NCT01479608,Overall survival,2012-04-11,RECRUITING,INTERVENTIONAL,['NA'],,
9065,NCT03680183,Average plasma concentration of the drugs (TKIs),2018-05-22,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of adverse reaction caused by TKIs
9066,NCT02043288,Overall survival (OS),2014-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life (QoL) using EORTC QLQ-C30
9067,NCT03411200,Lower body strength measured with the 30-second chair stand test,2018-04-04,COMPLETED,INTERVENTIONAL,['NA'],,Survival
9068,NCT04972994,early recurrence of the cancer,2021-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,
9069,NCT06048913,Overall Survival,2022-07-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE1'],,Toxic side reactions
9070,NCT03053544,Pathological Complete Response (pCR) rate,2016-12-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor Hypoxia
9071,NCT00955240,Objective response (complete and partial) according to RECIST criteria at 8 weeks after completion of study treatment,2009-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Duration of objective response
9072,NCT03868228,Progression free survival assessed by laparoscopy and cross sectional imaging,2019-02-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PIPAC related safety regulation breaches / adverse events in theatre
9073,NCT05159050,Determine the maximum tolerated dose (MTD) of intraperitoneal Paclitaxel-loaded Tumor Penetrating Microparticles (TPM),2022-04-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,Assess whether intra-abdominal pressure is location-dependent
9074,NCT04389151,effectiveness of neoadjuvant therapy,2020-03-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
9075,NCT06261814,False discovery rate,2024-08-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Ability of the model to predict binary treatment response
9076,NCT04262635,Efficacy: Maintenance PFS,2021-09-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Change from Baseline in Mutation Status of Selected Genes tested by Next-Generation Sequencing during Treatment Period,Overall Survival
9077,NCT03311750,Evaluation of overall response rate of the addition of panitumumab rechallenge to standard third-line therapy,2018-03-26,TERMINATED,INTERVENTIONAL,['PHASE2'],,Mutations analysis on platelet-resorbed tumour RNA (with Real-time PCR) in exon 20 of PIK3CA gene mutations
9078,NCT03694600,Independent performance measure of sensitivity and specificity of a multi-analyte blood test vs Ultrasound,2019-02-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,To compare the performance (sensitivity and specificity) of ultrasound alone to the multi-analyte Test alone for the detection of liver cancer lesions that are ≤ 2cm in diameter.
9079,NCT00436241,Overall response rate,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"AEs, laboratory parameters."
9080,NCT03257033,Overall Survival,2018-03-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Safety, defined as adverse event rate, and tolerability, defined as occurrence of treatment discontinuation"
9081,NCT00881504,Progression-free Survival,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety and Toxicity
9082,NCT00890305,The primary endpoint will be the median progression free survival in patients treated with CT-011 plus FOLFOX compared to that of patients treated with FOLFOX alone.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor and immunological markers.
9083,NCT03400280,Composite primary endpoint,2018-01-08,UNKNOWN,INTERVENTIONAL,['NA'],,Cost-effectiveness
9084,NCT05654896,Liver abscess and intervention,2022-11-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,
9085,NCT00104689,Efficacy in terms of stabilization or improvement by 1 point on Katz's Activities of Daily Living scale,2003-06-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pharmacokinetics
9086,NCT02325739,Overall Response Rate (ORR) Based on Local Assessment: Group 3 (Phase II Only),2014-12-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,T1/2 of FGF401: Phase I
9087,NCT03171428,Short-term outcome: Occurrence of postoperative complications or death after surgery,2007-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
9088,NCT04331041,Progression-free survival (PFS),2021-08-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Local control
9089,NCT00213486,clinical complete response defined as no tumor detectable on esophagus endoscopy and no appearance of distant metastasis on CT scan,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival rate at one and two years
9090,NCT02678013,Recurrence-free survival,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0
9091,NCT03640572,Overall survival (OS),2007-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Systemic recurrence
9092,NCT00881621,Overall Survival,2009-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Adverse Events
9093,NCT03723304,Tumour-specific liver transplant failure rate,2018-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
9094,NCT05859945,Number of hepatocellular carcinoma study participants who remain in clinical trial until completion.,2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9095,NCT05248048,Maximal Tolerable Dose#MTD#,2021-09-13,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Antitumor efficacy-Overall survival (OS)
9096,NCT05267080,Local Tumour Control,2023-01-25,RECRUITING,OBSERVATIONAL,['NA'],,Economic aspects
9097,NCT00265824,Progression-free survival during maintenance therapy,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
9098,NCT05965531,Objective response rate,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
9099,NCT02866019,Proportion of participants without stenosis until 8 weeks after endoscopic submucosal dissection (ESD),2016-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,QOL assessed by the EORTC QLQ-OG 25
9100,NCT03198975,Presence of microvascular invasion,2017-06-23,UNKNOWN,OBSERVATIONAL,['NA'],,
9101,NCT00005629,Safety,1999-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival
9102,NCT03716089,3-year disease free survival rate,2018-10-11,RECRUITING,OBSERVATIONAL,['NA'],,The variation of C-reactive protein
9103,NCT04224402,Regression Free Survival,2020-01-31,COMPLETED,INTERVENTIONAL,['PHASE2'],EORTC Quality of Life Questionnaire(QLQ)-C30,Overall Survival
9104,NCT00485316,Overall survival and disease-free survival,1993-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Direct cost
9105,NCT05084456,The hematological and non-hematological toxicity profile of oral docetaxel in combination with ritonavir,2017-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
9106,NCT01046864,"Safety-Toxicity, evaluated according to NCI Common Terminology Criteria for Adverse Events v3.0. Assessments based on medical review of adverse events, results of vital signs, ECGs, echocardiography, physical examinations, and clinical laboratory tests",2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Exploratory Measures (Biomarkers for Predictive Analysis): Potential predictive markers, including activity of FGF, VEGF and related pathways as well as K-RAS mutation status, will be evaluated based on blood or tumor samples"
9107,NCT01585428,Number of Participants With an Objective Clinical Response,2012-04-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Serious and Non-serious Adverse Events
9108,NCT05616403,Textbook outcome,2010-01-18,COMPLETED,OBSERVATIONAL,['NA'],,
9109,NCT01005875,Determine the Safety and Tolerability of Sequential SBRT and Sorafenib in Patients With Unresectable Hepatocellular Carcinoma,2009-11,TERMINATED,INTERVENTIONAL,['NA'],,The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by ADC (Apparent Diffusion Coefficient).
9110,NCT00037180,Incidence of NCI CTC grade 2-4 diarrhea during the first cycle (6 weeks) of CPT-11/5-FU/LV chemotherapy,2002-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Health resource utilization (collected data to be evaluated separately from this protocol)
9111,NCT04272619,Change in intentions about communicating with healthcare provider - liver cancer risk,2020-02-11,COMPLETED,INTERVENTIONAL,['NA'],,
9112,NCT01786278,The highest improvement of stricture diameter,2013-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Cost analysis,Quality of life
9113,NCT00081549,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9114,NCT00054873,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9115,NCT03330964,Levi sensory nerve toxicity classification standard,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA'],National Cancer Institute(NCI)Common Toxicity Criteria,The quality of life questionnaire(QLQ)-C30
9116,NCT05916846,Assess the efficacy of EUS-RFA post-procedure after one year,2023-04-24,RECRUITING,INTERVENTIONAL,['NA'],,Assess the long-term response to EUS-RFA for efficacy of significant and durable ablation response
9117,NCT05133544,Adenoma detection rate,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Total number of polyp or adenoma per patient.
9118,NCT06280508,1-year EFS rate,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
9119,NCT01494012,The rate of grade 3 or greater non-hematologic acute toxicity as graded by the CTCAE v. 4.0,2012-04,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival
9120,NCT02016391,Patient Satisfaction With Sedation Technique,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,Maximal pain intensity
9121,NCT03770559,Posteroperative length of stay,2020-07-01,RECRUITING,INTERVENTIONAL,['NA'],,R0 resection
9122,NCT05657418,RP2D,2022-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,ORR
9123,NCT03475615,overall survival,2018-03-16,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
9124,NCT06153394,Number pf participants with hypercoagulability identified via TEG testing,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease Free Survival
9125,NCT01540461,Accumulation index calculated as the ratio: AUC(TAU) at steady-state (Day 8) divided by AUC(TAU) after the first dose (Day 1) [AI] of Brivanib,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Preliminary evidence of anti-tumor activity as measured by objective response rate (ORR) and disease control rate (DCR) in Chinese subjects with advanced HCC treated with Brivanib
9126,NCT06126419,Liver regeneration improvement after high-dose insulin therapy after LVD measured CT volumetry,2023-11-08,RECRUITING,INTERVENTIONAL,['NA'],,
9127,NCT00052962,Progression Free Survival,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With an Adverse Event
9128,NCT00496678,"To develop, implement, and evaluate a primary care-based, patient navigation program using specially-trained community health workers. We will investigate the effect of this intervention on timing and quality of cancer-related care.",2007-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Secondary aims examine the impact of navigation on disparities in care, improvement in patient activation and total costs."
9129,NCT03009747,Risk factors of bowel dysfunction after sphincter-preserving surgery,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of bowel dysfunction after sphincter-preserving surgery
9130,NCT00287976,Best overall response (complete response and partial response),2003-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Surgical resection (complete or incomplete)
9131,NCT04163068,Treatment burden,2020-01-08,COMPLETED,OBSERVATIONAL,['NA'],,
9132,NCT00032110,Objective response or disease stabilization,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Molecular changes with therapy
9133,NCT03612726,Overall survival,2018-07-16,RECRUITING,OBSERVATIONAL,['NA'],,Frequency and Severity of Adverse Events
9134,NCT00003557,Objective Response Rate,1999-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9135,NCT02665299,Utility of plasma ctDNA measurements to detect colon cancer or precancerous conditions.,2016-01,COMPLETED,OBSERVATIONAL,['NA'],,Determination of incident rate of new colon or other cancers in patients who underwent initial measurement of ctDNA
9136,NCT01646554,Progression free survival,2012-12,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Safety
9137,NCT03242187,Number of lymph nodes retrieved,2017-05-25,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Functional outcome
9138,NCT03619317,• Left ventricular systolic function estimated by 2D longitudinal strain (GLS) and ejection fraction (EF) at rest and peak exercise,2018-06-25,UNKNOWN,OBSERVATIONAL,['NA'],,Left ventricular systolic function estimated by 2D longitudinal strain (GLS) and ejection fraction (EF) at rest and peak exercise
9139,NCT06244537,Pathological complete response (pCR),2024-02-29,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
9140,NCT05160740,3-year disease free survival rate,2021-09-23,RECRUITING,INTERVENTIONAL,['NA'],,Mortality rates
9141,NCT06152276,Overall major complications,2024-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
9142,NCT01462890,Progression Free Survival (PFS),2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Translational Research - Complementary and Alternative Treatment Questionnaires
9143,NCT03971201,overall survival,2019-09-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,progression free survival
9144,NCT04725994,Dose Limiting Toxicities (DLTs),2021-06-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,
9145,NCT00556413,Complete response rate,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival
9146,NCT01065688,the postoperative quality of life (QOL),2009-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,"the incidence of postoperative complications, nutritional status, and the incidence of the remnant gastritis and the reflux esophagitis"
9147,NCT00653484,Physical activity-energy expenditure,2008-03,COMPLETED,INTERVENTIONAL,['NA'],,Body weight and composition
9148,NCT01904656,Rates of colorectal cancer screening-within-guidelines (status obtained by medical record review).,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,Effect Modification
9149,NCT00940563,tumor response /RecIST criteria),2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"which early predictive factors of tumor response may be of relevance, i.e. conventional pathologic characteristics of tumor and radiological aspects."
9150,NCT00877045,,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,
9151,NCT04451343,"Assess how the patients, their relatives and their family members, face the disease.",2018-07-06,COMPLETED,OBSERVATIONAL,['NA'],,
9152,NCT04959448,Baseline Disease Characteristics,2021-08-12,RECRUITING,OBSERVATIONAL,['NA'],,Physician Assessment: Global Impression for Disease Severity (Global Physician Assessment)
9153,NCT00189566,Progression-free survival of patients in the three groups,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
9154,NCT01215565,Objective response,2009-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Biomarkers of radiological response
9155,NCT01635595,,2006-01,COMPLETED,OBSERVATIONAL,['NA'],,
9156,NCT00671996,Neutropenia,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life
9157,NCT06220045,Incidence of surgical wound infection,2024-01-15,RECRUITING,INTERVENTIONAL,['NA'],,Morbidity and mortality rates
9158,NCT00335816,Effect of different chemoradiation-to-surgery intervals on postoperative complications,2008-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
9159,NCT05407272,"the knowledge, attitudes, service intentions and service start-up effects of the eight major non-cancer disease end-stage caregivers on well-being and palliative care",2021-09-14,COMPLETED,INTERVENTIONAL,['NA'],,
9160,NCT05281159,Opening link within SMS Text message,2022-02-21,COMPLETED,INTERVENTIONAL,['NA'],,Overall completion of any CRC screening test
9161,NCT00901732,The primary objective is to estimate ht incidence of OM in H&N cancer patients undergoing radiation therapy with or without chemotherapy and/or sensitizer who receive Caphosol.,2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"The secondary objective of this study is to correlate components of OM data with clinical outcomes (pain, narcotic use, oral intake)"
9162,NCT05004376,Screening,2022-01-03,COMPLETED,INTERVENTIONAL,['NA'],,Phone Interview for refinement of Intervention
9163,NCT02727309,Progression free survival,2015-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Objective response rates
9164,NCT02903498,Progression Free Survival (PFS),2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events
9165,NCT01437514,local recurrence,2011-08,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,short-term complication of the surgery
9166,NCT04046601,impedance,2019-10-09,COMPLETED,INTERVENTIONAL,['NA'],,differences in impedance
9167,NCT04837833,measurement differences between ultrasound tumor volumes,2021-04-06,RECRUITING,INTERVENTIONAL,['NA'],,
9168,NCT05497778,"National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0",2022-10-21,RECRUITING,INTERVENTIONAL,['PHASE1'],,
9169,NCT01590719,Progression-free survival (PFS) in patients with Met-positive tumors,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of response (DOR)
9170,NCT00082862,Changes in quality of life,2002-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Changes in cellular and cytokine immune function
9171,NCT00195572,Survival time,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Response rate, duration of response, time to progression, safety, quality of life"
9172,NCT02413476,Five-year disease free survival rate,2015-05,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Intraoperative situation (The number of lymph node dissection,the number of positive lymph nodes,extra-cavity anastomosis time,intraoperative blood loss,the rate of conversion)"
9173,NCT03767764,Yliver,2018-12-27,COMPLETED,OBSERVATIONAL,['NA'],,AAb AFP
9174,NCT04216251,Change in the Marine Omega-3 Polyunsaturated Fatty Acid (MO3PUFA) Composition in Colorectal Tissues as a Result of the AMR101 Treatment.,2020-12-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in Stool Metabolite Profile
9175,NCT00276705,Event-free and overall survival following tumor resection,2005-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Efficacy and tolerability following course 2 and 4 of pre-operative chemotherapy
9176,NCT00003926,,1998-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,
9177,NCT04491929,Feasibility and translational analysis,2020-11-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival
9178,NCT00851045,Progression free survival based on tumor assessments (CT/MRI),2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Safety in the CT-322 plus irinotecan, 5-FU and leucovorin arm as measured by incidence of serious and non-serious adverse events, significant laboratory evaluations and significant physical examination findings in subjects"
9179,NCT00606619,Days of hospital stay after operation,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Postoperative morbidity rate in hospital days: Clinically definite morbidity confirmed by physicians according to offered protocol
9180,NCT05265754,Sujok Therapy's positive cahange in nausea and vomiting Experienced by Patients with Gastrointestinal System Cancer,2022-02-01,COMPLETED,INTERVENTIONAL,['NA'],,
9181,NCT00825110,the primary endpoint is the identification of cases with evidence of loss of the product of one of the four main MMR genes on tumour histology.,2008-11,UNKNOWN,OBSERVATIONAL,['NA'],,Secondary outcome measure is the survival and response to treatment of the identified cases.
9182,NCT02155140,Fatigue,2011-02,TERMINATED,INTERVENTIONAL,['NA'],,Health economic analysis
9183,NCT04190589,Lymph node count,2020-05-18,RECRUITING,INTERVENTIONAL,['NA'],Conversion rate,Readmissions
9184,NCT03264898,FIT Result,2017-10-02,UNKNOWN,OBSERVATIONAL,['NA'],,
9185,NCT01640808,Recurrence-free Survival,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to Recurrence
9186,NCT00081094,Relative sensitivity and specificity of positron emission tomography (PET) scanning with carbon-11 acetate and fludeoxyglucose F 18,2003-09,COMPLETED,INTERVENTIONAL,['NA'],,Obtain a preliminary estimate of the impact of PET on management of patients with HCC.
9187,NCT03148119,Incidence of QRH-882260 Heptapeptide administration-related adverse events,2017-03-31,TERMINATED,INTERVENTIONAL,['PHASE1'],Efficacy of QRH-882260 Heptapeptide administration for detection of dysplasia in the setting of IBD,Efficacy of QRH-882260 Heptapeptide administration for detection of polypoid and non-polypoid colonic neoplasia
9188,NCT00467116,Maximum Tolerated Dose,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor response rate
9189,NCT01375972,Progression-free survival rate at 6 months,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
9190,NCT03515356,Sensory neuropathy at 8 weeks,2018-06-13,COMPLETED,INTERVENTIONAL,['NA'],MI Fidelity Measure at 9 months,Mood at 8 weeks
9191,NCT00044031,Survival,2001-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants with Serious and Non-Serious Adverse Events
9192,NCT00499486,Severity of Adverse Events as Assessed by NCI CTCAE v3.0,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9193,NCT00855348,Clinical/surgical diagnosis of invasive colorectal adenocarcinoma detected by optical colonoscopy and confirmed by histology compared to the Septin 9 Biomarker classification.,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,"Detection of adenomatous polyp(s) equal to or greater than 10 mm, flat lesion (s) or non-invasive adenocarcinoma by colonoscopy and confirmed by histology compared to the Septin 9 Biomarker classification will also be described."
9194,NCT06328868,Concentration of Serum prealbumin,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Feeding amount
9195,NCT02912559,Disease free survival (DFS),2017-10-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events
9196,NCT03621644,Gastrointestinal toxicity assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5,2019-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Patient-reported quality of life (QOL)
9197,NCT05288205,Number of participants with dose limiting toxicities,2022-04-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free survival (PFS)
9198,NCT00793455,Colorectal Cancer Screening Completion.,2008-10,COMPLETED,INTERVENTIONAL,['NA'],,Colorectal Cancer Screening Completion
9199,NCT04795869,Overall objective response rate (ORR),2020-03-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival
9200,NCT02803515,Changes in serum levels of HSP90 and 70 on peripheral venous samples.,2017-01-16,TERMINATED,INTERVENTIONAL,['NA'],,
9201,NCT01679340,replase free survival,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
9202,NCT00335010,differences in microvascular hemoglobinsaturation,2005-05,COMPLETED,INTERVENTIONAL,['NA'],,differences in anastomotic stenosis
9203,NCT01582750,Endoscopic ultrasound measurement of the primary tumor maximum diameter changes in absolute / relative values,2010-10,UNKNOWN,OBSERVATIONAL,['NA'],,
9204,NCT02510911,Time to first bowel movement,2015-08,TERMINATED,INTERVENTIONAL,['NA'],preoperative caffeine consumption,Consumption of sleep inducing drugs
9205,NCT05287672,Weight gain by BMI by kg/m2,2022-06,UNKNOWN,OBSERVATIONAL,['NA'],,
9206,NCT03479814,complete pathological response (pCR),2016-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluation of PET-response as predictive factor
9207,NCT05064618,Phase II study; response rate (based on RECIST ver1.1),2021-08-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Response rate （Phase I）
9208,NCT01249352,Overall survival and assessment of the complete endoscopic response,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Complete clinical response rate
9209,NCT00318604,,na,UNKNOWN,OBSERVATIONAL,['NA'],,
9210,NCT00628810,Tolerability evaluated by NCI CTC v. 2.0 criteria,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life using the EuroQOL EQ5D questionnaire
9211,NCT01301495,Palliation assessment based on Dysphagia Scores,2010-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Assessment of Complications and MD Anderson Dysphagia Score
9212,NCT03486678,Incidence of Treatment-Emergent Adverse Events,2018-02-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,OS
9213,NCT01183559,Maximum Tolerated Dose of Vandetanib,2008-08-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,The Number of Participants With Adverse Events
9214,NCT06031480,"Objective response rate (ORR, RECIST v1.1)",2023-10-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
9215,NCT05898854,Patient management,2024-02-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Prognostic value
9216,NCT05520866,Proportion of days before surgery engaged in prehabilitation,2023-03-14,RECRUITING,INTERVENTIONAL,['NA'],Median Satisfaction Scores,Change in Mean score on the SF-36
9217,NCT05056714,Develop a severity score for PNS using latent variable modeling: Polyps Severity Index (PSI),2022-01-27,RECRUITING,OBSERVATIONAL,['NA'],,
9218,NCT05568420,genomic analysis of tissue,2022-09-30,RECRUITING,OBSERVATIONAL,['NA'],,
9219,NCT05982301,"Progression-Free survival 2, PFS2",2023-02-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,After Effects
9220,NCT03257332,Global health status/quality of life: EORTC QLQ-C30,2019-11-12,WITHDRAWN,OBSERVATIONAL,['NA'],Physical performance,Low anterior resection syndrome
9221,NCT01196260,To determine prognosis of patients with metastatic colorectal cancer received the combination of drugs,2004-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,To evaluate the time to progression of metastatic colorectal cancer after treatment
9222,NCT01697371,Phase I of study: Number of participants with adverse events as a measure of safety and tolerability,2012-08-22,RECRUITING,INTERVENTIONAL,['NA'],,Phase II -local control within irradiated fields at 2 years
9223,NCT02997228,Progression free survival (PFS),2018-01-19,RECRUITING,INTERVENTIONAL,['PHASE3'],Mechanism of immune resistance to PD-1 blockade in mismatch repair deficient (dMMR)/microsatellite instability-high metastatic colorectal cancer (mCRC) by comparative analysis of tumor samples collected,Duration of SD
9224,NCT00525005,overall response rate,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"safety, progression-free survival, and overall survival"
9225,NCT01286818,Number of Participants With Ramucirumab Drug-Related Adverse Events or Serious Adverse Events,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Best Overall Response [Anti-Tumor Activity of FOLFIRI Plus Ramucirumab (IMC-1121B)]
9226,NCT00288119,Assay of DNA and RNA markers,2005-10-01,RECRUITING,OBSERVATIONAL,['NA'],,Score of tolerability and acceptability
9227,NCT04744688,The difference between changes in concentration of prothrombin fragment 1+2.,2021-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Incidence of deep venous thrombosis measured by doppler ultrasonography in colorectal cancer patients undergoing cytoreductive surgery with HIPEC
9228,NCT01837446,Mucositis severity,2011-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Patient's satisfaction
9229,NCT06105203,intersphincteric resection (ISR),2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,3-year defecation function
9230,NCT00381173,"Determine the feasibility, safety and tolerability of administering ZYC300 intramuscularly every other wk for 6 doses (400 micrograms DNA/total dose) to the study pop. pre-dosed with 600 mg/m^2 cyclophosphamide intravenously 3 days prior to study drug.",2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Assess the effect of cyclophosphamide on T reg number and function. Assess the generation of CYP1B1-specific immun. as a result of vac. regimen. Assess the effect of vac. regimen on tumor response, if any, in pat. pop."
9231,NCT01273805,2-month Progression-Free Survival Rate,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Grade 4-5 Treatment-Related Toxicity
9232,NCT02649491,Change in Olfactory Signatures in patient sample,2015-11,UNKNOWN,OBSERVATIONAL,['NA'],,"Changes in the scores of Inflammatory Bowel Questionnaire,"
9233,NCT00657995,the incidence of severe hypoglycemia (< 40 mg/dl) during the intensive care period following pancreatic resection in patients monitored using the artificial pancreas,2007-04,COMPLETED,INTERVENTIONAL,['NA'],,the total amount of insulin required for glycemic control after pancreatic resection
9234,NCT05988814,Progression-free survival (PFS),2024-01-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life (QoL)
9235,NCT00226746,One-year overall survival rate,2003-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Occurrence of pathological response or shrinkage of the tumor (becomes resectable)
9236,NCT04409223,Progression-free survival (PFS),2020-09-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,Adverse Events and Serious Adverse Events
9237,NCT04524676,1-year rebleeding rate,2020-08-31,UNKNOWN,INTERVENTIONAL,['NA'],,Complications of portal hypertension
9238,NCT01506115,Complications associated with the procedure,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,Survival time
9239,NCT05921942,Progression free survival,2020-04-15,COMPLETED,INTERVENTIONAL,['PHASE3'],,Common terminology criteria adverse events (CTCAE 4.0)
9240,NCT03559543,Nutritional status,2018-10-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9241,NCT04165031,Phase 2: Progression-Free Survival (PFS) Non-Small Lung Cancer (NSCLC Cohorts),2019-11-28,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Phase 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, and SD"
9242,NCT05731726,Pathological complete response rates,2023-02-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,single cell sequence
9243,NCT05353582,Progression free survival,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Hospitalization time
9244,NCT05557656,Overall survival (OS),2023-01-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Adverse events (AEs)
9245,NCT02585362,Change in physical performance,2016-03,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival
9246,NCT05980416,Number of patients with clinically significant changes in laboratory tests,2023-08-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,
9247,NCT01395537,PHASE II: To Assess the Response Rate to This Regimen.,2011-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To Determine the Overall Survival
9248,NCT03383159,Differences In Microbiota,2016-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Predictive model validation
9249,NCT00860691,"Fe, transferrin, ferritin",2008-01,UNKNOWN,INTERVENTIONAL,['NA'],,"loss of blood during the surgery, postoperative hospital stay, morbidity, and mortality within 30 days after surgery"
9250,NCT01282333,Maximum-tolerated dose of veliparib in combination with cisplatin and gemcitabine,2011-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Recommended phase II dose
9251,NCT03777462,Overall time,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease free time
9252,NCT05249114,Establish the maximal tolerated dose of cabozantinib in combination with Lu-177 dotatae at a standard dose of 7.4 GBg in four 8-week cycles followed by continuation of cabozantinib.,2022-12-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Establish objective response rate as measured by RECIST 1.1
9253,NCT02841046,Number of Days Needed for Anal Exsufflation After Surgery,2016-07-27,COMPLETED,INTERVENTIONAL,['NA'],Complication After Surgery,Number of Days in Hospital
9254,NCT02555358,The pathological complete response rate,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events
9255,NCT00027521,,2000-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
9256,NCT03061370,Survival,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
9257,NCT01566942,disease-free survival（DFS）,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,overall survival(OS)
9258,NCT03891654,DCE-CT Perfusion Metrics: Blood Flow,2019-08-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Correlation Between Patient Demographics and Blood Flow: Clinical Stage of Disease
9259,NCT00133913,,2004-03,UNKNOWN,OBSERVATIONAL,['NA'],,
9260,NCT05357196,To obtain best disease control rate (DCR) data(Phase II),2020-04-13,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Area under the plasma concentration versus time curve (AUC)
9261,NCT03576872,80% or higher rate of completing at least 3 of 4 nurse-led encounters with participants,2018-07-09,COMPLETED,INTERVENTIONAL,['NA'],,80% or higher on the index of rates for follow-up phone calls and binder review prior to cycle 2 of chemotherapy
9262,NCT05404347,Overall Survival,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,RFS
9263,NCT04416490,Overall Survival (OS),2020-03-25,RECRUITING,OBSERVATIONAL,['NA'],Results on blood pressure,Quality of Life Assessment (FACT/GOG-NTX-12)
9264,NCT03568669,Neurocognitive Outcomes,2016-01,RECRUITING,OBSERVATIONAL,['NA'],,Neourcognitive Outcomes
9265,NCT00131586,,2003-04,TERMINATED,OBSERVATIONAL,['NA'],,
9266,NCT01277406,Phase II: Progression free survival (PFS),2011-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Phase II: Pharmacokinetics: AUClast, AUCtau, cmax, tmax, t ½, CL/F of resminostat, Irinotecan (SN-38), 5-FU and folinic acid"
9267,NCT04645251,Map the natural course of PLD,2021-01-21,RECRUITING,OBSERVATIONAL,['NA'],,Determine whether rate of liver growth can be used to predict disease progression
9268,NCT00963092,"Creation of repository of blood, saliva, and tumor samples",2002-08,UNKNOWN,OBSERVATIONAL,['NA'],,
9269,NCT02969122,Overall survival,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,morbidity and mortality of HIPEC and EIPL
9270,NCT05379972,Objective Response Rate (ORR) of unirradiated tumors,2023-01-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0 during concurrent SBRT/olaparib
9271,NCT02026583,Progression free survival,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9272,NCT01853618,Number of Participants With Serious and Non-Serious Adverse Events Regardless of Attribution,2013-05-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
9273,NCT05093907,Objective Response Rate(ORR)(Phase 2) assessed by investigator following administration of BEY1107 in combination with Capecitabine,2021-08-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease control rate(DCR) assessed by investigator following administration of BEY1107 in combination with Capecitabine
9274,NCT00720668,The Rate of Exacerbation of chronic hepatitis B after RFA,2006-06,UNKNOWN,OBSERVATIONAL,['NA'],,mortality
9275,NCT00001276,Treatment Outcomes,1991-05-21,RECRUITING,OBSERVATIONAL,['NA'],,
9276,NCT05547919,Number of patients with identified tumor lesion sites,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,PSMA uptake on 18F-PSMA-1007 PET
9277,NCT06301828,ORR,2024-02-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events
9278,NCT03817411,ORR,2019-01-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DCR
9279,NCT05664139,Objective tumor response rate (ORR),2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],"Changes of CD4+ cells count, CD8+ cells count, Th1 cells count, Th2 cells count, Treg cells count in peripheral blood",Adverse event collection
9280,NCT03382886,Determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D),2018-04-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Survival
9281,NCT04739722,Colosense specificity for subjects with negative findings,2021-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
9282,NCT00419978,,2004-06,TERMINATED,INTERVENTIONAL,['NA'],,
9283,NCT06241066,DFS,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
9284,NCT00609505,Patient satisfaction,2008-08,COMPLETED,INTERVENTIONAL,['NA'],,Cost-effectiveness
9285,NCT01856322,Difference in Circulating S100A4 Transcript in Patients Receiving Sulindac 150 mg BD (Twice Daily) by Mouth Following Resection of Colorectal Cancer Metastases Compared to Those Who do Not.,2013-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,
9286,NCT02274376,Safety and tolerability: incidence and nature of adverse drug reactions,2008-08,COMPLETED,OBSERVATIONAL,['NA'],,Incidence and nature of dose interruptions
9287,NCT02985034,Local tumor progression (LTP),2010-10,COMPLETED,OBSERVATIONAL,['NA'],,immediate technical success on registration-software assessment
9288,NCT04810663,Efficacy of Radiotherapy in operated gastric cancer,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9289,NCT00831181,Pathologic Response and Complete Response,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Comparison of Preoperative Stage With Post-treatment Pathologic Stage
9290,NCT06262581,pathological complete regression rate,2023-09-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease free survival
9291,NCT01066741,Rate of occurrence of grade ≥ 3 (RTOG classification) mucositis during irradiation (only the first occurrence will be reported),2009-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,Evaluation of the cost of severe mucositis treatment
9292,NCT02967094,"""Visibility score"" evaluated by blinded performing endoscopist",2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,Duration of endoscopy
9293,NCT04641637,The completeness of coverage of the tumor vasculature by therapeutic agent at the completion of the treatment as evaluated on non-contrast CT scan,2022-06-30,COMPLETED,INTERVENTIONAL,['NA'],,Tumor response
9294,NCT01522573,Safety,2011-11,UNKNOWN,OBSERVATIONAL,['NA'],,Survival duration
9295,NCT02375672,Median Progression Free Survival (mPFS),2015-05-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Grade 3 or Higher Treatment Related Adverse Event
9296,NCT02646241,diagnostic accuracy,2016-01-02,COMPLETED,INTERVENTIONAL,['NA'],,accuracy of malignant potential on contrast enhanced EUS
9297,NCT00689624,Objective Response Rate,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Q-Twist analysis of Quality of life
9298,NCT00003834,response rate,1999-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
9299,NCT02525952,overall survival,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],,Time to recurrence
9300,NCT06187610,Symptom self-management knowledge,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Patients engagement while learning
9301,NCT05981235,"Changes from baseline in vital signs, laboratory parameters, physical examination, and 12-lead ECG.",2023-12-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,PFS
9302,NCT01927328,Hemoglobin differences between groups,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Differences in hematinic markers.
9303,NCT04694404,PFS,2016-05-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The number of participants with treatment-related adverse events as assessed by CTCAE v4.0
9304,NCT00355004,Rate of colorectal cancer screening,2005-03,COMPLETED,INTERVENTIONAL,['NA'],,Number and dates of sigmoidoscopies and colonoscopies scheduled and performed
9305,NCT00598156,progression-free survival,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,overall survival
9306,NCT02572050,Number of retrieved lymph nodes in the topographical N2 area,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
9307,NCT02745561,response rate,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
9308,NCT00717990,Objective Response Rate,2008-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
9309,NCT01582841,Implementation effectiveness,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,
9310,NCT00027534,Safety,2002-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immune response
9311,NCT04929587,Frailty assessed by Frailty Phenotype (FP),2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Sleep assessed by Pittsburgh Sleep Quality Index (PSQI)
9312,NCT05007015,EORTC-QLQ-C30,2022-01-15,RECRUITING,INTERVENTIONAL,['NA'],,Bowel diaries
9313,NCT03836131,The percentage of cancer in patients with GM-LSTs treated with endoscopic resection.,2018-12-31,COMPLETED,OBSERVATIONAL,['NA'],,
9314,NCT02967289,Disease Free Survival (DFS),2017-03-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
9315,NCT01218854,The difference between MD-NASS and standard method,2012-03-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9316,NCT05872828,Depression score,2023-04-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Immune variables 8
9317,NCT01315548,Contrast enhanced harmonic endoscopic ultrasound,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,
9318,NCT03780439,diagnostic accuracy of procalcitonin to detect post-operative infection,2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],,diagnostic accuracy of procalcitonin to detect overall post-operative complications
9319,NCT02045030,A biomarker (in blood or tissue) that may be predictive of level of response to aflibercept,2014-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,The quality of life impact of treating with FOLFIRI in combination with Aflibercept
9320,NCT03620461,Assess adverse events (per CTCAE v4.0 criteria),2013-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
9321,NCT05957367,Objective response rate (ORR) (Expansion Phase),2023-09-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Area under the concentration-time curve (AUC)
9322,NCT01475331,Number of Participants With the Changing in Cyst Volume,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9323,NCT04198337,Complete resection of GIST,2014-08-01,RECRUITING,INTERVENTIONAL,['NA'],,technical success in complete resection
9324,NCT06275165,Change from Baseline in gastrointestinal symptom distress Scale at study day 5(end day),2024-03-27,RECRUITING,INTERVENTIONAL,['NA'],,
9325,NCT04515082,"Sensitivity, specificity, positive predictive value and negative predictive value of bi-target stool DNA testing (the methylation status of SDC2 and SFRP2) with comparison to colonoscopy, both with respect to cancer and advanced precancerous neoplasm.",2020-08,UNKNOWN,OBSERVATIONAL,['NA'],,"To compare the performance of the bi-target stool DNA testing to a commercially available FIT assay, both with respect to cancer and advanced precancerous neoplasm."
9326,NCT02873195,Progression Free Survival (PFS),2017-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Event Deemed at Least Possibly Related to Treatment (Toxicity)
9327,NCT02347735,Anastomotic leakage,2015-08,COMPLETED,OBSERVATIONAL,['NA'],,
9328,NCT00780988,To assess the feasibility of using an autologous tumor cell vaccine in combination with standard chemotherapy followed by investigational autologous hematopoietic and immune cell rescue in terms of acceptable clinical toxicity.,na,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Ex vivo analysis of immune response
9329,NCT02933944,Immunological Activation in Tumour Mass by Assessing Number of Patients With Increased Intra-tumoural Lymphocytes.,2016-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,Changes in the Tumour Marker Carcinoembryonic Antigen (CEA) Throughout Treatment Will be Assessed by Analysis of Blood Samples to Follow the Evolution of Disease Under Treatment
9330,NCT04203459,Animal model experiment: to verify the ability of intestinal bacteria to control anti msln car-t targeted killing pancreatic cancer cells.,2019-10-20,UNKNOWN,OBSERVATIONAL,['NA'],,
9331,NCT03033719,Global postoperative morbidity in both arms,2017-07-04,UNKNOWN,INTERVENTIONAL,['NA'],To compare our molecular classification with the different classifications already published in the literature on colorectal cance,Timed Get-up-and-go (TGUG)
9332,NCT01596582,Concordance Between Patient Preference and Test Ordered,2012-04,COMPLETED,INTERVENTIONAL,['NA'],Concordance Between Patient Preferences for a Screening Tests Other Than Colonoscopy and Test Ordered for High Versus Low Risk Patients,Provider Satisfaction
9333,NCT00841282,Increments of medications used for sedation,2008-10,COMPLETED,INTERVENTIONAL,['NA'],,willingness to repeat colonoscopy
9334,NCT05857631,3-year cumulative incidence of grade ≥2 gastrointestinal or genitourinary toxicity,2023-05-29,RECRUITING,INTERVENTIONAL,['NA'],,C-MOSES scoring
9335,NCT03817489,"Change of Week 1 Practice Compliance at Week 2 to 7 of intervention, and 6-month post-intervention",2017-01-04,UNKNOWN,INTERVENTIONAL,['NA'],,
9336,NCT00835133,Collection of familial data and biospecimens in a data and tissue repository for familial pancreas research,2002-08,RECRUITING,OBSERVATIONAL,['NA'],,
9337,NCT05879783,Accuracy of pCLE optical biopsy,2022-09-15,RECRUITING,INTERVENTIONAL,['NA'],,The positive predictive value and negative predictive value of pCLE optical biopsy
9338,NCT04385316,DNA extraction of tumer tissue samples and high-throughput sequencing,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,"DNA extraction of tumer tissue samples, blood tissue and urine samples and high-throughput sequencing"
9339,NCT05053971,Objective response rate (ORR) (Phase II),2022-11-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Non-sequencing biomarker analysis,Progression free survival
9340,NCT05623787,Early peritoneal recurrence,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Early distant recurrence
9341,NCT02021604,Accuracy of PET imaging compared to intraoperative pancreatic biopsy in patients with congenital hyperinsulinism,2013-10-09,RECRUITING,INTERVENTIONAL,['PHASE1'],,Ratio of Standard Uptake Value max to sub max
9342,NCT00256932,to compare alvimopan with placebo for efficacy in the treatment of OBD,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Safety and tolerability, quality of life, pharmacokinetics, pharmacogenetics (dependent on results from other data)"
9343,NCT02300727,Number of Participants With Serious and Non-Serious Adverse Events,2015-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in Health Providers Assessment of Oral Mucositis and Healing Time Measured by the Common Terminology Criteria for Adverse Events (CTCAE) and World Health Organization's (WHO's) Oral Toxicity Scale (OTS)
9344,NCT00282100,To study the changes of selected genetic or protein markers through the treatment and find out whether some of them can be potential biomarkers for disease relapse.,2005-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To evaluate the effect of gefitinib as an adjuvant therapy on recurrence free survival in patients with resectable hepatocellular carcinoma; to evaluate the treatment toxities of genifitib.
9345,NCT00812942,Participation to colorectal cancer screening,2003-11,COMPLETED,INTERVENTIONAL,['NA'],,
9346,NCT00343668,response rate,2005-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,treatment-related toxicities
9347,NCT00064207,"Overall survival as measured by Logrank every 3 months in years 1-2, and every 6 months thereafter in phase III",2003-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of life as measured by Quality of Life Questionnaire Core 30 (QLQ-C30) v3.0 and EORTC QLQ PAN-26 every 3 months in years 1-2 and every 6 months thereafter
9348,NCT03425773,Incidence of Serious Adverse Events assessed with CTCAE v4.03,2018-02-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change of tumor burden
9349,NCT00105443,Time to Symptomatic Progression (TTSP),2005-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Patients Reported Outcome (PRO) by Use of the FACT-Hep Questionnaire
9350,NCT03278106,16-Week Progression-free Survival (PFS) Rate,2017-10-20,COMPLETED,INTERVENTIONAL,['PHASE2'],Mutation Status of the Tumor,"Overall Toxicity Rates (Percentages) for Grade 3 or Higher Adverse Events Considered at Least Possibly Related to Treatment, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (v4)"
9351,NCT00149396,Clinical Laboratory Safety - Coagulation,2004-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacodynamic Effects of NV1020: Serum Cytokines (TNF-alpha)
9352,NCT02662478,Success rate,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,Accuracy of classification system
9353,NCT05161572,Pathological complete regression (pCR) rate,2021-09-28,RECRUITING,INTERVENTIONAL,['PHASE2'],To study the influence of preoperative therapy on the tumor immune microenvironment (TIME) and systemic immune status.,Safety of surgery after preoperative therapy include chemo(radio)therapy and PD-1 antibody.
9354,NCT04812054,Model for early graft dysfunction score,2021-04-05,UNKNOWN,INTERVENTIONAL,['NA'],Allograft ATP content,Postoperative complications
9355,NCT03189953,Tumor visualization by 68Ga-NODAGA-exendin-4 PET/CT and standard imaging,2015-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,GLP-1 receptor expression by histology compared to tracer uptake
9356,NCT03516708,Phase II Treatment Cohort only: Neoadjuvant Rectal (NAR) Score,2019-10-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase I and Phase II Treatment Cohort only: Complete clinical response rate (cCR)
9357,NCT02292758,6-month and 12-month Progression-free Survival (PFS) Rates,2014-12-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Dynamic Change in Mutation Concentration While the Patient is Receiving Cetuximab Treatment,Relative Dose Intensity (RDI)
9358,NCT03738787,Rate of postoperative mortality,2015-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,Variation of Body Mass Index after pancreatoduodenectomy
9359,NCT05229900,Number of participants with DLTs by dose level,2022-04-21,TERMINATED,INTERVENTIONAL,['PHASE1'],,Combined RECIST/CA-125 overall response rate according to GCIG (subjects with ovarian cancer only)
9360,NCT00101036,Response Rate,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate.
9361,NCT06096896,5-years overall survival (OS) after MWA for early HCC,2023-08-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Rate of completed ablation after MWA
9362,NCT05934058,Impact of major gastric cancer risk factors on its aetiology in rarer patients subgroups,2023-07-25,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Development of a genome-wide modelling of Polygenic risk score (PRS) in gastric cancer
9363,NCT01643460,Cyst resolution,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,
9364,NCT06205732,Progression-Free-Survival,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
9365,NCT02135419,Anal Cancer Incidence,2014-09-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of Life Assessment Measured by the A-HRSI (Validated Tool),Change in Physical Symptom Score From Baseline (2-7 Days Post Randomization) Until 4 Weeks Post Randomization
9366,NCT02503631,To provide stool and blood specimens to assess new markers for the detection of CRC,2014-10,TERMINATED,OBSERVATIONAL,['NA'],,To provide quality control material for use in assessing performance of developed assays
9367,NCT05954078,ctDNA clearance rate,2023-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment Completion Rate
9368,NCT05355155,"Objective Response Rate (ORR) ,Based on RECIST 1.1",2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety as measured by number and grade of adverse events
9369,NCT06104579,Rate of Organ-space surgical site infection,2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
9370,NCT05657145,Visualization of papilla,2023-01-27,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
9371,NCT05910970,Recurrene-free survival,2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse events
9372,NCT01133951,Gastric cancer incidence,2010-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Histopathological changes
9373,NCT06131840,Number of participants with DLTs by dose level,2023-11-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
9374,NCT01389986,Time to first flatus,2011-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Patients' satisfaction
9375,NCT03854799,The primary objective of this trial is to evaluate the rate of complete pathologic response (pCR),2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Sphincter preservation rate
9376,NCT00614601,The primary objective of this Phase II trial is to assess disease-free survival (DFS) at one (1) year following initiation of treatment as the primary endpoint of the study in subjects treated with the HyperAcute®-Pancreatic Cancer Vaccine,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,We will use overall survival and adverse events rates as secondary endpoints.
9377,NCT03594630,Time to surgery or death,2024-03-13,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Pathologic Findings
9378,NCT04059731,Postoperative complications,2019-06-20,UNKNOWN,INTERVENTIONAL,['NA'],,Hospital Stay
9379,NCT05233540,Overall survival according to circulating tumour DNA status,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival according to circulating tumour DNA and immune markers.
9380,NCT00003617,,1995-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
9381,NCT03007407,Overall Objective Response Rate (ORR) of Dual Immune Checkpoint Blockade by RECIST 1.1,2017-07-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Frequency of Adverse Events Assessed by CTCAE 4.0, From Beginning of Treatment to 90 Days After Last Dose"
9382,NCT04823416,Risk Factors for Mortality in cases of obstructed left colonic Carcinoma,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
9383,NCT00756951,Efficacy of Oral Mucositis assessment will be completed by trained site personnel. The WHO score will be the primary measure and NCI CTCAE will be a secondary measure for assessing Oral Mucositis.,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9384,NCT04457193,Percentage of participants with normal esophageal acid exposure time,2018-06-07,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Change in Gastroesophageal Reflux Disease (GERD) symptoms assessed by the Reflux Symptom Index (RSI)
9385,NCT00021268,,2001-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
9386,NCT06134388,Investigating the possible efficacy of sulfasalazine through evaluation of its impact on disease control rate (DCR).,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Evaluating the safety and tolerability of sulfasalazine through investigating Renal function test (serum creatinine (mg/dL), blood urea nitrogen (mg/dL) and creatinine clearance (mL/min))."
9387,NCT02345889,Adenomas Per Colonoscopy,2015-02,COMPLETED,INTERVENTIONAL,['NA'],,"Percent of Sessile Serrated Polyps in the Right Side of the Colon, Which Includes the Cecum, Ascending Colon, and Hepatic Flexure."
9388,NCT01550510,Number of Participants That Experience Serious Adverse Events as Defined by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0.,2011-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants That Are Alive After 11 Weeks.
9389,NCT01149434,Tumor Response in the Ovarian Cancer Cohort,2010-09,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor Response
9390,NCT00182715,Overall survival at 2 years,2005-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Time of disease control at 2 years
9391,NCT03774589,Bilioenteric anastomotic leakage,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Bilioenteric anastomotic stricture
9392,NCT00779311,Determination of the Maximum Tolerated Dose (MTD) of Sorafenib When Given in Combination With mFOLFOX6 and Bevacizumab,2008-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Determination of Quality of Life (QoL) as Indicated by Patient Care Monitor (PCM) Data Among Patients on This Regimen
9393,NCT00685568,Toxicity,2002-11-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (plasma drug trough concentrations)
9394,NCT03188991,Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability),2017-09-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Cyst Volume Response
9395,NCT05061017,Objective Response Rate (ORR) - (Cohorts 2 & 3),2021-12-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,2-year Overall Survival (OS)
9396,NCT05254847,1 year DFS rate,2021-12-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,AE
9397,NCT01378507,Short-term result after ESD,2009-01,UNKNOWN,INTERVENTIONAL,['NA'],,The safety of ESD procedure
9398,NCT05514158,The incidence and severity of adverse events (AE),2022-09-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free survival
9399,NCT00508872,Complete Gross Resection Rate,2005-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
9400,NCT04896931,Establishment of BTC population,2022-07-12,RECRUITING,OBSERVATIONAL,['NA'],,establishment of sample collection (tumorblocks and blood)
9401,NCT03350490,Relief degree of tumors,2017-11-30,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall survival（OS）
9402,NCT05424159,2-year cumulative local regional progression rate (LRP),2022-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Late toxicity
9403,NCT01758679,Progression-free survival,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
9404,NCT05057845,Objective Response Rate (ORR),2021-09-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
9405,NCT02571946,one-year overall survival,2015-08,COMPLETED,INTERVENTIONAL,['NA'],,Hepatobiliary phase signal change after proton beam therapy
9406,NCT04147494,To define and document the biodistribution of gallium Ga 68 FAPi-46 (68Ga-FAPi-46) and gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) in normal and cancer tissues of patients with various non-prostate malignancies,2019-11-05,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Additional correlation of biodistribution of standard of care tracer,evaluate the 68Ga-FAPI-46 biodistribution correlation with 18F-FDG biodistribution
9407,NCT00646139,Maximum tolerated dose,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biological effects
9408,NCT03705754,Number of tumors visualised from peritoneal cavity/number of tattoos visualised form peritoneal cavity,2019-02-06,RECRUITING,INTERVENTIONAL,['NA'],,
9409,NCT02395250,Adverse events attributed to the administration of the anti-GPC3 CAR T cells,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9410,NCT05363722,Objective response rate (ORR),2022-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Immune Best Overall Response（iBOR）according to iRECIST criteria
9411,NCT05088304,postoperative complications,2015-09-01,COMPLETED,OBSERVATIONAL,['NA'],,hospitalization cost
9412,NCT06022978,Diagnostic accuracy for T1a and T1b staging,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
9413,NCT01943318,"Liver-related outcome: Decompensated liver cirrhosis (ascites, variceal bleeding, hepatic encepahlopathy), occurence of hepatocellular carcinoma",2013-01,COMPLETED,OBSERVATIONAL,['NA'],,Liver-related mortality
9414,NCT03853473,6 Minute Walk Test Distance (Pre Surgery),2019-02-22,COMPLETED,INTERVENTIONAL,['NA'],Length of Hospital Stay,Intraoperative Blood Pressure Variability
9415,NCT00552058,Percentage of Subjects in Clinical Remission at Week 6,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6
9416,NCT03123432,immunomodulating effects,2011-06-01,COMPLETED,INTERVENTIONAL,['NA'],,length of hospital stay after surgery
9417,NCT00900419,Genetic mutations or altered growth factor expression,2001-05-03,RECRUITING,OBSERVATIONAL,['NA'],,Establishment of a tissue repository of normal and dysplastic respiratory epithelium
9418,NCT04825470,Graft Survival,2022-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Disease free survival
9419,NCT03636607,Calculating the overall diagnostic sensitivity and specificity and ROC,2018-06-13,RECRUITING,INTERVENTIONAL,['NA'],,Calculating the overall diagnostic sensitivity and specificity and summarizing the intrinsic correlations
9420,NCT04312360,Change in bacterial composition (Exploratory primary outcome 2),2020-01-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Assessment of any adverse events or side effects regarding the spraying of the right hemicolon with fosfomycin/metronidazole gel in track 2.
9421,NCT04400136,Percentage of post-operative GERD based on the trial protocol. Clinical evaluation,2020-07-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,evaluate in each group of the study (arm type) the endoscopic finding of peptic lesions of the esophagus-gastro-duodenal mucosa at 24 months of follow-up
9422,NCT03065257,Number of participants with reduction in clinical symptoms,2017-03-15,UNKNOWN,OBSERVATIONAL,['NA'],Number of participants with successful completion of treatment,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
9423,NCT02961283,Part B: evaluates the preliminary efficacy of ASN003 in subjects with selected BRAF and PI3 kinase mutated cancers,2016-10,TERMINATED,INTERVENTIONAL,['PHASE1'],Change in tumor mutational status,Appearance of new tumor lesions
9424,NCT00001587,,1997-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9425,NCT02700555,Incidence of newly developed diabetes mellitus,2016-02,TERMINATED,OBSERVATIONAL,['NA'],,3-year recurrence-free survival & 5-year recurrence-free survival
9426,NCT04177316,disease free survival (DFS),2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
9427,NCT05040360,Recurrence-free survival (RFS),2022-05-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
9428,NCT03070262,overall survival (OS),2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,progression-free survival (PFS)
9429,NCT04516681,Objective Response Rate,2020-09-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall Survival
9430,NCT04894643,Perioperative Mortality and Complications,2020-09-14,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life questionnaire: Brief Pain Inventory
9431,NCT04280393,adenoma detection rate per patient,2020-02-10,COMPLETED,INTERVENTIONAL,['NA'],,Demonstrate the non-inferiority of patient experience when comparing Endocuff Colonoscopy and Standard Colonoscopy
9432,NCT04739501,Post_TACE hepatic cell failure,2020-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9433,NCT04445532,Collected samples,2020-10-11,RECRUITING,OBSERVATIONAL,['NA'],,Multi-omics analysis to further type and find therapeutic targets
9434,NCT00006812,,2001-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,
9435,NCT01540435,Failure-free survival (FFS@18),2012-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Pathologic response rate
9436,NCT01020006,Number of Participants With Treatment Emergent Adverse Events (AEs),2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9437,NCT04488549,Predictive power of respondents' and hospitals' demographics on delaying colorectal cancer care across 6 geographical regions,2020-05-20,COMPLETED,OBSERVATIONAL,['NA'],,
9438,NCT00585312,Time to Disease Progression,2006-09,TERMINATED,INTERVENTIONAL,['PHASE3'],,Colorectal Polyp Burden
9439,NCT00910819,Course of Antineoplastic Treatment,2006-09,COMPLETED,OBSERVATIONAL,['NA'],,
9440,NCT03322592,EUS-FNB diagnostic accuracy,2018-03-29,COMPLETED,INTERVENTIONAL,['NA'],,Macroscopic on-site evaluation [MOSE]
9441,NCT03367611,Colonic lesion.,2018-03-15,COMPLETED,INTERVENTIONAL,['NA'],,
9442,NCT00565682,To measure the amount of rescue medication (opioid) needed to relief,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,To determine the overall analgesic effect using the visual analog scale (VAS)
9443,NCT06253611,Objective response rate (ORR) at 4 months,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,1-year and 2-year PFS
9444,NCT05624099,Objective Response Rate(ORR),2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival(PFS)
9445,NCT00978107,Maximal tolerated dose,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor response of injected and non-injected lesions Viral dissemination Proof of concept: 5-FU concentration in plasma and in tumors
9446,NCT01525069,Dose-limiting toxicities (DLTs),2012-04-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Time to progression (TTP)
9447,NCT05943041,Incidence of Adverse Events from baseline to 8 weeks,2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE1'],Changes of LARS(Low Anterior Resection Syndrome) score from baseline to 8 weeks,
9448,NCT05346536,CTC-AXL measurement concordance rate,2022-06-16,RECRUITING,INTERVENTIONAL,['NA'],,Evaluation of circulating immune system: platelets
9449,NCT03906110,Fecal Immunochemical Test (FIT) Use- Time Point 3,2018-04-03,COMPLETED,OBSERVATIONAL,['NA'],,
9450,NCT05028725,Proportion of True-Negatives (specificity) detected with the EsoCAN assay after specimen collection using 'EsophaCap' sponge sampling (ESCC cases & controls only),2022-05-16,RECRUITING,INTERVENTIONAL,['NA'],,Median Acceptability Scores
9451,NCT05734820,Diagnostic performance of AI-assisted polyp detector,2020-01-11,RECRUITING,INTERVENTIONAL,['NA'],,Adenoma Miss Rate (AMR)
9452,NCT03028831,colonic mucosal proliferation,2017-12-11,COMPLETED,INTERVENTIONAL,['NA'],,colonic secondary bile acids
9453,NCT00262171,,2002-05,UNKNOWN,OBSERVATIONAL,['NA'],,
9454,NCT02723253,Number of patients defined as good responders (G1 or G2) according to the Mandard regression grading system.,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,The number of patients still alive at the end of follow-up
9455,NCT01669109,Health-related quality of life,2012-09,COMPLETED,INTERVENTIONAL,['NA'],Qualitative Interviews,Spiritual well-being
9456,NCT05889325,Progression-Free Survival (PFS),2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Duration of Response (DoR)
9457,NCT04369053,Specificity of the Freenome test,2020-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
9458,NCT03894384,Diagnostic value of trefoil factor family 3 (TFF3) in serum of gastric cancer as non invasive marker,2019-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9459,NCT04902144,Clinical and Patient Reported Outcomes Following Genetic Test Results,2020-08-03,COMPLETED,INTERVENTIONAL,['NA'],,
9460,NCT05677490,Overall survival (OS),2023-01-23,RECRUITING,INTERVENTIONAL,['PHASE3'],Feasibility and compliance of intervention,Patient reported outcomes
9461,NCT02887313,Pathological complete response rate,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease free survival
9462,NCT05846035,the prevalence of Paraneoplastic Syndrome in cirrhotic Patients with HCC.,2023-04-15,RECRUITING,OBSERVATIONAL,['NA'],,
9463,NCT00002515,,1992-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9464,NCT02353858,Pathological complete response rate,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,post operative morbidity
9465,NCT02772029,time to progression,2016-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival
9466,NCT01839539,Progression-free survival (PFS),2013-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Laboratory findings (The number of CD3+ (or CD8+ or CD4+ or CD56+)T cell)
9467,NCT00882973,The recommended phase II dose of the combination therapy with Genexol-PM and gemcitabine,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety profiles
9468,NCT00436072,"To determine the tolerability and maximum tolerated dose of combining ZD6474, cetuximab and irinotecan in patients with metastatic colorectal cancer refractory to prior cytotoxic chemotherapy.",2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Determine response rate, progression-free survival and overall survival of adding ZD6474 to cetuximab and irinotecan in this patient population."
9469,NCT01653496,Overall compliance to the ERAS program,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Mortality
9470,NCT02137356,Number of patients with adverse events,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Number of patients whose tumors demonstrate pathological complete response at resection
9471,NCT00611000,"DNA methylation (overall, p53 coding, p16 promoter, MLH1 promoter) in PBMCs and rectal biopsy cells",2003-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Differential gene expression in colonic and PBMCs by microarray analysis
9472,NCT02471313,Number of Participants for Which Uptake of [18F]-FMISO Was Successful and Hypoxic Tumors Were Observed During PET Scan Imaging Post TACE Procedure,2015-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9473,NCT03183219,Overall survival（OS）,2017-06-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9474,NCT04787341,Overall survival,2020-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
9475,NCT03259009,Progression-free survival (PFS),2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival (OS)
9476,NCT00748215,Number of Participants With Grade 3/4 Diarrhea,2009-02-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9477,NCT04619342,Progression Free Survival（PFS）,2020-10-30,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse Events
9478,NCT02569645,To determine the pathological complete response rate in patients with high-risk locally advanced rectal cancer treated with standard neo-adjuvant chemotherapy and radiation in combination with rosuvastatin.,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Dose normalized AUC will be collected as pharmacokinetic data
9479,NCT01292369,System performance,2011-02,UNKNOWN,OBSERVATIONAL,['NA'],,
9480,NCT06242470,Number of participants with adverse events (AEs) and serious AEs (SAEs),2024-03-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of participants who develop anti-MGC026 antibodies (immunogenicity)
9481,NCT02997241,patients treated with chemotherapy based on clinical prognosis compared to Oncocare detection prognosis,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival at 5 years
9482,NCT01744353,"Assessment of Toxicities to Define MTD of FOLFOX-Abraxane (A) for Newly Diagnosed, Advanced Pancreatic Cancer.",2012-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Response Rate (if Patient's Tumor(s)Are Progressing or Being Controlled) Following Treatment With FOLFOX-A for Patients With Newly Diagnosed, Advanced Pancreatic Cancer."
9483,NCT01846520,Effects of FCPCI on psychological distress,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,Caregiver out-of-pocket costs
9484,NCT05387681,pathological complete response (pCR),2022-05-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,pathological partial response(MPR)
9485,NCT06109805,Plasma metabolite content,2023-10-20,RECRUITING,OBSERVATIONAL,['NA'],,
9486,NCT04985981,Occurrence of Anastomotic leak,2021-04-01,SUSPENDED,OBSERVATIONAL,['NA'],Additive curative surgery (no/yes: liver; lung; locoragional relapse),Time to diagnosis of anastomotic leak
9487,NCT01740947,anastomotic leakage and/or abscess,2013-01,TERMINATED,INTERVENTIONAL,['PHASE4'],In hospital and out-of-hospital costs,Disease free survival
9488,NCT06002789,pCR rate,2022-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,3 years OS Rate
9489,NCT05630794,Mean change in human adenoma tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression in polyps induced by ONC201,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Adenoma-derived organoid take rates between samples obtained prior to and following treatment,Proportion and severity of treatment emergent adverse events
9490,NCT04357171,The rate of readmissions due to severe dehydratation,2012-01-14,COMPLETED,INTERVENTIONAL,['NA'],,The rate of early postoperative complications after stoma closure operation
9491,NCT00628368,Role of predictive factors in the EGFR signaling pathway in response to treatment,2005-11,UNKNOWN,INTERVENTIONAL,['NA'],,Establishment of a tissue bank
9492,NCT06202183,Gut Microbiome Genomes,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Change in Chemotherapy Toxicity
9493,NCT05095519,True Negative Rate per lesion.,2021-09-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,GLUT-1 expression
9494,NCT05942768,Overall Survival (OS),2019-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Treatment-Related Adverse Events (TRAE)
9495,NCT06121622,Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours,2024-01-16,RECRUITING,OBSERVATIONAL,['NA'],,
9496,NCT01523353,Anaerobic threshold prior to liver resection,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Recovery of fitness
9497,NCT04345770,overall survival,2020-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,complication rate
9498,NCT04620473,Objective Response Rate（ORR）,2023-11-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Postoperative complications
9499,NCT03401294,Rate of liver metastasectomy,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
9500,NCT00147147,Overall survival,1993-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,the site of recurrence
9501,NCT02056691,Assess the feasibility of carrying out a two week preoperative exercise program in patients with colorectal cancer and assess the effects of preoperative exercise on the proliferation of colorectal cancer cells,2014-10,COMPLETED,INTERVENTIONAL,['NA'],,Irisin levels
9502,NCT05339763,bowel function,2019-08-12,COMPLETED,INTERVENTIONAL,['NA'],,fecal incontinence
9503,NCT03359616,Disease-free survival (DFS),2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,mortality rate
9504,NCT04207463,Overall response rate (ORR),2020-06-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
9505,NCT00513331,"To standardize physician recommendations and provide cutting edge technology to patients with BE and GERD, and establish a Valley Hospital Center for Barrett's Esophagus and GERD",2007-07,COMPLETED,OBSERVATIONAL,['NA'],,"To assess clinical outcomes of patients enrolled in The Valley Hospital Center for Barrett's Esophagus and GERD, and modify algorithms as appropriate."
9506,NCT05022719,"The interference level of detrimental effects on the visualization of the colonic mucosa during CCE, due to use of MB-MMX per colonic segment.",2021-10-04,COMPLETED,INTERVENTIONAL,['NA'],,To evaluate the safety of CCE procedure while using MB-MMX.
9507,NCT01600209,Sensitivity and Specificity of the Exact CRC diagnostic screening test.,2011-10,COMPLETED,OBSERVATIONAL,['NA'],,
9508,NCT04163237,Disease-free Survival,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall Survival
9509,NCT06117241,Stool,2023-10-17,RECRUITING,INTERVENTIONAL,['NA'],,
9510,NCT01697462,Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs),2009-07,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants With Hand-Foot Syndrome (HFS)
9511,NCT04683939,Occurrence of dose-limiting toxicities (DLTs) within a patient during the DLT evaluation period,2022-01-18,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,BNT141 - Duration of response (DOR)
9512,NCT06144827,Feasibility of Quantitative Multiparametric MRI,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Change in Total Liver Volume and Volume of non-irradiated and irradiated lobes
9513,NCT03904043,Clinical complete response rate,2020-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Organ preservation rate
9514,NCT05720559,Overall Survival (OS),2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
9515,NCT02572687,Number of Participants with Dose Limiting Toxicities (DLTs),2016-02-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants with Treatment Emergent Anti MEDI4736 Antibodies
9516,NCT00394992,"3-year disease free survival, defined as the percentage of disease free patients 3 year after randomisation.",2006-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,"Overall survival, defined as the percentage of patients alive 5 year after randomisation."
9517,NCT05021172,Responses to Qualitative Acceptability survey,2021-08-24,COMPLETED,INTERVENTIONAL,['NA'],Proportion of patients screened for colorectal cancer,
9518,NCT05571644,Pathological complete response (pCR) rates,2023-07-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Local recurrence rate
9519,NCT03919461,Biomarkers in blood samples assessing pro- and anti-metastatic processes,2019-02-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Fatigue
9520,NCT04807972,Phase 2: Overall Survival,2021-05-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Percentage of Participants Experiencing Adverse Events
9521,NCT05837065,the Harrell concordance index (C-index),2022-09-15,RECRUITING,OBSERVATIONAL,['NA'],,the time-dependent area under the receiver operating characteristic curve(tdAUROC)
9522,NCT01807390,Change in pain perceptions,2012-07,UNKNOWN,OBSERVATIONAL,['NA'],,Change in general health related quality of life
9523,NCT02502656,"Concordance regarding the mutation of RAS (yes vs no, dichotomous variable) between the two methods",2015-07,UNKNOWN,OBSERVATIONAL,['NA'],,Comparisons of the costs between the two methods
9524,NCT05477836,Length of colon explored,2022-10-18,COMPLETED,INTERVENTIONAL,['NA'],,Perception of difficulty
9525,NCT04353882,MOR-1 expression by polymerase chain reaction (RT-qPCR) in tumor tissue and adjacent healthy tissue.,2020-06-01,UNKNOWN,OBSERVATIONAL,['NA'],Concomitant Diseases,MOR-1 expression by immunohistochemistry in tumor tissue and adjacent healthy tissue.
9526,NCT02451956,Object response rate (ORR),2015-01-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of subjects with Adverse Events as a Measure of safety and tolerability
9527,NCT00812240,Progression Free Survival (PFS),2009-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
9528,NCT01269567,Pelvic sepsis,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Rate of closure of stoma
9529,NCT01932385,progression free survival and overall survival,2013-08-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,response rate
9530,NCT00184782,Increase in metabolic activity of liver metastases after resection of the primary tumor compared to the activity of metastases in patients without primary tumor resection,2003-09,UNKNOWN,INTERVENTIONAL,['NA'],,
9531,NCT01975077,safety and tolerability,2012-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival (OS)
9532,NCT00587184,,2006-07,COMPLETED,OBSERVATIONAL,['NA'],,
9533,NCT01525056,"efficacy of PET, CT-perfusion and MRI to stage patients with rectal cancer",2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9534,NCT05163483,Objective Response Rate（ORR）,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival(OS)
9535,NCT05609695,Overall Survival,2023-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Progress Free Survival
9536,NCT04093648,Dose Limiting Toxicity (DLT) Rate,2020-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Response Rate according
9537,NCT06287671,Correlation between biomarker in plasma and tissue,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9538,NCT00154700,Response rate,2001-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
9539,NCT05027425,Cellular rejection rates,2021-12-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Recurrence-free survival and overall survival outcomes based on survival follow up reporting
9540,NCT00683241,To determine the feasibility and safety of administering DCVax-L intradermally combined with intravenous bevacizumab and oral metronomic cyclophosphamide in patients with recurrent ovarian or primary peritoneal cancer.,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To assess the immunogenicity of DCVax-L administered intradermally in patients with recurrent ovarian or recurrent primary peritoneal cancer, combined with intravenous bevacizumab and oral metronomic cyclophosphamide."
9541,NCT05923255,3-year disease free survival,2023-05-14,RECRUITING,INTERVENTIONAL,['NA'],,5-year overall survival rate (OS)
9542,NCT03453164,Disease control rate,2018-03-28,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Peak antigen-specific cytotoxic T lymphocyte population
9543,NCT04166604,Rate of patients free of trifluridine/tipiracil dose reduction or postponement of cycles of > 7 days at 6 months or at progression or death or stop of treatment for another cause than neutropenia if observed in 6 months.,2020-05-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Clinical or biological factors at baseline associated with the occurrence of grade 3-4 neutropenia
9544,NCT00837239,Progression Free Survival at 4 Months,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival
9545,NCT05444088,Objective Response Rate,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-Free-Survival assessed by investigator
9546,NCT00357942,Use of supplemental analgesics,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,Oral intake of food
9547,NCT00137761,To determine the response rate of Iressa and docetaxel in patients with advanced pancreatic cancer following failure of gemcitabine-based therapy,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To determine the safety, radiologic response rate, progression-free survival and overall survival of patients treated with Iressa and docetaxel"
9548,NCT03507140,"Comparison of the relative abundance of pathobionts and symbionts before and 6 months after liver transplantation, in the bile of recipients.",2019-04-16,UNKNOWN,OBSERVATIONAL,['NA'],,"Biobanking of blood, saliva, bile, feces and urine for further analyses such as metabolomic studies on blood, urine and feces metagenomic studies on saliva, and immunomonitoring on blood."
9549,NCT04508764,Number of primary barriers to genetic testing for family members,2021-04-09,RECRUITING,INTERVENTIONAL,['NA'],,
9550,NCT05412082,Incidence of Toxicity Among Participants After Start Receiving MRI-g Pelvic ART,2022-10-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Health-related Quality of Life (HRQOL) Scores: Pittsburgh Sleep Quality Index (PSQI)
9551,NCT00003446,,1997-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9552,NCT00895323,Tissue distribution,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
9553,NCT02824835,percentage of cells in G2/M arrest after dose-dependent exposure,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],,
9554,NCT02177084,LARS score,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,morbidity
9555,NCT03558724,Safety of bevacizumab-800CW administration by monitoring vital signs and/or (serious) adverse events.,2018-10-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,The variation in fluorescence intensity between fluorescence molecular endoscopy before and after neoadjuvant chemoradiotherapy defined as the tumor to background ratio and intrinsic fluorescence.
9556,NCT00145015,Apoptosis in colonic biopsy samples,2004-12,COMPLETED,INTERVENTIONAL,['NA'],,gene transcription
9557,NCT01666756,"Recommended phase II dose, determined according to incidence of dose-limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4",2014-06-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Change in levels of soluble biomarkers,Sorafenib tosylate concentration after co-administration with Chinese herbal formulation PHY906
9558,NCT03260647,Optimization of multidisciplinary care,2017-08-04,RECRUITING,OBSERVATIONAL,['NA'],,Evaluate cannabis use in patient population
9559,NCT06097416,Overall survival,2024-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Progression-free survival
9560,NCT00642603,Progression-free Survival (PFS) in U.S. Patients Only,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,
9561,NCT03957031,Exposure to a variety of potential sources of GC risk factors,2019-05-31,UNKNOWN,OBSERVATIONAL,['NA'],,
9562,NCT02094105,incidence and mortality of ESCC,1999-11,COMPLETED,INTERVENTIONAL,['NA'],,"Cumulative incidence and mortality of total cancer, and gastric cardia cancer"
9563,NCT03300544,Incidence of dose limiting toxicities of TVEC,2017-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
9564,NCT03421288,Comparison of Event free survival (EFS) between arms,2018-09-14,RECRUITING,INTERVENTIONAL,['PHASE2'],ctDNA clearance on treatment,Overall survival (OS) and EFS in the subgroup of patients with PD-L1 CPS score ≥ 5 and ≥ 10 and patients with MSI
9565,NCT02352259,Evaluation of Safety Related to Electrochemotherapy,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response to Treatment (Determined by Modified RECIST Criteria).
9566,NCT02855788,response rate,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
9567,NCT03803267,Postoperative pain score,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Serum C-reactive protein (CRP)
9568,NCT00475722,Adherence to Dietary Goals,2007-05,COMPLETED,INTERVENTIONAL,['NA'],,
9569,NCT03622229,"EUS-FNB procurement yield of tissue ""core"" using two different FNB needles.",2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Macroscopic on-site evaluation (MOSE)
9570,NCT06231680,RCCEP response rate at 3 weeks,2024-01-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Thalidomide treatment-related adverse events
9571,NCT01833546,Number of Participants Who Experienced Any Dose-Limiting Toxicity (DLT) During First Cycle - Day 1 to 28,2013-04-18,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 2 or Higher Than 2
9572,NCT03760003,Modified Mayo Score,2019-09-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of clinically-significant laboratory abnormalities
9573,NCT04387695,Progression-free survival (PFS) rate,2020-04-30,RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease control rate
9574,NCT02106858,Percentage of patients with adverse drug reactions (ADRs),2014-06-25,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival (OS)
9575,NCT03875781,Survival,2019-06-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life - physical functioning: QLQ-C30
9576,NCT05546892,Anastomotic leak rate,2023-02-10,RECRUITING,INTERVENTIONAL,['NA'],,Bowel preparation compliance
9577,NCT03536793,"Measurement of the accuracy of protein markers (e.g., TF, AM) in detecting early stage pancreatic cancer by comparison of laboratory results from ELISA assays and platform technologies to patient clinical data.",2018-10-24,RECRUITING,OBSERVATIONAL,['NA'],,
9578,NCT01247506,,2010-02,UNKNOWN,OBSERVATIONAL,['NA'],,
9579,NCT05611034,safety as measured by acute lung injury findings,2023-02-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of mechanical ventilation
9580,NCT01671592,Ability to track the labeled DC vaccine by MRI,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,May assess the disease-free survival and overall survival
9581,NCT04363801,Part C: Progression Free Survival (PFS) in G/GEJ DKK1 high and overall patients treated with DKN-01 in combination with tislelizumab and chemotherapy vs tislelizumab and chemotherapy as a first-line therapy,2020-07-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Dickkopf-1 (DKK1) concentration in serum and plasma relative to safety and efficacy outcomes in G/GEJ patients treated with DKN-01 in combination with tislelizumab as a second-line therapy,Part C:To characterize the frequency of toxicity ≥Grade 3 treatment-related adverse events (TRAE) associated with each of the treatment arms.
9582,NCT04727307,Recurrence-free survival,2021-01-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,
9583,NCT03755921,M. D. Anderson Dysphagia Inventory (MDADI),2018-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Deglutition evaluation
9584,NCT04500548,Incidence of adverse events,2021-01-28,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Overall survival
9585,NCT01875198,Bleeding amount,2013-04,TERMINATED,INTERVENTIONAL,['NA'],,postoperative complication
9586,NCT06098560,Correlation of ctDNA changes with pCR rate and the duration of cCR,2023-08-16,RECRUITING,OBSERVATIONAL,['NA'],,Correlation of ctDNA changes with 2 years PFS
9587,NCT01116791,Overall survival time (OS) following CRS+HIPC (from surgery to cancer-related death),2010-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,In-hospital perioperative complications
9588,NCT00238160,,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
9589,NCT05641233,"Hardness of pancreas texture, determined by Durometer measurement",2020-12-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,30-day mortality and in-hospital mortality
9590,NCT04082455,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2018-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,progression-free survivals
9591,NCT02915393,Detection of helicobacter pylori by Urea Breath Test(UBT),2016-09,UNKNOWN,OBSERVATIONAL,['NA'],,TCM syndrome type diagnosed by two professional TCM doctors
9592,NCT06172036,12-month EFS rate,2024-01-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events
9593,NCT05396937,"Objective response rate, ORR",2022-01-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
9594,NCT03209765,Compliance rate,2017-06-16,COMPLETED,INTERVENTIONAL,['NA'],,Compliance rate of second round
9595,NCT02384005,Kappa agreement will be calculated between lay person and nurse practitioner on the anal exam results.,2015-02,COMPLETED,INTERVENTIONAL,['NA'],,Number of persons who state they intend to seek subsequent care in the event of an abnormal result to a self-DAE.
9596,NCT05491889,mortality,2022-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9597,NCT04628780,Objective response rate (ORR) in the Expansion cohorts (Part 2),2020-12-16,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival (OS) in the Expansion Cohorts (Part 2)
9598,NCT01151007,Frequency of KRAS mutation,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,The incidence of the colorectal carcinoma
9599,NCT03499795,Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL and no Evidence of HPV-16/18 at Week 36,2018-05-15,COMPLETED,INTERVENTIONAL,['PHASE2'],"Percent Change From Baseline in the Size of Peri-Anal Lesions as Determined by the Investigator at Weeks 36, 64, and 88",Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL or no Evidence of HPV-16/18 at Week 36
9600,NCT04441580,Rate of patients detected with 3 or more adenomas.,2020-05-04,RECRUITING,INTERVENTIONAL,['NA'],,Specific contribution of AI
9601,NCT03630393,Postoperative Pain Medication Use,2019-05-09,TERMINATED,INTERVENTIONAL,['NA'],,Discharge Day (Post-operative Day 0 or 1)
9602,NCT02547610,The imaging biomarkers determined by MR-PET,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],,
9603,NCT00603460,"Disease status will be assessed with CT (or MRI) of chest/abdomen/pelvis at enrollment, after vaccine 2 and at the conclusion of the study . Rates of disease progression will be recorded at the time of study conclusion.",2012-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9604,NCT04221555,Pathologic complete regression (pCR) rate,2020-05-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease free survival (DFS)
9605,NCT00443573,"Safety measured by major hemorrhage (NCI CTCAE v3.0 grade 3 or greater), during and up to 30 days after completion of study drug administration or, if treatment is ongoing, by 8 months after study enrollment (Stage I) or randomization (Stage II)",2006-12,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Tumor response rate, as assessed by RECIST criteria"
9606,NCT03561142,Clinical complete response rate,2018-06-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
9607,NCT05086250,Feasibility of enrolling subjects which will be measured by the proportion of patients dropping out of study for any reason prior to the end of treatment visit.,2022-10-20,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,"To investigate the tolerability of oral ketamine in patients with pancreatic cancer and anxiety, which will be measured by patient-reported Ketamine Adverse Symptom Checklist and Impact scores."
9608,NCT03658044,Self empowerment measured by Cancer Behavior Inventory (CBI) scale,2018-12-01,COMPLETED,INTERVENTIONAL,['NA'],,Generated Knowledge in Online Discussions
9609,NCT05319054,Adherence of participants to the treatment programme,2022-05-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,LARS treatment history
9610,NCT06166147,Performance of cfDNA methylation-based model for discriminating pancreatic cancer versus non-cancer,2023-12-22,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Performance of pre-defined model in clinical sub-groups of interest
9611,NCT05707338,early postoperative complications,2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
9612,NCT02573974,Measurement of muscle mitochondrial bioenergetics,2016-01-19,COMPLETED,INTERVENTIONAL,['NA'],,Determining the isotopic composition of nitrogen hair
9613,NCT02677389,Feasibility as defined by recruitment rate,2016-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Physical activity as measured by the ActiGraph GT3X+ accelerometer (Arm II)
9614,NCT05510388,The incidence of hypoxia,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Complications related to high-flow nasal cannula
9615,NCT05118451,Main evaluation indicators,2020-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Secondary evaluation index
9616,NCT02870049,Screening completion rate,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],,
9617,NCT04904042,Pathological evaluation,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Global mortality.
9618,NCT02661971,Phase III: Overall Survival (OS): time from randomization to death of any cause,2016-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Phase II/III: Subgroup analyses: PFS (medians and rates) according to subgroup (intestinal vs. diffuse/mixed or unknown and GEJ vs. gastric)
9619,NCT02606916,Clinical response rate,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,grade 3 or 4 toxicities according to CTCAE4.0
9620,NCT06199466,Overall Response Rate (ORR) of YL-13027 in combination with gemcitabine and nab-paclitaxel,2024-01-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,
9621,NCT01622543,Progression Free Survival,2012-10-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
9622,NCT04420130,6-month PFS rate,2020-08-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Incidence of Treatment-Emergent Adverse Events
9623,NCT01846650,Area Under Curve (AUC),2012-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9624,NCT00165061,Overall survival,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,4.Recurrence of the disease
9625,NCT06204835,HCC lesions,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,
9626,NCT03875235,Overall Survival (OS) Rate at 24 Months,2019-04-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease Control Rate (DCR) - 48 Weeks
9627,NCT01248962,Number of Participants With and Without Hypersensitivity Reaction,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Odds Ratio for the Relationship of Baseline Variables to the Carboplatin Hypersensitivity Rate
9628,NCT02651974,Percentage of individuals who complete FIT screening measured by return FIT kit,2015-09,COMPLETED,INTERVENTIONAL,['NA'],,"Pre-post analysis of current results reporting strategy (which will utilize a white envelope for normal results, and a red envelope for abnormal results) to prior generic envelope for FIT result reporting for both normal and abnormal results."
9629,NCT03586869,Overall Response Rate by RECIST Version 1.1,2018-07-28,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of Life by patient-reported outcomes (PROs),ORR by RECIST Version 1.1
9630,NCT05319145,Short Physical Performance Battery (SPPB),2022-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Days spent at home (number of days)
9631,NCT03072641,Changes in microbiota composition after probiotics use,2010-06-03,COMPLETED,INTERVENTIONAL,['NA'],,Epigenetic changes after probiotics use
9632,NCT00307736,"Maximum Tolerated Dose (MTD) of Erlotinib When Administered in Combination With 5-fluorouracil (5-FU), Bevacizumab, and External Beam Radiation Therapy",2006-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pathologic Complete Response,"Post-operative Complications After Resection of Rectal Cancers Following Preoperative 5-FU, Bevacizumab, Erlotinib, and External Beam Radiation Therapy."
9633,NCT04975516,Progression free survival,2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
9634,NCT05831488,"Assess the relationship between Seismofit®-estimated VO2 peak and CPET-measured VO2 peak in HPB, gastro-oesophageal or colorectal cancer patients undergoing preoperative assessment for major surgery.",2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],,Assess patient experience of the Seismofit® test using a brief measure that has been used previously in CPET research
9635,NCT05705791,Objective response rate,2023-02-07,RECRUITING,INTERVENTIONAL,['NA'],,Evaluate alternative response evaluation criteria
9636,NCT00790140,Preservation of body compostition after surgery,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Reduced immuno-inflammatory response to surgery
9637,NCT01374074,To examine the association between BE and environmental factors,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,To investigate the association between BE and genetic and epigenetic status of Cdx1/Cdx2
9638,NCT04096118,Survival rates,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
9639,NCT00171912,To assess the efficacy and the safety of imatinib mesylate therapy,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the effects of imatinib on quality of life and healthcare resource use
9640,NCT02197351,Detection of Intestinal Metaplasia or Dysplasia,2014-07,RECRUITING,INTERVENTIONAL,['NA'],,Helicobacter pyrlori detection
9641,NCT04906343,Advanced neoplasia and colorectal cancer incidence at 3 years,2021-06-05,UNKNOWN,INTERVENTIONAL,['NA'],,
9642,NCT03473327,Oxidative and immunological gene-expression before and after laparoscopic surgery for colon cancer using whole blood gene expression profiling from blood samples,2016-01,COMPLETED,OBSERVATIONAL,['NA'],,Assessement of inflammatory tumor invasion using immunohistochemestry on tumor tissue samples
9643,NCT02697058,Progression Free Survival (PFS) in Part 2 of Study,2016-03-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Volume of Distribution at Steady-State (Vss)-Total Irinotecan, SN-38, and SN-38-Glucuronide (SN-38G)"
9644,NCT01972672,time to progress（TTP）,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Gene expression profiling of blood cells and tumor biopsies,Laboratory abnormal findings
9645,NCT02164240,Number of Participants With Serious and Non-Serious Adverse Events,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Median Progression Free Survival (mPFS)
9646,NCT00547612,Proportion of tumors detected by [18F]-labeled substance P antagonist receptor quantifier positron emission tomography,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9647,NCT03114085,time to progression,2017-05-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
9648,NCT03031171,Colonoscopy completion,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,
9649,NCT05427669,3-year Disease-free Survival (DFS),2022-10-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,3-year distant metastatic-free survival （DMFS）
9650,NCT05352542,CAR transgene levels in peripheral blood,2022-05-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of anti-LCAR-H93T antibody
9651,NCT01273090,Toxicities of imetelstat sodium,2011-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9652,NCT02402842,Progression-free survival rate,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,HPV-specific T cell responses measured by ELISPOT assay before and after DCF treatment
9653,NCT06022692,disease control rate (DCR),2020-06-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival (OS)
9654,NCT00265850,Overall Survival,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of Tumor Response
9655,NCT04011969,Fecal immunochemical test (FIT),2019-07,UNKNOWN,OBSERVATIONAL,['NA'],,
9656,NCT03151642,Number of MRIs,2017-04-05,COMPLETED,OBSERVATIONAL,['NA'],,
9657,NCT01253161,Progression-free Survival (PFS) at One Year,2011-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse Events Possibly Related to Study Treatment
9658,NCT01052376,"Evaluate and validate CEM in terms of its ability to diagnose neoplastic lesions and to distinguish between normal and neoplastic mucosa in vivo, based on comparison between ""optical biopsies"" and standard histology.",2008-12,TERMINATED,INTERVENTIONAL,['NA'],,
9659,NCT03708952,Numbers of participants with polyps,2018-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Numbers of participants died,Numbers of participants with cardiometabolic diseases
9660,NCT05351398,Objective Response Rate,2022-04,UNKNOWN,OBSERVATIONAL,['NA'],,R0 resection rate
9661,NCT00769483,Progression Free Survival,2008-11-13,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Correlation Between Plasma IGF-I Expression in Patients Treated With MK-0646 and OS,Treatment Toxicity
9662,NCT02868151,World Health Organization criteria of grading oral mucositis.for head and neck cancer patients,2016-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
9663,NCT05205629,Progression Free Survival,2022-01-30,UNKNOWN,OBSERVATIONAL,['NA'],,Conversion rate
9664,NCT06043466,To obtain the maximum tolerable dose of C-13-60 cells [Safety and Tolerability],2023-08-11,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival(OS) of C-13-60 cell treatment in patients with CEA-positive advanced malignancies[Effectiveness],The content of CEA in peripheral blood after infusion of C-13-60 cell [Cell dynamics]
9665,NCT05802407,Disease-free survival,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],The prognostic role of targeted therapy selected based on MRD,Overall survival
9666,NCT01091428,Phase 2: Progression-Free Survival (PFS),2010-04-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Banked Tumor Specimens for Candidate Markers of Response to Alisertib and Taxanes,Phase 2: Number of Participants With Clinically Significant Vital Sign Findings
9667,NCT01665625,overall surviva,2012-08,UNKNOWN,INTERVENTIONAL,['NA'],,surgical complications
9668,NCT04582500,Patient Satisfaction,2021-02-15,RECRUITING,OBSERVATIONAL,['NA'],,Assessing Workflow of incomplete colonoscopies
9669,NCT00837876,Number of Patients With Progression-free Survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Worst Grade Toxicities
9670,NCT03289273,"Number of patients with treatment emergent adverse events (TEAEs) leading to dose modifications (including reductions, interruptions and permanent discontinuation)",2017-09-13,COMPLETED,OBSERVATIONAL,['NA'],,Duration of regorafenib treatment
9671,NCT01484925,,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,
9672,NCT04852653,Positivity of the liquid biopsy,2021-09-21,RECRUITING,OBSERVATIONAL,['NA'],,Genetic profile of the primary tumor predictive of the response to nCRT
9673,NCT02246322,Clinical performance of 22G and 25G needles,2013-08,UNKNOWN,INTERVENTIONAL,['NA'],,Major complications
9674,NCT04823754,Evaluate the concordance between the patient's perception of his prognosis and treatment side effects with the one of his treating physician.,2021-07-12,COMPLETED,OBSERVATIONAL,['NA'],,Evaluate the association between individual prognosis expectation (patient and physician) and data from the available literature.
9675,NCT06124131,Difference in proportion of participants completing colorectal cancer screening between study arms,2023-11-11,RECRUITING,INTERVENTIONAL,['NA'],Number of patients who receive intended treatment,"Difference in proportion of participants completing all three services between study arms: colorectal cancer screening, COVID-19 shot, flu shot"
9676,NCT03948763,Number of Participants Who Discontinued Study Treatment Due to an AE,2019-06-26,COMPLETED,INTERVENTIONAL,['PHASE1'],T-cell receptor (TCR),Mutant KRAS Specific T cells
9677,NCT03794193,3-year Disease-free Survival,2016-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Distant organ metastasis rate
9678,NCT05823584,Sensitivity (vh-DNA vs AFP) (the vh-DNA which could be detected in the pre-operative plasma of participants.),2019-12-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Sensitivity (TERT C228T vs AFP/AFP-L3/PIVKA-II)
9679,NCT02746224,Anorectal functional outcome at 12 months assessed by LARS scale,2016-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Distance to surgical margins
9680,NCT00482222,Progression-free survival,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Safety
9681,NCT03398291,Real overall survival,2018-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Postoperative mortality
9682,NCT01323400,Progression-free survival,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Overall survival in patients not randomly assigned to pazopanib, but receiving pazopanib on a compassionate basis after progression"
9683,NCT00383266,Overall Response Rate (ORR),2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
9684,NCT02706782,Number of patients with adverse event,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Detection of transferred T cells in the circulation using quantitative -PCR
9685,NCT03642093,Frailty Measurement,2018-08-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Quality of Life (QoL) Assessment
9686,NCT00628147,Neoplasm Miss Rate,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Procedure Complications
9687,NCT05861947,Pharmacokinetics: Terminal elimination half life,2023-08-26,RECRUITING,INTERVENTIONAL,['PHASE1'],Exploratory endpoint (PD biomarker): IFN-γ level,Laboratory abnormalities
9688,NCT05002608,change from baseline health insurance literacy to 5-month follow-up,2021-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
9689,NCT05127096,Specificity of the FirstSight test,2020-12-15,UNKNOWN,OBSERVATIONAL,['NA'],,
9690,NCT05419362,"To assess the anti-tumor activity of GEN-001, when administered as combined with avelumab",2022-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Microbiota,Overall Survival (OS)
9691,NCT00496509,Assess by dynamic contrast-enhanced magnetic resonance imaging the effect of once daily dosing with ZD6474 on tumour perfusion and vascular permeability in patients with advanced colorectal cancer and liver metastases.,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Assessment of the effectiveness of ZD6474 as measured by objective response rate and progression free survival based on RECIST.
9692,NCT03647527,the highest grade of oral mucositis,2016-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9693,NCT01360411,Malignant or benign lesion,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,Value of a Visual Analog Scale for strain image categorisation
9694,NCT00264979,Rate of patients with at least one postoperative severe complication within 60 days after each surgery,2006-03-02,TERMINATED,INTERVENTIONAL,['NA'],,Two years recurrence rate
9695,NCT06314958,Recurrence-Free Survival,2023-03-15,RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival
9696,NCT01451658,Rebleeding,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],,complication survival
9697,NCT03868215,Sensitivity,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9698,NCT03819088,Quality of life scores,2019-04-17,COMPLETED,INTERVENTIONAL,['NA'],,Serum albumin level
9699,NCT01712971,intra-operative blood loss,2012-11,WITHDRAWN,OBSERVATIONAL,['NA'],,hospital costs
9700,NCT01921699,proliferation and migration of PANC1 cell line in the tested groups.,2013-08,UNKNOWN,INTERVENTIONAL,['NA'],,To determine whether direct cell-to-cell interaction or soluble factors participate in MIC.
9701,NCT03668431,"Number of participants with grade 3, 4 and 5 adverse events",2018-10-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Mechanisms of response and resistance to dabrafenib, trametinib, and PDR001"
9702,NCT02204150,Feasibility of OFDI Imaging in Subjects Swallowing the OFDI Capsule,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,
9703,NCT02559687,Objective Response Rate (ORR) According to Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR),2015-12-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
9704,NCT00278889,Progression Free Survival,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,QOL: Time to Worsening of FACT Colorectal Cancer Symptom Index(FCSI)
9705,NCT00922181,Variability of ablation diameters,2008-08,COMPLETED,INTERVENTIONAL,['NA'],,
9706,NCT00677612,safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),2008-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate immunological responses
9707,NCT01519999,Change in colorectal cancer screening adherence,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,Providers'/staff shared decision-making experience
9708,NCT03601156,Pathological Complete Response (pCR),2014-06,UNKNOWN,INTERVENTIONAL,['NA'],,Number of Postoperative Complication
9709,NCT02726997,"Pharmacodynamic Changes Induced by Treatment with Durvalumab in Combination with Paclitaxel and Carboplatin in Women with Advanced Stage, Metastatic Ovarian Cancer Using a 2-Sample T-Test",2016-07-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Feasibility of Treatment with Durvalumab in Combination with Paclitaxel and Carboplatin in Women with Advanced Stage, Metastatic Ovarian Cancer Determined by Methods of Thall et all"
9710,NCT03556384,Overall Response Rate,2018-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events related to TMZ
9711,NCT03706248,"Sensitivity, specificity, positive predictive value and negative predictive value",2018-07-28,COMPLETED,OBSERVATIONAL,['NA'],,
9712,NCT03228043,Number of Participants overall survival,2020-03-01,WITHDRAWN,INTERVENTIONAL,['NA'],Number of Participants overall survival,Number of Participants overall survival
9713,NCT02204332,"The efficacy of cabazitaxel measured by estimating the overall response rate (ORR), as the percentage of individuals who achieve a complete tumor response (CR) or partial tumor response (PR) in each arm and between arms.",2013-03,TERMINATED,INTERVENTIONAL,['PHASE2'],"Safety and toxicity in the experimental arm. Toxicity is graded according to the Common Terminology Criteria for Adverse Events (NCI-CTCAE, v 4.0).",Progression-free survival (PFS)
9714,NCT02251977,rates of grade 2 or more chronic cumulative neurotoxicity of both arms,2014-09,COMPLETED,INTERVENTIONAL,['PHASE3'],genetic polymorphisms of oxaliplatin induced severe and cumulative neurotoxicity,rates of 3 year disease free survival of both arms
9715,NCT00579163,To establish a bank of DNA and frozen lymphoblastoid cell lines for the purpose of facilitating genetic epidemiology investigations of familial cancers.,1994-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,A related goal is to provide patients with cancer and their living relatives the opportunity to preserve DNA samples so that they may be used for future genetic counseling regarding inherited cancer risk.
9716,NCT02869152,2nd Phase: Detection rate of refined protocol in identifying SLN,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],,Ergonomic optimization of the protocol as measured by surgeon satisfaction
9717,NCT00867126,"Changes in symptoms and quality of life as measured by the validated FACT-Hep scale version 4 questionnaire at baseline, every 4 weeks during therapy, and then at the completion of therapy",2009-03-02,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Time to disease progression
9718,NCT05279287,Number of errors in an operation using validated methodology- Objective Clinical Human Reliability Analysis (OCHRA),2023-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Application of Machine learning and Artificial Intelligence to video analysis
9719,NCT04223401,Postoperative morbidity rate by Clavien-Dindo,2020-02-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Psychological status by Hospital Anxiety and Depression Scale (HADS).
9720,NCT03973112,ORR,2019-09-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DOR
9721,NCT05843188,Overall response rate,2023-08-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidences and severity of adverse events
9722,NCT02196935,Successful ERCP or EUS,2010-09,RECRUITING,OBSERVATIONAL,['NA'],,Definitive Diagnosis
9723,NCT03675737,Overall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10,2018-11-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE)
9724,NCT00354679,Evaluation of Safety and Toxicity,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9725,NCT06229041,The PCR rate between total neoadjuvant treatment ±immunotherapy,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE3'],,
9726,NCT03636893,Total Percentage of Patients With Pathological Complete Tumor Regression (TRG1a) and Sub-total Tumor Regression (TRG1b) in the Primary Tumour,2018-08-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) Disease Free Survival (DFS)
9727,NCT00177853,"Determine efficacy of combination of irinotecan, celecoxib and concurrent radiotherapy on pancreatic cancer; determine highest/safest doses of these drugs",2006-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Tumor diminishment for safe excision
9728,NCT00483080,Progression Free Survival (PFS),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety according to NCI-CTCAE criteria (version 3)
9729,NCT00417287,Determine if there is a difference in effect on circulating Trx-1 protein levels between two dose levels of PX-12,2006-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Assess the effects of metabolic excretion of PX-12
9730,NCT03316677,the predictive value of intraoperative anastomosis testing on anastomotic leak.,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,The sensitivity of the 2 methods of intraoperative anastomosis testing.
9731,NCT06022861,Objective Response Rate(ORR) as assessed by IRC,2023-10-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (Nab)
9732,NCT01596634,Change in the Taste Visual Analog Scale (VAS) and taste and smell questionnaire responses,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life as quantified by the Functional Assessment of Anorexia/Cachexia Treatment (FAACT) questionnaire
9733,NCT05001009,Percent of patients with a goals of care conversation note documented in Stage 2,2022-09-13,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Percent of patients with a goals of care conversation note documented in Stage 1
9734,NCT01752933,Disease Control Rate (DCR) at 16 Weeks for Patients Treated With Guadecitabine After Failure of Sorafenib,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
9735,NCT06124001,Phase IIa:ORR,2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase Ib and Phase IIa: herpes simplex virus type I antibodies
9736,NCT04989387,"Evaluation of Recommended Dose for Expansion (RDE) of INCA00186 as monotherapy and in combination with retifanlimab and/or INCB106385 as measured by safety, PK and PD data",2021-10-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,"Duration of Response (DOR) from earliest date of disease response until earliest date of disease progression as determined by radiographic disease assessment, or death if occurring sooner than progression"
9737,NCT03718221,Patient-level Colorectal Cancer (CRC) Screening,2018-08-30,COMPLETED,INTERVENTIONAL,['NA'],,Neighborhood-level Screening
9738,NCT04927897,Maximum distance of microscopic tumor spread per patient in all directions from the macroscopic tumor remnant in the pathology specimen,2022-08-16,RECRUITING,OBSERVATIONAL,['NA'],Analysis of (re)biopsy material,Evaluation of risk factors for the presence and/or the extent of microscopic tumor spread identified by the meta-analysis we performed
9739,NCT02762448,HCV clearance and complete regression of NHL by ASV+ DCV,2016-07,WITHDRAWN,OBSERVATIONAL,['NA'],,
9740,NCT02611700,Median time of overall survival(OS),2015-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events
9741,NCT04694794,Utility of Educational Brochure assessment,2021-03-24,COMPLETED,INTERVENTIONAL,['NA'],Feasibility Assessment,Baseline Educational Assessment
9742,NCT02611661,Safety and tolerability of administering hepatic locoregional therapy following radioembolization as measured by occurrences of grade 3 or higher toxicities of interest,2016-01-19,TERMINATED,INTERVENTIONAL,['PHASE1'],,Response rates associated with radioembolization followed by dosimetry-guided subsequent hepatic locoregional therapy
9743,NCT05722223,To explore the feasibility of a trimodal prehabilitation program in the hospital setting,2022-03-15,RECRUITING,INTERVENTIONAL,['NA'],Circulating tumor DNA and mutational variations,Anxiety and depression
9744,NCT03426514,Early morbidity rate,2018-03-25,RECRUITING,INTERVENTIONAL,['NA'],,5-year overall survival rate
9745,NCT05850559,Assessment of the Diagnostic Role of Serum Insulin-like Growth Factor Binding Protein-3 as a Potential Biomarker for Colorectal Cancer (CRC) in Egypt,2023-10-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9746,NCT05616533,The coincidence rate of tumor response obtained from 50 PDX models with clinical real tumor response acquired from corresponding patients received neoadjuvant therapy.,2023-09-12,RECRUITING,OBSERVATIONAL,['NA'],,
9747,NCT00798746,Reflux Symptoms: Open Esophagectomy versus Minimally Invasive,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,
9748,NCT02069041,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])
9749,NCT05668793,validity,2023-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,reliability
9750,NCT06255379,Progression Free Survival (PFS),2024-03-22,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events (AE)
9751,NCT05952947,Adverse events and serious adverse events,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE1'],T cell subgroup in peripheral blood,Concentration of Cytokines (IL-2、IL-6、IL-10、TNFα、IFNγ)
9752,NCT04736043,Overall survival rate,2021-01-31,RECRUITING,OBSERVATIONAL,['NA'],,
9753,NCT03814005,"Part A, Cmax: Maximum Observed Plasma Concentration for Pevonedistat Following a Single Dose",2019-07-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Part B, Percentage of Solid Tumors Participants with CR or PR"
9754,NCT05124704,Predicted effect-site concentration of propofol (Ceprop) at certain time points,2021-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative exhaust time
9755,NCT01542177,Measure the hypoxia level in Patients with Pancreatic Cancer using Positron Emission Tomography (PET) with 18F-Fluoroazomycin Arabinoside (18F-FAZA).,2012-02,COMPLETED,OBSERVATIONAL,['NA'],,Determine the feasibility of using dynamic and static PET imaging of FAZA uptake in patients with pancreatic cancer.
9756,NCT04616950,Hospital course of patients with cancer of the digestive system,2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Modeling of the hospital journey based on observations made during the period preceding the COVID-19 epidemic
9757,NCT05640609,the objective Response Rate (ORR) of the experimental group.,2023-03-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,disease control rate (DCR)
9758,NCT05220020,Two-Years Overall Survival Rate,2022-05-18,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Evaluate the patients cancer-related QoL using the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ), the EORTC QLQ-C30."
9759,NCT04138654,Change in whole genome gene expression analyses in colonic biopsies and blood between baseline levels and each intervention period (transcriptomics),2014-04-17,COMPLETED,INTERVENTIONAL,['PHASE1'],Change in O6-MeG in colonic biopsies between baseline levels at the start of the intervention and each intervention period,Change in the microbiome in feacal samples and in saliva between baseline levels at the start of the intervention and each intervention period
9760,NCT03944252,Primary endpoint is Objective Response Rate (ORR).,2018-09-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
9761,NCT04633512,"Support personnel satisfaction with ActivSightTM, as quantified by Likert scale.",2020-11-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Ability of ActivSightTM to display biliary tree.
9762,NCT01581840,Response to treatment,2012-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
9763,NCT05615818,Progression-free survival (PFS),2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Incidence of Adverse Events,Percentage change in tumour size
9764,NCT02530437,Pathologic Complete Response Rate (Phase II),2017-03-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
9765,NCT01271712,Progression-free Survival,2011-01-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of Response (DOR)
9766,NCT06097078,Rate of patients with anastomotic leakage,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Rate of intraluminal hemorrhage
9767,NCT05651672,Overall response rate (ORR),2022-12-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
9768,NCT04635488,metastasis rate of lateral lymph node,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9769,NCT04544852,The proportion of participants that completed the FIT test within three months post enrollment.,2017-12-04,RECRUITING,INTERVENTIONAL,['NA'],,
9770,NCT04843189,Number of lymph nodes harvested,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,5-year overall survival
9771,NCT03120195,Feasibility of EndoRotor® for the ablation of Barrett's mucosa,2017-01-27,COMPLETED,INTERVENTIONAL,['NA'],,Ease of performing the EndoRotor® procedure
9772,NCT06242067,progression-free survival(PFS),2023-04-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of Response (DOR)
9773,NCT01735799,,2012-11,UNKNOWN,OBSERVATIONAL,['NA'],,
9774,NCT02781935,Negative Predictive Value (NPV) of the diagnostic imaging (DW-MRI),2016-11,COMPLETED,OBSERVATIONAL,['NA'],,Long term outcomes of patients who underwent surgery in terms of: - recurrence rates for 2 years after surgery - progression free survival for 2 years after surgery - overall survival for 2 years after surgery
9775,NCT06330441,Number of participants with newly diagnosed pancreatic ductal adenocarcinoma,2022-01-07,RECRUITING,INTERVENTIONAL,['NA'],,KRAS mutation status evaluation
9776,NCT03412877,Response rate,2018-09-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerance
9777,NCT03113318,5-year overall survival,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],,30-day mortality
9778,NCT00437502,Date of first objective finding will be used to define the date of relapse,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9779,NCT00545545,To determine safety and maximum tolerated dosage of Imprime PGGwhen used in combination with cetuximab with and without irinotecan therapy in patients with recurrent/progressive colorectal carcinoma previously treated with a 5-FU regimen.,2007-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To determine the tumor response rates (complete response, partial response, stable disease, overall response rate), time to progression, duration of overall tumor response, and the duration of stable disease in patients receiving the combination therapy."
9780,NCT03516071,Time to Progress (TTP),2017-05-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
9781,NCT00449995,diagnostic accuracy of confocal laser scanning microscopy for detection of metaplasia or neoplasia in Barrett´s esophagus,2007-03,COMPLETED,INTERVENTIONAL,['NA'],,inter- and intra observer variability for confocal laser scanning microscopy
9782,NCT04344847,Excision of GIST during LSG,2016-12-12,UNKNOWN,INTERVENTIONAL,['NA'],,
9783,NCT00398086,Number of Participants With Dose-limiting Toxicities,2006-11-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Maximal Degree of Anemia
9784,NCT00407186,overall survival,2007-01-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,health-related quality of life
9785,NCT04312633,Primary Outcome Measure:,2020-04-01,RECRUITING,OBSERVATIONAL,['NA'],,Secondary Outcome Measure:
9786,NCT02972541,Rate of stoma formation,2016-09-30,UNKNOWN,INTERVENTIONAL,['NA'],,Chemotherapy related complication
9787,NCT03259867,Overall Response Rate,2017-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
9788,NCT06230471,Objective response rate,2024-01-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival rate
9789,NCT03829852,"Effectiveness of regorafenib use in routine clinical practice setting, assessed by tumor response",2019-02-11,COMPLETED,OBSERVATIONAL,['NA'],"Exploratory outcome: Image pattern as the potential predictive factor for regorafenib treatment outcome in overall cohort and long-term responders, assessed by changes in image patterns","Eligibility of subsequent therapies and the outcome, assessed by PFS"
9790,NCT01868971,The primary endpoint is reaching the cecum of the colon with the ENDORINGS™.,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,7. Patient satisfactory.
9791,NCT00824785,Overall survival,2008-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,"response rate, toxicity, quality of life and PFS"
9792,NCT06006026,The safety profile of combining ropivacaine and lidocaine,2023-08-28,COMPLETED,INTERVENTIONAL,['NA'],,The plasma concentration of lidocaine
9793,NCT02746432,The anti-inflammatory effects of intraoperative hyper-insulinimic euglycemic therapy in patients undergoing colorectal cancer surgery.,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Thirty days post-operative mortality,The immunomodulatory effect of intraoperative hyper-insulinimic euglycemic infusion.
9794,NCT03138720,CA19-9 value,2017-05-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
9795,NCT02349958,measure treatment response to HIPEC and tumor debulking,2006-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],QOL,Toxicity Monitoring
9796,NCT03621982,Part 1 Combination Therapy: Number of Patients who Experience a Dose Limiting Toxicity (DLT),2018-11-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,Part 2 Combination Therapy: Number of Patients with Confirmed Positive Anti-drug Antibody (ADA) Responses
9797,NCT05055648,Pulmonary complications,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],Concordance of observed cardiac complications with predicted,Overall survival (OS)
9798,NCT03162510,MTD of Oxaliplatin,2018-06-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
9799,NCT03187951,Change in 6 Minute Walk Test (6MWT),2017-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
9800,NCT00382720,Time to Progression,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
9801,NCT05010681,Objective Response Rate (ORR),2021-08-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
9802,NCT03368859,Progression Free Survival (PFS),2018-03-20,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
9803,NCT05266300,Adverse events,2020-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Rate of discontinuation of fluoropyrimidines due to adverse events
9804,NCT04923529,16-week progression-free survival (PFS) rate,2021-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety outcome measures
9805,NCT03031691,Percentage of patients with anti-brontictuzumab antibodies,2017-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
9806,NCT02465060,Objective response rate,2015-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival
9807,NCT00220064,Disease stabilization rate or tumour marker response,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9808,NCT05057052,Objective Response Rate (ORR),2021-09-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
9809,NCT04973306,Overall survival(OS),2022-03-02,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Correlation between genetic profile and tumor response
9810,NCT00003186,,1997-04,COMPLETED,INTERVENTIONAL,['NA'],,
9811,NCT04315311,Change In Coefficient Of Fat Absorption (CFA) From Baseline,2020-05-06,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Change In Gastrointestinal Quality Of Life Index (GIQLI) From Baseline
9812,NCT06039280,Prevention of post-embolization syndrome,2023-09-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Adverse events of Dexamethasone and NAC in patients undergoing transarterial chemoembolisation for HCC
9813,NCT04740346,3-year overall survival,2021-07-05,RECRUITING,INTERVENTIONAL,['NA'],,Incidence of vitamin B12 deficiency
9814,NCT01868347,evaluation of arterial oxygenation,2013-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],variation of gas exchange in post operative period,evaluation of difference between arterial end-tidal partial pressure of carbon dioxide
9815,NCT06178926,Sedation efficacy,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,Injection pain
9816,NCT00006006,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9817,NCT00297128,feasibility and tolerance of preoperative therapy with Cetuximab in combination with Capecitabine and radiotherapy for patients with locally advanced operable rectal carcinoma,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"collection of response rate (T-downstaging, pCR), correlation of responsiveness with EGFR-status"
9818,NCT01186731,Response rate of tumor size reduction at 110 mg/m2 LE-DT dose level,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,SPARC tumor expression following the treatment of LE-DT at 110 mg/m2 dose level
9819,NCT04168944,Tumor free survival rate,2019-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",the side effects,Overall survival rate
9820,NCT04375930,means of quality of life change,2019-01-18,COMPLETED,INTERVENTIONAL,['NA'],,
9821,NCT02694562,Local Tumor Control,2013-11,COMPLETED,INTERVENTIONAL,['NA'],,Time To Tumor Progression
9822,NCT02381561,Maximum tolerated dose (MTD) defined as the dose below which 2 or more of 6 patients experience dose-limiting toxicity,2016-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Tumor response relationship to the %iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation using Response Evaluation Criteria in Solid Tumors (RECIST) criteria based on high-pressure liquid chromatography (HPLC) and flow cytometry measurements
9823,NCT01213004,To determine whether motion-corrected cone-beam CT (CBCT) can visualize and localize abdominal tumors using intravenous contrast enhancement.,2010-09,COMPLETED,INTERVENTIONAL,['NA'],,To determine whether tumor and organ-at-risk positions localized in cone-beam CT (CBCT)
9824,NCT03606317,Prognosis and practice patterns in the management of cachexia and its associated symptoms.,2013-11-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
9825,NCT03258398,Part 2: Overall Response Rate,2017-09-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9826,NCT02563158,Serum total bilirubin on postoperative day 5,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,Long-term survival
9827,NCT02024607,The Objective Response Rate of Napabucasin Administered in Combination in FOLFIRI in Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer,2014-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer
9828,NCT01003600,"Assess colorectal cancer survivors' basic knowledge of their own cancer history, including date of diagnosis, stage, and treatments received.",2009-10,COMPLETED,OBSERVATIONAL,['NA'],,Assess whether survivors who had concerns about working after cancer treatment spoke with health care professionals about their concerns.
9829,NCT01133132,Change in level of physical activity,2010-02,COMPLETED,INTERVENTIONAL,['NA'],,
9830,NCT00114179,Overall survival rate,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rate
9831,NCT00002664,,1995-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
9832,NCT05025826,Demonstrate a 50% decrease of the grade> or = 2 neurotoxicity at 4 months after oxaliplatin-based chemotherapy start in the PHYCOCARE arm,2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Comparison between the two arms of Neurological toxicities
9833,NCT05425940,Overall Survival,2022-09-07,RECRUITING,INTERVENTIONAL,['PHASE3'],Duration of Response (DOR) as assessed by the Investigator per RECIST 1.1,Overall Survival
9834,NCT01472029,"Rate of complete pathological responses (percentage of patients with pCR referring to the total number of enrolled and eligible patients), as evaluated centrally by a reference pathologist.",2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
9835,NCT03347630,diagnostic performance for staging,2017-10-02,UNKNOWN,INTERVENTIONAL,['NA'],,Diagnostic performance to assess tumor response
9836,NCT00364364,"For patients who undergo surgery after the 111In-hPAM4 study, targeting will be correlated against surgical findings.",2007-05,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,"Targeting with 111In-hPAM4 will be compared to other radiological (e.g., CT) and nuclear (FDG-PET; optional)findings."
9837,NCT00031694,Response Rate of at Least 30%,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Bryostatin 1 Pharmacokinetics,Overall Survival
9838,NCT03866525,The anti-tumor activity of OH2 monotherapy and in combination with irinotecan or HX008,2019-04-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The immunogenicity of OH2
9839,NCT01474642,response rate,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,predictive marker
9840,NCT03300570,"Pharmacological Effect on Cyclic Guanosine Monophosphate (cGMP) Levels for Dolcanatide Arm Versus (vs.) Placebo, as Measured by the Differences in Mean cGMP Levels After 7 Days of Intervention",2018-07-27,COMPLETED,INTERVENTIONAL,['PHASE1'],,Percentage of Participants With Grade 3 or Higher Diarrhea Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
9841,NCT00892593,"rate of significant colon neoplasia among those who enter a screening or surveillance program with FIT testing added at yearly intervals vs. that of ""usual care"" patients in the same patient population.",2009-05,UNKNOWN,INTERVENTIONAL,['NA'],,the pathology found at repeat colonoscopy in each group.
9842,NCT00994903,Total complications,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change in functional recovery
9843,NCT01605734,Time to Progression,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,AFP
9844,NCT04316000,Initial Fear of Cancer degree,2019-11-22,SUSPENDED,OBSERVATIONAL,['NA'],,Long-term Fear of Cancer degree
9845,NCT05732662,ORR,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment Related Severe Adverse Effects
9846,NCT06104241,Dose-limiting toxicity (DLT）,2023-10-22,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,PFS
9847,NCT03171298,intraoperative complication,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,Mesorectal completeness
9848,NCT04293497,The comparison of sensitivity between conventional staining method and new staining method,2020-02-17,COMPLETED,INTERVENTIONAL,['NA'],,The evaluation of correlation index of staining at three type slides
9849,NCT05172635,Pathological response of the primary tumour,2014-06-01,COMPLETED,OBSERVATIONAL,['NA'],,90 day mortality
9850,NCT05188209,Adverse Events (AEs),2021-05-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The proportion of patients with positive of anti-drug antibody (ADA)
9851,NCT04984980,objective response rate,2020-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival
9852,NCT01712347,Overall survival from the time of starting first-line therapy,2012-10-11,COMPLETED,OBSERVATIONAL,['NA'],,Number of participants with adverse events
9853,NCT05226169,Maximum change of Hb concentration,2022-04-29,RECRUITING,INTERVENTIONAL,['PHASE3'],,OS
9854,NCT05512520,1-year progression-free survival,2022-09-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-related adverse events
9855,NCT02997293,Hospital length of stay,2017-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
9856,NCT03474354,CORRELATION OF LUMI DISTRIBUTION WITH NECROSIS,2018-05-02,COMPLETED,OBSERVATIONAL,['NA'],,Distribution of radiopaque beads and correlation with necrosis
9857,NCT00415155,Phase 2: Time to progression,2008-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Safety
9858,NCT04186117,Isolation of circulating tumoral cells,2016-09-09,RECRUITING,INTERVENTIONAL,['NA'],,
9859,NCT00353262,AUC0-inf for Free Platinum,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Marked Laboratory Abnormalities
9860,NCT00535353,"Correlation, if any, between the toxicity profile and pharmacokinetics",2008-01-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacodynamic outcomes
9861,NCT00003381,Evaluate the quality of life of patients,1998-07,TERMINATED,OBSERVATIONAL,['NA'],,
9862,NCT01528501,objective response rate within the first six treatment cycles,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety and tolerability of LBH 589
9863,NCT03343301,Number of Participants With Dose Limiting Toxicities (DLTs),2017-11-30,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Treatment Induced Anti-bemarituzumab Antibodies
9864,NCT03401827,survival rate,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,adverse event
9865,NCT03699371,Long-term quality of life at 6 months,2018-11-01,UNKNOWN,INTERVENTIONAL,['NA'],PCS SF-36 change,Antibiotic-free days
9866,NCT02489214,Number of Participants with Adverse Events,2016-05-16,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free survival time
9867,NCT02442323,Patient-reported outcome of quality of life,2013-08-09,COMPLETED,INTERVENTIONAL,['NA'],,
9868,NCT05718115,Predict response to anti-HER2 directed therapy using DLR,2023-02-15,RECRUITING,OBSERVATIONAL,['NA'],,
9869,NCT00878657,Disease-free survival (Phase II),2009-04,TERMINATED,INTERVENTIONAL,['PHASE1'],,
9870,NCT04161287,Local control rates,2019-10-11,RECRUITING,OBSERVATIONAL,['NA'],,Adverse reaction
9871,NCT03437200,12-Month Progression-free survival using RECIST 1.1,2019-01-17,TERMINATED,INTERVENTIONAL,['PHASE2'],,Relative dose intensity of 5FU
9872,NCT02586701,Six Minute Walk Test (6MWT),2013-09,COMPLETED,INTERVENTIONAL,['NA'],,
9873,NCT00297648,Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Central Blinded Assessments,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 54
9874,NCT03042169,Overall survival,2021-08-25,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of interventional palliative procedures per patient
9875,NCT04866381,Objective Response Rate,2021-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Subject safety
9876,NCT03777475,OS,2016-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,PFS
9877,NCT03839706,18F-FDG PET/MRI results can identify aggressive HCC behavior and recurrence post transplant,2018-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,18F-FDG PET/MRI are related to presence of circulating tumor DNA in plasma
9878,NCT02352337,Rate of patients alive and without radiological and/or clinical progression,2014-12-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression survival
9879,NCT01770405,performance evaluation,2013-09,COMPLETED,OBSERVATIONAL,['NA'],,Safety and feasibility evaluation
9880,NCT02965209,Diagnostic yield of NMSE in patients with suspected small bowel diseases,2015-11,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
9881,NCT04525313,response rate,2020-08,UNKNOWN,OBSERVATIONAL,['NA'],,progression free survival
9882,NCT04039360,stoma rate,2014-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
9883,NCT02600143,Genetic predisposition for immunotherapy-induced colitis,2013-08,COMPLETED,OBSERVATIONAL,['NA'],,Analysis of the gut microbiome in stool samples
9884,NCT05530746,Detection of advanced colorectal adenoma,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Detection of non-advanced colorectal adenoma
9885,NCT01467921,disease-free survival,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
9886,NCT00002615,,1994-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
9887,NCT01605305,TPP,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,OS
9888,NCT03072472,Adenoma Detection Rate,2017-02-14,COMPLETED,INTERVENTIONAL,['NA'],,Compare the baseline ADR of each colonoscopist prior to trial recruitment with their individual ADR in patients where EndocuffTM Vision was not used.
9889,NCT01214343,Overall survival,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Biomarker predicting the efficacy
9890,NCT05856305,Acute Toxicity,2023-07-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Tumor Volume reduction kinetics
9891,NCT01725490,the mean percentage change of the number and size of polyps in colon and/or duodenum.,2013-02-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9892,NCT05432193,Treatment emergent adverse events,2022-07-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Uptake of the [Ga-68]-PNT6555 imaging agent and optimal scanning specifications for future studies,Uptake of [Ga-68]-PNT6555 in tumor lesions
9893,NCT04180761,Incidence of peritoneal metastases and proportion of patients free from peritoneal metastasis after one year after HIPEC.,2019-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by grading according to CTCAE v5.0 and Clavien-Dindo.
9894,NCT02176746,The number of participants with adverse events,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The dose of CSC vaccine,The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
9895,NCT01110798,Major anastomotic leak rate,2009-10,UNKNOWN,INTERVENTIONAL,['NA'],,"Bowel function, fecal incontinence, and quality of life, evaluated with validated questionnaires"
9896,NCT03676075,Sensitivity and specificity of the model in the diagnosis of colorectal cancer and adenoma,2018-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9897,NCT04469556,Progression free survival(PFS) in mFFX and GA arms pancreatic ductal adenocarcinoma (PDAC) in a randomized phase II trial.,2020-10-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Cluster Tendency analysis using artificial neural networks and radiomic methods combined
9898,NCT05520385,"an association between occurrence of CRC and blood group A+ , O + .",2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,an association between occurrence of CRC and overweight and class І obesity patients
9899,NCT04704934,Overall Survival in Participants Who Were Administered Trastuzumab Deruxtecan Compared With Ramucirumab in Combination With Paclitaxel,2021-05-21,RECRUITING,INTERVENTIONAL,['PHASE3'],,Percentage of Participants Who Have Treatment-emergent ADAs
9900,NCT05694338,Percent of patients considered frail assessed by Clinical Risk Analysis Index (RAI-C) Scores of 21 or higher,2023-03-13,RECRUITING,OBSERVATIONAL,['NA'],,Adverse outcomes after major surgery
9901,NCT00188110,To evaluate the performances of the WE-CT in patients suspected of having a colon tumor,2003-03,UNKNOWN,INTERVENTIONAL,['NA'],,To demonstrate the advantages of the WE-CT compared to the CT and magnetic resonance (MR) colonography for the diagnosis and local staging of colon tumors
9902,NCT01269216,pathologic complete response rate,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9903,NCT06311396,Omics studies and functional morphological studies,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
9904,NCT04131192,Rate of dose limiting toxicities of each subject,2019-11-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
9905,NCT04177602,Rate of pathological complete remissions (pCR)/Phase 2 part,2019-11-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Rate of perioperative complications
9906,NCT02954913,Comprehensive Complication Index,2017-02-14,COMPLETED,INTERVENTIONAL,['NA'],,Cost Analysis
9907,NCT05605600,Development of LARS Severity tool,2022-10-03,COMPLETED,OBSERVATIONAL,['NA'],,Commence initial psychometric evaluation of the New LARS score
9908,NCT04625803,Tumor regression rate of MSS/pMMR patients,2021-01-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,mortality rate
9909,NCT00769782,Recurrence-free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Types and severities of adverse events
9910,NCT05051358,Safety of procedure,2021-02-11,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Cost Effectiveness
9911,NCT05323409,Instrument to measure Self-Management (IMSM),2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Supportive Care Needs Survey (SCNS)
9912,NCT02665026,Postoperative complication,2016-01-04,COMPLETED,INTERVENTIONAL,['NA'],,Disease-free survival
9913,NCT00274209,Prevalence of dysplastic lesions by white light vs. chromoendoscopy,2005-12,COMPLETED,OBSERVATIONAL,['NA'],,
9914,NCT05480306,Progression Free Survival (PFS),2022-08-30,RECRUITING,INTERVENTIONAL,['PHASE2'],Exposure-response relationships for DKN-01 as data permit.,Incidence of ≥Grade 3 related treatment-related adverse events (TRAEs).
9915,NCT04949672,Completeness of mesorectal fascia and specimen quality (specimen integrity after rectal resection),2017-01,COMPLETED,OBSERVATIONAL,['NA'],,Cancer specific survival (CSS)
9916,NCT00267020,Overall Survival (OS),2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Experiencing Serious Adverse Events (SAEs) and Adverse Events (AEs) (Toxicity)
9917,NCT03976739,corelation between the bile reflux and gastric mucosa diseases,2019-06-17,COMPLETED,OBSERVATIONAL,['NA'],,the risk factors of primary bile reflux gastritis
9918,NCT04361162,Overall response rate (ORR),2020-05-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS) in patients
9919,NCT04552093,Completion of 2 combined chemotherapy cycles (feasibility),2020-09-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Quality of life assessment,Conversion rate colorectal liver metastases (CRLM)
9920,NCT04521491,Recurrence free survival(RFS),2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival(OS)
9921,NCT03609268,progression free survival,2018-06-30,UNKNOWN,INTERVENTIONAL,['NA'],,overall survival
9922,NCT06210724,Colorectal Cancer,2023-10-09,RECRUITING,OBSERVATIONAL,['NA'],Blood tests,Microscopic colitis
9923,NCT02636088,Local tumour Control,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
9924,NCT01802320,Overall Response Rate (CR+PR) Evaluated Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Validation of the Enrichment Biomarker Signature in Metastatic Sites,Progression-free Survival (PFS)
9925,NCT02070822,tumor response,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],,change of baseline MRI parameters
9926,NCT04450732,Maximum Tolerated Dose (MTD) or Dose Recommended for Dose Expansion (DRDE),2020-07-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,Preliminary Efficacy
9927,NCT02191566,"3-year recurrence-free survival, RFS",2015-05,TERMINATED,INTERVENTIONAL,['PHASE2'],compliance for chemotherapy,"5-year overall survival, OS"
9928,NCT06111326,Phase II: Dose Expansion Part-objective response rate (ORR),2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9929,NCT04793958,Progression-free Survival (PFS),2021-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of Life Assessment
9930,NCT01662609,Number of Abnormalities Detected by EUS,2007-08-23,COMPLETED,OBSERVATIONAL,['NA'],,
9931,NCT06260293,Shorts Physical Performance Battery(SPPB),2023-01-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
9932,NCT05181306,Recurrence,2010-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Cost
9933,NCT01876407,Evaluate the effectiveness of using low-intensity laser compared with placebo as preventive and therapeutic intervention of oral mucositis induced by radiation therapy and chemotherapy.,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Assess the intervention tolerance and side effects of it.
9934,NCT00176735,,2001-12,TERMINATED,INTERVENTIONAL,['NA'],,
9935,NCT05067153,Prothrombin fragment F1+2,2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Mortality
9936,NCT01262040,"Determine the feasibility of Narrow Band Imaging (NBI) at the time of thorascopic, laparoscopic or robotic surgery.",2010-12-14,COMPLETED,INTERVENTIONAL,['NA'],,Determine what percentage of patients have surface metastasis identified with NBI that were not seen on white light imaging.
9937,NCT00625573,"To evaluate the efficacy by means of response rate of Abraxane and capecitabine in combination, in the treatment of patients with colorectal cancer in the 2nd or 3rd line metastatic setting following failure of irinotecan or oxaliplatin based therapy",2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate overall survival, time to progression, response duration, time to response and safety of this combination"
9938,NCT06148636,Determine recommended therapeutic dose of [212Pb] VMT-α-NET,2023-11-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Maximum tolerated radiation dose for kidneys
9939,NCT01214681,Faecal calprotectin concentration,2010-05,UNKNOWN,INTERVENTIONAL,['NA'],,Plasma short chain fatty acid concentration
9940,NCT01456455,HER2 Status,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],Outcome according to ethnicity of patients,Outcome according to HER2 Status
9941,NCT00081289,Pathologic Complete Response Rate,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in EORTC QLQ-CR38 Defecation Symptom Score at Two Years
9942,NCT02785380,Overall survival,2016-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Number of Participants With Treatment-Related Adverse Events as Assessed by,Recurrence-free survival
9943,NCT01438437,Local tumor response,2001-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Change from baseline in Child status at 1 year
9944,NCT05013697,Progression free survival (PFS， RECIST assessment),2021-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-related adverse Events
9945,NCT06006923,"Progression-free Survival (PFS), Randomize Phase",2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Objective Response Rate (ORR), Randomized Phase"
9946,NCT04486651,Overall Survival (OS) in Participants With PD-L1 CPS≥1,2020-09-16,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
9947,NCT02789891,3-year disease overall survival rate,2016-06,UNKNOWN,INTERVENTIONAL,['NA'],,EORTC QLQ-C30 and QLQ - STO22
9948,NCT01284504,"Blood Samples Taken Before Initiation of Study, Day of Surgery, Days 1 and 3 Post-op, and 30 Days Post-op. Analyzed for 50 Serum Cytokines, Cell-specific Gene Expression, and TCR Repertoire.",2011-01,TERMINATED,INTERVENTIONAL,['NA'],,"Surveys to Evaluate Patient Pain, Fatigue, and Quality of Recovery, Recorded From Day of Surgery to 30 Days Post-op."
9949,NCT05145647,To estimate the local control rate at primary tumor site,2022-01-01,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival (OS),Treatment toxicity grading according to the CTCAE
9950,NCT01998152,Change in skeletal muscle area (cm2) between individualized nutritional counselling versus usual nutritional care,2013-11,COMPLETED,INTERVENTIONAL,['NA'],,"Associations of (changes in) muscle area with (changes in) mid-upper arm muscle circumference, whole body fat free mass (BIA) and whole body lean body mass (DEXA)."
9951,NCT03563326,EpCAM CAR-T cells treatment related adverse events,2018-08-30,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progress free survival outcome
9952,NCT00005030,,1999-09-29,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
9953,NCT04768218,To externally validate the EGGIM score classification using BLI,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
9954,NCT01032967,Overall survival and disease-free survival,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life and function outcomes
9955,NCT00997685,To investigate the progression free survival (PFS) advantage of Xeloda plus oxaliplatin in the peri-operative treatment of potential resectable metastatic colorectal cancer,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To evaluate the safety profile of XELOX peri-operative treatment
9956,NCT01198548,Rate of Sufficient Cholecalciferol,2010-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,PFS of Patients Receiving Study Treatment
9957,NCT05091346,Phase 2 Part: Objective Response Rate (ORR),2021-10-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2 Part: Apparent Clearance for Lenvatinib When Co-administered With E7386 and Pembrolizumab
9958,NCT03542877,12-Week Progression Free Survival,2018-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) by PIK3CA Mutation Status
9959,NCT04868227,GENE EXPRESSION CHANGE,2014-03-28,COMPLETED,INTERVENTIONAL,['NA'],,VITAMIN D STATUS CHANGE
9960,NCT05382364,Percentage of participants discontinuing from study therapy due to AE,2022-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of Response (DOR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)
9961,NCT02958163,Objective response rate at 6 months,2017-02-20,TERMINATED,INTERVENTIONAL,['PHASE2'],MRI description of tumors at the hepatobiliary phase at 6 months after treatment,Overall response rate based on the MRI evaluation in Child Pugh B7 patients
9962,NCT05440552,Detection rate,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
9963,NCT03348241,The effect of Gum Arabic to prevent Chemotherapy-induced Oral Mucositis was the primary outcome that assessed using World Health Organization Mucositis Scoring.,2015-10-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9964,NCT00353015,Participant Response Rate of Irinotecan and Cisplatin,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9965,NCT04833959,Incidence of treatment emergent adverse events assessed by CTCAE v5,2021-03-26,SUSPENDED,INTERVENTIONAL,['PHASE1'],,
9966,NCT00125021,To assess the response rate associated with capecitabine and OSI-774 in patients with advanced pancreatic cancer,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,to estimate the time to progression and overall survival of patients with advanced pancreatic cancer treated with capecitabine and OSI-774
9967,NCT03604991,Disease-free survival (DFS) (Step 2),2019-05-03,SUSPENDED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Percent change in mean volumetric apparent diffusion coefficient (ADC),DFS
9968,NCT05225844,progression-free survival（PFS）,2019-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate(DCR)
9969,NCT06207656,Efficacy of cetuximab in combination with encorafenib plus binimetinib as induction therapy for the treatment of BRAF-V600E mutated MSS aCRC to perform radical treatment of the primary and/or metastases,2024-01-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],To determine the presence/expression level/levels of serum and tumour tissue biomarkers associated with cell and tumour growth and/or involved in the mechanisms of action of EBC,Incidence and severity of AEs CTCAE v5 criteria
9970,NCT02231723,Determination of the Recommended Phase 2 Dose by assessing dose-limiting toxicities (DLTs),2014-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Assess pharmacodynamic activity of BBI608 when administered in combination with standard chemotherapies
9971,NCT02705651,Growth rate of the tumor in mm,2019-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Documentation of lymph node and/or distant metastases
9972,NCT04001101,Out-of-field ORR improvement,2019-10-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Quality of life score
9973,NCT05583292,rate of mortality,2023-02-11,COMPLETED,OBSERVATIONAL,['NA'],,
9974,NCT00054912,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9975,NCT00408122,,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,
9976,NCT00361231,Median Progression Free Survival,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Response Rate
9977,NCT01691664,Disease free survival,2012-09,UNKNOWN,INTERVENTIONAL,['NA'],Immunological assessment,quality of life
9978,NCT01099527,To assess response rate in phase II,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9979,NCT01188109,Recurrence-free Survival as Measured by CT Scan,2010-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Immunohistochemistry to Determine Status of Excision Repair Cross Complementation Gene-1 (ERCC1) Expression
9980,NCT00053924,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9981,NCT02235324,Progression-free survival during the second phase of the study,2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],"mRNA level of VEGFR1, VEGFR2, and VEGF-A",Incidence of adverse events graded according to NCI CTCAE version 4.0
9982,NCT01652196,Proportion of patients alive and progression-free,2012-11-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Proportion of patients who go off treatment due to adverse reactions or even those who refuse further treatment for lesser toxicities that inhibit their willingness to continue participation on the trial
9983,NCT05305001,BRCA 1/2 germline mutation prevalence,2020-09-09,COMPLETED,OBSERVATIONAL,['NA'],The proportion of germline mutation carriers who accept pancreatic cancer surveillance.,Clinical and pathological characteristics
9984,NCT05049317,Incidence of urinary dysfunction,2021-11-24,RECRUITING,INTERVENTIONAL,['NA'],,Incidence of urinary dysfunction
9985,NCT00502177,PedsQL 4.0 Generic Core Scale,2007-06-19,COMPLETED,OBSERVATIONAL,['NA'],,
9986,NCT04186156,Proportion of patients alive and progression free at 4 months,2020-03-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To determine the pharmacodynamic response to KA2507
9987,NCT00695227,The primary aim of the study is to establish that patients with symptoms of LPR who are referred to an otolaryngology clinic have a prevalence of Barrett's metaplasia equivalent to that of a population with GERD symptoms.,2004-05,COMPLETED,INTERVENTIONAL,['NA'],,
9988,NCT01409005,8-weeks progression free survival rate (PFS rate),2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Patients with Adverse Events
9989,NCT03963206,survival of the patient after start of treatment,2019-09-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of patients with each dose of Cabozantinib
9990,NCT03579199,Histological analysis of explanted liver parts,2019-03-18,UNKNOWN,INTERVENTIONAL,['NA'],,bilirubin and prothrombin levels
9991,NCT01721941,Maximum tolerated dose of TH-302 use in TACE,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Objective response rate
9992,NCT03490461,A new lesion with radiographic features compatible with HCC was defined as recurrence of HCC.,2017-11-22,COMPLETED,OBSERVATIONAL,['NA'],,
9993,NCT06275997,Miss rate reduction,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,patient satisfaction
9994,NCT05314946,Feasibility of the trial,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Post-operative mortality
9995,NCT00342472,PAH exposure,1998-02-12,COMPLETED,OBSERVATIONAL,['NA'],,
9996,NCT00822991,Size of HCC which is detected first,2009-01,UNKNOWN,INTERVENTIONAL,['NA'],,The improvement of prognosis of patients who are diagnosed in this study
9997,NCT05992584,Progression free survival (PFS) according to mRECIST,2023-08-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
9998,NCT05116085,Major pathological response (MPR) rate,2022-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants with Treatment-emergent Adverse Events (TEAEs)
9999,NCT06079229,Evolution in the ADL questionnaire score between pre-operative and post-operative 3 to 30 months after surgery.,2023-11-06,RECRUITING,OBSERVATIONAL,['NA'],,
10000,NCT06091930,Part IV: Objective response based on the response evaluation criteria in solid tumors (RECIST v1.1),2024-01-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Part IV: Area under the concentration-time curve of BI 765049 over a uniform dosing interval τ (AUCτ) after multiple administrations
10001,NCT02702986,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Disease specific survival (DSS)
10002,NCT01608022,Overall Response Rate,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10003,NCT03959774,demonstrate that the adherence rate of digital follow-up is greater than 70% in a population of elderly patients.,2020-12-30,UNKNOWN,INTERVENTIONAL,['NA'],,
10004,NCT03653052,Clinical response to therapy (durvalumab),2018-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Ex-vivo effect of compounds on tumour/cell models,
10005,NCT00021320,,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10006,NCT04798781,Progression-free survival,2021-07-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence and severity of adverse events
10007,NCT03229096,Objective response rate (ORR),2017-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,3-year overall survival rate
10008,NCT06050447,Mortality rate,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Recurrence-free survival
10009,NCT00940303,Progression-free survival,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Proportion of patients with NCI-CTC grade 3-5 adverse events; adverse events, laboratory parameters, ECOG performance status."
10010,NCT03797326,Percentage of Participants Receiving Lenvatinib Monotherapy who Discontinue Study Treatment Due to an Adverse Event (AE),2019-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Plasma Concentration of Lenvatinib
10011,NCT04295811,Primary Efficacy,2020-06-18,RECRUITING,INTERVENTIONAL,['NA'],"Safety outcome of EsoCheck Device (510k cleared, non-invasive, esophageal cell collection device) on all patients who undergo the device procedure.",Secondary Efficacy
10012,NCT06269341,Overall Survival,2010-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
10013,NCT01487343,adherence to oral chemotherapy,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,improve the care of patients
10014,NCT04692454,The number of CD8+ T,2020-08-31,COMPLETED,INTERVENTIONAL,['NA'],,
10015,NCT02319928,Colorectal cancer incidence,2015-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
10016,NCT05610904,Accuracy of stoma implementation,2022-12-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Rate of stoma reverse
10017,NCT00108953,Time to Progression (TTP),2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants for Whom Disease Control Was Achieved
10018,NCT05158621,Primary,2021-12-14,COMPLETED,OBSERVATIONAL,['NA'],,
10019,NCT05038813,Objective Response Rate(ORR),2022-03-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival(OS)
10020,NCT01314027,Progression-free survival,2009-09,TERMINATED,INTERVENTIONAL,['PHASE3'],,feasibility of adjuvant chemotherapy
10021,NCT06227325,pathological complete response (pCR) rate,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of Participants who experience one or more adverse events (AEs).
10022,NCT05975749,Disease-free survival,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Side effects
10023,NCT02821559,Evolution of Raltitrexed plasma levels,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival (OS)
10024,NCT04877340,Compare the diagnostic yield,2020-11-26,UNKNOWN,INTERVENTIONAL,['NA'],,adverse event rate
10025,NCT02836977,Disease free survival,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],,
10026,NCT05579353,expressional quantity,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
10027,NCT04167436,Changes in immunological function,2019-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Remission and cancer free survival
10028,NCT02274753,Relapse in relation with the immunoscore determined on a tumor section and criteria defined in the monitoring of patients,2015-03-11,UNKNOWN,OBSERVATIONAL,['NA'],,Relapse in relation with the immunoscore on biopsies
10029,NCT06168812,Change in mean interstitial glucose level for Cohort 1 participants before and after initiation of glipizide,2023-12-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,
10030,NCT03131102,Acute Fatigue Score (AFS),2017-08-29,COMPLETED,OBSERVATIONAL,['NA'],Quality of life,Hospital length of stay
10031,NCT05291156,OS,2022-07-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of treatment-related adverse events as assessed by CTCAE v5.0
10032,NCT01091558,"L-Arginine (L-Arg) availability in ulcerative colitis (UC) patients and normal control subjects, and correlate with disease activity",2009-09,COMPLETED,OBSERVATIONAL,['NA'],,L-Arg intake in the diet of UC patients and control subjects
10033,NCT05640830,Progression-free survival,2023-01-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10034,NCT00474903,Change in Mean Tissue Prostaglandin E2 (PGE2) Concentration as Determined From Barrett's Research Mucosal Biopsy Samples,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
10035,NCT02909114,local control assessed by RECIST,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
10036,NCT00911196,Expression of c-MET in the same hepatocellular carcinoma tumor samples,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,
10037,NCT02243267,Response to Treatment,2014-09,COMPLETED,OBSERVATIONAL,['NA'],,
10038,NCT02326948,Number of participants with alcohol consumption,2014-08,COMPLETED,OBSERVATIONAL,['NA'],Number of participants with polypoid lesions of gallbladder,
10039,NCT00507598,"•Perform metabolic profiling of tissue,serum & urine from pts w/ colorectal cancer (stages I-IV), healthy controls & pts w/ colorectal polyps & correlate results.",2007-07,COMPLETED,OBSERVATIONAL,['NA'],,"Correlate changes of serum & urine biomarkers /p trt to predict response or toxicity,& correlate w/other treatment outcomes. Compare the metabolic profile between pts w/various stages of colorectal cancer."
10040,NCT02399735,GVHD,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Acute rejection
10041,NCT03819387,Number of patients with treatment-related adverse events as assessed by CTCAE v5.0,2019-03-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],To evaluate correlation between KRAS mutations and clinical outcome,Additional pharmacokinetic parameters for siRNA
10042,NCT02274012,Change of tumor burden (in centimeters) for participants during protocol therapy,2014-05-29,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,ErbB2 levels benefit during therapy.
10043,NCT02958059,Rate of complication that related with infection.,2016-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Grade of post-ERCP infectious complication
10044,NCT03797443,Disease control rate (CR+PR+SD x18 weeks),2019-01-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Changes in patient's self-reported pain levels
10045,NCT00966251,To assess the safety and tolerability of CT-011 in patients with Primary Hepatocellular Carcinoma,2009-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10046,NCT00134758,SPIGELMAN severity score of duodenal lesion after 2 years of follow-up,2004-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Compliance to the treatment
10047,NCT03722875,Overall survival(OS),2018-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,
10048,NCT00047333,Progression-free survival,2002-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
10049,NCT01933958,Number of Patients with serious adverse drug reactions (SADRs) from the first administration of Regorafenib,2013-09-04,COMPLETED,OBSERVATIONAL,['NA'],,Integration analysis for safety in drug use investigations (DUIs) for both colorectal cancer and gastrointestinal stromal tumor.
10050,NCT03872908,Cohort 2: Efficacy of compression induced by surgical gloves vs peripheral neuropathies development in patients treated by oxaliplatine after a cumulative dose of 595 mg/m2,2019-09-29,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Cohort 2: Evaluation of the peripheral neuropathies percentage for each hand
10051,NCT01367275,Number of Participants With Median Progression-Free Survival (PFS),2011-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
10052,NCT02874885,Change in circulating tumor cells status,2013-09-05,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
10053,NCT04233151,Progression-free Survival（PFS）,2020-01-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,
10054,NCT06194734,Overall survival (OS),2024-02-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of Life (QOL) scores
10055,NCT04222413,To determine the Objective Response Rate (ORR) according to Evaluation Criteria (RECIST 1.1) in patients treated with metarrestin at the MTD,2020-10-27,RECRUITING,INTERVENTIONAL,['PHASE1'],,To assess safety and tolerability of metarrestin in subjects with metastatic solid tumors
10056,NCT03928678,length of hospital stay in days,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],,
10057,NCT00452205,,2007-04,UNKNOWN,OBSERVATIONAL,['NA'],,
10058,NCT06329869,Overall objective response rates (ORR),2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Biomarkers-related endpoints,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
10059,NCT01624363,Prevalence of Pancreatic Cysts During Routine EUS,2009-09,COMPLETED,OBSERVATIONAL,['NA'],,
10060,NCT00465023,"To determine the maximum tolerated dose (MTD) of proton beam irradiation in patients with unresectable or locally recurrent hepatocellular cancer, cholangiocarcinoma, or hepatic metastases.",2003-06,COMPLETED,INTERVENTIONAL,['NA'],,"to evaluate tumor response, local control and survival in this patient population."
10061,NCT02953743,Mean area under the concentration-time curve over the dosing interval on multiple dosing (AUC(0-τ)),2016-09-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
10062,NCT03488953,Overall survival three years after 2nd-stage of hepatectomy,2018-04-10,UNKNOWN,INTERVENTIONAL,['NA'],,Morbidity of the donor
10063,NCT03630068,Recurrence-free survival,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Clinical and radiological complications
10064,NCT05908916,Progression-free survival,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
10065,NCT05026905,Best objective response rate (ORR),2021-12-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-related Adverse Events [Safety and Tolerability]
10066,NCT00672828,Self-reported colorectal cancer (CRC) screening adherence with medical record verification of screening test completion,2008-01,COMPLETED,INTERVENTIONAL,['NA'],Clinic variables as CRC screening predictors,Self-reported stage of CRC screening test adoption
10067,NCT05114798,Weight change (% kg),2022-05-17,RECRUITING,INTERVENTIONAL,['NA'],,Saliva microbiota
10068,NCT05228743,R0 resection rate,2020-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,1 year overall survival
10069,NCT04734249,Objective response rate (ORR),2021-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Assess the anti-tumor activity:DCR
10070,NCT05759741,Wexner incontinence score,2023-01-17,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Rate of postoperative complications
10071,NCT00003486,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
10072,NCT02020928,Incidence of Oral Mucositis,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Degree of mucositis
10073,NCT00958737,Disease-free survival (DFS),2009-05-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment compliance
10074,NCT02561546,glycosylated hemoglobin (A1C),2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,postprandial glucose (PPG)
10075,NCT01388101,The performance of e- Ab sensor,2010-09,UNKNOWN,INTERVENTIONAL,['NA'],,
10076,NCT02592304,"DECT as imaging tool for diagnosing response to chemo radiotherapy of malignant lymph nodes, and tumors.",2014-09,UNKNOWN,INTERVENTIONAL,['NA'],,
10077,NCT03707574,Obtaining tumor tissue and blood specimens,2019-04-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Genomic analysis
10078,NCT03693677,The progression free survival at 6 months according to the RECIST 1.1 criteria,2018-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment safety
10079,NCT00031941,,2002-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10080,NCT03003065,Safety (will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0),2014-03-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Quality of life (in every visit, European Organization for Research and Treatment of Cancer core questionnaire [EORTC QLQ-C30] will be filled and specific symptom enquiry is made; itchiness, fever and general well-being over a Likert 0-4 scale."
10081,NCT00613665,Safety measures: injection site and systemic reactions,2001-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunogencity measures: antigen-specific antibodies and cellular immune response
10082,NCT03962478,6-month survival rate,2019-05-31,COMPLETED,INTERVENTIONAL,['NA'],,Stent dysfunction free survival
10083,NCT00845819,Incidence of oral mucositis of grade 2 or higher (NCI CTCAE 3.0),2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,OMDQ (oral mucositis daily questionnaire) score during treatment
10084,NCT01200121,paracentesis-free survival (ParFS),2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in laboratory values and vital signs.
10085,NCT02163785,Assessment of the circumferential resection margin,2014-06,TERMINATED,INTERVENTIONAL,['NA'],Morbidity of the perineal incision.,Histopathological quality of surgical specimen
10086,NCT00230399,"To determine the objective response rate to the combination of celecoxib, capecitabine, and irinotecan in patients with metastatic colorectal cancer.",2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate the time to progression of metastatic colorectal cancer after treatment with celecoxib, capecitabine, and irinotecan."
10087,NCT02620865,Median Overall Survival (OS),2015-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,TTP
10088,NCT02768428,knowledge about TACE (A 40-item exam is performed to test the patients' knowledge),2015-10,UNKNOWN,INTERVENTIONAL,['NA'],,
10089,NCT00043199,,na,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10090,NCT06261008,adherence rate,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,qualitative factors associated with repeat FIT adherence
10091,NCT05007613,Overall response rate,2021-06-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety
10092,NCT04034459,Overall Response Rate (ORR),2016-11-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
10093,NCT06101277,Number of participants with controlled disease,2023-10-05,RECRUITING,INTERVENTIONAL,['NA'],,Time to treatment failure
10094,NCT05308732,Maximum tolerated dose,2021-05-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of Oral Mucositis
10095,NCT02459652,R0 resection rate,2012-12-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,R0 resection rate in borderline resectable pancreatic cancer
10096,NCT05635929,"Quality of life evaluation of radiotherapy, with or without chemotherapy, long-term symptoms (6 months) after 1 month of use of the tested composition in head & neck cancer patients.",2022-10-11,COMPLETED,INTERVENTIONAL,['NA'],,Comparison between oral mucositis severity in patients receiving radiotherapy with patients receiving radiotherapy plus chemotherapy.
10097,NCT01099085,Progression free survival of XP ± simvastatin,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10098,NCT00753675,Progression Free Survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
10099,NCT00160030,Percentage of patients having completed the full treatment and Endoscopic complete response rate,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profile (NCI-CTC).
10100,NCT01748773,Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status Score,2013-01-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
10101,NCT03903185,Measurement of the pharmacokinetics of LDV\SOF,2019-03-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Measurement of the number of participants with sustained virological response (SVR12), 12 weeks after discontinuation of therapy with ledipasvir-sofosbuvir (LDV-SOF)."
10102,NCT01326000,Progression-free survival: tumour assessments by CT scan or MRI according to RECIST criteria,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Effect of concomitant FOLFIRI on pharmacokinetics of RO5083945 and vice versa
10103,NCT03027401,Identify incidental and secondary findings in germline DNA and actionable somatic mutations for reporting clinical results from a CLIA-certified lab into CRIS medical records.,2017-01-10,WITHDRAWN,OBSERVATIONAL,['NA'],,Assessment of effects of the informed consent process
10104,NCT05875402,Adverse Events (AE),2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,
10105,NCT05535998,Progression-free survival,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Conversion rate
10106,NCT02582918,Patient satisfaction and acceptability,2018-03-26,COMPLETED,INTERVENTIONAL,['NA'],,Repeat Screening
10107,NCT02489916,Number of participants with Adverse Events,2014-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Area under the plasma concentration versus time curve (AUC),Progression Free Survival
10108,NCT04913233,Colorectal cancer screening sensitivity,2021-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
10109,NCT00041262,Survival,2004-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
10110,NCT04265417,Disease-free survival,2015-01-06,COMPLETED,OBSERVATIONAL,['NA'],,Postoperative C-reactive protein
10111,NCT02301962,Number of subjects with adverse event.,2015-07-28,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Duration of response.
10112,NCT03413254,Proportion of peritoneal metastases detected after a negative second look DLS,2018-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life assessed with the EQ-5D-5L questionnaire
10113,NCT04095195,"This clinical study will assess the diagnostic yield of a clinical surveillance program for pancreatic neoplasia or predisposing conditions (PanIN, IPMNs) in high risk individuals",2019-08-20,RECRUITING,OBSERVATIONAL,['NA'],,"This study will investigate possible risk factors for the incidence or the progression of for pancreatic neoplasia or predisposing conditions (PanIN, IPMNs) in high risk individuals"
10114,NCT03029793,Pathologic Response,2016-05,UNKNOWN,OBSERVATIONAL,['NA'],,Overall Survival
10115,NCT04798820,Change from preoperative weight change at postoperaive 18 months in SE and IE groups.,2021-03-09,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life of the patients
10116,NCT04602611,Overall Survival,2020-11-03,COMPLETED,INTERVENTIONAL,['NA'],Oncology Nurse Navigation Provider Comparison for Outcomes,Oncology Nurse Navigation Comparison for Satisfaction
10117,NCT03200834,5-year survival,2017-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Disease free survival 5 years after initial surgery
10118,NCT00077545,Objective response rate (CR + PR),2004-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of improvement of dysphagia
10119,NCT05125094,Overall Survival,2021-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,tumor response
10120,NCT03457844,Progression Free Survival(PFS),2018-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease Control Rate(DCR)
10121,NCT01395459,Change in population level cancer screening level at the health clinics involved.,2008-09,COMPLETED,INTERVENTIONAL,['NA'],For the substudy: return rate of gFOBT kits vs. FITs,
10122,NCT02330913,Anastomosis related complication rate,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,
10123,NCT00882310,Number of Subjects Who Experience Dose Limiting Toxicities (DLTs),2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Score on FACT-Hep (Version 4)
10124,NCT01087268,Gastrointestinal symptoms score using the IBDQ quality-of-life questionnaire,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Health economics data
10125,NCT05569668,OS(overall survival),2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,DFS(disease-free survival)
10126,NCT05110573,Major complication rate,2000-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Oncological outcomes
10127,NCT04157322,clinically detectable recurrence at 1 year after surgery.,2019-08-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
10128,NCT01858805,overall survival,2010-04,COMPLETED,OBSERVATIONAL,['NA'],,recurrence-free survival
10129,NCT01476592,Notch1 activation in post-treatment tumor biopsy specimens when compared to pretreatment levels,2011-12,COMPLETED,INTERVENTIONAL,['NA'],,Describe the effect of resveratrol on tumor growth as demonstrated by standard cross sectional imaging and tumor markers.
10130,NCT03046745,Prediction of risk factors for gastric cancer and definition of optimal endoscopic screening interval,2016-08,UNKNOWN,OBSERVATIONAL,['NA'],,Reservation of frozen serum for novel gastric cancer serologic marker analysis
10131,NCT04807673,Event Free Survival (EFS),2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life differences (EORTC QLQ-OES18)
10132,NCT01423799,"Quality of Life (QOL), measured with the EORTC QLQ-C30",2012-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,QOL assessed by the EORTC QLQ-OG 25
10133,NCT03548948,Change in colonic inflammation,2015-07-15,COMPLETED,INTERVENTIONAL,['NA'],,Change in serum hepcidin
10134,NCT00819754,"Phase II: Using the RD established in phase I, assess efficacy of the IXO with bevacizumab combination as measured by progression-free survival",2003-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Qualitative and quantitative toxicity
10135,NCT02246153,Postoperative complication rate,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Postoperative recovery index
10136,NCT06231017,Objective response rate (ORR),2024-01-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (Safety）
10137,NCT04638010,Number of participants who complete needed cancer screening and prevention services,2011-02-16,COMPLETED,INTERVENTIONAL,['NA'],,
10138,NCT01047618,To evaluate the incidence of VTE in advanced gastric cancer with chemotherapy and to identify risk factors and biomarkers for VTE in this population,2009-12,COMPLETED,OBSERVATIONAL,['NA'],,To investigate the significant impact of VTE on overall survival and in this population
10139,NCT01486134,Rate of complete ablation one month after one RFA procedure,2012-06-20,TERMINATED,INTERVENTIONAL,['NA'],,Agreement of 2D and 3D measurements of ablations zones on IRMT° images and those measured on conventional magnitude MR images.
10140,NCT02169388,Frequency and severity of Adverse effects during Chemotherapy,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,The observed changes in nutritional status after chemotherapy
10141,NCT02659241,Change in level of protein expression in p53-related pathways,2016-02-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
10142,NCT01182922,Percentage of invitees attending screening colonoscopy in each invitation letter group,2010-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,"Percentage of forms with consent for examination, sent back after invitation letter but before reminding letter. Differences in attendance between men and women depending on type of the invitation."
10143,NCT01822613,Phase II primary outcome measure: Progression free survival (PFS),2013-07-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression free survival (PFS) per RECIST 1.1 (Ph 1b )
10144,NCT00942383,Comparison of transverse ablation diameter between intraoperative ultrasound elasticity imaging (USEI) and postoperative cross-sectional imaging (CT or MRI).,2007-09,TERMINATED,OBSERVATIONAL,['NA'],,Feasibility of image processing and image segmentation using this clinical free-hand system.
10145,NCT05420909,Duration of Systemic Treatment,2019-01-28,COMPLETED,OBSERVATIONAL,['NA'],,
10146,NCT05775146,Progression free survival (PFS),2024-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory endpoints/outcomes. To identify blood biomarkers that can correlate with disease events,Toxicity Assessment
10147,NCT00375024,Questionnaire Results Regarding Time to Diagnosis,2007-05,COMPLETED,INTERVENTIONAL,['NA'],,Questionnaire Results Regarding Patient Navigators
10148,NCT01790425,Cecal intubation,2011-08,COMPLETED,INTERVENTIONAL,['NA'],Patient discomfort Patient pain rating during and after procedure,Amount of opiate and benzodiazepines used for sedation.
10149,NCT02682394,Blood levels of free DNA,2015-09,UNKNOWN,OBSERVATIONAL,['NA'],,
10150,NCT00909402,"Use National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) to establish the MTD, Dose Limiting Toxicity (DLT(s)) and safety profile of BMS-833923 administered in combination with Cisplatin and Capecitabine",2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,The pharmacokinetic parameters that will be assessed include: AUC(TAU) (Area under the concentration-time curve in one dosing interval)
10151,NCT04936581,Vaizey score,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative complications
10152,NCT03585166,"The survival rate of primary liver cancer treated by laparoscopic hepatectomy and laparoscopic hepatectomy,Telephone pays a return visit",2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Comparison between laparoscopic hepatectomy and laparoscopic hepatectomy in primary hepatocellular carcinoma Unit: times
10153,NCT00553813,Survival,2007-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Evaluate the gene expression profile in relation to clinical outcomes
10154,NCT01658813,Progression Free Survival,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Survival
10155,NCT02106650,Grade 2 Oral Mucositis Prevention,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
10156,NCT05095636,PFS,2021-03-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],,AEs
10157,NCT01270698,Safety,2011-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,efficacy
10158,NCT01735968,Characteristics of dose limiting toxicities (DLTs),2013-02-27,COMPLETED,INTERVENTIONAL,['PHASE1'],,Effect of basic PK parameter: CL/F
10159,NCT00373347,Identify new blood markers of liver cancer,2004-11,RECRUITING,OBSERVATIONAL,['NA'],,
10160,NCT02499783,Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4,2015-08-17,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in Fecal Calprotectin Level Over Time (Any Adalimumab Set)
10161,NCT05541445,Major pathologic response,2022-08-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
10162,NCT01067053,Time to progression,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety of treatment according to the number of adverse events reported
10163,NCT03981679,AUC,2018-06-05,COMPLETED,INTERVENTIONAL,['NA'],,Intplex parameters
10164,NCT04130399,Local control rate among PDAC patients treated with neoadjuvant chemotherapy followed by SBRT,2019-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Rate of grade 3-4 non hematological toxicity rates
10165,NCT01478373,Antitumor Activity of Dovitinib in Terms of Disease Control Rate (DCR): Complete Response+Partial Response +Stable Disease,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,DCR (CR+PR+SD) at the End of Treatment
10166,NCT00173277,,2003-06,UNKNOWN,OBSERVATIONAL,['NA'],,
10167,NCT04223635,Volume of Distribution in the Terminal Phase (Vz/F) Following a Single Dose in Participants With Moderate Hepatic Impairment Compared to Healthy Participants,2020-01-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Number of Participants Reporting Treatment-Emergent Adverse Events (TEAE) by System Organ Class and Preferred Term Following a Single Dose of Pexidartinib in Participants With Moderate Hepatic Impairment Compared to Healthy Participants
10168,NCT05541601,Positive/Negative predictive values of novel diagnostic approaches for the early diagnosis of HCC in enrolled patients who are diagnosed with HCC by conventional approaches.,2022-02-23,RECRUITING,OBSERVATIONAL,['NA'],,To better understand the incidence of HCC in a UK population stratified by underlying cirrhosis aetiology
10169,NCT04198051,The change of concentration of P-hydroxyphenylalanine metabolites in urine during chemotherapy,2019-12-20,UNKNOWN,INTERVENTIONAL,['NA'],,The change of the number of tumor necrosis factor(TNF)-α in blood during chemotherapy
10170,NCT05280444,Objective Response Rate(ORR),2022-05-28,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse Events(AEs)
10171,NCT05620706,AE/SAE,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],,ORR
10172,NCT04899739,Rate of lymph nodes wrongly categorised by ultrasound endoscopy. (Specificity),2021-12-05,RECRUITING,INTERVENTIONAL,['NA'],,Development of an algorithm capable of characterizing lymph nodes metastases by the mean of artificial intelligence
10173,NCT05202314,Pathological complete remission,2021-12-12,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival
10174,NCT00004258,To evaluate the safety and tolerability of escalating doses of twice weekly EMD 121974 in patients with cancer.,1999-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10175,NCT04801355,R1 resection rate,2020-12-01,RECRUITING,INTERVENTIONAL,['NA'],,The incidence and structure of postoperative complications
10176,NCT00798447,reduction of pro inflammatory activity,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10177,NCT05971108,Stage of hepatocellular carcinoma at diagnosis,2024-01-08,RECRUITING,INTERVENTIONAL,['NA'],,Survival rates
10178,NCT00327132,Hp eradication rate and complete histological rate,2006-07,COMPLETED,INTERVENTIONAL,['NA'],,overall survival (OS)Relapse-free survival (RFS)
10179,NCT06186700,The incidence of mucositis in the two groups using WHO grading of oral mucositis,2023-12-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidence of adverse effects
10180,NCT05325528,Objective Response Rate (ORR),2022-04-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,progression-free survival
10181,NCT01655693,Overall Survival (OS),2012-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants Experiencing Clinically Significant Changes in Left Ventricular Ejection Fraction (LVEF) and the Severity of the Event,Objective Response Rate (ORR)
10182,NCT01896531,Progression-Free Survival (PFS) in All Randomized Participants and Participants With PTEN Loss Tumors at Primary Analysis,2013-08-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Serum Concentration of Ipatasertib
10183,NCT04707560,Quantification of tissue quality,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],Complication,Diagnostic performance between different suction method
10184,NCT01762254,pain score,2009-06,COMPLETED,INTERVENTIONAL,['NA'],length of hospital stay,wound complication
10185,NCT00858338,toxicity of IP FUDR after surgery prior to chemoradiation,2002-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Time to relapse, disease specific survival"
10186,NCT00503035,13-HODE Colonic Tissue Levels,2003-08-20,COMPLETED,INTERVENTIONAL,['PHASE2'],,PGE2 Colonic Tissue Levels
10187,NCT03917966,Major pathological response（MPR）,2020-04-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
10188,NCT05130710,presence of peritoneal seeding,2020-02-25,COMPLETED,OBSERVATIONAL,['NA'],,presence of peri-gastric lymph node involvement
10189,NCT01490866,Progression-free Survival,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency of Adverse Events as a Measure of Safety
10190,NCT00310076,Time to Progression,2002-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Events of Toxicity Graded 3 and 4
10191,NCT01671683,,2010-07,COMPLETED,OBSERVATIONAL,['NA'],,
10192,NCT01688700,Pathology complete remission rate,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
10193,NCT02951091,progression free survival,2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
10194,NCT03974672,Measuring severity of complications with the Dindo Clavien complications scale,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
10195,NCT03350412,Thoroughness to report molecular profiling,2015-10,UNKNOWN,OBSERVATIONAL,['NA'],,Percentage of complete data capture for treatment-related check-point events
10196,NCT00230646,Minutes of moderate-intensity physical activity (PA) at 3 months among 134 sedentary patients who have completed treatment for colorectal cancer (CRC).,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Examine the maintenance of outcomes (minutes of moderate intensity activity, physical functioning, vigor, fatigue and body esteem) at 6 and 12 months."
10197,NCT03583528,Sensitivity of 68Ga-DOTATOC PET/CT in the diagnosis of SSTR positive tumors.,2018-07-11,RECRUITING,OBSERVATIONAL,['NA'],,Total number of lesions per anatomic location identified by 68Ga-DOTATOC PET/CT
10198,NCT02788669,LRP1 molecular expression,2015-11,UNKNOWN,OBSERVATIONAL,['NA'],,
10199,NCT01333475,pERK and pAKT Levels in Tumor Biopsies on C1D1 and C1D22 Post-administration of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Participants With Advanced Colorectal Cancer,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
10200,NCT05193604,Overall response rate (ORR),2022-03-24,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
10201,NCT00427492,Time to defecation after colonic resection,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
10202,NCT03412773,Safety Run-In Substudy[Japan only]: Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings,2017-12-28,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings
10203,NCT04319302,Bile drainage,2005-01,COMPLETED,OBSERVATIONAL,['NA'],Complications,Complications of procedure
10204,NCT04230603,Inflammatory classification with HSI,2019-06-06,UNKNOWN,INTERVENTIONAL,['NA'],,Tissue perfusion
10205,NCT03558048,Relationship between IBD and PSA,2019-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Location of disease
10206,NCT02468076,Feasibility (ratio of technically successful RFA-applications to all examinations in which RFA-use was intended),2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety (number and type of adverse events)
10207,NCT04573881,Primary Safety: Procedure-Related Major Complications,2021-06-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Secondary Safety: All Adverse Events
10208,NCT05426850,Relationship between ctDNA status after chemoradiotherapy and relapse.,2021-06-01,RECRUITING,OBSERVATIONAL,['NA'],,"Relationships between radiomics features, ctDNA status and relapse."
10209,NCT01728480,"The percentage of patients with mucositis, measured using the World Health Organization (WHO) mucositis global severity score and the oral mucositis daily questionnaire (OMDQ)",2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
10210,NCT05970302,Objective Response Rate (ORR),2023-07-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
10211,NCT05227014,Transfusion rate,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative hemoglobin values
10212,NCT04813627,Occurrence of ctDNA positivity in the first post-AdCTx blood sample,2021-07-02,RECRUITING,OBSERVATIONAL,['NA'],,Transfer of participants from the BNT000-001 study to the BNT122-01 clinical trial
10213,NCT00385177,Pharmacokinetic parameters for SN2310 and SN-38,2006-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10214,NCT03323944,Number of study subjects with treatment-related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.03,2017-09-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,Objective response rate
10215,NCT05721300,Incidence of early liver cancer,2023-02-10,RECRUITING,INTERVENTIONAL,['NA'],,
10216,NCT02730533,The total bleeding rate according to grading of intraoperative bleeding during ESD procedure,2016-03,COMPLETED,INTERVENTIONAL,['NA'],,The mean percentage of mucosal defect reduction at follow-up endoscopy on 28 days after ESD procedure.
10217,NCT02864043,Performance of manually identified VLE features in predicting biopsy defined dysplasia,2016-09,UNKNOWN,INTERVENTIONAL,['NA'],,Per Biopsy performance of VLE compared to standard-of-care for detecting dysplasia
10218,NCT00823810,Survival,2008-12,TERMINATED,INTERVENTIONAL,['NA'],,Time to progression
10219,NCT03113955,Number of Participants With Objective Tumor Response at 6 Months by MRI (Magnetic Resonance Imaging),2017-10-24,COMPLETED,INTERVENTIONAL,['NA'],,Kaplan-Meier Analyses the Percent of Participants for Time to Extrahepatic Spread
10220,NCT01600196,Survival time,2006-01,TERMINATED,INTERVENTIONAL,['PHASE4'],,Number of Adverse Events
10221,NCT01898741,Safety,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10222,NCT02911363,Histological quality of the EMR specimen obtained during the procedure will be analyzed and compared to cassette vs. no cassette for pathology review.,2016-01,COMPLETED,INTERVENTIONAL,['NA'],,Ease of use of the Captivator tissue cassette will be comparable to Standard of Care.
10223,NCT04202601,Arms 3:≥second-line therapy group,2019-12-13,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Arms 3:≥second-line therapy group
10224,NCT02511223,Objective Response Rate (ORR) by using RECIST 1.1,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10225,NCT01629004,Uptake of appropriate CRC screening,2011-04,COMPLETED,INTERVENTIONAL,['NA'],,Uptake of lower gastrointestinal investigations
10226,NCT04291976,detection rate of neoplasia for each technique,2020-03-13,COMPLETED,INTERVENTIONAL,['NA'],,Size of the lesion in mm
10227,NCT00627042,Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer Treated With the Monoclonal Antibody Ramucirumab,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Drug-Related Treatment-Emergent Adverse Events
10228,NCT05663788,Pooled sensitivity of endoscopic optical diagnosis for predicting deep submucosal invasion in routine colonoscopies,2022-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Pooled LR- of endoscopic optical diagnosis for predicting deep submucosal invasion in a 20-image test before and after the learning module in the intervention group
10229,NCT04831632,diagnostic performance,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,qualitative iFOBT positivity rate
10230,NCT06278701,Albumin rising,2023-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Improved quality of life
10231,NCT01333033,Complete Pathological Response (pCR) of PET/CT Non-responders,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS) Among PET/CT Non-responders Within Each Induction Treatment Group
10232,NCT05193253,Disease-free survival (DFS).,2000-02-01,COMPLETED,OBSERVATIONAL,['NA'],,
10233,NCT00225641,Overall and cancer-specific mortality,2006-03,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life. Cost-effectiveness of follow-up
10234,NCT02835924,Percentage of patients with G3/G4 treatment-related AEs in each arm according to CTCAE v4.03 criteria.,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
10235,NCT06305728,Sensitivity of ImmunoPET to identify presence or absence of adenocarcinoma,2024-03-04,RECRUITING,OBSERVATIONAL,['NA'],,
10236,NCT05093608,Maximum Tolerated Dose,2021-11-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Survival
10237,NCT00502502,Patient Symptom Assessment (Questionnaire),2002-11,COMPLETED,OBSERVATIONAL,['NA'],,
10238,NCT03315195,Postoperative complications,2017-11-25,UNKNOWN,INTERVENTIONAL,['NA'],,
10239,NCT00471965,Overall survival,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Response rate, secondary resection rate, quality of life"
10240,NCT03291951,Number of moderate and severe chemotherapy-associated toxicities,2018-02-23,COMPLETED,INTERVENTIONAL,['NA'],,
10241,NCT00008398,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10242,NCT03182179,Change in LARS score,2016-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Irritable Bowel Syndrome-Quality of Life
10243,NCT02215447,Response rate,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Rates of adverse events as defined by NCI- Common Terminology Criteria for Adverse Events (CTCAE) V4.0
10244,NCT01383746,Progression -free survival at 6 months (from date of inclusion),2011-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Safety of RADIOEMBOLIZATION using the NCI-CTCAE V3.0 classification.
10245,NCT02866344,Local disease control at the site of intervention,2016-08,TERMINATED,INTERVENTIONAL,['NA'],,Postoperative mortality
10246,NCT05592925,Postoperative pathological results of tumor N stage.,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
10247,NCT03601988,DFS,2018-07-28,UNKNOWN,INTERVENTIONAL,['PHASE3'],,OS
10248,NCT00540579,"The Safety and Tolerability of Protocol Treatment, Defined as the Percentage of Patients Experiencing Severe or Life-threatening Side Effects Per CTCAE Version 3.0",2007-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10249,NCT00355862,Recurrence free survival,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10250,NCT00136669,To determine the duration of acupuncture effects,2003-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10251,NCT05088889,"Objective tumor response rate 2 (ORR2) after first progression, assessed by RECIST v1.1",2022-01-25,RECRUITING,INTERVENTIONAL,['PHASE1'],Assessment of disease biomarkers as a surrogates or predictors to response following administration of SBRT and immunotherapy: Exploratory,"Incidence of Treatment-Emergent Adverse Events, as assessed by CTCAE version 5.0"
10252,NCT05537402,Progression-free survival,2023-09-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to deterioration of quality of life
10253,NCT00917384,Overall Survival (OS),2009-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Developed Antibodies Against IMC-1121B
10254,NCT00919009,Time to progression (TTP) in patients treated with TACE plus sorafenib,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall response rate will be evaluated
10255,NCT05770635,Objective response rate (ORR) 1 month after the last TACE -mRECIST evaluation,2022-12-28,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
10256,NCT02764801,Percentage of Patients Correctly Identified as Requiring Tumor Re-treatment One Month After Initial Chemoembolization,2016-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10257,NCT02756468,Specificity of PCT and CRP for anastomotic leak (AL) after pancreatic surgery,2015-01,UNKNOWN,OBSERVATIONAL,['NA'],,PCT and CRP cuts-off in 5th POD with a good NPV for AL
10258,NCT01789073,Overall postoperative complications after major gastrointestinal (GI) elective surgery.,2013-02,COMPLETED,INTERVENTIONAL,['NA'],"Weight stability, functional capability and patients´ satisfaction with the overall study course.",Length of hospital stay after major gastrointestinal (GI) elective surgery
10259,NCT06133062,Progression free survival (PFS),2023-11-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence and severity of adverse events
10260,NCT05515315,progression free survival,2022-05-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
10261,NCT05139199,Quality of Life (EORTC QLQ-PAN26 ),2022-02-23,COMPLETED,INTERVENTIONAL,['NA'],,Physical Activity(Exercise Counseling and Programming Preferences)
10262,NCT04380506,Validate the ability of the diameter (in cm) of abdominal collection detected during the contrast-free abdomen CT in POD3 to predict risk of biliary fistula,2020-03-15,UNKNOWN,INTERVENTIONAL,['NA'],,
10263,NCT06099119,Change in body weight over study period.,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,
10264,NCT03083002,Transcriptomics characterization of liver tissue: the purpose is molecular evaluation of possible predisposing factors to development of hepatocellular carcinoma in patients with cirrhosis.,2013-05,UNKNOWN,OBSERVATIONAL,['NA'],,Transcriptomics characteristics of newly diagnosed hepatocellular carcinoma: the purpose is to verify if we can predict the survival of patients considering the molecular features of HCC at first diagnosis.
10265,NCT03287375,"Number of patients with major/complete histologic response (PRGS 1+2) peritoneal biopsies, within a series of three PIPAC procedures.",2016-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of patients where MRI is accurate in describing PM distribution and progressive/regressive disease
10266,NCT04809142,Overall survival (OS),2021-02-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival at 12 months
10267,NCT01434199,caecal intubation rate,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Caecal intubation time
10268,NCT03546998,Detection of epidermoid carcinoma of the esophagus,1973-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Result of achalasia treatment by investigating dysphagia and gastro-esophageal reflux
10269,NCT03108885,Esophageal Cancer Mutation,2017-10-01,TERMINATED,OBSERVATIONAL,['NA'],,Marker for Recurrence
10270,NCT04074538,Adenoma or advanced adenoma incidence,2013-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Second primary cancer incidence
10271,NCT02595931,"Recommended phase 2 dose (RP2D) of ATR kinase inhibitor M6620 (VX-970, berzosertib) and irinotecan hydrochloride",2016-07-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Change in biomarker levels,"Pharmacodynamic parameters of M6620 (VX-970, berzosertib) in combination with irinotecan hydrochloride"
10272,NCT04130971,Tumour response to treatment,2019-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Normal tissue response to treatment
10273,NCT05163977,Post-Operative Pancreatic Fistula,2021-06-12,UNKNOWN,INTERVENTIONAL,['NA'],,primary or reactionary hemorrhage
10274,NCT00005874,,1999-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10275,NCT03384316,Recommended Phase 2 Dose (RP2D),2018-01-31,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Dose Limiting Toxicities (DLTs),Overall Survival (OS)
10276,NCT04592211,dose limiting toxicity,2021-10-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall response rate
10277,NCT04752215,Number of patients with dose limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period,2021-05-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,Objective response based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1) in patients with measurable disease
10278,NCT00844077,Conversion from Barrett's intestinal metaplasia to dysplasia or esophageal adenocarcinoma.,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,
10279,NCT00619541,"N° of non progressive disease (complete and partial responses, stable disease)",2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Toxicity of the combination,ORR,Duration of responses, TTP and OS.PK, PD,Baseline pERK concentration, phospho VEGF-R2 concentration, plasma proteomics and gene expression profiling on blood cells and tumor biopsy"
10280,NCT04817813,Survival and disease-free survival at 5th year.,2021-03-15,UNKNOWN,OBSERVATIONAL,['NA'],,Follow up- Date of death
10281,NCT00183872,"Objective Response (Complete, Partial, Stable and Progression)",2005-04-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
10282,NCT01953406,Time-to-progression(TTP)of lung metastasis,2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Adverse Events,Disease control rates (CR + PR + SD)of lung metastasis
10283,NCT03961373,Overall survival analysis,2018-11-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Percentage of completion of protocol treatment
10284,NCT00016042,,2001-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
10285,NCT01442935,The main objective is to compare resection rates (R0 or R1) for hepatic metastases,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
10286,NCT03071237,Distribution of IPA origin,2017-03-04,COMPLETED,OBSERVATIONAL,['NA'],,Reconstruction rate of IPA by CT scan
10287,NCT00107315,Time to Progression,2004-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity
10288,NCT04523389,Association between the number and size of exosomes and their content on cancer stage and progression,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10289,NCT05210322,Tube free survival,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Complication rate
10290,NCT02585479,Progression-Free-Survival,2015-10,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time-to-Progression outside the liver
10291,NCT01238055,time to progression,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression free survival
10292,NCT02525237,Safety will be assessed by incidence of adverse events,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life (QoL)
10293,NCT03989310,Disease control rate (DCR),2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with laboratory test abnormalities
10294,NCT00590434,"proportion of patients with complications including perforation, bleeding, MI or CVA within 24 hours of colonoscopy in >80 vs. <80 agr group",2006-08,COMPLETED,OBSERVATIONAL,['NA'],,Five year disease free survival and five year mortality rates after the diagnosis of colon cancer in older (>80 yrs) vs. younger group (<80 yrs)
10295,NCT05515185,Maximum tolerable dose,2022-09-09,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
10296,NCT00559676,Pharmacogenetic and pharmacokinetic predictors of therapeutic response and toxic effects,2005-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,Predictive value of pharmacogenetic and pharmacokinetic parameters on disease-free and overall survival
10297,NCT03275376,Overall survival,2017-12-21,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression free survival
10298,NCT05004441,objective response rate (ORR),2021-07-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events (AE)
10299,NCT04678583,Intrahepatic disease-free survival (iDFS),2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,"Assessment of additional oncological and perioperative outcomes: Assessment of ""Quality of life"" (QoL)"
10300,NCT02831842,Overall Survival (OS) in Participants With mCRC and a Documented KRAS Mutation who Received Bevacizumab-Containing Treatment or Chemotherapy Alone in Routine Clinical Practice,2016-06-09,COMPLETED,OBSERVATIONAL,['NA'],,OS in Participants With mCRC and a Documented KRAS Wild Type Status who Received Bevacizumab-Containing Treatment or Anti-EGFR Treatment in Routine Clinical Practice
10301,NCT02862613,Progress-free survival,2016-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
10302,NCT05274945,pathological assessment of response to treatment,2020-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,adverse events of chemotherapy
10303,NCT01318161,Long-term (up to 5 yrs) all-cause mortality,2011-03,TERMINATED,INTERVENTIONAL,['PHASE3'],Postoperative pain and early recovery,Cancer recurrence detected by MRI; perioperative complications
10304,NCT05307926,Disease-free survival,2019-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
10305,NCT03199144,patient overall survival,2017-04-20,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,CEA level post operatively at one month
10306,NCT05959226,3-year overall survival rate,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,QLQ-C30 assessment
10307,NCT01254617,"Maximum-tolerated dose of lenalidomide with cetuximab, defined as the highest dose level at which 0 or 1 patients out of 6 experiences a dose limiting toxicity graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",2011-02-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Immune cell activation,Natural killer cell activation
10308,NCT01822444,Identification of biomarkers,2012-11,COMPLETED,OBSERVATIONAL,['NA'],,Validation of identified biomarkers
10309,NCT00152230,Relapse-free survival and overall survival,1996-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events
10310,NCT01198522,Maximum tolerated dose and the preliminary tolerability profile.,2007-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,Antitumor activity
10311,NCT01822210,Change of tumor volume in the stomach.,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,performance status
10312,NCT03628651,Biomarker Identification,2018-04-02,COMPLETED,OBSERVATIONAL,['NA'],,
10313,NCT03801915,Number of Grade 3-5 Adverse Events Related and/or Not Related to Drug,2019-11-13,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Define Disease Free Survival (DFS) for Participants Treated With Preoperative MVT-5873
10314,NCT00033462,Proportion of patients who are progression-free at 24 weeks,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall response rate in EGFR positive patients
10315,NCT01796145,Overall survival,2013-02-27,RECRUITING,INTERVENTIONAL,['NA'],,Liver stiffness (kPa)
10316,NCT05720195,Overall survival among HCC patients as assessed by the platelet-albumin-bilirubin (PALBI) score,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival among HCC patients according to treatment modality as assessed by the platelet-albumin-bilirubin (PALBI)
10317,NCT00034216,"Collection of tissue, urine, saliva, stool and blood components, which include serum, leukocytes, peripheral blood mononuclear cells (PBMC), and circulating tumor cells (cTC), of human subjects.",2002-07-16,RECRUITING,OBSERVATIONAL,['NA'],,
10318,NCT00519324,To Assess disease control rate (DCR) as defined CR + PR + SD assessed by RECIST criteria,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To describe the safety profile (incidence and severity of adverse events, serious adverse events) assessed by NCI CTCAE version 3.0"
10319,NCT03656627,Dose-Limiting Toxicity (DLT),2019-06-27,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Survival
10320,NCT02861430,Concordance between immunochemistry and molecular biology,2014-04,UNKNOWN,OBSERVATIONAL,['NA'],,Disease-free survival
10321,NCT01746043,Proportion of Patients Under Each Treatment Arm Who Experienced a Mean Symptom Increase of 2 Units or More From Baseline to 6 Weeks.,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10322,NCT04293315,Effective Screening,2018-06-09,UNKNOWN,INTERVENTIONAL,['NA'],,Implementation outcomes according to the RE-AIM framework
10323,NCT02078726,Adenoma Detection Rate (ADR) During Colonoscopy Procedure,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,
10324,NCT05192460,Objective Response Rate (ORR),2022-03-28,RECRUITING,INTERVENTIONAL,['NA'],,The concentration of Lymphocyte
10325,NCT06096493,Disease free survival.,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
10326,NCT02558504,complete histological eradication of the high grade glandular epithelial neoplasia,2013-01-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Percentage of patients with severe adverse reaction and minor adverse reactions linked to the procedure used, described by anatomical site"
10327,NCT06258434,Sensitivity and specificity of the multiomics Colorectal Cancer (CRC) screening test (CRC-Appareo) with comparison to colonoscopy,2024-02-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"Sensitivity of the multiomics Colorectal Cancer (CRC) screening test (CRC-Appareo) with comparison to FIT, with respect to advanced adenoma (AA) and CRC"
10328,NCT03567863,cumulative length of tissue core biopsies per needle pass,2018-06-24,COMPLETED,INTERVENTIONAL,['NA'],,intra-observer evaluation of the anatomopathological criteria used
10329,NCT04906382,T-cell receptor (TCR) diversity,2021-07-01,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of adverse events
10330,NCT01483638,progression-free survival,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Adverse events
10331,NCT01419769,Safety - Freedom From Major Complications: SAE's,2011-08,COMPLETED,INTERVENTIONAL,['NA'],,Clinical Success
10332,NCT02736552,Disease-free survival,2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Treatment expense,Side effects
10333,NCT06139042,"The sensitivity and specificity of the cfDNA methylation model in detection of liver, biliary tract and pancreatic cancers.",2023-11-01,RECRUITING,OBSERVATIONAL,['NA'],,"The sensitivity and specificity of the combined model in detection of different stages of liver, biliary tract and pancreatic cancers."
10334,NCT02166255,Overall survival,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10335,NCT03349255,Toxicity profile of ET1402L1-CART-cell treatment,2017-10-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,AUC of serum cytokine levels
10336,NCT03720678,Incidence of dose-limiting toxicities (DLTs) during dose escalation phase,2018-11-18,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunomodulatory activity in subsets for AB928 in combination with mFOLFOX
10337,NCT01914692,fistula of pancreas,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4'],postoperative pancreatitis,infection of incisional wound
10338,NCT03519308,Number of Adverse Events,2020-07-29,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Proportion of Margin Negative Surgical Resections
10339,NCT03819920,Screening Behavior: Differences in colorectal cancer screening completion rates between usual care (UC) and CCRAT,2015-10-06,COMPLETED,INTERVENTIONAL,['NA'],Fear: Health Belief Model Likert Scale,Colorectal cancer screening rates at 12 months as a function of CCRAT score
10340,NCT05815082,5-year progression-free survival,2023-02-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,Complications
10341,NCT04797507,ORR based on RECIST v1.1,2021-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
10342,NCT06232395,The performance of the new biomarkers in the post-operative monitoring of gastric cancer,2024-02-18,RECRUITING,OBSERVATIONAL,['NA'],,The performance of the new biomarkers as prognostic biomarkers
10343,NCT00290485,Patient response rate according to RECIST criteria,2005-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Evaluate whether the response rate can predict survival
10344,NCT00885950,Histologically proven hepatic sinusoidal injury,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,90-day morbidity and mortality
10345,NCT04015245,Series changes of Prothrombin Time-Intemrnational Normalized Ratio,2018-04-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,Series changes of blood pressure levels before and after TACE
10346,NCT01666444,Overall Survival,2012-10-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency and Severity of Adverse Events (AEs)
10347,NCT04607421,Cohort 3: Objective response rate by blinded independent review,2020-12-21,RECRUITING,INTERVENTIONAL,['PHASE3'],,Cohort 3: Trough concentrations of encorafenib and its metabolite LHY746
10348,NCT04272034,Number of treatment-emergent adverse events,2021-03-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Vz/F of INCB099318
10349,NCT00303927,Toxicity,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rate
10350,NCT06217250,Success rate of resection defined as absence of residual/recurrence in SC1 and/or SC2,2024-02-26,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Avarage time of procedure and polyp resection time
10351,NCT03001518,immune response,2017-05-04,COMPLETED,OBSERVATIONAL,['NA'],,disease-free survival
10352,NCT03243916,overall survival(OS),2017-08-15,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life (QOL)
10353,NCT05122221,"Incidence of treatment related AEs, AEs of special interest and serious adverse events (SAEs).",2022-07-17,RECRUITING,INTERVENTIONAL,['PHASE1'],Negative conversion rate among HPV-16 positive patients detected by tissue biopsy,Progression-Free Survival（PFS）
10354,NCT06096779,Percentage of Participants with Adverse Events,2024-03-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change From Baseline in IL46 Scores
10355,NCT06185556,Local control,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Cost-effectiveness ratio (ICER) per patient
10356,NCT01908478,Maximum-tolerated dose (MTD) of veliparib based on the incidence of dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I),2013-10-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change in PAR [Poly(ADP-ribosyl)ation] levels in peripheral blood mononuclear cells
10357,NCT01710215,Cost: Cost per-patient effectively screened.,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,Cost: Incremental costs for the FIT and Colo strategies relative to the Usual Care strategy.
10358,NCT01877096,Screening colonoscopy completion,2013-08,COMPLETED,INTERVENTIONAL,['NA'],,Psychological mediators
10359,NCT00418938,Progression-free Survival (PFS),2006-11-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
10360,NCT01396668,Time to progression,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,clinical benefit rate
10361,NCT05169528,6-minute-walk-test,2020-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Patient Satisfaction Survey
10362,NCT02809898,Pathological diagnosis of gallbladder polyps （Cholesterol / Adenoma / Others）,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],,Tumor status （worse/ maintain/ better）
10363,NCT01130337,Percentage of Participants With Disease-free Survival (DFS) at Month 18,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Objective Response
10364,NCT06272214,2-year DFS,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Recurrence
10365,NCT00887822,Overall Survival,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Cycle 1 in EORTC QLQ-STO22 Scale Over Time
10366,NCT02872519,Number of lesions detected by (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET imaging before and after neoadjuvant chemotherapy treatment,2018-06,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Conditional predictive models of imaging performance and agreement
10367,NCT06260943,Proportion of Participants Enrolled in Clinical Research,2024-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
10368,NCT01705002,Pharmacokinetic (PK) profile of PROMITIL,2012-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Toxicity profile of PROMITIL
10369,NCT05176860,CBCT Image Quality,2022-12-20,COMPLETED,INTERVENTIONAL,['NA'],,Patient Experience
10370,NCT04568330,Scale,2014-03-21,COMPLETED,INTERVENTIONAL,['NA'],Scale,Scale
10371,NCT05171075,"Time to first event of centrally adjudicated VTE recurrence consisting of new proximal deep venous thrombosis, new pulmonary embolism (PE) or fatal PE, including unexplained death for which PE cannot be ruled out",2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Net clinical benefit defined as survival without VTE recurrence, or major or CRNM bleeding"
10372,NCT04999072,Relapse free survival,2020-04-19,UNKNOWN,OBSERVATIONAL,['NA'],,
10373,NCT00610389,Response rate,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Immunological response
10374,NCT01719926,Number of dose limiting toxicities at each dosage cohort,2012-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Efficacy
10375,NCT06265883,Time to progression (TTP),2019-07-01,COMPLETED,OBSERVATIONAL,['NA'],,treatment-related adverse events (TRAEs)
10376,NCT03565029,Distant Relapse-Free Survival (DRFS),2018-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patient reported outcomes
10377,NCT04713618,Change in sexual function,2021-01-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Change in vaginal microbiome
10378,NCT04589975,Conversion to open rate: predictive factors oncological outcomes,2000-01,COMPLETED,OBSERVATIONAL,['NA'],,
10379,NCT05967910,Effect of Chronic stress on efficacy of immune checkpoint inhibitors,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],The correlation between peripheral immune cells signature and chronic stress and the efficacy of ICIs,Effect of chronic stress on quality of life
10380,NCT03366155,Response rate (RR),2019-06-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Extra-hepatic progression-free survival
10381,NCT03174574,"Genomic and risk factor differences among family members who share identical predisposing CDKN2A gene mutations, with different phenotypes; will discover patterns of tumorigenesis, tissue specificity, gene-gene, and gene-environment interactions.",2016-08-17,COMPLETED,OBSERVATIONAL,['NA'],,
10382,NCT02250209,3-year disease-free survival (DFS),2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Prognostic value of biomarkers
10383,NCT01360541,Prevalence of low grade dysplasia 3 years after randomization,2010-12-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Detection rate of dysplasia and Barrett's oesophagus with the confocal endomicroscopy technique
10384,NCT05701553,Incidence of adverse events,2023-01-26,RECRUITING,OBSERVATIONAL,['NA'],,12-month survival rate
10385,NCT05849571,Children's International Mucositis Evaluation Scale (ChIMES),2023-03-01,COMPLETED,INTERVENTIONAL,['NA'],,
10386,NCT05920928,Clinical complete response,2023-09-23,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
10387,NCT03627728,PFS1,2018-06-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,biomarker evaluation
10388,NCT05458388,Early gastric cancer detection rate,2022-07-12,RECRUITING,INTERVENTIONAL,['NA'],,
10389,NCT01886287,Number of Participants With Improved Frequency of Diarrhea,2013-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Rate of Progression Free Survival (PFS) at 6 Months
10390,NCT01395667,Maximally tolerated dose,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Improved rate
10391,NCT02510378,percentage of patients undergo R0 surgery during the follow-up,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The rate of early toxicity of radiotherapy according to the NCI Common Toxicity Criteria for Adverse Effects (version 3.0)
10392,NCT01934634,Percentage of patients with Dose-Limiting Toxicities,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Objective Response Rate
10393,NCT01534637,Number of Patients With Gastrointestinal Toxicities (Grade 3 and 4 Nausea and Vomiting) Associated With Delivering Fluorouracil/Gemcitabine Hydrochloride-based Chemotherapy With Upper Abdominal Radiation,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Impact of Aprepitant/5HT-3 Antagonist Therapy on the Patient Quality of Life as Measured by the Number of Patients Taking Anti Nausea Drugs
10394,NCT03071458,Genetic and transcriptomic landscape,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,Validation of the molecular classification by integrative analysis
10395,NCT06228963,6-months CR rate,2024-03,RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory biomarkers,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
10396,NCT02871245,Number of participants and classification with operation-related adverse events as assessed by CTCAE v4.03.,2016-09-21,UNKNOWN,INTERVENTIONAL,['NA'],,Immune cell number ratio in blood.
10397,NCT00003677,Number of Patients with Toxicity,1999-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10398,NCT02639065,Percentage of Participants With One-Year Relapse Free Survival (RFS) With Post-Operative Durvalumab,2016-04-27,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Adverse Events as a Measure of Safety and Tolerability
10399,NCT04730388,predictive factor for progression-free survival,2021-01-18,UNKNOWN,OBSERVATIONAL,['NA'],,
10400,NCT05840263,Extract key themes to integrate into preliminary drafts,2023-05-31,RECRUITING,OBSERVATIONAL,['NA'],,
10401,NCT00741676,2 year survival,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,efficacy and clinical out come
10402,NCT05162755,Assessment of antitumor activity using RECIST v1.1 (Dose expansion part),2021-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS) (Dose escalation and dose expansion parts)
10403,NCT02889328,Disease control rate,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profile by the NCI-CTCAE v4.03
10404,NCT02437916,AMG 228 half-life (t1/2),2015-04-21,TERMINATED,INTERVENTIONAL,['PHASE1'],,Changes in numbers of cytotoxic T lymphocytes (CTL)
10405,NCT04970056,Development of PDAC,2020-09-18,RECRUITING,OBSERVATIONAL,['NA'],,
10406,NCT01992406,Transanal specimen extraction possible or not,2013-11,UNKNOWN,OBSERVATIONAL,['NA'],,quality of life
10407,NCT04692987,Number of participants with colorectal cancer screening completion,2021-03,UNKNOWN,INTERVENTIONAL,['NA'],,Barriers towards the colorectal cancer screening uptake
10408,NCT01266187,Disease free survival,2011-07,TERMINATED,INTERVENTIONAL,['NA'],,Secondary objectives
10409,NCT00310115,Number of Patients with Smoking Abstinence,2002-04,COMPLETED,OBSERVATIONAL,['NA'],,Number of Cigarettes Smoked Daily
10410,NCT04117100,Assess the number of patients with intraprocedural bleeding,2018-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
10411,NCT04228614,prediction accuracy of recurrent rate,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Mutation Consistency of tissue and blood sample
10412,NCT01473303,Convergent validity of each selected PRO-CTCAE item (phase II),2012-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Responsiveness (sensitivity to change) of PRO-CTCAE (phase II)
10413,NCT06185907,Duration of stay,2021-04-15,COMPLETED,OBSERVATIONAL,['NA'],,
10414,NCT02455648,Post-operative stenosis,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,
10415,NCT00114244,Objective Response (OR = CR or PR) as Determined by the RECIST Criteria,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival
10416,NCT02386397,Limiting toxicity,2014-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10417,NCT06034860,Proportion of participants with objective response,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Evaluate the immunogenicity of MT-8421 in patients with selected advanced solid tumors.
10418,NCT00006046,Number of Patients With Dose-limiting Toxicities (DLTs),2000-07-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Patients With Tumor Responses
10419,NCT03719924,survival at 9 months,2019-03-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life (questionnaires)
10420,NCT01145404,Objective response rate (ORR),2010-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Biomarker analysis
10421,NCT02652663,Disease free survival,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10422,NCT01953419,ORR,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10423,NCT00867334,Number of Patients With Adverse Events,2009-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Stabilization or Reduction in Tumor Size
10424,NCT01326065,Long term outcome,2011-02,TERMINATED,OBSERVATIONAL,['NA'],,Quality of the surgical specimen
10425,NCT02485834,Overall Survival,2015-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Change in FDG-PET SUV Measures,Number of Participants Who Reported Grade 3 or Higher Adverse Events
10426,NCT06016400,Within two months from the start of chemotherapy,2021-06-14,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Length of hospital stay of patients in vitamin D treatment group and placebo group
10427,NCT02789709,Disease-free survival,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,Postoperative mortality
10428,NCT04281290,Evaluation of feasibility and safety,2020-07-13,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Survival
10429,NCT04292366,Number of residents participating in colorectal cancer screening,2020-10-02,COMPLETED,INTERVENTIONAL,['NA'],,
10430,NCT02218801,Number of post-operative complications,2015-05,COMPLETED,OBSERVATIONAL,['NA'],,Number of post-operative complications in the first 50 patients compared to the second 50 patients
10431,NCT02475772,Adverse events according to CTCAE criteria,2016-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Plasma concentrations of cisplatin and doxorubicin,Clinical benefit according to RECIST criteria
10432,NCT03598998,Overall response rate (ORR) according to Lugano classification (Phase II),2019-02-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of unacceptable toxicity assessed by NCI CTCAE version 5.0
10433,NCT03272659,fluorescence with photodynamic diagnostics (PDD) in colorectal cancer,2018-04-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Accurate depiction of the extent of disease burden by correlating pre-and post surgical results after neoadjuvant chemotherapy and radiation.,Detect malignant lesions
10434,NCT04889742,Local tumor recurrence,2024-05-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Patient reported quality of Life
10435,NCT00022139,Proportion of successes,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
10436,NCT06256705,"Clinical response defined by the PFS as the time measured from the day of first administration of PRRT to first progression or death at 18 months, whichever occurs first",2024-03-25,RECRUITING,INTERVENTIONAL,['NA'],,
10437,NCT01428752,prevalence of colorectal adenoma(any size),2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,prevalence of advanced adenoma
10438,NCT02264886,"Feasibility of the online, adaptive, MRI-guided SBRT",2015-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Patient-reported quality of life
10439,NCT01650428,Pathological Complete Response (PCR),2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumour Cell Density
10440,NCT00107341,Confirmed tumor response rate,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of response
10441,NCT00733746,Overall Survival at 2 Years,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response Rate
10442,NCT01653327,Change in Pain Score,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Analgesic Effect
10443,NCT03476057,cfDNA,2018-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,Tumor mutation burden
10444,NCT04137107,Chronic neuropathic pain response (Phase III),2020-05-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Incidence of adverse events, including duloxetine side effects of nausea, dry mouth, dizziness, somnolence, fatigue, and insomnia (Phase III)"
10445,NCT03459235,assessment of quality of life of patients operated for a rectal cancer (rectal resection) - Sexual sequelae (for men),2018-03-20,UNKNOWN,INTERVENTIONAL,['NA'],,
10446,NCT05319314,Recommended Phase 2 dose (RP2D) based on incidence of dose-limiting toxicities (DLTs) during 3+3 dose escalation study,2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Tmax: The time to reach maximum(peak) in peripheral blood or other body fluid drug concentration after single dose administration (days)
10447,NCT01933945,Overall survival (OS),2013-10-28,COMPLETED,OBSERVATIONAL,['NA'],Duration of treatment of sorafenib after TACE,TTP from initiation of sorafenib
10448,NCT04332705,Prevalence of Cryptosporidium,2020-06-30,RECRUITING,OBSERVATIONAL,['NA'],,Rate of development of a neoplastic lesion in the human explants
10449,NCT00856375,Kaplan-Meier Estimate of PFS by Central Radiological Review: ITT Population,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,PK Parameters of NKTR-102 or Irinotecan and Respective Metabolites
10450,NCT01084629,detection of dysplasic areas,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,
10451,NCT05007548,Correlation of the ICGR15 with the conventional liver function tests,2021-12-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Comparison of CTV and Ga68-Dolacga PET parameters in patients with PHLF
10452,NCT03181334,Increase in colorectal cancer screening rate of the 5 tested invitation approaches.,2017-09-05,COMPLETED,INTERVENTIONAL,['NA'],,
10453,NCT05278195,Overall Survival(OS),2022-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,Accuracy
10454,NCT03334890,mSEPT9 level,2016-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,"CR,PR,SD,PD"
10455,NCT04466124,Establish a cohort of liver cancer patients treadted with proton beam therapy.,2018-09-21,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
10456,NCT03470883,Complete long-term remission (> 12 months),2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Endoscopic description and anatomopathological results
10457,NCT03392103,The ratio of patients occured Grade 3 or higher adverse events,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,3-year overall survival probability
10458,NCT06038578,Progression free Survival (PFS),2023-10-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change from Baseline in Patient Reported Quality of Life assessed by Questionnaire - EuroQOL Five Dimensions questionnaire 3L (EQ-5D-3L) scores
10459,NCT03969784,percentage of microparticule,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,
10460,NCT00601510,Overall tumor response as assessed by RECIST,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Quality of life
10461,NCT01230697,Identify the value variations of hormones involved in phosphate homeostasis during sorafenib administration,2010-06,UNKNOWN,OBSERVATIONAL,['NA'],,Identify correlations between phosphate related hormones variations and patients outcome (TTP and overall survival)
10462,NCT00016250,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10463,NCT01838109,Body weight decrease rate 8weeks after discharge compared with preoperative body weight,2013-04,COMPLETED,INTERVENTIONAL,['NA'],ONS related gastrointestinal adverse event,serum albumin
10464,NCT06014944,cCR rate,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
10465,NCT02556619,Change in Health-Related Quality of Life (HRQoL),2019-04-02,UNKNOWN,INTERVENTIONAL,['NA'],,Cost Utilization
10466,NCT01853813,Response Rate,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],RECIST criteria and those defined by Chun,"evaluation of serum IL-8, bFGF, HGF, PlGF, SDF-1, MCP-3"
10467,NCT05526846,Effect of the intervention on participant's Healthy Plant-Based Diet Index,2024-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Secondary health gains associated with adopting a plant-based diet
10468,NCT05179837,Proportion of participants that have a lesion that can be adequately evaluated with OCT,2022-01-24,RECRUITING,INTERVENTIONAL,['NA'],,Weighted kappa
10469,NCT00006038,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10470,NCT05855200,Event-free Survival (EFS) Assessed by Blinded Independent Central Review (BICR),2023-08-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants with Anti-Drug Antibodies against Dostarlimab
10471,NCT04963088,ORR,2021-03-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free survival
10472,NCT00504322,Expression of CD40L and cytokines,2011-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10473,NCT05716594,Disappearance rate of pseudocyst（PDR） after stent implantation,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time of disappearance of pseudocyst after stent implantation
10474,NCT00265798,Objective Response Rate,2005-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
10475,NCT04039607,Overall Survival (OS),2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to Symptom Deterioration (TTSD)
10476,NCT00122720,"The functional capacity measured by postoperative fatigue, work capacity, balance, and quality of life",2003-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,Postoperative complications
10477,NCT03885219,6-month progression-free survival (PFS),2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (ORR)
10478,NCT00079066,Overall survival,2003-12-30,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety profile
10479,NCT04499924,Incidence of dose modifications (Phase 2 only),2021-03-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Utility index values as assessed by the EQ-5D-5L
10480,NCT00575523,Occurrence of dysrhythmias,2003-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Clinical complications
10481,NCT01275222,Progression-free Survival (PFS) - Phase II,2002-11-13,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Relationship Between Drug-induced Changes in Tumoral Metabolism, as Shown by Functional Imaging With 18F-fluorodeoxyglucose Positron Emission Tomography (FDC-PET), With Clinical Outcome and Changes in Molecular Pathology."
10482,NCT03524677,Early recurrence,2019-01-23,UNKNOWN,OBSERVATIONAL,['NA'],,N stage
10483,NCT02066272,The frequency of adverse events on induction of remission and maintenance treatment using anti-TNFs (including biosimilars) in a cohort of IBD patients,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10484,NCT04562727,DFS,2021-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Tumor reactivity assessment
10485,NCT05568017,objective response evaluation,2020-09-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,analysis of tumor specific circulating NET transcripts
10486,NCT01596283,Postoperative Complications,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Postoperative Length of Stay
10487,NCT00056537,Maximum Tolerated Dose (MTD) as a function of pre-treatment anti-SEA/E-120 levels,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to progression and Survival
10488,NCT03834701,Incidence of adverse events (AEs) after EUS-guided radiofrequency ablation (RFA),2019-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Rates of secondary surgery
10489,NCT02730663,Number of Participants With Clinical Success,2016-03-21,COMPLETED,INTERVENTIONAL,['NA'],,Other Adverse Events
10490,NCT00861094,Progression-free survival (Phase III),2008-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of life as assessed by EORTC QLQ-C30 (version 3) and EORTC QLQ-OES18 (Phase III)
10491,NCT04595604,Change in preoperative functional status - FVC by the end of rehabilitation,2020-09-07,SUSPENDED,INTERVENTIONAL,['NA'],,Change of alpha- and beta-diversity of fecal microbata
10492,NCT04150120,Cost-utility ratios,2019-10-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,EQ-5D-3L
10493,NCT01375088,NCI.CTC Scale,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,hyposalivation scale
10494,NCT05229003,ORR,2022-03-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,AEs
10495,NCT00981162,Maximum tolerated dose of everolimus (Phase I),2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Toxicity and adverse events as assessed by NCI CTCAE v3.0
10496,NCT05572788,Rate of post-procedure pancreatitis following EUS-guided fine needle aspiration of pancreatic cysts,2022-09-26,RECRUITING,INTERVENTIONAL,['NA'],,Length of hospitalization in any patient hospitalized with acute pancreatitis
10497,NCT05010434,ORR (objective response rate),2021-08-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse effects
10498,NCT00449137,Thymidylate synthase expression,2005-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10499,NCT01556815,Effectiveness of sorafenib in increasing the effectiveness of transarterial chemoembolization (TACE),2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Survival in the two treatment groups
10500,NCT02029157,Progression-free survival (PFS),2014-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall survival
10501,NCT01341756,Response of bleeding to radiotherapy,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Number of patients who develop anorexia, nausea, vomiting as per common toxicity criteria v3.0"
10502,NCT03749083,One year local recurrence rate in participants that test positive for ctDNA compared to participants that tested negative for ctDNA,2019-12-31,WITHDRAWN,OBSERVATIONAL,['NA'],,Median Fecal Incontinence Severity Index (FISI) score
10503,NCT05153746,Adenoma detection rate,2022-02-10,RECRUITING,INTERVENTIONAL,['NA'],,Flat adenoma detection rate
10504,NCT04503967,Objective response rate,2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
10505,NCT06126120,Participant non-adherence to 2-yearly colonoscopy check-up.,2024-01-17,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,The four most important challenges to having colonoscopy check-up for participants.
10506,NCT01647776,Efficacy of sDNA testing for the detection of advanced adenomas,2012-04-01,COMPLETED,OBSERVATIONAL,['NA'],,"To investigate the association of activated (phosphorylated) IRS1, AKT and mTOR with colon adenomas."
10507,NCT00817895,disease free survival,2008-12,COMPLETED,INTERVENTIONAL,['NA'],,overall survival
10508,NCT04079049,Survival,2020-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,
10509,NCT00630890,To determine the maximal tolerated dose of the Cyberknife radiosurgery boost,2007-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,To estimate disease specific and overall survival
10510,NCT00809081,To evaluate the impact of early postoperative enteral feeding,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,To evaluate the nutritional status
10511,NCT00541125,Toxicities by NCI-CTC v. 2.0,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to treatment failure
10512,NCT04606992,Resection margin,2020-02-10,COMPLETED,INTERVENTIONAL,['NA'],,Complication rate
10513,NCT01355107,measurement of selenium levels in hcv- infected patients,2011-04,COMPLETED,OBSERVATIONAL,['NA'],,selenium levels and MELD(Na)score
10514,NCT00570713,Overall Survival (OS),2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Best Overall Response Rate
10515,NCT01789229,Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.,2003-09,RECRUITING,OBSERVATIONAL,['NA'],,
10516,NCT05985798,Overall survival (OS),2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse Events (AEs)
10517,NCT00436657,Maximum Tolerated Dose (MTD) of continuous hyperthermic peritoneal perfusion (CHPP) with cisplatin in children with peritoneal cancer,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10518,NCT04472767,Complete Response Rate,2020-08-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Conversion Rate to Resectable
10519,NCT06313268,Adverse events,2022-04-21,RECRUITING,OBSERVATIONAL,['NA'],,
10520,NCT03239158,Relief degree of tumors,2017-09-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall survival（OS）
10521,NCT00003298,Grade 3 or Higher Toxicity Incidence on Step 1,1999-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
10522,NCT00828984,Difference (After Treatment Minus Before Treatment) of EGFR Expression,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in E-cadherin Expression as Measured in Endoscopically Normal (Non-ACF) Mucosal Biopsies
10523,NCT00237900,"Parts 2 and 3: Safety and tolerability of gefitinib in combination with 5-FU, LV and radiotherapy",2003-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Exploratory outcome: Parts 2 and 3: sVEGF levels, EGFR activation, Biomarkers such as cyclin D1, IL-1, GI-associated TOP2A, GAS, EST AA552509"
10524,NCT00134589,Completion of colorectal cancer screening,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Patient's intention to ask/patient asking medical provider for colorectal cancer screening
10525,NCT02080260,Number of Patients Progression Free and Surviving at 16 Weeks as a Percent of All Enrolled Subjects,2014-06-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control
10526,NCT03623464,Readmission rate,2017-05-31,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life: Return to Baseline Function-Activities of Daily Living (ADLs)
10527,NCT01643447,the overall survival rate of each group,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,
10528,NCT01377220,,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10529,NCT02081547,IPC status,2012-04,UNKNOWN,OBSERVATIONAL,['NA'],,Survival
10530,NCT01229813,To demonstrate that maintenance treatment with bevacizumab + erlotinib following first line chemo- and anti-angiogenetic therapy results in a significant increase in progression free survival (PFS) compared to treatment with only bevacizumab.,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,To explore the activity of bevacizumab and low dose metronomic capecitabine in patients with KRAS mutated tumors.
10531,NCT05874726,Tissue sample repository,2023-07-19,RECRUITING,OBSERVATIONAL,['NA'],,
10532,NCT05374369,Tumor detection rate in the positive screening results,2022-03-29,COMPLETED,OBSERVATIONAL,['NA'],,
10533,NCT00436410,Comparison of the impact of distribution time and histology on accumulation of treatment particles in tumor vs normal tissues,2006-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Long-term toxicity of treatment as assessed by CTCAE v3.0
10534,NCT01895257,Time to progression (TTP1 overall),2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],SIR-spheres treatment,Overall Survival (OS)
10535,NCT02537171,Progression-free survival (PFS),2015-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Events(AEs)
10536,NCT02425735,Reduced size of the tumors,2015-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10537,NCT05935384,Sensitivity of ctDNA to Detect Disease Progression,2023-10-25,RECRUITING,OBSERVATIONAL,['NA'],,Lead Time
10538,NCT05415709,Incidence of chemotherapy-related adverse events,2022-06-13,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Quality of life (QOL) assessment EORTC QLQ-C30
10539,NCT06248528,Overall survival,2019-12-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse effects
10540,NCT05642338,HGD/EAC,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,The rate of progression to HGD/EAC after a WATS-positive-biopsy-negative diagnosis for HGD/EAC
10541,NCT06283121,Objective response rate (ORR),2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
10542,NCT02287597,"Effectiveness: Second-line time to progression, in months",2014-11-13,COMPLETED,OBSERVATIONAL,['NA'],,"Safety (composite outcome measure): Incidence, nature and severity of all serious adverse events reported in second line mCRC treatment with Avastin plus chemotherapy and information on outcome and action taken with the drug"
10543,NCT02867592,Objective Response (Osteosarcoma Stratum),2017-05-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Change in Immune Biomarkers,Overall Survival (OS)
10544,NCT03403296,overall survival(OS),2016-07-13,COMPLETED,OBSERVATIONAL,['NA'],,
10545,NCT04616495,five year overall survival (OS),2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Quality of life using EORTC questionnaires: QLQ-C30
10546,NCT06138769,Progression-free survival,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
10547,NCT02799212,presence of postoperative ascites during the postoperative course,2018-01-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Postoperative morbidity on Renal failure
10548,NCT03632850,Decisional Conflict Scale,2019-02-19,COMPLETED,OBSERVATIONAL,['NA'],,Usability: System Usability Scale (SUS)
10549,NCT01609075,Proportion of patients with Avastin treatment discontinuation due to either disease progression or Avastin-related adverse events,2012-06,COMPLETED,OBSERVATIONAL,['NA'],,Progression-free survival (patients with treatment discontinuation due to disease progression or Avastin-related toxicity as compared to patients with treatment discontinuation due to other causes)
10550,NCT03503630,The primary objective of the study is to evaluate the pathologic complete response (pCR) rate following short-course radiation then mFOLFOX-6/COMPOUND 2055269,2018-07-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life of the patients in a neoadjuvant setting with COMPOUND 2055269 as assessed by FACT-C questionnaire
10551,NCT04314349,Correlation of radiogenomics,2020-08-01,COMPLETED,OBSERVATIONAL,['NA'],,Treatment response and survival
10552,NCT01510730,Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of gastric tumor.,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,effect of eradication of Helicobacter pylori on incidence of High grade dysplasia development after endoscopic resection of gastric tumor.
10553,NCT01197664,"Toxicity and tolerability of the paricalcitol regimen, as measured by calcium levels",2010-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Patterns of gene expression in tumor samples of patients who receive chemoradiation with and without paricalcitol
10554,NCT04485286,Ability of [68Ga]CBP8 to detect collagen deposition in areas of radiation injury.,2020-07-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,
10555,NCT02677597,PFS,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
10556,NCT00956254,Cmax of Fentanyl,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,AUC0-last of Fentanyl
10557,NCT01991379,Best Response Rate (phase II portion),2013-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,RR by EORTC criteria
10558,NCT04054713,Comparing the incidence of dysplasia by directed biopsies with acetic acid chromoendoscopy against taking non-directed protocolized biopsies( Seattle protocol) in patients with Barrett's esophagus.,2019-07-03,RECRUITING,INTERVENTIONAL,['NA'],,
10559,NCT05924282,5-year overall survival,2010-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Readmission
10560,NCT04178642,The survival rate without hepatic recurrence at 1 year,2020-09-22,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival
10561,NCT02937519,Number of Participants with Adverse Events as a Measure of Safety,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
10562,NCT04722055,Kappa coefficient,2021-01-26,COMPLETED,OBSERVATIONAL,['NA'],,
10563,NCT00955149,To examine the safety and tolerability of Tarceva (Erlotinib) in patients with primary sclerosing cholangitis and trisomy 7 on biliary cytology.,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,To assess among patients with primary sclerosing cholangitis and trisomy 7 the resolution of this cytologic abnormality following treatment with Tarceva (Erlotinib).
10564,NCT00162110,Evaluate the efficacy of Erbitux in the treatment of mucinous gastrointestinal adenocarcinoma involving the peritoneal surfaces based on clinical response rate.,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaulate surgically resected tumor specimens of the EGF receptor, mucins 1-6, and anglogenic indices such as vessel counts, VEGF expression, and Ki-67 expression. To evaluate the safety of Erbitux monotherapy in this patient population."
10565,NCT05426005,Objective response rate (ORR),2023-02-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Toxicity assessed using the The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0."
10566,NCT03899415,Safety evaluation based in Incidences of adverse events/serious adverse events,2019-04-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival rate
10567,NCT05658679,5-year survival rate,2016-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
10568,NCT01766479,"Number of patients in whom colorectal polyps and colorectal neoplasia have been detected by CT colonography, by adopting colonoscopy as gold standard, as a measure of efficacy.",2009-05,COMPLETED,INTERVENTIONAL,['NA'],,
10569,NCT04597970,Progression free overall survival，PFS,2020-10-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival， OS
10570,NCT01493206,clinical outcomes,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicities
10571,NCT02066064,G-EYE™ colonoscopy detection rate of adenomas and serrated lesions compared to the standard colonoscopy detection rate of the same.,2013-11,COMPLETED,INTERVENTIONAL,['NA'],,"polyp and adenoma detection, procedure times and safety"
10572,NCT04008511,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2019-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall response rate (ORR)
10573,NCT04245683,patient preferences for operative vs. non-operative management of rectal cancer,2020-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Patient adherence to surveillance protocols
10574,NCT03206151,Progression-free Survival (PFS),2017-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of anti-CMAB009 antibody
10575,NCT05869097,Overall Survival (OS),2020-11-01,COMPLETED,OBSERVATIONAL,['NA'],,Treatment-Related Adverse Events (TRAE)
10576,NCT00763425,Complete removal rate of colorectal polyps,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,Complication rate
10577,NCT00434161,Incidence of Cataract Development or Progression at Month 12.,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of Second Primary Malignancies or Other Malignancies
10578,NCT05856500,Appendicular skeletal muscle mass index(kg/㎡),2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Survival rate(%)
10579,NCT00574353,"the feasibility of a non-invasive method of detecting hypoxia, using F-FMISO-PET imaging in colorectal cancer patients.",2007-12,WITHDRAWN,INTERVENTIONAL,['NA'],,"determine volume of hypoxic tumor ROIs as a proportion of the entire tumor volume by this non-invasive imaging technique. ROIs are defined as those voxels, within the tumor volume defined on FDG PET/CT, for which the 18F-F-FMISO radioactivity concent"
10580,NCT04149613,microRNA expression Level,2018-05-25,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Dietary pattern
10581,NCT00885885,Objective response rate,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of molecular predictive markers for response.
10582,NCT03399110,DFS,2017-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,OS
10583,NCT02987699,Tumor response,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of of Patients developed Adverse Events
10584,NCT01106066,MTD/pathologic CR,2009-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10585,NCT00712790,Tumour response rate (liver ± any site).,2008-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Rate of downstaging to surgical resection or ablative therapy.
10586,NCT05028933,Adverse Event(AE),2021-09-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of circulating tumor cells (CTC) in peripheral blood
10587,NCT03172377,Cumulative incidence of persistent disease flares.,2017-05-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],,The decremental cost effectiveness ratio of this interval lengthening strategy
10588,NCT03700398,detect rate,2017-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,
10589,NCT03729687,Pathological complete response (pCR) rate and clinical complete response (cCR) rate,2016-07-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Long-term Adverse Events
10590,NCT01457976,"Survey respondents are presented with scenarios that seek to elicit views and attitudes on the concepts of personal responsibility, and the acceptability of financial incentives. The analysis will present these views and attitudes in aggregate form.",2011-09,WITHDRAWN,OBSERVATIONAL,['NA'],,
10591,NCT05088733,Survival rate,2020-07-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,quality of life (QOL) questionnaire
10592,NCT02273167,Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens),2014-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Polyp Detection Rate (Overall Colon)
10593,NCT00454116,Number of Patients With an Objective Disease Progression Event,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10594,NCT04845490,overall survival,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The positive rate of cancer cells of participants by exfoliative cytology examination
10595,NCT00379639,Best Overall Response,2006-07-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10596,NCT04123574,To characterize the quantitative and qualitative effects of BXCL701 on relevant immune effector cytokines and various immunological effector cells that are consistent with its known mechanism of action.,2019-10-15,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Genomic analysis before and after treatment.
10597,NCT00263055,Occurrence of dose-limiting toxicity,2004-08,COMPLETED,INTERVENTIONAL,['PHASE4'],,Long term toxicity
10598,NCT05847855,Sensitivity and specificity,2023-04-27,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Sensitivity and specificity in distinguishing different AJCC stages
10599,NCT00591045,5 year overall survival,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,R0 resection rate
10600,NCT00854971,Determine response rate,2009-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Determine safety of combination,time to treatment failure, overall survival time"
10601,NCT04771520,Overall response rate (ORR),2021-01-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
10602,NCT00962494,Health Behaviors,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Satisfaction with intervention
10603,NCT05643677,Progression-free survival (PFS),2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival（OS）
10604,NCT05025371,Overall survival,2021-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
10605,NCT04979663,Safety: the incidence of adverse events and serious adverse events,2020-12-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
10606,NCT00441311,Colorectal cancer screening recommendations,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,
10607,NCT00582452,To assess levels of intention in prophylactic colectomy among individuals at increased familial risk of colorectal cancer and to identify distinctive decision types based on profiles of perceived pros and cons of prophylactic colectomy;,2004-11,COMPLETED,OBSERVATIONAL,['NA'],,
10608,NCT03731442,"1-, 2-, 3-year overall survival",2018-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Toxicities according to RTOG and CTCAE criteria, including hematological and non-hematological toxicities"
10609,NCT02264665,Number of Participants With Adverse Events Leading to Death - Based on Treatment Received At-least Once During the Study,2015-05-12,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants With Types of Main Lines of Treatment Received During the Follow-up - Based on Targeted Therapy Group and Other Treatments Group at Inclusion
10610,NCT05408182,Postoperative pain score,2022-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Readmission rate
10611,NCT04912258,liver relapse-free survival,2021-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,response rate
10612,NCT00030342,Safety as measured by NCI common toxicity table at study completion,2001-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10613,NCT05493332,Conversion therapy success rate,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Patient reported outcome（PRO）
10614,NCT00792350,"Efficacy: status of tumor, patients performance status",2008-04,COMPLETED,OBSERVATIONAL,['NA'],,Reports of adverse events
10615,NCT02124148,Part E: Maximum Tolerated Dose of Prexasertib in Combination with LY3023414,2014-06-18,COMPLETED,INTERVENTIONAL,['PHASE1'],,"B2, E2, E3 Dose Expansion: Duration of Response"
10616,NCT04104633,Feasibility of molecular karyotype performed from liquid biopsy: copies number variations (CNV),2018-06-14,UNKNOWN,INTERVENTIONAL,['NA'],,Identification of patient's tumor genomic profile with blood sample
10617,NCT04712604,Acceptability of the intervention,2021-03-14,COMPLETED,INTERVENTIONAL,['NA'],,Change in quality of life
10618,NCT05093231,Objective Response Rate (ORR),2022-03-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,European Organisation for Research and Treatment of Cancer Pancreatic Cancer Quality of Life Questionnaire (EORTC PAN26)
10619,NCT01505166,Percent of Patients Who Survived After Treatment (Part 2),2012-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Alive Subjects (Part 1),
10620,NCT05104268,Change in Patient-Reported Oral Mucositis Symptom (The Modified PROMS Questionnaire) Pain Score,2024-11-30,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,"Change of oral mucositis grade in the World Health Organization Grade,(WHO Mucositis Grade)"
10621,NCT05318027,Number of triage visits,2023-05-22,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life scores
10622,NCT05355168,Major pathological remission rate,2021-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"1-, 2-, 3-year Disease-free survival rate (DFS)."
10623,NCT02383797,Number and severity of adverse events to vaccination,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
10624,NCT00153998,"Tumor response, defined as partial and complete response according to RECIST (Response Evaluation Criteria in Solid Tumors) - criteria in the intention-to-treat [ITT-] population",2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Molecular predictive markers for response and toxicity
10625,NCT00807911,disease-free survival,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"overall survival, pattern of failure,safety, quality of life"
10626,NCT01324882,Intubation of Cecum,2010-06,COMPLETED,INTERVENTIONAL,['NA'],,
10627,NCT01825603,"Recommended dose of ADH-1, defined as the highest dose tested which results in dose-limiting toxicities in no more than 1 of 6 evaluable patients based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",2013-04-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Survival
10628,NCT02671357,The incidence of severe complications,2016-03,COMPLETED,OBSERVATIONAL,['NA'],Delayed gastric emptying (DGE) rate,"Postoperative in-hospital, 30-day and 90-day mortality"
10629,NCT03058289,Rate and severity of treatment-emergent adverse events ≥ grade 3 attributed to study drug using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5),2017-02-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Exploratory: Overall Subject Outcome,"Key pharmacokinetic parameters, half live (hours) of each of the 3 main components of INT230-6."
10630,NCT04996914,1-year local control rate,2022-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Quality of life based on EORTC QLQ-HCC18
10631,NCT02238847,"Sustained Biliary Drainage, Defined as Absence of Reinterventions for the Management of Biliary Obstructive Symptoms",2015-03-24,COMPLETED,INTERVENTIONAL,['NA'],,"For Participants Not Undergoing Curative Intent Surgery, Sustained Biliary Drainage to One Year After Stent Placement"
10632,NCT00462501,Complete Pathologic Response,2007-03,COMPLETED,INTERVENTIONAL,['NA'],,
10633,NCT00117299,Response rate,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10634,NCT02844075,complete pathologic response rate,2017-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of adverse event based on CTCAE 4.0.
10635,NCT00479050,overall survival,2001-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,tumor response
10636,NCT01643824,local progression-free survival,2012-06-07,COMPLETED,INTERVENTIONAL,['NA'],,overall survival
10637,NCT05178628,The number of VTE events during the trial,2022-02-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Change from baseline in QoL
10638,NCT03292991,"Safety as per CTCAE 4.03, incidence of AEs and baseline change in liver function paired t-test or Wilcoxon signed rank test.",2015-06-09,UNKNOWN,OBSERVATIONAL,['NA'],,Liver transplantation rate
10639,NCT05755607,Rate of long-term Survival,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of postoperative complications
10640,NCT00849979,Validation of M. D. Anderson Symptom Inventory - Gastrointestinal (MDASI-GI) Questionnaire (Response),2008-07,COMPLETED,INTERVENTIONAL,['NA'],,
10641,NCT03466593,PaO2,2017-12-18,COMPLETED,INTERVENTIONAL,['NA'],,Lenght of stay
10642,NCT01473121,Descriptive analysis of clinical profile of newly diagnosed HCC patients,2012-08-13,COMPLETED,OBSERVATIONAL,['NA'],,Descriptive analysis of tumor properties
10643,NCT00020761,To determine the antitumor activity of irinotecan and paclitaxel in patients with unresectable adenocarcinoma of the esophagus and gastric cardia.,2000-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the toxicities of irinotecan and paclitaxel in this patient population.
10644,NCT03257163,Recurrence-free survival (RFS) rate,2017-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,
10645,NCT00677924,Number of Participants With Adverse Events (AEs),2008-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Best Overall Tumour Response (BOR)
10646,NCT05760430,Conversion rate,2022-12-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
10647,NCT01508000,Progression free survival,2013-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety
10648,NCT01260194,Median Progression Free Survival (PFS),2011-06,TERMINATED,INTERVENTIONAL,['PHASE4'],,Number of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Gastric Cancer
10649,NCT05316818,Rate of adverse events,2018-01-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival time (OS)
10650,NCT02418988,overall survival,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,progression-free survival
10651,NCT00130689,Overall Response Rate,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10652,NCT05561907,Time to initiation of solid oral intake without symptoms of GOO,2022-10-28,RECRUITING,INTERVENTIONAL,['NA'],,Chemotherapeutic regimen tolerance
10653,NCT04975620,Comparison of EUS-FNB sensitivity using two types of FNB needles,2021-08-01,COMPLETED,INTERVENTIONAL,['NA'],,Comparing the score of blood content n for each pass in two types of FNB needles.
10654,NCT04053985,PFS,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,DCR
10655,NCT00019344,,1997-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10656,NCT04152356,Disease-free Survival,2019-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall Survival
10657,NCT00072553,Response rate,2003-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
10658,NCT00076609,"Alphafetoprotein measurements every 3 weeks for first 3 courses, then every 6 weeks thereafter",2003-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival follow-up every 2 months
10659,NCT04603040,Objective response rate (ORR),2020-09-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],JS001 anti-drug antibody assessment,OS rates at 9 months and 12 months
10660,NCT00080002,,2003-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,
10661,NCT05503381,disease-free survival rate,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
10662,NCT00437268,Percentage of Participants With Progression-Free Survival (PFS) at 6 Months (PFS Rate),2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events (AEs) or Who Died
10663,NCT04535414,Determine if Bethesda protocol provides improved sensitivity for detection of early stage gastric cancer in CDH1 germline mutation carriers compared to the Cambridge method,2023-06-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,To estimate and compare the difference in crude cancer detection rates between endoscopy using the Bethesda protocol and the Cambridge method
10664,NCT01482442,Median overall survival time,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Health care costs
10665,NCT01196130,Rate of Successful Biomarker Determination,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,
10666,NCT05722275,The aera under the receiver operating characteristic curve (AUC) of intelligent analysis system,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],Overall survival,The accuray of intelligent analysis system in predicting peritoneal metastasis
10667,NCT04395118,Hepatitis C Screening,2020-08-15,WITHDRAWN,INTERVENTIONAL,['NA'],,Cost Per HCV Diagnosis
10668,NCT02045368,Maximum Tolerated Dose (MTD),2014-01-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,Disease Response based on RECIST Criteria
10669,NCT03069950,Resection rate assessed using RECIST (version 1.1),2017-02-28,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
10670,NCT05545046,Visual Analogue Scale (VAS),2019-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
10671,NCT00056446,Overall survival,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Tolerability and safety profile
10672,NCT06086002,Technique efficacy,2023-09-18,RECRUITING,INTERVENTIONAL,['NA'],,
10673,NCT01440855,Reported uptake of behavioral actions recommended in Facing Forward,2005-02,COMPLETED,INTERVENTIONAL,['NA'],,Usability of Facing Forward
10674,NCT01982227,Sensitivity (true positive) of the fluorescence ex vivo compared to histological analysis s detected by fluorescence ex vivo,2013-03,COMPLETED,OBSERVATIONAL,['NA'],,Specificity (true negative) of the in-vivo fluorescence compared to histological analysis s detected by fluorescence ex vivo PCI score with and without fluorescence
10675,NCT01348503,Number of Participants with Dose Limiting Toxicities as a Measure of Safety of the combination of lenalidomide and sorafenib.,2011-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,
10676,NCT05505370,Intubation of terminal ileum and cecum,2022-04-21,COMPLETED,INTERVENTIONAL,['NA'],,User feedback for operating characteristics of the device
10677,NCT04763824,Percent change in evidence based cancer screening,2020-11-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Participation rates in the Telementoring and Practice Facilitation Sessions,
10678,NCT02056548,Cumulative incidence rate of hepatitis B viral reactivation,2014-03,UNKNOWN,OBSERVATIONAL,['NA'],,Severity of reactivation of hepatitis B
10679,NCT05858736,Incidence of treatment emergent adverse events (TEAE),2023-07-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,"Overall survival (OS),"
10680,NCT02217891,qualitive data,2014-08,COMPLETED,OBSERVATIONAL,['NA'],,
10681,NCT01182272,Significant pathological changes,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Tolerance of liver resection after sorafenib tosylate treatment
10682,NCT02103322,AUC0-tau,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Fluctuation Rate
10683,NCT04058600,Hospital Anxiety and Depression Scale (HAD),2018-04-11,COMPLETED,INTERVENTIONAL,['NA'],,
10684,NCT04703101,Complete clinical response rate,2021-02-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Prediction of complete clinical response rate status by radiomics
10685,NCT05362617,ORR（objective response rate）,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,QoL（quality of life）
10686,NCT03806244,"Accuracy of Surgical stereotactic navigation defined as the distance, in millimetres, between the position of the surgical landmark and the position determined by the navigation system",2019-07-17,TERMINATED,INTERVENTIONAL,['NA'],,Number of intra and/or postoperative complication
10687,NCT05948449,Pathological complete response rate (pCR),2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
10688,NCT03095209,Serum inflammation markers,2017-02-24,COMPLETED,OBSERVATIONAL,['NA'],,Quality of life and pain
10689,NCT02930278,3-year disease overall survival rate,2016-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,Visual Analog Score for pain
10690,NCT02010801,Complete treatment,2012-04,COMPLETED,INTERVENTIONAL,['NA'],,adverse effect
10691,NCT02017366,overall survival from day of surgery,2018-10,WITHDRAWN,INTERVENTIONAL,['NA'],,postoperative weight loss
10692,NCT01843218,assess erectile dysfunction,2008-03,TERMINATED,INTERVENTIONAL,['NA'],,Evaluate objectively the presence of erectile dysfunction before and 12 months after the medico-surgical treatment of rectal cancer
10693,NCT01637350,,2012-08,UNKNOWN,OBSERVATIONAL,['NA'],,
10694,NCT00952497,The primary objective is to assess progression free survival (PFS). PFS will be measured from the date of first study drug administration to the date of first scan that first documents disease progression.,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Other efficacy variables are overall survival, overall response rate, safety and tolerability. Exploratory analyses may be performed to investigate the correlation of biomarker status with treatment effect and response."
10695,NCT05225038,"Change in participants physical capacity, as represented by hand grip strength",2022-06-13,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Physical capacity as represented by 6-Minute Walk Test
10696,NCT03533920,Objective Response Rate by independent evaluator,2017-10-25,COMPLETED,INTERVENTIONAL,['NA'],,
10697,NCT01076517,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
10698,NCT01134276,Incidence of Infectious Complications After Biliary Drainage,2010-08,COMPLETED,INTERVENTIONAL,['NA'],,Total Hospital Cost During Admission After Biliary Drainage
10699,NCT03450447,The first day of food intake of enrolled patients,2018-03-10,UNKNOWN,OBSERVATIONAL,['NA'],,The severity of stenosis
10700,NCT00334984,,2007-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
10701,NCT02933307,Expectations & experiences of care givers,2015-04,COMPLETED,INTERVENTIONAL,['NA'],Performed surgical procedure,System usability Scale
10702,NCT04012021,Evaluate the correlation between the characteristics detected by the MRI equipment and the histological composition of ex-vivo specimens from hepatic and pancreatic tissues and lesions,2019-05-24,UNKNOWN,INTERVENTIONAL,['NA'],,
10703,NCT00333099,Frequency and grade of mucositis,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,Cost
10704,NCT00033540,Response,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Survival Time for Participants With Relevant Biologic Markers
10705,NCT00004910,,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10706,NCT01437618,Progression-Free Survival,2009-06,COMPLETED,OBSERVATIONAL,['NA'],,
10707,NCT04361682,Predictive value of PIBs and drains amylase values for Pancreatic Fistula (PF),2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
10708,NCT00070265,Rate of complete resection (R0 resection),2003-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Positron emission tomography response rate
10709,NCT00448682,Number of Patients Achieving Clinical Response,2005-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants Experiencing Adverse Events
10710,NCT01887158,quality of bowel preparation rated according to a modified Ottawa bowel preparation scale,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,Lesion detection (type and lesion detection rate/patient)
10711,NCT05148572,Metabolome profiling for recurrence prediction.,2021-11-10,RECRUITING,OBSERVATIONAL,['NA'],,
10712,NCT03291054,Overall Response Rate,2018-02-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
10713,NCT00504153,Progression-free Survival Rate,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in Plasma Vascular Endothelial Growth Factor (VEGF) Levels Over 15 Days
10714,NCT05361161,OS,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
10715,NCT00881036,,2006-08,COMPLETED,OBSERVATIONAL,['NA'],,
10716,NCT05806931,Disease control rate (DCR):,2023-05-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of Response
10717,NCT04965454,Lack of Objective Response,2022-03-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control
10718,NCT05977478,Correlating tissue biochemical composition with the Raman spectra and histopathologic results to differentiate between the gastric disease states based on distinct features in the biochemical composition of pre-cancerous / cancerous lesions.,2022-10-27,RECRUITING,INTERVENTIONAL,['NA'],,
10719,NCT05396755,"occurrence of cholangiosepsis (defined by SEPSIS-3 criteria and diagnosis of acute cholangitis according to the Tokyo Guidelines), whatever occurs first.",2022-11-14,TERMINATED,INTERVENTIONAL,['NA'],occurrence of serious adverse events,Occurrence of unplanned hospital admissions (necessity and days free of hospital care within 6 months)
10720,NCT02268825,Safety of combination mFOLFOX and MK-3475,2015-01-23,TERMINATED,INTERVENTIONAL,['PHASE1'],,
10721,NCT03759548,Impact in Quality of Life during pharmacological treatments,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,Pharmacological treatment-related adverse events
10722,NCT04162158,Overall survival,2019-03-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease control rate
10723,NCT03528876,Progression free survival,2018-09-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Decline in quality of life
10724,NCT03277716,Overall survival (OS),2017-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Distant metastasis-free survival
10725,NCT00239200,"Primary Objective: To determine the response rate of metastatic or recurrent squamous cell carcinoma of the esophagus, when treated with lapatinib (GW572016)",2005-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Secondary Objective: To determine the toxicity of this regimen
10726,NCT04622423,Definition of the antigenic landscape and TCR repertoire of CRC and PDAC liver MTS,2019-11-06,RECRUITING,OBSERVATIONAL,['NA'],,Biobanking of biospecimens collected from CRC and PDAC patients and from healthy donors
10727,NCT05359042,Change in overall score of EQ-5D,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Predictive value of ED Visit and/or hospital admission
10728,NCT05238558,Summary of Adverse Events,2022-01-31,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10729,NCT02198274,Anti-tumour response,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Mean residence time (MRT)
10730,NCT05969171,PFS,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,DCR
10731,NCT05621629,Pena's questionnaires score before treatment,2022-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
10732,NCT02301286,5 year overall survival,2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to Treatment Failure
10733,NCT04949282,Overall response rate (ORR),2021-05-10,RECRUITING,OBSERVATIONAL,['NA'],,Health-related Quality of Life (HRQoL)
10734,NCT02184663,Health-related quality of life (HRQoL) at 16 weeks,2014-11-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,anxiolytic / antidepressant consumption
10735,NCT00737373,response (WHO criteria),2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10736,NCT05743426,Disease-free survival,2023-03-17,RECRUITING,OBSERVATIONAL,['NA'],,Quality of life Toronto Extremity Salvage Score (TESS)
10737,NCT04875793,The enrollment rate of individuals who underwent CRC screening in the intervention group vs. control group,2021-06-10,COMPLETED,INTERVENTIONAL,['NA'],,The percentage of individuals who screened positive and enrolled in colonoscopy for follow-up in the intervention group vs. control group.
10738,NCT02495051,presence of gastric and / or intestinal metaplasia diagnosed at histology,2010-02,COMPLETED,OBSERVATIONAL,['NA'],,"evaluation of actual other symptoms (respiratory, dysphagia)"
10739,NCT00386594,Elimination of high-grade dysplasia in Barrett's esophagus,2006-10,TERMINATED,INTERVENTIONAL,['NA'],,
10740,NCT01659619,degree of food stasis,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10741,NCT05991102,Overall response rate (ORR),2023-12-15,RECRUITING,INTERVENTIONAL,['NA'],,Acute and late toxicity
10742,NCT00939666,Local recurrence,2009-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of patients that chooses the minimal invasive strategies over standard surgery
10743,NCT00041691,,na,TERMINATED,INTERVENTIONAL,['PHASE1'],,
10744,NCT06060899,Intraoperative blood loss,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Length of hospital stay
10745,NCT01269229,complete resection (R0) rate for rectal and liver lesions.,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profile
10746,NCT03223142,Local control rate,2017-07,UNKNOWN,INTERVENTIONAL,['NA'],,Complication rate
10747,NCT03132740,Impact on complication of three dimensional visualization technique,2017-03-15,UNKNOWN,OBSERVATIONAL,['NA'],,Postoperative results of paraffin wax and immunohistochemical index
10748,NCT01319890,Return to normal activity/work,2011-07,UNKNOWN,OBSERVATIONAL,['NA'],,Cancer free survival
10749,NCT02295930,10 months-progression free rate (10m-PFR),2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall toxicity rate
10750,NCT00083226,Objective Response Rate Measured by Response Evaluation Criteria In Solid Tumors (RECIST),2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
10751,NCT01710293,Median Time from Initial Follow-up Delay to Follow-up Action,2017-01-27,WITHDRAWN,INTERVENTIONAL,['NA'],,
10752,NCT04943679,Incidence of adverse events,2021-06-15,RECRUITING,OBSERVATIONAL,['NA'],,12-month survival rate
10753,NCT04954521,OS,2021-06-30,RECRUITING,OBSERVATIONAL,['NA'],,PFS
10754,NCT00605722,Percentage of Participants With Progression-free Survival (PFS),2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
10755,NCT01671488,"To Evaluate the 6-month Clinical Complete Response Rate for Patients With Anal Cancer Treated With ADXS11-001 Mitomycin, 5-FU and IMRT.",2013-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To Evaluate Progression-free and Overall Survival for Patients With Anal Cancer Treated With ADXS11-001, Mitomycin, 5-FU and IMRT."
10756,NCT01400620,Proportion of WHO score 3-4 Oral Mucositis at a Cumulative Radiation Dosage of 50 Gy in the active and Placebo Groups,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of grade 2-3-4 Oral Mucositis as measured by the WHO scale at increasing increments of cumulative radiation exposure
10757,NCT05068206,Disease Control Rate (DCR),2021-10-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of disease remission (DOR)
10758,NCT03844347,Manifestations of Psychological Well-being Measurement,2019-10-21,RECRUITING,INTERVENTIONAL,['NA'],,Physical activity evaluation
10759,NCT02775461,Number of individuals with pancreatic diseases,2013-03-01,RECRUITING,OBSERVATIONAL,['NA'],,
10760,NCT03654950,Patient reported experiences in themes,2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Patient reported experiences divided into themes
10761,NCT02441998,"ASGE PIVI Thresholds: >90% NPV in rectosigmoid, > 90% agreement in surveillance intervals",2013-10,COMPLETED,OBSERVATIONAL,['NA'],,"Ex vivo overall and individual performance assessed by accuracy, sensitivity, specificity, positive predictive value, negative predictive value"
10762,NCT00324987,Progression Free Survival,2008-04,TERMINATED,INTERVENTIONAL,['PHASE3'],,Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
10763,NCT00576563,"The metabolic tumour response by PET scan will be determined according to the EORTC criteria (appendix 1)61. The pathological tumour response will be determined according to Dworak and Wheeler.62,63",2007-03,COMPLETED,INTERVENTIONAL,['NA'],,"Clinical examination(weight, performance status including the CTCv3.0 scale for acute and late reactions)"
10764,NCT04179084,Objective Response Rate (ORR),2019-08-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression-free survival (PFS)
10765,NCT02147301,Number of Patients Who Developed New Severe Adverse Events,2014-12-17,TERMINATED,INTERVENTIONAL,['NA'],,Median Area Under Curve (AUC)
10766,NCT05978349,Follow-up and record DFS of patients,2022-02-14,RECRUITING,INTERVENTIONAL,['NA'],,Follow-up and record OS of patients
10767,NCT05893056,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,2023-06-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
10768,NCT05725473,Clinical efficacy,2023-01-12,RECRUITING,INTERVENTIONAL,['NA'],,
10769,NCT00541112,Complete remission at ≥ 6 months by abdomino-pelvic-thoracic scan and a pelvic MRI,2007-10-29,TERMINATED,INTERVENTIONAL,['PHASE2'],,Predictive biomarkers of response to cetuximab
10770,NCT03172559,Difference between the two treatment arms in the proportion of participants that get to be transplanted (do not drop-out from the waiting list due to tumor progression).,2020-09,WITHDRAWN,INTERVENTIONAL,['NA'],,Difference between the two arms in disease-free survival
10771,NCT06241352,Decrease rate of CA19-9,2024-01-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate
10772,NCT02834169,Incidence of rare peritoneal surface malignancies,2010-10,UNKNOWN,OBSERVATIONAL,['NA'],,Impact of specific treatment strategies
10773,NCT00059930,"Correlate thymidylate synthase, dihydropyrimidine dehydrogenase, and ERCC-1 with survival and recurrence as measured by normal and tumor liver tissue",2003-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
10774,NCT04774952,Number of participants with dose limiting toxicities (DLTs),2021-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of Response (DOR)
10775,NCT05498051,Safety of SLN identification,2022-09-01,COMPLETED,INTERVENTIONAL,['NA'],,number of SLNs identified
10776,NCT02924714,Progression free survival (PFS),2017-01,SUSPENDED,INTERVENTIONAL,['NA'],,Quality of Life (QoL)
10777,NCT01189903,,2011-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
10778,NCT03336216,Progression free survival (PFS) by Blinded Independent Central Review (BICR),2017-12-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of clinically significant changes in lab assessment: Urine
10779,NCT00316914,Percentage of Patients With Oxaliplatin-induced Grade 2+ Chronic Neuropathic Adverse Event,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in Quality of Life (QOL) at One Month
10780,NCT05976282,Acceptability of Participants Who Feel FIT is an Acceptable Method of Screening,2016-03-15,COMPLETED,INTERVENTIONAL,['NA'],,
10781,NCT04611165,Progression-free survival (PFS),2019-11-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10782,NCT00844688,RECIST criteria for response evaluation by CT sacan abdomen in Target lesion of HCC,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity evaluation in accordance with CTCAE v3.0
10783,NCT02702323,Progress Free Survival,2016-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Toxicity as measured by CTCAE V4.0
10784,NCT01727921,Diagnostic accuracy,2013-01,COMPLETED,INTERVENTIONAL,['NA'],Complications,Technical success
10785,NCT00041340,Response rate,2002-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10786,NCT05983315,Correlation between endoscopic CONECCT's classification,2021-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
10787,NCT04142203,Analgesic consumption postoperatively,2017-05-16,COMPLETED,OBSERVATIONAL,['NA'],Adverse events after 23 h surgery,Analgesic use after 23 h surgery
10788,NCT03792347,Safety (Number of Participants With Grade 3 and Higher-grade Treatment-related Adverse Events),2019-01-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Radiographic Response
10789,NCT04231552,Pathological complete response,2019-11-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,3-year overall survival rate
10790,NCT00573911,The specific aim of this proposal will be: To assess the association between acid reflux and subepithelial fibroblasts in Barrett's esophagus.,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10791,NCT00711672,"Correlation of degree of ""narrative agreement"" with validated quality of life measures",2008-07,COMPLETED,OBSERVATIONAL,['NA'],,
10792,NCT05587088,Safety and efficacy,2022-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival
10793,NCT02919553,Rate of core tissue acquisition adequate for histologic analysis.,2018-01,WITHDRAWN,INTERVENTIONAL,['NA'],,"Cell block will be assessed of presence of any core tissue with intact architecture with this scale: graded 0 = none, 1 = present but marginal adequacy, 2 = present and adequate. Dimensions of the largest core will be noted if possible."
10794,NCT04237740,3 years recurrence-free survival rate,2020-05-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,5 years overall survival rate
10795,NCT05305820,Change in Cardiorespiratory Fitness,2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Change in Smoking Status,Change in Nutritional Status- Blood Screening
10796,NCT02185443,Local Progression Free Survival,2014-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity
10797,NCT00902759,FACIT (Facit Fatigue Scale) and Medical Outcomes Study Short Form-36 (MOS-SF-36) questionnaires,2009-01-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
10798,NCT01991873,Progression-free survival,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Health and skin related Quality of life
10799,NCT05714553,Number of patients achieving a reduction in tumour volume (Objective response rate; ORR),2023-03-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10800,NCT00428597,Progression Free Survival (PFS),2007-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,EORTC QLQ-C30 - Pain Subscale
10801,NCT06315855,oral health related quality of life,2024-03-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,comorbidities
10802,NCT01871545,SubStudy 2: Perfusion Fraction (PF),2013-06,COMPLETED,INTERVENTIONAL,['NA'],,Tumor Response
10803,NCT05174156,Objective Response Rate (ORR),2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AEs)
10804,NCT04460352,Eating restrictions,2020-11-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,Gender stratified analyses of all endpoints
10805,NCT01807936,Overall survival,2013-03-20,COMPLETED,INTERVENTIONAL,['NA'],locoregional recurrence and recurrence pattern,Disease free survival
10806,NCT04374175,Serum adiponectin concentration,2020-04-01,RECRUITING,OBSERVATIONAL,['NA'],,Serum adiponectin concentration
10807,NCT02320123,Intent to Discuss Hospice Care (Based on the Transtheoretical Stages of Change Model),2016-05-23,COMPLETED,INTERVENTIONAL,['NA'],,Health Care Utilization: Mean Number of Hospitalizations in Six Months by Group
10808,NCT02148731,Occurrence of Adverse Events,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,Performance of the brief screening tool
10809,NCT05261113,Outcome relevance of CE-IOUS,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Sensitivity and Specificity of CE-IOUS compared to other imaging methods
10810,NCT02371304,Recurrence free at 3 year follow-up,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Treatment related morbidity
10811,NCT03297255,Time of Death,2013-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Time of metastasis
10812,NCT04618692,Biliary complications after living donor liver transplantation,2020-12-02,COMPLETED,INTERVENTIONAL,['NA'],,Time to biliary complications
10813,NCT00083616,Duration of Response,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
10814,NCT04643366,Three-year disease free survival (DFS),2021-01-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients who do not require an ostomy at time of surgery
10815,NCT04097795,Costs,2019-07-01,TERMINATED,OBSERVATIONAL,['NA'],,Care-related burden among informal caregivers
10816,NCT03998202,Number of Chemotherapy Toxicities (Grade 3 - 5),2019-09-23,RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival
10817,NCT00959738,Severe stoma specific morbidity rate,2008-08,TERMINATED,INTERVENTIONAL,['NA'],Number of stoma bags and self-adhesive plates needed in the first month after the operation,Predictive factors for stomal complications
10818,NCT00003237,,1998-06-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10819,NCT03801083,Objective Response Rate (ORR),2019-02-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,EuroQol 5 dimensions 5 levels (EQ-5D-5L)
10820,NCT01188980,determine if early increase blood supply (EIBS)can predict presence of Dysplasia,2010-06,COMPLETED,OBSERVATIONAL,['NA'],,determine if EIBS can predict presence of BE in patients undergoing upper endoscopy
10821,NCT02430662,Number of participants with Adverse events,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival (OS)
10822,NCT05616494,Overall response rate (ORR) by Independent Review Committee (IRC),2022-12-06,RECRUITING,INTERVENTIONAL,['PHASE2'],Plasma concentration of docetaxel (free and total),Disease control rate (DCR) by IRC and investigator
10823,NCT05938504,Skeletal Muscle Index (SMI) change rate,2023-03-14,RECRUITING,INTERVENTIONAL,['NA'],,Oral nutritional supplement (ONS) sensory evaluation
10824,NCT01540344,Progression-free survival (PFS),2010-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Pathohistological regression
10825,NCT00675012,To determine the feasibility and safety of NGRhTNF administered at low (0.8 mcg/sqm) and high (45 mcg/sqm) doses in combination with a standard oxaliplatin-based regimen in two sequential cohorts of patients with metastatic colorectal cancer.,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluate the pharmacokinetic profile of NGRhTNF and to measure plasma levels of sTNF-RI and sTNF-RII
10826,NCT03791073,Predictive value of each protein contained in Cytolyt® for the positive diagnosis of pancreatic ductal adenocarcinoma,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,"Biomarkers that are prognostically significant on disease free or overall survival in patients with pancreatic cancer, identified using the survival analysis"
10827,NCT03650348,Incidence of DLTs and recommended Phase 2 dose (RP2D) of PRS-343 administered in combination with atezolizumab,2018-08-21,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Presence and/or concentration of anti-PRS-343 and anti-atezolizumab antibodies (anti-drug antibodies [ADAs])
10828,NCT05485909,Objective response rate (ORR),2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to disease progression (TTP)
10829,NCT04002479,Safety - Adverse events,2020-10-20,RECRUITING,INTERVENTIONAL,['NA'],,Change in quality of life: QLQ-PAN26
10830,NCT05975463,Objective response rate (ORR),2023-09-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
10831,NCT01924741,Morbidity and mortality (peripoerative),2013-08,UNKNOWN,OBSERVATIONAL,['NA'],Inclusion criteria by registry participants,Liver Growth as assessed by imaging-based volumetry
10832,NCT02209415,Number of patients eligible for treatment,2011-04,UNKNOWN,INTERVENTIONAL,['NA'],,
10833,NCT04583488,Maximum Tolerated Dose (MTD),2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival
10834,NCT05329597,Genotyping,2020-06-24,UNKNOWN,OBSERVATIONAL,['NA'],,
10835,NCT01360255,"comparison of liver cancer markers AFP, AFP-L3% and DCP before and after TACE",2010-05,COMPLETED,OBSERVATIONAL,['NA'],,progression- free - time
10836,NCT04089657,Disease control rate(DCR),2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events（AE）
10837,NCT06184555,postoperative complication,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
10838,NCT02120911,% of patients completing trastuzumab and pertuzumab treatment.,2014-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",SUV of pre-treatment trastuzumab-PET,Pharmacokinetics of pertuzumab and trastuzumab
10839,NCT01079780,Progression-free Survival,2011-01-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
10840,NCT00513266,Pathological complete response rate of lesions of less than or equal to 30 mm in size assessed by pathologic examination in resected specimens,2007-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity as assessed by NCIC criteria
10841,NCT05545436,"Pathological complete response rate (pCR, Becker criteria, TRG 1A)",2022-09-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,"R0 resection rate and objective response rate (ORR, RECIST 1.1)"
10842,NCT02721563,Objective response rate,2016-02-25,COMPLETED,INTERVENTIONAL,['PHASE4'],,Progression free survival
10843,NCT00338988,Number of Participants With Objective Response,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10844,NCT03334591,progress free survival(PFS),2017-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
10845,NCT00268840,Overall response rate,2001-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the frequency and severity of the adverse events related to the combination of gemcitabine and docetaxel
10846,NCT02942706,Progression Free Survival 1 (PFS1),2021-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of life (QoL)
10847,NCT02824185,Specificity of FCH-PET/MRI for the detection of preoperative lesions,2017-06-14,COMPLETED,INTERVENTIONAL,['NA'],,Costs avoided and induced by performing FCH-PET/MRI
10848,NCT04402424,Colorectal Cancer,2019-07-16,COMPLETED,OBSERVATIONAL,['NA'],,Other Significant Colorectal Disease
10849,NCT06202001,Objective Response Rate (ORR),2022-10-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety and tolerability by incidence, severity and outcome of adverse events"
10850,NCT01946061,3-year disease-free survival,2015-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,
10851,NCT01733147,Change in Esophageal Tissue PGE2 Levels,2012-11,COMPLETED,INTERVENTIONAL,['PHASE4'],,Change in Esophageal Macrophage Markers
10852,NCT04381130,Overall survival,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in quality of life assessed with European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 version 3.0
10853,NCT03572101,Quality of life (EQ-5D-5L scores),2018-01-11,COMPLETED,OBSERVATIONAL,['NA'],"Overall level of support received by patients/caregivers from homecare, cancer centre, long term care, hospital and hospice services at end of life","Patient-reported concerns (emotional, social/family/spiritual, practical, physical, mobility, nutrition, informational, other)"
10854,NCT02897375,Recommended phase 2 dose (RP2D) as the highest doses of palbociclib and cisplatin or palbociclib and carboplatin,2016-10-24,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic (PK) characteristics of cisplatin including maximum concentration (Cmax)
10855,NCT00503932,Maximum Tolerated Dose (MTD),2007-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10856,NCT00006103,overall survival,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10857,NCT02141906,Response,2015-01-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression
10858,NCT03548844,DFS,2018-05-24,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life
10859,NCT01924533,Overall Survival,2013-09-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of Response
10860,NCT01668849,Pain caused by oral mucositis,2012-08-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Level of immune biomarkers in mucosal tissue
10861,NCT04258956,"Participants Achieving 3-Month Progression-Free Survival (PFSR) Rate of participants who are progression-free at 3 months after the start of protocol therapy, using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria",2019-04-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10862,NCT02552017,Adenoma detection rate,2014-11,UNKNOWN,INTERVENTIONAL,['NA'],,Adenoma detection rate of individual endoscopist before and after trial commencement
10863,NCT05795595,Phase 2 (Cohort Expansion): Objective response rate (ORR),2023-03-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10864,NCT05430841,Diagnostic accuracy,2022-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Number of lesions
10865,NCT01148056,Bowel Quality of Life,2010-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Accuracy
10866,NCT01836926,Early Complications number,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,Clinical functional outcome
10867,NCT06193733,Disease-free survival,2024-02-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
10868,NCT00414271,Number of Participants With Pathological Response,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlation of CGH and Gene Expression Profile and Their Changes After Chemotherapy With the Same Clinical Outcomes
10869,NCT04874519,Build a Fibrolamellar Cancer/FLC registry,2021-11-24,RECRUITING,OBSERVATIONAL,['NA'],,
10870,NCT00711243,Response Rate in Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction (Phase II),2005-04-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity Profile
10871,NCT06200259,"Test the hypothesis that ""Spot Delete"" technique in proton therapy reduces late toxicity in low- and intermediate-risk prostate cancer patients",2024-01-08,RECRUITING,INTERVENTIONAL,['NA'],,
10872,NCT01236690,"The evaluation of the patient's respondence for the therapy is carried out every phase, according to RECIST:CR,PR,SD and PD.",2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10873,NCT00963352,3-year disease free survival (DFS),2007-01,UNKNOWN,OBSERVATIONAL,['NA'],,5-year overall survival (OS)
10874,NCT00162669,"The main response parameter will be the disease control rate, defined by the objective response and stable disease rate (Response Evaluation Criteria in Solid Tumors [RECIST criteria]) after two consecutive tumor evaluations during treatment.",2005-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Evaluation of vascular changes will be performed using Doppler ultrasound with injection of sonographic contrast agent
10875,NCT06006650,Pathologic complete response rate (pCR),2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival(OS)
10876,NCT01703390,Response,2012-12-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of adverse events during study treatment
10877,NCT04152018,Duration of Response (DR) for Dose Expansion,2019-11-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival
10878,NCT03627390,Sum CTC score,2014-12-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of registered adverse events
10879,NCT03478449,Migration of pN stage in gastric cancer patients,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,
10880,NCT04005339,"The efficacy of fluorouracil, leucovorin, and nanoliposomal irinotecan in advanced biliary tract cancers following progression on or intolerance of gemcitabine and platinum chemotherapy.",2019-07-29,RECRUITING,INTERVENTIONAL,['PHASE2'],"Archived tumor tissue using next-generation sequencing (NGS) and immunohistochemistry (IHC) in order to elucidate potential mutational biomarkers predictive of response to fluorouracil, leucovorin, and nanoliposomal irinotecan.","Maximum change in tumor marker, CA19-9."
10881,NCT00256321,Determine time to progression,2004-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Evaluate the expression of the Cox-2 on paraffin-embedded tumor sections from patients enrolled on the study and correlate expression with clinical response
10882,NCT03779035,Disease free survival (DFS) rate,2018-12-15,UNKNOWN,INTERVENTIONAL,['PHASE3'],,The rate of patients with hepatic or locoregional recurrence
10883,NCT00531297,Recurrence rate,2005-12-01,TERMINATED,INTERVENTIONAL,['NA'],,Perioperative mortality
10884,NCT05575765,"Tumor images of multimodal digestive endoscopy, combination of high-definition white light endoscopy, endoscopic cerenkov luminescence imaging (ECLI) and probe-based confocal laser endomicroscopy (pCLE)",2023-08-14,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
10885,NCT01665274,3-year DFS,2013-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,overall survival
10886,NCT06236321,To assess if subsets of Rectal Cancers can be correlated with FFC scan hydrogen ion dissociation curves,2022-11-04,RECRUITING,INTERVENTIONAL,['NA'],,To determine correlation between faecal microbial composition and response to neoadjuvant chemoradiotherapy
10887,NCT02414009,Progression-free survival of FOLFIRI versus CAPTEM,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life measured by EORTC FACT-C
10888,NCT02849717,The primary outcome measure for this study is fatigue assessed by the FACIT-F fatigue subscale..,2016-03,COMPLETED,INTERVENTIONAL,['NA'],,Quality of Life (QOL) on self reported psychological distress questionnaires: Spielberg State/Trait Anxiety Inventory (STAI Form Y-1).
10889,NCT04540159,Immune Checkpoint levels,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
10890,NCT00531115,Confirmed objective response rate,2007-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Treatment safety
10891,NCT03646110,Overall survival rate,2018-08-17,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative pulmonary complication
10892,NCT05916040,Response to therapy,2023-10-03,RECRUITING,OBSERVATIONAL,['NA'],,Anxiety and depression state via HADS
10893,NCT02847429,Progression-free survival (PFS) will be measured from the date of randomization to the date of the first objective radiological disease progression according to centralized committee assessment using modified RECIST version 1.1 or death.,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival (OS) will be measured from the date of randomization to the date of death from any cause. OS will be estimated using the Kaplan-Meier method.
10894,NCT05794841,Diagnostic performance of positive predictive value (PPV) and negative predictive value (NPV).,2023-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
10895,NCT03131921,Resting energy expenditure,2016-04-05,COMPLETED,OBSERVATIONAL,['NA'],,Total energy expenditure
10896,NCT06235164,pathological complete response,2019-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,major pathological response
10897,NCT01362790,Recommended Phase 2 Dose (RP2D) in Drug Lot FIL129J01,2011-05-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Count of Participants SS1P Cycles Received Following Onstudy,Duration of Response
10898,NCT05563922,Organ preservation rate at 3 years,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,5-year overall survival（OS） rates
10899,NCT04891016,pathological complete response rate,2021-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,disease-free survival
10900,NCT02185937,imatinib area under the curve,2014-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,number of adverse events
10901,NCT00177307,Progression Free Survival (PFS),2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"1-, 2-, and 3-year Overall Survival"
10902,NCT02905188,Number of Patients with Dose Limiting Toxicity,2019-03-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,Median T cell persistence
10903,NCT05359861,"Progression Free Survival (PFS) according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)",2022-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Serum concentrations of atezolizumab
10904,NCT03612674,Adenoma Detection Rate (ADR),2018-04-04,UNKNOWN,INTERVENTIONAL,['NA'],,Colonoscopists' ADR in the previous year
10905,NCT03009227,Overall survival,2017-02-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Quality of life in patients after D2 and D3 lymph node dissection using questionnaire
10906,NCT03404921,The procedure time,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,The rate of injury to the muscular layer
10907,NCT05786716,Durable Clinical Benefit (DCB),2023-03-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Mean change from baseline in the PedsQL 4.0 Standardised Area Under total Scale Score Curve (PedsSAUC) in parents from paediatric participants
10908,NCT03209076,Urinary dysfunction,2018-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Costs
10909,NCT04783844,Accuracy,2019-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10910,NCT01674907,Clinical/demographic patient characteristics at baseline,2010-03,COMPLETED,OBSERVATIONAL,['NA'],,Relationship between termination of Avastin treatment and time point of progression
10911,NCT04447092,Objective Response Rate,2020-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Immune-related response
10912,NCT05877599,Adverse events and serious adverse events,2023-07-27,RECRUITING,INTERVENTIONAL,['PHASE1'],,"Preliminary anti-tumor activity of NT-175 in subjects with unresectable, advanced, and/or metastatic solid tumors"
10913,NCT06210360,2-year Overall Survival Rate,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
10914,NCT01267695,Rate of disease recurrence at 2 years,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine the safety and tolerability of this drug in these patients.
10915,NCT00033748,Recurrence free survival,2001-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
10916,NCT02647177,Detection of early progression to Tumor,2015-05,RECRUITING,OBSERVATIONAL,['NA'],,
10917,NCT03494543,technical success,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,concordance of histology pre- and post endoscopi papillectomy
10918,NCT00834028,tumor progression,2007-02,COMPLETED,OBSERVATIONAL,['NA'],,
10919,NCT00827554,time-to-progression(TTP),2008-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Progression Free Survival (PFS)
10920,NCT01251666,Ratio of sensitivities (RSN) for detection of advanced neoplasias,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Positivity rate
10921,NCT03649035,Number of participants with feasible EUS-guided Cryothermal Ablation,2018-07-12,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Number of participants with treatment-related adverse events
10922,NCT03577808,Response of the rectal cancer organoids to irradiation and the same chemotherapy drugs as the corresponding patient.,2018-08-17,UNKNOWN,OBSERVATIONAL,['NA'],,Response of the rectal cancer patients to neoadjuvant chemoradiation.
10923,NCT06187597,Progression-free survival,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation between serum cytokines and overall survival and immune-related adverse events,Treatment-related adverse events
10924,NCT02790333,Pancreatic fibrosis accessed by histopathology and pancreatic stellate cell,2016-05,COMPLETED,INTERVENTIONAL,['NA'],,Readmission rate
10925,NCT01101906,Time to progression (TTP),2011-01-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Safety assessed via physical examination, vital signs, clinical laboratory tests, electrocardiograms (ECGs) and recording adverse events"
10926,NCT04985071,Pancreatic fistula,2021-08-18,RECRUITING,OBSERVATIONAL,['NA'],,Bleeding complication
10927,NCT02374931,Standard uptake value (SUV) measured as percent injected dose per cc,2015-04,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,IHC staining intensity in tissue samples
10928,NCT04466189,Establish a cohort of Pancreatic cancer patients treadted with proton beam therapy.,2018-09-21,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
10929,NCT01747096,Detection of Gastroenteropancreatic Neuroendocrine Tumors lesions in the initial assessment or during the search of recurrence.,2012-11,COMPLETED,INTERVENTIONAL,['NA'],Tolerance of 68-Ga-DOTANOC,Compare the diagnostic performance of PET / CT with 68Ga-DOTANOC with the standard process
10930,NCT04969029,3-year relapse-free survival,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
10931,NCT00469963,Tumor response,2003-12,TERMINATED,INTERVENTIONAL,['NA'],,Survival
10932,NCT03689231,Could the evolution of the initial liver tumor volume (on two follow-up CT scans / MRI over a period of 3 to 6 months) be predictive of progression-free survival according to the RECIST criteria?,2018-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,Could the evolution of the initial liver tumor volume (on two follow-up CT scans / MRI over a period of 3 to 6 months) be predictive of progression-free survival according to the RECIST criteria?
10933,NCT03606863,morbi-mortality,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
10934,NCT00008060,,2000-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10935,NCT00241722,To compare alvimopan with placebo for long-term safety and tolerability,2005-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Quality of life, pharmacokinetics, pharmacogenetics (dependent on results from other data)"
10936,NCT03674801,"Percentage of different managements according to the described method : The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon (Gastrointest. Endosc. 58, S3-43 (2003)",2019-02-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"""SF36"" questionnaire"
10937,NCT02089373,The percentage of cancer cells in biopsy samples,2014-03,COMPLETED,INTERVENTIONAL,['NA'],,
10938,NCT06125262,Overall survival and disease-free survival.,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,Event-free survival
10939,NCT05010226,To evaluate clinical benefit response (CBR),2021-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Impact on Quality of Life and Cost,
10940,NCT00544362,Tolerance to neoadjuvant therapy,2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Mortality
10941,NCT04011982,Determination of the correlation between clinical characterizations and biological characterizations of patients suffering from exocrine pancreatic cancer,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Comparison of healthy tissu and tumor stroma from primitive tumor versus from metastases
10942,NCT00457691,Progression-free Survival (PFS),2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in EuroQol (EQ) Visual Analog Scale (VAS) (EQ-VAS)
10943,NCT04518800,Incidence of degree 3-4 neutropenia in each cycle of chemotherapy,2020-08-18,UNKNOWN,INTERVENTIONAL,['NA'],,The proportion of patients receiving antibiotics during the entire chemotherapy period.
10944,NCT01966081,Measure of polyunsaturated fatty acids in adipose tissue lipids.,na,UNKNOWN,INTERVENTIONAL,['NA'],,
10945,NCT03474341,Histopathologic response,2018-04-09,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival.
10946,NCT02476045,Efficacy,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
10947,NCT05016869,progression-free survival (PFS),2022-04-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse events (AEs)
10948,NCT02071043,The primary study end point was the response rate of preoperative XELOX followed by surgery in gastric cancer patients with PAN involvement,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Grade 3 or 4 Adverse Events as a Measure of Safety
10949,NCT02899325,Sensitivity of 18F-FDGal in the diagnosis of HCC on per-patient basis,2019-10,WITHDRAWN,OBSERVATIONAL,['NA'],,Specificity of 18F-FDGal in the diagnosis of HCC
10950,NCT01321957,progression free survival rate,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life evaluated by questionnaire
10951,NCT00873756,Incidence and nature of dose-limiting toxicities,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Incidence of anti-dulanermin antibodies
10952,NCT03127007,Rate of complete pathological response,2017-04-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10953,NCT04812912,"Change in testosterone, inhibin B, steroid hormone binding globulin (SHBG) and FSH in young male patients (<50y) undergoing therapy for colorectal cancer",2021-03-18,RECRUITING,OBSERVATIONAL,['NA'],,
10954,NCT06258824,Diagnostic Value as measured by Area under the Curve (AUC) for candidate miRNAs,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
10955,NCT01335958,Nature of dose-limiting toxicities (DLTs) graded per NCI CTCAE v4.0,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Volume of distribution
10956,NCT00460603,Percentage of Participants With Objective Response: Phase 2,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change From Baseline in M.D. Anderson Symptom Assessment Inventory - Diarrhea (MDASI-D) Symptom Severity and Interference Subscale Scores at Day 1 of Cycle 2 Through Day 1 Cycle 42 and Follow-up: Phase 2
10957,NCT01762813,Cancer-specific survival,2013-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Recurrence-free survival
10958,NCT02853500,Capillary permeability (Ktrans) calculated by software that analyzes enhancement on post-contrast MRI.,2016-07,RECRUITING,INTERVENTIONAL,['NA'],,Time To Tumor Progression
10959,NCT04185779,Occurrence of colorectal neoplasia,2019-12-13,RECRUITING,OBSERVATIONAL,['NA'],,Number of participants who consent for future contact
10960,NCT00555620,Number of Participants With First-cycle Dose Limiting Toxicities (DLTs),2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS)
10961,NCT05018156,Genetics referrals,2021-11-10,COMPLETED,INTERVENTIONAL,['NA'],,Genetic testing
10962,NCT04716010,Percentage of Red Meat Containing Products,2021-10-18,COMPLETED,INTERVENTIONAL,['NA'],Ease of Store Use,Intention to Reduce
10963,NCT01462513,Comparative evaluation of recurrence-free survival (RFS) time and 3 year overall survival (OS) time between the treatment groups (L-BLP25 plus cyclophosphamide versus placebo and saline infusion).,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival time in a subgroup of MUC1 positive cancers
10964,NCT05442749,Efficacy of niraparib in patients with HR-deficient pancreatic cancer,2022-10-28,RECRUITING,INTERVENTIONAL,['PHASE2'],PD biomarkers of response and resistance to niraparib,Safety and tolerability of niraparib in pancreatic cancer patients
10965,NCT03469557,Host immunogenicity: BGB-A317 anti-drug antibody (ADA),2017-07-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10966,NCT06026800,Number of Participants with Adverse Events (AEs) [safety and tolerability],2023-09-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Cytokines Level [immunogenicity]
10967,NCT00044863,"Determine the response rate of cetuximab in patients with EGFR-positive, metastatic carcinoma",2002-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10968,NCT00516945,incidence of chemotherapy interruptions,2004-09,COMPLETED,INTERVENTIONAL,['NA'],,chemotherapy dose intensity reduction due to hepatitis B reactivation
10969,NCT06049511,World Health Organization Oral Mucositis Toxicity Scale,2021-08-15,COMPLETED,INTERVENTIONAL,['NA'],,Oral assessment guide
10970,NCT00003487,"Number of Participants With Objective Response, Stable Disease, Progressive Disease or Not Evaluable",1996-05-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,
10971,NCT05494320,neurotoxicity,2021-08-15,RECRUITING,OBSERVATIONAL,['NA'],,
10972,NCT02296203,percentage of patients achieving a decrease equal or more than 30% in the sum of the longest diameters of target lesions,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10973,NCT04506840,Strength,2020-01-21,RECRUITING,INTERVENTIONAL,['NA'],,Depression and anxiety
10974,NCT04736472,Penetrance: proportion of pharmacogenetic tests ordered by providers,2021-03-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Grade 3 or higher toxicity
10975,NCT00483834,Objective Response Rate,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10976,NCT00444782,Response rate (Partial and Complete Response) according to modified RECIST.,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Immune Response
10977,NCT01775514,"Number of Participants with Gastric Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region",2012-10,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants Categorized by Tumor Localization
10978,NCT03899636,Overall Survival,2021-02-23,RECRUITING,INTERVENTIONAL,['PHASE3'],,
10979,NCT04278274,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of AI prediction system and expert radiologists in prediction tumor response,2020-02-08,RECRUITING,OBSERVATIONAL,['NA'],,The sensitivity of AI prediction system and expert radiologists in prediction tumor response
10980,NCT05544812,AE,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,OS
10981,NCT02173756,change in pain of mucositis before and after meal,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Evaluation of the local tolerance and other topical treatment taken throughout the mucositis
10982,NCT04225364,Pathologic complete remission (PCR),2020-01-17,COMPLETED,INTERVENTIONAL,['PHASE2'],perioperative adverse events,Overall survival (OS)
10983,NCT02861300,PHASE 2: Number of patients with response to treatment,2016-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PHASE 1: proportion of patient who respond to treatment
10984,NCT05497739,The incidence of peritoneal metastasis,2022-06-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,The safety
10985,NCT05782608,Assessment of Pain,2023-04-01,COMPLETED,INTERVENTIONAL,['NA'],,
10986,NCT03151759,Matrilysin levels,2002-11-06,COMPLETED,OBSERVATIONAL,['NA'],,
10987,NCT06060106,Recurrence free survival (RFS),2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Post-operative hospitalization days
10988,NCT03069833,"Sensitivity, Specificity, False Positive, False Negative",2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,
10989,NCT02806037,localization rate of liver tumor,2015-11,COMPLETED,OBSERVATIONAL,['NA'],,
10990,NCT02767557,Overall survival at 6 months,2017-01-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life (Quality of Life Questionnaire C30 (QLQ-C30) Version 3.0).
10991,NCT02497157,Response rate (RR) by response evaluation criteria in solid tumors (RECIST v1.1),2015-05-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Deepness of response (DoR),Incidence of adverse events
10992,NCT03517176,Optimal Biological Dose (OBD) of CEND-1 when given in combination,2018-07-31,COMPLETED,INTERVENTIONAL,['PHASE1'],Immunohistochemical assessment of tumor biopsies for the expression of Neuropilin-1 in order to study if the response to CEND-1 therapy can be predicted based on the Neuropilin-1 expression level,Preliminary evidence of anti-tumor activity of CEND-1 when given in combination with nabpaclitaxel bound and gemcitabine by objective radiographic assessment according to RECIST 1.1
10993,NCT00171977,To evaluate the relapse-free survival (RFS) in patients receiving postoperative adjuvant therapy,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,Safety
10994,NCT00022373,,2000-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
10995,NCT02965521,Adherence,2017-04-10,COMPLETED,INTERVENTIONAL,['NA'],,Change in fasting glucose
10996,NCT05862181,Overall Survival (OS),2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Duration of Response (DoR)
10997,NCT05036265,Prognostic factors,2011-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
10998,NCT00937456,To decrease postoperative major 30-days morbidity from 45% in the open arm to 25% in the laparoscopically-assisted arm.,2009-10-07,COMPLETED,INTERVENTIONAL,['NA'],,economical interest of the surgical technique apprehended through a hospital point of view
10999,NCT06178809,The advance time of ctDNA dynamic detection compared with AFP+ imaging in monitoring of primary hepatocellular carcinoma recurrence or progression,2023-12-25,RECRUITING,OBSERVATIONAL,['NA'],,
11000,NCT02460432,Cumulative stent patency during 6months after stent placement,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
11001,NCT01442506,diagnostic yield of targeted biopsies with high definition endoscopy using i scan virtual chromoendoscopy and acetic acid guided biopsies,2009-04,UNKNOWN,OBSERVATIONAL,['NA'],,
11002,NCT04609592,Measure Complication free Surgery,2021-03-17,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
11003,NCT01896986,Immunogenicity to HPV Vaccine Gardasil,2012-03,TERMINATED,OBSERVATIONAL,['NA'],,
11004,NCT03840239,Rate of clinical complete response,2018-12-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,5 year overall survival
11005,NCT04181931,"Progression-free survival, PFS",2019-12-16,RECRUITING,INTERVENTIONAL,['NA'],,"Overall survival, OS"
11006,NCT05414448,ADR,2023-03-07,RECRUITING,INTERVENTIONAL,['NA'],,False positive rate
11007,NCT04616183,Best overall response (complete response [CR] + partial response [PR]),2020-12-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of adverse events
11008,NCT00410462,"Six-month progression-free survival, in terms of complete response, partial response, or no change",2006-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
11009,NCT03880877,Progression-free survival,2019-02-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Duration of treatment
11010,NCT06048133,"Estimate the progression free survival (PFS) with gemcitabine, cisplatin, quemliclustat (AB680) and zimberelimab (AB122) in patients with advanced BTCs.",2024-03-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Evaluate safety of the proposed drug combination.
11011,NCT00670553,Establish Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD),2008-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety profile of oral LBH589 when given in combination with standard Radiotherapy
11012,NCT03191110,Quality of life (EORTC QLQ-C30),2010-08-03,RECRUITING,OBSERVATIONAL,['NA'],,Co-morbidities
11013,NCT04364373,5-year overall survival,2020-03-31,RECRUITING,INTERVENTIONAL,['NA'],,Late postoperative complications rate
11014,NCT02238769,SUVratio of FECH PET,2014-07,UNKNOWN,OBSERVATIONAL,['NA'],Data analysis,Patients' lifespan
11015,NCT01663272,Maximum Tolerated Dose,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Median Progression-free Survival (PFS)
11016,NCT01049880,"Blood cell counts (neutropenia, thrombocytopenia) and serum chemistries (liver function tests, creatinine)",2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Survival
11017,NCT04115163,Overall response rate (ORR),2020-06-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
11018,NCT03781960,Objective Response Rate,2019-07-31,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
11019,NCT00352755,Safety and Tolerability of the Planned Treatment Regimen as Measured by Number of Participants With Grade 3 or Higher Adverse Events,2006-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
11020,NCT03652896,prognosis,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA'],volume of transfusion,hospital stay
11021,NCT01334112,Response rate,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety
11022,NCT01292356,Main criteria is the variation of skin pro-inflammatory cytokines in pre and post-therapeutic punch skin biopsies,2010-12-20,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11023,NCT03373188,Evaluate treatment effects of the study drugs on tumor cluster of differentiation 8+ (CD8+) T cell infiltration between the treatment groups.,2017-12-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Incidence of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events scale version 4.0
11024,NCT03320317,Length of stay,2018-03-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Complication rate
11025,NCT00438256,Number of Participants With Grade 3 or Greater Toxicity in Phase II,2007-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Treatment Related Serious Adverse Events
11026,NCT03099629,Changes of forced vital capacity (FVC),2015-03,COMPLETED,INTERVENTIONAL,['NA'],,Changes of dyspnea using Modified Borg Dyspnea score
11027,NCT04756648,Adverse Event of Special Interest （ AESI）,2021-03-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,Antitumor efficacy-Duration of disease control (DDC)
11028,NCT05700656,Objective response rate (ORR),2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"RNA sequencing, THG-b signaling, other"
11029,NCT06173375,Proportion of Follow-up colonoscopy after abnormal stool blood test result,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Number of colorectal cancer cases detected
11030,NCT01507545,Progression-Free Survival (PFS),2012-03-27,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Biomarkers Based OS, Within Treatment Group"
11031,NCT02868632,Overall Survival,2016-08-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Immune-related Response Criteria (irRC)
11032,NCT00565370,Progression-free Survival,2007-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity Profile (According to National Cancer Institute Common Terminology Criteria for Adverse Event Version 3.0)
11033,NCT02181556,Rate of Patients Alive and Progression-free 6 Months After Inclusion.,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival
11034,NCT02425657,MCSAT (Mayo Clinical Skills Assessment Tool),2016-09-14,UNKNOWN,OBSERVATIONAL,['NA'],,Endoscopy training computer generated data - Total score
11035,NCT04890171,3-year disease-free survival in the ITT population,2021-06-11,RECRUITING,INTERVENTIONAL,['NA'],,Cost-effectiveness measured with Incremental cost effective ratio (ICER)
11036,NCT04219332,Total Number of Retrieved Lymph Nodes,2019-12-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,3-year overall survival rate
11037,NCT02852161,Diagnostic accuarcy,2016-07,COMPLETED,INTERVENTIONAL,['NA'],,comfort
11038,NCT01527409,"Changes from Baseline in Exercise, Diet, and Posttraumatic Growth Inventory(PTGI)",2012-02,UNKNOWN,INTERVENTIONAL,['NA'],,Cancer Belief System(CBS)
11039,NCT03849352,"To evaluate whether patients who have undergone CRC treatment are able to comply with remote follow-ups using telephone reviews and digital technology to help promote and track individual healthy lifestyle, diet and PA changes.",2019-03-18,UNKNOWN,INTERVENTIONAL,['NA'],,To ascertain whether there was any change in diet and lifestyle factors from baseline to end of intervention (2 months)
11040,NCT03253822,CRC screening participation,2017-08-15,COMPLETED,INTERVENTIONAL,['NA'],,Ethnicity
11041,NCT00680420,Gene expression profile is 95% accurate in diagnosis of malignancy,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,
11042,NCT03645148,Number of participants experiencing clinical and laboratory adverse events (AEs),2017-10-24,COMPLETED,INTERVENTIONAL,['PHASE1'],Peripheral blood T cell receptor sequencing analysis,Progression Free Survival
11043,NCT05559151,mortality rate,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
11044,NCT01520324,Intraepithelial Neoplasia (IN) Detection Rate (False Negative Findings),2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Bowel Cleansing Quality Evaluated by Boston Bowel Preparation Scale After Intake of Bowel Cleansing Formulation and of a Total Dose of 200 mg of Methylene Blue MMX Tablets Administered During and at the End of the Intake of the Bowel Cleansing Formulation
11045,NCT02526953,3-year disease-free survival,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Quality of life according to European organization for research and treatment of cancer (EORTC) Quality of Life questionnaire (QLQ)-C30 (v.3) scale,Late toxicity measured according to Radiation Therapy Oncology Group (RTOG) criteria
11046,NCT00309517,Overall survival,1997-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,
11047,NCT01536054,"Safety of ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine in combination with varying dose levels and schedules of sirolimus, assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4",2012-08-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to disease progression
11048,NCT00188292,,2002-08,COMPLETED,OBSERVATIONAL,['NA'],,
11049,NCT00893295,Intervention impact on colorectal cancer (CRC) screening utilization over the 6-month observation period,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Intervention impact on population health-management representations related to CRC screening, as assessed by perceived salience and coherence and self-efficacy-related CRC screening measured with 6 to 10 Likert-type items on both the baseline and end ..."
11050,NCT02980146,"The phenotype of TIL will be precised by immunohistochemisry and flow cytometry using various combinations of monoclonal antibodies to identify different subset of TIL and their frequency, especially those expressing NKG2A or NKG2C chain.",2016-06-01,COMPLETED,OBSERVATIONAL,['NA'],,
11051,NCT03260842,Pancreas Cancer,2017-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
11052,NCT01270360,"To determine the performances (sensitivity, specificity and likelihood ratios) of a panel of blood and/or faecal molecular DNA markers",2010-09,COMPLETED,OBSERVATIONAL,['NA'],,To create biological collections for screening purposes (asymptomatic subjects)
11053,NCT04497038,Maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D),2021-08-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetic (PK) profile: Elimination clearance (L/hr)
11054,NCT04183088,Randomized cohorts: Progression-free survival (PFS) (co-primary),2020-12-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Randomized cohort: progression-free survival (PFS)
11055,NCT04008407,Rate of surgical referral,2017-08-14,RECRUITING,INTERVENTIONAL,['NA'],,Adenoma recurrence rate
11056,NCT02174575,Postoperative acute kidney injury,2014-07,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Urine albumin concentration
11057,NCT02867865,Overall Survival,2016-09-06,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Deterioration free rate of quality of life (QOL) scores at baseline and three monthly
11058,NCT05648318,Bowel preparation,2022-01-08,COMPLETED,INTERVENTIONAL,['NA'],,withdrawal time
11059,NCT05216237,Objective Response Rate (ORR),2022-02-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AEs)
11060,NCT02243735,Normalization of Hb-level.,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Difference in Morbidity score
11061,NCT01453894,Completion of a Fecal Occult Blood Test (FOBT),2012-03,COMPLETED,INTERVENTIONAL,['NA'],,
11062,NCT06302400,"The incidence of adverse and serious adverse events in patients receiving individualized treatment with 166Ho- microspheres, using National Cancer Institute CTCAE v5.0.",2024-02-22,RECRUITING,INTERVENTIONAL,['NA'],,"The rate of efficacy as defined as overall response rate (ORR) in patients receiving individualized treatment with 166Ho- microspheres, using modified RECIST (mRECIST) response evaluation criteria."
11063,NCT00341575,,2005-09-28,COMPLETED,OBSERVATIONAL,['NA'],,
11064,NCT02534246,Direct Comparison of pancreatic mass histologic tissue adequacy using two EUS guided fine needle biopsy needles,2016-08,WITHDRAWN,INTERVENTIONAL,['NA'],,
11065,NCT01099111,Colonic-Mucosa Associated Microbial Species Per Compiled Participants in 5 Different Arms,2010-07,COMPLETED,OBSERVATIONAL,['NA'],,
11066,NCT00327496,,2005-06,UNKNOWN,INTERVENTIONAL,['NA'],,
11067,NCT01555450,Reduction of social inequalities,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,Evaluation of psychological mechanisms
11068,NCT00737230,"Improvement in gastrointestinal symptoms as measured by the modified IBDQ-B score, Rockwood Fecal Incontinence Quality of Life score, St Mark's Incontinence score, and the LENTSOMA score at baseline, 6 months, and 1 year",2007-04,COMPLETED,INTERVENTIONAL,['NA'],,Other unmet healthcare needs as a direct result of pelvic radiotherapy
11069,NCT02221778,Local Progression Free Survival,2014-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
11070,NCT01189942,To the determine the maximum tolerated dose of OMP-21M18 plus FOLFIRI,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,To determine the preliminary efficacy of FOLFIRI plus OMP-21M18
11071,NCT06162650,Complete response (CR) rate,2023-11-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety profiles
11072,NCT05621499,1-year DFS rate,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Adverse Events (AEs)
11073,NCT04137822,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
11074,NCT01909362,number of drug targetable genetic changes found in tumor tissue sample,2013-07,COMPLETED,OBSERVATIONAL,['NA'],,number of physicians who took into consideration regimens that were suggested by the results of the sequencing analysis when deciding their patients' next line of therapies.
11075,NCT04116073,Disease Control Rate (DCR) at 4 months using RECIST 1.1,2020-04-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants experiencing study drug-related toxicities
11076,NCT03433014,measure pain scores (Visual Analog Scale) in the postoperative period,2018-03-31,COMPLETED,INTERVENTIONAL,['NA'],,objective is to compare the VAS scores between the two types of technique used for specimen retrieval incision
11077,NCT04135313,3-year disease-free survival,2019-10-20,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3'],,Sphincter preservation rate
11078,NCT05193162,16sRNA and metagenomics,2019-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
11079,NCT02519075,Variation of SUVmax (Maximal Standardized Uptake Value) in patients undergoing TARE for HCC,2015-04,COMPLETED,OBSERVATIONAL,['NA'],,
11080,NCT00658801,all cause mortality,2007-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,
11081,NCT02075385,Swallowing function,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11082,NCT03790475,Completion of the assigned screening strategy within 18 weeks of enrollment,2018-08-25,UNKNOWN,INTERVENTIONAL,['NA'],,Diagnostic yield for CRC and advanced adenomas
11083,NCT02606292,Sensitivity and specificity of PA endoscopic imaging for identification of Barrett's epithelium compared to esophageal biopsy,2014-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
11084,NCT04948697,Objective Response Rate (ORR) as assessed by the investigator,2021-08-20,COMPLETED,INTERVENTIONAL,['PHASE2'],,Immunogenic Response to BAT1706
11085,NCT03439761,Disease Control Rate (DCR),2018-03-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,AE
11086,NCT00196105,Time to Death,2003-09,COMPLETED,INTERVENTIONAL,['NA'],,
11087,NCT02632305,Overall response rates,2016-07-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
11088,NCT06076252,The rate of POPF,2023-07-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
11089,NCT04143516,Tumor response,2019-10-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
11090,NCT00622804,Bile reflux by Dual scintigraphy,2007-07,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Morbidity and Mortality
11091,NCT00919061,Median PFS,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11092,NCT01025570,To estimate the median disease-free survival rate of patients with completely resected pancreatic cancer treated with this combination,2010-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,To estimate both disease-free and overall survival at one and two years of patients with completely resected pancreatic cancer treated with this combination
11093,NCT00494221,Progression Free Survival,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
11094,NCT02471170,Collection of blood and tissue samples from subjects with pancreatic diseases,2015-09-10,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
11095,NCT03834272,Initial efficacy of LUM015 in labeling peritoneal surface malignancies by molecular imaging by comparing imaging results with pathology,2019-03-18,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of patients with reported adverse events
11096,NCT02681796,Total consumption of morphine or morphine-equivalent in patients undergoing pancreatic resections in the control group compared with the study group,2016-06-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Effect of epidural analgesia during the initial post-operative period as measured by relative ratios of blood level inflammatory markers
11097,NCT01539681,Efficacy (analyzed by overall survival rate) of sorafenib under real-life practice conditions in patients with Hepatocellular Carcinoma.,2012-02,COMPLETED,OBSERVATIONAL,['NA'],,Time to Progression
11098,NCT02564887,Tongue Pressure Generation (i.e. Tongue Strength) in Kilopascals (kPa) Using the IOPI Device,2016-01,TERMINATED,INTERVENTIONAL,['NA'],,Swallowing Impairment-Objective
11099,NCT00776399,Primary Outcome Measures:3-year survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Secondary Outcome measures:safety, change in respiratory function, cancer-specific survival, and local tumor progression, Radiological studies"
11100,NCT00927485,Size of Polyps,2007-11,COMPLETED,INTERVENTIONAL,['NA'],,
11101,NCT05638698,Molecular disease control rate,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Correlation between molecular response and disease free survival
11102,NCT01470742,Overall survival of XELOX(XELODA/oxaliplatin) vs X(XELODA),2010-09,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,response rate
11103,NCT01294826,Incidence of dose limiting toxicity (DLT),2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival of patients treated with AUY922.
11104,NCT02528175,Acute toxicities,2015-04,COMPLETED,INTERVENTIONAL,['NA'],,Assessment of radiologic response following treatment.
11105,NCT00165217,To assess the anti-tumor activity of capecitabine and thalidomide when administered to patients with previously treated metastatic colorectal cancer.,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the safety of capecitabine and thalidomide in this patient population.
11106,NCT03380689,Maximum tolerance dose,2018-01-05,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Overall survival
11107,NCT04879953,Overall survival at 6 months,2020-02-01,COMPLETED,OBSERVATIONAL,['NA'],,overall survival from the diagnosis of carcinomatosis and from the diagnosis of the primary tumour.
11108,NCT01721174,Stent patency rate,2012-11,TERMINATED,INTERVENTIONAL,['NA'],,Unscheduled readmission rates
11109,NCT03265418,Positional stability of BioXmark liquid fiducial markers during the treatment course,2018-01-02,COMPLETED,INTERVENTIONAL,['NA'],,Potential BioXmark induced alterations in the surgical specimen
11110,NCT01258192,response to induction therapy,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety and tolerability
11111,NCT05332496,Overall Survival(OS),2022-12-28,RECRUITING,OBSERVATIONAL,['NA'],,Adverse event(AE) per Common Terminology Criteria for Adverse Events(CTCAE) 5.0
11112,NCT04518280,Complete response (CR) rate,2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Scores of Quality of Life
11113,NCT06238167,1-year Disease-free survival rate,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Safety will be analyzed through the incidence of adverse events, serious adverse events"
11114,NCT01232296,Overall Survival - Overall Survival,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pharmacokinetic (PK) Parameter of AUCtau Following a Single Dose of TKI258
11115,NCT00003798,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11116,NCT00824707,time-to-progression(TTP),2008-12,COMPLETED,INTERVENTIONAL,['NA'],,The overall response rate
11117,NCT05009550,Numeric Pain Scale assesment,2021-05-15,UNKNOWN,INTERVENTIONAL,['NA'],,Incidences of adverse effects (like nausea and vomiting)
11118,NCT05682768,Post operative Pancreatic Fistula,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11119,NCT01497444,Overall response rate (Phase II),2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,AFP response rate (Phase II)
11120,NCT00082082,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11121,NCT05918094,Progression-Free Survival (PFS),2023-04-30,RECRUITING,INTERVENTIONAL,['PHASE3'],,Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-STO22 (EORTC QLQ- STO22)
11122,NCT03107416,estimate the local tumor progression (LTP) rates (phase II),2017-04-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11123,NCT00320515,Objective Best Tumor Response,2004-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
11124,NCT02558959,Progression Free Survival,2015-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
11125,NCT05764551,The correlation between serum DNA methylation and HCC recurrence or treatment response,2023-03-28,RECRUITING,INTERVENTIONAL,['NA'],,
11126,NCT01687673,Median Time to Progression (TTP),2012-10-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Whom Discontinued Treatment Due to Intolerable Toxicity
11127,NCT02696408,prevalence of grade 3 mucositis and more,2016-06-27,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety
11128,NCT00445653,"Polymorphisms in DNA repair genes or the p53 pathways (e.g., ERCC2, XRCC1, p53, p73, CCND1, p21)",2005-08,COMPLETED,OBSERVATIONAL,['NA'],,
11129,NCT06134089,Number of messages generated by participants,2023-12-05,COMPLETED,OBSERVATIONAL,['NA'],,
11130,NCT01693419,Objective response rate,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profiles
11131,NCT02027545,Number of Participants With CRC Screening Ordered,2015-11-20,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants With CRC Screening Utilized
11132,NCT04835324,overall survival,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of Adverse Events (AEs)
11133,NCT03962088,Change in expression levels of plasma miRNA,2019-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,miRNA expression and surveillance
11134,NCT03218345,Severe adverse events,2016-08,RECRUITING,INTERVENTIONAL,['NA'],,Survival
11135,NCT00892658,Determine the MTD of sorafenib and RT in patients with hepatocellular carcinoma using an iso-toxicity radiation dose allocation scheme. Determine the acute toxicity (< 3 months) of sorafenib when combined with RT.,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Determine late toxicities, in-field local control at 3 months, overall survival, progression time, and progression free survival. Quantify alteration in perfusion parameters.Assess serum and tissue biomarkers. Assess quality of life in these patients."
11136,NCT00552149,Evaluation of treatment efficacy by assessing the crude progression-free survival (PFS) rate at 4 months,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of PFS and over
11137,NCT03163186,To assess potential patient preference for the performance of hepatic embolization procedures via transradial versus transfemoral approach.,2015-12-01,COMPLETED,OBSERVATIONAL,['NA'],,To identify potential risk factors for complications in transradial approach.
11138,NCT02615574,overall survival,2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Changes of tumor microenvironment,immune-related Progression-Free Survival (irPFS)
11139,NCT04581473,"Phase II: Progression-free survival (PFS), as assessed by IRC, of CT041 autologous CAR T-cell injection versus Physician's Choice",2020-10-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Phase II: Disease control rate (DCR), as assessed by IRC and by Investigators"
11140,NCT02039336,Progression free survival,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
11141,NCT00001576,,1997-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11142,NCT00004108,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11143,NCT04547166,PFS,2021-03-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,DCR
11144,NCT03996681,Disease control rate (DCR),2019-07-20,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Adverse Events
11145,NCT04929912,Incidence of Treatment-Emergent Adverse Events (CTCAE),2021-06-24,RECRUITING,OBSERVATIONAL,['NA'],,Modified FACE-Q evaluation for Skin Cancers
11146,NCT04230499,Efficacy of eRapa in delaying polyp progression in patients with FAP as measured by change in polyp burden over time.,2021-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Explore correlation between immune markers influenced by mTOR inhibition and clinical outcomes,Clinical effect of eRapa on duodenal polyp number and burden.
11147,NCT01171651,Determine safety and tolerability of intravenous infusion of JX-594 followed by intratumoral injections with JX-594 prior to standard sorafenib therapy,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine overall survival time
11148,NCT03676478,Functional recovery (6mWD - 6-minute Walked Distance),2019-03-25,RECRUITING,INTERVENTIONAL,['NA'],Levels of Haemoglobin A1c (HbA1c),Global Health status score
11149,NCT05743504,Pathological complete response rate,2023-09-18,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with delay in planned radical esophagectomy
11150,NCT00003485,,1996-04-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11151,NCT04368078,Objective Response Rate (ORR),2020-07-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AE)
11152,NCT00907166,"To determine the safety and MTD of CPI-613, when used in combination with Gemcitabine, in cancer patients.",2009-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To compare the safety and efficacy of CPI-613 Gemcitabine combination vs. Gemcitabine alone in patients with carcinoma of the pancreas.
11153,NCT06311851,Objective response rate,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse event
11154,NCT01512589,Total Toxicity Burden (TTB),2012-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
11155,NCT01489332,Pathological complete remission rate (pCR),2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
11156,NCT00365144,Safety and Toxicity,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Proportion of Patients With ≥ 25% Decline in Serum CA19-9 Biomarker
11157,NCT00668161,Proliferation rate in the upper part of colon and rectal mucosa crypts.,2001-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,quality of life (measured by standardized self-report instruments) and sleep quality
11158,NCT01895673,Local site recurrence (LSR) detection,2013-06,COMPLETED,OBSERVATIONAL,['NA'],,Patients experience with PET-CT and PET-MRI
11159,NCT01579071,Abdominal pain related to each insufflation,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
11160,NCT05795296,Objective response rate (ORR),2022-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
11161,NCT02438436,xerostomia,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11162,NCT00155883,tumor response rate,2004-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,"clinical benefit response, toxicities, quality of life, time to disease progression, overall survival"
11163,NCT01155258,To assess the response rate based on the Response Evaluation Criteria in Solid Tumors (RECIST),2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-free and overall survival
11164,NCT03687515,"Clinical responses including 4 major symptoms(nasal obstruction, rhinorrhea, loss of smell,and headache/facial pain)",2015-01-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Physicians' assessment of nasal polyp size reduction
11165,NCT06043999,Three years disease-free survival rate,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Urinary function
11166,NCT02188927,Participation rate,2014-08,UNKNOWN,INTERVENTIONAL,['NA'],Cost of including Advance Notification Letter,Response rate
11167,NCT05966246,Quantitative intestinal motility measurement using radio-opaque markers,2022-01-25,COMPLETED,INTERVENTIONAL,['NA'],,"Measurement of the amount of food intake, first flatus time and first defecation time"
11168,NCT00392366,Accuracy of predicted lesion geometry to histologically measured dimensions,2006-07,COMPLETED,INTERVENTIONAL,['NA'],,
11169,NCT00112528,Survival at 6 months,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
11170,NCT00417976,Rate of Progression Free Survival at 6 Months (24 Weeks) From Initiation of Therapy,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response Rates Defined by RECIST 1.0
11171,NCT01457599,Sensitivity,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,
11172,NCT00709826,Progression Free Survival,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
11173,NCT04160650,"The rate of self care activation (Patient Activation Measure PAM, Insignia Health; Hibbard et al. 2004)",2019-10-21,COMPLETED,INTERVENTIONAL,['NA'],Incidence of morbidity,"The rate of quality of life (The Functional Assessment of Cancer Therapy Scale - Colorectal, FACT-C, Cella et al. 1993)"
11174,NCT02966509,Number of Participants With Completed Goals of Care Documentation. We Will Evaluate if 75% of Patients in the Intervention Arm Have a Documented Goals of Care Titled Medical Note Within 6 Months of Patient Enrollment in the Study.,2013-08,COMPLETED,INTERVENTIONAL,['NA'],,Patient Satisfaction With Decision-Making Using the Satisfaction With Decision Survey
11175,NCT05690035,Objective Response Rate (ORR),2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events
11176,NCT04592861,Overall survival duration,2020-11-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,"Quality-of-life, measured using the EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30 questionnaire"
11177,NCT00003434,Progression Free Survival,1998-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,
11178,NCT00335543,Median survival,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Quality of life before, during, and after therapy"
11179,NCT04425226,Recurrence-Free Survival (RFS),2020-08-06,RECRUITING,INTERVENTIONAL,['NA'],,Objective Response Rate (ORR)
11180,NCT01533740,Impact of Tregs frequency on overall survival,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,Impact of Tregs frequency radiologic response rate
11181,NCT01591798,Quality of mesorectal excision,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Long-term outcome
11182,NCT01784900,Progression Free Survival,2012-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
11183,NCT03836352,Safety as measured by the rate of adverse events,2018-12-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in immune cell infiltration,Overall survival
11184,NCT05862337,Recurrence-free survival (RFS),2023-05-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Objective response rate (ORR) after first recurrence
11185,NCT02305615,Progression-Free Survival (PFS),2015-01-13,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants with Adverse Events (AEs) and Serious AEs
11186,NCT01212718,Best response to first-line chemotherapy (recist),2001-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"overall survival, toxicity, treatment related complications, time to progression"
11187,NCT02409849,PFS,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS
11188,NCT04734691,Progression free survival,2021-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life C30
11189,NCT01379612,Tumor regression grade,2010-05,COMPLETED,OBSERVATIONAL,['NA'],,
11190,NCT04724291,Comparison to EGD in Identifying Lesions.,2021-02-10,COMPLETED,INTERVENTIONAL,['NA'],,Safety of MCC Compared to EGD. Documentation of Any Adverse Event Patient Encounters up to the 30 Day Follow-up.
11191,NCT02385617,Ad libitum calorie intake,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Subjective symptom scores
11192,NCT00035035,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11193,NCT00003610,severity of mouth pain,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11194,NCT02558881,Acceptance rate of colonic capsule versus virtual colonoscopy.,2014-06,COMPLETED,OBSERVATIONAL,['NA'],,Additional costs generated by the implementation of a complementary action of screening for patients with a positive FOBT and did not realize optical colonoscopy
11195,NCT06190665,Disease control rate (DCR) for target lesions 1 month after the last TACE treatment,2023-12-19,RECRUITING,INTERVENTIONAL,['NA'],,Number of TACE treatments for target lesions
11196,NCT04929223,Objective Response Rate,2021-10-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,Plasma Concentrations of Divarasib
11197,NCT05880446,Mean Delta of EORTC Proctitis Module (PRT20) score,2023-10-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Low Physical Activity Level prevalence and its association with PRT20 and QLQ-C30 Delta,Mean Delta of EORTC Quality of Life Questionnaire (QLQ-C30) score
11198,NCT03039309,Curative resection rate,2016-08-05,RECRUITING,OBSERVATIONAL,['NA'],,Mortality rates
11199,NCT00829335,Technical feasibility,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,Morbidity and mortality
11200,NCT02220062,percentage of participants with 50% decrease or less than 3 points in Pain Visual Analogue Scale (VAS),2014-08,UNKNOWN,INTERVENTIONAL,['NA'],,
11201,NCT03741166,Blood-based biomarkers associated with genetic and epigenetic alterations.,2018-11-08,COMPLETED,OBSERVATIONAL,['NA'],,
11202,NCT00040820,,2002-01,COMPLETED,INTERVENTIONAL,['NA'],,
11203,NCT00678535,Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety - Number of Participants With Adverse Events (AEs)
11204,NCT04027556,HCC conspicuity,2019-06-27,COMPLETED,INTERVENTIONAL,['NA'],,Radiation dose
11205,NCT04337333,Cumulative patency of inner covered stent and Two-in-one stent,2016-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Stent dysfunction-free patient survival
11206,NCT04001478,Determine the diagnostic accuracy of breath test for detection of early oesophageal cancer and Barrett's high grade dysplasia,2019-10-01,RECRUITING,OBSERVATIONAL,['NA'],,Diagnostic validation study of the breath profile for prediction of early oeosphageal cancer and high grade dysplasia
11207,NCT02948348,Pathological complete response,2016-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,macroscopic evaluation of (rectal cancer) resected specimen
11208,NCT00075712,Quality of life by Quality of Life Questionnaire Core 30 Items (QLQ-C30) and QLQ-ovarian cancer (QLQ-OV28),2003-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
11209,NCT01054924,,2009-11,COMPLETED,OBSERVATIONAL,['NA'],,
11210,NCT01269060,Harvested numbers of lymph node,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Postoperative mortality, morbidity"
11211,NCT00467974,progression free survival,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,consumption of hospital resources
11212,NCT02959541,THF - adjacent mucosa,2016-09,UNKNOWN,INTERVENTIONAL,['NA'],,Gene expression - correlation adjacent mucosa tissue concentration of the reduced folates
11213,NCT04238637,Objective Response rate (ORR) according to RECIST 1.1,2019-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Translational research,Overall Survival (OS)
11214,NCT00238147,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11215,NCT03072095,FIT completion within 3 months,2017-04-17,COMPLETED,INTERVENTIONAL,['NA'],,Response to text-based CRC screening outreach
11216,NCT05447611,"The main objective of the EMPACOL project is to investigate, in non-metastatic CRC patients, a possible correlation, between perceived HCP's empathy and survival (OS and DFS).",2022-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"The relationship between caregiver empathy, as perceived by the patient, and quality of life (QoL) will be studied."
11217,NCT03598348,PFS,2018-01-16,UNKNOWN,INTERVENTIONAL,['PHASE3'],,OS
11218,NCT03816345,Clinical measures of interest,2019-07-16,RECRUITING,INTERVENTIONAL,['PHASE1'],,
11219,NCT01549067,,2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,
11220,NCT03092518,Overall survival,2017-06-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,morbidity
11221,NCT05228431,Rate of pCR,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
11222,NCT05052086,"Accuracy of mesorectal lymph node diagnosis with MMUS, compared with preoperative MRI",2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
11223,NCT00714077,3-year disease free survival rate,2008-04,UNKNOWN,OBSERVATIONAL,['NA'],,safety
11224,NCT05726188,Recurrence,2022-04-01,RECRUITING,OBSERVATIONAL,['NA'],,Cancer-related survival
11225,NCT00109070,,2000-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11226,NCT02153398,Aggravation of Regurgitation at Week 8 by Investigators,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Apparent Volume of Distribution (Vz/F) of Esomeprazole After at Least 5 Days of Repeated Dose
11227,NCT00009906,"Toxicity defined as any grade 3 or greater organ toxicity, or any grade 4 or greater hematological toxicity as assessed by CTCAE version 2.0",2000-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,
11228,NCT04037319,"Incidence of atrial fibrillation within 90 days of colorectal cancer surgery, defined as ≥30 seconds of atrial fibrillation identified on a 24-hour cardiac monitor OR absence of p waves and irregularly irregular rhythm on an electrocardiogram",2020-01-16,UNKNOWN,OBSERVATIONAL,['NA'],,Number of events of use of health services for atrial fibrillation or sequelae of atrial fibrillation
11229,NCT03220711,"Depth-imaging capability of the confocal endomicroscope using an imaging contrast agent, fluorescein",2017-07-28,TERMINATED,INTERVENTIONAL,['NA'],,
11230,NCT04081831,Incidence rate ratio of esophageal cancer among users of low-dose-aspirin (exposed) and users of paracetamol monotherapy (non-exposed),2019-07-31,COMPLETED,OBSERVATIONAL,['NA'],,Case-fatality and survival rate
11231,NCT01914068,Change in physical fitness measured by CPET (ml/kg/min),2013-08,COMPLETED,INTERVENTIONAL,['NA'],TNM Staging,Physical activity
11232,NCT04188002,Metabolic Equivalent Task Hours (METs) for Physical Activity,2017-03-25,COMPLETED,INTERVENTIONAL,['NA'],,Number of Times Visiting the Site
11233,NCT04495088,disease-free survival,2020-09-30,RECRUITING,INTERVENTIONAL,['PHASE3'],,Patient reported outcome: Functional outcome according to Wexner score
11234,NCT05208775,2-year disease-free survival rate,2022-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Esophageal stenosis rate at 3 months
11235,NCT01522612,Progression free survival,2013-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by social situation questionnaire"
11236,NCT00654160,Maximum tolerated dose of genotype-based dosing of FOLFIRI with or without monoclonal antibody therapy,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response rate of genotype-based dosing in the subset of patients that has colorectal cancer
11237,NCT05382741,Disease Free Survival,2022-03-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
11238,NCT00570531,Disease Free Survival Time,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,The Proportion of Toxicities Experienced by Participants
11239,NCT05892289,The Proportion of Patients With Reflux Esophagitis Within 12 Months Postoperatively,2023-06-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Proportion of participants need to rehospitalized after surgery
11240,NCT03820531,Pancreas cyst with HGD or carcinoma,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
11241,NCT00064259,Maximum Tolerated Dose (MTD) of Oblimersen in Combination With Cisplatin and 5-FU,2003-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Microarray Data
11242,NCT03551951,Quantity of cfDNA in bone marrow,2016-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
11243,NCT03865563,"Safety as measured by number of participants with Grade 3, 4, and 5 toxicities",2019-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Efficacy as assessed by change in levels of gemcitabine and dFdu in peripheral blood samples
11244,NCT01512745,Overall Survival(OS),2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Adverse Events
11245,NCT01375816,Tumor response,2011-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Correlation of UGT1A family polymorphism and the toxicity of liposome-encapsulated irinotecan hydrochloride PEP02 or irinotecan hydrochloride
11246,NCT01612325,Target lesions tumour response,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity according CTC v 4 criteria
11247,NCT03237325,Duration of Severe Oral Mucositis (SOM),2017-12-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11248,NCT01890291,To evaluate recurrence-free survival,2013-06,COMPLETED,OBSERVATIONAL,['NA'],,To determine the response rate to evaluate overall survival and cause specific survival and changes of Alpha feto protein (AFP) figures from baseline to the last observation date.
11249,NCT02717949,Number Subjects Who Experience Adverse Events on HCV Treatment as Assessed by Division of AIDS (DAIDS) Adverse Event (AE) Grading Table Version 2.0.,2016-02-25,TERMINATED,INTERVENTIONAL,['PHASE4'],,Number of Subjects Who Have a Change in Lymph Node Size From Baseline After HCV Treatment
11250,NCT04678349,ileostomy stoma output,2021-05-01,COMPLETED,INTERVENTIONAL,['NA'],,dietary intake
11251,NCT04512508,Percentage of positive results for Anal Test system versus anal liquid cytology and anoscopy for the presence of high-risk human papillomaviruses,2020-08-30,UNKNOWN,INTERVENTIONAL,['NA'],,Number and percentage of patients to have a positive opinion to use Self-Test system.
11252,NCT06090643,Return rate of completed FIT kits,2019-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
11253,NCT00207155,Prediction of response to Erbitux in subjects with metastatic colorectal cancer,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Radiographic Response
11254,NCT02950064,Part 2 - Progression-free survival (PFS) measured as the time from the date of initiation of BTP-114 treatment to the documented disease progression (PD) or death from any cause.,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],Part 1 - Plasma Pharmacokinetics (PK) estimates of platinum concentration Half-life (T1/2).,
11255,NCT05969444,High grade dysplasia/Gastric adenocarcinoma,2015-06-01,COMPLETED,OBSERVATIONAL,['NA'],,
11256,NCT02423174,Intraoperative Serious Adverse Events as a Measure of Safety and Feasibility,2016-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Evaluation of post-operative complications
11257,NCT01378143,Overall survival (OS),2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of response (DR)
11258,NCT02203409,Safety of the procedure defined as the incidence of postoperative complications and mortality,2014-07,UNKNOWN,OBSERVATIONAL,['NA'],,survival rate
11259,NCT05601505,"Disease-related treatment failure, DrTF",2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,"overall survival, 2yOS"
11260,NCT04054518,Six-month progression-free survival,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Six-month progression-free survival according to immune biomarkers,Incidence of distant progression
11261,NCT00012246,Frequency and severity of toxic effects,2002-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11262,NCT04748380,Change in CRC Screening Intentions,2023-01-18,RECRUITING,INTERVENTIONAL,['NA'],,Feelings of usefulness of the decision aid
11263,NCT00003843,,1998-10,TERMINATED,OBSERVATIONAL,['NA'],,
11264,NCT05714111,Local progression free survival,2022-03-04,RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival
11265,NCT03813784,Overall survival (OS) of SHR-1210 in combination with capecitabine + oxaliplatin sequenced by SHR-1210+apatinib versus capecitabine + oxaliplatin in all subjects or programmed cell death ligand 1 (PD-L1) positive participants,2019-03-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of Subjects with treatment-related adverse events (AEs)
11266,NCT02392637,Median Progression Free Survival (PFS),2015-04-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment Response Rate
11267,NCT02288728,postoperative mortality and morbidity,2014-12,TERMINATED,INTERVENTIONAL,['NA'],,reflux esophagitis
11268,NCT04150042,Overall incidence rate of Grade 3-5 adverse events,2021-01-13,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival
11269,NCT05000697,Decision to Watch and Wait due to clinical complete response,2021-07-14,RECRUITING,INTERVENTIONAL,['NA'],,Colostomy-free survival at 3 years
11270,NCT04232735,SOURCE observational scale,2020-10-13,RECRUITING,INTERVENTIONAL,['NA'],SOURCE evaluation questionnaire (tailor made evaluation questionnaire),Health care providers' (numerical) precision of treatment outcome information measured with SOURCE observational scale simulated patient consultations (effect intervention)
11271,NCT01876511,Progression Free Survival (PFS) at 20 Weeks in MSI Positive Solid Tumor Malignancies Using Response Evaluation Criteria in Solid Tumors (RECIST 1.1),2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Does MSI as a Marker Predict Treatment Response
11272,NCT03295500,Overall survival rate,2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],,the value of ICG R15
11273,NCT03954756,Overall survival rate,2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
11274,NCT06177522,pCR rate,2023-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,
11275,NCT04196816,Overall survival,2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Progression-free survival
11276,NCT02632201,Overall survival,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
11277,NCT03503162,The Rate of Adequate Cleansing Level Before and After the Use of the Pure-Vu System,2018-05-17,COMPLETED,INTERVENTIONAL,['NA'],,
11278,NCT04643041,1 year DFS rate,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,3 years OS rate
11279,NCT02589496,Response Rate,2016-03-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11280,NCT02186574,Rate of reverse seroconversion,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,All-cause mortality
11281,NCT00026299,Recommended dose of ZD1839 in combination with oxaliplatin,2001-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11282,NCT04761614,Dose limiting toxicities (DLTs),2021-04-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Change in levels of circulating cytotoxic T cells,Pharmacokinetic (PK) profile of riluzole (AUC)
11283,NCT00613730,Overall Survival at 1 Year,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Overall Response
11284,NCT02779465,Change in serum levels of 25-hydroxy vitamin D,2016-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,Number of participants on Vitamin D treatment with adverse events
11285,NCT00987766,Maximum tolerated dose and recommended phase II dose of erlotinib hydrochloride in combination with gemcitabine hydrochloride and oxaliplatin,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"E-cadherin, vimentin, fibronectin, amphiregulin, and Kras status in the tumors and their relationship to response"
11286,NCT02086656,Pathological response rate,2013-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,RECIST Response rate
11287,NCT04005118,Rate of prolonged postoperative ileuss,2019-05-28,UNKNOWN,OBSERVATIONAL,['NA'],,Expression intensity in cytoplasm of protein ligase HACE1 in tumoral and non-tumoral tissues
11288,NCT01319877,Percentage of Participants With Bevacizumab-related Serious Adverse Events,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,Quality of Life: European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 Questionnaire
11289,NCT06173726,Dose-Limiting Toxicity,2023-12-05,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
11290,NCT01837381,overall survival and treatment-related toxicity,2007-02,COMPLETED,INTERVENTIONAL,['NA'],,Tumor response
11291,NCT03740503,Genomic Characterization of Tumor Samples,2013-11-01,RECRUITING,OBSERVATIONAL,['NA'],,
11292,NCT03818165,Assess preliminary efficacy by overall survival,2019-07-29,TERMINATED,INTERVENTIONAL,['PHASE1'],Assess if circulating tumor cells (CTC) correlate with response,Assess preliminary efficacy by in-liver progression free survival (PFS)
11293,NCT04779125,Complications,2021-03-19,COMPLETED,INTERVENTIONAL,['NA'],,Gluteus muscle function measured by time stands test
11294,NCT01992705,Rate of downstaging to resectability in patients with borderline resectable pancreatic cancer receiving FOLFIRINOX and SBRT as preoperative therapy.,2014-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Quality of life through and after treatment,Survival status (disease-free-survival vs. overall survival) time to recurrence and site of recurrence in patients with borderline resectable pancreatic cancer receiving preoperative FOLFIRINOX followed by SBRT
11295,NCT05013216,Maximal percentage of change of interferon (IFN-γ) producing mutant-KRAS-specific CD8 and CD4 T cells,2022-04-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Fold change in interferon-producing mutant-KRAS-specific CD8 and CD4 T cells at 17 weeks.
11296,NCT01139242,"Higher incidence of CRC screening, if needed, among experimental participants.",2008-02,COMPLETED,INTERVENTIONAL,['NA'],,
11297,NCT03914820,Local recurrence free survival (LRFS),2020-06-19,RECRUITING,INTERVENTIONAL,['NA'],,mortality at 30 and 90 days from surgery
11298,NCT03061708,Objective response rate (ORR) by RECIST 1.1,2017-02-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11299,NCT02401802,Inadequate bowel preparation.,2015-01,COMPLETED,INTERVENTIONAL,['NA'],,"Acceptability of the preparation (interference with work, leisure activities or sleep"
11300,NCT00003786,Clinical Response Rate,1999-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
11301,NCT04293419,Pathological complete response (pCR) rate,2019-12-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Calculation of the neoadjuvant rectal (NAR) score
11302,NCT00111904,Safety,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11303,NCT02948309,Overall survival (OS),2016-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of treatment-emergent adverse events (AE)
11304,NCT01188785,Number of Participants with Adverse Events,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11305,NCT01239082,The primary outcome is colorectal cancer mortality.,2012-04-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,FIT Positive - If Colonoscopy is Warranted
11306,NCT03764137,Image Quality,2019-03-14,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11307,NCT04037046,Acceptance of the interventions,2019-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Effectiveness of each strategy: rate of HCV positivity
11308,NCT04836741,Disease free survival,2015-07-01,COMPLETED,INTERVENTIONAL,['NA'],,
11309,NCT03274804,Feasibility Rate of a Combined Therapy,2018-04-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
11310,NCT01231347,To determine if AMG 479 in combination with gemcitabine improves overall survival as compared with placebo in combination with gemcitabine in subjects with metastatic adenocarcinoma of the pancreas,2011-04,TERMINATED,INTERVENTIONAL,['PHASE3'],,Number of subjects with adverse events
11311,NCT00147550,"Objective Response Rate, Safety.",2004-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Time to progression, overall survival, patient reported outcomes."
11312,NCT04403022,Adverse Events Rates,2021-06-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
11313,NCT01550055,Overall response rate,2009-05-31,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Progression-free Survival
11314,NCT00475293,objective response rate,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,adverse events
11315,NCT04667351,overall survival,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Events
11316,NCT01782573,"the positive rate of the baseline culture , the preoperative culture , and the postoperative culture",2011-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,the post - operative surgical site infection
11317,NCT04693546,"Sensitivity and specificity for the LifeKit Prevent Colorectal Neoplasia Test for adenoma, including advanced adenoma",2021-06,UNKNOWN,OBSERVATIONAL,['NA'],,Sensitivity of the LifeKit Prevent Colorectal Neoplasia Test is superior to that of FIT for advanced adenoma
11318,NCT05801211,Stoma rate at 1 year after tumor resection,2023-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,type of chemotherapy regimen
11319,NCT04034953,Breast cancer detection rate,2018-08-06,UNKNOWN,INTERVENTIONAL,['NA'],,
11320,NCT02864381,Objective Response Rate (ORR),2016-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities
11321,NCT01701310,To determine if the use of intravenous ferric carboxymaltose can reduce the need for allogeneic blood transfusion compare to oral ferrous sulphate in patients with colorectal adenocarcinoma related anaemia,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,To determine differences in anemia symptomatology response between groups.
11322,NCT03281382,Toxicity of the gene therapy,2017-07-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,PET imaging
11323,NCT00486356,Toxicities of combined chemotherapy regimen,2004-10-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor activity
11324,NCT03027895,clinical success,2018-09,UNKNOWN,INTERVENTIONAL,['NA'],,technical success
11325,NCT03122548,Objective Response Rate (ORR),2017-08-14,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
11326,NCT04652271,Mortality,2021-09,UNKNOWN,OBSERVATIONAL,['NA'],,Morbidity
11327,NCT00554905,Overall Survival,2006-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Recurrence rates
11328,NCT05596630,Local control rate（LC）,2023-05-08,RECRUITING,INTERVENTIONAL,['NA'],,Progression-free survival (PFS)
11329,NCT06132087,R0 resection rate,2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],,Time to distant metastases
11330,NCT04899908,Local Recurrence,2021-09-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Neurocognitive function: cognitive impairment
11331,NCT04526483,The success rate of laparoscopic gastric surgery,2020-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,Lymph node dissection rate
11332,NCT03295591,Cutoff value of CTC counts,2017-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
11333,NCT00509561,Overall survival,2008-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Health economics
11334,NCT03944304,Disease control rate,2019-05-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,
11335,NCT03788226,3-year disease-free survival,2019-02-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,safety (The incidence of chemotherapy related adverse events)
11336,NCT01103323,Overall Survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Tumor Response
11337,NCT01639911,Optimally Tolerated Dose,2013-08-14,COMPLETED,INTERVENTIONAL,['PHASE1'],,Toxicity Profile
11338,NCT05237193,Assess the value of UCAD for malignant biliary obstruction patient follow-up,2021-09-03,RECRUITING,OBSERVATIONAL,['NA'],,Comparison of the sensitivity and specificity of the UCAD analysis versus bile cytology
11339,NCT02686372,To Evaluate safety of the TCR-T treatment,2018-05-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate objective response rate
11340,NCT01132469,5-year disease(gastric cancer)-free survival rate after ESD procedure,2010-05,UNKNOWN,INTERVENTIONAL,['NA'],,The safety of ESD procedure
11341,NCT04287335,Sensitivity and specificity of the ColoClear screening test with comparison to colonoscopy,2018-09-18,COMPLETED,OBSERVATIONAL,['NA'],,"Sensitivity of the ColoClear screening test with comparison to FIT, with respect to advanced adenoma (AA) and CRC"
11342,NCT02237157,Determine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the Pancreas,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,CA19-9 Tumor Reduction
11343,NCT03990974,30-day postoperative infection rate,2020-09,SUSPENDED,INTERVENTIONAL,['PHASE3'],,Distant infection rate
11344,NCT05022511,Participation,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],Survey evaluation,Rate of compliance to follow-up with colonoscopy after a positive FIT
11345,NCT01768988,Pain intensity (Visual Analogue Scale; VAS Score),2012-08,TERMINATED,INTERVENTIONAL,['PHASE4'],,Neuropathic Pain
11346,NCT05665868,Anxiety tendency of patients in the past week assessed by self rating anxiety scale,2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],,
11347,NCT03957486,difference between SpHb value and SaHb value (SpHb - SaHb) in g/dL,2019-05-14,COMPLETED,INTERVENTIONAL,['NA'],,
11348,NCT00947206,ever had a CRC screening test,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,up-to-date for CRC screening
11349,NCT00906997,Colorectal cancer-related mortality,2008-11,COMPLETED,INTERVENTIONAL,['NA'],,Advanced colorectal neoplasm detection rate
11350,NCT01760694,Efficacy - Progression Free Survival,2013-01,TERMINATED,INTERVENTIONAL,['NA'],,Safety
11351,NCT05215535,Cost effectiveness,2022-04-12,RECRUITING,INTERVENTIONAL,['NA'],,Survival
11352,NCT01535326,Proportion of Patients Without Pain,2012-02,COMPLETED,INTERVENTIONAL,['NA'],Post-procedure Discomforts and 30 Day Complication Rate,Number of Participants With at Least One Adenoma
11353,NCT00126542,Response rate of patients treated with the combination of bevacizumab and OSI-774,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
11354,NCT04612309,effectiveness,2020-10-28,RECRUITING,OBSERVATIONAL,['NA'],,
11355,NCT03466424,Pathological complete response(pCR) rate,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Incidence of acute toxicities during radiation or chemotherapy
11356,NCT02304978,TNM primary colorectal tumor stage,2009-06-22,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Interaction plate / tumor cell
11357,NCT04404647,90-day complication rate and severity,2020-06-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Longitudinal changes in nutritional status assessment
11358,NCT04988191,"Pathological complete response rate based on blinded, independent, central review",2020-12-24,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Treatment-Related Adverse Events
11359,NCT00165854,"to determine the safety, tolerability and efficacy (in terms of response rate and progression-free survival) of the combination in patients with metastatic CRC.",2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,measure duration of response and stable disease; to measure median and one year survival.
11360,NCT05727007,Diagnostic accuracy in T stage,2019-01-23,COMPLETED,INTERVENTIONAL,['NA'],,Diagnostic accuracy in peritoneal or nearby organ infiltration
11361,NCT02688114,Change in the Percent of Mucosa Healed by Neosquamous Epithelium,2017-10-18,COMPLETED,INTERVENTIONAL,['NA'],,Change in inflammatory cell infiltrate
11362,NCT02738606,Overall survival,2016-05-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Patients who abandon treatment
11363,NCT00527111,Percentage of Pathologic Response Rate (pCR) With 95% Confidence Interval.,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,KRAS Mutation Rate
11364,NCT04112836,Percent of planned chemotherapy delivered,2019-03-15,UNKNOWN,OBSERVATIONAL,['NA'],,Factors associated with the percent of chemotherapy received
11365,NCT03260712,Detection of progression-free survival (PFS) rate at 6 months defined according to RECIST 1.1.,2020-01-07,COMPLETED,INTERVENTIONAL,['PHASE2'],"Biomarkers predictive of response and toxicity (protein profiling, HLA typing)",Progression free survival rate at 6 months according to iRECIST
11366,NCT06266091,"Puncture-free survival, PuFS",2021-11-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Peak serum concentration (Cmax)
11367,NCT06251726,Lymph node invasion rate,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Molecular profile of the tumor
11368,NCT01662752,Subjects in Which the SLN(s) Are Identified,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Frequency and Tumour-bearing Status of Aberrant SLN(s,Sensitivity and Specificity of Tumour-bearing Status of SLN(s) as a Measure of Lymph Node Status When Assessed by Standard Techniques
11369,NCT02602067,Dose Limiting Toxicity evaluated using NCI Common Toxicity Criteria (CTCAE 4.03),2015-11,TERMINATED,INTERVENTIONAL,['PHASE1'],Tumor response,Adverse Events
11370,NCT03552744,"Number of PCPs who have at least one patient ever tested with FOBT, or who prescribe at least one FOBT to eligible patients (patients not already tested within recommended intervals, with no contra-indication for screening).",2018-04-26,COMPLETED,INTERVENTIONAL,['NA'],,Change in PCPs' future intentions to prescribe colonoscopy vs. FOBT over the next 6 months
11371,NCT01124994,Accuracy of CLE-EMR,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,
11372,NCT00754468,Depth of Injury,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4'],,Side Effects of Subjects Receiving Cryospray Therapy.
11373,NCT05058846,Proportion of participants with of abnormal magnetic resonance imaging (MRI) findings,2022-01-20,RECRUITING,OBSERVATIONAL,['NA'],Change in scores on the Disease Specified Perceived Risk Survey,Proportion of participants who have additional medical procedures
11374,NCT01700062,biochemistry data; Various inflammation-related cytokines ;,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,clinical outcome(hospital stay..)
11375,NCT03923335,disease free survival,2019-04-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
11376,NCT00585728,The utility of CT virtual proctoscopy (CTVP) for evaluation of rectal cancer.,2007-09,COMPLETED,INTERVENTIONAL,['NA'],,
11377,NCT04664504,R0 resection rate,2020-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,3yLRRFS
11378,NCT02707328,Maximum tolerable dose,2015-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,quality of life
11379,NCT02752698,complication,2015-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,change of blood and biochemiacl
11380,NCT01366586,,2011-05,COMPLETED,OBSERVATIONAL,['NA'],,
11381,NCT01670110,Change in Kidney Volume,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in Quality of Life
11382,NCT00209677,Determine the clinical response rate with Recommended dose in Phase II setting.,2004-12,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the MST(Median Survival Time) and DFS(Disease Free Survival) in Phase II setting.
11383,NCT05139082,Overall response rate (ORR),2021-11-24,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
11384,NCT03899649,Overall Survival,2019-05-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
11385,NCT03919383,6 months progression free survival rates,2019-04-15,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
11386,NCT03346915,HPV vaccine series start and completion,2018-08-14,COMPLETED,INTERVENTIONAL,['NA'],,Wheel of Wellness (WoW) feasibility
11387,NCT00003543,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11388,NCT02867280,Recurrence free survival,2016-06-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,Incidence of dose modification of sorafenib due to adverse events.
11389,NCT00373737,,1999-05,COMPLETED,OBSERVATIONAL,['NA'],,
11390,NCT00561275,Toxicity of multiple peptide vaccinations,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Immune responses including LY6K, VEGFR1 and VEGFR2 specific T cells"
11391,NCT03748680,DFS,2018-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,TR
11392,NCT01584544,Number of Participants Experienced Dose Limited Toxicity,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11393,NCT03450512,the arisen of EC in the CT scan,2019-01-14,RECRUITING,OBSERVATIONAL,['NA'],,
11394,NCT01053013,Overall Survival - Based on Most Recent Scan,2010-04-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Pain Assessment of Pancreatic Cancer Participants,Overall Survival - Based on Stage IV Disease Diagnosis
11395,NCT05203978,Complete colonoscopy defined by caecum intubation (binary criterion : yes or no),2022-03,UNKNOWN,OBSERVATIONAL,['NA'],,Polyp removal (binary criterion : yes or no)
11396,NCT03410758,Overall survival,2016-02-15,COMPLETED,OBSERVATIONAL,['NA'],,
11397,NCT01865565,progression free survival,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival (OS)
11398,NCT01266707,Toxicities as assessed by NCI-CACAE ver3,2007-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Survival
11399,NCT05704413,"Relation between biological parameters and outcomes of digestive disease (IBD, CRC)",2021-06-17,RECRUITING,OBSERVATIONAL,['NA'],,Brain-microbiota interaction
11400,NCT00933816,Dose limiting toxicity in phase I and Time to progression in Phase II,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase I and II: Adverse effect (AE)
11401,NCT01386242,Overall survival (OS),2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate
11402,NCT02632019,Overall survival,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
11403,NCT05619016,Percentage of HER2-positive lesions,2022-11-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Dynamic PET parameters,Safety aspects of ABY-025
11404,NCT03416244,Overall survival,2018-02-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events
11405,NCT04417010,local tumor progression,2020-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,
11406,NCT02776878,"Progression-free survive, calculated from registration until progression or death",2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,"Tumor control probability, defined as CR＋PR＋SD, determined according to RECIST 1.1 criteria"
11407,NCT03517618,Disease Control Rate (DCR),2014-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Incidence of adverse events (AEs), serious adverse events (SAEs) [Safety and Tolerability]"
11408,NCT04047004,Surgical complications,2020-03-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Adjuvant chemotherapy
11409,NCT05886465,Progression free survival rate at 6 months,2023-05-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
11410,NCT03221400,"Phase 2a: Efficacy of PEN-866 in patients with squamous cell carcinoma of the genitalia (anus, cervix, vulva, or penis) using best overall response rate",2017-08-29,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2a: Overall survival
11411,NCT05801783,Systemic immune response,2022-12-02,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Quality of Life Assessment
11412,NCT04170179,Progression free survival rate at 6 months,2019-11-19,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
11413,NCT05171530,Maximum tolerated dose of lenvatinib,2022-01-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],Exploratory Outcome,Overall survival (OS)
11414,NCT01626001,Patient Percentage with 4DCT Acquisition Artifacts,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Artifact Reproducibility Reducing 4DCT Acquisition
11415,NCT01416662,capability of CDA to predict the occurrence of early severe hematological toxicity upon gemcitabine,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
11416,NCT05916014,Specificity of AI model to diagnose the Kimura-Takemoto classification,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,The MIOU value of AI model in semantic segmentation of endoscopic atrophy picture
11417,NCT00036517,,2002-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11418,NCT03755791,Duration of Overall Survival (OS) for the experimental arm vs. the control arm,2018-06-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Duration of Progression Free Survival (PFS) for the single-agent arm vs. the control arm
11419,NCT00559858,Incidence of capecitabine dose modifications (dose delay and dose reductions) due to toxicity,2004-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Measurement of biomarkers that might predict the occurrence of HFS
11420,NCT05797467,median of disease-free survival,2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Complications
11421,NCT05738772,Serum level of Soluble PDGFRβ,2023-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
11422,NCT01844908,Incidence of prolonged ileus,2013-05,UNKNOWN,INTERVENTIONAL,['NA'],,30-day mortality rate
11423,NCT05445778,Assess Progression-free survival (PFS),2022-12-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,Patient-reported outcome health-related quality of life (HRQoL) of disease-related symptoms using the NCCN-FACT Ovarian Symptom Index (NFOSI-18) DRS-P (disease-related symptom subscale - physical).
11424,NCT04851106,The negative predictive value (NPV) determined from shear wave elastography,2021-09-21,UNKNOWN,OBSERVATIONAL,['NA'],,
11425,NCT06310564,Progression-free survival (PFS).,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,questionnaire QLQ-C30
11426,NCT00989651,Incidence of DLTs occurring in the first 4 courses of treatment (feasibility phase),2009-10-28,COMPLETED,INTERVENTIONAL,['PHASE1'],Genomic BRCA mutation status,"Incidence of toxicity, graded according to National Cancer Institute CTCAE version 4.0"
11427,NCT05496491,Disease Free Survival,2022-08-30,RECRUITING,INTERVENTIONAL,['NA'],,Treatment Compliance
11428,NCT05069766,Registration of treatment related side effects assessed by CTCAE V 5.0,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],,
11429,NCT00439517,Progression-free Survival (PFS),2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety - Number of Patients Experiencing Any Adverse Event
11430,NCT00006389,Observed Response Rate.,2000-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival
11431,NCT00389610,Number of Patients Experiencing a Grade 3 or Above Treatment- Related Toxicity,2006-09-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease-free Survival (DFS)
11432,NCT05223673,"Overall Survival (OS) (In Double Negative, KRAS/NRAS and BRAF Wild Type Patients) (Phase III Part)",2022-04-21,TERMINATED,INTERVENTIONAL,['PHASE3'],,Adverse Events (Phase III Part)
11433,NCT01694277,Overall Survival (OS),2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival (PFS)
11434,NCT05439993,Progression-free survival rate (PFSR) at 4 months,2022-03-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11435,NCT03550001,lymph node yield,2018-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,Local recurrence rate
11436,NCT03075553,Response Rate for Participants Who Achieve a CR or PR [CT-based Response],2017-05-17,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Events
11437,NCT01017822,Overall survival (Phase II),na,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Response rate (Phase II)
11438,NCT02399813,Progression Free Survival,2016-06-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
11439,NCT01102569,Frequency of Three BRCA1/2 Mutations in Ashkenazi Jewish Patients,2008-01,RECRUITING,OBSERVATIONAL,['NA'],,Frequency of disease modifying mutations
11440,NCT03225560,Quality of Bowel Preparation,2018-11-21,COMPLETED,INTERVENTIONAL,['NA'],,Patient reported adherence to bowel preparation instructions
11441,NCT04967183,Adverse effects,2022-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Preferences of the subjects
11442,NCT05580393,The number of cases with subtypes of human Blastocystis isolates in Sohag,2022-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The number of cases with Blastocystis infection is recorded.
11443,NCT03780049,Overall survival (OS),2018-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Conversion rate to resection
11444,NCT04216901,Accuracy of Vision location,2019-12-24,UNKNOWN,OBSERVATIONAL,['NA'],,Consistent of vision positioning between diagnostic system and endoscopists
11445,NCT00644618,Survival,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,"response rate, clinical benefit response, and safety"
11446,NCT00669136,Immunological response rate in PBMC as indicated by the ELISPOT assay,2009-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,Immunological response rate in lymph nodes as indicated by the ELISPOT assay
11447,NCT00490373,To evaluate the efficacy.,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,To characterize the quantitative and qualitative toxicities of pemetrexed in this population of pancreatic cancer patients.
11448,NCT01149304,HDR-brachytherapy isodose (measured in Gy) that corresponds to the irradiated liver tissue without enhancement of Gd-EOB-DTPA in MR imaging using an axial T1 THRIVE sequence.,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety of the study drugs.
11449,NCT00055692,To Collect Information on Hepatic Function and Hepatitis Viral Activity in Cirrhosis and Upon Potential Alterations in the Setting of VEGF-inhibition,2003-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease Stability,
11450,NCT03524287,overall postoperative morbidity rates,2018-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Lymph node noncompliance rate
11451,NCT03609489,Progression-free survival,2018-09-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease Control rate
11452,NCT02563548,"Dose Expansion Phase: Objective Response Rate (ORR): Percentage of Participants With Objective Response, as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1",2015-10-22,COMPLETED,INTERVENTIONAL,['PHASE1'],,Dose-Expansion Phase: Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)
11453,NCT01315522,The stent patency,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,adverse events
11454,NCT00606944,Recovery,2007-06,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative Complication
11455,NCT02588560,Increase (log) of HCV Viral Load between Baseline and after Chemotherapy,2015-09,UNKNOWN,OBSERVATIONAL,['NA'],,Number of Participants with Early Stop of Chemotherapy due to Hepatotoxicity
11456,NCT00267787,"Genetic analysis of blood sample as well as tissues , will provide us with any possible tumor marker for a better prognostic indicator.",2004-09,TERMINATED,OBSERVATIONAL,['NA'],,
11457,NCT03843554,Oral mucosal severity,2019-09-23,TERMINATED,INTERVENTIONAL,['NA'],,Overall survival
11458,NCT03064490,Number of Participants With Pathologic Complete Response (pCR),2017-10-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety of the Combined Drug Therapy With Radiation Therapy.
11459,NCT00925769,Part 1: PRD of Bevacizumab for Part 2,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Part 2: Overall Survival
11460,NCT05257122,progression free survival (PFS),2022-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety: the potential side effects
11461,NCT04747951,The rate of complete responses,2020-10-30,UNKNOWN,INTERVENTIONAL,['PHASE4'],,rate of intraoperative and postoperative complications
11462,NCT00004042,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11463,NCT03405272,Objective response rate,2018-02-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
11464,NCT02713269,Local tumor control rate,2016-08-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in quality of life (QOL) assessed by SF-12 healthy survey (v2)
11465,NCT03384511,Tumor response defined by RECIST criteria,2016-09-30,COMPLETED,INTERVENTIONAL,['PHASE4'],,Treatment-Related Adverse Events as Assessed by CTCAE
11466,NCT06265285,Change in patient-reported rating of Cancer CARE Cancer Connected Access and Remote Expertise (CARE) after 8 weeks,2024-03-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
11467,NCT00454636,Percentage of Participants With Grade 3 Hand-Foot Syndrome (HFS),2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Response
11468,NCT02129257,Progression-Free Survival (PFS) rate at 1 year,2014-05-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Enzyme-linked immunosorbent assay (ELISA) plasma concentrations of VEGFA, soluble VEGFR1, soluble VEGFR2, VEGF-B, PlGF, basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF). Predictive significance for response rate, PFS, OS."
11469,NCT03676426,New documentation of advance care planning in the EHR,2018-10-15,COMPLETED,INTERVENTIONAL,['NA'],,Surrogate preferences
11470,NCT05997147,Recurrence-free survival,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
11471,NCT03549338,"Number of Participants With Adverse Events (AEs) by Nature, Severity, and Occurrence.",2018-11-29,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11472,NCT01183156,Attendance to screening colonoscopy,2010-08,UNKNOWN,INTERVENTIONAL,['NA'],,Response rate to the re-invitation letter or invitation to the educational meeting
11473,NCT06070376,Reinterventions,2023-06-26,RECRUITING,INTERVENTIONAL,['NA'],,Patency time of the prostheses.
11474,NCT05383066,Progression-Free Survival,2022-05-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,disease control rate
11475,NCT05648487,R0 resection,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Relapse-Free Survival
11476,NCT04390958,Pathological complete response (pCR) rate,2020-05-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Surgical complications
11477,NCT01471756,Efficacy of Two Devices used in EMR,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Compare the Use of Two Injectates
11478,NCT05259488,LOS,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Time of tolerated food intake
11479,NCT05442502,The rate of early postoperative complications.,2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Time of esophagojejunostomy
11480,NCT05382442,Number of participants with adverse events (AEs),2022-07-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
11481,NCT00816777,Progression Free Survival,2008-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
11482,NCT04139967,Number of participants who experience a grade 2 adverse event,2020-01-20,TERMINATED,INTERVENTIONAL,['NA'],,Number of participants with improved symptoms
11483,NCT06301464,The level of serum pepsinogens,2003-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
11484,NCT05906615,Pain score,2021-01-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Dose reduction of opioids
11485,NCT03127111,Time to recurrence (TTR),2022-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Overall survival (OS)
11486,NCT06287788,The AUC of the predictive model,2024-03-01,RECRUITING,OBSERVATIONAL,['NA'],,The important predictors of severe oropharyngeal mucositis in the predictive model
11487,NCT04154124,"Number of patient that shown the different between diagnostic value of single PET/MR scan in RC staging and compare it to that of MRI alone, PET/CT alone, and combined MRI and PET/CT",2019-11-23,UNKNOWN,INTERVENTIONAL,['NA'],,
11488,NCT00261092,Overall response rate based on RECIST criteria,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
11489,NCT00041275,Survival measured weekly,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life as measured by EORTC quality of life instrument monthly
11490,NCT02864485,disease-free survival,2016-08-03,RECRUITING,INTERVENTIONAL,['NA'],,disease-free survival
11491,NCT04558684,Clinical complete response rate (cCR),2019-11-01,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of adverse events (AEs)
11492,NCT02305290,Observed procedural data,2014-08,RECRUITING,OBSERVATIONAL,['NA'],,Analysis of the costs of this procedure compared to previous treatments
11493,NCT04535024,Objective Response Rate,2021-03-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Acute Toxicity
11494,NCT04357587,Treatment response as measured by Carcinoembryonic antigen (CEA) blood test,2020-08-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,
11495,NCT04856046,Multi-target hepatocellular carcinoma panel (MHP) score,2021-11-06,RECRUITING,OBSERVATIONAL,['NA'],,
11496,NCT03029988,Visualization of Lesions by FDG PET/CT Imaging and by Tc 99m Tilmanocept SPECT/CT Imaging.,2017-07-26,TERMINATED,INTERVENTIONAL,['PHASE1'],,
11497,NCT03191123,3-year overall survival,2016-07-05,UNKNOWN,INTERVENTIONAL,['NA'],mortality,Recurrence rates
11498,NCT06214611,Accumulated dose distribution in CTV,2023-11-15,RECRUITING,INTERVENTIONAL,['NA'],,Side effects (CTC AE)
11499,NCT00599924,Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs),2005-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Initial Area Dnder the Contrast Agent Concentration-Time Curve (IAUC) of Tumors in a Selected Group of Subjects Assessed by DCE-MRI
11500,NCT00324753,Communication Content,2007-04,COMPLETED,INTERVENTIONAL,['NA'],,
11501,NCT02308384,The positive predictive value for detecting colorectal cancer in relation to indications of using iFOBT,2015-09,COMPLETED,INTERVENTIONAL,['NA'],,The rate of performed colonoscopies
11502,NCT02069561,Changes of apoptosis,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Change of Microbiota composition from baseline
11503,NCT05299840,progression-free survival,2023-06-07,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life of patients
11504,NCT01348412,progression-free survival,2010-12-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Estimate the quality of life (QLQ C30) and the fatigue MFI20
11505,NCT03619681,The proportion of patients experiencing dose limiting toxicities.,2018-09-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression free survival according to RECIST 1.1 criteria.
11506,NCT03563586,Surgical Site Infections,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,Time to beginning of adjuvant treatment for colorectal cancer
11507,NCT03087864,feasibility defined as percentage completion of treatment with atezolizumab.,2017-06-28,COMPLETED,INTERVENTIONAL,['PHASE2'],"Potential biomarker development based on assessment of tumour biopsies, blood- and faecal samples and the proposed mechanism of action of study drugs.",Overall survival
11508,NCT05764720,Acute Grade 3+ treatment related GI toxicities,2023-05-14,RECRUITING,INTERVENTIONAL,['NA'],,Progression Free Survival
11509,NCT02416609,Progression-free survival,2014-01,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
11510,NCT02078843,Number of patients correctly identified as not having GEP-NET by using Gallium-68-DOTATATE PET/CT and Indium-111-pentetreotide scintigraphy (SPECT/CT),2014-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of patients with adverse events
11511,NCT05201352,Overall survival,2022-10-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11512,NCT04163900,Overall Survival (OS),2019-12-24,TERMINATED,INTERVENTIONAL,['PHASE3'],,
11513,NCT02880020,Overall response rate defined as the number of subjects with a best objective response of confirmed CR or PR divided by the number of subjects,2016-12-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rate by Choi criteria
11514,NCT05719480,Achieve the expected number of enrolled cases,2022-11-20,RECRUITING,OBSERVATIONAL,['NA'],,
11515,NCT05646043,Individual patient compliance,2022-12-01,RECRUITING,INTERVENTIONAL,['NA'],,Laboratory examinations - coagulation factors (fibrinogen)
11516,NCT02686944,Adverse events according to CTCAE v 4.03,2016-06-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Levels of alloimmunization parameters
11517,NCT05229822,Change in number of Participants with Post-operative infectious and inflammatory complications,2021-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,16s rRNA in mesenteric lymph nodes
11518,NCT00927680,"We will recruit individuals with colorectal cancer with and without family history of CRC and their immediate family members and obtain the following: paraffin-embedded tumors blocks, blood samples, risk factor and food frequency questionnaires.",2007-07,RECRUITING,OBSERVATIONAL,['NA'],,"We will study the following parameters that we help us plan the larger population-based study such as: response rate of probands and their selected relatives, response rate of participants (probands and relatives), etcetera."
11519,NCT01308723,Part II: Safety/tolerability: Incidence of adverse events,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety: additional anti-drug antibodies sampling after termination of study drug treatment
11520,NCT06173037,Overall Response Rate (ORR) by Independent Review Committee (IRC),2023-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Expression of MSLN using IHC
11521,NCT06166576,Duration of response according to localized mRECIST,2023-11-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Post-treatment dosimetry based on Y90 PET-CT,Changes in ECOG (Eastern Cooperative Oncology Group) performance status scale
11522,NCT00964171,Non-morphological progression as defined by RECIST criteria,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Tolerability and safety as assessed by NCI CTCAE v 3.0
11523,NCT03905967,Overall survival,2019-06-16,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Time to progression
11524,NCT05399394,Incidence of Treatment-Emergent Adverse Events,2016-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Local-regional Tumor Control
11525,NCT02415036,Objective response rate in percentage of Melphalan/HDS treatment,2014-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression free survival in months of patients receiving Melphalan/HDS treatment.
11526,NCT00094003,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11527,NCT00286000,Response rate,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,TTP
11528,NCT03691090,OS,2018-12-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Antidrug Antibodies (ADAs),AE
11529,NCT03631407,Number of Participants Who Discontinued Study Treatment Due to an AE,2018-09-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,Trough Plasma Concentration (Ctrough) of Vicriviroc
11530,NCT01880554,Clinical Utility of Intraoperative Contrast Ultrasound in the Surgery of Colorectal Cancer Liver Metastases.,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,Performance Evaluation of Intraoperative Ultrasound Contrast Per Lesion: Characterisation Rate
11531,NCT00142428,Progression free survival in patients treated with cetuximab for unresectable or metastatic hepatocellular carcinoma,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
11532,NCT02966821,Progression-free survival (PFS) rate at Week 16,2017-01-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
11533,NCT03139942,Diagnostic accuracy of hyperplastic vs adenoma classification,2017-03-14,COMPLETED,INTERVENTIONAL,['NA'],,Mean time added to endoscopy due to additional imaging
11534,NCT04724551,Incidence of clinically relevant pancreatic fistula,2012-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Biological markers
11535,NCT00691054,Overall Survival Rate at 6 Months,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival of Participants
11536,NCT02613728,Cumulative Hospital Length of Stay (LOS),2016-05-13,COMPLETED,INTERVENTIONAL,['NA'],,Patient Satisfaction
11537,NCT03273608,Overall survival,2016-09-14,UNKNOWN,OBSERVATIONAL,['NA'],"Exploratory Objectives, Downstaging",Adverse Event (AE)
11538,NCT02608203,level of changes (%) between care management before DOTANOC PET and care management after DOTANOC PET,2016-05-26,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,number of patients for whom PET allowed the detection of lesions not described by standard imaging
11539,NCT06145074,Overall survival 5-years after surgery,2024-03-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Feasibility of implementing preoperative propranolol in the preoperative setting for patients with pancreatic cancer using the APEASE framework.,Safety of 40 mg propranolol twice daily on heart rate.
11540,NCT00526331,Length of Hospital Stay (LOS) by Participant,2007-08,COMPLETED,INTERVENTIONAL,['PHASE4'],,
11541,NCT06054906,Percentage of participants with ≤10% tumor cell survival in resection specimens,2023-09-25,RECRUITING,INTERVENTIONAL,['PHASE2'],Distribution of immune cells in tumor tissue,Number of participants with treatment-related adverse events as assessed by NCI-CTC
11542,NCT04617522,Percentage of Participants who Develop Positive Anti-Sacituzumab Govitecan-hziy Antibodies,2021-04-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,
11543,NCT00006348,response,2000-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11544,NCT06244446,"Objective response rate (ORR), which is defined as the proportion of patients with complete response (CR) and partial response (PR) at 6 months . CR or PR is assessed in accordance with mRECIST.",2024-02-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"Number of Participants with biomarkers change ( AFP , PIVKA II) in both groups."
11545,NCT00101582,Number of Participants With Severe (Grade 3 or 4) Oral Mucositis,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Unplanned Breaks in Radiotherapy
11546,NCT00607828,Maximum tolerated dose,2007-11-16,COMPLETED,INTERVENTIONAL,['NA'],,
11547,NCT04735198,To evaluate the rate of biliary stone disease associated to patients with midgut NET that have gone through primary tumor surgery.,2021-01-20,RECRUITING,INTERVENTIONAL,['NA'],,To compare quality of life in patients who went through a prophylactic cholecystectomy against those who did not.
11548,NCT01511653,Measure the sensitivity of a blood based panel of biomarkers relative to fecal immunochemical testing,2011-10,COMPLETED,OBSERVATIONAL,['NA'],,To measure the sensitivity and specificity of a combined panel of blood and stool based biomarkers for the detection of colorectal cancer
11549,NCT02075086,Progression Free Survival,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Feasibility
11550,NCT02232490,changes in plasma AFP,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],adverse effects,CT scan
11551,NCT02406170,Toxicity graded according to NCI Common Terminology Criteria for Adverse Events Version 4.0,2015-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
11552,NCT05287165,Incidence of Treatment Related adverse events (AEs),2022-03-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood)
11553,NCT03430635,Identification of PET/CT parameters that can be predictors of survival,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11554,NCT04499586,ORR(Objective Response Rate) includes CR(Complete Rate) and PR(Partial Rate),2019-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,the morbidity of hematological adverse events and diarrhea as assessed by CTCAE v4.0
11555,NCT05006131,Proportion of screening patients found to have high-risk pancreatic lesions amenable to treatment,2020-07-10,RECRUITING,OBSERVATIONAL,['NA'],,Proportion of screening patients who experience complications/adverse events of screen-related procedures
11556,NCT04907864,Median change (kg) in handgrip strength,2020-01-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Rate of toxicity with clinical significance, and possible relationship to either study intervention"
11557,NCT00268398,disease-free survival,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Pharmacogenetics
11558,NCT05901779,postoperative infectious complications,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,total bilirubin
11559,NCT03063554,Efficacy of Stent Patency,2016-10-18,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of Life
11560,NCT01572428,Number of Serrated Lesions Proximal to the Sigmoid Colon Per Patient,2011-04,COMPLETED,INTERVENTIONAL,['NA'],,Patients With 1 or More Conventional Adenomas
11561,NCT00002570,Survival,1994-07-15,COMPLETED,INTERVENTIONAL,['PHASE3'],,response duration
11562,NCT05125614,Overall survival,2020-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
11563,NCT00001228,,1988-10-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11564,NCT03359187,Change of mucositis grading,2016-02,COMPLETED,INTERVENTIONAL,['NA'],,Patient satisfaction with the mouth wash
11565,NCT02350530,The conversion rate of liver metastases,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life (QLQ C30)
11566,NCT00433576,Concentrations of biomarkers,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11567,NCT00028626,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11568,NCT05685602,Dose limiting toxicity rate,2023-06-12,RECRUITING,INTERVENTIONAL,['PHASE1'],Pharmacokinetics (PK) of both CA-4948 and nab-paclitaxel,Overall survival (OS)
11569,NCT02882620,Annual Completion of the FIT Kit,2016-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Change in Self-Efficacy
11570,NCT03130634,GI associated adverse events,2016-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,
11571,NCT00323583,Quality of life,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Tolerance and Safety NCI-CTC version 2
11572,NCT05444686,SUV of primary and metastases lesions,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
11573,NCT02311465,Functional Assessment of Cancer Therapy: General (FACT-G) Health Related Quality of Life Questionnaire,2015-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Hospitalizations
11574,NCT01678664,Rate of hepatic progression free survival at 24 months,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicities treatment
11575,NCT02027363,progression-free survival (PFS),2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
11576,NCT05791448,Incidence of adverse events,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics evaluation - Peak time (Tmax)
11577,NCT01216189,Change in Sexual Function (Total FSFI Scores) Between Baseline and 2 Years Follow-up.,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,
11578,NCT02795104,Percentage of Participants Who Received All Needed Screening and Any Needed Screening Across the Three Randomized Arms,2016-11,COMPLETED,INTERVENTIONAL,['NA'],,Cost of the Interventions
11579,NCT03471273,recur or not in 2 years after endoscopic surgical procedure or surgery,2017-09-18,UNKNOWN,INTERVENTIONAL,['NA'],,
11580,NCT04815746,The Gastrointestinal Symptom Rating Scale (GSRS),2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
11581,NCT03251612,Progression free survival 8 weeks after start of treatment,2017-09-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life as measured by questionnaire EQ-5D-5L
11582,NCT05350384,funduscopic examination,2021-06-18,COMPLETED,OBSERVATIONAL,['NA'],Therapy,abdominal CT-scan
11583,NCT01661088,The Percentage of Patients That Underwent an R0 Resection,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival Time
11584,NCT04657848,Rate of reflux esophagitis after operation,2020-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative nutrition status
11585,NCT06013098,the occurrence of atelectasis,2023-09-06,RECRUITING,INTERVENTIONAL,['PHASE4'],,oxygenation index
11586,NCT06247293,Intra-abdominal recurrence-free survival (RFS),2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,survival rate
11587,NCT00539318,there is no primary outcome measures in this study,2007-08,TERMINATED,OBSERVATIONAL,['NA'],,
11588,NCT00054457,Proportion of successes,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Quality of life as measured by the LASA, FACT-E and Patient Uniscale Swallowing questionnaires"
11589,NCT04336839,Progression-Free Survival,2020-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Histology predictive value
11590,NCT00845247,Quality of Life measures(questionnaire),2009-03,COMPLETED,INTERVENTIONAL,['NA'],,Care process measures in terms of monitoring of data from the National Patient Registry
11591,NCT03717298,Quality of Life: EORTC QLQ-C30,2018-10-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Compliance with the treatment with chemotherapy (CT) and Immunotherapy (IT) test
11592,NCT03278626,Phase 2: Number of Subjects Who Achieved cCR (Clinical Complete Response) or pCR (Pathological Complete Response),2017-06-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11593,NCT04977739,signal intensity of the probes,2021-08-03,COMPLETED,OBSERVATIONAL,['NA'],,
11594,NCT05606549,Fear of Progression Questionnaire-Short form (FoP-Q-SF) for Partners,2022-10-19,RECRUITING,INTERVENTIONAL,['NA'],,Dyadic Coping Inventory(DCI)
11595,NCT05726864,Phase 2: Compare ELI-002 7P versus standard of care (SOC; observation) in DFS (disease free survival),2023-04-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Determine the objective response rate (ORR) in subjects who crossover from Observation to ELI-002 7P treatment after confirmed progressive disease according to iRECIST
11596,NCT03364582,Colorectal cancer risk,2016-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Mortality
11597,NCT03486418,Optical diagnosis of each colorectal polyp,2018-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,
11598,NCT04844970,Weight change,2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Chemotherapy Dose change,AEs
11599,NCT03303833,Overall cancer diagnoses,2006-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
11600,NCT00114231,3-Year Disease-free Survival,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Local Recurrence Rate
11601,NCT05789797,"Difference of average ALP values in both of the groups, between the two timepoints: Visit 3 vs. baseline at Visit 1 (before starting therapy with the study medicines).",2022-05-12,RECRUITING,OBSERVATIONAL,['NA'],,"Proportion of patients with detected toxic damage to at least one system or organ (by selected parameters), according to the criteria of common toxicity grade III of the CTCAE scale, from the baseline (Visit 1) to Visit 4, measured in both groups."
11602,NCT01693523,Average Area Under the Curve (AUC) of Apriori Selected MDASI Symptoms,2013-01-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Relationship Between Dynamic Changes in Inflammation Biomarkers and Symptom Outcomes, Controlling for the Grouping Variables (Tumor Markers, Weight Loss), Evidence of Infection, ECOG PS, Age and Gender Examined"
11603,NCT04897854,Quality adjusted overall survival,2021-04-22,RECRUITING,INTERVENTIONAL,['PHASE3'],Level of CA 19.9,Number of patients with adverse events
11604,NCT00509964,response rate,2007-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety
11605,NCT06122636,Quality of life rate,2022-10-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
11606,NCT05627414,R0 resection rate,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,safety profile
11607,NCT00952029,Disease-control duration,2010-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Geriatric evaluation
11608,NCT04976634,Confirmed Objective Response Rate (ORR) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR),2021-08-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Arm 2: Number of Participants Who Discontinued Study Treatment Due to an AE
11609,NCT04618367,Progression free survival rate at 6 months,2021-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
11610,NCT00841607,pancreatic leak/fistula,2006-08,COMPLETED,INTERVENTIONAL,['NA'],,overall morbidity
11611,NCT06099951,Complete tumor response rate.,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Sphincter preservation rate
11612,NCT02616692,"Preference weight scores for 13 selected HCC treatment attributes associated with Sorafenib, repeated TACE, and HAIC",2016-05-09,COMPLETED,OBSERVATIONAL,['NA'],,Maximum acceptable risk of life-threatening side effect willing to take for oral anti-cancer therapy (Sorafenib) therapy that will stop cancer from getting worse for a specified period of time
11613,NCT04513808,Recurrence-free survival,2020-08-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,QoR-15
11614,NCT02223078,Antibody Levels,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants with Serious and Non-Serious Adverse Events
11615,NCT03826862,postoperative complication,2018-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,disease-free survival
11616,NCT00348699,Plasma area under the curve (AUC) of AFP464,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Percent change in CYP1A1
11617,NCT02658214,Tumor assessment based on RECIST 1.1 (for cohort 6 only),2016-04-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11618,NCT03651154,Packed Red Blood Cell Transfusion Rates,2018-09-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Changes in physiologic parameters (Pulse Pressure Variation)
11619,NCT05025033,Progression Free Survival,2019-05-30,COMPLETED,INTERVENTIONAL,['PHASE2'],biomolecular markers,adverse events
11620,NCT02419716,Positive and Negative Predictive Value,2015-04,COMPLETED,OBSERVATIONAL,['NA'],The adverse event rate (events occurring between collection kit distribution and sample submission),Colorectal Cancer Incidence
11621,NCT06190847,pCR,2023-07-01,RECRUITING,OBSERVATIONAL,['NA'],,the surgical conversion rate
11622,NCT05263830,evaluate concentration of circulating GPC-3,2023-09-08,RECRUITING,OBSERVATIONAL,['NA'],,Evaluation of the HCC response to treatment on Imaging assessment (CT-scan and MRI) every 3 months according to the miRECIST criteria (combination of mRECIST and iRECIST criteria)
11623,NCT03214835,Efficacy of EndoCDx brush,2018-02-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Assessment of pain
11624,NCT00587652,Any dysplasia or adenocarcinoma detected over all biopsies using each method.,2002-12,COMPLETED,OBSERVATIONAL,['NA'],,The association between staining patterns and histologic grade of the biopsies obtained using methylene blue will be assessed.
11625,NCT03210948,Diagnostic accuracy,2019-01-23,UNKNOWN,INTERVENTIONAL,['NA'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
11626,NCT00939848,Progression free survival,2011-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"• Response Rate (RECIST) • Toxicity • Survival (as part of the follow-on phase III study) • Biomarker evaluation (inc. circulating VEGF, sVEGFR-2, bFGF, LDH and CA 19-9) • Quality of Life"
11627,NCT05870800,"Determine the rate of complete histopathologic response to neoadjuvant immunotherapy with neoadjuvant chemotherapy in pMMR resectable, non-metastatic colon cancer.",2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Assess short and long-term quality of life through Patient-Reported Outcomes (PROs)
11628,NCT06311565,Healthy lifestyle behaviors scale II,2024-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
11629,NCT04071964,Number of participants with an anastomotic leak,2019-07-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Number of participants with cancer reoccurence
11630,NCT00020150,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11631,NCT00026403,overall survival,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,quality of life
11632,NCT01918683,Progression Free Survival,2013-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
11633,NCT00317772,Maximum Tolerated Dose (MTD) of Topotecan,2004-09-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Response Rate
11634,NCT06061276,Objective response rate (ORR),2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Overall survival (OS),Progression free survival (PFS)
11635,NCT01249521,Disease control (ie non progression) at 6 months,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Response rate
11636,NCT04395352,Adenoma detection rate (ADR),2018-11-01,COMPLETED,OBSERVATIONAL,['NA'],,Number of patients with delayed adverse events
11637,NCT06071052,"Time to progression, TTP",2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Safety evaluation
11638,NCT00825474,overall survival,2008-08,COMPLETED,INTERVENTIONAL,['NA'],,
11639,NCT03908671,Number of participants with treatment-related adverse events as assessed by CTCAE v4.03,2019-10-18,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival (OS)
11640,NCT04264676,"Disease Free Survival, DFS",2020-03-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Recurrence Rate, RR"
11641,NCT00368329,Patients' responses to therapy will be evaluated clinically after completion of their neoadjuvant chemoradiation.,2006-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,Patterns of failure and the 2-year progression-free survival (PFS) rate.
11642,NCT01815307,1 year recurrent free survival rate,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of overall survival
11643,NCT03279601,Overall response rate (ORR),2017-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events （Safety and Tolerability）
11644,NCT05586061,objective response rate (ORR),2022-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,duration of response (DOR)
11645,NCT03175705,Incidence of Treatment-Emergent Adverse Events [Safety],2017-05-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Disease Control Rate (DCR),Biological activity of infused T cells
11646,NCT01775644,Median Progression-Free Survival Time in Defined Participant Subgroups as Assessed by Response Evaluation Criteria In Solid Tumors (RECIST),2012-12-14,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants in Defined Participant Subgroups Showing Overall Response in Daily Routine Practice as Assessed by RECIST
11647,NCT04308174,Ro resection rate,2020-05-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Response rate
11648,NCT03001362,"Feasibility of a ""wait and see"" approach",2015-03,RECRUITING,INTERVENTIONAL,['NA'],,
11649,NCT04443985,Lymph node,2020-06-01,COMPLETED,OBSERVATIONAL,['NA'],,
11650,NCT03245788,Rates of unplanned hospitalization and ER visits,2017-02-15,COMPLETED,INTERVENTIONAL,['NA'],,Utilization of non-treatment-related cancer services
11651,NCT02646137,Number of patients with successful ablation,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
11652,NCT05308446,Progression-free survival (PFS),2022-07-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
11653,NCT04276090,Percent Completion of 1st Cycle of Hepatic Artery Chemotherapy,2020-05-01,TERMINATED,INTERVENTIONAL,['NA'],,Percent of Patients Who Remain on Hepatic Artery Infusion Pump Chemotherapy at 6 Months.
11654,NCT03858855,Effects of essential oils on nausea and anxiety,2019-02-18,COMPLETED,INTERVENTIONAL,['NA'],,Acceptability of using a personal inhalation bottle for inhalation of essential oils - perception of benefit of essential oil for symptoms
11655,NCT03982407,Evaluation of PSMA PET-MR for identification of intra and extrahepatic hepatocellular carcinoma in patients,2019-06-27,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
11656,NCT05390398,Change in cancer-related fatigue,2022-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Clinical parameters,Cost-effectiveness evaluation
11657,NCT03422432,Time to adjuvant systemic chemotherapy,2017-09-28,UNKNOWN,INTERVENTIONAL,['NA'],,
11658,NCT04920214,Specificity,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
11659,NCT01307956,Complete Pathological Response (pCR) Rate,2011-02-28,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival,Number of Patients Who Can Undergo Resection
11660,NCT03146520,Clinical performance of EarlyTect Colon Cancer to detect colorectal cancer,2016-12-13,COMPLETED,OBSERVATIONAL,['NA'],,Positive ratio of SDC2 methylation in other cancers
11661,NCT00079261,Complete response as assessed by Cheson criteria,2004-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Freedom from treatment failure as assessed by Cheson criteria
11662,NCT04300959,12 months OS rate,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent 3/4 Adverse Events
11663,NCT03291106,Distribution of Lynch syndromes in endometrial cancer,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,Reliability of clinical criteria for screening Lynch syndromes
11664,NCT01444456,Percentage of Participants Receiving Darbepoetin Alfa With Improvement in Patient Perceived Fatigue (PPF) and Increase in Hemoglobin ≥ 1 g/dL,2011-10,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants With Increase in Hemoglobin ≥ 1 g/dL at Any Time
11665,NCT05793593,number of people beyond the index participants who complete FIT screening,2023-03-17,RECRUITING,INTERVENTIONAL,['NA'],,
11666,NCT06118762,Progression free survival (PFS),2023-10-20,RECRUITING,INTERVENTIONAL,['PHASE4'],,Security
11667,NCT06017297,Incidence of related treatment emergent adverse events,2024-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Event Free Survival (EFS)
11668,NCT05783570,Development of anti-drug antibodies (ADA),2023-08-24,RECRUITING,INTERVENTIONAL,['PHASE1'],Immunological assessment,OS
11669,NCT04194359,Adverse Events and Serious Adverse Events,2021-02-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival
11670,NCT01088204,noncompliance rate,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,3-year disease free survival
11671,NCT02551237,IADL (Instrumental Activities of Daily Living) Score,2016-01-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,EORTC QLQ-C30 + EDL14
11672,NCT02686424,overall survival,2010-03,SUSPENDED,OBSERVATIONAL,['NA'],,
11673,NCT02777814,Incidence of hepatitis B virus associated hepatitis,2015-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Interruption of chemotherapy due to hepatitis
11674,NCT06103890,pCR,2023-05-22,RECRUITING,OBSERVATIONAL,['NA'],,OS
11675,NCT01879943,Number of patients with full colonic exploration and detection of lesions,2013-10-18,TERMINATED,INTERVENTIONAL,['NA'],,Health-economic assessment
11676,NCT02002806,Pain Control,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,"Disease-specific, recurrence-free survival"
11677,NCT06315361,Prevalence of significant fibrosis by non invasive tests,2019-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Identification of MACE
11678,NCT01433146,Temperament in non-metastatic colorectal cancer patients,2011-09,COMPLETED,OBSERVATIONAL,['NA'],,
11679,NCT00924092,To determine the safety and tolerability of escalating doses of a heated-killed yeast-based vaccine that targets tumors that express CEA.,2009-03-13,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To evaluate CD4 and CD8 immunologic response. To evaluate humoral immune response to yeast antigen. To evaluate evidence of clinical benefit such as PFS, OR, &amp; decreases in circulating tumor cells &amp; tumor markers."
11680,NCT06146946,3-year disease free survival rate,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,3-year overall survival rate
11681,NCT03451643,POSTOPERATIVE MORBIDITY,2013-02,UNKNOWN,INTERVENTIONAL,['NA'],,QUALITY OF LIFE
11682,NCT05366829,Safety as assessed by number of participants experiencing adverse events,2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Response and progression will be evaluated in this trial using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee (v1.1).
11683,NCT02374411,Collect questionnaire data from 150 HIPEC surgeons,2014-09,COMPLETED,OBSERVATIONAL,['NA'],,HIPEC surgeon attitudes toward patient nutritional support self-assessed by questionnaire
11684,NCT05009927,Progression-free-rate at 6 months (PFR 6m),2022-01-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response (DOR)
11685,NCT05518643,Rate of Postoperative Pancreatic Haemorrhage (PPH),2022-07-15,RECRUITING,OBSERVATIONAL,['NA'],,Cancer recurrence rate
11686,NCT02340065,number and rate of missed adenomas,2015-01,COMPLETED,INTERVENTIONAL,['NA'],,mean number of adenomas per procedure
11687,NCT02510469,Disease free survival,2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
11688,NCT04158635,Compliance,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Quality of life assessment,Time to treatment failure (TTF)
11689,NCT01528683,Safety and Efficacy,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
11690,NCT00855452,CR:disappearance of disease.PR:<50% decrease in the total tumor load of the lesions SD:<50% reduction and 25% increase in the sum of the products of the longest perpendicular diameters of the measured lesions.PD:>25% increase in the size of lesion.,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11691,NCT05482516,Rate of ctDNA Progression of Disease (POD) or Clinical/radiographic Relapse,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE3'],,Reasons for failure of enrollment
11692,NCT02184182,Percentage of R0 resections,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,hepatic diesease free survival
11693,NCT00131638,Incidence percentage of severe oral mucositis (Grades 3 or 4 on the WHO oral mucositis scale),2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of >/equal to 5 missed consecutive fractions of scheduled RT (to include discontinuations of RT)
11694,NCT02904031,"Progression Free Survival (PFS). PFS is defined as the time from randomization to the first documentation of objective disease progression or death due to any cause, whichever occurs first.",2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
11695,NCT04000529,"Dose interruptions, reductions and dose intensity, by treatment",2019-07-30,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Survival
11696,NCT05482477,Clock Drawing Task(CDT),2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The time of get out of bed for the first time after operation
11697,NCT00410956,"Antitumor efficacy (complete and partial response, stable and progressive disease)",2007-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity as measured by NCI Common Toxicity Criteria
11698,NCT03931980,Conversion to open surgery,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Time of surgery
11699,NCT06134193,Progress free survival (PFS) per RECIST v1.1,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence rate of adverse events
11700,NCT05101629,Objective response rate (ORR) according to RECIST 1.1 criteria,2022-05-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and toxicity
11701,NCT02688699,effectiveness of EndoClotTM in preventing post-procedural bleeding,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,
11702,NCT02206360,Premalignant or malignant pancreatic conditions found with alternating EUS and MRI testing.,2014-04,RECRUITING,OBSERVATIONAL,['NA'],,Non-Pancreatic cancers diagnosed while on this protocol
11703,NCT05495529,Clinical success,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Progression free survival
11704,NCT06059170,Frequency of LARS,2017-03-17,COMPLETED,INTERVENTIONAL,['NA'],,
11705,NCT02280278,Disease free survival,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,toxin-side effect
11706,NCT05303298,Objective gastro-oesophageal reflux (GOR),2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Survival
11707,NCT06280495,3-year Progression-Free Survival Rate,2024-02-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Treatment-related adverse events
11708,NCT00002631,,1995-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11709,NCT00867750,Health-related quality of life (HRQL),2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pharmaco-economic assessment
11710,NCT03179579,Median overall survival,2017-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Risk factors for morbidity and mortality
11711,NCT03964753,OS,2019-04-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of Adverse Event
11712,NCT05800418,Area under drug concentration - time curve (AUC0-t),2019-11-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Apparent volume of distribution (Vd)
11713,NCT04755036,Measurement of consensus in therapeutical decisions in pancreatic cancer between low/mid vs high volume hospitals,2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11714,NCT06056804,pCR rate,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],The expression of CD8,irAE
11715,NCT01613469,To assess the complete clinical response rate following neoadjuvant chemoradiation in patients with distal rectal cancer.,2011-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,The proportion of subjects with complete pathological response at surgical resection
11716,NCT03457454,Assess the care coordination and communication with primary care providers by colonoscopy clinics/practitioners,2017-09-08,COMPLETED,OBSERVATIONAL,['NA'],,
11717,NCT05908747,Surgical complete resection rate (R0),2023-05-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AEs)
11718,NCT05957640,Objective response rates (ORR),2023-05-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Resection rate of liver target lesions
11719,NCT04996459,overall response rate,2020-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,Safety (the incidence of adverse events and serious adverse events)
11720,NCT00020267,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11721,NCT02949947,Complete Response Rate in Hemoglobin (HGB),2017-12-18,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11722,NCT06074029,Progression free survival,2021-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to treatment discontinuation
11723,NCT06219941,Objective Response Rate (ORR).,2023-12-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,"ADA status will be determined along with prevalence and incidence of anti-drug antibodies to AZD0901, and titer established."
11724,NCT03890198,Systemic Cytokine Concentrations,2019-04-22,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Overall Survival (OS) after administration
11725,NCT05322577,Part 2: Objective Response (OR) as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1),2022-05-17,RECRUITING,INTERVENTIONAL,['PHASE1'],,Part 2: OS
11726,NCT01124630,Progression Free Survival,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Serum concentrations
11727,NCT03857737,5-year DSS,2019-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Complication
11728,NCT02342847,Change from baseline of the Karnofsky index,2014-12-10,COMPLETED,OBSERVATIONAL,['NA'],,Physical examinations
11729,NCT01595256,Exploration the Effect of Walking Program in Patients With Colorectal Cancer.,2011-10,COMPLETED,INTERVENTIONAL,['NA'],,
11730,NCT05794971,Overall Survival (OS),2023-06-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse enents
11731,NCT05514561,The diagnostic performance of fecal calprotectin in diagnosis of significant ileocolonic lesions,2020-03-22,COMPLETED,OBSERVATIONAL,['NA'],,The diagnostic performance of fecal immunochemical test in diagnosis of significant ileocolonic lesions
11732,NCT01567930,Disease Progression,2010-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Circulating tumor cells levels
11733,NCT02424955,Changes in Blood Perfusion (Relative Blood Flow),2014-11-18,COMPLETED,INTERVENTIONAL,['NA'],,
11734,NCT05301465,PFS,2021-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
11735,NCT00898846,mRNA levels,2006-10,COMPLETED,OBSERVATIONAL,['NA'],,Histopathological examination
11736,NCT05446129,Composite endpoint: Proportion of patients with at least one occurrence of a safety or feasibility event,2022-09-27,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Radiographic response on pre-surgical imaging, following receipt of the neoadjuvant therapy, as per response evaluation criteria in solid tumors (RECIST) v1.1"
11737,NCT00041639,,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11738,NCT03016026,Rehabilitative rate,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Mortality rates
11739,NCT02575300,Overall Radiographic Response Rate (ORR),2015-10-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
11740,NCT02329860,Overall Survival,2014-03-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease Control Rate
11741,NCT04389892,Differentiation between murale nodules and mucus clots or debris,2018-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Guiding EUS-FNA by the enhancement pattern
11742,NCT03318380,Negative Predictive Value of contrast-enhanced ultrasound evaluation (CEUS) for diagnosis of Hepatocellular cancer using a 95% confidence interval,2018-01-19,COMPLETED,INTERVENTIONAL,['NA'],,
11743,NCT03957135,2 year survival,2019-05-20,RECRUITING,INTERVENTIONAL,['NA'],,
11744,NCT00501410,"Maximum Tolerated Dose (MTD) of Dasatinib, Cetuximab and FOLFOX",2007-04-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response-Rate of Dasatinib and Modified FOLFOX6 With or Without Cetuximab
11745,NCT01032928,Optimal Respiratory - Swallow Phase,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Impairment According to the Penetration-Aspiration Scale
11746,NCT04084158,PFS,2019-09-07,SUSPENDED,INTERVENTIONAL,['PHASE2'],,TTDM
11747,NCT06047015,Abscopal effect: percent change in non-treated colorectal liver metastasis.,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life questionnaire
11748,NCT01338558,Progression-free survival: native versus mutated K-RAS; tumour assessments according to RECIST criteria,2011-06,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Progression-free survival: comparison of the two treatment regimens in the native K-RAS arms
11749,NCT04508140,Safety: Adverse Events,2020-06-17,TERMINATED,INTERVENTIONAL,['PHASE2'],,Survival Rate
11750,NCT00247338,Infectious complications,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Post-operative nutritional cost & total treatment cost
11751,NCT00436215,Clinical Response Rate.,2006-12-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
11752,NCT03384940,Number of Participants With Objective Response Rate Based on Independent Central Review (Confirmed and Unconfirmed) Following DS-8201a Treatment in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Advanced Colorectal Cancer,2018-02-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment-Emergent Adverse Events (TEAEs) Reported By ≥20% Of Participants Following Treatment With DS-8201a in Participants With HER2-expressing Advanced Colorectal Cancer
11753,NCT05580224,Local tumor progression rate,2022-10-04,RECRUITING,INTERVENTIONAL,['NA'],,Recurrence-free survival
11754,NCT06302660,Identify microbiome dysbiosis in stool associated with long-term functional symptoms.,2022-03-09,RECRUITING,OBSERVATIONAL,['NA'],,Propose a strategy for treatment of long-term symptoms in oesophageal adenocarcinoma survivors.
11755,NCT04666727,Somatic mutation burden,2020-09-29,RECRUITING,OBSERVATIONAL,['NA'],,
11756,NCT04196062,Complete (R0) resection,2020-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Technical Success
11757,NCT03829748,Increase in diagnostic yield of pancreatic solid lesions,2019-01-16,COMPLETED,INTERVENTIONAL,['NA'],,Number of passes to reach diagnosis
11758,NCT00489268,Percentage of Participants With Histological Clearance of Barrett's Metaplasia,2003-11,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Participants With Sub-squamous Intestinal Metaplasia
11759,NCT00931203,"The primary objective is to determine the pathological complete response (pCR) of combining preoperative tegafur-uracil, folinate, radiation and celecoxib for locally advanced rectal cancer.",2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Sphincter preservation rate.
11760,NCT06311929,Disease-free survival,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,Overall survival
11761,NCT05723978,Disease-free survival (DFS),2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11762,NCT02591784,The rate of AE(adverse event) or toxicity ( Both acute and chronic toxicity will be evaluated.),2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
11763,NCT04248452,Overall survival,2020-05-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,Progression-free survival
11764,NCT01872104,Survival rate,2013-08,SUSPENDED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Quality of life,Progression-free survival
11765,NCT05907772,Overall survival,2022-08-27,COMPLETED,OBSERVATIONAL,['NA'],,
11766,NCT04319484,3 years recurrence-free survival rate,2020-05-02,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,5 years overall survival rate
11767,NCT00516269,Mean Difference Between Post-Methylphenidate and Post-Placebo Measurement,2004-08,TERMINATED,INTERVENTIONAL,['PHASE3'],,
11768,NCT02288611,Change from baseline in large intestinal microbiota composition verses control intervention (0-3 months),2012-05,COMPLETED,INTERVENTIONAL,['NA'],,Change from baseline in Bowel function verses the control intervention (0-3 months
11769,NCT05722327,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)",2023-12-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,
11770,NCT01764087,Tumor Overall Response Rates (ORRs) in Phase II Portion,2012-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Exploratory Biomarker Evaluation in Phase II Portion,Pharmacokinetic (PK) Evaluation in Phase II Portion
11771,NCT03478943,Disease-free surviva,2016-01-30,UNKNOWN,OBSERVATIONAL,['NA'],,Disease Control Rate
11772,NCT04010227,Short-form of Zarit Burden Interview,2019-09-16,COMPLETED,INTERVENTIONAL,['NA'],,Value Progress Subscale of the Valuing Questionnaire.
11773,NCT05959564,Intentions toward HPV vaccination,2023-07-26,COMPLETED,INTERVENTIONAL,['NA'],,Ratings of the Chatbot
11774,NCT03110926,Disease-free survival rate,2017-06-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall disease-free survival
11775,NCT05105828,Shear wave elastography score,2020-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
11776,NCT01812577,Intensity of postoperative pain after radiofrequency ablation of liver lesion,2012-12,UNKNOWN,OBSERVATIONAL,['NA'],Satisfaction of patient and of the operator,Consumption of post-operative opioid
11777,NCT05068193,Cmax,2021-09-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11778,NCT02981862,Assessement of CaptHPV method,2016-12-19,COMPLETED,INTERVENTIONAL,['NA'],,
11779,NCT03390517,Anastomotic Leak Rate,2017-11-09,COMPLETED,INTERVENTIONAL,['NA'],,
11780,NCT05025631,PFS,2020-11-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlation between geriatric assessment and efficacy and safety
11781,NCT01127711,"Fractures, hip fractures",1997-09,COMPLETED,OBSERVATIONAL,['NA'],,
11782,NCT03480971,Mucositis,2019-05-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Mucositis
11783,NCT04067986,Objective response rate,2019-08-20,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Treatment-Emergent Adverse-Events
11784,NCT04903340,Average dose value (Gy) of tumor liver and healthy liver obtained according to reconstruction configuration.,2021-04-12,COMPLETED,OBSERVATIONAL,['NA'],,
11785,NCT03081494,Incidence of Dose-limiting toxicity (DLT),2017-06-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Severity of AEs and SAEs
11786,NCT02624271,Sensitivity of GastroPanel blood test,2016-08-04,COMPLETED,INTERVENTIONAL,['NA'],,
11787,NCT01219920,Response rate (RR),2001-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life (QoL)
11788,NCT00693290,Clarity of the mucosa evaluated by the Ottawa Scale.,2008-06,UNKNOWN,INTERVENTIONAL,['NA'],,Concordance with the bowel preparation.
11789,NCT03907579,Number of Participants With Varying Levels of Behavioral Intentions Related to Colorectal Cancer Screening and Prevention,2017-03-11,COMPLETED,INTERVENTIONAL,['NA'],,
11790,NCT01150877,"The metabolic consequences, including tolerability and toxicity, of prolonged, high-dose physiological vitamin D in patients with colorectal cancer.",2011-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Patient survival with regards to high-dose vitamin D supplementation.
11791,NCT03539822,Phase II- Overall Response Rate (ORR),2018-10-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
11792,NCT02509169,overall survival,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,progression free survival
11793,NCT04878185,Change in maximal walking distance,2021-05-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Mortality
11794,NCT02338297,APS improvement,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Response Rate
11795,NCT05452473,Gastric lesion detection rate,2022-07-06,RECRUITING,INTERVENTIONAL,['NA'],,Lesion classification accuracy
11796,NCT03491540,Postoperative 30-day surgical site infection (SSI).,2018-09-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Temporary stoma closure rate
11797,NCT05242237,Time to progression or death (months),2021-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
11798,NCT00766636,Difference in Positive Margin Resection (R1) Rate in Patients Undergo Surgery Between the Two Treatment Groups.,2008-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11799,NCT01504126,Proportion of patients who successfully complete 6 cycles of chemotherapy with propranolol hydrochloride,2012-03-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],"Changes in immune response, measured by serum levels of VEGF",Changes in mood state as measured by Center for Epidemiologic Studies Depression Scale (CES-D
11800,NCT01112280,Adenoma detection rate,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,Surveillance
11801,NCT03008278,Objective response rate (Phase II),2018-02-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Tumor cells for PDX model, and biobanked tumor tissue and peripheral blood",Incidence of adverse events
11802,NCT01685632,heat shock protein expression (blood/cell ratio)compared to baseline values,2012-09,TERMINATED,INTERVENTIONAL,['NA'],,
11803,NCT00435097,,na,UNKNOWN,OBSERVATIONAL,['NA'],,
11804,NCT05994859,Success rate of conversion to resection,2023-08-10,RECRUITING,INTERVENTIONAL,['NA'],,Adverse Events (AEs)
11805,NCT02025244,To compare the yield and success of KHB and EUS-FNA in cytological / histological and immunohistochemical diagnostics of Upper Gastrointestinal Submucosal Tumors.,2010-11,UNKNOWN,INTERVENTIONAL,['NA'],,Detection of mitotic activity in case of Gastrointestinal Stromal Tumors
11806,NCT03676517,pathologic complete response (pCR) rate,2019-03,UNKNOWN,INTERVENTIONAL,['NA'],,Cost effectiveness
11807,NCT03946852,Ischemic Cholangiopathy,2019-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Re-operation rate,Graft survival
11808,NCT03340558,Change in CD8 T cell immune infiltrates,2018-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
11809,NCT02021110,Effect of UDCA on total liver volume,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse events as a measure of tolerability and safety of UDCA,Effect of UDCA on absolute total kidney volume
11810,NCT01743469,"Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All Cohorts).",2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Further Cancer-related Treatment During Follow-up Period (All Cohorts).
11811,NCT01423708,Everolimus monotherapy,2010-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
11812,NCT05233787,Quality of life over the 12 months after surgery,2022-03-24,RECRUITING,INTERVENTIONAL,['NA'],,Changes in microbiome composition and diversity from baseline to 1 month
11813,NCT04866108,Objective Response Rate (ORR),2021-12-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL)
11814,NCT00557102,Tumor response rate,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tolerability
11815,NCT02454647,R0 resection rate,2013-09,COMPLETED,OBSERVATIONAL,['NA'],,Adverse events are assessed according to CTC criteria v 4.0
11816,NCT04868747,serum concentration of NET(neutrophil extracellular trapping)-related biomarker,2021-04-01,WITHDRAWN,INTERVENTIONAL,['NA'],,survival of patients
11817,NCT04085211,"Sensitivity, specificity, positive predictive value of specific endoscopic image enhancement findings to diagnose or stage the severity of different gastrointestinal conditions",2019-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,median duration for image enhanced endoscopy procedures
11818,NCT02584556,recurrence free survival,2015-10,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time of tumor distant metastasis
11819,NCT05714475,Disease free survival,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Disease free survival (12)
11820,NCT02901301,The overall response rate using RECIST 1.1,2017-02-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to response
11821,NCT02324556,Number of specimens with grade I specimen according to Quirke,2015-01,TERMINATED,OBSERVATIONAL,['NA'],,Postoperative complications scored according to Clavien-Dindo within the first 12 months
11822,NCT05835778,Incidence of ADRs,2023-06-07,RECRUITING,OBSERVATIONAL,['NA'],,
11823,NCT04717648,Early predictive factors of anastomotic leakege,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11824,NCT00932724,Tumor assessment by using CT scans and/or MRIs,2009-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Assessment of survival by ""physical exam"""
11825,NCT03443661,pCR,2016-02-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
11826,NCT03291288,Overall Summary of Treatment-emergent Adverse Events,2018-02-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic Analysis: Metabolite to Parent Ratio (MPR) for Midazolam
11827,NCT00447746,5 year overall survival,2007-03,UNKNOWN,INTERVENTIONAL,['NA'],,: Postoperative morbidity and mortality rates
11828,NCT00003912,Resection rate,1998-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11829,NCT04982939,Pathological complete response (pCR) rate,2021-06-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
11830,NCT05165446,Novel MRE technique to assess tissue viscoelasticity as a risk factor for liver cancer,2022-01-27,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Studies on liver injury and glycemic control.
11831,NCT03615170,Disease free survival,2017-07-19,UNKNOWN,OBSERVATIONAL,['NA'],,
11832,NCT00422864,Tolerability rate,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Distant response rate
11833,NCT04561791,Prevalence of Barrett's esophagus within the single Primary Care Practice cohort.,2019-01-02,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
11834,NCT05849480,Phase II: Overall response rate (ORR),2024-04-07,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,5-year overall survival
11835,NCT03668158,recurrence rate,2018-11-20,UNKNOWN,OBSERVATIONAL,['NA'],,
11836,NCT06126575,AUC from time zero to infinity (AUC0-∞),2024-01-24,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
11837,NCT02814864,Decrease of one grade on the LENT SOMA,2021-04-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Frequency of diarrhea
11838,NCT06035731,Patient Centricity Questionnaire (PCQ): Patient reported outcome: impact of supportive care,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Anxiety
11839,NCT03513198,Change of Wash-in Perfusion Index (WiPI) from baseline to 2 months after the first course of treatment,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Tumor response to treatment
11840,NCT02193594,The patient's survival time and recurrence time,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",The pathologic profiles and the pathologic response rates,The number of patients with complications
11841,NCT01205828,Clinical Benefit Rate,2010-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Biomarker Analysis
11842,NCT00906373,Progression Free Survival (PFS),2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Number of Participants With Serum Anti-Cixutumumab Antibody Assessment (Immunogenicity)
11843,NCT02226224,the consistency between EUS and pathologic determination of tumor depth,2014-06,UNKNOWN,OBSERVATIONAL,['NA'],,
11844,NCT04198025,Number of post operative complications (Clavien-Dindo grade 3-4) during inpatient hospital stay.,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Post operative complications beyond hospital discharge.
11845,NCT00516841,Efficacy as measured by objective response rate (ORR). Tumor response based on RECIST criteria.,2007-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11846,NCT00089401,Duration of response,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
11847,NCT02964260,Overall survival,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,Times of interventional procedures
11848,NCT04889495,Safety profile,2024-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Efficacy profile
11849,NCT05779553,Tumor endothelial marker 1 in colorectal cancer,2023-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
11850,NCT02070146,Progression free survival,2013-05,RECRUITING,OBSERVATIONAL,['NA'],,Work Ability Index (WAI)
11851,NCT01304160,Number of participants with adverse events,2010-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival
11852,NCT04699487,Percentage of patients with at least one OM grade >2 at any time during radiotherapy.,2021-05-10,COMPLETED,INTERVENTIONAL,['NA'],"For each neck dermatitis lesion: date of onset, location and CTCAE v5 grade",Evolution of body weight over time
11853,NCT03080701,CRC Screening Within 6 Months Following Randomization,2017-03-23,COMPLETED,INTERVENTIONAL,['NA'],,
11854,NCT04069975,Detection rate of precancerous lesions and cancer of upper digestive system improvement,2019-06-02,UNKNOWN,OBSERVATIONAL,['NA'],,
11855,NCT01042743,surgical quality based on pathological examination,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,complication
11856,NCT02791503,Overall survival,2016-05-30,COMPLETED,INTERVENTIONAL,['NA'],,Tumor marker CA 19.9
11857,NCT03979547,Acceptability-scientifically adequate,2019-01-03,TERMINATED,INTERVENTIONAL,['NA'],,visceral adipose tissue (VAT)
11858,NCT03913962,Maximal lipid oxidation rate during submaximal incremental exercise,2019-05-02,RECRUITING,INTERVENTIONAL,['NA'],,Blood sample calprotectin
11859,NCT03473925,Number of Participants Who Discontinue Study Treatment Due to an AE,2018-04-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Navarixin Trough Plasma Concentration (Ctrough)
11860,NCT02626091,Correlation between the perfusion evaluated by the ICG fluorescence-based enhanced reality and the metabolic state of the intestine,2016-09-14,COMPLETED,INTERVENTIONAL,['NA'],,Distance between the resection site based on the surgeon's appreciation and the resection site based on the digital analysis and the peri-operative samplings
11861,NCT04859400,QoL,2021-06-07,RECRUITING,INTERVENTIONAL,['NA'],,Success of recruitment rate in comparison to former studies
11862,NCT05079503,Immune modulation in tissue,2021-12-15,UNKNOWN,INTERVENTIONAL,['NA'],,Identify predictive biomarkers for pathologic responders
11863,NCT02718859,Relief degree,2016-03-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
11864,NCT04893252,Objective response rate,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
11865,NCT06321055,Time to Next Therapy (TTNT) therapy after regorafenib,2024-03-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Number of patients with evidence of surgery on or after the index date during the follow-up period using Current Procedural Terminology (CPT) codes and International Classification of Disease 9/10 Procedure codes (ICD-PC).
11866,NCT03013972,Cancer-related fatigue evaluation by brief fatigue inventory-Taiwanese form(BFI-T),2015-11,UNKNOWN,OBSERVATIONAL,['NA'],,Quality of life assessments by functional assessment of cancer therapy-general 7 (FACT-G7)
11867,NCT03561350,MSI status in blood sample,2017-09-28,UNKNOWN,OBSERVATIONAL,['NA'],,
11868,NCT02651701,the concordance rate between rectal cancer staging performed by WB MR-PET and the current standard of care (chest/abdominopelvic CT and rectal MRI,2016-01,COMPLETED,OBSERVATIONAL,['NA'],Transient dyspnea,concordance rate of clinical stagings and true M staging obtained by biopsy or follow-up
11869,NCT05286099,Effective detection of early hepatocellular carcinoma,2022-01-15,UNKNOWN,OBSERVATIONAL,['NA'],,
11870,NCT03381352,Response rate,2015-12-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
11871,NCT03736824,Correlation of endoscopic findings and symptoms,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,The infection rate of Helicobacter Pylori
11872,NCT03867799,Disease Control Rate (DCR),2019-03-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
11873,NCT04660760,Progression-free survival,2021-06-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
11874,NCT05880667,To assess the ability of adaptive SBRT to deliver increased doses of radiation safely to patients with challenging anatomical locations of metastatic disease without causing unacceptable toxicity.,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,
11875,NCT00088660,,2004-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
11876,NCT03211598,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2016-10,UNKNOWN,INTERVENTIONAL,['NA'],,FACT Hep4 Questionnaire
11877,NCT01732783,Percentage of Participants With at Least One Concomitant Chemotherapy Dose Delay,2012-12-10,COMPLETED,OBSERVATIONAL,['NA'],,Type of Post-Panitumumab Anti-cancer Treatment
11878,NCT00232453,Assess acute toxicity and complete remission rate of combined preoperative radiation and chemotherapy,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11879,NCT03506529,CT scan with measurement,2018-09-17,COMPLETED,OBSERVATIONAL,['NA'],,
11880,NCT03123042,detection rate (%),2017-03-20,RECRUITING,INTERVENTIONAL,['NA'],,False negative rate
11881,NCT04789486,Compare Local Control at 12 months of Maximum tolerated dose MTD - Phase 2,2021-05-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of Life (QoL)-Completion of Daily Activities utilizing PROMIS Physical and Mental Health batteries
11882,NCT00156975,Disease free survival,2004-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Secondary outcomes:overall survival,acute- and longtime toxicity of chemotherapy, molecular predictive markers for the risk of relapse and toxicity"
11883,NCT04937673,biomarkers related to pCR,2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
11884,NCT03753399,Average trajectory of C-ESAS over time,2019-01-04,COMPLETED,INTERVENTIONAL,['NA'],,Number of Circulating tumor cells detected using microfluidic chip
11885,NCT05800054,Body weight and body mass index (BMI),2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,ORR
11886,NCT03505229,freedom of local failure,2018-12-18,RECRUITING,INTERVENTIONAL,['NA'],,Feasibility of Using Kilovoltage Intra-fraction Monitoring (KIM) to determine pancreas motion
11887,NCT01335945,Abdominal pain reduction following cryoablation of the celiac plexus,2011-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Safety assessment
11888,NCT00352131,Maximum tolerated dose,2005-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor activity
11889,NCT01525940,To evaluate the completeness of colonic exploration in patients with a previous incomplete conventional colonoscopy due to technical failure (not due to inadequate cleansing level).,2011-11,COMPLETED,INTERVENTIONAL,['NA'],,To evaluate the difference in terms of accuracy and completeness between PCCE and CT-colonography
11890,NCT05039177,Adverse Events,2021-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of Response (DOR)
11891,NCT03042780,Objective Radiographic Response Rate (ORR),2017-02-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Treatment Related Morbidity,Progression Free Survival (PFS)
11892,NCT03509298,Objective response rate,2018-04-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Symptom remission rate
11893,NCT02448173,Disease-Free Survival,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Recurrence-Free Interval
11894,NCT04517227,Discontinue rate caused by any AEs,2021-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
11895,NCT04566614,PREVAIL ctDNA Part 2 Study,2020-06-18,RECRUITING,OBSERVATIONAL,['NA'],,PREVAIL ctDNA Part 2 Study secondary end point 6d
11896,NCT04280666,"sensitivity, specificity, positive predictive value, and negative predictive value",2019-06-20,UNKNOWN,OBSERVATIONAL,['NA'],,Characteristics of the gene map and the correlations with clinical characteristics
11897,NCT00385021,The primary objective is to determine if the rate of adverse events among patients receiving chronoFOLFOX plus Avastin is acceptable compared to that in previous studies using the FOLFOX4 regimen.,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11898,NCT00930410,The principal outcome is the percentage of successful in vivo examination according to the localisation of the stenosis. A successful examination is defined by the obtention of exploitable image for the anatomopathology.,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,Frequency and grade of adverse effects induced by the confocal endomicroscopy
11899,NCT01055743,To assess the clinical benefit of fluorouracil implants regional chemotherapy during the radical resection in early stage hepatocellular carcinoma patients. The primary endpoint is disease-free survival (DFS).,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
11900,NCT03082053,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) or Recommended Phase II Dose (RP2D) in Phase I setting.,2017-01-31,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Pharmacokinetics: varlinitib, capecitabine and 5-FU metabolites levels in terms of Elimination half-life of Phase β (t1/2β)"
11901,NCT04920032,Percentage of ctDNA positivity in treatment cohort after 6 cycles or at least 3 months of adjuvant treatment,2021-08-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,Percentage of Grade 3-5 Adverse Events
11902,NCT03712774,Quality of life,2018-10-12,RECRUITING,OBSERVATIONAL,['NA'],,late toxicity
11903,NCT00875147,Overall complications,2009-04,COMPLETED,OBSERVATIONAL,['NA'],,"specific complications such as liver insufficiency, length of hospital stay"
11904,NCT04103398,Overall Survival,2019-10-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Scoring of Quality of Life
11905,NCT03447106,cost of treatment,2018-02-28,UNKNOWN,INTERVENTIONAL,['NA'],"the all number of postoperative complications（ frequency,reflux esophagitis and bile reflux gastritis）",the operation time
11906,NCT02305043,Percentage of Participants With Objective Response,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,overall survival
11907,NCT06206603,Traceability of microRNA/mRNA expression of polyps and cancer in blood,2024-01,RECRUITING,OBSERVATIONAL,['NA'],,Correlation of Intestinal microbiota and microRNA/mRNA expression
11908,NCT01280825,Feasibility of incorporating pharmacogenomic testing into routine medical care,2011-01-14,RECRUITING,OBSERVATIONAL,['NA'],To determine whether access to pharmacogenomic information improves satisfaction with care.,Find out whether availability of pharmacogenomic information impacts drug decision making in the health care setting
11909,NCT01259024,Monitor Safety After Treatment of DEB by Measuring Liver Function Tests and Assessing Performance Status.,2011-12,TERMINATED,INTERVENTIONAL,['NA'],,To Track Survival Following Treatment With DEB to Confirm That Any Gains in Response Are Associated With an Increase in Survival.
11910,NCT00820053,Overall survival,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to recurrence
11911,NCT06202014,ORR,2024-01-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of grade 3 and above adverse events
11912,NCT01092481,disease-free survival,2010-01-26,UNKNOWN,INTERVENTIONAL,['PHASE3'],,safety profiles
11913,NCT05914610,Surgical conversion rate,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life (QOL)
11914,NCT00825240,Colorectal Cancer Patients' Concerns + Behavior Changes Post Treatment,2008-12,COMPLETED,OBSERVATIONAL,['NA'],,
11915,NCT04720430,"Incidence of ""Wait List Drop Off""",2019-12-03,COMPLETED,OBSERVATIONAL,['NA'],,Clinical Status of the subset of patients successfully reaching liver transplant
11916,NCT05514171,Disease free survival,2023-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
11917,NCT03508570,Maximum tolerated dose (MTD)/recommended phase II dose (RP2D) of intraperitoneal (i.p.) nivolumab in combination with ipilimumab,2018-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
11918,NCT05871567,survival rate,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,recurrence rate
11919,NCT02424279,Change from baseline pain intensity at 1 year (BPI questionnaires),2014-09,UNKNOWN,INTERVENTIONAL,['NA'],,"Quality of life and pain intensity measurement (measured with the QLQ- C30, FACIT and BPI questionnaires)"
11920,NCT03278444,Overall Survival,2017-07-18,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Chinese Quality of Life Questionnaire - EORTC QLQ-C30 score
11921,NCT04831528,Objective response rate,2021-04-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,duration of response
11922,NCT01340755,Adequacy of the total mesorectal excision based on standard guidelines on pathologic evaluation of TME specimens.,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,Oncologic outcomes in subjects receiving transanal endoscopic rectosigmoid resection
11923,NCT00578201,"objective response rate (ORR) at 12 weeks with radiochemotherapy (first evaluation), and if applicable, within 2 to 4 weeks following the end of additional treatment with the combination Cetuximab-FOLFOX (second evaluation)",2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression free survival Quality of life Dysphagia score Overall survival toxicity of this regimen
11924,NCT00922688,"The effect of intravenously and enterally administered dipeptide alanyl-glutamine preoperatively on postoperative insulin resistance in colon cancer patients.given, on postoperative insulin resistance in colon cancer patients.",2010-12,UNKNOWN,INTERVENTIONAL,['NA'],,The effect of dipeptide alanyl-glutamine on key enzymes involved in glucose production.
11925,NCT02008383,Objective response rate (ORR) of cabozantinib monotherapy in patients with prospectively identified MET amplified metastatic colorectal cancer,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,To describe the safety and tolerability of cabozantinib monotherapy in patients with MET amplified colorectal cancer
11926,NCT04227951,30 day reoperation AND/OR additional drain placement,2019-12-17,COMPLETED,INTERVENTIONAL,['NA'],,Drain related complications
11927,NCT00002893,,1995-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
11928,NCT04678492,Helicobacter pylori eradication,2020-12-20,COMPLETED,INTERVENTIONAL,['PHASE4'],,adverse events
11929,NCT03847753,Risk of Cancers,2000-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11930,NCT01839981,Overall Survival,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety profile assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
11931,NCT00661882,"Development of the Pancreatic Cancer Collaborative Registry (PCCR) infrastructure as a repository for socio-demographic, environmental, clinical, and family history data",2003-02,COMPLETED,OBSERVATIONAL,['NA'],,
11932,NCT00464295,To evaluate response rate and overall survival after completing minimum of three cycles of Capecitabine in Advance HCC,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate the time to progression, toxicity and quality of life for patients on chemotherapy"
11933,NCT00429858,Correlate Intratumoral Expression Level of Ribonucleotide Reductase Subunit 1 (RRM1) With Response to Gemcitabine in Patients With Advanced Pancreatic Cancer.,2007-01-22,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Patients With at Biomarker Response
11934,NCT01481545,Percentage of Patients With Complete Tumor Regression Rate (TRG1),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patients With Metastatic Lymphnodes at Pathology Exam After Surgery
11935,NCT02504411,Complete adenoma resection rate (CARE) for adenoma > 10 mm in diameter as determined by Colonoscopy,2015-08,WITHDRAWN,INTERVENTIONAL,['NA'],,Cecal Intubation Rate (CIR)
11936,NCT05029453,Progression Free Survival [PFS],2021-08-26,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Adverse Events [AEs]
11937,NCT06317272,Reproducibility DIBH,2021-02-10,TERMINATED,INTERVENTIONAL,['NA'],,
11938,NCT04591821,QoL,2018-02-15,COMPLETED,OBSERVATIONAL,['NA'],,Correlation LARS score QoL
11939,NCT02852096,The positive rate of cohort using dual or multiple tumor tissue paraffin blocks,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],,
11940,NCT05039333,Complication rate,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,
11941,NCT04894370,Progression-Free Survival (PFS) rate at 1 year.,2022-06-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival (PFS) median.
11942,NCT00848237,Adverse Event Incidence,2007-07,COMPLETED,INTERVENTIONAL,['NA'],,
11943,NCT00005638,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11944,NCT02429622,Disease-free survival (DFS),2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Adverse events,Overall survival (OS)
11945,NCT05887661,The proportion of allogeneic red blood cell products transfusion,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Number of Participants with postoperative complications (overall)
11946,NCT01609309,3-year disease free survival rate,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Inflammatory and immune response
11947,NCT06152471,Occurrence of Abemaciclib induced diarrhea - STIDAT,2023-06-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,Breast cancer recurrence
11948,NCT03497819,The Percentage of Adverse Events (AEs) ≥ grade 3 assessed through MedDra and CTCAE v4.03 [Time frame: from infusion to 3 month afterward],2017-10-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Overall Response Rate defined as any improvement measured by imaging following RECIST 1.1 [Time Frame: Day 14 and 1 month after infusion]
11949,NCT03858712,ePRO Oral Response Rate,2019-03-13,COMPLETED,INTERVENTIONAL,['NA'],,ePRO oral ease of use
11950,NCT04562428,FACT-G,2020-11-20,UNKNOWN,INTERVENTIONAL,['PHASE4'],,pulse diagnosis
11951,NCT00396487,Response according to RECIST criteria.,2006-11,TERMINATED,INTERVENTIONAL,['PHASE3'],,Toxicity
11952,NCT04228601,Objective Response Rate,2020-01-21,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to maximum concentration (Tmax)
11953,NCT05730673,"Overall response rate (ORR, defined as Complete Response (CR) + Partial Response (PR)) in subjects with CCR5+ mCRC treated with Leronlimab (PRO 140) and Regorafenib.",2022-09-20,WITHDRAWN,INTERVENTIONAL,['PHASE2'],"Measure serum level of CCL2, CCL3, CCL4 and CCL5 and correlate with therapeutic benefit (PFS) in patient with mCRC.",The change from baseline in circulating tumor cells (CTC) in the peripheral blood.
11954,NCT04803994,Time to failure of treatment strategy,2021-07-06,RECRUITING,INTERVENTIONAL,['PHASE3'],Exploratory endpoint - PD-L1 expression,QoL (EORTC QLQ-C30 and HCC18 sub-questionnaire)
11955,NCT00001823,Results of screening tests,1999-07-11,RECRUITING,OBSERVATIONAL,['NA'],,
11956,NCT03439891,Overall response rate (ORR) (Part 2),2018-04-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of participants with Child Pugh B Liver Function reporting immune-related adverse event (irAE)
11957,NCT00254267,The objective response rate as assessed by modified RECIST,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Duration of response, progression-free survival, time to response, overall survival, PK and safety profile"
11958,NCT01599052,Social cognitive performance,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,Influence of Biographical/Medical characteristics
11959,NCT00324415,Local Failure Rate at 3 Years,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (Complete and Partial)
11960,NCT02120885,QoL(quality of life),2014-03-14,COMPLETED,INTERVENTIONAL,['PHASE3'],,nutrition condition
11961,NCT02956876,Number of side effects of chemotherapy for WHO grade greater than 2,2016-12-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of provisional chemotherapy orders
11962,NCT03218423,Detection of colorectal cancer,2017-08-18,UNKNOWN,OBSERVATIONAL,['NA'],,Assay Failure Rate
11963,NCT06135649,Metastatic involvement of second nodal echelon,2013-01,RECRUITING,OBSERVATIONAL,['NA'],,Recurrence-free survival
11964,NCT00587236,Compare the dysplasia detection rate between scope modalities and biopsy type; surveillance or targeted biopsies in CUC patients with concurrent PSC.,2006-03,COMPLETED,OBSERVATIONAL,['NA'],,Assess the impact of patient related factors on the difference in dysplasia detection rate between while light colonoscopy and the AFI and NBI techniques in patients with CUC and concurrent PSC.
11965,NCT05927857,To evaluate disease objective response rate (ORR),2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,•To study the blood biomarkers
11966,NCT05786924,Dose Expansion: Progression-free survival (PFS),2023-04-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,Dose Escalation/Expansion: Overall survival
11967,NCT04348058,Participation rate to screening colonoscopy within PCSP per recruitment strategy,2020-08-20,UNKNOWN,INTERVENTIONAL,['NA'],,Response rate to invitation to screening colonoscopy
11968,NCT03778957,Progression Free Survival (PFS) for Arm B vs Arm C,2018-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Pharmacokinetics (PK) of Durvalumab and Bevacizumab as determined by peak serum concentrations,Disease-related symptoms measured by European Organization for Research and Treatment of Cancer (EORTC) 18-item hepatocellular cancer health-related quality of life questionnaire (QLQ-HCC18)
11969,NCT05176665,Clinical benefit rate(CBR) as assess by RECIST v1.1,2021-10-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical benefit rate(CBR) as assess by RECIST v1.1
11970,NCT00005594,The primary outcome measure of this study is to estimate the response rate and observe the time to tumor progression of the patients treated on this study.,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine the duration of response in responding patients. Further characterize the safety profile of ISIS 2503 at the recommended dose and schedule.
11971,NCT02971631,Nadir Blood Glucose,2017-08-10,COMPLETED,INTERVENTIONAL,['NA'],,Total Meal Consumption
11972,NCT04790695,Overall survival,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11973,NCT03510416,Time To Progression,2018-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
11974,NCT01651026,"list of diagnostic procedures used in clinical practice, according to participating Institute",2011-01,RECRUITING,OBSERVATIONAL,['NA'],predictive factors for response to treatment,
11975,NCT03781778,Feasibility: Retention,2019-05-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Variability in Gut Microbial Communities From Human Stool Samples -- BETA DIVERSITY
11976,NCT06173986,Treatment completion rate,2023-01-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Adverse events (AE) or severe adverse events (SAE)
11977,NCT04305730,Rate of return of bowel function,2021-03,UNKNOWN,INTERVENTIONAL,['NA'],,Length of time under general anesthesia
11978,NCT03011268,Proportion of patients in sustained clinical remission,2017-06-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Adverse events and serious adverse events frequency and severity
11979,NCT01972919,Overall Survival,2015-12-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Efficacy of dose escalation
11980,NCT03776487,Incidence of adverse events,2019-01-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease-free survival
11981,NCT03934606,baseline to post-results change in distress levels,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
11982,NCT01648504,Completion rate of colonoscopy procedure,2012-06,COMPLETED,INTERVENTIONAL,['NA'],Feasibility of intervention in practice,Patient satisfaction
11983,NCT05045911,The technical success rate,2021-09-20,UNKNOWN,INTERVENTIONAL,['NA'],,Clips used post-ESD
11984,NCT02311595,Compliance rate (Japanese Research Society of Gastric Cancer (JRSGC) lymph node grouping),2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
11985,NCT03807687,Overall survival,2016-12-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative morbidity
11986,NCT01983878,Percentage of Participants Who Are Progression-Free at 12 Weeks (Progression-Free Survival [PFS] Rate at 12 Weeks),2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,PK: Area Under the Curve Time Zero to Infinity (AUC[0-∞]) of Ramucirumab
11987,NCT01478685,Number of participants with adverse events,2011-11-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Duration of Response
11988,NCT00584363,To diagnose Pancreatic Cancer,2004-06,COMPLETED,OBSERVATIONAL,['NA'],,Preventing patient form being misdiagnosed
11989,NCT02935309,Maximum Tolerated Dose (MTD),2016-10-14,COMPLETED,INTERVENTIONAL,['PHASE1'],Radiosensitivity Index (RSI),Occurrence of Treatment Related Adverse Events
11990,NCT06192030,Peritoneal-free survival,2022-08-27,RECRUITING,OBSERVATIONAL,['NA'],,Rates of key gene mutation
11991,NCT06179459,Treatment outcomes in patients undergoing endoscopic treatment of pancreatic fluid collections.,2021-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Timing of intervention
11992,NCT01273051,Response,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,The number of sphincter saving procedures
11993,NCT01463605,Safety of Nimotuzumab combined with Radiotherapy for older patients,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Efficacy of Nimotuzumab combined with Radiotherapy for older esophageal cancer patients
11994,NCT03291379,Concentration of N-desmethyl Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814,2017-05-17,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],"Study Tissue Biomarkers to Explore Key Immune, Inflammatory and Drug Related Mechanisms","Assessment of Changes in Blood Flow on Dynamic Contrast-Enhanced (DCE) MRI Following Treatment With BTG-002814. The Following Parameters Will be Derived From DCE-MRI Images: Ktrans, Kep and Ve."
11995,NCT05411926,4) the dose and drug concentration of tacrolimus after liver transplantation in patients with hepatocellular carcinoma;,2021-03-17,UNKNOWN,OBSERVATIONAL,['NA'],,5) the overall survival (OS) and relapse-free survival(RFS) after liver transplantation in patients with hepatocellular carcinoma.
11996,NCT02354560,Evaluation of changes in size of desmoid tumors,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
11997,NCT01398306,"Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and healthy controls, and patients with low grade neuroendocrine tumours and healthy controls.",2011-07,COMPLETED,OBSERVATIONAL,['NA'],,Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and low grade neuroendocrine tumours with and without medication.
11998,NCT01997957,Time to progression(TTP),2013-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Number of Participants with Serious and Non-Serious Adverse Events
11999,NCT05564403,Overall survival (OS),2024-02-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Detection of mutations as well as prediction of outcomes,Incidence of adverse events
12000,NCT06068257,"To Identify and test thresholds, specificity and sensitivity for FGF19, (and associated markers) for detection in human blood of breast and colorectal in cancer patients, and see if occurs at higher rates than healthy controls.",2023-06-06,RECRUITING,OBSERVATIONAL,['NA'],,
12001,NCT01972451,Procedure time and withdrawal time,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Colonoscopy procedure completeness,Number of people attending the screening
12002,NCT00777504,"Signs of progressive disease on CT-scan, DCE-MRI or Avastin scan",2008-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Effect on Quality of life as record by questionaires
12003,NCT05482451,Overall response,2021-03-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Overall survival,Progression-free survival
12004,NCT00630786,Number of Participants With an Objective Response,2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Post-baseline Laboratory Values Grade 3 or Higher
12005,NCT02847468,Vital status,2017-03-27,TERMINATED,INTERVENTIONAL,['NA'],,Questionnaire of quality of life (EORTC QLQ-C30)
12006,NCT03976284,Stool weight,2019-03-17,UNKNOWN,INTERVENTIONAL,['NA'],,Sugary beverage intake
12007,NCT00002968,Survival,1997-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease-free survival
12008,NCT04767750,"Measurement of the gene expression levels of LncRNA H19 & IGF-1R mRNA, normalized to the housekeeping gene GAPDH expression level, in HCC and T2DM in comparison with healthy controls using Real-Time Quantitative PCR (by the 2^-ΔΔCT method).",2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
12009,NCT04632459,Objective Response Rate (ORR),2021-06-16,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Best Overall Response Rate (ORR)
12010,NCT05009979,Positive predictive value,2023-01-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in 18F-DCFPyL PET/CT uptake between pre- and post-treatment
12011,NCT02028442,Phase 1b - Selection of suitable schedule for repeat cycle IV administration,2012-09-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12012,NCT05972655,Pathological complete response (pCR) rate,2023-08-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Validation of the Wexner score
12013,NCT05095467,"3-year Overall Survival, OS",2021-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,NCI CTC Adverse Events Version 4.0
12014,NCT05174169,Disease-Free Survival (DFS),2022-03-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Compliance with adjuvant chemotherapy
12015,NCT04977401,Increase the dissection speed of the ESD procedure,2021-09-21,TERMINATED,INTERVENTIONAL,['NA'],Adverse events,Total procedure duration
12016,NCT00820157,the overall survival rate of each group,2008-11,COMPLETED,INTERVENTIONAL,['NA'],,the disease-free survival rate of each group
12017,NCT00372840,Number of sections of the Facing Forward manual read with satisfaction and comprehension,2006-05,COMPLETED,INTERVENTIONAL,['NA'],,Changes in psychological outcomes from baseline to 8-week follow-up
12018,NCT00843934,response rate,2009-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
12019,NCT04367805,Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France,2020-04-27,RECRUITING,OBSERVATIONAL,['NA'],,
12020,NCT05518929,Incidence of hypoxia and severe hypoxia,2022-09-08,RECRUITING,INTERVENTIONAL,['PHASE4'],,Proportion of corrective hypoxic measures
12021,NCT01996540,Quality of Life (QoL),2012-08,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival (OS)
12022,NCT02430298,"Percentage of occurrence of mucositis level 3 or more by using the criteria of CTCAE version 4.0, World Health Organization scale and MTSscores",2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life (FACT- H&N Version 4)
12023,NCT06254248,Rate of Acute cellular rejection (ACR) (defined by a Histological Banff score ≥ 5) at 6 months (confirmed by an external expert center),2024-05-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Donor Specific Antibodies (DSA) median
12024,NCT02662959,Overall Survival,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Adverse Events
12025,NCT01420588,Discrimination between Malignant and Benign Gastric Lesions with Na-nose,2011-08-01,COMPLETED,OBSERVATIONAL,['NA'],Proof seeking from metabolomics and transcriptomics,Geographical comparison of VOCs between China and Latvia
12026,NCT05996666,Performance of liver cancer early detection model based on selected cfDNA methylation markers using qPCR,2023-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Comparison of currently used biomarkers for liver cancer detection
12027,NCT03049215,Decrease in Pancreatic Fluid Collection (PFC),2017-11-06,TERMINATED,INTERVENTIONAL,['NA'],,Incidence of Early (<30 Days) Endoscopic Reintervention
12028,NCT00042510,To evaluate the effects of G17DT in combination with cisplatin and 5-FU chemotherapy on tumor response assessed by radiographic means.,2000-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate the clinical efficacy of G17DT in combination with cisplatin and 5-FU chemotherapy as measured by time to disease progression, best overall response and survival."
12029,NCT04276857,1 year progression free survival rate of patients with locally advanced pancreatic cancer who are treated with IRE and combination chemotherapy.,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Prognostic bio-markers
12030,NCT00225290,overall survival,2003-02,TERMINATED,INTERVENTIONAL,['PHASE3'],,
12031,NCT03167268,Skin toxicity reduction,2016-08-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12032,NCT01412294,Progression-free survival,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
12033,NCT04427761,Extent of the change experienced by patients with pancreatic cancer,2020-06-05,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
12034,NCT00897741,Gene expression profiles,2004-12,COMPLETED,OBSERVATIONAL,['NA'],,
12035,NCT04339374,Area under the receiver operating curve (ROC),2017-07-19,RECRUITING,OBSERVATIONAL,['NA'],,Performance characteristics of the novel endorectal ultrasound probe as measured by variability in image production
12036,NCT04358185,To assess efficacy of Itacitinib by overall response rate: objective response rate (ORR),2018-12-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Correlation of JAK1 mutations with treatment,Efficacy of Itacitinib by overall survival
12037,NCT03225781,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],2017-07-01,TERMINATED,INTERVENTIONAL,['NA'],,Immunomonitoring
12038,NCT00556023,Dose Limiting Toxicities: assessed through adverse event data collected weekly,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival:
12039,NCT05584137,Objective Response Rate (ORR) per RECIST 1.1 as Assessed by Investigator (the second stage),2023-06-15,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Duration of Response (DOR) per RECIST 1.1 assessed by Investigator
12040,NCT01474187,toxicity,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE1'],,pathological complete response (pCR)
12041,NCT00004861,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12042,NCT03959800,Tumor infiltrating cells which express immune checkpoints,2015-06-22,RECRUITING,OBSERVATIONAL,['NA'],,Response to chemotherapy
12043,NCT06165094,Overall survival,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
12044,NCT00583934,"Early detection of esophageal cancer or dysplasia in patients without symptoms, after treating their primary cancer, may improve their chances of being cured of a secondary disease.",2007-09,COMPLETED,OBSERVATIONAL,['NA'],,
12045,NCT00606398,two-year disease free survival (DFS),2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Overall survival rate (OS), patterns of treatment failure, treatment efficacy (R0 resection rate), peri-operative morbidity and mortality rates, health related quality of life, hospital length of stay"
12046,NCT02150408,"interest of the realization of 68Ga-DOTATATE PET-CT in the detection of tumor sites in TNE diagnosis, staging and restaging",2014-04-22,COMPLETED,INTERVENTIONAL,['NA'],"therapeutic impact of 68Ga-DOTATATE PET-CT in addition to reference imaging (SRS, CT, MRI): we will document the rate of changes in treatment options induced by PET-CT","therapeutic impact of 68Ga-DOTATATE PET-CT in addition to reference imaging (SRS, CT, MRI): we will document the rate of changes in treatment options induced by PET-CT"
12047,NCT01540968,Quality of life,2012-03,COMPLETED,INTERVENTIONAL,['NA'],,
12048,NCT02639403,Change of the obstructive symptoms,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Obstruction/colostomy-free survival
12049,NCT03784326,Pathological complete response (PathCR),2019-02-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Tumor regression determined by CT or MRI
12050,NCT05022654,Optimal combination dose (only IIa),2021-12-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,ADA
12051,NCT01531452,Progression Free Survival,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,number of participants with adverse events
12052,NCT03058926,"Protocol and Regulatory Compliance for Consortium Studies for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)",2017-01-19,UNKNOWN,OBSERVATIONAL,['NA'],,
12053,NCT04707547,Analysis of the number of CD8+ T,2019-10-16,COMPLETED,INTERVENTIONAL,['PHASE4'],,
12054,NCT00582062,The primary objective of this pilot trial is to investigate the ability of quantitative RT-PCR to detect cancer cells in peritoneal washings of patients undergoing laparoscopy for gastric or pancreatic cancer.,2006-03,COMPLETED,OBSERVATIONAL,['NA'],,"The secondary objective of this pilot study is to estimate the sensitivity, specificity, false positive, and false negative rate of peritoneal cancer cell detection by quantitative RT-PCR."
12055,NCT01280643,"Feasibility, Defined as a Sufficient Proportion of Subjects Having Available Tissue and an Acceptable Composite Assay Success Rate Among Tested Subjects",2010-03,TERMINATED,INTERVENTIONAL,['NA'],,Progression-free Survival
12056,NCT03634202,"maximum tolerated radiation dose (MTD) delivered by IMRT with SIB, in combination with oral capecitabine, for initially metastatic, low and middle rectal cancer after 4 induction cycles of mFolfox6 regimen.",2015-05-05,TERMINATED,INTERVENTIONAL,['NA'],,The prognostic value of PET
12057,NCT01652976,Progression Free Survival (PFS),2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Quality of Life, as Measured by the Functional Assessment of Chronic Illness Therapy; Hepatobiliary Cancer (FACT-Hep) Questionnaire (Version 4.0)"
12058,NCT01882218,Morbidity,2012-09,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Cytokine levels
12059,NCT04096417,Overall Response Rate (ORR),2020-08-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
12060,NCT03395847,Objective response rate (ORR),2018-02-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of adverse events
12061,NCT04274972,Microbiome evaluation,2020-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Microbiome long-term evaluation
12062,NCT04593277,Proportion of HCA-cancer surveillance (SM),2022-10-23,RECRUITING,INTERVENTIONAL,['NA'],,Proportion of healthcare adherence (HCA)-all
12063,NCT01846611,Overall Survival (OS),2013-10-16,COMPLETED,INTERVENTIONAL,['PHASE3'],,Objective Response Rate (ORR)
12064,NCT03581344,TRG (Tumor Regression Grade),2018-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,Impact of therapy on quality of life (QoL)
12065,NCT01447199,Time to Onset for Colorectal Cancer,1994-09,UNKNOWN,OBSERVATIONAL,['NA'],,
12066,NCT01628328,Changes of circulating tumor cell level before and after colonic stenting for patients with obstructive colorectal cancer,2010-07,COMPLETED,OBSERVATIONAL,['NA'],,
12067,NCT00040898,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12068,NCT05494866,occurrence of DLTs,2022-12-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,
12069,NCT03602092,To establish the database for GIST,2018-10-16,RECRUITING,OBSERVATIONAL,['NA'],,
12070,NCT03257761,Tumor response (dose expansion),2018-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free survival
12071,NCT01855854,Objective response rates,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
12072,NCT00003950,Reduction in occurrences of severe diarrhea due to CPT-11 administration,2000-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12073,NCT02135887,"The primary endpoint is the incidence of grade 4 neutropenia during the chemotherapy period, defined as an absolute neutrophil count (ANC) <500/mm3.",2013-11-04,UNKNOWN,OBSERVATIONAL,['NA'],,Increase in Body Weight
12074,NCT03582618,Objective Response Rate (ORR),2018-07-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Pharmacodynamics analysis for the relationship of AUC and Adverse Event (AE)
12075,NCT03256201,Adherence,2016-02-01,RECRUITING,INTERVENTIONAL,['NA'],,Assessment of Symptoms
12076,NCT03798132,peritoneal carcinomatosis,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,surgical decision making.
12077,NCT02402972,disease-free survival,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,adverse events of Chemotherapy and IPC
12078,NCT04283994,EHR documentation of Goals of Care discussions,2021-07-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Key Implementation Factors,Goal concordance
12079,NCT00785889,Increments of medications used for sedation,2008-03,COMPLETED,INTERVENTIONAL,['NA'],,willingness to repeat colonoscopy
12080,NCT00344552,Safety,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to progression (TTP)
12081,NCT03524274,Objective response rate,2018-04-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Symptom remission rate
12082,NCT02489422,Fatigue Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS),2016-08,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants With Successful Qualitative Data Collection
12083,NCT05108753,incidence of anastomotic leakage,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],,incidence of positivecircumferential resection margin
12084,NCT01193517,"Maximum Tolerated Dose (MTD) of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX)",2010-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Response Rate of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX)"
12085,NCT06118437,Overall detection rate of gastrointestinal cancer,2023-11-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12086,NCT04920422,Percentage of patients that follow each dosing patterns during first two cycles of treatment,2021-07-15,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of patients that start cycle 3 based on dosing patterns.
12087,NCT05396300,Obtain the maximum tolerated dose of CEA-CAR-T cells[Safety and Tolerability],2022-05-25,RECRUITING,INTERVENTIONAL,['PHASE1'],Changes in the number of tumor-infiltrating immune cells of CEA- CAR-T treatment in patients with CEA-positive,Pharmacodynamics of CEA-CAR-T cells[Cell dynamics]
12088,NCT03970616,Incidence of Treatment Emergent Adverse Events (TEAEs),2019-09-30,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
12089,NCT01447667,Number of patients who experienced HCC recurrence after RFA,2011-10,COMPLETED,INTERVENTIONAL,['NA'],,Sensitivity and specificity of each indicator of hepatic fibrosis compared to the gold-standard histology score
12090,NCT01964001,Antioxidant capacity,2014-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Inflammation markers
12091,NCT03608540,Incidence of all Adverse Device Effects,2018-07-09,TERMINATED,INTERVENTIONAL,['NA'],,R0 resection
12092,NCT01365169,ECOG Performance Status,2011-05-25,RECRUITING,INTERVENTIONAL,['NA'],,"CYCORE Data availability for clinicians and researchers in order to be able to daily monitor patients using home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales)."
12093,NCT00290693,Rate of Participants Achieving Complete Response or Partial Response to Therapy.,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Study Participants Experiencing Toxicity After Receiving Protocol Therapy
12094,NCT04595747,Objective radiographic response,2021-05-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Banking of tumor material, germline deoxyribonucleic acid, and peripheral blood",Incidence of adverse events
12095,NCT01640444,progression free survival (PFS),2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR)"
12096,NCT00202787,Determine confirmed objective response rate,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"determination of polymorphisms of the intron 1 of the EGFR gene, TS, XRCC1, XPD, serum levels of EGFR and ATP7A and ATP7B, nº of copies of EGFR gene, the levels of PTEN, EGFR, AKT y MAPK proteins, and mutations at EGFR, PI3KCA, K-RAS y B-RAF genes"
12097,NCT00373906,to induce objective/histologic responses in patients with MALT-Lymphoma,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,to evaluate the impact of bortezomib on progression free survival
12098,NCT05087992,Phase 1b: Number of patients with DLTs during the MTD evaluation period assessed in the first 6 patients,2021-11-24,COMPLETED,INTERVENTIONAL,['PHASE1'],,Phase 1b: AUC0-t2: Area under the concentration-time curve of BI 9057 after multiple cycles
12099,NCT03044977,absolute neutrophil count decreased,2017-05-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Overall survival (OS)
12100,NCT05334251,sPO2,2022-04,UNKNOWN,OBSERVATIONAL,['NA'],,
12101,NCT05683470,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
12102,NCT01682031,Incidence of >= Grade 3 Mucositis,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Plasma Cisplatin and Selenium PK and PD Markers (NZ Only)
12103,NCT01444547,Overall response rate (ORR),2007-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to event efficay
12104,NCT03992599,3 year disease-free survival (DFS),2019-08-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Distribution of metastatic LNs
12105,NCT05489419,Efficacy of a multimodal prehabilitation,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Evaluation of complications severity
12106,NCT01286064,Colorectal cancer detection by means of optical fluoroscopy,2010-10,UNKNOWN,INTERVENTIONAL,['NA'],,
12107,NCT03155542,colorectal cancer diagnosis,2016-12,COMPLETED,OBSERVATIONAL,['NA'],,
12108,NCT02041065,Peroperative bloodloss,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Hospital stay in days
12109,NCT00524316,Progression-free Survival,2007-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Tumor Marker Response (AFP)
12110,NCT05150691,Phase 2: Percentage of Objective Response Rate (ORR) as assessed by RECIST 1.1.,2022-01-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2 Cohort b only: Overall Survival
12111,NCT00019773,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12112,NCT01939210,Changes in the length of the end expiration or end inspiration defined as when the breathing trace or internal motion change direction,2010-02,TERMINATED,INTERVENTIONAL,['NA'],,"Change in patients' self-reported levels of psychological distress, physical pain and discomfort, and post-traumatic stress associated with cancer diagnosis and radiation treatment"
12113,NCT05836584,Event-free survival (EFS),2023-12-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,Circulating tumor-derived deoxyribonucleic acid (ctDNA)
12114,NCT01409733,Proportion of patients completing scheduled treatment plan,2010-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12115,NCT06265272,Assessment of LI-RADS with Ga-PSMA-PET/MRI,2023-12-10,RECRUITING,OBSERVATIONAL,['NA'],,PET/MR protocol in liver cirrhosis
12116,NCT02967770,4 month progression free survival rate,2016-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Change in tumor marker levels
12117,NCT01851174,Overall Survival Based on Toxicity Profile of Adverse Events.,2013-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival Time
12118,NCT02834546,Adverse events related to Sorafenib needing a dose adjustment or a symptomatic medication,2017-07-25,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
12119,NCT04109755,Tumour regression grade,2020-06-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,EORTC QLQ-CR29
12120,NCT01272557,Time to progression (TTP) according to RECIST 1.1 criteria,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"• Assessment of overall survival (OS) of disease control rate (CR, PR, SD) to RECIST 1.1 criteria and to EASL criteria • Assessment of safety and quality of life (FACT-Hep) and potential of biomarkers to predict the tumor response"
12121,NCT00369109,Level of p-Chk1 and phospho-histone 2AX (p-H2AX) and possibly downstream pathway markers in hair follicles from skin biopsies of patients treated with gemcitabine hydrochloride or irinotecan hydrochloride for advanced solid tumors,2006-02,COMPLETED,OBSERVATIONAL,['NA'],,Dynamic time course of p-Chk1 and p-H2AX after administration of a DNA-damaging agent
12122,NCT02795988,Clinical efficacy of IMU-131 (Phase 2),2017-08-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Exploratory Outcome (Phase 2): Measurement of immunological and biochemical markers,Incidence of TEAE's (Phase 2)
12123,NCT06181656,Impact of grade IV radiation-induced lymphopenia on serologic responses to pneumococcal vaccination,2024-02-05,RECRUITING,OBSERVATIONAL,['NA'],,
12124,NCT00138242,Reduction rate of myelosuppression,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to disease progression
12125,NCT03283527,Response prediction by EC-PDO,2017-12-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival (OS) in months
12126,NCT03502343,Disease control rate,2018-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse event
12127,NCT02734680,Overal survival,2016-02,UNKNOWN,INTERVENTIONAL,['NA'],,Local control rate
12128,NCT03350763,"Stent failure rate, and need for re-procedure before pancreaticoduodenectomy.",2017-11-18,WITHDRAWN,INTERVENTIONAL,['NA'],,"Other complications related to preoperative biliary decompression, and post-surgical complications"
12129,NCT04431076,Pancreatic fistula,2020-05-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Return to preoperative exercise capacity
12130,NCT05106244,Degree of satisfaction of patients and their families,2022-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
12131,NCT02038296,overall survival,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12132,NCT05848843,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-04-25,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
12133,NCT00312000,Overall survival,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Toxicity profile
12134,NCT00898482,Test new hypotheses as they emerge,2005-05,COMPLETED,OBSERVATIONAL,['NA'],,
12135,NCT01441388,Dose Limiting Toxicities (DLTs).,2011-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Peak plasma concentration (Cmax) of crizotinib and each VEGF inhibitor
12136,NCT05750329,Three-year overall survival rate after surgery,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative tumor-free survival period
12137,NCT02918162,Pathologic Complete Response (pCR) Rate,2017-11-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Response Rate (ORR)
12138,NCT00494806,Time to First Postoperative Flatus in Days Was the End of Postoperative Ileus (POI) Indicator.,2005-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
12139,NCT01870817,Participant recruitment and retention rates,2012-07,COMPLETED,INTERVENTIONAL,['NA'],,Nutritional parameters
12140,NCT00841035,Epidermal Growth Factor Receptor Signaling(EGFR) in the Presence of Pancreatic Tumor Related to the Mechanism to Erlotinib.,2009-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,The Secondary Objectives Include Analysis of Recurrence-free and Overall Survival and the Development of a Predictive Assay for Response to Erlotinib Based on Selected Bio-markers in Endoscopic Ultrasound-Fine-needle Aspiration Specimens.
12141,NCT01777477,Maximum tolerated dose (MTD) of orally administered Chloroquine with concomitant intravenous Gemcitabine.,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12142,NCT04224363,Image Quality,2020-01,UNKNOWN,INTERVENTIONAL,['NA'],,Tolerance
12143,NCT03126708,Progression free survival,2017-04-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
12144,NCT00101686,Time to Progression (TTP) at Primary Completion: FOLFIRI and mIFL,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Relative Dose Intensity of Irinotecan
12145,NCT01152853,progression-free survival at 4-months (PFS4mo),2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicity
12146,NCT05877001,Safety profiles by NCI-CTCAE version 5 .0,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival (PFS)
12147,NCT03168737,Incidence of adverse events per Common Terminology Criteria for Adverse Events version 4.03,2017-09-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
12148,NCT04601428,HCC blood flow,2021-01-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Determine tumor response to intra-arterial infusion of CSR02-Fab-TF
12149,NCT02936193,Progression-free Survival,2017-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,3 years overall survival
12150,NCT01424293,Evaluate the Vascular Supply of the Bowel Intra-operatively and Correlate This With Postoperative Complications Identified During Their Hospital Stay at One Week and One Month Postoperatively.,2010-05,COMPLETED,INTERVENTIONAL,['NA'],,
12151,NCT00961129,supportive cancer care needs,2009-03,UNKNOWN,OBSERVATIONAL,['NA'],,
12152,NCT01670409,Toxicities,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Complete blood count
12153,NCT00671463,Pancreatic leak,2008-04,WITHDRAWN,INTERVENTIONAL,['NA'],,Clinical outcomes
12154,NCT02085005,Progression Free Survival rate at 10 months (PFS@10m),2014-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events
12155,NCT06091683,Safety of adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC),2021-04-30,RECRUITING,INTERVENTIONAL,['NA'],,Peritoneal disease-free survival
12156,NCT03185429,Proportion of the number of cases that has produced tumor-specific antigen-specific T cells in peripheral blood.,2017-12,UNKNOWN,INTERVENTIONAL,['NA'],,Quality score of life improvement
12157,NCT04515394,Number of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigators,2021-01-28,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With At Least 1 Postive Anti-Drug Antibodies (ADAs) for Cetuximab
12158,NCT02156505,The patency rate at 8 weeks after placement.,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,migration rate
12159,NCT03323489,Change in Pain level from baseline - as measured using BPI,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,hand grip strength
12160,NCT00591981,"Morbidity (Cardiac, pulmonary, infectous, etc.) and Mortality in Cohort",2007-08,COMPLETED,OBSERVATIONAL,['NA'],,
12161,NCT03940001,"major pahological response, MPR",2019-05-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
12162,NCT04623515,Urinary Dysfunction - International Consultation on Incontinence Questionnaire - Female Lower Urinary Tract Symptoms (ICIQ-FLUTS),2021-05-05,TERMINATED,OBSERVATIONAL,['NA'],,Short Form-12 Questionnaire - General Health and Well Being
12163,NCT01515748,"Percentage of Participants With 3-Year Progression-Free Survival (PFS), as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.1",2011-12-30,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Shift of Laboratory Parameters (Creatinine Clearance [Chronic Kidney Disease]) From Baseline Grade to Worst NCI-CTCAE Grade >=3
12164,NCT04831944,Pharmacokinetics Parameter : AUC(0-t) of parsaclisib,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics Parameter : Vz/F of parsaclisib
12165,NCT03328234,Overall survival (OS),2017-09-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse events
12166,NCT02309788,overall survival,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12167,NCT03798626,Part 2 (Expansion) and Part 1b (Safety run-in): Progression free survival (PFS) rate [Cohort C subjects at RDE level],2019-05-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of patients with anti-drug antibodies for ramucirumab in the combination regimens
12168,NCT00004233,Six month survival,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,evaluate quantitative and qualitative toxicities
12169,NCT02271464,progression-free survival (PFS),2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall toxicity rate
12170,NCT03258034,3 year OS,2017-08-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
12171,NCT01793168,"To accelerate research into rare disorders by connecting individuals who are interested in research and who have been diagnosed with a rare disorder (or a disorder of unknown prevalence, or who are undiagnosed) with researchers who study rare diseases.",2010-07,RECRUITING,OBSERVATIONAL,['NA'],,
12172,NCT02997553,Non-inferiority of indocyanine green guided sentinel lymph node biopsy,2017-11-29,COMPLETED,INTERVENTIONAL,['PHASE3'],,fluorescence imaging
12173,NCT01952951,downstaging rate,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,quality of life
12174,NCT04627363,Progression free survival rate at 6 months,2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
12175,NCT03025152,Changes from baseline in total scores of Spleen Qi Deficiency Symptoms Grading and Quantifying Scale (Units on a scale),2016-11-11,TERMINATED,INTERVENTIONAL,['NA'],,Incidence of withdrawn due to adverse events
12176,NCT04607590,The patient 6-minute walk test (6-MWT) over the 6-month follow up (6-MFU),2019-05-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Treatment efficacy,Patient and partner short form survey (SF-36) domains
12177,NCT01703650,Evaluation of the correlation between the initial perfusion parameters of the tumor and response of the chemotherapy,2012-11,UNKNOWN,OBSERVATIONAL,['NA'],,comparison of perfusion parameters among the pancreas tumors and parenchyma
12178,NCT03176082,Polypectomies,2016-10,COMPLETED,INTERVENTIONAL,['NA'],,
12179,NCT04631445,Progression-free survival per RECIST 1.1,2020-12-02,RECRUITING,INTERVENTIONAL,['NA'],,To compare quality of life between arms via the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire QLC-C30 (EORTC QLQ-C30) assessment.
12180,NCT02319304,Primary Outcome Measure (Overall Survival Rate),2015-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Secondary Outcome Measure (Number of Adverse Events)
12181,NCT04949256,Part 2 (Main Study): Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in all Participants,2021-07-28,RECRUITING,INTERVENTIONAL,['PHASE3'],,Part 2 (Main Study): TTD in HRQoL Score Using EORTC QLQ-OES18
12182,NCT03269526,Overall survival,2017-07-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Examine tumor tissue for immune system cells, cytokines and proteins to estimate whether the type and number of immune cells correlates with clinical responses"
12183,NCT04324476,Progression Free Survival 1 (PFS 1),2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The occurrence of adverse reactions (AEs)
12184,NCT00154752,oncologic results,1999-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,functional results
12185,NCT00569387,The primary objective of this Phase II trial is to assess disease-free survival (DFS) at one (1) year following initiation of treatment as the primary endpoint of the study in subjects treated with the HyperAcute®-Pancreatic Cancer Vaccine,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,We will use overall survival and adverse events rates as secondary endpoints.
12186,NCT05269056,Area under curve of the model for detecting stage I/II gastric cancer,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Area under curve of the early detection model at sequencing depth downsampling
12187,NCT05100082,Number of Participants with Grade 3 or higher Adverse Events,2021-11-17,RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival (OS)
12188,NCT04755920,To determine the feasibility of SGM-101 for intraoperative imaging of colorectal brain metastases.,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
12189,NCT01697917,Change in QOL (Quality of Life),2012-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Nutritional status of patients
12190,NCT02079363,Number of methylated genes for each participant.,2013-08,UNKNOWN,OBSERVATIONAL,['NA'],Number of methylated genes in patients with chronic pancreatitis.,Number of methylated genes for each participant related to prognosis
12191,NCT01959269,Overall survival,2013-10-31,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of treatment emergent adverse events (TEAE)
12192,NCT05304572,feeding vessels detectability,2022-05-01,COMPLETED,OBSERVATIONAL,['NA'],,inter-observer agreement
12193,NCT02585271,Creation of stoma,2015-10-01,TERMINATED,INTERVENTIONAL,['NA'],,Overall survival
12194,NCT01247298,Local Recurrence Rate,2010-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Percentage of Participants With Local Failure Patterns
12195,NCT04896073,disease control rate,2022-03-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
12196,NCT01232101,The primary aim of the present study was to compare and stent patency between covered and uncovered bileduct SEMS,2007-03,COMPLETED,INTERVENTIONAL,['NA'],,"Secondary objectives were to study difference in technical success, efficacy of drainage and complication rate between covered and uncovered metal stents"
12197,NCT01590732,Incidence of adverse events,2012-10-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Complete response
12198,NCT02781012,Berg's Interrogative Biology® Platform,2016-03,UNKNOWN,OBSERVATIONAL,['NA'],,
12199,NCT05281003,Major hypoxia signals in baseline or post-treatment tumor samples from all eligible participants with locally advanced ESCC,2023-02-20,RECRUITING,INTERVENTIONAL,['PHASE2'],"EFS in eligible participants with locally advanced ESCC, stratified by PD-L1 biomarker expression (CPS ≥10, ≥1 and <1)",Cell lineage-specific hypoxia signals in baseline or post-treatment tumor samples from all eligible participants with locally advanced ESCC
12200,NCT02973672,Number of patients with treatment-related adverse events,2016-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum SGM-101 concentrations
12201,NCT00489359,Phase 2 - Percentage of Participants With Overall Tumor Response (Response Rate),2005-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2 - Progression-Free Survival
12202,NCT03087591,Incidence of adverse events Common Terminology Criteria for Adverse Events version 4.0,2017-04-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,Survival as assessed by RECIST
12203,NCT00453661,Screening Rates,2007-03,COMPLETED,OBSERVATIONAL,['NA'],,Compliance Rate Across 5 Cancer Types
12204,NCT02991092,recovery time of intestinal function,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],body weight（Kg）,hospitalization time after operation（day）
12205,NCT02285660,Whole body 4D PET-CT for improved Target Definition/Delineation (feasibility and benefit) (ability to identify the cancer and ability to show areas within the cancer that are potentially more active allowing target of higher dose to these areas),2011-06,UNKNOWN,INTERVENTIONAL,['NA'],,
12206,NCT04561830,feasibility of procedure,2015-04,COMPLETED,INTERVENTIONAL,['NA'],,recurrence
12207,NCT02815436,Rate of completion of FOBT in the year of receiving the interventions/control,2016-04,COMPLETED,INTERVENTIONAL,['NA'],,Rate of return of FOBT tubes in the year of receiving the interventions/control
12208,NCT01157013,Response to sorafenib therapy shown in PET Scans,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,Tumor response evaluated by CT and MRI
12209,NCT02057874,"Correlation of Changes in Imaging Biomarkers (Ktrans, ADC, MTR, and APTasym) as Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively, With Changes in Tumor Volume (mRECIST).",2014-02,TERMINATED,INTERVENTIONAL,['NA'],,"Correlation of Changes in Ktrans, ADC, MTR, and APTasym (Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively) With Overall Survival (OS)"
12210,NCT02277158,Maximum Tolerated Dose (MTD),2014-11,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Quality of Life
12211,NCT01988493,Phase 2: Time to Progression (TTP) Based on Tumor Assessment by an Independent Review Committee (IRC),2014-01-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Percentage of Participants With Disease Control Based on Tumor Assessment by Investigator According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria
12212,NCT00498225,Over all survival(OS),2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"progression-free survival (PFS), response rate (RECIST, if measurable), incidence rate of adverse events, incidence rate of adverse drug reactions, QOL (EQ-5D)"
12213,NCT02481635,Type and the severity of side effects,2016-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Progression
12214,NCT00725400,Objective tumor response rate,2010-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Quality of life
12215,NCT01744509,Sensitivity of PillCam Colon Capsule 2 (R) in identifying significant colonic polyps,2011-03,UNKNOWN,INTERVENTIONAL,['NA'],,to evaluate the tolerability of PCC2 as compared to optical colonoscopy (OC) and CT-colonography (CTC).
12216,NCT05484024,Disease-free survival rate,2022-08-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of life (QoL)
12217,NCT03551444,Recurrence rate,2017-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Identifications of predictive factors of HCC recurrence
12218,NCT04752384,The number of subjects who achieve at least a 30 percent decrease in pain from baseline in VAS pain score calculated from BPI questionnaire.,2021-07-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,The number of subjects who achieve at least a 30 percent decrease in pain from baseline in average daily pain score calculated by OM pain app.
12219,NCT05965843,All-cause mortality in patients with underline disease after Covid-19 infection.,2023-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Severe disease in patients with underline disease after Covid-19 infection.
12220,NCT02136277,Changes in microvascular blood flow during colorectal surgery,2015-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12221,NCT05476380,pCR,2021-02-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,DFS
12222,NCT04867525,Course of treatment (treatment reality).,2021-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"Carcinoma Health-related quality of life (Patient-reported outcome, PRO)."
12223,NCT00456599,Two-year Disease Free Survival.,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
12224,NCT01056601,Progression-Free Survival,2010-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Duration of Response
12225,NCT00551213,Number of Participants With a >20% Decrease in Positron Emission Tomography (PET)-Assessed Tumor Glucose Metabolism: Fluorodeoxyglucose (FDG) Standardized Uptake Value (SUV) in the Target Lesion,2007-11-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in Tumor Growth Rate
12226,NCT03586050,Number of Patients Whose Ablation Resulted in Technical Success,2017-12-11,COMPLETED,INTERVENTIONAL,['NA'],,Number of Patients Whose Ablation Resulted in Technique Efficacy
12227,NCT02349867,Recommended phase 2 dose and schedule,2015-01-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
12228,NCT04645160,Phase I: Determine safety and establish the recommended Phase II dose (RP2D) of tivozanib in patients with cholangiocarcinoma who were previously treated with first-line chemotherapy.,2022-03-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Evaluate disease control response (DCR- complete response [CR] plus partial response [PR] plus stable disease [SD]) in patients with cholangiocarcinoma treated with tivozanib
12229,NCT02080221,Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone.,2014-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response of Patients With Metastatic Pancreatic Cancer Who Receive the FOLFOX-A Regimen
12230,NCT00893503,"Compare the diagnostic performance characteristics of the guaiac based Hemoccult II FOBT and two FIT's, the Hemoccult ICT and MagStream HemSp, using colonoscopy as the gold standard.",2008-04,COMPLETED,OBSERVATIONAL,['NA'],,Estimate the probability of participants of the SCOPE pilot who have adenomas or colorectal cancer using urine metabolomics and correlate those with results from the FOBT / FIT's and screening colonoscopy.
12231,NCT00619814,,2003-09,COMPLETED,INTERVENTIONAL,['NA'],,
12232,NCT03484962,Objective response rate,2018-03-25,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Symptom remission rate
12233,NCT02725996,Overall Survival(OS) :Overall survival was measured from the date of randomization until death from any cause.,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12234,NCT02000050,Complete pathological response (pCR),2013-10-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Intention-to-treat (ITT) population
12235,NCT00019513,,1998-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12236,NCT00873275,Pharmacokinetics of ursodiol,2009-03-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
12237,NCT04108936,Overall survival,2016-10,RECRUITING,OBSERVATIONAL,['NA'],,Quality of life (Questionnaire-WHOQOL-BREF)
12238,NCT03835663,Difference in the amount of bacteria of the gastric mucosa between the three previously described groups.,2018-06-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
12239,NCT03608878,time-to-ITTVP,2019-04-26,TERMINATED,INTERVENTIONAL,['PHASE2'],,
12240,NCT00023972,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12241,NCT04912765,Induced immune response against vaccinated NAs,2021-04-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
12242,NCT04060342,"Phase 2 - Basket Cohorts 1, 2 and 3: Objective Response Rate (ORR)",2019-08-13,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Phase 2 - Basket Cohort 1, 2 and 3: PK profile of GB1275"
12243,NCT05499195,Disease-free Survival (DFS),2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
12244,NCT01237665,Pathological complete response (pCR),2010-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS
12245,NCT05475366,Objective Response Rate (ORR) at 4 months based on thorax-abdomen-pelvis (TAP) CT scan every 8 weeks according to RECIST v1.1.,2022-12-12,RECRUITING,INTERVENTIONAL,['NA'],,Feasibility of study procedure
12246,NCT01973725,Disease control rate,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,EORTC QLQ-C30 and QLQ-OES18
12247,NCT02982694,Overall Response Rate,2017-11-24,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety and tolerability (adverse event assessment according to CTCAE v 4.0)
12248,NCT05489458,The evolution of the degree of vascular involvement in 64-MDCT scans,2022-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The Resection Rate at the end of the observation period.
12249,NCT04194801,Phase II: Objective Response Rate (ORR) Assessed by Investigator Based on RECIST Version 1.1,2019-12-16,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetic Parameters of Time to Maximum Serum Concentration (Tmax) of Sugemalimab (CS1001)
12250,NCT01991522,Transfer of Skills to Clinical Colonoscopy,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,Retention of Clinical Skills
12251,NCT02431078,three-year disease free survival rate,2015-06,UNKNOWN,OBSERVATIONAL,['NA'],,baseline detection of ZEB1 expression
12252,NCT00666978,Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Slow and Fast Metabolizers by Genotype
12253,NCT05557838,≥Grade 3 Adverse Events and Adverse Events of Special Interest of Cohort 1,2023-02-22,RECRUITING,INTERVENTIONAL,['PHASE3'],,Duration of response (DoR) per RECIST 1.1/mRECIST
12254,NCT04191655,Detection rate of dysplastic lesions in High Definition White Light Colonoscopy versus Dye Spraying Chromo-colonoscopy,2019-04-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Appropriateness of reported follow up recommendations per standard guideline recommendations
12255,NCT03460197,The classification of Papanicolaou was used for the terminology in pancreatobiliary cytological evaluation of biopsy samples.,2018-04-20,COMPLETED,OBSERVATIONAL,['NA'],,
12256,NCT00224562,,2004-02,UNKNOWN,OBSERVATIONAL,['NA'],,
12257,NCT00110721,frequency of stable disease,2005-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,safety of GM-CT-01 plus 5-FU
12258,NCT05200442,Phase 2 Primary Objective: Objective Response Rate of Participants Who Take Phase I /MTD Dose of VS-6766 combined with Cetuximab,2022-08-22,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II Objective: Stable Disease
12259,NCT05622136,Proportion of patients who complete 4 cycles of treatment,2023-09-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Score in the The 5-level EuroQol EQ-5D-5L questionnaire
12260,NCT01461915,Number of Patients who Achieved Progression-Free Survival,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Proportion of Patients who Achieved Overall Survival
12261,NCT05065801,Progression-free survival,2022-01-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Collection of circulating tumor DNA (ctDNA)
12262,NCT02761356,Visual assesment of Tc-99m-MAA in liver lesions compared to visual assesment of Y-90 sirtex.,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,
12263,NCT05856188,Change in the level of salivary transforming growth factor beta 1 during radiotherapy.,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Change in Pain visual analog scale during radiotherapy.
12264,NCT05865756,acoustic cough features in HNC patients as biomarkers for dysphagia/aspiration.,2021-04-01,RECRUITING,INTERVENTIONAL,['NA'],,
12265,NCT02272894,overall survival,2014-07,UNKNOWN,OBSERVATIONAL,['NA'],,disease free survival
12266,NCT01329718,Effectiveness of the Epi proColon test,2011-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
12267,NCT03772132,Progression Free Survival,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,percentage of patients with Clinical Benefit Response
12268,NCT01969292,%Clear,2013-09,TERMINATED,INTERVENTIONAL,['NA'],,Ottawa Stool Score
12269,NCT01483443,Overall survival,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease free survival
12270,NCT04785820,"Overall Survival, Defined as the Time from Randomization to Death from Any Cause",2021-06-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Baseline PDL1, CD8+PD1+, CD8+TIM3+, and CD8+LAG3+ Expression in the Tumor Microenvironment"
12271,NCT03300414,Associate viral sequences and host gene expression signatures with established HCC risk factors in Asian Americans.,2017-03-20,COMPLETED,OBSERVATIONAL,['NA'],,
12272,NCT05086601,Disease-free survival time,2020-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,Pathological TNM stage
12273,NCT02305810,"Circulating angiogenic factors, molecular imaging and tumor tissue factors changes during treatment with RAD001 at baseline, week 4, week 12 and at disease progression.",2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"TTP, time to progression"
12274,NCT01814501,Progression free survival(PFS),2013-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
12275,NCT02557503,Progression-free survival (PFS),2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,overall survival (OS)
12276,NCT03837132,Impact of early palliative care on quality of life in patients with advanced pancreatic cancer,2018-10-15,COMPLETED,OBSERVATIONAL,['NA'],,"To explore the impact of early palliative care on symptom management, depression, anxiety and survival in patients with advanced pancreatic cancer"
12277,NCT05488587,Serum level of Zinc in cirrhotic patients and HCC,2022-08,RECRUITING,OBSERVATIONAL,['NA'],,serum level of Zinc and the Barcelona clinic classification
12278,NCT02216578,Progression Free Survival (PFS),2017-02-02,COMPLETED,INTERVENTIONAL,['PHASE2'],circulating plasma DNA,Occurence of adverse events
12279,NCT01465425,"Rates of Follow Up Imaging, Hospitalization, Intervention",2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,Estimate Differences in Cost
12280,NCT05410977,Specificity of mt-sDNA 2.0 test to detect colorectal dysplasia,2022-03-30,RECRUITING,OBSERVATIONAL,['NA'],,
12281,NCT03779464,PFS,2019-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety profile :Adverse events of nab-Paclitaxel plus S-1
12282,NCT00087360,Colorectal cancer (CRC) screening rates by chart review at 4 months,2003-11,COMPLETED,INTERVENTIONAL,['NA'],,CRC risk perception by questionnaires at 4 and 12 months
12283,NCT03255070,Phase 1b: Objective response rate (ORR: complete response + partial response) per imaging assessment based on RECIST version 1.1.,2018-03-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunogenicity profile of ARX788
12284,NCT04437953,"Number of patients who achieve platelet counts of ≥ 100,000/mcL",2020-05-27,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of patients who can undergo systemic cancer therapy without more than one dose delay or dose reduction
12285,NCT01277653,the difference of curative treatments & survival rates,2007-06,UNKNOWN,OBSERVATIONAL,['NA'],,the difference of early detection rates of HCC between both groups
12286,NCT01991847,Target sample size,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Adverse and serious adverse events
12287,NCT05637788,"Evaluate the association between different radiomics and computer-vision features, and the survival after surgery",2021-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"Evaluate the association between different radiomics and computer-vision features, and the short-terms results after surgery"
12288,NCT00576199,Progression-free Survival,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor Necrosis
12289,NCT06134687,Total Procedure Time,2024-03-18,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,User-feedback post-procedure
12290,NCT02777710,part 2 (extension part) : objective response rate (ORR),2016-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Peak Pexidartinib plasma concentration (Cmax)
12291,NCT00003276,objective tumor response rate,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,time to progression
12292,NCT03467529,Concordance between FFOCT findings and pathology based on the Paris classification of superficial esophageal cancer in pathology,2018-11-06,COMPLETED,OBSERVATIONAL,['NA'],,
12293,NCT05904665,Secondary resection rate,2023-06-15,RECRUITING,INTERVENTIONAL,['NA'],,ctDNA clearance rate
12294,NCT00294359,Phase III: - progression free survival,2005-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,- cost of therapy and assessment of gain in quality-adjusted progression free survival
12295,NCT02540850,Ct Value (Ct Values From PCR Reaction),2014-02,COMPLETED,OBSERVATIONAL,['NA'],,Consistency (the Overall Ratio of True Positive and True Negative)
12296,NCT05262335,Objective response rate (ORR),2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Radical Resection Rate of Liver Metastases
12297,NCT00599378,"Follow up survey to assess participant compliance with CRC screening. For those non compliant participants, randomized to either Control group or CPI2 group - active intervention with implementation intentions-based communication concepts",2007-09,COMPLETED,INTERVENTIONAL,['NA'],,120 day followup survey to assess perceived barriers and screening decisional stage
12298,NCT05554744,Imaging response,2015-06-18,RECRUITING,INTERVENTIONAL,['NA'],,Safety of EUS-FNI
12299,NCT01661049,,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
12300,NCT01260701,Overall Survival (OS),2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
12301,NCT03253250,Recurrence-free Survival Rate (RFS）,2017-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Overall Survival Rate (OS）
12302,NCT04654975,Odds ratio (OR) for brain metastasis,2020-06-02,UNKNOWN,OBSERVATIONAL,['NA'],,Characteristics of brain metastases
12303,NCT00808743,Change in number and size of duodenal adenomas (assessed directly and by evaluation of video and photographic material from endoscopic procedures),2009-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Biliary acid profile (if present)
12304,NCT04753996,Number of participants in study.,2021-03-08,RECRUITING,OBSERVATIONAL,['NA'],,Number of clinical phenotypes and/or observations.
12305,NCT02163187,Change in Bowel Function,2014-06-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of Life
12306,NCT01259193,numbers of adverse events,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Overall survival (OS), time to progression (TTP)"
12307,NCT03021135,Local recurrence.,2018-06-07,COMPLETED,INTERVENTIONAL,['NA'],,Sydney resection ratio (characterized by the following equation - lesion size in millimeters
12308,NCT02533271,Disease-free survival rate,2015-08,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life (QoL)
12309,NCT02009176,Survival rate,2013-03,UNKNOWN,INTERVENTIONAL,['NA'],,postoperative complications
12310,NCT06231160,overall survival,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Pain relief rate
12311,NCT01128803,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2009-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Analysis of T lymphocytes
12312,NCT03599752,Overall survival (High risk),2018-07-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
12313,NCT01751880,"changes of result of blood sample test, cardio pulmonary function test and vital signs reflecting of inflammation level and nutrition condition in patients with minimally invasive gastrectomy",2012-08-08,COMPLETED,INTERVENTIONAL,['NA'],,
12314,NCT03393403,analgesic effect - pain intensity,2017-12-23,UNKNOWN,INTERVENTIONAL,['NA'],,analgesic effect - opioid consumption
12315,NCT00203411,Number of Subjects Requiring Dose Modifications,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life of Patients
12316,NCT05594381,Pathological complete response rate (pCR),2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Genomic changes of ctDNA,Incidence of Treatment-Emergent Adverse Events（Safety）
12317,NCT04053972,RFS,2018-01-31,UNKNOWN,INTERVENTIONAL,['PHASE3'],,recurrence rate
12318,NCT01963702,objective response,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],overall survival(OS),progression free survival (PFS)
12319,NCT05978141,Number of participants populating the T-cell Lymphoma Master Repository/TCLMR,2023-07-27,RECRUITING,OBSERVATIONAL,['NA'],,
12320,NCT01348009,Progression-free survival rate (in Phase 2 portion of study),2011-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percentage of patients with adverse events (in Phase 1 and Phase 2 portions)
12321,NCT03674294,Complete response rate during the overall phase,2015-08-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Effects of CINV on daily life
12322,NCT05495308,The main objective of the study is to update long-term oncologic follow-up of those patients treated for LARC with nCRT and surgery (either TME or subtotal TME; S-TME) who had obtained a pCR.,2021-09-01,COMPLETED,OBSERVATIONAL,['NA'],,"To analyze clinical data in search of related factors to adverse oncologic outcomes, like distant recurrence or tumor-related deaths."
12323,NCT03359681,Expression of Ki67 on tumor samples,2018-07-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,microbiota
12324,NCT01305200,Duration of Severe Oral Mucositis (WHO Grade 3 or 4),2011-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Ancillary Validation Study of ChIMES,Severity of Mucositis
12325,NCT02054533,Post-Operative Infection,2014-02,COMPLETED,OBSERVATIONAL,['NA'],,Hypomotility complication
12326,NCT05199649,Species and abundance of gut microbiota,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Explore the changes of intestinal flora and metabolomics before and after medication
12327,NCT01472198,Progression free survival,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective response
12328,NCT03092895,The safety and tolerability,2017-04-27,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
12329,NCT02063412,"Composite preparation, dispensing, and administration time",2013-08,WITHDRAWN,OBSERVATIONAL,['NA'],,
12330,NCT04363983,Overall survival (OS),2021-01-13,RECRUITING,INTERVENTIONAL,['NA'],,Survival without progression (SWP)
12331,NCT02704520,To show that patients can successfully avoid surgery after achieving a good response to treatment as measured on MRI (mrTRG).,2016-03,RECRUITING,INTERVENTIONAL,['NA'],,To assess whether the detection of ctDNA predicts for relapse in patients with locally advanced rectal cancer
12332,NCT00073905,Ability of palliative capecitabine and gemcitabine,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Clinical benefit response alone as measured after 3 courses
12333,NCT04174781,Progression Free Survival (PFS) per mRECIST,2019-11-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AEs)
12334,NCT01181557,"Questionnaire number 1, to Assess the Quality of Life of Rectal Cancer Patients With or Without Stoma",2008-09,COMPLETED,OBSERVATIONAL,['NA'],,"Questionnaire number 3, to Assess the Quality of Life of Rectal Cancer Patients With or Without Stoma"
12335,NCT05716477,Beliefs about colorectal screening,2022-12-23,RECRUITING,OBSERVATIONAL,['NA'],,
12336,NCT03895008,Disease Free Survival（DFS）,2019-07-08,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival(OS)
12337,NCT00008294,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12338,NCT01646853,Objective Tumor Response,2012-08,UNKNOWN,INTERVENTIONAL,['NA'],,adverse events
12339,NCT00754494,Change in ACF pERK Levels,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Reported at Least 1 Diarrhea Side Effect During the Study
12340,NCT01622803,The time taken to insert bilateral stent,2011-08,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
12341,NCT06027086,Objective response rate (ORR) using immune Response Evaluation Criteria for Solid Tumors (RECIST 1.1),2024-02-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
12342,NCT04732286,Incidence of Treatment Discontinuations of Atezolizumab and/or Bevacizumab Due to Adverse Events of Grade ≥ 3,2021-05-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Albumin-Bilirubin (ALBI) Assessment Grades of 1 to 3
12343,NCT00439608,Reponse Rate at Time of Surgery by Tissue,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Number of Participants With Grade 2 and/or 3 Rash in Patients With Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus, Gastroesophageal Junction, or Stomach."
12344,NCT03460483,Incidence of tumors with microsatellite instability and/or somatic POLE mutations,2018-03-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
12345,NCT00873002,Assessment of Safety and Tolerability,2009-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Adverse events and abnormal laboratory value severity as assessed by NCI CTCAE version 3.0
12346,NCT03414983,Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR),2018-02-20,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Disease Control Rate (DCR) Per Investigator
12347,NCT01632306,Change From Baseline to 4 Hours Post-Treatment on Day 0 in Glycogen Synthase Phosphorylation,2013-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]
12348,NCT05453383,Objective response rate,2022-07-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival
12349,NCT00686166,Pathologic Complete Response Rate,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to This Regimen.
12350,NCT04157985,Progression-free Survival (PFS),2019-11-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Best Objective Response (BOR)
12351,NCT00271986,anastomotic leakage,2006-01,COMPLETED,OBSERVATIONAL,['NA'],,
12352,NCT01507740,Progression free survival under antiangiogenic therapy,2009-07,TERMINATED,OBSERVATIONAL,['NA'],,
12353,NCT05730361,Objective Response Rate (ORR),2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Detection of Lentivirus Copy Number
12354,NCT03964064,Progression-free survival (PFS),2019-06-11,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse reactions
12355,NCT05007132,Objective response rate,2021-12-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival
12356,NCT04642924,Resection status,2019-10-22,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
12357,NCT00496704,Overall response rate as assessed by RECIST criteria,2007-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to response
12358,NCT05025748,Self-efficacy in managing patient-physician interactions,2021-08-25,COMPLETED,INTERVENTIONAL,['NA'],,Perceptions of the Question Prompt List
12359,NCT02711033,Early complication rate,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Metastasis rate of lymph nodes posterior to splenic vessel
12360,NCT06225843,Treatment-Emergent Adverse Events,2024-02-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Presence of ADA
12361,NCT03212625,Cumulative incidence of Hand-Foot Skin Reaction(HFSR) on each group,2016-01-28,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Incidence of HFSR on 2, 4, 8, and 12 weeks on each group"
12362,NCT00028015,,2001-10-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12363,NCT04016948,Accuracy of optical biopsy,2017-06-28,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative function recovery
12364,NCT03900871,disease free survival,2019-04-10,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
12365,NCT01159171,Percentage of Participants by Best Overall Response,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
12366,NCT04191889,Objective response rate (ORR) by RECIST 1.1,2020-04-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Exploratory outcome measure: The quality of life (QoL)
12367,NCT00999843,The safety and tolerability of maintenance Sorafenib.,2009-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Time to progression (TTP), progression-free survival (PFS) and overall survival (OS)"
12368,NCT04170530,MFS,2019-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Reported Adverse events
12369,NCT00359320,The primary endpoint will be the pancreatic fistula rate.,2006-05-25,TERMINATED,INTERVENTIONAL,['NA'],,Death
12370,NCT00833625,Pathologic Response,2009-02,COMPLETED,INTERVENTIONAL,['NA'],,
12371,NCT01226979,Number of Participants With Pathologic Complete Response,2010-10-26,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants With Acute Gastrointestinal Toxicity Associated With High-Dose-Rate Endorectal Brachytherapy (HDRBT) as Assessed by CTCAE v4.0
12372,NCT01061840,To determine safety following the administration of bi-shRNAfurin and GMCSF autologous tumor cell (Vigil™) vaccine in advanced solid tumor patients who have no acceptable form of standard therapy with curative intent.,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,To determine time to progression. To evaluate the effect of Vigil™ vaccine on immune stimulation. To evaluate whether lower cell doses would activate ELISPOT responses and to compare durability of dose elicited responses.
12373,NCT00021281,,2000-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
12374,NCT05692323,PREHAB Program feasibility will be measured by tracking participant attendance at PREHAB sessions. PREHAB will be considered feasible if 50% of participants attend at least 60% of scheduled sessions.,2023-04-04,RECRUITING,INTERVENTIONAL,['NA'],,PREHAB Program safety will be assessed through the reporting of unanticipated problems from the baseline visit through to the 3 Month visit.
12375,NCT02731313,Simple Kappa Coefficient of Human Epidermal Growth Factor Receptor 2 (HER-2) Status Between Local and Centralized Laboratory Assessments,2012-07,COMPLETED,OBSERVATIONAL,['NA'],,Weighted Kappa Coefficient Between Immunohistochemistry (IHC) 4B5 and Silver in Situ Hybridization (SISH) Techniques for HER-2 Testing in Centralized Laboratories
12376,NCT05374044,pathological tumor regression grade(pTRG),2020-05-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,local recurrence
12377,NCT00757172,Number of Participants With Pathologic Complete Response Following Surgery,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Frequent (>=15% Grade 3/4 Incidence) Adverse Events Regardless of Attribution
12378,NCT02452853,Number of Complications reported using the National Cancer Institute Common Toxicity Criteria grading version 4.0,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
12379,NCT01563484,"Change from Baseline in serum creatinine, blood urea nitrogen, direct bilirubin, indirect bilirubin, alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase, lactate dehydrogenase, alkaline phosphatase, cholinesterase.",2012-03,UNKNOWN,OBSERVATIONAL,['NA'],,
12380,NCT01651624,Costs of the three different screening strategies proposed,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,Number and type of complications in all groups
12381,NCT03086642,Maximum Tolerated Dose (MTD),2017-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
12382,NCT05401318,"Induction of immunotherapy efficacy by chemotherapy in colorectal cancer, measured by advanced imaging analysis",2022-03-28,RECRUITING,OBSERVATIONAL,['NA'],,
12383,NCT00003422,"Local recurrence by biopsy, imaging, or imaging and carcinoembryonic antigen result",1998-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Economic implications
12384,NCT00388206,,2006-11,COMPLETED,OBSERVATIONAL,['NA'],,
12385,NCT02254486,Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens),2014-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Polyp Detection Rate (Overall Colon)
12386,NCT03411915,Identify the maximum tolerated dose (MTD) and/or recommended dose (RD) and schedule of XmAb18087,2018-01-22,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12387,NCT00202969,Response rate,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Safety profile, time to treatment failure"
12388,NCT01567917,The incidence of symptomatic or asymptomatic VTE,2011-06,UNKNOWN,OBSERVATIONAL,['NA'],,Risk factors for the development of VTE
12389,NCT05721872,Response to D-isoascorbic Acid (D-VC) in combination with arsenic trioxide (ATO),2023-02-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change from baseline number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 24 hours
12390,NCT03803553,Clearance rate of ctDNA,2020-04-16,RECRUITING,INTERVENTIONAL,['PHASE3'],,Clearance rate of Arm 6: Herceptin/Perjeta
12391,NCT00624546,gene expression,2009-01,TERMINATED,OBSERVATIONAL,['NA'],,
12392,NCT02295956,Feasibility of Prehabilitation Program Among Pancreatic Patients,2015-02-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
12393,NCT03300401,Local tumor response to therapy,2017-11-07,WITHDRAWN,INTERVENTIONAL,['NA'],,
12394,NCT03975452,The reduction of gastrointestinal (GI) toxicity,2007-11,UNKNOWN,INTERVENTIONAL,['NA'],,The disease-free survival (DFS)
12395,NCT04017845,Performance Indicators of Colonoscopic Examination,2015-04-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],safety and tolerance of colonoscopy.,
12396,NCT01476553,Peritoneal Conversion Rate (PCR),2011-02,TERMINATED,INTERVENTIONAL,['NA'],,Perioperative in-hospital morbidity
12397,NCT02161822,pathologic complete response rate,2014-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,lipid lowering effect of simvastatin
12398,NCT04965714,Necrosis of tumors,2022-04-13,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Immune biomarker analysis,Overall survival (OS)
12399,NCT05023720,Regorafenib in combination with other drugs,2021-07-20,UNKNOWN,OBSERVATIONAL,['NA'],,Survival differences among the patients with different clinical phenotypes and genotypes
12400,NCT00159484,Once MTD is established we propose to expand the dose level of the MTD to 62 new patients to evaluate whether the addition of Celebrex to EPO906 can reduce the incidence of grade 3-4 diarrhea to 6% or less.,2004-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To investigate whether the molecular biomarkers including protein expression changes from plasma, the expression levels of VEGF, E-cadherin, TP, COX-2, and β-tubulin in tumor tissue associated with clinical outcome for this regimen."
12401,NCT05850130,2-point improvement in the global NRS,2023-11-22,RECRUITING,INTERVENTIONAL,['NA'],,Peripheral sensory neuropathy grading scale
12402,NCT03291574,Gastrointestinal function score,2017-07-29,UNKNOWN,INTERVENTIONAL,['NA'],,Physical fitness index
12403,NCT02299596,Recovery measured as physical recovery measured in questionnaire,2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Health economic analysis
12404,NCT06234072,Objective response rate (ORR),2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of participants with R0 resection
12405,NCT02583659,Overall survival(OS) . overall survival Overall survival(OS),2013-01,UNKNOWN,OBSERVATIONAL,['NA'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
12406,NCT05694936,Progression free survival,2023-01-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Quantification of total circulating tumour DNA (ctDNA),Quantification of the incidence of treatment-emergent adverse events according to CTCAE V5.0
12407,NCT06090916,Calorie intake from Myfitness Pal,2023-01-17,RECRUITING,INTERVENTIONAL,['NA'],,
12408,NCT03314896,Overall survival,2016-10,RECRUITING,INTERVENTIONAL,['NA'],,Adverse events (mortality and morbidity)
12409,NCT02014116,Maximum Tolerated Dose (MTD) of LY3009120,2013-11-26,TERMINATED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the End of Dosing Interval at Steady State (AUC[0-τ]) of LY3009120 Cycle 1 Day 28
12410,NCT05900648,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-05-17,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
12411,NCT00173472,,2002-07,UNKNOWN,OBSERVATIONAL,['NA'],,
12412,NCT00305188,Clinical evaluation of peripheral sensory neuropathy using the Oxaliplatin specific scale for dose adjustment,2005-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Other: progression free survival and survival
12413,NCT03140592,Successful generation of pancreatic organoids,2015-01-14,UNKNOWN,OBSERVATIONAL,['NA'],,
12414,NCT05033522,overall survival,2023-08-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time to Symptomatic Progression
12415,NCT06076837,Safety and Tolerability,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Baseline neutrophil lymphocyte ratio (NLR),"CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9)"
12416,NCT00621556,"MR & MRCP - Images will be evaluated for quality, main and branch duct visualization, ductal diameter and improved visualization of structural abnormalities with and without use of RG1068.",2008-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,Laboratory
12417,NCT02232152,"MTD of 6,8-bis(benzylthio)octanoic acid in combination with fluorouracil based on the incidence of dose-limiting toxicities graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0",2015-01-06,COMPLETED,INTERVENTIONAL,['PHASE1'],"Disease control rate (DCR) (i.e., sum of CR, PR, and stable disease)","PK parameters (maximum observed concentration, area under the curve, half-life, elimination rate constant, drug clearance, and volume of distribution) of 6,8-bis(benzylthio)octanoic acid in plasma samples"
12418,NCT00929097,The number of colorectal cancer patients following the most optimal follow up program according to the guidelines.,2009-10,UNKNOWN,INTERVENTIONAL,['NA'],,Costs of the implementation procedure
12419,NCT03630978,Morbidity,2018-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Readmission rate
12420,NCT05973266,quality of bowel preparation,2021-06-03,RECRUITING,INTERVENTIONAL,['NA'],,Anxiety
12421,NCT02031952,Recurrence-free survival,2005-12,COMPLETED,INTERVENTIONAL,['NA'],,Post-operation complication
12422,NCT04871399,Disease-free survival at 3 years,2020-07-13,RECRUITING,INTERVENTIONAL,['NA'],,Other Oncologic outcomes.
12423,NCT01615653,Pain assessed using a numerical rating scale (NRS) from 0 to 10.,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,
12424,NCT01813994,Proportion of the patients with high-risk (III/IV) OLGA stages,2014-11,COMPLETED,INTERVENTIONAL,['NA'],,
12425,NCT03766178,Objective Response Rate (ORR),2021-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,12-month survival rate
12426,NCT03094884,Rate of severe acute esophagitis in patients with lung cancer and esophageal cancer treated with concurrent CRT using PLDR technique.,2017-02-24,RECRUITING,INTERVENTIONAL,['PHASE1'],,Response rate based
12427,NCT03895970,Progression-free Survival (PFS),2019-04-20,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Event,Stable Disease
12428,NCT04475159,Best Overall Response Rates (BORR),2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Recurrence free survival (RFS)
12429,NCT05662644,Nature of gross picture of specimen,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Occurence of ostoperative reflux
12430,NCT04674956,Progress free survival,2021-03-04,RECRUITING,INTERVENTIONAL,['PHASE3'],CA19-9 in serum,Duration of Response
12431,NCT06147180,score of Quality of life,2023-11-27,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Recurrence or metastasis
12432,NCT04740307,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR),2021-03-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,TTP per mRECIST as assessed by BICR
12433,NCT05776524,Overall Survival,2023-06-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate
12434,NCT00756509,"To evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors. Efficacy is defined as the proportion of patients showing stable disease (SD), partial response (PR) or complete response (CR) during the",2008-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,population pharmacokinetics of Nilotinib
12435,NCT05328908,OS in all randomized participants,2022-04-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,DoR by investigator per RECIST v1.1 in all randomized participants
12436,NCT04567615,Overall response rate (ORR) assessed by blinded independent central review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2021-02-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
12437,NCT01382407,Relationship between acne and skin rash,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,
12438,NCT05516394,Postoperative complications,2020-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Number of patients readmitted to hospital after discharge
12439,NCT02005315,Phase 1b: Safety and tolerability of vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated Stage IV pancreatic cancer,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (PK) of vantictumab when administered in combination with nab-paclitaxel and gemcitabine to patients with previously untreated Stage IV pancreatic cancer
12440,NCT01314105,Dose Limiting Toxicities During Treatment Course 1,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change From Baseline in Safety Laboratory Parameters
12441,NCT04299919,Three-year recurrence,2007-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival
12442,NCT04818476,overall mortality,2020-02-10,UNKNOWN,OBSERVATIONAL,['NA'],,
12443,NCT04905329,Relative dose-intensity (RDI) of the myelosupressive therapy course,2020-04-28,UNKNOWN,OBSERVATIONAL,['NA'],,Serious adverse events frequency
12444,NCT05141149,PART 1 (PHASE 1): Determine the recommended Phase 2a dose (R2PD) of PBP1510,2023-06-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PART 2 (PHASE 2a) Exploratory Endpoint: Analysis of PAUF in tumour tissue pre-treatment and after treatment with PBP1510 administered in combination with gemcitabine.,PART 2 (PHASE 2a): Presence of ADA and NAb against PBP1510 administered in combination with gemcitabine.
12445,NCT05882396,Total Neuropathy Score,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The 4-Stage Balance Test
12446,NCT04996095,Analysis of Predictive Markers,2021-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
12447,NCT01994213,Objective Response Rate,2011-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percent of Participants with OS of one year
12448,NCT01387061,Overall survival plus multivariate analysis,2001-06,COMPLETED,INTERVENTIONAL,['NA'],,Disease-free survival
12449,NCT01383252,Success of colonoscopy,2010-02,COMPLETED,INTERVENTIONAL,['NA'],,Polyp detection
12450,NCT02281266,Recurrence-free Survival,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,"number of patients with abnormal laboratory value, vital signs and ECG result"
12451,NCT01804790,disease-free survival,2012-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival
12452,NCT03599154,Overall survival,2018-01-30,COMPLETED,OBSERVATIONAL,['NA'],,
12453,NCT03725254,Progression-free survival,2018-10-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,local control rate
12454,NCT01264705,Number of Patients With Dose Limiting Toxicity,2011-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Months of Disease Specific Survival Calculated From Treatment Initiation to Death From Advanced HCC (Hepatocellular Carcinoma) or Last Follow-up.
12455,NCT06093009,Disease-free survival,2002-06,COMPLETED,OBSERVATIONAL,['NA'],,
12456,NCT01824875,Progression-free Survival,2013-08-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Association Between Methyl Guanine Methyltransferase (MGMT) Status by Promoter Methylation and Response
12457,NCT00359476,"The Response Rate (RR: Complete Response [CR]+Partial Response [PR], as defined by Response Evaluation Criteria in Solid Tumors [RECIST]",2007-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The evaluation of the safety profile of vinflunine
12458,NCT04085055,Degree of cellularity in biopsy sample,2019-09-09,UNKNOWN,INTERVENTIONAL,['NA'],,Diagnostic operating characteristics
12459,NCT00185874,To determine the toxicity of this regimen,2004-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,To evaluate the immune response of patients treated with RFA + DC based on the presence and characterization of tumor infiltrating white blood cells
12460,NCT04351009,Upstaging rate,2020-06-08,COMPLETED,INTERVENTIONAL,['NA'],,Aberrant lymph node drainage
12461,NCT05461794,Arms A and C: Overall Response Rate (ORR),2022-10-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of participants with clinically significant changes from baseline in vital signs
12462,NCT03284879,Change from baseline activity for arthritis,2017-09-05,COMPLETED,OBSERVATIONAL,['NA'],,
12463,NCT05402891,Change in clone size distribution positive for NOTUM.,2022-06-02,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],"History of smoking, if yes number of pack years","Safety outcomes by analysing reported adverse events, physical examination and laboratory findings."
12464,NCT05105815,DFS,2021-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,EORTC-QLQ30
12465,NCT00579865,"To determine how surgical or percutaneous drainage affects HRQL scores in patients with MBO, and to determine if these changes are sustained or change over time.",2005-05,COMPLETED,OBSERVATIONAL,['NA'],,"To identify factors associated with changes in HRQL after drainage(e.g. diagnosis, level of obstruction, degree of pruritus)"
12466,NCT03279198,"Primary Outcome:differences in stage of adoption (precontemplation, contemplation, action) when controlling for adherence to BC screening at baseline, among women who are randomized to 1) usual care; 2) a TIWeb; 3) a CSC, and 4) a TIWeb plus a CSC.",2010-07-22,COMPLETED,INTERVENTIONAL,['NA'],,Secondary outcome:Intervention Costs
12467,NCT04220944,Progression Free Survival (PFS),2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Incidence of Treatment Emergent Adverse Events as assessed by NCI CTCAE V5.0 (Safety and Tolerability)
12468,NCT00003687,,1998-06-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12469,NCT00442637,Progression-free survival after re-introduction of MTD chemotherapy and bevacizumab (PFS2),2007-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Translational research
12470,NCT03839277,"Adenoma detection rate, ADR",2019-06-12,SUSPENDED,INTERVENTIONAL,['NA'],,"Polyp detection rate, PDR"
12471,NCT03347162,Cohort 2: Medical treatment complications,2017-12-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Change in physical activity level
12472,NCT04314401,Percentage of minority and underserved study participants accrued,2020-11-11,RECRUITING,OBSERVATIONAL,['NA'],,Percentage of collected biospecimens that are delivered to the Patient Derived Models Repository
12473,NCT00537121,Recommended phase II dose (RPTD) of SAHA when administered continuously and intermittently with standard doses of FOLFIRI,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
12474,NCT02784262,adverse events,2016-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,change in quality of life expressed by Patients' Global Impression of Change (PGIC)
12475,NCT00028496,"Maximum tolerated dose of recombinant fowlpox-CEA(6D)/TRICOM vaccine determined by dose-limiting toxicities graded according to NCI Common Toxicity Criteria, version 2.0",2001-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12476,NCT05943210,Number of research specimens obtained at the time of surgery.,2023-05-22,RECRUITING,INTERVENTIONAL,['NA'],,Comparing levels of cell death related to radio responsiveness will be measured by quantifying cleaved caspase-3
12477,NCT02865811,Clinical Benefit Rate [CBR],2016-09-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
12478,NCT04587739,Drop-out rate,2021-01-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Actuarial overall survival and disease-free survival.
12479,NCT06301763,Body Mass Index Level,2022-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Penetration-Aspiration Scale
12480,NCT03320629,Progression free survival,2017-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Side effects
12481,NCT04008537,"Feasibility of the device as measured by successful completion of the full CBCT-guided online ART workflow, from volumetric imaging through phantom delivery in at least 90% of attempted fractions",2019-09-04,COMPLETED,INTERVENTIONAL,['NA'],,
12482,NCT05034887,Major pathological response [MPR] rate: by central assessment,2022-01-31,RECRUITING,INTERVENTIONAL,['PHASE2'],AE rate in the Exploration Part,AE rate
12483,NCT03875612,Specificity of registered level of tie,2016-12-12,COMPLETED,OBSERVATIONAL,['NA'],,Cancer recurrence by tie level
12484,NCT02249975,Presence of residual Barrett's Esophagus,2015-01,COMPLETED,INTERVENTIONAL,['NA'],,Device Performance
12485,NCT06195111,PFS (Progression-free survival),2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Quality of life: EORTC QLQ-C30
12486,NCT02128425,Progression-free survival after induction and maintenance chemotherapy (PFS1),2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Translational research
12487,NCT02445456,Number of Operations Where There Was Any Surgical Difficulty Due to Tracer Injection Based on Qualitative Assessment by Surgeon,2016-12,TERMINATED,INTERVENTIONAL,['NA'],,Number of TEM Operations Where the Sentinel Lymph Node Can be Identified and Removed
12488,NCT05651971,The distance from LCA to IMA and IMV,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,postoperative anastomotic leakage rate
12489,NCT01889680,The time to disease progression,2014-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,The severity of adverse events
12490,NCT05222204,overall survival,2021-07-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12491,NCT02138383,Maximum Tolerated Dose (MTD),2014-05-22,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12492,NCT04368702,Rate of Pathologic complete response-Gastric,2021-05-01,SUSPENDED,INTERVENTIONAL,['NA'],,Characterizing MRI-based tumor alterations/changes following MR-image guided radiation
12493,NCT04200027,oncological outcomes RLAR vs TaTMe,2021-11-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12494,NCT00102752,Overall objective response rate,2004-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum CA-19-9
12495,NCT04068194,Objective response rate (ORR) (Phase 2),2020-04-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",T cell receptor (TCR) clonality,Differential response to therapy (Phase 2)
12496,NCT01207895,Utility of [18F]-FLT PET to assess cellular proliferation in neoadjuvant trials of patients with rectal cancer,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Correlative biology
12497,NCT04430842,Determination of maximum tolerated dose (MTD),2020-07-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to maximum concentration of QBS10072S in plasma (Tmax)
12498,NCT02529878,radical resection rate,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,reaction rate
12499,NCT01738139,Maximum tolerated dose (MTD),2013-02-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12500,NCT02004782,Rate of symptomatic stricture formation,2022-03,WITHDRAWN,INTERVENTIONAL,['PHASE4'],Cost,Recurrence
12501,NCT00616941,Overview of Treatment-emergent Adverse Events (TEAEs),2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor Measurement Results According to the Response Evaluation Criteria for Solid Tumors (RECIST) Up to 16 Weeks Post-Baseline
12502,NCT02123407,the number of harvested lymph nodes,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,the diameter of harvested lymph nodes
12503,NCT00858429,Time to tumor progression,2009-04-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12504,NCT01683422,One-year Survival Rate,2013-01-02,TERMINATED,INTERVENTIONAL,['NA'],,
12505,NCT04258657,DFS,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS
12506,NCT03101566,The Percentage of Patients Alive and Without Progression at 6 Months Following the Initiation of Treatment,2017-09-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Response Rate (ORR)
12507,NCT05171439,Bioinformatics analysis of single-cell sequencing in hepatocellular carcinoma,2022-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events(AE)
12508,NCT00307723,to determine the survival of patients treated with this regimen.,2006-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,to evaluate the toxicities.
12509,NCT02052908,Incidence of toxicity,2014-01-27,COMPLETED,INTERVENTIONAL,['PHASE1'],,Changes in the number and type of immune and mesenchymal cells recruited to the colorectal mucosa
12510,NCT05961969,Completion of transabdominal ISR,2022-02-21,RECRUITING,OBSERVATIONAL,['NA'],,Fecal incontinence
12511,NCT05992220,progression-free survival rate,2022-10-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Tumor marker response (AFP, PIVKA-II)"
12512,NCT04782791,Adverse events,2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 rate
12513,NCT02083653,Overall Survival (OS) Time,2014-03-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life Assessed by FACT-EGFRI-18 for Skin Rash
12514,NCT03007550,Early operative morbidity and mortality rate,2017-01-04,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative hospital stay
12515,NCT04231175,Number of preventable unnecessary laparoscopies and explorative laparotomies defined as,2019-10-28,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of Life between diagnostic arms by EQ5D5L
12516,NCT03255434,Evaluation of neurotoxicity associated with Oxaliplatin,2017-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
12517,NCT02829385,Objective Response Rate (ORR),2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
12518,NCT01147965,"The primary objective of this protocol is to determine the safety of immunization with Ad5 [E1-, E2B-]-CEA(6D), in patients with advanced or metastatic CEA-expressing malignancies, including Maximum Tolerated Dose (MTD).",2010-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The secondary objectives of this protocol are to evaluate CEA-specific immune responses to the immunizations and to obtain preliminary data on clinical response rate.
12519,NCT03161574,The rate of R0 resection,2017-08-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Reported Adverse events
12520,NCT04659603,Incidence of dose-limiting toxicites (DLTs)- Cohort C Part 1,2021-03-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Maximum concentration observed after infusion (Cmax) of gemcitabine metabolite
12521,NCT01105377,Confirmed Tumor Response,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Progression
12522,NCT06263205,Rate of Postoperative Wound Healing Complications,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Medical Costs Associated with Wound Care
12523,NCT02037048,Recurrence Free Survival (RFS) compared to historical averages,2014-02-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Prognostic effect of CTCs, Ki-67, and HER2 overexpression on pathologic response",Loco-regional control (LRC)
12524,NCT02054923,Change in screening centre adenoma detection rate before and after intervention,2014-03,COMPLETED,INTERVENTIONAL,['NA'],,Rates of proximal (to the splenic flexure) serrated polyps ≥10mm in size
12525,NCT05354674,progression free survival,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,overall survival
12526,NCT05561504,H. pylori resistance profiles,2021-03-31,RECRUITING,OBSERVATIONAL,['NA'],,risk factors for gastric cancer
12527,NCT00352261,Compare pharmacodynamic efficacy of esomeprazole 40 mg & lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients by evaluation of the percentage of time that intragastric pH is >4.0 over a 24 hr period steady state,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Compare pharmacodynamic efficacy of esomeprazole 40 mg & lansoprazole 30 mg bid in controlling intragastric pH in BE patients by evaluation of the % of time intragastric pH is >4.0 over 24 hr period at steady state
12528,NCT02423343,Phase 1b: Maximum Tolerated Dose (MTD) of Galunisertib in Combination With Nivolumab,2015-01-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Overall Survival (OS)
12529,NCT02159339,Metastasis and/ or recurrence of gastric carcinoma,2012-12,COMPLETED,OBSERVATIONAL,['NA'],,Disease-free (Recurrence/metastasis-free) survival (DFS) and overall survival (OS) of patients with gastric carcinoma after surgical resection
12530,NCT02762266,Number of Participants With a Local Progression Event,2016-02-27,TERMINATED,INTERVENTIONAL,['PHASE3'],,The Impact of Elevated Serum Alpha-Fetoprotein Level (AFP) on Overall Survival (OS)
12531,NCT02092948,Assess the safety of [124I] PSCA-Minibody,2013-08-22,COMPLETED,INTERVENTIONAL,['PHASE1'],,Compare the sensitivity and specificity of [124I] PSCA-Minibody with conventional imaging
12532,NCT00905918,"Presence in colon tissue of α-, γ-, and δ-tocopherols, cell proliferation and apoptosis indicators, β-catenin localization, RXR expression, and cyclooxygenase-2, 8-OHdG, and 3-nitrotyrosine levels",2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12533,NCT05831150,Number of study participants who remain in clinical research until completion.,2024-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12534,NCT05864755,Overall response rate ( ORR) per RECIST 1.1,2023-06-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time To Progress(TTP) per RECIST 1.1
12535,NCT01892072,"the variation of the quantity of VEGF signal pathway genes in normal liver tissue,peri tumor,tumor and metastasis.",2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,
12536,NCT01064375,To evaluate the safety and immunogenicity of a DNA immunisation approach where tetwtCEA DNA will be administered in combination with electroporation.,2009-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To compare effects (safety and immunogenicity) of additional adjuvance with GM-CSF
12537,NCT03015389,Detection rate of Barrett's associated high grade esophageal dysplasia and esophageal adenocarcinoma (HGD/EAC) using WATS3D and random 4 quadrant forceps biopsies taken at 2 cm intervals.,2017-09-27,COMPLETED,OBSERVATIONAL,['NA'],,Number of participants with Barrett's related dysplasia and adenocarcinoma diagnosed with random forceps biopsies and WATS3D biopsies used in alternating fashion.
12538,NCT06329102,Surgical complications defined by Calvien Dindo II to V,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Quality of life after surgery measured with the 15D instrument
12539,NCT00583674,Progression Free Survival (PFS),2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patient Reported Outcomes
12540,NCT03777813,cPFS (centrally reviewed cPFS),2018-12-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Quality of Life OES18, used for patients with oesophageal cancer always complemented by the QLQ-C30 measuring 5 functional scales (physical, everyday activity, cognitive, emotional and social) and 3 symptoms scales (fatigue, pain, nausea and vomiting)"
12541,NCT00033384,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12542,NCT03600831,Disease-free survival (DFS),2018-08-20,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of life(QOL)
12543,NCT02260505,Disease Free Survival (DFS),2014-12-24,COMPLETED,INTERVENTIONAL,['PHASE3'],,Patient's Quality of Life (QoL)
12544,NCT02277834,"Compare the proteomic signature of pancreatic adenocarcinoma , pancreatic cancer and control participants to the disease process",2014-08,COMPLETED,OBSERVATIONAL,['NA'],,Compare the proteomic profile between pancreatic cancer and pancreatitis
12545,NCT01479894,Compare the prognosis of colon cancer patients compared to gene expression.,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,
12546,NCT01276483,Radiologic-pathologic correlation,2011-02,COMPLETED,OBSERVATIONAL,['NA'],,
12547,NCT02420691,Number of Participants With Response Rate Per Response Evaluation Criteria in Solid Tumors Version 1.1,2015-08-25,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Ki-67 With Treatment,Progression Free Survival (PFS)
12548,NCT05922358,Completion rate of 3 cycles of re-chemotherapy with oxaliplatin,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Concordance rate between oxaliplatin skin test results and clinicians' judgment
12549,NCT02813928,The presence of recurrences detected for patients curatively treated for a CRC stages II and III within the 3 years of follow-up.,2016-07,COMPLETED,INTERVENTIONAL,['NA'],,
12550,NCT00480298,endoscopic evaluation of the nasal polyp size compared to baseline,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Nasal Polyp score: endoscopic evaluation of the nasal polyp size compared to baseline. Nasal polyposis signs and symptoms including nasal discharge, nasal congestion, postnasal drip, sense of smell,olfactory test (sites Gent, Stockholm and Huddinge) and"
12551,NCT00681252,safety (Phase I: toxicities as assessed by NCI CTCAE version 3) and efficacy (Phase II: Feasibility as evaluated by RECIST),2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate immunological responses
12552,NCT03541304,clinical response rate,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,overall survival
12553,NCT02266056,intra-abdominal pressure,2014-08,COMPLETED,INTERVENTIONAL,['NA'],,
12554,NCT00003287,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12555,NCT01821963,Number of Participants With Undetectable Viral Load 12 Weeks Post-transplant,2013-04,TERMINATED,INTERVENTIONAL,['PHASE3'],,Sustained Virological Response (SVR)
12556,NCT05389527,Major pathological response (MPR),2022-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event (AE)
12557,NCT05039736,To evaluate overall response rate,2023-02-24,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
12558,NCT04021589,progression free survival,2019-07-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
12559,NCT01285778,Three-year disease-free survival rate,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Predictive potential of different biomarkers
12560,NCT05064553,To demonstrate that Oncoguard™ Liver HCC specificity exceeds 82%,2021-07-26,RECRUITING,OBSERVATIONAL,['NA'],,To determine a point estimate and 95% confidence interval for Oncoguard™ Liver overall HCC sensitivity
12561,NCT03710486,Number of Participants With Change From Baseline in Endoscopic Findings,2019-02-19,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants with AE Outcome
12562,NCT01343901,Percentage of Participants Without Detectable Metastatic Disease After a Complete Response Without Surgery,2010-09-30,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants With Unresectability Criteria
12563,NCT04137536,Evaluate toxicity,2019-10-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
12564,NCT00003254,Confirmed Response Rate,1998-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicities
12565,NCT01745107,Disease-free survival time,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,overall survival time
12566,NCT03109301,Efficacy,2017-04-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
12567,NCT02272244,Overall Screening Adherence,2014-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Screening Knowledge and Perceptions
12568,NCT02900677,Self-report Questionnaire,2015-08,UNKNOWN,INTERVENTIONAL,['NA'],Self-report Questionnaire,Self-report Questionnaire
12569,NCT04137679,Disease-free survival,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
12570,NCT05779917,Number of Patients with Dose Limiting Toxicity,2023-03-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,Median CAR-T cell persistence
12571,NCT00862082,Maximum Tolerated Dose (MTD) of PR104 When Used in Combination With Standard Dose Sorafenib in the Phase I Population,2009-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group)
12572,NCT05141747,Adverse Events (AEs),2022-01-19,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Immunogenicity (ADA)
12573,NCT02935634,Kaplan-Meier Analysis of Progression Free Survival Rate (PFSR) at 24 Weeks,2016-11-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Laboratory Abnormalities in Specific Liver Tests
12574,NCT00005869,,1998-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
12575,NCT01430052,Two year survival rate,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rate
12576,NCT05996484,Pathologic complete remission (PCR),2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change From Baseline in HRQoL Score Using EORTC Quality of Life Questionnaire-Oesophageal Module (QLQ-OES18)
12577,NCT01219985,Number of Detected Uptakes on PET Images,2008-04,COMPLETED,INTERVENTIONAL,['NA'],,Lesions Uptake Measurement (SUVmax)
12578,NCT00626054,"Cleanliness of the bowel, as determined by the examiner, and ease of use, as determined by a patient satisfaction questionnaire in the two study arms",2009-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Effect of external factors (demographic parameters, length of hospitalization, procedural diagnosis) on the quality of the bowel preparation"
12579,NCT02588248,Adenoma Detection Rates,2017-04-27,TERMINATED,INTERVENTIONAL,['PHASE3'],,Patient Comfort Level Recorded on Post-procedure Survey
12580,NCT00276861,Response Rate as Measured by RECIST Criteria,2005-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Time to Progression as Measured by the Kaplan Meyer Curve at Completion of Study Treatment
12581,NCT05883800,Incidence of acute gastro-intestinal toxicity equal or higher than grade 2,2023-06-22,RECRUITING,INTERVENTIONAL,['NA'],Patient reported bowel-related outcome measures,Incidence of late gastro-intestinal toxicity equal or higher than grade 2
12582,NCT05631873,Implement a new process using a structured result letter template to set the electronic health record follow-up interval after a screening colonoscopy.,2022-11-18,COMPLETED,INTERVENTIONAL,['NA'],,
12583,NCT01764477,The Maximum Tolerated Dose (MTD) of PRI-724 + Gemcitabine measured by the number of dose limiting toxicities (DLTs) that occur.,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Gene expressions in hair follicle epithelial cells
12584,NCT05502666,Colorectal Cancer Screening,2017-07-08,COMPLETED,INTERVENTIONAL,['NA'],,
12585,NCT06040801,Assess the level of quality of life in frail and non-frail patient groups before and after treatment using EORTC QLQ-C30 v3 and EORTC QLQ-ELD14.,2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],,
12586,NCT06305364,Primary Efficacy Endpoint - Gixam's diagnostic accuracy,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,
12587,NCT00641147,Polyp Number,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Akt Phosphorylation Levels,Change in Apoptosis Index Levels
12588,NCT02826837,Maximum tolerated dose,2022-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Changes in global health/QoL standardized score at post-treatment visits compared to baseline
12589,NCT02863172,Variations in Clinical Features Compared Between Proband Group and Family Member Group,2012-05-22,RECRUITING,OBSERVATIONAL,['NA'],,Variations in the Overall Disease Phenotype Between Proband Group and Family Member Group
12590,NCT02140593,Surgical Rating Score,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,The Surgical Rating Score During Fascial Closure
12591,NCT05128825,Overall Response Rate defined by the revised RECIST v1 .1. and assessed by ICR.,2022-02-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time To Response as defined by the revised RECIST v1 .1. and assessed by ICR and the Investigator.
12592,NCT01201655,,2010-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12593,NCT02021253,Area under the plasma concentration versus time curve (AUC) of endotoxins circulating levels,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,
12594,NCT06116864,Adenoma detection rate,2023-10-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Procedure complication (bleeding or perforation) by the end of the procedure. (Following lexicon for endoscopic adverse events methods)
12595,NCT02053324,Dose Limiting Toxicity evaluated using NCI Common Toxicity Criteria (CTCAE 4.03),2013-11-11,TERMINATED,INTERVENTIONAL,['PHASE1'],tumor response,Adverse Events
12596,NCT03638297,Response rate,2018-08-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,duration of response
12597,NCT03486574,Genes with logarithm of odds (LOD)>2 in linkage analysis,2016-12-07,COMPLETED,OBSERVATIONAL,['NA'],,
12598,NCT05350917,Objective Response Rate (ORR),2022-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Study on the mechanism of drug resistance after progression
12599,NCT02672917,Group F - Determine the MTD and/or the RP2D of MVT-5873 administered in combination with the modified FOLFIRINOX regimen (mFOLFIRINOX) in the PDAC adjuvant setting,2016-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Group F - Evaluate time to recurrence
12600,NCT04566367,Detection rate of a second cancer or precancerous lesions,2020-09-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
12601,NCT02631590,Progression Free Survival (PFS),2016-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
12602,NCT00191412,Antitumor activity as measured by Response Evaluation Criteria in Solid Tumors,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival: Enroll. to death of any cause
12603,NCT03287947,Disease Control Rate,2017-11-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Treatment Administration of Nintedanib, as Measured by Average Daily Dose of Nintedanib."
12604,NCT04676633,Limited Dose Toxicity (LTD),2021-03-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12605,NCT00254436,Patient Iron Levels,2001-10-31,TERMINATED,INTERVENTIONAL,['PHASE3'],,
12606,NCT00005832,Survival rate in patients with advanced adenocarcinoma of the pancreas treated with R115777,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Assess confirmed response (complete & partial) in patients with measurable advanced adenocarcinoma of the pancreas
12607,NCT00003862,,1999-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12608,NCT05390112,Radiological response at 1 month according to mRECIST and ctDNA detection,2021-05-20,RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival and overall survival
12609,NCT04111172,Antigen-specific T-cell response to guanylyl cyclase C (GCC),2020-11-10,SUSPENDED,INTERVENTIONAL,['PHASE2'],,
12610,NCT02131493,DFS,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,OS
12611,NCT02446925,Y-90 distribution and concentration as determined by post embolization PET-CT,2015-05-01,TERMINATED,INTERVENTIONAL,['NA'],,Secondary outcome (time to death from first treatment)
12612,NCT05468008,Evaluate the utility of ESD for treatment of gastrointestinal lesions,2022-02-04,RECRUITING,OBSERVATIONAL,['NA'],,Safety- Adverse Events
12613,NCT01319942,Response rate,2010-06,UNKNOWN,OBSERVATIONAL,['NA'],,Time-to radiological progression interval
12614,NCT05194995,Dose Expansion phase: Overall response rate (ORR),2022-02-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Dose Expansion phase: Progression-free survival (PFS)
12615,NCT03047837,NFκB,2017-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Metformin concentration
12616,NCT02898077,Overall Survival (OS),2017-03-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in Participant-Reported EQ-5D-3L Visual Analog Scale (VAS) Score
12617,NCT03307408,Dosage of the inflammatory cells in liver,2017-02-28,UNKNOWN,OBSERVATIONAL,['NA'],,Dosage of the glucose
12618,NCT00384878,"The primary end point of the study is confirmed objective response rates (by RECIST, Response Evaluation Criteria in Solid Tumors).",2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"The secondary end points of the study are progression-free survival, overall survival, and treatment-related toxicities."
12619,NCT00098982,Maximum tolerated dose and recommended dose of bortezomib as measured by CTC v3.0,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to progression as measured by Kaplan Meier and RECIST every 8 weeks
12620,NCT01001377,Overall Survival,2010-02-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Adverse Events (AEs)
12621,NCT00844623,Adverse Events,2002-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor response by WHO criteria
12622,NCT00024427,Open Label Randomized Phase 3 Multi-Center Trial of PN401 plus high dose 5-FU versus Gemcitabine in Advanced Pancreatic Cancer Patients,2001-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12623,NCT05086627,Pathological complete response rate,2022-10-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
12624,NCT00482625,Reduction in Number of Positive IPMN Celss and Staining Intensity After Treatment,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants Reported at Least 1 Adverse Event With a Grade of 3 and Above
12625,NCT02830620,chimiokine MCP1 expression,2012-08-01,COMPLETED,INTERVENTIONAL,['NA'],,
12626,NCT03204994,Number & location of lymph nodes identified with and without fluorescent probe during rectal cancer surgery,2017-08-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of lymph nodes lying outside the CRM identified by fluorescence
12627,NCT03568110,90-day mortality,2019-03-05,COMPLETED,OBSERVATIONAL,['NA'],,Health-related Quality of life at 12 months (EORTC-QLQ-STO22)
12628,NCT05086614,3-year disease-free survival rate,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,rate of adverse events related to thymosin-alpha 1
12629,NCT05162898,RFS,2022-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,2-year OS%
12630,NCT03042091,"Incidence of post-operative surgical site infection (SSI) including superficial/incisional, deep, and organ space, anastomotic dehiscence and leak",2016-09,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of mortality
12631,NCT00906984,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
12632,NCT05245565,Postoperative anal function assessed by Vaizey scale,2021-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
12633,NCT04323618,Improvement in reproducibility of respiratory-related tumour motion (via fiducial maker surrogacy) for liver cancer patients treated with the AV biofeedback respiratory guidance system.,2014-04,COMPLETED,INTERVENTIONAL,['NA'],,
12634,NCT04133324,CRP_D4/CRP_D2 Colorectal,2018-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,CRP_D2 colorectal
12635,NCT04457284,Response,2020-11-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
12636,NCT01138124,Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin,2010-03,COMPLETED,OBSERVATIONAL,['NA'],,
12637,NCT05346146,R0-surgery resection rate,2021-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Biomarkers predictive of response and toxicity,All the adverse events by NCI CTCAE v 5.0
12638,NCT05982899,frailty trajectories,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
12639,NCT01020812,Freedom From Local Progression of TACE and SBRT at 12 Months,2009-09,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Progression Free Survival
12640,NCT01479907,"Assessment of gastrointestinal function-related quality of life at 1, 3 and 6 months postoperatively",2010-11,COMPLETED,INTERVENTIONAL,['NA'],,
12641,NCT01912443,Laboratory parameters,2013-08,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival (OS) of treatment line
12642,NCT04166383,Best Overall Response (BOR),2020-08-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),6-month Progression-free Survival (PFS)
12643,NCT01363843,Incidence of Complete Resection,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluate the Toxicity of Study Therapy
12644,NCT03563352,The way patients with cancer choose and obtain nutritional supplements to support medical management,2018-08-30,WITHDRAWN,OBSERVATIONAL,['NA'],,Associations of gastrointestinal side effects with specific diagnoses and respective medical therapies
12645,NCT02066688,"The primary objective of this study is to investigate the incidence of colorectal adenoma (CRA) after Folic acid, calcium and vitamin D intervention.",2013-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']","Changes in routine blood count, urine and stool routine test, liver and kidney functions",differences in Histological types of CRA OR CRC
12646,NCT04600154,Change in cachexia staging score from baseline,2021-08-10,RECRUITING,INTERVENTIONAL,['NA'],Progression free survival,QLQ-C30 Global health status/QoL
12647,NCT01850316,One year local progression-free rate,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],,Functional imaging with 11C-choline/18F-FDG CT-PET and perfusion CT to that characterize treatment-related effects
12648,NCT02631564,number of adverse events,2015-06,UNKNOWN,OBSERVATIONAL,['NA'],,Time to progression
12649,NCT01525953,Identification of prognostic factors for overall survival,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,Disease-free survival
12650,NCT00066404,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12651,NCT03127072,Overall survival in subjects receiving RFA plus chemotherapy ± target therapy compared to chemotherapy ± target therapy alone was assessed from the date of study entry until death from the disease.,2017-04-30,UNKNOWN,INTERVENTIONAL,['PHASE4'],,The differences in the incidence or severity of adverse events in the RFA plus chemotherapy ± target therapy arm compared to the chemotherapy ± target therapy only arm were was assessed by of complications after therapy.
12652,NCT00660153,"To determine the safety, tolerability, and maximum tolerated dose of tivozanib (AV-951) in combination with FOLFOX6 chemotherapy.",2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To characterize the pharmacokinetic profile of tivozanib (AV-951) and FOLFOX6 chemotherapy when administered together, and to assess the antineoplastic activity of the combination of tivozanib (AV-951) and FOLFOX6 chemotherapy."
12653,NCT01767675,determine the proportion of patients who are without evidence of disease progression,2013-01-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,pharmacokinetics
12654,NCT02702960,1 year disease-free survival (at 1 year after BMT),2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Efficacy measure- proportion off immunosuppression without graft versus host disease (GVHD) or liver rejection,Liver allograft failure
12655,NCT03902899,Proximal serrated polyp detection rate (PSPDR),2014-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Adenoma detection rate (ADR)
12656,NCT03172572,Major morbidity,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
12657,NCT06238843,overall survival(OS),2024-03-29,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,neutralizing antibody (NAb)
12658,NCT01420874,"Determining in a dose-escalation phase Ib trial the safety of 3 infusions of EGFR2Bi aATC, and a booster infusion after 3 months, for patients with advanced colorectal or pancreatic cancer.",2011-08-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
12659,NCT00275119,Progression-free survival,2003-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Locoregional and metastatic progression-free survival
12660,NCT04397783,parastomal hernia rate by imaging,2019-04-15,UNKNOWN,INTERVENTIONAL,['NA'],,Ease / difficulty in the management of stomatherapy devices
12661,NCT02606097,Overall clinical benefit rate,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Changes in vital signs by body temperature,Overall survival (OS)
12662,NCT01626781,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
12663,NCT05052931,AE,2021-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
12664,NCT05552651,Rate of pCR,2022-09-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Rate of SAE,Rate of MPR
12665,NCT00675636,Identification of patients at high risk of developing hereditary colorectal cancer,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,Establishment of a tissue and data repository
12666,NCT04123340,Feasibility of the use of co-registration software (>80%),2019-08-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quantitatively assessed ablation margin
12667,NCT03104439,Disease Control Rate,2017-05-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Median Overall Survival
12668,NCT04212598,Percentage of patients with disease progression within 2 years after treatment,2020-08-03,RECRUITING,INTERVENTIONAL,['PHASE2'],The number of patients with treatment-related toxicity between the treatment period and half a year after treatment,Percentage of patients who died within 2 years after treatment
12669,NCT02486094,"Apoptotic index, Ki67 and Geminin in cells per mm cubed from resected tumour",2015-06,COMPLETED,OBSERVATIONAL,['NA'],,Overall Survival (OS)
12670,NCT02024633,The number of patients who suffer adverse events,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression-free survival
12671,NCT00590031,Pathologic Complete Response,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluate Toxicity and Tolerability Including Surgical Morbidity and Mortality
12672,NCT00004142,Patient Tumor Response Rate,1998-08-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12673,NCT06125145,Describe the percentage of participants that complete 2 out of 3 study visits,2024-03-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life
12674,NCT00952926,Frequency of local recurrence,2009-10,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
12675,NCT04653389,Event Free Survival（EFS）,2020-12-26,TERMINATED,INTERVENTIONAL,['PHASE2'],,Tumor biomarker
12676,NCT05827796,To evaluate the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) in subjects with advanced pancreatic cancer.,2022-12-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Treatment-Related AEs
12677,NCT01051479,To evaluate our ability to obtain reliable and meaningful 11C-Choline PET-CT images of esophageal cancer (pre- and post- chemotherapy).,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Perform semi-quantitative analysis of tracer uptake using standard uptake values (SUV) and qualitative analysis using pure visual analysis.
12678,NCT03519412,Overall response rate (ORR),2019-01-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
12679,NCT03634332,Progression Free Survival,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Evaluate Blood Translational Biomarkers--T cell receptor (TCR) sequencing,Overall Survival
12680,NCT00912847,,1997-10,COMPLETED,OBSERVATIONAL,['NA'],,
12681,NCT04482309,Objective Response Rate (ORR),2020-08-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The immunogenicity of T-DXd assessed by the presence of ADAs for T-DXd
12682,NCT02849106,Number of interpretable chemogram,2011-05,COMPLETED,INTERVENTIONAL,['NA'],,time to obtain chemogram
12683,NCT02834052,Phase 1 and 2: Determine the response rate of metastatic MRP colon cancer (that has progressed following two lines of therapy in the metastatic setting) to the combination of pembrolizumab and poly-ICLC,2018-01-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the duration of response of recurrent metastatic MRP colon cancer to the combination of pembrolizumab and poly-ICLC
12684,NCT02703142,"Number of participants with the major complications of gastric conduit (strictures, leakage, necrosis)",2015-10,COMPLETED,OBSERVATIONAL,['NA'],,Biological examination of gastric conduit as assessed by the Mitochondrial DNA copy number
12685,NCT02755311,Overall survival,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Mortality
12686,NCT04771988,Response to radioembolization,2013-05-08,COMPLETED,OBSERVATIONAL,['NA'],,Progression-free survival
12687,NCT03043664,Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1),2017-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,ORR as Measured by Immune-related Response Criteria (irRC)
12688,NCT06055387,"Utilize CTCAE v5.0 to assess the grade and frequency of adverse events and treatment-related toxicity in frail and non-frail patient groups, and compare the differences between the two.",2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,To compare overall survival between two distinct groups: frail and non-frail patients.
12689,NCT04986085,Risk of malnutrition in GEP NET,2021-02-24,RECRUITING,OBSERVATIONAL,['NA'],,Subjective Global Assessment (SGA) rates
12690,NCT05468138,3 year Disease Free Survival,2022-08-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,5 year Overall Survival
12691,NCT04826406,Objective Response Rate (ORR),2021-02-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Safety as measured by the rate of AEs, SAEs and laboratory abnormalities"
12692,NCT02304289,"Pharmacokinetic analysis of Cmax, Cmin, Tmax, and AUC.",2014-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Quality of life based on the ""Functional Assessment of Cancer Therapy Hep-30 scale"" (FACT-Hep-30)"
12693,NCT05318794,Feasibility and safety of combined neoadjuvant systemic chemotherapy and pressurised intraperitoneal aerosol chemotherapy (PIPAC),2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease recurrence and survival
12694,NCT05261542,Accuracy of intraoperative Flow Cytometry for cancer cell identification in colorectal cancer.,2017-01-26,COMPLETED,OBSERVATIONAL,['NA'],,
12695,NCT02539212,"Cumulative survival rates were calculated by the Kaplan-Meier method, and comparison between MWA and RFA was done by the log-rank test.",2008-10,COMPLETED,INTERVENTIONAL,['NA'],,Wilcoxon test was used for comparing liver function between MWA and RFA.
12696,NCT03759756,the diagnosis efficiency of the AI model,2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
12697,NCT00429078,,2007-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
12698,NCT04734821,Evaluation of the usefulness of ICG fluorescence to guide lymphadenectomy in oncological esogastric resections,2021-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Evaluation of the impact of fluorescence guidance in intraoperative evaluation of pre-anastomotic tissue perfusion
12699,NCT04486131,Lateral local recurrence,2020-10-06,RECRUITING,OBSERVATIONAL,['NA'],,Quality of life as assessed by the QLQ-C30
12700,NCT01786538,Progression-free survival,2013-06,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Number of participants with adverse events
12701,NCT05360277,Disease-free survival,2023-08-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
12702,NCT05056337,Tumor response: Objective response rate (assessed based on mRECIST criteria),2021-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Events as assessed by CTCAE 5.0 criteria
12703,NCT00149279,overall survival,1995-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,quality of life
12704,NCT00060268,,1997-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12705,NCT02041819,response rate,2014-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse events
12706,NCT02199223,Safety of regorafenib + panitumumab,2014-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,
12707,NCT05113186,One-year local recurrence-free survival,2022-02-02,RECRUITING,INTERVENTIONAL,['PHASE2'],"Consittution of a sequential biobank comprising peripheral samples (serum, plasma)",Per nodule assessment of local recurrence
12708,NCT05770102,Durable Clinical Benefit (DCB),2023-10-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Mean change from baseline in the PedsQL 4.0 Standardised Area Under total Scale Score Curve (PedsSAUC) in parents from paediatric participants.
12709,NCT01729923,"Rate of CR, Assessed According to CEA and CA 19-9 Measurements and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",2013-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Relapse Free Survival in Patients Achieving CR
12710,NCT06224738,Adverse effects,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Overall Survival (OS)
12711,NCT02018367,The diagnostic yield (defined as the proportion of mucosal biopsy samples with neoplasia) of HRME with directed biopsy,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],The clinical impact of HRME on the diagnosis and endoscopic surveillance of BE- associated neoplasia,"The diagnostic accuracy (sensitivity, specificity, positive predictive value, negative predictive value) of HRME for the in-vivo diagnosis of neoplasia."
12712,NCT04310553,Overall survival,2017-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,"clinical benefit rate, CBR"
12713,NCT03471468,"Microparticles level will be assessed by automated and standardised measure of their procoagulant power using Kit STA©Procoag-PPL (Diagnostica Stago, Asnière, France)",2018-07-23,TERMINATED,INTERVENTIONAL,['NA'],,"Khorana score does assess the risk of thrombosis uner chemotherapy according to 3 levels :Score 0, 1, 2 or 3"
12714,NCT04915144,Compare the 12-month progression-free survival (PFS) of subjects receiving personalized or standard injected activity PRRT with Choi criteria.,2023-01-15,WITHDRAWN,INTERVENTIONAL,['PHASE2'],PFS and QoL scores to ctDNA levels,Correlation of QoL scores (EQ-5D) to ctDNA
12715,NCT05599347,Anti-drug antibody development,2023-04-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Endoscopic remission
12716,NCT01930630,Number of participants with adverse events,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Efficacy of extraesophageal saline separating esophagus from adjacent organs detected by EUS or computerized tomography (CT) just after ESI
12717,NCT01423214,Surgical quality based on pathological examination,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,5-year disease-free survival rate
12718,NCT00760604,"Disease free survival defined as the time from surgical resection to the time of recurrent disease, death from esophageal cancer, or death from any cause.",2008-09,TERMINATED,INTERVENTIONAL,['PHASE3'],,To determine mortality and morbidity in arm A vs. arm B
12719,NCT04509635,disease control rate,2020-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,overall survival
12720,NCT04135664,5-year overall survival rate,2019-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life differences (EORTC QLQ-OES18)
12721,NCT02732860,Rate of pPDX engraftment,2015-12,RECRUITING,OBSERVATIONAL,['NA'],,Correlation between pPDX and organoid drug sensitivities
12722,NCT01891539,tumor response,2013-05,UNKNOWN,OBSERVATIONAL,['NA'],,time to progression
12723,NCT04739046,Objective Response Rate,2021-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
12724,NCT04584775,Change from baseline in FACT-G at week 4,2021-02,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival,Change from baseline in FAMCARE-2 at week 4 and 8
12725,NCT05875584,"Evaluating the sensitivity, specificity, and accuracy of rbcDNA in colorectal cancer screening",2023-05-18,COMPLETED,OBSERVATIONAL,['NA'],,"Sensitivity of the rbcDNA screening test with comparison to FIT, with respect to advanced adenoma (AA) and CRC"
12726,NCT02022852,Disease free survival,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Compliance,Pathologic complete response
12727,NCT03340636,occurrence of severe adverse effects (grades 3-5),2018-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12728,NCT03511183,Time to failure of strategy（TFS）,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to failure of strategy（TFS）
12729,NCT02109341,Dose finding safety and activity,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Safety profile
12730,NCT00395252,disease free survival,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
12731,NCT04099641,Objective Response Rate (ORR),2019-09-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12732,NCT04431791,Time To Treatment Failure,2020-05-25,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of adverse events（AEs）
12733,NCT02384811,Local control rate,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety: Frequencies of treatment-related adverse event categories by NCI-CTC
12734,NCT02002416,Overall survival,2006-01,UNKNOWN,OBSERVATIONAL,['NA'],,Positive rate of C-met
12735,NCT01733004,Severity and number of adverse events related to escalating doses of MM-141,2012-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12736,NCT05625529,Clinical performance of ExoVerita™ assay,2022-12-19,RECRUITING,OBSERVATIONAL,['NA'],,Stage Shift
12737,NCT01814345,Incidence of Her2 testing in Gastric cancer,2013-06,TERMINATED,OBSERVATIONAL,['NA'],,
12738,NCT04856787,Phase 3:PFS,2021-06-22,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Duration of response
12739,NCT01212822,Disease-free Survival,2011-04-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Biomarker Levels,Progression Free Survival
12740,NCT06033716,depression,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
12741,NCT03809403,Presence of ctDNA,2019-02-05,UNKNOWN,OBSERVATIONAL,['NA'],,MSI status
12742,NCT00341523,esophageal squamous dysplasia and cancer,2016-11-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Death from any cause
12743,NCT01126866,surgically complete resectability; S-CR,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Survival rate (OS) and progression free survival (PFS)
12744,NCT02472249,Liver blood flow,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
12745,NCT00591279,evaluate strategies for the surveillance of post-polypectomy patients,1981-02,COMPLETED,OBSERVATIONAL,['NA'],,
12746,NCT05915637,Fatigue Assessment,2021-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
12747,NCT00003748,To determine the antitumor activity of irinotecan hydrochloride (CPT-11) in patients with unresectable adenocarcinoma of the esophagus and gastric cardia who have failed prior chemotherapy,1998-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluate the toxicities of irinotecan hydrochloride (CPT-11) in the patient population
12748,NCT00712855,"Type, frequency, and severity of adverse events.",2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12749,NCT05649969,Efficacy of STRONG Program on Treatment Outcomes,2022-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
12750,NCT03358849,Maximum Tolerated Dose,2017-10-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12751,NCT03068403,Area under the echo-power curve (AUC),2018-06-18,COMPLETED,INTERVENTIONAL,['NA'],,mrTNM staging
12752,NCT02448810,Part 1: Number of Participants With Occurrence of Dose Limiting Toxicity (DLT),2015-06-15,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change From Baseline for Quality of Life (QoL) Measure - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
12753,NCT00397904,Complete and Partial Response Rate,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12754,NCT03763526,postoperative complications,2018-12-20,COMPLETED,OBSERVATIONAL,['NA'],Length of hospital stay,operative nutrition status
12755,NCT01964235,Time to progression using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1,2016-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Tolerability of study drug
12756,NCT00766220,Progression Free Survival,2009-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
12757,NCT02435758,Sexual function,2015-04,COMPLETED,INTERVENTIONAL,['NA'],,Urinary function
12758,NCT00019435,,1998-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12759,NCT00797251,The primary outcome is the safety of the anatomical right posterior sectionectomy performed IOUS-guided finger compression.,2007-09,UNKNOWN,OBSERVATIONAL,['NA'],,The secondary outcome is the efficacy of the anatomical right posterior sectionectomy performed by IOUS-guided finger compression.
12760,NCT04741165,Objective Response Rate (ORR),2021-01-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events (AEs)
12761,NCT00407407,Primary: Safety/tolerability endpoints are the maximum tolerated dose and dose-limiting toxicities,2006-11-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Safety-AEs, SAEs, Lab abnormalities, incidence of patients experiencing dose modification of those interruptions &/or premature of d/c pf study drug"
12762,NCT02980861,Number of group Splenic Hilum (No.10) lymph nodes harvested,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
12763,NCT01531621,Resectability,2012-02,RECRUITING,OBSERVATIONAL,['NA'],,Radiological assessment
12764,NCT03686254,"Overall survival (OS), Month",2018-07-16,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Time to progression (TTP), Month"
12765,NCT00027768,Recurrence-free survival,2001-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival
12766,NCT01857726,Overall survival,2013-07,WITHDRAWN,INTERVENTIONAL,['NA'],,Progression-free survival
12767,NCT04229459,Incidence of Treatment-Emergent Adverse Events (Safety),2019-12-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
12768,NCT00372567,Progression-Free Survival (PFS),2007-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Euro Quality of Life (EQ-5D)- Visual Analog Scale (VAS) - Imatinib Treatment Arm
12769,NCT04416685,peri-operative or postoperative complication,2014-05-01,COMPLETED,INTERVENTIONAL,['NA'],in hospital mortality,hospital stay
12770,NCT03694080,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability),2018-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Cell proliferation as a marker for metastatic ability
12771,NCT03484949,Diagnostic rate of patients with early gastric cancer,2017-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Characterization of the high-rik individual for gastric cancer
12772,NCT03488446,Pathological lymph node status of every station,2017-08-30,UNKNOWN,OBSERVATIONAL,['NA'],,Lymph node stage (N stage)
12773,NCT02188615,Overall survival rate,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Mortality of perioperation
12774,NCT01898104,number of patients with complete pathological tumor regression,2012-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",predictive and prognostic factors of tumor and circulating cells,changes in quality of life from baseline
12775,NCT03853928,Number of patients developing Hepatocellular carcinoma,2019-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse events found in cirrhosis with or without treatment with probiotics.
12776,NCT06276686,withdrawal rate,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Physical activity levels
12777,NCT02607826,Response to therapy on MRI or CT scancs will be measured using the RECIST criteria version 1.1.,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,
12778,NCT05357846,Overall survival,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Perioperative mortality
12779,NCT04910789,3-year disease-free survival,2019-12-11,RECRUITING,INTERVENTIONAL,['NA'],,The incidence of perioperative mortality
12780,NCT05102110,Correlation of SNP allele frequency in genes associated with known aero-digestive cancers in paired samples of tumour type and rectal mucus.,2021-12-01,RECRUITING,OBSERVATIONAL,['NA'],,
12781,NCT06034197,Feasibility of VGT-309,2023-09-27,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
12782,NCT04139070,Incidence of Treatment-Emergent Adverse Events (CTCAE),2020-06-15,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Tumor volume
12783,NCT04428905,Quality of life: survey,2020-07-11,RECRUITING,INTERVENTIONAL,['NA'],Outcome Measure for facilitators,
12784,NCT04890054,Likelihood of any colorectal cancer (CRC) screening (for study-eligible patients),2021-05-14,RECRUITING,INTERVENTIONAL,['NA'],,Colonoscopy referral
12785,NCT02222259,Quality of life,2014-09,COMPLETED,INTERVENTIONAL,['NA'],,Functional status
12786,NCT05943288,Positive Predictive Value (PPV),2023-04-25,RECRUITING,OBSERVATIONAL,['NA'],Non-neoplastic resection rate,Endoscope withdrawal time
12787,NCT03800693,Effect of 2 versus 6-hour oxaliplatin infusion time on neuropathy as measured by patient reported outcome (PRO) scores on the European Organization for Research and Treatment of Cancer (EORTC) chemotherapy-induced peripheral neuropathy (CIPN-20) scale,2019-03-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Frequency of dose holds or reductions
12788,NCT03981146,Durable Clinical Benefit,2019-08-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival Time
12789,NCT00400114,"To determine the feasibility and efficacy of adjuvant Sutent therapy after concurrent neoadjuvant therapy with Irinotecan, Cisplatin, external beam conformal radiotherapy plus surgery for potentially resectable esophageal cancer.",2006-09-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine the pattern of relapse (local versus distant) with the addition of adjuvant targeted therapy to esophageal cancer multimodality therapy
12790,NCT04070898,Development of acute urine retention after removal of the bladder catheter after colon surgery.,2019-09-15,UNKNOWN,INTERVENTIONAL,['NA'],,Morbidity changes
12791,NCT00726622,Comparing Laparoscopic-assisted Resection to Open Rectal Resection for Rectal Cancer as Measured by the Percentage of Patients With Successful Resection Based on Pathological Evaluation.,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Bowel and Stoma Function
12792,NCT04853784,Incidence of postoperative complications,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,5-year overall survival OS
12793,NCT05059821,Assessment of immunological response,2021-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression free survival and overall survival time
12794,NCT05620004,"Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0.""",2021-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in tumor volume before and after treatment
12795,NCT01412684,Splenic function,2011-09,WITHDRAWN,OBSERVATIONAL,['NA'],,Lymph node retrieval
12796,NCT04722341,Patient-reported outcomes (PROs),2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Sleep
12797,NCT03533582,Response rate for Group F patients,2018-05-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Percentage of participants with adherence to surgical guidelines,
12798,NCT06163729,Pathologic complete response (PCR),2022-08-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
12799,NCT03485105,overall survival,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12800,NCT03592407,Incidence of adverse events per Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0,2018-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
12801,NCT03781323,Proportion of Patients With a Complete Clinical Response.,2019-05-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of Patients With Survival
12802,NCT04348188,Changes in Health Related Quality of Life: EORTC QLQ-30,2020-06,UNKNOWN,INTERVENTIONAL,['NA'],,Valuation of the measured force
12803,NCT00770991,Change in Burden of Rectal Polyps,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Apoptosis and Cell Proliferation Measured by Percent Difference in Staining.
12804,NCT06109272,Stage 2: Overall Survival (OS),2024-01-11,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Change from Baseline in Global Health Status (GHS)/Quality of Life (QoL) Domain as Measured by the GHS/QoL Domain of the EORTC QLQ-C30
12805,NCT03931044,Accuracy (%; 95% CI),2019-04,UNKNOWN,INTERVENTIONAL,['NA'],,Mean difference of total number of LNs retrieved during the lymphadenectomy of the D2 anatomical plane (mean±DS).
12806,NCT01827553,Overall survival,2013-04-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Changes in Quality of life
12807,NCT05497336,Objective response rate (ORR),2022-08-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of participants with abnormality in ECG parameters
12808,NCT01683240,Efficacy of cholangioscopy in gallstone therapy and stricture diagnosis,2011-02,COMPLETED,INTERVENTIONAL,['NA'],,Stricture diagnostic
12809,NCT00495924,,2006-10,COMPLETED,OBSERVATIONAL,['NA'],,
12810,NCT01840436,Incidence of grade 2 or higher oral mucositis,2013-03,COMPLETED,INTERVENTIONAL,['NA'],,Weight curve
12811,NCT02647125,Local control rate,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,progress-free survival
12812,NCT03484221,The ratio of tumor downstaging to stage 0 and stage I,2018-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life (QLQ C30)
12813,NCT00022477,Response rate of BMS-247550 in colon cancer,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12814,NCT06084481,Objective Response Rate (ORR),2023-11-09,RECRUITING,INTERVENTIONAL,['PHASE1'],,Neutralizing Antidrug Antibody (nADA)
12815,NCT01938300,Change of MCF of EXTEM,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,Change of Fibrinogen
12816,NCT02945566,Phase III Primary Outcome: Organ Preservation,2017-06-14,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Phase III: For analyses incorporating the non-randomised standard surgery comparator - Decision Regret
12817,NCT02084524,Perioperative nutritional management,2013-10,UNKNOWN,INTERVENTIONAL,['NA'],,Evolution of the activities of daily living
12818,NCT06030622,Primary Outcome: Safety and tolerability,2023-12-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Secondary Outcome: Biomarkers
12819,NCT03572283,Change in cell proliferation by Ki-67 expression in tumor cells,2018-04-08,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Number of Adverse Events
12820,NCT01195415,Median Percent at Baseline and 3 Weeks in CD44+/ CD24+/ ESA+ Cells From Needle Biopsy Calculated Using FACS,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Treated Patients Experiencing Grade 3+ Toxicity Per National Cancer Institute Common Toxicity Criteria (CTC) Version 3.0
12821,NCT03351959,Overall Survival,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Molecular Profile of N+
12822,NCT03465501,Evaluation of the tolerance of interstitial brachytherapy of the anal canal,2007-08-17,COMPLETED,OBSERVATIONAL,['NA'],,Comparison of the incidence of toxicities (CTCAE v4) between the 2 groups
12823,NCT04763707,serum Visfatin & serum Vaspin levels,2021-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
12824,NCT01523457,Progression Free Survival,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Correlate Time to Progression, Objective Response, and Overall Survival With Early Changes in Glucose Metabolism Using FDG-positron Emission Tomography (PET) Scanning"
12825,NCT02988440,Dose intensity,2017-04-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Area Under the Plasma Concentration-time Profile (AUCtau) of sorafenib
12826,NCT00002947,,1996-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
12827,NCT03958188,Standardization of a reading grid for PreOPerative Imaging of NeuroEndocrine Tumors,2019-03-31,UNKNOWN,OBSERVATIONAL,['NA'],,
12828,NCT00003548,,1998-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12829,NCT00493883,Survival time,2006-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12830,NCT00581724,Descriptive statistics will be generated to describe the prevalence of pain and its psychosocial correlates.,2007-05,COMPLETED,OBSERVATIONAL,['NA'],,
12831,NCT05475301,Overall survival of patients with locally recurrent rectal cancer,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
12832,NCT02596256,Progression free survival,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12833,NCT04720924,Detection rate of early cancer and precancerous lesions on upper gastrointestinal tract confirmed by pathological examination,2021-01-16,UNKNOWN,INTERVENTIONAL,['NA'],,"Detection rate of early cancer and precancerous lesions on upper gastrointestinal tract from senior, intermediate and primary endoscopist with assistance of AQCS."
12834,NCT01718626,Progression-free survival(PFS),2012-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival(OS)
12835,NCT03948100,Patient 6-minute walk test (6MWT),2018-12-20,RECRUITING,INTERVENTIONAL,['NA'],,Patient and caregiver quality of life (QOL)
12836,NCT00763776,Intra-operative blood loss during liver transection (ml).,2008-07,TERMINATED,INTERVENTIONAL,['NA'],,60-day postoperative complications
12837,NCT02280694,The median progression free survival (mPFS),2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12838,NCT00405587,Percentage of Participants With BOR of CR or PR According to RECIST v1.0 - Dose Escalation: MBP Formulation,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Tumor Levels of Phosphorylated Extracellular Signal-Regulated Kinapse (ERK), Cyclin D1, and Ki-67"
12839,NCT01967875,Progression-Free Survival (PFS),2013-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of Life(QOL)
12840,NCT05225116,Number of patients who complete pre-op treatment and proceed to surgery,2023-01-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Recurrence free survival(RFS)
12841,NCT01350648,Progression of liver disease in patients with HBV,2011-08-23,COMPLETED,OBSERVATIONAL,['NA'],,
12842,NCT02683824,Dosimetry of [18F]FP-R01-MG-F2 (mSv/MBq),2016-01-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
12843,NCT04517708,Change of quality of life after 8 weeks: European Organisation for Research and Treatment of Cancer (EORTC) version 3.0,2016-01-15,COMPLETED,INTERVENTIONAL,['NA'],,
12844,NCT04997850,Conversion resection rate,2020-05-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,OS
12845,NCT05755685,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2023-02-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,the recurrence rate of metastasis and long-term survival of participants accepted the treatment of rmhTNF in the treatment of peritoneal metastases in colorectal cancer.
12846,NCT00646022,Study the natural history of familial carcinoid tumors,2008-08-25,RECRUITING,OBSERVATIONAL,['NA'],,Screen for occult disease and determine whether early detection affects the natural history of the disease
12847,NCT00623831,"Number of Participants With Pyrogenicity at Each Dose Level Tested in the Intrasubject Dose Escalation Performed Over a Dose Range of 250 to 547,000 EU",2007-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Best Overall Tumor Response
12848,NCT05456165,Incidence and Severity of Adverse Events,2022-05-19,TERMINATED,INTERVENTIONAL,['PHASE2'],,T-cell response using Peripheral Blood Mononuclear Cells (PBMCs)
12849,NCT04115618,Toxicity Effect,2017-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS
12850,NCT01741597,Change in volume transfer coefficient (Ktrans) during DCE-MRI with tumor-homing peptide iRGD compared to a baseline DCE-MRI without tumor-homing peptide iRGD,2014-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,The potential for tumor-homing peptide iRGD to enhance uptake of key anti-cancer agents
12851,NCT00003057,,1997-03-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12852,NCT04658147,Number of patients who complete pre-op treatment and proceed to surgery,2021-05-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,Disease free survival (DFS) at 5 years
12853,NCT05774964,Progression Free Survival (PFS),2023-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
12854,NCT01882920,rate of abdominal complications,2010-06,COMPLETED,INTERVENTIONAL,['NA'],length of hospital stay,Overall Survival
12855,NCT04907539,RXC004 + nivolumab Combination: Objective response rate (ORR) using each patients BOR according to RECIST 1.1,2021-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients with adverse events (AEs)
12856,NCT05498168,The ratio of predicted neoantigens being immunogenic,2022-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12857,NCT00005938,,2000-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12858,NCT01065805,Phase II: To determine general biodistribution of 18F-FLT and correlate 18F-FLT uptake with hENT1 expression and Ki-67 scores.,2009-03-20,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Phase II: to correlate 18F-FLT uptake with patient outcomes (treatment response, progression-free survival, overall survival), over the first 12 months of follow-up after completion of tx, subsequently over the remainder of the disease course"
12859,NCT04615312,To determine the maximum tolerated dose of a CDK4 / 6 inhibitor and a MEK inhibitor therapy,2020-11-14,UNKNOWN,INTERVENTIONAL,['PHASE1'],,ORR
12860,NCT00209716,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.,2003-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the MST(Median Survival Time) and PFS(Progression Free Survival) in Phase II setting.
12861,NCT05115916,Overall Colorectal Cancer Screening Uptake,2019-08-28,COMPLETED,INTERVENTIONAL,['NA'],,Effect of electronic primer message on CRC uptake among participants who opened
12862,NCT05664906,Comparison of the proportion of the most severe modified WHO Mucositis Grades,2023-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of analgesic and antibiotics use daily
12863,NCT02647047,Assessment of postoperative pain control by mean of the visual analog scale at hospital discharge,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,Ready to discharge status
12864,NCT01952353,overall survival time,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Adverse Events
12865,NCT02089386,Extent of Barrett's involvement and changes in histology,2014-07-09,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Changes in the length of Barrett's esophagus involvement
12866,NCT05579340,Change in peak oxygen consumption (VO2peak),2023-04,RECRUITING,INTERVENTIONAL,['NA'],,Postoperative complications
12867,NCT05703555,intratumoral DM4 concentration,2024-02-16,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,features in tumor micro-environment
12868,NCT03238820,Complications,2014-01-10,COMPLETED,INTERVENTIONAL,['NA'],,Body composition
12869,NCT01225744,Objective response rate (according to RECIST criteria),2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to progression (TTP)
12870,NCT00044343,Tumor response rate (complete or partial).,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to response duration of response time to progression 4-month progression-free survival 6-month progression-free survival overall survival safety data biomarkers
12871,NCT01608464,Pathological Complete Response ( regression score 1a- see response assessment) in each treatment group,2012-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Rate of conversion from PET non responder to responder with each type of salvage therapy
12872,NCT04439812,evaluate the influence of positive margins on the tumour's recurrence and OS after gastrectomy for GC,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,The secondary outcome was to analyse the possible confounding factors that could affect the recurrence and OS after gastrectomy.
12873,NCT01417494,"Tolerance, in terms of no grade 4 arterial hypertension, grade 3-4 thromboembolic event, grade 3-4 cardiac insufficiency, and hospitalization not related to chemotherapy",2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival with no deterioration of autonomy
12874,NCT00752570,To estimate the treatment effect as measured by progression free survival (PFS) in subjects treated with AMG 386 + FOLFIRI relative to subjects treated with FOLFIRI + placebo.,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate patient reported outcomes (PROs), relative dose intensity, incidence of anti AMG 386 antibody formation, pharmacokinetics of AMG 386 (Cmax and AUC) and safety (incidence of AEs and significant laboratory changes)"
12875,NCT03286920,Percentage of 5% body weight loss on Day 30,2017-09-20,UNKNOWN,OBSERVATIONAL,['NA'],,Re-hospitalization ratio
12876,NCT03455595,Evaluation of the CONECCT endoscopic score so as to improve colon therapeutic treatment polyps,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],,
12877,NCT04889456,30-day morbidity with Clavien-Dindo grading,2021-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,"Long term morbidity: incisional hernia, adhesion related small bowel obstruction, readmissions, reinterventions"
12878,NCT05051592,Detection rate of alterations of anti-epidermal growth factor receptor primary resistance using Circulating tumour DNA,2021-03-26,UNKNOWN,OBSERVATIONAL,['NA'],,Adverse reactions experience by patient
12879,NCT03263741,Objective response rate(ORR),2017-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate(DCR)
12880,NCT02929082,Tumoral environment invasion assessed by the presence of microvascular invasion of the tumor capsule after pathological examination of the surgical pieces,2018-01-23,COMPLETED,INTERVENTIONAL,['NA'],,Interstitial force and traction force at the cell/tumor interface assessed by FRM
12881,NCT02576080,Rate of metastatic relapse in GIST patient,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Patients' quality of life
12882,NCT03674073,Safety of neoantigen-based DC vaccine as measured by the number of subjects experiencing each type of adverse event according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.,2018-10-15,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression-free survival at 2 years
12883,NCT01586117,Acute radiation-induced toxicity: daily diarrhea frequency,2012-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12884,NCT00183846,"To determine the maximum tolerated dose of irinotecan when administered as a 5-day continuous infusion with concomitant radiation therapy in patients with upper gastrointestinal tumors (pancreas, stomach, duodenum, and common bile duct)",2000-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,To obtain preliminary information related to the efficacy of this combination
12885,NCT03992456,Overall survival (OS),2020-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor tissue studies,Patient-reported quality of life
12886,NCT03867916,Rate of Participation,2018-12-13,COMPLETED,INTERVENTIONAL,['NA'],,Patient Acceptability
12887,NCT00243633,Medical and economic interest of CEUS,2005-04,COMPLETED,INTERVENTIONAL,['NA'],,Harmony inter-readers
12888,NCT02711553,Progression Free Survival (PFS),2016-05-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change From Baseline in Participant-Reported EQ-5D-5L Visual Analog Scale (VAS) Score
12889,NCT01505413,Response rate,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
12890,NCT01995227,Safety,2013-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival (OS),Tumor Biomarker Status
12891,NCT01510561,Safety (change in hematology and chemistry laboratory values from baseline),2012-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Efficacy
12892,NCT02117895,Overall survival,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Pain Control,"Disease-specific, recurrence-free survival"
12893,NCT04636008,Adverse reaction,2020-08-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life questionnaire
12894,NCT01041404,Overall Survival - Time to Event,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Trastuzumab Maximum Serum Concentration (Cmax)
12895,NCT00281996,Overall survival at 6 months,2005-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,
12896,NCT04190121,infective complications,2019-03-26,UNKNOWN,INTERVENTIONAL,['NA'],patient's serum albumin changes,length of stay in the ICU
12897,NCT05573217,Evaluate efficacy,2021-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
12898,NCT01918852,Incidence of HFS in first line treatment,2013-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Response rate
12899,NCT00068068,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12900,NCT01626963,Operative Time,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,CRP
12901,NCT04523662,PFS,2020-08-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12902,NCT01789723,Optimal dose and schedule of Fusilev to prevent or reduce mucositis,2013-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Overall Response Rate (ORR),Relationship between Fusilev use and oral mucositis
12903,NCT04617067,Overall survival (OS),2020-10-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of hypercalcaemia,Tumour response rate Duration of response
12904,NCT04913896,Predictive value of CT and MRI after the neoadjuvant treatment for developing a pCR at surgery,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,Prediction model based on CT and MRI of response in AGC
12905,NCT04936399,Distribution of patient quality of life through EQ-5D-3L (EQ-5D) every two weeks for 24 weeks post-treatment initiation following patient enrolment into the EAMS,2020-06-25,COMPLETED,OBSERVATIONAL,['NA'],,
12906,NCT04391426,Composition of the biliary microbiota,2021-06-03,UNKNOWN,OBSERVATIONAL,['NA'],,
12907,NCT03556345,Objective Response Rate （ORR）,2018-07-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival(OS)
12908,NCT05481463,Progression-Free Survival (PFS),2022-03-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events (AE)
12909,NCT01859442,Exponential rate constant of post-chemoradiotherapy and post-exercise phosphocreatine recovery.,2012-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Alterations in mitochondrial energetics post-chemoradiotherapy and exercise
12910,NCT04415567,Disease-free survival (DFS),2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],3-year Recurrence rate (RR),Overall survival (OS)
12911,NCT06078787,To evaluate the ORR according to RECIST 1.1 following Olaparib administration,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,To evaluate the OS according to RECIST 1.1 following Olaparib
12912,NCT04423354,Perioperative mortality,2019-03-25,UNKNOWN,INTERVENTIONAL,['NA'],,5-year disease-free survival rate
12913,NCT03219372,Time to Recurrence,2018-09-27,TERMINATED,INTERVENTIONAL,['PHASE2'],,Levels of Liver Tissue Markers Related to HCC
12914,NCT04400383,Stage 2: The incidence and case number of DLT (Dose Limiting Toxicity) during observation period,2020-06-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Efficacy: overall survival (OS) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
12915,NCT05078866,Rates of grade 2/3 adverse events and symptom reactivity following revaccination (Cohort II),2022-11-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Mismatch repair and/or microsatellite instability status of polyps (and adjacent normal mucosa as control)
12916,NCT00025090,Recurrence-free survival,2001-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Cause-specific and overall survival
12917,NCT05379205,Post-surgery complications.,2022-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Fecal microbiota analysis
12918,NCT03273231,natural killer cell cytotoxicity,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,metastasis
12919,NCT04095299,Rectal preservation at two years,2020-01-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Frequency of grade 3-4 toxicity according to CTCAE v4
12920,NCT04856423,The accuracy of us-qFIT to diagnose colorectal advanced adenoma.,2021-04-19,UNKNOWN,OBSERVATIONAL,['NA'],,Develop a predictive model of advanced colorectal neoplasms which includes the value of us-qFIT.
12921,NCT00030563,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12922,NCT02002299,invasive front growth pattern,2013-08,UNKNOWN,OBSERVATIONAL,['NA'],,
12923,NCT05470738,"The main study's objective is to definite the effective rate of adjuvant chemotherapy performed after surgery (at the 3-month post operatively), which is essential marker recognized as improving overall survival.",2022-09-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"The secondary objective of the study is to know, in patients operated for pancreatic adenocarcinoma, the rate of postoperative complications, the rate of the postoperative morbidity and mortality, and the quality of the resection."
12924,NCT01300858,Tumor Growth Assessment by X-ray/CT,2011-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of study subjects with adverse events
12925,NCT00052559,Maximum tolerated dose of bevacizumab when administered concurrently with 5-fluorouracil (5-FU) and external beam radiation therapy (EBRT) in patients with cT3 and T4 rectal cancer prior to surgery,2002-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
12926,NCT00004150,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12927,NCT01375699,The difference in left ventricular ejection fraction (LVEF) between arms,2011-08-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Comparison of candidate early markers of cardiac injury
12928,NCT02652702,colostomy associated complications,2016-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,
12929,NCT06190730,SASSI,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
12930,NCT03943173,Feasibility of olaparib,2019-06-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Symptom burden and health status
12931,NCT00054951,,2001-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12932,NCT04526886,Unplanned chemotherapy treatment delay,2020-10-15,COMPLETED,INTERVENTIONAL,['NA'],,Out of pocket costs associated with chemotherapy treatment visits
12933,NCT02146313,Percentage of Participants with Adverse Events (AEs) or Serious Adverse Events (SAEs),2014-06-22,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-free Survival (PFS) as Assessed by RECIST v1.1
12934,NCT01372787,"Prevalence and severity of patient-reported symptoms as measured by the NFOSI-18, the FACIT-F subscale, and the FACT/GOG-AD and NTX subscales",2011-04-12,UNKNOWN,OBSERVATIONAL,['NA'],,
12935,NCT04947930,Sensitivity and specificity of the screening tool generated from fecal metagenomics and metabolomics data.,2021-07,UNKNOWN,OBSERVATIONAL,['NA'],,
12936,NCT02387268,Safety as Measured by Number of Serious Adverse Events and Major Complications.,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Participants in Whom the Cecum Was Reached
12937,NCT04710641,Progression free survival (PFS),2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
12938,NCT01719380,Phase 2: Progression Free Survival (PFS),2012-11-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Phase 2: Number of Participants With Any Variant in Gene Status at Baseline
12939,NCT03413605,Colorectal Cancer Screening Rate,2016-06-01,COMPLETED,INTERVENTIONAL,['NA'],,
12940,NCT04714983,Maximum tolerated dose (MTD) achieved during dose-escalation phase,2021-02-15,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Measure Immune response with ELISPOT
12941,NCT02906943,Utilization rates of molecular profiling information provided to treating physicians in guiding future treatment decisions,2016-08,RECRUITING,OBSERVATIONAL,['NA'],,Concordance between administrative data and clinically abstracted data comparing variables using 2x2 concordance tables
12942,NCT04566848,Immune Checkpoints,2020-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
12943,NCT03008512,Progression-free survival rate at 6 months,2016-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Adverse events
12944,NCT01075399,Reproducibility of [F18]HX4 PET Imaging in Measuring Hypoxia in Tumors,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12945,NCT04094688,Progression-free survival (PFS),2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Prognostic effect of highest achieved 25(OH)D
12946,NCT02457299,The number of participants with gastric conduit failures as a measure of safety and tolerability in the one-stage esophagectomy as compared with the two-stage esophagectomy.,2015-05,TERMINATED,INTERVENTIONAL,['NA'],,Quality of Life (QOL) scores of patients in both arms
12947,NCT00526669,Percentage of Participants (Par.) With 5-month Progression-free Survival (PFS),2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Number of Participants With Change From Baseline (Measured as AGI, ItoG3, and ItoG4) in Toxicity Grades for White Blood Cell (WBC) Count at the Indicated Time Points"
12948,NCT04659005,HCC screening uptake rates,2021-02-01,COMPLETED,INTERVENTIONAL,['NA'],,Decisional conflict scale
12949,NCT03120572,Change of forced vital capacity (FVC),2013-08,COMPLETED,OBSERVATIONAL,['NA'],,Change of dyspnea
12950,NCT00454376,"Reliability, scaling, scale correlation, and clinical validity of the gastrointestinal neuroendocrine tumor module (QLQ-G.I.NET21)",2006-10,UNKNOWN,OBSERVATIONAL,['NA'],,Response to change after various treatments
12951,NCT00874406,progression free survival,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,overall survival
12952,NCT05513144,The sensitivity and specificity of ctDNA detection. Profiling of the most frequently detected gene mutations and level of mutations in ctDNA,2021-12-24,RECRUITING,OBSERVATIONAL,['NA'],,Relative frequency of targetable mutations (incl. TMB and MSI status).
12953,NCT03777657,Overall Survival (OS),2018-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,time to response (TTR)
12954,NCT00059618,Maximum Tolerated Dose (MTD) of Bortezomib with Carboplatin Chemotherapy,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12955,NCT06159634,Dissection speed,2023-12-05,RECRUITING,INTERVENTIONAL,['NA'],,Abdominal pain
12956,NCT05909410,Perception about the impact of CHCs on favoring/contrasting specific symptoms onset,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12957,NCT01238094,Progression free survival,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
12958,NCT05686226,Tumor response,2023-03-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
12959,NCT06028516,ctDNA positive patients are detedcted before PET-CT,2021-01-06,RECRUITING,OBSERVATIONAL,['NA'],,
12960,NCT02843750,Postoperative Pneumonia,2016-06,WITHDRAWN,INTERVENTIONAL,['NA'],Quality of Life,Postoperative Pulmonary Complications
12961,NCT03841201,"Safety and tolerability (AEs, SAEs according to NCI-CTCAE V 4.03)",2019-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Translational research
12962,NCT04008056,Authorization for preparation of chemotherapy based on patient reported outcome (decision 3),2019-11-16,COMPLETED,OBSERVATIONAL,['NA'],,Patient satisfaction with the patient reported outcome questionnaire
12963,NCT03458689,"Use of analgesics - ""change"" is being assessed",2018-02-28,UNKNOWN,INTERVENTIONAL,['NA'],,"Sedation scores - ""change"" is being assessed"
12964,NCT00185588,Time-to-Treatment Failure (Intent-To-Treat Analysis),2004-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Time-to-Progression, Evaluable Patients"
12965,NCT06206382,Mortality,2024-01-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Morbidity
12966,NCT01486329,Safety and tolerability,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor perfusion
12967,NCT02513199,Number of Participants With Objective Response Rate,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in Child-Turcotte-Pugh (CTP) Score
12968,NCT01642953,Drop rate from critical pathway,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Recovery after surgery
12969,NCT03015038,Immune cells trafficking,2017-02-05,UNKNOWN,OBSERVATIONAL,['NA'],,"Safety (Number of adverse events, ECOG status)"
12970,NCT00084617,Response Rates (RR) in Metastatic Gastric/GE Junction Tumors,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
12971,NCT02509507,Part 2 Only: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE),2016-02-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12972,NCT02952989,Incidence of dose-limiting toxicities (DLTs),2017-02-23,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival
12973,NCT02945033,"Number of patient with local or distant recurrence or second colorectal cancer or death from any cause, whichever occurred first",2018-07-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of participants with treatment-related adverse events
12974,NCT05111626,Part 2: Overall Survival in FGFR2b ≥ 10% 2+/3+ Tumor Cell Staining Participants,2022-03-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,Part 2: Number of Participants With Anti-Bemarituzumab Antibody Formation
12975,NCT04587128,Cohort B Progression Free Survival (PFS),2020-10-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Circulating Tumor DNA (ctDNA) at time of Progression,Overall Survival (OS)
12976,NCT02730546,Pathological Complete Response (PathCR) Rate,2016-06-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Dose-limiting Toxicities (DLTs) Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
12977,NCT03476122,Detection of circulating tumor cells,2018-03-15,UNKNOWN,OBSERVATIONAL,['NA'],,
12978,NCT03074461,Stool frequency,2017-04-05,UNKNOWN,INTERVENTIONAL,['NA'],,Antimotility drug usage
12979,NCT05964530,Overall disease-free survival,2023-04-19,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
12980,NCT00376948,Median Overall Survival Estimate,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,pAKT (Pichia Anomala Killer Toxin) and NF (Nuclear Factor)-kappaB Activation
12981,NCT01677312,Median Number of Passes to Establish Diagnosis,2012-08,COMPLETED,INTERVENTIONAL,['NA'],,Complications
12982,NCT02085031,Anastomosis-related early complication rate,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Postoperative quality of life
12983,NCT05169177,Standard deviation of difference between software and ground truth measure,2022-10-17,RECRUITING,OBSERVATIONAL,['NA'],,Modelling of patient or treatment features that contributed to the success or failure of the KIM method
12984,NCT03291938,Maximum tolerated dose,2017-11-13,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacodynamic and predictive biomarkers of activity of IACS-010759,Duration of response
12985,NCT04665921,Incidence of dose limiting toxicities,2021-01-18,TERMINATED,INTERVENTIONAL,['PHASE1'],,Incidence of antidrug antibodies (ADA)
12986,NCT00827723,concordance rate between ICGR-15 and Portal Pressure values in patients with resectable HCC and cirrhosis Child A from alcoholic and non-alcoholic origin.,2009-02,COMPLETED,OBSERVATIONAL,['NA'],,postoperative liver failure.
12987,NCT04520906,Complete tumor ablation rate,2020-12-17,UNKNOWN,INTERVENTIONAL,['NA'],,Complete ablation rate of lesions
12988,NCT04323813,Assessments of diagnosis of CRC by EMT-TF mRNA levels in blood,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,Prediction of prognosis of CRC by EMT-TF mRNA levels in blood
12989,NCT05933980,ORR,2023-12-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,DoR
12990,NCT06102772,Progression Free Survival,2023-11-10,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
12991,NCT05664607,Harris Benedict Equation,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
12992,NCT00003103,,1997-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12993,NCT03431428,OS,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,QOL
12994,NCT04324307,ORR,2019-11-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,OS
12995,NCT04492215,Rate of organised colorectal cancer screening at 24 months,2021-05-31,RECRUITING,INTERVENTIONAL,['NA'],,Identification of denial of the colorectal cancer screening
12996,NCT00436423,Response rate by RECIST criteria,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Evaluate the following efficacy measure Duration of response,Time to treatment failure,Time to documented disease progression, Overall survival"
12997,NCT05947201,pathologic complete response (pCR) of the patients' resected tumors,2023-05-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
12998,NCT03247231,Removal of the subepithelial tumour (initial clinical success).,2017-03-31,TERMINATED,OBSERVATIONAL,['NA'],,Long-term recurrence.
12999,NCT02988921,Evaluation of tumor heterogeneity with IBEX software,2016-10,RECRUITING,INTERVENTIONAL,['NA'],,Reduction in acute and late side effects based on modified RT treatment volumes with pre- and post-chemoradiotherapy based on MRI and CT simulation
13000,NCT02403531,overall response rate (clinical complete response and partial response),2015-05-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival
13001,NCT02240771,Survival rate-,2006-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Tumor response
13002,NCT02545556,Number of participants with Adverse events,2015-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
13003,NCT03250091,Risk stratification,2017-06-19,RECRUITING,OBSERVATIONAL,['NA'],,"Gastric, faecal microbiome in cancer patients and patients with precancerous lesions"
13004,NCT04984174,"age, sex, types of institutions and chemotherapy regimens",2021-08-04,RECRUITING,OBSERVATIONAL,['NA'],,
13005,NCT06134973,Application prospect of liquid biopsy technique in monitoring HCC in high risk population,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
13006,NCT05485974,"adverse events (AEs), and serious adverse events (SAEs) overall",2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic variables including volume of distribution
13007,NCT05420558,early postoperative recurrence,2022-06-23,RECRUITING,OBSERVATIONAL,['NA'],,diagnostic performance
13008,NCT05596435,Area under curve of the model for detecting stage I/II/III pancreatic cancer,2022-10-10,RECRUITING,OBSERVATIONAL,['NA'],,Specificity of the early detection model
13009,NCT03699657,Minimum diameter of ablative zone,2014-12-15,COMPLETED,INTERVENTIONAL,['NA'],Maximal diameter of ablative zone,2-year LTP
13010,NCT05707598,Hospital stay after surgery,2023-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Disease-free survival
13011,NCT02583087,Rate of histologically complete (R0) resection of esophageal adenocarcinoma or high grade dysplasia,2016-01-02,UNKNOWN,OBSERVATIONAL,['NA'],,rate of buried glands
13012,NCT00316862,Proportion of Patients With Adenocarcinoma Achieving a Pathologic Complete Response (CR) After Surgery,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Proportion of Patients Experiencing Grade 3 or Greater Hematologic and Non-hematologic Toxicity
13013,NCT03176680,Postoperative complications,2017-06-15,UNKNOWN,INTERVENTIONAL,['NA'],,Inflammatory markers
13014,NCT05963776,pulmonary complications of liver cirrhosior or HCC,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
13015,NCT05302557,Ileus,2021-12-09,RECRUITING,INTERVENTIONAL,['NA'],,Hospital readmission
13016,NCT00273312,Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST),2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
13017,NCT04053725,the proportions of patients with positive serum ctDNA that have postoperative relapse,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,The proportion of ctDNA content decreased in patients with good therapeutic effect
13018,NCT05551039,Proportion of patients with reasons for discontinuation,2022-08-15,COMPLETED,OBSERVATIONAL,['NA'],,Descriptive summary of Pre-existing comorbidities
13019,NCT05759858,Disease-free survival,2022-12-14,RECRUITING,OBSERVATIONAL,['NA'],,"The incidence and mortality of postoperative hemorrhage, bile leakage and other complications."
13020,NCT04617457,Overall survival after R0/R1 resection (OS-res),2021-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,QoL-adjusted OS
13021,NCT05547529,Disease-free survival,2022-09-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,R0 resection rate
13022,NCT02350517,Progression free survival,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
13023,NCT00562666,"Onset of: thrombosis of hepatic artery, grade 4 liver toxicity, or grade 3 or more allergic, neurological, dermatological, infectious, or respiratory reaction",2008-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Onset of clinical, biological signs or images evocative of lymphocyte-induced tumor cytotoxicity and/or of a persistence of gamma-delta T cells in peripheral blood. Tumor response will be evaluated with the RECIST criteria."
13024,NCT05170438,Overall response rate,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival (PFS)
13025,NCT02798224,CRC Screening use,2017-06-14,COMPLETED,INTERVENTIONAL,['NA'],,
13026,NCT00375661,Incidence of adverse effect of interferon,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
13027,NCT03637647,Fitness,2012-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Sarcopenia defined by skeletal muscle radiation attenuation
13028,NCT01919242,the type of complications and the incidence of it,2013-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13029,NCT03199586,Establish the safe recommended phase 2 dose,2017-12-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Cmax
13030,NCT01361061,development of HCC,2010-06,COMPLETED,OBSERVATIONAL,['NA'],,"comparison of these liver cancer markers (AFP, AFP-L3% and DCP) between different etiologies"
13031,NCT04751149,to compare the incidence of acute urine retention after removal of the urinary catheter in the postoperative period of rectal resection.,2019-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Incidence of postoperative complications
13032,NCT05836870,Safety and adverse events (AEs),2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE3'],,
13033,NCT02240433,Number of Participants with LY2157299 Dose-Limiting Toxicities (DLT),2014-11-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,"The Number of Participants with Best Response of Partial Response (PR), Complete Response (CR), Stable Disease (SD), or Progressive Disease (PD)"
13034,NCT05573035,Determine recommended Phase 2 Dose Range (RP2DR),2022-12-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
13035,NCT04709380,TTP,2021-03-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of grade 3 and above adverse events
13036,NCT00397787,Response (CR/PR/stable disease) as measured by RECIST criteria,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
13037,NCT03265743,Realization of human papillomavirus vaccination,2017-09-25,COMPLETED,OBSERVATIONAL,['NA'],,Reasons for non-vaccination
13038,NCT03947840,Rate of immunological response,2019-01-30,COMPLETED,OBSERVATIONAL,['NA'],,Rate of recovery in physical activity
13039,NCT02725424,major Pathological response rate,2015-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13040,NCT03843229,tumor size,2019-01-27,UNKNOWN,INTERVENTIONAL,['PHASE4'],,"Interleukin(IL)-2,Interleukin(IL)-4,Interleukin(IL)-6,tumor necrosis factor(TNF)-α，interferon(INF)-γ in blood"
13041,NCT02286492,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
13042,NCT04840186,Median overall survival,2021-03-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life
13043,NCT04639180,"Recurrence-Free Survival (RFS), as Determined by the blinded independent review committee (BIRC)",2021-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0
13044,NCT05910099,Rate of patients who remain in a rectal cancer clinical study to completion,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
13045,NCT05802420,Progression-free survival,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],The prognostic role of targeted therapy selected based on MRD,Overall survival
13046,NCT05259384,Complication Rate,2021-04-17,RECRUITING,INTERVENTIONAL,['NA'],,The rate of spleen-preservation
13047,NCT05380557,Overall survival,2021-08-23,TERMINATED,OBSERVATIONAL,['NA'],,
13048,NCT03052478,Objective response rate (ORR) by RECIST 1.1,2017-02-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13049,NCT03851133,Presence of Visceral Adiposity,2019-03-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Progression Free Survival
13050,NCT01628458,Safety,2012-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Chemotherapy
13051,NCT03605186,"Change in ""patient-reported oral mucositis"".",2019-02,UNKNOWN,INTERVENTIONAL,['NA'],,"Change in ""Clinical assessment of oral mucositis""."
13052,NCT04181333,The incidence of adverse drug reactions in this surveillance,2023-08-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Assessment of tumor response: Assess the tumor response according to RECIST Ver. 1.1.
13053,NCT02350400,Establish safety and toxicity profile of the irinotecan loaded DEBIRI beads (number of patients with adverse events according to Health Science Authority's Safety Reporting for Clinical Trials),2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumour response (measured by mRECIST)
13054,NCT06088940,Effects of probiotic on depression symptoms,2023-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Relationships between bacterial taxa and symptoms,Probiotic effects on gut microbiota differential taxonomic abundance
13055,NCT03418922,Part 1 and Part 2: Number of Participants with Any Serious and/or Non-serious Adverse Event,2018-01-30,COMPLETED,INTERVENTIONAL,['PHASE1'],,Part 1 and Part 2: Serum Concentration of Nivolumab
13056,NCT05074264,Most efficient algorithm for detection of anogenital human papillomavirus (HPV)-related cancers and high-grade squamous intraepithelial lesions (HSIL),2021-11-30,RECRUITING,INTERVENTIONAL,['NA'],,
13057,NCT04316013,Comparison of disease free survival (DFS) with lidocaine compared with no lidocaine,2020-07-31,RECRUITING,INTERVENTIONAL,['PHASE3'],MINS Substudy,Health utility with intravenous lidocaine versus no lidocaine
13058,NCT00506623,Pathologic stage Tumor regression grade,2004-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity
13059,NCT04616768,Patient perceptions of symptom management,2020-11-19,COMPLETED,INTERVENTIONAL,['PHASE3'],Additional analysis of the primary outcome between different arms (3 month) (exploratory),Fitbit step data
13060,NCT00055822,,2002-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13061,NCT01320241,Overall Mean Survival and Median Survival,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Number of Participants with Adverse Events as a Measure of Technical Success, Clinical Success, Safety (including WBC and Immunological changes of lab, Leakage of the radioactive seeds and Complications related to the procedure."
13062,NCT05865132,ORR,2023-04-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
13063,NCT01008657,2 years global (local+distant) recurrence rate,2010-02-09,COMPLETED,INTERVENTIONAL,['NA'],,Primary treatment effectiveness (assessed 1 month after completion of treatment course which can include up to 3 radiofrequency ablation (RFA) procedures performed monthly)
13064,NCT03047226,Pathogenic germline mutation,2017-02-28,COMPLETED,OBSERVATIONAL,['NA'],,Variant of uncertain significance of germline mutation
13065,NCT04847167,Enteroscopy success rate,2020-02-24,COMPLETED,INTERVENTIONAL,['NA'],,Therapeutic success rate
13066,NCT00879385,Evaluate safety & feasibility of sequential use of a DNA methyltransferase (DNMT) inhibitor (decitabine) with targeted biological agent against EGFR (panitumumab) for KRAS wild type tumors in second or third line treatment of colorectal cancer.,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Measure CEA levels at the beginning of each cycle to examine if they correlate with treatment response or disease progression.
13067,NCT04960943,Objective Response Rate (ORR),2020-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety and Tolerability,Progression Free Survival (PFS)
13068,NCT03336229,Change in cardiorespiratory fitness,2018-04,UNKNOWN,INTERVENTIONAL,['NA'],Feasibility of home-based exercise,Survival
13069,NCT02931825,Comparison of the performed colonoscopy rate within 12 months following randomization / send letter in the 2 arms,2017-05-23,COMPLETED,INTERVENTIONAL,['NA'],,
13070,NCT04838327,Feasibility and translational analysis,2021-08-16,RECRUITING,OBSERVATIONAL,['NA'],,Quality of Life by EORTC QLQ-C30
13071,NCT03608631,Progression-free survival (PFS),2021-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
13072,NCT03898102,Difference in grade 2 or worse HFSR incidence within the first 8 weeks of regorafenib treatment between mCRC patients who receive regorafenib treatment with or without zinc supplementation,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of patients with adverse events (graded by NCI-CTCAE v4.03),Duration of treatment of regorafenib (DoT)
13073,NCT01254591,"Prognosis (6-month, 1-year, 3-year, and 5-year mortality including local/distance recurrence rates)",2006-11,UNKNOWN,INTERVENTIONAL,['NA'],,
13074,NCT00687830,"Comparing All Morning Bowel Prep to Evening Bowel Prep for Patients Undergoing Afternoon Colonoscopies. (Using Ottawa Scale Scores, Range 0-14) Lower Score Indicates a Better Outcome.",2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Patient Satisfaction in the Two Groups, All Morning Prep vs. All Evening Bowel Prep."
13075,NCT03742596,The Level of C-reactive protein (CRP),2018-11-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",The level of neutrophils,The gastrointestinal toxicity
13076,NCT04273100,objective response rate (ORR),2019-11-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],conversion rate of hepatectomy,overall survival
13077,NCT02395471,Number of Participants With Adequate Cytosponge™ Sample,2015-08,COMPLETED,INTERVENTIONAL,['NA'],,Ongoing Safety Measures
13078,NCT00005833,Confirmed complete and partial response rate to R115777,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency & severity of toxicities
13079,NCT02072356,Adverse experiences,2010-10-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
13080,NCT04710589,Progression free survival time (PFS),2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Side effects,Overall survival time (OS)
13081,NCT03507699,Number of participants with serious dose-limiting treatment-related adverse events as assessed by CTCAE v5.0,2018-12-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression free survival
13082,NCT05271110,Feasibility of treatment,2022-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Quality of life after surgery
13083,NCT00024362,,2001-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13084,NCT02355119,Disease free survival (DFS),2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
13085,NCT03236636,Overall survival (OS),2017-09-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],"Genome level (DNA, mRNA, miRNA) biomarker analysis",Assessment on Quality of life 2
13086,NCT06016855,Gene mutations,2024-04-30,RECRUITING,INTERVENTIONAL,['PHASE4'],,
13087,NCT02909452,Changes from baseline in ECG results,2016-09-20,COMPLETED,INTERVENTIONAL,['PHASE1'],Best overall tumor response,Vd (clearance and volume of distribution) of entinostat when given in combination with pembrolizumab
13088,NCT06055439,Objective Response Rate (ORR),2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
13089,NCT02210364,Recommended dose of PM01183 in combination with capecitabine,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13090,NCT05589597,Safety and tolerability of EO4010 in combination with nivolumab,2023-06-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival to the date of death due to any cause. Patients alive will be censored at the date of the last documented follow-up
13091,NCT00278694,Number of patients obtaining pCR,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Clinical, radiological and molecular response to treatment"
13092,NCT02817685,The incidence of Hepatocellular carcinoma,2016-05,UNKNOWN,OBSERVATIONAL,['NA'],,
13093,NCT02416635,The number of Circulating Tumor Cells (CTCs),2013-06,COMPLETED,OBSERVATIONAL,['NA'],,
13094,NCT00399009,Clinical anastomotic leak,2004-01,TERMINATED,INTERVENTIONAL,['NA'],,
13095,NCT02967523,Objective tumor response,2016-05,TERMINATED,OBSERVATIONAL,['NA'],,Changes in alpha-fetoprotein (AFP) blood levels
13096,NCT01294358,MTD (Maximum Tolerated Dose),2011-01-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Serious and Non-Serious Adverse Events
13097,NCT03253133,Maximum tolerated dose,2016-05-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Area Under the Curve (AUC)
13098,NCT02827565,"Technical Optimization of KRAS, BRAF and NRAS mutations detection",2016-02-03,COMPLETED,INTERVENTIONAL,['NA'],,"KRAS, NRAS et BRAF mutational status"
13099,NCT05855278,Overall survival,2019-08-13,COMPLETED,INTERVENTIONAL,['NA'],,
13100,NCT04879927,Rate of Treatment Interruption,2021-05-17,COMPLETED,INTERVENTIONAL,['NA'],,
13101,NCT03329690,Percentage of Participants With Best Overall Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set),2017-11-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Summary of Most Common Treatment-Emergent Adverse Events (TEAEs) ≥20% of Any Grade by Preferred Term Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Safety Analysis Set)
13102,NCT04430725,Time to local recurrence per treated nodule,2019-08-07,RECRUITING,OBSERVATIONAL,['NA'],,Changes in patient reported outcomes per patient
13103,NCT00216424,Tumor response and resectability of tumor following treatment with radiation and capecitabine (Xeloda).,2005-02,TERMINATED,INTERVENTIONAL,['PHASE4'],,
13104,NCT02649647,Incidence of major bowel dysfunction,2016-02,RECRUITING,INTERVENTIONAL,['NA'],Postoperative hospital stay by days,Quality of life impairment
13105,NCT03598231,Proportion of Responders of Low Anterior Resection Syndrome,2018-05-25,COMPLETED,INTERVENTIONAL,['NA'],,Urinary function
13106,NCT03857763,The pathological complete response rate(pCR),2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events Toxicity
13107,NCT05075421,5-year survival rates,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
13108,NCT00178243,,na,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13109,NCT00043043,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13110,NCT05859750,The number of subjects experiencing adverse events (AEs),2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of subjects who develop detectable anti-drug antibodies (ADAs)
13111,NCT04848311,number of harvested station 253 lymph nodes,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA'],complications,number of total lymph nodes harvested
13112,NCT05385809,Surgical conversion rate,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,adverse event (AEs)
13113,NCT05007587,Objective Response Rate and Disease Control Rate of the HCC Participants,2021-07-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Hepatitis B infection,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0
13114,NCT05878405,Change in oral pain,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE3'],,Change in the amount of daily requirements of oral morphine equivalents
13115,NCT03908840,Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) observed during the trial,2019-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Determination of Maximum Tolerated Dose
13116,NCT04588909,Early post operative mortality,2020-03-23,UNKNOWN,OBSERVATIONAL,['NA'],,Rate of hospital acquired SARS CoV 2 infection among operated patients.
13117,NCT00265720,"Colorectal Cancer Screening Rate; This measurement(Impact) is taken 90 days from last intervention session. If a person is not screened, an additional measurement(Post-Impact) is taken 90 days from the Impact.",2003-03,COMPLETED,INTERVENTIONAL,['NA'],,"Knowledge, Attitudes and Beliefs; this measurement is taken at baseline and post intervention session. Sessions vary by intervention group after the initial recruitment sessions:"
13118,NCT00113776,Incidence of HAHA formation,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13119,NCT00003600,Quality of life,1998-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Response rate
13120,NCT03054987,Rates of death attributable to the procedure.,2016-09,COMPLETED,INTERVENTIONAL,['NA'],,Reintervention
13121,NCT00911391,Post-operative functional recovery,2009-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Perioperative Complications
13122,NCT02447263,Number of participants with Adverse events,2015-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
13123,NCT05523154,Reduction in surgical site infections,2023-01-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Timeliness of sample analysis
13124,NCT06269445,Progression-free survival(PFS),2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Quality of life of the patients
13125,NCT03814629,Clinical symptom score is assessing a change,2015-08-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,kidney function test
13126,NCT02338752,efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,immunology index
13127,NCT02788955,Change/maintenance in muscle mass,2016-04,COMPLETED,INTERVENTIONAL,['NA'],,Change in physical function
13128,NCT04945720,One-Year Overall Survival Rate,2022-04-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory study endpoints,"Evaluate the patient's cancer-related QoL using the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ), the EORTC QLQ-HCC18."
13129,NCT05837598,Patient satisfaction assessed by patient feedback questionnaire.,2023-05-31,RECRUITING,INTERVENTIONAL,['NA'],Patient receipt of mental health care assess by electronic medical record review.,Tumor board participant satisfaction assessed by in-session feedback questionnaire.
13130,NCT00983268,Maximum tolerated dose of vorinostat when given in combination with capecitabine and radiotherapy,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biological effect
13131,NCT05489237,Phase 1b - Objective Response Rate (ORR) mRESIST v1.1,2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Phase 1b - Overall survival
13132,NCT04661150,Pathological Complete Regression (pCR) Rate,2021-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Adverse Events
13133,NCT03873532,Overall survival (OS),2018-07-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Detection of biomarkers,Duration of response (DOR)
13134,NCT03271047,Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1,2017-10-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Concentration Versus Time Summary of Plasma Concentration of Binimetinib
13135,NCT03468231,Overall survival,2018-03-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Tumor response
13136,NCT04708470,Determine RP2D of entinostat,2021-10-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of Response (DoR)
13137,NCT00826800,To Determine the Pathologic Complete Response (Path CR) Rate in Patients With Locally Advanced (Stage II or III) Colon Cancer to FOLFOX-bevacizumab Administered as Neoadjuvant.,2009-02,TERMINATED,INTERVENTIONAL,['NA'],,
13138,NCT04440943,Safety and Tolerability of CDX-527 as assessed by CTCAE v5.0,2020-08-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic Evaluation
13139,NCT02999295,Progression free survival rate after 6 months,2017-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival (PFS)
13140,NCT03333785,Team/Cross Boundary Continuity subscale of the Nijmegen Continuity Questionnaire,2018-02-05,COMPLETED,INTERVENTIONAL,['NA'],Team/Cross Boundary Continuity subscale of the Nijmegen Continuity Questionnaire,Patient experience of the care process
13141,NCT05832398,1. Progression-free survival,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
13142,NCT03301493,Timing of molecular profiling,2017-03-30,RECRUITING,OBSERVATIONAL,['NA'],,Outcome of treatment
13143,NCT01915602,Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review,2013-09-27,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events as a measure of safety and tolerability
13144,NCT00024401,,2001-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13145,NCT02340117,Objective response rate (ORR),2015-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
13146,NCT03940976,Objective response rate,2019-04-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
13147,NCT02070705,Change in tumor margins in patients who have undergone chemotherapy for pancreatic cancer (Group III),2014-01-31,RECRUITING,INTERVENTIONAL,['NA'],,DCE- MRI imaging parameters and descriptional analysis of normal pancreas DCE- MRI images (Group IV)
13148,NCT05394259,Accuracy is defined as the number of concordant cases between PYLARIFY PET-CT and the gold standard truth divided by the total sample size.,2022-10-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,
13149,NCT03436719,Rate of Surgical Site Infection,2017-11-06,UNKNOWN,INTERVENTIONAL,['NA'],,
13150,NCT02451553,Recommended phase 2 dose (RP2D) (Phase Ib),2015-11-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to progression
13151,NCT01624220,Assess Use of Implanted Fiducial Markers in Treatment Planning and Delivery Workflow for Frame-Based Spinal Stereotactic Body Radiation Therapy (Spinal SBRT),2012-06-18,COMPLETED,INTERVENTIONAL,['NA'],,Esophageal Tolerance to Hyperfractionation
13152,NCT00574275,Overall Survival (OS),2007-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Anti-drug Antibodies
13153,NCT03435289,The maximally tolerated dose of CPI 613 combined with Gemcitabine and nab-paclitaxel,2017-10-19,UNKNOWN,INTERVENTIONAL,['PHASE1'],,The number of participants with complete or partial response
13154,NCT04695964,anastomotic leak,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Length of post-operative hospital stay
13155,NCT01030263,Whether specialized columnar epithelium was detected.,2008-06,TERMINATED,INTERVENTIONAL,['PHASE4'],,
13156,NCT05524428,Primary Outcome 3: Appropriateness of Implementation Strategies,2023-03-24,RECRUITING,INTERVENTIONAL,['NA'],,Secondary Outcome: CRC Screening Rates
13157,NCT06209983,Length of hospital stay,2018-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],costs of hospitalization,Complication rates
13158,NCT05938309,Overall postoperative morbidity,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,3-year recurrence pattern
13159,NCT00753844,Safety(Phase I:toxicities as assessed by NCI CTCAE version3),2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,evaluate immunological responses
13160,NCT04250948,TRG0/1,2019-10-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
13161,NCT02586753,Overall survival (OS),2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression-free survival (PFS)
13162,NCT01012804,,2000-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
13163,NCT03961945,Aim 3 - Dysplasia Detection Sensitivity and Specificity,2021-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Aim 3 - Dysplasia Detection Rate of Missed Dysplasia
13164,NCT01053390,"(Response Evaluation Criteria in Solid Tumors, RECIST,2009 ), CR(complete response) and PR(partial response)",2009-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,"A: KPS (karnofsky performance score) B:Laboratory tests: Reexamination of CA19-9（Carbohydrate Antigen 19-9）、 CEA（ carcinoembryonic antigen）, especially for those which are abnormal prior to chemotherapy"
13165,NCT01811108,Number of Participants with AE,2009-07,COMPLETED,OBSERVATIONAL,['NA'],,Patients Overall Survival
13166,NCT02027311,Number of Intervention,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Event of Hypoxia
13167,NCT05312372,Objective response per central review of antitumor activity (using Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) (Phase 2),2025-05,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Changes in vital signs : SBP, DBP, respiratory rate and temperature (Phase 2)"
13168,NCT05994521,Rate of gastric outlet obstruction (GOO),2024-03-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Nutritional status
13169,NCT02735941,Analysis of cannabinoid receptors in blood leukocytes and biopsies from patients with IBD and colon cancer,2017-06-13,COMPLETED,OBSERVATIONAL,['NA'],,Assessment of malignancy of colon cancer by tumor staging
13170,NCT04161911,Overall Survival,2018-10-29,COMPLETED,OBSERVATIONAL,['NA'],,
13171,NCT00102700,Document progression free survival after treatment with ARQ 501 and gemcitabine,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Document safety and efficacy of ARQ 501 in combination with gemcitabine
13172,NCT04810910,Relapse Free Survival(RFS),2021-03-30,RECRUITING,INTERVENTIONAL,['PHASE1'],Peripheral blood T cell receptor sequencing analysis,Overall Survival(OS)
13173,NCT03162198,Number of cell-free DNA (cfDNA) in cirrhotic patients with hepatocellular carcinoma (HCC),2017-05-15,COMPLETED,OBSERVATIONAL,['NA'],,Number of cfDNA amount with the Barcelona Clinic of Liver Cancer (BCLC) stage of HepatoCellular Carcinoma.
13174,NCT05816187,Changes in Health Related Quality of Life: EORTC QLQ-30,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The five Times Sit to Stand Test (5x Sit-To-Stand Test)
13175,NCT00252889,"Subjective parameters including ECOG performance status, specific symptoms, and side effects are graded according to standard Common Terminology Criteria for Adverse Events (CTCAE) v.30 criteria.",2004-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13176,NCT05266820,Progression-free survival (PFS),2021-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events
13177,NCT03785873,Phase II: Median Progression-Free Survival (PFS),2019-05-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Overall Survival (OS)
13178,NCT03005002,Incidence of adverse events assessed by NCI CTCAE version 4.03,2017-06-28,COMPLETED,INTERVENTIONAL,['PHASE1'],Tumor immune profiling,Overall response rate (both hepatic and extrahepatic disease) assessed by RECIST 1.1
13179,NCT01249859,To test the hypothesis that 5-year survival rate is significantly lower in the signet ring cells (SRC) adenocarcinoma when compared to non-SRC adenocarcinoma in the upper digestive tract,2010-03,COMPLETED,OBSERVATIONAL,['NA'],,"Overall 3 year survival according to tumor stage, node invasion, and tumor localization"
13180,NCT01714466,Cleansing success rate,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,PEG3350 concentration
13181,NCT04248816,HCC Screening Completion,2020-11-19,COMPLETED,INTERVENTIONAL,['NA'],,HCC Screening Method
13182,NCT00003514,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
13183,NCT01228045,Overall Response Rate (ORR),2011-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety Evaluations
13184,NCT00430027,Overall Toxicity,2006-11,TERMINATED,INTERVENTIONAL,['NA'],,
13185,NCT03683004,Change from Beck Depression Inventory (BDI) from baseline to 12 and 24 weeks (Specific Aim III),2018-01-22,COMPLETED,OBSERVATIONAL,['NA'],,Change from Optical Coherence Tomography baseline at 12 weeks and 24 weeks
13186,NCT04450836,To evaluate the feasibility of treatment sequence (R-TT or TT-R),2020-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,To evaluate the safety (Treatment-Emergent Adverse Events) during treatment
13187,NCT03787667,Sensitivity,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13188,NCT01264432,Maximum tolerable dose defined as the highest dose at which 0 or 1 dose-limiting toxicities are observed in six patients as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,2011-01-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Proportion of toxicities of the combination of veliparib and LDRWAR as graded by the NCI CTCAE version 4.0
13189,NCT01135849,Development of cardiomyopathy,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,
13190,NCT02151123,False negative rate of test for colon cancer,2019-03,UNKNOWN,OBSERVATIONAL,['NA'],,
13191,NCT00118339,,2003-07,COMPLETED,INTERVENTIONAL,['NA'],,
13192,NCT03445416,Change in vaccine awareness,2018-09,WITHDRAWN,INTERVENTIONAL,['NA'],,Change in healthcare engagement
13193,NCT05112016,"Quality of life, including functional and symptom scales, incontinence scores, sexual function",2007-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Costs
13194,NCT04452357,"Acute grade 3+ gastrointestinal toxicity possibly, probably or definitely related to radiation.",2020-01-13,SUSPENDED,INTERVENTIONAL,['NA'],,
13195,NCT05328765,Overall survival,2023-06-09,RECRUITING,OBSERVATIONAL,['NA'],,
13196,NCT06206733,Progression Free Survival (PFS),2024-01-25,RECRUITING,INTERVENTIONAL,['PHASE3'],Number of anti-drug antibody (ADA) Positive Participants,Overall Survival (OS)
13197,NCT05098847,Objective Response Rate,2021-10-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
13198,NCT00658840,all cause mortality,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13199,NCT01877135,at least one anal cancer,2013-08,UNKNOWN,OBSERVATIONAL,['NA'],,patient's feelings about his therapeutic care and impact on his emotional life
13200,NCT03392584,Monitoring intermediate metabolites in the remnant muscular tissue of the pelvis floor with microdialysis catheters after neoadjuvant CRT and subsequent APR for LARC.,2016-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Measure intermediate metabolites and inflammatory mediators after neoadjuvant CRT and subsequent APR for LARC with reconstruction of the perineum with VRAM.
13201,NCT00711997,Maximal Tolerated Dose (MTD) & Dose Limiting Toxicity (DLT) of Intratumoral Injections of BC-819,2009-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor Resectability
13202,NCT00609336,Median Overall Survival of Patients With Adenocarcinoma of the Pancreas,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percent of Patients Surviving at Annual Intervals
13203,NCT02635087,DFS,2015-12,RECRUITING,OBSERVATIONAL,['NA'],,OS
13204,NCT01344304,"Patient diary recording nausea, emesis, food ingestion, and rescue therapy",2011-04,COMPLETED,INTERVENTIONAL,['NA'],,
13205,NCT03043729,Pathologic complete response (pCR),2017-03-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,ECOG
13206,NCT01267578,overall survival,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression free survival
13207,NCT03798951,Post-operative complications,2019-06-05,TERMINATED,INTERVENTIONAL,['NA'],,
13208,NCT04715581,Recurrence-free survival after surgery.,2021-11-25,RECRUITING,INTERVENTIONAL,['NA'],"Physical activity at 3 months, 6 months and 1 year after surgery.",Physical activity at 30 days after surgery (sub-study).
13209,NCT03350477,Relief degree of tumors,2017-11-30,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall survival
13210,NCT03109262,Image Quality for 90-Y PET/CT Scans,2017-02-15,COMPLETED,INTERVENTIONAL,['NA'],,Radiopharmaceutical Dosimetry Accuracy for 90-Y PET/CT Scans and 99mTc-MAA SPECT/CT Scans
13211,NCT02449109,Number of participants with Adverse events,2015-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
13212,NCT00193219,"Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment",2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Adverse Events as a Measure of Safety With FOLFOX6 Combined With Bevacizumab and Cetuximab
13213,NCT03303469,Measure Changes in Treated HCC Tumor Hypoxia Following TACE and Radiotherapy,2017-10-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13214,NCT00422409,Change/improvement i Quality of life,2006-10,COMPLETED,INTERVENTIONAL,['NA'],,Death
13215,NCT05617469,Tumor regression grade,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
13216,NCT03765736,Companion Trial Enrollment,2020-04-20,TERMINATED,OBSERVATIONAL,['NA'],,
13217,NCT02188264,Incidence of DLT defined as any grade 3 non-hematological toxicity or grade 4 hematological toxicity attributed to selumetinib or cyclosporine graded per National Cancer Institute (NCI) CTCAE version 4.0,2014-08-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Change in expression of phosphorylated-mitogen-activated protein kinase 1,Progression-free survival (PFS)
13218,NCT03104582,Acute cholangitis,2011-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall procedure related complication rate
13219,NCT02158988,The primary outcome measure is overall survival,2014-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],frequency of necessary secondary surgical procedures and the length of hospitalisation,quality of life
13220,NCT02716012,Part 2 - Change in tumour size from baseline using RECIST 1.1 and mRECIST in patients treated with MTL-CEBPA in combination with sorafenib,2016-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Part 2 - Safety and tolerability of co-administering MTL-CEBPA with sorafenib assessed using frequency of adverse events graded according to toxicity criteria (NCI CTCAE v 5.0) and categorised by body system
13221,NCT05438667,The duration of efficacy,2022-06-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Adverse events
13222,NCT00072098,toxicity grading,2003-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,tumor response compared at four weeks to baseline
13223,NCT05901194,The proportion of patients with lenvatinib who have a Liver transplantation (LT),2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Treatment-Emergent Adverse Events
13224,NCT04443309,Objective Response Rate (ORR),2020-09-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Biomarker,Adverse Events (AE)
13225,NCT00911170,Percentage of Participants With Grade 3/4 Febrile Neutropenia Across the First 4 Cycles of Chemotherapy,2009-11-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Adverse Events (AEs)
13226,NCT02113384,Overall survival,2012-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
13227,NCT05043532,Rate of ability to perform successful molecular profiling in core tissue obtained during EUS-guided fine needle biopsy,2021-08-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Type of actionable mutations detected on molecular profiling
13228,NCT00826488,"It is anticipated that out of 100 subjects recalled for additional breast imaging that 10 women will be recalled for biopsy. By adding 2D & 3D imaging, it is anticipated that 30 subjects out of 100 will have needed no workup.",2009-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
13229,NCT00215462,To assess the anti-tumor activity of vinorelbine when administered to patients with locally advanced or metastatic esophageal or gastric adenocarcinoma.,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the toxicities of vinorelbine in this patient population.
13230,NCT05871762,3-year OS,2023-06-04,RECRUITING,OBSERVATIONAL,['NA'],,30-day mortality
13231,NCT05942807,Overall survival,2021-05-15,RECRUITING,OBSERVATIONAL,['NA'],,
13232,NCT03149679,Objective response rate (ORR),2017-05-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety and tolerability of the study treatment including recording of number of participants with treatment-related adverse events as assessed by CTCAE v4.0
13233,NCT04268121,Relapse-free survival (RFS) - prospective cohort,2021-01-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events grade 3-4 as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0 - Prospective cohort
13234,NCT02291198,NK cell activity,2014-10,COMPLETED,INTERVENTIONAL,['NA'],,
13235,NCT04199832,Body Weight Change from baseline to the end of treatment,2019-12-20,COMPLETED,OBSERVATIONAL,['NA'],,Overall Survival
13236,NCT00049023,"Evaluate the short term and long term safety (mild/moderate/severe/life-threatening adverse events, premature discontinuations and serious adverse events)",2002-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13237,NCT02573220,Maximum Tolerated Dose (MTD),2015-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,metastectomy (with curative intent) rate
13238,NCT05844514,Validation and further discovery of VOC biomarkers for CRC.,2022-09-23,RECRUITING,OBSERVATIONAL,['NA'],,Exploratory comparison between the breath test and FIT.
13239,NCT01473290,Average area under the curve (AUC) of the FACIT-D diarrhea subscale score assessed weekly during treatment and for two weeks following the completion of RT,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Disease-free survival
13240,NCT00495846,Prolongation of the survival curve (>6 months),2007-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Improvement of quality of life according with SF36 questionnaire
13241,NCT05035446,Rate of complications,2021-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,pain intensity
13242,NCT01436617,Validate the utility of an IgE anti-cetuximab test in the treatment strategy,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,
13243,NCT02030561,Time-to-Event Outcome Measure,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13244,NCT06077591,tumor response,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,rate of grade III/IV toxicities.
13245,NCT02546596,"T stage (0 - 4), N (0 - 3) stage, tumor regression grade (0 - 4)",2014-03-25,UNKNOWN,INTERVENTIONAL,['NA'],,Treatment toxicity (grade 0 - 5)
13246,NCT02075905,Risk Stratification,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,
13247,NCT01010945,Maximum Tolerated Dose,2010-02-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
13248,NCT03383458,Recurrence-free Survival (RFS),2018-04-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to recurrence (TTR)
13249,NCT05213741,Safety of magnetic-assisted colonoscope system,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
13250,NCT04886635,"Safety of active surveillance (including delayed surgery), measured by the number of patients with adverse events",2021-03-09,RECRUITING,OBSERVATIONAL,['NA'],,The number of biopsies taken and quality of the biopsies
13251,NCT03161535,Quality of life (EORTC QLQ-OES 18 ),2017-09-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Circadian rhythms
13252,NCT01859806,Postoperative pancreatic fistula (POPF),2011-01,COMPLETED,INTERVENTIONAL,['NA'],,hospital stay
13253,NCT03766555,Overall survival,2018-05-21,RECRUITING,INTERVENTIONAL,['NA'],,Hospital stay
13254,NCT05841420,PFS (Progression Free Survival),2023-06-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Cumulative worst toxicity during treatment
13255,NCT03385213,Transcriptional changes in gut microbiota,2016-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Epigenetic changes
13256,NCT01130233,Bladder function,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
13257,NCT02047994,Gastric cancer mortality,2013-03,RECRUITING,INTERVENTIONAL,['PHASE4'],,Incidence of- and mortality from other medical conditions
13258,NCT04340440,Operative mortality rate,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,2 years Overall survival rate
13259,NCT02350686,Progression-free survival,2015-05-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
13260,NCT01157806,percentage of patients not requiring palliative surgery during the follow-up,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Determination of prognostic factors indicating the need for immediate palliative surgery.
13261,NCT04519905,overall survival difference of definitive radiotherapy and chemoradiotherapy groups,2020-01-06,RECRUITING,INTERVENTIONAL,['NA'],,cancer specific survival
13262,NCT00789633,Overall Survival (OS),2008-11-25,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival (PFS)
13263,NCT03745170,Overall survival (OS),2018-12-19,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of participants experiencing clinical and laboratory adverse events (AEs)
13264,NCT05635266,Biospecimen & Clinical Data Collection,2021-10-26,RECRUITING,OBSERVATIONAL,['NA'],,
13265,NCT01321658,Postoperative complications,2011-02,COMPLETED,INTERVENTIONAL,['NA'],,Living at home or in institution
13266,NCT02958592,Stage of hepatic fibrosis,2015-06,COMPLETED,OBSERVATIONAL,['NA'],,
13267,NCT03138031,Overall survival rate,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Tumor response rate
13268,NCT05047926,Adherence to each prehabilitation component based on patient reported adherence (Cohorts 2 & 3),2021-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Acceptability of remote setting in Cohort 3
13269,NCT05356156,The incidence of internal hernia within 3 years after surgery,2022-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival at 3 years after surgery
13270,NCT06202105,3 year relapse-free survival by Kaplan Mayer,2024-01-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,hospital stay
13271,NCT00660348,Number of Subjects Per Arm With Decrease in Pain Scores,2008-03,TERMINATED,INTERVENTIONAL,['NA'],,
13272,NCT03240679,Completeness of EMR Site Healing at Follow up Endoscopy,2017-03-22,TERMINATED,INTERVENTIONAL,['NA'],,Presence of Stricture Formation at Follow up Endoscopy
13273,NCT05883345,Validity of blood tests for gastric cancer screening and gastritis type,2023-04-24,RECRUITING,OBSERVATIONAL,['NA'],,
13274,NCT04040842,LARS score change comparing before surgery and 1 year after the surgery.,2019-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
13275,NCT01891344,Objective Response Rate (ORR) by RECIST v1.1 in Molecularly-defined HRD Subgroups (Part 2 of Study),2013-10-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Steady State Trough (Cmin) Level Rucaparib Concentrations
13276,NCT01310985,"Evaluate the safety of pre-operative concurrent chemotherapy with capacitabine (Xeloda), weekly cetuximab (Erbitux), and external beam radiation.",2008-03,COMPLETED,OBSERVATIONAL,['NA'],,"Evaluate efficacy of sphincter preserving surgery rate, local recurrence rate and the disease free and overall survival in patients."
13277,NCT02999672,Best Overall Response (BOR) Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors [RECIST] 1.1).,2016-12-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Plasma/Serum Concentrations of Trastuzumab Emtansine
13278,NCT03534843,Overall survival of all patients,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Short-term mortality of non-surgical subgroup
13279,NCT05866783,Disease-free survival,2023-04-28,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
13280,NCT01808599,Complete remission rate,2013-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Event-free-survival (EFS)
13281,NCT02333279,Number of solid cancers,2008-05,COMPLETED,OBSERVATIONAL,['NA'],,
13282,NCT06164691,Clinical Complete Response,2022-08-14,TERMINATED,INTERVENTIONAL,['NA'],,Prealbumin Level
13283,NCT02063529,"the percentage of patients who had a curative liver treatment following protocol treatment, i.e., liver metastases that can be completely resected and/or ablated with no evidence of residual malignant disease.",2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life (QLQ C30)
13284,NCT00774501,To assess safety & feasibility of single dose image-guided intensity modulated radio (IG-IMRT) using gen anesthesia with apneic oxygenation & controlled ventilation to temp suspend respiratory motion for tx of mets liver disease during localization & tx.,2008-10,COMPLETED,INTERVENTIONAL,['NA'],,
13285,NCT00603577,"Neurological sensory assessment using the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE, Version 3.0)",2008-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,"AE graded with NCI-CTCAE (Version 3.0) and coded using Medical Dictionary for Regulatory Activities (MedDRA, version 9.1)"
13286,NCT01545804,disease stabilization,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13287,NCT00441155,Safety and tolerability of nilotinib either as single agent or in combination with Imatinib,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,To assess any clinical responses in Imatinib-resistant GIST patients. Assessment of tumor response will be made based on modified RECIST criteria - to be assessed at the end of every cycle of treatment
13288,NCT03231917,Adenoma Miss Rate,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Adenoma < 6mm Detection Rate
13289,NCT00003055,,1997-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13290,NCT05235490,The main objective of this work is to identify biomarkers from CT scan (non-invasive imaging phenotypes from radiological images) which have a prognostic value for an early recurrence in patients with hepatocellular cancer.,2021-01-28,COMPLETED,OBSERVATIONAL,['NA'],To correlate the imaging signatures predictive of recurrence with the cell population molding of tissue microenvironment (TME) and the tumor biology using tissue assessment as reference.,Identify biomarkers from CT scan (non-invasive imaging phenotypes from radiological images) which have a prognostic value for a tardive recurrence in patients with hepatocellular cancer.
13291,NCT02810418,Maximum Tolerated Dose (MTD) of Continuous Infusion LMB-100,2016-08-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm B1 and Arm B2,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0).
13292,NCT00123760,To demonstrate the safety of 18F-FDG synthesized from cyclotron produced radiofluoride in the Coincidence Technologies automated synthesis unit (ASU) in the Edmonton PET Centre facility,2004-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,To confirm the diagnostic effectiveness of 18F-FDG in subjects with known or suspected oncologic disease and compare this to literature values
13293,NCT04848051,Total number of participants who completed their colorectal cancer screening,2021-10-12,COMPLETED,INTERVENTIONAL,['NA'],,Screening outcomes: diagnostic results
13294,NCT03896399,Number of participants with a grade 2 or higher complication after laparoscopic ischemic conditioning,2019-04-09,UNKNOWN,INTERVENTIONAL,['NA'],,Redistribution of blood flow by measurement of indocyanine green (ICG) fluorescence angiography
13295,NCT00842348,Adverse Events,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival (PFS): Kaplan-Meier Estimate
13296,NCT01820091,Optimal dose and Schedule of Fusilev to prevent or reduce Oral Mucositis,2013-04,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Impact of Fusilev on number of Folotyn doses delivered
13297,NCT03600623,Number of participants with adverse events as a measure of safety and tolerability,2017-09-25,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Proportion of participants undergoing surgery after preoperative chemoradiation therapy
13298,NCT05493215,Incidence of Grade 3/4 adverse events attributable to imatinib per CTCAE v5.0,2024-03-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Average dose of imatinib required to achieve therapeutic levels and drug dose over 3 years
13299,NCT06055543,Improvement in nutritional status,2023-08-09,RECRUITING,INTERVENTIONAL,['PHASE4'],,ONS Satisfaction
13300,NCT02042443,Overall Survival,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival
13301,NCT05743842,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-03-14,RECRUITING,INTERVENTIONAL,['NA'],,
13302,NCT01501903,Diagnostic accuracy,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,Number of passes for diagnosis
13303,NCT02506842,Overall survival,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
13304,NCT02562755,Overall Response Rate (ORR),2015-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
13305,NCT01326390,"Proportion of patients that develop renal failure (defined as a decline of renal function, as measured by glomerular filtration rate, of 25% or more from pre-procedural)",2010-05,TERMINATED,OBSERVATIONAL,['NA'],,
13306,NCT01286155,The primary outcome from the survey will be the proportion of patients willing to undergo an esophageal capsule study compared to those willing to undergo an endoscopic procedure (Esophagogastroduodenoscopy or transnasal endoscopy),2010-01,COMPLETED,OBSERVATIONAL,['NA'],,"Study established (age, gender, ethnicity, reflux) and potential risk factors (sleep apnea, visceral adiposity, Helicobacter pylori infection, Metabolic Syndrome)to develop a clinical risk factor model for diagnosis of Barrett's esophagus(BE)."
13307,NCT02644603,Treatment related complications,2016-02,UNKNOWN,INTERVENTIONAL,['NA'],,Serum complement
13308,NCT02325986,overall response rate,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
13309,NCT01675999,Histological tumor response in the primary tumor according to the simplified Tumor Regression Grade (TRG) of Ryan,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,•Evaluation of another histopathological grade
13310,NCT04072445,Progression-free Survival (PFS),2019-10-18,COMPLETED,INTERVENTIONAL,['PHASE2'],Prediction of Clinical Benefit by Thymidine Kinase 1 (TK1),Number of Participants With Adverse Events
13311,NCT00006050,,1999-04-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13312,NCT03981614,Progression Free Survival (PFS),2019-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
13313,NCT01505400,Molecular profiling data to be made available in patient's electronic medical records.,2012-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Clinical trial accrual rates among patients with available molecular profiling data
13314,NCT01521091,,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,
13315,NCT04456699,Progression Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR).,2020-08-19,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Discontinuing Study Intervention Due to an AE
13316,NCT00303940,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13317,NCT06219031,CR、PR、SD、PD,2023-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
13318,NCT05460403,Overall survival (OS),2022-04-23,RECRUITING,OBSERVATIONAL,['NA'],Adverse events,Distant metastasis (DM)
13319,NCT04674696,Evaluate MRI good response rate after the total neoadjuvant treatment,2020-11-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Describe the safety and tolerability of total neoadjuvant treatment.
13320,NCT06199297,progression free survival，PFS,2021-03-02,COMPLETED,OBSERVATIONAL,['NA'],,"overall survival, OS"
13321,NCT00701012,Assessment of bowel function,2008-01,COMPLETED,INTERVENTIONAL,['NA'],,comparison of leakage rate
13322,NCT03763214,Stent migration,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Survival rate
13323,NCT02311205,Overall survival (OS),2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate (DCR)
13324,NCT04109495,EORTC Questionnaires - Quality of Life,2017-02-22,COMPLETED,INTERVENTIONAL,['NA'],,Skeletal muscle index change
13325,NCT05223088,Total/moderate tumor regression rate under pathology,2021-10-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
13326,NCT03587480,3-year disease-free survival,2018-12-17,RECRUITING,INTERVENTIONAL,['NA'],,the score of quality of life
13327,NCT06251973,Overall Response Rate,2024-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
13328,NCT03591965,ORR,2018-08-07,TERMINATED,INTERVENTIONAL,['PHASE2'],Additional metabolites of ATG-008 in plasma and urine,"6, 9 and 12 month of survival rate"
13329,NCT05653427,Objective Response Rate (ORR),2022-12-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants with Anti-amivantamab Antibodies
13330,NCT00848510,Whole Tumor Volume and Enhancing Tumor Volume,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS) Time
13331,NCT04905030,(Long Term) Posterior beliefs about false risks of the HPV vaccine,2021-04-28,UNKNOWN,INTERVENTIONAL,['NA'],,Subjective vs Objective vaccination measure (binary indicators)
13332,NCT05613465,Cancer-related fatigue,2022-10-25,RECRUITING,INTERVENTIONAL,['NA'],,Immunologic function
13333,NCT03015298,The results of the PET/MRI and PET/CT examination,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],,Follow-up data
13334,NCT04921488,Estimation of the sensitivity of the automatic characterization system CAD EYE.,2021-10-21,COMPLETED,INTERVENTIONAL,['NA'],,"Compare the diagnostic performance to determine the malignancy of polyps between the automated colonic polyp detection device by the CAD EYE system, and the investigator performing the colonoscopy for colorectal cancer screening."
13335,NCT05745415,Progression free survival,2018-03-29,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
13336,NCT02234180,Disease Free Survival (DFS),2014-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
13337,NCT01139229,the incidence of anastomotic stricture,2007-11,COMPLETED,INTERVENTIONAL,['NA'],,the clinicopathological parameters in relation to postoperative complications
13338,NCT01179750,amount of blood loss,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,drainage from peritoneal cavity during hospital
13339,NCT06026943,"Safety- Adverse events, Safety will be determined according to the overall incidence of device-related SAE's graded according to CTCAE v5.0 criteria",2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Exploratory Objective -to evaluate the changes in the immune markers by Blood samples for immune response,Efficacy- Alpha DaRT seeds
13340,NCT00390182,Overall Response,2003-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Time of Advanced/Recurrent Disease Without Distant Metastases.,
13341,NCT02594696,Feasibility of implementing the intervention in patients with SMI and cancer,2015-11-09,COMPLETED,INTERVENTIONAL,['NA'],,Change in alliance with the oncology clinician
13342,NCT00005597,"Assess response (confirmed & unconfirmed, complete & partial response)",2000-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicities
13343,NCT02043730,Progression Rate,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
13344,NCT06140823,Performance metrics for LIRIC model risk quantiles,2023-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Tumor stage at HCC diagnosis
13345,NCT00118755,Progression-free Survival (PFS),2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Overall Clinical Response (CR or PR)
13346,NCT06314750,OS,2010-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
13347,NCT00094445,Six-Month Participant Survival,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13348,NCT00828607,"Malignancy of the liver mass, as determined on US, on CEUS, and on CECT or CEMRI.",2009-01,COMPLETED,OBSERVATIONAL,['NA'],,"Diagnosis of the liver mass, as determined on US, on CEUS, and on CECT or CEMRI."
13349,NCT01652482,Progression-free Survival (PFS) According to Modified RECIST v1.1 Criteria,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Minimum Observed Serum Concentration (Cmin) of MEHD7945A
13350,NCT05091528,Number of Participants With an Objective Response Rate,2022-02-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Proportion of Participants With Clinical Benefit Rate
13351,NCT01704820,Per patient adenoma detection rate (average # adenomas detected/ patient in each arm of the study).,2012-09,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluate endoscopist comfort with performing retroflexion in the proximal colon.
13352,NCT02520141,Progression Free Survival of Ramucirumab in Advanced Biliary Cancers,2015-12-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Disease Control Rate
13353,NCT04567459,5)Sarcopenia assessment,2021-01-27,UNKNOWN,INTERVENTIONAL,['NA'],,
13354,NCT04600518,Prognostic equivalence,2020-10-07,COMPLETED,OBSERVATIONAL,['NA'],,Multivariate analysis
13355,NCT03086538,Overall Response Rate,2017-05-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13356,NCT06071598,To define the functional role of MFSD2A in CRC through Polyunsaturated fatty acid (PUFA) ad genes analysis.,2023-03-15,RECRUITING,OBSERVATIONAL,['NA'],,
13357,NCT04619329,Median Overall Survival (mOS),2020-10-30,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse Events
13358,NCT02859064,Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability,2017-07-28,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
13359,NCT01006369,Progression-free Survival,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
13360,NCT00439179,Toxicity (Number of Patients Who Experiened DLTs),2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Patients Who Experienced a Partial Response
13361,NCT02279771,anastomotic leak,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],,Number of overall postoperative complications
13362,NCT00113256,survival,2005-02,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
13363,NCT06113796,Costs of treatment,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,30-days Readmission
13364,NCT04406311,Lars score,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Single question on QoL
13365,NCT01125111,The difference in 1 month between two surgical methods in terms of Bladder function.,2009-06,COMPLETED,OBSERVATIONAL,['NA'],,"The serial change of Bladder and sexual function according to times, in each operation method."
13366,NCT05387005,Detection rates of H. pylori infection,2022-05-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The compliance(/adherence) of screening tests for H. pylori infection in the two randomized groups
13367,NCT06159049,SUVmaxFAPI and SUVmaxFDG for each target (Standardized Uptake Value),2022-07-21,COMPLETED,OBSERVATIONAL,['NA'],,
13368,NCT00483405,Disease Response Rate,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Progression
13369,NCT06046963,Ascites objective response rate (ORR),2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Changes of ascite cell subsets in patients
13370,NCT03081988,Prediction model for CCRT response based on clinical and genetic molecular factors,2015-10-19,RECRUITING,OBSERVATIONAL,['NA'],Clinical prediction factors for CCRT response (retrospective study),in-vitro prediction of CCRT using primary esophageal cancer organoid
13371,NCT00154713,evaluate the clinical responses of vaccinated patients 6 weeks after the first injection,2005-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,evaluate the safety of this treatment and the immune responses against CEA before and after the treatment 6 weeks after the first injection
13372,NCT03662841,Time to progression,2018-07-13,TERMINATED,INTERVENTIONAL,['NA'],,Tumor response
13373,NCT04977453,Objective Response Rate (ORR) according to RECIST version 1.1,2021-08-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Immunophenotyping of peripheral blood mononuclear cells will be performed by flow cytometry at various time points,DCR per iRECIST guidelines
13374,NCT05980624,Nutrition status - scored Patient-Generated Subjective Global Assessment (PG-SGA),2023-07-20,RECRUITING,INTERVENTIONAL,['NA'],,common adverse effects
13375,NCT05863195,Overall survival (OS),2023-12-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events
13376,NCT02277093,Progression-free Survival (PFS),2015-09-22,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
13377,NCT06089590,"Number of SAE declared by patients (cancer, serious infections, arterial and venous thrombotic events)",2023-11-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"Number and duration of hospitalization, surgery, endoscopy and other imaging"
13378,NCT02685228,overall survival,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],,Evidence of the size of the lesion in pancreas confirmed by non-investigational CT or MRI
13379,NCT01137084,patient and graft survival,2005-01,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative complications
13380,NCT04202848,The change of concentration of P-hydroxyphenylalanine metabolites in urine,2019-12-20,UNKNOWN,OBSERVATIONAL,['NA'],,The change of the number of Gastrin in blood during the therapy
13381,NCT02033551,Number of subjects with adverse events,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor Assessment
13382,NCT00646607,disease free survival (DFS),2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,"overall Survival (OS), Toxicity and incidence of adverse events"
13383,NCT05866510,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in all participants,2023-05-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Related Adverse Events
13384,NCT01760070,Procedure time for ESD,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,Bleeding Rate
13385,NCT04008797,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs),2019-07-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of Response (DOR)
13386,NCT00002884,,1996-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
13387,NCT03663114,Number of Participants With Hepatic Encephalopathy Risk Factors,2018-07-02,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants with Hepatic Encephalopathy
13388,NCT04220151,Percentages of methylation of DNA in patients with HCC,2020-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13389,NCT00087282,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13390,NCT02749513,Inhibition of Hedgehog pathway signaling as measured by real-time PCR.,2016-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Inhibition of VEGFR2 pathway signaling as measured by Western blot
13391,NCT04934618,Overall Suvival time（OS）,2020-05-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety and tolerability,Disease control rate（DCR）
13392,NCT05010850,Safety Major Complications,2022-01-17,SUSPENDED,INTERVENTIONAL,['NA'],,
13393,NCT05606094,Percentage of Participants Receiving Locoregional Treatment for Localized Disease and Metastasis (Radiotherapy and/or Surgery),2023-03-09,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants with Adverse Events of Special Interest (AESI) In Each Line of Treatment
13394,NCT02179970,Safety of Investigational Medicinal Product (IMP),2015-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Disease status,Pharmacokinetics of the Investigational Medicinal Product (IMP) within the body.
13395,NCT00408564,Progression-free Survival at 6 Months,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine the Biomarker Response of CA 19-9 to Therapy
13396,NCT03752398,Treatment-related adverse events as assessed by CTCAE v4.03,2019-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
13397,NCT02151864,Rate of dose limiting toxicities,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13398,NCT06217042,Disease-free survival (DFS),2024-02-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,5-year overall survival rate
13399,NCT02079220,anti-tumor activity of ziv-aflibercept in combination with XELOX in the first-line treatment of patients with metastatic colorectal cancer (mCRC),2014-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Progression-free survival (PFS)
13400,NCT04102436,Response rate,2024-03-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Immune monitoring
13401,NCT00035334,,2001-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
13402,NCT06244225,Progression free survival (PFS) per RECIST v1.1,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,The treatment-related adverse events (TRAEs）
13403,NCT01882972,Retention feasibility,2013-06,WITHDRAWN,INTERVENTIONAL,['NA'],,Self-reported Exercise-related Injury
13404,NCT06182072,Determine a single ideal dose which will be selected for further investigation in the dose escalation cohort.,2023-12-29,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Evaluate patient tumor blood perfusion pre and post treatment with ProAgio.,Evaluate patient tumor response.
13405,NCT06013943,6-month progression-free survival rate (PFS),2023-03-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,Objective response rate (ORR) per RECIST 1.1
13406,NCT00003321,,1998-02,COMPLETED,OBSERVATIONAL,['NA'],,
13407,NCT01401907,Functional Assessment of Cancer Therapy (Quality of Life Measure),2011-05,COMPLETED,INTERVENTIONAL,['NA'],,Coping (Brief Cope)
13408,NCT04153721,"Change, during the preoperative phase, of the psychological condition of the patients, assessed by GAD7 questionnaire scoring.",2020-03-11,COMPLETED,INTERVENTIONAL,['NA'],,Evaluation of the number of postoperative critical values
13409,NCT04455945,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal Cancer 29 (EORTC QLQ-CR29) Symptom scales,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
13410,NCT06274879,Any grade 3 or 4 adverse events (AE) leading to chemo-immune checkpoint inhibitor-therapy (CICI) discontinuation up to six months after enrolment.,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,Total dose of CICI applied
13411,NCT00260364,Part B (Phase II): Overall response rate (complete response and partial response),2005-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,and Assessment of pain
13412,NCT00614913,Median Survival Without Tumor Progression,1998-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13413,NCT06120803,Grade 2 or higher radiation induced esophagitis,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
13414,NCT04482608,Progression-Free Survival (PFS),2019-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
13415,NCT00078468,To determine the overall objective response rate (complete and partial responses) of AG-2037 in patients with metastatic colorectal cancer who failed treatment with 5FU/LV regimen and up to one other chemotherapeutic regimen.,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To correlate the various genetic markers of MTAP, folate and purine metabolism with clinical response."
13416,NCT02868255,evaluation of the SIRP/CD47 expression,2016-01-03,COMPLETED,OBSERVATIONAL,['NA'],,
13417,NCT00697047,Long-term adherence to CRC screening,2008-07,COMPLETED,INTERVENTIONAL,['NA'],,Impact of SOS interventions on outcomes and CRC-related costs
13418,NCT04538313,Progression-Free Survival,2020-08-26,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,EQ-5D score
13419,NCT04297254,Number of Participants with Grades 1 and 2 Treatment-emergent Adverse Events (TEAEs),2021-02-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Time to First Dose Reduction
13420,NCT03158103,Recommended phase II dose (RP2D),2017-04-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of participants with partial response
13421,NCT00004885,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
13422,NCT05806151,Progression/Recurrence,2023-01-17,RECRUITING,OBSERVATIONAL,['NA'],,
13423,NCT00463840,Resectability After Chemoradiation,2004-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Overall Survival
13424,NCT06023966,hepatic metastasis,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,interval between the surgery and hepatic metastasis
13425,NCT01373346,Operation Related Mortality,2010-02,COMPLETED,INTERVENTIONAL,['NA'],,Albumin : Good Response Group
13426,NCT04288323,Reader reliability of screening modalities,2018-04-27,RECRUITING,INTERVENTIONAL,['PHASE4'],,
13427,NCT05433467,The position of the needle,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Intraoperative bleeding
13428,NCT02462564,Incidence for early postoperative cognitive dysfunction in the patients with peritoneal surface malignancies undergoing cytoreductive surgery and hyperthermic intraperitoneal chemo-therapy,2014-06,COMPLETED,OBSERVATIONAL,['NA'],,Risk factor for early postoperative cognitive dysfunction in the patients with peritoneal surface malignancies undergoing cytoreductive surgery and hyperthermic intraperitoneal chemo-therapy
13429,NCT04248647,"Functional capacity: Six-minute walk test (Enright, 2003)",2016-10-26,COMPLETED,INTERVENTIONAL,['NA'],,"Nutritional status: body weight loss, serum albumin, hand grip strength, body mass index, lean body mass and percentage of body fat"
13430,NCT04938336,Assessment of the usability of the decision aid tool through individual interviews,2022-04-22,RECRUITING,OBSERVATIONAL,['NA'],,
13431,NCT02072317,Progression-free survival (PFS),2013-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13432,NCT06196554,Predictive specificity of drug sensitivity,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Concordance between organoids and source tumor tissue
13433,NCT00197470,,2000-01,UNKNOWN,INTERVENTIONAL,['NA'],,
13434,NCT05270824,The number of CD8+ tumor-infiltrating lymphocytes in tumor tissue and adjacent tissue before and after treatment,2022-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Surgical safety
13435,NCT00756977,Efficacy - Preparation Quality Using a 4 Point Scale,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Serum Chemistry Results (Osmolality)
13436,NCT04414956,HCC occurrence,2016-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Early HCC occurrence
13437,NCT01918644,Incidence of dose-limiting toxicity defined as any grade 3-4 non-hematologic toxicity or grade 5 toxicity attributable to combination chemo-radiotherapy per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,2014-04-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,OS
13438,NCT00972751,"Correlation of expression of these proteins with tumor stage, disease-free survival, overall survival, and risk of recurrence",2009-02,COMPLETED,OBSERVATIONAL,['NA'],,
13439,NCT05677048,Measure response rate to baseline and follow-up surveys by probands and at-risk relatives,2023-04-14,RECRUITING,INTERVENTIONAL,['NA'],,
13440,NCT02820077,mortality,2016-08-06,TERMINATED,INTERVENTIONAL,['NA'],,Hospital length of stay
13441,NCT01894269,overall survival,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],HBV resistance to lamivudine or entecavir,HBV reactivation
13442,NCT00563095,regression of tumour size,2004-03,UNKNOWN,INTERVENTIONAL,['NA'],,side effects
13443,NCT02768532,Vedolizumab concentration at week 6,2016-07-01,TERMINATED,INTERVENTIONAL,['PHASE4'],,Specific antibodies (anti-integrins) level at week 54
13444,NCT03494946,Overall Survival,2016-12-05,RECRUITING,INTERVENTIONAL,['NA'],,
13445,NCT05021029,Pre-malignant progression,2021-07-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Recruitment response rates
13446,NCT00558207,Evaluate progression-free survival (PFS) in patients receiving ARQ 197 versus gemcitabine.,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Further characterize the safety profile of ARQ 197
13447,NCT06157892,Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by investigator assessment,2024-04-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of anti-drug antibodies (ADAs) against disitamab vedotin
13448,NCT00402961,To determine whether a Phase III trial of acupuncture for postoperative recovery after colorectal surgery is warranted as defined by evidence of reduction of postoperative ileus when compared to sham acupuncture,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of emetic episodes during hospital stay
13449,NCT03997435,Rate of pathologic complete response,2019-09-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of response to neoadjuvant therapy
13450,NCT00677287,safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),2008-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate immunological responses
13451,NCT04412161,overall and disease free survivals,2006-04-19,COMPLETED,OBSERVATIONAL,['NA'],,
13452,NCT04971304,Number of patients who develop febrile neutropenia,2015-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Number of patients who develop G-CSF associated adverse events
13453,NCT01388257,Percentage of patients having a clinical healing of their anoperineal fistulas in Crohn disease,2011-10,UNKNOWN,INTERVENTIONAL,['NA'],,Change in discomfort and impact assessed by the patient using a visual analog scale (VAS)
13454,NCT03228095,Performance of nanoarray sensor testing to detect target lesions and diseases,2017-07-24,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Groups of gastrointestinal microbiota correlating to VOCs
13455,NCT05080621,Expansion Phase Only: Evaluate the objective response rate (ORR) of ripretinib in combination with binimetinib by modified RECIST,2021-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Evaluate the time to response (TTR) of ripretinib in combination with binimetinib
13456,NCT06277908,the type of complications and the incidence of it,2024-03-18,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
13457,NCT01084330,Progression Free Survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Evaluate Safety by measuring cardiac safety, recording Adverse Events (AEs) and tracking the tolerability of AUY922"
13458,NCT02308631,Safety and Tolerability of the procedure,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of animals with Adverse Events in the colostomy.
13459,NCT00365391,Number of Patients With Confirmed Tumor Response Defined to be Either a Complete Response (CR) or Partial Response (PR).,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Treatment Failure
13460,NCT03329248,Objective response rate by RECIST,2017-11-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Patient-reported outcomes of pancreatic cancer symptoms
13461,NCT03366961,3-year overall survival,2017-12-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Response rate of chemotherapy
13462,NCT00899158,Urinary 3-methylhistidine levels,2005-06,COMPLETED,OBSERVATIONAL,['NA'],,
13463,NCT06282445,Progression-free survival,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,TRAEs
13464,NCT05352646,dose-limiting toxicity (DLT),2022-07-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,recurrence-free survival(RFS) rate
13465,NCT04965870,Progression Free Survival,2021-06-30,COMPLETED,OBSERVATIONAL,['NA'],,Disease Control Rate
13466,NCT02777437,Disease free survival,2016-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The proportion of completion of laparoscopic surgery
13467,NCT02716688,response rate,2016-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Dysphagia score,Overall survival
13468,NCT04769713,Changes in narcotic use after a hepatic hilar nerve block during and immediately after liver chemoembolization,2021-11-23,RECRUITING,INTERVENTIONAL,['PHASE4'],,Differences in disease response post liver tumoral chemoembolization between patients with hepatic hilar nerve block and those with sham procedure
13469,NCT05475288,Overall survival of patients with locoregionally recurrent colon cancer;,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
13470,NCT01959906,overall survival,2013-07,UNKNOWN,OBSERVATIONAL,['NA'],,
13471,NCT03118882,screening-related indicators,2010-05,COMPLETED,INTERVENTIONAL,['NA'],,Circulating biomarkers association with breast and colorectal cancer
13472,NCT02521285,Differences in the Activation Status of NF-kB by Assessing Levels of Total and Phospho-p65 and Cytoplasmic to Nuclear Translocation of Phospho-p65 at 12 Months (Location C),2016-01-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Barrett's Esophagus (BE) Recurrence,Differences in the Change of a13pge2 at 12 Months (Location C)
13473,NCT01845454,Efficacy of Spray Cryotherapy Dose: Percent Regression of Disease Following Baseline Spray Cryotherapy,2013-04,TERMINATED,INTERVENTIONAL,['NA'],,Safety Outcomes
13474,NCT04392700,Recurrence of HCC,2019-07-25,RECRUITING,INTERVENTIONAL,['PHASE3'],,The number of overall patients
13475,NCT00671372,The safety and tolerability of dulanermin administered in combination with FOLFIRI (with or without Bevacizumab),2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13476,NCT00842647,,2006-07,UNKNOWN,OBSERVATIONAL,['NA'],,
13477,NCT02039635,Area Under Curve (AUC) of Brief Fatigue Index (BFI) on the intake trial drugs up to 16 weeks,2013-12,COMPLETED,INTERVENTIONAL,['NA'],"Change in blood cytokine(IL-2, IL-8, IL-10) level after 16 weeks of trial drug intake",adverse events
13478,NCT01786200,Klintrup-Makinen immune score,2013-02,UNKNOWN,INTERVENTIONAL,['NA'],,Local inflammatory response
13479,NCT01134640,Safety and toxicity of Erbitux in clinical practice,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,
13480,NCT03601689,Distant recurrence rate,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Predictive factors of disease free survival
13481,NCT00862784,Progression-Free Survival (PFS),2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Serum Anti-IMC-1121B (Immunogenicity) at Day 1
13482,NCT00764140,mortality,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,distant metastasis
13483,NCT03067012,"micronutrients' deficiency (iron, folate, vitamin B12)",2015-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Remission rates of co-morbidities
13484,NCT04532736,Lund-Kennedy endoscopic grading system (NPS),2017-09-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Presence of peripheral eosinophilia (PE, > 500/mcl) in blood samples"
13485,NCT01371240,Pancreatic tumor conspicuity on MRI,2011-06,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,post-injection complications and side effects of secretin
13486,NCT05494359,"The number of 15 Nitrogen, 14 Nitrogen, 28 Nitrogen, 29 Nitrogen, 30 Nitrogen",2023-04-04,RECRUITING,OBSERVATIONAL,['NA'],,The stage of the cancer
13487,NCT06091592,Serum autotaxın level,2020-12-30,COMPLETED,OBSERVATIONAL,['NA'],,tumor differentiation grade
13488,NCT00339742,Esophageal Cancer,2003-03-25,COMPLETED,OBSERVATIONAL,['NA'],,
13489,NCT06233981,Median Overall Survival,2024-01-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity
13490,NCT06008054,Recommended Phase II Dose (RP2D),2023-11-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-Emergent Adverse Event (TEAE)
13491,NCT05884255,Progression-free survival (PFS) assessed by BICR,2023-07-06,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence and severity of AE and SAE
13492,NCT04682847,Develop a platform to maintain liver functionality during treatment for liver cancer,2020-11-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Examine the dose-response of tumor and liver tissue in patients who received liver transplant after receiving SBRT
13493,NCT02307812,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
13494,NCT05701436,The one-year DFS rate,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse events
13495,NCT05030090,Evaluate nutritional status indicators change,2021-06-25,COMPLETED,INTERVENTIONAL,['NA'],,Evaluate quality of life indicators change
13496,NCT05487924,postoperative complication,2023-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,time to first flatus
13497,NCT03026803,Response Rate,2006-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13498,NCT05394415,Treatment safety,2022-05-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
13499,NCT00638612,Incidence of treatment emergent adverse events,2008-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Functional Assessment of Cancer Therapy - Pancreas (FACT-Hep)
13500,NCT01656746,"Oncologic sample including size of specimen removed, number of lymph nodes (LN) removed, pathological type and staging, lymph node, vessel or perineural invasion, and status of margins",2010-05,COMPLETED,INTERVENTIONAL,['NA'],,"Visual analogue cosmesis scale scored on the scale from 0 to 10 where 0 is ""worst scar"", and 10 is the ""best scar"""
13501,NCT03622437,Health-related quality of life and symptom burden,2016-02-26,COMPLETED,INTERVENTIONAL,['NA'],,Cost-benefit - QALY's
13502,NCT04032353,"the incidence of upper gastrointestinal cancers, including gastric cancer and esophageal cancer.",2018-12-31,UNKNOWN,INTERVENTIONAL,['NA'],adverse events,tthe focal lesions of upper gastrointestinal tract
13503,NCT02352831,Progression-free Survival (PFS) Rate,2015-08-31,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With a CA19-9 Response
13504,NCT00030082,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13505,NCT01383343,"Maximum tolerated dose of sorafenib tosylate in combination with FOLFIRI and bevacizumab, defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients)",2011-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Time until hematologic nadirs (ANC, platelets, hemoglobin)"
13506,NCT03041571,Patient provider orientation scale score (PPOS),2017-03-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Medical honors students focus group
13507,NCT05688176,Identification of biomarkers (messenger RNAs) for therapy response prediction,2016-06,RECRUITING,OBSERVATIONAL,['NA'],,Development of a quantitative Polymerase Chain Reaction (qPCR) test for clinical use
13508,NCT01863420,Hematologic toxicity,2012-11,UNKNOWN,OBSERVATIONAL,['NA'],,Conformity and Homogeneity of IMRT plan
13509,NCT01769534,To validate the Sendai criteria prospectively in patients with pancreatic cysts.,2012-06,TERMINATED,OBSERVATIONAL,['NA'],,
13510,NCT06038552,Overall survival,2002-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
13511,NCT00493857,The primary goal is to assess the Objective Response Rate (ORR) that the combination of irinotecan and nimotuzumab will produce in patients with irinotecan-refractory metastatic colorectal cancer,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Assess the incidence of acneiform rash,drug reaction,adverse events, the assessment of progression-free survival,stable disease,time to disease progression, overall survival, objective response rates, safety and trough levels in the serum of patients."
13512,NCT05489250,Tumor mutations and their impact on treatment decisions in gastrointestinal cancer patients,2020-10-28,RECRUITING,OBSERVATIONAL,['NA'],"Feasibility of the PLATON WebApp - an interactive platform that connects the participating physicians on cases, cancer types, mutations, protein expressions and therapies, possible trials and discussion options for medical professionals",QoL via EORTC QLQ-STO22 questionnaire in genetically defined cohorts of EC/GC patients
13513,NCT03985670,Pathological complete response rate,2019-07-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,disease-free survival rate
13514,NCT02972034,Percentage of Participants Who Experience a Dose-limiting Toxicity (DLT),2017-01-13,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as Assessed by the Investigator
13515,NCT03112837,the incidence of Radiation Therapy Oncology Group grade 3 mucositis,2017-03-10,UNKNOWN,INTERVENTIONAL,['NA'],,
13516,NCT04712643,Overall Survival (OS),2021-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Adverse Events
13517,NCT00912327,Objective response rate (ORR),2009-06,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
13518,NCT04602117,Overall response rate (ORR),2021-07-28,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Duration of response (DOR) of patients treated with the weekly paclitaxel with tri-weekly trastuzumab duocarmazine (SYD985) combination
13519,NCT05093920,Tumor size,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Serum Alpha-fetoprotein level ng/ml.
13520,NCT01274143,Colonoscopy,2008-05,COMPLETED,INTERVENTIONAL,['NA'],,Decisional Conflict
13521,NCT03528941,Number of patients with hepatitis B reactivation,2018-11-28,COMPLETED,OBSERVATIONAL,['NA'],,Rate of adverse events during ibrutinib treatment
13522,NCT03052556,Prevalence of HPV carriage,2017-03-08,COMPLETED,INTERVENTIONAL,['NA'],,Rate of worsening of cervical dysplasia
13523,NCT03659903,median OS,2004-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
13524,NCT04761185,tolerable dose,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
13525,NCT03852251,Anti-tumor activity of AK104 using objective response rate (ORR) based on RECIST v1.1 as assessed by the investigator (Phase II),2019-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of subjects who develop detectable anti-drug antibodies (ADAs)
13526,NCT05440565,Detection rate,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
13527,NCT03877601,Fluorescence signal in patients with Barrett's Esophagus,2019-07-29,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Interrogate potential new EC biomarkers
13528,NCT01999634,anastomotic leaks rate,2014-02-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,functional success of microdialysis
13529,NCT02272036,Bowel cleanness measured by Boston Bowel preparation Scale,2015-12,COMPLETED,INTERVENTIONAL,['NA'],,Patient satisfaction and compliance
13530,NCT03524716,Text message response rate,2018-03-06,COMPLETED,INTERVENTIONAL,['NA'],,Social support
13531,NCT04975256,Establish Maximum Tolerated Dose,2021-08-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Evaluate preliminary clinical activity of the combination regimen
13532,NCT03941080,Prediction of response to conventional systemic anti-tumor therapy conventional systemic anti-tumor therapy for metastatic or irresectable colorectal cancer,2020-09-09,RECRUITING,OBSERVATIONAL,['NA'],,Prediction of serious side effects to conventional systemic anti-tumor therapy for metastatic or irresectable colorectal cancer
13533,NCT04728750,Complete enucleation of a tumor in the pancreas,2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
13534,NCT04248634,Perineal complications,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Quality of life assessement: EORTC QLQ30 score
13535,NCT06189846,The rate of complete and/or nearly complete response,2024-01-04,RECRUITING,OBSERVATIONAL,['NA'],,Rate of changing attitude after using the digital rectoscope platform (intra-observer changing management).
13536,NCT04764643,Mean Visual analogue scale change,2020-02-01,COMPLETED,INTERVENTIONAL,['NA'],,exam time
13537,NCT00514020,"Number of Patients With Each Response in ""Good Risk"" Genotype (Thymidylate Synthase Promoter Enhancer Region [TSER]*2/*2 or TSER*2/*3 Genotype [Low TS Expression])",2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13538,NCT01247246,Efficacy,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
13539,NCT02528526,Safety and tolerability as measured by collection of adverse effects information,2014-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Efficacy as measured by MRI
13540,NCT01883908,Number of Patients Completing Acupuncture Treatment,2012-12,TERMINATED,INTERVENTIONAL,['NA'],,
13541,NCT02241551,"Safety and Efficacy Using Neo-adjuvant Gemcitabine Plus Nab-paclitaxel in Patients Receiving SBRT and Surgery for Borderline Resectable Pancreatic Cancer, Using Neo-adjuvant mFOLFIRINOX as a Control",2014-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of Life Effects of Chemotherapy on Patients Receiving Chemotherapy and SBRT
13542,NCT02557932,H. pylori eradication rate,2015-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Factors associated with H. pylori reinfection
13543,NCT04913376,Time until Grade 2 or higher patient-reported peripheral neuropathy after start of treatment in the first 12 weeks,2021-05-17,UNKNOWN,INTERVENTIONAL,['NA'],,Secondary Outcome Measures regarding comfort hilotherapy
13544,NCT05667064,Incidence of ADRs,2023-05-10,RECRUITING,OBSERVATIONAL,['NA'],,
13545,NCT01263171,Proportion of patients who commence neoadjuvant chemotherapy and radiotherapy and then undergo surgical resection,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Local recurrence-free, distant metastasis-free, and overall survival at 1 year after surgery"
13546,NCT05311189,Progression-free survival,2022-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE
13547,NCT06300879,Postoperative TNM staging by Pathological findings .,2024-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life at 3 Months Postoperatively will be assessed by EORTC QLQ-STO22 scale
13548,NCT03277144,incidence of duodenal stump leak,2017-09-11,UNKNOWN,INTERVENTIONAL,['NA'],,Frequency of DSF by surgical volume
13549,NCT05937919,Standardized uptake value,2023-05-28,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Number of participants with drug-related adverse events
13550,NCT04514822,SUVmax 60/30 comparison between MLNs and BLNs,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],Accuracy,SUVmax 60/30 comparison from PTs between N0 and non-N0 stage
13551,NCT02041793,Resolution of Pseudocyst,2010-05,COMPLETED,INTERVENTIONAL,['NA'],,Recurrence rate of pseudocyst
13552,NCT05751343,Objective response rate,2023-03-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,progress-free survival
13553,NCT03713593,Overall Survival (OS),2018-12-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Discontinued Study Drug Due to an Adverse Event
13554,NCT00006117,,1999-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13555,NCT01504477,Maximum Tolerated Dose,2011-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of Disease Control
13556,NCT00826540,Progression-free Survival Rate,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Feasibility of Study Treatment
13557,NCT03374254,Percentage of participants with a dose limiting toxicity (DLT),2018-02-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)
13558,NCT00705731,"Adherence to colorectal cancer (CRC) screening, defined as completion of the screening strategy (the subject agrees to pursue/scheduled by the primary care provider).",2007-03,COMPLETED,OBSERVATIONAL,['NA'],,Identification of variables in the survey (based on the Health Belief Model) which are associated with non-adherence to screening.
13559,NCT04850157,Relapse-free survival( RFS),2021-04-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
13560,NCT01494363,Response rate,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
13561,NCT06064344,The cumulative occurrence rate of complications of grade ≥2 within 2 years after the start of treatment,2023-10-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,2-year overall survival rate
13562,NCT04841616,False negative rate,2021-07-01,RECRUITING,INTERVENTIONAL,['NA'],,the need to repeat procedure
13563,NCT04763642,Intra-abdominal infection,2020-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],progression-free survival,Length of hospital stay (day)
13564,NCT01097018,Overall Survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression-free Survival
13565,NCT05844046,ORR,2023-04-06,RECRUITING,INTERVENTIONAL,['PHASE2'],QOL,ORR-BICR
13566,NCT00757614,Evaluation of interactions between polymorphisms in predisposition genes and potential lifestyle risk factors,2008-02,UNKNOWN,OBSERVATIONAL,['NA'],,
13567,NCT05842525,Objective response rate (ORR),2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Disease Control Rate (DCR),Progression-Free Survival (PFS)
13568,NCT04643405,Overall Response Rate (Applicable for: phase II stage) .,2021-03-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse events
13569,NCT03942328,Progression-free survival rate at 2 years (Phase II),2019-09-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in immunologic correlates before and after vaccination treatment,Progression-free survival
13570,NCT02072720,Change of VEGFR2 phosphorylation with IHC,2014-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Changes in vascular parameters in the tumor tissue to asses ongoing angiogenesis
13571,NCT05848947,Effective dose (Gy) for the whole body,2023-04-25,COMPLETED,INTERVENTIONAL,['PHASE4'],,
13572,NCT02190071,positive malignancy rate of cover slides set and base slides set.,2014-06,COMPLETED,OBSERVATIONAL,['NA'],,"positive malignancy rate of (1) cytologic smear, (2) cell block and (3) histologic biopsy"
13573,NCT02705196,Number of patient with dose-limiting toxicities (DLTs) as evaluated accordingly to CTCAE 4.0,2016-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
13574,NCT00005876,,2000-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13575,NCT00767273,Evaluate the performance of the novel imaging methods,2006-10,COMPLETED,INTERVENTIONAL,['NA'],,Correlate FLT activity with clinical outcomes
13576,NCT00677456,"Patients should live for 6 months at least, and with acceptable life quality",2008-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,There are significant differences among life qualities of the four reconstructions
13577,NCT01594125,Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Nintedanib,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Response by Alpha Fetoprotein (AFP)
13578,NCT02210260,Neuroendocrine response to surgery,2013-09,COMPLETED,INTERVENTIONAL,['NA'],,Inflammatory pathway
13579,NCT01091207,Disease-control rate,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rate
13580,NCT02066974,Response rate,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],,"Overall survival, relapse-free survival"
13581,NCT01151839,operative mortality,2010-06,UNKNOWN,INTERVENTIONAL,['NA'],,Treatment toxicity
13582,NCT04529850,Incidence of Treatment Emergent AE's,2020-06-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Cumulative Incidence of Severe OM
13583,NCT04291651,Indolency,2019-10-08,RECRUITING,OBSERVATIONAL,['NA'],,
13584,NCT04361708,The maximum dose tolerated,2020-05-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival rate
13585,NCT00615420,Severity of Mucositis According to the Radiation Therapy Oncology Group (RTOG) for Patients Who Had a Minimum of 2 Mucositis Assessments,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
13586,NCT02921646,Resting energetic expenditure measurement by indirect calorimetry,2017-07-10,TERMINATED,INTERVENTIONAL,['NA'],,
13587,NCT03127774,Progression Free Survival,2017-09-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
13588,NCT05103007,FLR,2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],,Progression-free survival (PFS)
13589,NCT03033446,Response Rate,2016-12-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events from the combination of RE and nivolumab assessed by NCI CTCAE v4.0
13590,NCT00002842,2 Year Disease-free Survival .,1994-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13591,NCT04008082,Presence or absence of factors with a possible influence on OS,2019-05-14,COMPLETED,OBSERVATIONAL,['NA'],,
13592,NCT00077441,"Proportion of confirmed tumor responses, defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 6 weeks apart",2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to treatment failure
13593,NCT02549053,Research of HPV DNA in esophagus biopsies using real time polymerase chain reaction (PCR),2012-02,COMPLETED,INTERVENTIONAL,['NA'],,
13594,NCT00478010,Decision satisfaction,2007-01-19,COMPLETED,INTERVENTIONAL,['NA'],,
13595,NCT01759901,Post-operative surgical complications,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Recurrence rate of hepatocellular carcinoma
13596,NCT05396807,Progression Free Survival (PFS),2023-03-21,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life (QoL)
13597,NCT00078975,Prolonged stable disease rate,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and tolerability
13598,NCT05544253,recurrence-free-survival,2022-10-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
13599,NCT00514163,response rate,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,clinical benefit response
13600,NCT04326296,"Safety, Tolerability",2020-05-30,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
13601,NCT03349957,tumeur response,2017-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
13602,NCT03568019,A retrospective review to determine if PET can be used to identify cachexia-inducing lung and gastrointestinal tumors,2013-11-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
13603,NCT06210334,Overall Survival (OS),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AE)
13604,NCT02298946,Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),2014-11-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to Maximum Observed Plasma Concentration (Tmax) of AMP-224
13605,NCT03604653,Disease-free Survival,2018-05-15,COMPLETED,OBSERVATIONAL,['NA'],,Toxicity as measured by treatment related adverse events according to the NCI CTCAE v 4.0
13606,NCT04304131,sensitivity and specificity of EarlyTect,2020-06-07,COMPLETED,INTERVENTIONAL,['NA'],,
13607,NCT05224518,Quality of life of cancer patients(EORTC QLQ-CR29),2022-02-21,RECRUITING,INTERVENTIONAL,['NA'],,Exercise Counseling and Programming Preferences
13608,NCT02730611,Blood bile acids (micromols per liter),2016-03,COMPLETED,OBSERVATIONAL,['NA'],,Hepatic FXR expression
13609,NCT00258232,Response rate by RECIST criteria at every other course,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to treatment failure
13610,NCT00654212,successful one-stage operation,2002-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,"cumulative operative time, cumulative blood loss, conversion rate, post-operative pain, cumulative length of hospital stay, operative mortality, post-operative complications, ates of permanent stoma creation,disease recurrence, survival"
13611,NCT01952847,Severity of Oral Mucositis for mTOR Inhibitor Patients,2014-07-10,TERMINATED,INTERVENTIONAL,['PHASE3'],,Summary of Adverse Events by Grade and Relationship - mTOR Inhibitor Cohort
13612,NCT03111732,Progression Free Survival (PFS),2017-06-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),"Number of Participants With Grade 1-4 Adverse Events Unrelated, Unlikely, Possibly, and Probably Related to Capecitabine"
13613,NCT00909350,miR expression between tissue from Barrett's esophagus and that from normal tissues,2008-04,COMPLETED,OBSERVATIONAL,['NA'],,expression of miR in Barrett's esophagus patients with cancer in comparison to those who do not progress to cancer
13614,NCT05927142,Phase II: Determine the clinical benefit rate of combination therapy with durvalumab and rintatolimod.,2024-01-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the clinical effect of combination therapy on quality of life using questionnaires
13615,NCT00055809,Tumor response rate (CR + PR) as measured by RECIST criteria,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity graded according to CTC v3.0 criteria for adverse outcomes
13616,NCT04589884,To collect human tissue spectral features to build a spectral tissue library and build successively machine learning algorithm to enable real-time automated tissue recognition,2020-09-22,TERMINATED,OBSERVATIONAL,['NA'],,To correlate HSI values with pathological data obtained as standard of care
13617,NCT04407247,Treatment-related adverse events,2020-07-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in frequencies of immune cells in tissue/blood/stool samples,Recurrent immune-related diarrhea/colitis
13618,NCT04588805,ncidence Rate of Perioperiative VTE,2020-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13619,NCT04700527,The rate and severity of patient reported and physician determined toxicities between subjects who receive therapeutic SCFA and those who receive placebo.,2023-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Subject reported acute toxicity profile as ascertained by patient-reported outcomes version of the CTCAE (PRO-CTCAE) for both subjects who receive therapeutic SCFA versus those who receive placebo.
13620,NCT00634725,Overall survival,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,tolerance to erlotinib
13621,NCT03430440,Postoperative pain (numerical rating scale: 0 ~ 10),2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Side effects of PCA (area and vomiting / hypotension / muscle weakness
13622,NCT06047158,Immune related index,2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],,Hospitalization related
13623,NCT00077337,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13624,NCT05187416,Elastic modulus measured by Ultrasonic shear wave and tumor stromal component assessed by pathological analysis in pancreatic cancer,2022-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13625,NCT04247503,Incidence of cancer in the risk cohort,2019-12-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Measurement of test accuracy of biomarkers to detect pancreatic cancer
13626,NCT00002593,"Compare effectiveness of bolus 5-FU, leucovorin, levamisole vs continuous infusion 5-FU, levamisole as adjuvant therapy for patients with colon cancer, measured in overall survival",1994-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease free survival
13627,NCT05963191,to evaluate the effectiveness of the CAD EYE system in screening for neoplastic lesions in Lynch syndrome.,2023-10-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Time of Colonoscopies
13628,NCT04673136,Detection of advanced lesions,2021-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Characteristics of GI-GENIUS
13629,NCT00897442,Make available tissue and blood for proposed projects,1992-06,COMPLETED,OBSERVATIONAL,['NA'],,
13630,NCT00867464,Increase in the rate of cervical lesions associated with other carcinogenic HPV types that the vaccine does not protect against from prevention of HPV-16/18 associated cervical lesions through vaccination,2009-03-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
13631,NCT00618384,determination of time to progression (TTP),2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,adverse events
13632,NCT02735317,EORTC QLQ-C30,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The change of body weight from baseline.
13633,NCT05226221,30-day morbidity rate,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Emergency Surgical Frailty Index (EmFSI)
13634,NCT03787056,ROC curve AUC regarding diagnostic accuracy of progastrin levels at baseline in cancer patients compared to non-cancer controls,2018-12-04,RECRUITING,INTERVENTIONAL,['NA'],,"Comparison of the initial values and of the kinetics of other serum tumor markers (CA15-3, CA 19-9, CA125, CEA, PSA, AFP) with those of progastrin"
13635,NCT05526339,The incidence of hypoxia,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The incidence of other adverse events
13636,NCT05447234,Overall Survival,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,AEs
13637,NCT05287880,Comparison of BP between MLN and BLN.,2022-03-10,UNKNOWN,OBSERVATIONAL,['NA'],,
13638,NCT03708328,"Expansion: Progression Free Survival, Assessed According to RECIST v1.1",2018-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,"Dose Escalation: Progression Free Survival, Assessed According to RECIST v1.1"
13639,NCT01286662,mortality,1978-01,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of desmoid tumors
13640,NCT03345225,Comparing the change in the Lencioni score between the SureFire infusion system and a standard endhole microcatheter,2018-05,WITHDRAWN,INTERVENTIONAL,['NA'],,Number of Adverse Event
13641,NCT05388513,Survival,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,
13642,NCT02993731,Overall Survival,2016-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall Response Rate in Biomarker Positive Patients,Mean Change From Baseline for Global Quality of Life (QoL) at 8 Weeks.
13643,NCT04097067,Response rate,2019-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Acute and chronic toxicities
13644,NCT00751036,Progression-free Survival (PFS),2009-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
13645,NCT03480152,Number of Non-Serious Adverse Events Probably Related to Treatment,2018-05-18,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Maximum Tolerated Dose (MTD,Number of Participants With an Increase in the Quantity and Quality of Circulating Antigen-specific T Cells
13646,NCT00766480,Complete histological response,2007-01,UNKNOWN,INTERVENTIONAL,['NA'],,
13647,NCT05884723,Perioperative blood transfusion,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Cancer-related mortality
13648,NCT02521727,number of participants having advanced neoplasms.,2015-11-26,COMPLETED,OBSERVATIONAL,['NA'],,number of participants having advanced neoplasms based on age of the proband
13649,NCT01643278,Maximum tolerated dose defined as the highest dose studied for which the observed incidence of dose-limiting toxicity is less than 33% according to the National Cancer Institute Common Toxicity Criteria,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Genotype (v-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog [KIT] and platelet-derived growth factor receptor-alpha [PDGFR-a]) mutation status,"RR as measured by RECIST 1.1, Choi and immune-related response criteria"
13650,NCT02911961,APAP-CYS Concentrations Over Time - Acetaminophen Group,2021-08,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Relationship between APAP-CYS and other biochemical markers of liver function
13651,NCT02907086,Number of blood samples collected,2017-07-07,COMPLETED,OBSERVATIONAL,['NA'],,
13652,NCT00007930,Local recurrence at 3 years,1999-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Disease-free and overall survival at 5 years
13653,NCT05177393,Median Overall Survival,2019-02-28,RECRUITING,OBSERVATIONAL,['NA'],,
13654,NCT03129685,Short term mortality rate,2017-05-20,UNKNOWN,INTERVENTIONAL,['NA'],,Tumor response rate according to mRECIST criteria.
13655,NCT05628441,Combined performance of endoscopist + CADe system in terms of per-patient sensitivity and specificity,2022-05-16,COMPLETED,OBSERVATIONAL,['NA'],,Stand-alone performance of CADe system in terms of per-patient sensitivity and specificity
13656,NCT02973490,postoperative complications,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],,
13657,NCT05738616,Overall survival at 2 years,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life assessment
13658,NCT02041325,Positive for Hepatitis B Surface Antigen,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Phenotypic Changes
13659,NCT01755585,all cause mortality,2011-07,UNKNOWN,OBSERVATIONAL,['NA'],,
13660,NCT04310540,Association between prostate specific membrane antigen (PSMA) uptake in hepatocellular carcinoma at PET with tissue PSMA expression,2020-06-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
13661,NCT01835925,Tumor tissue to predict likelihood of achieving pathologic complete response post standard treatment.,2013-07,COMPLETED,OBSERVATIONAL,['NA'],,Tumor tissue results with clinical outcome post standard treatment. .
13662,NCT03926338,Pathological complete response (pCR) rates,2019-05-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Surgery feasibility
13663,NCT04166721,Main phase IIB (efficacy) phase: Best objective response rate (ORR) using RECIST 1.1 criteria,2020-02-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
13664,NCT00100815,Progression-free Survival,2004-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
13665,NCT01216527,Overall survival rate,2007-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Disease free survival rate
13666,NCT00788697,Specificity: Percentage of True Negative Lesions Among All Malignant Lesions Per Truth Standard,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Inter-reader Agreement
13667,NCT04149015,Pathological complete and subtotal regression (TRG1a/b by Becker),2019-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13668,NCT05450029,Pathological complete response,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Correlation between minimal residual disease (MRD) and survival
13669,NCT01832116,The in vivo biodistribution measured in SUV values and organ pharmacokinetics (PK) of 89Zr-MMOT0530A,2013-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of patients with adverse events after 89Zr-MMOT0530A injection as a measure of safety and tolerability
13670,NCT03035253,Incidence of dose limiting toxicities,2016-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Progression Free Survival
13671,NCT03220009,Recurrence free survival (RFS),2017-11-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],T cell inflammation,Rate of delayed surgery
13672,NCT05817994,"Number of endoscopic, endosonographic, and radiologic interventions undergone to reach a diagnostic liver biopsy [Phase 2]",2023-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Number of diagnostic liver biopsies
13673,NCT03569761,CRC screening intentions,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],,CRC screening completion
13674,NCT04175756,Total operative time,2020-01-02,COMPLETED,OBSERVATIONAL,['NA'],,Quality of excision: M.E.R.C.U.R.Y. criteria
13675,NCT00081627,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13676,NCT02653313,Shedding of viral genomes [Vg],2015-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical outcome
13677,NCT00268411,Objective response rate,2004-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Progression-free and overall survival
13678,NCT00793871,Progression-free Survival (PFS),2008-11,COMPLETED,INTERVENTIONAL,['PHASE4'],Time to Tumor Response (TTR),Eastern Cooperative Oncology Group (ECOG) Performance Status
13679,NCT00088868,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13680,NCT04239001,Incidence of degree 3-4 neutropenia in each cycle of chemotherapy,2020-02,UNKNOWN,INTERVENTIONAL,['NA'],,The proportion of patients receiving antibiotics during the entire chemotherapy period.
13681,NCT06204484,Relapse-free survival (RFS) time in MRD-negative groups,2023-07-26,RECRUITING,INTERVENTIONAL,['NA'],Performance of landmark MRD status and longitudinal MRD status in prediction of recurrence.,OS time in MRD+ groups
13682,NCT00932438,Tumor Response,2009-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Serious Adverse Events
13683,NCT04380545,Incidence of adverse events,2021-01-13,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Tissue and blood immunohistochemistry,Progression-free survival (PFS)
13684,NCT04902872,Phase 2: Overall response rate (ORR),2021-05-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Incidence of TEAEs
13685,NCT03603366,Patients' benefit/risk trade-offs,2019-08-14,COMPLETED,OBSERVATIONAL,['NA'],,Preferences of aspirin using in different subgroups
13686,NCT05002855,Evaluate the effect of the implementation of this protocol on 3-year overall survival.,2021-01-20,COMPLETED,OBSERVATIONAL,['NA'],,
13687,NCT03599895,operation time,2018-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,hospitalization expenses
13688,NCT06042998,3-year disease-free survival,2023-07-07,RECRUITING,INTERVENTIONAL,['NA'],,postoperative recovery course
13689,NCT03595345,Tumour-specific death,2016-12-15,COMPLETED,OBSERVATIONAL,['NA'],,Drop-out
13690,NCT00005049,,1997-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13691,NCT06143605,DFS,2013-01-30,COMPLETED,OBSERVATIONAL,['NA'],,
13692,NCT05326152,Immediate adverse effects,2020-11-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Recurrence
13693,NCT02430636,Number of participants with Adverse events,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival (OS)
13694,NCT00738790,The rate of patients with downstaging after radiotherapy to pathological complete response or ypT1 disease with negative margins.,2003-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"The rate of local control, overall survival and disease-free survival and toxicity."
13695,NCT01962168,Freedom from symptomatic recurrent biliary obstruction requiring reintervention,2013-12,COMPLETED,OBSERVATIONAL,['NA'],,Ease of use
13696,NCT03946969,Safety and feasibility,2019-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory Outcomes,Overall Survival (OS)
13697,NCT05434026,the rate of postoperative complications,2022-08-03,RECRUITING,OBSERVATIONAL,['NA'],,
13698,NCT04856761,"RFS, recurrence-free survival",2020-11-01,RECRUITING,OBSERVATIONAL,['NA'],,"OS, overall survival"
13699,NCT00216086,Pathological Complete Response (pCR) Rate,2005-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Disease-Free Survival
13700,NCT01415609,Ease of use of the overall procedure and Time of procedure.,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,Complications and Rate of Completion
13701,NCT01839487,Percentage of Participants in the PAG Arm Who Experienced Any Thromboembolic (TE) Event in Stage 2 of the Study,2013-05-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Area Under the Concentration-Time Curve From Time 0 to Last Quantifiable Concentration (AUC0-last) of PEGPH20
13702,NCT05919264,During dose expansion describe the Overall Response Rate using RECIST v1.1,2023-05-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,During dose expansion describe Progression Free Survival
13703,NCT00921531,Overall survival,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,time to progression
13704,NCT04080024,Number of treatment related adverse events (AEs),2019-08-23,COMPLETED,INTERVENTIONAL,['PHASE1'],Visualization of the pancreatic duct,Pharmacokinetics as measured by apparent volume of distribution at steady state (Vss) for Mn (L) the terminal phase half-life (T½) for manganese (Mn)
13705,NCT02103062,Progression Free Survival (PFS) Rate as Measured at Week 8,2014-05-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Kaplan Meier Estimate of PFS by Investigator Assessment,Number of Participants With Adverse Events
13706,NCT05331131,Assessing Pain Response,2022-09-19,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse events
13707,NCT02777463,The statistical analysis of the correlation between pretreatment ADC value of diffusion MRI and pathologic response evaluated by Evans grade in patients with borderline resectable pancreatic carcinoma (BRPC) who undergo neoadjuvant therapy.,2016-06,COMPLETED,OBSERVATIONAL,['NA'],,The statistical analysis of the correlation between tumor's limb sign in diffusion MRI and the rate of tumor cell destruction more than 10%.
13708,NCT03619538,Estimate morphine consumption,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,
13709,NCT00351195,Response,2006-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Survival
13710,NCT01929421,Response rate,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,number of participants with adverse events
13711,NCT06028737,Histopathological tumor response rate (Becker regression criteria).,2023-08-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Correlation between the pathohistological response and overall and disease-free survival.
13712,NCT00574860,NCI v3 to measure severity of OM,2007-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,WHO criteria for measuring severity of OM
13713,NCT01097083,,2010-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13714,NCT06033976,Rate of curative resection,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],Rate of delayed bleeding,Rate of R0 resection
13715,NCT00913757,Large-scale molecular profiling study to identify HCC biomarkers for early diagnosis and prevention.,2009-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
13716,NCT00915850,Safety (Phase I: toxicities as assessed by NCI CTCAE version3) and efficacy (Phase II: Feasibility as evaluated by RECIST),2007-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,median survival time (Phase II)
13717,NCT00005599,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13718,NCT00268437,Pathologic Complete Response Rate,2006-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
13719,NCT02717091,R0 resection rate,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,quality of the tumor
13720,NCT05568433,Role of the cyst fluid concentrations of the specific biomarkers for differentiation the pancreatic cystic lesions,2018-04-02,COMPLETED,OBSERVATIONAL,['NA'],,The Correlation between cyst fluid concentration and serum level of the specific biomarkers
13721,NCT00786747,Up to date colorectal cancer screening status,2010-02,COMPLETED,INTERVENTIONAL,['NA'],,Readiness to undergo colorectal cancer screening
13722,NCT03256344,Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT),2018-03-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
13723,NCT03368651,Overall survival (OS),2016-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,recurrence rate
13724,NCT04713007,Perception of Care Coordination Caregiver,2021-06-03,RECRUITING,INTERVENTIONAL,['NA'],,
13725,NCT01596361,Verify the differences observed in the frequency of germline pharmacogenetic variants related to chemotherapy between Asian and Caucasian CRC patients,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],,Characterise the deletion status of heat shock protein molecules and determine the association between heat shock protein deletion status and clinico-pathological outcomes in Asian and Caucasian patients with CRC
13726,NCT04462042,Acute grade >2 hematological side effects,2021-04-07,RECRUITING,INTERVENTIONAL,['NA'],Cost-utility analysis,Overall survival
13727,NCT01347645,Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs),2011-09-30,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Percentage of Participants With Overall Response
13728,NCT03875144,overall survival,2020-08-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life evaluation
13729,NCT06222944,ORR,2024-02-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
13730,NCT00985556,Progression-free survival,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to progression
13731,NCT02297269,the incidence of DVT,2014-12,UNKNOWN,OBSERVATIONAL,['NA'],,incidence of incision infection
13732,NCT00397540,"1,3,5 Year-Disease Free Survival (or Recurrence Free Survival)",2004-10,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
13733,NCT03575637,time to treatment failure,2018-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Progression free survival time (PFS), overall survival time (OS)."
13734,NCT03117972,Progression Free Survival,2017-08-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
13735,NCT00967603,6-month progression-free survival,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,pharmacodynamics
13736,NCT02742597,Evaluation of Intervention Effectiveness - Change in Patient-Centredness,2016-01-12,COMPLETED,INTERVENTIONAL,['NA'],,Evaluation of Intervention Effectiveness - Change in Demographics
13737,NCT02461407,Overall Survival (OS),2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Disease Control Rate (DCR)
13738,NCT01291615,frequency in adverse events,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13739,NCT04019808,H. pylori prevalence and drug resistance,2019-07-30,UNKNOWN,OBSERVATIONAL,['NA'],,
13740,NCT01803009,Preferred CRC screening test,2012-11,COMPLETED,INTERVENTIONAL,['NA'],,Uptake of CRC screening
13741,NCT03894618,Maximum Tolerated Dose (MTD) of SL-279252,2019-03-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Volume of distribution
13742,NCT03311152,Presence of hepatocellular carcinoma.,2018-02-12,RECRUITING,INTERVENTIONAL,['NA'],,Presence of early hepatocellular carcinoma. Early hepatocellular carcinoma will be defined as a tumor smaller than 30 mm according to Kudo M (Liver Cancer. 2013;2:69-72).
13743,NCT00003851,,1999-03,TERMINATED,INTERVENTIONAL,['NA'],,
13744,NCT02414100,"Identification of germline mutations in known cancer genes from whole blood genomic deoxyribonucleic acid, and somatic mutations in conditionally reprogrammed cells derived from pre-treatment and post-treatment (e.g., resistant) tumors",2013-12-12,WITHDRAWN,OBSERVATIONAL,['NA'],,
13745,NCT01815359,disease-free survival,2013-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,chemotherapy toxicity grade 3 to 5
13746,NCT00987857,Overall survival,2009-03,UNKNOWN,INTERVENTIONAL,['NA'],,Frequency of endoscopy
13747,NCT02164292,Feasibility of the procedure defined as percentage of patients that complete both surgical stages.,2011-06,COMPLETED,OBSERVATIONAL,['NA'],,Risk factors for a reduced kinetic growth rate of the future liver remnant (<35 cc/day)
13748,NCT05813028,"Change of Beck Anxiety Inventory score at baseline and one week later fisrt,second,third and forth chemothraphy.",2022-07-15,RECRUITING,INTERVENTIONAL,['NA'],,
13749,NCT05489211,PSA50 response (Substudy 3 only),2022-09-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,CA-125 response (Substudy 4)
13750,NCT05323058,Severity of mucositis,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Patient-Reported Oral Mucositis( PROMS scale),Pain and burning sensation
13751,NCT05483075,Number of Intervention Arm Participants in Compliance with HCP Exercise Intervention,2022-11-15,RECRUITING,INTERVENTIONAL,['NA'],,Minutes Spent in Rapid Eye Movement (REM) Sleep
13752,NCT01403727,Radiation Dose,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,Accuracy of needle targeting
13753,NCT01412957,Overall Survival,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Maximum Post-baseline Change From Baseline in Corrected QT (QTc) Interval
13754,NCT06074536,"The Measurement of the achievement oh the shared decision shared decision making in CRC screening using the patient shared a self-decision-making questionnaire (SDM-Q9), validated in French",2024-03-06,RECRUITING,INTERVENTIONAL,['NA'],,Explore understanding of the shared decision process among general practitioners and patients
13755,NCT05415917,Safety as assessed by number of participants experiencing adverse events,2022-07-29,RECRUITING,INTERVENTIONAL,['PHASE2'],To measure the tumor with the Response Evaluation Criteria in Solid Tumors (RECIST),
13756,NCT01710592,"Determine in a randomised study if the response rate to docetaxel and oxaliplatin (ElTax) is comparable to epirubicin, oxaliplatin and capecitabine (EOX) and warrants further evaluation in advanced gastro-oesophageal cancer",2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,To examine the effect of treatment on Quality of life.
13757,NCT01783158,To detect early synchronous second primary esophageal carcinoma,2004-01,COMPLETED,OBSERVATIONAL,['NA'],,
13758,NCT00460174,Response rate,2005-10-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profile of bevacizumab and gemcitabine with radiation therapy
13759,NCT04345978,Disease-free Survival,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,"IL-1β，IL-2,IL-4,IL-5,IL-6,IL-8,IL-10,IL-17A,IL-17F,TNF-α，TNF-β，"
13760,NCT01216930,,2010-10,COMPLETED,OBSERVATIONAL,['NA'],,
13761,NCT02877056,Predictive Tumor Cell Biomarkers After Chemoradiation Treatment for Colorectal Cancer,2005-08,UNKNOWN,OBSERVATIONAL,['NA'],,
13762,NCT04527068,Progression-free survival (PFS),2020-09-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Duration of Response (DOR)
13763,NCT02508467,"Number of patients with adverse events, serious adverse events and changes in physical findings, vital signs, clinical laboratory results and ECG findings",2015-07-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Preliminary evidence of fisogatinib (BLU-554) antineoplastic activity
13764,NCT03711058,6-month Objective Response Rate (ORR) of Patients Treated With Copanlisib and Nivolumab,2019-01-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants Experiencing Study Drug-related Toxicities
13765,NCT00026091,Response rate (CR or PR),2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Molecular change
13766,NCT02812641,Pathological complete response rate (randomized phase),2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Serum biomarker (VEGF-A),Overall survival
13767,NCT05427396,The incidence of adverse events (AE) and serious adverse events (SAE) were assessed,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE1'],PFS,TTP
13768,NCT05227261,Sensitivity and specificity of the test in early detecting cancers,2022-04-10,RECRUITING,OBSERVATIONAL,['NA'],,Rate of cancer development in the high-risk group as compared to the moderate-risk population
13769,NCT05400018,Ct Value (Ct Values From PCR Reaction),2020-11-20,COMPLETED,OBSERVATIONAL,['NA'],,Kappa coefficient
13770,NCT05479240,Pathological complete response rate,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],overall survival,
13771,NCT00417209,overall survival (OS) defined as the time interval from the date of randomization to the date of death due to any cause,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression free survival (PFS); Overall Response Rate (proportion of patients with confirmed RECIST-defined complete response (CR) or partial response (PR); clinical benefit based on the measurement of tumor related symptoms;
13772,NCT00499369,Progression-free Survival (PFS),2007-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Toxicity
13773,NCT02625272,the content RNA of CEA and CK20 in circulating tumor cells and ascites,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,3-year local recurrence
13774,NCT01619696,acceptation rate of the entire sequence by eligible patients,2011-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,"radiological changes while on chimiotherapy, to tumour regression, and prognosis"
13775,NCT01824459,Overall Survival,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events (AE)
13776,NCT00718913,The proportion of patients completing protocol therapy (feasibility),2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
13777,NCT01328171,overall response rate,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,translational research (EGFR genetics and proteomics): prognostic and predictive impact on efficacy outcomes
13778,NCT01111604,Progression-Free Survival (PFS),2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
13779,NCT05952661,Correlations of minimal residual disease (MRD) and efficacy,2023-02-22,RECRUITING,OBSERVATIONAL,['NA'],ctDNA mutation profiles in ESCC patients undergoing adjuvant immunotherapy.,The timing of MRD advance warning of recurrence in patients ahead of imaging cues
13780,NCT01070290,Compare the progression-free survival (PFS) of ARQ 197 versus investigator's choice of second-line chemotherapy in patients with advanced gastric cancer who have failed first-line treatment.,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Further characterize the safety profile of ARQ 197
13781,NCT00114829,Sensitivity in determining malignant or benign diagnose,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Sensitivity/specificity of MR colonography
13782,NCT00865982,R0-resection rate,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Event free survival rate
13783,NCT02757391,Incidence of toxicity defined as grade 3 or 4 non-hematologic or grade 4 hematologic toxicity per Common Terminology Criteria for Adverse Events version 4.0,2019-08-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival
13784,NCT00086931,Complete pathological response rate at time of surgery,2003-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Disease-free survival, safety, and overall survival at 5 years"
13785,NCT05396846,Weight Loss,2023-04-29,RECRUITING,INTERVENTIONAL,['NA'],Skin Carotenoids,
13786,NCT00005804,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13787,NCT04902261,1-Year Survival Rates,2020-11-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
13788,NCT04384757,3 year relapse-free survival by Kaplan Mayer,2020-07-29,RECRUITING,INTERVENTIONAL,['NA'],,Resected lymph nodes
13789,NCT04891146,investigate the effect of anesthesia management on the change of preoperative systemic inflammatory immune index(SII) and postoperative 2.hour and 24.hour SII value,2020-03-05,COMPLETED,OBSERVATIONAL,['NA'],,
13790,NCT02058849,Endurance,2014-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Total Body Mass,Muscle Strength
13791,NCT06335966,Patient acceptability: Number of patients interested in being screened via SECD at other care centers,2024-01-25,RECRUITING,OBSERVATIONAL,['NA'],,Access: time to full diagnostic work up for patients with positive SECD results
13792,NCT05803746,MPR,2022-07-15,RECRUITING,INTERVENTIONAL,['NA'],,PFS
13793,NCT05873699,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-08-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,
13794,NCT03717038,Overall survival (OS) time following treatment with Sym004 versus TAS-102.,2019-02,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Pharmacokinetic (PK) Parameters of Sym004: Maximum Concentration (Cmax)
13795,NCT05682157,Change in LARS score,2023-03-21,RECRUITING,INTERVENTIONAL,['NA'],,
13796,NCT04801719,Overall survival,2010-01-04,COMPLETED,INTERVENTIONAL,['NA'],,Complications of endoluminal RFA of biliary tract
13797,NCT05171660,Progression free survival time,2022-02-08,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse Events
13798,NCT06272656,"comparison of liver cancer markers AKR1B10, AFP, AFP-L3% and DCP before and after TACE",2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,progression- free - time
13799,NCT03269994,Compare the effectiveness of cefoxitin with piperacillin-tazobactam as surgical antibiotic prophylaxis in decreasing the overall rate of postoperative surgical site infections in participants undergoing pancreatoduodenectomy,2017-11-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,
13800,NCT02694718,Percentage of Participants With Pathological Complete Tumor Response,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Any Adverse Events and Serious Adverse Events
13801,NCT05233007,Predicting treatment resistance to anti-cancer therapy,2022-01-25,SUSPENDED,OBSERVATIONAL,['NA'],,
13802,NCT05290220,PFS,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,DOR
13803,NCT06152757,"AE, SAE, AESI, CRS, ICANS, TEAE",2023-10-09,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
13804,NCT05811481,Overall survival,2022-12-27,RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival for the first subsequent treatment PFS 2
13805,NCT03851913,OS,2018-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,PFS
13806,NCT02028806,Disease control rate,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,EORTC QLQ-C30
13807,NCT04524260,Change of Anxiety,2020-08-31,UNKNOWN,INTERVENTIONAL,['NA'],Socio-economic: ability to return to work,Change of Health related quality of life - SF-12
13808,NCT05911633,Technical success,2024-02-29,RECRUITING,INTERVENTIONAL,['NA'],,Best overall response
13809,NCT01161186,"to establish the maximal tolerated dose (MTD) of the AGX combination in patients with previously untreated, metastatic pancreatic adenocarcinoma.",2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To obtain a preliminary assessment of the clinical efficacy of AGX as measured by time to tumor progression, overall survival, objective radiographic response (ORR), and CA 19-9 biomarker response"
13810,NCT05147545,Change in circulating DNA induced by moderate effort in subjects free of malignacy,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Change in circulating DNA induced by hyperlipidic meal in patients with colon cancer
13811,NCT03679429,Accuracy optical biopsy,2018-11,UNKNOWN,OBSERVATIONAL,['NA'],,Adenoma detection rate
13812,NCT05639413,Overall Survival (OS),2023-07-24,RECRUITING,INTERVENTIONAL,['NA'],,Correlation between predictive biomarkers and response to treatment
13813,NCT03307603,Phase II: Response rate,2018-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Overall survival
13814,NCT05886257,ORR per RECIST 1.1,2022-12-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,PD-L1 Biomarker
13815,NCT01638533,Pharmacokinetic (PK) profile of romidepsin in patients with varying degrees of hepatic dysfunction using liquid chromatography-electrospray ionization tandem mass spectrometric method,2012-06-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Antitumor activity assessed using Response Evaluation Criteria in Solid Tumors and the International Workshop Lymphoma Response Criteria
13816,NCT05420922,The treatment-related adverse events (TRAEs),2021-11-01,RECRUITING,OBSERVATIONAL,['NA'],,The progression-free survival (PFS)
13817,NCT02543411,Fentanyl consumption during sedation,2015-09,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of nausea and vomiting
13818,NCT01864070,Dose Limiting Toxicities (DLT) for Combination of TheraSphere and Everolimus,2014-05,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
13819,NCT01105169,Expression of Cox2 in rectal epithelia,2010-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Urine excretion of prostaglandin E2 metabolite (PGE-M)
13820,NCT00765180,Colorectal adenoma detection rate,2007-01,COMPLETED,INTERVENTIONAL,['NA'],,"Procedure time, complication"
13821,NCT02575508,Overall survival (Phase II),na,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Potential associations between response rate and tumor biomarkers (Phase II)
13822,NCT01455311,Rank The Diagnostic Accuracy of Specimen,2010-09,TERMINATED,OBSERVATIONAL,['NA'],,Cataloging Proteins
13823,NCT02595424,PFS,2016-04-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Prognostic significance of well differentiated non-small cell gastroenteropancreatic neuroendocrine tumors,Response rate (complete response or partial response) by RECIST 1.1
13824,NCT05480280,Objective Response Rate (ORR),2022-07-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
13825,NCT04591431,OVERALL RESPONSE RATE (ORR),2020-10-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
13826,NCT02132468,"Number of Participants With Improved, Stable, or Worsened Change In Serotonin Biomarker Levels From Baseline",2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Number of Participants With Partial Response (PR), Progressive Disease (PD), or Stable Disease (SD) Based on RECIST 1.1"
13827,NCT01057017,Number of Patients With Toxicity to Combination of Panitumumab and Bevacizumab,2010-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13828,NCT03708445,The usefulness of new staining method,2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],,
13829,NCT03548961,number of patients whose tumor can be resected by local excision with negative margins,2018-05-11,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Disease-free survival (DFS) of patients
13830,NCT05609149,3-year event-free survival rate,2016-10-30,COMPLETED,OBSERVATIONAL,['NA'],,Local recurrence
13831,NCT05615103,Pathologic complete response rate (pCR),2022-11-08,RECRUITING,OBSERVATIONAL,['NA'],,Safety as measured by number of participants with Grade 3 and 4 adverse events
13832,NCT02409524,To evaluate survival compared to historical controls,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Tumor-Specific Immunity,To evaluate safety in advanced HCC (adverse events)
13833,NCT03504293,Diagnostic accuracy,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Adverse event rate
13834,NCT00036712,Proportion of patients not experiencing ulcerative mucositis within the first 14 days posttransplant,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to heal
13835,NCT02196688,Progression Free Survival (PFS),2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Over Survival (OS)
13836,NCT05591053,Usability of the device by surgeon and support personnel satisfaction;,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Ability of ActivSightTM to display blood vessels.
13837,NCT03875690,frequency of patients with postoperative major complications occurring within 30 days after surgery,2019-07-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,
13838,NCT06265350,Objective response rate (ORR),2024-02-02,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival (OS)
13839,NCT05053750,To assess macrophage counts by image cytometry in women with platinum resistant ovarian cancer treated with weekly paclitaxel/bevacizumab and ZA relative to weekly paclitaxel/bevacizumab,2021-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
13840,NCT01715532,Progression free survival,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
13841,NCT06274190,Responsiveness of the newly developed bowel e-diary in patients after rectal surgery for rectal cancer. The newly validated e-diary is the primary outcome.,2024-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
13842,NCT00470535,Progression-free Survival,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Correlation of Response, QOL, and Survival With EGFR, E-cadherin, P-cadherin, Vimentin, Cytokeratin, ki67, and Fibronectin and With Other Prognostic Variables, Such as Age and Tumor Grade"
13843,NCT02518529,Measurable Gastrin-17 Antibody Titer,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival from date of randomization to death or end of study
13844,NCT01619423,Number of Patients With Neuropathy Grade 2 or Higher (According to the Oxaliplatin Specific Sanofi Scale (OSSS) Criteria Related Paraesthesia/Dysaesthesia),2012-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13845,NCT01348217,Survival without locoregional relapse at 2 years (time elapsed between date of randomisation and onset of local relapse and/or lymph node involvement),2011-05-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Evaluation of the post-operative morbi-mortalities
13846,NCT04865471,Percent of transplanted patients receiving second stage hepatectomy within 4 weeks of segment 2/3 transplantation,2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Complication rate
13847,NCT01164150,Reduction in the incidence of ≥ grade 2 acute genitourinary (GU) and gastrointestinal (GI) toxicity according to NCI CTCAE v.3.0,2010-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival rate
13848,NCT00482846,Maximum tolerated dose of melphalan when treated with palifermin to prevent mucositis,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Reduction in incidence and duration of mucositis
13849,NCT06031818,Clinical effectiveness of the explanation framework,2023-12-10,RECRUITING,OBSERVATIONAL,['NA'],,Usability of the explanation framework
13850,NCT03718078,malignant pCLE criteria,2019-03,UNKNOWN,INTERVENTIONAL,['NA'],,pCLE criteria diagnostic performance
13851,NCT02575391,Measurement of Tolerability,2009-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Treatment Break Measurement
13852,NCT01908426,Overall Survival (OS),2013-09-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,Objective Response Rate (ORR)
13853,NCT03978481,Overall survival,2019-01-30,COMPLETED,OBSERVATIONAL,['NA'],,Metachronous cancer (remnant stomach cancer)
13854,NCT04571047,Overall survival,2020-10-15,COMPLETED,OBSERVATIONAL,['NA'],,Radical surgery
13855,NCT05524090,In-hospital major morbidity,2021-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Shared decision-making: patients' healthcare satisfaction
13856,NCT02275403,Change in Measure Yourself Medical Outcome Profile (MYMOP2) score of the most troubling symptom of CIPN,2015-04-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Uptake of the offer of acupuncture at 10 weeks
13857,NCT02175095,[18F]FLT-PET SUV_MAX,2014-07,UNKNOWN,INTERVENTIONAL,['NA'],,Response evaluation by RECIST 1.1
13858,NCT00216372,Percentage of responder patients (patient with 1 or less vomiting episode per day during at least 3 consecutive days or in whom nasogastric tube (NGT) has been removed during at least three consecutive days without vomiting recurrence),2003-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Symptom relief duration
13859,NCT00197873,Effect on the treatment-related grade 2 to 4 diarrhoea,2005-09,COMPLETED,INTERVENTIONAL,['NA'],,Effect on resectability of liver metastases
13860,NCT04513431,Adverse events that related to treatment,2020-08-30,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Maximum tolerated dose (MTD) of CEA targeted CAR T cells
13861,NCT00265811,Disease-free survival,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall survival
13862,NCT03227510,MicroRNAs and its Correlation to Development and prediction of HCC,2017-11,UNKNOWN,OBSERVATIONAL,['NA'],,
13863,NCT01393093,Time to progression,2011-03,UNKNOWN,INTERVENTIONAL,['NA'],,remission rate
13864,NCT06241326,Adverse events,2024-02-26,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
13865,NCT02970539,Maximum tolerated dose (MTD),2016-12-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Preliminary activity of Oraxol plus ramucirumab as determined by overall survival
13866,NCT06019455,Incidence of >=Grade 3 toxicities,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival
13867,NCT01089413,Duration of Bevacizumab Treatment,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status
13868,NCT01580540,Non-inferiority of Epi proColon test result compared to FIT result using a 95% confidence interval for difference in sensitivities and differences in specificities below a strictly defined margin.,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
13869,NCT03245892,number of patients with dose limiting toxicities weekly paclitaxel/carboplatin plus nivolumab and ipilimumab,2017-08-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
13870,NCT00001532,evaluating the role of hereditary factor,1996-09-13,RECRUITING,OBSERVATIONAL,['NA'],,"low dose radiation CT scan, and Zoom Scan"
13871,NCT00631410,Number of Participants With Adverse Events,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Sunitinib Relative Dose Intensity in the Treatment Arm B
13872,NCT04162665,Complete pathologic response (pCR - primary and nodal) rate,2020-02-14,RECRUITING,INTERVENTIONAL,['PHASE2'],Average percent difference in coverage of planning target volume (PTV) by 95% isodose line,Proportion of patients able to complete a full course of total neoadjuvant chemotherapy
13873,NCT01589900,,2005-01,COMPLETED,OBSERVATIONAL,['NA'],,
13874,NCT02973204,Concordance between specific DNA mutations found in patient biopsies and plasma circulating tumor DNA,2016-11,COMPLETED,OBSERVATIONAL,['NA'],,Correlations between mutations fund in circulating DNA and circulating tumor cells
13875,NCT00564720,Overall Survival,2006-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Symptoms improvement
13876,NCT05164315,Overall Survival (OS),2022-01-03,RECRUITING,INTERVENTIONAL,['NA'],,defecation function
13877,NCT04543019,Progression free survival (PFS) and overall survival (OS),2020-12,UNKNOWN,OBSERVATIONAL,['NA'],,response to systemic therapy
13878,NCT04294264,Overall response rate,2019-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
13879,NCT00135577,"Incidence of reported adverse events, including serious adverse events",2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Incidence of treatment-limiting toxicities, changes in pain intensity, patient satisfaction, health outcome measures"
13880,NCT00782834,Response Rate,2008-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13881,NCT05031949,Progression-free survival based on RECIST v1.1,2021-10-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of Subjects with one or more adverse events as assessed by CTCAE 5.0
13882,NCT03098589,Adverse Events (AEs),2017-05-30,RECRUITING,OBSERVATIONAL,['NA'],,
13883,NCT01773980,Number of participants with improved cancer screening,2013-08,COMPLETED,OBSERVATIONAL,['NA'],,
13884,NCT04318834,Number of participants with tumour whole genome sequencing returned within 8 weeks,2020-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Number of patients who received a targeted therapy (after first-line treatment)
13885,NCT05677724,single cell RNA sequencing,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
13886,NCT01023633,DDC: Duration of Disease Control,2009-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],,"OS, RR, PFS, DCR, safety,"
13887,NCT03215290,Cutting surface related complications,2016-10,COMPLETED,INTERVENTIONAL,['NA'],,Interventions for cutting surface related complications
13888,NCT03036436,Change in quality of life,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],,
13889,NCT00820456,To determine the alteration in tumor vascularity (assessed by percentage change in tumor Ktrans) in Arm A participants with metastatic colorectal cancer to the liver after one cycle of chemotherapy including bevacizumab compared to baseline Ktrans value.,2008-04,TERMINATED,OBSERVATIONAL,['NA'],,To determine the functional status as a predictor of response or disease-free survival in participants in Arm A.
13890,NCT02310971,"Assessment of safety and tolerability of CVac. (adverse events, vital signs, 12 lead ECG, relevant changes in physical examination)",2015-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Assessment of the change in quality of life (QoL) following the initiation of Cvac in this patient population,Assessment of Progression-Free Survival (PFS) and Overall Survival (OS) following the initiation of Cvac in this patient population
13891,NCT03965325,Assess the most accurate trend of the Global Health Status (Quality of Life evolution) over time in colorectal cancer patients evaluated by the EORTC-QLQ-C30 questionnaire.,2019-06-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Measure healthcare costs during the study period
13892,NCT05746182,Rate of overall pathogenic germline mutations,2023-04-07,RECRUITING,OBSERVATIONAL,['NA'],,Rate of completion of testing
13893,NCT01547130,Efficacy of Large Bowel Cleansing as Assessed by the Physician Performing the Colonoscopy,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Total Preparation Time
13894,NCT01858207,The rate of complete necrosis (CN),2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Major complication
13895,NCT05197504,collected blood samples,2021-12-20,RECRUITING,OBSERVATIONAL,['NA'],,Biomarkers on the efficacy of Atezolizumab+Bevacizumab for advanced HCC
13896,NCT03264807,Superiority verification of disease-free survival after lymphadenectomy for D2 + 14v lymph node dissection in gastric resection in patients with T3N + and T4N + stomach cancer,2015-08-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
13897,NCT03564938,Change in heart rate (beats/min),2018-07-30,COMPLETED,INTERVENTIONAL,['PHASE4'],,Overall survival (OS)
13898,NCT04276415,Progression-free Survival (PFS) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) (Dose Expansion),2020-05-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Anti-drug Antibodies Against DS-6157a Following Intravenous Administration of DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumors (GIST)
13899,NCT00745927,Degree of abdominal discomfort during and after colonoscopy,2008-06,UNKNOWN,INTERVENTIONAL,['NA'],,Number of neoplasm detected
13900,NCT03064646,Percentage of organ preservative strategies after neoadjuvant treatment in locally advanced rectal cancer,2017-03-10,RECRUITING,INTERVENTIONAL,['NA'],Colostomy free survival,Quality of Life in patient with rectal cancer
13901,NCT01524575,6 month overall survival,2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Duration of overall response
13902,NCT05077839,ORR,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
13903,NCT04212273,"The sensitivity, specificity and accuracy of Sonazoid-CEUS and EOB-MRI",2019-12-21,RECRUITING,INTERVENTIONAL,['NA'],,The detection rate of the additionally found HCC
13904,NCT01074216,To Achieve Target Vitamin D Level,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13905,NCT01191138,Gastric Emptying assessed clinically and correlated objectively with liquid and solid emptying of radionucleotide,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,Correlation of pancreatic duct leak with gastric emptying
13906,NCT02259647,Overall Survival,2014-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Safety
13907,NCT01507064,Effectiveness of sorafenib in increasing the effectiveness of laser ablation (LA),2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival in the two treatment groups
13908,NCT00003995,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13909,NCT03649971,Percentage Change from Baseline in Rectal/pouch Polyp Burden at Week 24,2018-11-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,Relative Changes to Baseline in Levels of Interleukin (IL)-23 Effector Proteins in Biopsy Tissue
13910,NCT05248581,percentage overall survival,2019-08-16,RECRUITING,OBSERVATIONAL,['NA'],,
13911,NCT00510796,Feasibility to perform both colon and endometrial cancer screening at the time of colonoscopy in women at high risk for colon and endometrial cancer.,2002-03,COMPLETED,OBSERVATIONAL,['NA'],,
13912,NCT04646915,Incidence of transfer to inpatient ward,2019-12-15,UNKNOWN,OBSERVATIONAL,['NA'],,Mortality
13913,NCT05065957,To assess disease control rate (DCR),2022-03-29,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,To assess overall survival (OS)
13914,NCT00940758,To characterize the pharmacokinetics of biweekly PEP02 in patients with metastatic colorectal cancer who failed to first-line oxaliplatin-based chemotherapy,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,To explore the association of the pharmacogenetics of PEP02 including UGT1A family - UGT1A1 and UGT1A9 with pharmacokinetic parameters and toxicity
13915,NCT04522687,Overall Survival,2012-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Progression Free Survival
13916,NCT04918472,The combined diagnostic accuracy of MCCE and UBT as gold standard,2021-08-06,COMPLETED,INTERVENTIONAL,['NA'],,"Adverse events up to 2 weeks after UBT, MCCE, UGI endoscopy"
13917,NCT00154817,"The primary objective is to evaluate response rate, tolerability and failure pattern of local radiotherapy for the treatment of locally advanced HCC.",2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,The second objective is to correlate parameters of tumor perfusion assessed by dynamic contrast enhanced MRI (DCEMRI) and serum cytokine levels with clinical outcomes.
13918,NCT05795920,progression free survival progression free survival,2023-03-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response Duration of Response
13919,NCT02432963,"Tolerability of combined modified vaccinia virus Ankara vaccine expressing p53 and pembrolizumab, using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.3",2016-06-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,"T cell reactivity to p53, assessed by flow cytometry"
13920,NCT05059444,Distant Recurrence Free Interval (D-RFi),2021-09-07,RECRUITING,OBSERVATIONAL,['NA'],Rate of ctDNA clearance with adjuvant chemotherapy,Lead Time
13921,NCT01385579,Completion of a Colorectal Cancer Screening,2010-01,COMPLETED,INTERVENTIONAL,['NA'],,
13922,NCT02734849,Change in Total Polys Score (TPS),2016-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13923,NCT00003648,frequency of defective DNA mismatch repair in individuals with familial colon cancer versus all colon cancers by using antibodies to the hMSH2 and hMLH1 protein products,1998-07,COMPLETED,OBSERVATIONAL,['NA'],,
13924,NCT03318562,Level of biomarkers of antitumor activation,2017-11-21,TERMINATED,INTERVENTIONAL,['PHASE2'],,PK plasma concentrations
13925,NCT01906008,Average Area Under the Curve (AUC) for Numbness/Tingling Over 4 Months,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Average Area Under the Curve (AUC) for Fatigue Over 4 Months
13926,NCT05846295,"Participant entered rate of accurate polyp size classification into diminutive (1-5 mm), small (6-9 mm), or large (≥10 mm) category on 40 question polyp sizing test.",2021-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Proportion of participant responses that underestimate actual polyp size category versus overestimate actual polyp size category on the 40-question polyp sizing test.
13927,NCT04513223,DLT and the recommended Phase 2 dose (RP2D),2021-03-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
13928,NCT03113942,Histological High Grade Squamous Intraepithelial Lesions (HSIL) clearance at 6 months of therapy,2017-06-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,effect of pomalidomide on self-reported health related quality of life and cancer anxiety during and after therapy
13929,NCT04089631,Disease free Survival (DFS),2020-06-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,Frequency of adverse events from start of chemotherapy until 30 days after chemotherapy
13930,NCT00813137,Time to progression,2008-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13931,NCT01979029,The Blood Pressure of the Arterial Arcade,2013-02,COMPLETED,INTERVENTIONAL,['NA'],Systemic Blood Pressure,Distal Colon Length
13932,NCT03532711,Objective Response Rate (ORR),2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Progression Free Survival (PFS)
13933,NCT06192212,perioperative 90-day mortality.,2023-12-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Albumin loss rate
13934,NCT00052585,Response rate,2002-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13935,NCT00639925,"Adverse effect, toxicities as assessed by NCI CTCAE version3.0",2007-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],,feasibility
13936,NCT02088333,Completion of CRC Screening,2014-06,COMPLETED,INTERVENTIONAL,['NA'],,Usability of the mCRC system
13937,NCT04847726,Diagnostic accuracy for HCC: non-inferiority test,2020-06-09,COMPLETED,INTERVENTIONAL,['NA'],Role of perfluorobutane enhanced USG in EASL diagnostic algorithm of HCC,Diagnostic performance of perfulorobutane enhanced USG using different definition of washout
13938,NCT01607957,Overall Survival,2012-06-17,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths"
13939,NCT05027347,The sensitivity and and specificity of our mutation-based assay for detecting early-stage gastric cancer patients,2021-10-10,UNKNOWN,OBSERVATIONAL,['NA'],,The concordance rate of mutation results between plasma and tissue biopsy assay
13940,NCT00243854,"To determine if giving chemotherapy, radiation, and Tarceva,(EGFR-tyrosine kinase inhibitor)will have side effects that will prevent surgery following this therapy",2005-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13941,NCT05341206,Change of CTCAE 4.0,2022-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change of common aerobic culture
13942,NCT02485015,Overall Survival(OS),2015-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,Disease-free survival
13943,NCT00990535,Tumor stabilization,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Decrease of chromogranin-A
13944,NCT04837742,Drug spread level of erector spinae plane block,2021-04-14,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative recovery quality
13945,NCT00199862,Toxicity defined by NCI Common Toxicity Criteria,2004-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,HAHA levels - measured by plasmon resonance surface (Biacore®) assay
13946,NCT00569790,Safety,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Progression-free survival, Response rate, Overall survival, Treatment situation"
13947,NCT03556956,Overall survival,2015-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Progression Free Survival (PFS)
13948,NCT03821025,Number of patients without stent failure,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Cost
13949,NCT04286984,Transfusion Rate,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of failure-to-rescue
13950,NCT06128785,Time of first postoperative exhaust,2023-11-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Adverse Event Assessment,Biochemical indexes 3
13951,NCT01039519,Percentage of Participants Showing Clinical Benefit Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Count of Participants With Treatment-Emergent Adverse Events (AEs)
13952,NCT00501813,Overall survival rate,2006-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of live
13953,NCT04022109,Specific chemistry identification in the exhaled breath,2019-11-01,RECRUITING,OBSERVATIONAL,['NA'],Confounding factor analysis,Gut microbiota analysis in relation to breath VOCs
13954,NCT00806611,The primary endpoint is cancer related pain control.,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
13955,NCT04764227,Local control rate,2020-05-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
13956,NCT04123925,Predictive Biomarkers,2018-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Metabolic Response
13957,NCT04149093,Long-term outcomes (Quality of life questionnaire),2020-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Functional outcomes
13958,NCT04920435,Prediction of the complete response (pCR) to neoadjuvant chemoradiotherapy,2019-01-02,COMPLETED,OBSERVATIONAL,['NA'],,
13959,NCT05006092,adenoma detection rate,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Boston Bowl Preparation Score
13960,NCT03826446,Recurrence rate in open and laparoscopic complete mesocolic excision groups in right cancer colon,2016-01-13,COMPLETED,INTERVENTIONAL,['NA'],,
13961,NCT05247515,Severe post-resection bleeding rate up to Day 30,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Rate and duration of hospitalizations
13962,NCT05240040,time to recurrence,2016-04-26,UNKNOWN,OBSERVATIONAL,['NA'],,
13963,NCT00484939,Progression-free Survival,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"AEs, Laboratory Parameters, Vital Signs"
13964,NCT02707315,percentage of subjects who successfully undergo pancreaticoduodenectomy,2013-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
13965,NCT00826813,Overall survival,2009-01,UNKNOWN,INTERVENTIONAL,['NA'],,Dysphagia relief
13966,NCT02068131,Overall response rate(ORR),2014-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events(AEs)
13967,NCT01672892,"Acute Gastrointestinal Toxicity, as Measured by Change in Expanded Prostate Cancer Index Composite (EPIC) Bowel Domain Score at 5 Weeks From the Start of Pelvic Radiation",2012-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Mean Change From Baseline in EPIC Bowel and Urinary Domain (Validation - Sensitivity to Treatment)
13968,NCT03864211,Progression free survival,2019-06-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The general health status
13969,NCT03852576,SFE ability to detect dimer with contrast,2019-05-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,
13970,NCT04636099,Intraoperative blood loss,2020-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,3 years DFS
13971,NCT06236386,Clinician Feedback,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Medication Use
13972,NCT01841736,Progression-free Survival (PFS),2013-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Biochemical Response,Time to Second Progression for Patients Who Crossover From Placebo to Active Therapy
13973,NCT04553458,"PROGRESSIVE((Number of patients with progression of the disease) (measured by follow-up CT scans, increase in size, appearance of new intratumoral lesions, or appearance of new lesions",2015-06,COMPLETED,OBSERVATIONAL,['NA'],,DEATH (Number of patients died from the disease)
13974,NCT01220934,Overall survival according to Response Evaluation Criteria in Solid Tumors (RECIST),2010-04-16,COMPLETED,OBSERVATIONAL,['NA'],,Safety (incidence of adverse events)
13975,NCT00519688,To evaluate the overall response rate of UFUR and thalidomide in the treatment of advanced HCC by RECIST criteria,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,To establish the safety profile.
13976,NCT02042378,Overall Response Rate (ORR) per RECIST v1.1 as assessed by the investigator,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Trough (Cmin) level rucaparib concentrations
13977,NCT03682133,Truncated logistic regression analysis,2018-06-27,TERMINATED,OBSERVATIONAL,['NA'],,
13978,NCT01798160,Overall-Survival,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4'],,
13979,NCT02724345,Overall survival,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,Time to recurrence
13980,NCT03169777,ORR by Immune-related response criteria (irRC ),2018-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03"
13981,NCT03939845,OS,2019-04-23,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
13982,NCT01503411,Primary Effectiveness Endpoint,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,
13983,NCT00923481,Response Rate,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
13984,NCT05209750,True malignant node (yes/no),2022-07-13,RECRUITING,INTERVENTIONAL,['NA'],,To describe the value of FAPI PET/CT on tumour response evaluation following neoadjuvant treatment.
13985,NCT05875753,Adverse events after injection of 68Ga-FAPI-FS,2022-06-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,SUVmax of tumor lesions on 68Ga-FAPI-FS
13986,NCT01384695,to determine whether tissue is neoplastic or non-neoplastic,2009-06,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,
13987,NCT05971628,Tolerance of the RAPID procedure,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Comparison of the graft survival at 2 years after LT between RAPID group and control group
13988,NCT04922853,pathological Tumor Regression Grade evaluation,2021-08-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,cumulative local recurrence rate
13989,NCT03601611,Rate of at least one grade improvement using the NCI CTCAE v5.0,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],Biomarkers,Rate of sustained glucocorticoid-free remission
13990,NCT02337946,Progression-Free Survival Rate (PFS Rate) at 9 Months After Randomization,2014-10-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Grade 3 or Higher Skin Toxicity
13991,NCT04429841,Operative mortality rate,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,5 years Overall survival rate
13992,NCT05091775,"Acute anal fissure after diarrhea. Standard management of acute fissure (Diltiazem Jelly, supportive care, placebo suppository, sitz bath)",2020-06-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Acute anal fissure after diarrhea. Intervention group (Asacol suppository, supportive care, placebo suppository, sitz bath)"
13993,NCT02858141,Collection of oncogeriatric data for future research studies,2015-05,UNKNOWN,OBSERVATIONAL,['NA'],,
13994,NCT00373022,Effect of moderate physical activity on quality of life as measured by the Functional Assessment of Cancer Therapy-Colon questionnaire,2004-01,COMPLETED,INTERVENTIONAL,['NA'],,"Correlation of serum levels and patterns of immune function (cytokine, neutrophil, T cell, B cell, NK cell, and immunoglobulin levels) with physical activity levels"
13995,NCT00910741,Incidence of DLT and Response rate,2009-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
13996,NCT03483922,DNA methylation of circulated tumor and PBMC DNA and its Correlation to Development and prediction of HCC,2018-08-20,COMPLETED,OBSERVATIONAL,['NA'],,
13997,NCT01413022,Optimal dose and dose-limiting toxicity of PF-04136309 in combination with FOLFIRINOX,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Prevalence and function of MDSC in peripheral circulation before and after treatment with PF-04136309 plus FOLFIRINOX or with FOLFIRINOX alone
13998,NCT03076372,Maximum tolerated dose (MTD) of MM-310 monotherapy administered once every 3 weeks in patients with metastatic solid tumors.,2017-02-22,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression Free Survival
13999,NCT06200831,"Comprehensive Complication Index, CCI",2024-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life: EORTC QLQ-30
14000,NCT06026774,Number of Participants with Adverse Events (AEs) [safety and tolerability],2023-09-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Cytokines Level [immunogenicity]
14001,NCT02228889,Overall complication rate at 1 year,2015-01,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life postoperatively
14002,NCT00217737,Disease-free survival,2005-09-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Impact of tumor biologic characteristics and their relationship to overall survival
14003,NCT04735107,Defunction ileostomy rate,2018-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative morbidity
14004,NCT01410760,Recruitment rate to this voluntary study and acquisition of sufficient data for perfusion analysis,2011-04,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Correlation between the tumour perfusion pattern on perfusion CT studies at baseline and shortly after the start of therapy and morphological response by RECIST criteria on CT scan 3 months post therapy in both arms of the FOXFIRE trial.
14005,NCT05686122,Feasibility of PainPac,2023-09-28,RECRUITING,INTERVENTIONAL,['NA'],,Change in PROMIS - Emotional Distress (Depression) Short Form
14006,NCT03268499,Time to progression (TTP),2016-09-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14007,NCT03310008,The objective response rate (ORR) before resection as measured by RECIST (version 1.1),2017-08-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,The overall survival (OS)
14008,NCT05172310,Diagnostic accuracy of FAPI-PET/CT in primary tumors,2021-06-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Safety of 68Ga-FAPI-46
14009,NCT05209295,Cmax: Observed maximum concentration,2024-03-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of participants with a recording of concomitant procedures
14010,NCT00779272,Postoperative Complications and liver regeneration,2008-09,COMPLETED,OBSERVATIONAL,['NA'],,
14011,NCT00944463,Time to progression,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlative analyses
14012,NCT05715775,The LN dissection rate,2016-08-01,COMPLETED,OBSERVATIONAL,['NA'],,LN noncompliance
14013,NCT02277392,Number of Adverse Events,2014-09,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
14014,NCT00323518,the incidence of grade 3/4 oral mucositis using WHO grading system,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14015,NCT05812287,Early gastric cancer detection rate,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
14016,NCT06279351,ETS,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,PFS
14017,NCT01840592,overall survival,2013-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,toxicity
14018,NCT06108310,Identification of radiogenomics signature (ATTRACT AI-model) of stage II-III colon tumors,2021-01-02,RECRUITING,OBSERVATIONAL,['NA'],,Correlation of radiogenomics signature (ATTRACT AI-model) of colon cancer with clinical outcomes (DFS and RFS)
14019,NCT05143099,Objective response rate (ORR),2021-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],biomarker analysis,Overall survival (OS）
14020,NCT04575935,Disease free survival (DFS),2020-08-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Cost of the procedure
14021,NCT04456140,Incidence rate of germline pathogenic genetic mutations in cancer patients seen at St Vincent's and uptake rate of cascade testing in families,2020-06-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Differences in survey responses between patient groups
14022,NCT02554448,The number of Circulating Tumor Cells (CTCs),2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,
14023,NCT00287222,Number of Participants Who Remained Free of Progression at the 27th Week.,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14024,NCT04911959,Recurrence-free survival (RFS) evaluation,2022-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival ( OS) evaluation
14025,NCT05079438,≥Grade 2 proctitis,2021-09-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,
14026,NCT06334965,Clinical response,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
14027,NCT02721056,Determination of the early Dose Limiting Toxicities,2016-01-28,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Local Progression Free Survival
14028,NCT05014399,The Proteome Profiler Human XL Cytokine Array Kit (https://www.rndsystems.com/products/proteome-profiler-human-xl-cytokine-array-kit_ary022b),2021-09-20,RECRUITING,OBSERVATIONAL,['NA'],,
14029,NCT03554356,Incidence of CryoBalloon-related serious adverse events,2018-09-04,RECRUITING,INTERVENTIONAL,['NA'],,Proportion of Barrett's Esophagus surface area reverted to neosquamous epithelium
14030,NCT03492827,infection rate 8 hours after ESD,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],complications of ESD,infection rate 72 hours after ESD
14031,NCT00900003,Cellular localization of BRCA1 as a predictor of response to cytotoxic agents or radiotherapy,2007-05,COMPLETED,OBSERVATIONAL,['NA'],,Application of a method of extracting and identifying secreted cytokines and growth factors from biopsy tissue to the pancreatic cancer population
14032,NCT01319084,,2011-03,UNKNOWN,OBSERVATIONAL,['NA'],,
14033,NCT01434264,Changes in personal concerns identified by the patient in the MYCaW questionnaire.,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,Changes in Daily physical performance
14034,NCT04777851,Progression-free Survival (PFS) Assessed by the Investigator as per Modified Response Evaluation Criteria in Solid Tumors (mRECIST) for HCC,2023-10-11,RECRUITING,INTERVENTIONAL,['PHASE3'],,Change from Baseline in Health-Related Quality of Life as Assessed by the EuroQol's 5-level EQ-5D Health Questionnaire (EQ-5D-5L)
14035,NCT01259414,overall survival,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to progression
14036,NCT03045107,Length of hospital stay,2017-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life
14037,NCT04493125,The number of radiopaque markers transferred to the large intestine 3 days after surgery,2020-07-27,UNKNOWN,INTERVENTIONAL,['NA'],,
14038,NCT00800969,Diagnostic Accuracy of PET-CT,2008-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
14039,NCT04826107,ORR(Objective Response Rate),2021-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AEs and SAEs
14040,NCT05723107,Percentage of Participants who Complete Therapy without Grade III-IV Adverse Events (AEs) as Assessed by CTCAE v. 5.0,2023-03-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Percentage of Participants who Report Post-Procedural Complications
14041,NCT06269744,Proportion of Participants who Complete FIT Test by Month 6,2024-03-13,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Proportion of Participants with Positive FIT who Complete Colonoscopy by Month 6
14042,NCT03957590,Progression-free survival (PFS),2019-06-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,The incidence and severity of treatment-emergent adverse events (TEAEs) graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events'.
14043,NCT05571839,Number of participants with dose limiting toxicities,2023-01-03,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
14044,NCT02854072,Overall Survival,2015-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Toxicity according to the NCI CTCAE v4.03
14045,NCT01135498,Progression-Free Survival,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
14046,NCT05572151,lymph node number,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14047,NCT02519582,Progression free survival,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Serious Adverse Events
14048,NCT05171309,Objective response rate (ORR),2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
14049,NCT02217865,Effectiveness of Colorectal Cancer (CRC) Surveillance,2014-07-16,COMPLETED,OBSERVATIONAL,['NA'],,
14050,NCT06171854,Progression free survival (PFS),2019-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety as the description of adverse events
14051,NCT05196087,Change from Baseline in ctDNA collected from biospecimens,2022-07-20,RECRUITING,OBSERVATIONAL,['NA'],,Number of participants that are identified as high risk of clinical relapse with artificial intelligence (AI) and machine learning algorithms
14052,NCT00569673,Number of Participants With Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Progression-free Survival and Overall Survival
14053,NCT02867839,disease-free survival,2017-04-24,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Incidence of Treatment-Emergent Adverse Events [Safety]
14054,NCT01702558,Phase 1 (LA/mGC): MTD of Capecitabine When Combined With Trastuzumab Emtansine (2.4 mg/kg QW),2012-12-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Phase 1 (LA/mGC): t1/2 of 5-Fluorouracil (Metabolite of Capecitabine)
14055,NCT01887509,Concordance in identification of lower pole of tumor,2013-11-07,TERMINATED,INTERVENTIONAL,['NA'],,Assessment of predictive value of interpretation criteria
14056,NCT04732442,Change in expression of inflammatory cytokines in tumor tissue samples obtained prior and after intervention.,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Changes in tissue neutrophil infiltration after preoperative nutritional intervention in tumor tissue samples obtained prior and after intervention.
14057,NCT05036109,To estimate the ctDNA clearance rate of colorectal cancer patients with minimal residual disease,2021-10-12,RECRUITING,INTERVENTIONAL,['NA'],,
14058,NCT00287768,overall survival,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,safety
14059,NCT02527057,Pathologic response,2014-10,UNKNOWN,OBSERVATIONAL,['NA'],,Progression free survival
14060,NCT00003760,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14061,NCT00490685,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14062,NCT03100461,CRC screening completion rate,2018-01-22,UNKNOWN,INTERVENTIONAL,['NA'],,Cost analysis of each intervention pathway
14063,NCT03413930,Circumferential resection margin (CRM),2019-06,WITHDRAWN,INTERVENTIONAL,['NA'],,5-year overall survival rate
14064,NCT03940027,the incidence of serious complications,2019-02-10,UNKNOWN,INTERVENTIONAL,['NA'],,Improvement of quality of life
14065,NCT02500797,Number of Participants Who Achieved a Confirmed Response,2015-08-13,COMPLETED,INTERVENTIONAL,['PHASE2'],OS in Patients Who Crossover From Single Agent Nivolumab to Dual Agent Treatment Following Progression,Overall Survival (OS)
14066,NCT03732547,Objective response rate (ORR),2018-10-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Level of alpha-fetoprotein (AFP)
14067,NCT02863367,Objective Response Rate (ORR),2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
14068,NCT05155878,Overall survival,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Radical resection
14069,NCT02568267,Objective Response Rate,2015-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Bone Biomarkers
14070,NCT06239194,Phase 1: Recommended Phase 2 dose (RP2D),2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,All Phases: Correlation between tumor antigen expression and anti-tumor activity of MDX2001
14071,NCT02506946,Difference in percentage liver fat between PCOS and controls in adolescents and young adults,2013-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,The association of percentage liver fat by magnetic resonance spectroscopy with total body adipose tissue
14072,NCT03817658,OS,2019-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The incidence and severity of adverse events (AEs)
14073,NCT00645710,Recommended Phase II Dose,2005-02-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free Survival
14074,NCT01747551,6-month Progression-free Survival (PFS),2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Objective Response
14075,NCT05307367,Muscle mass,2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Patient-reported Quality-of-Life (QoL)
14076,NCT01930942,gene expression in different response groups,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],toxicity,"overall survival, disease free survival and local-regional free survival"
14077,NCT06049901,Evaluating the change in the serum level of Protein disulfide isomerase (PDI),2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Evaluating the safety and tolerability of nitazoxanide through investigating Hematological parameters (hemoglobin (mg/dL), erythrocytes (cells/μL), leukocytes (cells/μL), platelets (cells/μL) and ANC (cells/μL))."
14078,NCT05229588,Evaluate the antitumor activity,2022-06-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment safety
14079,NCT02231086,Peritoneal Recurrence Free Survival at 18 Months,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of Life Questionnaire Survey 5- Year Follow-up
14080,NCT04221165,Average Pain Rating measured on the 11 Numeric Rating Scale,2020-08-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Death
14081,NCT03173001,Prevalence of intestinal protozoa (commensals) in patients with colorectal cancer and association with cancerogenesis,2015-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14082,NCT01051765,overall survival,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,polymorphism of UGT1A
14083,NCT04790448,"Overall response rate from the date of first drug administration until the date of first documented progression or date of death, whichever came first.",2020-07-27,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of patients with adverse events and severity according to NCI CTCAE v5.0
14084,NCT02759718,"Diagnostic accuracy of th CgA in the patient with PNET, change from preoperative levels of CgA at 3 months",2012-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,"Disease progression of PNET using CT imaging, change from preoperative imaging of CT at 3, 6,12, and 24 months"
14085,NCT06194708,1-year non-reversal rate of temporary stoma,2023-05-15,RECRUITING,OBSERVATIONAL,['NA'],,
14086,NCT01490749,Phase I portion to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of RAD001 in combination with radiation,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Rate of surgical pathologic complete remission (pCR) (absence of evidence of cancer after surgery)
14087,NCT03050268,Identification of novel cancer predisposing genes,2017-04-06,RECRUITING,OBSERVATIONAL,['NA'],,
14088,NCT05600803,detection rate,2022-10-30,RECRUITING,OBSERVATIONAL,['NA'],,Number needed to screen
14089,NCT02399410,surgical morbidity and mortality,2015-11-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,pathological gross response of peritoneal tumour deposits to neoadjuvant combination chemotherapy with bevacizumab
14090,NCT04279080,functional bowel outcome after low anterior resection,2003-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14091,NCT00550108,"Patients not progressing to operation due to the development of symptoms, growth to a maximum diameter of >3cm, or development of a mural nodule.",2007-10,TERMINATED,INTERVENTIONAL,['PHASE3'],,A decrease in size by >1 cm on MRCP Relative decrease in size of cyst after 1 or 2 injections with ethanol Is reduction in size durable (over what length of time)?
14092,NCT00019604,Response,1998-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Evaluate the Ability of Fludeoxyglucose (18F) Positron-Emission Tomography (FDG-PET) to Monitor Response Following Radiofrequency Ablation (RFA)
14093,NCT00375310,To evaluate the safety and tolerability of the combined treatment with Gemcitabine with Sorafenib and radiotherapy in patients with localized unresectable pancreatic cancer.,2006-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate the maximum tolerated dose (MTD) for Sorafenib during Chemo-radiation.
14094,NCT01576666,Dose Limiting Toxicities,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Plasma pharmacokinetics (PK) parameters
14095,NCT04423965,MFS,2020-05-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Reported Adverse events
14096,NCT04638751,Determine whether the microbiome composition can predict risk for colorectal cancer,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Build a library of samples and data for future research
14097,NCT05173077,Specific chemistry identification in the exhaled breath,2022-02-01,UNKNOWN,OBSERVATIONAL,['NA'],Confounding factor analysis,Gut microbiota analysis in relation to breath VOCs
14098,NCT04274790,5-FU in ribosome,2021-06-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Specific molecular signature
14099,NCT05349110,"The Area Under ROC Curve (AUC) of AI4CRP per image modality (HDWL, BLI, LCI, i-scan).",2021-08-20,UNKNOWN,OBSERVATIONAL,['NA'],,The agreement in surveillance interval based on optical diagnosis and histopathology.
14100,NCT03211715,Quality of life in association to the severity of bowel dysfunction,2017-07-19,UNKNOWN,OBSERVATIONAL,['NA'],,
14101,NCT04468607,Maximum Tolerated Dose(s) MTD(s) of BLYG8824A,2020-08-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Presence of Anti-drug Antibodies (ADAs)
14102,NCT02603302,Pathologic complete response,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
14103,NCT04336397,Colorectal cancer screening,2021-04-29,RECRUITING,INTERVENTIONAL,['NA'],,Diagnostic follow-up
14104,NCT05184751,"incidence of early onset colorectal neoplasias, risk factors",2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14105,NCT06256055,Incidence of Dose-limiting Toxicities (DLTs),2024-03-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
14106,NCT02372747,Length of the incision,2012-10,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative complication
14107,NCT03304860,Change in CRC screening rate of eligible parents of internal medicine residents at NYU from before to after the intervention,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],,
14108,NCT05494853,HCC screening positive,2022-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
14109,NCT02403271,Phase 2: Efficacy of Ibrutinib in Combination With Durvalumab (MEDI4736) in Participants With Relapsed or Refractory Solid Tumors by Assessing the ORR Per RECIST 1.1.,2015-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Pharmacodynamics
14110,NCT02900950,Evaluate R1 rate differences between multicolour and monocolour inking of the specimen,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Relation between Disease Free Survival and Overall Survival of the participants and R status
14111,NCT06308354,DFS,2011-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
14112,NCT01101672,Post-operative pain on coughing,2009-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Recurrence and survival for cancer patient
14113,NCT05490719,PFS assessed by investigators,2022-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"The rates and severity of Adverse Events, Serious Adverse Events"
14114,NCT01757366,Progression-free survival (PFS),2012-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
14115,NCT00607594,Prolonged Stable Disease Rate (Defined as Stable Disease for ≥ 16 Weeks),2008-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Association Between Correlative Markers and Clinical Outcomes
14116,NCT02713763,6 months progression free survival,2017-02-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
14117,NCT02970513,Hamilton anxiety and depression score comparison,2017-03-27,COMPLETED,INTERVENTIONAL,['NA'],,personality traits comparison
14118,NCT05827055,Safety of oral proglumide therapy at 1200mg daily dose with chemotherapy,2024-01-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Effects of proglumide on Pain
14119,NCT06059924,Cancer-specific survival,1991-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence-free survival
14120,NCT01260415,"To determine the 2 year disease-free survival rate in patients with resectable colorectal liver metastases treated with FOLFOX/FOLFIRI + panitumumab for 2 months pre-operatively and 4 months post-operatively, followed by panitumumab alone for 6 months.",2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To determine the incidence of hepatocellular damage (fibrosis, steatosis) in normal liver tissue induced by preoperative chemotherapy."
14121,NCT02559674,Overall Survival; Phase II,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Correlation between the level of tumor DNA in patient plasma and response to study treatment
14122,NCT06195514,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
14123,NCT02548169,Safety and feasibility of combining the DC vaccine with chemotherapy DC vaccine dose-limiting toxicities will be measured according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03,2015-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Average of all changes in Quality of Life (QoL) Score
14124,NCT04525768,History of variceal bleeding,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Complications of portal hypertension
14125,NCT05596890,Pathologic complete response rate,2022-11-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Dysphagia relief score
14126,NCT03776591,Complications,2016-09-01,RECRUITING,INTERVENTIONAL,['NA'],Hospitalization,Prognostic significance of CTCs
14127,NCT00857246,"Clinical Response Rate of an Induction Regimen Consisting of Irinotecan, Cisplatin and Cetuximab",2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival (Adjuvant Therpary)
14128,NCT00600613,"Number of Participants Eligible for Cone Beam Tumor Localization""",2006-01,COMPLETED,INTERVENTIONAL,['NA'],,
14129,NCT04336202,Workload,2024-08,RECRUITING,INTERVENTIONAL,['NA'],,Local control
14130,NCT00864513,Progression-free Survival,2007-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
14131,NCT00112463,Toxicity as Assessed Using the Expanded Common Toxicity Criteria Version 3,2005-01-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival
14132,NCT01197820,Temperature standard deviation,2010-09,TERMINATED,INTERVENTIONAL,['NA'],,HIFU platform improvements
14133,NCT01910948,blood immune factors,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
14134,NCT00051441,The primary endpoint is the cumulative proportion of patients with severe mucositis (WHO mucositis score of at least 3) at a cumulative radiation dose of 5500 cGy,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,Secondary endpoints include cumulative RT to first use of an opioid for oral mucositis; cumulative RT to first ulceration; cumulative RT to first RT suspension due to oral mucositis
14135,NCT04970212,Effectiveness - DICE,2021-09-24,COMPLETED,OBSERVATIONAL,['NA'],,Difference between T=0 and T=24hrs CECT tissue damage
14136,NCT02942563,Pelvic complete resection rate,2016-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The incidence of >=3 grade adverse events
14137,NCT00004236,,1998-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14138,NCT02638584,The Ulcer healing rate after endoscopic submucosal dissection,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,The evaluation of symptom score as assessed by the Korean Gastrointestinal Symptom Rating Scale questionnaire.
14139,NCT05229809,2-year disease-free survival rate,2022-03-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Percentage of Participants With Adverse Events
14140,NCT03178929,Time to tumor recurrence,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
14141,NCT04761536,Anastomotic leak,2006-01,COMPLETED,OBSERVATIONAL,['NA'],,need of postoperative blood transfusion
14142,NCT05345613,Postprocedural bleeding,2022-05-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Intraprocedural bleeding
14143,NCT01444755,Survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14144,NCT05638984,PFS,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
14145,NCT03541486,Overall survival (OS),2025-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Exploration of patient reported outcomes during combined therapy [qualitative string],Pathologic characteristics
14146,NCT00813293,Coagulation Zone Volume,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Treatment-Related Grade 1-4 Adverse Events (AEs) One Month After Radiofrequency Ablation (RFA)
14147,NCT06080854,R0 resection rate,2023-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
14148,NCT04796948,RP2D,2021-04-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,CL
14149,NCT03654729,Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN),2018-11-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
14150,NCT00361244,To determine the response rate of SU011248 when given in combination with irinotecan and cetuximab in this patient population.,2006-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"to assess overall survival, progression-free survival, time to progression and duration of response."
14151,NCT00060021,,2003-03,COMPLETED,INTERVENTIONAL,['NA'],,
14152,NCT04723030,Objective remission rate(ORR),2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Subject safety
14153,NCT00070122,Overall survival in patients with colorectal cancer treated with fluorouracil/leucovorin calcium and oxaliplatin with and without becavizumab versus those treated with capecitabine and oxaliplatin with our without bevacizumab,2004-04,TERMINATED,INTERVENTIONAL,['PHASE3'],,Whether gene expression variables are predictive of survival and progression-free survival
14154,NCT00229554,colorectal cancer screening compliance,2006-03,COMPLETED,OBSERVATIONAL,['NA'],,
14155,NCT00809796,"Any severe events, tumor marker CEA, and tumor size (CT scan)",2008-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14156,NCT01670721,Percentage of Participants With Adverse Events (AEs),2012-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in HRQL EQ-5D-3L VAS Score
14157,NCT05795010,Positive rate of preoperative MRD test,2023-03-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Positive rate of MRD test 1 month and 3 months after operation
14158,NCT02758587,Adverse events (AEs) using CTCAE v4.03 (to determine dose limiting toxicities (DLTs) and maximum tolerated dose (MTD)),2017-07-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in immune cell infiltrate
14159,NCT03422835,Positive rate of circumferential resection margin (CRM) of the specimens,2018-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life outcomes evaluation,the rate of postoperative complications
14160,NCT04213118,Disease free survival,2020-04-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events Safety and Tolerability
14161,NCT02128243,Overall Survival (OS),2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse Events,Quality of Life
14162,NCT02179489,Disease-free survival,2014-11-01,COMPLETED,INTERVENTIONAL,['NA'],,QOL
14163,NCT05160896,ORR,2021-11-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,AEs
14164,NCT02577263,Quality of life deterioration > 10% (dichotomic),2015-04,UNKNOWN,OBSERVATIONAL,['NA'],,Significant chemotherapy induced neurotoxicity > 10%
14165,NCT00819650,Overall survival,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to recurrence
14166,NCT04543617,Arm B vs Arm C: OS,2020-09-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With ADAs to Atezolizumab
14167,NCT02366039,distinguishing between normal esophageal squamous mucosa and Barrett's dysplasia,2014-09,COMPLETED,OBSERVATIONAL,['NA'],,
14168,NCT00337389,Progression Free Survival,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Incidence and Severity of Adverse Events
14169,NCT02430948,Effect of educational intervention on providers' recommendations,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Patient compliance
14170,NCT00587964,Local Control,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14171,NCT06175845,"Time to first event, ie stent dysfunction",2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Total days of overnight-hospital-stays
14172,NCT01060007,Preoperative Gastrointestinal Morbidity,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine Quality of Anorectal Function
14173,NCT00821912,Response rate,2006-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
14174,NCT05502835,Intraoperative fluid volume,2022-08-20,COMPLETED,INTERVENTIONAL,['NA'],,intestinal oedema
14175,NCT03990025,Difference in detection rate of duodenal lesions between Linked Color Imaging and White Light Imaging,2019-03-27,COMPLETED,INTERVENTIONAL,['NA'],,Sensitivity and Specificity of detection of duodenal lesions
14176,NCT03153280,Incidence of dose limiting toxicity (DLT) within the two first cycles at each dose level.,2022-01-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of adverse events reported as per the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. (Safety and Tolerability).
14177,NCT03592706,Progression-Free Survival (PFS),2009-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Improvement of immune responses
14178,NCT05218889,ORR,2021-08-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety and tolerability by incidence, severity and outcome of adverse events"
14179,NCT03051802,Optimize the clinical protocol using this technology,2017-01-27,TERMINATED,INTERVENTIONAL,['NA'],,
14180,NCT04996446,recurrence free survival,2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
14181,NCT01522937,The Percentage of Patients With Local Control at 1 Year Post Treatment,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Number of Patients That Experience Grade 4+ Gastrointestinal Bleeding
14182,NCT05420259,Mean Change in interleukin 6 (IL6),2022-03-21,RECRUITING,INTERVENTIONAL,['NA'],,Change in skeletal muscle
14183,NCT02445014,Feasibility for Imaging of Esophagus Using an SECM Tethered Endoscopic Capsule.,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,
14184,NCT01183494,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2009-12-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate the pharmacokinetic profile of irinotecan in combination with bevacizumab.
14185,NCT05361252,The incidence of postoperative complications in the two groups.,2017-02-01,COMPLETED,INTERVENTIONAL,['NA'],,The pain scale
14186,NCT00276744,6-month Overall Survival,2005-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14187,NCT01404650,Progression-free Survival (PFS),2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Adverse Events as a Measure of Safety and Tolerability
14188,NCT01858662,Major Pathological Response Rate,2014-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Chemotherapy-associated hepatotoxicity:
14189,NCT04774198,Number of patients with persistent postoperative hypotension (<65 mmHg) after surgery,2021-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Number of patients with development of delirium after surgery
14190,NCT05738447,Overall Survival,2023-02-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,
14191,NCT01621451,delayed ulcer bleeding,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,ulcer healing rate
14192,NCT00361842,Progression-free Survival (PFS) Per RECIST Version 1.0,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response (DoR) Per RECIST Version 1.0
14193,NCT05403177,Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data,2022-06-23,RECRUITING,OBSERVATIONAL,['NA'],,Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine
14194,NCT02704143,One-year Overall Survival Rate,2016-02,COMPLETED,INTERVENTIONAL,['NA'],,Median Overall Survival Will be Determined.
14195,NCT02920554,Survival rates,2014-07,UNKNOWN,INTERVENTIONAL,['NA'],,
14196,NCT00399035,Overall Survival,2006-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to Wound Healing Complications
14197,NCT01793207,"Methylation markers present in peripheral blood of patients with colorectal cancer(Sept 9, CDKN2B-p15, CDH4, SFRP2, ALX4, Neurog1 and CDH13)in comparison to their presence in other subjects",2012-12,COMPLETED,OBSERVATIONAL,['NA'],,"Methylation markers present in peripheral blood of patients with hyperplastic polyps(Sept 9, CDKN2B-p15, CDH4, SFRP2, ALX4, Neurog1 and CDH13)in comparison to their presence in other subjects"
14198,NCT00570635,"Clinical benefit, defined as either confirmed complete response, confirmed partial response, or evidence of stable disease lasting ≥16 weeks, in subjects with advanced GIST resistant to/intolerant of imatinib and/or sunitinib",2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Further characterize the pharmacokinetic and pharmacodynamic parameters of XL820 in subjects with advanced GIST
14199,NCT00547144,To determine the time to tumor progression for this regimen.,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14200,NCT00576992,"Determine the prevalence of gastric and esophageal disease in patients presenting with the complaints of dyspepsia, GERD, or extraesophageal symptoms",2003-01,TERMINATED,OBSERVATIONAL,['NA'],,"Determine whether the presence of any factors (hiatal hernia, NSAID use, age, race, gender, etc.) contribute to the above endoscopic diagnoses"
14201,NCT02574663,"Adverse events as a measure of safety and tolerability of TGR-1202 as a single agent and in combination in combination with nab-paclitaxel + gemcitabine, or with oxaliplatin + leucovorin + 5-FU (FOLFOX) or with FOLFOX + bevacizumab.",2015-09-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic (PK) profile of TGR-1202. Area under the plasma concentration versus time curve (AUC)
14202,NCT01227018,Disease Control Rate,2010-12,TERMINATED,INTERVENTIONAL,['PHASE2'],Biomarker Evaluation,Number of Patients With Each Worst Grade Toxicity
14203,NCT04529135,postoperative recovery time,2020-08-26,COMPLETED,INTERVENTIONAL,['NA'],,opioid related side effect.
14204,NCT05356520,Disease-free survival time,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Tumor recurrence
14205,NCT05069571,Adenoma detection rate,2020-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,Proportion of withdrawal overspeed
14206,NCT03086096,"Number of indications that the device is being used for, as assessed by stage and previous treatment(s)",2018-02-02,COMPLETED,OBSERVATIONAL,['NA'],,"The quality of participants' lives, as assessed by the QLQ-C30 questionnaire (developed by EORTC)"
14207,NCT02015065,Number of Participants With a Clinical Activity-radiographic Response,2013-12-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Maximum Standardized Uptake Value (SUVmax) on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
14208,NCT02415101,"Complete histological response proportion, using the Chirieac grading system.",2015-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Nutritional status of patients in each study arm.
14209,NCT05681390,MedianProgression free survival(mPFS),2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,disease control rate(DCR)
14210,NCT05580835,Degree of PSMA uptake by HCC,2022-09-05,RECRUITING,INTERVENTIONAL,['NA'],,Presence of PSMA uptake on treated liver lesions
14211,NCT04864067,Quality of Life and Funcional Outcomes,2021-06-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
14212,NCT02304445,Tumor response rate,2015-11,WITHDRAWN,INTERVENTIONAL,['NA'],Overall survival,Number of patients eligibility for liver transplantation
14213,NCT03380130,"Rate and type of adverse events, liver decompensation, and transient and permanent drug discontinuations due to toxicity.",2017-09-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pattern of progression according to RECIST 1.1 criteria.
14214,NCT04611997,3-year disease free survival rate,2020-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Total number of retrieved lymph nodes
14215,NCT02635503,Early morbidity rate,2015-11,RECRUITING,INTERVENTIONAL,['PHASE3'],,Plasma levels of several cytokines after colorectal cancer surgery
14216,NCT01808638,"Maximum concentration (Cmax), area under the curve (AUC), time to maximum concentration (tmax), and half life (t½) of the Atu027 siRNA single strand (A-strand), and of AtuFect01 and the helper lipid DPyPE",2013-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
14217,NCT04425239,Progression-free Survival,2018-05-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Metabolomic profiling,Overall Survival (OS)
14218,NCT02173119,Imaging response,2014-08,COMPLETED,OBSERVATIONAL,['NA'],,Survival
14219,NCT03892252,"According to the 16s rDNA sequencing results, analyze the differences in intestinal flora of colon cancer patients with different TCM syndromes and TCM constitutions before and after surgery and their correlations",2019-03-10,COMPLETED,OBSERVATIONAL,['NA'],,
14220,NCT05195294,Objective response rate (ORR),2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
14221,NCT00926757,The primary endpoint is the incidence of HBV reactivation during and within 12 months after chemotherapy,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,The incidence of HBsAg reverse seroconversion during and within 12 months after completing chemotherapy.
14222,NCT05721651,Progression free survival (PFS),2023-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Safety and tolerance evaluated by incidence, severity and outcomes of AEs"
14223,NCT05966194,Incidence of Severe Oral Mucositis through 60 Gy of the Radiation Treatment Plan,2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Narcotic use through resolution of SOM
14224,NCT01365130,Number of Patients Without Progression at 3 Months,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Patients Experienced a Toxicity Associated With Cabazitaxel for Patients With Metastatic Gastroesophageal Adenocarcinomas That Have Progressed After at Least One Line of Therapy for Metastatic Disease.
14225,NCT06134700,To compare the efficacy of low pressure versus standard pressure pneumoperitoneum in laparoscopic nephrectomy,2023-11-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
14226,NCT05513183,Association between the concentration of intraoperative mitomycin-C absoprtion and severe neutropenia after CRS/HIPEC,2021-05-20,COMPLETED,OBSERVATIONAL,['NA'],,Quality of Life: QoR-40 questionnaire
14227,NCT04196803,Plasma methionine cycle metabolites,2016-02-01,COMPLETED,INTERVENTIONAL,['NA'],,
14228,NCT01791140,Median progression-free survival,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,Median progression-free survival according to age group (65-74 years; >/= 75 years)
14229,NCT02148159,Percentage weight change over 8 weeks between two arms,2014-10,COMPLETED,INTERVENTIONAL,['NA'],symptom experience,body composition
14230,NCT02329821,changes of lactate level,2014-11,COMPLETED,OBSERVATIONAL,['NA'],,changes of acid-base status
14231,NCT04185272,"evaluation of BTNL3, BTNL8 and BTNL9 expression by transcriptomics and immunohistochemistry",2020-06-30,RECRUITING,INTERVENTIONAL,['NA'],,
14232,NCT05198934,Progression-free Survival (PFS),2022-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,AUC of Panitumumab
14233,NCT01717391,Percent Difference From Baseline IMRT Plan (%),2012-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Standardized Toxicity Severity Grades for Decreased Lymphocyte Counts.
14234,NCT01877187,Baseline Enhancing Tumor and Response by RECIST Criteria,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,6-month Survival Rate of Patients With HCC and Liver Metastases Treated With Conventional TACE
14235,NCT03713749,Rate of unsuccessful LND along the left RLN,2018-10-22,UNKNOWN,INTERVENTIONAL,['NA'],,"European Organisation for Research and Treatment of Cancer(EORTC) QLQ-C30 , QLQ-OES18"
14236,NCT01579357,Influence of Cetuximab on metabolic activation of Capecitabine,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14237,NCT05355298,Part B: efficacy of AMP945,2022-05-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Effects on biomarkers,AMP945 levels in plasma
14238,NCT02549911,R0 resection,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival time
14239,NCT05818072,The yield rate of intestinal metaplasia,2023-03-13,RECRUITING,INTERVENTIONAL,['NA'],,Procedure time
14240,NCT03216395,Bleeding free probability in 30 days after randomization,2018-01-02,COMPLETED,INTERVENTIONAL,['NA'],,cost analysis (Based on the cost data from the Hospital
14241,NCT05759728,To determine the overall best response to CNA3103.,2023-10-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To determine progression-free survival
14242,NCT02548403,the quality of the bowel preparation using Preparation Scale,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,the endoscopist's tolerability[Visual Analog Score for fatigue]
14243,NCT02495337,"Effectively culture, proliferate, and store primary gastro-esophageal cell lines in order to create a bank of primary esophageal / gastric cancers for research purposes",2015-05,RECRUITING,OBSERVATIONAL,['NA'],,
14244,NCT05569343,postoperative complications,2020-05-08,COMPLETED,OBSERVATIONAL,['NA'],,Readmission
14245,NCT02215577,"Surgical success rate, the rate of liver resection in each study arm",2014-06,UNKNOWN,INTERVENTIONAL,['NA'],Health economy,Liver growth rate
14246,NCT01525706,Efficacy: Degree of Ablation,2012-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,Efficacy: Cyst Resolution
14247,NCT01755013,Efficacy Profile,2012-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Safety Profile
14248,NCT04527666,Changes of portal vein thrombosis,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
14249,NCT03018418,Rates of Acute Toxicity,2017-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life Changes
14250,NCT05039983,Recommended phase 2 dose (RP2D),2021-08-20,UNKNOWN,INTERVENTIONAL,['NA'],,change in blood biochemical indicators
14251,NCT02156739,Specificity of combining gadoxetate disodium and gadobutrol in diagnosing tumor lesions radiologically using magnetic resonance imaging (MRI),2014-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
14252,NCT04659018,The ability to predict the presence of adenomas and colorectal cancers.,2020-08-24,COMPLETED,OBSERVATIONAL,['NA'],,
14253,NCT03530267,Progression-free survival (PFS),2018-09-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,PRO: Overall treatment utility
14254,NCT04248582,Dose limiting toxicity (DLT),2020-02-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
14255,NCT01834170,Number of participants with adverse events as a measure of safety and tolerability,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Proportion of participants who remain alive one year after enrollment compared to the historical matched control group
14256,NCT02497820,cancer preventive properties of enteric coated aspirin in Lynch syndrome are dose sensitive by comparing overall cumulative Lynch syndrome cancer,2016-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall cumulative of of new adenomas at five years
14257,NCT05339919,Long-term results after operation,2020-05-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Hospitalization expenses
14258,NCT04186234,Best objective response,2015-01-01,UNKNOWN,INTERVENTIONAL,['NA'],Changes in Child-Pugh status,Overall survival
14259,NCT00976170,Dose limiting toxicity and maximum tolerated dose,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Repeat-dose pharmacokinetic behavior of GC33 and Sorafenib
14260,NCT04163887,Rate of overall complications using the comprehensive complication Index (CCI),2021-01-27,RECRUITING,INTERVENTIONAL,['NA'],,Disease-free and overall survival at 3 years.
14261,NCT04063293,Wexner fecal incontinence score change,2019-05-15,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Number of participants with PRP injection-related adverse events as assessed by CTCAE v4.0
14262,NCT00030667,Toxicity reported using the CTC version 2.0,2002-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to disease progression
14263,NCT00882765,Changes in microvessel density of tumor specimen after 2 weeks of treatment with genistein,2009-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,"To evaluate the impact of genistein on the angiogenic factors VEGF, CXCL1, CXCL5, and CXCL8"
14264,NCT03884751,Maximum tolerated dose (MTD),2019-08-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor efficacy-Disease control rate (DCR)
14265,NCT01137123,survival rate,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14266,NCT02216955,Disease-specific survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],Disease-free survival,Overall survival
14267,NCT01741363,Detection rate of upper gastrointestinal tract diseases,2012-07,UNKNOWN,INTERVENTIONAL,['NA'],,Helicobacter pylori eradication rate
14268,NCT02935478,Weight,2017-10-18,SUSPENDED,INTERVENTIONAL,['NA'],,Eligibility for liver transplant
14269,NCT04715061,"Change in the concentration of different peripheral blood mononuclear cells (Natural Killer Cells, T cells and monocytes)",2020-11-04,COMPLETED,INTERVENTIONAL,['NA'],,Heart rate variability
14270,NCT03739801,Progression-free survival (PFS) (Phase II),2020-04-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of adverse events graded according to CTCAE version 4.0
14271,NCT04915326,Nodal metastasis in early rectalò cancer,2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
14272,NCT03484299,Incidence of Adverse and Serious Adverse events will be captured (safety and tolerability),2018-05-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression free survival
14273,NCT02527785,overall response rate,2015-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profiles - The number of participants and grade of intensity of treatment related adverse events
14274,NCT04404101,Safety of EUS-FNA plus MFB with that of EUS-FNA by recording adverse events per published ASGE (American Society for Gastrointestinal Endoscopy) criteria.,2021-05-11,RECRUITING,INTERVENTIONAL,['NA'],,Time taken for FNA and time for MFB
14275,NCT01238653,The number of accurate liver surface registrations obtained in the laparoscopic environment compared to accurate liver surface registrations obtained in open procedures,2010-11,TERMINATED,OBSERVATIONAL,['NA'],,
14276,NCT00113230,Pathologic Local Tumor Response,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14277,NCT02967887,Objective tumor response,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Exploratory endpoint: Diagnostic performance of biomarkers,Progression-free-survival
14278,NCT05690490,R0 resection rate,2020-11-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,intra- and postoperative complications rate
14279,NCT03637491,Phase 2: Confirmed Objective Response (OR) Based on Investigator Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.,2018-08-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Phase 2: Number of Participants With Programmed Death-Ligand 1 (PD-L1) Expression, DNA Damage Repair (DDR) Gene Alterations, and Tumor Mutational Burden (TMB) in Baseline Tumor Tissue."
14280,NCT06157060,2-year recurrence-free survival rate,2023-11-20,RECRUITING,OBSERVATIONAL,['NA'],,Correlation between ctDNA-MRD status dynamic changes and relapse
14281,NCT06102902,Recommended phase 2 dose (dose escalation cohort),2024-11-12,RECRUITING,INTERVENTIONAL,['PHASE1'],Presence or absence of a given gene mutation,MAPK inhibition
14282,NCT01937208,Progression-free survival,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],radiation-related advent events,Overall survival
14283,NCT06254521,Pathological complete response (pCR) rate,2024-02-22,RECRUITING,INTERVENTIONAL,['PHASE2'],Molecular pathological analysis of tumor tissue,3-year local recurrence rate
14284,NCT05240625,Adenoma detection rate,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Withdrawal time
14285,NCT00389870,Overall survival of patients treated with Ir vs Ir and panitumumab (IrP) and no prior cetuximab,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Patient-assessed symptom/quality of life/acceptability scores at 12 and 24 weeks in patients treated with Ir vs IrP and prior cetuximab
14286,NCT01742065,FIT Completion,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Any CRC Screening
14287,NCT04231526,To measure the feasibility of neoadjuvant pembrolizumab in early stage colon cancer,2020-05-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Measure the immune response in early stage colon cancer after neoadjuvant pembrolizumab
14288,NCT05643391,Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0,2020-06-15,COMPLETED,INTERVENTIONAL,['NA'],"Comparison between ""pre-scout"" HBS and HBS just after ""scout dose""",Evaluation of efficacy of 166Ho radioembolization in unresectable hepatocellular using metabolic assessments (FDG and choline PET/CT)
14289,NCT00250796,"Determine the response rate and time to progression of the combination of thalidomide, interferon, and octreotide in patients with unresectable hepatocellular carcinoma.",2000-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14290,NCT01952730,Number of Patients Who Fail to Receive the First Six Scheduled Vaccinations Because of Toxicity,2013-11-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Two Year Survival
14291,NCT02114411,Sensitivity and Specificity of the GastroPanel test for the detection of AG,2017-01-31,UNKNOWN,OBSERVATIONAL,['NA'],,
14292,NCT00005956,Safety,2000-02,COMPLETED,INTERVENTIONAL,['NA'],,
14293,NCT00549835,Frequency of any adverse effects,2007-08,WITHDRAWN,INTERVENTIONAL,['NA'],,Total amount of conventional analgesics used and Total days on Analgesic
14294,NCT05176002,Safety of Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.,2021-09-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Efficacy of Camrelizumab in Combination With Radiotherapy for Neoadjuvant
14295,NCT00217087,Change in Quality of Life,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14296,NCT05411718,To establish the effect of naproxen or aspirin on the abundance of T cells and other immune,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,
14297,NCT04989985,pCR,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
14298,NCT05281328,Height-adjusted total liver volume (htTLV),2022-06-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse events (AEs)
14299,NCT00785421,DVT/TVE event rate,2004-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"TTP, OS, side effects"
14300,NCT03985644,Overall survival,2019-07,UNKNOWN,OBSERVATIONAL,['NA'],,Recurrence rate
14301,NCT04400903,Compliance statistics for wristband use (Stage II),2020-09-21,TERMINATED,OBSERVATIONAL,['NA'],,Time of PDAC diagnosis among high-risk participants who developed PDAC (Stage II)
14302,NCT05582031,Progression Free Survival at 6 months (PFS-6) as per Investigator Assessment,2023-04-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Frequency and Severity of Adverse Events (AEs) and Laboratory Abnormalities
14303,NCT06135896,Primary endpoint,2023-12-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,biomarkers
14304,NCT01097239,"Quality of life scores (EORTC QLQ-C30 and/or EORTC QLQ-CR38, EORTC QLQ-CX24, EORTC QLQ-EN24 or EORTC QLQ-OV24)",2009-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumour marker changes (CEA and CA19.9)
14305,NCT03002831,Overall Survival,2016-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of life assessed by Questionnaire
14306,NCT04895722,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR),2021-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants Discontinuing Study Treatment Due to an AE
14307,NCT01257711,The aim of this study is to compare Billroth II and Roux En Y reconstruction after radical distal subtotal gastrectomy for gastric cancer in terms of postoperative outcomes.,2008-10-09,COMPLETED,INTERVENTIONAL,['NA'],,Grading of gastritis and/or esophagitis on endoscopy
14308,NCT03311451,Safety: Incidence of Dose-related SAEs,2023-01-16,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Efficacy: Treatment
14309,NCT04530890,To assess the prognostic impact of ctDNA (mortality) in digestive and gynecological / breast cancers.,2021-01-20,RECRUITING,INTERVENTIONAL,['NA'],,Evaluate the possibility of detecting certain molecular alterations using ctDNA and exosomes
14310,NCT05132738,No Evidence of Disease Rate (NED Rate),2021-08-01,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival (OS),Objective response rate (ORR)
14311,NCT00220077,To determine whether specific gene expression profiles are associated with response in oesophago-gastric cancer.,2002-06,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluation of the association of gene expression profiling and progression free survival and overall survival in patients with oesophago-gastric cancer.
14312,NCT05059119,Rate of associated comorbidity or intervention,2020-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
14313,NCT01698190,Number of needle passes needed to obtain a pathologic diagnosis.,2011-12,UNKNOWN,INTERVENTIONAL,['NA'],,Frequency of adverse side effects.
14314,NCT00446290,Number of Participants With DLTs,2006-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14315,NCT00300950,Recurrence free time and survival,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14316,NCT06077981,Volume of solution,2023-06-19,RECRUITING,INTERVENTIONAL,['NA'],,Number of additional injections
14317,NCT06064331,Cost of Desflurane used to maintain BIS 40-60,2021-01-21,COMPLETED,INTERVENTIONAL,['NA'],,Opioid usage (mcg/kg)
14318,NCT00985400,Effect size of the exercise intervention on physical function,2010-11-05,UNKNOWN,INTERVENTIONAL,['NA'],,Effect size of the exercise intervention on symptoms and quality of life
14319,NCT01643811,Proportion of patients who quit previous medication for hypertension because of improved disease,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,"difference of serum levels of c-peptide, Ghrelin, GIP, GLP-1, glucagon, insulin between before and after operation"
14320,NCT04924686,NOD2 ligands in fecal and plasma,2020-05-10,UNKNOWN,OBSERVATIONAL,['NA'],,
14321,NCT05230329,we will assess the Number of harvested lymph nodes after colonic resectio,2022-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Health related quality of life
14322,NCT04223102,16s rRNA gene sequencing to study bacterial phylogeny and taxonomy,2020-02-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,rectal microbiota to study bacteria strains
14323,NCT06294873,Detection of colon cancer or precancer,2023-07-20,RECRUITING,OBSERVATIONAL,['NA'],,
14324,NCT05089266,Dose-limiting toxicity （DLT）,2021-11-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Objective response rate (ORR)
14325,NCT01440127,Expression of CD133 in tumors from patients treated or not treated with metformin,2011-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,
14326,NCT04634539,"Recommended phase II dose (RP2D) of combination gemcitabine, nab-paclitaxel, and L-glutamine in treatment-naive metastatic pancreatic cancer.",2021-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Describe any preliminary evidence of antitumor activity of the combination by assessment of overall survival as determined by RECIST 1.1 criteria in patients with measurable disease.
14327,NCT03211806,Adherence,2019-06-06,COMPLETED,INTERVENTIONAL,['NA'],,Readmission
14328,NCT00986440,Percentage Rate of Progression-free Survival at 18 Weeks Following Use of CS-7017 in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy,2009-07-31,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-Emergent Adverse Events Related to Study Drug With an Incidence of ≥5% Following Use of CS-7017 Or Placebo in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy
14329,NCT02607982,response rate,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
14330,NCT00291486,Number of Patients With Dose-Limiting Toxicities (DLT),2003-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Patients With Human Anti-human Antibodies (HAHA) to 131I-huA33
14331,NCT01074385,Impact of Dignity Therapy,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,Establish a correlation between terminal illness acknowledgement and presence of peaceful awareness with preferences for life sustaining therapy and end-of-life goals of care.
14332,NCT01960023,Number of patients with Overall response rate (ORR)(complete response/partial response) and progression free survival (PFS) during the Phase II portion of the study,2013-10,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The frequency and severity of adverse events to evaluate the overall toxicity in the Phase II portion of the study.
14333,NCT03193424,Progression-free survival (PFS),2016-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Total Survival (OS)
14334,NCT05131776,Adverse events,2021-11-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Progression Free Survival
14335,NCT04677413,To determine the maximal tolerated dose (MTD) of dose-escalated hypofractionated RT.,2021-06-03,RECRUITING,INTERVENTIONAL,['PHASE1'],,"To evaluate the rate of distant failure, defined as development of disease outside of the pelvis."
14336,NCT02001623,Dose Expansion Part: Evaluation of Treatment-Emergent Adverse Events,2013-11-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Dose Expansion Part: Duration of Response (DOR)
14337,NCT02886247,pancreatic cancer,1994-06,RECRUITING,OBSERVATIONAL,['NA'],,
14338,NCT01580241,,2010-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14339,NCT04368507,"2a cohort: Safety, Tolerability of YYB101 by ORR",2019-08-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,2a cohort
14340,NCT06192771,Study feasibility as measured by data fidelity for patient-reported outcomes,2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],,
14341,NCT02944006,T-staging,2016-11-28,UNKNOWN,OBSERVATIONAL,['NA'],transient dyspnea,mean diffusivity
14342,NCT04393584,median overall survival,2019-01-29,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,R0-Resection rate
14343,NCT00007943,,2000-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14344,NCT00434109,Percentage of Participants With Progression Free Survival (PFS) at 12 Months,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Overall Survival (OS) at 4 Years
14345,NCT01151761,Progression-free Survival at 12 Months,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Median Time to Overall Survival
14346,NCT01608711,Incidence of anti-AGS-1C4D4 antibody formation,2012-08-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14347,NCT03019016,Chart review on PeriOperative Information,2016-08,COMPLETED,OBSERVATIONAL,['NA'],,Chart review on Postoperative Information
14348,NCT05100329,Objective response rate (ORR),2021-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-emergent adverse events (TEAEs)
14349,NCT02022995,evaluate the overall survival of patients with PRMT (arginine methyltransferase),2014-01,COMPLETED,OBSERVATIONAL,['NA'],,evaluate the disease-free survival of patients with PRMT (arginine methyltransferase)
14350,NCT00862680,Impact of the difference in SUVmax on the lesion detectability and staging of the evaluated patients,2009-03-12,COMPLETED,OBSERVATIONAL,['NA'],,
14351,NCT00003907,Time to Progression,1999-12-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
14352,NCT04731441,Feasibility of doing exercises,2021-03-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life after CRS-HIPEC
14353,NCT04000425,Description of ctDNA changing to adjuvant chemotherapy response,2018-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,The ctDNA level/mutations in gastric cancer preoperatively
14354,NCT00016380,,2001-02-28,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14355,NCT04534218,objective response rate,2020-10-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14356,NCT06293612,Heterochronous distant metastasis,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Distant metastasis-free survival
14357,NCT01906216,Overall survival,2013-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",AFP response,Adverse events
14358,NCT04193553,Progression-Free Survival (PFS),2020-01-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Pharmacokinetic properties of lenvatinib for patient in the blinded part of the study,Progression-Free Survival (PFS) In patients from the placebo arm who switched into the active treatment group
14359,NCT03590119,The difference in post-treatment tumor-to-non-tumor (T/N) activity concentration ratio on SPECT/CT between the intra-arterial treated liver lobe and the intravenous treated liver lobe.,2018-08-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The difference in kidney uptake of 177Lu-dotatate between the IA treated patients and historical controls
14360,NCT01593098,Prevalence of adenoma and CRC,2010-06-08,RECRUITING,OBSERVATIONAL,['NA'],,Differences in genetic profile between siblings of patients with advanced neoplasm and controls
14361,NCT02426879,Safety measured by the percentage of overall postoperative complications grade 3b and higher as stated by the modified Clavien-Dindo classification (MCDC),2015-02-11,COMPLETED,INTERVENTIONAL,['NA'],pathology results 10,postoperative recovery
14362,NCT05534906,Biomarkers associated with small HCC (Early detection [EDx] biomarkers),2022-05-23,RECRUITING,OBSERVATIONAL,['NA'],,Proportion of patients with HCC events according to time since treatment with curative intent.
14363,NCT03965546,Frequency of ARTEMIS T cell treatment-related adverse events,2019-05-30,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,IFN-γ serum levels
14364,NCT05728710,Surgery,2019-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,30-days mortality rate
14365,NCT03784040,Response Rate,2019-02-21,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Overall Survival
14366,NCT02528643,Overall Survival (OS),2015-11-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
14367,NCT03751761,response rate,2018-06-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14368,NCT04273061,"Overall response rate (ORR) in each tumour-defined cohort, as defined by RECIST 1.1",2020-06-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Compare the utility of iRECIST for response assessment to RECIST 1.1 in each tumour-defined cohort,Duration of response (DoR) in each tumour-defined cohort
14369,NCT00003951,,1999-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14370,NCT03645876,Objective response rate,2018-11-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Biomarkers and ADA,12month and 24 month OS rate
14371,NCT00154544,,2004-08,UNKNOWN,OBSERVATIONAL,['NA'],,
14372,NCT02694081,the amount of blood loss during operations of Uncut Roux-en-Y Reconstruction and Billroth II Reconstruction,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],the number of patients with the complication of gastroesophageal reflux disease(GERD),the number of patients with the complication of Reflux esophagitis
14373,NCT05404503,Choledochal cyst and cholangiocarcinoma,2022-10,RECRUITING,OBSERVATIONAL,['NA'],,
14374,NCT03175016,Tumor Response of six months,2017-06-20,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of life
14375,NCT00047307,Maximum tolerated dose of flavopiridol when administered biweekly in conjunction with radiation for patients with locally advanced pancreatic or extrahepatic bile duct cancer,2002-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Molecular correlates of apoptosis including PARP cleavage and caspase-3 activation, as well as changes in expression of p21, phosphorylation status of pRb and cyclin D1"
14376,NCT02896907,Number of Participants With Adverse Events as Determined by CTCAE Version 4.03,2016-10-18,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Change in Quality of Life as Defined by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30
14377,NCT01450319,Overall Survival (OS) Time,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Beta 2-microglobulin
14378,NCT05262452,Percentage of subjects that were subject to surgical resection,2021-08-09,RECRUITING,INTERVENTIONAL,['NA'],,Survival time
14379,NCT02146352,Safety/Adverse Event Outcome Measure 6,2014-06,COMPLETED,INTERVENTIONAL,['NA'],,Technical Success Outcome Measure 2
14380,NCT02715804,Overall Survival,2016-03-14,TERMINATED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Clinically Significant Abnormalities in Vital Signs
14381,NCT01959672,"Number of Participants With Progressive Disease,",2013-09-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With CA-125-Specific T-cell Signal.,"Tumor Response Rate, Evaluated on the Pathology Specimen"
14382,NCT04524650,the severity of portal hypertension,2020-08-31,UNKNOWN,OBSERVATIONAL,['NA'],,
14383,NCT05566093,The Chang The change of tumor size,2018-09-28,RECRUITING,INTERVENTIONAL,['NA'],,Incidence of Treatment-Emergent Adverse Events
14384,NCT02978313,PFS,2016-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,QoL
14385,NCT01419860,Evaluation of microcirculation in colon wall and bowel anastomosis by laser induced fluorescence video angiography of indocyanine green,2010-01,COMPLETED,INTERVENTIONAL,['NA'],,Predicting perfusion deficit with laser-induced ICG fluorescence video angiography
14386,NCT03038256,Pathological complete response rate,2018-01-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,quality of surgery
14387,NCT00999921,Number of Participants Analysed for Reduction in Mastalgia (Cardiff Breast Pain Score).,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Participants Analysed for Response of Cyclical Mastalgia (Good Response Was Defined as Disappearance of Mastalgia)
14388,NCT05743036,Dose Expansion Phase - Objective response rate (ORR),2023-02-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor tissue BRAF V600E mutational status
14389,NCT05199259,Independent performance measure of sensitivity and specificity of a multi-analyte blood test,2022-03-01,RECRUITING,OBSERVATIONAL,['NA'],,Ascertain Sample Stability
14390,NCT06304974,Overall survival (OS),2024-03-19,RECRUITING,INTERVENTIONAL,['PHASE3'],,Anti-drug antibody (ADA)
14391,NCT03957460,difference between SpHb value in g/dL and SaHb value in g/dL (SpHb - SaHb),2017-11-20,COMPLETED,OBSERVATIONAL,['NA'],,
14392,NCT05416073,Pain intensity at 3 hours after HAIC treatment,2022-06-22,RECRUITING,INTERVENTIONAL,['PHASE4'],Degree of satisfaction,Pain intensity on the 21st after HAIC treatment
14393,NCT00108745,Overall Survival,2005-03-21,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Patient-Reported Peripheral Neuropathy Symptoms
14394,NCT05310643,Objective response rate (ORR) by RECIST 1.1,2022-05-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,MSI/MMR status
14395,NCT05592873,Lateral nodal recurrence,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14396,NCT02130726,Extent of lymph node dissection,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,Disease-free survival
14397,NCT04031963,Early cancer changes in the colon,2009-09,COMPLETED,OBSERVATIONAL,['NA'],,
14398,NCT01902849,measurement of interleukins IL6 and IL 10 plasmatic level,2012-02,COMPLETED,OBSERVATIONAL,['NA'],total opioid dose of remifentanil (mg ) used during surgery,total opioid analgesic dose (mg)
14399,NCT03530969,Participants satisfaction with Health Care Provider (HCP) training,2018-05-07,COMPLETED,INTERVENTIONAL,['NA'],,
14400,NCT03765450,Inter-compartmental Difference in Infliximab Concentration,2018-12-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Change in Mayo Clinic Endoscopic Score
14401,NCT02529761,Overall survival,2015-08,UNKNOWN,INTERVENTIONAL,['NA'],,Prognostic factor
14402,NCT06197178,Area Under the Curve (AUC) last,2024-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of anti-LCAR-G08 antibody and positive sample titer
14403,NCT04862949,Organ-specific response rate,2021-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
14404,NCT04068103,"Recurrence-free survival (RFS) the ""baseline ctDNA detected"" patient subset (Phase III)",2019-12-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Cost effectiveness of the use of ctDNA versus standard of care,Incidence (presence or absence) of ctDNA in blood following resection of stage II colon cancer
14405,NCT05150548,Sepsis or septic shock,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14406,NCT04518774,Safety evaluation: Maximum-tolerated dose (MTD),2020-08-15,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Efficacy evaluation: γδT cells in peripheral blood
14407,NCT04632303,Adjusted mean change in global health status/QoL score at 12 weeks,2021-06-23,RECRUITING,INTERVENTIONAL,['NA'],,Chemotherapy dose intensity.
14408,NCT05438927,Participant Rating on Ease of Use for the Mobile Application - Usability,2022-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Participant Compliance with Dietary Log - Intervention Adherence
14409,NCT05090215,Anaerobic threshold change,2022-05-13,RECRUITING,INTERVENTIONAL,['NA'],,Change to the values inflammatory markers using venous blood samples after the application of a 12 week postoperative exercise programme
14410,NCT00005818,Time to disease progression (TTP),2000-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity graded using the NCI CTC version 2.0
14411,NCT04579380,Confirmed objective response rate (cORR) per investigator assessment,2021-01-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Trough concentration (Ctrough)
14412,NCT03377270,Change in MBSImP physiologic function metrics of the oropharyngeal swallow,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Functional Oral Intake Scale (FOIS)
14413,NCT00095966,Response rate as measured by RECIST criteria,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
14414,NCT02838836,"CTC/DTC numbers measured in blood, urine and bone marrow samples will be correlated with patient outcome",2016-07-01,RECRUITING,OBSERVATIONAL,['NA'],,ctDNA characteristics will be correlated with survival data
14415,NCT04300114,PFS by Blinded Independent Central Review (BICR) Using RECIST v1.1,2020-08-19,TERMINATED,INTERVENTIONAL,['PHASE3'],,Number of participants with treatment-emergent adverse events
14416,NCT05896956,overall survival,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,progression-free survival
14417,NCT01234935,Disease-free survival,2011-01-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease-free survival
14418,NCT03661047,The change in the marine omega-3 polyunsaturated fatty acid (MO3PUFA) composition in colorectal tissues as a result of the AMR101 treatment for up to 30 days.,2019-11-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,The change in the gut microbiome composition and function between pre- and post- AMR101 treatment period
14419,NCT00090025,To compare survival duration for XL119 and 5-FU/LV treated subjects,2004-09,TERMINATED,INTERVENTIONAL,['PHASE3'],,"To determine time to progressive disease for XL119 and 5-FU/LV treated subjects, to evaluate clinical benefit for XL119 and 5-FU/LV treated subjects, and to assess the safety profile of XL119"
14420,NCT02553031,The recurrence rate at 1 year after surgery,2014-07,UNKNOWN,OBSERVATIONAL,['NA'],,The overall survival at 1 year after surgery
14421,NCT05969860,Mean patient-reported rating of Cancer Connected Access and Remote Expertise,2023-08-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
14422,NCT05788484,Tumor-specific expansion cohorts: To further evaluate the safety of CDX-585 by tumor type.,2023-05-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity Evaluation
14423,NCT03558945,Incidence and grades of adverse events as assessed by CTCAE v5.0,2018-07-12,RECRUITING,INTERVENTIONAL,['PHASE1'],Percentages of immune cell populations in peripheral blood during the vaccination,Serum CA19-9 or CA72-4 levels
14424,NCT03403049,Dose-limiting toxicity,2016-04-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,The impact in terms of overall quality of life of radiation therapy as assessed by the QLQ-C30 questionnaire
14425,NCT01801059,Completion rate of CRC screening,2007-09,COMPLETED,INTERVENTIONAL,['NA'],,
14426,NCT06302179,Venous Thromboembolism,2015-01,COMPLETED,OBSERVATIONAL,['NA'],,
14427,NCT02393755,"Progression Free Survival (PFS) Rate, Defined as the Proportion of Patients Who Survive Without Disease Progression Via the RECIST Version 1.1 (Phase II)",2015-05-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Aggregate Rates of Adverse Events Measured by CTCAE Version 4.0 (Phase II)
14428,NCT04767295,pathologic complete response (pCR),2021-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14429,NCT04035096,"Change from baseline by computerized tomography of Chest, abdomen and pelvis",2020-01-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with changes of tumor markers
14430,NCT00544908,Progression-free Survival (PFS) Rate at 4 Months,2007-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Response Rate
14431,NCT03997617,"Number of patients for which a treatment recommendation for their specific cancer can be formulated, based on PFP",2019-03-11,RECRUITING,INTERVENTIONAL,['NA'],,Number of patients for which the treatment recommendation issued by PFP were followed by the investigator
14432,NCT04301986,7 Days Post-EGD Impact of Events Score (IES),2020-08-11,COMPLETED,INTERVENTIONAL,['NA'],,Factors Influencing the Preferred Screening Modality
14433,NCT06019312,gut microbiota composition,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,Clostridioides difficile infection
14434,NCT02947971,Assessment of quality and performance of Compact Imaging System (CIS),2016-04-15,RECRUITING,INTERVENTIONAL,['NA'],,
14435,NCT02751177,"KRAS, NRAS et BRAF mutational status",2016-03-25,COMPLETED,INTERVENTIONAL,['NA'],,
14436,NCT05414383,Diagnostic accuracy,2024-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Diagnostic time
14437,NCT05336617,percentage of complete colonoscopies,2022-05-13,COMPLETED,OBSERVATIONAL,['NA'],,Quality of colonic preparation (Boston score)
14438,NCT03546257,the accuracy in predicting the invasion depth of EGC.,2019-03,UNKNOWN,OBSERVATIONAL,['NA'],,The NBI findings that affect the accuracy for predicting of depth.
14439,NCT01978184,Age-Adjusted Charlson Comorbidity Index,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of R0 Resection
14440,NCT05954897,Objective Response Rate,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
14441,NCT03958240,Percentage of CD4 and CD8 T cells expressing PD-1,2020-01-17,RECRUITING,INTERVENTIONAL,['NA'],,Rate of patients presenting a high Trm (Tissue resident memory) infiltrate in tumor samples
14442,NCT02479984,Probability of diagnosis of metastasis (frequency),2011-08,UNKNOWN,INTERVENTIONAL,['NA'],,
14443,NCT01707641,incidence of grade III/IV mucositis,2012-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],percentage of patients who need enteral nutrition,percentage of patients able to complete the chemo-radiotherapy treatment
14444,NCT00323830,disease free survival,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14445,NCT01588990,Association Between Neutrophil to Lymphocyte Ratio (NLR) [NLR ≤5 Versus NLR >5] and Progression-Free Survival (PFS) as Assessed by Hazard Ratio,2012-06-26,COMPLETED,INTERVENTIONAL,['PHASE4'],,FACT-C Score: Phase B
14446,NCT04234568,Dose limiting toxicity (DLT),2020-07-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Change in deoxyribonucleoside concentrations,Overall survival
14447,NCT00100321,,2004-12-21,TERMINATED,OBSERVATIONAL,['NA'],,
14448,NCT00212615,Toxicity: before treatment (each 3 weeks) and by SAE (Serious Adverse Event),2004-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Tumor assesment: after every 3rd treatment (each 9th weeks)
14449,NCT02727894,Colorectal Cancer Stage (pTNM),2013-03,COMPLETED,OBSERVATIONAL,['NA'],,Colorectal Cancer and Palliative Therapy
14450,NCT02381847,overall survival,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,time to distant metastasis
14451,NCT01351714,Number of additional lymph nodes removed through radical D3 resection,2011-05,UNKNOWN,INTERVENTIONAL,['NA'],,Disease free survival 2 and 5 years after initial surgery
14452,NCT02202096,Number of post-operative ER visits and readmissions,2015-02,WITHDRAWN,INTERVENTIONAL,['NA'],,
14453,NCT05945901,Progression-Free Survival (PFS) Assessed by IRC（Phase III）,2023-08-14,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Serious Adverse Events (SAE)（Phase III）
14454,NCT04259944,Number of post-surgery and post-adjuvant false negative cases after a double ctDNA-negative detection,2020-06-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients experiencing ctDNA seroconversion (i.e. ctDNA+ that become ctDNA-) after any chemotherapy regimen remaining disease free
14455,NCT00586872,Number and types of adverse events in participants who have undergone endoscopic mucosal resection with documented adverse events will be evaluated for predictors of complications,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,
14456,NCT06044961,Use of radiomics,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14457,NCT00524498,Antitumor effect (tumor size reduction),2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease control rate Overall survival Progression-free survival
14458,NCT03202758,Evaluation of the safety of Durvalumab plus Tremelimumab in combination with FOLFOX chemotherapy,2017-08-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14459,NCT03609424,Disease control rate,2019-02-14,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Mutational analysis
14460,NCT05776940,Occurrence of diarrhea,2023-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Involved organ response（kidney）at 3 and 6 months after enrollment
14461,NCT02384850,Numbers of Patients With Dose Limiting Toxicities,2015-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Patients Experiencing Adverse Events
14462,NCT01907230,HBV reactivation,2013-09-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Hepatitis flare (ALT > 100 U/L) related to biological treatments
14463,NCT06204497,Incidence of severe complications within 90-day,2024-01-31,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life evaluation
14464,NCT02705300,Time to first serious adverse event,2016-05-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Resection rate
14465,NCT04895137,PCR rate,2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,3 years OS Rate
14466,NCT01949545,Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 27 mg/m²,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Adverse Events (AEs)
14467,NCT02012829,participation rate of patients for CRC screening,2011-12,COMPLETED,INTERVENTIONAL,['NA'],,GPs participation rate over 45%
14468,NCT00003993,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14469,NCT04239573,"Occurrence of an ""unfavorable"" outcome",2020-06-16,RECRUITING,INTERVENTIONAL,['NA'],Predictive accuracy of radiomic markers for dysplasia and pancreatic cancer,Biomarker analysis from collected samples to compare the predictive performance of known and future biomarkers for dysplasia or cancer
14470,NCT04032704,Prostate-specific antigen (PSA) response rate as determined by investigator according to Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria (Cohort 7 only),2019-10-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Incidence of antitherapeutic antibodies (ATAs) to LV
14471,NCT00001569,,1997-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14472,NCT04035876,Recurrence-free survival,2019-07-16,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse effect
14473,NCT03876106,"Safety and tolerability (maximum tolerated dose, MTD) of LUT014 topically applied qd for 4 weeks in metastatic colorectal cancer (mCRC) patients with epidermal growth factor receptor inhibitor (EGFRI) induced acneiform lesions.",2019-08-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Functional Assessment of Cancer Therapy-EGFRI 18 (FACT-EGFRI-18) on health-related quality of life (HRQoL) questionnaire
14474,NCT04933435,change in quality of life in patient cohorts receiving either Interventional Radiology Liver Directed Therapies or Hypofractionated Image-Guided Radiation Therapy,2020-11-12,RECRUITING,INTERVENTIONAL,['NA'],,total healthcare system cost associated with Hypofractionated Liver Directed Therapy
14475,NCT02642913,Progression-free survival,2015-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14476,NCT00425152,,1989-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14477,NCT02640898,overall survival rate,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,progression free survival rate
14478,NCT00222378,Prevalence of Cytomegalovirus and Epstein Barr Virus in inflamed colonic tissue from patient with mild to moderate IBD as compared to inflamed mucosa from patients with other inflammatory diseases of the colon,2005-04,COMPLETED,OBSERVATIONAL,['NA'],,
14479,NCT02163291,Pathological complete response rate,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"R0 rate, surgical morbidity and mortality"
14480,NCT04020276,Number of Participants with Acute Dose Limiting Toxicity (DLT),2019-11-04,SUSPENDED,INTERVENTIONAL,['PHASE1'],,Local Control Rates
14481,NCT04134559,Immune-related best overall response (irBOR),2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,DNA sequencing of specimens
14482,NCT00975247,"Bowel preparation quality, as measured by the Ottawa scale.",2008-04,COMPLETED,INTERVENTIONAL,['NA'],,Withdrawal Time
14483,NCT02682082,Difference in pain scores at 1 month and end of the trial,2016-05-27,TERMINATED,INTERVENTIONAL,['NA'],,Difference in survival
14484,NCT02830737,Recurrence Rate,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],Number of Participants with Adverse Events,Overall Survival Rate
14485,NCT02356406,Numerical Rating Scale (NRS) pain score difference from baseline,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Safety profile of the procedure - measuring the frequency and severity of treatment side effects, mainly GI toxicities"
14486,NCT02745600,Comparison of the spatial coordiantes of the real ablation zone one month after RFA treatment of liver tumors with the simulation results of the ClinicIMPPACT software.,2016-02,UNKNOWN,INTERVENTIONAL,['NA'],,"Does the follow - up (3, 6 ,12months) imaging support the assumptions regarding local tumor control"
14487,NCT01935700,Overall Survival,2013-06-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Grade III Severe Adverse Events
14488,NCT04379232,Symptoms of Covid after surgery,2020-03-19,COMPLETED,OBSERVATIONAL,['NA'],,
14489,NCT05052723,Progression-free survival,2022-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall participant survival rate
14490,NCT03641976,6-month PFS rate (%),2019-01-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,surrogate markers predictive of survival: ctDNA
14491,NCT02481219,Bowel Cleansing Level of Two Different Bowel Preparation Methods for PillCam® Colon Capsule Endoscopy (CCE),2015-05,COMPLETED,INTERVENTIONAL,['NA'],,Adverse Events Rate Between Two Different Bowel Preparation Methods for PillCam CCE
14492,NCT00546468,5 year disease free survival,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall survival
14493,NCT05580887,Intestinal bacterial structure in BC and PnC (separately) patients with disease progression,2022-05-12,RECRUITING,OBSERVATIONAL,['NA'],,Change from baseline in intestinal bacterial structure in PnC patients with disease relapse on or after combined treatment completion (follow up 12 months)
14494,NCT01448668,Overall survival time (OS).,2010-09,UNKNOWN,OBSERVATIONAL,['NA'],,"Number of patients with adverse events (AE) contributed to conventional oncological therapy (radio-, chemo-, targeted therapy)."
14495,NCT01465659,Overall Response Rate (ORR) in Patients With Advanced Neuroendocrine Tumors (PNET) Treated With Temozolomide and Pazopanib Combination Treatment at the RP2D in Phase II,2011-12-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Amount of a Particular Tumor Biomarker in Blood as Correlated With Progression Free Survival,Number of Months That Patients Maintain a Response to Treatment Until Disease Progression or Death (Duration of Response)
14496,NCT01238939,Number of patients with dose-limiting toxicity as determinant of the maximum tolerated dose/recommended dose,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Peak Plasma Concentration (Cmax) of NK012 and fluorouracil
14497,NCT05698082,Original survival,2020-12-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
14498,NCT01329458,evaluation of contrast enhanced ultrasound in the assessment of de novo focal liver lesions,2010-12,UNKNOWN,OBSERVATIONAL,['NA'],,
14499,NCT01896778,"Changes in tumor vascular (blood flow, blood volume)",2013-10-04,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
14500,NCT05596188,Independent risk factors of preoperative anxiety and establishment of prediction model,2022-11-10,RECRUITING,OBSERVATIONAL,['NA'],,Incidence of preoperative anxiety
14501,NCT04079946,Lymph nodes harvest,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,
14502,NCT05781074,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,2023-03-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
14503,NCT01219829,Number of subjects with histological features of PanIN lesions assessed,2009-03-18,COMPLETED,OBSERVATIONAL,['NA'],,Evaluation of Recurrence Mechanism in PDC
14504,NCT00142350,overall survival,2000-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,non-hospitalized survival
14505,NCT01814969,• The rate of patients with downstaging after radiotherapy or radiochemotherapy to pathological response or disease with negative margins,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,The rate of early toxicity of neoadjuvant treatment according to the NCI CTCAE (version 4.0)
14506,NCT03846882,Can FDG-PET / MR in combination with blood and tumor tissue biomarkers provide additional prognostic information for intermediate and high-risk rectal cancer?,2015-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,How does the accumulation of FDG change in rectal cancer tissue when examined after 60 minutes vs examination after 90 minutes?
14507,NCT03961646,Diagnostic accuracy,2019-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Image quality
14508,NCT05344664,Percentage of adverse events,2022-04-14,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
14509,NCT01075555,Overall survival,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to progression
14510,NCT05548114,Composite end point of inability to tolerate a solid diet (defined as gastric outlet obstruction scoring system score <2) or requiring endoscopic or surgical intervention or supplemental nutrition or procedure-related adverse events.,2022-09-15,RECRUITING,INTERVENTIONAL,['NA'],,Overall treatment costs from index procedure until 6 months post-index procedure.
14511,NCT05253430,Disease-free survival,1990-04,COMPLETED,OBSERVATIONAL,['NA'],,Postoperative mortality
14512,NCT00179348,Program satisfaction measured by Yoga - Daily Practice Calendar and Yoga Class Attendance Record and Yoga Evaluation Form,2001-02-08,COMPLETED,INTERVENTIONAL,['NA'],,spiritual well-being
14513,NCT01706822,The Ability to Achieve Adequate Distal Margins (Defined as >2cm [or >1cm With Clear Histologic Evaluation]) in the Low Rectum. The Reported Value Represents the Number of Participants in Whom the Criteria Was Met,2013-04,TERMINATED,INTERVENTIONAL,['PHASE4'],,Maneuverability Measured by Surgeon Usability Questionnaire. The Reported Values Represent Percentage of Cases Surgeon Agree/Strongly Agree
14514,NCT03426722,Proportion of patients who have occurrence of muscle cramps ( numeric rating scale score > 4),2018-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,recurrence rate
14515,NCT05072041,Incidence of liver function impairment,2021-10-31,RECRUITING,INTERVENTIONAL,['NA'],,Hepatic artery damage
14516,NCT00002796,"Efficacy of FU in combination with PB, indomethacin and rhIFNg in patients with advanced colorectal cancer (Phase II)",1997-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14517,NCT05044065,Skeletal muscle cross sectional area,2021-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Prognostic markers
14518,NCT00937079,"Detection of insulinomas, cure rate",2007-11,COMPLETED,OBSERVATIONAL,['NA'],,
14519,NCT00140894,Safety and tolerability,2002-08-06,TERMINATED,INTERVENTIONAL,['PHASE4'],,Proportions of patients with improved overall colon rating
14520,NCT01280058,Progression-free Survival Using RECIST v. 1.1,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Patients With Ras Pathway Activation,Overall Survival
14521,NCT04006275,CEUS LI-RADS Grades of SonoVue and Sonazoid agents in enrolled patients.,2019-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],,The sensitivity and specificity of CEUS-LI-RADS by different contrast agencies.
14522,NCT03161379,CD8 count (cells/mm^3) in the tumor microenvironment,2018-02-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pathologic complete response (pCR) rate at surgical resection
14523,NCT03403452,PFS（progress free survival）,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DCR（disease control rate)
14524,NCT00858000,Proportion of hepatocellular carcinoma cancer patients whose tumor tissue -expresses any one or more of specific target antigens -overexpresses c-MET -expresses a pre-defied gene-expression signature,2009-07,COMPLETED,OBSERVATIONAL,['NA'],,
14525,NCT04707118,Ascites control,2021-02-23,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
14526,NCT02282839,Oral mucositis,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
14527,NCT01288339,Progression-free survival time according to the MMP7 status (PFS),2010-11-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Molecular predictive markers for response.
14528,NCT02834780,Number of Participants With Clinically Significant Change From Baseline in Vital Sign Parameters,2016-12-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Part 2, Dose Expansion Phase: Time to Response (TTR) Based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST) v1.1"
14529,NCT02321813,proportion of patients in both groups with diseased quality of life (<50 points in at least one dimension),2014-01,COMPLETED,INTERVENTIONAL,['NA'],,rates of patients with diseased quality of life in each dimension of the profile
14530,NCT02287727,Disease free survival (DFS),2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival
14531,NCT06137248,Change in the hydrogen sulfide-metabolizing species of bacteria,2024-02-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Microbiome changes and tolerance
14532,NCT03636620,overall survival,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,objective response rate
14533,NCT02599116,"Determine whether the intestinal microbiome of patients with appendiceal tumors with peritoneal carcinomatosis differs from that of a healthy, age-matched cohort",2015-12,RECRUITING,INTERVENTIONAL,['NA'],Identify alterations in the gut microbiome post-CRS/HIPEC,Compare the gut microbiome of appendiceal tumors by histopathology
14534,NCT02682992,Percentage of Participants With Severe (CTCAE v. 4.0 Grade 3-5) Oral Mucositis,2016-06,COMPLETED,INTERVENTIONAL,['NA'],,Breaks in Chemoradiotherapy
14535,NCT03264274,Overall survival,2017-02-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Progression-free survival
14536,NCT02257541,Phase Ib Portion: Response Rate (RR),2014-10-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase Ib Study: Response Rate (RR)
14537,NCT03700411,Change in number of circulating tumor cells prior to surgery to 2 - 4 weeks after surgery,2019-01-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,Pain assessment
14538,NCT04491565,Adequacy of bowel prep,2019-11-13,COMPLETED,INTERVENTIONAL,['NA'],,
14539,NCT01170299,"Change in IBDQ-B (Inflammatory Bowel Disease Questionnaire - Bowel Subset) score between baseline (i.e., Day 1 of radiotherapy treatment) and the nadir score during treatment",2009-10,COMPLETED,INTERVENTIONAL,['NA'],,Costs for symptom management
14540,NCT04225026,Number of Subjects With of Acute Radiation Esophagitis (Defined as Grade >/= 2; NCI CTCAE Version 5) Through the End of Chemoradiotherapy for Non-Small Cell Lung (NSCLC) or Small Cell Lung Cancer (SCLC) When Avasopasem Was Added.,2019-12-19,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Subjects With Acute Severe Radiation Esophagitis (Defined as Grade 3-4; NCI CTCAE Version 5) Through Completion of Chemoradiotherapy.
14541,NCT01575717,Change in serum levels of 25-hydroxyvitamin D,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],,Change in Model for End stage Liver Disease score (MELD)
14542,NCT04122937,P2X7R-inflammasome activity,2017-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
14543,NCT01227707,Percentage of Participants With Pathological Complete Response (pCR),2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,TTP - Time to Event
14544,NCT01232374,3-yr overall survival,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
14545,NCT04788368,Complications after surgery,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
14546,NCT02055560,Overall survival,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,
14547,NCT03663712,Non-dose limiting toxicities for talimogene laherparepvec,2019-05-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14548,NCT00258323,Distant metastatic control at 1 year,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity of maintenance gefitinib as measured by CTC version 2.0 every 8 weeks after the completion of radiotherapy
14549,NCT00687570,Bowel purity degree,2008-07,COMPLETED,INTERVENTIONAL,['NA'],,physiological function
14550,NCT01402908,Disease-Free Survival (DFS),2011-08,TERMINATED,INTERVENTIONAL,['PHASE3'],,Tumor Recurrence Rate (TR Rate)
14551,NCT03737539,ctDNA methylation markers versus CT/MRI,2018-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
14552,NCT00374036,Time until therapeutic failure : to make pass TET from 15 weeks with ECC in first line to 20 weeks with FOLFIRI in first line,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,"The tolerance, the quality of life, duration of hospitalization"
14553,NCT03947762,Progression-free survival (PFS) rate at 24 months,2019-07-03,TERMINATED,OBSERVATIONAL,['NA'],,Patient satisfaction
14554,NCT04393116,Development of patients' Distress,2017-07-11,COMPLETED,OBSERVATIONAL,['NA'],,Patient's global health status
14555,NCT03220984,the disease control rate (DCR),2017-03-16,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14556,NCT03951792,Microbial 16S rDNA Biomarkers,2021-06-30,RECRUITING,OBSERVATIONAL,['NA'],,Protein Measurements
14557,NCT04920149,Change in the occurrence of any colorectal neoplasia in LS patients,2022-03-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Significant findings & illnesses - adverse events
14558,NCT02909478,Complete response,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Complete response in the delay phase (25 hours-120 hours)
14559,NCT02971696,Event free survival,2016-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Sorafenib induced side effects
14560,NCT05273489,Survival,2004-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Neoadjuvant Chemotherapy
14561,NCT02107105,Health state utilities,2014-05-16,RECRUITING,OBSERVATIONAL,['NA'],,
14562,NCT04759235,change of metabolites,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
14563,NCT01320267,Successful completion of the right hemicolectomy,2011-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Postoperative Measure of Pain
14564,NCT00284817,The recommended Phase II dose will be based on acceptable dose-limiting toxicity,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetic parameters may also be factored into the determination of a Phase II dose and; Tumor response
14565,NCT03659448,Surgical resection histopathology.,2019-06-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,
14566,NCT00582660,Subjects With Positive Response 72 Hours After Administration of Study Treatment as Measured by Immunoblot,2001-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14567,NCT04471272,Ideal technical success rate,2020-01-06,UNKNOWN,INTERVENTIONAL,['NA'],,Technical time
14568,NCT02786342,PFS,2016-02-15,UNKNOWN,OBSERVATIONAL,['NA'],,OS
14569,NCT04637061,Rate of 30 day-anastomotic failure (AF),2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Procalcitonin (PCT) measurement
14570,NCT00004870,,2000-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14571,NCT01591135,3-yr overall survival,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number and grade of Participants with Adverse Events
14572,NCT01787539,cancer free and overall survival,2013-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",quality of life,the rate of chemotherapy cessation
14573,NCT06214572,Median overall survival,2024-01-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of life assessment (Liver specific)
14574,NCT01474694,"TRE, measuring the error in the prediction of a surgical target location when using the navigation system.",2011-10,COMPLETED,OBSERVATIONAL,['NA'],,1.Identification of suitable landmarks for registration
14575,NCT02478476,"Occurrence of chemotherapy related toxicities including Anemia, Nephrotoxicity, Neutropenia, Neuropathy, and Thrombocytopenia associated with genotype.",2015-07,UNKNOWN,OBSERVATIONAL,['NA'],,
14576,NCT05557955,overall survival.,2022-09-27,COMPLETED,OBSERVATIONAL,['NA'],,recurrence.
14577,NCT03049124,Number of Participants with Adverse Events,2017-11-01,WITHDRAWN,INTERVENTIONAL,['NA'],Socio-Demographic and Medical Information Questionnaire,
14578,NCT05638243,Sensitivity and specificity of the model in the diagnosis of colorectal cancer and adenoma,2022-08-20,RECRUITING,OBSERVATIONAL,['NA'],,
14579,NCT04733794,Sexual function,2016-02-19,COMPLETED,INTERVENTIONAL,['NA'],,
14580,NCT01123473,Progression-free survival,2010-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Concordance of diagnostic tests
14581,NCT02906059,"Number of participants dose limiting toxicities with treatment-related adverse events as assessed by common terminology criteria for adverse events (CTCAE), version 4.",2016-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Tumor assessment by imaging techniques using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1"
14582,NCT05323201,Objective response of fhB7H3.CAR-T cells,2022-02-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),In vivo persistence of fhB7H3.CAR-T cells
14583,NCT00005997,Determine the response rate in patients with advanced hepatobiliary carcinoma treated with rebeccamycin analogue.,1999-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Assess the toxicity associated with this drug in this patient population.
14584,NCT05932719,Measure of patient loss of chance when comparing a set of activity indicators between 2020 and the average activities of previous periods (2017-2019),2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],,
14585,NCT04605185,Dose limiting toxicity(DLT),2021-01-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of response (DOR)
14586,NCT01110785,Percentage of patients free from progression and alive at 11 weeks after the first dose of panitumumab measured by RECIST v 1.1,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Correlation between proteomics and objective response rate
14587,NCT05837767,Overall Response Rate (ORR),2023-07-24,RECRUITING,INTERVENTIONAL,['NA'],,
14588,NCT04843176,Diagnostic accuracy for HCC,2021-03-19,RECRUITING,INTERVENTIONAL,['NA'],,Occurrence of technical failures
14589,NCT01727570,Six-Minute Walk Test (6MWT),2012-09,COMPLETED,INTERVENTIONAL,['NA'],,
14590,NCT06059001,"Number of AEs, SAEs to evaluate the safety and tolerability of OMO-103 plus gemcitabine/nab-paclitaxel",2023-08-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,To evaluate quality of life (QoL) in patients with metastatic pancreatic cancer
14591,NCT06004687,Postoperative delirium,2023-07-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Neurotransmitters in the blood,Recovery time
14592,NCT05411094,Dose-limiting toxicities (DLTs) for olaparib in combination with durvalumab and radiation,2023-05-22,SUSPENDED,INTERVENTIONAL,['PHASE1'],Correlation of efficacy endpoints with clinicopathologic variables,Number and diversity of T cells
14593,NCT01447238,"Assess the yield of combination modalities in the diagnosis of pancreatic cysts using EUS/FNA, Fiber optics (direct visualization probe), and prototype needle based confocal laser-induced endomicroscopy miniprobe (nCLE)",2010-09-15,COMPLETED,OBSERVATIONAL,['NA'],,
14594,NCT03623737,pathological complete response,2017-03-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Number of participants with treatment-related adverse events as assessed by the NCI Common Toxicity Criteria (CTC)
14595,NCT02508077,4-month Progression-free Survival (PFS) Rate,2016-02-16,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14596,NCT01847599,evaluation of the efficacy of the implementation of an educational program on adherence to capecitabine alone or in combination to lapatinib,2011-09-06,TERMINATED,INTERVENTIONAL,['NA'],,safety and tolerability as determined by adverse events frequency
14597,NCT04264754,To develop a molecular blood test that will be able to detect HCC based on change in methylation patterns between HCC and normal hepatic tissue,2018-02-13,TERMINATED,OBSERVATIONAL,['NA'],,Liver EpiCheck Performance
14598,NCT05278039,Change in Penetration-Aspiration Scale scores,2021-08-12,RECRUITING,INTERVENTIONAL,['NA'],Change in M.D. Anderson Dysphagia Inventory (MDADI) scores,Change in Modified Barium Swallow Impairment Profile (MBSImP) scores
14599,NCT05602974,marginal recurrence rate,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Quality of life by EORTC QLQ-C30
14600,NCT02101580,Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer,2014-11-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14601,NCT03385148,diagnosis effecacy,2017-01-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
14602,NCT00209664,objective tumor response,2004-01,SUSPENDED,INTERVENTIONAL,['PHASE2'],,"Response duration, time to progression, median survival time, and safety will also be assessed."
14603,NCT00336141,Toxicity,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response
14604,NCT05023863,Incidence and severity of radiation induced oral mucositis,2021-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time to develop grade III or IV radiation induced oral mucositis:
14605,NCT02757846,quantitative image features extracted from CT images can be used as imaging marker for prognosis,2017-04,UNKNOWN,OBSERVATIONAL,['NA'],,
14606,NCT04692051,PFS,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,AEs
14607,NCT01900691,Number of Patients With Successful Removal of Study Stent,2013-09,COMPLETED,INTERVENTIONAL,['NA'],,Number of Patients With Benign Indications That Achieved Clinical Success
14608,NCT06147414,% of inconclusive results,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Estimated delay for result in standard care diagnosis condition
14609,NCT03416777,DNA damage,2019-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Oxidative stress
14610,NCT02972372,2-year disease-free survival rate,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,2 year overall survival
14611,NCT04015466,"Development of a new diagnostic algorithm for gastric cancer that includes molecular landscape, patient history, histopathological and environmental factors, personal microbiome and immune landscape",2019-06-12,UNKNOWN,OBSERVATIONAL,['NA'],,Daily routines as assessed by a new study-specific questionnaire
14612,NCT03451370,Progression Free Survival (PFS),2017-11-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14613,NCT01507168,Progression-free survival (tumor assessments according to RECIST criteria),2012-02-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,GPC-3 expression in tumor tissue (biopsy) by immunohistochemistry (IHC) assay
14614,NCT04217096,Progression free survival,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Adverse events
14615,NCT01399190,Progression-free Survival,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants With Adverse Events
14616,NCT02077296,Plasma and tissue cytokine levels,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,
14617,NCT00058149,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14618,NCT01533324,DCR,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety
14619,NCT01604564,Evaluation of postoperatieve recovery,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,
14620,NCT00965718,Progressive Disease(PD),2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL) Assessed Using Quality of Life Questionnaire Core 30(QLQ-C30) in Patients With Pancreatic Cancer(QLQ-PAN26 Questionnaire)
14621,NCT00707889,Progression-free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective response rate
14622,NCT00511862,Hepatic Progression-free Survival According to Response Evaluation Criterian in Solid Tumors (RECIST),2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
14623,NCT03852836,Global quality of the images evaluated with a Likert score,2019-02-26,TERMINATED,INTERVENTIONAL,['NA'],,"Performance of each sequence in the visualization of the pathology and / or an anatomical variant in the 1.5T magnetic field group, evaluated in percentage"
14624,NCT03337347,CEA mRNA positive circulating tumor cells in colorectal cancer patients,2004-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Cancer specific survival in CTC positive CRC patients
14625,NCT04754672,Progression free survival,2021-03-02,RECRUITING,INTERVENTIONAL,['NA'],,Physical activity
14626,NCT03053284,Hypoglycemia,2017-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Serum glucose regulators
14627,NCT00016133,,2001-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14628,NCT00233415,Efficacy of Conventional Chemoradiotherapy Followed by Stereotactic Radiosurgery,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14629,NCT03066167,Translation of scores to the Swedish language,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,
14630,NCT03418298,Recruitment rate,2018-02-27,COMPLETED,INTERVENTIONAL,['NA'],,Change in anxiety and depression
14631,NCT04327700,Progression-Free Survival,2021-01-26,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Change in Alpha-fetoprotein Levels
14632,NCT01239381,Local Control Rate,2010-06,COMPLETED,INTERVENTIONAL,['NA'],,Median Survival Among Participants With Colorectal Cancer
14633,NCT02859324,Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1),2016-09-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Apparent Volume of Distribution (Vz/F)
14634,NCT03814824,Time for Image Interpretation (Median - Scaled),2019-01-23,COMPLETED,INTERVENTIONAL,['NA'],,Subjects With Dysplasia on Biopsies
14635,NCT05994482,colorectal cancer incidence,2023-10-01,RECRUITING,OBSERVATIONAL,['NA'],,perspectives on surveillance in older adults
14636,NCT04131803,objective response rate,2021-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
14637,NCT02016326,Adenoma Detection Rate (ADR) in the right colon using High Definition White Light Colonoscopy Versus I-Scan enhanced Colonoscopy.,2012-11,UNKNOWN,INTERVENTIONAL,['NA'],Presence or absence of learning effect while using this technology,Adenoma Detection Rate (ADR) of High Definition White Light Colonoscopy Versus I-Scan colonoscopy through out the entire colon.
14638,NCT03265483,"Blood 1,25-dihydroxyvitamin D2",2014-09,COMPLETED,INTERVENTIONAL,['NA'],,
14639,NCT01152164,To prospectively evaluate the quality of life of patients one year after rectal cancer resection,2008-01,UNKNOWN,OBSERVATIONAL,['NA'],,To prospectively evaluate the quality of life of patients two years after rectal cancer resection
14640,NCT00220155,Proportion of patients obtaining disease control in the form of tumour response or stabilisation,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression free survival
14641,NCT02220088,Progression free survival,2014-12,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,overall survival
14642,NCT05808790,Local recurrence-free survival,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Multiparameter flow cytometric analyses (FACS)
14643,NCT00409864,Quality of life,2003-10,COMPLETED,INTERVENTIONAL,['NA'],,Stent patency time will be defined by time to stent occlusion
14644,NCT05501353,the correlation between ctDNA mutations with methylation status and recurrence,2022-07-22,RECRUITING,OBSERVATIONAL,['NA'],,Compare the difference of DNA with ctDNA in predicting postoperative recurrence through statistical method
14645,NCT03149523,Sequencing of the exome and tumor RNA,2017-05,UNKNOWN,OBSERVATIONAL,['NA'],,Transcriptomic profile of urinary RNAs
14646,NCT05684211,Progression-free survival (PFS),2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,incidence of adverse events
14647,NCT00960349,"Safety of each treatment arm will be measured in terms of adverse events, vital signs, clinical chemistry, haematology, urinalysis, electrocardiogram, and physical examinations.",2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Pharmacokinetics will be assessed in terms of Css,max, Css,min, tmax, AUCss and AUC0-8 for cediranib, and Cmax, tmax, AUC, AUC(0-t), CL or CL/F, t½λz for capecitabine, cisplatin and TS-1. Additional PK parameters may be determined."
14648,NCT04799080,Semmens Weinstein Monofilament Test (SWMT),2021-03-06,COMPLETED,OBSERVATIONAL,['NA'],,Functional Assessment of Cancer Therapy-Breast (FACT-B+)
14649,NCT01985698,postoperative complications,2013-12,COMPLETED,INTERVENTIONAL,['NA'],self reported sexual function for female patients,locoregional recurrence rate
14650,NCT00755118,Objective Response Rate,2008-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
14651,NCT05760404,Evaluate the motor effects of drugs that act on the various components of this system,2022-12-19,RECRUITING,OBSERVATIONAL,['NA'],,
14652,NCT06317103,Clinical Specificity in classifying early gastric cancer (EGC) based on the depth of invasion (%),2023-08-22,COMPLETED,OBSERVATIONAL,['NA'],,"Accuracy in classifying the depth of invasion categories (""Mucosa"" or ""Submucosa"") for early gastric cancer (%)"
14653,NCT00180960,To study overall survival,2003-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,To study mortality-morbidity
14654,NCT05928312,Objective response rate (ORR),2023-08-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Assess the anti-tumor activity:DCR
14655,NCT04294498,The rate of HBV reactivation during durvalumab treatment,2020-11-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,To assess the adverse events during durvalumab treatment.
14656,NCT01848015,CTCs,2013-06,UNKNOWN,OBSERVATIONAL,['NA'],,Recurrence of gastric cancer after radical resection
14657,NCT02848079,Overall Response Rate,2016-10-31,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
14658,NCT02908048,Diagnosis of liver cancer based on tumor markers and imaging studies.,2014-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14659,NCT01923337,"MTD, defined as the highest dose tested in which fewer than 33% of patients experience dose-limiting toxicity (DLT) attributable to the study drugs, graded using the National Cancer Institute (NCI) CTCAE version 4.0",2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to failure
14660,NCT05160727,Objective response rate,2021-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
14661,NCT03878550,AUROC,2019-05-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Sensitivity
14662,NCT00002527,Disease free survival,1993-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14663,NCT05062720,Progression free survival,2021-07-29,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Patient reported outcomes (PROs)
14664,NCT00006340,,1994-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14665,NCT02738294,Specificity in distinguishing HGN from non-HGN,2013-06,COMPLETED,INTERVENTIONAL,['NA'],,Negative predictive value (NPV) in distinguishing HGN from non-HGN
14666,NCT06122896,"Number of Imaging-Negative, Assay-Positive Pancreatic Cancers or High-Grade Neoplasms",2023-11-21,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Clinical Predictors of Neoplastic Development
14667,NCT05468827,proportion of pN+ patients in which affected lymph nodes are detected only within margins of ICG distribution,2022-07-26,RECRUITING,INTERVENTIONAL,['NA'],,feasibility of ICG mapping for colon flexure tumours
14668,NCT02713373,"Number of Participants With a Response, Evaluated According to RECIST 1.1",2016-08-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression Free Survival (PFS)
14669,NCT01494324,Tumor response,2009-10-27,RECRUITING,INTERVENTIONAL,['NA'],,Duration of treatment response
14670,NCT02991677,Sensory pain,2018-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Nerve fiber density
14671,NCT04814030,overall response rate,2021-04-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14672,NCT04785287,Incidence of adverse events,2021-03-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor response
14673,NCT02670122,Safety and Tolerability,2015-03,COMPLETED,OBSERVATIONAL,['NA'],,OS
14674,NCT00637247,To Evaluate and Compare the Tolerability and Toxicity of the Two Treatment Arms by Comparing Adverse Events,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
14675,NCT03377972,Comparison WHO diagnosis standard with JAPAN in Early Esophageal Cancer patients by accessing pathological section.,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14676,NCT03833466,Tumor microenvironment,2019-02-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Rate of pathologic complete response（pCR）
14677,NCT01937286,Recurrence of Hepatocellular carcinoma after LDLT,2002-01,COMPLETED,OBSERVATIONAL,['NA'],,
14678,NCT02794337,In-field Progression Free Survival,2014-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Toxicity Assessment
14679,NCT02439008,"Analyse of immunological parameters, decription of secreted markers and nanovesicles production",2015-09-16,TERMINATED,INTERVENTIONAL,['NA'],,Number of Participants with Adverse Events related to radiotherapy
14680,NCT05357508,Self-reported appropriate screening uptake,2022-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Linkage to Vaud tumor registry
14681,NCT03950154,Progression-free survival,2019-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,
14682,NCT00630552,Safety,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Response
14683,NCT03190265,Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1),2017-12-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Experiencing Grade 3 or Above Study Drug-related Adverse Events (AEs)
14684,NCT00540332,"Pharmacokinetic profile to include Systemic clearance, volume of distribution at steady state, estimated initial concentration, area under the conc-time curve, terminal half-life and mean residual time",2007-10,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence (%) and duration (days) of severe Oral Mucositis WHO grade 3 or 4
14685,NCT01656265,"Number of participants with dose-limiting toxicity (DLT), as a measure of safety and tolerability",2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor effects according to RECIST 1.1.
14686,NCT06158516,2-year disease-free survival (2y-DFS),2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,2-year Overall survival
14687,NCT06113718,Length of hospital,2023-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative gastrointestinal symptoms
14688,NCT03498326,disease free survival,2018-04-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Common Toxicity Criteria for Adverse Effects
14689,NCT00079274,Disease-free Survival (Arms A and D: Wild-type KRAS Patients),2004-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Mutant KRAS Patients)"
14690,NCT02060188,Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator,2014-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,ORR by RECIST v1.1 by Independent Radiology Review Committee (IRRC)
14691,NCT03701373,maintenance progression-free survival (PFS),2016-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,toxicity relevant to S-1 maintenance/observation
14692,NCT00004065,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14693,NCT02820389,3-month cost analysis per patient undergoing either Optical Colonoscopy or CTC as the initial imaging modality (measured in £ per patient),2016-06-14,UNKNOWN,OBSERVATIONAL,['NA'],,Cost per correctly diagnosed medium to large polyps (≥6mm) and colorectal cancer using CTC as the initial investigation (measured in £ per patient)
14694,NCT06256289,liver steatosis index CAP (Controlled Attenuation Parameter) measured by FibroScan,2024-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,Gut Microbiota diversity sequencing by 16s rRNA Amplicon Sequencing Analysis
14695,NCT00811590,The Size of Intestinal Polyps,2008-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14696,NCT00600496,Safety and tolerability of twice daily oral doses of AZD6244 when administered in combination with standard doses of selected chemotherapies.,2007-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Tumor response.
14697,NCT00026468,,1999-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
14698,NCT02870153,Response Rate,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
14699,NCT01661686,Number of Participants With Recurrent Dysphagia.,2012-07,COMPLETED,INTERVENTIONAL,['NA'],,Median Survival After SEMS Placement
14700,NCT00174564,To evaluate response rate according to RECIST criteria,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,To investigate safety using NCI-CTC criteria version 2
14701,NCT03338166,serum LDH level as a predictor of response in hepatocellular carcinoma,2018-01-02,UNKNOWN,OBSERVATIONAL,['NA'],,
14702,NCT01216202,Sexual Function,2010-04,COMPLETED,OBSERVATIONAL,['NA'],,
14703,NCT01380392,,2011-02,UNKNOWN,OBSERVATIONAL,['NA'],,
14704,NCT00068432,Overall Survival at 6 months,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall response rate
14705,NCT00796718,Percentage of Participants With Pathological Complete Response,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Adverse Events
14706,NCT00632268,To evaluate the confirmed objective response rates (complete and partial responses),2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To assess the overall survival(OS), progression-free survival(PFS), treatment-related toxicities, and pharmacokinetic profile of RAD001 used in combination with 5-FU and cisplatin"
14707,NCT01974869,changes in inflammatory cytokines,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,30 postoperative day complications.
14708,NCT00408551,Hepatic toxicity,2005-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Therapeutic efficacy based on the proportion of patients who achieve down-staging among all chemo-SIRT treated patients
14709,NCT00025350,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14710,NCT00027729,,2001-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14711,NCT01045538,"Phase 1 - maximum tolerated dose, Phase 2 - response rate",2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
14712,NCT00192075,Tumor Response by Response Evaluation Criteria In Solid Tumors (RECIST),2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Response - A+FOLFOX4 - Avastin Subgroup,Duration of Response
14713,NCT04426955,PFS assessed by IRC,2020-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],,AE
14714,NCT00034281,Optimal Dosing for Phase II Studies.,2002-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response Evaluation Criteria in Solid Tumors Documentation of Objective Tumor Response.
14715,NCT03182894,Phase ll: Objective Response Rate (ORR),2018-09-30,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
14716,NCT03307811,Diagnostic adequacy of the liver biopsy specimen,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],,Complications/Infection
14717,NCT06319924,Assess the quality of the bowel preparation assessed by Boston Bowel Preparation Scale (BBPS),2020-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Caecal intubation rate
14718,NCT00687349,"Patient and family ratings on the ""End-of-Life domain"" of the Quality of Communication Questionaire (QOC)",2007-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Patient-, family-, and nurse-assessed ratings of the quality of end-of-life care provided by study clinicians using Quality of End-of-Life Care questionaire"
14719,NCT05417932,Tumor response of SCG101 (Phase 2),2022-10-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Persistence of viral vector copy number (VCN) after SCG101 infusion
14720,NCT02487017,Overall survival,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Phenotypic analysis of T cells
14721,NCT05652920,Maximum tolerated dose of Ori-C101,2022-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Objective Response Rate
14722,NCT01944540,En Bloc resection rate,2013-08,UNKNOWN,INTERVENTIONAL,['NA'],,complication rate
14723,NCT03843398,"3-year overall survival, 3y OS",2019-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative mortality at 30 days
14724,NCT01073358,rate of disease recurrence,2010-03-09,UNKNOWN,INTERVENTIONAL,['NA'],,
14725,NCT00559598,Gather information about clinical factors surrounding the date of blood extraction that may influence the proteomic patterns of the blood samples by reviewing clinical records of participants,2004-08,COMPLETED,OBSERVATIONAL,['NA'],,
14726,NCT02514031,Maximum Tolerated Dose,2016-03-24,TERMINATED,INTERVENTIONAL,['PHASE1'],,Tolerability
14727,NCT01219192,MDT,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,PFS
14728,NCT05660915,Rate of mortality after surgery,2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Incidence of postoperative complications
14729,NCT01549522,,2012-03,UNKNOWN,OBSERVATIONAL,['NA'],,
14730,NCT03519295,Progression free survival rate (PFS),2018-07-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Tolerance graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] criteria v4.03
14731,NCT04870034,Incidence of adverse events,2024-01-15,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Immune subsets within the pre and posttreatment tumor tissue
14732,NCT02853422,"Survey on the clinical utility of the QLQ-GINET21, which the investigator is to complete for each patient enrolled",2016-04,COMPLETED,OBSERVATIONAL,['NA'],,Clinical assessment of patient's health status by the investigator
14733,NCT05214495,Oral Mucositis Severity,2022-02-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
14734,NCT00075556,Objective tumor response rate,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Comparison of the conversion rate from the effects of mutilating surgery vs surgery with sphincter preservation
14735,NCT04627012,Overall survival (OS),2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Adverse events
14736,NCT02186236,To validate the Trovagene urine assay,2014-07,COMPLETED,OBSERVATIONAL,['NA'],,EGFR detection in plasma circulating tumor cells [CTC] and plasma cfDNA)
14737,NCT05130060,Incidence of adverse events (AE),2022-01-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression free survival (PFS)
14738,NCT02727062,The number of subjects who comply with the compulsory four-time daily pain entries.,2018-02-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14739,NCT02477553,Colorectal Cancer (CRC) Screening Intention: Change From Baseline to Post-intervention,2015-06,COMPLETED,INTERVENTIONAL,['NA'],,Number of Patients With High and Low Subjective Numeracy
14740,NCT03133273,Occurrence of the progression or death of the patient.,2017-07-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Grade 3 and higher adverse events related to chemotherapy
14741,NCT06314516,Longitudinal variation in body composition,2017-12-27,COMPLETED,OBSERVATIONAL,['NA'],,Patient and disease-specific factors
14742,NCT03002727,Differential expression of CD133 based on microsatellite status and correlation with clinicopathological features.,2016-12,UNKNOWN,OBSERVATIONAL,['NA'],,"If radiotherapy increases the count of CD +ve 133 cells , does that increase significantly affects the progression free survival"
14743,NCT04349384,Morbidity,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Readmission
14744,NCT01088789,Disease free overall survival.,2010-04-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
14745,NCT04483349,"Importance patients place on each of the attributes of value (i.e., outcomes, quality of life [QOL], cost, experience)",2020-06-11,COMPLETED,OBSERVATIONAL,['NA'],,"Importance care providers (i.e., physicians, nurses, administrators) place on each of the attributes of value (i.e., outcomes, quality of life [QOL], cost, experience)"
14746,NCT02833753,Define the maximum tolerated dose (MTD) of intraperitoneal (IP) oxaliplatin given with systemic FOLFIRI in patients with peritoneal carcinomatosis (PC) of colorectal or appendiceal origin,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14747,NCT05083338,Chronic postsurgical pain,2021-08-10,COMPLETED,OBSERVATIONAL,['NA'],,
14748,NCT05368636,Accuracy,2022-06-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
14749,NCT03449966,The percentage of remnant cancer cells in biopsy samples,2018-02-20,UNKNOWN,INTERVENTIONAL,['NA'],,pCLE findings of residual cancer cells after chemotherapy
14750,NCT03365882,Progression-free Survival(PFS),2017-11-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs.
14751,NCT04067778,Adverse Events occurrence,2020-11-06,COMPLETED,INTERVENTIONAL,['NA'],,Rate of Missed 2-Week Post-Procedural Assessment for Complications
14752,NCT00134095,Safety,2004-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14753,NCT05013944,Measuring and/or Improving Quality of Care,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
14754,NCT02451124,Average Methylation of Zinc Finger Protein 793 Assay,2015-07,COMPLETED,INTERVENTIONAL,['NA'],,
14755,NCT04359199,"Swallowing function 12-24 months after concurrent radiation and systemic therapy for HNC, as measured by the PCR",2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Correlation between radiation dose and location of swallowing function and quantitative swallowing function
14756,NCT04588246,Time to Neurologic Death,2020-12-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of Adverse Events associated with the interventions
14757,NCT05462613,overall survival (OS) (phase III),2023-05-09,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
14758,NCT02729506,Time to Progression (TTP) is the primary outcome.,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,"Treatment-related costs, in terms of cost of therapy and number of hospitalization days."
14759,NCT03588442,Liver-related disease progression,2018-07-15,UNKNOWN,OBSERVATIONAL,['NA'],,Non-hepatocellular carcinoma malignant neoplasm
14760,NCT03007446,reaction rate,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
14761,NCT00885248,Staging of pancreatic cancer,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],,Diagnosis of pancreatic cancer
14762,NCT00099346,,2005-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,
14763,NCT06167967,Recurrence-free survival at 3 years,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The proportion of patients in the low-risk cohort who did not receive adjuvant chemotherapy
14764,NCT04211168,Rate of adverse events (AE),2020-08-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Biomarkers,6-months and 1-year mortality rate
14765,NCT04839471,ORR (RECIST 1.1),2021-08-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To explore the treatment-related adverse events as assessed by CTCAE v5.0
14766,NCT03825289,Rate of dose-limiting toxicities during the DLT assessment window.,2019-01-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,Response Rate
14767,NCT00756782,radiologically proven progression-free survival (PFS),2008-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,The relationship between tumor gene expression (mRNA expression) of co-activators and co-repressors and efficacy parameters
14768,NCT04803851,Disease control rate (DCR) based on RECIST v. 1 1,2021-05-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
14769,NCT05571293,Number of complications leading to delays of 12 weeks or more in surgery after initiation of treatment,2023-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Changes in Minimal Residual Disease assessed using ctDNA pre- and post-surgical resection
14770,NCT01969110,"plasma resolvin E1, cell-mediated immunity",2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,infectious complication rate
14771,NCT05433701,"Local progression-free survival rate, per-protocol (PP)",2022-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"Local progression-free survival rate according to the tumor location, ITT"
14772,NCT05970133,The surgical efficiency of both NOSE procedures,2023-04-07,RECRUITING,INTERVENTIONAL,['NA'],,CD4+ to CD8+ ratio
14773,NCT03899870,Recurrence,2000-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14774,NCT04066816,Urolithin Phenotype and Colonic Health,2019-05-20,COMPLETED,INTERVENTIONAL,['NA'],,Identify Changes in Microbiota and Microbes Responsible for Urolithin Formation Followed by Walnuts Consumption using Metagenomics Sequencing
14775,NCT03245554,Tumor size will be measured.,2018-05-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
14776,NCT05931068,Change in energy expenditure using indirect calorimetry,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Hospital anxiety and depression scale
14777,NCT00537901,Effectiveness,2007-10,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life
14778,NCT02821754,6 Month Progression Free Survival (PFS),2016-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),Number of Grades 1-5 Adverse Events Related to Tremelimumab and Durvalumab
14779,NCT02346032,Response rate,2015-06-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
14780,NCT03084380,Safety: Measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0,2017-06-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Persistence: Duration of CAR-positive T cells in circulation
14781,NCT03179657,Nonalcoholic fatty liver disease (NAFLD),2008-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Cognitive function
14782,NCT06217224,Evaluate the best photobiomodulation protocol for preventing oral mucositis,2022-10-17,RECRUITING,INTERVENTIONAL,['NA'],,Hospital internment
14783,NCT02894944,Number of participants with treatment-related adverse events assessed by CTCAE v4.03,2016-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Detection of adenoviral DNA in blood by PCR
14784,NCT02591407,Post-operative pain control day 3 using the numeric pain scale,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],Patient use of supplemental narcotic analgesia post-operative day 3,Overall benefits of analgesia treatment post-operative day 3
14785,NCT04680260,Recurrence Free Rate,2021-10-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Cost-effectiveness analysis
14786,NCT01270984,To evaluate the pharmacokinetics of Luckyvec 400mg tablet and Glivec 100mg tablet in healthy subjects,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To evaluate the safety of Luckyvec 400mg tablet and Glivec 100mg tablet from vital signs, physical exam, ECG, laboratory test, adverse event and so on."
14787,NCT04392167,Percentage of Correctly Identified Negative (Non-Dysplastic) Biopsies,2020-11-24,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Participants With Adequate Tissue Contact to Acquire a High Quality Image
14788,NCT03765411,In-hospital Complications,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Costs and Charges
14789,NCT05657080,Sensitivity of Cytosponge for GIM,2023-01-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Number of participants with device-related adverse events as assessed by CTCAE v4.0
14790,NCT00892736,"MTD, DLT, recommended phase II dose of chronically dosed single-agent veliparib in patients with either a refractory BRCA 1/2- mutated solid cancer; platinum- refractory ovarian, fallopian tube, or primary peritoneal cancer; or basal-like breast cancer",2009-04-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Changes in BRCA 1/2 expression in tumor blocks
14791,NCT01273402,Determine the number of adverse events,2011-02,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Efficacy will be evaluating using CT scans and possibly PET imaging.
14792,NCT00465725,Comparison of platinum levels excreted in urine from 0-8 and 8-24 hours after start of IV or oral drug,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14793,NCT02510066,"Pain scores, assessed with numeric rating scale (NRS)",2015-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Blood levels of nerve growth factor
14794,NCT03787251,PFS,2019-01-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,ORR
14795,NCT04006951,Proportion of patients who gave their consent to participate in the study,2014-10-08,RECRUITING,INTERVENTIONAL,['NA'],,
14796,NCT05551832,Marginal ulcer incidence,2022-10-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,QOL
14797,NCT04526470,Progression-free survival rate at 4 months,2020-09-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Exploratory biomarker analysis for efficacy and resistance of alpelisib plus paclitaxel combination (using collected clinical samples) including mutations and RNA/protein expression levels of PI3K pathway genes,Time to response
14798,NCT01198821,Establish the safety and tolerability of oral sodium bicarbonate in patients with advanced pancreatic carcinoma treated with gemcitabine,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Determine if oral bicarbonate improves overall survival, progression free-survival and response rate in patients with advanced pancreatic cancer"
14799,NCT04648917,overall survival (OS),2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,progression-free survival (PFS)
14800,NCT03222089,Progression-free survival (PFS) rate at 10 months,2017-07-20,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Quality of life (QLQ C30)
14801,NCT06145230,Pathological characteristics,2023-12-12,RECRUITING,OBSERVATIONAL,['NA'],,Risk factors
14802,NCT01463501,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
14803,NCT01010126,Tumor Response Rate,2009-09-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Treatment Failure
14804,NCT05684432,Frequency and classification of radiation-induced diarrhrea in patients with prostate and rectal cancer during curative external radiotherapy,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
14805,NCT04401813,Evaluation of the objective response rate of IBI310 combined with 308 in the second-line treatment of advanced hepatocellular carcinoma,2020-06-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Evaluate the ORR of IBI310 combined with 308 in the second-line treatment of advanced hepatocellular carcinoma (researched by the investigator according to RECIST V1.1).
14806,NCT01011478,"Occurrence of ≥ 1 Adenomatous Polyp of the Colon or Rectum, Metachronous Colorectal Carcinoma, or Colon Cancer Recurrence (APMC+R)",2010-03,TERMINATED,INTERVENTIONAL,['PHASE3'],,Measurements of Relevant Tumor and Blood Markers
14807,NCT00569335,Safety,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Progression-free survival, Response rate, Overall survival, Time to treatment failure, Treatment situation"
14808,NCT00191984,Best Overall Tumor Response,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
14809,NCT03200366,Participants Completing CRC Screening Per Electronic Medical Record Documentation,2017-07-26,COMPLETED,INTERVENTIONAL,['NA'],,Change in Perceived Self-Efficacy for CRC Screening by FIT
14810,NCT02754115,Changes in arterial blood gas in perioperative period,2016-04,RECRUITING,OBSERVATIONAL,['NA'],,Mortality
14811,NCT05496777,Therapist appreciation,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life measurement
14812,NCT05653180,Objective response rate (ORR),2023-03-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Overall Survival,OS"
14813,NCT04652986,Disease-free survival at five years,2004-01,UNKNOWN,OBSERVATIONAL,['NA'],Operative morbidity,Five years overall survival
14814,NCT04526080,Overall Survival,2021-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Response Rates
14815,NCT04954794,Objective Response Rate (ORR),2021-07-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
14816,NCT05215964,Total psoas muscle change,2020-09-29,UNKNOWN,OBSERVATIONAL,['NA'],,Total kidney volume change
14817,NCT05040646,Consensus in / No important outcome,2021-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
14818,NCT01694589,Changes in mean Gli-1 levels before and after drug,2012-11,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Complications from surgery by time of hospital discharge up to 30 days post-operatively
14819,NCT02228668,Overall Survival (OS) up to 8 and 10 years median follow-up of the stage III population randomized in the AVANT study.,2015-03,COMPLETED,OBSERVATIONAL,['NA'],,Cancer Specific Survival (CSS) in patients with stage II and stage III colon cancer.
14820,NCT05116891,To assess the preliminary efficacy of CAN04 in combination with chemotherapy regimens measured as tumour response.,2021-09-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To assess ADA formation against CAN04.,To assess PK of CAN04 after a single dose and at steady state
14821,NCT00574327,"The goal of this study is to follow GERD and BE pts prospectively for development of dysplasia and adenocarcinoma, to identify factors responsible for progression of GERD to BE to dysplasia and adenocarcinoma.",2006-01,RECRUITING,OBSERVATIONAL,['NA'],,The secondary goal is to create a tissue and serum repository for future biomarker studies.
14822,NCT06027775,relapse-free survival,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,overall survival
14823,NCT05787197,Disease-free survival (DFS) in patients who undergo curative-intent resection of colorectal liver metastasis (CRLM),2024-01-09,RECRUITING,OBSERVATIONAL,['NA'],,Association between ctDNA and clinical features.
14824,NCT01573468,Overall survival,2012-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
14825,NCT00671645,"feasibility and tolerance of preoperative therapy with Bevacizumab in combination with Capecitabine and radiotherapy for patients with locally advanced, locally operable rectal carcinoma",2008-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,"collection of response rate (T- and M-downstaging, pathological complete remission)"
14826,NCT00414232,Quality of Life (QoL),2006-11,COMPLETED,OBSERVATIONAL,['NA'],,
14827,NCT04712032,90-days Anastomotic Leakage (AL) rate,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,days in hospital stay
14828,NCT02399631,Actual hospital stay,2012-01,TERMINATED,INTERVENTIONAL,['NA'],,Nutritional status
14829,NCT02406547,Number of polyps detected with both techniques (NBI versus WLE),2015-03,COMPLETED,INTERVENTIONAL,['NA'],,Number of accurate detection of adenomas with morphologic features with both groups (NBI and WLE) compared to histopathology
14830,NCT00998751,Objective response rate according to Response Evaluation Criteria In Solid Tumors (RECIST),2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
14831,NCT04859595,Maintenance of functional capacities,2021-07-29,COMPLETED,INTERVENTIONAL,['NA'],,
14832,NCT04572711,Number of adverse events,2020-09-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Healthcare Utilization
14833,NCT00739167,Quality of life differences between treatment groups,2008-04,COMPLETED,OBSERVATIONAL,['NA'],,
14834,NCT05717738,Number of Patients Amendable to Curative Surgical Interventions,2022-01-20,RECRUITING,OBSERVATIONAL,['NA'],,Quality of Life (QoL) after treatment
14835,NCT03357276,Relief degree of tumors,2017-11-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
14836,NCT00339469,Biomarkers of insulin resistance and inflammation,2005-08-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Weight loss
14837,NCT03415802,Objective response rate（ORR）,2015-05-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety profile: Adverse events of nab-Paclitaxel plus S-1 for advanced pancreatic cancer
14838,NCT01215539,Objective Response,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Economic evaluation
14839,NCT04945733,Objective Response Rate (ORR),2021-08-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants with Anti-Amivantamab Antibodies
14840,NCT02463877,Rate of postoperative complications,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14841,NCT04773080,Incidence of postoperative acute kidney injury,2021-01-21,COMPLETED,OBSERVATIONAL,['NA'],,Increase in length of hospital stay
14842,NCT00618319,Changes in FDG-PET imaging,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Characterize the safety profile of BIIB021
14843,NCT04653480,Overall Response Rate,2021-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
14844,NCT06176885,PFS（Disease-free Survival）,2023-12-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,DCR（Disease control rate）
14845,NCT03452553,Efficacy: Time to progression (TTP),2018-07-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Physician rating of the handling and visibility of LC Bead LUMI™.
14846,NCT00562068,"Incidence of infection (number of days with fever ≥ 38 degrees C, days of intravenous antibiotics, number of inpatient days, number of episodes of cytomegalovirus reactivation)",2007-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Epstein-Barr virus copy number (measured retrospectively)
14847,NCT05601323,Overall Survival,2023-01-31,RECRUITING,INTERVENTIONAL,['NA'],,Adverse Events
14848,NCT00805896,Time to tumor progression(TTP),2008-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
14849,NCT01646112,,2012-04-25,COMPLETED,OBSERVATIONAL,['NA'],,
14850,NCT02865135,Changes in CD8+ T Cells in Peripheral Blood and Tumor Tissue,2017-03-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Progression (TTP)
14851,NCT06115733,PFS,2023-12-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,DCR
14852,NCT00028002,Rate of Disease Progression at 2 Years,2002-03-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,"FDG-PET as Biological Marker of Metabolic Response(MR) During Imatinib Mesylate (IM) Treatment, in Patients With GIST Who Are naı¨ve to Tyrosine Kinase Inhibitor Therapy"
14853,NCT01333332,To determine the safety of neoadjuvant accelerated fraction standard dose radiotherapy to 50 Gy with concomitant capecitabine in patients with resectable and borderline resectable pancreas cancer.,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14854,NCT03788655,Technical feasibility of intrahepatic stenting,2018-12-31,UNKNOWN,OBSERVATIONAL,['NA'],,Survival rate
14855,NCT03615326,Overall Survival (OS),2018-10-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment Discontinuations Due to AEs
14856,NCT04143230,Accuracy of the Simplified Screening Tool (SST) with respect to the SIAARTI/NCCN screening tool (EST),2017-05-23,COMPLETED,INTERVENTIONAL,['NA'],,Clinical characteristics and outcomes of palliative care patients referred to an acute palliative care unit
14857,NCT04763408,Number of Participants with one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations of Lenvatinib,2021-04-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Number of Participants with one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations of Sorafenib
14858,NCT05322590,Objective Response Rate (ORR),2023-01-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Post Oxaliplatin Assessment
14859,NCT00487695,Diagnostic Yield for Neoplasia in High Risk Patients(Suspected Neoplasia),2007-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Mean Number of Biopsies Taken in Barrett's Surveillance Patients
14860,NCT00902343,To determine if nomogram-based allocation of ANH is superior to allocation using extent of resection alone (planned resection of 3 or more liver segments) in patients undergoing partial hepatectomy.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,To assess the impact of nomogram-based allocation of ANH compared to standard allocation on the need for fresh frozen plasma (FFP) transfusions.
14861,NCT03667612,correlation between the expression levels of the genes involved in the regulation of endothelial activation and the degree of tumor-infiltrating lymphocytes,2018-01-31,UNKNOWN,OBSERVATIONAL,['NA'],,The RER phenotype (the replication error phenotype)
14862,NCT01099826,completing CRC screening test,2004-10,COMPLETED,INTERVENTIONAL,['NA'],,
14863,NCT01784081,Feasibility of the patients with metastatic pancreas cancer to meet with the palliative care team and to complete symptom assessments.,2014-04,WITHDRAWN,OBSERVATIONAL,['NA'],,"Changes in hospice referral, use, acceptance, and length of stay, compared to similar patients in the prior 12 months (from retrospective review)"
14864,NCT01639703,Permeability Surface (PS) According to Degree of Lesions Differentiation,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Permeability Surface According to Immunohistochemistry Parameter (CD31)
14865,NCT03767660,Total venous malformation lesion load,2018-07-31,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Concentration of D-dimer in blood
14866,NCT01204476,"Safety profile of cixutumumab and everolimus with octreotide acetate among patients with advanced neuroendocrine tumors, defined by the incidence of adverse events",2010-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Changes in molecular markers,Anti-tumor activity as determined by RECIST
14867,NCT04430452,Objective response rate (ORR),2022-02-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
14868,NCT00744640,Response rate,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free survival and overall survival
14869,NCT01642875,Frequency of delayed gastric emptying,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Rehospitalization rate
14870,NCT04197856,Uptake of genetic counselling among the patient's at-risk relatives,2020-02-06,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Intervention - Collection of letters (only intervention group),
14871,NCT06129422,Safety and tolerability of a single infusion of NMK89: Frequency and severity of abnormal ECOG PS (Eastern Cooperative Oncology Group Performance Status),2023-10-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Public Safety: Radiation measurement
14872,NCT02172690,Peritoneal Metastasis or Positive Cytology,2014-06,UNKNOWN,INTERVENTIONAL,['NA'],,Safety
14873,NCT04531930,3yCR,2020-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,3yOSR
14874,NCT05543057,"1-, 2-, 3-year overall survival",2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],Biomarkers to predict radiotherapy efficacy,Quality of life of patients with oesophageal cancer
14875,NCT01281618,activated myofibroblasts,2008-10,COMPLETED,OBSERVATIONAL,['NA'],,
14876,NCT05515705,Evaluation of the EUS navigation system's procedure duration compared to standard procedure times,2023-01-10,RECRUITING,INTERVENTIONAL,['NA'],,Assessment of technological maturity and ergonomics
14877,NCT05239338,Disease-free survival,2021-12-06,RECRUITING,OBSERVATIONAL,['NA'],,Physical activity (Accelerometer)
14878,NCT05161585,Secondary resection rate,2021-11-01,RECRUITING,INTERVENTIONAL,['NA'],,ctDNA clearance rate
14879,NCT00535652,Tissue (Total) Concentrations of Ertapenem in the Colorectal Tissue,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,Safety Assessment
14880,NCT04168788,Correlate pharmacogenetic analysis with veno-occlusive disease.,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Participant characteristics.
14881,NCT06283238,Number of participants with Progressive Disease,2024-04-25,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
14882,NCT03712566,"Characterization of Genomic, epigenetic and Immune Profiling Features",2018-11-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Enable Data-Sharing
14883,NCT01045941,To determine if it is safe to administer gemcitabine to patients with pancreatic cancer one week after laparoscopic distal pancreatectomy.,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To determine the if the 1-year survival in patients with pancreatic cancer is improved with administration of gemcitabine one week following laparoscopic distal pancreatectomy
14884,NCT04101292,Evaluation of the sensitivity of Bevacizumab-IRDye800 to visualize tumour tissue compared to anti-VEGF antibodies by the means of fluorescence intensity measurements,2021-04,WITHDRAWN,INTERVENTIONAL,['NA'],,Level of accuracy of Full-field optical coherence tomography (FF-OCT) by the means of a qualitative analysis
14885,NCT00846313,Body weight,2003-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Dietary intake
14886,NCT06168552,Accuracy and sensitivity of the imaging agent,2023-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14887,NCT03234842,Compare the rate of a clinically significant reduction of DLCO (defined as a decrease of ≥ 10% from baseline) between protons and photons after preoperative or definitive chemoradiation,2017-10-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Compare overall survival rates
14888,NCT05167409,"Objective response rate (ORR, per RECIST v1.1) (%)",2022-07-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerability according to the NCI CTCAE v5.0
14889,NCT02843412,compare the positive rate,2016-08,UNKNOWN,OBSERVATIONAL,['NA'],,
14890,NCT00805688,Patient Reported Symptom Severity and Interference,2008-11-12,COMPLETED,OBSERVATIONAL,['NA'],,
14891,NCT01693276,Increase overall survival,2012-09,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Rate of local control
14892,NCT02836847,Progression Free Survival,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,percentage of patients with Clinical Benefit Response
14893,NCT04805788,3-month rate of patients experiencing an increase in Child-Pugh score by 2 or more points of 5-fraction stereotactic body proton radiotherapy in the treatment of hepatocellular carcinoma (HCC),2021-08-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Blood bank patient specimens for future analysis,Value of volumetric imaging analysis
14894,NCT02264496,Length of stay,2014-03,COMPLETED,INTERVENTIONAL,['NA'],,Quality of Life Questionnaires
14895,NCT04767568,correlation between the biological signature of the test and the stage of the disease in patients whose diagnosis of adenocarcinoma was identified by pathology prior to surgery.,2021-03-30,RECRUITING,INTERVENTIONAL,['NA'],,
14896,NCT00493441,Pharmacokinetics,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14897,NCT02753881,Pharmacokinetics Profile-- Time of Maximum Concentration,2015-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Assessment and Frequency of Toxicities (Laboratory and Clinical Adverse Events) According to NCI Common Toxicity Criteria for AE (CTCAE) 5.0.
14898,NCT03702985,the morbidity of hematological adverse events and diarrhea as assessed by CTCAE v4.0,2018-05-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,the morbidity of late radiation proctitis
14899,NCT05475041,Major complications,2022-06-30,COMPLETED,OBSERVATIONAL,['NA'],,Intraoperative incidents
14900,NCT05723705,Textbook Outcome in Liver Surgery (TOLS),2023-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Intra-operative ICG-margin assessment
14901,NCT00141466,Efficacy of referral of patients who are MSI positive to a clinical geneticist by surgeons.,2005-09,UNKNOWN,INTERVENTIONAL,['NA'],,Cost efficacy of the implementation procedures.
14902,NCT03949933,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2015-05-01,COMPLETED,INTERVENTIONAL,['NA'],,progression-free survivals
14903,NCT03001596,Overall survival(OS),2017-01,COMPLETED,INTERVENTIONAL,['NA'],,Recurrence-free survival (RFS)
14904,NCT06071845,Accuracy of the Oncoguard Esophagus (OGE) test,2023-10-16,RECRUITING,INTERVENTIONAL,['NA'],,Trauma to the esophagus from the passage of the Cytosponge device
14905,NCT00012220,Overall Survival,2001-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
14906,NCT01707511,,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14907,NCT02615210,"Number of malignant diagnoses across hree-sample techniques (Spy bite, forceps biopsy, brushings)",2015-11,TERMINATED,INTERVENTIONAL,['NA'],,Time from procedure to the initiation of treatment (in cases of malignancy)
14908,NCT03409848,Overall Survival,2018-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Central Imaging Review - PFS
14909,NCT04316507,Days from decision to test to receiving genetic test results,2020-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,
14910,NCT03200171,Behavior of hepatocellular carcinoma,2018-02-10,COMPLETED,OBSERVATIONAL,['NA'],,Progression-free survival (PFS)
14911,NCT04641455,"Visibility score"" evaluated by blinded performing endoscopist",2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],Duration of endoscopy,"Visibility score"" evaluated by two blinded endoscopists using 10 endoscopic images captured during endoscopy"
14912,NCT04814485,ORR (Objective Response Rate),2021-04-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events (per CTCAE v5.0 criteria)
14913,NCT00250328,Functioning anastomosis without leaks or obstructions,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Functioning anastomosis without stenosis
14914,NCT01927393,Symptom burden using the FACT-Trial Outcome Index (TOI),2014-12,WITHDRAWN,INTERVENTIONAL,['NA'],,"Health care resource use including presence of advanced care planning, chemotherapy in the last 14 days of life, and length of time between hospice referral and death"
14915,NCT06292975,withdrawal rate,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Physical activity levels
14916,NCT05659914,Overall Response Rate (ORR),2022-11-28,RECRUITING,INTERVENTIONAL,['PHASE2'],"To characterize the immune microenvironment of this tumours and biomarkers of HRD status, and RAD51 status in tumour tissue samples and blood samples",Incidence and severity of AEs CTCAE v5 criteria
14917,NCT00003192,Objective response rate Objective response rate Objective response rate Objective response rate,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14918,NCT01172548,Recurrence Free Survival Rate,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment Compliance - tracking if the patient is coming to visits as per visit schedule in protocol
14919,NCT02724475,Overall survival,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
14920,NCT01486992,adverse events,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,disease control rate
14921,NCT01313442,Collected samples,2011-03-02,RECRUITING,OBSERVATIONAL,['NA'],,
14922,NCT00643877,5 years disease-free survival,2008-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,5 years overall survival and liver metastasis-free survival
14923,NCT05627635,Overall response (phase II),2023-05-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Surgical resection (phase II)
14924,NCT04106453,time to complete ablation,2019-09-14,COMPLETED,INTERVENTIONAL,['NA'],,ablation completeness
14925,NCT05354882,Change of physical activity (connected device),2022-03-29,RECRUITING,INTERVENTIONAL,['NA'],Socio-demographic variables,Motivation to physical activity pratice
14926,NCT02903771,Pharmacokinetic (PK) profile of Cantrixil after intra-peritoneal (IP) administration,2016-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Expression of Stem Cell Markers,CA-125 level
14927,NCT02923921,Overall Survival,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants Alive at 1 Year (12-Month Survival Rate)
14928,NCT04297202,Major pathologic response,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety as measured by the rate of AEs
14929,NCT05743959,Relapse-free survival,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
14930,NCT02288377,Proportion of Patients Alive and Progression-free at 6 Months,2015-01,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall Survival
14931,NCT01186237,urinary retention,2010-06,COMPLETED,INTERVENTIONAL,['NA'],,
14932,NCT00640978,Number of Participants Surviving at 6 Months,2008-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14933,NCT04953962,Three-month progression free survival rate (3M PFSR),2021-12-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
14934,NCT05490147,Intraoperative blood loss,2022-08-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Satisfaction scale of the operator and participants
14935,NCT02031939,overall survival,2014-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Respond rate
14936,NCT03253185,Number of participants with dose-limiting toxicities (DLTs),2017-09-13,TERMINATED,INTERVENTIONAL,['PHASE1'],,Maximum observed serum concentration (Cmax) of SC-007
14937,NCT02101593,Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with sorafenib in advanced HCC,2014-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14938,NCT01766219,Overall Survival,2013-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Adverse Events Using the National Cancer Institute Common Terminology Criteria
14939,NCT00084383,Disease-free Survival,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Estimate the Association of Specific in Vivo Parameters of Immune Response With Clinical Responses in Patients Treated With Combination Chemoradiotherapy Together With the Irradiated Allogeneic GM-CSF Transfected Pancreatic Tumor Cell Lines.
14940,NCT00541593,Mortality,2007-09,TERMINATED,INTERVENTIONAL,['NA'],,
14941,NCT03410732,progression-free survival,2017-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse event rate
14942,NCT03922230,Hydroxymethylation level,2019-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14943,NCT05611658,"Change of interobserver variability in target volume delineation on CT, PET CT and MR.",2020-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14944,NCT01326364,"Tumor response to treatment in SBRT patients, based on WHO criteria (No Change/Progressive Disease vs. Partial/Complete Response)",2010-03,TERMINATED,OBSERVATIONAL,['NA'],,
14945,NCT03247296,HCC,2017-02-28,UNKNOWN,OBSERVATIONAL,['NA'],,
14946,NCT03332498,Phase II - Disease Control Rate at 4 Months,2018-01-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14947,NCT04191928,Serum Apixaban Level,2020-03-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14948,NCT02448953,Long term survival,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative complications
14949,NCT02939807,To assess objective response rate (per modified RECIST) of single agent ABC294640 in treatment of HCC,2019-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To assess the relationship between changes in immune cell subsets in peripheral blood from subjects being given ABC294640
14950,NCT00938210,Fatigue,2009-05,COMPLETED,INTERVENTIONAL,['NA'],,Social support
14951,NCT02746796,Overall survival (only Part 2),2016-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Safety will be analyzed through the incidence of laboratory abnormalities
14952,NCT02878109,Hepatic and tumor blood flow before HCC treatment,2016-06,COMPLETED,OBSERVATIONAL,['NA'],,
14953,NCT01950403,Dose of linaclotide acetate that produces a 60% response rate for cGMP levels in rectal tissue by radioimmunoassay (RIA),2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],"PD effect of linaclotide acetate on GCC signaling (i.e., VASP phosphorylation) and general proliferation (Ki67 expression)",PD effect on cGMP levels (Stage II)
14954,NCT00701168,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
14955,NCT03923036,Difference in rates of cardiovascular adverse events leading to hospitalization between chemotherapy treated patients and chemotherapy-free patients.,2019-04,UNKNOWN,OBSERVATIONAL,['NA'],,Dose-effect relation ship between individual anticancer drugs combination/protocol and cardiovascular adverse events
14956,NCT05648682,Thyme honey group patients' quality-of-life scores as assessed by The University of Washington Quality of Life Questionnaire,2020-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
14957,NCT03941457,Occurrence of treatment related adverse events as assessed by CTCAE v4.03,2019-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14958,NCT00016172,,2000-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14959,NCT01290926,Overall survival at 6 months fixed endpoint,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To determine the correlation of growth modulation index (GMI), defined as the time to progression under the study regimen over the time to progression un-der the latest prior regimen administered to the patient, with overall survival and progression-free"
14960,NCT00881751,Overall Survival,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response Rate
14961,NCT05526079,Local recurrence free survival,2018-07-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life using LARS score
14962,NCT02204124,Post-op Morbidity,2015-01-01,TERMINATED,INTERVENTIONAL,['NA'],,Number of Participants Who Experienced Postoperative Complications
14963,NCT01229111,The Response Rate of Patients Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2010-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Identification of Factors That Predict Survival
14964,NCT05717400,Overall Response Rate,2023-02-07,RECRUITING,INTERVENTIONAL,['PHASE4'],,
14965,NCT00032175,Survival at 1 year,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Objective response rate
14966,NCT01490996,Completion of dose escalation over 2 cycles of therapy,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Efficacy in terms of disease response and survival
14967,NCT04581005,Oxygen consumption (VO2),2019-08-19,UNKNOWN,INTERVENTIONAL,['NA'],,
14968,NCT00311116,"Objective mucositis score at 7, 10, 14, and 17 days post initiation of chemotherapy",2002-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Chemotherapy decrements or delays due to mucositis
14969,NCT03049345,Specificity of Sentinel Lymph Node Sampling Method,2016-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse surgical events
14970,NCT01833299,Effectiveness of sorafenib combined with TACE,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to progression
14971,NCT00005607,,2000-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14972,NCT03575117,Change in physical active level,2018-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Change in colorectal cancer risk and physical activity coherence
14973,NCT02297217,Proportion of patients who achieve relief of dysphagia,2019-11-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Dysphagia progression free survival
14974,NCT05390684,anastomotic leak,2022-05-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,infection
14975,NCT01327794,Association between 25(OH)D level and OS,2011-06,COMPLETED,OBSERVATIONAL,['NA'],,Association between 25(OH)D level and PFS
14976,NCT00043433,,2002-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14977,NCT02379377,Immunohistochemistry,2022-02-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,Milan classification
14978,NCT05293054,The rate of successful use and application of Obsidian as a supplemental procedure in the creation of rectal anastomosis with minimal invasive technique,2021-12-15,COMPLETED,OBSERVATIONAL,['NA'],,2-year mortality
14979,NCT05959213,Quantitative data - Preoperatory levels of CA 19.9 (U/ml),2000-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14980,NCT04370418,Incidence of treatment adverse events as assessed by National Cancer Institute Common Terminology Criteria for adverse events version 4.0,2020-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,assess disease local control and the response rate after short course radiotherapy concurrent with dose escalation infusion 5-fu followed by mFOLFOX and delayed surgery.
14981,NCT04791982,The effects of education provided to family members caring for colorectal cancer patients receiving chemotherapy on Caregiver Reaction Assessment Scala.,2018-08-18,COMPLETED,INTERVENTIONAL,['NA'],,
14982,NCT01553019,Radiation Toxicity,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rate via CA 19-9
14983,NCT00006332,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14984,NCT06118125,time from date of first symptoms of cancer to the date of first MDT,2019-06-01,COMPLETED,OBSERVATIONAL,['NA'],,overall survival.
14985,NCT04149691,Safety profile,2019-07-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Kel: Terminal elimination rate constant
14986,NCT01127815,,2010-03,UNKNOWN,OBSERVATIONAL,['NA'],,
14987,NCT03445260,The number of patients randomized to the study,2018-10-17,COMPLETED,INTERVENTIONAL,['NA'],,Length of Hospital Stay
14988,NCT00378482,Efficacy Endpoints: Survival,2007-03-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Free Survival
14989,NCT05152498,Time to Progression,2021-01-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,complete response
14990,NCT00888407,Obtain HBV Screening Test,2006-09,COMPLETED,INTERVENTIONAL,['NA'],,"Knowledge and Attitudes Regarding Hepatitis B, Health and Nutrition"
14991,NCT03269955,Incidence of clinically relevant pancreatic fistula,2017-02-27,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Period of hospitalization after surgery
14992,NCT02371655,"overall quality of bowel preparation using a 0-3 scale for each parameter (Homogeneity of solid-fluid fecal tagging, volume of residual fluid, colon distension).",2015-10-01,COMPLETED,INTERVENTIONAL,['NA'],,compliance of patients
14993,NCT02020707,Maximum tolerated dose,2014-02-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of adverse events (soft tissue expansion cohort)
14994,NCT05517408,Calculating the the median effective dose (ED50) of ciprofol for sedation gastrointestinal endoscopy in obese patients.,2022-09-19,RECRUITING,INTERVENTIONAL,['NA'],,Calculating the the ED95 of ciprofol for sedation gastrointestinal endoscopy in obese patients.
14995,NCT00040391,,2002-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14996,NCT03005314,progression- free survival,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],,overall survival
14997,NCT05109052,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],2022-09-20,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14998,NCT02923934,To determine the clinical efficacy of the combination treatment of ipilimumab with nivolumab in rare cancers.,2017-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,To identify whether a common predictive biomarker or immune signature can be identified in responding patients that can occur irrespective of tumour type.
14999,NCT04241731,The time from the beginning of maintenance treatment until the disease progresses.,2019-11-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life score
15000,NCT01366118,ypTN,2009-10,COMPLETED,INTERVENTIONAL,['NA'],,Feasibility
15001,NCT06312982,CR,2024-02-20,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,immune-related adverse event rate
15002,NCT00860249,Completion of CRC Screening,2009-03,TERMINATED,INTERVENTIONAL,['NA'],,The Secondary Outcome for the Study is the Time to Screening Completion.
15003,NCT01486472,The incidence of LDO,2010-11,UNKNOWN,OBSERVATIONAL,['NA'],,Correlation between the concentration of S-1-related chemical compounds and the developement of LDO
15004,NCT05671315,Change of HBsAg level compared to baseline,2019-07-03,RECRUITING,INTERVENTIONAL,['NA'],,Incidence of liver cirrhosis and hepatocellular carcinoma
15005,NCT02843425,Changes in Blood Markers and Metabolites,2016-07-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
15006,NCT05039762,Overall complication rate,2020-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Hernia rate
15007,NCT06271837,Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR),2024-02-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Immunogenicity of T-DXd
15008,NCT01299688,To survey the frequency of HER2(+) CTC in gastric cancer,2010-03,COMPLETED,OBSERVATIONAL,['NA'],,
15009,NCT00004074,Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 2.0 (CTCAE v2.0),1999-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
15010,NCT03880747,Dumping syndrome,2017-08-09,COMPLETED,OBSERVATIONAL,['NA'],Hospital stay,Incidence of gallstones
15011,NCT05495672,Progression-free survival (PFS) in advanced colorectal cancer patients with metastatic small pulmonary nodules under ctDNA guided therapeutic strategies,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],,The ctDNA clearance rate after chemotherapy in patients achieving NED (Cohort 2)
15012,NCT05410847,Conversion to negative rate,2022-06-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
15013,NCT06039202,Number of subjects with treatment-related adverse events as assessed by NCI-CTCAE v5.0,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life measured by European Organization for the research and treatment of cancer quality of life questionnaire (EORTC QLQ-C30).,To evaluate the efficacy of CA102N in combination with trifluridine/tipiracil (TAS-102) by overall survival (OS).
15014,NCT02514434,Resectability rate of HCC,2015-03-30,UNKNOWN,INTERVENTIONAL,['NA'],,Post-treatment recurrence rate
15015,NCT02082210,Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)],2014-03-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies
15016,NCT06141564,HCC recurrence diagnosed by dynamic contrast enhanced CT,2023-10-16,RECRUITING,OBSERVATIONAL,['NA'],,
15017,NCT02690350,Number of Patients with Dose-Limiting Toxicities (DLTs),2016-02-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,Area Under the Curve to the Last Quantifiable Measure (AUClast)[
15018,NCT00003441,Antitumor Activity of MGI-114,1998-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
15019,NCT05001204,Standardized uptake value of 68Ga-NOTA-RM26 in gastrointestinal stromal tumor,2021-05-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Adverse events collection
15020,NCT05588297,Tumor regression grade (TRG）,2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life score (QoL score）
15021,NCT00165867,The objective response rate as defined by RECIST criteria.,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety and tolerability of the combination
15022,NCT03366883,Overall Survival,2018-02-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Rate of R0 resection
15023,NCT04351867,disease free survival,2020-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Assessment of life quality
15024,NCT04762888,Correlate biomarkers derived from PET/MRI with PSMA immuno-histochemical (IHC) grading,2021-02-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,
15025,NCT01815879,Adverse events at day 0-90 post 90Y therapy using CTCae 3.0 criteria.,2012-12,UNKNOWN,OBSERVATIONAL,['NA'],,"Radiographic response rate at 90 days (+/- 45 days) from treatment day, compared to pretreatment scans."
15026,NCT04398446,Change in sleep quality,2020-05-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of side effects using medical-grade CBD concentrates
15027,NCT02016287,progression free survival,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],quality of life,overall survival
15028,NCT00046995,Disease-free survival,2001-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
15029,NCT05553080,Evaluation of immunohistochemical staining of colorectal carcinoma by Fascin-1,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
15030,NCT06149923,assess ABO gene polymorphism (rs8176746) in the patients histopathologically confirmed gastric and/colorectal cancers relative to healthy controls.,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
15031,NCT03115372,Proportion of participants who report ever having had a CRC screening test,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,Proportion of participants who intend to obtain CRC screening in the next 6 months
15032,NCT05457075,Soluble immune checkpoints,2022-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
15033,NCT04020614,The awareness of patients about colorectal cancer,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,
15034,NCT02579616,Objective Response Rate (ORR),2015-10-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Plasma Concentrations of Lenvatinib
15035,NCT02509806,Progression free survival,2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
15036,NCT04874207,Time from inclusion to death,2021-10-22,RECRUITING,INTERVENTIONAL,['PHASE4'],,Body composition
15037,NCT02305914,Change in the Levels of fecal elastase-1,2014-11,UNKNOWN,OBSERVATIONAL,['NA'],,outpatient clinic and phone questionnaire
15038,NCT05405673,Sensitivity of FIT/FOBT,2022-06-29,RECRUITING,OBSERVATIONAL,['NA'],,Microbiota changes in subjects with adenomas or normal findings after polypectomy
15039,NCT00250029,To collect pathological tumor specimens of patients with metastatic colorectal cancer in a prospective fashion for correlative studies of response to an oxaliplatin based chemotherapy regimen,2004-04,COMPLETED,INTERVENTIONAL,['NA'],,
15040,NCT03418909,Altered salivatory function,2017-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Treatment related pain
15041,NCT04589468,Identify the recommended phase 2 dose (RP2D) of exercise for testing in the phase 1b.,2020-10-02,RECRUITING,INTERVENTIONAL,['NA'],,
15042,NCT01374100,Change in Quality of Life (QoL),2009-02,TERMINATED,INTERVENTIONAL,['NA'],,Program Satisfaction
15043,NCT03138239,Measure the absorption of PET-CT F-18-FDG and of PET -CT Ga-68-PSMA,2017-07-02,UNKNOWN,INTERVENTIONAL,['NA'],,
15044,NCT02435602,Positive predictive value,2013-12,COMPLETED,INTERVENTIONAL,['NA'],,Evaluation of endoscopy ( NBI versus Lugol staining) tolerance using Visual Analogue Scale (VAS)
15045,NCT05462314,Levels of gene expression of the identified species in Gastrointestinal Malignancy,2022-03-29,RECRUITING,OBSERVATIONAL,['NA'],,Relationship between treatment efficacy and microbiome diversity
15046,NCT00316888,Local Failure Rate at 3 Years,2007-02-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,3-year Colostomy-free Survival Rate
15047,NCT03289988,Diagnostic Power for prediction of advanced colorectal neoplasms,2017-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,
15048,NCT01498952,Phase 2: Time to Progression,2012-01-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Phase 1b and Phase 2: Area Under Serum Concentration-time Curve From Time Zero to Day 22 (AUC0-Day22) of MEDI-573 for Cycle 1
15049,NCT00510107,response rate,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety
15050,NCT03129074,Biomarker,2018-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events and changes from baseline in safety parameters
15051,NCT03859557,Yield of WATS biopsies compared to Forceps biopsies,2017-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
15052,NCT05511688,"Time to recurrence for stage I , II or III colorectal cancers",2017-03-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
15053,NCT03576963,Recommended phase 2 dose (RP2D) of guadecitabine when given in combination with nivolumab,2020-01-30,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence and severity of adverse events
15054,NCT04494282,The impact of the pancreatography in the endoscopic treatment of pancreatic pseudocysts,2015-08,COMPLETED,INTERVENTIONAL,['NA'],,
15055,NCT04027790,Test Positivity,2019-05-03,COMPLETED,OBSERVATIONAL,['NA'],,
15056,NCT02683200,"Quality of real-time image guidance provided the tri-60Co system, as defined by the treating radiation oncologist's ability to visualize the target lesion using the on-board MRI",2015-06-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Validity of automatically segmented contours generated by the MRI-guided tri-60Co teletherapy system through independent evaluation of images obtained
15057,NCT00004003,,1999-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
15058,NCT06005740,Recommended Phase 2 Dose (RP2D),2023-12-04,RECRUITING,INTERVENTIONAL,['PHASE1'],,Accumulation ratio (Rac) of TORL-4-500
15059,NCT03808766,arterial flow through the tumor,2018-08-13,TERMINATED,INTERVENTIONAL,['NA'],,The degree of tumor necrosis
15060,NCT01016002,Rate of local response and depth of tumoricidal tissue penetration of Foscan-PDT,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity using WHO criteria and criteria for local toxicity in the biliary system
15061,NCT05256459,Time the patients were diagnosed.,2022-05-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
15062,NCT05166772,ORR（Objective Response Rate）,2021-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AE（Adverse events）
15063,NCT04090463,Disease-specific survival,2019-10-01,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Resection rate
15064,NCT05794737,Detection of INHBA in Colorectal Carcinoma.,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Correlation between INHBA expression in Colorectal Carcinoma and clinicopathological parameters.
15065,NCT01732380,Progression-Free-Survival,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,Response Rate
15066,NCT05487248,Optimal timepoint and cut-off value for early on-treatment ctDNA changes,2023-10-12,RECRUITING,INTERVENTIONAL,['NA'],prognostic value of ctDNA.,CGP changes during treatment
15067,NCT04687280,arterial enhancement,2009-04-22,COMPLETED,OBSERVATIONAL,['NA'],,
15068,NCT05680077,validity,2022-10-28,COMPLETED,OBSERVATIONAL,['NA'],,reliability
15069,NCT03326791,Disease Free Survival (DFS) after three years treatment,2017-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,ASA in CRC and Cost-Effectiveness Analyses III
15070,NCT03566355,3-year local control ratio of the treated lung area,2018-05-23,RECRUITING,INTERVENTIONAL,['NA'],,3-year disease-free survival rate of treated patients
15071,NCT05795725,The diagnostic accuracy of the AI-assisted fecal microbiome testing in detecting colon cancer compared to colonoscopy,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,
15072,NCT02928510,The Mechanism of Action (MOA) of idelalisib will be assessed with a number of tests in order to provide variability in comparisons for the units of measure.,2016-02-01,TERMINATED,OBSERVATIONAL,['NA'],,
15073,NCT05061199,length of the resection margin,2022-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
15074,NCT05466019,Pathological complete response (pCR),2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,type and number of intestinal flora
15075,NCT03063840,tumor evaluation,2016-07,WITHDRAWN,INTERVENTIONAL,['NA'],,Assess for presence of adverse events
15076,NCT03989115,Number of Participants With Dose Limiting Toxicities (DLTs),2019-07-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Response Rate (ORR)
15077,NCT00183794,"Tumor Response Type: CR, PR, SD or PD",2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Time to Progression (Months)
15078,NCT00178867,,2002-01,COMPLETED,OBSERVATIONAL,['NA'],,
15079,NCT00352703,The primary efficacy endpoints are the incidence (%) and duration of severe oral mucositis (WHO grades 3 or 4).,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,
15080,NCT02467582,Disease-free survival (DFS),2016-06-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse events (AEs)
15081,NCT02650375,incidence of adverse events,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,CL for Metatinib
15082,NCT00596401,the annual incidence of gastric cancer in Iijima town,2007-09,COMPLETED,OBSERVATIONAL,['NA'],,The annual medical care cost in Iijima town
15083,NCT06169163,To develop a breath test for detection of OSCC,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,To evaluate the effects of known confounding variables on the target VOCs in OSCC
15084,NCT03213444,cardiac function evaluation,2015-07,COMPLETED,INTERVENTIONAL,['NA'],,Proinflammatory cytokines
15085,NCT05717998,Changes in myocardial metabolism,2021-04-02,RECRUITING,OBSERVATIONAL,['NA'],,Blood-based biomarkers
15086,NCT05823272,incidence of sarcopenia 6-month after discharge,2024-03-22,RECRUITING,INTERVENTIONAL,['NA'],,Changes in BMI (weight and height will be combined to report BMI in kg/m^2)
15087,NCT02654639,Length of Progression-Free Survival,2016-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,
15088,NCT00325871,,2006-04,COMPLETED,OBSERVATIONAL,['NA'],,
15089,NCT05265962,OS,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],PD-L1 CPS,Adverse Events (Safety)
15090,NCT02942862,survival,2015-02,COMPLETED,OBSERVATIONAL,['NA'],,
15091,NCT05384496,best objective response,2022-05-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,
15092,NCT04034251,Progression Free Survival (PFS) in Participants With Peritoneal Metastases From Gastric Cancer After Repeated Intraperitoneal Chemotherapeutic Infusion (IPC) and Systemic Paclitaxel Administration With Concomitant Capecitabine Therapy,2020-06-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),Number of Participants With Intra-peritoneal Progression Free Survival (iPFS)
15093,NCT00543842,Maximal tolerated dose (MTD),2007-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
15094,NCT03879109,Proportion of curative surgery,2019-07-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Tolerance to treatment
15095,NCT03206073,Number of Participants With Grade 1-5 Adverse Events,2017-12-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.3),Number of Participants With Response
15096,NCT00506168,Maximal response rate and toxicities,2001-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression-free survival and overall survival
15097,NCT01844817,Overall Survival,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
15098,NCT04185350,Standardized uptake value,2019-05-05,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of Adverse Events
15099,NCT01836237,Surgical Site Infection (SSI) Rate,2013-02,COMPLETED,INTERVENTIONAL,['NA'],,
15100,NCT00992199,Metastasis in Peritoneum and peritoneal cavity,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
15101,NCT02372500,Bowel function (as assessed by questionnaire),2015-03,UNKNOWN,INTERVENTIONAL,['NA'],,Morbidity
15102,NCT04901585,Postoperative complications,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
15103,NCT02343601,Incidence of patients presenting at least one complication after colorectal surgery,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Medico economic evaluation of cost of treatment,Perioperative mortality
15104,NCT00387842,Primary endpoint is cancer free survival at three years.,1997-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Secondary endpoints are overall survival at three and five years, 28 day mortality and morbidity, quality of life, costs, location and rates of recurrences and pathologic anatomic characteristics of the resected specimen."
15105,NCT01900327,3-Year Survival Rate,2014-02,TERMINATED,INTERVENTIONAL,['PHASE3'],,First site of tumor recurrence
15106,NCT00149201,overall survival,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,toxicity
15107,NCT05035147,Progression-free Survival (PFS),2021-03-25,RECRUITING,INTERVENTIONAL,['PHASE4'],,Overall survival(OS)
15108,NCT02962219,Change in Quality of Life,2016-09,UNKNOWN,INTERVENTIONAL,['NA'],,
15109,NCT05634564,Objective Response Rate (ORR),2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
15110,NCT03427242,PFS,2017-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS
15111,NCT05346874,Pathological complete response (pCR) rate,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progressive free survival
15112,NCT04070677,Symptomatic relief of radiation-induced esophagitis grade ≥2 in cancer patients undergoing radiotherapy and radiochemotherapy after administration of ZIVEREL®.,2019-06-15,UNKNOWN,INTERVENTIONAL,['NA'],,Analyze the health-related quality of life during the treatment
15113,NCT01775501,Time to Progression,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
15114,NCT02650804,Overall Response Rate (ORR),2016-07-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
15115,NCT06242197,The effectiveness of written advice VS. standard verbal advice in transferring knowledge to first degree relatives of colorectal cancer patients,2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Determining the knowledge level about colorectal cancer in first degree relatives of CRC patients
15116,NCT02123511,Groningen Radiotherapy-Induced Xerostomia (GRIX) Sticky Saliva Total Score Area Under the Curve (AUC),2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Adverse Event, as Measured by the Number of Patients With a Maximum Grade of Any Adverse Event"
15117,NCT02026362,Time of tumor recurrence or metastasis,2013-07,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival
15118,NCT06285591,The duration of Severe Oral mucositis (WHO grade ≥3),2023-11-10,RECRUITING,INTERVENTIONAL,['NA'],,Mouth and throat soreness (MTS) scores
15119,NCT04564482,Intratumoral changes of PD-L1 expression during neoadjuvant CRT/SCPRT,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],,Pathological therapy response
15120,NCT05062837,Overall survival,2021-06-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Objective response rate of extrahepatic target lesions
15121,NCT04086901,Loco-regional control,2020-01-01,TERMINATED,INTERVENTIONAL,['NA'],,Treatment completion rate
15122,NCT00532987,,2003-12,TERMINATED,OBSERVATIONAL,['NA'],,
15123,NCT05842174,Local Progression Free Survival,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
15124,NCT04745754,Preventive care services,2021-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Self-reported patient demographics,Cancer recurrence
15125,NCT01391572,Survival,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Failure pattern
15126,NCT04407611,Participant uncertainty from cancer risk assessment at 12 months,2023-03-06,RECRUITING,INTERVENTIONAL,['NA'],,
15127,NCT00579748,The OCT images will be correlated to the specific biopsy site and biopsy number.,2005-06,COMPLETED,OBSERVATIONAL,['NA'],,
15128,NCT02130648,Analysis circulating free fetal DNA,2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,
15129,NCT00668863,Progression-Free Survival (PFS),2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Grade 3 or Higher Adverse Events According to Common Terminology Criteria (CTCAE)."
15130,NCT02512328,Feasibility,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],,patient´s satification
15131,NCT04803890,Local tumor progression (LTP) rate,2019-04-01,TERMINATED,INTERVENTIONAL,['NA'],,Complication rate
15132,NCT04758195,Number of participants with major low anterior resection syndrome score (LARS score),2021-03-01,RECRUITING,INTERVENTIONAL,['NA'],Anorectal function impairment,Fecal continence impairment
15133,NCT00866944,Disease free survival rate (DFS),2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life
15134,NCT00441376,To determine the Pharmacokinetics (PK) of ThermoDox,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,To determine the cardiotoxicity of ThermoDox through enhanced ECG monitoring.
15135,NCT02041936,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life on the EORTC QLQ-PAN26 and EORTC QLQ-C30
15136,NCT01517152,Perceptions of the clarity and ease of response to a series of questions,2012-01-04,COMPLETED,OBSERVATIONAL,['NA'],,
15137,NCT05260385,Objective Response Rate (ORR),2022-01-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse events (AEs)
15138,NCT03532347,The sensitivity of standard Beacon FNA needle compared with the SharkCore (FNB) core biopsy needle in the sampling of solid pancreatic mass lesions.,2017-05-22,COMPLETED,INTERVENTIONAL,['NA'],,Duration of sampling procedures
15139,NCT05662527,Pathological complete response (pCR),2023-02-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Endoscopic tumour assessment,Gene expression by mRNA
15140,NCT02686567,Incidence of AL,2016-02,COMPLETED,INTERVENTIONAL,['NA'],Incidence of DT-related adverse events : iatrogenic colonic perforations,Incidence of TDT-related Adverse Events: bleeding
15141,NCT00142480,"To determine the progression free survival rate at one year for locally advanced, or resected with positive margins, biliary tract and gallbladder cancer patients",2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate the safety of the combination capecitabine, oxaliplatin, bevacizumab in patients with biliary tract and gallbladder cancer"
15142,NCT01124214,compare diagnostic yield,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,compare the specificity and sensitivity of HRE with EM
15143,NCT04763174,Change in psychological distress,2021-09-15,RECRUITING,INTERVENTIONAL,['NA'],Change in Parenting Concerns,Change in Self-Efficacy for Symptom Management
15144,NCT03604926,immunological features of metastasis,2017-10-05,COMPLETED,OBSERVATIONAL,['NA'],,
15145,NCT01093222,Progression-free Survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
15146,NCT01542281,Change in six minute walk test,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],,Nutritional status
15147,NCT05406089,Recurrence of the hepatocellular carcinoma after hepatectomy,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Surgery information
15148,NCT04813783,oral mucositis area measurement,2021-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
15149,NCT02715362,Safety of CAR-T cell infusion mediated by TAI as measured by number of participants with adverse Events,2016-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum cytokine levels
15150,NCT00268346,"The Number of Patients With Complete or Partial Response Rate of Single Agent ZD1839 in a Patient Population With Recurrent or Metastatic Cancer of the Esophagus or Gastroesophageal Junction, Using the RECIST 1.0 Criteria.",2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
15151,NCT04933227,Objective Response Rate (ORR) in the Full Analysis Set (FAS) Population,2021-08-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
15152,NCT00872755,Laparoscopic Nissen fundoplication combined with posterior gastropexy may prevent postoperative paraesophageal or sliding herniation in surgical treatment of GERD,2002-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
15153,NCT02788565,Proportion of subjects with injection problems according to the subject,2016-03,COMPLETED,OBSERVATIONAL,['NA'],,"Proportion of nurses who reported ""moderately"" or ""very"" or ""very much"" confidence in giving injections"
15154,NCT02611453,Technical success of CO2 cholangiography vs. iodinated contrast,2016-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Radiation usage/exposure of CO2 cholangiography using conventional fluoroscopy or digital subtraction fluoroscopy vs. iodinated contrast
15155,NCT02642809,Tolerability of localized esophageal hypofractionated brachytherapy administered in two fractions when combined with pembrolizumab as measured by treatment related adverse events,2016-06-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
15156,NCT00425906,"Determination of whether ≥ 50% of patients utilize nicotine for treating ""hunger pain"" ≥ 2 times over a 48-hour period",2003-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Change in circulating hormonal concentrations (for patients enrolled at the Mayo Rochester Clinic only)
15157,NCT03428425,Conversion to negative rate,2018-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
15158,NCT06158139,Neurotoxicity,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Objective response rate- no bridging therapy
15159,NCT04616040,Adverse events of Camrelizumab,2020-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Correlations between biomarkers and clinical activity,Objective Response Rate (ORR)
15160,NCT00515190,Overall survial in the two treatment arms,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Response rate, toxicity, duration of response, time to progression, Quality of life in the two treatment arms,the effect of CYP2A6 genetic polymorphisms on the pharmacokinetics, treatment efficacy and toxicity"
15161,NCT05740267,C-reactive protein (CRP) level,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative Recovery course:
15162,NCT02682446,To estimate the incidence (number of participants) of metachronous gastric neoplasm after ESD between H. pylori eradicated group and H. pylori persistent group,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,To evaluate the incidence of metachronous gastric neoplasm after ESD based on diffferent cut off point of serum pepsinogen.
15163,NCT00763516,"Cumulative incidence of grade 3+ bowel perforation, grade 3+ bleeding and grade 4+ nonhematologic acute adverse events (occuring within 90 days of treatment start)",2009-02,COMPLETED,INTERVENTIONAL,['NA'],,Collect and analyze tumor control outcomes
15164,NCT04234113,Part B: Number of Participants With Eastern Cooperative Oncology Group [ECOG],2019-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity analysis to assess antibodies to SO-C101
15165,NCT02162563,Progression-free survival (PFS),2014-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,Correlation of evaluation by the panel with outcome
15166,NCT03157128,Phase 2: Objective Response Rate,2017-05-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 1 and 2: PK: Maximum Concentration (Cmax) of LOXO-292 (Selpercatinib)
15167,NCT01024387,Objective Response Rate,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,1-Year Overall Survival
15168,NCT00914355,"Determine one year local progression free rate, defined as lack of progression within the irradiated volume, using RECIST criteria",2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Cytokine response to radiation and association with complications
15169,NCT02594943,Highest proportion (number) of representative biopsies from tumors of diffuse gastric cancer,2018-08,WITHDRAWN,INTERVENTIONAL,['NA'],,Amount of (mm2 and %) submucosal tissue within the biopsies.
15170,NCT03762564,Overall survival (OS) at 6 months,2019-03-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence and severity of adverse events
15171,NCT02241720,Number of Participants With Stable Disease at Eight Weeks Post-Treatment,2014-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,
15172,NCT00354367,"Investigation of Clinical efficacy of certolizumab pegol for fistula closure, as measured by the proportion of patients with fistula improvement after 16 weeks of treatment.",2007-01,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Investigation of Clinical efficacy of certolizumab pegol for maintenance of fistula closure.
15173,NCT05985707,Overall response rate,2023-08-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Frequency of adverse events
15174,NCT04989764,The disease-free survival,2015-01,COMPLETED,OBSERVATIONAL,['NA'],,
15175,NCT02086968,Correlation Between Screening Hepcidin and Change in Hemoglobin From Baseline to Highest Observed Hemoglobin Change (Proportion of Responders).,2014-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
15176,NCT03515824,Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE),2018-08-13,TERMINATED,INTERVENTIONAL,['PHASE1'],,Minimum Serum Concentration (Cmin) of MK-1697
15177,NCT01968629,Calculate the percent absolute enhancement of HCCs following Eovist administration at multiple phases,2013-12,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,
15178,NCT01331928,objective tumor response rate,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"the progression-free survival, overall survival, toxicity profiles"
15179,NCT02848066,AUC(Area Under the Curve),2015-07,COMPLETED,OBSERVATIONAL,['NA'],,Relative abundance of glycosylations
15180,NCT00520091,Rate of pathologic complete remission in patients with resectable disease,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response Rate
15181,NCT05667415,Disease progression (PD),2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
15182,NCT03170180,response rate,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
15183,NCT04270890,To measure change in treatment volume between freebreathing and abdominal compression scans,2018-06-21,UNKNOWN,INTERVENTIONAL,['NA'],,Reported patient feedback regarding device comfort and compliance of use.
15184,NCT04576858,Time to recurrence,2020-02-03,RECRUITING,OBSERVATIONAL,['NA'],,Response duration RECIST 1.1
15185,NCT00735345,Percentage of complete remissions and resection rate,2008-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Evaluation of Quality of Life
15186,NCT05071755,Overall survival,2021-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
15187,NCT02202564,Recurrence-free survival rate,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
15188,NCT05625841,oral mucositis severity,2022-11-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,microbiota level
15189,NCT00201838,Anti-tumor Effect as Measured by the Proportion of Patients Free of Disease-progression at Six Months After Treatment Initiation,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serial Levels of TNF (Tumor Necrosis Factor) and Other Inflammatory Cytokines
15190,NCT05125393,Operation time,2021-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of at least one serious complication within 30 days after resection
15191,NCT02013778,Number of Participants With Adverse Events,2013-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
15192,NCT04247984,Progression-free survival (PFS),2018-05-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life (QoL) Questionnaire
15193,NCT00085371,Survival in patients receiving triapine as second-line therapy,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Confirmed tumor response, defined to be a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart"
15194,NCT01406574,Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs),2011-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Best Overall Response
15195,NCT05140746,Target-to-background ratio(TBR),2020-09-10,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
15196,NCT05107674,Objective Response Rate (ORR) per disease-specific response criteria as assessed by the Investigator,2021-09-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,PD Biomarkers: Changes from baseline in tumor tissue biopsies of immune cell infiltration or other histological features
15197,NCT03780634,Progression Free Survival (PFS),2019-04-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
15198,NCT05249569,Response Rate of Combination Therapy,2022-11-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety Profile as Measured by the Number of Participants With Lab Abnormalities as Graded by NCI CTCAE v5.0
15199,NCT00835055,,2005-04,WITHDRAWN,OBSERVATIONAL,['NA'],,
15200,NCT04619082,The rate of HBV reactivation during TAF prophylaxis,2021-07-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,The dynamic change of eGFR during TAF prophylaxis
15201,NCT03963193,Progression-free Survival (PFS),2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Assessment of Health-related quality of life
15202,NCT04252560,Microbiome,2020-01-31,RECRUITING,OBSERVATIONAL,['NA'],,
15203,NCT06205849,Safety and tolerability,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Systemic immune effects
15204,NCT02423954,The recommended phase 2 dose (RP2D) of chemotherapy in combination with nivolumab in subjects with advanced cancer.,2015-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quantify changes in amount of blood proteins and circulating tumor DNA in patients enrolled on this study
15205,NCT05155189,AESIs,2021-12-09,RECRUITING,INTERVENTIONAL,['PHASE1'],,progression-free survival by mRECIST 1.1
15206,NCT04180371,Part B: Overall survival (OS) at 1 year in participants solid tumors historically known for high expression of EphA2 receiving BT5528 treatment,2019-11-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part B: The association between EphA2 expression level and overall survival (OS) at 1 year by RECIST v1.1 in participants with advanced solid tumors with high EphA2 levels receiving BT5528 treatment
15207,NCT01287286,Gastrointestinal symptoms in case group reduces 10% than control group during chemotherapy.,2010-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Life quality estimates of 10% improvement than control group.
15208,NCT01065870,To determine the effect of neoadjuvant regimen of GTX on the 2-year disease free survival rate,2009-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"To describe the effect of neoadjuvant GTX regimen on resectability for those with arterial involvement and those with venous involvement, separately"
15209,NCT04586491,development of oral mucositis,2019-10-07,COMPLETED,INTERVENTIONAL,['NA'],,recovery time of oral mucositis
15210,NCT01547923,Number and nature of grade IV toxicity.,2008-06-16,TERMINATED,INTERVENTIONAL,['NA'],,Medical-financial study of pre-therapeutic screening.
15211,NCT05924789,Describe the treatment patterns,2023-08-11,RECRUITING,OBSERVATIONAL,['NA'],,
15212,NCT05457244,Success rate (%),2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Postoperative Parameters:Readmission and reoperation rate
15213,NCT00640471,Overall survival,2008-05-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Molecular markers
15214,NCT04696848,Maximum tolerated dose,2021-02-24,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Translational biomarker assessments obtained from blood,Overall survival
15215,NCT00454363,Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST),2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Plasma Trough Level of GW786034,Percent Change in Tumor Blood Flow Assessed by Functional CT
